-DOCSTART- -X- O O 25040756

postoperative JJ 4_p
analgesia NN 4_p
in IN 4_p
neonates NNS 4_p
neonatal JJ 4_p
cardiac JJ 4_p
and CC N
general JJ 4_p
surgery NN 4_p
. . 4_p

postsurgical JJ 4_p
neonates NNS 4_p
. . N

Neonates NNP N
born VBD N
≥32 JJ N
weeks NNS N
postmenstrual JJ N
age NN N
days NNS N
postthoracoabdominal JJ 4_p
surgery NN 4_p
RESULTS NNP N
Seventy-one JJ 3_p
neonates NNS N
participated VBD N
group NN N
of IN N
postsurgical JJ N
neonates NNS N
with IN 1_p
adults NNS 1_p
-DOCSTART- -X- O O 11700823

common JJ 4_p
cold NN 4_p
. . N

-DOCSTART- -X- O O 25807670

patients NNS 1_p
aged VBD 1_p
16 CD 1_p
and CC 1_p
above IN 1_p
who WP N
were VBD N
referred VBN N
to TO N
the DT N
Oral NNP 4_p
Surgery NNP 4_p
Clinic NNP 4_p
of IN N
our PRP$ N
institution NN N
, , N
with IN N
an DT N
indication NN N
for IN N
non-surgical JJ 4_p
extraction NN 4_p
of IN 4_p
pathologic JJ 4_p
teeth NNS 4_p
experimental JJ 3_p
group NN 3_p
( ( 3_p
n JJ 3_p
= NNP 3_p
80 CD 3_p
) ) 3_p
second JJ 3_p
group NN 3_p
( ( 3_p
n JJ 3_p
= NNP 3_p
80 CD 3_p
) ) 3_p
-DOCSTART- -X- O O 1396108

non-dependent JJ N
humans NNS N
. . N

seven CD 3_p
non-physically-dependent JJ N
opioid JJ 4_p
abuser NN 4_p
volunteers NNS N
-DOCSTART- -X- O O 24436115

lymph JJ 4_p
node-positive JJ 4_p
breast NN 4_p
cancer NN 4_p
. . N

-DOCSTART- -X- O O 10517189

brucellosis NN N
. . N

Forty JJ N
patients NNS N
were VBD N
diagnosed VBN N
with IN N
brucellosis NN N
based VBN N
on IN N
clinical JJ N
and CC N
microbiological JJ N
findings NNS N
. . N

-DOCSTART- -X- O O 392623

84 CD 4_p
women NNS 4_p
at IN 4_p
39-43 JJ 4_p
weeks NNS 4_p
of IN 4_p
pregnancy NN 4_p
-DOCSTART- -X- O O 22306962

children NNS 1_p
with IN 4_p
attention NN 4_p
deficit NN 4_p
hyperactivity NN 4_p
disorder NN 4_p
. . 4_p

children NNS 1_p
with IN N
attention NN 4_p
deficit NN 4_p
hyperactivity NN 4_p
disorder NN 4_p
( ( N
ADHD NNP 4_p
) ) N
. . N

Forty NNP N
children NNS 1_p
with IN N
ADHD NNP 4_p
-DOCSTART- -X- O O 10599355

patients NNS N
with IN N
scleroderma NN 4_p
( ( 4_p
SSc NNP 4_p
) ) 4_p
. . N

41 CD 3_p
patients NNS N
with IN N
SSc NNP N
. . N

-DOCSTART- -X- O O 23280086

adults NNS 1_p
with IN N
acute JJ 4_p
lymphoblastic JJ 4_p
leukemia NN 4_p
: : N
adults NNS N
with IN N
acute JJ N
lymphoblastic JJ N
leukemia NN N
( ( N
ALL DT N
) ) N
patients NNS N
with IN N
Philadelphia NNP N
chromosome NN N
( ( N
Ph NNP N
) ) N
-positive VBP N
ALL NNP N
. . N

accrued VBD N
patients NNS N
from IN N
August NNP N
1996 CD N
to TO N
October NNP N
2004 CD N
. . N

median JJ 1_p
patient NN 1_p
age NN 1_p
was VBD 1_p
43 CD 1_p
years NNS 1_p
. . N

Responses NNS N
were VBD N
evaluated VBN N
in IN N
164 CD 3_p
patients NNS N
. . N

patients NNS N
-DOCSTART- -X- O O 12814457

moderate JJ 4_p
persistent NN 4_p
asthmatics NNS 4_p
. . N

patients NNS 4_p
with IN 4_p
moderate JJ 4_p
to TO 4_p
severe VB 4_p
asthma NN 4_p
moderate JJ N
persistent JJ N
asthmatics NNS N
Twenty NNP 3_p
moderate NN 4_p
to TO 4_p
severe VB 4_p
persistent JJ 4_p
asthmatics NNS 4_p
-DOCSTART- -X- O O 6630328

40 CD 4_p
children NNS 4_p
with IN 4_p
severe JJ 4_p
and CC 4_p
persistent JJ 4_p
soiling NN 4_p
and CC 4_p
often RB 4_p
with IN 4_p
a DT 4_p
history NN 4_p
of IN 4_p
faecal JJ 4_p
retention NN 4_p
. . 4_p

-DOCSTART- -X- O O 16882628

ondelayed-onset JJ N
muscle NN N
soreness NN N
. . N

Ten CD 3_p
healthy JJ N
males NNS 3_p
and CC N
ten VB N
healthy JJ N
females NNS 3_p
aged VBD N
21.5 CD N
+/- JJ N
3.2 CD N
years NNS N
( ( N
mean JJ N
+/- NNP N
s NN N
) ) N
participated VBD N
in IN N
the DT N
study NN N
delayed-onset JJ N
muscle NN N
soreness NN N
( ( N
DOMS NNP N
) ) N
. . N

-DOCSTART- -X- O O 14589718

Fake NNP 4_p
bad JJ 4_p
test NN 4_p
response NN 4_p
bias NN 4_p
effects NNS 4_p
variables NNS 4_p
of IN 4_p
attention NN 4_p
. . 4_p

faking VBG 4_p
bad JJ 4_p
( ( 4_p
FB NNP 4_p
) ) 4_p
Test NNP 4_p
of IN 4_p
Variables NNP 4_p
of IN 4_p
Attention NNP 4_p
( ( N
TOVA NNP N
) ) N
using VBG N
subjects NNS N
-DOCSTART- -X- O O 15302787

patients NNS N
with IN N
in-stent JJ 4_p
restenosis NN 4_p
: : N
patients NNS N
with IN N
ISR NNP 4_p
. . N

Three NNP 3_p
hundred VBD 3_p
symptomatic JJ 4_p
patients NNS 4_p
with IN 4_p
ISR NNP 4_p
-DOCSTART- -X- O O 10093945

typhoid JJ 4_p
fever NN 4_p
in IN N
children NNS 1_p
. . N

Dong NNP N
Nai NNP N
Pediatric NNP N
Center NNP N
patients NNS N
with IN N
multidrug-resistant JJ 4_p
typhoid NN 4_p
fever NN 4_p
in IN N
Vietnam NNP N
. . N

In IN N
an DT N
open JJ N
trial NN N
children NNS 1_p
with IN N
suspected JJ N
typhoid NN 4_p
fever NN 4_p
82 CD 3_p
patients NNS N
( ( N
44 CD N
in IN N
the DT N
cefixime NN N
group NN N
, , N
38 CD N
in IN N
the DT N
ofloxacin JJ N
group NN N
) ) N
and CC N
70 CD 3_p
( ( N
85 CD N
% NN N
) ) N
of IN N
the DT N
isolates NNS N
were VBD N
multidrug-resistant JJ N
. . N

cefixime-treated JJ N
patients NNS N
uncomplicated JJ 4_p
typhoid NN 4_p
fever NN 4_p
in IN N
children NNS 1_p
-DOCSTART- -X- O O 21054362

patient NN N
's POS N
historical JJ N
triptan NN N
response NN N
. . N

patients NNS 4_p
respond NN 4_p
to TO 4_p
triptans NNS 4_p
and CC 4_p
telcagepant NN 4_p
. . 4_p

migraine NN N
patients NNS N
who WP N
can MD N
not RB N
be VB N
adequately RB N
helped VBN N
with IN N
triptans NNS N
patients NNS N
' POS N
self-reported JJ N
historical JJ N
triptan NN N
response NN N
( ( N
HTR NNP N
) ) N
: : N
( ( N
1 CD N
) ) N
good JJ N
HTR NNP N
( ( N
N NNP N
= NNP N
660 CD N
) ) N
: : N
response NN N
in IN N
75-100 CD N
% NN N
of IN N
attacks NNS N
; : N
( ( N
2 CD N
) ) N
intermediate NN N
HTR NNP N
( ( N
N NNP N
= NNP N
248 CD N
) ) N
: : N
response NN N
in IN N
25-74 JJ N
% NN N
of IN N
attacks NNS N
; : N
( ( N
3 CD N
) ) N
poor JJ N
HTR/no NNP N
use NN N
( ( N
N NNP N
= NNP N
407 CD N
) ) N
: : N
response NN N
in IN N
< JJ N
25 CD N
% NN N
of IN N
attacks NNS N
, , N
or CC N
patient NN N
did VBD N
not RB N
take VB N
triptans NNS N
. . N

the DT 4_p
last JJ 4_p
subgroup NN 4_p
comprised VBD 4_p
mainly RB 4_p
( ( 4_p
91 CD 4_p
% NN 4_p
) ) 4_p
patients NNS 4_p
who WP 4_p
reported VBD 4_p
that IN 4_p
they PRP 4_p
did VBD 4_p
not RB 4_p
take VB 4_p
triptans NNS 4_p
, , 4_p
but CC 4_p
it PRP 4_p
was VBD 4_p
not RB 4_p
known VBN 4_p
whether IN 4_p
these DT 4_p
patients NNS 4_p
were VBD 4_p
triptan-naïve JJ 4_p
or CC 4_p
had VBD 4_p
previously RB 4_p
used VBN 4_p
triptans NNS 4_p
and CC 4_p
stopped VBD 4_p
taking VBG 4_p
them PRP 4_p
. . 4_p

-DOCSTART- -X- O O 9808499

transplant NN N
recipients NNS N
and CC N
dialysis NN N
patients NNS N
transplant NN N
and CC N
dialysis NN N
patients NNS N
with IN N
different JJ N
levels NNS N
of IN N
renal JJ N
function NN N
. . N

23 CD 3_p
patients NNS 3_p
who WP N
were VBD N
either CC N
a DT N
recipient NN N
of IN N
an DT N
organ JJ N
transplant NN N
or CC N
on IN N
hemodialysis NN N
. . N

patients NNS N
with IN N
end-stage JJ 4_p
renal JJ 4_p
failure NN 4_p
transplant JJ N
patients NNS N
human JJ 4_p
immunodeficiency NN 4_p
virus-infected JJ 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 18299305

infants NNS 1_p
younger JJR 1_p
than IN 1_p
6 CD 1_p
months NNS 1_p
of IN 1_p
age NN 1_p
. . N

Young NNP 1_p
children NNS 1_p
children NNS 1_p
< $ 1_p
6 CD 1_p
months NNS 1_p
of IN 1_p
age NN 1_p
. . N

children NNS N
. . N

healthy JJ 4_p
children NNS 1_p
6 CD 1_p
to TO 1_p
< VB 1_p
24 CD 1_p
weeks NNS 1_p
of IN 1_p
age NN 1_p
. . N

Healthy NNP 4_p
infants NNS 1_p
aged VBD 1_p
6 CD 1_p
to TO 1_p
< VB 1_p
16 CD 1_p
weeks NNS 1_p
and CC 1_p
16 CD 1_p
to TO 1_p
< VB 1_p
24 CD 1_p
weeks NNS 1_p
infants NNS N
aged VBD N
6 CD 1_p
to TO 1_p
< VB 1_p
16 CD 1_p
weeks NNS 1_p
those DT N
aged VBN N
16 CD 1_p
to TO 1_p
< VB 1_p
24 CD 1_p
weeks NNS 1_p
children NNS N
6 CD 1_p
to TO 1_p
< VB 1_p
16 CD 1_p
weeks NNS 1_p
of IN N
age NN N
infants NNS N
6 CD 1_p
to TO 1_p
< VB 1_p
24 CD 1_p
weeks NNS 1_p
of IN N
age NN N
. . N

infants NNS N
< VBP N
6 CD 1_p
months NNS 1_p
of IN N
age NN N
. . N

-DOCSTART- -X- O O 19996335

idiopathic JJ N
pulmonary JJ N
fibrosis NN N
( ( N
IPF NNP N
) ) N
patients NNS N
with IN N
IPF NNP N
. . N

subjects NNS N
with IN N
IPF NNP N
who WP N
completed VBD N
the DT N
6MWT CD N
, , N
Saint NNP N
George NNP N
's POS N
Respiratory NNP N
Questionnaire NNP N
( ( N
SGRQ NNP N
) ) N
and CC N
forced VBN N
vital JJ N
capacity NN N
( ( N
FVC NNP N
) ) N
123 CD N
subjects NNS N
alive JJ N
and CC N
able JJ N
to TO N
complete VB N
the DT N
6MWT CD N
at IN N
both DT N
follow-up JJ N
time NN N
points NNS N
patients NNS N
with IN N
IPF NNP N
with IN N
moderate JJ N
physiological JJ N
impairment NN N
patient JJ N
population NN N
. . N

-DOCSTART- -X- O O 15275765

postoperative JJ 4_p
pain NN 4_p
after IN N
vaginal JJ 4_p
hysterectomy NN 4_p
. . N

animals NNS N
and CC N
volunteers NNS N
humans NNS N
) ) N
patients NNS N
undergoing VBG N
elective JJ N
vaginal JJ N
hysterectomy NN N
-DOCSTART- -X- O O 2116385

incontinent JJ 4_p
elderly RB 1_p
in IN 4_p
nursing VBG 4_p
homes NNS 4_p
: : 4_p
133 CD N
incontinent JJ 4_p
elderly RB 1_p
in IN N
seven CD N
nursing NN N
homes NNS N
Trainees NNS N
with IN N
a DT N
high JJ N
frequency NN N
of IN N
incontinence NN 4_p
during IN N
baseline NN N
, , N
relatively RB N
more RBR N
cognitive JJ N
residents NNS N
, , N
and CC N
residents NNS N
with IN N
a DT N
normal JJ N
bladder NN N
capacity NN N
nursing JJ N
home NN N
residents NNS N
. . N

-DOCSTART- -X- O O 21262119

endocrine NN 4_p
physiology NN 4_p
and CC 4_p
metabolism NN 4_p
in IN N
rats NNS N
. . N

experimental JJ N
animals NNS N
Male JJ N
Sprague-Dawley JJ N
rats NNS N
( ( N
n JJ N
= $ N
6 CD 3_p
per IN 3_p
group NN 3_p
) ) N
-DOCSTART- -X- O O 9734727

disrupt VB N
cognitive JJ N
, , N
neurophysiologic JJ N
, , N
or CC N
behavioral JJ 4_p
functioning NN 4_p
in IN N
normal JJ N
individuals NNS N
. . N

Forty-eight NNP 3_p
healthy JJ N
volunteers NNS N
healthy JJ 4_p
young JJ 1_p
adults NNS 1_p
. . N

-DOCSTART- -X- O O 7584286

memory NN 4_p
Four CD 3_p
experiments NNS N
memory NN 4_p
for IN N
high JJ 4_p
imagery NN 4_p
and CC N
low JJ 4_p
imagery NN 4_p
texts NN N
. . N

between-subjects NNS N
subjects NNS N
-DOCSTART- -X- O O 8260242

Seventy-two JJ 3_p
oncology NN 4_p
nurses NNS 4_p
-DOCSTART- -X- O O 15591756

transitionally RB N
frail JJ N
older JJR N
adults NNS N
: : N
falling VBG N
risk NN N
among IN N
older JJR N
adults NNS N
. . N

older JJR N
fall-prone NN N
individuals NNS N
. . N

transitionally RB 4_p
frail JJ 4_p
older JJR 4_p
adults NNS 4_p
. . 4_p

30 CD N
transitionally RB N
frail JJ N
older JJR N
adults NNS N
( ( N
mean JJ N
age NN N
82.6 CD N
+/- JJ N
7.1 CD N
years NNS N
, , N
90 CD N
% NN N
female NN N
) ) N
walking VBG N
alone RB N
, , N
performing VBG N
a DT N
simple JJ N
arithmetic JJ N
task NN N
, , N
or CC N
performing VBG N
a DT N
task NN N
of IN N
verbal JJ N
fluency NN N
. . N

transitional JJ N
older NN N
adults NNS N
older JJR N
adults NNS N
-DOCSTART- -X- O O 10560780

young JJ 4_p
urban JJ 4_p
black JJ 4_p
men NNS 4_p
. . 4_p

young JJ 4_p
black JJ 4_p
man NN 4_p
with IN 4_p
HBP NNP 4_p
hypertensive JJ N
young JJ N
urban JJ N
black JJ N
men NNS N
309 CD N
enrolled VBD N
men NNS N
. . N

A DT N
majority NN N
of IN N
the DT N
men NNS N
encountered VBD N
a DT N
variety NN N
of IN N
barriers NNS N
including VBG N
economic JJ N
, , N
social JJ N
, , N
and CC N
lifestyle JJ N
obstacles NNS N
to TO N
adequate VB N
BP NNP N
care NN N
and CC N
control NN N
, , N
including VBG N
no DT N
current JJ N
HBP NNP N
care NN N
( ( N
49 CD N
% NN N
) ) N
, , N
risk NN N
of IN N
alcoholism NN N
( ( N
62 CD N
% NN N
) ) N
, , N
use NN N
of IN N
illicit NN N
drugs NNS N
( ( N
45 CD N
% NN N
) ) N
, , N
social JJ N
isolation NN N
( ( N
47 CD N
% NN N
) ) N
, , N
unemployment NN N
( ( N
40 CD N
% NN N
) ) N
, , N
and CC N
lack NN N
of IN N
health NN N
insurance NN N
( ( N
51 CD N
% NN N
) ) N
. . N

Having VBG N
health NN N
insurance NN N
negative JJ N
urine JJ N
drug NN N
screen NN N
Men NNP N
currently RB N
using VBG N
illicit JJ N
drugs NNS N
counterparts NNS N
who WP N
did VBD N
not RB N
use VB N
illicit JJ N
drugs NNS N
men NNS N
currently RB N
taking VBG N
HBP NNP N
medication NN N
men NNS N
not RB N
taking VBG N
HBP NNP N
medication NN N
. . N

high JJ N
risk NN N
group NN N
. . N

-DOCSTART- -X- O O 25764092

in IN 4_p
post-myocardial JJ 4_p
infarction NN 4_p
( ( 4_p
MI NNP 4_p
) ) 4_p
patients NNS 4_p
In IN N
155 CD 3_p
patients NNS 3_p
with IN N
inferolateral JJ 4_p
zone NN 4_p
MI NNP 4_p
, , N
as IN N
detected VBN N
by IN N
CE-CMR NNP N
-DOCSTART- -X- O O 22490110

primary JJ 1_p
school NN 1_p
children NNS 1_p
: : 1_p
youngsters NNS 1_p
and CC 1_p
adolescents NNS 1_p
. . 1_p

primary JJ 1_p
school NN 1_p
children NNS 1_p
. . 1_p

primary JJ 1_p
school NN 1_p
children NNS 1_p
( ( 1_p
age NN 1_p
10-13 CD 1_p
years NNS 1_p
) ) 1_p
entitled VBD 1_p
'Fun CD N
without IN N
Smokes NNP N
' POS N
-DOCSTART- -X- O O 9337835

man NN 2_p
. . 2_p

humans NNS N
. . N

Sixteen NNP 3_p
healthy JJ N
subjects NNS N
healthy JJ N
humans NNS N
-DOCSTART- -X- O O 1391736

peptic JJ 4_p
ulcer JJ 4_p
disease NN 4_p
peptic JJ 4_p
ulcer JJ 4_p
disease NN 4_p
human JJ 2_p
and CC N
animal JJ 4_p
ulcers NNS 4_p
. . N

peptic JJ 4_p
ulcer JJ 4_p
disease NN 4_p
-DOCSTART- -X- O O 18948032

systemic JJ 4_p
inflammatory NN 4_p
response NN 4_p
to TO 4_p
cardiac VB 4_p
surgery NN 4_p
. . 4_p

Patients NNS N
scheduled VBN N
for IN N
coronary JJ N
artery NN N
bypass NN N
graft NN N
surgery NN N
with IN N
CPB NNP N
. . N

n JJ N
= NNP N
22 CD N
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
21 CD N
) ) N
patients NNS N
undergoing JJ N
cardiac JJ N
surgery NN N
. . N

-DOCSTART- -X- O O 7015093

stress NN 4_p
ulcers NNS 4_p
stress NN 4_p
ulcers NNS 4_p
100 CD N
patients NNS N
postoperatively RB N
. . N

-DOCSTART- -X- O O 1623694

healthy JJ 4_p
male NN 4_p
volunteers NNS 4_p
healthy JJ N
subjects NNS N
. . N

-DOCSTART- -X- O O 20924261

predominantly RB N
classic JJ N
neovascular JJ N
age-related JJ N
macular JJ 4_p
degeneration NN 4_p
Predominantly NNP 4_p
Classic NNP 4_p
Choroidal NNP 4_p
Neovascularization NNP 4_p
[ NNP 4_p
CNV NNP 4_p
] NNP 4_p
in IN N
Age-Related NNP 4_p
Macular NNP 4_p
Degeneration NNP 4_p
) ) N
423 CD 3_p
patients NNS N
received VBN N
ranibizumab NNS N
( ( N
0.3 CD N
or CC N
0.5 CD N
mg NN N
) ) N
monthly RB N
+ NNP N
sham NN N
PDT NNP N
or CC N
PDT NNP N
+ NNP N
monthly JJ N
sham NN N
injection NN N
. . N

-DOCSTART- -X- O O 17387192

after IN 4_p
congenital JJ 4_p
heart NN 4_p
surgery NN 4_p
. . 4_p

after IN 4_p
congenital JJ 4_p
heart NN 4_p
surgery NN 4_p
. . 4_p

Between NNP 4_p
September NNP 4_p
2002 CD 4_p
and CC 4_p
September NNP 4_p
2004 CD 4_p
, , 4_p
among IN 4_p
a DT 4_p
group NN 4_p
of IN 4_p
postoperative JJ 4_p
children NNS 4_p
with IN 4_p
large JJ 4_p
septal JJ 4_p
defects NNS 4_p
, , 4_p
moderate VBP 4_p
to TO 4_p
severe VB 4_p
pulmonary JJ 4_p
hypertension NN 4_p
[ NNP 4_p
pulmonary JJ 4_p
artery NN 4_p
( ( 4_p
PA NNP 4_p
) ) 4_p
to TO 4_p
aortic JJ 4_p
( ( 4_p
Ao NNP 4_p
) ) 4_p
pressure NN 4_p
ratio NN 4_p
of IN 4_p
0.76 CD 4_p
+/- JJ 4_p
0.17 CD 4_p
] NN 4_p
and CC 4_p
systemic JJ 4_p
desaturation NN 4_p
( ( 4_p
Ao NNP 4_p
Sat NNP 4_p
= VBD 4_p
0.89 CD 4_p
+/- JJ 4_p
0.11 CD 4_p
) ) 4_p
, , 4_p
oral JJ 4_p
sildenafil NN 4_p
( ( 4_p
0.3 CD 4_p
mg NN 4_p
x NN 4_p
kg NN 4_p
( ( 4_p
-1 NNP 4_p
) ) 4_p
, , 4_p
every DT 4_p
3 CD 4_p
hours NNS 4_p
) ) 4_p
was VBD 4_p
administered VBN 4_p
for IN 4_p
a DT 4_p
period NN 4_p
of IN 4_p
24-48 JJ 4_p
hours NNS 4_p
( ( 4_p
sildenafil JJ 4_p
group NN 4_p
) ) 4_p
. . 4_p

patients NNS 4_p
22 CD 3_p
children NNS 3_p
with IN 3_p
similar JJ 3_p
pathologies NNS 3_p
who WP 3_p
did VBD 3_p
not RB 3_p
receive VB 3_p
sildenafil NN 3_p
( ( 3_p
control VB 3_p
group NN 3_p
) ) 3_p
. . 3_p

-DOCSTART- -X- O O 19620953

stroke NN 4_p
patients NNS 4_p
patients NNS N
after IN N
a DT N
stroke NN 4_p
. . N

Ten CD 3_p
patients NNS 3_p
( ( N
mean JJ 1_p
age NN 1_p
47.7 CD 1_p
yrs NN 1_p
) ) N
with IN N
cognitive JJ N
deficits NNS N
after IN N
a DT N
first-ever JJ N
stroke NN N
participated VBD N
patients NNS N
after IN N
a DT N
stroke NN 4_p
. . N

-DOCSTART- -X- O O 24006504

nephroureterectomy NN 4_p
: : N
nephroureterectomy NN N
for IN N
upper JJ 4_p
urinary JJ 4_p
tract NN 4_p
urothelial JJ 4_p
carcinoma NN 4_p
. . N

data NN N
from IN N
the DT N
Pirarubicin NNP N
Monotherapy NNP N
Study NNP N
Group NNP N
trial NN N
36 CD 3_p
patients NNS N
in IN N
the DT N
control NN N
group NN N
, , N
14 CD 3_p
with IN N
positive JJ N
urine JJ N
cytology NN N
22 CD 3_p
patients NNS N
with IN N
negative JJ N
cytology NN N
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
. . N

72 CD 3_p
patients NNS N
in IN N
the DT N
Pirarubicin NNP N
Monotherapy NNP N
Study NNP N
Group NNP N
trial NN N
Among IN N
the DT N
31 CD 3_p
patients NNS N
, , N
17 CD 3_p
patients NNS N
who WP N
received VBD N
pirarubicin JJ N
instillation NN N
14 CD 3_p
patients NNS N
who WP N
received VBD N
control NN N
treatment NN N
-DOCSTART- -X- O O 7924475

patients NNS N
who WP N
presented VBD N
for IN N
treatment NN N
of IN N
acute JJ 4_p
asthma NN 4_p
. . N

94 CD 3_p
patients NNS N
( ( N
mean JJ N
age NN N
, , N
35.6 CD N
+/- JJ N
11.2 CD N
years NNS N
) ) N
with IN N
moderate JJ 4_p
to TO 4_p
severe VB 4_p
acute JJ 4_p
asthma NN 4_p
. . N

-DOCSTART- -X- O O 16093405

moderately RB N
hypercholesterolemic JJ 4_p
adults NNS 1_p
: : N
hyperlipidemic JJ 4_p
men NNS 2_p
and CC N
women NNS 2_p
. . 2_p

159 CD 3_p
subjects NNS N
. . N

-DOCSTART- -X- O O 8063943

nephrectomy JJ 4_p
specimen NNS N
removed VBD N
for IN N
ipsilateral JJ 4_p
renal JJ 4_p
cell NN 4_p
carcinoma NN 4_p
. . N

nephrectomy JJ N
specimen NNS N
removed VBD N
for IN N
primary JJ 4_p
renal JJ 4_p
cell NN 4_p
carcinoma NN 4_p
primary JJ 4_p
renal JJ 4_p
cell NN 4_p
carcinoma NN 4_p
-DOCSTART- -X- O O 11305684

autism NN 4_p
and CC 4_p
pervasive JJ 4_p
developmental JJ 4_p
disorder NN 4_p
. . 4_p

children NNS 4_p
with IN 4_p
autism NN 4_p
and CC 4_p
pervasive JJ 4_p
developmental JJ 4_p
disorder NN 4_p
. . 4_p

children NNS 4_p
with IN 4_p
autism NN 4_p
and CC 4_p
pervasive JJ 4_p
developmental NN 4_p
disorder NN 4_p
Thirty-seven JJ 1_p
children NNS 1_p
between IN 1_p
3 CD 1_p
and CC 1_p
11 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
with IN 1_p
a DT 1_p
diagnosis NN 1_p
of IN 1_p
autism NN 1_p
and/or JJ 1_p
pervasive JJ 1_p
developmental NN 1_p
disorder NN 1_p
children NNS N
who WP N
participated VBD N
in IN N
this DT N
study NN N
were VBD N
a DT N
heterogeneous JJ N
group NN N
-DOCSTART- -X- O O 23332872

patients NNS N
with IN N
metastatic JJ 4_p
renal NN 4_p
cell NN 4_p
carcinoma VBZ 4_p
previously RB 4_p
treated VBN 4_p
with IN 4_p
a DT 4_p
tyrosine JJ 4_p
kinase NN 4_p
inhibitor NN 4_p
and CC 4_p
everolimus VB 4_p
36 CD 3_p
patients NNS N
treated VBN N
in IN N
France NNP N
in IN N
the DT N
RECORD-1 JJ N
Trial NNP N
. . N

patients NNS N
with IN N
metastatic JJ 4_p
renal NN 4_p
cell NN 4_p
carcinoma NN 4_p
( ( 4_p
mRCC NN 4_p
) ) 4_p
patients NNS N
with IN N
disease JJ 4_p
progression NN 4_p
after IN 4_p
a DT 4_p
TKI-everolimus JJ 4_p
sequence NN 4_p
. . N

patients NNS N
enrolled VBN N
in IN N
RECORD-1 NNP N
( ( N
Renal NNP N
Cell NNP N
Cancer NNP N
Treatment NNP N
With IN N
Oral NNP N
RAD001 NNP N
Given NNP N
Daily NNP N
) ) N
at IN N
French JJ N
sites NNS N
. . N

patients NNS N
treated VBN N
with IN N
a DT N
TKI-everolimus-TKI JJ N
sequence NN N
. . N

Thirty-six JJ 3_p
patients NNS N
-DOCSTART- -X- O O 23774272

dairy NN N
food NN N
consumption NN N
on IN N
cardio-metabolic JJ N
risk NN N
factors NNS N
. . N

180 CD 3_p
healthy JJ 3_p
volunteers NNS 3_p
176 CD 3_p
( ( N
98 CD N
% NN N
) ) N
subjects VBZ N
CONCLUSIONS NNP N
In IN N
healthy JJ 4_p
volunteers NNS N
-DOCSTART- -X- O O 15191260

persons NNS 4_p
with IN 4_p
heart NN 4_p
failure NN 4_p
persons NNS 4_p
with IN 4_p
chronic JJ 4_p
heart NN 4_p
failure NN 4_p
9 CD N
persons NNS N
with IN N
heart NN N
failure NN N
to TO N
mentor VB N
other JJ N
heart NN N
failure NN N
patients NNS N
( ( N
37 CD N
% NN N
) ) N
of IN N
the DT N
eligible JJ N
population NN N
of IN N
hospitalized JJ N
patients NNS N
agreed VBD N
to TO N
participate VB N
. . N

-DOCSTART- -X- O O 12139152

papular JJ 4_p
urticaria NN 4_p
in IN 4_p
children NNS 1_p
. . 4_p

Papular JJ 4_p
urticaria NN 4_p
( ( N
PU NNP N
) ) N
-DOCSTART- -X- O O 23988781

cardiac JJ 4_p
surgery NN 4_p
: : N
a DT N
western JJ N
Canadian JJ N
tertiary NN N
care NN N
hospital NN N
. . N

Consisted NNP N
of IN N
61 CD 3_p
consecutive JJ N
male NN 2_p
and CC N
female JJ 2_p
patients NNS N
from IN N
ages NNS 1_p
40 CD 1_p
to TO 1_p
80 CD 1_p
who WP N
were VBD N
scheduled VBN 4_p
for IN 4_p
cardiac JJ 4_p
surgery NN 4_p
with IN 4_p
cardiopulmonary JJ 4_p
bypass NN 4_p
. . N

-DOCSTART- -X- O O 23392460

coformulated JJ N
elvitegravir/cobicistat/emtricitabine/tenofovir NN N
disoproxil NN N
fumarate NN N
versus NN N
efavirenz/emtricitabine/tenofovir NN N
disoproxil NN N
fumarate NN N
for IN N
initial JJ N
treatment NN N
of IN N
HIV-1 NNP 4_p
infection NN 4_p
: : 4_p
( ( N
EVG/COBI/FTC/TDF NNP N
, , N
n JJ N
= NNP N
348 CD 3_p
) ) N
( ( N
EFV/FTC/TDF NNP N
, , N
n JJ 3_p
= NNP 3_p
352 CD 3_p
) ) N
-DOCSTART- -X- O O 11300174

children NNS 1_p
in IN N
need NN N
of IN N
treatment NN N
in IN N
Northern NNP N
Ireland NNP N
. . N

children NNS N
with IN N
a DT N
dental JJ 4_p
health NN 4_p
need NN N
children NNS 1_p
with IN N
a DT N
treatment NN N
need NN N
Sixty-four JJ 3_p
participating NN N
schools NNS N
A DT N
total NN N
of IN N
2,321 CD 3_p
children NNS 3_p
were VBD N
screened VBN N
, , N
with IN N
980 CD 3_p
having VBG N
a DT N
positive JJ N
result NN N
. . N

664 CD 3_p
completed VBN N
questionnaires NNS N
-DOCSTART- -X- O O 21115906

patients NNS N
with IN N
breast JJ 4_p
cancer NN 4_p
. . N

( ( N
α-βA JJ N
) ) N
in IN N
breast NN 4_p
cancer NN 4_p
patients NNS N
during IN N
chemotherapy NN N
series NN N
of IN N
30 CD 3_p
breast NN 4_p
cancer NN 4_p
patients NNS N
who WP N
underwent VBP N
standardised VBN N
chemotherapy NN N
-DOCSTART- -X- O O 12456431

gastroesophageal NN N
reflux NN N
( ( N
GER NNP N
) ) N
patients NNS 4_p
undergoing VBG 4_p
thoracotomy NN 4_p
in IN 4_p
the DT 4_p
lateral JJ 4_p
position NN 4_p
80 CD 3_p
adult NN N
patients NNS N
undergoing VBG N
thoracotomy NN N
. . N

Patients NNS N
at IN N
high JJ N
risk NN N
of IN N
GER NNP N
were VBD N
excluded VBN N
from IN N
the DT N
study NN N
. . N

Patients NNS N
undergoing JJ N
thoracotomy NNS N
-DOCSTART- -X- O O 16879274

grading NN 4_p
of IN 4_p
breast NN 4_p
cancer NN 4_p
aspirates VBZ 4_p
. . N

-DOCSTART- -X- O O 1457622

SDAT NNP 4_p
and CC N
MID NNP 4_p
. . N

96 CD 3_p
mildly RB N
to TO N
moderately RB N
demented JJ 4_p
patients NNS N
( ( N
72 CD 3_p
women NNS 2_p
, , N
24 CD 3_p
men NNS 2_p
) ) N
, , N
aged VBN 1_p
61-96 CD 1_p
years NNS 1_p
( ( 1_p
mean VB 1_p
82 CD 1_p
) ) 1_p
, , N
diagnosed VBD N
according VBG N
to TO N
DSM-III NNP N
criteria NNS N
. . N

Patients NNS N
were VBD N
off RP N
drugs NNS N
for IN N
at IN N
least JJS N
2 CD N
weeks NNS N
and CC N
subdiagnosed VBD N
according VBG N
to TO N
the DT N
modified VBN N
Marshall-Hachinski NNP N
ischemic JJ N
score NN N
and CC N
CT NNP N
in IN N
45 CD 3_p
senile JJ 4_p
dementia NN 4_p
of IN N
the DT N
Alzheimer NNP 4_p
type NN 4_p
( ( N
SDAT NNP 4_p
) ) N
and CC N
51 CD 3_p
multiinfarct NN 4_p
dementia NN 4_p
( ( N
MID NNP 4_p
) ) N
patients NNS N
. . N

-DOCSTART- -X- O O 8852235

obesity NN 4_p
. . 4_p

Subjects NNS N
were VBD N
1,504 CD 3_p
police NNS N
trainees NNS N
( ( N
85 CD N
% NN N
male NN 2_p
, , N
15 CD N
% NN N
female NN 2_p
) ) N
with IN N
an DT N
ethnic JJ N
distribution NN N
of IN N
82 CD N
% NN N
white JJ N
, , N
16 CD N
% NN N
African JJ N
American NNP N
, , N
and CC N
2 CD N
% NN N
other JJ N
. . N

Data NNS N
were VBD N
collected VBN N
at IN N
25 CD N
sites NNS N
across IN N
the DT N
state NN N
of IN N
North NNP N
Carolina NNP N
. . N

-DOCSTART- -X- O O 20122038

Alzheimer NNP 4_p
's POS 4_p
caregiver NN N
health NN N
II NNP N
intervention NN N
. . N

CG NNP N
and CC N
care VB N
recipient NN N
( ( N
CR NNP N
) ) N
homes NNS N
in IN N
five CD N
U.S. NNP N
cities NNS N
. . N

Four CD 3_p
hundred CD 3_p
ninety-five JJ 3_p
dementia NN 4_p
CG NNP 4_p
and CC 4_p
CR NNP 4_p
dyads NNS 4_p
( ( N
169 CD N
Hispanic NNP N
, , N
160 CD N
white JJ N
, , N
and CC N
166 CD N
African JJ N
American NNP N
) ) N
receiving VBG N
intervention NN N
and CC N
their PRP$ N
controls NNS N
. . N

racially RB N
and CC N
ethnically RB N
diverse JJ N
CGs NNP N
of IN N
people NNS N
with IN N
dementia NN 4_p
. . N

-DOCSTART- -X- O O 8530236

Laparoscopic NNP 4_p
hysterectomy NN 4_p
: : N
two CD N
hundred CD N
and CC N
thirty VB N
laparoscopic JJ 4_p
hysterectomies NNS 4_p
during IN N
the DT N
period NN N
from IN N
March NNP N
1991 CD N
to TO N
October NNP N
1993 CD N
. . N

Sixty CD 3_p
patients NNS N
were VBD N
later RB N
included VBN N
in IN N
this DT N
study NN N
. . N

-DOCSTART- -X- O O 26551184

Nulliparous NNP N
Women NNP 2_p
at IN N
39 CD N
Weeks NNP N
of IN N
Gestation NNP 4_p
: : N
nulliparous JJ N
women NNS 2_p
with IN N
an DT N
unfavorable JJ 4_p
cervix NN 4_p
Nulliparous JJ N
woman NN N
between IN N
38 CD N
0/7 CD N
and CC N
38 CD N
6/7 CD N
weeks NNS N
of IN N
gestation NN N
who WP N
were VBD N
least JJS N
18 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
with IN N
a DT N
singleton NN N
gestation NN N
and CC N
a DT N
Bishop NNP N
score NN N
of IN N
5 CD N
or CC N
less JJR N
were VBD N
randomized VBN N
to TO N
elective JJ N
induction NN N
of IN N
labor NN N
or CC N
expectant JJ N
management NN N
. . N

From IN N
March NNP N
2010 CD N
to TO N
February NNP N
2014 CD N
, , N
82 CD 3_p
patients NNS 3_p
were VBD N
randomly RB N
allocated VBN N
to TO N
induction NN N
of IN N
labor NN N
and CC N
80 CD N
to TO N
expectant VB N
management NN N
. . N

nulliparous JJ N
women NNS N
with IN N
a DT N
Bishop NNP N
score NN N
of IN N
5 CD N
or CC N
less JJR N
-DOCSTART- -X- O O 8610775

outpatient JJ N
100 CD 3_p
low-risk JJ N
patients NNS N
having VBG N
well-dated JJ N
pregnancies NNS 4_p
. . N

Women NNS N
with IN N
a DT N
Bishop NNP 4_p
score NN 4_p
< NN 4_p
or CC 4_p
= VB 4_p
6 CD 4_p
at IN N
38 CD 4_p
to TO 4_p
40 CD 4_p
weeks NNS 4_p
' POS 4_p
gestation NN 4_p
50 CD 3_p
patients NNS N
patients NNS N
with IN N
an DT N
unfavorable JJ 4_p
cervix NN 4_p
-DOCSTART- -X- O O 3503390

recurrent NN 4_p
gastric JJ 4_p
carcinoma NN 4_p
. . 4_p

cancer NN 4_p
patients NNS N
a DT N
group NN N
of IN N
patients NNS N
with IN N
recurrent JJ N
gastric JJ N
cancer NN N
1 CD N
) ) N
Intradermal NNP N
group NN N
( ( N
ID NNP N
Group NNP N
) ) N
, , N
42 CD 3_p
patients NNS N
given VBN N
an DT N
intradermal JJ N
injections NNS N
of IN N
OK-432 NNP N
. . N

2 CD N
) ) N
Intramuscular NNP N
group NN N
( ( N
IM NNP N
Group NNP N
) ) N
, , N
40 CD 3_p
patients NNS N
given VBN N
an DT N
intramuscular JJ N
injections NNS N
of IN N
OK-432 NNP N
. . N

3 CD N
) ) N
Control NNP N
group NN N
( ( N
C NNP N
Group NNP N
) ) N
, , N
39 CD 3_p
patients NNS N
not RB N
given VBN N
injections NNS N
. . N

-DOCSTART- -X- O O 21902704

100 CD 3_p
patients NNS N
who WP N
had VBD N
anterior CC 4_p
or CC 4_p
premolar JJ 4_p
teeth NNS 4_p
with IN 4_p
irreversible JJ 4_p
pulpitis NN 4_p
without IN N
any DT N
signs NNS N
and CC N
symptoms NNS N
of IN N
acute NN 4_p
or CC 4_p
chronic JJ 4_p
apical JJ 4_p
periodontitis NN 4_p
and CC N
moderate VB N
to TO N
severe VB N
pain NN N
-DOCSTART- -X- O O 2860373

Primary JJ 4_p
hypothyroidism NN 4_p
interferon JJ 4_p
therapy NN 4_p
of IN 4_p
breast NN 4_p
cancer NN 4_p
. . 4_p

-DOCSTART- -X- O O 17089419

carers NNS N
of IN N
adolescents NNS 1_p
with IN N
bulimia NN 4_p
nervosa NN 4_p
. . N

adolescents NNS 1_p
with IN N
Bulimia NNP 4_p
Nervosa NNP 4_p
( ( 4_p
BN NNP 4_p
) ) 4_p
/Eating VBG 4_p
Disorder NNP 4_p
not RB 4_p
otherwise RB 4_p
specified VBN 4_p
( ( 4_p
EDNOS NNP 4_p
) ) 4_p
Hundred NNP 3_p
and CC 3_p
twelve VB 3_p
carers NNS 3_p
and CC N
68 CD 3_p
adolescents NNS 1_p
with IN N
BN/EDNOS NNP 4_p
completed VBD N
self-report JJ N
measures NNS N
( ( N
General NNP N
Health NNP N
Questionnaire NNP N
, , N
Experience NNP N
of IN N
Caregiving NNP N
Inventory NNP N
, , N
Level NNP N
of IN N
Expressed JJ N
Emotion NNP N
, , N
Self-report NNP N
Family NNP N
Inventory NNP N
, , N
Inventory NNP N
of IN N
Interpersonal NNP N
Problems NNP N
) ) N
patient NN N
caregiver NN N
-DOCSTART- -X- O O 15701493

stapled JJ N
versus NN N
open JJ N
hemorrhoidectomy NN 4_p
. . N

hemorrhoids NNS 4_p
Milligan NNP N
Morgan NNP N
hemorrhoidectomy NN N
. . N

84 CD 3_p
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
the DT N
stapled VBN N
( ( N
n JJ N
= NNP N
42 CD 3_p
) ) N
or CC N
open JJ N
group NN N
( ( N
n JJ N
= NNP N
42 CD 3_p
) ) N
. . N

All DT N
patients NNS N
were VBD N
operated VBN N
on IN N
under IN N
spinal JJ N
anesthesia NN N
. . N

mean JJ N
age NN N
of IN N
patients NNS 1_p
was VBD 1_p
46.02 CD 1_p
years NNS 1_p
( ( N
SD NNP N
, , N
12.33 CD N
) ) N
in IN N
the DT N
stapled JJ N
group NN N
and CC N
48.64 CD 1_p
years NNS 1_p
( ( 1_p
14.57 CD 1_p
) ) N
in IN N
the DT N
open JJ N
group NN N
. . N

Grade NNP N
III NNP N
or CC N
IV NNP N
hemorrhoids NNS 4_p
were VBD N
more JJR N
common JJ N
in IN N
men NNS N
( ( N
ie NN N
, , N
80.9 CD N
% NN N
and CC N
85.7 CD N
% NN N
in IN N
the DT N
stapled JJ N
and CC N
open JJ N
group NN N
, , N
respectively RB N
) ) N
. . N

grade NN N
III NNP N
and CC N
grade VBD N
IV NNP N
hemorrhoids NNS N
. . N

-DOCSTART- -X- O O 21719717

A DT N
total NN N
of IN N
120 CD N
healthy JJ N
postmenopausal NN 4_p
women NNS 2_p
were VBD N
enrolled VBN N
, , N
and CC N
doses NNS N
of IN N
10 CD N
to TO N
600 CD N
mg NNS N
once RB N
daily JJ N
and CC N
50 CD N
and CC N
300 CD N
mg NN N
twice RB N
daily RB N
were VBD N
evaluated VBN N
in IN N
15- JJ N
and CC N
28-day JJ N
multiple-dosing JJ N
cohorts NNS N
. . N

-DOCSTART- -X- O O 18382824

individuals NNS 4_p
with IN 4_p
chronic JJ 4_p
stroke NN 4_p
chronic JJ 4_p
stroke NN 4_p
survivors NNS 4_p
. . 4_p

Sixty-three JJ 3_p
community-dwelling JJ N
individuals NNS N
( ( N
mean JJ 1_p
age NN 1_p
= VBD 1_p
65 CD 1_p
years NNS 1_p
, , N
age NN 1_p
range NN 1_p
= NNP 1_p
50-87 CD 1_p
years NNS 1_p
) ) N
with IN N
a DT N
chronic JJ N
stroke NN N
( ( N
post-stroke JJ 4_p
duration NN N
: : N
mean JJ N
= VBP N
5.5 CD N
years NNS N
, , N
range NN N
= NNP N
1-28 CD N
years NNS N
) ) N
. . N

-DOCSTART- -X- O O 8971536

men NNS N
with IN N
flat JJ 4_p
( ( 4_p
FC NNP 4_p
) ) 4_p
or CC 4_p
acuminata NN 4_p
( ( 4_p
CA NNP 4_p
) ) 4_p
condylomata NN 4_p
with IN N
interferon JJ N
alpha-2a NN N
. . N

C.A NNP N
. . N

or CC N
F.C NNP N
. . N

of IN N
the DT N
male JJ N
genital JJ N
tract NN N
. . N

From IN N
March NNP N
1986 CD N
to TO N
September NNP N
1991 CD N
, , N
1372 CD 3_p
men NNS N
, , N
sexual JJ N
partners NNS N
of IN N
women NNS N
with IN N
F.C NNP N
. . N

or CC N
C.A NNP N
. . N

or CC N
cervical JJ N
intraepithelial JJ N
neoplasia NN N
, , N
were VBD N
submitted VBN N
to TO N
peoscopy VB N
. . N

One CD 3_p
thousand NN 3_p
and CC 3_p
nineteen JJ 3_p
( ( N
74.27 CD N
% NN N
) ) N
men NNS N
presented VBN N
with IN N
various JJ N
penile JJ N
lesions NNS N
caused VBN N
by IN N
HPV NNP N
( ( N
histologically RB N
confirmed VBN N
) ) N
; : N
505 CD 3_p
were VBD N
treated VBN N
for IN N
C.A NNP N
. . N

or CC N
F.C NNP N
. . N

or CC N
a DT N
combination NN N
of IN N
F.C NNP N
. . N

and CC N
C.A NNP N
. . N

C.A NNP N
. . N

or CC N
F.C NNP N
. . N

or CC N
combined VBN 4_p
condylomata NNS 4_p
-DOCSTART- -X- O O 6125181

left JJ N
ventricular JJ N
function NN N
. . N

hypertensives NNS N
with IN N
incipient JJ 4_p
heart NN 4_p
failure NN 4_p
. . N

left VBD N
ventricular JJ N
function NN N
-DOCSTART- -X- O O 21724047

epiretinal JJ 4_p
membrane NN 4_p
surgery NN 4_p
. . 4_p

-DOCSTART- -X- O O 9180065

patients NNS N
with IN N
the DT N
chronic JJ 4_p
fatigue NN 4_p
syndrome NN 4_p
. . N

chronic JJ 4_p
fatigue NN 4_p
syndrome NN 4_p
. . N

66 CD 3_p
patients NNS N
with IN N
the DT N
chronic JJ 4_p
fatigue NN 4_p
syndrome NN 4_p
who WP N
had VBD N
neither CC N
a DT N
psychiatric JJ 4_p
disorder NN 4_p
nor CC N
appreciable JJ 4_p
sleep JJ 4_p
disturbance NN 4_p
. . N

patients NNS N
with IN N
the DT N
chronic JJ 4_p
fatigue NN 4_p
syndrome NN 4_p
. . N

-DOCSTART- -X- O O 19309326

anxiety NN 4_p
in IN 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
: : 4_p
Children NNP 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
comorbid NN N
anxiety NN N
disorders NNS N
that WDT N
cause VBP N
significant JJ N
functional JJ N
impairment NN N
. . N

children NNS 4_p
with IN 4_p
ASD NNP 4_p
Forty NNP 1_p
children NNS 1_p
( ( 1_p
7-11 CD 1_p
years NNS 1_p
old JJ 1_p
) ) 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
-DOCSTART- -X- O O 25865762

during IN N
valve JJ 4_p
repair NN 4_p
in IN N
16 CD 3_p
patients NNS N
. . N

Three CD 3_p
patients NNS 3_p
had VBD N
Sievers NNP N
type JJ N
0 CD N
valves NNS N
, , N
11 CD 3_p
had VBD N
Sievers NNP N
type JJ N
1 CD N
, , N
and CC N
2 CD 3_p
had VBD N
Sievers NNP N
type JJ N
2 CD N
. . N

Thirteen JJ 3_p
patients NNS 3_p
had VBD N
left-/right-coronary JJ N
cusp NN N
fusion NN N
, , N
1 CD N
had VBD N
right-/noncoronary JJ N
cusp NN N
fusion NN N
, , N
and CC N
2 CD N
had VBD N
both DT N
. . N

Moderate NNP N
to TO N
severe VB N
aortic JJ N
insufficiency NN N
( ( N
AI NNP N
) ) N
was VBD N
present JJ N
in IN N
13 CD N
of IN N
16 CD N
patients NNS N
, , N
and CC N
3 CD N
had VBD N
mild VBN N
AI NNP N
with IN N
aortic JJ N
aneurysms NNS N
. . N

-DOCSTART- -X- O O 21214129

combined JJ N
study NN N
population NN N
( ( N
N NNP N
= NNP N
2813 CD 3_p
) ) N
of IN N
participants NNS N
with IN N
moderate JJ 4_p
to TO 4_p
severe VB 4_p
acne JJ 4_p
vulgaris NN 4_p
. . N

significantly RB N
improved VBN N
participant-reported JJ N
HRQL NNP N
-DOCSTART- -X- O O 7706098

two CD N
intensive JJ N
care NN N
units NNS N
in IN N
two CD N
adult NN N
acute NN N
care NN N
hospitals NNS N
. . N

Thirty NNP 3_p
patients NNS N
admitted VBD N
to TO N
the DT N
intensive JJ N
care NN N
unit NN N
who WP N
had VBD N
a DT N
thermodilution NN 4_p
pulmonary JJ 4_p
artery NN 4_p
catheter NN 4_p
in IN N
place NN N
. . N

Ages NNS N
ranged VBD N
from IN N
39 CD 1_p
to TO 1_p
80 CD 1_p
years NNS N
( ( N
mean NN N
of IN N
66.4 CD N
+/- JJ N
11.3 CD N
years NNS N
) ) N
. . N

-DOCSTART- -X- O O 7644960

exercise NN N
therapy NN N
in IN N
patients NNS N
with IN N
acute JJ 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
. . N

patients NNS N
with IN N
acute JJ N
low JJ N
back RB N
pain NN N
. . N

Patients NNS N
with IN N
acute JJ 4_p
nonspecific NN 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
and CC N
a DT N
paid VBN 4_p
job NN 4_p
were VBD N
included VBN N
for IN N
analysis NN N
. . N

40 CD N
general JJ N
practices NNS N
363 CD 3_p
patients NNS N
who WP N
were VBD N
gainfully RB N
employed VBN N
were VBD N
included VBN N
. . N

patients NNS N
with IN N
acute JJ N
low JJ N
back RB N
pain NN N
-DOCSTART- -X- O O 11056245

Premenstrual NNP N
women NNS 2_p
with IN N
laparoscopically RB 4_p
diagnosed VBN 4_p
endometriosis NN 4_p
who WP N
required VBD 4_p
GnRH NNP 4_p
agonist JJ 4_p
therapy NN 4_p
for IN N
treatment NN N
and CC N
did VBD 4_p
not RB 4_p
have VB 4_p
significant JJ 4_p
depressive JJ 4_p
or CC 4_p
premenstrual JJ 4_p
mood NN 4_p
symptoms NNS 4_p
at IN 4_p
baseline NN 4_p
. . 4_p

Participants NNPS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either CC N
the DT N
sertraline JJ N
treatment NN N
group NN N
or CC N
to TO N
the DT N
placebo NN N
group NN N
for IN N
the DT N
3-month JJ N
duration NN N
of IN N
the DT N
GnRH NNP N
agonist NN N
therapy NN N
. . N

-DOCSTART- -X- O O 2177746

14 CD 3_p
outpatient JJ 4_p
autistic JJ 4_p
children NNS N
. . N

Fourteen NNP 3_p
children NNS N
( ( N
12 CD 3_p
infantile NN 4_p
autism NN 4_p
full JJ 4_p
syndrome NN 4_p
present NN N
, , N
2 CD 3_p
atypical JJ 4_p
pervasive JJ 4_p
developmental JJ 4_p
disorder NN 4_p
) ) N
between IN N
5 CD 1_p
and CC 1_p
13 CD 1_p
years NNS N
of IN N
age NN N
-DOCSTART- -X- O O 18431478

children NNS 1_p
of IN N
non-severe JJ 4_p
pneumonia NN 4_p
with IN N
wheeze NN 4_p
: : N
developing NN N
countries NNS N
. . N

children NNS 1_p
presenting VBG N
with IN N
non-severe JJ 4_p
pneumonia NN 4_p
with IN N
wheeze NN 4_p
, , N
who WP N
have VBP N
persistent VBN N
fast RB N
breathing NN N
after IN N
nebulisation NN N
with IN N
salbutamol NN N
, , N
and CC N
have VBP N
normal JJ N
chest NN N
radiograph NN N
. . N

eight CD N
government NN N
hospitals NNS N
in IN N
India NNP N
. . N

Participants NNS N
were VBD N
children NNS 1_p
aged VBN N
2-59 JJ 1_p
months NNS N
of IN N
age NN N
836 CD 3_p
cases NNS N
in IN N
placebo NN N
and CC N
835 CD 3_p
in IN N
amoxycillin NN N
group NN N
. . N

children NNS 1_p
with IN N
non-severe JJ 4_p
pneumonia NN 4_p
and CC N
wheeze NN 4_p
-DOCSTART- -X- O O 22325844

adults NNS N
with IN N
smear-positive JJ 4_p
pulmonary JJ 4_p
tuberculosis NN 4_p
( ( 4_p
TB NNP 4_p
) ) 4_p
human JJ 4_p
immunodeficiency NN 4_p
virus NN 4_p
( ( 4_p
HIV NNP 4_p
) ) 4_p
infected VBD 4_p
participants NNS 4_p
who WP 4_p
were VBD 4_p
not RB 4_p
receiving VBG 4_p
antiretroviral JJ 4_p
therapy NN 4_p
( ( 4_p
ART NNP 4_p
) ) 4_p
at IN 4_p
TB NNP 4_p
treatment NN 4_p
initiation NN 4_p
. . 4_p

Of IN N
750 CD 3_p
participants NNS 3_p
who WP N
received VBD N
at IN N
least JJS N
one CD N
dose NN N
of IN N
study NN N
treatment NN N
, , N
123 CD N
( ( N
16 CD N
% NN N
) ) N
were VBD N
HIV-infected JJ 4_p
. . N

HIV-infected JJ N
participants NNS N
HIV-infected JJ N
participants NNS N
HIV-infected JJ N
persons NNS N
HIV-infected JJ 4_p
persons NNS 4_p
-DOCSTART- -X- O O 8245359

70 CD N
patients NNS N
( ( N
without IN N
previous JJ N
history NN N
of IN N
cerebral JJ N
or CC N
systemic JJ N
embolus NN N
) ) N
undergoing VBG N
cardiac JJ N
catheterization NN N
. . N

-DOCSTART- -X- O O 18836092

scheduled JJ N
vaccination NN N
children NNS N
. . N

in IN N
239 CD N
children NNS N
aged VBN N
4-12 CD N
years NNS N
old JJ N
. . N

in IN N
4- JJ N
to TO N
12-year-old JJ N
children NNS N
. . N

239 CD N
children NNS N
were VBD N
enrolled VBN N
by IN N
25 CD N
family NN N
practitioners NNS N
4- JJ N
to TO N
12-year-old JJ N
children NNS N
. . N

children NNS N
-DOCSTART- -X- O O 1707337

patients NNS N
with IN N
intermediate JJ 4_p
and CC 4_p
high-grade JJ 4_p
non-Hodgkin NN 4_p
's POS 4_p
lymphoma NN 4_p
. . N

Twenty-seven JJ 3_p
patients NNS N
were VBD N
fully RB N
evaluable JJ N
. . N

-DOCSTART- -X- O O 17280773

nocturia NNS 4_p
: : 4_p
Adults NNP 1_p
aged VBD 1_p
> NNP 1_p
or CC 1_p
=18 NNP 1_p
yr NN 1_p
with IN 1_p
nocturia NNS 1_p
( ( 1_p
> CD 1_p
or CC 1_p
=2 VB 1_p
voids/night NN 1_p
) ) 1_p
127 CD N
patients NNS N
were VBD N
randomised VBN N
-DOCSTART- -X- O O 23436524

broiler NN 4_p
chicks NNS 4_p
. . N

poultry NN 4_p
broiler NN N
chicks NNS N
infected VBN N
with IN N
Eimeria NNP 4_p
maxima NN 4_p
. . N

chicks NNS N
from IN N
hatch NN N
to TO N
d VB N
16 CD N
posthatch NN N
. . N

growth NN N
in IN N
young JJ N
broiler NN N
chicks NNS N
infected VBN N
with IN N
E. NNP N
maxima NNS N
-DOCSTART- -X- O O 872859

L1210 NNP N
mice NN N
and CC 3_p
men NNS 3_p
. . N

-DOCSTART- -X- O O 25053766

children NNS 1_p
with IN N
autism NN 4_p
. . N

children NNS 1_p
with IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorder NNP 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
; : N
children NNS 1_p
with IN N
ASD NNP 4_p
. . N

Seventeen NNP 3_p
children NNS 1_p
, , 1_p
ages VBZ 1_p
6 CD 1_p
to TO 1_p
9 CD 1_p
, , N
with IN N
a DT N
diagnosis NN N
of IN N
ASD NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
music NN N
therapy NN N
group NN N
( ( N
MTG NNP N
) ) N
or CC N
the DT N
no-music JJ N
social JJ N
skills NNS N
group NN N
( ( N
SSG NNP N
) ) N
children NNS 1_p
with IN N
ASD NNP 4_p
. . N

-DOCSTART- -X- O O 17009630

myometrium NN N
and CC N
uterine JJ N
myomas NN N
of IN N
gnRH JJ N
analogue-treated JJ N
women NNS N
. . N

women NNS 2_p
with IN N
uterine JJ 4_p
myomas NN 4_p
, , N
untreated VBD 4_p
or CC 4_p
treated VBN 4_p
with IN 4_p
GnRH NNP 4_p
analogue NN 4_p
. . N

females NNS N
with IN N
myomas NN N
-DOCSTART- -X- O O 11837468

patients NNS N
of IN N
noninsulin JJ 4_p
dependent JJ 4_p
diabetes VBZ 4_p
mellitus NN 4_p
-- : N
a DT N
50 CD N
patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
mellitus VBP 4_p
in IN 4_p
uncontrolled JJ 4_p
state NN 4_p
Fifty JJ N
patients NNS N
of IN N
uncontrolled JJ 4_p
type NN 4_p
2 CD 4_p
diabetes NNS 4_p
-DOCSTART- -X- O O 8467027

pneumonia NN 4_p
69 CD 4_p
artificially RB 4_p
ventilated JJ 4_p
patients NNS N
the DT N
clinical JJ N
, , N
bacteriological JJ N
and CC N
pharmacological JJ N
effects NNS N
of IN N
endotracheally RB N
administered VBN N
tobramycin NN N
-DOCSTART- -X- O O 4346973

post-operative JJ 4_p
pain NN 4_p
. . N

-DOCSTART- -X- O O 12604982

enteric JJ 4_p
microflora NNS 4_p
in IN 4_p
low-birth-weight JJ 4_p
neonates NNS 4_p
. . 4_p

neonatal JJ N
gut NN N
function NN N
. . N

neonatal JJ N
gut NN N
71 CD N
preterm JJ N
infants NNS N
of IN N
less JJR N
than IN N
2000 CD N
g JJ N
birth NN N
weight NN N
. . N

Infants VBZ 4_p
less JJR 4_p
than IN 4_p
1500 CD 4_p
g NN 4_p
infants NNS N
weighing VBG N
1500 CD N
to TO N
1999 CD N
g NN N
infants NNS 4_p
weighing VBG 4_p
less JJR 4_p
than IN 4_p
1500 CD 4_p
g NN 4_p
infants NNS N
weighing VBG N
less JJR N
than IN N
1500 CD N
g NN N
at IN N
birth NN N
-DOCSTART- -X- O O 23510581

autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . 4_p

Autism NNP 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
healthy JJ N
adults NNS 1_p
. . N

adults NNS 1_p
with IN N
Asperger NNP 4_p
syndrome NN 4_p
( ( 4_p
AS IN 4_p
) ) 4_p
. . N

14 CD 3_p
individuals NNS 3_p
with IN N
AS NNP N
and CC N
a DT N
group NN N
of IN N
14 CD 3_p
neurotypical JJ N
control NN N
participants NNS N
ASD NNP 4_p
ASD NNP 4_p
-DOCSTART- -X- O O 25549656

Stroke NNP 4_p
. . N

Twenty-six JJ 3_p
hemiplegic JJ 4_p
subjects NNS N
with IN N
chronic JJ 4_p
stroke NN 4_p
-DOCSTART- -X- O O 15745138

dialysis NN 4_p
patients NNS N
. . N

28 CD 3_p
patients NNS N
were VBD N
randomized VBN N
to TO N
maintenance NN N
of IN N
Cndi NNP N
at IN N
13.6 CD N
mS/cm NNS N
( ( N
equivalent JJ N
to TO N
135 CD N
mmol/L NN N
of IN N
Na+ NNP N
) ) N
or CC N
serial JJ N
reduction NN N
of IN N
Cndi NNP N
in IN N
steps NNS N
of IN N
0.2 CD N
mS/cm NNS N
, , N
guided VBN N
by IN N
symptoms NNS N
and CC N
blood NN N
pressure NN N
. . N

-DOCSTART- -X- O O 24101716

children NNS N
with IN N
autism NN 4_p
. . N

caregivers NNS N
of IN N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
10 CD 3_p
families NNS N
participated VBN N
in IN N
the DT N
treatment NN N
condition NN N
-DOCSTART- -X- O O 9926538

alcohol-dependent JJ 4_p
clients NNS N
Outpatients NNPS 4_p
Outpatients NNS N
from IN N
five CD N
clinical JJ N
research NN N
units NNS N
distributed VBN N
across IN N
the DT N
United NNP N
States NNPS N
. . N

Eight NNP 3_p
hundred VBD 3_p
and CC 3_p
six CD 3_p
alcohol-dependent JJ 4_p
clients NNS N
. . N

-DOCSTART- -X- O O 8255984

autism NN 4_p
. . 4_p

autistic JJ 1_p
children NNS 1_p
in IN 1_p
residential JJ 1_p
treatment NN 1_p
. . 1_p

Residential JJ 1_p
school NN 1_p
children NNS 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
18 CD 1_p
) ) 1_p
-DOCSTART- -X- O O 1922868

patients NNS N
with IN N
different JJ N
degrees NNS N
of IN N
immunosuppression NN 4_p
] NNP N
patients NNS N
with IN N
different JJ N
degrees NNS N
of IN N
immunodepression NN 4_p
-DOCSTART- -X- O O 14998846

metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
. . N

first-line JJ 4_p
treatment NN 4_p
of IN 4_p
women NNS 4_p
with IN 4_p
metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
( ( 4_p
MBC NNP 4_p
) ) 4_p
. . 4_p

Women NNP 2_p
( ( N
n=509 JJ N
) ) N
with IN N
MBC NNP 4_p
and CC 4_p
normal JJ 4_p
cardiac JJ 4_p
function NN 4_p
were VBD N
randomized VBN N
-DOCSTART- -X- O O 22456820

From IN N
2,834 CD N
single JJ N
pregnancies NNS N
, , N
1,415 CD N
were VBD N
selected VBN N
at IN N
random NN N
-DOCSTART- -X- O O 24713222

Hemodialysis NNP 4_p
catheter NN 4_p
design NN 4_p
and CC 4_p
catheter NN 4_p
performance NN 4_p
: : N
302 CD 3_p
hemodialysis NN N
patients NNS N
who WP N
required VBD N
a DT N
tunneled JJ N
cuffed NN N
catheter NN N
as IN N
temporary JJ N
or CC N
definite JJ N
vascular JJ N
access NN N
. . N

-DOCSTART- -X- O O 12660676

patients NNS 4_p
with IN 4_p
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
: : N
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
. . N

inhospital JJ N
ventricular JJ N
fibrillation NN N
( ( N
VF NNP N
) ) N
and CC N
ventricular JJ N
tachycardia NN N
( ( N
VT NNP N
) ) N
and CC N
compared VBN N
30-day JJ N
and CC N
1-year JJ N
mortality NN N
rates NNS N
of IN N
patients NNS N
who WP N
did VBD N
( ( N
n VB N
= NNP N
1121 CD N
) ) N
and CC N
did VBD N
not RB N
( ( N
n JJ N
= NNP N
13,921 CD N
) ) N
have VBP N
these DT N
arrhythmias NNS N
during IN N
the DT N
index NN N
hospitalization NN N
. . N

acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
-DOCSTART- -X- O O 1862788

cocaine NN 4_p
dependence NN 4_p
. . N

Subjects NNS N
were VBD N
54 CD 3_p
outpatients NNS N
who WP N
met VBD N
DSM NNP N
III-R NNP N
criteria NNS N
for IN N
active JJ N
cocaine NN N
dependence NN N
and CC N
who WP N
completed VBD N
a DT N
minimum NN N
of IN N
2 CD N
weeks NNS N
of IN N
treatment NN N
. . N

did VBD N
not RB N
differ VB N
for IN N
lifetime NN N
cocaine NN N
use NN N
, , N
lifetime JJ N
histories NNS N
of IN N
psychopathology NN N
, , N
admission NN N
scores NNS N
on IN N
psychometric JJ N
assessments NNS N
, , N
and CC N
sociodemographics NNS N
. . N

-DOCSTART- -X- O O 8018108

Twenty NNP 3_p
healthy JJ N
men NNS N
, , N
aged VBN N
18-55 CD 1_p
years NNS 1_p
-DOCSTART- -X- O O 19062727

high-risk JJ 4_p
breast NN 4_p
cancer NN 4_p
] NNP N
high-risk JJ 4_p
breast NN 4_p
cancer NN 4_p
. . N

101 CD 3_p
patients NNS 3_p
with IN N
high-risk JJ 4_p
breast NN 4_p
cancer NN 4_p
after IN 4_p
surgical JJ 4_p
resection NN 4_p
101 CD 3_p
patients NNS 3_p
. . N

Ninety-eight JJ 3_p
patients NNS 3_p
completed VBD 3_p
the DT 3_p
chemotherapy NN N
as IN N
planed VBN N
. . N

high-risk JJ 4_p
breast NN 4_p
cancer NN 4_p
. . N

-DOCSTART- -X- O O 2882234

cardiac JJ 4_p
arrest NN 4_p
. . 4_p

Twelve CD 3_p
patients NNS N
presenting VBG N
to TO N
an DT N
accident NN N
and CC N
emergency NN N
department NN N
in IN N
asystolic JJ N
cardiac JJ N
arrest NN N
were VBD N
randomly RB N
allocated VBN N
to TO N
treatment NN N
with IN N
endotracheal JJ N
adrenaline NN N
( ( N
five CD N
patients NNS N
) ) N
or CC N
peripheral JJ N
intravenous JJ N
adrenaline NN N
( ( N
seven CD N
patients NNS N
) ) N
. . N

-DOCSTART- -X- O O 16752282

96 CD N
hips NNS N
randomized VBN N
to TO N
3 CD N
types NNS N
of IN N
fixation NN N
. . N

90 CD N
patients NNS N
( ( N
96 CD N
hips NNS N
) ) N
scheduled VBN N
for IN N
THA NNP N
All DT N
patients NNS N
received VBD N
the DT N
Spectron NNP N
EF NNP N
stem NN N
. . N

-DOCSTART- -X- O O 15492789

Colorectal JJ 4_p
carcinoma NN 4_p
colorectal JJ 4_p
cancer NN 4_p
patients NNS 4_p
and CC N
healthy JJ 4_p
control NN 4_p
subjects VBZ 4_p
colorectal JJ 4_p
cancer NN 4_p
patients NNS N
-DOCSTART- -X- O O 10837440

Patients NNS N
with IN N
acute JJ 4_p
exacerbations NNS 4_p
of IN 4_p
chronic JJ 4_p
bronchitis NN 4_p
548 CD 3_p
patients NNS N
enrolled VBD N
, , N
281 CD 3_p
( ( N
51 CD N
% NN N
) ) N
were VBD N
evaluable JJ N
. . N

evaluable JJ N
patients NNS N
treated VBN N
with IN N
cefdinir NN 4_p
and CC 4_p
cefprozil NN 4_p
patients NNS N
treated VBN N
with IN N
cefdinir NN 4_p
( ( N
17 CD N
% NN N
) ) N
than IN N
for IN N
patients NNS N
treated VBN N
with IN N
cefprozil NN N
( ( N
6 CD N
% NN N
) ) N
patients NNS N
acute JJ 4_p
exacerbations NNS 4_p
of IN 4_p
chronic JJ 4_p
bronchitis NN 4_p
-DOCSTART- -X- O O 7562882

aged JJ 1_p
patients NNS 4_p
with IN 4_p
hypertension NN 4_p
. . 4_p

Thirty NNP 3_p
elderly JJ 1_p
, , N
mildly RB 4_p
hypertensive JJ 4_p
patients NNS N
elderly JJ 1_p
hypertensive JJ 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 12037693

endogenous JJ N
fibrinolysis NN N
. . N

hypertensive JJ 4_p
patients NNS 4_p
. . 4_p

Fifty-five JJ N
hypertensive JJ N
participants NNS N
( ( N
35 CD N
African-American JJ N
, , N
20 CD N
white JJ N
) ) N
whites NNS N
African-Americans NNP N
white JJ 4_p
, , 4_p
but CC 4_p
not RB 4_p
African-American JJ 4_p
hypertensive JJ 4_p
individuals NNS 4_p
. . 4_p

whites NNS N
or CC N
African-Americans NNS N
. . N

-DOCSTART- -X- O O 18374024

Multicenter NNP N
; : N
a DT N
university NN N
tertiary-care JJ N
hospital NN N
and CC N
a DT N
private JJ N
practice NN N
endoscopy NN N
clinic NN N
. . N

A DT N
total NN N
of IN N
633 CD 3_p
patients NNS 3_p
undergoing JJ N
PEG NNP N
Ninety-seven JJ 3_p
patients NNS N
who WP N
had VBD N
malignant JJ 4_p
stenotic JJ 4_p
oropharyngeal NN 4_p
stricture NN 4_p
patients NNS N
potentially RB N
at IN N
high JJ N
risk NN N
of IN N
peristomal JJ N
infectious JJ N
complications NNS N
( ( N
those DT N
with IN N
advanced JJ 4_p
oropharyngeal JJ 4_p
malignancy NN 4_p
) ) N
-DOCSTART- -X- O O 2956874

Seventeen JJ 3_p
patients NNS 3_p
with IN N
stable JJ 4_p
congestive JJ 4_p
heart NN 4_p
failure NN 4_p
( ( 4_p
class NN 4_p
II NNP 4_p
and CC 4_p
III NNP 4_p
New NNP 4_p
York NNP 4_p
Heart NNP 4_p
Association NNP 4_p
) ) 4_p
-DOCSTART- -X- O O 10463377

patients NNS 4_p
with IN 4_p
senile JJ 4_p
dementia NN 4_p
of IN 4_p
the DT 4_p
Alzheimer NNP 4_p
type NN 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
mild JJ 4_p
to TO 4_p
moderate VB 4_p
probable JJ 4_p
Alzheimer NNP 4_p
's POS 4_p
disease NN 4_p
. . 4_p

A DT N
total NN N
of IN N
204 CD N
patients NNS N
with IN N
probable JJ N
Alzheimer NNP N
's POS N
disease NN N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Of IN N
these DT N
, , N
136 CD N
patients NNS N
were VBD N
eligible JJ N
for IN N
the DT N
according-to-protocol JJ N
analysis NN N
of IN N
efficacy NN N
, , N
167 CD N
subjects NNS N
for IN N
the DT N
intention-to-treat JJ N
analysis NN N
of IN N
efficacy NN N
, , N
and CC N
181 CD N
patients NNS N
were VBD N
included VBN N
in IN N
the DT N
safety NN N
analysis NN N
. . N

placebo NN N
group NN N
. . N

-DOCSTART- -X- O O 10986363

autism NN N
. . N

children NNS N
with IN N
and CC N
without IN N
autism NN N
The DT N
children NNS N
with IN N
autism NN N
individuals NNS N
with IN N
autism NN N
-DOCSTART- -X- O O 12602669

This DT N
multicenter NN N
enrolled VBD 1_p
1,214 CD 1_p
healthy JJ 1_p
, , 1_p
nonsmoking JJ 1_p
outpatients NNS 1_p
aged VBD 1_p
15 CD 1_p
to TO 1_p
85 CD 1_p
years NNS 1_p
with IN 1_p
spring NN 1_p
allergic NN 1_p
rhinitis NN 1_p
, , 1_p
positive JJ 1_p
skin NN 1_p
test NN 1_p
to TO 1_p
a DT 1_p
spring NN 1_p
allergen NN 1_p
, , 1_p
and CC 1_p
predefined VBD 1_p
daytime JJ 1_p
nasal NN 1_p
symptoms NNS 1_p
. . 1_p

patients NNS N
with IN N
seasonal JJ N
allergic JJ N
rhinitis NN N
. . N

-DOCSTART- -X- O O 19174717

cystoid JJ N
macular JJ N
edema NN N
in IN N
branch JJ N
retinal JJ N
vein NN N
occlusion NN N
. . N

patients NNS N
with IN N
perfused JJ N
branch NN N
retinal JJ N
vein NN N
occlusion NN N
. . N

Thirty NNP N
eyes NNS N
of IN N
30 CD N
consecutive JJ N
patients NNS N
with IN N
cystoid JJ N
macular JJ N
edema NN N
secondary JJ N
to TO N
nonischemic JJ N
branch NN N
retinal JJ N
vein NN N
occlusion NN N
were VBD N
assigned VBN N
-DOCSTART- -X- O O 19911168

healthy JJ 4_p
male JJ 4_p
subjects NNS 4_p
. . 4_p

12 CD 1_p
healthy JJ 1_p
male NN 1_p
volunteers NNS 1_p
. . 1_p

-DOCSTART- -X- O O 6653648

acute JJ N
hypertension NN N
13 CD N
patients NNS N
and CC N
the DT N
alpha-beta JJ N
adrenoceptor NN N
blocking VBG N
agent JJ N
labetalol NN N
in IN N
12 CD N
patients NNS N
were VBD N
compared VBN N
in IN N
46 CD N
severe JJ N
acute NN N
hypertensive JJ N
episodes NNS N
during IN N
haemodialysis NN N
. . N

diazoxide-treated JJ N
patients NNS N
patients NNS N
-DOCSTART- -X- O O 16801333

cancer NN 4_p
patients NNS 4_p
' POS 4_p
anxiety NN 4_p
following VBG N
a DT N
medical JJ N
consultation NN N
: : N
patients NNS N
' POS N
Physicians NNP 4_p
, , N
after IN N
attending VBG N
the DT N
BT NNP N
physicians NNS N
' POS N
satisfaction NN N
Physicians NNS N
-DOCSTART- -X- O O 24090047

patients NNS N
with IN N
schizophrenia NN 4_p
. . N

individual JJ N
patient NN N
with IN N
schizophrenia NN 4_p
receiving VBG N
medication NN N
. . N

healthcare NN N
setting VBG N
in IN N
Japan NNP N
. . N

patients NNS N
with IN N
schizophrenia NN N
aged VBN 1_p
20 CD 1_p
years NNS 1_p
or CC 1_p
over IN 1_p
who WP N
required VBD N
antipsychotic JJ N
medication NN N
or CC N
switching NN N
of IN N
the DT N
current JJ N
medication NN N
to TO N
others NNS N
for IN N
reasons NNS N
such JJ N
as IN N
lack NN N
of IN N
efficacy NN N
and CC N
intolerability NN N
. . N

The DT N
target NN N
number NN N
of IN N
subjects NNS N
was VBD N
set VBN N
at IN N
300 CD 3_p
. . N

patients NNS N
with IN N
schizophrenia NN 4_p
highly RB N
valuable JJ N
to TO N
perform VB N
this DT N
effectiveness NN N
study NN N
under IN N
ordinary JJ N
healthcare NN N
setting VBG N
in IN N
Japan NNP N
. . N

-DOCSTART- -X- O O 21193295

patients NNS 4_p
with IN 4_p
mild JJ 4_p
obstructive JJ 4_p
sleep NN 4_p
apnea NN 4_p
. . 4_p

cardiovascular JJ 4_p
diseases NNS 4_p
in IN N
obstructive JJ 4_p
sleep NN 4_p
apnea NN 4_p
( ( 4_p
OSA NNP 4_p
) ) 4_p
overweight JJ 4_p
patients NNS N
with IN N
mild JJ 4_p
OSA NNP 4_p
. . 4_p

Patients NNPS N
were VBD N
randomized VBN N
to TO N
supervised VBN N
intensive JJ N
lifestyle JJ N
intervention NN N
group NN N
( ( N
N=28 NNP 3_p
) ) N
or CC N
to TO N
control VB N
group NN N
( ( N
N=31 NNP 3_p
) ) N
, , N
which WDT N
received VBD N
routine JJ N
lifestyle JJ N
advices NNS N
. . N

overweight JJ 4_p
patients NNS N
with IN N
mild JJ 4_p
OSA NNP 4_p
OSA NNP 4_p
patients NNS N
-DOCSTART- -X- O O 23874533

children NNS 1_p
with IN N
autism NN 4_p
: : N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
children NNS 1_p
with IN N
ASD NNP 4_p
. . N

Forty-six NNP 3_p
age- JJ N
and CC N
IQ-matched JJ N
ASD NNP 4_p
children NNS 1_p
patients NNS N
with IN N
self-control JJ 4_p
problems NNS 4_p
. . N

-DOCSTART- -X- O O 22395144

cesarean JJ N
delivery NN N
: : N
primary JJ N
and CC N
repeat JJ N
cesarean JJ N
deliveries NNS N
258 CD 3_p
women NNS 2_p
undergoing VBG N
primary JJ 4_p
and CC 4_p
repeat JJ 4_p
cesarean JJ 4_p
deliveries NNS 4_p
at IN N
32 CD N
weeks NNS N
of IN N
gestation NN N
or CC N
more JJR N
to TO N
creation NN N
( ( N
n=131 JJ 3_p
) ) N
or CC N
omission NN N
( ( N
n=127 JJ 3_p
) ) N
of IN N
the DT N
bladder NN N
flap NN N
. . N

-DOCSTART- -X- O O 19545929

advanced JJ 4_p
non-small JJ 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
: : N
patients NNS N
with IN N
locally RB N
advanced JJ 4_p
or CC 4_p
metastatic JJ 4_p
non-small JJ 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
( ( 4_p
NSCLC NNP 4_p
) ) 4_p
Patients NNPS N
in IN N
stage NN N
IIIB NNP N
or CC N
IV NNP N
NSCLC NNP 4_p
105 CD 3_p
( ( N
GA NNP N
arm NN N
, , N
51 CD 3_p
; : N
PG NNP N
arm NN N
, , N
54 CD 3_p
) ) N
eligible JJ N
patients NNS N
( ( N
stage NN N
IV NNP N
, , N
32 CD 3_p
and CC N
30 CD 3_p
, , N
respectively RB N
) ) N
-DOCSTART- -X- O O 22153696

patients NNS N
with IN N
hypertriglyceridemia NN 4_p
. . N

patients NNS N
with IN N
hypertriglyceridemia NN 4_p
. . N

Fifty JJ 3_p
patients NNS N
in IN N
each DT N
group NN N
patients NNS N
with IN N
hypertriglyceridemia NN 4_p
. . N

-DOCSTART- -X- O O 24011178

chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
people NNS N
with IN N
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
( ( N
COPD NNP 4_p
) ) N
people NNS N
with IN N
COPD NNP 4_p
. . N

at IN N
two CD N
centres NNS N
will MD N
recruit VB N
166 CD 3_p
individuals NNS N
with IN N
spirometrically RB N
confirmed VBN N
COPD NNP 4_p
. . N

Participants NNS N
will MD N
be VB N
randomly RB N
allocated VBN N
to TO N
hospital-based JJ N
or CC N
home-based JJ N
pulmonary JJ N
rehabilitation NN N
. . N

-DOCSTART- -X- O O 15223903

allogeneic JJ 4_p
sibling VBG 4_p
stem-cell JJ 4_p
transplantation NN 4_p
: : N
French JJ N
study NN N
. . N

prospective JJ N
French JJ N
study NN N
comparing VBG N
four CD N
doses NNS N
of IN N
immunoglobulins NNS N
. . N

hematopoietic JJ 4_p
stem-cell NN 4_p
transplant NN 4_p
recipients NNS 4_p
85 CD 3_p
patients NNS N
from IN N
five CD N
centers NNS N
were VBD N
collected VBN N
prospectively RB N
and CC N
costed VBN N
patient NN N
's POS N
pretransplant JJ 4_p
status NN 4_p
and CC 4_p
transplant-related JJ 4_p
complications NNS 4_p
. . 4_p

homogeneous JJ N
group NN N
of IN N
patients NNS N
. . N

-DOCSTART- -X- O O 16116055

patients NNS N
with IN N
ST-segment-elevation NNP 4_p
myocardial JJ 4_p
infarction NN 4_p
. . N

patients NNS N
with IN N
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
. . N

368 CD 3_p
patients NNS N
with IN N
first JJ 4_p
ST-segment-elevation NNP 4_p
myocardial JJ 4_p
infarction NN 4_p
undergoing VBG 4_p
percutaneous JJ 4_p
coronary JJ 4_p
intervention NN 4_p
( ( N
PCI NNP N
) ) N
. . N

patients NNS N
with IN N
ST-segment-elevation NNP N
myocardial JJ N
infarction NN N
. . N

-DOCSTART- -X- O O 25465111

ruptured JJ 4_p
cerebral JJ 4_p
aneurysms NNS 4_p
: : 4_p
UK NNP 4_p
cohort NN 4_p
of IN 4_p
the DT 4_p
International NNP 4_p
Subarachnoid NNP 4_p
Aneurysm NNP 4_p
Trial NNP 4_p
( ( 4_p
ISAT NNP 4_p
) ) 4_p
. . N

International NNP 4_p
Subarachnoid NNP 4_p
Aneurysm NNP 4_p
Trial NNP 4_p
( ( 4_p
ISAT NNP 4_p
) ) 4_p
cohort NN 4_p
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
either DT N
neurosurgical JJ N
clipping NN N
or CC N
endovascular JJ N
coiling NN N
after IN N
a DT N
subarachnoid JJ N
haemorrhage NN N
, , N
assuming VBG N
treatment NN N
equipoise NN N
, , N
between IN N
Sept NNP N
12 CD N
, , N
1994 CD N
, , N
and CC N
May NNP N
1 CD N
, , N
2002 CD N
. . N

1644 CD 3_p
patients NNS N
in IN N
22 CD N
UK NNP N
neurosurgical JJ N
centres NNS N
for IN N
death NN N
and CC N
clinical JJ N
outcomes NNS N
for IN N
10·0-18·5 JJ N
years NNS N
-DOCSTART- -X- O O 5052446

Hodgkin NNP 4_p
's POS 4_p
disease NN 4_p
. . 4_p

-DOCSTART- -X- O O 23942329

South JJ N
African JJ N
patients NNS N
with IN N
DLBCL NNP 4_p
. . N

93 CD 3_p
de NNS N
novo FW N
diffuse RB N
large JJ N
B-cell NNP N
lymphoma NN N
patients NNS N
seen VBN N
between IN N
1995 CD N
and CC N
2009 CD N
randomly NN N
receiving VBG N
either CC N
standard JJ N
combination NN N
chemotherapy NN N
( ( N
CHOP NNP N
, , N
n=48 NN 3_p
) ) N
or CC N
the DT N
identical JJ N
program NN N
with IN N
rituximab NN N
( ( N
n=45 JJ 3_p
) ) N
South JJ N
African JJ N
public JJ N
hospitals NNS N
-DOCSTART- -X- O O 25070364

finishing VBG N
pigs NNS N
. . N

A DT N
total NN N
of IN N
1,480 CD 3_p
pigs NNS N
finishing VBG N
pigs NNS N
. . N

1,198 CD 3_p
pigs NNS N
( ( N
PIC NNP N
Line NNP N
337 CD N
× NN N
1050 CD N
; : N
initially RB N
46.1 CD N
kg NNS N
) ) N
2 CD N
, , N
270 CD 3_p
pigs NNS N
( ( N
PIC NNP N
Line NNP N
327 CD N
× NN N
1050 CD N
; : N
initially RB N
46.5 CD N
-DOCSTART- -X- O O 25304947

patients NNS N
with IN N
1-3 JJ 4_p
brain NN 4_p
metastases NNS 4_p
; : N
poststratified VBN N
by IN N
the DT N
graded JJ N
prognostic JJ N
assessment NN N
( ( N
GPA NNP N
) ) N
. . N

Radiation NNP N
Therapy NNP N
Oncology NNP N
Group NNP N
( ( N
RTOG NNP N
) ) N
patients NNS N
with IN N
1 CD 4_p
but CC 4_p
not RB 4_p
2 CD 4_p
or CC 4_p
3 CD 4_p
brain NN 4_p
metastasis NN 4_p
( ( 4_p
BM NNP 4_p
) ) 4_p
252 CD 3_p
of IN 3_p
the DT 3_p
331 CD 3_p
patients NNS 3_p
were VBD N
evaluable JJ N
by IN N
GPA NNP N
. . N

Of IN N
those DT N
, , N
211 CD N
had VBD N
lung NN 4_p
cancer NN 4_p
. . N

Breast NNP 4_p
cancer NN 4_p
patients NNS N
were VBD N
excluded VBN N
treatment NN N
groups NNS N
lung JJ 4_p
cancer NN 4_p
patients NNS N
patients NNS N
with IN N
high JJ N
GPA NNP N
patients NNS N
with IN N
multiple JJ N
BM NNP N
and CC N
high JJ N
GPA NNP N
when WRB N
treated VBN N
with IN N
WBRT NNP N
and CC N
SRS NNP N
-DOCSTART- -X- O O 24350695

children NNS 4_p
at IN 4_p
three CD 4_p
years NNS 4_p
of IN 4_p
age NN 4_p
. . 4_p

children NNS N
's POS N
development NN N
of IN N
speech NN N
and CC N
language NN N
at IN N
three CD N
years NNS N
of IN N
age NN N
. . N

population-based JJ N
children NNS N
with IN N
hearing VBG N
impairment NN N
( ( N
LOCHI NNP N
) ) N
. . N

Participants NNP N
were VBD N
44 CD N
of IN N
the DT N
450 CD N
children NNS N
in IN N
the DT N
LOCHI NNP N
cohort NN N
. . N

children NNS N
children NNS N
using VBG N
NLFC NNP N
and CC N
those DT N
using VBG N
conventional JJ N
amplification NN N
. . N

-DOCSTART- -X- O O 2688237

[ NN N
EMLA NNP N
cream NN N
( ( N
lidocaine/prilocaine NN N
) ) N
versus NN N
infiltration NN N
analgesia NN N
with IN N
carbocaine NN N
( ( N
mepivacaine NN N
) ) N
in IN N
vasectomy NN N
] NN N
13 CD N
bilateral JJ N
vasectomies NNS N
. . N

-DOCSTART- -X- O O 25262168

80 CD 3_p
patients NNS 3_p
receiving VBG N
stroke NN 4_p
rehabilitation NN N
in IN N
two CD N
stroke VBD N
units NNS N
in IN N
a DT N
health NN N
board NN N
area NN N
of IN N
Scotland NNP N
( ( N
40 CD 3_p
patients NNS N
in IN N
each DT N
arm NN N
) ) N
. . N

-DOCSTART- -X- O O 6397729

developmental JJ 4_p
age NN 4_p
Thirty NN 4_p
patients NNS 4_p
( ( 4_p
mean JJ 4_p
age NN 4_p
: : 4_p
10.38 CD 4_p
years NNS 4_p
) ) 4_p
affected VBN 4_p
by IN 4_p
primary JJ 4_p
headache NN 4_p
were VBD 4_p
selected VBN 4_p
-DOCSTART- -X- O O 3410812

autistic JJ 4_p
children NNS 1_p
with IN N
minimal JJ N
verbal JJ N
language NN N
. . N

60 CD 3_p
minimally RB 4_p
verbal JJ 4_p
autistic JJ 4_p
children NNS 4_p
. . N

-DOCSTART- -X- O O 8435259

Forty NNP 3_p
ASA NNP 4_p
I PRP N
or CC N
II NNP N
patients NNS N
undergoing VBG 4_p
surgical JJ 4_p
procedures NNS 4_p
20 CD 3_p
patients NNS N
who WP N
received VBD N
edrophonium NN N
-DOCSTART- -X- O O 21329577

anhedonia NN 4_p
: : 4_p
preliminary JJ 4_p
findings NNS 4_p
of IN 4_p
the DT 4_p
Lifestyle NNP 4_p
Intervention NNP 4_p
Treatment NNP 4_p
Evaluation NNP 4_p
Study NNP 4_p
in IN 4_p
northern JJ 4_p
Finland NNP 4_p
. . N

major JJ 4_p
depression NN 4_p
, , N
chronic JJ 4_p
depression NN 4_p
or CC N
specific JJ N
symptoms NNS 4_p
of IN 4_p
depression NN 4_p
82 CD 3_p
overweight JJ N
adults NNS 1_p
participating VBG N
in IN N
the DT N
Lifestyle NNP 4_p
Intervention NNP 4_p
Treatment NNP 4_p
Evaluation NNP 4_p
( ( 4_p
LITE NNP 4_p
) ) 4_p
follow-up NN N
study NN N
at IN N
Oulu NNP N
University NNP N
Hospital NNP N
in IN N
northern JJ N
Finland NNP N
. . N

-DOCSTART- -X- O O 8507025

20 CD 3_p
patients NNS N
undergoing JJ N
oral JJ 4_p
surgery NN 4_p
with IN N
intravenous JJ N
midazolam NNS N
sedation NN 4_p
. . N

-DOCSTART- -X- O O 19852789

children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
: : N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS N
ages VBZ N
3-8 CD 1_p
years NNS 1_p
. . N

Phase NNP N
1 CD N
involved VBD N
65 CD 3_p
children NNS 1_p
who WP N
received VBD N
one CD N
round NN N
of IN N
DMSA NNP N
( ( N
3 CD N
days NNS N
) ) N
. . N

Participants NNS N
who WP N
had VBD N
high JJ 4_p
urinary JJ 4_p
excretion NN 4_p
of IN 4_p
toxic JJ 4_p
metals NNS 4_p
phase NN N
2 CD 3_p
, , 3_p
49 CD 3_p
participants NNS N
-DOCSTART- -X- O O 19169289

patients NNS 4_p
with IN 4_p
solid JJ 4_p
tumours NNS 4_p
. . N

patients NNS N
with IN N
solid JJ 4_p
tumours NN 4_p
patients NNS 3_p
( ( 3_p
N=61 NNP 3_p
) ) 3_p
-DOCSTART- -X- O O 8831332

sweating NN 4_p
threshold NN 4_p
gain NN N
of IN N
sweating VBG N
. . N

Six NNP N
healthy JJ N
male NN N
volunteers NNS N
were VBD N
evaluated VBN N
-DOCSTART- -X- O O 9109702

moderate JJ 4_p
asthma NN 4_p
. . N

asthma NN 4_p
patients NNS N
with IN N
moderate JJ 4_p
asthma NNS 4_p
previously RB 4_p
treated VBN 4_p
with IN 4_p
an DT 4_p
inhaled JJ 4_p
corticosteroid NN 4_p
. . N

342 CD 3_p
adolescent NN 1_p
and CC 1_p
adult NN 1_p
patients NNS N
with IN N
moderate JJ 4_p
asthma NNS 4_p
[ RB N
forced VBD 4_p
expiratory JJ 4_p
volume NN 4_p
in IN 4_p
1 CD 4_p
second JJ 4_p
( ( 4_p
FEV1 NNP 4_p
) ) 4_p
between IN 4_p
50 CD 4_p
% NN 4_p
and CC 4_p
80 CD 4_p
% NN 4_p
of IN 4_p
predicted JJ 4_p
] NNP N
treated VBD N
previously RB N
by IN N
beclomethasone NN N
dipropionate NN N
or CC N
triamcinolone NN N
acetonide RB N
. . N

patients NNS N
with IN N
moderate JJ 4_p
asthma NNS 4_p
. . N

-DOCSTART- -X- O O 15206990

Fifteen NNP 3_p
atopic NN 4_p
asthmatics NNS 4_p
were VBD N
randomized VBN N
in IN N
double-blind NN N
, , N
cross-over JJ N
fashion NN N
to TO N
receive VB N
for IN N
1 CD N
week NN N
either CC N
levocetirizine JJ N
5 CD N
mg NN N
or CC N
placebo NN N
. . N

-DOCSTART- -X- O O 8936541

children NNS 1_p
with IN 4_p
malignant JJ 4_p
diseases NNS 4_p
. . 4_p

children NNS 1_p
with IN 4_p
malignant JJ 4_p
diseases NNS 4_p
. . 4_p

Twenty CD 3_p
children NNS N
were VBD N
included VBN N
in IN N
the DT N
study NN N
but CC N
four CD 3_p
( ( N
two CD 3_p
in IN N
each DT N
group NN N
) ) N
had VBD N
to TO N
be VB N
excluded VBN N
; : N
three CD 3_p
because IN N
the DT N
entry NN N
criteria NNS N
turned VBD N
out RP N
not RB N
to TO N
be VB N
fulfilled VBN N
and CC N
one CD 3_p
because NN N
of IN N
lack NN N
of IN N
data NNS N
. . N

children NNS N
with IN N
malignant JJ 4_p
diseases NNS 4_p
. . N

-DOCSTART- -X- O O 18161677

hemodialysis NN 4_p
population NN 4_p
. . 4_p

Patients NNPS N
AVF NNP 4_p
creation NN 4_p
patients NNS 4_p
Twenty-seven JJ 3_p
patients NNS 3_p
participated VBN 3_p
in IN 3_p
the DT 3_p
study NN 3_p
. . 3_p

patients NNS 4_p
with IN 4_p
BB NNP 4_p
and CC 4_p
PTFE NNP 4_p
AVFs NNP 4_p
. . 4_p

-DOCSTART- -X- O O 8387067

161 CD 3_p
recurrence-free JJ 4_p
breast NN 4_p
cancer NN 4_p
patients NNS N
. . N

breast NN N
cancer NN N
patients NNS N
, , N
treated VBD N
according VBG N
to TO N
the DT N
Danish JJ N
Breast NNP N
Cancer NNP N
Cooperative NNP N
Group NNP N
protocols VBZ N
. . N

One NNP N
hundred CD N
and CC N
sixty-one JJ N
recurrence-free JJ N
breast NN N
cancer NN N
patients NNS N
were VBD N
examined VBN N
for IN N
radiation-induced JJ N
brachial JJ N
plexopathy NN N
after IN N
a DT N
median JJ N
follow-up JJ N
period NN N
of IN N
50 CD N
months NNS N
( ( N
13-99 JJ N
months NNS N
) ) N
. . N

high-risk JJ N
patients NNS N
younger JJR 1_p
patients NNS N
-DOCSTART- -X- O O 24184410

effects NNS 4_p
of IN 4_p
ostracism NN 4_p
. . N

emotional JJ 4_p
effects NNS 4_p
of IN 4_p
ostracism NN 4_p
. . N

participants NNS 4_p
were VBD 4_p
given VBN 4_p
25g CD 4_p
of IN 4_p
glucose NN 4_p
or CC N
a DT 4_p
sucralose JJ 4_p
placebo NN 4_p
before IN 4_p
being VBG 4_p
ostracized VBN 4_p
while IN 4_p
playing VBG 4_p
Cyberball NNP 4_p
. . N

-DOCSTART- -X- O O 17968030

ADHD NNP 4_p
, , N
autism NN 4_p
, , N
and CC N
reading-writing JJ 4_p
disorder NN 4_p
: : N
Sixty NNP 3_p
boys VBZ 2_p
with IN N
ADHD NNP 4_p
, , N
Asperger NNP 4_p
syndrome/high-functioning JJ 4_p
autism NN 4_p
( ( 4_p
AS/HFA NNP 4_p
) ) 4_p
, , N
and CC N
reading NN 4_p
and CC 4_p
writing VBG 4_p
disorder NN 4_p
( ( 4_p
RD/WD NNP 4_p
) ) 4_p
-DOCSTART- -X- O O 4772206

highly RB N
selective JJ N
vagotomy NN 4_p
without IN N
drainage NN N
and CC N
selective JJ 4_p
vagotomy NN 4_p
with IN 4_p
pyloroplasty NN 4_p
. . N

-DOCSTART- -X- O O 3059450

distal JJ 4_p
ulcerative JJ 4_p
colitis NN 4_p
. . N

Twenty-nine JJ 3_p
patients NNS 3_p
with IN N
attacks NNS 4_p
of IN 4_p
distal JJ 4_p
ulcerative JJ 4_p
colitis NN 4_p
distal JJ 4_p
ulcerative JJ 4_p
colitis NN 4_p
. . N

-DOCSTART- -X- O O 9732932

patients NNS 4_p
with IN 4_p
primary JJ 4_p
biliary JJ 4_p
cirrhosis NN 4_p
. . 4_p

patients NNS N
with IN N
primary JJ N
biliary JJ N
cirrhosis NN N
. . N

32 CD N
patients NNS N
( ( N
18 CD N
ursodeoxycholic JJ N
acid NN N
, , N
14 CD N
placebo NN N
) ) N
placebo NN N
group NN N
. . N

-DOCSTART- -X- O O 24399100

children NNS 1_p
with IN N
autism NN 4_p
spectrum NN N
disorders NNS N
and CC N
developmental JJ N
disabilities NNS N
in IN N
a DT N
population-based JJ N
study NN N
. . N

preschoolers NNS 1_p
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
) ) N
and CC N
other JJ N
developmental JJ N
disabilities NNS N
( ( N
DD NNP N
) ) N
. . N

Participants NNS N
were VBD N
578 CD 3_p
children NNS 1_p
who WP N
were VBD N
part NN N
of IN N
an DT N
ongoing JJ N
population-based JJ N
, , N
case-control JJ N
study NN N
of IN N
2- JJ 1_p
to TO 1_p
5-year JJ 1_p
olds NNS 1_p
with IN N
ASD NNP N
, , N
DD NNP N
, , N
and CC N
the DT N
general JJ N
population NN N
. . N

Four CD 3_p
hundred VBD 3_p
fifty-three JJ 3_p
children NNS N
with IN N
ASD NNP N
and CC N
125 CD 3_p
DD NNP N
children NNS 1_p
were VBD N
included VBN N
. . N

Hispanic JJ N
families NNS N
non-Hispanic JJ N
families NNS N
. . N

Families NNS N
Underimmunized VBN N
children NNS 1_p
families NNS N
of IN N
young JJ 1_p
children NNS 1_p
with IN N
neurodevelopmental JJ N
disorders NNS N
-DOCSTART- -X- O O 12618690

advanced JJ 4_p
chronic JJ 4_p
venous JJ 4_p
insufficiency NN 4_p
( ( 4_p
CVI NNP 4_p
) ) 4_p
832 CD 4_p
patients NNS 4_p
stratified VBN 4_p
by IN 4_p
CEAP NNP 4_p
classification NN 4_p
. . 4_p

300 CD N
patients NNS N
with IN N
C4 NNP N
CVI NNP N
, , N
119 CD N
patients NNS N
with IN N
C5 NNP N
CVI NNP N
, , N
and CC N
413 CD N
patients NNS N
with IN N
C6 NNP N
CVI NNP N
. . N

92 CD 4_p
patients NNS 4_p
with IN 4_p
C4 NNP 4_p
disease NN 4_p
92 CD N
randomized VBD N
patients NNS N
with IN N
C4 NNP N
disease NN N
832 CD N
patients NNS N
-DOCSTART- -X- O O 1553169

infertility NN 4_p
and CC N
endometriosis NN 4_p
surgery NN N
. . N

Sixty-three JJ 3_p
infertility NN 4_p
patients NNS N
-DOCSTART- -X- O O 16942963

fear NN 4_p
of IN 4_p
flying VBG 4_p
. . N

fear NN 4_p
of IN 4_p
flying VBG 4_p
( ( 4_p
FOF NNP 4_p
) ) N
Eighty-three JJ 3_p
participants NNS 3_p
with IN 4_p
FOF NNP 4_p
Seventy-five JJ 3_p
participants NNS 3_p
, , N
25 CD 3_p
per IN 3_p
group NN 3_p
, , N
completed VBD N
the DT N
study NN N
. . N

Twenty-three JJ 3_p
WL JJ N
participants NNS N
completed VBD N
randomly RB N
assigned VBN N
treatment NN N
-DOCSTART- -X- O O 2023746

traumatic JJ 4_p
hyphema NN 4_p
. . N

One CD 3_p
hundred VBD 3_p
twelve NN 3_p
patients NNS N
who WP N
sustained VBD 4_p
hyphema NN 4_p
after IN 4_p
blunt NN 4_p
trauma NN 4_p
were VBD N
enrolled VBN N
Blacks NNS N
comprised VBD N
53 CD N
% NN N
of IN N
the DT N
study NN N
population NN N
, , N
and CC N
the DT N
mean JJ 1_p
age NN 1_p
of IN 1_p
the DT 1_p
patients NNS 1_p
was VBD 1_p
23.5 CD 1_p
years NNS 1_p
. . N

-DOCSTART- -X- O O 11965204

of IN N
type NN 4_p
1 CD 4_p
diabetic JJ 4_p
subjects NNS N
. . N

Referral JJ N
clinics NNS N
in IN N
27 CD N
academic JJ N
centers NNS N
. . N

PATIENTS NNP N
Type NNP N
1 CD N
diabetics NNS 4_p
. . N

males NNS 2_p
and CC N
females NNS 2_p
, , N
tobacco NN N
users NNS N
Female JJ N
smokers NNS N
male JJ N
tobacco NN N
users NNS N
female JJ N
and CC N
male JJ N
tobacco NN N
users NNS N
. . N

former JJ N
tobacco NN N
users NNS N
-DOCSTART- -X- O O 25542821

uterine JJ 4_p
fibroids NNS 4_p
. . 4_p

symptomatic JJ 4_p
uterine JJ 4_p
fibroids NNS 4_p
. . 4_p

Gynecology NNP 4_p
centers NNS 4_p
. . 4_p

total NN N
of IN N
451 CD 3_p
patients NNS N
with IN N
symptomatic JJ 4_p
uterine JJ 4_p
fibroid NN 4_p
( ( 4_p
s NN 4_p
) ) 4_p
and CC 4_p
heavy JJ 4_p
bleeding NN 4_p
. . N

-DOCSTART- -X- O O 16804044

patients NNS N
on IN N
thyroid JJ 4_p
hormone NN 4_p
replacement NN 4_p
. . N

697 CD 3_p
patients NNS N
on IN N
thyroid JJ 4_p
hormone NN 4_p
replacement NN 4_p
therapy NN 4_p
at IN N
entry NN N
to TO N
a DT N
randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
combined JJ N
T NNP N
( ( N
4 CD N
) ) N
and CC N
T NNP N
( ( N
3 CD N
) ) N
replacement NN N
therapy NN N
. . N

All DT N
patients NNS N
were VBD N
on IN N
100 CD N
mug NN N
or CC N
more JJR N
T NNP N
( ( N
4 CD N
) ) N
. . N

treated JJ N
hypothyroid NN 4_p
patients NNS N
-DOCSTART- -X- O O 18609155

diabetic JJ 4_p
gastroparesis NN 4_p
. . N

seven CD 3_p
diabetic JJ 4_p
patients NNS N
with IN N
medically RB 4_p
refractory JJ 4_p
gastroparesis NN 4_p
. . N

-DOCSTART- -X- O O 23952636

patients NNS N
with IN N
amyotrophic JJ 4_p
lateral JJ 4_p
sclerosis NN 4_p
. . N

ALS NNP 4_p
. . N

-DOCSTART- -X- O O 15463829

three-centre JJ N
study NN N
investigated VBD N
the DT N
preference NN N
of IN N
cystic JJ 4_p
fibrosis NN 4_p
( ( 4_p
CF NNP 4_p
) ) 4_p
patients NNS N
Fifty-nine JJ 3_p
patients NNS N
with IN N
a DT N
mean JJ 1_p
age NN 1_p
10 CD 1_p
years NNS 1_p
( ( 1_p
range VB 1_p
3-17 NNP 1_p
) ) 1_p
51 CD 3_p
of IN 3_p
54 CD 3_p
patients NNS N
who WP N
completed VBD N
the DT N
study NN N
CF NNP 4_p
children NNS 1_p
-DOCSTART- -X- O O 15051597

middle-aged JJ N
men NNS 2_p
and CC N
women NNS 2_p
. . N

middle-aged JJ N
men NNS N
and CC N
women NNS N
. . N

Men NNP N
and CC N
women NNS N
aged VBN N
40-65 JJ 1_p
y NN 1_p
( ( N
n JJ N
= NNP N
38 CD N
) ) N
underwent NN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
, , N
crossover JJ N
trial NN N
of IN N
treatment NN N
with IN N
0.7 CD N
g NNS N
DHA/d NNP N
for IN N
3 CD N
mo NNS N
. . N

middle-aged JJ N
men NNS N
and CC N
women NNS N
. . N

-DOCSTART- -X- O O 14670288

patients NNS 4_p
with IN 4_p
respiratory JJ 4_p
allergies NNS 4_p
. . 4_p

Adult NNP 4_p
and CC 4_p
pediatric JJ 4_p
patients NNS 4_p
with IN 4_p
allergic JJ 4_p
rhinoconjunctivitis NN 4_p
and/or NN 4_p
asthma NN 4_p
were VBD 4_p
included VBN 4_p
in IN 4_p
the DT 4_p
study NN 4_p
. . 4_p

Ten CD N
subjects VBZ N
Forty-three JJ N
subjects NNS N
patients NNS N
with IN N
respiratory JJ N
allergies NNS N
-DOCSTART- -X- O O 24910215

A NNP N
total NN N
of IN N
64 CD 3_p
patients NNS N
, , N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

They PRP N
were VBD N
considered VBN N
eligible JJ N
if IN N
they PRP N
had VBD N
; : N
unstable JJ N
extra-articular JJ N
distal JJ N
radius NN N
fractures NNS N
and CC N
simple JJ N
intra-articular JJ N
distal JJ N
radius NN N
fractures NNS 4_p
suitable JJ 4_p
for IN N
closed JJ N
reduction NN N
( ( N
AO NNP N
types NNS N
; : N
A2.2 NNP N
, , N
A2.3 NNP N
, , N
A3.1 NNP N
C2.1 NNP N
, , N
C2.2 NNP N
) ) N
. . N

Patients NNS N
in IN N
group NN N
Group NNP N
1 CD N
group NN N
2 CD N
complications NNS N
occurred VBD N
group NN N
1 CD N
and CC N
. . N

Follow-up NN N
time NN N
of IN N
12 CD N
months NNS N
-DOCSTART- -X- O O 2087856

selected VBN 4_p
patients NNS 4_p
following VBG 4_p
aortocoronary JJ 4_p
bypass NN 4_p
operation NN 4_p
] NNP N
Two CD 3_p
groups NNS 3_p
of IN 3_p
9 CD 3_p
male JJ 2_p
patients NNS N
( ( N
age NN 1_p
: : 1_p
59 CD 1_p
+/- JJ 1_p
4 CD 1_p
and CC 1_p
56 CD 1_p
+/- JJ 1_p
6 CD 1_p
years NNS 1_p
, , 1_p
resp NN 1_p
. . N

) ) N
each DT N
trained VBN N
on IN N
bicycle NN N
ergometer JJ N
start NN N
on IN N
post-operative JJ N
days NNS N
24 CD N
and CC N
26 CD N
, , N
resp NN N
. . N

-DOCSTART- -X- O O 9547958

amnesics VB 4_p
memory-impaired JJ 4_p
acquired VBD 4_p
brain-injured JJ 4_p
persons NNS N
Forty NNP 3_p
individuals NNS N
comprised VBD N
the DT N
simulating NN N
and CC N
control NN N
group NN N
Twenty CD 3_p
memory-impaired JJ 4_p
patients NNS N
, , N
all DT N
of IN N
whom WP N
had VBD N
been VBN N
diagnosed VBN N
as IN N
suffering VBG N
from IN N
a DT N
memory NN 4_p
impairment NN 4_p
following VBG N
acquired VBD 4_p
brain NN 4_p
damage NN 4_p
, , 4_p
participated VBD N
as IN N
the DT N
memory-impaired JJ N
control NN N
group NN N
. . N

-DOCSTART- -X- O O 12108617

children NNS 4_p
with IN 4_p
autism NN 4_p
. . 4_p

autistic JJ N
spectrum NN N
disorders NNS N
Parent NN N
and CC N
teacher NN N
data NNS N
from IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
eight CD N
male JJ N
children NNS N
-DOCSTART- -X- O O 22392415

patients NNS 4_p
with IN 4_p
autistic JJ 4_p
disorders NNS 4_p
. . 4_p

Autism NNP 4_p
Spectrum NNP 4_p
Disorder NNP 4_p
. . 4_p

Forty-seven JJ 3_p
outpatients NNS N
with IN N
a DT N
DSM-IV-TR JJ 4_p
diagnosis NN 4_p
of IN 4_p
autism NN 4_p
ages NNS 1_p
between IN 1_p
4 CD 1_p
and CC 1_p
12 CD 1_p
years NNS 1_p
patients NNS 4_p
under IN 4_p
30 CD 4_p
kg NNS 4_p
patients NNS 4_p
above IN 4_p
30 CD 4_p
kg NNS 4_p
. . 4_p

-DOCSTART- -X- O O 15965311

volunteers NNS N
. . N

Volunteer NNP N
subjects NNS N
( ( N
N NNP N
= NNP N
37 CD N
) ) N
subjects NNS 4_p
taking VBG 4_p
placebo NN 4_p
. . 4_p

-DOCSTART- -X- O O 7655889

Parkinson NNP 4_p
's POS 4_p
disease NN 4_p
. . N

Parkinson NNP 4_p
's POS 4_p
disease NN 4_p
Parkinson NNP 4_p
's POS 4_p
disease NN 4_p
subjects NNS N
and CC N
age-matched JJ N
controls NNS N
. . N

Parkinson NNP 4_p
's POS 4_p
disease NN 4_p
patients NNS N
-DOCSTART- -X- O O 9225710

patient NN 4_p
with IN 4_p
autism NN 4_p
. . 4_p

patient NN N
with IN N
autism NN N
and CC N
hyperactivity NN N
disorder NN N
in IN N
a DT N
private JJ N
physician NN N
, , N
office-based JJ N
practice NN N
. . N

A DT N
child NN N
with IN N
autism NN N
, , N
which WDT N
was VBD N
diagnosed VBN N
by IN N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
Third NNP N
Edition NNP N
, , N
Revised VBN N
, , N
criteria NNS N
, , N
was VBD N
studied VBN N
. . N

autism NN N
-DOCSTART- -X- O O 18849616

children NNS N
with IN N
bronchial JJ N
asthma NN N
and CC N
mite NN N
allergy NN N
. . N

children NNS N
with IN N
allergic JJ N
asthma NNS N
due JJ N
to TO N
house NN N
dust NN N
mite NN N
allergy NN N
. . N

34 CD N
children NNS N
( ( N
6-18 CD N
years NNS N
) ) N
with IN N
allergic JJ N
asthma NNS N
cluster VB N
( ( N
n JJ N
= NNP N
22 CD N
) ) N
classic JJ 4_p
SIT NNP 4_p
( ( 4_p
n JJ 4_p
= NNP 4_p
12 CD 4_p
) ) 4_p
. . 4_p

children NNS N
. . N

-DOCSTART- -X- O O 22648717

children NNS 1_p
with IN N
cystic JJ 4_p
fibrosis NN 4_p
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN N
CF NNP 4_p
. . N

44 CD 3_p
CF NNP N
patients NNS N
( ( N
aged VBN 1_p
7-19 CD 1_p
y NN 1_p
; : N
20 CD 2_p
males NNS 2_p
) ) N
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
magnesium NN N
( ( N
n JJ N
= VBZ N
22 CD 3_p
; : N
300 CD N
mg/d NN N
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
22 CD 3_p
) ) N
for IN N
8 CD N
wk NN N
with IN N
a DT N
4-wk JJ N
washout NN N
period NN N
between IN N
trials NNS N
. . N

-DOCSTART- -X- O O 9430799

healthy JJ N
young JJ N
adults NNS 1_p
. . N

nine CD 3_p
healthy JJ N
young JJ N
volunteers NNS N
. . N

-DOCSTART- -X- O O 2228570

inpatient JJ 4_p
alcoholics NNS 4_p
. . 4_p

inpatient JJ 4_p
alcoholics NNS 4_p
with IN 4_p
nursing NN 4_p
home NN 4_p
residents NNS 4_p
( ( 4_p
NHRs NNP 4_p
) ) 4_p
Fifty NNP 3_p
alcoholic JJ 3_p
inpatients NNS 4_p
were VBD 4_p
randomly RB 4_p
assigned VBN 4_p
to TO 4_p
the DT 4_p
PALS NNP 4_p
program NN 4_p
( ( 4_p
n JJ 4_p
= NNP 4_p
25 CD 4_p
) ) 4_p
or CC 4_p
to TO 4_p
the DT 4_p
library NN 4_p
for IN 4_p
free JJ 4_p
reading NN 4_p
time NN 4_p
( ( 4_p
n JJ 4_p
= NNP 4_p
25 CD 4_p
) ) 4_p
. . N

-DOCSTART- -X- O O 16859579

Adjuvant NNP 4_p
subcutaneous JJ 4_p
interleukin-2 NN 4_p
in IN 4_p
patients NNS 4_p
with IN 4_p
resected JJ 4_p
renal JJ 4_p
cell NN 4_p
carcinoma NN 4_p
: : 4_p
patients NNS 4_p
with IN 4_p
resected JJ 4_p
renal JJ 4_p
cell NN 4_p
carcinoma NN 4_p
( ( 4_p
RCC NNP 4_p
) ) 4_p
at IN 4_p
high JJ 4_p
risk NN 4_p
for IN 4_p
recurrent JJ 4_p
disease NN 4_p
( ( 4_p
TNM NNP 4_p
stages VBZ 4_p
III NNP 4_p
and CC 4_p
IV NNP 4_p
resected VBD 4_p
distant JJ 4_p
metastases NNS 4_p
) ) 4_p
. . 4_p

Patients NNPS 4_p
with IN 4_p
surgically RB 4_p
resected VBN 4_p
locally RB 4_p
advanced JJ 4_p
( ( 4_p
T3-4 CD 4_p
or CC 4_p
N1-2 NNP 4_p
) ) 4_p
or CC 4_p
metastatic JJ 4_p
RCC NNP 4_p
Forty-one JJ 1_p
patients NNS 1_p
were VBD 1_p
entered VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
and CC 1_p
40 CD 1_p
were VBD 1_p
evaluable JJ 1_p
for IN 1_p
toxicity NN 1_p
. . 1_p

patients NNS 4_p
with IN 4_p
surgically RB 4_p
resected VBN 4_p
RCC NNP 4_p
at IN 4_p
high JJ 4_p
risk NN 4_p
of IN 4_p
recurrence NN 4_p
. . 4_p

-DOCSTART- -X- O O 9411221

patients NNS N
resuscitated VBN N
from IN N
near-fatal JJ N
ventricular JJ N
arrhythmias NN N
. . N

patients NNS N
who WP N
had VBD N
been VBN N
resuscitated VBN N
from IN N
near-fatal JJ N
ventricular JJ N
fibrillation NN N
or CC N
who WP N
had VBD N
undergone JJ N
cardioversion NN N
from IN N
sustained VBN N
ventricular JJ N
tachycardia NN N
. . N

Patients NNS N
with IN N
ventricular JJ N
tachycardia NN N
also RB N
had VBD N
either CC N
syncope NN N
or CC N
other JJ N
serious JJ N
cardiac NN N
symptoms NNS N
, , N
along IN N
with IN N
a DT N
left JJ N
ventricular JJ N
ejection NN N
fraction NN N
of IN N
0.40 CD N
or CC N
less JJR N
. . N

Of IN N
1016 CD N
patients NNS N
( ( N
45 CD N
percent NN N
of IN N
whom WP N
had VBD N
ventricular JJ N
fibrillation NN N
, , N
and CC N
55 CD N
percent NN N
ventricular JJ N
tachycardia NN N
) ) N
, , N
507 CD N
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
with IN N
implantable JJ N
cardioverter-defibrillators NNS N
and CC N
509 CD N
to TO N
antiarrhythmic-drug JJ N
therapy NN N
. . N

survivors NNS N
of IN N
ventricular JJ N
fibrillation NN N
or CC N
sustained VBN N
ventricular JJ N
tachycardia NN N
causing VBG N
severe JJ N
symptoms NNS N
-DOCSTART- -X- O O 7527453

intermediate-grade JJ 4_p
and CC 4_p
high-grade JJ 4_p
non-Hodgkin NN 4_p
's POS 4_p
lymphoma NN 4_p
in IN 4_p
first JJ 4_p
complete JJ 4_p
remission NN 4_p
: : 4_p
a DT N
study NN N
of IN N
464 CD 3_p
patients NNS N
. . N

patients NNS 4_p
with IN 4_p
aggressive JJ 4_p
non-Hodgkin NN 4_p
's POS 4_p
lymphoma NN 4_p
. . N

intermediate- JJ N
and CC N
high-grade JJ N
non-Hodgkin NN N
's POS N
lymphoma NN N
. . N

Patients NNPS N
were VBD N
younger JJR 1_p
than IN 1_p
55 CD 1_p
years NNS 1_p
and CC N
had VBD N
at IN N
least JJS N
one CD N
adverse JJ N
prognostic JJ N
factor NN N
. . N

464 CD 3_p
patients NNS 3_p
-DOCSTART- -X- O O 20506785

upper JJ 4_p
lobectomy NN 4_p
-- : 4_p
randomized VBD 4_p
Sixty NNP N
patients NNS N
who WP N
underwent VBP N
upper JJ N
lobectomy NN N
30 CD 4_p
patients NNS 4_p
-DOCSTART- -X- O O 9718870

a DT N
report NN N
on IN N
218 CD 3_p
patients NNS N
with IN N
a DT N
median JJ N
follow-up NN N
of IN N
eight CD N
years NNS N
. . N

patients NNS N
with IN N
advanced JJ 4_p
stage NN 4_p
Hodgkin NNP 4_p
's POS 4_p
disease NN 4_p
( ( 4_p
HD NNP 4_p
) ) 4_p
, , N
as RB N
well RB N
as IN N
in IN N
early JJ 4_p
stage NN 4_p
patients NNS 4_p
with IN 4_p
systemic JJ 4_p
symptoms NNS 4_p
and/or VBP 4_p
bulky JJ 4_p
disease NN 4_p
. . N

218 CD 3_p
patients NNS N
with IN N
previously RB N
untreated VBN N
HD NNP 4_p
entered VBD N
this DT N
study NN N
: : N
106 CD 3_p
patients NNS 3_p
in IN N
arm NN 4_p
A NNP 4_p
( ( 4_p
ABVD/MOPP NNP 4_p
) ) N
and CC N
112 CD 3_p
in IN N
arm NN 4_p
B NNP 4_p
( ( 4_p
ABVD/OPP NNP 4_p
) ) 4_p
. . 4_p

patients NNS N
who WP N
entered VBD N
the DT N
ABVD/MOPP NNP 4_p
arm NN 4_p
. . N

-DOCSTART- -X- O O 2694356

shoulder NN 4_p
tendonitis NN 4_p
. . 4_p

30 CD 3_p
patients NNS N
with IN 4_p
supraspinatus NN 4_p
or CC 4_p
bicipital JJ 4_p
tendonitis NN 4_p
were VBD N
randomly RB N
allocated VBN N
-DOCSTART- -X- O O 24018545

children NNS 1_p
and CC N
adolescents NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
and CC 4_p
comorbid VB 4_p
attention-deficit/hyperactivity JJ 4_p
disorder NN 4_p
symptoms NNS 4_p
. . N

-DOCSTART- -X- O O 22040533

moderate JJ 4_p
to TO 4_p
severe VB 4_p
COPD NNP 4_p
. . N

in IN N
subjects NNS N
with IN N
symptomatic JJ N
moderate NN N
to TO N
severe VB N
COPD NNP N
study NN N
. . N

Subjects VBZ N
40 CD N
years NNS N
or CC N
older JJR N
with IN N
cigarette NN N
smoking VBG N
history NN N
≥10 JJ N
pack-years NNS N
and CC N
with IN N
the DT N
diagnosis NN N
of IN N
COPD NNP N
and CC N
post-bronchodilator NN N
FEV NNP N
( ( N
1 CD N
) ) N
≥40 NN N
to TO N
≤ VB N
80 CD N
% NN N
of IN N
predicted VBN N
normal JJ N
and CC N
FEV NNP N
( ( N
1 CD N
) ) N
/FVC NN N
of IN N
≤0.70 NN N
were VBD N
addition NN N
of IN N
FSC NNP N
to TO N
subjects NNS N
-DOCSTART- -X- O O 24982504

after IN N
matched VBN N
donor NN 4_p
allogeneic NN 4_p
HCT NNP 4_p
. . N

matched VBN N
, , N
related VBN N
donor NN N
( ( N
MRD NNP N
) ) N
allogeneic VBZ N
hematopoietic JJ N
cell NN N
transplantation NN N
( ( N
HCT NNP N
) ) N
recipients NNS N
. . N

304 CD 3_p
randomized JJ N
subjects NNS N
. . N

after IN N
MRD NNP N
HCT NNP N
. . N

-DOCSTART- -X- O O 2181434

population-based JJ N
cancer NN 4_p
registry NN N
United NNP N
States NNPS N
population-based JJ N
registries NNS N
postmenopausal JJ 4_p
women NNS N
with IN N
node JJ 4_p
negative JJ 4_p
breast NN 4_p
cancer NN 4_p
. . 4_p

140 CD 3_p
subjects NNS N
in IN N
this DT N
single JJ N
institution NN N
study NN N
, , N
the DT N
Wisconsin NNP N
Cancer NNP 4_p
Reporting NNP N
System NNP N
( ( N
WCRS NNP N
) ) N
, , N
a DT N
population-based JJ N
cancer NN 4_p
registry NN N
, , N
was VBD N
used VBN N
. . N

3,585 CD N
women NNS N
who WP N
met VBD N
the DT N
study NN N
criteria NNS N
with IN N
respect NN N
to TO N
age NN N
, , N
stage NN N
, , N
and CC N
previous JJ N
therapy NN N
. . N

women NNS 2_p
eligible JJ N
and CC N
interested JJ N
women NNS N
. . N

140 CD 3_p
women NNS N
were VBD N
entered VBN N
on IN N
study NN N
. . N

population-based JJ N
cancer NN 4_p
registry NN N
-DOCSTART- -X- O O 1707797

Half PDT N
the DT N
subjects NNS N
were VBD N
instructed VBN N
not RB 4_p
to TO 4_p
blink VB 4_p
-DOCSTART- -X- O O 12462350

children NNS N
with IN N
autism NN N
. . N

children NNS N
with IN N
autism NN N
, , N
and CC N
2 CD N
) ) N
to TO N
assess VB N
the DT N
feasibility NN N
of IN N
home NN N
recordings NNS N
using VBG N
time-lapse JJ N
videosomnography NN N
in IN N
children NNS N
with IN N
autism NN N
. . N

Participants NNS N
were VBD N
a DT N
subset NN N
of IN N
subjects NNS N
from IN N
two CD N
double JJ N
blind NN N
, , N
placebo-control NN N
, , N
multi-center JJ N
clinical JJ N
trials NNS N
. . N

enrolled VBD N
some DT N
of IN N
the DT N
children NNS N
from IN N
each DT N
of IN N
the DT N
two CD N
trials NNS N
-DOCSTART- -X- O O 6390445

Treatment NN N
of IN N
bladder NN 4_p
cancer NN 4_p
with IN N
intravesical JJ N
instillation NN N
of IN N
adriamycin NN N
. . N

-DOCSTART- -X- O O 10213554

risk NN 4_p
of IN 4_p
cardiovascular JJ 4_p
events NNS 4_p
. . 4_p

-DOCSTART- -X- O O 2285166

vascular JJ 4_p
tonic JJ 4_p
drug NN 4_p
] NN 4_p
-DOCSTART- -X- O O 8785132

middle JJ 4_p
ear NN 4_p
surgery NN 4_p
. . N

30 CD 3_p
patients NNS N
middle VB N
ear JJ N
surgery NN N
using VBG N
induced JJ N
hypotension NN 4_p
to TO N
a DT N
mean JJ N
arterial JJ N
pressure NN N
of IN N
55 CD N
mm NN N
Hg NNP N
. . N

middle JJ N
ear NN N
surgery NN N
-DOCSTART- -X- O O 1350581

infantile JJ 4_p
autism NN 4_p
: : 4_p
infantile JJ 4_p
autism NN 4_p
. . N

9 CD 3_p
children NNS 1_p
with IN N
autism NN 4_p
, , N
likely RB N
severely RB N
mentally RB 4_p
retarded JJ 4_p
. . N

-DOCSTART- -X- O O 1715416

patients NNS N
with IN N
disseminated JJ N
testicular JJ N
tumors NNS N
] VBP N
patients NNS N
with IN N
disseminated JJ N
testicular JJ N
tumors NNS N
. . N

Of IN N
34 CD N
patients NNS N
registered VBD N
, , N
10 CD N
patients NNS N
were VBD N
with IN N
minimal JJ N
disease NN N
in IN N
stages NNS N
IIA NNP N
, , N
IIIO NNP N
and CC N
IIIA NNP N
and CC N
24 CD N
with IN N
extensive JJ N
disease NN N
in IN N
IIB NNP N
, , N
IIIB2 NNP N
and CC N
IIIC NNP N
. . N

Seminomas NNP N
were VBD N
found VBN N
in IN N
10 CD N
patients NNS N
, , N
while IN N
non-seminomatous JJ N
tumors NNS N
in IN N
24 CD N
. . N

-DOCSTART- -X- O O 7946102

patients NNS 4_p
with IN 4_p
HIV NNP 4_p
infection NN 4_p
A NNP 4_p
total NN 4_p
of IN 4_p
121 CD 3_p
HIV-infected JJ 4_p
patients NNS 4_p
with IN 4_p
CD4+ NNP 4_p
cell NN 4_p
counts VBZ 4_p
< CD 4_p
or CC 4_p
= VB 4_p
200 CD 4_p
x JJ 4_p
10 CD 4_p
( ( 4_p
6 CD 4_p
) ) 4_p
/l NN 4_p
or CC 4_p
an DT 4_p
AIDS JJ 4_p
diagnosis NN 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 20934759

in IN N
elderly JJ 1_p
subjects NNS 1_p
. . N

Fifty-seven CD 3_p
elderly JJ 1_p
females NNS 2_p
who WP N
live VBP N
independently RB N
( ( 1_p
age NN 1_p
74.8±5.6 CD 1_p
years NNS 1_p
) ) N
were VBD N
recruited VBN N
-DOCSTART- -X- O O 15353873

patients NNS N
with IN N
essential JJ 4_p
hypertension NN 4_p
. . N

42 CD 3_p
patients NNS N
( ( N
27 CD 3_p
males NNS 2_p
, , N
15 CD 3_p
females NNS 2_p
) ) N
. . N

hypertensive JJ 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 16108749

children NNS N
undergoing VBG N
laparoscopy NN N
. . N

50 CD N
children NNS N
undergoing JJ N
laparoscopy NN N
for IN N
diagnostic JJ N
and CC N
therapeutic JJ N
purposes NNS N
. . N

Their PRP$ N
ages NNS N
ranged VBN N
from IN N
3 CD N
to TO N
13 CD N
years NNS N
, , N
and CC N
all DT N
belonged VBD N
to TO N
American NNP N
Society NNP N
of IN N
Anesthesiologists NNP N
( ( N
ASA NNP N
) ) N
class NN N
I PRP N
or CC N
II NNP N
. . N

-DOCSTART- -X- O O 9581739

50 CD 3_p
consecutive JJ N
patients NNS N
. . N

Each DT N
patient NN N
98 CD 3_p
% NN 3_p
of IN N
patients NNS N
had VBD N
low JJ N
( ( N
< JJ N
15 CD N
J NNP N
) ) N
thresholds VBZ N
dual-coil JJ N
lead NN N
system NN N
88 CD 4_p
% NN 4_p
of IN N
patients NNS N
with IN N
the DT N
single-coil JJ N
configuration NN N
-DOCSTART- -X- O O 16647616

antihypertensive JJ N
treatment NN N
. . N

patients NNS N
whose WP$ N
untreated JJ N
daytime JJ N
diastolic JJ N
ambulatory NN N
BP NNP N
averaged VBD N
> NNP N
or CC N
= $ N
85 CD N
mm NN N
Hg NNP N
Ninety-eight JJ N
patients NNS N
completed VBD N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 19523697

elderly JJ 4_p
patients NNS 4_p
after IN 4_p
a DT 4_p
stay NN 4_p
in IN 4_p
a DT 4_p
medical JJ 4_p
intensive JJ 4_p
care NN 4_p
unit NN 4_p
( ( 4_p
ICU NNP 4_p
) ) 4_p
: : 4_p
elderly JJ 1_p
patients NNS N
after IN N
a DT N
stay NN 4_p
in IN 4_p
a DT 4_p
medical JJ 4_p
intensive JJ 4_p
care NN 4_p
unit NN 4_p
( ( 4_p
ICU NNP 4_p
) ) N
45 CD 3_p
patients NNS N
aged VBN 1_p
> JJ 1_p
or=75 CD 1_p
years NNS 1_p
. . N

patients NNS N
elderly JJ 1_p
patients NNS 1_p
-DOCSTART- -X- O O 6189335

normal JJ 4_p
human JJ 4_p
facial JJ 4_p
skin NN 4_p
flora NN 4_p
. . N

Eighteen JJ 3_p
volunteers NNS N
-DOCSTART- -X- O O 9777899

frail JJ 4_p
older NN 1_p
adults NNS 1_p
: : N
frail JJ 4_p
older JJR 1_p
people NNS 1_p
living VBG N
in IN N
the DT N
community NN N
. . N

Seattle NNP N
total NN N
of IN N
201 CD 3_p
chronically RB N
ill JJ N
older JJR N
adults NNS N
seniors NNS N
aged VBD N
70 CD 1_p
and CC 1_p
older JJR 1_p
recruited VBN N
through IN N
medical JJ N
practices NNS N
. . N

101 CD 3_p
intervention NN N
participants NNS N
chronically RB 4_p
ill JJ 4_p
older JJR 1_p
adults NNS 1_p
. . N

-DOCSTART- -X- O O 9231814

patients NNS N
with IN N
hypertension NN 4_p
: : N
patients NNS N
with IN N
mild JJ 4_p
or CC 4_p
moderate JJ 4_p
hypertension NN 4_p
who WP N
received VBD N
nifedipine JJ N
with IN N
active JJ N
drug NN N
controls NNS N
. . N

MEDLARS NNP N
search NN N
using VBG N
the DT N
MeSH NNP N
heading NN N
" NNP N
hypertension NN N
" NN N
and CC N
the DT N
text NN N
word NN N
" NNP N
nifedipine NN N
" NN N
to TO N
identify VB N
all DT N
articles NNS N
that WDT N
were VBD N
published VBN N
between IN N
1966 CD N
and CC N
August NNP N
1995 CD N
in IN N
English NNP N
, , N
French NNP N
, , N
German NNP N
, , N
Italian NNP N
, , N
and CC N
Spanish JJ N
languages NNS N
and CC N
that DT N
involved VBD N
human JJ N
subjects NNS N
. . N

Review NNP N
of IN N
1880 CD N
citations NNS N
revealed VBD N
98 CD N
randomized VBN N
controlled VBD N
clinical JJ N
trials NNS N
that WDT N
met VBD N
protocol NN N
criteria NNS N
. . N

Articles NNS N
were VBD N
extracted VBN N
independently RB N
by IN N
two CD N
doctors NNS N
who WP N
were VBD N
blinded VBN N
for IN N
author NN N
, , N
institution NN N
, , N
and CC N
treatment NN N
regimen NNS N
, , N
using VBG N
a DT N
structured VBN N
, , N
pretested VBN N
extraction NN N
form NN N
. . N

-DOCSTART- -X- O O 24658964

Older JJR 1_p
patients NNS N
with IN N
chronic JJ 4_p
myeloid NN 4_p
leukemia NN 4_p
( ( N
≥65 CD N
years NNS N
) ) N
than IN N
younger JJR N
patients NNS N
: : N
in IN N
older JJR N
patients NNS N
with IN N
chronic JJ N
myeloid NN N
leukemia NN N
in IN N
chronic JJ N
phase NN N
randomized JJ N
five-arm JJ N
treatment NN N
optimization NN N
study NN N
in IN N
newly RB N
diagnosed VBN N
BCR-ABL-positive JJ N
chronic JJ N
myeloid NN N
leukemia NN N
in IN N
chronic JJ N
phase NN N
. . N

Patients NNS N
randomized VBD N
to TO N
imatinib VB N
400 CD N
mg/day NN N
( ( N
IM400 NNP N
) ) N
or CC N
imatinib $ N
800 CD N
mg/day NN N
( ( N
IM800 NNP N
) ) N
and CC N
stratified VBD N
according VBG N
to TO N
age NN N
( ( N
≥65 CD N
years NNS N
vs. FW N
< RB N
65 CD N
years NNS N
) ) N
tolerability NN N
. . N

A DT N
total NN N
of IN N
828 CD N
patients NNS N
were VBD N
randomized VBN N
IM800 NNP N
. . N

Seven NNP N
hundred VBD N
eighty-four JJ N
patients NNS N
were VBD N
evaluable JJ N
( ( N
IM400 NNP N
, , N
382 CD N
; : N
IM800 NNP N
, , N
402 CD N
) ) N
. . N

One CD 3_p
hundred VBD 3_p
ten JJ 3_p
patients NNS N
( ( N
29 CD N
% NN N
) ) N
on IN N
IM400 NNP N
and CC N
83 CD N
( ( N
21 CD N
% NN N
) ) N
on IN N
IM800 NNP N
were VBD N
≥65 JJ N
with IN N
which WDT N
older JJR N
later RBR N
than IN N
younger JJR N
-DOCSTART- -X- O O 21596605

type NN N
2 CD N
diabetic JJ N
patients NNS N
-- : N
but CC N
non-diabetic JJ N
individuals NNS N
. . N

subjects NNS N
included VBN N
in IN N
the DT N
study NN N
came VBD N
from IN N
a DT N
randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
type NN N
2 CD N
diabetes NNS N
. . N

diabetic JJ N
individuals NNS N
non-diabetic JJ N
women NNS N
diabetic JJ N
and CC N
non-diabetic JJ N
populations NNS N
. . N

-DOCSTART- -X- O O 25424398

adolescents NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
and CC N
comorbid NN N
anxiety NN N
. . N

early JJ N
adolescents NNS 1_p
with IN N
high-functioning JJ 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
( ( 4_p
ASDs NNP 4_p
) ) 4_p
and CC N
co-occurring JJ N
anxiety NN N
Thirty-one CD 3_p
children NNS 3_p
( ( 1_p
11-16 CD 1_p
years NNS 1_p
) ) 1_p
with IN N
ASD NNP 4_p
and CC N
clinically RB N
significant JJ N
anxiety NN N
anxious JJ N
youth NN N
with IN N
ASD NNP 4_p
to TO N
early JJ N
adolescents NNS 1_p
. . N

-DOCSTART- -X- O O 10663363

women NNS 2_p
with IN N
established VBN N
postmenopausal NN 4_p
osteoporosis NN 4_p
. . N

postmenopausal JJ 4_p
women NNS 2_p
with IN N
established VBN 4_p
osteoporosis NN 4_p
. . N

80 CD N
study NN N
centers NNS N
in IN N
Europe NNP N
and CC N
Australia NNP N
. . N

Postmenopausal NNP N
women NNS 2_p
( ( N
n JJ 3_p
= NN 3_p
1226 CD 3_p
) ) N
with IN 4_p
two CD 4_p
or CC 4_p
more JJR 4_p
prevalent JJ 4_p
vertebral JJ 4_p
fractures NNS 4_p
severe JJ 4_p
postmenopausal NN 4_p
osteoporosis NN 4_p
women NNS 2_p
with IN 4_p
established VBN 4_p
disease NN 4_p
. . N

-DOCSTART- -X- O O 1319876

12 CD 3_p
healthy JJ 4_p
young JJ 1_p
volunteers NNS N
. . N

-DOCSTART- -X- O O 8210831

randomized JJ N
trial NN N
of IN N
treatments NNS N
for IN N
B NNP 4_p
non-Hodgkin JJ 4_p
lymphoma NN 4_p
. . N

children NNS 1_p
with IN N
B NNP 4_p
non-Hodgkin JJ 4_p
lymphoma NN 4_p
-DOCSTART- -X- O O 22244705

alcohol NN N
dependent JJ N
treatment NN N
sample NN N
. . N

alcohol NN N
problems NNS N
. . N

posttreatment NN N
levels NNS N
of IN N
alcohol NN N
use NN N
men NNS N
and CC N
women NNS N
( ( N
N=77 NNP N
) ) N
enrolled VBD N
in IN N
a DT N
12-week JJ N
cognitive-behavioral JJ N
intervention NN N
for IN N
alcohol NN N
dependence NN N
. . N

those DT 4_p
seeking VBG 4_p
treatment NN 4_p
for IN 4_p
alcohol NN 4_p
dependence NN 4_p
. . 4_p

-DOCSTART- -X- O O 10356632

dependent JJ 4_p
amphetamine NN 4_p
users NNS N
. . N

dependent JJ 4_p
amphetamine NN 4_p
users NNS N
Amphetamine JJ N
users NNS N
( ( N
n JJ N
= NNP N
19 CD 3_p
) ) N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
, , N
high JJ N
dependence NN N
( ( N
n JJ N
= NNP N
10 CD 3_p
) ) N
and CC N
low JJ N
dependence NN N
( ( N
n JJ N
= NNP N
10 CD 3_p
) ) N
, , N
based VBN N
on IN N
amphetamine JJ N
Severity NNP N
of IN N
Dependence NNP N
Scale NNP N
scores NNS N
, , N
and CC N
compared VBN N
to TO N
an DT N
age-matched JJ N
control NN N
group NN N
( ( N
n JJ N
= NNP N
9 CD 4_p
) ) N
. . N

dependent JJ N
users NNS N
-DOCSTART- -X- O O 24878589

subacute JJ 4_p
stroke NN 4_p
: : 4_p
subacute JJ 4_p
stroke NN 4_p
patients NNS 4_p
. . 4_p

70 CD 3_p
subacute NN N
stroke NN N
patients NNS N
subacute NN 4_p
stroke NN 4_p
-DOCSTART- -X- O O 8966003

condylomata NN N
acuminata NNS N
] RB N
treatment NN N
of IN N
condylomata NN 4_p
acuminata NNS 4_p
. . N

118 CD 3_p
evaluable JJ N
patients NNS N
: : N
32 CD 3_p
in IN N
the DT N
laser-CO2 JJ N
group NN N
, , N
34 CD 3_p
in IN N
the DT N
5-fluorouracil JJ N
group NN N
and CC N
52 CD 3_p
in IN N
the DT N
interferon NN N
group NN N
. . N

-DOCSTART- -X- O O 16719652

double-mediation NN 4_p
model NN 4_p
. . N

relation NN 4_p
between IN 4_p
tradeoff NN 4_p
size NN 4_p
and CC 4_p
conflict NN 4_p
. . N

-DOCSTART- -X- O O 20206437

female JJ 2_p
stress NN 4_p
urinary JJ 4_p
incontinence NN 4_p
: : N
female JJ 2_p
stress NN 4_p
urinary JJ 4_p
incontinence NN 4_p
( ( 4_p
SUI NNP 4_p
) ) 4_p
. . N

Women NNP 2_p
with IN N
urodynamic JJ 4_p
SUI NNP 4_p
were VBD N
enrolled VBN N
Subjects NNPS N
Of IN N
285 CD 3_p
women NNS 2_p
, , N
144 CD 3_p
had VBD N
the DT N
U-type JJ N
method NN N
and CC N
141 CD 3_p
had VBD N
the DT N
H-type JJ N
method NN N
. . N

female JJ N
SUI NNP 4_p
. . N

-DOCSTART- -X- O O 14966713

after IN 4_p
stroke NN 4_p
: : 4_p
Public NNP 4_p
rehabilitation NN 4_p
center NN 4_p
in IN 4_p
France NNP 4_p
. . 4_p

Twenty NNP N
patients NNS N
with IN N
hemiplegia NN N
after IN N
a DT N
single-hemisphere JJ N
stroke NN N
that WDT N
occurred VBD N
at IN N
least JJS N
12 CD N
months NNS N
before IN N
the DT N
study NN N
. . N

All DT N
patients NNS N
completed VBD N
the DT N
program NN N
. . N

-DOCSTART- -X- O O 3303886

early JJ 4_p
recurrent NN 4_p
ischemia NN 4_p
after IN N
non-Q-wave JJ N
myocardial JJ N
infarction NN N
: : N
576 CD 3_p
patients NNS N
with IN N
non-Q-wave JJ 4_p
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
enrolled VBN N
in IN N
the DT N
Diltiazem NNP N
Reinfarction NNP N
Study NNP N
, , N
246 CD N
( ( N
43 CD N
% NN N
) ) N
had VBD N
1 CD N
or CC N
more JJR N
episodes NNS N
of IN N
angina NN N
at IN N
rest NN N
or CC N
with IN N
minimal JJ N
effort NN N
during IN N
10.5 CD N
days NNS N
of IN N
treatment NN N
with IN N
either DT N
diltiazem NN N
( ( N
90 CD N
mg NN N
every DT N
6 CD N
hours NNS N
) ) N
or CC N
placebo NN N
. . N

patients NNS N
with IN N
early JJ 4_p
postinfarction NN 4_p
angina NN 4_p
-DOCSTART- -X- O O 18779477

posterior JJ 4_p
uveitis NN 4_p
noninfectious JJ 4_p
posterior JJ 4_p
uveitis NN 4_p
. . N

0.59-mg JJ N
FA NNP N
intravitreous JJ N
implant NN N
in IN N
110 CD 3_p
patients NNS N
and CC N
the DT N
2.1-mg JJ N
FA NNP N
intravitreous JJ N
implant NN N
in IN N
168 CD 3_p
patients NNS N
. . N

subjects NNS N
with IN N
noninfectious JJ 4_p
posterior JJ 4_p
uveitis NN 4_p
. . N

-DOCSTART- -X- O O 12074271

symptomatic JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
. . N

atrial JJ 4_p
fibrillation NN 4_p
( ( 4_p
AF NNP 4_p
) ) N
Patients NNS N
with IN N
symptomatic JJ 4_p
paroxysmal NN 4_p
or CC N
persistent JJ 4_p
AF NNP 4_p
who WP N
had VBD N
converted VBN N
to TO N
sinus VB 4_p
rhythm NN 4_p
( ( 4_p
SR NNP 4_p
) ) N
Of IN N
the DT N
141 CD 3_p
patients NNS N
from IN N
36 CD 3_p
participating VBG N
centers NNS N
, , N
47 CD 3_p
were VBD 3_p
given VBN 3_p
aprindine NN 3_p
, , N
47 CD 3_p
digoxin NN 3_p
, , N
and CC N
47 CD 3_p
were VBD 3_p
on IN 3_p
placebo NN 3_p
. . N

-DOCSTART- -X- O O 23592849

autism NN 4_p
33 CD 3_p
kindergarten-through-second-grade JJ 1_p
autism NN 4_p
support NN N
classrooms NNS N
and CC N
119 CD 3_p
students NNS N
, , N
aged VBN 1_p
5-8 CD 1_p
years NNS 1_p
in IN N
the DT N
School NNP N
District NNP N
of IN N
Philadelphia NNP N
. . N

Students NNS N
student NN N
. . N

students NNS N
in IN N
Strategies NNP N
for IN N
Teaching NNP N
based VBN N
on IN N
Autism NNP 4_p
Research NNP N
students NNS N
in IN N
Structured NNP N
Teaching NNP N
students NNS N
in IN N
Structured NNP N
Teaching NNP N
students NNS N
in IN N
Strategies NNP N
for IN N
Teaching NNP N
based VBN N
on IN N
Autism NNP 4_p
Research NNP N
-DOCSTART- -X- O O 16311751

Sixty-four JJ 3_p
patients NNS N
with IN N
a DT N
first-time JJ N
sick NN N
leave VBP N
between IN N
3 CD N
and CC N
12 CD N
weeks NNS N
due JJ N
to TO N
low VB 4_p
back RB 4_p
pain NN 4_p
-DOCSTART- -X- O O 605912

chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
. . N

10 CD 3_p
patients NNS N
with IN N
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
patients NNS N
with IN N
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
. . N

-DOCSTART- -X- O O 8292465

patients NNS N
with IN N
mild JJ 4_p
to TO 4_p
moderate VB 4_p
hypertension NN 4_p
. . N

A DT N
total NN N
of IN N
2242 CD 3_p
patients NNS N
with IN N
mild JJ 4_p
to TO 4_p
moderate VB 4_p
hypertension NN 4_p
( ( N
diastolic JJ N
pressure NN N
95-120 CD N
mmHg NN N
) ) N
Patients NNS N
were VBD N
identified VBN N
who WP N
: : N
( ( N
a DT N
) ) N
met VBD N
the DT N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
criteria NNS N
for IN N
first-dose JJ N
hypotension NN N
( ( N
sitting VBG 4_p
or CC 4_p
standing VBG 4_p
systolic JJ 4_p
BP NNP 4_p
< NNP 4_p
100 CD 4_p
mmHg NN 4_p
, , N
or CC N
a DT 4_p
fall NN 4_p
in IN 4_p
systolic JJ 4_p
BP NNP 4_p
> NN 4_p
or CC 4_p
= $ 4_p
20 CD 4_p
mmHg NN 4_p
on IN 4_p
standing VBG 4_p
) ) N
; : N
( ( N
b NN N
) ) N
had VBD N
symptoms NNS 4_p
suggestive JJ 4_p
of IN 4_p
hypotension NN 4_p
; : N
and CC N
( ( N
c NN N
) ) N
met VBD N
the DT N
BP NNP N
criteria NNS N
and CC N
had VBD N
symptoms NNS N
. . N

low-risk JJ 4_p
population NN 4_p
-DOCSTART- -X- O O 3839157

Eastern NNP N
Cooperative NNP N
Oncology NNP N
Group NNP N
patients NNS N
with IN N
metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
. . N

162 CD 3_p
women NNS N
( ( N
90 CD 3_p
premenopausal NN 4_p
and CC N
72 CD 3_p
postmenopausal NN 4_p
) ) N
with IN N
metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
Eastern JJ N
Cooperative NNP N
Oncology NNP N
Group NNP N
( ( N
ECOG NNP N
) ) N
-DOCSTART- -X- O O 7591314

European JJ N
pre-hospital JJ N
thrombolysis NN 4_p
. . N

patients NNS N
with IN N
suspected JJ N
myocardial JJ 4_p
infarction NN 4_p
patients NNS N
with IN N
suspected JJ N
myocardial JJ 4_p
infarction NN 4_p
total NN N
of IN N
5469 CD 3_p
patients NNS 3_p
in IN N
16 CD N
countries NNS N
were VBD N
randomised VBN N
by IN N
198 CD N
mobile JJ N
emergency NN N
units NNS N
to TO N
receive VB N
either DT N
pre-hospital JJ N
treatment NN N
with IN N
anistreplase NN N
, , N
the DT N
thrombolytic JJ N
agent NN N
used VBN N
, , N
followed VBN N
by IN N
placebo NN N
after IN N
hospital JJ N
admission NN N
( ( N
pre-hospital JJ N
group NN N
; : N
2750 CD N
patients NNS N
) ) N
, , N
or CC N
placebo NN N
followed VBN N
by IN N
anistreplase NN N
( ( N
hospital JJ N
group NN N
; : N
2719 CD N
patients NNS N
) ) N
. . N

patients NNS N
with IN N
suspected JJ N
myocardial JJ N
infarction NN N
-DOCSTART- -X- O O 7946254

small JJ 4_p
group NN 4_p
student NN N
interaction NN N
for IN N
children NNS N
with IN N
autism NN N
and CC N
developmental JJ N
disabilities NNS N
. . N

24 CD N
elementary JJ N
age NN N
students NNS N
with IN N
autism NN N
and CC N
developmental JJ N
disabilities NNS N
. . N

-DOCSTART- -X- O O 24007198

psychiatric JJ 4_p
inpatient JJ 4_p
treatment NN 4_p
: : 4_p
patients NNS 4_p
who WP 4_p
receive VBP 4_p
psychiatric JJ 4_p
treatment NN 4_p
. . 4_p

patients NNS N
who WP N
had VBD N
no DT 4_p
pre-discharge JJ 4_p
contact NN 4_p
with IN 4_p
outpatient NN 4_p
services NNS 4_p
discharged VBD N
patients NNS N
who WP N
are VBP N
not RB 4_p
well RB 4_p
linked VBN 4_p
to TO 4_p
their PRP$ 4_p
outpatient NN 4_p
care NN 4_p
networks NNS 4_p
Approximately RB N
160 CD 3_p
patients NNS N
are VBP N
recruited VBN N
in IN N
two CD N
care NN N
units NNS N
at IN N
Psychiatrie-Zentrum NNP N
Hard NNP N
Embrach NNP N
and CC N
two CD N
care NN N
units NNS N
at IN N
Klinik NNP N
Schlosstal NNP N
Winterthur NNP N
. . N

-DOCSTART- -X- O O 17097398

secondarily RB 4_p
infected VBN 4_p
dermatitis NN 4_p
: : 4_p
patients NNS 1_p
with IN 1_p
secondarily RB 1_p
infected VBN 1_p
dermatitis NN 1_p
( ( 1_p
SID NNP 1_p
) ) 1_p
. . 1_p

Patients NNPS 4_p
with IN 4_p
SID NNP 4_p
patients NNS 4_p
with IN 4_p
SID NNP 4_p
-DOCSTART- -X- O O 26606872

Patients NNS N
With IN N
Dysphagia NNP 4_p
With IN 4_p
Medullary NNP 4_p
Infarction NNP 4_p
. . N

patients NNS N
with IN N
dysphagia NN 4_p
with IN 4_p
medullary JJ 4_p
infarction NN 4_p
. . N

Patients NNPS N
with IN N
dysphagia NN 4_p
with IN 4_p
medullary JJ 4_p
infarction NN 4_p
( ( N
N=82 NNP 3_p
) ) N
. . N

for IN 4_p
patients NNS 4_p
with IN 4_p
dysphagia NN 4_p
with IN 4_p
medullary JJ 4_p
infarction NN 4_p
-DOCSTART- -X- O O 21392837

patients NNS 4_p
with IN 4_p
chronic JJ 4_p
heart NN 4_p
failure NN 4_p
: : 4_p
Chronic NNP 4_p
heart NN 4_p
failure NN 4_p
( ( 4_p
CHF NNP 4_p
) ) 4_p
patients NNS 4_p
with IN 4_p
CHF NNP 4_p
CHF NNP 4_p
patient NN 4_p
A NNP N
total NN N
of IN N
120 CD 3_p
patients NNS N
hospitalised VBN N
for IN N
CHF NNP 4_p
-DOCSTART- -X- O O 11136837

women NNS N
with IN N
and CC N
without IN N
heart NN N
disease NN N
: : N
women NNS N
with IN N
a DT N
history NN N
of IN N
coronary JJ N
heart NN N
disease NN N
( ( N
CHD NNP N
) ) N
. . N

women NNS N
with IN N
and CC N
without IN N
CHD NNP N
13 CD N
388 CD N
women NNS N
at IN N
increased VBN N
risk NN N
for IN N
breast NN N
cancer NN N
Cardiovascular JJ N
follow-up NN N
was VBD N
available JJ N
for IN N
13 CD N
194 CD N
women NNS N
, , N
1048 CD N
of IN N
whom WP N
had VBD N
prior RB N
clinical JJ N
CHD NNP N
. . N

women NNS N
with IN N
or CC N
without IN N
heart NN N
disease NN N
-DOCSTART- -X- O O 21830957

nonvalvular JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
. . 4_p

patients NNS N
with IN N
atrial JJ N
fibrillation NN N
double-blind JJ N
trial NN N
, , N
we PRP N
randomly VBP N
assigned VBD N
14,264 CD 3_p
patients NNS 3_p
with IN N
nonvalvular JJ N
atrial JJ N
fibrillation NN N
who WP N
were VBD N
at IN N
increased VBN N
risk NN N
for IN N
stroke NN N
-DOCSTART- -X- O O 16930934

patients NNS N
with IN N
subclinical JJ 4_p
hypothyroidism NN 4_p
. . N

subclinical JJ 4_p
hypothyroidism NN 4_p
( ( N
SH NNP N
) ) N
SH NNP 4_p
patients NNS N
. . N

42 CD 3_p
patients NNS 3_p
( ( N
29 CD 3_p
women NNS 1_p
and CC N
13 CD 3_p
men NNS 1_p
; : N
mean JJ N
age NN N
53.2+/-14.2 JJ 1_p
years NNS N
; : N
body NN N
surface JJ N
area NN N
1.76+/-0.14 JJ N
m2 NN N
) ) N
with IN N
SH NNP 4_p
, , N
as IN N
judged VBN N
by IN N
elevated JJ N
serum NN N
TSH NNP N
levels NNS N
( ( N
> $ N
3.6 CD N
mIU/l NN N
; : N
range NN N
, , N
3.8-12.0 JJ N
) ) N
and CC N
normal JJ N
free JJ N
thyroid NN N
hormones NNS N
( ( N
FT4 NNP N
and CC N
FT3 NNP N
) ) N
and CC N
30 CD N
euthyroid JJ N
volunteer NN N
. . N

Subjects NNS N
with IN N
cardiac NN 4_p
, , 4_p
metabolic NN 4_p
, , 4_p
neurological JJ 4_p
disease NN 4_p
or CC N
any DT N
other JJ N
systemic JJ 4_p
disease NN 4_p
that WDT N
could MD N
affect VB N
autonomic JJ N
activity NN N
were VBD N
excluded VBN N
from IN N
the DT N
study NN N
. . N

Patients NNS N
with IN N
SH NNP 4_p
Patients NNPS N
with IN N
SH NNP 4_p
SH NNP 4_p
patients NNS N
-DOCSTART- -X- O O 10993031

biochemical JJ 4_p
markers NNS 4_p
of IN 4_p
bone NN 4_p
metabolism NN 4_p
and CC 4_p
bone JJ 4_p
mineral JJ 4_p
density NN 4_p
. . 4_p

bone NN 4_p
mineral JJ 4_p
density NN 4_p
and CC 4_p
biochemical JJ 4_p
markers NNS 4_p
of IN 4_p
bone NN 4_p
metabolism NN 4_p
. . 4_p

postmenopausal JJ N
women NNS N
four CD N
treatment NN N
groups NNS N
: : N
hysterectomized VBN N
women NNS N
Women NNS N
with IN N
intact JJ N
uteri NNS N
HRT NNP N
alone RB N
group NN N
( ( N
n=30 NN N
) ) N
HRT NNP N
+ NNP N
T NNP N
group NN N
( ( N
n=27 RB N
) ) N
. . N

The DT N
subjects NNS N
were VBD N
of IN N
similar JJ N
age NN N
( ( N
54.0 CD N
+/- JJ N
0.8 CD N
years NNS N
) ) N
, , N
height VBD N
( ( N
64.0 CD N
+/- JJ N
0.3 CD N
in IN N
) ) N
, , N
weight VBD N
( ( N
157.6 CD N
+/- JJ N
4.2 CD N
lb NN N
) ) N
, , N
and CC N
had VBD N
similar JJ N
baseline NN N
follicle-stimulating NN N
hormone NN N
( ( N
66.4 CD N
+/- JJ N
3.2 CD N
mIU/L NN N
) ) N
, , N
E2 NNP N
( ( N
26.4 CD N
+/- JJ N
1.5 CD N
pg/ml NN N
) ) N
, , N
P4 NNP N
( ( N
0.3 CD N
+/- JJ N
0.1 CD N
ng/ml NN N
) ) N
, , N
total JJ N
T NNP N
( ( N
19.0 CD N
+/- JJ N
1.5 CD N
ng/dL NN N
) ) N
, , N
and CC N
bioavailable JJ N
T NNP N
( ( N
3.7 CD N
+/- JJ N
0.3 CD N
ng/dL NN N
) ) N
levels NNS N
. . N

-DOCSTART- -X- O O 6882809

Sixteen JJ 4_p
males NNS 4_p
and CC 4_p
females NNS 4_p
-DOCSTART- -X- O O 22092038

human JJ N
atherosclerosis NN 4_p
: : N
atherosclerotic JJ 4_p
disease NN 4_p
. . N

human JJ N
atherosclerosis NN 4_p
. . N

biobank NN N
of IN N
aortic JJ 4_p
wall NN 4_p
samples NNS N
from IN N
organ JJ N
donors NNS N
. . N

in IN N
patients NNS N
with IN N
symptomatic JJ N
peripheral JJ N
artery NN N
disease NN N
for IN N
progressive JJ N
human JJ N
atherosclerotic JJ N
disease NN N
-DOCSTART- -X- O O 8616024

multiple JJ 4_p
myeloma NN 4_p
. . N

newly RB N
diagnosed VBN N
multiple JJ 4_p
myeloma NN 4_p
524 CD 3_p
( ( N
90.2 CD N
% NN N
) ) N
of IN N
581 CD 3_p
patients NNS N
enrolled VBN N
in IN N
the DT N
NMSG NNP N
4/90 CD N
completed VBD N
the DT N
first JJ N
questionnaire NN N
, , N
and CC N
484 CD 3_p
( ( N
83.3 CD N
% NN N
) ) N
completed VBD N
all DT N
questionnaires NNS N
given VBN N
to TO N
them PRP N
. . N

-DOCSTART- -X- O O 22965298

minimally RB N
verbal JJ N
children NNS N
with IN N
autism NN N
: : N
3 CD N
to TO N
5 CD N
year NN N
old JJ N
, , N
minimally RB N
verbal JJ N
children NNS N
with IN N
autism NN N
who WP N
were VBD N
attending VBG N
a DT N
non-public JJ N
preschool NN N
. . N

deficits NNS N
in IN N
minimally RB N
verbal JJ N
children NNS N
with IN N
-DOCSTART- -X- O O 19301086

inguinal JJ 4_p
herniorrhaphy NN 4_p
patients NNS N
. . N

patients NNS N
undergoing JJ N
inguinal JJ 4_p
herniorrhaphy NN 4_p
adults NNS 1_p
undergoing VBG N
elective JJ N
, , N
outpatient JJ N
, , N
unilateral JJ 4_p
inguinal JJ 4_p
herniorrhaphy NN 4_p
. . N

Fifty-five JJ 3_p
subjects NNS N
completed VBD N
the DT N
study NN N
. . N

outpatient JJ 4_p
inguinal JJ 4_p
hernia NN 4_p
repair NN N
. . N

-DOCSTART- -X- O O 7174605

autistic JJ 4_p
children NNS 4_p
. . 4_p

autistic JJ N
children NNS N
-DOCSTART- -X- O O 16472720

insula NN 4_p
and CC 4_p
amygdala JJ 4_p
brain NN 4_p
areas NNS 4_p
activated VBN 4_p
by IN N
misleading VBG N
information NN N
during IN 4_p
an DT 4_p
expectancy NN 4_p
period NN 4_p
rostral JJ N
anterior JJ N
cingulate NN N
cortex NN N
( ( N
rACC NN N
) ) N
, , N
orbitofrontal JJ N
cortex NN N
( ( N
OFC NNP N
) ) N
, , N
and CC N
dorsolateral JJ N
prefrontal NN N
cortex NN N
-DOCSTART- -X- O O 25246693

under-five-year-old JJ 1_p
Nigerian JJ N
children NNS N
. . 1_p

747 CD 3_p
children NNS 3_p
< JJ 1_p
5 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
with IN N
uncomplicated JJ 4_p
malaria NNS 4_p
from IN N
six CD N
geographical JJ N
areas NNS N
of IN N
Nigeria NNP N
. . N

anemic JJ 4_p
children NNS 1_p
young JJ 1_p
Nigerian JJ N
children NNS 1_p
. . N

-DOCSTART- -X- O O 9205762

110 CD 4_p
duodenal JJ 4_p
ulcer NN 4_p
patients NNS 4_p
-DOCSTART- -X- O O 25675062

central JJ N
spinal JJ N
stenosis NN N
: : N
lumbar VBP 4_p
spinal JJ 4_p
stenosis NN 4_p
United NNP N
States NNPS N
. . N

120 CD 3_p
patients NNS N
assigned VBN N
to TO N
2 CD N
groups NNS N
. . N

with IN N
lumbar JJ 4_p
central JJ 4_p
spinal JJ 4_p
stenosis NN 4_p
-DOCSTART- -X- O O 25229605

eccentric-exercise-induced JJ 4_p
hamstring NN 4_p
muscle NN 4_p
damage NN 4_p
. . N

Thirty-six NNP 3_p
young JJ 1_p
male NN 2_p
students NNS 1_p
performed VBD 4_p
5 CD 4_p
min NN 4_p
of IN 4_p
jogging NN 4_p
as IN 4_p
a DT 4_p
warm-up JJ 4_p
and CC N
were VBD N
allocated VBN N
to TO N
1 CD N
of IN N
3 CD N
groups NNS N
: : N
3 CD N
min NN N
of IN N
static JJ N
active JJ N
stretching NN N
( ( N
SAS NNP N
) ) N
, , N
3 CD N
min NN N
of IN N
dynamic JJ N
active JJ N
stretching NN N
( ( N
DAS NNP N
) ) N
, , N
or CC N
control NN N
( ( N
CON NNP N
) ) N
. . N

subjects NNS N
performed VBN N
eccentric JJ 4_p
exercise NN 4_p
immediately RB 4_p
after IN 4_p
stretching VBG 4_p
. . N

-DOCSTART- -X- O O 23909380

male JJ N
mink NN N
( ( N
Neovison NNP N
vison NN N
) ) N
. . N

Eighty-six JJ N
male JJ N
mink NN N
were VBD N
exposed VBN N
to TO N
low VB N
( ( N
19 CD N
% NN N
of IN N
ME NNP N
from IN N
CP NNP N
; : N
crude JJ N
protein NN N
) ) N
or CC N
adequate JJ N
( ( N
31 CD N
% NN N
of IN N
ME NNP N
from IN N
CP NNP N
) ) N
protein NN N
provision NN N
in IN N
utero NN N
, , N
and CC N
to TO N
LP NNP N
( ( N
~20 CD N
% NN N
of IN N
ME NNP N
from IN N
CP NNP N
) ) N
or CC N
AP NNP N
( ( N
30-42 CD N
% NN N
of IN N
ME NNP N
from IN N
CP NNP N
) ) N
provision NN N
post-weaning NN N
. . N

mink NN N
-DOCSTART- -X- O O 19590523

patients NNS 4_p
with IN 4_p
primary JJ 4_p
open-angle JJ 4_p
glaucoma NN 4_p
( ( 4_p
POAG NNP 4_p
) ) 4_p
refractory NN 4_p
to TO 4_p
medical JJ 4_p
therapy NN 4_p
. . N

30 CD 3_p
consecutive JJ N
eyes NNS N
-DOCSTART- -X- O O 288173

Bronchial JJ 4_p
carcinoma NN 4_p
. . N

inoperable JJ N
patients NNS N
with IN N
advanced JJ N
disease NN N
. . N

Forty-eight JJ 3_p
bronchial JJ 4_p
carcinoma NN 4_p
patients NNS N
in IN N
clinicoanatomical JJ N
stage NN N
4 CD N
of IN N
the DT N
disease NN N
( ( N
advanced JJ N
disease NN N
) ) N
randomly RB N
assigned VBN N
groups NNS N
-DOCSTART- -X- O O 21324150

patients NNS N
with IN N
high JJ 4_p
normal JJ 4_p
blood NN 4_p
pressure NN 4_p
and/or RB N
high JJ 4_p
normal JJ 4_p
blood NN 4_p
glucose NN 4_p
( ( 4_p
SNAC NNP 4_p
) ) 4_p
: : N
individuals NNS N
with IN N
high JJ 4_p
risk NN 4_p
for IN 4_p
disease NN 4_p
patients NNS N
at IN N
risk NN N
( ( N
ie JJ N
high-normal JJ 4_p
blood NN 4_p
pressure NN 4_p
or CC 4_p
impaired JJ 4_p
glucose JJ 4_p
tolerance NN 4_p
) ) N
. . N

Staged NNP N
Nutrition NNP N
and CC N
Activity NNP N
Counseling NNP N
( ( N
SNAC NNP N
) ) N
study NN N
cardiovascular JJ N
disease NN N
risk NN N
factors NNS N
and CC N
vascular JJ N
function NN N
in IN N
patients NNS N
at IN N
risk NN N
in IN N
primary JJ N
care NN N
. . N

-DOCSTART- -X- O O 3538985

following VBG 4_p
appendicectomy NN 4_p
: : N
following VBG 4_p
appendicectomy NN 4_p
. . N

Consecutive JJ N
patients NNS N
undergoing VBG 4_p
emergency NN 4_p
appendicectomy NN 4_p
postappendicectomy NN 4_p
patient NN 4_p
-DOCSTART- -X- O O 7007454

gingivitis NN N
in IN N
pregnancy NN N
. . N

gingival JJ 4_p
inflammation NN 4_p
during IN 4_p
the DT 4_p
fourth JJ 4_p
and CC 4_p
eighth JJ 4_p
months NNS 4_p
of IN 4_p
pregnancy NN 4_p
. . 4_p

Thirty JJ N
women NNS N
gingival JJ N
health NN N
in IN N
pregnancy NN N
. . N

-DOCSTART- -X- O O 20920086

Chinese JJ N
patients NNS N
with IN N
fractured JJ 4_p
limbs NNS 4_p
. . N

-DOCSTART- -X- O O 2276106

patients NNS 4_p
' POS 4_p
well-being NN 4_p
in IN 4_p
a DT 4_p
radiation NN 4_p
therapy NN 4_p
department NN 4_p
. . 4_p

patients NNS 4_p
' POS 4_p
well-being JJ 4_p
. . 4_p

Fifty-five JJ N
subjects NNS N
undergoing VBG N
radiation NN N
therapy NN N
for IN N
cure NN N
and CC N
who WP N
were VBD N
able JJ N
to TO N
communicate VB N
by IN N
telephone NN N
comprised VBD N
the DT N
sample NN N
. . N

control NN N
group NN N
, , N
who WP N
received VBD N
the DT N
usual JJ N
care NN N
or CC N
to TO N
an DT N
experimental JJ N
group NN N
-DOCSTART- -X- O O 3519550

breast NN N
cancer NN N
-- : N
long-term JJ N
Oslo NNP 4_p
study NN 4_p
. . 4_p

the DT N
effect NN N
of IN N
postoperative JJ N
radiotherapy NN N
as IN N
an DT N
adjuvant NN N
to TO N
radical JJ N
mastectomy NN N
are VBP N
presented VBN N
. . N

1115 CD 4_p
patients NNS 4_p
including VBG 4_p
27 CD 4_p
protocol JJ 4_p
deviants NNS 4_p
. . 4_p

-DOCSTART- -X- O O 17408924

third JJ N
molar JJ N
surgery NN N
. . N

patients NNS N
undergoing VBG N
lower JJR N
third JJ N
molar JJ N
surgical JJ N
extraction NN N
with IN N
bone NN N
removal NN N
. . N

Patients NNS N
There EX N
were VBD N
86 CD N
patients NNS N
( ( N
31 CD N
in IN N
the DT N
single-dose JJ N
group NN N
, , N
28 CD N
in IN N
the DT N
5-day JJ N
group NN N
and CC N
27 CD N
in IN N
the DT N
placebo NN N
group NN N
) ) N
enrolled VBD N
in IN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 23337964

40 CD 3_p
healthy JJ 4_p
subjects NNS N
. . N

-DOCSTART- -X- O O 1992319

after IN 4_p
treatment NN 4_p
of IN 4_p
cryptococcal JJ 4_p
meningitis NN 4_p
in IN 4_p
the DT 4_p
acquired JJ 4_p
immunodeficiency NN 4_p
syndrome NN 4_p
. . 4_p

patients NNS N
with IN N
the DT N
acquired JJ 4_p
immunodeficiency NN 4_p
syndrome NN 4_p
( ( 4_p
AIDS NNP 4_p
) ) 4_p
all DT N
participants NNS N
had VBD N
sterile JJ N
cultures NNS N
of IN N
cerebrospinal JJ N
fluid NN N
, , N
blood NN N
, , N
and CC N
urine JJ N
after IN N
following VBG N
a DT N
standardized JJ N
course NN N
of IN N
therapy NN N
for IN N
culture-proved JJ N
cryptococcal JJ 4_p
meningitis NN 4_p
. . N

Of IN N
84 CD 3_p
patients NNS N
initially RB N
enrolled VBD N
, , N
16 CD 3_p
( ( N
19 CD N
percent NN N
) ) N
were VBD N
found VBN N
to TO N
have VB N
silent JJ N
, , N
persistent JJ N
infection NN 4_p
on IN N
the DT N
basis NN N
of IN N
cultures NNS N
that WDT N
became VBD N
positive JJ N
after IN N
entry NN N
into IN N
the DT N
study NN N
; : N
7 CD 3_p
other JJ N
patients NNS N
were VBD N
lost VBN N
to TO N
follow-up NNS N
shortly RB N
after IN N
entry NN N
remaining VBG N
61 CD 3_p
patients NNS N
patients NNS N
with IN N
AIDS NNP 4_p
-DOCSTART- -X- O O 3116609

90 CD 3_p
ASA NNP 4_p
class NN 4_p
I-II NNP 4_p
urologic JJ 4_p
patients NNS N
during IN N
extracorporeal JJ N
shock NN N
wave NN N
lithotripsy NN N
. . N

six CD N
groups NNS N
-DOCSTART- -X- O O 9664917

Delta NNP N
Research NNP N
Group NNP N
. . N

various JJ N
demographic JJ N
groups NNS N
. . N

103 CD 3_p
healthy JJ N
men NNS 2_p
and CC N
women NNS 2_p
aged VBD N
22 CD N
to TO N
67 CD N
years NNS N
at IN N
4 CD N
field NN N
centers NNS N
. . N

-DOCSTART- -X- O O 18289310

abomasal JJ N
emptying VBG N
rate NN N
in IN N
suckling VBG N
calves NNS N
. . N

Five CD N
male JJ N
Holstein-Friesian JJ N
calves NNS N
( ( N
8-15 JJ N
days NNS N
of IN N
age NN N
) ) N
. . N

dairy NN N
calves NNS N
-DOCSTART- -X- O O 6871470

thrombocytopenic JJ 4_p
patients NNS N
with IN N
acute JJ 4_p
leukemia NN 4_p
. . N

54 CD 3_p
thrombocytopenic JJ 4_p
patients NNS N
with IN N
acute JJ 4_p
leukemia NN 4_p
. . N

-DOCSTART- -X- O O 15247730

caliceal JJ N
calculi JJ N
extraction NN N
during IN N
flexible JJ N
ureteroscopy NN N
. . N

stone NN N
capture NN N
rate NN N
of IN N
9 CD N
commercially RB N
available JJ N
tipless NN N
stone NN N
baskets NNS N
in IN N
an DT N
in IN N
vitro NN N
model NN N
3 CD N
novice NNS N
and CC N
3 CD N
experienced VBD N
basket NN N
operators NNS N
. . N

Each DT N
operator NN N
performed VBD N
stone JJ N
extraction NN N
of IN N
2 CD N
, , N
5 CD N
and CC N
8 CD N
mm NN N
calculi NN N
novice NN N
expert JJ N
operators NNS N
urology NN N
residents NNS N
and CC N
nursing NN N
assistants NNS N
. . N

-DOCSTART- -X- O O 22131601

Ninety-five JJ 3_p
primary JJ N
insomniacs NN 4_p
, , N
32-64 CD 1_p
years NNS 1_p
old JJ 1_p
and CC 1_p
55 CD 1_p
age- JJ 1_p
and CC N
sex-matched JJ N
general JJ N
population-based JJ N
, , N
representative JJ N
controls NNS N
. . N

participants NNS N
with IN N
primary JJ 4_p
insomnia NNS 4_p
insomniacs NN N
-DOCSTART- -X- O O 11459079

children NNS N
with IN N
autistic JJ 4_p
spectrum NN 4_p
disorders NNS 4_p
: : N
children NNS N
with IN N
autistic JJ 4_p
spectrum NN 4_p
disorders NNS 4_p
. . N

9 CD 3_p
Caucasian JJ 3_p
boys NNS N
, , N
3.8-8.1 CD 1_p
years NNS 1_p
old JJ N
, , N
with IN N
a DT N
DSM-IV JJ 4_p
diagnosis NN 4_p
of IN 4_p
a DT 4_p
pervasive JJ 4_p
developmental NN 4_p
disorder NN 4_p
, , N
living VBG N
with IN N
their PRP$ N
families NNS N
, , N
receiving VBG N
no DT N
chronic JJ N
medications NNS N
, , N
and CC N
without IN N
significant JJ N
gastrointestinal JJ N
symptoms NNS N
. . N

Children NNP N
with IN N
marked VBN N
stereotypy NN N
( ( N
meaningless NN N
, , N
repetitive JJ N
behaviors NNS N
) ) N
Our PRP$ N
subjects NNS N
did VBD N
not RB N
have VB N
prominent JJ N
gastrointestinal JJ N
symptoms NNS N
children NNS N
with IN N
autistic JJ N
spectrum NN N
disorders NNS N
-DOCSTART- -X- O O 20548043

psychogenic JJ 4_p
nonepileptic JJ 4_p
seizures NNS 4_p
: : N
psychogenic JJ 4_p
nonepileptic JJ 4_p
seizures NNS 4_p
( ( 4_p
PNES NNP 4_p
) ) N
. . N

Sixty-six JJ 3_p
PNES NNP 4_p
patients NNS N
were VBD N
randomized VBN N
video-EEG JJ N
telemetry NN N
for IN N
most JJS N
patients NNS N
. . N

Exclusion NNP N
criteria NNS N
included VBD N
comorbid JJ N
history NN N
of IN N
epilepsy NN N
, , N
< VBP N
2 CD N
PNES/month NNP N
, , N
and CC N
IQ NNP N
< NNP N
70 CD N
. . N

PNES NNP N
patients NNS N
. . N

patients NNS N
with IN N
PNES NNP 4_p
-DOCSTART- -X- O O 15930233

preterm JJ 4_p
infants NNS 4_p
. . 4_p

preterm JJ N
infants NNS N
100 CD 4_p
hospitalized JJ 4_p
preterm NN 4_p
infants NNS 4_p
with IN 4_p
birth JJ 4_p
weights NNS 4_p
of IN 4_p
500 CD 4_p
to TO 4_p
1300 CD 4_p
g NN 4_p
-DOCSTART- -X- O O 12970516

vascular JJ 4_p
dementia NN 4_p
: : N
patients NNS N
with IN N
vascular JJ N
dementia NN N
( ( N
VaD NNP N
) ) N
Patients NNPS N
( ( N
n=603 JJ N
; : N
mean JJ 1_p
age NN 1_p
, , 1_p
73.9 CD 1_p
years NNS 1_p
; : N
55.2 CD N
% NN N
men NNS 2_p
) ) N
with IN N
probable JJ N
( ( N
70.5 CD N
% NN N
) ) N
or CC N
possible JJ N
( ( N
29.5 CD N
% NN N
) ) N
VaD NNP N
, , N
according VBG N
to TO N
criteria NNS N
of IN N
the DT N
National NNP N
Institute NNP N
of IN N
Neurological NNP N
Disorders NNP N
and CC N
Stroke NNP N
( ( N
NINDS NNP N
) ) N
and CC N
the DT N
Association NNP N
Internationale NNP N
pour VBP N
la NN N
Recherche NNP N
et CC N
l'Enseignement JJ N
en NN N
Neurosciences NNP N
( ( N
AIREN NNP N
) ) N
-DOCSTART- -X- O O 9366821

moderate JJ 4_p
acne NN 4_p
vulgaris NN 4_p
. . N

patients NNS N
with IN N
acne NN 4_p
Two CD 3_p
hundred VBD 3_p
fifty-seven RB 3_p
healthy JJ 4_p
female NN 2_p
subjects NNS N
, , N
15 CD 1_p
to TO 1_p
49 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
with IN N
moderate JJ 4_p
acne NNS 4_p
vulgaris NN 4_p
160 CD 3_p
subjects NNS N
placebo NN N
group NN N
in IN N
women NNS 2_p
with IN N
no DT N
known VBN N
contraindication NN N
to TO N
OC NNP N
therapy NN N
. . N

-DOCSTART- -X- O O 9778067

12 CD N
normal JJ N
subjects NNS N
( ( N
6 CD N
men NNS N
, , N
6 CD N
women NNS N
; : N
ages VBZ N
21 CD N
to TO N
26 CD N
years NNS N
) ) N
before IN N
and CC N
after IN N
ingestion NN N
of IN N
caffeine NN N
normal JJ N
subjects NNS N
-DOCSTART- -X- O O 24958585

low-resourced JJ N
preschoolers NNS 1_p
with IN N
autism NN 4_p
: : N
preschool-aged JJ 1_p
children NNS 1_p
with IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorder NNP 4_p
who WP N
had VBD N
low JJ N
resources NNS N
. . N

Participants NNP N
included VBD N
112 CD 3_p
families NNS N
of IN N
a DT N
child NN 1_p
who WP N
had VBD N
Autism NNP 4_p
Spectrum NNP 4_p
Disorder NNP 4_p
who WP N
met VBD N
criteria NNS N
for IN N
being VBG N
low-resourced JJ N
and CC N
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
2 CD N
3-month JJ N
interventions NNS N
, , N
group NN N
caregiver NN N
education NN N
or CC N
individualized VBN N
caregiver-mediated JJ N
intervention NN N
( ( N
CMM NNP N
) ) N
. . N

low-resourced JJ N
families NNS N
. . N

-DOCSTART- -X- O O 20305865

periodontal JJ 4_p
healing NN 4_p
. . 4_p

nonsurgical JJ 4_p
therapy NN 4_p
( ( 4_p
scaling VBG 4_p
and CC 4_p
root NN 4_p
planing NN 4_p
, , 4_p
SRP NNP 4_p
) ) 4_p
on IN 4_p
the DT 4_p
subgingival NN 4_p
microbiota NN 4_p
in IN 4_p
chronic NN 4_p
( ( 4_p
CP NNP 4_p
) ) 4_p
and CC 4_p
aggressive JJ 4_p
( ( 4_p
AP NNP 4_p
) ) 4_p
periodontal JJ 4_p
disease NN 4_p
. . 4_p

Ninety-seven NNP N
CP NNP N
and CC N
AP NNP N
subjects NNS N
underwent JJ N
full-mouth JJ N
SRP NNP N
on IN N
2 CD N
consecutive JJ N
days NNS N
. . N

-DOCSTART- -X- O O 11500608

Sixty-two JJ 4_p
patients NNS 4_p
( ( 4_p
19 CD 4_p
men NNS 4_p
and CC 4_p
43 CD 4_p
women NNS 4_p
; : 4_p
mean JJ 4_p
age NN 4_p
, , 4_p
54 CD 4_p
years NNS 4_p
; : 4_p
range NN 4_p
, , 4_p
32-77 CD 4_p
years NNS 4_p
) ) 4_p
with IN 4_p
heartburn NN 4_p
and CC 4_p
regurgitation NN 4_p
and CC 4_p
normal JJ 4_p
upper JJ 4_p
endoscopy NN 4_p
findings NNS 4_p
patients NNS 4_p
with IN 4_p
reflux NN 4_p
symptoms NNS 4_p
. . 4_p

-DOCSTART- -X- O O 7486842

obesity NN 4_p
. . 4_p

obesity NN N
42 CD 3_p
obese JJ N
women NNS N
( ( N
body NN N
mass NN N
index NN N
35.9 CD N
+/- JJ N
5.3 CD N
kg/m2 NN N
) ) N
. . N

obese JJ N
patients NNS N
obese JJ N
subjects NNS N
. . N

-DOCSTART- -X- O O 1467386

healthy JJ 4_p
subjects NNS 4_p
. . 4_p

10 CD N
healthy JJ N
men NNS N
-DOCSTART- -X- O O 15623613

familial JJ N
adenomatous JJ N
polyposis NN N
. . N

patients NNS N
with IN N
familial JJ N
adenomatous JJ N
polyposis NN N
( ( N
FAP NNP N
) ) N
. . N

FAP NNP N
patients NNS N
. . N

relevance-M66I NN N
, , N
P153L NNP N
, , N
E158K NNP N
, , N
V257M NNP N
, , N
E305X NNP N
, , N
E308G NNP N
, , N
and CC N
R492W-in NNP N
21 CD N
and CC N
20 CD N
FAP NNP N
patients NNS N
, , N
who WP N
received VBD N
sulindac NN N
and CC N
placebo NN N
, , N
respectively RB N
. . N

41 CD N
patients NNS N
sulindac-treated JJ N
patients NNS N
patients NNS N
on IN N
sulindac NN N
-DOCSTART- -X- O O 3319640

mild NN N
and CC N
moderate JJ N
hypertension NN 4_p
. . N

22 CD 3_p
patients NNS N
with IN N
mild JJ 4_p
or CC 4_p
moderate JJ 4_p
essential JJ 4_p
hypertension NN 4_p
-DOCSTART- -X- O O 12839657

adolescents NNS 4_p
with IN 4_p
higher JJR 4_p
blood NN 4_p
pressure NN 4_p
] NNP 4_p
adolescents NNS N
with IN N
higher JJR N
blood NN N
pressure NN N
. . N

220 CD N
adolescents NNS N
with IN N
higher JJR N
blood NN N
pressure NN N
, , N
aged VBD N
18 CD N
- : N
22 CD N
years NNS N
, , N
who WP N
were VBD N
randomly RB N
divided VBN N
into IN N
supplementary JJ N
group NN N
( ( N
n JJ N
= NNP N
110 CD N
) ) N
and CC N
control NN N
group NN N
( ( N
n JJ N
= NNP N
110 CD N
) ) N
. . N

Each DT N
of IN N
the DT N
subjects NNS N
in IN N
the DT N
supplementary JJ N
group NN N
and CC N
their PRP$ N
family NN N
members NNS N
adolescents NNS N
with IN N
higher JJR N
blood NN N
pressure NN N
. . N

-DOCSTART- -X- O O 22782459

children NNS 4_p
with IN 4_p
autistic JJ 4_p
disorder NN 4_p
: : 4_p
40 CD 3_p
outpatient JJ 3_p
children NNS 3_p
with IN N
a DT N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
fourth JJ N
edition NN N
, , N
text JJ N
revision NN N
clinical JJ N
diagnosis NN N
of IN N
autism NN N
risperidone VB 4_p
alone RB 4_p
in IN 4_p
treating VBG 4_p
-DOCSTART- -X- O O 20061873

patients NNS 4_p
with IN 4_p
severe JJ 4_p
negative JJ 4_p
trauma-related JJ 4_p
cognitions NNS 4_p
patients NNS N
with IN N
severe JJ N
negative JJ N
trauma-related JJ N
cognitions NNS N
54 CD N
PTSD NN N
patients NNS N
-DOCSTART- -X- O O 9531360

patients NNS N
treated VBN N
for IN N
localized JJ N
prostatic JJ N
carcinoma NN N
in IN N
a DT N
Phase NNP N
III NNP N
radiotherapy NN N
( ( N
RT NNP N
) ) N
protocol NN N
, , N
Radiation NNP N
Therapy NNP N
Oncology NNP N
Group NNP N
( ( N
RTOG NNP N
) ) N
77-06 NN N
. . N

Patients NNS N
with IN N
T18N0M0 NNP N
( ( N
A2 NNP N
) ) N
or CC N
T2N0M0 NNP N
( ( N
B NNP N
) ) N
disease NN N
after IN N
lymphangiogram NN N
( ( N
LAG NNP N
) ) N
or CC N
staging VBG N
laparotomy NN N
( ( N
SL NNP N
) ) N
were VBD N
randomized VBN N
between IN N
prophylactic JJ N
radiation NN N
to TO N
the DT N
pelvic JJ N
lymph NN N
nodes NNS N
and CC N
prostatic JJ N
bed NN N
vs. FW N
prostatic JJ N
bed NN N
alone RB N
. . N

A NNP N
total NN N
of IN N
449 CD N
eligible JJ N
males NNS N
were VBD N
entered VBN N
into IN N
RTOG NNP N
protocol NN N
7706 CD N
between IN N
1978 CD N
and CC N
1983 CD N
. . N

117 CD N
( ( N
26 CD N
% NN N
) ) N
patients NNS N
had VBD N
SL NNP N
, , N
while IN N
332 CD N
( ( N
74 CD N
% NN N
) ) N
had VBD N
LAG NNP N
. . N

-DOCSTART- -X- O O 10052279

patients NNS N
of IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
undergoing VBG N
coronary JJ N
artery NN N
bypass NN N
graft NN N
surgery NN N
. . N

patients NNS N
with IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
who WP N
undergo VBP N
coronary JJ N
artery NN N
bypass NN N
graft NN N
surgery NN N
Forty-five JJ 3_p
patients NNS N
posted VBD N
for IN N
coronary JJ N
artery NN N
bypass NN N
graft NN N
surgery NN N
-DOCSTART- -X- O O 4404700

paranoid NN 4_p
and CC 4_p
nonparanoid JJ 4_p
schizophrenics NNS 4_p
. . N

-DOCSTART- -X- O O 11916791

3 CD N
groups NNS N
of IN N
healthy JJ 4_p
male JJ 2_p
patients NNS N
: : N
Control NNP N
( ( N
n JJ N
= NNP N
35 CD 3_p
) ) N
, , N
2.5 CD N
microg/kg NN N
Clonidine NNP N
( ( N
n JJ N
= NNP N
36 CD 3_p
) ) N
, , N
and CC N
5.0 CD N
microg/kg NNS N
Clonidine NNP N
( ( N
n JJ N
= NNP N
36 CD 3_p
) ) N
groups NNS N
. . N

-DOCSTART- -X- O O 1410028

strength NN N
of IN N
the DT N
radius NN N
Fifty NNP 3_p
pairs NN N
of IN N
sheep JJ N
tibiae NN N
were VBD N
utilized VBN N
Five CD 3_p
pairs NNS N
were VBD N
used VBN N
in IN N
a DT N
pilot NN N
study NN N
and CC N
45 CD 3_p
pairs NNS N
were VBD N
used VBN N
in IN N
the DT N
main JJ N
experiment NN N
. . N

Five CD 3_p
pairs NNS N
of IN N
human JJ N
radii NN N
were VBD N
used VBN N
for IN N
the DT N
control NN N
in IN N
the DT N
pilot NN N
study NN N
. . N

control NN N
group NN N
( ( N
group NN N
1 CD N
) ) N
had VBD N
no DT N
alteration NN N
to TO N
the DT N
bone NN N
. . N

-DOCSTART- -X- O O 17467416

overtaxed JJ N
men NNS 2_p
. . N

-DOCSTART- -X- O O 6391269

inhalation NN 4_p
anaesthesia NN 4_p
. . N

eight CD 3_p
out IN N
of IN N
15 CD 3_p
healthy JJ 4_p
patients NNS N
undergoing VBG N
body NN 4_p
surface NN 4_p
surgery NN 4_p
-DOCSTART- -X- O O 23021480

parent NN N
toddlers NNS 1_p
at IN N
risk NN N
for IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
: : N
toddlers NNS N
at IN N
risk NN N
for IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
( ( N
ASD NNP 4_p
) ) N
aged VBD N
14 CD 1_p
to TO 1_p
24 CD 1_p
months NNS 1_p
and CC N
their PRP$ N
families NNS N
. . N

98 CD 3_p
children NNS N
and CC N
families NNS N
-DOCSTART- -X- O O 18271235

severe JJ N
head NN 4_p
injury NN 4_p
patients NNS N
] VBP N
severe JJ N
head NN N
injury NN N
patients NNS N
. . N

Ninety-six JJ 4_p
patients NNS N
48 CD 4_p
cases NNS N
in IN N
each DT N
group NN N
. . N

severe JJ N
head NN N
injury NN N
patients NNS N
. . N

-DOCSTART- -X- O O 17316832

Two CD N
hundred VBD N
children NNS N
undergoing VBG N
bilateral JJ N
TT NNP N
placement NN N
were VBD N
categorized VBN N
as IN N
having VBG N
unilateral JJ N
( ( N
" JJ N
wet/dry NN N
" NN N
) ) N
, , N
bilateral JJ N
( ( N
" JJ N
wet/wet NN N
" NN N
) ) N
, , N
or CC N
no DT N
( ( N
" VB N
dry/dry RB N
" NNP N
) ) N
effusion NN N
at IN N
the DT N
time NN N
of IN N
surgery NN N
. . N

patients NNS N
with IN N
bilateral JJ N
effusion NN N
at IN N
the DT N
time NN N
of IN N
surgery NN N
. . N

-DOCSTART- -X- O O 21967909

adult NN 1_p
ambulatory NN 4_p
surgery NN 4_p
patients NNS 4_p
. . N

surgical JJ 4_p
patients NNS 4_p
578 CD 3_p
adult NN 1_p
ambulatory NN 4_p
surgery NN 4_p
patients NNS 4_p
-DOCSTART- -X- O O 2035777

shivering VBG 4_p
in IN N
elective JJ 4_p
caesarean JJ 4_p
section NN 4_p
under IN 4_p
epidural JJ 4_p
analgesia NN 4_p
. . N

parturients NNS 4_p
who WP N
underwent VBP 4_p
elective JJ 4_p
Caesarean JJ 4_p
section NN 4_p
under IN N
epidural JJ 4_p
analgesia NN 4_p
patients NNS N
-DOCSTART- -X- O O 7733183

cytomegalovirus NN 4_p
retinopathy NN 4_p
Patients NNPS N
Patients NNPS N
receiving VBG N
higher JJR N
doses NNS N
of IN N
foscarnet NN N
patients NNS N
with IN N
cytomegalovirus NN N
retinopathy NN N
. . N

-DOCSTART- -X- O O 9134405

after IN N
a DT N
first JJ 4_p
trimester NN 4_p
miscarriage NN 4_p
treated VBD N
surgically RB N
or CC N
medically RB N
. . N

-DOCSTART- -X- O O 16413605

Project NN N
Towards NNP N
No NNP 4_p
Drug NNP 4_p
Abuse NNP 4_p
: : N
Project NNP N
Towards NNP N
No NNP 4_p
Drug NNP 4_p
Abuse NNP 4_p
( ( N
Project NNP N
TND NNP N
) ) N
, , N
a DT N
drug NN N
abuse NN N
prevention NN N
program NN N
conducted VBN N
in IN N
South NNP N
California NNP N
alternative JJ N
high JJ N
school NN N
system NN N
during IN N
years NNS N
1994-1999 JJ N
. . N

Twenty-one CD 3_p
schools NNS N
Among IN N
1578 CD 3_p
baseline NN N
subjects NNS N
, , N
follow-up JJ N
data NNS N
were VBD N
available JJ N
for IN N
68 CD N
% NN N
( ( N
year NN N
1 CD N
) ) N
, , N
66 CD N
% NN N
( ( N
years NNS N
2 CD N
or CC N
3 CD N
) ) N
, , N
and CC N
46 CD N
% NN N
( ( N
years NNS N
4 CD N
or CC N
5 CD N
) ) N
of IN N
subjects NNS N
, , N
respectively RB N
. . N

high-risk JJ N
youth NN 1_p
-DOCSTART- -X- O O 3998250

agoraphobia NN 4_p
. . 4_p

-DOCSTART- -X- O O 21599896

breathlessness NN 4_p
in IN 4_p
advanced JJ 4_p
disease NN 4_p
. . N

patients NNS N
breathless NN 4_p
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
disease NN 4_p
( ( 4_p
regardless NN 4_p
of IN 4_p
cause NN 4_p
) ) 4_p
patients NNS N
with IN N
malignant JJ 4_p
disease NN 4_p
( ( N
intervention NN N
delivered VBN N
over IN N
two CD N
weeks NNS N
) ) N
and CC N
one CD N
for IN N
patients NNS N
with IN N
non-malignant JJ 4_p
disease NN 4_p
( ( N
intervention NN N
delivered VBN N
over IN N
four CD N
weeks NNS N
) ) N
. . N

patients NNS N
with IN N
malignant JJ 4_p
conditions NNS 4_p
( ( N
four CD N
week NN N
protocol NN N
) ) N
and CC N
one CD N
for IN N
patients NNS N
with IN N
non-malignant JJ 4_p
conditions NNS 4_p
-DOCSTART- -X- O O 17069545

children NNS 1_p
with IN N
pervasive JJ 4_p
developmental JJ 4_p
disorders NNS 4_p
: : N
children NNS N
with IN N
pervasive JJ 4_p
developmental NN 4_p
disorders NNS 4_p
. . N

Twenty-four JJ 3_p
children NNS 3_p
( ( N
aged VBN 1_p
5-17 CD 1_p
years NNS 1_p
) ) N
with IN N
pervasive JJ N
developmental NN N
disorders NNS N
and CC N
co-morbid JJ N
disruptive JJ N
behavior NN N
who WP N
responded VBD N
favorably RB N
to TO N
open-label JJ N
treatment NN N
with IN N
risperidone NN N
as IN N
part NN N
of IN N
a DT N
previously RB N
described VBN N
controlled VBN N
discontinuation NN N
study NN N
children NNS N
with IN N
pervasive JJ N
developmental NN N
disorders NNS N
. . N

-DOCSTART- -X- O O 17695603

Patients NNS N
immediately RB N
after IN N
treatment NN N
-DOCSTART- -X- O O 16167251

procedure NN N
for IN N
prolapse NN 4_p
and CC 4_p
hemorrhoids NNS 4_p
] NNP N
From IN N
November NNP N
2002 CD N
to TO N
July NNP N
2003 CD N
, , N
80 CD 3_p
patients NNS N
who WP N
received VBD N
PPH NNP 4_p
-DOCSTART- -X- O O 7326194

43 CD 4_p
patients NNS 4_p
with IN 4_p
carcinoma NN 4_p
of IN 4_p
the DT 4_p
cervix NN 4_p
uteri NN 4_p
, , 4_p
all DT 4_p
of IN 4_p
whom WP 4_p
were VBD 4_p
treated VBN 4_p
by IN 4_p
radical JJ 4_p
surgery NN 4_p
. . 4_p

All DT N
patients NNS N
had VBD N
carcinoma NNS N
confined VBN N
to TO N
the DT N
cervix NN N
, , N
the DT N
upper JJ N
part NN N
of IN N
the DT N
vagina NN N
or CC N
the DT N
parametrial JJ N
region NN N
. . N

When WRB N
the DT N
malignancy NN N
had VBD N
spread VBN N
to TO N
the DT N
parametrial JJ N
region NN N
, , N
additional JJ N
postoperative NN N
radiotherapy NN N
was VBD N
given VBN N
. . N

22 CD N
patients NNS N
received VBD N
immunotherapy JJ N
10 CD N
days NNS N
before RB N
surgery NN N
, , N
whereas IN N
the DT N
remaining VBG N
21 CD N
control NN N
patients NNS N
received VBD N
no DT N
immune JJ N
stimulation NN N
. . N

15 CD N
patients NNS N
with IN N
more RBR N
advanced JJ N
malignancies NNS N
were VBD N
added VBN N
to TO N
our PRP$ N
studies NNS N
. . N

-DOCSTART- -X- O O 26725450

healthy JJ 1_p
adults NNS 1_p
: : 1_p
Centre NNP N
Hospitalier NNP N
Universitaire NNP N
Vaudois NNP N
, , N
Lausanne NNP N
, , N
Switzerland NNP N
. . N

Participants NNS 1_p
( ( 1_p
aged VBN 1_p
18-65 CD 1_p
years NNS 1_p
) ) 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
individuals NNS N
potentially RB N
deployed VBN N
in IN N
endemic JJ N
areas NNS N
and CC N
those DT N
not RB N
deployed VBN N
NCT02289027 NNP N
. . N

FINDINGS NNP N
Between NNP N
Oct NNP N
24 CD N
, , N
2014 CD N
, , N
and CC N
June NNP N
22 CD N
, , N
2015 CD N
, , N
we PRP N
randomly VBP N
assigned VBN N
120 CD 3_p
participants NNS 3_p
, , N
of IN N
whom WP N
18 CD 3_p
( ( 3_p
15 CD 3_p
% NN 3_p
) ) 3_p
were VBD 3_p
potentially RB 3_p
deployed VBN 3_p
and CC N
102 CD 3_p
( ( 3_p
85 CD 3_p
% NN 3_p
) ) 3_p
were VBD 3_p
non-deployed JJ 3_p
, , N
to TO N
receive VB N
high-dose JJ N
vaccine NN N
( ( N
n=49 JJ N
) ) N
, , N
low-dose JJ N
vaccine NN N
( ( N
n=51 JJ N
) ) N
, , N
or CC N
placebo NN N
-DOCSTART- -X- O O 3890395

type NN 4_p
II NNP 4_p
hypertensive NN 4_p
diabetics NNS 4_p
. . 4_p

hypertension NN 4_p
in IN 4_p
diabetic JJ 4_p
subjects NNS 4_p
26 CD N
type NN N
II NNP N
( ( N
non-insulin-dependent JJ N
) ) N
diabetics NNS N
, , N
in IN N
fairly RB N
good JJ N
metabolic NN N
control NN N
and CC N
with IN N
moderate JJ N
hypertension NN N
( ( N
orthostatic JJ N
diastolic NN N
pressure NN N
from IN N
100 CD N
to TO N
115 CD N
mmHg NN N
) ) N
-DOCSTART- -X- O O 15610252

patients NNS 4_p
with IN 4_p
kidney JJ 4_p
disease NN 4_p
: : 4_p
patients NNS 4_p
with IN 4_p
congestive JJ 4_p
heart NN 4_p
failure NN 4_p
( ( 4_p
CHF NNP 4_p
) ) 4_p
patients NNS 4_p
with IN 4_p
and CC 4_p
without IN 4_p
kidney NN 4_p
disease NN 4_p
[ NNP 4_p
glomerular JJ 4_p
filtration NN 4_p
rate NN 4_p
( ( 4_p
GFR NNP 4_p
) ) 4_p
less JJR 4_p
than IN 4_p
60 CD 4_p
mL/min/1.73 JJ 4_p
m NN 4_p
( ( 4_p
2 CD 4_p
) ) 4_p
) ) 4_p
presenting VBG 4_p
with IN 4_p
acute JJ 4_p
dyspnea NN 4_p
. . 4_p

452 CD 3_p
consecutive JJ 3_p
patients NNS 3_p
( ( N
240 CD 3_p
with IN 3_p
kidney NN 3_p
disease NN 3_p
and CC N
212 CD 3_p
without IN 3_p
kidney NN 3_p
disease NN 3_p
) ) N
Patients NNS 4_p
with IN 4_p
kidney JJ 4_p
disease NN 4_p
were VBD 4_p
older JJR 4_p
, , 4_p
more RBR 4_p
often RB 4_p
had VBD 4_p
CHF NNP 4_p
as IN 4_p
the DT 4_p
cause NN 4_p
of IN 4_p
acute JJ 4_p
dyspnea NN 4_p
, , 4_p
and CC 4_p
more RBR 4_p
often RB 4_p
died JJ 4_p
in-hospital JJ 4_p
or CC 4_p
within IN 4_p
30 CD 4_p
days NNS 4_p
as RB 4_p
compared VBN 4_p
to TO 4_p
patients NNS 4_p
without IN 4_p
kidney NN 4_p
disease NN 4_p
-DOCSTART- -X- O O 11162323

smokers NNS 4_p
general JJ N
population NN N
. . N

Smokers NNS N
initial JJ N
subject JJ N
pool NN N
was VBD N
the DT N
24,178 JJ 3_p
members NNS N
of IN N
a DT N
managed VBN N
care NN N
company NN N
. . N

19,236 CD 3_p
members NNS N
( ( N
79.6 CD N
% NN N
) ) N
, , N
of IN N
whom WP N
4,653 CD 3_p
were VBD N
smokers NNS N
; : N
85.3 CD N
% NN N
of IN N
the DT N
smokers NNS N
were VBD N
enrolled VBN N
. . N

Thirty-eight JJ N
percent NN N
were VBD N
in IN N
the DT N
precontemplation NN N
stage NN N
, , N
45 CD N
% NN N
in IN N
the DT N
contemplation NN N
stage NN N
, , N
and CC N
only RB N
17 CD N
% NN N
in IN N
the DT N
preparation NN N
stage NN N
. . N

population NN N
of IN N
smokers NNS N
-DOCSTART- -X- O O 7104637

Intraoperative JJ N
microscopy NN N
of IN N
bile NN N
-- : N
is VBZ N
during IN N
cholecystectomy NN 4_p
in IN N
111 CD 3_p
patients NNS N
in IN N
23 CD 3_p
patients NNS N
, , N
11 CD 3_p
of IN N
83 CD 3_p
undergoing JJ N
cholecystectomy NN 4_p
alone RB N
and CC N
12 CD 3_p
of IN N
28 CD 3_p
undergoing JJ N
exploration NN 4_p
of IN 4_p
the DT 4_p
common JJ 4_p
bile NN 4_p
duct NN 4_p
23 CD 3_p
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
an DT N
antibiotic JJ N
group NN N
or CC N
a DT N
control NN N
group NN N
; : N
14 CD 3_p
patients NNS N
intraoperative JJ N
microscopy NN N
of IN N
bile NN N
. . N

-DOCSTART- -X- O O 19357315

smokers NNS 4_p
quit VB 4_p
: : 4_p
nonsmoking VBG 4_p
support NN 4_p
persons NNS 4_p
. . N

59 CD 3_p
support NN N
persons NNS N
( ( N
mean JJ 1_p
age NN 1_p
= VBD 1_p
36 CD 1_p
years NNS 1_p
, , N
92 CD N
% NN N
female NN 2_p
, , N
95 CD N
% NN N
White NNP N
) ) N
support NN N
persons NNS N
smokers NNS 4_p
-DOCSTART- -X- O O 20491838

bony NN 4_p
defects NNS 4_p
bony NN 4_p
defects NNS 4_p
Thirty-two NNP 3_p
implants NNS N
were VBD N
randomly RB N
allocated VBN N
four CD N
types NNS N
of IN N
bone NN 4_p
defects NNS 4_p
: : N
marginal JJ 4_p
bone NN 4_p
loss NN 4_p
, , N
peri-apical JJ 4_p
bone NN 4_p
defect NN 4_p
, , N
constant JJ 4_p
width NN 4_p
dehiscence NN 4_p
and CC N
constant JJ 4_p
length NN 4_p
dehiscences NNS 4_p
. . N

-DOCSTART- -X- O O 11004058

pain NN 4_p
and CC 4_p
secondary JJ 4_p
hyperalgesia NN 4_p
in IN 4_p
healthy JJ 4_p
volunteers NNS 4_p
. . 4_p

non-neuropathic JJ 4_p
pain NN 4_p
experimental JJ 4_p
pain NN 4_p
in IN 4_p
24 CD 4_p
volunteers NNS 4_p
. . 4_p

low- JJ N
to TO N
mid-antiarrhythmic JJ N
range NN N
nonneuropathic JJ N
pain NN N
experimental-induced JJ N
hyperalgesia NN N
in IN N
25 CD N
volunteers NNS N
. . N

-DOCSTART- -X- O O 12036809

subjects NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
consuming VBG N
a DT N
high-fiber JJ N
diet NN N
subjects NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
. . N

Subjects VBZ N
with IN N
type NN 4_p
2 CD 4_p
diabetes NNS 4_p
( ( N
n JJ N
= NNP N
62 CD 3_p
) ) N
subjects NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
-DOCSTART- -X- O O 20008622

patients NNS N
with IN N
newly RB N
diagnosed VBN N
, , N
previously RB N
untreated VBN N
chronic JJ N
myeloid NN N
leukemia NN N
in IN N
chronic JJ N
phase NN N
patients NNS N
with IN N
newly RB N
diagnosed VBN N
chronic JJ N
myeloid NN N
leukemia NN N
in IN N
chronic JJ N
phase NN N
. . N

A NNP N
total NN N
of IN N
476 CD N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
-DOCSTART- -X- O O 17069542

cognition NN 4_p
and CC 4_p
behavior NN 4_p
in IN 4_p
fragile JJ 4_p
X JJ 4_p
syndrome NN 4_p
: : N
underlying JJ 4_p
disorder NN 4_p
in IN 4_p
fragile JJ 4_p
X NNP 4_p
syndrome NN 4_p
( ( 4_p
FXS NNP 4_p
) ) N
. . N

subjects VBZ N
with IN N
FXS NNP N
( ( N
n JJ 3_p
= NNP 3_p
49 CD 3_p
) ) N
Adult NNP 1_p
subjects VBZ 1_p
with IN N
FXS NNP 4_p
-DOCSTART- -X- O O 8332150

seven CD N
antiarrhythmic JJ N
drugs NNS N
in IN N
patients NNS N
with IN N
ventricular JJ 4_p
tachyarrhythmias NNS 4_p
. . N

patients NNS N
with IN N
ventricular JJ 4_p
tachyarrhythmias NNS 4_p
Patients NNPS N
486 CD 3_p
randomized VBN N
subjects NNS N
. . N

296 CD 3_p
patients NNS N
-DOCSTART- -X- O O 9806121

Swedish JJ N
adolescents NNS 1_p
. . N

1996 CD N
a DT N
randomized JJ N
sample NN N
of IN N
4,020 CD 3_p
Swedish JJ N
adolescents NNS 1_p
from IN N
three CD N
birth NN N
cohorts NNS N
A DT N
total NN N
of IN N
2,615 CD N
questionnaires NNS N
were VBD N
returned VBN N
. . N

Girls NNP 2_p
boys NNS 2_p
-DOCSTART- -X- O O 7941489

in IN N
schools NNS N
children NNS 1_p
. . 1_p

in IN 1_p
children NNS 1_p
in IN N
school NN N
settings NNS N
. . N

23 CD N
sixth NNS N
grade JJ N
children NNS N
in IN N
Winnipeg NNP N
, , N
Manitoba NNP N
-DOCSTART- -X- O O 3475309

Streptococcus NNP N
mutans NNS N
and CC N
approximal JJ N
dental JJ N
caries NNS N
. . N

Streptococcus NNP N
mutants NNS N
and CC N
approximal JJ N
dental JJ N
caries NNS N
One CD N
hundred CD N
and CC N
eighty-seven JJ N
13-year-old JJ N
individuals NNS N
with IN N
high JJ N
levels NNS N
of IN N
salivary JJ N
S. NNP N
mutans NNS N
( ( N
greater JJR N
than IN N
10 CD N
( ( N
6 CD N
) ) N
/mL NN N
) ) N
were VBD N
selected VBN N
. . N

-DOCSTART- -X- O O 7806134

post-menopausal JJ 4_p
women NNS 4_p
treated VBN 4_p
with IN 4_p
oral JJ 4_p
estrogens NNS 4_p
administered VBN 4_p
at IN 4_p
different JJ 4_p
times NNS 4_p
. . 4_p

twenty-four JJ 4_p
post-menopausal JJ 4_p
women NNS 4_p
. . 4_p

-DOCSTART- -X- O O 11302295

following VBG 4_p
sudden JJ 4_p
cardiac JJ 4_p
arrest NN 4_p
: : 4_p
sudden JJ 4_p
cardiac JJ 4_p
arrest NN 4_p
survivors NNS 4_p
. . 4_p

Survivors NNPS N
of IN N
out-of-hospital JJ N
ventricular JJ N
fibrillation NN N
or CC N
asystole NN N
( ( N
N NNP N
= NNP N
129 CD 3_p
) ) N
, , N
documented VBN N
by IN N
electrocardiograms NNS N
from IN N
registries NNS N
of IN N
a DT N
citywide NN N
Medic NNP N
One NNP N
unit NN N
and CC N
two CD N
countywide NN N
emergency NN N
units NNS N
sudden JJ N
cardiac JJ N
arrest NN N
survivors NNS N
. . N

-DOCSTART- -X- O O 18093356

paediatric JJ 4_p
cardiac JJ 4_p
catheterization NN 4_p
. . N

126 CD 3_p
patients NNS 3_p
scheduled VBN 4_p
for IN 4_p
cardiac JJ 4_p
catheterization NN 4_p
in IN 4_p
a DT 4_p
teaching JJ 4_p
hospital NN 4_p
. . N

They PRP 1_p
ranged VBD 1_p
in IN 1_p
age NN 1_p
from IN 1_p
4 CD 1_p
months NNS 1_p
to TO 1_p
15 CD 1_p
years NNS 1_p
. . 1_p

aged VBN 1_p
from IN 1_p
3 CD 1_p
to TO 1_p
6 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
children NNS 1_p
-DOCSTART- -X- O O 21975559

subgroups NNS N
with IN N
glucocorticoid-induced JJ N
osteoporosis NN N
. . N

different JJ N
subgroups NNS N
with IN N
glucocorticoid-induced JJ N
osteoporosis NN N
. . N

patients NNS 4_p
on IN 4_p
glucocorticoids NNS 4_p
different JJ N
patient NN N
subgroups NNS N
Patients NNPS N
subpopulations NNS N
] VBP N
were VBD N
subgrouped VBN N
by IN N
age NN N
; : N
gender NN N
; : N
menopausal NN N
status NN N
in IN N
women NNS N
; : N
dose VB N
and CC N
duration NN N
of IN N
prednisone NN N
during IN N
the DT N
trial NN N
; : N
and CC N
baseline VB N
serum JJ N
25-OH JJ N
vitamin NN N
D NNP N
, , N
LS NNP N
BMD NNP N
T-score NNP N
, , N
creatinine JJ N
clearance NN N
, , N
and CC N
concomitant JJ N
medication NN N
use NN N
BMD NNP N
. . N

Osteoporotic JJ N
patients NNS N
-DOCSTART- -X- O O 15383046

patients NNS N
with IN N
permanent JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
. . N

patients NNS N
with IN N
permanent JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
undergoing VBG N
mitral JJ N
surgery NN N
. . N

50 CD 3_p
patients NNS N
with IN N
permanent JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
and CC N
dilated VBD 4_p
left JJ 4_p
atrium NN 4_p
, , N
submitted VBN N
to TO N
surgical JJ N
mitral JJ N
repair NN N
25 CD 3_p
patients NNS N
with IN N
left JJ 4_p
auricular JJ 4_p
reduction NN 4_p
and CC 4_p
mitral JJ 4_p
surgery NN 4_p
25 CD N
patients NNS N
with IN N
isolated JJ 4_p
valve NN 4_p
surgery NN 4_p
. . N

-DOCSTART- -X- O O 11213870

type NN 4_p
2 CD 4_p
diabetic JJ 4_p
subjects NNS 4_p
. . 4_p

type NN N
2 CD N
diabetic JJ N
subjects NNS N
. . N

Twenty NNP 3_p
type NN 4_p
2 CD 4_p
diabetic JJ 4_p
subjects NNS N
participated VBN N
in IN N
a DT N
crossover NN N
trial NN N
. . N

type NN N
2 CD N
diabetic JJ N
subjects NNS N
. . N

-DOCSTART- -X- O O 19701509

96 CD 3_p
bovine NN N
incisors NNS N
40 CD 3_p
noncarious JJ N
human JJ N
molars NNS N
-DOCSTART- -X- O O 1342906

allergic JJ 4_p
pollinosic JJ 4_p
conjunctivitis NN 4_p
: : 4_p
allergic JJ 4_p
conjunctivitis NN 4_p
. . 4_p

40 CD N
patients NNS N
suffering VBG N
from IN N
seasonal JJ N
allergic JJ N
conjunctivitis NN N
due JJ N
to TO N
Parietaria NNP N
pollen NN N
, , N
during IN N
the DT N
pollen NN N
season NN N
( ( N
June-July NNP N
, , N
1990 CD N
) ) N
. . N

-DOCSTART- -X- O O 23812661

preschoolers NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . N

young JJ 1_p
children NNS 1_p
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

teachers NNS N
in IN N
high JJ N
quality NN N
special JJ N
education NN N
programs NNS N
total NN N
of IN N
198 CD 3_p
children NNS 1_p
conditions NNS N
, , N
children NNS N
's POS N
-DOCSTART- -X- O O 19763803

hypertensive JJ 4_p
patients NNS 4_p
undergoing VBG 4_p
coronary JJ 4_p
intervention NN 4_p
by IN 4_p
serial JJ 4_p
volumetric JJ 4_p
intravascular NN 4_p
ultrasound NN 4_p
analysis NN 4_p
in IN 4_p
Juntendo NNP 4_p
university NN 4_p
( ( 4_p
ALPS-J NNP 4_p
) ) 4_p
patients NNS N
with IN N
coronary JJ N
artery NN N
disease NN N
( ( N
CAD NNP N
) ) N
. . N

hypertensive JJ 4_p
CAD NNP 4_p
patients NNS 4_p
undergoing VBG 4_p
elective JJ 4_p
percutaneous JJ 4_p
coronary JJ 4_p
intervention NN 4_p
( ( 4_p
PCI NNP 4_p
) ) 4_p
. . 4_p

Patients NNPS 1_p
who WP 1_p
have VBP 1_p
hypertension NN 1_p
and CC 1_p
are VBP 1_p
scheduled VBN 1_p
for IN 1_p
PCI NNP 1_p
will MD 1_p
be VB 1_p
enrolled VBN 1_p
. . 1_p

hypertensive JJ 4_p
patients NNS 4_p
undergoing VBG 4_p
elective JJ 4_p
PCI NNP 4_p
. . 4_p

-DOCSTART- -X- O O 23326865

non-diabetic JJ 4_p
chronic JJ 4_p
kidney NN 4_p
disease NN 4_p
: : N
patients NNS N
with IN N
non-diabetic JJ N
chronic JJ N
kidney NN N
disease NN N
. . N

14 CD 3_p
patients NNS N
with IN N
nondiabetic JJ 4_p
chronic JJ 4_p
kidney NN 4_p
disease NN 4_p
with IN N
24-h JJ N
mean JJ N
proteinuria NN N
of IN N
2.01 CD N
g NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.36–2.66 CD N
) ) N
and CC N
estimated VBN N
creatinine JJ N
clearance NN N
of IN N
93±6.8 CD N
ml/min NN N
treatment NN N
of IN N
patients NNS N
with IN N
chronic JJ 4_p
proteinuric JJ 4_p
non-diabetic JJ 4_p
kidney NN 4_p
-DOCSTART- -X- O O 25795413

overweight NN 4_p
and CC 4_p
obese JJ 4_p
adults NNS 1_p
. . N

25 CD 3_p
healthy JJ N
lean NN N
and CC N
23 CD 3_p
overweight/obese JJ N
participants NNS N
-DOCSTART- -X- O O 20937044

patients NNS N
( ( N
n=209 JJ N
MG NNP N
, , N
n=96 RB N
placebo NN N
) ) N
with IN N
UC NNP N
in IN N
remission NN N
[ NNS N
revised VBN N
Sutherland NNP N
Disease NNP N
Activity NNP N
Index NNP N
( ( N
SDAI NNP N
) ) N
rectal NN N
bleeding=0 NN N
, , N
mucosal JJ N
appearance NN N
< VBD N
2 CD N
] NN N
who WP N
took VBD N
MG NNP N
1.5 CD N
g NN N
or CC N
placebo VB N
once-daily RB N
for IN N
up IN N
to TO N
6 CD N
months NNS N
The DT N
percentage NN N
of IN N
relapse-free JJ N
patients NNS N
at IN N
month NN N
6/end CD N
of IN N
treatment NN N
-DOCSTART- -X- O O 25449737

Humans NNPS 4_p
combine JJ 4_p
co-emitted JJ 4_p
social JJ 4_p
signals NNS 4_p
participants NNS N
observer NN N
-DOCSTART- -X- O O 3602307

autistic JJ 4_p
children NNS 1_p
: : N
-DOCSTART- -X- O O 17698601

after IN N
hip NN 4_p
fracture NN 4_p
surgery NN N
. . N

139 CD 3_p
nondepressed JJ N
elderly JJ 1_p
patients NNS N
( ( N
> JJ 1_p
60 CD 1_p
years NNS 1_p
) ) N
hospitalized VBD N
for IN N
hip NN 4_p
fracture NN 4_p
surgery NN N
nondepressed JJ N
patients NNS N
after IN N
hip-fracture JJ 4_p
surgery NN N
. . N

-DOCSTART- -X- O O 15572491

after IN 4_p
vaginal JJ 4_p
delivery NN 4_p
: : 4_p
after IN 4_p
vaginal JJ 4_p
delivery NN 4_p
. . 4_p

patients NNS N
between IN N
22 CD N
weeks NNS N
and CC N
42 CD N
weeks NNS N
of IN N
gestation NN N
with IN N
anticipated JJ N
vaginal JJ 4_p
delivery NN 4_p
. . N

a DT N
total NN N
of IN N
1,604 CD 3_p
patients NNS 3_p
would MD N
be VB N
required VBN N
in IN N
each DT N
group NN N
. . N

A DT N
total NN N
of IN N
848 CD 3_p
patients NNS 3_p
were VBD N
enrolled VBN N
and CC N
756 CD 3_p
randomly RB N
assigned VBN N
, , N
377 CD 3_p
in IN 3_p
the DT 3_p
misoprostol NN 3_p
group NN 3_p
and CC N
379 CD 3_p
in IN 3_p
the DT 3_p
placebo NN 3_p
group NN 3_p
. . N

Demographic NNP 4_p
, , 4_p
antepartum NN 4_p
, , 4_p
and CC 4_p
intrapartum NN 4_p
characteristics NNS 4_p
were VBD 4_p
similar JJ 4_p
between IN 4_p
the DT 4_p
groups NNS 4_p
. . N

-DOCSTART- -X- O O 9269786

acute JJ 4_p
promyelocytic JJ 4_p
leukemia NN 4_p
: : 4_p
acute JJ 4_p
promyelocytic JJ 4_p
leukemia NN 4_p
( ( 4_p
APL NNP 4_p
) ) 4_p
previously RB N
untreated VBN N
adult NN 1_p
APL NNP N
patients NNS N
registered VBD N
to TO N
protocol VB N
INT NNP N
0129 CD N
by IN N
the DT N
Eastern NNP N
Cooperative NNP N
Oncology NNP N
Group NNP N
, , N
the DT N
Southwest NNP N
Oncology NNP N
Group NNP N
, , N
and CC N
the DT N
Cancer NNP N
and CC N
Leukemia NNP N
Group NNP N
B NNP N
. . N

Of IN N
279 CD 3_p
clinically RB N
eligible JJ N
cases NNS N
, , N
230 CD 3_p
were VBD N
molecularly RB N
evaluable JJ N
APL NNP N
patients NNS N
. . N

-DOCSTART- -X- O O 24076133

patients NNS 4_p
with IN 4_p
major JJ 4_p
depressive JJ 4_p
disorder NN 4_p
( ( 4_p
MDD NNP 4_p
) ) 4_p
. . N

15 CD 3_p
MDD NNP 3_p
patients NNS 3_p
and CC N
14 CD 3_p
age-matched JJ 3_p
controls NNS 3_p
. . N

MDD NNP N
patients NNS N
and CC N
age-matched JJ N
controls NNS N
MDD NNP N
patients NNS N
-DOCSTART- -X- O O 25432505

4-year-old JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
: : N
4-year-old JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( N
experimental JJ N
n NN 3_p
= VBD 3_p
5 CD 3_p
, , N
control NN N
n JJ 3_p
= NNP 3_p
4 CD 3_p
) ) N
; : N
benefit VB N
young JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
-DOCSTART- -X- O O 2709180

episiotomy/laceration NN 4_p
. . N

Ninety NN 3_p
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
treatment NN N
groups NNS N
. . N

30 CD 3_p
subjects NNS N
applying VBG N
a DT N
warm JJ N
perineal NN N
pack NN N
, , N
30 CD 3_p
applying VBG N
a DT N
cold JJ N
perineal NN N
pack NN N
, , N
and CC N
30 CD 3_p
taking VBG N
a DT N
warm JJ N
sitz NN N
bath NN N
. . N

-DOCSTART- -X- O O 8060436

patients NNS N
with IN N
exacerbated JJ 4_p
bronchial JJ 4_p
asthma NN 4_p
who WP 4_p
required VBD 4_p
hospitalization NN 4_p
. . N

From IN 4_p
January NNP 4_p
to TO 4_p
May NNP 4_p
1990 CD 4_p
known NN N
asthmatics NNS N
admitted VBN N
with IN N
acute JJ 4_p
exacerbation NN 4_p
were VBD N
included VBN N
by IN N
established VBN N
criteria NNS N
. . N

Fifteen JJ 3_p
patients NNS N
enrolled VBN N
in IN N
both DT N
groups NNS N
, , N
two CD N
patients NNS N
of IN N
group NN N
I PRP N
were VBD N
excluded VBN N
-DOCSTART- -X- O O 1990041

beta-hemolytic JJ 4_p
streptococcal JJ 4_p
pharyngitis NN 4_p
group NN 4_p
A NNP 4_p
beta-hemolytic JJ 4_p
streptococcal JJ 4_p
pharyngitis NN 4_p
group NN N
A DT N
beta-hemolytic JJ N
streptococcal JJ N
organism NN N
from IN N
the DT N
throats NNS N
of IN N
93 CD N
patients NNS N
with IN N
pharyngitis NN N
. . N

37 CD N
patients NNS N
; : N
27 CD N
% NN N
of IN N
these DT N
had VBD N
one CD N
or CC N
more JJR N
pharyngeal JJ N
organisms NNS N
that WDT N
were VBD N
producing VBG N
beta-lactamase NN N
. . N

-DOCSTART- -X- O O 19798489

typical JJ N
adults NNS 1_p
and CC 1_p
adults NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . 4_p

People NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
people NNS 4_p
with IN 4_p
ASD NNP 4_p
adults NNS 1_p
with IN N
ASD NNP 4_p
-DOCSTART- -X- O O 26078323

in IN 4_p
Ethiopia NNP 4_p
. . N

a DT N
large JJ N
number NN N
of IN N
human JJ N
volunteers NNS N
in IN N
India NNP N
, , N
Vietnam NNP N
, , N
and CC N
Bangladesh NNP N
in IN N
Ethiopia NNP N
evaluated VBD N
the DT N
safety NN N
and CC N
immunogenicity NN N
of IN N
the DT N
vaccine NN N
in IN N
216 CD 3_p
healthy JJ N
adults NNS 1_p
and CC N
children NNS 1_p
. . 1_p

population NN N
outside IN N
Asia NNP N
-DOCSTART- -X- O O 20530107

manikin JJ N
model NN N
. . N

modified JJ N
resuscitation NN N
manikin NN N
Thirty-six NNP N
experienced VBD N
practitioners NNS N
-DOCSTART- -X- O O 7005474

essential JJ N
hypertension NN N
. . N

19 CD N
ambulatory JJ N
men NNS N
with IN N
moderated VBN N
essential JJ N
hypertension NN N
( ( N
supine JJ N
diastolic NN N
blood NN N
pressure NN N
[ NNP N
DPB NNP N
] NNP N
, , N
100 CD N
to TO N
120 CD N
mm NNS N
Hg NNP N
after IN N
receiving VBG N
placebo NN N
for IN N
two CD N
weeks NNS N
) ) N
whose WP$ N
sodium JJ N
intake NN N
was VBD N
unrestricted VBN N
. . N

The DT N
captopril NN N
group NN N
included VBD N
12 CD N
patients NNS N
and CC N
the DT N
propranolol NN N
group NN N
seven CD N
. . N

moderate JJ N
essential JJ N
hypertension NN N
. . N

-DOCSTART- -X- O O 19001830

hemodialysis NN 4_p
patients NNS N
. . N

101 CD 3_p
hemodialysis NN 4_p
patients NNS N
were VBD N
randomized VBN N
The DT N
71 CD 3_p
patients NNS N
who WP N
concluded VBD N
the DT N
study NN N
had VBD N
similar JJ N
baseline NN N
characteristics NNS N
. . N

-DOCSTART- -X- O O 21084429

metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
. . 4_p

patients NNS N
with IN N
metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
, , N
where WRB N
the DT N
alternate NN N
crossover NN N
monotherapy NN N
( ( N
GD→C NNP N
or CC N
CD→G NNP N
) ) N
was VBD N
predetermined VBN N
RESULTS NNP N
Despite IN N
over-accrual JJ N
of IN N
475 CD 3_p
patients NNS N
, , N
the DT N
trial NN N
matured VBD N
with IN N
only RB N
324 CD 3_p
of IN 3_p
385 CD 3_p
planned JJ N
TtP NNP N
events NNS N
due JJ N
to TO N
patient JJ N
discontinuations NNS N
-DOCSTART- -X- O O 2943781

acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
: : 4_p
28 CD N
patients NNS N
presenting VBG N
within IN N
12 CD N
hours NNS N
of IN N
the DT N
onset NN N
of IN N
symptoms NNS N
of IN N
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
were VBD N
prospectively RB N
randomized VBN N
. . N

14 CD N
patients NNS N
were VBD N
treated VBN N
with IN N
emergency NN N
angioplasty NN N
and CC N
14 CD N
patients NNS N
patients NNS N
with IN N
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
. . N

-DOCSTART- -X- O O 23838275

patients NNS 4_p
with IN 4_p
schizophrenia NN 4_p
. . N

patients NNS N
with IN N
schizophrenia JJ 4_p
displayed NNS N
lower JJR N
FMRP NNP N
levels NNS N
in IN N
peripheral JJ N
lymphocytes NNS N
control VB N
individuals NNS N
. . N

patients NNS N
-DOCSTART- -X- O O 2076713

in IN N
hypertensive JJ 4_p
subjects NNS N
. . N

double-blind NN N
, , N
placebo NN N
controlled VBD N
, , N
parallel FW N
group NN N
two CD 3_p
appropriate JJ N
groups NNS N
. . N

-DOCSTART- -X- O O 9849475

advanced JJ N
, , N
suboptimally RB N
debulked JJ N
ovarian JJ N
cancer NN N
. . N

176 CD N
eligible JJ N
patients NNS N
with IN N
advanced JJ N
suboptimally RB N
operated JJ N
ovarian JJ N
carcinoma NN N
Thirty-seven JJ N
platinum-resistant JJ N
and CC N
27 CD N
platinum-sensitive JJ N
tumours NNS N
Patients NNS N
with IN N
platinum-sensitive JJ N
tumours NNS N
suboptimally RB N
operated JJ N
ovarian JJ N
carcinoma NN N
patients NNS N
Patients NNS N
with IN N
recurrences NNS N
considered VBN N
as IN N
platinum-sensitive JJ N
-DOCSTART- -X- O O 11446476

gynaecologic JJ 4_p
oncologic JJ 4_p
surgery NN 4_p
: : 4_p
gynaecological JJ N
oncologic NN N
surgery NN N
. . N

102 CD N
consecutive JJ N
women NNS N
undergoing VBG N
gynaecologic JJ N
cancer NN N
surgery NN N
with IN N
pelvic NN N
and CC N
paraaortic JJ N
lymphadenectomy NN N
. . N

The DT N
two CD N
groups NNS N
were VBD N
well RB N
matched VBN N
for IN N
age NN N
, , N
weight NN N
, , N
and CC N
other JJ N
factors NNS N
-DOCSTART- -X- O O 16125499

patients NNS 4_p
with IN 4_p
left JJ 4_p
ventricular JJ 4_p
systolic JJ 4_p
dysfunction NN 4_p
and CC 4_p
heart NN 4_p
failure NN 4_p
receiving VBG 4_p
either CC 4_p
candesartan NN 4_p
or CC 4_p
enalapril NN 4_p
or CC 4_p
both DT 4_p
. . 4_p

patients NNS N
with IN N
systolic JJ N
dysfunction NN N
and CC N
heart NN N
failure NN N
receiving VBG N
therapeutic JJ N
inhibition NN N
of IN N
the DT N
renin-angiotensin-aldosterone NN N
system NN N
. . N

768 CD N
treated JJ N
patients NNS N
with IN N
heart NN N
failure NN N
measured VBN N
at IN N
baseline NN N
treated JJ N
patients NNS N
with IN N
heart NN N
failure NN N
-DOCSTART- -X- O O 8077143

cows NNS N
with IN N
endotoxin-induced JJ 4_p
mastitis NN 4_p
16 CD 3_p
cows NNS N
for IN N
6 CD N
milkings NNS N
8 CD 3_p
cows NNS N
were VBD N
treated VBN N
with IN N
isotonic JJ N
saline NN N
solution NN N
8 CD 3_p
cows NNS N
were VBD N
treated VBN N
with IN N
hypertonic JJ N
saline JJ N
solution NN N
. . N

cows NNS 2_p
-DOCSTART- -X- O O 12612897

healthy JJ 4_p
human JJ 4_p
volunteers NNS N
: : N
healthy JJ 4_p
human JJ 4_p
volunteers NNS N
. . N

Forty NNP 3_p
healthy JJ N
subjects NNS N
healthy JJ 4_p
volunteers NNS N
-DOCSTART- -X- O O 24101016

cancer NN 4_p
: : N
Patients NNPS N
with IN N
a DT N
resectable JJ 4_p
esophageal NN 4_p
cancer NN 4_p
were VBD N
randomized VBN N
to TO N
OE NNP N
( ( N
n JJ N
= NNP N
13 CD 3_p
) ) N
or CC N
MIE NNP N
( ( N
n JJ N
= NNP N
14 CD 3_p
) ) N
. . N

All DT N
patients NNS N
received VBD N
neoadjuvant JJ N
chemoradiotherapy NN N
. . N

-DOCSTART- -X- O O 862429

Comparison NNP N
of IN N
synemol JJ N
cream NN N
and CC N
other JJ N
topical JJ N
corticosteroid NN N
creams NNS N
using VBG N
the DT N
vasoconstrictor NN N
bioassay NN N
. . N

human JJ N
vasoconstrictor NN N
bioassay NN N
open JJ N
applications NNS N
of IN N
Synemol NNP N
cream NN N
( ( N
0.025 CD N
% NN N
) ) N
, , N
Diprosone NNP N
cream NN N
( ( N
0.05 CD N
% NN N
) ) N
, , N
Aristocort-A NNP N
cream NN N
( ( N
0.5 CD N
% NN N
) ) N
, , N
and CC N
Valisone NNP N
cream NN N
( ( N
0.1 CD N
% NN N
) ) N
. . N

vasoconstriction NN N
-DOCSTART- -X- O O 15200998

patients NNS N
with IN N
non-small JJ N
cell NN N
lung NN 4_p
cancer NN 4_p
: : N
non-small JJ N
cell NN N
lung NN 4_p
cancer NN 4_p
( ( N
NSCLC NNP N
) ) N
381 CD 3_p
patients NNS N
were VBD N
randomised VBN N
to TO N
chemotherapy VB N
( ( N
C NNP N
, , N
192 CD 3_p
patients NNS N
) ) N
or CC N
no DT N
chemotherapy NN N
( ( N
NoC NNP N
, , N
189 CD 3_p
patients NNS N
) ) N
. . N

-DOCSTART- -X- O O 8063348

in IN N
normal JJ N
male JJ N
college NN N
students NNS N
. . N

-DOCSTART- -X- O O 1945967

patients NNS N
with IN N
acute JJ 4_p
leukemia NN 4_p
. . N

rectal JJ 4_p
infections NNS 4_p
patients NNS N
with IN N
acute JJ 4_p
leukemia NN 4_p
. . N

sample NN N
consisted VBD N
of IN N
40 CD 3_p
patients NNS N
-DOCSTART- -X- O O 25840597

newly RB 4_p
diagnosed VBN 4_p
multiple JJ 4_p
myeloma NN 4_p
. . N

314 CD 3_p
of IN 3_p
604 CD 3_p
patients NNS 3_p
had VBD N
been VBN N
enrolled VBN N
. . N

598 CD 3_p
patients NNS 3_p
who WP N
received VBD N
at IN N
least JJS N
one CD N
dose NN N
of IN N
trial NN N
medication NN N
. . N

patients NNS 4_p
treated VBN 4_p
with IN 4_p
intravenous JJ 4_p
bortezomib NNS 4_p
patients NNS N
treated VBN 4_p
with IN 4_p
intravenous JJ 4_p
bortezomib NN 4_p
-DOCSTART- -X- O O 11867842

infants NNS 1_p
born VBN 4_p
to TO 4_p
anemic JJ 4_p
mothers NNS 4_p
: : 4_p
infants NNS N
born VBN N
to TO N
anemic VB N
mothers NNS N
at IN N
3 CD N
months NNS N
of IN N
age NN N
. . N

Teaching NNP N
hospital NN N
. . N

Infants NNPS N
born VBN N
to TO N
mothers NNS N
with IN N
hemoglobin NN N
( ( N
Hb NNP N
) ) N
< VBD N
100 CD N
g/L NNS N
102 CD N
neonates NNS N
neonates NNS N
born VBN N
to TO N
anemic VB N
mothers NNS N
-DOCSTART- -X- O O 3739807

Abstinence NN 4_p
or CC 4_p
controlled VBN 4_p
drinking NN 4_p
excessive JJ 4_p
drinkers NNS 4_p
46 CD 3_p
clients NNS N
of IN N
a DT N
clinical JJ N
psychology NN N
alcohol NN N
problems NNS N
service NN N
( ( N
30 CD 3_p
men NNS 2_p
, , N
16 CD 3_p
women NNS 2_p
) ) N
Those DT N
with IN N
dependence NN N
indicators NNS N
for IN N
abstinence NN N
-DOCSTART- -X- O O 7936677

Management NN 4_p
of IN 4_p
the DT 4_p
thyroid JJ 4_p
isthmus NN 4_p
in IN 4_p
tracheostomy NN 4_p
: : 4_p
a DT 4_p
prospective JJ 4_p
and CC 4_p
retrospective JJ 4_p
study NN 4_p
. . 4_p

-DOCSTART- -X- O O 1835223

skin NN 4_p
and CC 4_p
soft-tissue JJ 4_p
infections NNS 4_p
. . N

75 CD 3_p
patients NNS N
received VBD N
teicoplanin JJ N
intravenously RB N
( ( N
38 CD N
) ) N
or CC N
intramuscularly RB N
( ( N
37 CD N
, , N
of IN N
which WDT N
16 CD N
were VBD N
outpatients NNS N
) ) N
62 CD 3_p
clinically RB 3_p
evaluable JJ 3_p
patients NNS 3_p
-DOCSTART- -X- O O 18307223

after IN N
cardiac JJ N
catheterization NN N
: : N
450 CD N
patients NNS N
-DOCSTART- -X- O O 26653722

Cataract NNP 4_p
Patients NNPS 4_p
underwent JJ 4_p
either CC 4_p
image-guided JJ 4_p
femtosecond NN 4_p
laser NN 4_p
cataract NN 4_p
surgery NN 4_p
or CC N
conventional JJ 4_p
cataract NN 4_p
surgery NN 4_p
( ( 3_p
n JJ 3_p
= NNP 3_p
75 CD 3_p
) ) N
. . N

all DT 3_p
patients NNS 3_p
. . N

femtosecond NN 3_p
laser NN 3_p
group NN 3_p
, , N
patients NNS N
than IN N
patients NNS N
not RB N
pretreated VBN N
in IN N
patients NNS 4_p
treated VBN 4_p
with IN 4_p
image-guided JJ 4_p
femtosecond NN 4_p
laser NN 4_p
-DOCSTART- -X- O O 16454975

335 CD 3_p
patients NNS N
undergoing VBG N
percutaneous JJ 4_p
coronary JJ 4_p
intervention NN 4_p
in IN N
China NNP N
. . N

A DT N
total NN N
of IN N
335 CD 3_p
patients NNS N
were VBD N
randomized VBN N
A DT N
total NN N
of IN N
308 CD 3_p
patients NNS N
( ( N
91.9 CD N
% NN N
) ) N
completed VBD N
the DT N
study NN N
and CC N
145 CD 3_p
cases NNS N
( ( N
47.1 CD N
% NN N
) ) N
received VBD N
angiographic JJ N
follow-up NN N
. . N

post-PCI JJ N
patients NNS N
. . N

-DOCSTART- -X- O O 21300377

psychotic JJ 4_p
depression NN 4_p
patients NNS N
with IN N
major JJ 4_p
depression NN 4_p
. . N

major JJ 4_p
depression NN 4_p
with IN 4_p
psychotic JJ 4_p
features NNS 4_p
( ( 4_p
MDpsy NNP 4_p
) ) 4_p
. . N

MDpsy NNP 4_p
in IN N
patients NNS N
who WP N
participated VBD N
in IN N
the DT N
STOPD-PD NNP N
study NN N
, , N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
clinical JJ N
trial NN N
comparing VBG N
a DT N
subjects NNS N
with IN N
a DT N
history NN N
of IN N
no DT N
prior JJ N
treatment NN N
or CC N
inadequate JJ N
treatment NN N
who WP N
were VBD N
treated VBN N
with IN N
a DT N
combination NN N
of IN N
olanzapine NN N
and CC N
sertraline NN N
. . N

subjects NNS N
who WP N
had VBD N
previously RB N
failed VBN N
to TO N
respond VB N
to TO N
an DT N
antidepressant JJ N
alone NN N
and CC N
who WP N
were VBD N
treated VBN N
with IN N
olanzapine JJ N
monotherapy NN N
. . N

subjects NNS N
who WP N
had VBD N
previously RB N
failed VBN N
to TO N
respond VB N
to TO N
a DT N
combination NN N
of IN N
an DT N
antipsychotic JJ N
and CC N
an DT N
antidepressant NN N
. . N

patients NNS N
with IN N
MDpsy NNP 4_p
. . N

-DOCSTART- -X- O O 23061531

acute JJ 4_p
anterior JJ 4_p
ST-elevation NNP 4_p
myocardial JJ 4_p
infarction NN 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
acute JJ 4_p
anterior JJ 4_p
STEMI NNP 4_p
receiving VBG 4_p
thrombolytic JJ 4_p
treatment NN 4_p
( ( 4_p
TLT NNP 4_p
) ) 4_p
. . 4_p

101 CD N
patients NNS N
with IN N
acute JJ N
anterior JJ N
STEMI NNP N
who WP N
were VBD N
candidate NN N
for IN N
TLT NNP N
-DOCSTART- -X- O O 1584317

hemodialysis NN 4_p
patients NNS 4_p
. . N

80 CD 3_p
stable JJ N
chronic JJ 4_p
hemodialysis NN 4_p
patients NNS N
selected VBN N
on IN N
the DT N
basis NN N
of IN N
their PRP$ N
acceptable JJ N
control NN N
of IN N
serum NN N
phosphorus NN N
( ( N
P NNP N
) ) N
levels NNS N
with IN N
aluminum NN N
hydroxide NN N
( ( N
AH NNP N
) ) N
. . N

patients NNS N
were VBD N
dialyzed VBN N
against IN N
the DT N
same JJ N
calcium NN N
dialyzate NN N
-DOCSTART- -X- O O 8104273

stroke NN 4_p
patients NNS N
16 CD 3_p
consecutive JJ N
patients NNS N
( ( N
median JJ N
age NN N
58.5 CD 1_p
years NNS 1_p
, , 1_p
range VB 1_p
40-83 JJ 1_p
) ) N
Crying VBG 4_p
history NN 4_p
was VBD N
determined VBN N
from IN N
semistructured VBN N
interviews NNS N
and CC N
from IN N
diaries NNS N
kept VBN N
by IN N
the DT N
patients NNS N
. . N

13 CD 3_p
patients NNS N
in IN N
whom WP N
frequency NN N
of IN N
crying NN 4_p
-DOCSTART- -X- O O 26449739

male JJ 2_p
patients NNS N
with IN N
diffuse JJ 4_p
large JJ 4_p
B-cell NNP 4_p
lymphoma NN 4_p
. . N

multicentre NN N
321 CD 3_p
patients NNS 3_p
[ JJ N
161 CD 3_p
randomized VBN 3_p
to TO N
the DT N
treatment NN N
group NN N
( ( N
TG NNP N
) ) N
, , N
160 CD 3_p
to TO N
the DT N
observation NN N
group NN N
( ( N
OG NNP N
) ) N
] NN N
, , N
295 CD N
data NNS N
sets NNS N
( ( N
DLBCL NNP N
) ) N
subgroup NN N
in IN N
male JJ 2_p
patients NNS N
of IN N
the DT N
DLBCL NNP N
subgroup NN N
survival NN N
in IN N
male JJ 2_p
patients NNS N
-DOCSTART- -X- O O 15492949

men NNS 2_p
with IN N
moderate JJ 4_p
chronic JJ 4_p
renal JJ 4_p
insufficiency NN 4_p
and CC N
coronary JJ 4_p
disease NN 4_p
. . N

individuals NNS N
with IN N
chronic JJ 4_p
renal JJ 4_p
insufficiency NN 4_p
( ( 4_p
CRI NNP 4_p
) ) 4_p
. . N

people NNS N
with IN N
moderate JJ 4_p
CRI NNP 4_p
. . N

2,531 CD 3_p
men NNS 2_p
with IN N
coronary JJ 4_p
disease NN 4_p
, , N
HDL-C NNP N
levels NNS N
of IN N
40 CD N
mg/dL NN N
or CC N
less JJR N
( ( N
< NN N
or CC N
=1.0 VB N
mmol/L NN N
) ) N
, , N
low-density JJ 4_p
lipoprotein NN 4_p
cholesterol NN 4_p
levels NNS N
of IN N
140 CD N
mg/dL NN N
or CC N
less JJR N
( ( N
< NN N
or CC N
=3.6 VB N
mmol/L NN N
) ) N
, , N
and CC N
a DT N
range NN N
of IN N
triglyceride NN N
values NNS N
. . N

1,981 CD 3_p
individuals NNS N
, , N
of IN N
whom WP N
399 CD 3_p
individuals NNS N
( ( N
20.2 CD N
% NN N
) ) N
were VBD N
eligible JJ N
for IN N
inclusion NN N
. . N

399 CD 3_p
study NN N
subjects NNS N
individuals NNS N
with IN N
moderate JJ 4_p
CRI NNP 4_p
, , N
low JJ 4_p
HDL-C NNP 4_p
levels NNS 4_p
, , N
and CC N
concomitant JJ N
coronary JJ 4_p
disease NN 4_p
. . N

-DOCSTART- -X- O O 9203648

HIV-infected NNP 4_p
pregnant JJ N
women NNS 2_p
and CC N
their PRP$ N
newborns NNS N
. . N

first JJ N
28 CD 3_p
maternal-infant JJ 1_p
pairs NNS 1_p
enrolled VBN N
in IN N
a DT N
randomized JJ N
, , N
intravenous JJ 4_p
immunoglobulin NN 4_p
( ( N
IVIG NNP N
) ) N
-controlled VBD N
trial NN N
of IN N
HIVIG NNP N
maternal-infant JJ N
HIV NNP 4_p
transmission NN N
prophylaxis NN N
. . N

HIV-infected NNP N
pregnant JJ 2_p
women NNS 2_p
and CC N
their PRP$ 1_p
newborns NNS 1_p
-DOCSTART- -X- O O 18983318

single JJ 4_p
tooth NN 4_p
in IN N
the DT N
esthetic JJ 4_p
zone NN 4_p
. . N

Sixteen JJ 3_p
patients NNS 1_p
( ( 1_p
10 CD 1_p
women NNS 1_p
and CC 1_p
6 CD 1_p
men NNS 1_p
) ) 1_p
with IN 1_p
a DT 1_p
mean JJ 1_p
age NN 1_p
of IN 1_p
35 CD 1_p
years NNS 1_p
( ( 1_p
ranging VBG 1_p
from IN 1_p
21 CD 1_p
to TO 1_p
49 CD 1_p
years NNS 1_p
old JJ 1_p
) ) 1_p
were VBD 1_p
treated VBN 1_p
from IN 1_p
2004 CD 1_p
to TO 1_p
2005 CD 1_p
for IN 1_p
single-tooth JJ 4_p
replacement NN 4_p
in IN 4_p
the DT 4_p
upper JJ 4_p
arch NN 4_p
. . 1_p

The DT N
patients NNS N
were VBD N
randomly RB N
divided VBN N
All PDT N
the DT N
patients NNS N
received VBD N
tapered JJ 4_p
effect NN 4_p
( ( 4_p
TE NNP 4_p
) ) 4_p
implants NNS 4_p
from IN N
the DT N
Straumann NNP 4_p
Dental NNP 4_p
Implant NNP 4_p
System NNP 4_p
. . N

-DOCSTART- -X- O O 20936417

cancer NN 4_p
patients NNS N
. . N

patients NNS N
undergoing VBG N
therapy NN N
with IN N
neurotoxic JJ N
chemotherapy NN N
100 CD 3_p
patients NNS N
per IN N
arm NN N
Two-hundred JJ 3_p
seven CD 3_p
patients NNS N
were VBD N
enrolled VBN N
between IN N
December NNP N
1 CD N
, , N
2006 CD N
and CC N
December NNP N
14 CD N
, , N
2007 CD N
, , N
producing VBG N
189 CD 3_p
evaluable JJ N
cases NNS N
for IN N
analysis NN N
. . N

studied JJ N
group NN N
of IN N
patients NNS N
receiving VBG N
neurotoxic JJ N
chemotherapy NN N
-DOCSTART- -X- O O 23306077

underresourced JJ 4_p
, , 4_p
urban JJ 4_p
African JJ 4_p
American JJ 4_p
communities NNS 4_p
, , 4_p
2010 CD 4_p
. . 4_p

African JJ 4_p
Americans NNPS 4_p
in IN 4_p
an DT 4_p
underresourced JJ 4_p
community NN 4_p
. . 4_p

African JJ N
Americans NNPS N
in IN N
2 CD N
North NNP N
Carolina NNP N
neighborhoods NNS N
who WP N
had VBD N
high JJ N
blood NN N
pressure NN N
and CC N
used VBD N
fewer JJR N
than IN N
3 CD N
antihypertension NN N
medications NNS N
. . N

Of IN N
152 CD N
potential JJ N
participants NNS N
, , N
25 CD N
were VBD N
randomly RB N
assigned VBN N
to TO N
either CC N
the DT N
intervention NN N
( ( N
n JJ N
= NNP N
14 CD N
) ) N
or CC N
the DT N
control NN N
( ( N
n JJ N
= NNP N
11 CD N
) ) N
group NN N
; : N
22 CD N
were VBD N
women NNS N
, , N
and CC N
21 CD N
were VBD N
educated VBN N
beyond IN N
high JJ N
school NN N
. . N

At IN N
baseline NN N
, , N
mean JJ N
blood NN N
pressure NN N
was VBD N
130/78 CD N
mm JJ N
Hg NNP N
; : N
19 CD N
participants NNS N
used VBN N
antihypertension NN N
medications NNS N
, , N
and CC N
mean VB N
body NN N
mass NN N
index NN N
was VBD N
35.9 CD N
kg/m NN N
( ( N
2 CD N
) ) N
. . N

small JJ N
sample NN N
of IN N
African JJ N
Americans NNPS N
, , N
which WDT N
included VBD N
people NNS N
being VBG N
treated VBN N
for IN N
high JJ N
blood NN N
pressure NN N
. . N

-DOCSTART- -X- O O 11561265

mastectomy NN 4_p
with IN 4_p
immediate JJ 4_p
TRAM NNP 4_p
flap NN 4_p
breast NN 4_p
reconstruction NN 4_p
. . N

patients NNS N
undergoing VBG N
a DT N
major JJ 4_p
surgical JJ 4_p
procedure NN 4_p
( ( 4_p
i.e. FW 4_p
unilateral JJ 4_p
mastectomy NN 4_p
with IN 4_p
immediate JJ 4_p
transverse NN 4_p
rectus NN 4_p
abdominis VBP 4_p
musculocutaneous JJ 4_p
flap JJ 4_p
reconstruction NN 4_p
) ) 4_p
. . 4_p

Eighteen JJ 3_p
patients NNS N
-DOCSTART- -X- O O 14996351

412 CD 3_p
patients NNS N
with IN N
hepatitis NN 4_p
C NNP 4_p
infection NN 4_p
-DOCSTART- -X- O O 1562431

cadaver JJ 4_p
femoral JJ 4_p
osteotomy NN 4_p
. . N

46 CD 3_p
femoral JJ 4_p
shaft NN 4_p
fractures NNS 4_p
were VBD N
randomized VBN N
to TO N
treatment NN N
with IN N
Gross-Kempf NNP N
nails NNS N
, , N
24 CD 3_p
with IN N
slotted VBN 4_p
nails NNS 4_p
and CC N
22 CD 3_p
with IN N
non-slotted JJ 4_p
nails NNS 4_p
. . N

femoral JJ 4_p
fractures NNS 4_p
. . N

-DOCSTART- -X- O O 25861158

children NNS 1_p
with IN N
autism NN 4_p
: : N
autism NN 4_p
Twenty NNP 3_p
male JJ 2_p
children NNS 1_p
with IN N
autism NN 4_p
were VBD N
randomly RB N
assigned VBN N
-DOCSTART- -X- O O 15491374

low JJ 4_p
birth NN 4_p
weight NN 4_p
infants NNS 1_p
. . N

low JJ N
birth NN N
weight NN N
infants NNS N
. . N

low JJ N
birth NN N
weight NN N
infants NNS N
( ( N
average JJ N
birth NN N
weight NN N
1489 CD N
g NN N
) ) N
. . N

low JJ N
birth NN N
weight NN N
infants NNS N
-DOCSTART- -X- O O 11352886

humans NNS N
. . N

Patients NNP N
undergoing JJ 4_p
carotid NNS 4_p
endarterectomy VBP 4_p
( ( N
n=14 NN N
) ) N
( ( N
n=14 NN N
) ) N
( ( N
n=14 JJ N
) ) N
All DT N
patients NNS N
were VBD N
pretreated VBN N
with IN N
aspirin NN N
and CC N
given VBN N
heparin NNS N
during IN N
surgery NN N
. . N

thromboembolic JJ N
disease NN N
. . N

relatively RB N
small JJ N
numbers NNS N
of IN N
patients NNS N
. . N

-DOCSTART- -X- O O 7489845

diabetic JJ 4_p
nephropathy NN 4_p
. . 4_p

progressive JJ 4_p
glomerular JJ 4_p
injury NN 4_p
. . 4_p

34 CD 3_p
patients NNS N
with IN N
non-insulin-dependent JJ 4_p
diabetes NNS 4_p
mellitus NNS 4_p
. . N

-DOCSTART- -X- O O 20854436

humans NNS N
in IN N
vivo NN N
: : N
20 CD 3_p
healthy JJ N
women NNS 2_p
( ( N
median JJ 1_p
age NN 1_p
33 CD 1_p
years NNS 1_p
, , N
range VBP 1_p
21-47 JJ 1_p
; : N
phototype JJ N
I/II NNP N
) ) N
-DOCSTART- -X- O O 16731138

after IN 4_p
coronary JJ 4_p
artery NN 4_p
bypass NN 4_p
graft NN 4_p
surgery NN 4_p
using VBG 4_p
cardiopulmonary JJ 4_p
bypass NN 4_p
. . 4_p

Consecutively RB 4_p
listed VBD 4_p
candidates NNS 4_p
for IN 4_p
elective JJ 4_p
bypass NN 4_p
( ( 4_p
n JJ 4_p
= NNP 4_p
107 CD 4_p
) ) 4_p
-DOCSTART- -X- O O 16963850

retinal JJ N
angiomatous JJ N
proliferation NN N
: : N
retinal JJ N
angiomatous JJ N
proliferation NN N
( ( N
RAP NNP N
) ) N
Thirty-four JJ N
patients NNS N
with IN N
RAP NNP N
with IN N
any DT N
stage NN N
of IN N
neovascularization NN N
patients NNS N
with IN N
RAP NNP N
. . N

-DOCSTART- -X- O O 11545671

patients NNS N
with IN N
panic JJ 4_p
disorder NN 4_p
in IN N
primary JJ N
care NN N
. . N

One CD 3_p
hundred VBD 3_p
fifteen JJ 3_p
patients NNS N
with IN N
PD NNP 4_p
from IN N
3 CD N
primary JJ N
care NN N
clinics NNS N
primary JJ N
care NN N
PD NNP 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 3189201

childhood NN N
diarrhea NN 4_p
in IN N
urban JJ N
Bangladesh NNP N
: : N
childhood NN N
diarrhea NN N
Fifty-one CD 3_p
communities NNS 3_p
of IN 3_p
38 CD 3_p
families NNS 3_p
each DT 3_p
children NNS 1_p
less JJR 1_p
than IN 1_p
6 CD 1_p
y NN 1_p
childhood NN N
diarrhea NN N
-DOCSTART- -X- O O 24930383

regression NN N
of IN N
carotid JJ 4_p
atherosclerosis NN 4_p
. . N

subjects NNS N
with IN N
diabetes NNS 4_p
. . N

Hypercholesterolemic NNP N
subjects VBZ N
with IN N
type NN 4_p
2 CD 4_p
diabetes NNS 4_p
A DT N
total NN N
of IN N
97 CD 3_p
subjects NNS N
( ( N
51 CD 3_p
pitavastatin NN N
; : N
46 CD 3_p
pravastatin NN N
) ) N
completed VBD N
this DT N
36-month JJ N
study NN N
. . N

-DOCSTART- -X- O O 10939601

chemotherapy-naive JJ N
patients NNS N
with IN N
colorectal JJ 4_p
cancer NN 4_p
. . N

Forty-eight NNP 3_p
patients NNS N
were VBD N
randomized VBN N
Forty-five JJ 3_p
patients NNS N
were VBD N
assessable JJ N
for IN N
response NN N
: : N
-DOCSTART- -X- O O 9788685

nasal JJ 4_p
congestion NN 4_p
. . N

patients NNS 4_p
with IN 4_p
nasal JJ 4_p
congestion NN 4_p
. . 4_p

Twenty-four JJ 3_p
patients NNS N
with IN N
perennial JJ N
rhinitis NN N
due JJ N
to TO N
house-dust-mite JJ N
( ( N
HDM NNP N
) ) N
allergy NN N
were VBD N
recruited VBN N
-DOCSTART- -X- O O 15346745

humans NNS 4_p
. . N

Twenty-four NNP 3_p
subjects NNS N
, , N
each DT N
requiring VBG N
a DT N
nonmolar JJ 4_p
extraction NN 4_p
and CC N
delayed JJ 4_p
implant NN 4_p
placement NN 4_p
-DOCSTART- -X- O O 18078449

delayed JJ 4_p
sleep JJ 4_p
phase NN 4_p
syndrome NN 4_p
impaired JJ 4_p
sleep JJ 4_p
maintenance NN 4_p
children NNS 1_p
with IN N
neurodevelopmental JJ 4_p
disabilities NNS 4_p
. . N

delayed JJ 4_p
sleep JJ 4_p
phase NN 4_p
syndrome NN 4_p
impaired JJ 4_p
sleep JJ 4_p
maintenance NN 4_p
children NNS 1_p
with IN N
neurodevelopmental JJ 4_p
disabilities NNS 4_p
including VBG N
autistic JJ 4_p
spectrum NN 4_p
disorders NNS 4_p
. . N

Fifty-one CD 3_p
children NNS 1_p
( ( 1_p
age NN 1_p
range NN 1_p
2-18 CD 1_p
years NNS 1_p
) ) 1_p
who WP N
did VBD N
not RB N
respond VB N
to TO N
sleep VB N
hygiene NN N
intervention NN N
Children NNP 1_p
with IN N
neurodevelopmental JJ 4_p
disabilities NNS 4_p
had VBD N
treatment NN 4_p
resistant JJ 4_p
chronic JJ 4_p
delayed VBN 4_p
sleep JJ 4_p
phase NN 4_p
syndrome NN 4_p
and CC N
impaired JJ N
sleep JJ N
maintenance NN N
-DOCSTART- -X- O O 9648960

asthma NN 4_p
. . N

bronchial JJ 4_p
asthma NN 4_p
a DT N
group NN N
of IN N
asthmatic JJ N
subjects NNS N
. . N

asthmatic JJ N
patients NNS N
. . N

-DOCSTART- -X- O O 1827322

Hodgkin NNP 4_p
's POS 4_p
disease NN 4_p
. . 4_p

-DOCSTART- -X- O O 3353525

surgery NN N
of IN N
the DT N
abdominal JJ N
aorta NN N
] NNP N
lower JJR N
abdominal JJ N
surgery NN N
major JJ N
transabdominal JJ N
surgery NN N
. . N

31 CD N
patients NNS N
undergoing JJ N
elective JJ N
surgery NN N
of IN N
the DT N
abdominal JJ N
aorta NN N
-DOCSTART- -X- O O 17035531

individual JJ 4_p
differences NNS 4_p
in IN 4_p
sleep JJ 4_p
deprivation-induced JJ 4_p
12 CD 3_p
subjectively RB N
caffeine-sensitive JJ N
and CC N
10 CD 3_p
-insensitive JJ N
young JJ 1_p
men NNS 2_p
-DOCSTART- -X- O O 4187541

influenza NN 4_p
A2 NNP 4_p
infections NNS 4_p
in IN 4_p
the DT 4_p
family NN 4_p
environment NN 4_p
: : 4_p
-DOCSTART- -X- O O 20654755

female JJ 4_p
women NNS N
without IN N
previous JJ N
sexual JJ N
dysfunction NN N
. . N

Forty-nine JJ N
women NNS N
were VBD N
included VBN N
in IN N
the DT N
EE30/LNG150 NNP N
group NN N
and CC N
48 CD N
in IN N
the DT N
EE20/LNG100 NNP N
group NN N
. . N

-DOCSTART- -X- O O 25264862

young JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
: : 4_p
young JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
( ( 4_p
ASDs NNP 4_p
) ) 4_p
Children NNP 1_p
( ( N
N NNP 3_p
= NNP 3_p
128 CD 3_p
) ) N
with IN N
autism NN 4_p
or CC N
PDD-NOS NNP 4_p
( ( 4_p
DSM-4 NNP 4_p
criteria NNS 4_p
) ) 4_p
aged VBD 1_p
2 CD 1_p
years NNS 1_p
8 CD 1_p
months NNS 1_p
to TO 1_p
5 CD 1_p
years NNS 1_p
11 CD 1_p
months NNS 1_p
and CC 1_p
recruited VBN N
from IN N
5 CD N
disability NN N
agencies NNS N
in IN N
4 CD N
US JJ N
states NNS N
were VBD N
randomized VBN N
children NNS 1_p
with IN N
ASD NNP 4_p
and CC N
their PRP$ N
parents NNS N
. . N

-DOCSTART- -X- O O 22079088

in IN N
patients NNS N
with IN 4_p
pulmonary JJ 4_p
arterial JJ 4_p
hypertension NN 4_p
in IN N
patients NNS N
with IN 4_p
pulmonary JJ 4_p
arterial JJ 4_p
hypertension NN 4_p
( ( 4_p
PAH NNP 4_p
) ) 4_p
randomized VBD N
patients NNS N
with IN N
PAH NNP N
to TO N
receive VB N
placebo NN N
or CC N
sitaxsentan VB N
50 CD N
or CC N
100 CD N
mg NNS N
once RB N
daily RB N
RESULTS NNP N
Of IN N
98 CD 3_p
randomized JJ N
patients NNS N
, , N
61 CD 3_p
% NN 3_p
were VBD N
WHO NNP N
functional JJ N
class NN N
II NNP N
at IN N
baseline NN 4_p
not RB 4_p
6MWD CD 4_p
in IN 4_p
PAH NNP 4_p
patients NNS 4_p
who WP 4_p
were VBD 4_p
mostly RB 4_p
WHO NNP 4_p
functional JJ 4_p
class NN 4_p
II NNP 4_p
at IN 4_p
-DOCSTART- -X- O O 24821891

multiethnic JJ 4_p
sample NN 4_p
. . N

enrolled VBD 3_p
1,164 CD 3_p
patients NNS 3_p
stratified VBN N
by IN N
ethnicity NN N
and CC N
language NN N
( ( N
49.3 CD 3_p
% NN 3_p
non-Hispanic JJ 3_p
, , 3_p
27.2 CD 3_p
% NN 3_p
Hispanic/English NNP 3_p
, , 3_p
23.4 CD 3_p
% NN 3_p
Hispanic/Spanish NNP 3_p
) ) 3_p
from IN N
26 CD N
offices NNS N
around IN N
5 CD N
centers NNS N
( ( N
Sacramento NNP N
, , N
California NNP N
; : N
Rochester NNP N
and CC N
the DT N
Bronx NNP N
, , N
New NNP N
York NNP N
; : N
Denver NNP N
, , N
Colorado NNP N
; : N
and CC N
San NNP N
Antonio NNP N
, , N
Texas NNP N
) ) N
. . N

multiethnic JJ 4_p
sample NN 4_p
-DOCSTART- -X- O O 18390022

racial JJ 4_p
and CC 4_p
ethnic JJ 4_p
minorities NNS 4_p
in IN 4_p
the DT 4_p
Prostate NNP 4_p
, , 4_p
Lung NNP 4_p
, , 4_p
Colorectal NNP 4_p
and CC 4_p
Ovarian JJ 4_p
Cancer NNP 4_p
Screening NNP 4_p
Trial NNP 4_p
. . 4_p

Minority NNP N
populations NNS N
in IN N
the DT N
United NNP N
States NNPS N
, , N
especially RB N
blacks NNS N
and CC N
Hispanics NNPS N
ethnic JJ N
minorities NNS N
effectiveness NN 4_p
of IN 4_p
screening VBG 4_p
for IN 4_p
the DT 4_p
PLCO NNP 4_p
cancers NNS 4_p
. . N

Subjects NNS N
were VBD N
recruited VBN N
at IN N
10 CD N
U.S. NNP N
centers NNS N
between IN N
1993 CD N
and CC N
2001 CD N
. . N

blacks NNS N
Hispanics NNPS 4_p
. . N

155,000 CD 3_p
subjects NNS 3_p
enrolled VBN 3_p
in IN N
PLCO NNP N
, , N
minority NN N
enrollment NN N
was VBD N
as IN N
follows VBZ N
: : N
black JJ 3_p
( ( 3_p
5.0 CD 3_p
% NN 3_p
) ) 3_p
, , 3_p
Hispanic NNP 3_p
( ( 3_p
1.8 CD 3_p
% NN 3_p
) ) 3_p
and CC 3_p
Asian NNP 3_p
( ( 3_p
3.6 CD 3_p
% NN 3_p
) ) 3_p
. . N

PLCO NNP 3_p
centers NNS 3_p
that WDT 3_p
was VBD 3_p
14.0 CD 3_p
% NN 3_p
black JJ 3_p
, , 3_p
2.9 CD 3_p
% NN 3_p
Hispanic NNP 3_p
and CC 3_p
5.4 CD 3_p
% NN 3_p
Asian JJ 3_p
, , N
and CC N
an DT N
age-eligible JJ N
population NN N
across IN N
the DT N
U.S. NNP N
that WDT 3_p
was VBD 3_p
9.5 CD 3_p
% NN 3_p
black JJ 3_p
, , 3_p
6.5 CD 3_p
% NN 3_p
Hispanic NNP 3_p
and CC 3_p
3.0 CD 3_p
% NN 3_p
Asian JJ 3_p
. . N

( ( 3_p
45 CD 3_p
% NN 3_p
) ) 3_p
of IN 3_p
Hispanics NNPS 3_p
were VBD 3_p
recruited VBN 3_p
at IN 3_p
the DT 3_p
center NN 3_p
with IN 3_p
the DT 3_p
special JJ 3_p
Hispanic JJ 3_p
recruitment NN 3_p
effort NN 3_p
. . N

Seventy NNP 3_p
percent NN 3_p
of IN 3_p
blacks NNS 3_p
were VBD 3_p
recruited VBN 3_p
at IN 3_p
two CD 3_p
centers NNS 3_p
; : N
the DT N
one NN N
with IN N
the DT N
major JJ N
special JJ N
recruitment NN N
-DOCSTART- -X- O O 25776840

patients NNS 4_p
with IN 4_p
severe JJ 4_p
carotid NN 4_p
stenosis NN 4_p
. . N

patients NNS 4_p
with IN 4_p
severe JJ 4_p
carotid NN 4_p
stenosis NN 4_p
Ninety-six JJ 3_p
patients NNS N
with IN 4_p
severe JJ 4_p
carotid NN 4_p
stenosis NN 4_p
-DOCSTART- -X- O O 19462303

alcohol NN 4_p
withdrawal NN 4_p
syndrome NN 4_p
in IN N
a DT N
medical JJ N
intensive JJ N
care NN N
unit NN N
: : N
alcohol NN 4_p
withdrawal NN 4_p
syndrome NN 4_p
( ( 4_p
AWS NNP 4_p
) ) 4_p
. . N

Twenty-six NNP 3_p
alcoholic JJ 4_p
patients NNS N
with IN N
severe JJ 4_p
AWS NNP 4_p
and CC 4_p
concomitant JJ 4_p
medical JJ 4_p
diseases NNS 4_p
were VBD N
randomally RB N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 3882217

adults NNS 1_p
with IN 4_p
soft JJ 4_p
tissue NN 4_p
sarcomas NN 4_p
of IN 4_p
the DT 4_p
head NN 4_p
and CC 4_p
neck NN 4_p
, , 4_p
breast NN 4_p
, , 4_p
and CC 4_p
trunk NN 4_p
. . 4_p

Since IN N
1977 CD N
, , N
31 CD N
patients NNS N
were VBD N
entered VBN N
in IN N
a DT N
randomized JJ N
, , N
prospective JJ N
study NN N
testing VBG N
the DT N
efficacy NN N
of IN N
adjuvant JJ N
chemotherapy NN N
after IN N
aggressive JJ N
local JJ N
treatment NN N
of IN N
high-grade JJ N
sarcomas NN N
of IN N
the DT N
head NN N
, , N
neck NN N
, , N
breast NN N
, , N
and CC N
trunk NN N
( ( N
excluding VBG N
retroperitoneal VB N
sarcomas NN N
) ) N
. . N

All DT N
patients NNS N
had VBD N
complete JJ N
resection NN N
of IN N
gross JJ N
tumor NN N
and CC N
underwent JJ N
postoperative JJ N
radiotherapy NN N
( ( N
6000-6300 JJ N
rads NNS N
over IN N
7-8 JJ N
weeks NNS N
) ) N
. . N

Seventeen JJ N
patients NNS N
received VBD N
adjuvant JJ N
chemotherapy NN N
An DT N
additional JJ N
26 CD N
patients NNS N
entire JJ N
group NN N
of IN N
57 CD 3_p
patients NNS N
The DT N
subgroup NN 3_p
of IN 3_p
patients NNS 3_p
with IN 3_p
sarcomas NN 3_p
of IN 3_p
the DT 3_p
trunk NN 3_p
( ( 3_p
39 CD 3_p
patients NNS 3_p
) ) 3_p
-DOCSTART- -X- O O 9587285

human JJ 4_p
inferior JJ 4_p
alveolar JJ 4_p
nerve NN 4_p
block NN 4_p
. . N

30 CD 3_p
subjects NNS N
randomly RB N
received VBD N
an DT N
inferior JJ N
alveolar JJ N
injection NN N
at IN N
three CD N
successive JJ N
appointments NNS N
. . N

-DOCSTART- -X- O O 14627879

RUPP NNP 4_p
autism NN 4_p
study NN N
: : N
Research NNP N
Units NNP N
on IN N
Pediatric NNP N
Psychopharmacology NNP N
( ( N
RUPP NNP N
) ) N
Autism NNP N
Network NNP N
parents NNS N
94 CD 3_p
participants NNS N
had VBD N
usable JJ N
data NNS N
. . N

parents NNS N
of IN N
autistic JJ 4_p
children NNS 1_p
with IN N
irritable JJ 4_p
behavior NN 4_p
. . N

-DOCSTART- -X- O O 25234481

language NN N
function NN N
children NNS 1_p
with IN N
autism NN 4_p
: : N
( ( N
Autism $ N
17 CD N
( ( N
2 CD N
) ) N
:220-241 NN N
, , N
2013 CD N
) ) N
children NNS N
with IN N
autism NN 4_p
-DOCSTART- -X- O O 23929781

patients NNS 4_p
with IN 4_p
heart NN 4_p
failure NN 4_p
due JJ 4_p
to TO 4_p
reduced VB 4_p
left JJ 4_p
ventricular JJ 4_p
systolic JJ 4_p
function NN 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
heart NN 4_p
failure NN 4_p
( ( 4_p
HF NNP 4_p
) ) 4_p
due JJ 4_p
to TO 4_p
reduced VB 4_p
left JJ 4_p
ventricular JJ 4_p
ejection NN 4_p
fraction NN 4_p
( ( 4_p
HFREF NNP 4_p
) ) N
. . N

those DT N
with IN N
HFREF NNP 4_p
. . N

patients NNS 4_p
with IN 4_p
heart NN 4_p
failure NN 4_p
. . N

2331 CD 3_p
patients NNS 3_p
with IN N
HFREF NNP 4_p
. . N

Patients NNS 4_p
with IN 4_p
New NNP 4_p
York NNP 4_p
Heart NNP 4_p
Association NNP 4_p
class NN 4_p
II NNP 4_p
to TO 4_p
IV NNP 4_p
HF NNP 4_p
and CC N
left VBD 4_p
ventricular JJ 4_p
ejection NN 4_p
fractions NNS 4_p
of IN 4_p
≤ JJ 4_p
35 CD 4_p
% NN 4_p
were VBD N
recruited VBN N
as IN N
baseline NN N
Hb NNP N
< VBZ N
13 CD N
g/dL NN N
and CC N
< $ N
12 CD N
g/dL NN N
in IN N
men NNS 2_p
and CC N
women NNS 2_p
in IN N
1763 CD 3_p
subjects NNS N
( ( N
76 CD N
% NN N
of IN N
total JJ N
study NN N
population NN N
) ) N
; : N
their PRP$ 1_p
median JJ 1_p
age NN 1_p
was VBD 1_p
59.0 CD 1_p
years NNS 1_p
, , 1_p
73 CD N
% NN N
were VBD N
male JJ 2_p
, , N
and CC N
62 CD N
% NN N
were VBD N
Caucasian JJ N
in IN 4_p
patients NNS 4_p
with IN 4_p
chronic JJ 4_p
HFREF NNP 4_p
-DOCSTART- -X- O O 23676253

schizophrenia NN 4_p
. . N

schizophrenia NN 4_p
Twenty-three JJ 3_p
male JJ 2_p
veterans NNS N
with IN N
schizophrenia NN 4_p
schizophrenia NN 4_p
. . N

-DOCSTART- -X- O O 21844080

women NNS 4_p
with IN 4_p
suspected JJ 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
: : 4_p
women NNS 4_p
with IN 4_p
suspected JJ 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
( ( 4_p
CAD NNP 4_p
) ) 4_p
. . 4_p

women NNS N
with IN N
suspected JJ N
CAD NNP N
. . N

symptomatic JJ N
women NNS N
with IN N
suspected JJ N
CAD NNP N
, , N
an DT N
interpretable JJ N
ECG NNP N
, , N
and CC N
≥5 NNP N
metabolic JJ N
equivalents NNS N
on IN N
the DT N
Duke NNP N
Activity NNP N
Status NNP N
Index NNP N
A DT N
total NN N
of IN N
824 CD N
women NNS N
in IN N
symptomatic JJ N
women NNS N
with IN N
suspected JJ N
CAD NNP N
-DOCSTART- -X- O O 8582461

hypertensive JJ 4_p
patients NNS 4_p
. . 4_p

12 CD 4_p
patients NNS 4_p
with IN 4_p
essential JJ 4_p
hypertension NN 4_p
. . 4_p

-DOCSTART- -X- O O 11881749

cardiac JJ 4_p
catheterization NN 4_p
. . N

118 CD 3_p
left-heart JJ 4_p
catheterization NN 4_p
patients NNS 4_p
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
4 CD N
hours NNS N
or CC N
6 CD N
hours NNS N
of IN N
bed NN N
rest NN N
. . N

-DOCSTART- -X- O O 772759

Quantifications NNS N
of IN N
the DT N
major JJ N
urinary JJ N
metabolite NN N
of IN N
the DT N
E NNP N
prostaglandins NNS N
by IN N
mass NN N
spectrometry NN N
: : N
evaluation NN N
of IN N
the DT N
method NN N
's POS N
application NN N
to TO N
clinical JJ N
studies NNS N
. . N

man NN 2_p
urine NN N
males NNS 2_p
than IN N
in IN N
females NNS 2_p
( ( N
15.2 CD N
+/- JJ N
1.9 CD N
mug/24 NN N
hours NNS N
( ( N
n=24 NN N
) ) N
and CC N
3.3 CD N
+/- JJ N
0.3 CD N
mug/24 NN N
hours NNS N
( ( N
n=17 NN N
) ) N
, , N
respectively RB N
. . N

sexes NNS N
was VBD N
observed VBN N
in IN N
the DT N
pre-pubertal JJ 1_p
age-grou NN 1_p
( ( N
male NN N
: : N
2.9 CD N
+/- JJ N
0.8 CD N
mug/24 NN N
hours NNS N
, , N
n=5 RB N
; : N
female NN N
: : N
3.1 CD N
+/- JJ N
0.9 CD N
mug/24 NN N
hours NNS N
, , N
n=5 NN N
) ) N
or CC N
in IN N
the DT N
age-group NN 1_p
of IN 1_p
45-80 CD 1_p
years NNS 1_p
( ( N
male NN N
: : N
9.3 CD N
+/- JJ N
1.1 CD N
mug/24 NN N
hours NNS N
, , N
n=21 RB N
; : N
female NN N
: : N
7.3 CD N
+/- JJ N
0.9 CD N
mug/24 NN N
hours NNS N
, , N
n=12 RB N
) ) N
. . N

-DOCSTART- -X- O O 3324498

total JJ 4_p
gastrectomy NN 4_p
: : 4_p
a DT 4_p
randomized JJ 4_p
clinical JJ 4_p
trial NN 4_p
. . N

-DOCSTART- -X- O O 22692116

Sixteen JJ 3_p
strength-trained JJ 4_p
men NNS 2_p
performance NN N
in IN N
strength-trained JJ N
individuals NNS N
-DOCSTART- -X- O O 1911013

20 CD N
patients NNS N
undergoing JJ N
craniotomy NN N
for IN N
supratentorial JJ N
cerebral JJ N
tumours NNS N
. . N

-DOCSTART- -X- O O 24752311

Chinese NNP 4_p
type NN 4_p
2 CD 4_p
diabetes VBZ 4_p
patients NNS 4_p
. . N

PAX4 NNP 4_p
variants NNS 4_p
Chinese NNP 4_p
type NN 4_p
2 CD 4_p
diabtes NNS 4_p
mellitus FW 4_p
( ( 4_p
T2DM NNP 4_p
) ) 4_p
patients NNS 4_p
. . N

A DT 3_p
total NN 3_p
of IN N
209 CD 3_p
newly RB N
diagnosed VBN N
T2DM NNP N
patients NNS N
in IN 4_p
Chinese JJ 4_p
T2DM NNP N
patients NNS N
-DOCSTART- -X- O O 15673894

randomized VBN N
crossover NN N
study NN N
spinal JJ N
2-CP JJ N
( ( N
30 CD N
mg NN N
) ) N
with IN N
and CC N
without IN N
clonidine NN N
( ( N
15 CD N
microg NN N
) ) N
in IN N
eight CD 3_p
volunteers NNS N
. . N

-DOCSTART- -X- O O 10517426

experimental JJ N
human JJ N
influenza NN 4_p
: : N
treatment NN N
of IN N
influenza NN N
in IN N
experimentally RB N
infected JJ N
humans NNS N
. . N

2 CD N
large JJ N
US NNP N
university NN N
medical JJ N
schools NNS N
. . N

A DT N
total NN N
of IN N
117 CD 3_p
healthy JJ N
adult NN N
volunteers NNS N
( ( N
aged VBN 1_p
18-40 CD 1_p
years NNS 1_p
; : 1_p
median JJ 1_p
age NN 1_p
, , 1_p
21 CD 1_p
years NNS 1_p
) ) N
who WP N
were VBD N
susceptible JJ N
( ( N
hemagglutination-inhibition NN N
antibody NN N
titer NN N
< NN N
or CC N
=1:8 NN N
) ) N
. . N

experimental JJ N
human JJ N
influenza NN 4_p
-DOCSTART- -X- O O 25455414

patients NNS N
with IN N
chronic JJ 4_p
liver NN 4_p
disease NN 4_p
patients NNS 4_p
with IN 4_p
chronic JJ 4_p
liver NN 4_p
disease NN 4_p
. . 4_p

170 CD 3_p
consecutive JJ N
patients NNS N
( ( N
114 CD 3_p
men NNS 2_p
and CC N
56 CD 3_p
women NNS 2_p
; : N
age NN N
range NN N
, , N
40-85 JJ 1_p
years NNS 1_p
; : N
mean VB N
, , N
67.7 CD N
years NNS N
) ) N
with IN N
suspected VBN N
chronic JJ N
liver NN N
diseases NNS N
-DOCSTART- -X- O O 20486905

de FW N
novo FW N
liver NN 4_p
transplant NN 4_p
recipients VBZ N
de FW 4_p
novo FW 4_p
liver FW 4_p
transplantation NN 4_p
( ( 4_p
LT NNP 4_p
) ) 4_p
patients NNS N
Seventy-eight JJ 3_p
patients NNS N
were VBD N
randomized VBN N
monotherapy NN N
in IN N
de FW N
novo FW N
LT NNP N
patients NNS N
-DOCSTART- -X- O O 17521473

paediatric JJ 4_p
tonsillectomy NN 4_p
. . 4_p

From NNP N
July NNP N
2004 CD N
to TO N
April NNP N
2006 CD N
, , N
80 CD N
patients NNS N
aged VBN N
between IN N
10 CD N
and CC N
15 CD N
years NNS N
, , N
with IN N
tonsillectomy NN N
planned VBN N
for IN N
chronic JJ N
tonsillitis NN N
, , N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 21055113

patients NNS N
after IN N
abdominoperineal JJ 4_p
resection NN 4_p
( ( 4_p
APR NNP 4_p
) ) 4_p
. . N

patients NNS N
with IN N
rectal JJ 4_p
cancer NN 4_p
, , N
ulcerative JJ 4_p
colitis NN 4_p
or CC N
rectal JJ 4_p
gastrointestinal JJ 4_p
stromal JJ 4_p
tumor NN 4_p
, , N
who WP N
underwent JJ N
APR NNP N
or CC N
proctocolectomy NN N
74 CD 3_p
patients NNS N
were VBD N
enrolled VBN N
in IN N
present JJ N
study NN N
-DOCSTART- -X- O O 12370849

Nine NNP N
healthy JJ 4_p
volunteers NNS 4_p
( ( 4_p
age NN 1_p
, , 1_p
23.4 CD 1_p
+/- JJ 1_p
0.2 CD 1_p
years NNS 1_p
; : 4_p
body NN 4_p
mas VBZ 4_p
index NN 4_p
[ NNP 4_p
BMI NNP 4_p
] NNP 4_p
, , 4_p
23.5 CD 4_p
+/- JJ 4_p
1.6 CD 4_p
kg/m NN 4_p
( ( 4_p
2 CD 4_p
) ) 4_p
) ) 4_p
-DOCSTART- -X- O O 10550137

women NNS 4_p
with IN 4_p
early-stage JJ 4_p
breast NN 4_p
cancer NN 4_p
. . 4_p

early-stage JJ 4_p
breast NN 4_p
cancer NN 4_p
. . 4_p

20 CD N
women NNS N
with IN N
early-stage JJ N
breast NN N
cancer NN N
receiving VBG N
four CD N
courses NNS N
of IN N
cyclophosphamide NN N
and CC N
doxorubicin NN N
chemotherapy NN N
. . N

-DOCSTART- -X- O O 18523583

in IN N
sedentary JJ N
postmenopausal JJ N
women NNS N
postmenopausal JJ 4_p
women NNS 4_p
post-menopausal JJ N
women NNS N
supine JJ 4_p
resting VBG 4_p
HRV NNP 4_p
in IN 4_p
373 CD 4_p
post-menopausal JJ 4_p
women NNS 4_p
( ( 4_p
45-75 JJ 4_p
y NN 4_p
) ) 4_p
after IN 4_p
6-months CD 4_p
of IN 4_p
randomly NN 4_p
assigned VBN 4_p
sedentary JJ N
postmenopausal NN N
women NNS N
-DOCSTART- -X- O O 18394874

fiberoptic JJ 4_p
bronchoscopy NN 4_p
. . N

fiber-optic JJ 4_p
bronchoscopy NN 4_p
( ( 4_p
FOB NNP 4_p
) ) 4_p
One-hundred JJ 3_p
twenty NN 3_p
patients NNS N
were VBD N
enrolled VBN N
. . N

Patients NNPS N
undergoing VBG N
FOB NNP 4_p
-DOCSTART- -X- O O 16048456

screening VBG N
normally RB 4_p
intelligent JJ 4_p
persons NNS N
with IN N
pervasive JJ 4_p
developmental NN 4_p
disorders NNS 4_p
. . N

25 CD 3_p
normally RB 4_p
intelligent JJ 4_p
high-functioning JJ 4_p
pervasive JJ 4_p
developmental NN 4_p
disorder NN 4_p
( ( N
HPDD NNP 4_p
) ) N
patients NNS N
( ( N
mean JJ N
age NN N
, , N
24.2 CD 1_p
years NNS 1_p
; : N
24 CD 3_p
male NN 2_p
, , N
one CD 3_p
female NN 2_p
) ) N
and CC N
215 CD 3_p
controls NNS N
( ( N
mean JJ N
age NN N
, , N
30.4 CD 1_p
years NNS 1_p
; : N
86 CD 3_p
male NN 2_p
, , N
129 CD 3_p
female NN 2_p
) ) N
randomly RB N
selected VBN N
from IN N
the DT N
general JJ N
population NN N
. . N

-DOCSTART- -X- O O 21915543

One CD 4_p
hundred CD 4_p
and CC 4_p
ten JJ 4_p
patients NNS 4_p
with IN N
a DT N
femoral JJ 4_p
shaft NN 4_p
fracture NN 4_p
were VBD N
enrolled VBN N
in IN N
a DT N
prospective JJ N
, , N
randomized VBN N
study NN N
. . N

Fifty-four CD 3_p
patients NNS N
fifty-six JJ 3_p
-DOCSTART- -X- O O 24173178

actinic JJ 4_p
keratosis NN 4_p
Actinic NNP 4_p
keratosis NN 4_p
28 CD 3_p
patients NNS 3_p
with IN N
a DT N
clinical JJ N
diagnosis NN N
of IN N
actinic JJ N
keratosis NN N
-DOCSTART- -X- O O 24549163

acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
multicentre FW N
enrol VB N
100 CD 3_p
patients NNS 3_p
presenting VBG N
with IN N
an DT N
anterior JJ N
AMI NNP 4_p
demonstrating VBG N
anterior JJ N
regional JJ N
wall NN N
motion NN N
abnormality NN N
. . N

-DOCSTART- -X- O O 11485124

patients NNS N
who WP N
are VBP N
treated VBN N
with IN N
this DT N
modality NN N
for IN N
pelvic JJ 4_p
malignancies NNS 4_p
. . 4_p

31 CD 3_p
patients NNS N
receiving VBG N
pelvic JJ 4_p
radiotherapy NN 4_p
Groups NNP N
did VBD N
not RB N
differ VB N
in IN N
age NN N
, , N
gender NN N
, , N
tumor NN N
site NN N
, , N
or CC N
irradiation NN N
procedure NN N
. . N

the DT N
subjects NNS N
radiation-induced JJ 4_p
gastrointestinal JJ 4_p
injuries NNS 4_p
. . N

-DOCSTART- -X- O O 24119994

Western JJ N
Myanmar NNP N
. . N

Western JJ N
Myanmar NNP N
human JJ N
population NN N
4,824 CD 3_p
female JJ 2_p
anopheline NN N
mosquitoes NNS N
916 CD 3_p
person NN 3_p
nights NNS N
yielded VBD N
3,009 CD N
female JJ N
anopheline NN N
mosquitoes NNS N
between IN N
6 CD N
pm NNS N
and CC N
6 CD N
am VBP N
. . N

A DT N
large JJ N
proportion NN N
of IN N
children NNS 1_p
Western JJ N
Myanmar NNP N
-DOCSTART- -X- O O 18026891

children NNS 1_p
and CC N
adolescents NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
. . N

autistic JJ 4_p
disorder NN 4_p
. . N

in IN N
autistic JJ 4_p
children NNS 1_p
and CC N
adolescents NNS 1_p
. . N

A DT N
total NN N
of IN N
28 CD 3_p
subjects NNS 3_p
between IN N
8 CD 1_p
and CC 1_p
18 CD 1_p
ages NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
-DOCSTART- -X- O O 19430389

miosis NN N
during IN N
vitrectomy NN N
. . N

Fifty NNP N
consecutive JJ N
patients NNS N
undergoing VBG N
vitrectomy NN N
-DOCSTART- -X- O O 16600723

prostate NN 4_p
cancer NN 4_p
men NNS 2_p
receiving VBG N
the DT N
dual JJ N
5alpha-reductase JJ N
inhibitor NN N
dutasteride NN N
. . N

A NNP N
total NN N
of IN N
2,802 CD 3_p
men NNS N
50 CD 1_p
years NNS 1_p
or CC 1_p
older JJR 1_p
with IN N
a DT N
clinical JJ N
diagnosis NN N
of IN N
benign JJ 4_p
prostatic JJ 4_p
hyperplasia NN 4_p
, , N
no DT 4_p
history NN 4_p
of IN 4_p
prostate NN 4_p
cancer NN 4_p
, , 4_p
PSA NNP 4_p
1.5 CD 4_p
to TO 4_p
10 CD 4_p
ng/ml NNS 4_p
, , 4_p
prostate NN 4_p
volume NN 4_p
30 CD 4_p
cc NN 4_p
or CC 4_p
greater JJR 4_p
, , 4_p
an DT 4_p
American NNP 4_p
Urological NNP 4_p
Association NNP 4_p
symptom VBD 4_p
score NN 4_p
of IN 4_p
12 CD 4_p
or CC 4_p
greater JJR 4_p
and CC 4_p
peak JJ 4_p
urinary JJ 4_p
flow NN 4_p
rate NN 4_p
15 CD 4_p
ml NN 4_p
per IN 4_p
second NN 4_p
or CC 4_p
less JJR 4_p
were VBD N
randomized VBN N
to TO N
0.5 CD N
mg NNS N
dutasteride JJ N
daily RB N
or CC N
matching VBG N
placebo NN N
-DOCSTART- -X- O O 12418582

patients NNS N
with IN N
moderate-to-severe JJ 4_p
asthma NN 4_p
. . N

patients NNS N
with IN N
moderate-to-severe JJ N
asthma NNS N
Symptomatic JJ N
patients NNS N
( ( N
n JJ 3_p
= NNP 3_p
428 CD 3_p
) ) N
with IN 4_p
FEV1 NNP 4_p
of IN 4_p
50-85 CD 4_p
% NN 4_p
predicted JJ 4_p
and CC 4_p
increased JJ 4_p
symptom NN 4_p
scores NNS 4_p
or CC 4_p
reliever NN 4_p
use NN 4_p
during IN 4_p
run-in NN 4_p
-DOCSTART- -X- O O 21661164

[ JJ 4_p
Diabetic NNP 4_p
retinopathy NN 4_p
-DOCSTART- -X- O O 11570966

women NNS 2_p
with IN N
PCOS NNP 4_p
patients NNS N
with IN N
polycystic JJ 4_p
ovary JJ 4_p
syndrome NN 4_p
( ( 4_p
PCOS NNP 4_p
) ) 4_p
. . 4_p

From IN N
March NNP N
1998 CD N
to TO N
June NNP N
2000 CD N
, , N
a DT N
total NN N
of IN N
28 CD 3_p
women NNS 2_p
underwent JJ N
36 CD N
completed VBN N
treatment NN N
cycles NNS N
patients NNS N
with IN N
PCOS NNP 4_p
-DOCSTART- -X- O O 9703286

patients NNS N
with IN N
epithelial JJ 4_p
ovarian JJ 4_p
cancer NN 4_p
and CC N
relation NN N
to TO N
TP53 NNP N
gene NN N
status NN N
. . N

45 CD 3_p
ovarian JJ 4_p
cancer NN 4_p
patients NNS N
randomized VBN N
to TO N
treatment NN N
38 CD 3_p
patients NNS N
with IN N
clinically RB N
evaluable JJ N
disease NN N
after IN N
initial JJ N
surgery NN N
. . N

-DOCSTART- -X- O O 20124218

in IN N
children NNS 1_p
with IN N
standard-risk JJ 4_p
acute JJ 4_p
lymphoblastic JJ 4_p
leukemia NN 4_p
: : N
Children NNP 1_p
's POS 1_p
Cancer NNP N
Group NNP N
1952 CD N
( ( N
CCG-1952 NNP N
) ) N
standard-risk JJ 4_p
acute JJ 4_p
lymphoblastic JJ 4_p
leukemia NN 4_p
. . N

After IN N
remission NN N
induction NN N
, , N
2027 CD 3_p
patients NNS N
257 CD 3_p
patients NNS N
-DOCSTART- -X- O O 16202291

vulvovaginal JJ 4_p
candidiasis NN 4_p
] NN N
vulvovaginal JJ 4_p
candidiasis NN 4_p
( ( 4_p
VVC NNP 4_p
) ) 4_p
Three CD 3_p
hundred VBD 3_p
cases NNS N
of IN N
VVC NNP 4_p
were VBD N
recruited VBN N
. . N

300 CD 3_p
cases NNS N
of IN N
VVC NNP N
women NNS 2_p
with IN N
complicated JJ N
VVC NNP 4_p
-DOCSTART- -X- O O 7006663

Leukaemia NNP 4_p
in IN N
Adults NNP 1_p
. . N

Three CD 3_p
hundred VBD 3_p
and CC 3_p
seventy-two JJ 3_p
patients NNS N
good JJ 4_p
, , N
intermediate JJ 4_p
and CC N
poor JJ 4_p
renal-function NN N
groups NNS N
patients NNS N
in IN N
the DT N
good JJ 4_p
renal-function NN 4_p
group NN N
. . N

107 CD 3_p
patients NNS N
who WP N
presented VBD N
with IN N
good JJ 4_p
renal JJ 4_p
function NN 4_p
and CC N
with IN N
haemoglobin NNS N
above IN N
100 CD N
g/l NN N
-DOCSTART- -X- O O 24138011

autistic JJ 4_p
disorder NN 4_p
pediatric JJ 4_p
subjects NNS 4_p
receiving VBG 4_p
aripiprazole JJ 4_p
treatment NN 4_p
. . N

pediatric JJ N
subjects NNS N
with IN N
autistic JJ 4_p
disorder NN 4_p
, , N
aged VBN 1_p
6-17 CD 1_p
years NNS 1_p
. . 1_p

Subjects NNS N
were VBD N
stratified VBN N
by IN N
PAE NNP N
; : N
316 CD 3_p
randomized JJ 3_p
subjects NNS 3_p
, , N
259 CD 3_p
( ( 3_p
82.0 CD 3_p
% NN 3_p
) ) N
were VBD N
antipsychotic JJ N
naïve NN N
( ( N
AN NNP N
) ) N
and CC N
57 CD 3_p
( ( 3_p
18.0 CD 3_p
% NN 3_p
) ) 3_p
had VBD N
a DT N
PAE NNP N
that IN 1_p
younger JJR 1_p
subjects NNS 1_p
with IN N
higher JJR N
baseline NN N
weight VBD N
in IN N
younger JJR 1_p
subjects NNS 1_p
with IN N
a DT N
higher JJR N
baseline NN N
weight VBD N
z-score RB N
of IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
-DOCSTART- -X- O O 2576261

Forty-nine NNP 3_p
healthy JJ N
women NNS 2_p
aged VBN 1_p
20-35 JJ 1_p
years NNS 1_p
who WP N
had VBD N
not RB N
been VBN N
pregnant JJ N
or CC N
using VBG N
an DT N
oral JJ 4_p
contraceptive NN 4_p
( ( N
OC NNP N
) ) N
for IN N
the DT N
previous JJ N
3 CD N
months NNS N
-DOCSTART- -X- O O 7010854

unselected JJ N
hypertensive JJ 4_p
population NN N
. . N

One CD 3_p
hundred VBD 3_p
nineteen JJ 3_p
patients NNS N
with IN N
essential JJ 4_p
hypertension NN 4_p
( ( N
96 CD 3_p
completing VBG N
six CD N
months NNS N
and CC N
92 CD 3_p
a DT N
one CD N
year NN N
study NN N
period NN N
) ) N
all DT N
groups NNS N
smallest JJS N
patients NNS N
-DOCSTART- -X- O O 14617595

patients NNS N
undergoing VBG N
elective JJ 4_p
craniotomy NN 4_p
for IN N
supratentorial JJ 4_p
mass NN 4_p
lesions NNS 4_p
. . N

Ninety-one JJ 3_p
patients NNS N
-DOCSTART- -X- O O 16753722

Child NNP N
Health NNP 4_p
: : N
students NNS 1_p
receiving VBG N
structured JJ N
versus NN N
student-directed JJ N
learning NN N
for IN N
the DT N
two-week JJ N
Child NNP N
Health NNP N
outpatient NN N
module NN N
. . N

A DT N
total NN N
of IN N
138 CD 3_p
phase NN N
3 CD N
( ( N
year NN N
4 CD N
) ) N
medical JJ N
students NNS N
in IN N
10 CD N
two-week JJ N
paediatric JJ N
outpatient NN N
blocks NNS N
at IN N
the DT N
Department NNP N
of IN N
Child NNP N
Health NNP N
, , N
University NNP N
of IN N
Dundee NNP N
, , N
Scotland NNP N
129 CD 3_p
students NNS N
sat VBD N
both DT N
tests NNS N
. . N

-DOCSTART- -X- O O 24666361

the DT 4_p
Veterans NNP 4_p
Affairs NNP 4_p
Topical NNP 4_p
Tretinoin NNP 4_p
Chemoprevention NNP 4_p
trial NN 4_p
METHODS NNP N
This DT N
cohort NN N
study NN N
used VBN N
data NNS N
collected VBD N
from IN N
324 CD 3_p
participants NNS N
in IN N
the DT N
Veterans NNP N
Affairs NNP N
Topical NNP N
Tretinoin NNP N
Chemoprevention NNP N
trial NN N
who WP N
were VBD N
randomized VBN N
to TO N
apply VB N
tretinoin JJ N
cream NN N
on IN N
the DT N
face NN N
and CC N
ears NNS N
-DOCSTART- -X- O O 24554519

stress NN 4_p
and CC 4_p
anxiety NN 4_p
related VBN N
to TO N
the DT N
2011 CD N
Christchurch NNP N
earthquakes NNS N
: : N
Christchurch NNP N
Sixty-four JJ N
adults NNS 1_p
from IN N
the DT N
original JJ N
91 CD 3_p
participants NNS N
experiencing VBG N
heightened VBN N
anxiety NN N
or CC N
stress JJ N
2-3 JJ N
months NNS N
following VBG N
the DT N
22nd CD N
February NNP N
2011 CD N
earthquake NN N
and CC N
who WP N
had VBD N
been VBN N
randomized VBN N
to TO N
receive VB N
three CD N
different JJ N
doses NNS N
of IN N
micronutrients NNS N
completed VBN N
on-line JJ N
questionnaires NNS N
assessing VBG N
mood NN N
, , N
anxiety NN N
, , N
stress NN N
, , N
and CC N
symptoms NNS N
associated VBN N
with IN N
post-traumatic JJ N
stress NN N
disorder NN N
1 CD N
year NN N
after IN N
completing VBG N
the DT N
initial JJ N
study NN N
. . N

Twenty-one CD 3_p
out IN 3_p
of IN N
29 CD 3_p
nonrandomized JJ N
controls NNS N
who WP N
did VBD N
not RB N
receive VB N
the DT N
treatment NN N
also RB N
completed VBD N
the DT N
questionnaires NNS N
Disaster NNP 4_p
survivors NNS 4_p
-DOCSTART- -X- O O 3704665

polycythemia NN 4_p
vera NN 4_p
and CC N
the DT N
other JJ N
myeloproliferative JJ 4_p
diseases NNS 4_p
to TO N
accumulate VB N
well RB 3_p
over IN 3_p
1,000 CD 3_p
patients NNS N
with IN N
these DT N
various JJ N
disorders NNS N
-DOCSTART- -X- O O 1673324

patients NNS N
with IN N
intracranial JJ 4_p
arteriovenous JJ 4_p
malformations NNS 4_p
: : N
Thirty JJ 3_p
patients NNS N
undergoing VBG N
resection NN N
of IN N
arteriovenous JJ 4_p
malformations NNS 4_p
with IN N
deliberate JJ N
hypotension NN N
-DOCSTART- -X- O O 25304364

Alzheimer NNP 4_p
's POS 4_p
disease NN 4_p
: : N
Alzheimer NNP 4_p
's POS 4_p
disease NN 4_p
Alzheimer NNP 4_p
's POS 4_p
disease NN 4_p
community-dwelling JJ N
older NN 1_p
adults NNS 1_p
with IN N
mild-to-moderate JJ 4_p
Alzheimer NNP 4_p
's POS 4_p
disease NN 4_p
. . N

Ninety NNP 3_p
subjects NNS N
will MD N
be VB N
randomized VBN N
sample JJ N
size NN N
of IN N
90 CD 3_p
-DOCSTART- -X- O O 22348801

adolescents NNS 1_p
undergoing VBG N
burn NN 4_p
wound NN 4_p
care NN 4_p
: : N
adolescents NNS 1_p
during IN N
conscious JJ N
burn NN N
wound NN N
care NN N
procedures NNS N
. . N

Forty-one CD 3_p
adolescents NNS 1_p
( ( N
11-17 CD 1_p
years NNS 1_p
) ) N
-DOCSTART- -X- O O 14690574

lower JJR 4_p
rectal NN 4_p
cancer NN 4_p
] NNP N
locally RB 4_p
advanced VBN 4_p
lower JJR 4_p
rectal JJ 4_p
cancer NN 4_p
. . N

Sixty NNP 3_p
lower JJR N
rectal JJ N
cancer NN N
patients NNS N
30 CD 3_p
patients NNS N
-DOCSTART- -X- O O 16232016

Neonatal NNP N
intensive JJ N
care NN N
unit NN N
in IN N
a DT N
106-bed JJ N
quaternary JJ N
care NN N
pediatric JJ N
hospital NN N
. . N

Nine NNP N
neonates VBZ N
receiving VBG N
ECMO NNP N
who WP N
required VBD N
intravenous JJ N
nutrition NN N
. . N

-DOCSTART- -X- O O 8396304

acute JJ 4_p
infectious JJ 4_p
mononucleosis NN 4_p
. . 4_p

-DOCSTART- -X- O O 18235151

type NN 4_p
2 CD 4_p
diabetes NNS 4_p
. . N

patients NNS N
who WP N
had VBD N
diabetes NNS 4_p
and CC N
had VBD N
already RB N
been VBN N
treated VBN N
with IN N
angiotensin NN N
II NNP N
receptor NN N
blockers NNS N
and CC N
with IN N
or CC N
without IN N
thiazolidinedione NN N
Forty NNP 3_p
patients NNS N
who WP N
had VBD N
diabetes NNS 4_p
with IN N
nephropathy JJ 4_p
and CC 4_p
arteriosclerosis NN 4_p
obliterans NNS 4_p
and CC N
had VBD N
already RB N
been VBN N
treated VBN N
with IN N
angiotensin NN N
II NNP N
receptor NN N
blocker NN N
( ( N
n JJ N
= NNP N
40 CD N
) ) N
-DOCSTART- -X- O O 6148879

thyrotoxicosis NN 4_p
. . 4_p

20 CD 4_p
newly RB 4_p
diagnosed VBN 4_p
patients NNS 4_p
with IN 4_p
thyrotoxicosis NN 4_p
symptomatic JJ 4_p
treatment NN 4_p
of IN 4_p
thyrotoxicosis NN 4_p
-DOCSTART- -X- O O 8259746

labetalol NN 4_p
or CC 4_p
hydralazine JJ 4_p
therapy NN 4_p
during IN 4_p
hypertension NN 4_p
in IN 4_p
pregnancy NN 4_p
in IN 4_p
very RB 4_p
low JJ 4_p
birth NN 4_p
weight NN 4_p
infants NNS 4_p
. . 4_p

Ninety-seven JJ 4_p
women NNS 4_p
with IN 4_p
moderate JJ 4_p
to TO 4_p
severe VB 4_p
preeclampsia NN 4_p
( ( 4_p
PE NNP 4_p
) ) 4_p
22 CD N
women NNS N
with IN N
severe JJ N
PE NNP N
gave VBD N
birth NN N
to TO N
neonates NNS N
with IN N
VLBW NNP N
( ( N
very RB N
low JJ N
birth NN N
weight NN N
< NN N
or CC N
= JJ N
1500 CD N
g NN N
) ) N
. . N

Seven VBN N
were VBD N
allocated VBN N
to TO N
labetalol VB N
treatment NN N
( ( N
Group NNP N
A NNP N
) ) N
, , N
eight CD N
to TO N
hydralazine VB N
treatment NN N
( ( N
Group NNP N
B NNP N
) ) N
seven CD N
women NNS N
received VBD N
both DT N
drugs NNS N
due JJ N
to TO N
poor JJ N
blood NN N
pressure NN N
control NN N
with IN N
a DT N
single JJ N
drug NN N
therapy NN N
Gestational JJ N
age NN N
was VBD N
29.9 CD N
weeks NNS N
( ( N
25.4-32.5 JJ N
) ) N
28.6 CD N
weeks NNS N
( ( N
26.6-33.4 JJ N
) ) N
27.3 CD N
weeks NNS N
( ( N
26.7-31.1 JJ N
) ) N
13 CD N
of IN N
the DT N
22 CD N
infants NNS N
weighed VBN N
below IN N
1000 CD N
g. NN N
neonates NNS N
neonates NNS N
infants NNS 4_p
VLBW NNP N
infants NNS N
when WRB N
the DT N
hypertensive NN N
mother NN N
had VBD N
been VBN N
treated VBN N
with IN N
either DT N
hydralazine NN N
or CC N
labetalol NN N
. . N

-DOCSTART- -X- O O 15307010

antiretroviral-naive JJ 4_p
adults NNS 1_p
with IN N
HIV NNP 4_p
infection NN 4_p
: : N
554 CD 3_p
antiretroviral-naive JJ N
human JJ 4_p
immunodeficiency NN 4_p
virus-infected JJ 4_p
adults NNS 1_p
( ( N
plasma JJ N
HIV NNP N
type NN N
1 CD N
[ JJ N
HIV-1 NNP N
] NNP N
RNA NNP N
level NN N
, , N
> NNP N
or=400 VBZ N
copies/mL NN N
; : N
CD4 NNP N
( ( N
+ NNP N
) ) N
cell NN N
count NN N
, , N
> VBZ N
100 CD N
cells/mm NN N
( ( N
3 CD N
) ) N
) ) N
and CC N
compared VBN N
a DT N
300-mg JJ N
once-daily JJ N
( ( N
q.d JJ N
. . N

) ) N
regimen NNS N
of IN N
lamivudine NN N
( ( N
3TC CD N
) ) N
versus NN N
a DT N
150-mg JJ N
twice-daily JJ N
( ( N
b.i.d NN N
. . N

) ) N
regimen NNS N
of IN N
3TC CD N
, , N
combined VBN N
with IN N
zidovudine NN N
( ( N
300 CD N
mg NN N
b.i.d NN N
. . N

) ) N
and CC N
efavirenz $ N
( ( N
600 CD N
mg NN N
q.d NN N
. . N

) ) N
, , N
during IN N
a DT N
48-week JJ N
period NN N
. . N

-DOCSTART- -X- O O 25350539

child NN 1_p
risk NN 4_p
for IN 4_p
distress NN 4_p
children NNS 1_p
at IN N
high JJ 4_p
and CC 4_p
medium NN 4_p
risk NN 4_p
for IN 4_p
procedure-related JJ 4_p
distress NN 4_p
. . N

Children NNP N
undergoing VBG N
scheduled VBN 4_p
intravenous JJ 4_p
insertions NNS 4_p
for IN 4_p
diagnostic JJ 4_p
or CC 4_p
treatment NN 4_p
purposes NNS 4_p
and CC N
their PRP$ N
parents NNS N
participated VBN N
. . N

A DT N
total NN N
of IN N
574 CD 3_p
children NNS 1_p
, , N
ages VBZ 1_p
4-10 JJ 1_p
, , N
and CC N
their PRP$ N
parents NNS N
participated VBN N
. . N

children NNS 4_p
at IN 4_p
medium NN 4_p
and CC 4_p
high JJ 4_p
risk NN 4_p
for IN 4_p
distress NN 4_p
-DOCSTART- -X- O O 11876712

Helicobacter NNP N
pylori VBP N
6-year JJ N
period NN N
, , N
patients NNS N
with IN N
persistent JJ N
H. NNP N
pylori FW N
infection NN N
following VBG N
omeprazole-clarithromycin-amoxicillin JJ N
eradication NN N
therapy NN N
95 CD N
randomized JJ N
patients NNS N
, , N
88 CD N
( ( N
93 CD N
% NN N
) ) N
completed VBD N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 24626433

patients NNS 4_p
with IN 4_p
CKD NNP 4_p
, , 4_p
including VBG 4_p
dialysis NN 4_p
patients NNS 4_p
patients NNS N
with IN N
CKD NNP 4_p
to TO N
20 CD N
mg NN N
simvastatin NN N
plus CC N
10 CD N
mg NNS N
ezetimibe JJ N
daily JJ N
2353 CD 3_p
SHARP NNP N
participants NNS N
who WP 4_p
had VBD 4_p
functioning VBG 4_p
vascular JJ 4_p
access NN 4_p
-DOCSTART- -X- O O 17123125

children NNS N
with IN N
autistic JJ 4_p
disorder NN 4_p
and CC N
severely RB 4_p
disruptive JJ 4_p
behavior NN 4_p
. . N

Parents NNP N
of IN N
101 CD 3_p
children NNS 1_p
with IN N
autism NN 4_p
who WP N
had VBD N
participated VBN N
in IN N
a DT N
multi-site JJ N
8-week JJ N
double-blind JJ N
clinical JJ N
trial NN N
of IN N
risperidone NN N
were VBD N
given VBN N
a DT N
questionnaire NN N
at IN N
the DT N
end NN N
to TO N
elicit VB N
their PRP$ N
perceptions NNS N
of IN N
the DT N
appropriateness NN N
and CC N
acceptability NN N
of IN N
clinical JJ N
trial NN N
procedures NNS N
. . N

Ninety-six NNP N
( ( N
95.0 CD N
% NN N
) ) N
parents NNS N
returned VBD N
the DT N
questionnaire NN N
. . N

-DOCSTART- -X- O O 11789002

patients NNS N
with IN N
arterial JJ N
occlusive JJ N
disease NN N
of IN N
the DT N
lower JJR N
extremities NNS N
] VBP N
patients NNS N
with IN N
advanced JJ N
atherosclerosis NN N
manifested VBN N
by IN N
arterial JJ N
occlusion NN N
in IN N
the DT N
lower JJR N
extremities NNS N
without IN N
a DT N
baseline NN N
blood NN N
lipid JJ N
disorder NN N
statin NN N
treatment NN N
comparable JJ N
control NN N
group NN N
without IN N
statins VBZ N
patients NNS N
with IN N
arterial JJ N
occlusion NN N
of IN N
the DT N
lower JJR N
extremities NNS N
with IN N
baseline NN N
dyslipidaemia NN N
-DOCSTART- -X- O O 10188144

chronic JJ 4_p
idiopathic JJ 4_p
urticaria NNS 4_p
: : N
patients NNS N
with IN N
chronic JJ 4_p
idiopathic JJ 4_p
urticaria NN 4_p
( ( 4_p
CIU NNP 4_p
) ) 4_p
. . N

247 CD 3_p
patients NNS N
with IN N
CIU NNP 4_p
patients NNS N
who WP N
had VBD N
this DT N
symptom NN N
before IN N
treatment NN N
. . N

-DOCSTART- -X- O O 9003876

elderly JJ 4_p
people NNS 4_p
. . 4_p

elderly JJ N
people NNS N
. . N

glaucoma NN N
patients NNS N
, , N
over IN N
60 CD N
years NNS N
of IN N
age NN N
, , N
without IN N
history NN N
of IN N
bronchospasm NN N
and CC N
who WP N
were VBD N
using VBG N
timolol NN N
( ( N
0.5 CD N
% NN N
) ) N
, , N
60 CD N
patients NNS N
elderly JJ N
people NNS N
with IN N
glaucoma NN N
-DOCSTART- -X- O O 12394700

Transurethral JJ 4_p
prostate NN 4_p
resection NN 4_p
patients NNS N
with IN N
hematuria NNS 4_p
of IN 4_p
prostatic JJ 4_p
origin NN 4_p
. . 4_p

patients NNS 4_p
undergoing JJ 4_p
transurethral JJ 4_p
prostate NN 4_p
resection NN 4_p
A NNP N
total JJ N
70 CD 3_p
patients NNS N
scheduled VBN N
to TO 4_p
undergo VB 4_p
elective JJ 4_p
transurethral JJ 4_p
prostate NN 4_p
resection NN 4_p
were VBD N
randomized VBN N
68 CD 3_p
patients NNS 3_p
who WP 3_p
underwent JJ 3_p
transurethral JJ 3_p
prostate NN 3_p
resection NN 3_p
patients NNS 4_p
undergoing JJ 4_p
transurethral JJ 4_p
prostate NN 4_p
resection NN 4_p
. . N

-DOCSTART- -X- O O 6633131

vaginal JJ 4_p
adenosis NN 4_p
in IN N
DES-exposed JJ 4_p
offspring NN N
: : N
Seventy-nine JJ 3_p
patients NNS 3_p
with IN N
history NN N
and CC N
physical JJ N
findings NNS N
characteristic NN N
of IN N
antenatal JJ 4_p
DES NNP 4_p
exposure NN 4_p
Fourty-four CD 3_p
DES-exposed JJ 4_p
offspring VBG N
79 CD 3_p
DES-exposed JJ 4_p
offspring VBG N
DES-exposed JJ N
offspring NN N
. . N

DES-exposed JJ 4_p
offspring NN N
-DOCSTART- -X- O O 19772883

children NNS 1_p
with IN N
autism NN 4_p
. . N

Forty NNP 3_p
children NNS 1_p
between IN N
the DT N
ages NNS 1_p
4 CD 1_p
and CC 1_p
12 CD 1_p
years NNS 1_p
with IN N
a DT N
DSM NNP N
IV-TR NNP N
clinical JJ N
diagnosis NN N
of IN N
autism NN 4_p
were VBD N
recruited VBN N
. . N

The DT N
children NNS 1_p
presented VBN N
with IN N
a DT N
chief JJ N
complaint NN N
of IN N
severely RB N
disruptive JJ N
symptoms NNS N
related VBN N
to TO N
autistic JJ 4_p
disorder NN 4_p
. . N

children NNS 1_p
with IN N
autism NN 4_p
. . N

-DOCSTART- -X- O O 10726430

Ten CD 3_p
active JJ N
female JJ 2_p
subjects NNS N
participated VBD N
( ( N
32 CD 1_p
+/- JJ 1_p
7 CD 1_p
yrs NN 1_p
( ( 1_p
mean JJ 1_p
+/- NNP 1_p
SD NNP 1_p
) ) N
; : N
65.7 CD N
+/- JJ N
16.4 CD N
kg NN N
; : N
VO2peak NNP N
40.0 CD N
+/- JJ N
7.5 CD N
ml.kg-1.min-1 NN N
) ) N
. . N

-DOCSTART- -X- O O 18205945

uncomplicated JJ 4_p
falciparum NN 4_p
malaria NN 4_p
. . 4_p

multicentre JJ N
study NN N
, , N
conducted VBN N
in IN N
Senegal NNP N
and CC N
in IN N
Cameroon NNP N
in IN N
2005 CD N
any DT N
subject JJ N
weighting NN N
more JJR N
than IN N
10 CD N
kg NNS N
, , N
presenting VBG N
with IN N
a DT N
malaria NN N
paroxysm NN N
confirmed VBN N
by IN N
parasitaemia NN N
> NN N
or CC N
= $ N
1,000/microl CD N
, , N
after IN N
informed JJ N
consent NN N
. . N

Three-hundred JJ 3_p
and CC 3_p
sixteen JJ 3_p
patients NNS N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 2089829

local JJ 4_p
anesthesia NN 4_p
. . 4_p

-DOCSTART- -X- O O 20452382

adults NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . 4_p

Individuals NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
) ) N
29 CD 3_p
high-functioning JJ 3_p
adults NNS 3_p
with IN 3_p
ASD NNP 3_p
and CC N
matched VBD N
controls NNS N
. . N

Adults NNS 1_p
with IN N
ASD NNP N
-DOCSTART- -X- O O 20345030

cervical JJ 4_p
vertigo NN 4_p
] NN N
cervical JJ N
vertigo NN N
January NNP N
2002 CD N
to TO N
May NNP N
2008 CD N
, , N
168 CD 3_p
patients NNS N
with IN N
cervical JJ 4_p
vertigo NNS 4_p
were VBD N
randomly RB N
divided VBN N
into IN N
treatment NN N
group NN N
( ( N
84 CD 3_p
cases NNS 3_p
) ) N
and CC N
the DT N
control NN N
group NN N
( ( N
84 CD 3_p
cases NNS 3_p
) ) N
, , N
22 CD 2_p
males NNS 2_p
and CC 2_p
62 CD 2_p
females NNS 2_p
in IN N
treatment NN N
group NN N
; : N
24 CD 2_p
males NNS 2_p
and CC 2_p
60 CD 2_p
females NNS 2_p
in IN N
control NN N
group NN N
. . N

cervical JJ N
vertigo NN N
vertebral JJ 4_p
body NN 4_p
displacement NN 4_p
-DOCSTART- -X- O O 1444609

of IN N
Ta NNP 4_p
, , 4_p
T1 NNP 4_p
superficial JJ 4_p
bladder NN 4_p
tumors NNS 4_p
. . N

Fifty-seven JJ 3_p
patients NNS N
superficial JJ N
bladder NN N
tumors NNS N
-DOCSTART- -X- O O 23414585

postmenopausal JJ N
women NNS N
with IN N
advanced JJ N
, , N
hormone-receptor-positive JJ N
breast NN N
cancer NN N
: : N
patients NNS N
with IN N
hormone-receptor-positive JJ N
breast NN N
cancer NN N
. . N

outpatient JJ N
clinics NNS N
and CC N
hospitals NNS N
. . N

We PRP N
enrolled VBD N
postmenopausal JJ N
women NNS N
with IN N
hormone-receptor-positive JJ N
, , N
locally RB N
advanced VBD N
or CC N
metastatic JJ N
breast NN N
cancer NN N
previously RB N
treated VBN N
with IN N
endocrine JJ N
treatment NN N
. . N

We PRP N
screened VBD N
189 CD N
patients NNS N
and CC N
enrolled VBD N
156 CD N
( ( N
106 CD N
in IN N
the DT N
ganitumab NN N
group NN N
and CC N
50 CD N
in IN N
the DT N
placebo NN N
group NN N
) ) N
. . N

endocrine VB N
treatment NN N
in IN N
women NNS N
with IN N
previously RB N
treated VBN N
hormone-receptor-positive JJ N
locally RB N
advanced VBD N
or CC N
metastatic JJ N
-DOCSTART- -X- O O 15848979

temporomandibular JJ 4_p
disorder NN 4_p
patients NNS N
with IN N
myofascial JJ N
pain NN N
after IN N
6 CD N
and CC N
12 CD N
months NNS N
. . N

temporomandibular JJ 4_p
disorder NN 4_p
( ( N
TMD NNP 4_p
) ) N
patients NNS N
with IN N
myofascial JJ N
pain NN N
. . N

60 CD 3_p
patients NNS N
( ( N
mean JJ N
age NN N
29 CD 1_p
years NNS 1_p
) ) N
with IN N
myofascial JJ 4_p
pain NN 4_p
were VBD N
evaluated VBN N
after IN N
10 CD N
weeks NNS N
of IN N
treatment NN N
with IN N
either CC N
a DT N
stabilization NN N
appliance NN N
or CC N
a DT N
control JJ N
appliance NN N
. . N

60 CD 3_p
patients NNS N
patients NNS N
with IN N
myofascial JJ 4_p
pain NN 4_p
TMD NNP 4_p
patients NNS N
with IN N
myofascial JJ 4_p
pain NN 4_p
. . N

-DOCSTART- -X- O O 12093460

persons NNS N
with IN N
HIV/AIDS NNP N
. . N

persons NNS N
with IN N
human JJ N
immunodeficiency NN N
virus NN N
( ( N
HIV NNP N
) ) N
and CC N
acquired VBD N
immunodeficiency NN N
syndrome NN N
( ( N
AIDS NNP N
) ) N
. . N

11 CD 3_p
clinically RB N
stable JJ N
, , N
HIV-infected JJ N
adults NNS 1_p
had VBD N
been VBN N
treated VBN N
with IN N
highly RB N
active JJ N
, , N
antiretroviral JJ N
therapy NN N
and CC N
had VBD N
HIV NNP N
plasma NN N
RNA NNP N
levels NNS N
of IN N
less JJR N
than IN N
10 CD N
000 CD N
copies/mL NN N
. . N

persons NNS N
with IN N
HIV/AIDS NNP N
. . N

-DOCSTART- -X- O O 7820060

hairy NN 4_p
cell NN 4_p
leukemia NN 4_p
. . N

cohort NN N
of IN N
69 CD 3_p
patients NNS N
treated VBN N
from IN N
1983 CD N
to TO N
1986 CD N
. . N

69 CD 3_p
hairy NN 4_p
cell NN 4_p
leukemia NN 4_p
( ( 4_p
HCL NNP 4_p
) ) 4_p
patients NNS N
treated VBN N
with IN N
interferon JJ N
alfa-2b NN N
( ( N
IFN NNP N
) ) N
as IN N
primary JJ N
treatment NN N
from IN N
1983 CD N
to TO N
1986 CD N
. . N

-DOCSTART- -X- O O 1667693

high JJ 4_p
risk NN 4_p
trauma NN 4_p
patients NNS N
: : N
A DT N
group NN N
of IN N
48 CD 3_p
critically RB 4_p
injured JJ 4_p
patients NNS N
-DOCSTART- -X- O O 18626761

students NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . 4_p

Forty-two JJ N
students NNS N
with IN N
autism NN N
, , N
varying VBG N
in IN N
age NN N
and CC N
expressive JJ N
communication NN N
ability NN N
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
experimental JJ N
conditions NNS N
. . N

-DOCSTART- -X- O O 2225700

Mefloquine NNP 4_p
kinetics NNS 4_p
in IN 4_p
cured JJ 4_p
and CC 4_p
recrudescent JJ 4_p
patients NNS 4_p
with IN 4_p
acute JJ 4_p
falciparum NN 4_p
malaria NN 4_p
and CC 4_p
in IN 4_p
healthy JJ 4_p
volunteers NNS 4_p
. . 4_p

clinical JJ 4_p
trial NN 4_p
in IN 4_p
Thailand NNP 4_p
among IN 4_p
patients NNS 4_p
with IN 4_p
malaria NNS 4_p
and CC 4_p
healthy JJ 4_p
volunteers NNS 4_p
. . 4_p

administered VBN N
to TO N
11 CD N
patients NNS N
and CC N
5 CD N
volunteers NNS N
and CC N
750 CD N
mg NN N
was VBD N
given VBN N
to TO N
16 CD N
patients NNS N
and CC N
5 CD N
volunteers NNS N
. . N

cured JJ N
patients NNS N
taking VBG N
750 CD N
mg JJ N
mefloquine NN N
, , N
peak JJ N
plasma JJ N
drug NN N
concentration NN N
( ( N
Cmax NNP N
) ) N
and CC N
area NN N
under IN N
the DT N
plasma JJ N
concentration-time JJ N
curve NN N
( ( N
AUC NNP N
) ) N
patients NNS N
with IN N
malaria NNS N
and CC N
healthy JJ N
volunteers NNS N
-DOCSTART- -X- O O 22129897

autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . N

subjects NNS N
diagnosed VBN N
with IN N
an DT N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
subjects NNS N
diagnosed VBN N
with IN N
an DT N
ASD NNP 4_p
subjects NNS N
diagnosed VBN N
with IN N
an DT N
ASD NNP 4_p
. . N

trial NN N
using VBG N
oral JJ N
lipoceutical JJ N
glutathione NN N
( ( N
n=13 JJ 3_p
) ) N
or CC N
transdermal JJ N
glutathione NN N
( ( N
n=13 JJ 3_p
) ) N
in IN N
children NNS 1_p
, , N
3-13 CD 1_p
years NNS N
of IN N
age NN N
, , N
with IN N
a DT N
diagnosis NN N
of IN N
an DT N
ASD NNP 4_p
. . N

Subjects NNPS N
underwent JJ N
pre- JJ N
and CC N
post-treatment JJ N
lab NN N
testing VBG N
oral JJ N
and CC N
transdermal JJ N
treatment NN N
groups NNS N
subjects NNS N
diagnosed VBN N
with IN N
an DT N
ASD NNP 4_p
-DOCSTART- -X- O O 8858230

healthy JJ 4_p
volunteers NNS 4_p
. . 4_p

Ten NNP 4_p
healthy JJ 4_p
volunteers NNS 4_p
underwent JJ 4_p
two CD 4_p
upper JJ 4_p
gastrointestinal JJ 4_p
endoscopies NNS 4_p
in IN 4_p
a DT 4_p
random JJ 4_p
order NN 4_p
on IN 4_p
two CD 4_p
different JJ 4_p
days NNS 4_p
, , 4_p
with IN 4_p
the DT 4_p
procedure NN 4_p
being VBG 4_p
carried VBN 4_p
out RP 4_p
by IN 4_p
a DT 4_p
single JJ 4_p
experienced JJ 4_p
endoscopist NN 4_p
. . 4_p

-DOCSTART- -X- O O 21915740

young JJ N
adults NNS N
with IN N
high-functioning JJ N
autism NN N
spectrum NN N
disorders NNS N
: : N
young JJ N
adults NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
) ) N
high-functioning JJ N
young JJ N
adults NNS N
with IN N
ASD NNP N
( ( N
ages VBZ N
18-23 CD N
) ) N
young JJ N
adults NNS N
young JJ N
adults NNS N
' POS N
young JJ N
adults NNS N
with IN N
ASD NNP N
. . N

-DOCSTART- -X- O O 15533466

patients NNS N
with IN N
interstitial JJ 4_p
cystitis NN 4_p
( ( 4_p
IC NNP 4_p
) ) 4_p
. . 4_p

Thirteen NNP 3_p
female JJ 2_p
patients NNS N
( ( N
6 CD 3_p
in IN N
the DT N
United NNP N
States NNPS N
and CC N
7 CD 3_p
in IN N
Poland NNP N
) ) N
with IN N
IC NNP 4_p
according VBG N
to TO N
the DT N
criteria NNS N
of IN N
the DT N
National NNP N
Institute NNP N
of IN N
Diabetes NNP N
, , N
Digestive NNP N
and CC N
Kidney NNP N
Disease NNP N
were VBD N
included VBN N
. . N

100 CD 4_p
to TO 4_p
200 CD 4_p
U NNP 4_p
of IN 4_p
Dysport NNP 4_p
( ( N
Polish JJ N
patients NNS N
) ) N
or CC N
Botox NNP 4_p
( ( N
U.S. NNP N
patients NNS N
) ) N
Polish JJ N
patients NNS N
-DOCSTART- -X- O O 18339525

radiation NN 4_p
proctitis NN 4_p
: : N
study NN 3_p
of IN 3_p
40 CD 3_p
patients NNS 3_p
-DOCSTART- -X- O O 26742304

labour NN 4_p
pain NN 4_p
in IN N
women NNS 2_p
: : N
120 CD 3_p
participants NNS N
-DOCSTART- -X- O O 7410734

129 CD N
clinicians NNS N
-DOCSTART- -X- O O 25670026

one CD 3_p
male NN 2_p
and CC N
26 CD 3_p
female JJ 2_p
patients NNS N
with IN N
migraine NN 4_p
. . N

-DOCSTART- -X- O O 24573180

men NNS 2_p
. . N

Fourteen NNP N
young JJ N
healthy JJ N
men NNS N
( ( N
height NN N
: : N
177.0 CD N
± $ N
2.1 CD N
cm NN N
, , N
weight NN N
: : N
85.8 CD N
± $ N
5.5 CD N
kg NN N
, , N
age NN N
: : N
24.6 CD N
± $ N
1.1 CD N
yr NN N
) ) N
-DOCSTART- -X- O O 7200736

Prostaglandin NNP 4_p
E1 NNP 4_p
as IN 4_p
a DT 4_p
hypotensive JJ 4_p
drug NN 4_p
during IN 4_p
general JJ 4_p
anaesthesia NN 4_p
. . 4_p

during IN N
mastectomy NN 4_p
induced JJ N
hypotension NN N
-DOCSTART- -X- O O 23084254

cancer-related JJ 4_p
fatigue NN 4_p
. . 4_p

cancer NN N
patients NNS N
across IN N
diagnoses NNS N
during IN N
chemotherapy NN N
cancer NN N
patients NNS N
undergoing VBG N
chemotherapy NN N
. . N

213 CD N
cancer NN N
patients NNS N
with IN N
different JJ N
diagnoses NNS N
into IN 4_p
CRF NNP N
in IN N
cancer NN N
patients NNS N
undergoing VBG N
chemotherapy NN N
. . N

-DOCSTART- -X- O O 21204103

rheumatoid JJ N
arthritis NN N
: : N
rheumatoid NN N
arthritis NN N
( ( N
RA NNP N
) ) N
28 CD N
joints NNS N
( ( N
DAS28 NNP N
) ) N
patients NNS 4_p
with IN 4_p
RA NNP 4_p
in IN 4_p
whom WP 4_p
disease NN 4_p
had VBD 4_p
remained VBN 4_p
active JJ 4_p
despite IN 4_p
treatment NN 4_p
with IN 4_p
disease-modifying JJ 4_p
antirheumatic JJ 4_p
drugs NNS 4_p
. . 4_p

-DOCSTART- -X- O O 7910792

patients NNS N
who WP N
undergo VBP N
laparoscopic JJ 4_p
surgical JJ 4_p
operations NNS 4_p
. . N

42 CD 3_p
patients NNS N
subdivided VBD N
into IN N
four CD N
groups NNS N
namely RB N
, , N
higher JJR N
or CC N
lower JJR N
insufflation NN N
pressures NNS N
, , N
chemically RB N
inert JJ N
insufflation NN N
gas NN N
and CC N
control NN N
groups NNS N
; : N
-DOCSTART- -X- O O 2185458

The DT N
placebo NN N
effect NN N
. . N

Drug NNP N
trial NN N
considerations NNS N
. . N

-DOCSTART- -X- O O 10195003

low JJ 4_p
dose VBP 4_p
intravenous JJ 4_p
urography NN 4_p
. . N

392 CD N
patients NNS N
-DOCSTART- -X- O O 19470807

people NNS N
with IN N
multiple JJ 4_p
sclerosis NN 4_p
. . N

people NNS N
with IN N
multiple JJ 4_p
sclerosis NN 4_p
multiple JJ 4_p
sclerosis NN 4_p
. . N

In IN N
phase NN N
1 CD N
, , N
36 CD 3_p
participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
experimental VB N
and CC N
control VB N
groups NNS N
. . N

phase NN N
2 CD N
, , N
the DT N
control NN N
group NN N
people NNS N
with IN N
multiple JJ 4_p
sclerosis NN 4_p
( ( N
MS NNP 4_p
) ) N
-DOCSTART- -X- O O 25919773

patients NNS 4_p
treated VBN 4_p
with IN 4_p
concomitant NN 4_p
, , N
quadruple NN 4_p
, , 4_p
and CC 4_p
levofloxacin-based JJ 4_p
therapies NNS 4_p
. . N

individuals NNS 4_p
with IN 4_p
amalgam JJ 4_p
fillings NNS 4_p
. . 4_p

dyspeptic JJ 4_p
patients NNS 4_p
with IN 4_p
amalgam JJ 4_p
fillings NNS 4_p
and CC N
the DT 4_p
effect NN 4_p
of IN 4_p
the DT 4_p
amalgam JJ 4_p
fillings NNS 4_p
on IN 4_p
H. NNP 4_p
pylori JJ 4_p
eradication NN 4_p
rates NNS 4_p
in IN 4_p
these DT 4_p
patients NNS 4_p
. . N

Four NNP 3_p
hundred VBD 3_p
and CC 3_p
seventy-five JJ 3_p
patients NNS 3_p
who WP N
presented VBD N
with IN N
dyspeptic JJ 4_p
complaints NNS 4_p
and CC N
underwent JJ 4_p
upper JJ 4_p
gastrointestinal JJ 4_p
endoscopy NN 4_p
and CC N
gastric JJ 4_p
biopsy NN 4_p
were VBD N
included VBN N
filling NN N
group NN N
nonfilling VBG N
group NN N
H. NNP N
pylori-positive JJ 4_p
patients NNS 4_p
patients NNS 4_p
with IN 4_p
amalgam JJ 4_p
fillings NNS 4_p
patients NNS 4_p
with IN 4_p
amalgam JJ 4_p
fillings NNS 4_p
-DOCSTART- -X- O O 7159500

12 CD 4_p
patients NNS 4_p
with IN 4_p
familial JJ 4_p
hypercholesterolemia NN 4_p
( ( 4_p
corresponding VBG 4_p
to TO 4_p
the DT 4_p
HLP NNP 4_p
type NN 4_p
IIa NNP 4_p
pattern NN 4_p
) ) 4_p
. . 4_p

-DOCSTART- -X- O O 15536093

Syncope NNP N
syncope VB 4_p
patients NNS N
with IN N
syncope NN N
who WP N
are VBP N
at IN N
intermediate JJ N
risk NN N
for IN N
an DT N
adverse JJ N
cardiovascular JJ N
outcome NN N
. . N

single-center JJ N
study NN N
, , N
patients NNS N
One CD 4_p
hundred VBD 4_p
three CD 4_p
consecutive JJ 4_p
patients NNS 4_p
( ( 4_p
53 CD 4_p
women NNS 4_p
; : 4_p
mean JJ 4_p
age NN 4_p
64+/-17 CD 4_p
years NNS 4_p
) ) 4_p
entered VBD 4_p
the DT 4_p
study NN 4_p
. . 4_p

intermediate-risk JJ N
patients NNS N
. . N

-DOCSTART- -X- O O 8363113

poisoning NN 4_p
with IN 4_p
acetaminophen NN 4_p
: : N
Ten NNP 3_p
healthy JJ N
adult NN 1_p
volunteers NNS 1_p
victims NNS N
of IN N
acetaminophen NN 4_p
overdose NN 4_p
. . N

-DOCSTART- -X- O O 1908729

after IN 4_p
allogeneic JJ 4_p
T-cell NNP 4_p
depleted VBD 4_p
BMT NNP 4_p
. . 4_p

-DOCSTART- -X- O O 19897063

bone NN 4_p
turnover NN 4_p
in IN 4_p
postmenopausal JJ 4_p
women NNS 4_p
. . 4_p

accelerated JJ 4_p
bone NN 4_p
loss NN 4_p
following VBG 4_p
estrogen JJ 4_p
cessation NN 4_p
. . 4_p

postmenopausal NN 4_p
, , N
osteopenic JJ N
women NNS 2_p
. . N

Women NNS 2_p
aged VBD 1_p
50 CD 1_p
to TO 1_p
80 CD 1_p
years NNS 1_p
raloxifene NN N
( ( N
group NN N
1 CD N
, , N
n=20 NN 3_p
) ) N
or CC N
placebo NN N
( ( N
group NN N
2 CD N
, , N
n=20 NN 3_p
) ) N
for IN N
a DT N
further JJ N
96 CD N
weeks NNS N
. . N

A DT N
third JJ N
group NN N
( ( N
group NN N
3 CD N
, , N
n=14 NN 3_p
) ) N
received VBD N
no DT N
treatment NN N
. . N

accelerated VBD 4_p
bone JJ 4_p
loss NN 4_p
. . 4_p

-DOCSTART- -X- O O 17954768

Holstein NNP N
calves NNS N
during IN N
the DT N
preweaning NN N
and CC N
postweaning NN N
phases NNS N
. . N

Sixty NNP N
Holstein NNP N
calves VBZ N
( ( 4_p
30 CD 4_p
bulls NNS 4_p
, , 4_p
30 CD 4_p
heifers NNS 4_p
) ) 4_p
Calves NNS N
Calves NNS N
raised VBD N
in IN N
the DT N
barn NN N
-DOCSTART- -X- O O 21316048

women NNS 2_p
with IN N
oligo- JJ N
or CC N
anovulatory JJ 4_p
infertility NN 4_p
: : N
follicular NN N
development NN N
and CC N
ovulation NN N
in IN N
infertile JJ N
women NNS N
with IN N
ovulatory JJ 4_p
dysfunction NN 4_p
. . N

Infertile NNP N
women NNS N
with IN N
ovulatory JJ N
dysfunction NN N
, , N
aged VBN N
18-35 CD 1_p
years NNS 1_p
, , N
and CC N
body NN N
mass NN N
index NN N
< VBD N
35 CD N
kg/m NN N
( ( N
2 CD N
) ) N
. . N

-DOCSTART- -X- O O 8908106

mild JJ 4_p
renal JJ 4_p
failure NN 4_p
in IN 4_p
heart NN 4_p
transplantation NN 4_p
. . 4_p

-DOCSTART- -X- O O 7552649

patients NNS 4_p
with IN 4_p
chronic JJ 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
: : 4_p
patients NNS 4_p
with IN 4_p
chronic JJ 4_p
disabling VBG 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
( ( 4_p
LBP NNP 4_p
) ) 4_p
The DT N
subjects NNS N
included VBD N
132 CD N
patients NNS N
randomized VBN N
to TO N
the DT N
study NN N
, , N
of IN N
whom WP N
123 CD N
started VBD N
one CD N
of IN N
the DT N
treatment NN N
programs NNS N
. . N

They PRP N
had VBD N
all DT N
had VBN N
at IN N
least JJS N
6 CD N
months NNS N
of IN N
chronic JJ N
LBP NNP N
. . N

-DOCSTART- -X- O O 9330779

healthy JJ 4_p
subjects NNS N
. . N

12 CD 3_p
healthy JJ 4_p
male NN 2_p
volunteers NNS N
Six CD 3_p
subjects NNS N
fasted VBN N
conditions NNS N
from IN N
days NNS N
1 CD N
to TO N
6 CD N
and CC N
then RB N
crossed VBD N
over IN N
to TO N
fed VB N
conditions NNS N
from IN N
days NNS N
7 CD N
to TO N
12 CD N
. . N

six CD N
subjects NNS N
fed VBN N
for IN N
days NNS N
1-6 CD N
and CC N
fasted VBN N
for IN N
days NNS N
7-12 CD N
-DOCSTART- -X- O O 23404659

adolescent JJ 1_p
and CC 1_p
young JJ 1_p
adult NN 1_p
children NNS 1_p
of IN N
opiate JJ 4_p
addicts NNS 4_p
: : N
adolescent NN 1_p
and CC 1_p
young JJ 1_p
adult NN 1_p
children NNS 1_p
of IN N
parents NNS 4_p
enrolled VBN 4_p
in IN 4_p
methadone NN 4_p
treatment NN 4_p
for IN 4_p
opiate JJ 4_p
addiction NN 4_p
. . N

Data NNS N
are VBP N
from IN N
151 CD N
participants NNS N
( ( N
80 CD N
males NNS 2_p
, , 2_p
71 CD 2_p
females NNS 2_p
) ) N
in IN N
the DT N
Focus NNP N
on IN N
Families NNP N
( ( N
FOF NNP N
) ) N
project NN N
, , N
a DT N
randomized JJ N
trial NN N
of IN N
a DT N
family NN N
intervention NN N
and CC N
a DT N
study NN N
of IN N
the DT N
development NN N
of IN N
at-risk JJ 4_p
children NNS 4_p
. . N

The DT N
study NN N
participants NNS N
are VBP N
children NNS 4_p
of IN 4_p
parents NNS 4_p
enrolled VBN 4_p
in IN 4_p
methadone NN 4_p
treatment NN 4_p
between IN N
1990 CD N
and CC N
1993 CD N
. . N

Participants NNS N
were VBD N
interviewed VBN N
in IN N
2005 CD N
when WRB N
they PRP N
ranged VBD N
in IN N
age NN N
from IN N
15 CD 1_p
to TO 1_p
29 CD 1_p
years NNS 1_p
. . N

-DOCSTART- -X- O O 24661050

Forty-eight JJ 3_p
subjects NNS 3_p
underwent JJ N
conventional JJ 4_p
transthoracic NN 4_p
echocardiographic JJ 4_p
examination NN 4_p
with IN N
additional JJ N
intracardiac NN N
flow NN N
assessment NN N
with IN N
VFM NNP N
using VBG N
a DT N
Aloka NNP N
Alpha-10 NNP N
system NN N
and CC N
experimental JJ N
VFM NNP N
analysis NN N
software NN N
. . N

-DOCSTART- -X- O O 12511152

a DT 4_p
single JJ 4_p
institution NN 4_p
participating VBG 4_p
in IN 4_p
a DT 4_p
multicenter JJ 4_p
drug NN 4_p
study NN 4_p
-DOCSTART- -X- O O 18328090

patients NNS 4_p
with IN 4_p
osteoarthritis NN 4_p
. . 4_p

patients NNS 1_p
with IN 1_p
osteoarthritis NN 1_p
( ( 1_p
OA NNP 1_p
) ) 1_p
. . 1_p

male NN N
and CC N
female JJ N
patients NNS N
( ( N
aged VBN N
at IN N
least JJS N
40 CD N
years NNS N
) ) N
with IN N
symptomatic JJ N
primary JJ N
OA NNP N
of IN N
the DT N
hip NN N
, , N
knee NN N
, , N
hand NN N
or CC N
spine NN N
patients NNS N
with IN N
OA NNP N
. . N

-DOCSTART- -X- O O 17432640

postsurgical JJ 4_p
gastroparesis NN 4_p
syndrome NN 4_p
] NNP 4_p
postsurgical JJ 4_p
gastroparesis NN 4_p
syndrome NN 4_p
( ( 4_p
PGS NNP 4_p
) ) 4_p
. . N

Forty-one JJ 3_p
cases NNS N
of IN N
PGS NNP 4_p
were VBD N
randomly RB N
divided VBN N
into IN N
3 CD N
groups NNS N
in IN N
order NN N
of IN N
visiting VBG N
. . N

( ( N
n JJ N
= NNP N
17 CD N
) ) N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
PGS NNP 4_p
-DOCSTART- -X- O O 10997806

advanced JJ N
non-small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
( ( 4_p
NSCLC NNP 4_p
) ) 4_p
: : N
Since IN N
July NNP N
1996 CD N
, , N
198 CD 3_p
patients NNS N
with IN N
non-operable JJ 4_p
NSCLC NNP 4_p
and CC N
measurable JJ N
disease NN N
without IN N
previous JJ N
chemotherapy NN N
entered VBD N
the DT N
trial NN N
. . N

Ninety NNP 3_p
nine CD 3_p
patients NNS N
( ( N
group NN N
A DT N
) ) N
-DOCSTART- -X- O O 17114905

benign JJ 4_p
thyroid JJ 4_p
nodules NNS 4_p
. . N

subjects NNS N
with IN N
compressive JJ 4_p
symptoms NNS 4_p
due JJ 4_p
to TO 4_p
benign VB 4_p
thyroid JJ 4_p
nodules NNS 4_p
and/or VBP 4_p
at IN 4_p
high JJ 4_p
surgical JJ 4_p
risk NN 4_p
. . N

Twenty NNP 3_p
six CD 3_p
subjects NNS N
were VBD N
randomized VBN N
to TO N
the DT N
intervention NN N
( ( N
no DT N
. . N

13 CD 3_p
, , N
age NN N
68+/-3 JJ 1_p
yr NN 1_p
, , N
mean+/-SEM NN N
) ) N
or CC N
observation NN N
( ( N
no DT N
. . N

13 CD 3_p
, , N
age NN N
71+/-2 JJ 1_p
yr NN 1_p
) ) N
groups NNS N
. . N

benign JJ 4_p
thyroid JJ 4_p
nodules NNS 4_p
in IN N
patients NNS N
at IN N
high JJ N
surgical JJ N
risk NN N
. . N

-DOCSTART- -X- O O 8437833

threshold JJ 4_p
retinopathy NN 4_p
of IN 4_p
prematurity NN 4_p
. . N

retinopathy NN 4_p
of IN 4_p
prematurity NN 4_p
( ( N
ROP NNP 4_p
) ) N
Patients NNPS N
Nineteen JJ 3_p
infants NNS 3_p
( ( 3_p
33 CD 3_p
eyes NNS 3_p
) ) 3_p
were VBD N
treated VBN N
, , N
ranging VBG N
from IN N
485 CD N
to TO N
863 CD N
g NNS N
birth JJ N
weight NN N
( ( N
23 CD N
to TO N
27 CD N
weeks NNS N
gestational JJ N
age NN N
) ) N
; : N
18 CD 3_p
patients NNS 3_p
( ( 3_p
32 CD 3_p
eyes NNS 3_p
) ) 3_p
Four CD 3_p
patients NNS 3_p
( ( 3_p
8 CD 3_p
eyes NNS 3_p
) ) 3_p
had VBD N
bilateral JJ N
zone CD N
1 CD N
disease NN N
. . N

Postconceptional JJ N
age NN N
was VBD N
36 CD 1_p
to TO 1_p
45 CD 1_p
weeks NNS 1_p
at IN N
the DT N
time NN N
of IN N
treatment NN N
. . N

-DOCSTART- -X- O O 12440177

acute JJ N
contrast NN N
nephropathy NN 4_p
. . N

after IN N
exposure NN N
to TO N
radiocontrast VB 4_p
media NNS N
. . N

98 CD 3_p
subjects NNS N
who WP N
underwent VBP N
cardiac JJ 4_p
catheterization NN 4_p
The DT N
mean JJ N
age NN N
, , N
baseline NN 4_p
serum NN 4_p
Cr NNP 4_p
, , N
and CC N
Cr NNP 4_p
clearance NN 4_p
( ( N
CrCl NNP N
) ) N
were VBD N
69.3 CD 1_p
+/- JJ 1_p
10.8 CD 1_p
years NNS 1_p
, , 1_p
2.5 CD N
+/- JJ N
0.9 CD N
mg/dL NN N
, , N
and CC N
31.4 CD N
+/- JJ N
12.1 CD N
mL/min NN N
, , N
respectively RB N
. . N

-DOCSTART- -X- O O 25842725

young JJ 1_p
adults NNS 1_p
with IN N
essential JJ N
hypertension NN 4_p
. . N

young JJ 1_p
essential JJ N
hypertension NN 4_p
( ( N
YEH NNP N
) ) N
patients NNS N
with IN N
abundant JJ 4_p
phlegm-heat JJ 4_p
syndrome NN 4_p
Twelve NNP 3_p
male NN 2_p
YEH NNP N
patients NNS N
were VBD N
randomly RB N
selected VBN N
and CC N
serum JJ N
samples NNS N
were VBD N
collected VBN N
for IN N
examination NN N
before IN N
and CC N
after IN N
4 CD N
weeks NNS N
of IN N
the DT N
treatment NN N
with IN N
QRHT NNP N
. . N

Twelve NNP 3_p
healthy JJ N
males NNS 2_p
were VBD N
randomly RB N
selected VBN N
and CC N
their PRP$ N
serum NN N
samples NNS N
were VBD N
collected VBN N
as IN N
a DT N
control NN N
. . N

YEH NNP N
patients NNS N
with IN N
abundant JJ N
phlegm-heat JJ 4_p
syndrome NN 4_p
-DOCSTART- -X- O O 24898665

Patients NNS N
with IN 4_p
relapsed JJ 4_p
follicular JJ 4_p
lymphoma NN 4_p
-DOCSTART- -X- O O 17467265

locally RB N
advanced JJ 4_p
nasopharyngeal JJ 4_p
cancer NN 4_p
: : N
single JJ N
centre NN N
patients NNS N
with IN N
locoregionally RB 4_p
advanced JJ 4_p
nasopharyngeal JJ 4_p
cancer NN 4_p
From NNP N
August NNP N
1999 CD N
to TO N
December NNP N
2004 CD N
, , N
206 CD 3_p
patients NNS N
with IN N
locally RB N
advanced JJ N
NPC NNP N
were VBD N
randomised VBN N
with IN N
101 CD 3_p
to TO N
cisplatin VB N
arm NN N
and CC N
105 CD 3_p
to TO N
carboplatin VB N
arm NN N
. . N

locoregional JJ 4_p
advanced JJ 4_p
stage NN 4_p
NPC NNP 4_p
. . N

-DOCSTART- -X- O O 15198767

cervical JJ 4_p
intraepithelial JJ 4_p
neoplasia NN 4_p
: : 4_p
cervical JJ 4_p
intraepithelial JJ 4_p
neoplasia NN 4_p
( ( 4_p
CIN NNP 4_p
) ) 4_p
gynaecological JJ N
oncology NN N
centre NN N
and CC N
a DT N
teaching JJ N
hospital NN N
in IN N
West NNP N
London NNP N
. . N

Four CD N
hundred VBD N
and CC N
four CD N
women NNS N
due JJ N
to TO N
receive VB N
treatment NN N
for IN N
suspected JJ N
CIN NNP N
. . N

Four NNP N
randomised VBD N
women NNS N
-DOCSTART- -X- O O 20638818

advanced JJ 4_p
gastric JJ 4_p
cancer NN 4_p
. . 4_p

gastric JJ 4_p
cancer NN 4_p
patients NNS N
. . N

63 CD 3_p
gastric JJ N
cancer NN N
patients NNS N
. . N

Group NNP N
F NNP N
, , N
16 CD 3_p
cases NNS N
who WP N
received VBD N
a DT N
single JJ N
administration NN N
of IN N
5-fluorouracil JJ N
( ( N
5-FU JJ N
) ) N
; : N
Group NNP N
C NNP N
, , N
15 CD 3_p
cases NNS N
who WP N
received VBD N
a DT N
single JJ N
administration NN N
of IN N
cis-diamminedichloroplatinum NN N
( ( N
CDDP NNP N
; : N
cisplatin NN N
) ) N
; : N
Group NNP N
FC NNP N
, , N
16 CD 3_p
cases NNS N
who WP N
received VBD N
both DT N
5-FU+CDDP JJ N
; : N
a DT N
Control NNP N
group NN N
, , N
16 CD 3_p
cases NNS N
who WP N
did VBD N
not RB N
receive VB N
chemotherapy NN N
. . N

gastric JJ 4_p
cancer NN 4_p
-DOCSTART- -X- O O 14661011

patients NNS 4_p
presenting VBG 4_p
with IN 4_p
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
ST-elevation NNP 4_p
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
( ( 4_p
AMI NNP 4_p
) ) 4_p
. . 4_p

Patients NNS N
with IN N
ischemic JJ 4_p
chest NN 4_p
pain NN 4_p
with IN N
duration NN N
< NN N
or CC N
=12 NN N
hours NNS N
and CC N
no DT N
contraindication NN N
for IN N
thrombolytic JJ N
therapy NN N
were VBD N
included VBN N
. . N

Between NNP N
October NNP N
1993 CD N
and CC N
August NNP N
1995 CD N
, , N
58 CD 3_p
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
streptokinase VB N
( ( N
SK NNP N
) ) N
and CC N
54 CD 3_p
patients NNS N
to TO N
primary JJ N
PCI NNP N
. . N

Median JJ N
age NN N
( ( N
interquartile JJ N
range NN N
) ) N
was VBD N
68 CD 1_p
( ( N
58 CD N
, , N
75 CD N
) ) N
years NNS N
, , N
29 CD N
% NN N
were VBD N
women NNS 2_p
, , N
and CC N
78 CD N
% NN N
of IN N
the DT N
patients NNS N
met VBD N
at IN N
least JJS N
one CD N
criterion NN N
for IN N
" NNP N
not RB N
low JJ N
risk NN N
" NN N
AMI NNP N
( ( N
anterior JJ N
location NN N
, , N
age NN N
> VBD 1_p
70 CD 1_p
years NNS 1_p
old JJ N
, , N
previous JJ N
MI NNP N
, , N
systolic JJ N
blood NN N
pressure NN N
< VBZ N
100 CD N
mm NN N
Hg NNP N
, , N
and/or JJ N
heart NN N
rate NN N
> VBD N
100 CD N
bpm NN N
) ) N
. . N

-DOCSTART- -X- O O 12654143

very RB 4_p
preterm JJ 4_p
infants NNS 1_p
to TO N
term NN N
equivalent JJ N
age NN N
. . N

neuromotor NN 4_p
function NN 4_p
in IN N
very RB 4_p
preterm JJ 4_p
infants NNS 1_p
123 CD 3_p
very RB 4_p
preterm JJ 4_p
infants NNS 1_p
was VBD N
conducted VBN N
in IN N
the DT N
neonatal JJ N
intensive JJ N
care NN N
unit NN N
of IN N
the DT N
sole JJ N
tertiary JJ N
referral JJ N
centre NN N
in IN N
Western JJ N
Australia NNP N
. . N

Infants NNS 1_p
were VBD N
stratified VBN N
by IN N
gestational JJ N
age NN N
( ( N
< JJ N
29 CD 1_p
weeks NNS 1_p
or CC 1_p
29-30 JJ 1_p
weeks NNS 1_p
) ) N
-DOCSTART- -X- O O 24408892

for IN N
teens NNS N
with IN N
ASD NNP N
a DT N
parent-assisted JJ N
social JJ N
skills NNS N
training VBG N
for IN N
teens NNS N
with IN N
ASD NNP N
Korean NNP N
reviewed VBN N
by IN N
21 CD N
child JJ N
mental JJ N
health NN N
professionals NNS N
were VBD N
surveyed VBN N
by IN N
447 CD N
middle JJ N
school NN N
students NNS N
accordingly RB N
. . N

Participants NNS N
included VBD N
47 CD N
teens NNS N
between IN N
12 CD N
and CC N
18 CD N
years NNS N
of IN N
age NN N
with IN N
a DT N
diagnosis NN N
of IN N
ASD NNP N
and CC N
a DT N
verbal JJ N
intelligence NN N
quotient NN N
( ( N
IQ NNP N
) ) N
be VB N
efficacious JJ N
for IN N
teens NNS N
with IN N
treatment NN N
for IN N
adolescents NNS N
-DOCSTART- -X- O O 21126245

toddlers NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
: : N
toddlers NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
) ) N
. . N

Fifty NNP N
toddlers NNS N
with IN N
ASD NNP N
, , N
ages VBZ N
21 CD N
to TO N
33 CD N
months NNS N
toddlers NNS N
toddlers NNS N
with IN N
ASD NNP N
. . N

-DOCSTART- -X- O O 24451146

early JJ 4_p
breast NN 4_p
cancer NN 4_p
: : 4_p
in IN N
624 CD 3_p
( ( 3_p
94 CD 3_p
% NN 3_p
) ) 3_p
and CC N
462 CD 3_p
( ( N
69 CD N
% NN N
) ) N
, , N
respectively RB N
, , N
of IN N
667 CD 3_p
postmenopausal JJ 4_p
women NNS 2_p
with IN N
hormone NN N
responsive VBP N
early JJ N
breast NN 4_p
cancer NN 4_p
treated VBN N
by IN N
surgery NN N
followed VBN N
by IN N
adjuvant JJ N
treatment NN N
with IN N
tamoxifen JJ N
+/- JJ N
octreotide NN N
in IN N
a DT N
randomized JJ N
trial NN N
( ( N
NCIC NNP N
CTG NNP N
MA.14 NNP N
; : N
National NNP N
Cancer NNP N
Institute NNP N
of IN N
Canada NNP N
Clinical NNP N
Trials NNP N
Group NNP N
Mammary.14 NNP N
) ) N
. . N

2,540 CD 3_p
samples NNS 3_p
; : N
688 CD N
at IN N
baseline NN N
and CC N
1,852 CD N
collected VBN N
in IN N
women NNS 2_p
with IN N
hormone NN N
responsive VBP N
early JJ 4_p
breast NN 4_p
cancer NN 4_p
-DOCSTART- -X- O O 20796074

Malpura NNP N
ewes FW N
under IN N
semi-arid JJ N
tropical JJ N
environment NN N
. . N

Malpura NNP N
ewes NN N
. . N

Twenty-eight JJ 3_p
adult NN 1_p
Malpura NNP N
ewes NN N
were VBD N
used VBN N
animals NNS N
were VBD N
stall JJ N
fed VBN N
-DOCSTART- -X- O O 23875574

visual JJ 4_p
selective JJ 4_p
attention NN 4_p
. . N

Subjects NNS N
completed VBD N
an DT N
attentional JJ N
capture NN N
task NN N
alone RB N
( ( N
single-task JJ N
) ) N
or CC N
while IN N
engaged VBN N
in IN N
a DT N
working JJ N
memory NN N
task NN N
( ( N
dual-task JJ N
) ) N
. . N

-DOCSTART- -X- O O 18512510

The DT N
root NN 4_p
canals NNS 4_p
of IN N
30 CD 3_p
human JJ N
incisors NNS N
and CC N
canines NNS N
-DOCSTART- -X- O O 1616359

metronidazole NN 4_p
as IN 4_p
a DT 4_p
disease NN 4_p
modifying VBG 4_p
agent NN 4_p
in IN 4_p
the DT 4_p
treatment NN 4_p
of IN 4_p
rheumatoid JJ 4_p
arthritis NN 4_p
. . 4_p

treatment NN N
of IN N
rheumatoid JJ N
arthritis NN N
. . N

Fifty JJ N
patients NNS N
with IN N
active JJ N
rheumatoid NN N
arthritis NN N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
active JJ N
drug NN N
( ( N
n JJ N
= NNP N
24 CD N
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
26 CD N
) ) N
and CC N
reviewed VBN N
at IN N
weeks NNS N
0 CD N
, , N
1 CD N
, , N
4 CD N
, , N
8 CD N
, , N
12 CD N
, , N
16 CD N
, , N
and CC N
24 CD N
. . N

-DOCSTART- -X- O O 9028057

autism NN 4_p
: : N
Twelve NNP 3_p
autistic JJ 4_p
patients NNS N
ranging VBG N
from IN N
7 CD 1_p
to TO 1_p
15 CD 1_p
years NNS 1_p
, , N
diagnosed VBD N
according VBG N
to TO N
DSM-III-R NNP N
children NNS 1_p
. . N

population NN N
of IN N
autistic JJ 4_p
children NNS 1_p
-DOCSTART- -X- O O 25552279

central JJ 4_p
venous JJ 4_p
catheter NN 4_p
complications NNS 4_p
in IN N
preterm JJ 1_p
infants NNS 1_p
. . N

very RB 1_p
preterm JJ 1_p
infants NNS 1_p
. . N

150 CD 3_p
infants NNS N
were VBD N
randomised VBN N
with IN N
mean NN N
( ( N
SD NNP N
) ) N
birth NN N
weight NN N
( ( N
g NN N
) ) N
of IN N
900 CD N
( ( N
158 CD N
) ) N
versus NN N
884 CD N
( ( N
183 CD N
) ) N
in IN N
SCAMP NNP N
( ( N
n=74 NN 3_p
) ) N
and CC N
control NN N
( ( N
n=76 JJ 3_p
) ) N
groups NNS N
-DOCSTART- -X- O O 21334545

27 CD 3_p
subjects NNS N
( ( N
12 CD 3_p
men NNS 2_p
and CC N
15 CD 3_p
women NNS 2_p
) ) N
with IN N
lateral JJ N
epicondylitis NN 4_p
2 CD N
groups NNS N
. . N

-DOCSTART- -X- O O 15738536

Japanese JJ N
women NNS 4_p
with IN N
bone NN N
metastases NNS N
from IN N
breast NN 4_p
cancer NN 4_p
: : N
Women NNP 2_p
with IN N
bone NN N
metastases NNS N
( ( N
N NNP 3_p
= NNP 3_p
228 CD 3_p
) ) 3_p
Japanese JJ N
women NNS N
with IN N
bone NN N
metastases NNS N
from IN N
breast NN N
cancer NN N
. . N

-DOCSTART- -X- O O 23076431

humans NNS N
. . N

17 CD 3_p
healthy JJ 4_p
male NN 2_p
volunteers NNS 2_p
. . N

-DOCSTART- -X- O O 10901647

Eleven JJ N
patients NNS N
with IN N
12 CD N
traumatic JJ N
femur NN N
fractures NNS N
-DOCSTART- -X- O O 12804020

Thirty-five JJ 4_p
healthy JJ 4_p
adults NNS 4_p
age NN 4_p
35-69 CD 4_p
years NNS 4_p
were VBD 4_p
enrolled VBN 4_p
in IN 4_p
a DT 4_p
randomized JJ 4_p
, , 4_p
double-blind JJ 4_p
, , 4_p
placebo-controlled JJ 4_p
trial NN 4_p
of IN 4_p
8 CD 4_p
weeks NNS 4_p
' POS 4_p
duration NN 4_p
. . 4_p

All DT N
participants NNS N
Nineteen JJ N
participants NNS N
received VBD N
gelcaps NNS N
16 CD N
participants NNS N
received VBD N
gelcaps NNS N
-DOCSTART- -X- O O 14736356

during IN 4_p
transesophageal JJ 4_p
echocardiography NN 4_p
: : 4_p
Patients NNS 4_p
with IN 4_p
ischemic JJ 4_p
stroke NN 4_p
or CC 4_p
transient JJ 4_p
ischemic JJ 4_p
attack NN 4_p
undergoing JJ 4_p
TEE NNP 4_p
because IN 4_p
of IN 4_p
presumed JJ 4_p
cardioembolic JJ 4_p
origin NN 4_p
in IN 4_p
a DT 4_p
specialized JJ 4_p
stroke NN 4_p
unit NN 4_p
of IN 4_p
the DT 4_p
Johann NNP 4_p
Wolfgang NNP 4_p
Goethe-University NNP 4_p
, , 4_p
Frankfurt/Main NNP 4_p
, , 4_p
Germany NNP 4_p
. . 4_p

Forty-one CD 3_p
( ( 3_p
41 CD 3_p
) ) 3_p
patients NNS N
were VBD N
studied VBN N
. . N

-DOCSTART- -X- O O 25542620

patients NNS 4_p
with IN 4_p
Crohn NNP 4_p
's POS 4_p
disease NN 4_p
consecutive JJ N
patients NNS N
from IN N
17 CD N
centres NNS N
in IN N
Australia NNP N
and CC N
New NNP N
Zealand NNP N
undergoing JJ N
intestinal JJ N
resection NN N
of IN N
all DT N
macroscopic NNP N
Crohn NNP 4_p
's POS 4_p
disease NN 4_p
, , N
with IN N
an DT N
endoscopically RB N
accessible JJ N
anastomosis NN N
, , N
received VBD N
3 CD N
months NNS N
of IN N
metronidazole JJ N
therapy NN N
. . N

Patients NNS 4_p
at IN 4_p
high JJ 4_p
risk NN 4_p
of IN 4_p
recurrence NN 4_p
also RB N
received VBD N
a DT N
thiopurine NN N
, , N
or CC N
adalimumab RB N
if IN N
they PRP N
were VBD N
intolerant JJ N
to TO N
thiopurines NNS N
. . N

groups NNS N
) ) N
patients NNS N
Of IN N
122 CD 3_p
patients NNS 3_p
in IN 3_p
the DT 3_p
active JJ 3_p
care NN 3_p
group NN 3_p
-DOCSTART- -X- O O 1326339

autistic JJ 4_p
children NNS 4_p
: : 4_p
14 CD 4_p
autistic JJ 4_p
children NNS 4_p
autistic JJ N
children NNS N
-DOCSTART- -X- O O 10934908

neurophysiological JJ 4_p
manifestation NN 4_p
of IN 4_p
recollective JJ 4_p
experience NN 4_p
. . N

M.E NNP N
. . N

Smith NNP N
( ( N
1993 CD N
) ) N
obtained VBD N
event-related JJ 4_p
brain NN 4_p
potentials NNS 4_p
( ( 4_p
ERPs NNP 4_p
) ) 4_p
subjects NNS N
performing VBG N
a DT N
recognition NN N
memory NN N
task NN N
using VBG N
" JJ N
remember VB N
" NNP N
( ( N
R NNP N
) ) N
and CC N
" $ N
know VBP N
" NNP N
( ( N
K NNP N
) ) N
judgments NNS N
-DOCSTART- -X- O O 8436744

patients NNS N
with IN N
severe JJ 4_p
chronic JJ 4_p
congestive JJ 4_p
heart NN 4_p
failure NN 4_p
: : N
patients NNS N
with IN N
moderate JJ 4_p
to TO 4_p
severe VB 4_p
congestive JJ 4_p
heart NN 4_p
failure NN 4_p
. . N

1,068 CD N
patients NNS N
enrolled VBN N
in IN N
a DT N
survival NN N
study NN N
of IN N
class NN 4_p
III NNP 4_p
or CC 4_p
IV NNP 4_p
heart NN 4_p
failure NN 4_p
at IN N
the DT N
time NN N
of IN N
double-blind JJ N
randomization NN N
to TO N
milrinone VB N
, , N
a DT N
phosphodiesterase NN N
inhibitor NN N
, , N
or CC N
placebo NN N
. . N

-DOCSTART- -X- O O 22156577

lipoprotein JJ 4_p
subfractions NNS 4_p
15 CD 4_p
lipoprotein JJ 4_p
subfractions NNS 4_p
( ( 4_p
L1-L15 NNP 4_p
) ) 4_p
in IN 4_p
1791 CD 4_p
samples NNS 4_p
using VBG 4_p
( ( 4_p
1 CD 4_p
) ) 4_p
H-NMR NNP 4_p
( ( 4_p
nuclear JJ 4_p
magnetic JJ 4_p
resonance NN 4_p
) ) 4_p
spectroscopy NN 4_p
. . 4_p

-DOCSTART- -X- O O 20028938

ketosis-prone NN 4_p
type NN 4_p
2 CD 4_p
diabetes NNS 4_p
. . N

Over IN N
half NN N
of IN N
newly RB N
diagnosed VBN N
obese JJ 4_p
African JJ 4_p
Americans NNPS 4_p
with IN 4_p
diabetic JJ 4_p
ketoacidosis NN 4_p
( ( 4_p
DKA NNP 4_p
) ) 4_p
eight CD 3_p
obese JJ 4_p
African JJ N
Americans NNPS N
with IN N
KPDM NNP 4_p
, , N
eight CD 3_p
obese JJ N
subjects NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
with IN N
severe JJ 4_p
hyperglycemia NN 4_p
without IN N
ketosis NN N
( ( N
ketosis-resistant JJ N
type NN N
2 CD N
diabetes NNS N
) ) N
, , N
and CC N
nine CD 3_p
nondiabetic JJ N
obese NNS N
control NN N
subjects VBZ N
obese JJ N
African JJ N
American JJ N
patients NNS N
with IN N
KPDM NNP 4_p
and CC 4_p
ketosis-resistant JJ 4_p
type NN 4_p
2 CD 4_p
diabetes NNS 4_p
KPDM NNP 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 15975721

burned JJ 4_p
patients NNS 4_p
with IN N
sepsis NN 4_p
. . N

severely RB 4_p
burned VBN 4_p
patients NNS 4_p
with IN N
sepsis NN 4_p
. . N

Twenty NNP 3_p
adult NN N
severely RB 4_p
burned VBD 4_p
patients NNS 4_p
with IN 4_p
sepsis NN 4_p
were VBD N
studied VBN N
. . N

-DOCSTART- -X- O O 11948051

artery NN N
bypass NN N
grafting NN N
. . N

patients NNS N
who WP N
undergo VBP N
off-pump JJ N
coronary JJ N
artery NN N
bypass NN N
grafting NN N
( ( N
CABG NNP N
) ) N
. . N

Thirty-two JJ N
patients NNS N
with IN N
left JJ N
anterior JJ N
descending VBG N
coronary JJ N
artery NN N
( ( N
LAD NNP N
) ) N
or CC N
two-vessel JJ N
heart NN N
disease NN N
( ( N
including VBG N
LAD NNP N
) ) N
who WP N
were VBD N
to TO N
undergo VB N
off-pump JJ N
CABG NNP N
patients NNS N
undergoing VBG N
off-pump JJ N
myocardial JJ N
revascularization NN N
-DOCSTART- -X- O O 2168532

small JJ 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
. . 4_p

small JJ 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
. . N

-DOCSTART- -X- O O 9665186

randomised VBN 4_p
trials NNS 4_p
childhood NN N
acute NN N
lymphoblastic JJ N
leukaemia NN N
( ( N
UKALL NNP N
X NNP N
) ) N
randomised VBD N
patients NNS N
aged VBN N
0-14 CD N
years NNS N
inclusive JJ N
with IN N
an DT N
initial JJ N
white JJ N
blood NN N
count NN N
of IN N
less JJR N
than IN N
100 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
/l NN N
to TO N
receive VB N
an DT N
early JJ N
intensification NN N
block NN N
, , N
a DT N
late JJ N
intensification NN N
block NN N
, , N
both DT N
, , N
or CC N
neither RB N
. . N

UKALL NNP N
XI NNP N
, , N
for IN N
children NNS N
aged VBN N
1-14 CD N
years NNS N
all DT N
patients NNS N
were VBD N
also RB N
randomised VBN N
between IN N
late JJ N
intensification NN N
alone RB N
and CC N
both DT N
early JJ N
plus NN N
late JJ N
blocks NNS N
. . N

-DOCSTART- -X- O O 23688137

children NNS N
with IN N
autism NN 4_p
3-12 JJ 1_p
year-old JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
-DOCSTART- -X- O O 23484763

seasonal JJ 4_p
allergic JJ 4_p
conjunctivitis NN 4_p
: : N
ocular JJ 4_p
itching NN 4_p
associated VBN N
with IN N
AC NNP 4_p
in IN N
subjects NNS N
enrolled VBN N
in IN N
a DT N
natural JJ 4_p
exposure NN 4_p
trial NN 4_p
. . N

Eligible JJ N
subjects NNS N
-DOCSTART- -X- O O 24835171

changes NNS 4_p
in IN N
spinal JJ 4_p
inhibitory NN 4_p
networks NNS 4_p
in IN 4_p
healthy JJ 4_p
human JJ 4_p
subjects NNS 4_p
. . N

-DOCSTART- -X- O O 26388532

intravascular-catheter-related JJ 4_p
infection NN 4_p
consecutive JJ N
adults NNS 1_p
( ( N
age NN 1_p
≥18 CD 1_p
years NNS 1_p
) ) 1_p
admitted VBD N
to TO N
one CD N
of IN N
11 CD N
French JJ N
intensive-care JJ N
units NNS N
and CC N
requiring VBG N
at IN N
least JJS N
one CD N
of IN N
central-venous JJ 4_p
, , 4_p
haemodialysis NN 4_p
, , 4_p
or CC 4_p
arterial JJ 4_p
catheters NNS 4_p
FINDINGS NNP N
Between NNP N
Oct NNP N
26 CD N
, , N
2012 CD N
, , N
and CC N
Feb NNP N
12 CD N
, , N
2014 CD N
, , N
2546 CD 3_p
patients NNS 3_p
were VBD N
eligible JJ N
to TO N
participate VB N
in IN N
the DT N
study NN N
assigned VBD N
1181 CD 3_p
patients NNS 3_p
( ( N
2547 CD 3_p
catheters NNS 3_p
) ) N
-DOCSTART- -X- O O 20844187

childhood NN 1_p
. . N

500 CD N
mother-child JJ N
pairs NNS N
from IN N
a DT N
low-income JJ N
area NN N
of IN N
São NNP N
Leopoldo NNP N
, , N
State NNP N
of IN N
Rio NNP N
Grande NNP N
do VBP N
Sul NNP N
, , N
Brazil NNP N
, , N
to TO N
evaluate VB N
the DT N
impact NN N
of IN N
a DT N
nutritional JJ N
intervention NN N
in IN N
the DT N
first JJ N
year NN N
of IN N
life NN N
on IN N
the DT N
dietary JJ N
quality NN N
of IN N
3- JJ N
to TO N
4-y-old JJ N
children NNS N
for IN N
345 CD N
children NNS N
of IN N
children NNS N
in IN N
a DT N
low-income JJ N
population NN N
-DOCSTART- -X- O O 11028492

patients NNS N
with IN N
leg NN N
or CC N
pelvic JJ N
deep JJ N
venous JJ N
thrombosis NN N
( ( N
DVT NNP N
) ) N
. . N

250 CD N
patients NNS N
averaging VBG N
40 CD N
years NNS N
of IN N
age NN N
with IN N
acute JJ N
DVT NNP N
patients NNS N
with IN N
acute JJ N
DVT NNP N
12 CD N
patients NNS N
receiving VBG N
thrombolysis NN N
9 CD N
patients NNS N
on IN N
systemic JJ N
treatment NN N
-DOCSTART- -X- O O 8779018

Deep JJ 4_p
vein NN 4_p
thrombosis NN 4_p
after IN N
major JJ 4_p
reconstructive JJ 4_p
spinal NN 4_p
surgery NN 4_p
. . N

deep JJ 4_p
vein NN 4_p
thrombosis NN 4_p
after IN N
major JJ 4_p
adult NN 4_p
spinal JJ 4_p
surgery NN 4_p
major JJ 4_p
adult NN 4_p
spinal JJ 4_p
surgery NN 4_p
. . N

Three CD 3_p
hundred VBD 3_p
twenty-nine JJ 3_p
patients NNS N
One CD 3_p
hundred VBD 3_p
ten JJ 3_p
patients NNS N
-DOCSTART- -X- O O 8197064

behaviorally RB 4_p
disordered VBN 4_p
mentally RB 4_p
handicapped JJ 4_p
patients NNS N
on IN N
staff NN N
personnel NNS N
in IN N
residential JJ N
care NN N
] NNP N
mentally RB 4_p
handicapped JJ 4_p
persons NNS N
with IN N
severely RB N
disturbed VBN 4_p
or CC 4_p
autistic JJ 4_p
behavior NN 4_p
on IN N
their PRP$ N
staff NN N
personal JJ N
which WDT N
had VBD N
an DT N
active JJ N
role NN N
in IN N
the DT N
program NN N
. . N

-DOCSTART- -X- O O 8928893

7 CD 3_p
young JJ 1_p
[ $ 1_p
27 CD 1_p
+/- JJ 1_p
3 CD 1_p
( ( 1_p
SD NNP 1_p
) ) 1_p
yr NN 1_p
] NN 1_p
and CC N
10 CD 3_p
older JJR 1_p
( ( 1_p
69 CD 1_p
+/- JJ 1_p
6 CD 1_p
yr NN 1_p
) ) 1_p
healthy JJ 4_p
supine NN 4_p
humans NNS 4_p
before IN 4_p
and CC 4_p
after IN 4_p
double JJ 4_p
pharmacological JJ 4_p
autonomic NN 4_p
blockade NN 4_p
with IN 4_p
propranolol NN 4_p
( ( 4_p
0.2 CD 4_p
mg/kg RB 4_p
iv NN 4_p
) ) 4_p
and CC 4_p
atropine NN 4_p
( ( 4_p
0.04 CD 4_p
mg/kg RB 4_p
iv NN N
) ) N
. . N

young JJ 1_p
and CC 1_p
older JJR 1_p
subjects NNS 1_p
. . 1_p

-DOCSTART- -X- O O 21207788

partial JJ N
ceramic JJ N
crowns NNS N
partial JJ N
ceramic JJ N
crowns NNS N
( ( N
PCCs NNP N
) ) N
inserted VBD N
with IN N
RelyX NNP N
Unicem NNP N
( ( N
RXU NNP N
) ) N
34 CD N
patients NNS N
( ( N
15 CD N
male NN N
, , N
19 CD N
female NN N
) ) N
participated VBD N
in IN N
the DT N
investigation NN N
, , N
with IN N
a DT N
total NN N
of IN N
68 CD N
PCC NNP N
restorations NNS N
. . N

median JJ N
patient NN N
age NN N
was VBD N
41 CD N
years NNS N
( ( N
24-59 CD N
years NNS N
) ) N
. . N

All DT N
patients NNS N
were VBD N
available JJ N
for IN N
the DT N
three CD N
recall NN N
appointments NNS N
. . N

-DOCSTART- -X- O O 22690994

female JJ 2_p
nursing NN N
home NN N
residents NNS N
. . N

-DOCSTART- -X- O O 23869063

humans NNS N
. . N

. . N

Twelve NNP N
healthy JJ N
volunteers NNS N
were VBD N
included VBN N
( ( N
with IN N
valid JJ N
results NNS N
available JJ N
in IN N
9 CD N
) ) N
adenosine NN N
in IN N
normal JJ N
humans NNS N
-DOCSTART- -X- O O 20307262

oncologic JJ N
patients NNS N
cancer NN N
patients NNS N
. . N

cancer NN N
patients NNS N
with IN N
pain NN N
. . N

240 CD N
patients NNS N
with IN N
diagnosed JJ N
malignancy NN N
and CC N
pain NN N
> VBP N
3 CD N
days NNS N
and CC N
average JJ N
pain NN N
> JJ N
or= NN N
3/10 CD N
will MD N
participate VB N
in IN N
a DT N
cluster NN N
randomized VBN N
trial NN N
on IN N
18 CD N
wards NNS N
in IN N
2 CD N
German JJ N
university NN N
hospitals NNS N
. . N

-DOCSTART- -X- O O 20034362

autosomal JJ 4_p
dominant JJ 4_p
polycystic JJ 4_p
kidney NN 4_p
disease NN 4_p
. . 4_p

Autosomal NNP 4_p
dominant JJ 4_p
polycystic JJ 4_p
kidney NN 4_p
disease NN 4_p
( ( 4_p
ADPKD NNP 4_p
) ) 4_p
end-stage NN 4_p
kidney NN 4_p
failure NN 4_p
in IN 4_p
most JJS 4_p
patients NNS 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
ADPKD NNP 4_p
. . 4_p

Sixty CD 3_p
patients NNS 3_p
were VBD N
initially RB N
recruited VBN N
but CC N
49 CD 3_p
of IN N
these DT N
received VBN N
either RB N
pravastatin JJ N
20 CD N
mg NN N
or CC N
no DT N
treatment NN N
for IN N
2 CD N
years NNS N
. . N

-DOCSTART- -X- O O 9987969

hypertension NN 4_p
patients NNS N
] VBP N
85 CD 3_p
females NNS 2_p
with IN N
borderline JJ 4_p
mental JJ 4_p
disorders NNS 4_p
in IN N
essential JJ 4_p
hypertension NN 4_p
-DOCSTART- -X- O O 23652826

patients NNS 4_p
with IN 4_p
metabolic JJ 4_p
syndrome NN 4_p
. . 4_p

15 CD 3_p
aspirin-naive JJ 3_p
patients NNS 3_p
( ( N
mean JJ 1_p
age NN 1_p
48.8 CD 1_p
± JJ 1_p
10.2 CD 1_p
years NNS 1_p
) ) N
with IN N
the DT N
metabolic JJ 4_p
syndrome NN 4_p
-DOCSTART- -X- O O 2142040

patients NNS N
with IN N
newly RB N
diagnosed VBN N
type NN 4_p
1 CD 4_p
diabetes NNS 4_p
mellitus RB 4_p
. . 4_p

18 CD 3_p
patients NNS N
with IN N
Type NNP 4_p
1 CD 4_p
diabetes NNS 4_p
mellitus RB 4_p
. . N

All DT N
were VBD N
participating VBG N
in IN N
the DT N
Canadian-European JJ N
randomized JJ N
placebo-controlled JJ N
cyclosporin NN N
trial NN N
in IN N
newly RB N
diagnosed VBN N
Type NNP N
1 CD 4_p
diabetic JJ 4_p
patients NNS N
-DOCSTART- -X- O O 15472185

premenarcheal JJ 4_p
females NNS 4_p
: : 4_p
co-twin JJ N
premenarcheal JJ N
females NNS N
. . N

Fifty-one CD N
pairs NNS N
of IN N
premenarcheal JJ N
female NN N
twins NNS N
( ( N
27 CD N
monozygotic NN N
and CC N
24 CD N
dizygotic JJ N
; : N
mean JJ N
+/- JJ N
sd NN N
age NN N
, , N
10.3 CD N
+/- JJ N
1.5 CD N
yr NN N
) ) N
within-pair JJ 4_p
differences NNS 4_p
in IN 4_p
height NN 4_p
, , 4_p
weight NN 4_p
, , 4_p
or CC 4_p
calcium NN 4_p
intake NN 4_p
at IN 4_p
baseline NN 4_p
. . 4_p

-DOCSTART- -X- O O 24852722

school NN 1_p
age NN 1_p
in IN N
two CD N
sites NNS N
( ( N
Manaus NNP N
close RB N
and CC N
Salvador NNP N
further RB N
south RB N
from IN N
the DT N
equator NN N
) ) N
. . N

Seven VBN N
hundred CD N
and CC N
sixty VBD N
three CD N
state NN N
schools NNS N
were VBD N
matched VBN N
on IN N
socio JJ N
economic JJ N
characteristics NNS N
of IN N
the DT N
neighborhood NN N
and CC N
239,934 CD 3_p
children NNS 1_p
were VBD N
randomized VBN N
Salvador NNP N
Manaus NNP N
-DOCSTART- -X- O O 2895910

retinopathy NN 4_p
of IN 4_p
prematurity NN 4_p
: : 4_p
one CD N
randomly NN N
selected VBN N
eye NN N
172 CD N
infants NNS N
had VBD N
been VBN N
examined VBN N
3 CD N
months NNS N
after IN N
randomization NN N
. . N

-DOCSTART- -X- O O 7036084

[ JJ 4_p
Credé NNP 4_p
's POS 4_p
prevention NN 4_p
method NN 4_p
-DOCSTART- -X- O O 25313065

predominantly RB 2_p
males NNS 2_p
. . N

young JJ 1_p
men NNS 2_p
( ( 1_p
aged VBN 1_p
13-27 NNS 1_p
) ) N
with IN N
moderate JJ 4_p
to TO 4_p
severe VB 4_p
ASD NNP 4_p
of IN N
participants NNS 4_p
receiving VBG 4_p
sulforaphane NN 4_p
-DOCSTART- -X- O O 24097277

patients NNS N
with IN N
bladder JJ 4_p
tumor NN 4_p
and CC 4_p
lower JJR 4_p
urinary JJ 4_p
tract NN 4_p
symptoms NNS 4_p
. . N

patients NNS N
with IN N
bladder JJ 4_p
tumor NN 4_p
and CC 4_p
bladder NN 4_p
outlet NN 4_p
obstruction NN 4_p
caused VBN N
by IN N
benign JJ 4_p
prostate NN 4_p
hyperplasia NN 4_p
( ( 4_p
BPH NNP 4_p
) ) 4_p
. . N

Sixty-two JJ 3_p
patients NNS N
with IN N
bladder JJ N
tumor NN N
37 CD 3_p
men NNS 2_p
25 CD 3_p
patients NNS 3_p
patients NNS 4_p
with IN 4_p
bladder JJ 4_p
tumor NN 4_p
and CC 4_p
BPH NNP 4_p
. . N

-DOCSTART- -X- O O 1984893

Unstable JJ 4_p
angina NN 4_p
. . N

-DOCSTART- -X- O O 20204689

children NNS 1_p
with IN N
pervasive JJ 4_p
developmental JJ 4_p
disorders NNS 4_p
: : N
children NNS 4_p
with IN N
pervasive JJ 4_p
developmental NN 4_p
disorders NNS 4_p
. . N

Forty-four JJ 1_p
children NNS 1_p
, , 1_p
ages VBZ 1_p
8-11 CD 1_p
years NNS 1_p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
or CC N
wait JJ N
list NN N
. . N

Parents NNS 4_p
families NNS N
-DOCSTART- -X- O O 8487324

anemic JJ 4_p
cancer NN 4_p
patients NNS 4_p
on IN 4_p
combination NN 4_p
chemotherapy NN 4_p
. . N

Patients NNPS 4_p
with IN 4_p
advanced JJ 4_p
cancer NN 4_p
frequently RB 4_p
experience VBZ 4_p
clinically RB 4_p
significant JJ 4_p
anemia NN 4_p
cancer NN 4_p
patients NNS 4_p
. . N

patients NNS 4_p
with IN 4_p
advanced JJ 4_p
cancer NN 4_p
who WP 4_p
were VBD 4_p
receiving VBG 4_p
myelosuppressive JJ 4_p
chemotherapy NN 4_p
( ( 4_p
excluding VBG 4_p
cisplatin NN 4_p
) ) 4_p
. . N

153 CD 3_p
anemic JJ N
cancer NN N
patients NNS N
receiving VBG 4_p
cyclic JJ 4_p
combination NN 4_p
chemotherapy NN 4_p
patients NNS N
rHuEPO-treated JJ 4_p
group NN 4_p
placebo-treated JJ 4_p
group NN N
rHuEPO-treated JJ N
patients NNS N
placebo-treated JJ N
patients NNS N
rHuEPO-treated JJ 4_p
patients NNS 4_p
rHuEPO-treated JJ 4_p
group NN 4_p
. . N

-DOCSTART- -X- O O 22732966

heart NN 4_p
failure NN 4_p
: : N
heart NN 4_p
failure NN 4_p
patients NNS 4_p
. . N

heart NN 4_p
failure NN 4_p
patients NNS 4_p
. . 4_p

Forty NNP 3_p
six CD 3_p
patients NNS 3_p
Mean NNP 1_p
age NN 1_p
of IN 1_p
included JJ 1_p
patients NNS 1_p
was VBD 1_p
58 CD 1_p
± JJ 1_p
10 CD 1_p
years NNS 1_p
and CC N
70 CD N
% NN N
were VBD N
male JJ 2_p
. . N

in IN N
outpatients NNS 4_p
with IN 4_p
heart NN 4_p
failure NN 4_p
-DOCSTART- -X- O O 10826576

laparoscopically RB N
assisted VBN N
vaginal JJ N
hysterectomy NN N
: : N
abdominal JJ N
hysterectomy NN N
in IN N
patients NNS N
with IN N
symptomatic JJ 4_p
uterine JJ 4_p
fibroids NNS 4_p
. . N

patients NNS N
with IN N
uterine JJ 4_p
fibroids NNS 4_p
. . N

The DT N
San NNP N
Paolo NNP N
Hospital NNP N
, , N
Milan NNP N
. . N

Sixty-two JJ 3_p
patients NNS N
, , N
who WP N
were VBD N
not RB N
suitable JJ N
for IN N
a DT N
vaginal JJ N
hysterectomy NN N
, , N
requiring VBG N
treatment NN N
for IN N
uterine JJ 4_p
fibroids NNS 4_p
. . N

-DOCSTART- -X- O O 8838389

mental JJ 4_p
rotation NN 4_p
task NN 4_p
. . N

Forty-six JJ 3_p
females NNS 2_p
and CC N
46 CD 3_p
males NNS 2_p
-DOCSTART- -X- O O 1449552

after IN N
oophorectomy NN 4_p
: : N
-DOCSTART- -X- O O 19692186

Aspirin-associated JJ 4_p
iron NN 4_p
loss NN 4_p
as IN N
an DT N
anticancer NN 4_p
mechanism NN N
. . N

subjects NNS N
randomized VBN N
to TO N
iron VB N
reduction NN N
or CC N
observation NN N
. . N

regular JJ 4_p
aspirin NN 4_p
users NNS 4_p
. . N

-DOCSTART- -X- O O 12850861

postmenopausal JJ 4_p
women NNS 4_p
who WP 4_p
had VBD 4_p
received VBN 4_p
alendronate JJ 4_p
daily JJ 4_p
or CC 4_p
weekly JJ 4_p
in IN 4_p
tablets NNS 4_p
with IN 4_p
or CC 4_p
without IN 4_p
enteric JJ 4_p
coating NN 4_p
. . 4_p

75 CD 3_p
volunteers NNS 3_p
, , 4_p
aged VBD 1_p
45-58 JJ 1_p
with IN 4_p
moderate JJ 4_p
to TO 4_p
severe VB 4_p
osteopenia NN 4_p
( ( 4_p
T-score NNP 4_p
lower JJR 4_p
than IN 4_p
-2 JJR 4_p
SD NNP 4_p
) ) 4_p
assessed VBN 4_p
by IN 4_p
quantitative JJ 4_p
ultrasound NN 4_p
. . N

-DOCSTART- -X- O O 22219012

90 CD 3_p
medical JJ N
students NNS N
without IN N
previous JJ N
experience NN N
in IN N
laparoscopic NN N
techniques NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
undergo VB N
one CD N
of IN N
three CD N
procedures NNS N
: : N
CLS NNP N
, , N
SPLS NNP N
using VBG N
two CD N
pre-bent JJ N
instruments NNS N
( ( N
SPLS-pp NNP N
) ) N
, , N
or CC N
SPLS NNP N
using VBG N
one CD N
pre-bent NN N
and CC N
one CD N
straight NN N
laparoscopic NN N
instrument NN N
( ( N
SPLS-ps NNP N
) ) N
. . N

-DOCSTART- -X- O O 7743697

patients NNS 4_p
with IN 4_p
left JJ 4_p
ventricular JJ 4_p
dysfunction NN 4_p
. . 4_p

patients NNS N
with IN N
overt JJ N
, , N
symptomatic JJ N
heart NN N
failure NN N
( ( N
HF NNP N
) ) N
and CC N
in IN N
patients NNS N
with IN N
asymptomatic JJ N
left VBD N
ventricular JJ N
dysfunction NN N
. . N

Data NNS N
from IN N
the DT N
V-HeFT NNP N
II NNP N
show NN N
that WDT N
at IN N
2-year JJ N
follow-up NN N
-DOCSTART- -X- O O 8986845

17 CD 3_p
patients NNS N
with IN N
AS NNP 4_p
( ( N
ICD-10 NNP N
; : N
14 CD 2_p
male NN 2_p
, , N
3 CD 2_p
female NN 2_p
; : N
mean JJ 1_p
age NN 1_p
16.4 CD 1_p
years NNS 1_p
, , N
mean JJ N
full-scale JJ N
IQ NNP N
97 CD N
) ) N
compared VBN N
them PRP N
with IN N
a DT N
control NN N
group NN N
of IN N
13 CD 3_p
patients NNS N
with IN N
normal-intelligence JJ 4_p
autism NN 4_p
or CC N
high-functioning JJ 4_p
autism NN 4_p
( ( 4_p
HFA NNP 4_p
) ) 4_p
( ( N
ICD-10/DSM-III-R NNP N
; : N
12 CD 2_p
male NN 2_p
, , N
1 CD 2_p
female NN 2_p
; : N
mean JJ 1_p
age NN 1_p
15.5 CD 1_p
years NNS 1_p
, , N
mean JJ N
full-scale JJ N
IQ NNP N
81.2 CD N
) ) N
. . N

13 CD N
( ( N
76 CD N
% NN N
) ) N
of IN N
the DT N
AS NNP 4_p
patients NNS N
4 CD N
( ( N
31 CD N
% NN N
) ) N
of IN N
the DT N
HFA NNP 4_p
group NN N
-DOCSTART- -X- O O 21148666

patients NNS N
with IN N
atrial JJ N
fibrillation NN N
undergoing VBG N
cardiac JJ N
surgery NN N
. . N

atrial JJ N
fibrillation NN N
( ( N
AF NNP N
) ) N
patients NNS N
One CD N
hundred CD N
and CC N
fifty JJ N
patients NNS N
with IN N
documented JJ N
AF NNP N
One CD N
hundred CD N
and CC N
thirty-two JJ N
patients NNS N
were VBD N
included VBN N
in IN N
the DT N
cost-effectiveness NN N
study NN N
. . N

-DOCSTART- -X- O O 22421496

Barrett NNP 4_p
's POS 4_p
esophagus NN 4_p
( ( 4_p
BE NNP 4_p
) ) 4_p
. . 4_p

consecutive JJ N
patients NNS N
with IN N
BE NNP 4_p
or CC N
those DT N
referred VBN N
for IN N
diagnostic JJ N
assessment NN N
. . N

95 CD 3_p
patients NNS 3_p
randomized VBN N
, , N
82 CD 3_p
completed VBD N
the DT N
study NN N
. . N

of IN N
patients NNS N
with IN N
-DOCSTART- -X- O O 2382949

hypotensive JJ 4_p
eye NN 4_p
surgery NN 4_p
. . 4_p

Thirty NN 3_p
patients NNS N
undergoing VBG N
elective JJ 4_p
eye NN 4_p
surgery NN 4_p
-DOCSTART- -X- O O 25365653

methadone-maintained JJ N
individuals NNS N
with IN N
concurrent JJ 4_p
cocaine NN 4_p
dependence NN 4_p
. . N

persons NNS N
with IN N
chronic JJ 4_p
substance NN 4_p
use NN 4_p
disorders NNS 4_p
. . N

individuals NNS N
dually RB 4_p
dependent VBP 4_p
on IN 4_p
cocaine NN 4_p
and CC 4_p
opioids NNS 4_p
( ( N
n JJ N
= NNP N
18 CD 3_p
) ) 3_p
( ( N
n JJ N
= NNP N
22 CD 3_p
) ) N
individuals NNS N
with IN N
chronic JJ 4_p
opioid NN 4_p
and CC 4_p
cocaine NN 4_p
use NN 4_p
disorders NNS 4_p
-DOCSTART- -X- O O 12239480

dentinal JJ 4_p
cold JJ 4_p
sensitivity NN 4_p
. . 4_p

Postoperative NNP 4_p
cold VBD 4_p
sensitivity NN 4_p
after IN 4_p
the DT 4_p
cementation NN 4_p
of IN 4_p
indirect JJ 4_p
restorations NNS 4_p
with IN 4_p
composite JJ 4_p
cements NNS 4_p
The DT N
hypersensitive JJ N
root NN N
surfaces NNS N
of IN N
selected VBN N
teeth NNS N
sample JJ 3_p
size NN 3_p
was VBD 3_p
22 CD 3_p
. . N

-DOCSTART- -X- O O 25403582

premenopausal NN 4_p
early JJ 4_p
breast NN 4_p
cancer NN 4_p
: : 4_p
Austrian JJ 4_p
Breast NNP 4_p
and CC 4_p
Colorectal NNP 4_p
Cancer NNP 4_p
Study NNP N
Group NNP N
Trial NNP N
12 CD N
. . N

Patients NNPS N
were VBD N
premenopausal JJ N
women NNS 2_p
who WP N
had VBD N
undergone JJ N
primary JJ N
surgery NN N
for IN N
stage NN N
I/II NNP N
estrogen-receptor-positive JJ N
and/or NN N
progesterone-receptor-positive JJ N
breast NN N
cancer NN N
with IN N
< $ N
10 CD N
positive JJ N
lymph NN N
nodes NNS N
, , N
and CC N
were VBD N
scheduled VBN N
for IN N
standard JJ N
goserelin NN N
therapy NN N
. . N

1803 CD 3_p
patients NNS N
received VBN N
goserelin NNS N
( ( N
3.6 CD N
mg NN N
every DT N
28 CD N
days NNS N
) ) N
and CC N
were VBD N
randomized VBN N
to TO N
tamoxifen VB N
( ( N
20 CD N
mg/days NNS N
) ) N
or CC N
anastrozole JJ N
-DOCSTART- -X- O O 16900709

Percutaneous JJ N
Nephrolithotomy NNP N
( ( N
PCNL NNP N
) ) N
60 CD 3_p
patients NNS N
undergoing JJ N
PCNL NNP 4_p
. . N

Cases NNS 4_p
of IN 4_p
renal JJ 4_p
stone NN 4_p
regardless NN N
of IN N
stone NN N
size NN N
and CC N
configuration NN N
, , N
having VBG N
pre-operative JJ N
negative JJ N
urine JJ N
culture NN N
, , N
no DT N
coagulopathy NN N
, , N
and CC N
no DT N
visible JJ N
residual JJ N
stone NN N
in IN N
intra-operative JJ N
fluoroscopy NN N
, , N
were VBD N
included VBN N
. . N

Mean NNP N
age NN 1_p
of IN 1_p
cases NNS 1_p
were VBD 1_p
43.2 CD 1_p
( ( 1_p
25-70 JJ 1_p
) ) 1_p
, , 1_p
40.1 CD 1_p
( ( 1_p
25-73 JJ 1_p
) ) 1_p
, , 1_p
and CC 1_p
44 CD 1_p
( ( 1_p
25-70 JJ 1_p
) ) 1_p
years NNS 1_p
in IN N
groups NNS N
A NNP N
, , N
B NNP N
and CC N
C NNP N
, , N
respectively RB N
-DOCSTART- -X- O O 7539544

before IN N
endoscopic NN N
retrograde NN N
cholangiopancreatography NN N
. . N

endoscopic NN 4_p
retrograde NN 4_p
cholangiopancreatography NN 4_p
( ( 4_p
ERCP NNP 4_p
) ) 4_p
. . 4_p

studied JJ N
subjects NNS N
1 CD 4_p
mg NN 4_p
glucagon NN 4_p
( ( 4_p
n JJ 4_p
= NNP 4_p
38 CD 4_p
) ) 4_p
or CC 4_p
40 CD 4_p
mg JJ 4_p
hyoscine NN 4_p
N-butyl NNP 4_p
bromide NN 4_p
( ( 4_p
n JJ 4_p
= NNP 4_p
36 CD 4_p
) ) 4_p
-DOCSTART- -X- O O 15845130

children NNS 1_p
diagnosed VBN N
with IN N
autism NN 4_p
at IN N
age NN 1_p
2 CD 1_p
: : N
2 CD 1_p
and CC 1_p
3 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
sample NN N
of IN N
children NNS 1_p
diagnosed VBN N
with IN N
autism NN 4_p
at IN N
age NN 1_p
2 CD 1_p
. . N

Twenty-six JJ 3_p
children NNS 1_p
diagnosed VBN N
with IN N
autism NN 4_p
at IN N
age NN 1_p
2 CD 1_p
children NNS 1_p
with IN N
autism NN 4_p
at IN N
age NN 1_p
2 CD 1_p
years NNS 1_p
. . N

-DOCSTART- -X- O O 23609382

patients NNS N
with IN N
stable JJ 4_p
schizophrenia NN 4_p
: : N
patients NNS N
with IN N
stable JJ 4_p
schizophrenia NN 4_p
. . N

40 CD 3_p
patients NNS N
with IN N
schizophrenia NN 4_p
( ( N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
Fourth NNP N
Edition NNP N
) ) N
who WP N
were VBD N
stabilized VBN N
on IN N
risperidone NN N
for IN N
a DT N
minimum NN N
of IN N
8 CD N
weeks NNS N
were VBD N
randomized VBN N
to TO N
either DT N
memantine NN N
( ( N
20 CD N
mg NN N
) ) N
or CC N
placebo NN N
in IN N
addition NN N
to TO N
risperidone VB N
, , N
6 CD N
mg/d NN N
, , N
for IN N
eight CD N
weeks NNS N
. . N

All DT N
40 CD 3_p
patients NNS N
had VBD N
at IN N
least JJS N
one CD N
postbaseline NN N
measurement NN N
, , N
and CC N
38 CD 3_p
patients NNS N
completed VBD N
the DT N
trial NN N
. . N

-DOCSTART- -X- O O 20530957

varicocele JJ 4_p
Groups NNP N
were VBD N
divided VBN N
according VBG N
to TO N
whether IN N
they PRP N
would MD N
receive VB N
the DT N
Ivanissevich NNP N
technique NN N
( ( N
n JJ N
= NNP N
55 CD 3_p
) ) N
, , N
Tauber NNP N
's POS N
technique NN N
( ( N
n JJ N
= NNP N
51 CD 3_p
) ) N
or CC N
subinguinal JJ N
sclerotherapy NN N
( ( N
n JJ N
= NNP N
49 CD 3_p
) ) N
. . N

Selection NN N
criteria NNS N
were VBD N
: : N
infertility NN 4_p
> VBZ N
1 CD N
year NN N
, , N
subnormal JJ N
semen NNS N
, , N
sonographic JJ N
diameter NN N
of IN N
veins NNS N
> VBP N
3 CD N
mm NN N
and CC N
time NN N
of IN N
regurge NN N
> $ N
2 CD N
s. NN N
Patients NNS N
-DOCSTART- -X- O O 17907108

patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
mellitus RB 4_p
. . N

1,707 CD 3_p
patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
mellitus RB 4_p
. . N

-DOCSTART- -X- O O 11691528

nonaccidental JJ N
falls NNS N
in IN N
older JJR N
adults NNS N
older JJR N
adults NNS N
with IN N
cardioinhibitory JJ N
carotid NNS N
sinus VBP N
hypersensitivity NN N
( ( N
CSH NNP N
) ) N
. . N

syncope NN N
consecutive JJ N
older JJR N
patients NNS N
( ( N
> JJ N
50 CD N
years NNS N
) ) N
attending VBG N
an DT N
accident NN N
and CC N
emergency NN N
facility NN N
because IN N
of IN N
a DT N
non-accidental JJ N
fall NN N
. . N

One CD N
hundred VBD N
seventy-five JJ N
eligible JJ N
patients NNS N
( ( N
mean JJ N
age NN N
73 CD N
+/- JJ N
10 CD N
years NNS N
; : N
60 CD N
% NN N
women NNS N
) ) N
were VBD N
randomized VBN N
to TO N
the DT N
trial NN N
: : N
pacemaker NN N
87 CD N
; : N
controls NNS N
88 CD N
. . N

older JJR N
adults NNS N
who WP N
have VBP N
non-accidental JJ N
falls NNS N
. . N

-DOCSTART- -X- O O 16686565

men NNS 4_p
and CC 4_p
women NNS 4_p
. . 4_p

men NNS 4_p
and CC 4_p
women NNS 4_p
. . 4_p

College-age JJ 1_p
volunteers NNS 1_p
( ( 1_p
64 CD 1_p
women NNS 1_p
and CC 1_p
54 CD 1_p
men NNS 1_p
) ) 1_p
-DOCSTART- -X- O O 18333888

patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
mellitus RB 4_p
. . N

patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
. . N

patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
with IN 4_p
suboptimal JJ 4_p
metabolic JJ 4_p
control NN 4_p
. . N

Patients NNS N
with IN N
a DT N
baseline NN 4_p
haemoglobin NN 4_p
A NNP 4_p
( ( 4_p
1c CD 4_p
) ) 4_p
( ( 4_p
HbA NNP 4_p
( ( 4_p
1c CD 4_p
) ) 4_p
) ) 4_p
of IN 4_p
7.3 CD 4_p
to TO 4_p
11.0 CD 4_p
% NN 4_p
patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
-DOCSTART- -X- O O 10665129

patients NNS 4_p
with IN 4_p
stable JJ 4_p
COPD NNP 4_p
. . 4_p

27 CD N
patients NNS N
with IN N
stable JJ N
chronic JJ N
obstuctive JJ N
pulmonary JJ N
disease NN N
( ( N
COPD NNP N
) ) N
-DOCSTART- -X- O O 18535816

type NN 4_p
2 CD 4_p
diabetes NNS 4_p
. . N

patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
type NN 4_p
2 CD 4_p
diabetic JJ 4_p
patients NNS N
eight CD 3_p
patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
who WP N
were VBD N
being VBG N
treated VBN N
with IN N
oral JJ N
glucose-lowering JJ N
agents NNS N
. . N

type NN 4_p
2 CD 4_p
diabetic JJ 4_p
patients NNS N
atherosclerosis NN 4_p
in IN N
type NN 4_p
2 CD 4_p
diabetic JJ 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 24684867

Adults NNP 1_p
with IN N
uncomplicated JJ N
acute NN 4_p
appendicitis NN 4_p
The DT N
trial NN N
was VBD N
planned VBN N
for IN N
150 CD 3_p
patients NNS N
, , N
but CC N
was VBD N
halted VBN N
after IN N
75 CD 3_p
patients NNS N
when WRB N
planned VBN N
interim NN N
analysis NN N
showed VBD N
that IN N
SILS NNP N
patients NNS N
had VBD N
more RBR N
postoperative JJ 4_p
pain NN 4_p
-DOCSTART- -X- O O 8595286

traditional JJ N
British JJ N
antenatal JJ N
visit NN N
schedule NN N
with IN N
a DT N
reduced JJ N
schedule NN N
of IN N
visits NNS N
low JJ N
risk NN N
women NNS 2_p
women NNS 2_p
receiving VBG N
shared VBN N
care NN N
2794 CD 3_p
women NNS 2_p
at IN N
low JJ N
risk NN N
fulfilling VBG N
the DT N
trial NN N
's POS N
inclusion NN N
criteria NNS N
between IN N
June NNP N
1993 CD N
and CC N
July NNP N
1994 CD N
. . N

Pregnant JJ 4_p
women NNS 2_p
allocated VBD N
to TO N
new JJ N
style NN N
care NN N
-DOCSTART- -X- O O 11943119

a DT N
group NN N
of IN N
30 CD N
senior JJ N
medical JJ N
students NNS N
were VBD N
randomly RB N
assigned VBN N
30 CD N
senior JJ N
medical JJ N
students NNS N
used VBN N
in IN N
the DT N
first JJ N
study NN N
was VBD N
used VBN N
as IN N
novice JJ N
raters NNS N
. . N

-DOCSTART- -X- O O 2521868

herpes NNS 4_p
zoster NN 4_p
. . 4_p

herpes NNS N
zoster JJ N
infection NN N
. . N

-DOCSTART- -X- O O 16806442

cervical JJ 4_p
carcinoma NN 4_p
: : N
patients NNS N
affected VBN N
by IN N
cervical JJ N
cancer NN N
undergoing VBG N
radical JJ N
hysterectomy NN N
. . N

Consecutive JJ N
patients NNS N
affected VBN N
by IN N
stage NN N
IB-IIB JJ N
cervical JJ N
carcinoma NN N
scheduled VBN N
for IN N
radical JJ N
surgery NN N
All DT N
patients NNS N
underwent JJ N
classical JJ N
radical JJ N
hysterectomy NN N
. . N

168 CD 3_p
patients NNS N
entered VBD N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 20865678

patients NNS 4_p
with IN 4_p
stable JJ 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
: : N
patients NNS N
with IN N
stable JJ N
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
( ( N
CAD NNP N
) ) N
. . N

Sixty-four JJ 3_p
male NN 2_p
patients NNS N
, , N
mean JJ 1_p
age NN 1_p
55.6 CD 1_p
± JJ 1_p
6.0 CD 1_p
years NNS 1_p
training NN N
in IN N
CAD NNP 4_p
patients NNS N
-DOCSTART- -X- O O 15781531

perioperative JJ 4_p
radial JJ 4_p
arterial JJ 4_p
catheter NN 4_p
Two-hundred JJ N
patients NNS N
presence NN N
of IN N
hematoma NN N
at IN N
the DT N
puncture NN N
site NN N
after IN N
decannulation NN N
long JJ N
duration NN N
of IN N
cannulation NN N
age NN N
< VBP N
65 CD N
yr NN N
-DOCSTART- -X- O O 15889546

Automatic JJ N
detection NN N
of IN N
red JJ N
lesions NNS N
in IN N
digital JJ N
color NN N
fundus NN N
photographs NN N
. . N

digital JJ N
color NN N
fundus NN N
photographs NN N
diabetic JJ 4_p
retinopathy NN N
. . N

-DOCSTART- -X- O O 11022066

ruptured JJ N
cerebral JJ N
aneurysms NNS N
. . N

acute NN N
( ( N
< JJ N
72 CD N
hours NNS N
) ) N
aneurysmal VBP N
subarachnoid JJ N
hemorrhage NN N
( ( N
SAH NNP N
) ) N
. . N

One CD 3_p
hundred VBD 3_p
nine CD 3_p
consecutive JJ N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
One CD N
year NN N
postoperatively RB N
, , N
43/41 CD N
( ( N
surgical/endovascular JJ N
) ) N
patients NNS N
-DOCSTART- -X- O O 24902456

endoscopic NN N
procedures NNS N
. . N

Subjects NNS N
scheduled VBN 4_p
for IN 4_p
colonoscopies NNS 4_p
convenience NN N
sample NN N
of IN N
96 CD N
subjects NNS N
-DOCSTART- -X- O O 26138912

patients NNS N
with IN N
early-stage JJ 4_p
non-small JJ 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
( ( 4_p
ES-NSCLC NNP 4_p
) ) 4_p
treated VBD 4_p
with IN 4_p
stereotactic JJ 4_p
ablative JJ 4_p
radiation NN 4_p
therapy NN 4_p
( ( 4_p
SABR NNP 4_p
) ) 4_p
. . N

A NNP N
primary JJ N
dataset NN N
of IN N
703 CD 3_p
ES-NSCLC JJ 4_p
SABR NNP 4_p
patients NNS N
-DOCSTART- -X- O O 24938562

uveal JJ 4_p
melanoma NN 4_p
: : 4_p
uveal JJ 4_p
melanoma NN 4_p
. . N

from IN N
August NNP N
2010 CD N
through IN N
December NNP N
2013 CD N
among IN N
120 CD N
patients NNS N
with IN N
metastatic JJ 4_p
uveal JJ 4_p
melanoma NN 4_p
at IN N
15 CD N
academic JJ N
oncology NN N
centers NNS N
in IN N
the DT N
United NNP N
States NNPS N
and CC N
Canada NNP N
. . N

One CD N
hundred VBD N
one CD N
patients NNS N
were VBD N
randomized VBN N
in IN N
a DT N
1:1 CD N
ratio NN N
analysis NN N
, , N
19 CD N
patients NNS N
were VBD N
registered VBN N
and CC N
18 CD N
treated VBN N
with IN N
selumetinib NN N
without IN N
randomization NN N
to TO N
complete VB N
the DT N
planned VBN N
120-patient JJ N
enrollment NN N
hypothesis-generating JJ N
study NN N
of IN N
patients NNS N
with IN N
advanced JJ N
-DOCSTART- -X- O O 17852793

CABG NNP 4_p
patients NNS 4_p
. . N

Forty NNP 3_p
patients NNS 3_p
undergoing VBG N
elective JJ 4_p
coronary JJ 4_p
surgery NN 4_p
CABG NNP 4_p
patients NNS 4_p
-DOCSTART- -X- O O 12480867

autistic JJ 4_p
disorder NN 4_p
. . N

-DOCSTART- -X- O O 1922235

uncomplicated JJ N
gonorrhea NN 4_p
. . N

unblinded JJ N
multicenter NN N
study NN N
of IN N
209 CD 3_p
men NNS N
and CC N
124 CD 3_p
women NNS N
with IN N
uncomplicated JJ N
gonorrhea NN 4_p
-DOCSTART- -X- O O 23016708

coronary JJ 4_p
heart NN 4_p
diseases NNS 4_p
. . 4_p

Amiloride NNP N
and CC N
Optimal NNP N
Medical NNP N
Therapy NNP N
( ( N
OMT NNP N
, , N
n=35 JJ N
cases NNS N
) ) N
vs VBP N
OMT NNP N
alone RB N
( ( N
n=35 JJ N
cases NNS N
) ) N
in IN N
patients NNS N
having VBG N
angina RB 4_p
, , N
ST-T JJ 4_p
alteration NN 4_p
and CC N
a DT N
defective JJ N
RBC-K JJ N
transport NN N
. . N

All DT N
patients NNS N
had VBD N
serial JJ N
clinical JJ N
evaluation NN N
, , N
Ion NNP N
Transport NNP N
Studies NNP N
, , N
ECGs NNP N
and CC N
non-invasive JJ N
aortic JJ N
waveform NN N
and CC N
cardiovascular JJ N
hemodynamic JJ N
recordings NNS N
. . N

the DT N
heart NN N
, , N
in IN N
patients NNS N
receiving VBG N
optimal JJ N
medical JJ N
treatment NN N
-DOCSTART- -X- O O 23735703

early-stage JJ N
non-small-cell JJ N
lung NN N
cancer NN N
( ( N
IFCT NNP N
0002 CD N
trial NN N
) ) N
. . N

resectable JJ N
StageI-II JJ N
non-small-cell JJ N
lung NN N
cancer NN N
( ( N
NSCLC NNP N
) ) N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
528 CD N
patients NNS N
in IN N
early-stage JJ N
NSCLC NNP N
-DOCSTART- -X- O O 15909709

136 CD 3_p
women NNS 2_p
undergoing VBG N
primary JJ 4_p
caesarean JJ 4_p
delivery NN 4_p
at IN N
Havana NNP N
Specialist NNP N
Hospital NNP N
Lagos NNP N
Nigeria NNP N
. . N

-DOCSTART- -X- O O 19910076

patients NNS N
with IN N
advanced JJ N
non-small-cell JJ N
lung NN N
cancer NN N
: : N
quality NN N
of IN N
life NN N
directed VBN N
phase NN N
II NNP N
randomized VBD N
trial NN N
of IN N
Gruppo NNP N
Oncologico NNP N
Italia NNP N
Meridionale NNP N
. . N

metastatic JJ N
non-small-cell JJ N
lung NN N
cancer NN N
Patients NNPS N
37 CD N
pts NNS N
( ( N
88 CD N
% NN N
) ) N
in IN N
the DT N
DCT/CDDP NNP N
arm NN N
39 CD N
pts NNS N
( ( N
87 CD N
% NN N
) ) N
in IN N
the DT N
VNR/CDDP NNP N
one NN N
. . N

pts NNS N
with IN N
advanced JJ N
non-small-cell JJ N
lung NN N
cancer NN N
-DOCSTART- -X- O O 23647705

milk NN N
production NN N
of IN N
dairy NN N
cattle NNS N
in IN N
Canada NNP N
Gastrointestinal NNP 4_p
nematodes NNS 4_p
, , N
such JJ N
as IN N
Ostertagia NNP 4_p
ostertagi NN 4_p
and CC N
several JJ 4_p
species NNS 4_p
of IN 4_p
Cooperia NNP 4_p
, , N
are VBP N
ubiquitous JJ N
in IN N
temperate NN N
climates NNS N
and CC N
have VBP N
been VBN N
shown VBN N
to TO N
have VB N
detrimental JJ N
effects NNS N
on IN N
production NN N
in IN N
adult NN 1_p
dairy NN 1_p
cattle NNS 1_p
. . N

lose VBP N
approximately RB N
0.35 CD N
kg NNS N
of IN N
milk NN N
per IN N
parasitized VBN N
cow NN N
per IN N
day NN N
. . N

ELISA JJ N
results NNS N
from IN N
individual JJ N
cow NN N
milk NN N
samples NNS N
were VBD N
used VBN N
to TO N
predict VB N
milk NN N
production NN N
response NN N
-DOCSTART- -X- O O 9099447

Partial-area JJ 4_p
method NN 4_p
in IN 4_p
bioequivalence NN 4_p
bioequivalence NN 4_p
partial-area JJ N
method NN N
in IN N
establishing VBG N
bioequivalence NN N
. . N

-DOCSTART- -X- O O 12973849

children NNS 1_p
with IN N
centrally RB N
reviewed VBN N
low-grade JJ 4_p
gliomas NN 4_p
treated VBN N
with IN N
chemotherapy NN 4_p
with IN 4_p
or CC 4_p
without IN 4_p
radiotherapy NN 4_p
children NNS 1_p
who WP N
were VBD N
treated VBN N
with IN N
chemotherapy NN 4_p
and CC N
radiotherapy NN 4_p
on IN N
the DT N
Children NNP N
's POS N
Cancer NNP N
Group NNP N
( ( N
CCG NNP N
) ) N
high-grade NN 4_p
glioma NN 4_p
protocol NN N
( ( N
CCG-945 NNP N
) ) N
who WP N
were VBD N
diagnosed VBN N
with IN N
low-grade JJ 4_p
gliomas NN 4_p
on IN N
post NN N
hoc JJ N
central JJ 4_p
pathologic NN 4_p
review NN 4_p
Between NNP N
1985 CD N
and CC N
1991 CD N
, , N
250 CD 3_p
children NNS 1_p
with IN N
institutionally RB N
classified VBN N
high-grade JJ 4_p
gliomas NNS 4_p
were VBD N
enrolled VBN N
on IN N
CCG-945 NNP N
. . N

Patients NNS N
older JJR N
than IN N
24 CD 1_p
months NNS 1_p
with IN N
intracranial JJ 4_p
lesions NNS 4_p
younger JJR 1_p
patients NNS N
and CC N
those DT N
with IN N
primary JJ 4_p
spinal JJ 4_p
cord NN 4_p
tumors NNS 4_p
low-grade JJ 4_p
glioma NN 4_p
in IN N
70 CD 3_p
patients NNS N
, , N
who WP N
were VBD N
the DT N
focus NN N
of IN N
the DT N
current JJ N
study NN N
. . N

42 CD 3_p
males NNS 2_p
and CC N
28 CD 3_p
females NNS 2_p
( ( N
median JJ N
age NN N
, , N
7.7 CD 1_p
years NNS 1_p
) ) N
with IN N
a DT N
median JJ N
follow-up NN N
of IN N
10.4 CD 1_p
years NNS 1_p
. . N

-DOCSTART- -X- O O 22548691

outpatients NNS N
with IN N
cardiovascular JJ 4_p
disease NN 4_p
or CC N
cardiovascular JJ 4_p
risk NN 4_p
: : N
patients NNS N
with IN N
cardiovascular JJ 4_p
disease NN 4_p
( ( 4_p
CVD NNP 4_p
) ) 4_p
patients NNS N
with IN N
CVD NNP 4_p
. . N

patients NNS N
with IN N
CVD NNP 4_p
and/or VBP N
high JJ 4_p
or CC 4_p
intermediate JJ 4_p
cardiovascular NN 4_p
( ( 4_p
CV NNP 4_p
) ) 4_p
risk NN 4_p
attending VBG N
community NN N
pharmacies NNS N
in IN N
Spain NNP N
. . N

Patients NNPS N
aged VBD N
25 CD 1_p
to TO 1_p
74 CD 1_p
years NNS 1_p
attending VBG N
community NN N
pharmacies NNS N
with IN N
a DT N
prescription NN N
for IN N
at IN N
least JJS N
1 CD N
drug NN N
indicated VBN N
for IN N
CVD NNP 4_p
or CC N
CV NNP 4_p
risk NN 4_p
factors NNS N
Patients NNS N
were VBD N
recruited VBN N
from IN N
December NNP N
2005 CD N
to TO N
September NNP N
2006 CD N
714 CD 3_p
patients NNS N
mean JJ N
[ NNP N
SD NNP N
] NNP N
age NN N
was VBD N
62.8 CD 1_p
[ JJ 1_p
8.1 CD 1_p
] JJ 1_p
years NNS 1_p
. . N

patients NNS N
with IN N
CVD NNP 4_p
and/or VBP N
high JJ 4_p
or CC 4_p
intermediate JJ 4_p
CV NNP 4_p
risk NN 4_p
attending VBG N
community NN N
pharmacies NNS N
in IN N
Spain NNP N
. . N

-DOCSTART- -X- O O 16729400

transradial JJ 4_p
artery NN 4_p
catheterization NN 4_p
. . N

patients NNS N
undergoing VBG N
transradial JJ 4_p
coronary JJ 4_p
angiography NN 4_p
. . N

A NNP N
total NN N
of IN N
379 CD 3_p
patients NNS 3_p
undergoing VBG N
the DT N
procedure NN N
were VBD N
randomly RB N
enrolled VBN N
-DOCSTART- -X- O O 9758264

epileptic JJ 4_p
women NNS 4_p
before IN 4_p
and CC 4_p
during IN 4_p
pregnancy NN 4_p
12225 CD N
females NNS N
. . N

60 CD N
epileptic JJ N
women NNS N
with IN N
periconceptional JJ N
folic JJ N
acid NN N
-DOCSTART- -X- O O 9332112

acute NN 4_p
severe JJ 4_p
asthma NN 4_p
not RB 4_p
responding VBG 4_p
to TO 4_p
conventional JJ 4_p
therapy NN 4_p
. . 4_p

children NNS 1_p
with IN N
acute NN 4_p
severe JJ 4_p
asthma NN 4_p
not RB 4_p
responding VBG 4_p
to TO 4_p
conventional JJ 4_p
therapy NN 4_p
. . N

Pediatric NNP N
emergency NN N
service NN N
of IN N
a DT N
large JJ N
teaching NN N
hospital NN N
. . N

47 CD 3_p
children NNS 3_p
aged VBN 1_p
between IN 1_p
1-12 CD 1_p
years NNS 1_p
with IN N
acute NN N
severe JJ N
asthma NN N
showing VBG N
inadequate JJ N
or CC N
poor JJ N
response NN N
to TO N
3 CD N
doses NNS N
of IN N
nebulized JJ N
salbutamol NN N
given VBN N
at IN N
an DT N
interval NN N
of IN N
20 CD N
min NNS N
each DT N
. . N

patients NNS N
not RB N
responding VBG N
to TO N
conventional JJ N
therapy NN N
alone RB N
. . N

-DOCSTART- -X- O O 4101734

carcinoma NN 4_p
of IN 4_p
the DT 4_p
colon NN 4_p
. . N

-DOCSTART- -X- O O 12585821

10 CD 3_p
adolescent NN 1_p
or CC N
adult NN 1_p
subjects NNS N
with IN N
high-functioning JJ 4_p
autism NN 4_p
or CC 4_p
Asperger-syndrome NNP 4_p
were VBD N
included VBN N
in IN N
the DT N
investigation NN N
. . N

-DOCSTART- -X- O O 25471330

40 CD 3_p
patients NNS 3_p
with IN N
exudative JJ 4_p
age-related JJ 4_p
macular JJ 4_p
degeneration NN 4_p
were VBD 4_p
randomized VBN 4_p
-DOCSTART- -X- O O 26279130

patients NNS N
with IN N
Major JJ 4_p
Depressive NNP 4_p
Disorder NNP 4_p
-DOCSTART- -X- O O 19001103

online NN N
continuing VBG N
medical JJ N
education NN N
seminars NNS N
: : N
evidence NN N
for IN N
improving VBG N
clinical JJ N
practices NNS N
. . N

Primary NNP 3_p
care NN 3_p
physicians NNS 3_p
( ( 3_p
113 CD 3_p
) ) 3_p
participated VBN 3_p
in IN 3_p
a DT 3_p
randomized NN 3_p
controlled VBN 3_p
trial NN 3_p
to TO 3_p
evaluate VB 3_p
an DT 3_p
online NN 3_p
CME NNP 3_p
series NN 3_p
. . 3_p

Physicians NNPS N
physicians NNS 4_p
physician JJ N
clinical JJ N
practice NN N
. . N

-DOCSTART- -X- O O 15476575

patients NNS N
receiving VBG N
androgen JJ N
deprivation NN N
therapy NN N
for IN N
prostate NN 4_p
cancer NN 4_p
. . N

advanced JJ 4_p
prostate NN 4_p
cancer NN 4_p
patients NNS N
with IN N
prostate JJ 4_p
cancer NN 4_p
during IN N
androgen JJ N
ablation NN N
. . N

advanced JJ 4_p
prostate NN 4_p
cancer NN 4_p
. . N

Forty-eight NNP 3_p
osteoporotic JJ N
patients NNS N
with IN N
prostate JJ 4_p
cancer NN 4_p
, , N
treated VBN N
with IN N
3-month JJ N
depot NN N
triptorelina NN N
( ( N
n JJ N
= NNP N
24 CD 3_p
) ) N
( ( N
n JJ N
= NNP N
24 CD 3_p
) ) N
men NNS N
receiving VBG N
ADT NNP N
for IN N
prostate NN 4_p
cancer NN 4_p
. . 4_p

-DOCSTART- -X- O O 3168620

adult NN N
infants NNS 1_p
' POS N
10-month-old JJ 1_p
infants NNS N
. . N

infants NNS N
-DOCSTART- -X- O O 22370992

social JJ 4_p
impairment NN 4_p
in IN 4_p
individuals NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
: : 4_p
ARA NNP 4_p
added VBD 4_p
to TO 4_p
DHA NNP 4_p
( ( 4_p
n JJ 4_p
= NNP 4_p
7 CD 4_p
) ) 4_p
or CC 4_p
placebo NN 4_p
( ( 4_p
n JJ 4_p
= NNP 4_p
6 CD 4_p
) ) 4_p
in IN 4_p
13 CD 4_p
participants NNS 4_p
( ( 4_p
mean JJ 4_p
age NN 4_p
, , 4_p
14.6 CD 4_p
[ NN 4_p
SD NNP 4_p
, , 4_p
5.9 CD 4_p
] CD 4_p
years NNS 4_p
) ) 4_p
. . 4_p

individuals NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
-DOCSTART- -X- O O 6261782

the DT N
third JJ N
trimester NN N
of IN N
pregnancy NN N
in IN N
diabetic JJ 4_p
and CC N
non-diabetic JJ 4_p
women NNS 2_p
. . 2_p

ten JJ 3_p
non-diabetic JJ 4_p
, , N
ten JJ 3_p
chemical JJ 4_p
diabetic NN 4_p
and CC N
five CD 3_p
juvenile NN 4_p
diabetic JJ 4_p
women NNS 2_p
in IN N
late JJ N
pregnancy NN N
. . N

None NN N
of IN N
the DT N
women NNS 2_p
had VBD N
been VBN N
treated VBN N
with IN N
beta-sympathomimetic JJ N
drugs NNS N
earlier RBR N
in IN N
their PRP$ N
pregnancy NN N
. . N

juvenile NN 4_p
diabetic NN 4_p
non-diabetic JJ 4_p
chemical JJ 4_p
diabetic JJ 4_p
women NNS 2_p
. . N

patients NNS N
showing VBG N
criteria NNS N
of IN N
potential JJ N
diabetes NNS 4_p
. . N

-DOCSTART- -X- O O 24641638

obstetric JJ 4_p
patients NNS 4_p
with IN 4_p
accidental JJ 4_p
dural JJ 4_p
puncture NN 4_p
-- : 4_p
a DT N
obstetric JJ 4_p
patients NNS 4_p
experiencing VBG 4_p
a DT 4_p
severe JJ 4_p
post-dural JJ 4_p
puncture NN 4_p
headache NN 4_p
. . 4_p

Patients NNS N
who WP N
sustained VBD N
an DT N
accidental JJ 4_p
dural JJ 4_p
puncture NN 4_p
during IN 4_p
establishment NN 4_p
of IN 4_p
epidural JJ 4_p
analgesia NN 4_p
during IN 4_p
labour NN 4_p
or CC 4_p
at IN 4_p
caesarean JJ 4_p
delivery NN 4_p
Eleven NNP 3_p
of IN N
60 CD 3_p
( ( N
18.3 CD N
% NN N
) ) N
patients NNS N
39 CD 3_p
of IN N
49 CD 3_p
( ( N
79.6 CD N
% NN N
) ) N
obstetric JJ 4_p
patients NNS 4_p
. . N

-DOCSTART- -X- O O 20157845

epidemiologic JJ 4_p
control NN 4_p
group NN 4_p
. . 4_p

self-administered JJ 4_p
questionnaire NN 4_p
was VBD 4_p
sent VBN 4_p
to TO 4_p
parents NNS 4_p
in IN 4_p
the DT 4_p
municipality NN 4_p
of IN 4_p
Stockholm NNP 4_p
, , 4_p
Sweden NNP 4_p
, , 4_p
who WP 4_p
were VBD 4_p
to TO 4_p
be VB 4_p
used VBN 4_p
as IN 4_p
a DT 4_p
control NN 4_p
group NN 4_p
in IN 4_p
a DT 4_p
study NN 4_p
addressing VBG 4_p
stress NN 4_p
in IN 4_p
parents NNS 4_p
of IN 4_p
children NNS 1_p
with IN 4_p
cancer NN 4_p
. . 4_p

450 CD 3_p
parents NNS N
respondents NNS N
-DOCSTART- -X- O O 8275903

infantile JJ 4_p
autism NN 4_p
2 CD 3_p
autistic JJ 4_p
girls NNS 2_p
, , N
displaying VBG 4_p
serious JJ 4_p
self-injurious JJ 4_p
behavior NN 4_p
, , N
reduced VBD 4_p
crying NN 4_p
and CC N
a DT N
marked JJ 4_p
preference NN 4_p
for IN 4_p
salty NN 4_p
and CC 4_p
spicy NN 4_p
foods NNS 4_p
, , N
symptoms NNS N
that WDT N
could MD N
be VB N
related VBN N
to TO N
a DT N
dysfunction NN N
of IN N
the DT N
opioid JJ N
system NN N
. . N

4 CD 3_p
children NNS 1_p
with IN N
autism NN N
. . N

-DOCSTART- -X- O O 26551748

children NNS N
with IN N
autism NN 4_p
. . N

children NNS N
with IN N
autism NN 4_p
. . 4_p

Twenty-six JJ 3_p
pupils NNS N
( ( N
12 CD 3_p
boys NNS 2_p
and CC N
14 CD 3_p
girls NNS 2_p
) ) N
of IN N
a DT N
special JJ N
needs JJ N
school NN N
participated VBD N
104 CD N
analyses NNS N
children NNS 1_p
with IN N
autism NN N
-DOCSTART- -X- O O 1592650

randomized JJ N
multicenter NN N
study NN N
SAKK NNP N
40/81 CD N
: : N
curatively RB 4_p
resected VBN 4_p
colorectal JJ 4_p
cancer NN 4_p
] NN N
Between JJ N
1981 CD N
and CC N
1987 CD N
, , N
533 CD 3_p
patients NNS N
from IN N
9 CD N
institutions NNS N
have VBP N
been VBN N
entered VBN N
in IN N
a DT N
randomized JJ N
trial NN N
469 CD 3_p
evaluable JJ N
patients NNS N
at IN N
a DT N
median JJ N
follow-up NN N
of IN N
5.8 CD N
years NNS N
revealed VBD N
110 CD N
recurrences NNS N
in IN N
the DT N
control NN N
and CC N
94 CD N
recurrences NNS N
in IN N
the DT N
infusion NN N
group NN N
. . N

-DOCSTART- -X- O O 10986219

patients NNS 4_p
with IN 4_p
and CC 4_p
without IN 4_p
TIPS NNP 4_p
undergoing VBG 4_p
glutamine JJ 4_p
challenge NN 4_p
: : 4_p
cirrhotic JJ N
patients NNS N
awaiting VBG N
liver JJ N
transplantation NN N
patients NNS N
with IN N
hepatic JJ N
encephalopathy NN N
. . N

healthy JJ N
patients NNS N
with IN N
cirrhosis NN N
and CC N
no DT N
evidence NN N
of IN N
clinical JJ N
encephalopathy NN N
Eight NNP N
cirrhotics NNS N
( ( N
Child NNP N
's POS N
B NNP N
or CC N
C NNP N
) ) N
without IN N
transjugular JJ N
intrahepatic JJ N
portosystemic JJ N
shunts NNS N
( ( N
TIPS NNP N
) ) N
and CC N
seven CD N
with IN N
TIPS NNP N
patients NNS N
with IN N
cirrhosis NN N
without IN N
TIPS NNP N
-DOCSTART- -X- O O 16223394

peribulbar NN 4_p
block NN 4_p
analgesia NN 4_p
: : N
One CD 3_p
hundred VBD 3_p
patients NNS 3_p
were VBD N
randomized VBN N
patients NNS N
undergoing VBG N
trabeculectomy NN 4_p
. . N

-DOCSTART- -X- O O 20042310

patients NNS N
with IN N
locally RB 4_p
advanced VBN 4_p
resectable JJ 4_p
rectal JJ 4_p
cancer NN 4_p
. . N

Patients NNPS N
with IN N
stage NN 4_p
II/III NNP 4_p
LARC NNP 4_p
Thirty-seven JJ 3_p
patients NNS N
were VBD N
eligible JJ N
17 CD 3_p
patients NNS N
13 CD 3_p
patients NNS N
6 CD 3_p
patients NNS N
patients NNS N
with IN N
resectable JJ 4_p
LARC NNP 4_p
. . N

-DOCSTART- -X- O O 21692873

Labeo NNP N
rohita JJ N
fingerlings NNS N
reared VBD N
at IN N
higher JJR N
water NN N
temperature NN N
. . N

Labeo NNP N
rohita VBP N
fingerlings NNS N
exposed VBN N
to TO N
an DT N
elevated JJ N
temperature NN N
( ( N
ET NNP N
) ) N
of IN N
33 CD N
°C NNS N
. . N

Two CD N
hundred VBD N
and CC N
seventy JJ N
fingerlings NNS N
( ( N
6.71 CD N
± RB N
0.32 CD N
g NN N
) ) N
responses NNS N
of IN N
L. NNP N
rohita JJ N
fingerlings NNS N
status NN N
of IN N
L. NNP N
rohita JJ N
fingerlings NNS N
reared VBD N
at IN N
higher JJR N
water NN N
temperature NN N
-DOCSTART- -X- O O 11034038

Thirty NNP 3_p
nonbleeding VBG 4_p
patients NNS 4_p
with IN 4_p
international JJ 4_p
normalized JJ 4_p
ratios NNS 4_p
( ( 4_p
INRs NNP 4_p
) ) 4_p
ranging VBG 4_p
from IN 4_p
6.0-10.0 JJ 4_p
. . 4_p

Patients NNPS 4_p
were VBD 4_p
randomized VBN 4_p
to TO 4_p
receive VB 4_p
either CC 4_p
a DT 4_p
single JJ 4_p
oral JJ 4_p
dose NN 4_p
of IN 4_p
phytonadione NN 4_p
2.5 CD 4_p
mg NN 4_p
or CC 4_p
placebo NN 4_p
. . 4_p

asymptomatic JJ N
patients NNS N
with IN N
INRs NNP N
of IN N
6.0-10.0 NNP N
. . N

patients NNS N
at IN N
high JJ N
risk NN N
for IN N
bleeding VBG N
in IN N
whom WP N
the DT N
benefit NN N
of IN N
prompt JJ N
INR NNP N
reduction NN N
would MD N
outweigh VB N
the DT N
thromboembolic JJ N
risk NN N
associated VBN N
with IN N
INR NNP N
overcorrection NN N
. . N

-DOCSTART- -X- O O 11219757

Fifteen JJ 3_p
subjects NNS N
participated VBN N
in IN N
the DT N
experiment NN N
. . N

-DOCSTART- -X- O O 18371465

patients NNS N
undergoing VBG N
high-risk JJ 4_p
coronary JJ 4_p
artery NN 4_p
bypass NN 4_p
graft NN 4_p
surgery NN 4_p
: : N
patients NNS N
with IN N
obstructive JJ 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
; : N
high-risk JJ N
patients NNS N
High-risk JJ 4_p
patients NNS 4_p
undergoing VBG 4_p
CABG NNP 4_p
surgery NN 4_p
3023 CD 3_p
patients NNS 3_p
were VBD N
enrolled VBN N
at IN N
130 CD N
sites NNS N
in IN N
Canada NNP N
, , N
the DT N
United NNP N
States NNPS N
, , N
and CC N
Germany NNP N
between IN N
October NNP N
2006 CD N
and CC N
September NNP N
2007 CD N
, , N
with IN N
results NNS N
anticipated VBN N
shortly RB N
after IN N
completion NN N
of IN N
90-day JJ N
follow-up NN N
in IN N
March NNP N
2008 CD N
. . N

-DOCSTART- -X- O O 15249792

Adults NNS 1_p
with IN N
systolic JJ 4_p
BP NNP 4_p
120-159 JJ 4_p
mm NN 4_p
Hg NNP 4_p
and CC 4_p
diastolic JJ 4_p
BP NNP 4_p
80-95 JJ 4_p
mm NN 4_p
Hg NNP 4_p
subjects NNS N
with IN N
hypertension NN 4_p
at IN N
baseline NN N
-DOCSTART- -X- O O 24803366

adults NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . N

Adults NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
were VBD N
randomized VBN N
to TO N
VR-JIT NNP N
( ( N
n JJ N
= NNP N
16 CD 3_p
) ) N
or CC N
treatment-as-usual JJ N
( ( N
TAU NNP N
) ) N
( ( N
n JJ N
= NNP N
10 CD 3_p
) ) N
groups NNS N
. . N

VR-JIT JJ N
participants NNS N
TAU NNP N
participants NNS N
-DOCSTART- -X- O O 18802980

data NNS 4_p
show VBP 4_p
no DT 4_p
gender NN N
differences NNS 4_p
. . N

-DOCSTART- -X- O O 2932908

large JJ 4_p
bowel NN 4_p
carcinoma NN 4_p
-- : N
fluorouracil NN N
advanced JJ 4_p
measurable JJ 4_p
metastatic JJ 4_p
large JJ 4_p
bowel NN 4_p
carcinoma NN 4_p
6/32 CD N
( ( N
19 CD N
% NN N
) ) N
for IN N
FU NNP N
+ NNP N
HU NNP N
and CC N
5/32 CD N
( ( N
16 CD N
% NN N
) ) N
for IN N
MOF-Strep NNP N
; : N
patients NNS N
who WP N
received VBD N
-DOCSTART- -X- O O 18982929

age-related JJ 4_p
macular JJ 4_p
degeneration NN 4_p
Age-related JJ 4_p
macular JJ 4_p
degeneration NN 4_p
( ( 4_p
AMD NNP 4_p
) ) 4_p
subjects NNS N
at IN N
high JJ N
risk NN N
of IN N
AMD NNP 4_p
progression NN N
-DOCSTART- -X- O O 17935144

primary JJ 4_p
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
: : 4_p
primary JJ 4_p
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
treated VBN 4_p
in IN 4_p
community NN 4_p
settings NNS 4_p
highly RB N
distressed JJ N
patients NNS N
Three CD N
hundred VBD N
and CC N
fifty-three JJ N
women NNS N
within IN N
one CD N
year NN N
of IN N
diagnosis NN N
with IN N
primary JJ N
breast NN N
cancer NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
supportive-expressive JJ N
group NN N
therapy NN N
or CC N
to TO N
an DT N
education NN N
control NN N
condition NN N
. . N

Participants NNS N
were VBD N
recruited VBN N
from IN N
two CD N
academic JJ N
centers NNS N
and CC N
nine CD N
oncology NN N
practices NNS N
, , N
which WDT N
were VBD N
members NNS N
of IN N
NCI NNP N
's POS N
Community NNP N
Clinical NNP N
Oncology NNP N
Program NNP N
( ( N
CCOP NNP N
) ) N
and CC N
were VBD N
followed VBN N
over IN N
2 CD N
years NNS N
. . N

Highly NNP 4_p
distressed JJ 4_p
women NNS 4_p
women NNS N
with IN N
primary JJ 4_p
breast NN N
cancer NN N
. . N

women NNS 4_p
with IN 4_p
higher JJR 4_p
initial JJ 4_p
levels NNS 4_p
of IN 4_p
distress NN 4_p
. . 4_p

-DOCSTART- -X- O O 22092536

in IN N
humans NNS N
with IN N
naloxone NN N
, , N
the DT N
opioid JJ N
antagonist NN N
. . N

12 CD 3_p
healthy JJ N
male NN 3_p
volunteers NNS N
were VBD N
included VBN N
human JJ N
volunteers NNS N
-DOCSTART- -X- O O 19054718

Coronary NNP 4_p
Artery NNP 4_p
Bypass NNP 4_p
Graft NNP 4_p
patients NNS N
: : N
patients NNS N
who WP N
had VBD 4_p
CABG NNP 4_p
surgery NN 4_p
. . N

CABG NNP 4_p
patient NN 4_p
's POS N
convenience NN N
sample NN N
of IN N
first JJ 4_p
time NN 4_p
CABG NNP 4_p
patients NNS 4_p
. . N

individuals NNS N
who WP N
received VBD N
education NN N
post-discharge NN N
on IN N
the DT N
outcomes NNS N
. . N

-DOCSTART- -X- O O 15193939

Brain NNP 4_p
activity NN 4_p
correlates VBZ 4_p
differentially RB N
with IN N
increasing VBG N
temporal JJ N
complexity NN N
of IN N
rhythms NN N
during IN N
initialisation NN N
, , N
synchronisation NN N
, , N
and CC N
continuation NN N
phases NNS N
of IN N
paced JJ 4_p
finger NN 4_p
tapping VBG 4_p
. . N

parts NNS N
of IN N
the DT N
human JJ N
motor NN N
system NN N
-DOCSTART- -X- O O 21800222

obstructive JJ 4_p
sleep JJ 4_p
apnea NN 4_p
: : 4_p
obstructive JJ 4_p
sleep NN 4_p
apnea NN 4_p
( ( 4_p
OSA NNP 4_p
) ) 4_p
Patients NNPS N
with IN N
severe JJ N
OSA NNP N
currently RB N
using VBG N
CPAP NNP N
at IN N
≥4 NNP N
h/night NN N
with IN N
a DT N
nasal JJ N
mask NN N
were VBD N
examined VBN N
( ( N
including VBG N
Mallampati NNP N
scale NN N
, , N
incisal NN N
relationship NN N
, , N
and CC N
mandibular JJ N
protrusion NN N
) ) N
RESULTS NNP N
Twelve NNP 3_p
patients NNS N
completed VBD N
the DT N
trial NN N
( ( N
mean JJ N
± NNP N
SD NNP N
AHI NNP N
59.8 CD N
± VBD N
28.6 CD N
events/h NN N
; : N
CPAP NNP N
11.1 CD N
± VBD N
3.2 CD N
cmH NN N
( ( N
2 CD N
) ) N
O NNP N
; : N
BMI NNP N
37.7 CD N
± VBD N
5.0 CD N
kg/m NN N
( ( N
2 CD N
) ) N
) ) N
-DOCSTART- -X- O O 8686245

breast NN 4_p
cancer NN 4_p
patients NNS N
. . N

176 CD 3_p
patients NNS 4_p
with IN 4_p
T1-2N0M0 NNP 4_p
tumors NNS 4_p
. . 4_p

-DOCSTART- -X- O O 7017139

haemorrhoids NNS 4_p
. . N

89 CD 3_p
consecutive JJ N
patients NNS N
with IN N
haemorrhoids NNS 4_p
. . N

-DOCSTART- -X- O O 5090759

eczema NN 4_p
: : N
Seventy-two JJ 3_p
patients NNS N
with IN N
eczema NNS 4_p
-DOCSTART- -X- O O 6113821

Two CD 4_p
hundred VBD 4_p
twenty-eight JJ 4_p
first-admission NN 4_p
schizophrenic JJ 4_p
patients NNS 4_p
-DOCSTART- -X- O O 22588377

children NNS 1_p
with IN N
anxiety NN 4_p
and CC 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
: : N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) N
. . N

Twenty-two JJ 3_p
children NNS 1_p
( ( 1_p
ages VBZ 1_p
8-14 NN 1_p
; : 1_p
IQ NNP N
≥ NNP N
70 CD N
) ) N
with IN N
ASD NNP 4_p
and CC 4_p
clinically RB 4_p
significant JJ 4_p
anxiety NN 4_p
anxiety NN 4_p
in IN N
children NNS N
with IN N
high-functioning JJ N
-DOCSTART- -X- O O 24122191

early JJ N
thermal JJ N
burns NNS 4_p
early JJ 4_p
thermal NN 4_p
burns NNS 4_p
injury NN 4_p
in IN N
adult NN 1_p
patients NNS N
with IN N
< JJ 4_p
40 CD 4_p
% NN 4_p
total JJ 4_p
body NN 4_p
surface NN 4_p
area NN 4_p
( ( 4_p
TBSA NNP 4_p
) ) N
Seventeen JJ 3_p
subjects NNS N
were VBD N
randomized VBN N
into IN N
control NN N
( ( N
n JJ N
= NNP N
9 CD 3_p
) ) N
and CC N
HBOT NNP N
treatment NN N
( ( N
n JJ N
= NNP N
8 CD 3_p
) ) N
arms NNS N
. . N

Two CD N
HBOT NNP N
patients NNS N
and CC N
four CD N
control NN N
patients NNS N
-DOCSTART- -X- O O 15814479

Participants NNS N
consisted VBD N
of IN N
those DT N
subjects NNS N
in IN N
the DT N
WAIS-III JJ N
standardization NN N
sample NN N
that WDT N
has VBZ N
complete JJ N
demographic JJ N
data NNS N
( ( N
N=2,401 NNP N
) ) N
and CC N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

patients NNS N
with IN N
known VBN N
or CC N
suspected VBN N
neurological JJ N
dysfunction NN N
-DOCSTART- -X- O O 14732749

Outcomes NNS N
in IN N
patients NNS N
with IN N
diabetes NNS 4_p
mellitus VBP 4_p
undergoing VBG 4_p
percutaneous JJ 4_p
coronary JJ 4_p
intervention NN 4_p
in IN N
the DT N
current JJ N
era NN N
: : N
patients NNS N
undergoing VBG 4_p
percutaneous JJ 4_p
coronary JJ 4_p
intervention NN 4_p
( ( N
PCI NNP 4_p
) ) N
. . N

patients NNS N
undergoing VBG 4_p
PCI NNP 4_p
in IN N
the DT N
current JJ N
era NN N
. . N

The DT N
11 CD 3_p
482 CD 3_p
patients NNS N
enrolled VBN N
in IN N
the DT N
Prevention NNP N
of IN N
REStenosis NNP N
with IN N
Tranilast NNP N
and CC N
its PRP$ N
Outcomes NNP N
( ( N
PRESTO NNP N
) ) N
Trial NNP N
-DOCSTART- -X- O O 17961835

somatic JJ N
pain NN N
and CC N
temporal JJ N
summation NN N
. . N

20 CD 3_p
healthy JJ 4_p
volunteers NNS N
-DOCSTART- -X- O O 24158898

Helicobacter NNP 4_p
pylori JJ 4_p
infection NN 4_p
in IN N
India NNP N
. . N

at IN N
Lokmanya NNP N
Tilak NNP N
Municipal NNP N
General NNP N
Hospital NNP N
, , N
Mumbai NNP N
. . N

Two CD N
hundred CD N
and CC N
thirty-one JJ N
patients NNS N
with IN N
dyspepsia NNS N
-DOCSTART- -X- O O 2693850

119 CD 3_p
patients NNS 3_p
with IN N
disseminated JJ 4_p
malignant JJ 4_p
melanoma NN 4_p
One CD 3_p
hundred CD 3_p
and CC 3_p
ten JJ 3_p
patients NNS N
were VBD N
available JJ N
for IN N
evaluation NN N
of IN N
response NN N
. . N

-DOCSTART- -X- O O 18004169

obstetric JJ 4_p
triage NN 4_p
women NNS 1_p
in IN 1_p
labor NN 1_p
rooms NNS 1_p
. . 1_p

women NNS 4_p
who WP 4_p
met VBD 4_p
triage NN 4_p
criteria NNS 4_p
The DT N
total JJ N
sample NN N
size NN N
was VBD N
398 CD N
patients NNS N
. . N

-DOCSTART- -X- O O 305873

gastrointestinal JJ 4_p
bleeding NN 4_p
due JJ 4_p
to TO 4_p
cirrhosis NN 4_p
: : 4_p
-DOCSTART- -X- O O 17414940

randomized VBN 4_p
trial NN 4_p
with IN 4_p
32 CD 3_p
male JJ 2_p
volunteers NNS 4_p
. . 4_p

-DOCSTART- -X- O O 17959585

One CD 4_p
hundred CD 4_p
and CC 4_p
fifty JJ 4_p
ASA NNP 4_p
I-II NNP 4_p
patients NNS 4_p
undergoing VBG 4_p
general JJ 4_p
anaesthesia NN 4_p
-DOCSTART- -X- O O 20439105

practice NN N
nurses NNS N
: : N
Practice NNP N
nurses NNS N
nurses NNS N
This DT N
study NN N
was VBD N
nested VBN N
in IN N
the DT N
IMPALA NNP N
study NN N
, , N
a DT N
clustered VBN N
randomised VBN N
controlled VBN N
trial NN N
involving VBG N
24 CD N
general JJ N
practices NNS N
in IN N
The DT N
Netherlands NNP N
. . N

24 CD N
practice NN N
nurses NNS N
, , N
trained VBN N
in IN N
10-year JJ N
cardiovascular JJ N
risk NN N
assessment NN N
421 CD N
patients NNS N
without IN N
established VBN N
cardiovascular JJ N
diseases NNS N
but CC N
eligible JJ N
for IN N
cardiovascular JJ N
risk NN N
assessment NN N
. . N

Elderly JJ N
patients NNS N
male JJ N
patients NNS N
( ( N
vs. FW N
female NN N
smoking NN N
patients NNS N
( ( N
vs. IN N
non-smoking NN N
Ten NNP N
( ( N
28 CD N
% NN N
) ) N
of IN N
the DT N
36 CD N
patients NNS N
who WP N
should MD N
be VB N
assigned VBN N
to TO N
the DT N
high-risk JJ N
treatment NN N
category NN N
trained JJ N
practice NN N
nurses NNS N
in IN N
actual JJ N
practice NN N
nurses NNS N
in IN N
general JJ N
practice NN N
-DOCSTART- -X- O O 9278836

hip NN N
and CC N
knee NN N
arthroplasty NN 4_p
. . N

Inpatient NNP N
anesthesia NN N
at IN N
a DT N
university NN N
department NN N
of IN N
orthopedic JJ N
surgery NN N
. . N

PATIENTS CC N
30 CD 3_p
ASA NNP N
physical JJ N
status NN N
I PRP 3_p
and CC N
II NNP 3_p
patients NNS N
, , N
who WP N
were VBD N
scheduled VBN N
for IN N
elective JJ N
hip NN N
or CC N
knee VB N
arthroplasty JJ N
and CC N
were VBD N
free JJ N
from IN N
systemic JJ 4_p
disease NN 4_p
. . 4_p

elective JJ N
hip NN N
and CC N
knee NN N
arthroplasty NN N
-DOCSTART- -X- O O 1920171

subjects NNS 4_p
participating VBG 4_p
in IN 4_p
a DT 4_p
trial NN 4_p
of IN 4_p
the DT 4_p
treatment NN 4_p
of IN 4_p
heart NN 4_p
failure NN 4_p
. . 4_p

Patients NNS N
were VBD N
assessed VBN N
on IN N
entry NN N
and CC N
after IN N
three CD N
months NNS N
treatment NN N
. . N

fatigue JJ 4_p
, , 4_p
breathlessness NN 4_p
and CC 4_p
chest NN 4_p
pain NN 4_p
. . 4_p

-DOCSTART- -X- O O 19368912

microdose JJ 4_p
flare-up JJ 4_p
cycles NNS 4_p
in IN 4_p
poor JJ 4_p
responders NNS 4_p
microdose JJ N
gonadotropin-releasing JJ N
hormone NN N
analog NN N
( ( N
GnRH-a NNP N
) ) N
flare NN N
cycles NNS N
in IN N
poor JJ N
responders NNS N
. . N

total NN N
of IN N
119 CD N
women NNS N
119 CD N
patients NNS N
-DOCSTART- -X- O O 17724294

ischemic JJ N
stroke NN N
: : N
acute JJ N
ischemic JJ N
stroke NN N
patients NNS N
. . N

From IN N
215 CD N
patients NNS N
admitted VBD N
within IN N
24 CD N
hours NNS N
of IN N
a DT N
hemispheric JJ N
ischemic JJ N
stroke NN N
, , N
89 CD N
patients NNS N
on IN N
chronic JJ N
statin NN N
treatment NN N
were VBD N
randomly RB N
assigned VBN N
Patients NNS N
with IN N
statin NN N
withdrawal NN N
patients NNS N
without IN N
previous JJ N
treatment NN N
with IN N
statins NNS N
-DOCSTART- -X- O O 8549289

acne JJ 4_p
vulgaris NN 4_p
-DOCSTART- -X- O O 7714229

humans NNS N
. . N

Scopolamine-induced JJ 4_p
cognitive JJ 4_p
impairment NN 4_p
was VBD 4_p
used VBN 4_p
in IN 4_p
healthy JJ 4_p
men NNS 4_p
Eighteen JJ N
subjects NNS N
-DOCSTART- -X- O O 25963675

untrained JJ N
personnel NNS N
. . N

Four CD N
devices NNS N
group NN N
of IN N
210 CD 3_p
paramedics NNS N
-DOCSTART- -X- O O 25798729

African JJ N
American JJ N
substance NN N
users NNS N
' POS N
African JJ N
American NNP N
and CC N
White NNP N
cocaine NN 4_p
users NNS 4_p
. . N

African JJ N
American NNP N
( ( N
n JJ N
= NNP N
444 CD 3_p
) ) N
and CC N
White NNP N
( ( N
n JJ N
= NNP N
403 CD 3_p
) ) N
cocaine NN 4_p
abusers NNS 4_p
participating VBG N
in IN N
one CD N
of IN N
six CD N
randomized JJ N
clinical JJ N
trials NNS N
comparing VBG N
CM NNP N
to TO N
standard VB N
care NN N
. . N

African JJ N
American JJ N
and CC N
White NNP N
patients NNS N
who WP N
initiated VBD N
treatment NN N
with IN N
a DT N
cocaine-negative JJ N
urine JJ N
sample NN N
Whites NNS N
who WP N
began VBD N
treatment NN N
with IN N
a DT N
cocaine NN N
positive JJ N
sample NN N
African JJ N
Americans NNPS N
who WP N
initiated VBD N
treatment NN N
with IN N
a DT N
cocaine NN N
positive JJ N
sample NN N
African JJ N
American JJ N
patients NNS N
who WP N
are VBP N
using VBG N
cocaine JJ N
upon IN N
treatment NN N
entry NN N
. . N

-DOCSTART- -X- O O 1764390

EUROSCAN NNP 4_p
Study NNP N
. . N

EUROSCAN NNP N
Steering NNP N
Committee NNP N
. . N

-DOCSTART- -X- O O 16199793

people NNS 4_p
with IN 4_p
schizophrenia NN 4_p
in IN N
Beijing NNP N
, , N
China NNP N
: : N
people NNS N
with IN N
schizophrenia NN 4_p
and CC N
their PRP$ N
families NNS N
sample NN N
of IN N
Chinese JJ N
people NNS N
with IN N
schizophrenia NN 4_p
. . N

large JJ N
hospital NN N
with IN N
a DT N
sample NN N
of IN N
101 CD 3_p
patients NNS 3_p
with IN N
schizophrenia NN 4_p
and CC N
their PRP$ N
families NNS N
. . N

-DOCSTART- -X- O O 10814606

patients NNS N
with IN N
advanced JJ 4_p
non-small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
. . N

patients NNS N
with IN N
advanced JJ N
lung NN N
cancer NN N
. . N

Twelve CD 3_p
patients NNS N
with IN N
advanced JJ N
non-small-cell JJ N
lung NN N
cancer NN N
( ( N
NSCLC NNP N
) ) N
¿3- NN N
( ( N
13 CD N
) ) N
Călanine NNP N
. . N

Thirteen NNP N
NSCLC NNP N
patients NNS N
and CC N
eleven RB N
healthy JJ N
subjects NNS N
-DOCSTART- -X- O O 15312096

patients NNS N
with IN N
generalized JJ 4_p
aggressive JJ 4_p
periodontitis NN 4_p
. . N

patients NNS N
affected VBN N
by IN N
generalized JJ 4_p
aggressive JJ 4_p
periodontitis NN 4_p
( ( 4_p
GAP NNP 4_p
) ) 4_p
. . N

Eighteen NNP 3_p
subjects NNS N
, , N
six CD 3_p
males NNS 2_p
and CC N
12 CD 3_p
females NNS 2_p
, , N
mean JJ 1_p
age NN 1_p
: : 1_p
32.2 CD 1_p
years NNS 1_p
, , N
were VBD N
evaluated VBN N
. . N

GAP NNP 4_p
patients NNS N
-DOCSTART- -X- O O 21048041

metastatic JJ 4_p
colorectal JJ 4_p
cancer NN 4_p
. . 4_p

patients NNS N
with IN N
metastatic JJ 4_p
colorectal NN 4_p
cancer NN 4_p
( ( 4_p
mCRC NN 4_p
) ) 4_p
17 CD N
polymorphisms NNS N
in IN N
genes NNS N
encoding VBG N
drug NN N
targets NNS N
, , N
pathway NN N
molecules NNS N
and CC N
detoxification NN N
enzymes NNS N
was VBD N
analyzed VBN N
in IN N
279 CD 3_p
previously RB 4_p
untreated JJ 4_p
mCRC NN 4_p
patients NNS N
treated VBN N
with IN N
capecitabine NN N
, , N
oxaliplatin NN N
and CC N
bevacizumab NN N
( ( N
CAPOX-B NNP N
) ) N
. . N

mCRC NN 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 24502859

pediatric JJ 1_p
patients NNS N
with IN N
irritability NN 4_p
associated VBN N
with IN N
autistic JJ 4_p
disorder NN 4_p
. . N

autistic JJ 4_p
disorder NN 4_p
in IN N
pediatric JJ 1_p
patients NNS N
. . N

patients NNS N
( ( N
6-17 CD 1_p
years NNS 1_p
) ) N
who WP N
met VBD N
the DT N
current JJ N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
Fourth NNP N
Edition NNP N
, , N
Text NNP N
Revision NNP N
( ( N
DMS-IV-TR NNP N
) ) N
criteria NN N
for IN N
autistic JJ 4_p
disorder NN 4_p
and CC N
who WP N
also RB N
had VBD N
serious JJ 4_p
behavioral JJ 4_p
problems NNS 4_p
( ( N
ie VB N
, , N
tantrums NNS N
, , N
aggression NN N
, , N
self-injurious JJ N
behavior NN N
, , N
or CC N
a DT N
combination NN N
of IN N
these DT N
behavioral JJ N
problems NNS N
) ) N
between IN N
March NNP N
2011 CD N
and CC N
June NNP N
2012 CD N
. . N

Patients NNS N
with IN N
a DT N
stable JJ N
response NN N
( ( N
≥ JJ N
25 CD N
% NN N
decrease NN N
in IN N
Aberrant NNP N
Behavior NNP N
Checklist-irritability NNP N
subscale NN N
score NN N
and CC N
a DT N
rating NN N
of IN N
" JJ N
much JJ N
improved VBN N
" NN N
or CC N
" VB N
very RB N
much RB N
improved VBN N
" NN N
on IN N
the DT N
Clinical JJ N
Global NNP N
Impressions-Improvement NNP N
scale NN N
) ) N
for IN N
12 CD N
consecutive JJ N
weeks NNS N
RESULTS NNP N
Eighty-five JJ N
patients NNS N
were VBD N
randomized VBN N
in IN N
phase NN N
-DOCSTART- -X- O O 20089562

women NNS 2_p
with IN 4_p
metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
: : N
metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
. . N

Patients NNP 3_p
( ( 3_p
n JJ 3_p
= NNP 3_p
240 CD 3_p
) ) N
were VBD N
randomly RB N
assigned VBN N
-DOCSTART- -X- O O 17954800

catheter NN 4_p
insertion NN 4_p
sites NNS 4_p
Consecutively RB N
scheduled VBD N
central JJ 4_p
venous JJ 4_p
catheters NNS 4_p
inserted VBN N
into IN N
jugular NN N
or CC N
subclavian JJ N
veins NNS N
538 CD 3_p
catheters NNS N
randomized VBD N
, , N
481 CD 3_p
( ( N
89.4 CD N
% NN N
) ) N
produced VBD N
evaluable JJ N
culture NN N
results NNS N
. . N

-DOCSTART- -X- O O 7056921

in IN N
normal JJ 4_p
and CC 4_p
severely RB 4_p
disturbed JJ 4_p
children NNS 1_p
. . N

-DOCSTART- -X- O O 1420057

glaucoma NN 4_p
patients NNS N
undergoing JJ N
cataract JJ N
extraction NN N
with IN N
posterior JJ 4_p
chamber NN 4_p
lens NNS 4_p
implant VBP 4_p
. . N

glaucoma NN N
patients NNS N
. . N

Thirty NNP 3_p
six CD 3_p
patients NNS N
with IN N
glaucoma JJ N
undergoing JJ N
cataract NN N
extraction NN N
and CC N
posterior JJ N
chamber NN N
lens VBZ N
implantation NN N
glaucoma NN N
patients NNS N
-DOCSTART- -X- O O 7814161

elderly JJ 1_p
patient NN N
. . N

elderly JJ N
by IN N
recruiting VBG N
13 CD 3_p
subjects NNS N
> JJ 1_p
75 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
, , N
already RB N
fitted VBN N
with IN N
a DT N
physiological JJ N
pacing NN N
system NN N
. . N

All DT N
had VBD N
been VBN N
paced VBN 4_p
for IN 4_p
complete JJ 4_p
or CC 4_p
Mobitz NNP 4_p
II NNP 4_p
heart NN 4_p
block NN 4_p
. . N

-DOCSTART- -X- O O 25526832

peer NN N
engagement NN N
children NNS 1_p
with IN N
autism NN 4_p
on IN N
the DT N
school NN N
playground NN N
: : N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
. . N

four CD N
elementary JJ N
schools NNS N
. . N

immediate JJ N
treatment NN N
( ( N
IT NNP N
) ) N
group NN N
consisted VBD N
of IN N
13 CD 3_p
( ( N
2 CD 3_p
female NN 2_p
) ) N
elementary JJ 1_p
school NN 1_p
students NNS 1_p
with IN N
ASD NNP 4_p
and CC N
the DT N
wait-list NN N
( ( N
WL NNP N
) ) N
group NN N
contained VBD N
11 CD 3_p
( ( N
4 CD 3_p
female NN 2_p
) ) N
students NNS 1_p
with IN N
ASD NNP N
. . N

All DT N
of IN N
the DT N
children NNS 1_p
with IN N
ASD NNP 4_p
children NNS 1_p
with IN N
ASD NNP 4_p
-DOCSTART- -X- O O 8115195

distressed JJ 4_p
neonates NNS 1_p
neonates NNS 1_p
with IN N
respiratory JJ 4_p
distress NN 4_p
. . 4_p

84 CD 3_p
mechanically RB 4_p
ventilated VBN 4_p
distressed JJ 4_p
neonates NNS N
Newborns NNP 1_p
with IN N
respiratory JJ 4_p
difficulties NNS 4_p
-DOCSTART- -X- O O 23993773

young JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
: : N
spectrum NN 4_p
disorders NNS 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
parents NNS N
of IN N
young JJ N
children NNS N
with IN N
ASD NNP 4_p
Parents NNP N
of IN N
a DT N
sample NN N
of IN N
40 CD 3_p
young JJ N
children NNS N
diagnosed VBN N
with IN N
ASD NNP 4_p
with IN N
an DT N
average JJ N
age NN N
of IN N
3.5years CD 1_p
were VBD N
enrolled VBN N
in IN N
our PRP$ N
study NN N
. . N

20 CD 3_p
participants NNS N
in IN N
each DT N
group NN N
, , N
data NNS N
were VBD N
available JJ N
for IN N
15 CD 3_p
participants NNS N
randomized VBN N
to TO N
BPT NNP N
and CC N
18 CD 3_p
participants NNS N
randomized VBN N
to TO N
the DT N
comparison NN N
condition NN N
. . N

-DOCSTART- -X- O O 8450402

HIV NNP 4_p
infection NN 4_p
. . 4_p

HIV-infected JJ 4_p
patients NNS N
. . N

HIV-infected JJ 4_p
patients NNS N
. . N

Twenty-one CD 3_p
HIV-seropositive JJ 4_p
patients NNS N
HIV-infected JJ 4_p
patients NNS N
. . N

HIV-infected JJ 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 24032193

autism NN 4_p
children NNS 4_p
: : 4_p
autism NN 4_p
children NNS 4_p
. . 4_p

Sixty NNP 4_p
qualified VBD 4_p
autism NN 4_p
children NNS 4_p
autism NN 4_p
children NNS 4_p
autism NN N
children NNS N
-DOCSTART- -X- O O 16824797

adolescent JJ N
basketball NN N
players NNS N
. . N

young JJ 4_p
basketball NN 4_p
players NNS 4_p
. . 4_p

Twenty-seven JJ N
adolescent JJ N
basketball NN N
players NNS N
( ( N
14.7+/-0.5 CD N
years NNS N
; : N
Tanner NNP N
stage NN N
: : N
3.5+/-0.5 JJ N
) ) N
-DOCSTART- -X- O O 8669042

children NNS 1_p
with IN N
primitive JJ 4_p
neuroectodermal JJ 4_p
tumor NN 4_p
( ( 4_p
PNET NNP 4_p
) ) 4_p
of IN N
the DT N
pineal JJ N
region NN N
] NN N
-DOCSTART- -X- O O 15466792

femoropopliteal JJ 4_p
arterial JJ 4_p
disease NN 4_p
266 CD 3_p
patients NNS N
with IN N
stenotic JJ 4_p
or CC 4_p
occluded VBN 4_p
superficial JJ 4_p
femoral JJ 4_p
or CC 4_p
popliteal JJ 4_p
arteries NNS 4_p
patients NNS 4_p
undergoing VBG 4_p
femoropopliteal JJ 4_p
PTA NNP 4_p
-DOCSTART- -X- O O 25923852

older JJR 1_p
adolescents NNS 1_p
and CC N
young JJ 1_p
adults NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . N

Autism NNP 4_p
spectrum NN 4_p
disorders NNS 4_p
older JJR 1_p
adolescents NNS 1_p
young JJ 1_p
adults NNS 1_p
20 CD 3_p
older JJR 1_p
adolescents NNS 1_p
and CC N
young JJ 1_p
adults NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
-DOCSTART- -X- O O 8352625

chronic JJ 4_p
stage NN 4_p
II NNP 4_p
and CC N
stage NN 4_p
III NNP 4_p
decubitus NN 4_p
ulcers NNS 4_p
. . N

stage NN 4_p
II NNP 4_p
and CC N
stage NN 4_p
III NNP 4_p
chronic JJ 4_p
decubitus NN 4_p
ulcers NNS 4_p
. . N

Seventy-four JJ 3_p
ulcers NNS 4_p
were VBD N
treated VBN N
in IN N
four CD N
centers NNS N
. . N

Forty-three JJ 3_p
patients NNS N
were VBD N
selected VBN N
for IN N
the DT N
experimental JJ N
group NN N
, , N
and CC N
31 CD 3_p
control NN N
subjects NNS N
used VBD N
the DT N
sham JJ N
instrument NN N
( ( N
placebo JJ N
group NN N
) ) N
. . N

-DOCSTART- -X- O O 22382875

postmenopausal JJ N
women NNS N
: : N
older JJR N
population NN N
. . N

postmenopausal JJ N
women NNS N
. . N

45 CD N
postmenopausal JJ N
women NNS N
performance NN N
and CC N
post-exercise JJ N
-DOCSTART- -X- O O 543887

Comparison NNP 4_p
of IN 4_p
some DT 4_p
pharmacokinetic JJ 4_p
parameters NNS 4_p
of IN 4_p
( ( 4_p
+ NNP 4_p
) ) 4_p
-cyanidanol-3 NN 4_p
obtained VBN 4_p
with IN 4_p
specific JJ 4_p
and CC 4_p
non-specific JJ 4_p
analytical JJ 4_p
methods NNS 4_p
. . N

-DOCSTART- -X- O O 15695500

elderly JJ 4_p
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
, , 4_p
low-grade JJ 4_p
non-Hodgkin NN 4_p
's POS 4_p
lymphoma NN 4_p
before IN 4_p
the DT 4_p
era NN 4_p
of IN 4_p
monoclonal JJ 4_p
antibodies NNS 4_p
. . 4_p

elderly JJ 4_p
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
, , 4_p
low-grade JJ 4_p
non-Hodgkin NN 4_p
's POS 4_p
lymphoma NN 4_p
. . 4_p

One CD N
hundred CD N
and CC N
fifty-five JJ N
patients NNS N
were VBD N
randomized VBN N
, , N
144 CD N
were VBD N
evaluable JJ N
for IN N
safety NN N
and CC N
142 CD N
for IN N
response NN N
. . N

-DOCSTART- -X- O O 16234574

recalcitrant JJ 4_p
diabetic JJ 4_p
foot NN 4_p
ulcers NNS 4_p
: : N
multicenter NN N
recalcitrant JJ 4_p
diabetic JJ 4_p
foot NN 4_p
ulcers NNS 4_p
multicenter NN N
study NN N
was VBD N
conducted VBN N
in IN N
hospital-based JJ N
and CC N
private JJ N
wound NN N
care NN N
clinics NNS N
. . N

Patients NNS N
( ( N
55 CD 3_p
met VBD N
criteria NNS N
for IN N
efficacy NN N
analysis NN N
) ) N
received VBD N
standard NN N
of IN N
care NN N
, , N
which WDT N
included VBD N
products NNS N
that WDT N
provide VBP N
a DT N
moist NN N
environment NN N
, , N
offloading VBG N
diabetic JJ N
shoes NNS N
and CC N
socks NNS N
, , N
debridement NN N
, , N
wound JJ N
evaluation NN N
, , N
and CC N
measurement NN N
. . N

-DOCSTART- -X- O O 15098782

anastomotic JJ 4_p
bleeding NN 4_p
during IN N
aortic JJ N
reconstruction NN N
: : N
managing VBG N
anastomotic JJ 4_p
bleeding NN 4_p
after IN N
implantation NN N
of IN N
Dacron NNP N
grafts NNS N
during IN N
aortic JJ N
reconstruction NN N
for IN N
nonruptured JJ 4_p
aneurysms NNS 4_p
. . N

37 CD 3_p
experimental JJ N
( ( N
59 CD N
sites NNS N
) ) N
and CC N
17 CD 3_p
control NN N
subjects NNS N
( ( N
27 CD N
sites NNS N
) ) N
. . N

intraoperative JJ N
management NN N
of IN N
anastomotic JJ 4_p
bleeding NN 4_p
during IN N
aortic JJ N
reconstruction NN N
procedures NNS N
. . N

-DOCSTART- -X- O O 22884754

antipsychotic JJ N
drugs NNS N
risperidone NN 4_p
( ( N
N=16 NNP 3_p
) ) N
, , N
olanzapine JJ 4_p
( ( N
N=18 NNP 3_p
) ) N
and CC N
low JJ N
doses NNS N
of IN N
haloperidol NN 4_p
( ( N
N=18 NNP 3_p
) ) N
large JJ N
and CC N
heterogeneous JJ N
sample NN N
of IN N
schizophrenia NN 4_p
spectrum NN 4_p
patients NNS N
. . N

group NN N
of IN N
45 CD 3_p
healthy JJ 4_p
volunteers NNS N
was VBD N
also RB N
longitudinally RB N
evaluated VBN N
. . N

-DOCSTART- -X- O O 16757200

radiation-induced JJ 4_p
xerostomic JJ 4_p
subjects NNS 4_p
. . 4_p

head NN N
and CC N
neck NN N
cancer NN N
patients NNS N
. . N

Twenty-two JJ 3_p
head NN 3_p
and CC 3_p
neck NN 3_p
cancer NN 3_p
patients NNS 3_p
from IN 3_p
U. NNP 3_p
T. NNP N
M. NNP N
D. NNP N
Anderson NNP N
Cancer NNP N
Center NNP N
, , N
with IN N
radiation-induced JJ N
xerostomia NN N
Patients NNS 4_p
in IN 4_p
both DT 4_p
groups NNS 4_p
Patients NNS 4_p
in IN 4_p
the DT 4_p
control NN 4_p
group NN 4_p
-DOCSTART- -X- O O 11029568

analgesia NN 4_p
in IN 4_p
labour NN 4_p
. . N

during IN N
labour NN N
. . N

We PRP N
studied VBD N
41 CD 3_p
pregnant JJ N
women NNS 2_p
. . N

-DOCSTART- -X- O O 12886239

From IN N
February NNP N
1991 CD N
to TO N
December NNP N
1994 CD N
, , N
376 CD 3_p
patients NNS N
with IN N
newly RB 4_p
diagnosed VBN 4_p
CML NNP 4_p
in IN 4_p
chronic JJ 4_p
phase NN 4_p
340 CD 3_p
patients NNS N
were VBD N
Ph/BCR-ABL NNP 4_p
positive JJ N
and CC N
evaluable JJ N
. . N

a DT N
total NN N
of IN N
534 CD 3_p
patients NNS 3_p
were VBD N
evaluable JJ N
( ( N
226 CD 3_p
patients NNS 3_p
with IN 3_p
IFN/HU NNP 3_p
and CC N
308 CD 3_p
patients NNS 3_p
with IN 3_p
HU NNP 3_p
) ) N
. . N

nontransplanted JJ N
living NN N
patients NNS N
534 CD 3_p
patients NNS N
-DOCSTART- -X- O O 2014978

108 CD 3_p
volunteers NNS N
undergoing VBG N
an DT N
elective JJ 4_p
surgical JJ 4_p
procedure NN 4_p
patients NNS N
patients NNS N
15 CD 3_p
control NN N
volunteers NNS N
-DOCSTART- -X- O O 7612555

primary JJ 4_p
pterygium NN 4_p
. . N

primary JJ N
pterygium NN N
A NNP N
total NN N
of IN N
66 CD N
eyes NNS N
of IN N
54 CD 3_p
patients NNS N
with IN N
primary JJ N
pterygium NN N
primary JJ N
pterygium NN N
. . N

-DOCSTART- -X- O O 9819368

neurally RB 4_p
mediated VBN 4_p
syncope NN 4_p
. . N

subjects NNS 4_p
susceptible JJ 4_p
to TO 4_p
tilt-induced JJ 4_p
syncope NN 4_p
. . N

Eight NNP 3_p
previously RB N
characterized VBD N
patients NNS N
with IN N
recurrent JJ N
NMS NNP N
( ( N
five CD 3_p
females NNS 2_p
and CC N
three CD 3_p
males NNS 2_p
; : N
34+/-2 JJ 1_p
yr NN 1_p
) ) N
were VBD N
recruited VBN N
from IN N
the DT N
Vanderbilt NNP N
Syncope NNP N
Unit NNP N
eight CD 3_p
age-matched JJ 1_p
controls NNS 4_p
NMS NNP N
patients NNS N
. . N

patients NNS N
with IN N
NMS NNP N
-DOCSTART- -X- O O 17849093

symptomatic JJ N
carotid NN N
stenosis NN N
. . N

patients NNS N
with IN N
symptomatic JJ N
stenoses NNS N
. . N

1,214 CD N
patients NNS N
patients NNS N
with IN N
symptomatic JJ N
carotid NN N
artery NN N
stenosis NN N
. . N

-DOCSTART- -X- O O 19681257

Belgian JJ N
dental JJ N
school NN N
. . N

46 CD 3_p
healthy JJ N
adults NNS 1_p
were VBD N
randomly RB N
assigned VBN N
-DOCSTART- -X- O O 19646778

cetuximab-associated JJ 4_p
acnelike JJ 4_p
eruption NN 4_p
. . N

cetuximab-related JJ 4_p
facial JJ 4_p
rash NN 4_p
. . 4_p

In IN N
all DT N
, , N
24 CD 3_p
patients NNS N
with IN N
metastatic JJ 4_p
colorectal JJ 4_p
cancer NN 4_p
with IN 4_p
cetuximab JJ 4_p
facial JJ 4_p
rash NN 4_p
patients NNS N
with IN N
cetuximab-related JJ 4_p
facial JJ 4_p
rash NN 4_p
. . N

-DOCSTART- -X- O O 11295009

acute NN 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
: : 4_p
subjects NNS N
with IN N
acute NN N
low JJ N
back RB N
pain NN N
( ( N
LBP NNP N
) ) N
. . N

Outpatient NNP N
physiotherapy NN N
departments NNS N
in IN N
hospital NN N
and CC N
university NN N
settings NNS N
. . N

60 CD N
eligible JJ N
patients NNS N
with IN N
back JJ N
pain NN N
( ( N
28 CD N
men NNS N
, , N
32 CD N
women NNS N
) ) N
were VBD N
recruited VBN N
by IN N
general JJ N
practitioners NNS N
and CC N
self-referral JJ N
-DOCSTART- -X- O O 15778725

myeloma NN N
patients NNS N
undergoing VBG N
high-dose JJ N
melphalan NN N
conditioned VBN N
autologous JJ N
stem NN N
cell NN N
transplantation NN N
. . N

90 CD 3_p
patients NNS N
undergoing VBG N
autologous JJ 4_p
stem NN 4_p
cell NN 4_p
transplantation NN 4_p
( ( 4_p
ASCT NNP 4_p
) ) 4_p
were VBD N
randomised VBN N
Both DT N
groups NNS N
-DOCSTART- -X- O O 19729979

paclitaxel-pretreated JJ 4_p
patients NNS 4_p
with IN N
metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
: : N
patients NNS N
with IN N
metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
who WP N
have VBP N
failed VBN 4_p
a DT 4_p
paclitaxel-containing JJ 4_p
regimen NN 4_p
. . N

-DOCSTART- -X- O O 8454478

advanced JJ 4_p
laryngeal NN 4_p
and CC 4_p
hypopharyngeal NN 4_p
squamous JJ 4_p
carcinoma NN 4_p
. . 4_p

Two CD 3_p
hundred VBD 3_p
and CC 3_p
twelve JJ 3_p
patients NNS N
with IN N
previously RB 4_p
untreated VBN 4_p
advanced JJ 4_p
squamous JJ 4_p
carcinoma NN 4_p
of IN 4_p
the DT 4_p
larynx NN 4_p
or CC 4_p
hypopharynx NN 4_p
Two CD N
hundred VBD N
and CC N
nine CD N
of IN N
the DT N
212 CD N
patients NNS N
randomized VBN N
were VBD N
included VBN N
in IN N
the DT N
analyses NNS N
. . N

-DOCSTART- -X- O O 7944932

patients NNS 4_p
with IN 4_p
severe JJ 4_p
injuries NNS 4_p
. . 4_p

patients NNS 4_p
sustaining VBG 4_p
severe JJ 4_p
injury NN 4_p
. . 4_p

patients NNS N
with IN N
major JJ N
infection NN N
on IN N
day NN N
60 CD N
. . N

Nine JJ N
university-affiliated JJ N
level NN N
1 CD N
trauma NN N
centers NNS N
. . N

Four CD N
hundred JJ N
sixteen JJ N
patients NNS N
with IN N
severe JJ N
injuries NNS N
, , N
assessed VBN N
by IN N
Injury NNP N
Severity NNP N
Score NNP N
and CC N
degree NN N
of IN N
contamination NN N
. . N

patients NNS N
treated VBN N
with IN N
interferon NN N
gamma NN N
. . N

-DOCSTART- -X- O O 24323035

progressive JJ 4_p
, , 4_p
metastatic JJ 4_p
, , 4_p
castration-resistant JJ 4_p
prostate NN 4_p
cancer NN 4_p
. . 4_p

metastatic JJ N
castration-resistant JJ N
prostate NN N
cancer NN N
( ( N
mCRPC NN N
) ) N
. . N

Men NNP N
with IN N
progressive JJ N
mCRPC NN N
after IN N
docetaxel-based JJ N
chemotherapy NN N
873 CD N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
-DOCSTART- -X- O O 18670875

treatment NN 4_p
of IN 4_p
hot JJ 4_p
flashes NNS 4_p
in IN 4_p
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
: : N
Breast NNP 4_p
cancer NN 4_p
patients NNS N
with IN N
treatment-induced JJ N
menopause NN 4_p
experience NN N
frequent NN N
and CC N
severe JJ 4_p
hot JJ 4_p
flashes NNS 4_p
( ( 4_p
HF NNP 4_p
) ) 4_p
. . N

60 CD 3_p
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
experiencing VBG N
HF NNP 4_p
were VBD N
randomized VBN N
Thirty NNP 3_p
patients NNS 3_p
-DOCSTART- -X- O O 6343259

angina JJ 4_p
pectoris NN 4_p
. . N

11 CD 4_p
patients NNS N
with IN N
stable JJ N
angina NNS N
pectoris VBP N
-DOCSTART- -X- O O 10735900

very RB N
high-risk JJ N
childhood NN 4_p
acute NN 4_p
lymphoblastic JJ 4_p
leukemia NN 4_p
. . N

childhood NN 1_p
acute NN 4_p
lymphoblastic JJ 4_p
leukemia NN 4_p
( ( N
ALL DT 4_p
) ) N
. . N

Sixty-seven NNP 3_p
children NNS 1_p
with IN N
very RB N
high-risk JJ N
ALL NNP N
high-risk JJ 4_p
childhood NN 4_p
ALL NNP 4_p
-DOCSTART- -X- O O 16704894

treatment NN N
of IN N
prostates NNS 4_p
larger JJR 4_p
than IN 4_p
40 CD 4_p
grams NNS 4_p
: : N
men NNS 2_p
with IN N
bladder NN 4_p
outflow JJ 4_p
obstruction NN 4_p
( ( 4_p
BOO NNP 4_p
) ) 4_p
secondary VBP N
to TO N
benign VB 4_p
prostatic JJ 4_p
hyperplasia NN 4_p
with IN N
a DT N
minimum NN N
of IN N
24-month JJ N
follow-up JJ N
. . N

Sixty-one CD N
patients NNS N
All DT N
patients NNS N
had VBD N
BOO NNP 4_p
proven RB N
on IN N
urodynamic JJ N
studies NNS N
pre-operatively RB N
( ( N
prostate JJ 4_p
size NN 4_p
40-200 JJ 4_p
g NN 4_p
) ) N
. . N

30 CD N
patients NNS N
in IN N
each DT N
group NN N
. . N

-DOCSTART- -X- O O 8097925

12 CD 4_p
patients NNS 4_p
with IN 4_p
essential JJ 4_p
hypertension NN 4_p
. . 4_p

cardiovascular JJ 4_p
disorders NNS 4_p
angina JJ N
pectoris NN N
in IN N
patients NNS N
without IN N
hypertension NN 4_p
or CC N
cardiac JJ 4_p
arrhythmia NN 4_p
. . N

-DOCSTART- -X- O O 17019627

tutors NNS N
of IN N
children NNS 1_p
with IN N
autism NN 4_p
. . N

trained JJ N
tutors NNS N
. . N

novice JJ 4_p
tutors NNS 4_p
of IN N
children NNS 1_p
with IN N
autism NN 4_p
. . N

-DOCSTART- -X- O O 10172265

acute VB 4_p
stroke NN 4_p
patients NNS N
. . N

stroke VB 4_p
patients NNS N
-DOCSTART- -X- O O 19066101

intracerebral JJ 4_p
hemorrhage NN 4_p
evacuation NN N
( ( N
MISTIE NNP N
) ) N
younger JJR 1_p
patients NNS N
, , N
and CC N
produces VBZ N
relatively RB N
small JJ N
initial JJ N
injury NN N
to TO N
cerebral JJ N
tissues NNS N
-- : N
all DT N
factors NNS N
suggesting VBG N
that IN N
interventional JJ N
amelioration NN N
is VBZ N
possible JJ N
. . N

Subjects NNS N
in IN N
both DT N
groups NNS 3_p
medically RB 4_p
managed VBN 4_p
according VBG 4_p
to TO 4_p
standard JJ 4_p
ICU NNP 4_p
protocols NNS 4_p
. . 4_p

-DOCSTART- -X- O O 19169898

neonate NN N
: : N
critically RB N
ill JJ N
neonates NNS N
during IN N
the DT N
first JJ N
week NN N
of IN N
life NN N
. . N

200 CD 3_p
neonates NNS N
( ( N
gestational JJ N
ages NNS N
26.4-41 JJ N
weeks NNS N
) ) N
treated VBD N
with IN N
netilmicin JJ 4_p
( ( N
4-5 JJ N
mg/kg NN N
in IN N
extended JJ N
dosing NN N
intervals NNS N
) ) N
for IN N
postnatal JJ N
sepsis NN N
in IN N
the DT N
first JJ N
week NN N
of IN N
life NN N
critically RB N
ill JJ N
neonates NNS N
> VBP N
32 CD N
weeks NNS N
neonates NNS N
< VBP N
32 CD N
weeks NNS N
critically RB N
ill JJ N
neonates NNS N
> VBP N
32 CD N
weeks NNS N
-DOCSTART- -X- O O 9469367

chemotherapy-naive JJ 4_p
patients NNS 4_p
who WP 4_p
received VBD 4_p
moderately RB 4_p
emetogenic JJ 4_p
chemotherapy NN 4_p
. . 4_p

parallel-group NN 4_p
study NN 4_p
, , 4_p
patients NNS 4_p
naive VBP 4_p
to TO 4_p
emetogenic VB 4_p
chemotherapy NN 4_p
( ( 4_p
N NNP 4_p
= NNP 4_p
1,085 CD 4_p
) ) 4_p
who WP 4_p
were VBD 4_p
scheduled VBN 4_p
to TO 4_p
receive VB 4_p
cyclophosphamide- NN 4_p
( ( 4_p
500 CD 4_p
to TO 4_p
1,200 CD 4_p
mg/m2 NN 4_p
) ) 4_p
or CC 4_p
carboplatin NN 4_p
( ( 4_p
> CD 4_p
or CC 4_p
= VB 4_p
300 CD 4_p
mg/m2 NN 4_p
) ) 4_p
based VBN 4_p
chemotherapy NN 4_p
-DOCSTART- -X- O O 10811665

disseminated JJ 4_p
small JJ 4_p
noncleaved-cell JJ 4_p
lymphoma NN 4_p
and CC N
B-cell NNP 4_p
leukemia NN 4_p
: : N
Children NNP 1_p
's POS 1_p
Cancer NNP 4_p
Group NNP N
study NN N
. . N

patients NNS N
with IN N
disseminated JJ 4_p
small JJ 4_p
noncleaved-cell JJ 4_p
lymphoma NN 4_p
and CC N
B-cell NNP 4_p
leukemia NN 4_p
who WP N
were VBD N
treated VBN N
in IN N
four CD N
successive JJ N
Children NNP 1_p
's POS 1_p
Cancer NNP 4_p
Group NNP N
trials NNS N
. . N

462 CD 3_p
patients NNS N
with IN N
disseminated JJ 4_p
disease NN 4_p
, , N
49 CD 3_p
( ( N
10.6 CD N
% NN N
) ) N
had VBD N
CNS NNP 4_p
disease NN N
at IN N
diagnosis NN N
( ( N
CNS+ NNP 4_p
) ) N
. . N

Of IN N
the DT N
CNS+ NNP 4_p
patients NNS N
, , N
28 CD 3_p
had VBD N
M2 NNP N
( ( N
5 CD N
% NN N
to TO N
25 CD N
% NN N
blasts NNS N
) ) N
or CC N
M3 NNP N
( ( N
> VB N
25 CD N
% NN N
blasts NNS N
) ) N
bone NN N
marrow JJ N
involvement NN N
. . N

All DT 3_p
patients NNS N
received VBD N
protocol-based JJ N
systemic JJ N
and CC N
intrathecal JJ N
chemotherapy NN N
. . N

-DOCSTART- -X- O O 16027809

hypercholesterolemia NN 4_p
. . N

patients NNS N
with IN N
coronary JJ 4_p
heart NN 4_p
disease NN 4_p
and CC N
hypercholesterolemia NN 4_p
treated VBN N
with IN N
simvastatin NN 4_p
( ( 4_p
Zocor NNP 4_p
, , 4_p
inhibitor NN 4_p
of IN 4_p
the DT 4_p
key JJ 4_p
enzyme NN 4_p
of IN 4_p
cholesterol NN 4_p
synthesis NN 4_p
) ) 4_p
and CC N
preparation NN N
of IN N
polyunsaturated JJ 4_p
phospholipids NNS 4_p
( ( 4_p
lipostabil JJ 4_p
forte NN 4_p
) ) 4_p
. . N

-DOCSTART- -X- O O 25640884

cancer NN 4_p
patient JJ 4_p
navigation NN 4_p
. . N

Medicare NNP N
beneficiaries NNS N
. . N

cancer NN N
screening NN N
of IN N
Asian JJ N
and CC N
Pacific NNP N
Islander NNP N
Medicare NNP N
beneficiaries NNS N
. . N

The DT N
study NN N
setting NN N
was VBD N
Moloka'i NNP N
General NNP N
Hospital NNP N
on IN N
the DT N
island NN N
of IN N
Moloka'i NNP N
, , N
Hawai'i NNP N
, , N
which WDT N
was VBD N
one CD N
of IN N
six CD N
sites NNS N
participating VBG N
in IN N
the DT N
Cancer NNP N
Prevention NNP N
and CC N
Treatment NNP N
Demonstration NNP N
sponsored VBN N
by IN N
the DT N
Centers NNPS N
for IN N
Medicare NNP N
and CC N
Medicaid NNP N
Services NNPS N
. . N

Between JJ N
2006 CD N
and CC N
2009 CD N
, , N
488 CD 3_p
Medicare NNP 3_p
beneficiaries NNS 3_p
( ( N
45 CD 3_p
% NN 3_p
Hawaiian JJ 3_p
, , N
35 CD 3_p
% NN 3_p
Filipino NNP 3_p
, , N
11 CD 3_p
% NN 3_p
Japanese JJ 3_p
, , N
8 CD 3_p
% NN 3_p
other JJ 3_p
) ) N
-DOCSTART- -X- O O 21742443

rabbits NNS 4_p
under IN 4_p
high JJ 4_p
ambient JJ 4_p
temperature NN 4_p
. . 4_p

rabbits NNS N
Rabbits NNS N
oxidation NN N
. . N

Rabbits NNS N
of IN N
rabbits NNS N
-DOCSTART- -X- O O 17388667

14,916 CD N
men NNS N
initially RB N
free JJ N
of IN N
diagnosed JJ N
cancer NN N
, , N
we PRP N
identified VBD N
1,066 CD N
men NNS N
with IN N
incident JJ N
prostate NN N
cancer NN N
( ( N
including VBG N
496 CD N
with IN N
aggressive JJ N
disease NN N
, , N
defined VBD N
as IN N
stage NN N
C NNP N
or CC N
D NNP N
, , N
Gleason NNP N
7-10 CD N
, , N
metastatic JJ N
, , N
and CC N
fatal JJ N
prostate NN N
cancer NN N
) ) N
and CC N
1,618 CD N
cancer-free JJ N
, , N
age- JJ N
and CC N
smoking-matched JJ N
control NN N
participants NNS N
in IN N
the DT N
Physicians NNPS N
' POS N
Health NNP N
Study NNP N
. . N

men NNS N
with IN N
plasma NN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
levels NNS N
above IN N
the DT N
median NN N
-DOCSTART- -X- O O 23514246

Early-stage JJ N
squamous JJ 4_p
cell NN 4_p
carcinoma NN 4_p
of IN N
the DT N
oropharynx NN N
: : N
oropharyngeal JJ N
squamous JJ N
cell NN N
carcinoma NN N
( ( N
OPSCC NNP 4_p
) ) N
comprises NNS N
OPSCC NNP N
patients NNS N
who WP N
would MD N
be VB N
unlikely JJ N
to TO N
require VB N
chemotherapy JJ N
post-resection NN N
: : N
Tumor NN N
stage NN N
T1-T2 NN N
with IN N
likely JJ N
negative JJ N
margins NNS N
at IN N
surgery NN N
; : N
Nodal NNP N
stage NN N
N0-2 NNP N
, , N
≤3 NNP N
cm NN N
in IN N
size NN N
, , N
with IN N
no DT N
evidence NN N
of IN N
extranodal JJ N
extension NN N
on IN N
imaging VBG N
function NN N
. . N

A DT N
sample NN N
of IN N
68 CD N
-DOCSTART- -X- O O 21385365

chronic JJ 4_p
, , 4_p
non-healing JJ 4_p
ulcers NNS 4_p
of IN 4_p
the DT 4_p
lower JJR 4_p
limb NN 4_p
in IN N
patients NNS N
with IN N
diabetes NNS 4_p
mellitus NNS 4_p
: : N
diabetic JJ N
ulcers NNS N
. . N

patients NNS N
with IN N
diabetes NNS N
mellitus NNS N
and CC N
chronic JJ 4_p
ulcers NNS 4_p
of IN N
the DT N
lower JJR N
limb NN N
. . N

One CD 3_p
hundred CD 3_p
and CC 3_p
eighteen JJ 3_p
( ( N
59 CD 3_p
patients NNS N
per IN N
arm NN N
) ) N
patients NNS N
with IN N
non-healing JJ 4_p
diabetic JJ 4_p
ulcers NNS 4_p
of IN 4_p
the DT 4_p
lower JJR 4_p
limb NN 4_p
, , N
referred VBD N
to TO N
the DT N
Judy NNP N
Dan NNP N
Research NNP N
and CC N
Treatment NNP N
Centre NNP N
are VBP N
being VBG N
recruited VBN N
if IN N
they PRP N
are VBP N
at IN N
least JJS N
18 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
, , N
have VBP N
either DT N
Type NNP 4_p
1 CD 4_p
or CC 4_p
2 CD 4_p
diabetes NNS 4_p
with IN N
a DT N
Wagner NNP 4_p
grading NN 4_p
of IN 4_p
foot NN 4_p
lesions NNS 4_p
2 CD 4_p
, , 4_p
3 CD 4_p
or CC 4_p
4 CD 4_p
on IN 4_p
lower JJR 4_p
limb NN 4_p
not RB 4_p
healing VBG 4_p
for IN 4_p
at IN 4_p
least JJS 4_p
4 CD 4_p
weeks NNS 4_p
. . N

non-healing JJ N
ulcers NNS N
of IN N
the DT N
lower JJR N
limb NN N
. . N

diabetic JJ N
patients NNS N
. . N

-DOCSTART- -X- O O 18184678

CPAP NNP N
therapy NN N
in IN N
a DT N
cool JJ N
sleeping NN N
environment NN N
. . N

patients NNS N
with IN N
obstructive JJ N
sleep JJ N
apnoea NN N
syndrome NN N
( ( N
OSAS NNP N
) ) N
. . N

19 CD N
patients NNS N
with IN N
a DT N
first-ever JJ N
diagnosis NN N
of IN N
OSAS NNP N
-DOCSTART- -X- O O 22414705

adults NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . N

individuals NNS N
with IN N
an DT N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
14 CD 3_p
high-functioning JJ N
adults NNS 1_p
with IN N
ASD NNP 4_p
and CC N
a DT N
demographically-matched JJ N
comparison NN N
group NN N
of IN N
13 CD 3_p
typically RB N
developing VBG N
individuals NNS N
participated VBN N
. . N

Individuals NNS N
with IN N
ASD NNP 4_p
-DOCSTART- -X- O O 16740812

inner-city JJ N
children NNS N
with IN N
asthma NN 4_p
. . N

5- JJ 1_p
to TO 1_p
11-year-old JJ 1_p
children NNS N
( ( N
n JJ N
= NNP N
937 CD 3_p
) ) N
with IN N
moderate JJ N
to TO N
severe VB N
asthma RB N
receiving VBG N
health NN N
care NN N
in IN N
hospital- JJ N
and CC N
community-based JJ N
clinics NNS N
and CC N
private JJ N
practices NNS N
in IN N
7 CD N
inner-city JJ N
urban JJ N
areas NNS N
. . N

caretaker NN N
of IN N
each DT N
child NN N
-DOCSTART- -X- O O 7942578

20 CD 3_p
male JJ 2_p
subjects NNS N
-DOCSTART- -X- O O 20137718

rectal JJ 4_p
cancer NN 4_p
] NNP N
preoperative JJ N
staging NN N
of IN N
rectal JJ 4_p
cancer NN 4_p
. . N

patients NNS N
with IN N
rectal JJ 4_p
cancer NN 4_p
from IN N
October NNP N
2007 CD N
to TO N
October NNP N
2008 CD N
. . N

Total NNP N
of IN N
225 CD 3_p
cases NNS N
with IN N
rectal JJ 4_p
cancer NN 4_p
were VBD N
enrolled VBN N
in IN N
this DT N
study NN N
. . N

110 CD 3_p
cases NNS N
in IN N
MSCT NNP N
and CC N
SAA NNP N
combined VBD N
group NN N
and CC N
115 CD 3_p
cases NNS N
in IN N
MSCT NNP N
group NN N
. . N

-DOCSTART- -X- O O 7670096

very RB N
low JJ N
birthweight NN N
neonates NNS N
: : N
those DT N
of IN N
very RB N
low JJ N
birthweight NN N
( ( N
VLBW NNP N
) ) N
Twenty NNP N
VLBW NNP N
neonates NNS N
( ( N
500 CD N
to TO N
1,500 CD N
g NN N
) ) N
, , N
aged VBD N
< JJ N
72 CD N
hours NNS N
, , N
were VBD N
randomized VBN N
-DOCSTART- -X- O O 20831671

acute NN 4_p
and CC 4_p
prolonged JJ 4_p
diarrhoea NN 4_p
in IN N
children NNS 1_p
: : N
a DT N
community-based JJ N
trial NN N
in IN N
rural JJ N
Bangladesh NNP N
. . N

acute NN N
( ( N
< JJ N
7 CD N
days NNS N
) ) N
or CC N
prolonged VBN N
( ( N
≥ JJ N
7 CD N
days NNS N
) ) N
diarrhoea VBP N
among IN N
2968 CD 3_p
Bangladeshi NNP N
rural JJ N
children NNS N
6-36 JJ 1_p
months NNS 1_p
old JJ 1_p
of IN N
diarrhoeal JJ N
children NNS N
of IN N
acute NN N
and CC N
prolonged VBD N
childhood NN N
diarrhoea NN N
-DOCSTART- -X- O O 24069775

eclampsia NN N
: : N
Between NNP N
January NNP N
and CC N
June NNP N
2011 CD N
, , N
98 CD N
eclamptic JJ N
mothers NNS N
presenting VBG N
at IN N
the DT N
labour JJ N
ward NN N
of IN N
the DT N
University NNP N
of IN N
Maiduguri NNP N
Teaching NNP N
Hospital NNP N
-DOCSTART- -X- O O 18701020

patients NNS 4_p
with IN 4_p
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
mellitus RB 4_p
. . 4_p

type NN 4_p
2 CD 4_p
diabetics NNS 4_p
. . 4_p

71 CD N
type NN N
2 CD N
diabetics NNS N
completed VBD N
the DT N
study NN N
. . N

diabetic JJ N
and CC N
hyperglycemic JJ N
patients NNS N
in IN N
need NN N
of IN N
nutritional JJ N
support NN N
. . N

-DOCSTART- -X- O O 2148830

hormone-resistant JJ N
prostatic JJ N
cancer NN N
: : N
symptomatic JJ N
metastatic JJ N
hormone-resistant JJ N
prostatic JJ N
cancer NN N
. . N

total NN 4_p
of IN 4_p
79 CD 4_p
patients NNS 4_p
were VBD 4_p
included VBN 4_p
. . 4_p

-DOCSTART- -X- O O 8275152

one-handed JJ 4_p
and CC N
two-handed JJ 4_p
ventilation NN 4_p
techniques NNS 4_p
. . N

Subjects NNP N
( ( N
108 CD 3_p
healthcare NN N
providers NNS N
from IN N
a DT N
500-bed JJ N
teaching NN N
hospital NN N
) ) N
a DT N
simulated JJ 4_p
situation NN N
. . N

-DOCSTART- -X- O O 3950826

preterm JJ 4_p
infants NNS N
fed VBN N
standard JJ N
infant NN N
formulas NN N
. . N

preterm JJ 4_p
infants NNS N
fed VBN N
standard JJ N
infant NN N
formulas NNS N
, , N
Similac NNP N
With IN N
Iron NNP N
and CC N
Similac NNP N
With IN N
Whey NNP N
+ NNP N
Iron NNP N
. . N

rapidly RB N
growing VBG N
preterm JJ 1_p
infant NN 1_p
-DOCSTART- -X- O O 8570879

during IN N
routine JJ N
surgeries NNS N
One CD 3_p
hundred VBD 3_p
patients NNS N
aged VBN N
5-88 CD 1_p
years NNS 1_p
( ( N
56 CD 3_p
patients NNS 3_p
with IN N
a DT N
history NN N
of IN N
chronic JJ 4_p
respiratory NN 4_p
complaints NNS 4_p
and CC N
44 CD 3_p
patients NNS 3_p
without IN N
) ) N
entered VBD N
Phase NNP N
1 CD N
, , N
and CC N
100 CD 3_p
patients NNS 3_p
aged VBN N
6-82 JJ 1_p
years NNS 1_p
( ( N
62 CD 3_p
patients NNS 3_p
with IN N
a DT N
history NN N
of IN N
chronic JJ 4_p
respiratory NN 4_p
complaints NNS 4_p
and CC N
38 CD 3_p
patients NNS 3_p
without IN N
) ) N
entered VBD N
Phase NNP N
2 CD N
. . N

-DOCSTART- -X- O O 16119478

childhood NN 1_p
autism NN 4_p
. . N

Eighteen JJ 3_p
children NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
-DOCSTART- -X- O O 12872081

early JJ N
stage NN N
cancer NN N
of IN N
the DT N
esophagus NN N
. . N

100 CD N
consecutive JJ N
endoscopic NN N
resections NNS N
were VBD N
performed VBN N
in IN N
72 CD 3_p
patients NNS 3_p
with IN N
early JJ 4_p
stage NN 4_p
esophageal JJ 4_p
cancer NN 4_p
. . N

patients NNS N
who WP N
had VBD N
prior JJ N
endoscopic NN N
treatment NN N
. . N

-DOCSTART- -X- O O 7492424

a DT N
Danish JJ N
population NN N
. . N

healthy JJ 4_p
people NNS N
population-based JJ N
study NN N
in IN N
general JJ N
practices NNS N
in IN N
Ebeltoft NNP N
, , N
Denmark NNP N
. . N

All NNP N
general JJ N
practitioners NNS N
from IN N
the DT N
four CD N
practices NNS N
in IN N
Ebeltoft NNP N
and CC N
a DT N
random JJ N
sample NN N
of IN N
2000 CD 3_p
people NNS N
aged VBN N
between IN N
30 CD 1_p
and CC 1_p
50 CD 1_p
years NNS N
were VBD N
invited VBN N
to TO N
participate VB N
. . N

total NN N
of IN N
1370 CD 3_p
people NNS N
participated VBN N
in IN N
the DT N
study NN N
456 CD 3_p
participants NNS N
( ( N
96 CD N
% NN N
) ) N
64 CD N
% NN N
of IN N
the DT N
456 CD 3_p
participants NNS N
Eleven NNP 3_p
-DOCSTART- -X- O O 80115

in IN 2_p
human JJ 2_p
subjects NNS N
and CC N
in IN N
dogs NNS N
-DOCSTART- -X- O O 12629094

Final NNP N
height NN N
in IN N
girls NNS 2_p
with IN N
turner NN 4_p
syndrome NN 4_p
growth NN N
hormone NN N
treatment NN N
60 CD 3_p
girls NNS 2_p
with IN N
Turner NNP 4_p
syndrome NN 4_p
treated VBD N
in IN N
a DT N
randomized JJ N
dose-response JJ N
trial NN N
Girls NNP 2_p
Fifty NNP 3_p
of IN N
the DT N
60 CD 3_p
girls NNS 2_p
( ( N
83 CD N
% NN N
) ) N
had VBD N
reached VBN N
a DT N
normal JJ N
FH NNP N
( ( N
FH NNP N
SD NNP N
score NN N
, , N
more JJR N
than IN N
-2 NN N
) ) N
-DOCSTART- -X- O O 24325899

laparoscopic JJ N
radical JJ N
hysterectomy NN N
and CC N
pelvic JJ N
lymphadenectomy NN N
for IN N
gynecologic JJ 4_p
cancer NN 4_p
. . N

gynecologic JJ 4_p
tumors NNS 4_p
. . 4_p

Gynecologic NNP N
Oncology NNP N
Unit NNP N
of IN N
the DT N
Catholic NNP N
University NNP N
of IN N
the DT N
Sacred NNP N
Heart NNP N
in IN N
Rome NNP N
, , N
Italy NNP N
. . N

Fifty JJ 3_p
patients NNS N
with IN N
early JJ N
cervical JJ 4_p
cancer NN 4_p
( ( N
FIGO NNP N
stages VBZ N
IA2 NNP N
, , N
IB1 NNP N
, , N
IIA NNP N
< VBZ N
2 CD N
cm NN N
) ) N
or CC N
locally RB N
advanced JJ N
cervical JJ 4_p
cancer NN 4_p
( ( N
FIGO NNP N
stages VBZ N
IB2 NNP N
, , N
IIA NNP N
> NNP N
2cm CD N
, , N
IIB NNP N
) ) N
who WP N
received VBD N
neoadjuvant JJ N
treatment NN N
( ( N
chemotherapy NN N
or CC N
radiochemotherapy NN N
) ) N
and CC N
demonstrated VBD N
a DT N
complete JJ N
or CC N
partial JJ N
clinical JJ N
response NN N
and CC N
early JJ N
stage NN N
endometrioid JJ N
endometrial JJ N
cancer NN N
( ( N
FIGO NNP N
stages VBZ N
IB NNP N
, , N
II NNP N
) ) N
Fifty NNP 3_p
patients NNS N
were VBD N
available JJ N
for IN N
analysis NN N
, , N
with IN N
25 CD 3_p
women NNS 2_p
randomly RB N
assigned VBD N
to TO N
TB NNP N
( ( N
arm IN N
A NNP N
) ) N
and CC N
25 CD N
to TO N
SES NNP N
( ( N
arm NN N
B NNP N
) ) N
. . N

patients NNS N
with IN N
uterine JJ 4_p
cancer NN 4_p
. . N

-DOCSTART- -X- O O 7712308

patients NNS N
with IN N
hepatitis JJ 4_p
C NNP 4_p
virus-related JJ 4_p
chronic JJ 4_p
liver NN 4_p
disease NN 4_p
. . N

101 CD 3_p
patients NNS N
with IN N
hepatitis JJ 4_p
C NNP 4_p
virus-related JJ 4_p
chronic JJ 4_p
liver NN 4_p
disease NN 4_p
. . N

Forty-nine JJ N
patients NNS N
were VBD N
assigned VBN N
to TO N
receive VB N
UDCA NNP N
( ( N
450 CD N
mg/day NN N
) ) N
over IN N
a DT N
period NN N
of IN N
6 CD N
months NNS N
and CC N
52 CD N
to TO N
receive VB N
no DT N
treatment NN N
. . N

patients NNS N
who WP N
fail VBP N
to TO N
respond VB N
to TO N
interferon VB N
therapy NN N
. . N

-DOCSTART- -X- O O 22294238

acute JJ 4_p
depressive JJ 4_p
mixed JJ 4_p
state NN 4_p
. . N

patients NNS N
with IN N
mixed JJ 4_p
depressive JJ 4_p
state NN 4_p
. . N

72 CD 3_p
patients NNS N
were VBD N
randomized VBN N
-DOCSTART- -X- O O 22588803

among IN N
individuals NNS N
with IN N
heart NN 4_p
failure NN 4_p
Boston NNP N
, , N
Massachusetts NNP N
individuals NNS N
with IN N
stable JJ 4_p
heart NN 4_p
failure NN 4_p
. . N

100 CD 3_p
patients NNS N
Among IN N
patients NNS N
undergoing VBG N
treatment NN N
for IN N
heart NN N
failure NN N
-DOCSTART- -X- O O 8791949

Helicobacter NNP 4_p
pylori NN 4_p
. . N

Helicobacter NNP 4_p
pylori NN 4_p
. . N

Volunteers NNPS N
with IN N
H. NNP 4_p
pylori FW 4_p
infection NN N
( ( N
by IN N
13C-urea JJ N
breath NN N
test NN N
) ) N
dirithromycin JJ N
alone RB N
( ( N
n JJ N
= NNP N
6 CD N
) ) N
patients NNS N
with IN N
H. NNP 4_p
pylori JJ 4_p
infection NN N
. . N

-DOCSTART- -X- O O 7761019

20 CD 4_p
patients NNS N
, , N
ASA NNP N
I-II NNP N
, , N
aged VBD N
20-54 JJ 1_p
, , N
both DT 4_p
sexes NNS 4_p
, , N
scheduled VBN N
for IN N
abdominal JJ 4_p
surgery NN 4_p
. . N

-DOCSTART- -X- O O 8770026

humans NNS N
. . N

20 CD N
healthy JJ N
, , N
nondiabetic JJ N
Caucasian NNP N
male NN N
volunteers NNS N
[ VBP N
27 CD N
+/- JJ N
5 CD N
( ( N
SD NNP N
) ) N
yr NN N
, , N
72 CD N
+/- JJ N
9 CD N
kg NN N
, , N
20 CD N
+/- JJ N
7 CD N
% NN N
body NN N
fat JJ N
] NNP N
-DOCSTART- -X- O O 10155556

polyarteritis NN 4_p
nodosa NN 4_p
and CC N
Churg-Strauss JJ 4_p
syndrome NN 4_p
: : N
polyarteritis NN 4_p
nodosa NN 4_p
( ( N
PAN NNP 4_p
) ) N
and CC N
Churg-Strauss JJ 4_p
syndrome NN 4_p
( ( N
CSS NNP 4_p
) ) N
236 CD 3_p
patients NNS N
71 CD 3_p
patients NNS N
( ( N
1981-1983 JJ N
) ) N
compared VBN N
the DT N
association NN N
of IN N
CYC NNP N
with IN N
corticosteroids NNS N
( ( N
CS NNP N
) ) N
and CC N
PE NNP N
to TO N
CS NNP N
and CC N
PE NNP N
, , N
in IN N
order NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
CYC NNP N
given VBN N
as IN N
the DT N
first-line JJ N
treatment NN N
to TO N
control VB N
disease NN N
activity NN N
and CC N
subsequent JJ N
survival NN N
of IN N
PAN NNP N
and CC N
CSS NNP N
patients NNS N
. . N

December NNP N
1983 CD N
and CC N
December NNP N
1988 CD N
at IN N
patients NNS N
without IN 4_p
HBV NNP 4_p
markers NNS 4_p
and CC N
the DT N
second JJ N
at IN N
patients NNS N
with IN 4_p
HBV NNP 4_p
markers NNS 4_p
. . N

78 CD 3_p
patients NNS N
without IN 4_p
HBV NNP 4_p
markers NNS 4_p
33 CD 3_p
patients NNS N
with IN N
PAN NNP 4_p
related VBD N
to TO N
HBV NNP 4_p
56 CD 3_p
patients NNS N
and CC N
addressed VBD N
to TO N
severe VB 4_p
PAN NNP 4_p
without IN 4_p
HBV NNP 4_p
markers NNS 4_p
or CC N
CSS NNP N
PAN NNP 4_p
related VBD N
to TO N
HBV NNP N
-DOCSTART- -X- O O 4818631

pregnant JJ N
women NNS 2_p
in IN N
Switzerland NNP N
] NNP N
-DOCSTART- -X- O O 10348763

in IN N
children NNS 1_p
with IN N
malignant JJ 4_p
disease NN 4_p
: : 4_p
children NNS 1_p
with IN N
malignant JJ 4_p
disease NN 4_p
. . N

82 CD 3_p
children NNS N
who WP N
received VBD N
a DT N
full JJ N
course NN N
of IN N
6 CD N
days NNS N
or CC N
more JJR N
of IN N
AmB NNP N
( ( N
117 CD N
courses NNS N
) ) N
children NNS 1_p
with IN N
malignant JJ 4_p
disease NN 4_p
. . N

-DOCSTART- -X- O O 10754477

patients NNS 4_p
with IN 4_p
longstanding JJ 4_p
post-irradiation NN 4_p
GH NNP 4_p
insufficiency NN 4_p
. . N

patients NNS 4_p
post VBP 4_p
cranial JJ 4_p
irradiation NN 4_p
and CC N
in IN N
controls NNS 4_p
. . N

Five CD 3_p
adult NN 1_p
male NN 2_p
long-term JJ N
survivors NNS N
of IN N
childhood NN 3_p
brain NN 3_p
tumours NNS 3_p
( ( N
median JJ N
age NN N
21.8 CD N
years NNS N
( ( N
18.4-26.7 JJ N
) ) N
; : N
13.7 CD N
years NNS N
( ( N
11.4-15.7 JJ N
) ) N
post-radiotherapy NN N
, , N
> NNP N
30Gy CD N
) ) N
and CC N
five CD 3_p
matched VBN N
controls NNS N
were VBD N
studied VBN N
. . N

young JJ 1_p
males NNS N
adult JJ 1_p
long-term JJ N
survivors NNS N
of IN N
childhood NN 4_p
brain NN 4_p
tumours NN 4_p
. . N

-DOCSTART- -X- O O 19217236

randomized JJ N
, , N
prospective JJ N
study NN N
was VBD N
undertaken VBN N
with IN N
150 CD 3_p
volunteers NNS 4_p
who WP 4_p
performed VBD 4_p
management NN 4_p
of IN 4_p
a DT 4_p
standardized JJ 4_p
simulated JJ 4_p
cardiac NN 4_p
arrest NN 4_p
in IN 4_p
a DT 4_p
manikin NN 4_p
. . N

-DOCSTART- -X- O O 16684856

Eight NNP 3_p
sedentary JJ N
men NNS 2_p
( ( N
26 CD 1_p
+/- JJ 1_p
1 CD 1_p
yr NN 1_p
, , 1_p
77.4 CD N
+/- JJ N
3.7 CD N
kg NN N
) ) N
were VBD N
studied VBN N
in IN N
young JJ 1_p
, , N
healthy JJ N
normolipidemic JJ N
men NNS 2_p
young JJ 1_p
, , N
healthy JJ N
normolipidemic JJ 4_p
men NNS 2_p
in IN N
the DT N
postprandial JJ N
state NN N
-DOCSTART- -X- O O 8281875

gastroduodenal JJ 4_p
injury NN 4_p
. . 4_p

Twenty NNP 4_p
healthy JJ 4_p
volunteers NNS 4_p
were VBD 4_p
randomized VBN 4_p
Fourteen CD N
of IN N
the DT N
20 CD N
subjects NNS N
All DT N
six CD N
with IN N
no DT N
difference NN N
-DOCSTART- -X- O O 25616941

liver JJ 4_p
resection NN 4_p
with IN 4_p
intermittent JJ 4_p
clamping NN 4_p
( ( 4_p
INT NNP 4_p
) ) 4_p
. . N

A DT N
total NN N
of IN N
106 CD 3_p
patients NNS 3_p
without IN N
underlying VBG N
liver NN 4_p
disease NN 4_p
and CC N
submitted VBN N
to TO N
liver VB N
resection NN N
using VBG N
INT NNP N
-DOCSTART- -X- O O 11454840

coronary JJ N
artery NN N
dissections NNS N
523 CD 3_p
patients NNS N
undergoing JJ N
balloon NN 4_p
angioplasty NN 4_p
and CC 4_p
sequential JJ 4_p
intracoronary JJ 4_p
Doppler NN 4_p
measurements NNS 4_p
After IN N
successful JJ N
balloon NN N
angioplasty NN N
Patients NNS N
with IN N
severe JJ N
dissections NNS N
( ( N
n JJ N
= NNP N
128 CD N
) ) N
or CC N
without IN N
available JJ N
reference NN N
vessel NN N
CFVR NNP N
( ( N
n JJ N
= NNP N
139 CD N
) ) N
were VBD N
excluded VBN N
. . N

remaining VBG N
256 CD 3_p
patients NNS 3_p
-DOCSTART- -X- O O 6980168

stage NN 4_p
I PRP 4_p
endometrial JJ 4_p
carcinoma NN 4_p
: : N
some DT N
blood NN 4_p
lymphocyte JJ 4_p
subpopulations NNS 4_p
. . N

-DOCSTART- -X- O O 8467286

after IN 4_p
autologous JJ 4_p
marrow NN 4_p
transplantation NN 4_p
. . N

Eighteen JJ 3_p
patients NNS N
six CD 3_p
concurrent NN N
control NN N
and CC N
65 CD 3_p
historical JJ N
control NN N
patients NNS N
-DOCSTART- -X- O O 9632036

patients NNS N
hospitalized VBN N
for IN N
major JJ 4_p
depression NN 4_p
. . N

markedly RB N
or CC N
severely RB 4_p
depressed JJ 4_p
hospitalized JJ N
patients NNS N
. . N

patients NNS N
hospitalized VBN N
for IN N
major JJ 4_p
depression NN 4_p
. . N

120 CD N
patients NNS N
hospitalized VBN N
for IN N
DSM-III-R NNP N
diagnosed VBD N
major JJ N
depression NN N
( ( N
without IN N
psychosis NN N
) ) N
Patients NNS N
with IN N
dysthymia NN 4_p
in IN N
addition NN N
to TO N
major JJ 4_p
depression NN 4_p
marked VBN N
to TO N
severe VB N
major JJ 4_p
depression NN 4_p
in IN N
patients NNS N
requiring VBG N
hospitalization NN N
. . N

-DOCSTART- -X- O O 21629200

autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . 4_p

patients NNS 4_p
diagnosed VBN 4_p
with IN 4_p
an DT 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
Thirty NNP 4_p
subjects NNS 4_p
diagnosed VBD 4_p
with IN 4_p
an DT 4_p
ASD NNP 4_p
-DOCSTART- -X- O O 6354030

high-risk JJ N
patients NNS N
. . N

fat JJ 4_p
embolism NN 4_p
syndrome NN 4_p
high-risk JJ 4_p
patients NNS 4_p
with IN 4_p
long-bone JJ 4_p
fractures NNS 4_p
. . 4_p

corticosteroid- NN N
( ( N
0 CD N
of IN N
21 CD N
) ) N
and CC N
placebo-treated JJ N
patients NNS N
( ( N
9 CD N
of IN N
41 CD N
) ) N
patients NNS 4_p
at IN 4_p
high JJ 4_p
risk NN 4_p
for IN 4_p
the DT 4_p
fat JJ 4_p
embolism NN 4_p
syndrome NN 4_p
-DOCSTART- -X- O O 25488965

patients NNS N
with IN N
head NN 4_p
and CC 4_p
neck NN 4_p
cancer NN 4_p
. . N

patients NNS N
with IN N
head NN 4_p
and CC 4_p
neck NN 4_p
cancer NN 4_p
( ( N
HNC NNP 4_p
) ) N
patients NNS N
with IN N
stage NN 4_p
III NNP 4_p
or CC 4_p
IV NNP 4_p
HNC NNP 4_p
21 CD N
RTOG NNP N
HNC NNP 4_p
trials NNS N
( ( N
1997 CD N
to TO N
2002 CD N
) ) N
. . N

471 CD 3_p
patients NNS N
in IN N
RTOG NNP N
0129 CD N
( ( N
2002 CD N
to TO N
2005 CD N
) ) N
with IN N
known VBN 4_p
human JJ 4_p
papillomavirus NN 4_p
and CC 4_p
smoking NN 4_p
status NN 4_p
. . N

-DOCSTART- -X- O O 24559095

luminal NN 4_p
A NNP 4_p
breast NN 4_p
cancer NN 4_p
subgroup NN 4_p
two CD N
primary JJ N
breast NN N
cancer NN N
cohorts NNS N
( ( N
n JJ 4_p
= NN 4_p
144 CD 4_p
and CC 4_p
n JJ 4_p
= NNP 4_p
564 CD 4_p
) ) N
and CC N
mRNA JJ N
expression NN N
of IN N
YAP1 NNP N
was VBD N
evaluated VBN N
in IN N
a DT N
gene NN N
expression NN N
dataset NN N
( ( N
n JJ 4_p
= NN 4_p
1107 CD 4_p
) ) N
ER+ NNP N
( ( N
Estrogen NNP N
Receptor NNP N
α NNP N
positive JJ N
) ) N
subgroup NN N
the DT N
ER- NNP N
( ( N
Estrogen NNP N
Receptor NNP N
α NNP N
negative JJ N
) ) N
subgroup NN N
aggressive JJ N
luminal NN N
A NNP N
breast NN N
cancer NN N
subgroup NN N
-DOCSTART- -X- O O 5653418

One-trial JJ 4_p
learning VBG 4_p
with IN 4_p
control NN 4_p
of IN 4_p
item-difficulty NN 4_p
. . 4_p

-DOCSTART- -X- O O 219802

severe JJ N
persistent JJ 4_p
depressions NNS 4_p
in IN N
women NNS 2_p
. . N

severely RB 4_p
depressed JJ 4_p
, , N
inpatient JJ N
women NNS 2_p
who WP N
had VBD N
failed VBN N
to TO N
respond VB N
to TO N
various JJ N
conventional JJ N
treatments NNS N
of IN N
depression NN 4_p
. . N

23 CD 3_p
premenopausal NN N
and CC N
postmenopausal JJ N
inpatient JJ N
women NNS N
. . N

17 CD 3_p
similar JJ N
patients NNS N
. . N

women NNS 3_p
receiving VBG N
high JJ N
doses NNS N
of IN N
estrogens NNS N
. . N

-DOCSTART- -X- O O 7881024

Gastric JJ 4_p
ulcer NN 4_p
treatment NN N
( ( N
67/86 CD 3_p
) ) N
patients NNS N
receiving VBG N
6 CD N
micrograms NNS N
EGF NNP N
intravenously RB N
twice RB N
a DT N
week NN N
rat NN N
gastric JJ 4_p
ulcers NNS 4_p
-DOCSTART- -X- O O 12396317

disposition NN N
kinetics NNS N
of IN N
the DT N
hepatomegaly NN N
associated VBN N
with IN N
acute NN N
, , N
uncomplicated JJ N
, , N
Plasmodium NNP 4_p
falciparum NN 4_p
malaria NN 4_p
in IN N
children NNS 1_p
. . N

enlarged JJ 4_p
liver NN 4_p
associated VBN 4_p
with IN N
acute NN N
, , N
symptomatic JJ N
, , N
uncomplicated JJ N
, , N
Plasmodium NNP N
falciparum NN N
malaria NNS N
The DT N
subjects NNS N
, , N
131 CD 3_p
children NNS N
aged VBN N
0.6-12 CD 1_p
years NNS 1_p
who WP N
lived VBD N
in IN N
an DT N
endemic JJ N
area NN N
of IN N
Nigeria NNP N
early JJ N
and CC N
late JJ N
stages NNS N
of IN N
the DT N
resolution NN N
of IN N
the DT N
liver NN 4_p
enlargement NN 4_p
associated VBN N
with IN N
acute NN 4_p
, , 4_p
symptomatic JJ 4_p
, , 4_p
uncomplicated JJ 4_p
, , 4_p
P. NNP 4_p
falciparum NN 4_p
malaria NN 4_p
. . N

-DOCSTART- -X- O O 21694630

children NNS N
and CC N
adolescents NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . N

months NNS N
, , N
58 CD 3_p
of IN N
210 CD 3_p
families NNS 3_p
with IN N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
participating VBG N
in IN N
a DT N
larger JJR N
study NN N
of IN N
phenotypic NN N
and CC N
genotypic NN N
factors NNS N
reported VBD N
significant JJ N
concerns NNS N
about IN N
blood NN N
draws NNS N
and CC N
elected VBN N
to TO N
use VB N
the DT N
Blood NNP N
Draw NNP N
Intervention NNP N
Program NNP N
-DOCSTART- -X- O O 1878735

20 CD 3_p
patients NNS N
with IN N
leukaemia JJ 4_p
receiving VBG N
human JJ N
recombinant JJ N
granulocyte NN N
macrophage NN N
colony NN N
stimulating VBG N
factor NN N
( ( N
GM NNP N
CSF NNP N
) ) N
, , N
with IN N
20 CD 3_p
patients NNS N
receiving VBG N
placebo NN N
both DT N
patient JJ N
groups NNS N
. . N

-DOCSTART- -X- O O 6420374

parenterally-fed JJ 4_p
undernourished JJ 4_p
patients NNS 4_p
. . 4_p

Ten CD 3_p
undernourished JJ 4_p
patients NNS N
receiving VBG N
total JJ N
parenteral JJ N
nutrition NN N
and CC N
undergoing JJ N
major JJ N
intestinal JJ N
surgery NN N
major JJ N
surgery NN N
. . N

-DOCSTART- -X- O O 23964752

acute JJ 4_p
neck NN 4_p
pain NN 4_p
: : N
patients NNS N
with IN N
acute JJ 4_p
NP NNP 4_p
( ( N
n JJ N
= NNP N
72 CD 3_p
) ) N
tolerated VBN N
in IN N
the DT N
treatment NN N
that IN N
it PRP N
quickly RB N
-DOCSTART- -X- O O 2868645

supraventricular JJ 4_p
tachyarrhythmias NN 4_p
. . 4_p

patients NNS N
with IN N
supraventricular JJ 4_p
tachyarrhythmias NN 4_p
( ( N
heart NN N
rate NN N
greater JJR N
than IN N
120 CD N
bpm NN N
) ) N
Seventy-one CD 3_p
patients NNS N
-DOCSTART- -X- O O 9895371

after IN N
major JJ 4_p
abdominal JJ 4_p
surgery NN 4_p
. . N

-DOCSTART- -X- O O 6134180

41 CD 4_p
outpatients NNS N
who WP N
were VBD N
long-term JJ N
consumers NNS N
of IN N
diazepam NN N
in IN N
therapeutic JJ N
dosage NN N
were VBD N
gradually RB N
withdrawn VBN N
from IN N
the DT N
drug NN 4_p
over IN N
3 CD N
months NNS N
by IN N
stepwise NN N
reduction NN N
. . N

36 CD 4_p
patients NNS N
who WP N
completed VBD N
treatment NN N
-DOCSTART- -X- O O 15132762

adults NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . 4_p

11 CD N
adults NNS N
with IN N
autism NN N
or CC N
Aspergers NNS N
disorder VBP N
and CC N
8 CD N
age- JJ N
and CC N
gender-matched JJ N
healthy JJ N
controls NNS N
via IN N
randomized VBN N
double-blind NN N
, , N
m-CPP JJ N
and CC N
placebo JJ N
challenges NNS N
. . N

Patients NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
subjects VBZ N
with IN N
autism NN N
spectrum NN N
disorders NNS N
-DOCSTART- -X- O O 15545310

healthy JJ 4_p
subjects NNS 4_p
ingesting VBG 4_p
cephalexin NN 4_p
before IN N
and CC N
after IN N
steady-state JJ N
administration NN N
of IN N
ranitidine NN N
or CC N
omeprazole NN N
. . N

-DOCSTART- -X- O O 17453398

after IN N
hip NN 4_p
arthroplasty NN 4_p
. . N

primary JJ 4_p
total JJ 4_p
hip NN 4_p
arthroplasty NN 4_p
186 CD 3_p
patients NNS N
received VBD N
either RB N
indomethacin JJ N
3 CD N
times NNS N
daily RB N
, , N
or CC N
rofecoxib VB N
twice RB N
, , N
and CC N
1 CD N
placebo NN N
, , N
daily RB N
for IN N
7 CD N
days NNS N
. . N

12 CD 3_p
of IN N
the DT N
186 CD N
patients NNS N
included VBD N
discontinued VBN N
their PRP$ N
medication NN N
before IN N
the DT N
end NN N
of IN N
the DT N
trial NN N
due JJ N
to TO N
side VB N
effects NNS N
. . N

The DT N
remaining VBG N
174 CD 3_p
patients NNS N
were VBD N
included VBN N
in IN N
the DT N
analysis NN N
. . N

In IN N
the DT N
indomethacin NN N
group NN N
( ( N
n JJ N
= NNP N
89 CD 3_p
) ) N
, , N
77 CD N
patients NNS N
( ( N
87 CD N
% NN N
) ) N
showed VBD N
no DT N
HO NNP N
, , N
9 CD N
showed VBD N
HO NNP N
of IN N
grade NN N
1 CD N
and CC N
3 CD N
showed VBD N
HO NNP N
of IN N
grade NN N
2 CD N
according VBG N
to TO N
the DT N
Brooker NNP N
classification NN N
. . N

In IN N
the DT N
rofecoxib NN N
group NN N
( ( N
n JJ N
= NNP N
85 CD 3_p
) ) N
73 CD N
patients NNS N
( ( N
86 CD N
% NN N
) ) N
showed VBD N
no DT N
ossification NN N
, , N
9 CD N
showed VBD N
grade NN N
1 CD N
, , N
and CC N
3 CD N
showed VBD N
grade JJ N
2 CD N
. . N

-DOCSTART- -X- O O 19897177

youth NN 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . N

16 CD 3_p
male NN 2_p
youth NN 1_p
aged VBD 1_p
12 CD 1_p
to TO 1_p
19 CD 1_p
who WP N
were VBD N
diagnosed VBN N
with IN N
Autistic NNP 4_p
or CC 4_p
Asperger NNP 4_p
's POS 4_p
Disorder NNP 4_p
. . N

Participants NNS N
younger JJR 1_p
participants NNS N
aged VBD N
12 CD N
to TO N
15 CD N
young JJ N
people NNS N
diagnosed VBN N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

young JJ N
people NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

-DOCSTART- -X- O O 12193353

Neurosurgical JJ N
unit NN N
and CC N
haematology NN N
ward NN N
of IN N
university NN N
hospital NN N
. . N

100 CD 3_p
neurosurgical JJ N
patients NNS N
and CC N
40 CD 3_p
patients NNS N
with IN N
leukaemia NNS 4_p
who WP N
required VBD N
chemotherapy NN N
. . N

-DOCSTART- -X- O O 15182139

foreign-born JJ 4_p
adolescents NNS 1_p
treated VBN N
for IN N
latent JJ 4_p
tuberculosis NN 4_p
infection NN 4_p
in IN N
Los NNP N
Angeles NNP N
. . N

Two CD N
health NN N
clinics NNS N
in IN N
Los NNP N
Angeles NNP N
County NNP N
, , N
California NNP N
. . N

foreign-born JJ 4_p
adolescents NNS 1_p
treated VBN N
for IN N
latent JJ 4_p
tuberculosis NN 4_p
infection NN 4_p
( ( 4_p
LTBI NNP 4_p
) ) 4_p
. . N

A DT N
total NN N
of IN N
766 CD 3_p
low-income JJ 4_p
adolescents NNS 1_p
( ( N
79 CD N
% NN N
participation NN N
rate NN N
) ) N
, , N
including VBG N
610 CD 3_p
foreign-born JJ 4_p
, , N
were VBD N
recruited VBN N
. . N

Foreign-born JJ 4_p
adolescents NNS 1_p
foreign-born JJ 4_p
adolescents NNS 1_p
. . N

-DOCSTART- -X- O O 19282350

metastatic JJ N
colorectal JJ 4_p
cancer NN 4_p
. . N

patients NNS 4_p
with IN 4_p
epidermal JJ 4_p
growth NN 4_p
factor NN 4_p
receptor-expressing NN 4_p
, , 4_p
metastatic JJ 4_p
colorectal NN 4_p
carcinoma NN 4_p
with IN 4_p
disease JJ 4_p
progression NN 4_p
on IN 4_p
or CC 4_p
following VBG 4_p
fluoropyrimidine- JJ 4_p
, , 4_p
oxaliplatin- JJ 4_p
, , 4_p
and CC 4_p
irinotecan-containing JJ 4_p
chemotherapy NN 4_p
regimens NNS 4_p
. . N

patients NNS N
with IN N
metastatic JJ 4_p
colorectal JJ 4_p
cancer NN 4_p
. . N

Patients NNS N
receiving VBG N
panitumumab NN N
patients NNS N
receiving VBG N
bevacizumab NN N
and CC N
chemotherapy NN N
alone RB N
. . N

metastatic JJ N
colorectal NN 4_p
cancer NN 4_p
-DOCSTART- -X- O O 18845806

those DT 4_p
with IN 4_p
recent JJ 4_p
ischemic JJ 4_p
stroke NN 4_p
: : 4_p
50 CD N
patients NNS N
with IN N
acute JJ N
ischemic JJ N
stroke NN N
( ( N
17 CD N
, , N
17 CD N
, , N
and CC N
16 CD N
in IN N
the DT N
high JJ N
, , N
low JJ N
, , N
and CC N
placebo NN N
groups NNS N
, , N
respectively RB N
) ) N
Mean NNP N
( ( N
+/-SD NNP N
) ) N
age NN N
was VBD N
70 CD N
( ( N
+/-13 JJ N
) ) N
years NNS N
. . N

-DOCSTART- -X- O O 23477890

locally RB 4_p
advanced JJ 4_p
non-small JJ 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
: : 4_p
Patients NNPS 4_p
with IN 4_p
stages NNS 4_p
II NNP 4_p
and CC 4_p
IIIA/B NNP 4_p
non-small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
RESULTS VB N
243 CD N
patients NNS N
( ( N
pts NNS N
) ) N
were VBD N
enrolled VBN N
; : N
120 CD N
received VBD N
AM NNP N
, , N
123 CD N
received VBD N
no-AM JJ N
. . N

Two CD N
pts NNS N
on IN N
each DT N
arm NN N
were VBD N
found VBN N
ineligible JJ N
. . N

Overall JJ N
, , N
85 CD N
% NN N
of IN N
patients NNS N
were VBD N
≤70 JJ N
years NNS N
; : N
75 CD N
% NN N
had VBD N
a DT N
KPS NNP N
≥90 NNP N
. . N

34 CD N
% NN N
had VBD N
squamous JJ N
histology NN N
-DOCSTART- -X- O O 21030056

heart NN 4_p
of IN 4_p
broiler NN 4_p
chickens NNS 4_p
with IN 4_p
T NNP 4_p
( ( 4_p
3 CD 4_p
) ) 4_p
-induced VBD 4_p
pulmonary JJ 4_p
hypertension NN 4_p
. . N

broiler NN 4_p
chickens NNS 4_p
with IN 4_p
developmental JJ 4_p
pulmonary JJ 4_p
hypertension NN 4_p
. . N

-DOCSTART- -X- O O 9351400

LDL NNP N
oxidation NN N
. . N

atherogenesis NN N
. . N

healthy JJ N
persons NNS N
79 CD N
healthy JJ N
subjects NNS N
. . N

-DOCSTART- -X- O O 16382035

subarachnoid NN 4_p
and CC 4_p
intraventricular JJ 4_p
cysticercosis NN 4_p
. . N

Thirty-six JJ 3_p
patients NNS N
with IN N
subarachnoid JJ 4_p
and CC 4_p
intraventricular JJ 4_p
cysticercosis NN 4_p
-DOCSTART- -X- O O 8960488

in IN 1_p
children NNS 1_p
. . N

patients NNS 4_p
undergoing VBG 4_p
tooth DT 4_p
extraction NN 4_p
735 CD 3_p
anesthetized JJ N
children NNS 1_p
aged VBN 1_p
2-16 CD 1_p
years NNS 1_p
. . N

-DOCSTART- -X- O O 25102328

Patients NNS 4_p
with IN 4_p
schizophrenia JJ 4_p
Women VB 2_p
with IN N
schizophrenia NN 4_p
24 CD 3_p
overweight JJ 3_p
women NNS 2_p
with IN N
a DT N
diagnosis NN N
of IN N
schizophrenia NN 4_p
or CC 4_p
schizoaffective JJ 4_p
disorder NN 4_p
-DOCSTART- -X- O O 418433

humans NNS N
human JJ N
subjects NNS N
-DOCSTART- -X- O O 20102495

racing VBG 4_p
Alaskan NNP 4_p
sled VBD 4_p
dogs NNS 4_p
. . N

Randomized VBN N
placebo-controlled JJ N
study NN N
, , N
36 CD 3_p
sled VBD N
dogs NNS N
( ( N
3-8 CD N
years NNS N
) ) N
; : N
Randomized VBN N
positive-control NN N
study NN N
, , N
52 CD 3_p
sled VBD N
dogs NNS N
( ( N
2-8 CD N
years NNS N
) ) N
. . N

dogs NNS N
dogs NNS N
exercising VBG N
and CC N
racing VBG N
Alaskan NNP N
sled VBD N
dogs NNS N
. . N

-DOCSTART- -X- O O 21864416

breast NN 4_p
cancer NN 4_p
patients NNS 4_p
. . 4_p

cancer NN N
patients NNS N
receiving VBG N
chemotherapy NN N
and/or NN N
radiotherapy NN N
fifty-eight JJ 4_p
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
who WP 4_p
received VBD 4_p
chemotherapy NN 4_p
or CC 4_p
radiotherapy NN 4_p
were VBD 4_p
enrolled VBN 4_p
. . 4_p

-DOCSTART- -X- O O 1854617

childhood NN 1_p
acute NN 4_p
lymphoblastic JJ 4_p
leukaemia NN 4_p
. . N

127 CD 3_p
children NNS 1_p
undergoing JJ N
treatment NN N
for IN N
childhood NN N
non-T JJ 4_p
acute JJ 4_p
lymphoblastic JJ 4_p
leukaemia NN 4_p
( ( 4_p
ALL NNP 4_p
) ) 4_p
childhood NN 1_p
ALL NNP 4_p
. . N

-DOCSTART- -X- O O 11420161

CABG NNP 4_p
patients NNS N
. . N

CABG NNP 4_p
patients NNS N
Forty-three JJ 3_p
CABG NNP 4_p
patients NNS N
-DOCSTART- -X- O O 22039290

patients NNS N
with IN N
excessive JJ 4_p
sleepiness NN 4_p
associated VBN N
with IN N
shift NN N
work NN N
disorder NN N
: : N
patients NNS N
with IN N
excessive JJ 4_p
sleepiness NN 4_p
associated VBN N
with IN N
shift NN 4_p
work NN 4_p
disorder NN 4_p
( ( N
SWD NNP N
) ) N
. . N

randomized NNS N
463 CD 3_p
patients NNS N
with IN N
SWD NNP 4_p
, , N
1 CD N
with IN N
armodafinil JJ N
150 CD N
mg/d NN N
and CC N
1 CD N
with IN N
modafinil NN N
200 CD N
mg/d NN N
( ( N
both DT N
administered VBN N
around IN N
2200 CD N
h NN N
before IN N
night NN N
shifts NNS N
) ) N
-DOCSTART- -X- O O 3300426

nausea NN 4_p
and CC 4_p
vomiting NN 4_p
after IN 4_p
isoflurane NN 4_p
anesthesia NN 4_p
. . N

110 CD 3_p
patients NNS 3_p
undergoing JJ 4_p
elective JJ 4_p
abdominal JJ 4_p
hysterectomy NN 4_p
were VBD 4_p
anesthetized VBN 4_p
in IN 4_p
random JJ 4_p
order NN 4_p
all DT 4_p
patients NNS 4_p
-DOCSTART- -X- O O 8035029

AIDS NNP 4_p
: : 4_p
10 CD N
patients NNS N
with IN N
AIDS NNP N
and CC N
cryptosporidiosis NN N
-DOCSTART- -X- O O 1515255

patients NNS N
with IN N
relapsed JJ N
multiple JJ N
myeloma NN N
. . N

59 CD 3_p
patients NNS N
with IN N
relapsed JJ N
multiple JJ N
myeloma NN N
control NN N
and CC N
interferon NN N
patients NNS N
. . N

-DOCSTART- -X- O O 20369616

patients NNS N
with IN N
chronic JJ 4_p
hepatic JJ 4_p
disorders NNS 4_p
] VBP N
494 CD 4_p
patients NNS 4_p
with IN N
chronic JJ 4_p
hepatitis NN 4_p
B NNP 4_p
and CC 4_p
C. NNP 4_p
staying VBG N
in IN N
7 CD 4_p
clinics NNS 4_p
-DOCSTART- -X- O O 20605942

parent NN 4_p
young JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
. . 1_p

parent NN N
32 CD N
young JJ N
children NNS N
with IN N
a DT N
confirmed JJ N
diagnosis NN N
of IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
. . N

children NNS N
with IN N
ASD NNP N
-DOCSTART- -X- O O 6667628

24 CD 3_p
elderly JJ 1_p
patients NNS N
requiring VBG 4_p
chronic JJ 4_p
diuretic JJ 4_p
therapy NN 4_p
-DOCSTART- -X- O O 3532353

gastrointestinal JJ N
cancer NN N
: : N
Southeastern NNP N
Cancer NNP N
Study NNP N
Group NNP N
experience NN N
, , N
1979 CD N
to TO N
1983 CD N
. . N

gastrointestinal JJ N
cancer NN N
from IN N
1979 CD N
to TO N
1983 CD N
at IN N
30 CD N
member NN N
institutions NNS N
of IN N
the DT N
Southeastern NNP N
Cancer NNP N
Study NNP N
Group NNP N
( ( N
SECSG NNP N
) ) N
. . N

1,087 CD N
patients NNS N
. . N

America NNP N
. . N

-DOCSTART- -X- O O 8921775

early JJ 4_p
preintrusive JJ 4_p
atherosclerosis NN 4_p
. . 4_p

nonsmoking VBG 4_p
40- JJ 1_p
to TO 1_p
59-year-old JJ 1_p
men NNS 2_p
with IN N
previous JJ 4_p
coronary JJ 4_p
artery NN 4_p
bypass NN 4_p
graft NN 4_p
surgery NN 4_p
146 CD 3_p
subjects NNS N
subjects NNS N
not RB N
treated VBN N
with IN N
lipid-lowering JJ N
drugs NNS N
-DOCSTART- -X- O O 25623276

280 CD 3_p
patients NNS 3_p
undergoing JJ N
colorectal JJ 4_p
surgery NN 4_p
. . N

patients NNS N
Patients NNS N
-DOCSTART- -X- O O 24315548

hemodialysis NN 4_p
arteriovenous JJ 4_p
fistula NN 4_p
stenoses VBZ 4_p
resistant JJ 4_p
to TO 4_p
conventional JJ 4_p
balloon NN 4_p
angioplasty NN 4_p
. . 4_p

hemodialysis NN 4_p
autogenous JJ 4_p
fistula NN 4_p
stenoses VBZ 4_p
resistant JJ 4_p
to TO 4_p
conventional JJ 4_p
percutaneous JJ 4_p
transluminal JJ 4_p
angioplasty NN 4_p
( ( 4_p
PTA NNP 4_p
) ) 4_p
. . N

patients NNS N
with IN N
dysfunctional JJ 4_p
, , 4_p
stenotic JJ 4_p
hemodialysis NN 4_p
arteriovenous JJ 4_p
fistulas NNS 4_p
( ( 4_p
AVFs NNP 4_p
) ) 4_p
total NN N
of IN N
516 CD 3_p
patients NNS N
consented VBN N
to TO N
participate VB N
in IN N
the DT N
study NN N
from IN N
October NNP N
2008 CD N
to TO N
September NNP N
2011 CD N
, , N
85 CD N
% NN N
of IN N
whom WP N
( ( N
n JJ N
= NNP N
439 CD 3_p
) ) N
had VBD N
technically RB N
successful JJ N
conventional JJ N
PTA NNP N
. . N

71 CD 3_p
patients NNS N
( ( N
mean JJ 1_p
age NN 1_p
, , 1_p
60 CD 1_p
y NN 1_p
; : N
49 CD 3_p
men NNS N
) ) N
with IN N
suboptimal JJ N
PTA NNP N
results NNS N
-DOCSTART- -X- O O 2036277

patients NNS N
with IN N
postoperative JJ 4_p
dental NN 4_p
pain NN 4_p
. . N

One CD 3_p
hundred CD 3_p
and CC 3_p
fifty JJ 3_p
fit NN N
, , N
young JJ 1_p
adults NNS 1_p
participated VBD N
Patients NNS N
suffering VBG N
from IN N
moderate JJ 4_p
to TO 4_p
severe VB 4_p
pain NN 4_p
following VBG N
surgery NN N
were VBD N
monitored VBN N
for IN N
up RB N
to TO N
8 CD N
hours NNS N
. . N

-DOCSTART- -X- O O 20237484

retinopathy NN 4_p
of IN 4_p
prematurity NN 4_p
( ( 4_p
ROP NNP 4_p
) ) 4_p
40 CD 3_p
preterm JJ N
infants NNS 1_p
undergoing VBG N
ROP NNP 4_p
screening NN N
. . N

neonatal JJ N
intensive JJ N
units NNS N
for IN N
infants NNS N
undergoing VBG N
routine JJ N
ROP NNP N
screening VBG N
exams NNS N
. . N

RESULT NNP N
Forty NNP N
preterm NN N
infants NNS N
were VBD N
included VBN N
in IN N
the DT N
study NN N
screening VBG N
in IN N
preterm JJ N
-DOCSTART- -X- O O 17971587

5-year JJ N
failure-free JJ N
survival NN N
in IN N
group NN N
III NNP N
rhabdomyosarcoma NN N
: : N
osteosarcoma NN N
and CC N
Ewing NNP N
's POS N
sarcoma NN N
. . N

patients NNS N
with IN N
group NN N
III NNP N
rhabdomyosarcoma NN N
444 CD N
group NN N
III NNP N
patients NNS N
who WP N
received VBD N
induction NN N
therapy NN N
, , N
had VBD N
response NN N
assessed VBN N
at IN N
week NN N
8 CD N
by IN N
anatomic JJ N
imaging NN N
, , N
and CC N
continued VBD N
with IN N
protocol NN N
therapy NN N
. . N

group NN N
III NNP N
patients NNS N
-DOCSTART- -X- O O 16601648

children NNS 1_p
with IN N
autism NN 4_p
. . N

children NNS 1_p
with IN N
autistic JJ N
disorder NN N
who WP N
have VBP N
serious JJ N
behavior NN N
problems NNS N
Forty-eight JJ 3_p
children NNS 1_p
( ( 1_p
5 CD 1_p
years NNS 1_p
to TO 1_p
16 CD 1_p
years NNS 1_p
, , 1_p
5 CD 1_p
months NNS 1_p
) ) 1_p
who WP N
showed VBD N
behavioral JJ N
improvement NN N
during IN N
acute JJ N
treatment NN N
with IN N
risperidone NN N
children NNS N
with IN N
autistic JJ N
disorder NN N
-DOCSTART- -X- O O 3531514

patients NNS N
with IN N
hepatitis NN 4_p
B NNP 4_p
chronic NN 4_p
liver NN 4_p
disease NN 4_p
. . N

26 CD 3_p
patients NNS 3_p
with IN N
chronic JJ N
hepatitis NN N
B NNP N
liver NN N
disease NN N
. . N

-DOCSTART- -X- O O 10592853

841 CD 3_p
women NNS 2_p
at IN N
risk NN 4_p
for IN 4_p
pregnancy NN 4_p
. . N

subset NN N
of IN N
42 CD 3_p
women NNS 3_p
at IN N
one CD N
site NN N
underwent JJ N
colposcopy NN 4_p
. . N

women NNS N
-DOCSTART- -X- O O 18547294

tracheal JJ 4_p
intubation NN 4_p
. . N

Laryngoscopy NNP N
and CC N
tracheal JJ N
intubation NN N
laryngoscopy NN 4_p
and CC N
tracheal JJ 4_p
intubation NN 4_p
. . N

Forty-three JJ 3_p
female JJ 2_p
patients NNS N
tracheal JJ N
intubation NN N
-DOCSTART- -X- O O 2564725

atrial JJ 4_p
fibrillation NN 4_p
or CC N
atrial JJ N
flutter NN N
. . N

45 CD 3_p
patients NNS N
with IN N
atrial JJ N
fibrillation NN N
or CC N
atrial JJ N
flutter NN N
, , N
in IN N
a DT N
randomized JJ N
, , N
parallel JJ N
, , N
open-label JJ N
study NN N
. . N

Patients NNS N
with IN N
either DT N
new JJ N
onset NN N
( ( N
less JJR N
than IN N
48 CD N
hours NNS N
, , N
n JJ N
= NNP N
31 CD 3_p
) ) N
or CC N
old JJ N
onset NN N
( ( N
greater JJR N
than IN N
48 CD N
hours NNS N
, , N
n JJ N
= NNP N
14 CD 3_p
) ) N
of IN N
atrial JJ N
fibrillation NN N
or CC N
flutter NN N
with IN N
rapid JJ N
ventricular JJ N
rate NN N
were VBD N
stratified VBN N
-DOCSTART- -X- O O 10971538

snoring NN N
: : N
Patients NNS N
who WP N
had VBD N
been VBN N
referred VBN N
for IN N
investigation NN N
and CC N
treatment NN N
of IN N
their PRP$ N
snoring NN 4_p
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
either DT N
UPPP NNP N
or CC N
LAUP NNP N
. . N

Forty-seven JJ 3_p
patients NNS N
with IN N
confirmed JJ N
palatal JJ N
flutter NN N
had VBD N
surgery NN N
and CC N
all DT N
of IN N
them PRP N
had VBD N
a DT N
preoperative JJ N
and CC N
postoperative JJ N
objective JJ N
assessment NN N
of IN N
their PRP$ N
snoring NN N
loudness NN N
and CC N
duration NN N
in IN N
the DT N
home NN N
. . N

-DOCSTART- -X- O O 22001361

melanoma NN 4_p
families NNS N
families NNS N
families NNS N
affected VBN N
by IN N
melanoma NN 4_p
three CD 3_p
family NN 3_p
members NNS 3_p
per IN 3_p
family NN 3_p
for IN N
assessment NN N
- : N
the DT N
melanoma NN N
case NN N
, , N
a DT N
first-degree JJ N
relative NN N
( ( N
FDR NNP N
) ) N
, , N
and CC N
a DT N
relative NN N
who WP N
is VBZ N
a DT N
parent NN N
of IN N
a DT N
child JJ N
age NN N
18 CD 1_p
or CC 1_p
younger JJR 1_p
. . N

1380 CD 3_p
families NNS N
approached VBD N
, , N
313 CD 3_p
were VBD N
enrolled VBN N
, , N
263 CD N
were VBD N
excluded VBN N
because IN N
we PRP N
could MD N
not RB N
find VB N
or CC N
contact VB N
a DT N
family NN N
member NN N
( ( N
FDR CD N
or CC N
parent NN N
) ) N
, , N
331 CD N
did VBD N
not RB N
have VB N
eligible JJ N
family NN N
members NNS N
, , N
and CC N
473 CD N
refused VBD N
. . N

-DOCSTART- -X- O O 23611569

healthy JJ N
participants NNS N
: : N
major JJ N
depressive JJ N
disorder NN N
( ( N
MDD NNP N
) ) N
in IN N
adults NNS N
. . N

healthy JJ 4_p
volunteers NNS 4_p
. . 4_p

healthy JJ N
subjects NNS N
healthy JJ 4_p
adult NN 4_p
participants NNS 4_p
. . 4_p

-DOCSTART- -X- O O 15088136

patients NNS N
with IN N
common JJ N
cancers NNS 4_p
involving VBG N
bone NN N
receiving VBG N
intravenous JJ N
bisphosphonate NN N
therapy NN N
Enrolled NNP N
in IN N
the DT N
study NN N
were VBD N
184 CD 3_p
patients NNS N
12 CD 3_p
% NN 3_p
of IN N
eligible JJ N
patients NNS N
( ( N
16/138 CD N
) ) N
Cancer NNP 4_p
patients NNS N
-DOCSTART- -X- O O 16879331

occlusal JJ N
surfaces NNS N
Thirty NNP 3_p
premolars NNS N
cavities NNS N
-DOCSTART- -X- O O 17395055

patients NNS N
and CC N
in IN N
dogs NNS N
with IN N
experimentally RB N
induced JJ N
heart NN N
failure NN N
( ( N
HF NNP N
) ) N
both DT N
patients NNS N
and CC N
dogs NNS N
with IN N
chronic JJ N
HF NNP N
. . N

Six NNP N
dogs NNS N
with IN N
microembolizations-induced JJ N
HF NNP N
and CC N
9 CD N
HF NNP N
patients NNS N
underwent JJ N
CCM NNP N
leads NNS N
and CC N
generator NN N
( ( N
OPTIMIZER NNP N
II NNP N
) ) N
implantation NN N
. . N

-DOCSTART- -X- O O 11957440

All NNP N
152 CD 3_p
male NN 2_p
employees NNS 4_p
in IN 4_p
a DT 4_p
computer NN 4_p
company NN 4_p
, , N
25-45 JJ 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
, , N
were VBD N
invited VBN N
to TO N
participate VB N
Eighty-five JJ 3_p
( ( N
56 CD N
% NN N
) ) N
men NNS 2_p
participated VBD N
. . N

-DOCSTART- -X- O O 24083350

626 CD 3_p
patients NNS N
with IN N
reflux JJ 4_p
esophagitis NN 4_p
-DOCSTART- -X- O O 15377466

patients NNS 4_p
with IN 4_p
severe JJ 4_p
aplastic JJ 4_p
anemia NN 4_p
( ( 4_p
SAA NNP 4_p
) ) 4_p
treated VBD 4_p
with IN 4_p
anti-lymphocyte JJ 4_p
globulin NN 4_p
( ( 4_p
ALG NNP 4_p
) ) 4_p
, , 4_p
cyclosporin NN 4_p
( ( 4_p
CyA NNP 4_p
) ) 4_p
and CC 4_p
granulocyte JJ 4_p
colony-stimulating JJ 4_p
factor NN 4_p
( ( 4_p
G-CSF NNP 4_p
) ) 4_p
multicenter NN N
prospective JJ N
trial NN N
in IN N
77 CD 3_p
SAA NNP N
patients NNS N
treated VBD N
with IN N
horse NN N
ALG NNP N
( ( N
15 CD N
mg/kg/day RB N
day1-5 NN N
) ) N
and CC N
CyA NNP N
( ( N
5 CD N
mg/kg/day RB N
day NN N
1-180 JJ N
) ) N
. . N

Patients NNS N
were VBD N
randomized VBN N
Thirteen JJ N
patients NNS N
( ( N
5 CD N
in IN N
group NN N
A NNP N
and CC N
8 CD N
in IN N
group NN N
B NNP N
) ) N
patients NNS N
with IN N
SAA NNP N
receiving VBG N
ALG NNP N
and CC N
CyA NNP N
. . N

-DOCSTART- -X- O O 20460711

flow-mediated JJ 4_p
vasodilatation NN 4_p
flow-mediated JJ 4_p
vasodilatation NN 4_p
in IN 4_p
humans NNS 4_p
. . 4_p

postmenopausal JJ N
women NNS 2_p
vinegar NN N
( ( N
acetic JJ N
acid NN N
) ) N
administered VBD N
group NN N
-DOCSTART- -X- O O 24215858

Menopausal NNP N
menopause-related JJ 4_p
women NNS N
with IN N
vasomotor NN 4_p
symptoms NNS 4_p
. . N

. . N

Peri- NN N
and CC N
postmenopausal JJ N
women NNS N
, , N
40-62 JJ N
years NNS N
old JJ N
RESULTS NNP N
Among IN N
355 CD N
randomly NNS N
assigned VBN N
women NNS N
who WP N
average VBP N
age NN N
was VBD N
54.7 CD N
years NNS N
, , N
338 CD N
women NNS N
( ( N
95 CD N
% NN N
) ) N
completed VBD N
12-week JJ N
assessments NNS N
among IN N
healthy JJ N
sedentary JJ N
menopausal NN N
women NNS N
-DOCSTART- -X- O O 8856425

population NN 4_p
based VBN 4_p
Swedish JJ 4_p
sample NN 4_p
. . 4_p

postpartum NN N
41 CD N
women NNS N
identified VBN N
as IN N
depressed JJ N
-DOCSTART- -X- O O 15220594

Untreated VBN 4_p
silicone NN 4_p
breast NN 4_p
implant JJ 4_p
rupture NN 4_p
. . 4_p

271 CD 3_p
women NNS 2_p
who WP N
were VBD N
randomly RB N
chosen VBN N
from IN N
a DT N
larger JJR N
cohort NN N
of IN N
women NNS 2_p
having VBG 4_p
cosmetic JJ 4_p
breast NN 4_p
implants NNS 4_p
for IN 4_p
a DT 4_p
median JJ 4_p
period NN 4_p
of IN 4_p
12 CD 4_p
years NNS 4_p
( ( 1_p
range NN 1_p
, , 1_p
3 CD 1_p
to TO 1_p
25 CD 1_p
years NNS 1_p
) ) N
. . N

64 CD 3_p
women NNS 2_p
who WP N
had VBD N
at IN N
least JJS N
one CD N
ruptured VBN N
implant NN N
at IN N
the DT N
first JJ N
magnetic JJ N
resonance NN N
imaging VBG N
examination NN N
-DOCSTART- -X- O O 15473502

men NNS 4_p
with IN 4_p
localized JJ 4_p
prostate NN 4_p
cancer NN 4_p
. . 4_p

A NNP N
total NN N
of IN N
101 CD 3_p
patients NNS N
radical JJ N
external-beam NN N
radiation NN N
therapy NN N
( ( N
RT NNP N
) ) N
for IN N
localized JJ N
cancer NN N
of IN N
the DT N
prostate NN N
. . N

-DOCSTART- -X- O O 2486557

surgery NN N
in IN N
patients NNS N
with IN N
angina NN 4_p
. . N

patients NNS N
undergoing VBG N
coronary JJ 4_p
arteriography NN 4_p
at IN N
the DT N
fourteen JJ N
participating VBG N
centres NNS N
Patients NNS N
with IN N
arteriographically RB 4_p
proven JJ 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
are VBP N
considered VBN N
for IN N
the DT N
trial NN N
The DT N
trial NN N
will MD N
recruit VB N
at IN N
least JJS N
1000 CD 3_p
patients NNS N
who WP N
will MD N
be VB N
followed VBN N
for IN N
five CD N
years NNS N
. . N

-DOCSTART- -X- O O 17321529

postpartum NN 4_p
trial NN N
conducted VBN N
in IN N
a DT N
tertiary JJ N
maternity NN N
hospital NN N
622 CD 3_p
women NNS 2_p
-DOCSTART- -X- O O 7997386

patients NNS N
with IN N
left JJ 4_p
ventricular JJ 4_p
dysfunction NN 4_p
. . N

Urban NNP N
teaching VBG N
hospital JJ N
clinical JJ N
research NN N
center NN N
. . N

Individuals NNS N
with IN N
New NNP 4_p
York NNP 4_p
Heart NNP 4_p
Association NNP 4_p
functional JJ 4_p
class NN 4_p
II-III NNP 4_p
heart NN 4_p
failure NN 4_p
( ( 4_p
mild JJ 4_p
to TO 4_p
moderate VB 4_p
) ) N
. . N

patients NNS N
with IN N
mild JJ N
to TO N
moderate VB N
heart NN 4_p
failure NN 4_p
. . N

-DOCSTART- -X- O O 20484550

breast NN 4_p
fibroadenomas NN 4_p
in IN 4_p
Chinese JJ 4_p
women NNS 4_p
. . 4_p

Participants NNS N
were VBD N
women NNS N
in IN N
a DT N
breast NN N
self-examination NN N
trial NN N
in IN N
Shanghai NNP N
, , N
China NNP N
who WP N
were VBD N
diagnosed VBN N
with IN N
fibroadenomas NN N
( ( N
n JJ N
= NNP N
258 CD N
) ) N
and CC N
1035 CD N
controls NNS N
. . N

-DOCSTART- -X- O O 19278832

skeletally RB 4_p
matured VBN 4_p
non-syndromal JJ 4_p
patients NNS 4_p
with IN 4_p
transverse JJ 4_p
maxillary JJ 4_p
hypoplasia NN 4_p
. . 4_p

23 CD 3_p
bone-borne JJ N
and CC N
19 CD 3_p
tooth-borne JJ N
patients NNS N
were VBD N
analyzed VBN N
. . N

-DOCSTART- -X- O O 24564346

children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
( ( 4_p
ASDs NNP 4_p
) ) 4_p
. . N

children NNS 1_p
with IN N
ASDs NNP 4_p
subjects NNS N
with IN N
ASD NNP 4_p
. . N

-DOCSTART- -X- O O 24898574

tinnitus NN 4_p
: : N
tinnitus NN 4_p
patients NNS N
. . N

116 CD 3_p
patients NNS N
with IN N
chronic JJ N
tinnitus NN 4_p
-DOCSTART- -X- O O 15165532

nasal JJ N
CPAP NNP N
. . N

( ( N
CPAP NNP N
) ) N
therapy NN N
Fifteen NNP N
patients NNS N
with IN N
mouth JJ N
leak JJ N
complaining NN N
of IN N
mouth NN N
dryness NN N
and CC N
nasal JJ N
obstruction NN N
six CD N
patients NNS N
. . N

-DOCSTART- -X- O O 10632537

patients NNS 4_p
with IN 4_p
hepatocellular JJ 4_p
carcinoma NN 4_p
Group NNP 3_p
A NNP 3_p
( ( 3_p
19 CD 3_p
patients NNS 3_p
) ) 4_p
group NN 3_p
B NNP 3_p
( ( 3_p
18 CD 3_p
patients NNS 3_p
) ) 3_p
-DOCSTART- -X- O O 25898050

behavioral JJ 4_p
problems NNS 4_p
in IN N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
: : N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . N

children NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
and CC N
disruptive JJ 4_p
behavior NN 4_p
. . N

parent NN 1_p
training NN N
( ( N
n JJ 3_p
= NNP 3_p
89 CD 3_p
) ) 3_p
to TO N
parent VB 1_p
education NN 3_p
( ( 3_p
n JJ 3_p
= NNP 3_p
91 CD 3_p
) ) N
at IN N
6 CD N
centers NNS N
( ( N
Emory NNP N
University NNP N
, , N
Indiana NNP N
University NNP N
, , N
Ohio NNP N
State NNP N
University NNP N
, , N
University NNP N
of IN N
Pittsburgh NNP N
, , N
University NNP N
of IN N
Rochester NNP N
, , N
Yale NNP N
University NNP N
) ) N
. . N

We PRP N
screened VBD N
267 CD 3_p
children NNS 3_p
; : N
180 CD 3_p
children NNS 3_p
( ( N
aged VBN 1_p
3-7 CD 1_p
years NNS 1_p
) ) N
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
and CC N
disruptive JJ N
behaviors NNS N
were VBD N
randomly RB N
assigned VBN N
( ( N
86 CD N
% NN N
white JJ N
, , N
88 CD N
% NN N
male NN N
) ) N
between IN N
September NNP N
2010 CD N
and CC N
February NNP N
CONCLUSIONS NNP N
AND CC N
RELEVANCE NNP N
For IN N
children NNS 1_p
with IN N
-DOCSTART- -X- O O 25048751

cervical JJ 4_p
ripening NN 4_p
in IN 4_p
stillbirth NN 4_p
with IN 4_p
a DT 4_p
scarred JJ 4_p
uterus NN 4_p
: : 4_p
pregnant JJ 4_p
women NNS 2_p
with IN N
stillbirth NN N
, , N
unfavorable JJ N
cervix NN 4_p
and CC 4_p
scarred VBD 4_p
uterus NN 4_p
. . N

El NNP N
Minia NNP N
University NNP N
Hospital NNP N
, , N
El NNP N
Minia NNP N
, , N
Egypt NNP N
. . N

Two-hundred NNP 3_p
pregnant JJ 4_p
women NNS 2_p
with IN 4_p
stillbirth NN 4_p
, , 4_p
unfavorable JJ 4_p
cervix NN 4_p
and CC 4_p
scarred VBD 4_p
uterus NNS 4_p
pregnant JJ N
women NNS N
with IN N
stillbirth NN N
, , N
unfavorable JJ N
cervix NN N
and CC N
scarred VBD N
uterus NN N
. . N

-DOCSTART- -X- O O 16981901

healthy JJ 4_p
subjects NNS N
. . N

18 CD 3_p
healthy JJ N
male NN 2_p
subjects NNS N
healthy JJ 4_p
subjects NNS N
. . N

-DOCSTART- -X- O O 21222024

adding VBG N
highly RB N
dissimilar JJ N
fillers NNS N
increases VBZ N
confidence NN N
lineup JJ N
identifications NNS N
. . N

witness NN N
's POS N
identified VBN N
( ( N
non-dud JJ N
) ) N
lineup NN N
member NN N
Four CD N
studies NNS N
( ( N
N NNP N
witnesses NNS N
' POS N
dissimilar JJ N
lineup NN N
members NNS N
witnesses NNS N
' POS N
-DOCSTART- -X- O O 15193471

postoperative JJ N
disease NN N
management NN N
of IN N
moderate JJ 4_p
to TO 4_p
severe JJ 4_p
endometriosis NN 4_p
. . N

patients NNS N
treated VBN N
with IN N
triptorelin NN N
every DT N
6 CD N
weeks NNS N
. . N

Kwong NNP N
Wah NNP N
Hospital NNP N
, , N
a DT N
large JJ N
public JJ N
hospital NN N
in IN N
an DT N
urban JJ N
location NN N
( ( N
Hong NNP N
Kong NNP N
) ) N
. . N

Forty NNP 3_p
patients NNS N
after IN N
their PRP$ N
first JJ N
conservative JJ N
operation NN N
for IN N
endometriosis NN N
, , N
with IN N
surgical JJ N
confirmation NN N
of IN N
revised VBN N
AFS NNP 4_p
stage NN 4_p
III NNP 4_p
or CC 4_p
IV NNP 4_p
endometriosis NN 4_p
. . N

-DOCSTART- -X- O O 8458681

patients NNS 4_p
with IN 4_p
essential JJ 4_p
hypertension NN 4_p
: : 4_p
46 CD N
patients NNS N
with IN N
mild JJ N
to TO N
moderate VB N
essential JJ N
hypertension NN N
. . N

-DOCSTART- -X- O O 10361648

coronary JJ 4_p
artery NN 4_p
bypass NN 4_p
graft NN 4_p
( ( 4_p
CABG NNP 4_p
) ) 4_p
patients NNS 4_p
Two CD 3_p
hundred VBD 3_p
sixteen JJ 3_p
male NN 2_p
and CC N
female JJ 2_p
CABG NNP N
patients NNS N
-DOCSTART- -X- O O 9818888

migraine JJ 4_p
Forty-two JJ 3_p
patients NNS N
with IN N
migraine NN 4_p
without IN 4_p
aura JJ 4_p
underwent NN N
the DT N
test NN N
before IN N
and CC N
2 CD N
months NNS N
after IN N
antimigraine JJ N
therapy NN N
. . N

-DOCSTART- -X- O O 18721764

graft-versus-host JJ 4_p
disease NN 4_p
( ( 4_p
GVHD NNP 4_p
) ) 4_p
after IN 4_p
related VBN 4_p
donor NN 4_p
allogeneic NN 4_p
hematopoietic JJ 4_p
cell NN 4_p
transplantation NN 4_p
( ( 4_p
HCT NNP 4_p
) ) 4_p
. . 4_p

study NN N
conducted VBN N
from IN N
2000 CD N
to TO N
2003 CD N
of IN N
palifermin NN N
, , N
a DT N
recombinant JJ N
human JJ N
keratinocyte NN N
growth NN N
factor NN N
, , N
dosed VBN N
from IN N
240 CD N
microg/kg NNS N
to TO N
720 CD N
microg/kg NN N
, , N
in IN N
100 CD N
allogeneic JJ 4_p
hematopoietic JJ 4_p
stem NN 4_p
cell NN 4_p
transplantation NN 4_p
( ( 4_p
HCT NNP 4_p
) ) 4_p
recipients NNS N
. . N

allogeneic VB 4_p
HCT NNP 4_p
recipients NNS 4_p
. . 4_p

-DOCSTART- -X- O O 10674680

area NN N
of IN N
low JJ 4_p
malaria NNS 4_p
transmission NN N
in IN N
Colombia NNP N
. . N

Patients NNPS N
> JJ 1_p
or CC 1_p
=1 JJ 1_p
year NN 1_p
of IN 1_p
age NN 1_p
with IN N
a DT N
parasite JJ N
density NN N
> NN N
or CC N
=1,000 CD N
asexual JJ N
parasites NNS N
per IN N
microliter NN N
were VBD N
enrolled VBN N
in IN N
this DT N
study NN N
. . N

Forty-four CD 3_p
percent NN N
( ( N
24 CD N
of IN N
54 CD N
) ) N
of IN N
the DT N
CQ-treated JJ N
patients NNS N
were VBD N
therapeutic JJ N
failures NNS N
, , N
including VBG N
7 CD N
early JJ N
treatment NN N
failures NNS N
( ( N
ETFs NNP N
) ) N
and CC N
17 CD N
late JJ N
treatment NN N
failures NNS N
( ( N
LTFs NNP N
) ) N
. . N

Four CD N
( ( N
6 CD N
% NN N
) ) N
of IN N
67 CD N
-DOCSTART- -X- O O 25265770

after IN N
arthroscopic JJ 4_p
anterior JJ 4_p
cruciate NN 4_p
ligament NN 4_p
reconstruction NN 4_p
. . N

after IN N
anterior JJ 4_p
cruciate NN 4_p
ligament NN 4_p
( ( 4_p
ACL NNP 4_p
) ) 4_p
reconstruction NN 4_p
. . N

One NNP 3_p
hundred VBD 3_p
patients NNS N
were VBD N
randomized VBN N
-DOCSTART- -X- O O 9932558

obstetric JJ 4_p
care NN 4_p
practitioners NNS 4_p
: : 4_p
obstetric JJ 4_p
care NN 4_p
practitioners NNS 4_p
Thirty NNP N
health NN N
care NN N
practitioners NNS N
Obstetric NNP N
care NN N
practitioners NNS N
-DOCSTART- -X- O O 12088604

ulcerative JJ 4_p
colitis NN 4_p
patients NNS 4_p
and CC 4_p
their PRP$ 4_p
doctors NNS 4_p
6 CD N
specialists NNS N
and CC N
16 CD N
GPs NNP N
. . N

Patients NNS N
' POS N
views NNS N
were VBD N
obtained VBN N
from IN N
written VBN N
responses NNS N
to TO N
a DT N
postal JJ N
questionnaire NN N
( ( N
136 CD N
replies NNS N
) ) N
. . N

-DOCSTART- -X- O O 26442399

CIRRHOTIC NNP 4_p
PATIENTS NNP 4_p
UNDERGOING NNP 4_p
MAJOR NNP 4_p
LIVER NNP 4_p
RESECTION NNP 4_p
. . 4_p

cirrhotic JJ 4_p
patients NNS 4_p
undergoing VBG 4_p
major JJ 4_p
liver NN 4_p
resection NN 4_p
. . N

50 CD 3_p
patients NNS 3_p
( ( N
Child NNP 1_p
A NNP 1_p
) ) N
-DOCSTART- -X- O O 15189781

Type NNP 4_p
2 CD 4_p
diabetes NNS 4_p
. . N

Twenty NNP 3_p
Type NNP 4_p
2 CD 4_p
diabetic JJ 4_p
patients NNS 4_p
with IN 4_p
dyslipidemia NN 4_p
were VBD N
treated VBN N
-DOCSTART- -X- O O 8823584

anterior JJ 4_p
segment NN 4_p
surgery NN 4_p
. . N

local JJ N
anesthesia NN N
in IN N
ophthalmic JJ 4_p
surgery NN 4_p
Patients NNS N
undergoing VBG N
various JJ N
anterior JJ 4_p
segment NN 4_p
surgery NN 4_p
300 CD 3_p
were VBD N
operated VBN N
with IN N
1-quadrant JJ 4_p
sub-Tenon NN 4_p
's POS 4_p
anesthesia NN 4_p
( ( 4_p
1-QST JJ 4_p
) ) 4_p
and CC N
the DT N
results NNS N
were VBD N
compared VBN N
with IN N
270 CD 3_p
patients NNS 3_p
operated VBN N
with IN N
retrobulbar NN 4_p
anesthesia NN 4_p
. . N

Patients NNS N
undergoing VBG N
various JJ N
anterior JJ 4_p
segment NN 4_p
surgery NN 4_p
procedures NNS N
-DOCSTART- -X- O O 18410301

healthy JJ 4_p
women NNS 2_p
with IN 4_p
and CC 4_p
without IN 4_p
sexual JJ 4_p
arousal NN 4_p
disorder NN 4_p
. . N

women NNS N
with IN N
sexual JJ N
arousal NN N
disorder NN N
pre- NN 4_p
and CC 4_p
postmenopausal JJ 4_p
women NNS 2_p
with IN N
sexual JJ 4_p
arousal NN 4_p
disorder NN 4_p
Twenty-nine NNP 3_p
medically RB N
healthy JJ 4_p
women NNS 4_p
with IN N
sexual JJ 4_p
arousal NN 4_p
disorder NN 4_p
( ( N
15 CD 4_p
premenopausal NN 4_p
and CC N
14 CD 4_p
postmenopausal NN 4_p
) ) N
, , N
diagnosed VBD N
using VBG N
the DT N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
4th CD N
Edition NNP N
( ( N
DSM-IV NNP N
) ) N
criteria NN N
, , N
and CC N
30 CD 3_p
age-matched JJ N
women NNS N
without IN 4_p
sexual JJ 4_p
problems NNS 4_p
( ( N
16 CD N
premenopausal NN N
and CC N
14 CD N
postmenopausal NN N
) ) N
Women NNP 2_p
with IN N
sexual JJ N
arousal NN N
disorder NN N
diagnosed VBD N
according VBG N
to TO N
DSM-IV NNP N
medically RB N
healthy JJ 4_p
women NNS 2_p
-DOCSTART- -X- O O 24107284

sepsis-related JJ N
acute JJ N
kidney NN N
injury NN N
patients NNS N
. . N

sepsis-related JJ N
acute JJ N
kidney NN N
injury NN N
( ( N
AKI NNP N
) ) N
. . N

Twenty-eight JJ N
sepsis-related JJ N
AKI NNP N
patients NNS N
were VBD N
included VBN N
and CC N
randomized VBN N
into IN N
online JJ N
HDF NNP N
and CC N
high-flux JJ N
HD NNP N
. . N

hypercytokinemic JJ N
state NN N
in IN N
-DOCSTART- -X- O O 17093162

trial NN N
in IN N
Bangladesh NNP N
. . N

Populations NNPS N
in IN N
South NNP N
and CC N
East NNP N
Asia NNP N
and CC N
many JJ N
other JJ N
regions NNS N
of IN N
the DT N
world NN N
are VBP N
chronically RB 4_p
exposed VBN 4_p
to TO 4_p
arsenic-contaminated JJ 4_p
drinking NN 4_p
water NN 4_p
. . N

arsenic-exposed JJ N
adults NNS N
Two CD 3_p
hundred VBD 3_p
adults NNS 1_p
in IN N
a DT N
rural JJ N
region NN N
of IN N
Bangladesh NNP N
, , N
previously RB N
found VBN N
to TO N
have VB N
low JJ 4_p
plasma JJ 4_p
concentrations NNS 4_p
of IN 4_p
folate NN 4_p
( ( 4_p
< JJ 4_p
/=9 NNP 4_p
nmol/L NN 4_p
) ) 4_p
participants NNS N
with IN N
low JJ 4_p
plasma NN 4_p
folate NN 4_p
-DOCSTART- -X- O O 8885803

patients NNS N
with IN N
seasonal JJ 4_p
allergic JJ 4_p
rhinitis NN 4_p
. . N

seasonal JJ 4_p
allergic JJ 4_p
rhinitis NN 4_p
due JJ N
to TO N
ragweed VB N
. . N

One CD 3_p
hundred VBD 3_p
forty NN 3_p
patients NNS N
seasonal JJ 4_p
allergic JJ 4_p
rhinitis NN 4_p
due JJ N
to TO N
ragweed VB N
. . N

-DOCSTART- -X- O O 15735119

patients NNS N
with IN N
progressive JJ N
castrate NN N
metastatic JJ N
prostate NN N
cancer NN N
. . N

chemotherapy-naive JJ N
patients NNS N
with IN N
progressive JJ N
castrate NN N
metastatic JJ N
prostate NN N
cancer NN N
. . N

Between NNP N
December NNP N
2001 CD N
and CC N
October NNP N
2003 CD N
, , N
92 CD N
patients NNS N
were VBD N
enrolled VBN N
and CC N
randomly RB N
assigned VBN N
treatment NN N
with IN N
ixabepilone NN N
alone RB N
( ( N
45 CD N
patients NNS N
) ) N
or CC N
in IN N
combination NN N
with IN N
EMP NNP N
( ( N
47 CD N
patients NNS N
) ) N
. . N

patients NNS N
with IN N
castrate JJ N
metastatic JJ N
prostate NN N
cancer NN N
. . N

-DOCSTART- -X- O O 19019444

Collaborative NNP 4_p
Initial NNP 4_p
Glaucoma NNP 4_p
Treatment NNP 4_p
Study NNP 4_p
Six NNP N
hundred VBD N
seven CD N
newly RB N
diagnosed VBN N
glaucoma NN N
patients NNS N
. . N

607 CD 4_p
subjects NNS 4_p
with IN 4_p
newly RB 4_p
diagnosed VBN 4_p
open-angle JJ 4_p
glaucoma NN 4_p
subjects NNS 4_p
with IN 4_p
advanced JJ 4_p
VF NNP 4_p
loss NN 4_p
at IN 4_p
baseline NN 4_p
subjects NNS N
with IN N
diabetes NNS N
subjects NNS 4_p
with IN 4_p
more RBR 4_p
advanced JJ 4_p
VF NNP 4_p
loss NN 4_p
at IN 4_p
presentation NN 4_p
patients NNS 4_p
with IN 4_p
diabetes NNS 4_p
-DOCSTART- -X- O O 21272822

new JJ N
mothers NNS N
' POS N
low-income JJ N
, , N
first-time JJ N
mothers NNS N
' POS N
safety NN N
practices NNS N
during IN N
their PRP$ N
child NN N
's POS N
first JJ N
18 CD N
months NNS N
. . N

Primiparous JJ 4_p
women NNS 2_p
( ( N
n JJ N
= NNP N
167 CD 3_p
) ) N
-DOCSTART- -X- O O 11196396

premature JJ 4_p
ejaculation NN 4_p
. . N

premature JJ 4_p
ejaculation NN 4_p
. . N

Forty-three JJ 3_p
patients NNS N
suffering VBG N
from IN N
premature JJ N
ejaculation NN N
The DT N
exclusion NN N
criteria NNS N
were VBD N
erectile JJ N
dysfunction NN N
, , N
loss NN N
of IN N
libido NN N
, , N
alcohol NN N
and CC N
substance NN N
abuse NN N
, , N
mental JJ N
retardation NN N
, , N
diabetes VBZ N
mellitus NN N
, , N
thyroid JJ N
disease NN N
, , N
hypotension NN N
, , N
previous JJ N
use NN N
of IN N
these DT N
drugs NNS N
and CC N
urogenital JJ N
infections NNS N
. . N

The DT N
patients NNS N
' POS N
ages NNS N
ranged VBD N
from IN N
19 CD 1_p
to TO 1_p
48 CD 1_p
years NNS 1_p
( ( N
mean JJ N
age NN N
28 CD 1_p
+/- JJ 1_p
1.6 CD 1_p
) ) N
. . N

They PRP N
had VBD N
regular JJ N
sexual JJ N
lives NNS N
. . N

They PRP N
had VBD N
normal JJ N
psychiatric JJ N
consultation NN N
and CC N
the DT N
Glombock NNP N
Rast NNP N
Sexual NNP N
Satisfactory NNP N
Test NNP N
( ( N
GRISS NNP N
) ) N
psychiatric JJ N
test NN N
were VBD N
in IN N
accordance NN N
with IN N
premature JJ N
ejaculation NN N
. . N

No UH N
patients NNS N
were VBD N
excluded VBN N
from IN N
the DT N
study NN N
due JJ N
to TO N
side VB N
effects NNS N
. . N

premature JJ N
ejaculation NN N
. . N

-DOCSTART- -X- O O 21385351

acute JJ N
lung JJ N
injury NN N
: : N
patients NNS N
with IN N
acute JJ N
lung NN N
injury NN N
( ( N
ALI NNP N
) ) N
ALI NNP N
patients NNS N
152 CD N
patients NNS N
with IN N
ALI NNP N
enrolled VBD N
in IN N
the DT N
Fluid NNP N
and CC N
Catheter NNP N
Treatment NNP N
Trial NNP N
( ( N
FACTT NNP N
) ) N
from IN N
five CD N
NHLBI NNP N
ARDS NNP N
( ( N
Acute NNP N
Respiratory NNP N
Distress NNP N
Syndrome NNP N
) ) N
Network NNP N
sites NNS N
. . N

of IN N
71 CD N
and CC N
152 CD N
patients NNS N
than IN N
CVP NNP N
in IN N
patients NNS N
with IN N
status NN N
in IN N
patients NNS N
with IN N
acute JJ N
lung NN N
-DOCSTART- -X- O O 1833682

15 CD 4_p
and CC 4_p
19 CD 4_p
healthy JJ 4_p
women NNS 4_p
, , 4_p
respectively RB 4_p
. . 4_p

-DOCSTART- -X- O O 17723125

venous JJ 4_p
thromboembolism NN 4_p
after IN 4_p
abdominal JJ 4_p
surgery NN 4_p
: : 4_p
venous JJ 4_p
thromboembolism NN 4_p
after IN 4_p
abdominal JJ 4_p
surgery NN 4_p
Patients NNS 1_p
aged VBN 1_p
at IN 1_p
least JJS 1_p
40 CD 1_p
years NNS 1_p
undergoing JJ 1_p
abdominal JJ 1_p
surgery NN 1_p
1309 CD N
patients NNS N
fondaparinux-treated JJ N
patients NNS N
placebo-treated JJ N
patients NNS N
patients NNS 4_p
undergoing JJ 4_p
abdominal JJ 4_p
surgery NN 4_p
and CC 4_p
receiving VBG 4_p
intermittent JJ 4_p
pneumatic JJ 4_p
compression NN 4_p
-DOCSTART- -X- O O 3653128

patients NNS 4_p
with IN 4_p
prostatic JJ 4_p
cancer NN 4_p
. . 4_p

patients NNS N
( ( N
N NNP 3_p
= NNP 3_p
100 CD 3_p
) ) N
with IN N
prostatic JJ 4_p
cancer NN 4_p
. . N

patients NNS N
with IN N
prostatic JJ N
cancer NN N
. . N

-DOCSTART- -X- O O 21908036

patients NNS N
( ( 1_p
aged VBN 1_p
18-75 CD 1_p
years NNS 1_p
) ) 1_p
with IN 4_p
, , 4_p
or CC 4_p
with IN 4_p
high JJ 4_p
risk NN 4_p
of IN 4_p
, , 4_p
coronary JJ 4_p
heart NN 4_p
disease NN 4_p
189 CD 3_p
patients NNS N
were VBD N
screened VBN N
and CC N
130 CD 3_p
randomly RB N
assigned VBN 3_p
to TO N
placebo VB N
( ( N
66 CD 3_p
patients NNS N
) ) N
or CC N
dalcetrapib NN N
( ( N
64 CD 3_p
patients NNS N
) ) N
. . N

-DOCSTART- -X- O O 3166942

Psoriasis NN 4_p
of IN 4_p
the DT 4_p
scalp NN 4_p
40 CD 3_p
patients NNS N
Gy NNP N
of IN N
Grenz NNP N
rays NNS N
37 CD 3_p
patients NNS N
who WP N
completed VBD N
the DT N
trial NN N
patients NNS N
who WP N
healed VBD N
-DOCSTART- -X- O O 23857884

patients NNS N
with IN N
patellar JJ 4_p
instability NN 4_p
. . N

patients NNS N
with IN N
patellofemoral JJ 4_p
malalignment NN 4_p
and CC 4_p
instability NN 4_p
. . N

All DT N
patients NNS N
with IN N
patellar JJ 4_p
instability NN 4_p
who WP N
underwent VBD N
both DT N
CT NNP N
and CC N
MRI NNP N
of IN N
the DT N
knee NN N
from IN N
2003 CD N
to TO N
2011 CD N
were VBD N
included VBN N
( ( N
n JJ N
= $ N
59 CD N
knees NNS N
in IN N
54 CD 3_p
patients NNS N
) ) N
. . N

-DOCSTART- -X- O O 1819001

Response NN N
of IN N
patients NNS 4_p
to TO 4_p
enalapril VB 4_p
, , 4_p
felodipine NN 4_p
and CC N
their PRP$ N
combination NN N
. . N

-DOCSTART- -X- O O 26158622

healthy JJ 4_p
adults NNS 1_p
in IN N
China NNP N
. . N

adults NNS 1_p
in IN N
China NNP N
. . N

healthy JJ 4_p
adults NNS 1_p
healthy JJ 4_p
adults NNS 1_p
. . N

5143 CD 3_p
healthy JJ N
adults NNS 1_p
received VBD N
10 CD N
μg NNP N
hepatitis NN N
B NNP N
vaccine NN N
at IN N
0 CD N
, , N
1 CD N
and CC N
3 CD N
months NNS N
( ( N
group NN N
A NNP N
) ) N
, , N
0 CD N
, , N
1 CD N
and CC N
6 CD N
months NNS N
( ( N
group NN N
B NNP N
) ) N
, , N
or CC N
0 CD N
, , N
1 CD N
and CC N
12 CD N
months NNS N
( ( N
group NN N
C NNP N
) ) N
study NN N
, , N
2438 CD 3_p
healthy JJ N
adults NNS N
finished VBD N
the DT N
full JJ N
vaccination NN N
program NN N
and CC N
follow-up NN N
-DOCSTART- -X- O O 21402409

low-income JJ 4_p
Latina NNP 4_p
mothers NNS N
with IN N
infants NNS 1_p
. . N

217 CD 3_p
Latina NNP N
women NNS 2_p
enrolled VBD N
in IN N
a DT N
perinatal JJ 4_p
depression NN 4_p
prevention NN N
trial NN N
. . N

depressive JJ 4_p
symptoms NNS 4_p
during IN N
pregnancy NN 4_p
-DOCSTART- -X- O O 8208874

acute NN 4_p
antidepressant JJ 4_p
effects NNS 4_p
of IN N
sleep JJ 4_p
deprivation NN 4_p
: : 4_p
Early JJ N
morning NN N
sleep JJ 4_p
deprivation NN 4_p
( ( N
patient JJ N
awake NN N
from IN N
0200 CD N
to TO N
2200 CD N
hours NNS N
) ) N
patients NNS N
with IN N
major JJ 4_p
depression NN 4_p
. . 4_p

16 CD 3_p
depressed JJ 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 14752429

myocardial JJ 4_p
revascularization NN 4_p
in IN 4_p
elderly JJ 4_p
patients NNS 4_p
: : 4_p
elderly JJ 4_p
patients NNS 4_p
elderly JJ N
patients NNS N
. . N

160 CD N
patients NNS N
aged VBD N
more JJR N
than IN N
70 CD N
years NNS N
scheduled VBN N
to TO N
undergo VB N
isolated JJ N
myocardial JJ N
revascularization NN N
. . N

80 CD N
patients NNS N
undergoing JJ N
total JJ N
arterial JJ N
revascularization NN N
( ( N
left VBN N
internal JJ N
thoracic NN N
artery NN N
on IN N
left JJ N
anterior JJ N
descending VBG N
coronary JJ N
artery NN N
plus CC N
radial JJ N
artery NN N
) ) N
80 CD N
patients NNS N
undergoing JJ N
standard JJ N
coronary JJ N
artery NN N
bypass NN N
graft NN N
surgery NN N
( ( N
left VBN N
internal JJ N
thoracic NN N
artery NN N
on IN N
left JJ N
anterior JJ N
descending VBG N
coronary JJ N
artery NN N
plus CC N
saphenous JJ N
veins NNS N
) ) N
. . N

Preoperative JJ N
characteristics NNS N
and CC N
risk NN N
factors NNS N
( ( N
EuroSCORE NNP N
: : N
group NN N
1 CD N
= $ N
7.9 CD N
vs NN N
group NN N
2 CD N
= $ N
8.1 CD N
) ) N
, , N
number NN N
of IN N
grafted JJ N
coronary JJ N
vessels NNS N
( ( N
group NN N
1 CD N
= $ N
2.4 CD N
vs NN N
group NN N
2 CD N
= $ N
2.5 CD N
) ) N
, , N
aortic JJ N
crossclamping NN N
time NN N
( ( N
group NN N
1 CD N
= $ N
37 CD N
+/- JJ N
7 CD N
minutes NNS N
vs JJ N
group NN N
2 CD N
= $ N
38 CD N
+/- JJ N
7 CD N
minutes NNS N
) ) N
, , N
ventilation NN N
time NN N
( ( N
group NN N
1 CD N
= $ N
22 CD N
+/- JJ N
12 CD N
hours NNS N
vs JJ N
group NN N
2 CD N
= $ N
23 CD N
+/- JJ N
11 CD N
hours NNS N
) ) N
, , N
intensive JJ N
care NN N
unit NN N
stay NN N
( ( N
group NN N
1 CD N
= $ N
39 CD N
+/- JJ N
10 CD N
hours NNS N
vs JJ N
group NN N
2 CD N
= $ N
40 CD N
+/- JJ N
9 CD N
hours NNS N
) ) N
, , N
and CC N
hospital JJ N
mortality NN N
( ( N
group NN N
1 CD N
= RB N
3.8 CD N
% NN N
vs NN N
group NN N
2 CD N
= RB N
5 CD N
% NN N
) ) N
were VBD N
comparable JJ N
between IN N
the DT N
groups NNS N
. . N

elderly JJ N
patients NNS N
. . N

-DOCSTART- -X- O O 15895329

after IN N
lumbar JJ 4_p
disk NN 4_p
surgery NN 4_p
: : N
patient JJ N
outcome NN N
after IN 4_p
lumbar NN 4_p
disk NN 4_p
surgery NN 4_p
. . N

Departments NNS N
of IN N
physical JJ N
medicine NN N
and CC N
rehabilitation NN N
and CC N
orthopedics NNS N
at IN N
a DT N
Finnish JJ N
hospital NN N
. . N

Patients NNPS N
( ( N
N=126 NNP 3_p
) ) N
were VBD N
randomized VBN N
-DOCSTART- -X- O O 18251162

patients NNS N
with IN N
hepatocellular JJ 4_p
carcinoma NN 4_p
. . N

Forty-five JJ 3_p
patients NNS 3_p
with IN N
cured JJ N
or CC N
possibly RB N
cured VBN N
HCC NNP 4_p
-DOCSTART- -X- O O 21822762

sample NN N
of IN N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
and CC N
serious JJ 4_p
behavioral JJ 4_p
problems NNS 4_p
. . N

children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
and CC N
serious JJ N
behavior NN N
problems NNS N
. . N

children NNS 1_p
with IN N
a DT N
wide JJ N
range NN N
of IN N
demographic JJ N
and CC N
behavioral JJ N
characteristics NNS N
. . N

-DOCSTART- -X- O O 25101966

children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . N

adults NNS 1_p
and CC N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
children NNS 1_p
with IN N
ASD NNP 4_p
Twenty-one CD 3_p
children NNS N
with IN N
ASD NNP 4_p
( ( N
9-16 CD 1_p
years NNS 1_p
) ) N
were VBD N
compared VBN N
to TO N
typically RB N
developing VBG N
matched VBN N
groups NNS N
. . N

children NNS 1_p
with IN N
ASD NNP 4_p
typically RB N
matched VBD N
groups NNS N
children NNS 1_p
with IN N
ASD NNP 4_p
. . N

children NNS 1_p
with IN N
ASD NNP 4_p
-DOCSTART- -X- O O 12160584

patients NNS N
with IN N
advanced JJ 4_p
prostate NN 4_p
cancer NN 4_p
treated VBN N
by IN N
castration NN N
plus CC N
anandron NN N
or CC N
placebo NN N
: : N
399 CD 3_p
out IN N
of IN N
457 CD 3_p
patients NNS N
recruited VBN N
in IN N
this DT N
study NN N
were VBD N
divided VBN N
in IN N
a DT N
good JJ N
or CC N
poor JJ N
prognostic JJ N
group NN N
depending VBG N
on IN N
the DT N
presence NN N
of IN N
two CD N
or CC N
more JJR N
poor JJ N
prognostic JJ N
factors NNS N
, , N
these DT N
were VBD N
pain NN N
requiring VBG N
treatment NN N
, , N
> VBZ N
5 CD N
bone NN N
metastases NNS N
, , N
hydronephrosis NN N
, , N
and CC N
alkaline JJ N
phosphatase NN N
> VBD N
2 CD N
ULN NNP N
. . N

patients NNS N
with IN N
metastatic JJ 4_p
prostate NN 4_p
cancer NN 4_p
-DOCSTART- -X- O O 7029293

primary JJ N
, , N
nonmetastatic JJ N
Ewing NNP N
's POS N
sarcoma NN N
of IN N
bone NN N
: : N
264 CD N
children NNS N
and CC N
adults NNS N
with IN N
previously RB N
untreated VBN N
localized JJ N
Ewing NNP N
's POS N
sarcoma NN N
of IN N
bone NN N
between IN N
1973 CD N
and CC N
1978 CD N
by IN N
83 CD N
institutions NNS N
of IN N
three CD N
national JJ N
study NN N
groups NNS N
: : N
Children NNP N
's POS N
Cancer NNP N
Study NNP N
Group NNP N
, , N
Southwest NNP N
Oncology NNP N
Group NNP N
, , N
and CC N
Cancer NNP N
and CC N
Leukemia NNP N
Group NNP N
B NNP N
. . N

-DOCSTART- -X- O O 16961674

thromboprophylaxis JJ 4_p
prescriptions NNS 4_p
for IN 4_p
medical JJ 4_p
patients NNS 4_p
: : 4_p
30 CD N
Internal NNP N
Medicine NNP N
departments NNS N
of IN N
Assistance NNP N
Publique-Hôpitaux NNP N
de IN N
Paris NNP N
SUBJECTS NNP N
All DT N
inpatients NNS N
were VBD N
included VBN N
, , N
except IN N
those DT N
who WP N
were VBD N
either RB N
admitted VBN N
or CC N
discharged VBN N
on IN N
the DT N
day NN N
of IN N
the DT N
survey NN N
, , N
and CC N
those DT N
receiving VBG N
curative JJ N
anticoagulant JJ N
treatment NN N
RESULTS VB N
1,469 CD N
patients NNS N
were VBD N
included VBN N
-DOCSTART- -X- O O 8277075

Eight NNP 3_p
male NN 2_p
volunteers NNS N
-DOCSTART- -X- O O 16950955

constipated JJ 4_p
pediatric JJ 1_p
patients NNS 4_p
. . 4_p

children NNS 1_p
. . N

children NNS N
with IN N
idiopathic JJ N
chronic JJ N
constipation NN N
. . N

children NNS 4_p
with IN 4_p
constipation NN 4_p
. . 4_p

Fifty-six NNP 3_p
chronically RB 4_p
constipated VBD 4_p
children NNS 4_p
were VBD 4_p
randomly RB 4_p
assigned VBN 4_p
into IN 4_p
the DT 4_p
study NN 4_p
, , 4_p
but CC 4_p
only RB 4_p
48 CD 3_p
children NNS 4_p
completed VBD 4_p
it PRP 4_p
. . 4_p

These DT N
children NNS N
, , N
who WP N
were VBD N
aged VBN N
between IN N
3 CD 1_p
and CC 1_p
10 CD 1_p
years NNS 1_p
, , N
had VBD N
a DT N
diagnosis NN N
of IN N
chronic JJ 4_p
idiopathic JJ 4_p
constipation NN 4_p
. . N

chronic JJ N
idiopathic JJ N
constipation NN N
in IN N
children NNS N
. . N

pediatric JJ N
constipated JJ N
patients NNS N
with IN N
slow JJ N
colonic JJ N
transit NN N
time NN N
. . N

-DOCSTART- -X- O O 7608801

central JJ 4_p
venous JJ 4_p
catheter NN 4_p
infections NNS 4_p
in IN N
children NNS 1_p
. . N

Fifty-five JJ 3_p
children NNS 1_p
with IN N
cancer NN 4_p
and CC N
eight CD 3_p
children NNS 1_p
given VBN N
total JJ 4_p
parenteral JJ 4_p
nutrition NN 4_p
by IN 4_p
the DT 4_p
surgery NN 4_p
or CC 4_p
nutrition NN 4_p
support NN 4_p
services NNS 4_p
-DOCSTART- -X- O O 15538933

Healthy NNP 4_p
men NNS 4_p
( ( 4_p
20-33 CD 4_p
years NNS 4_p
old JJ 4_p
) ) 4_p
-DOCSTART- -X- O O 15509083

oral JJ 4_p
health NN 4_p
improvement NN 4_p
previous JJ N
users NNS N
of IN N
traditional JJ N
materials NNS N
in IN N
a DT N
rural JJ N
population NN N
in IN N
Andhra NNP N
Pradesh NNP N
, , N
India NNP N
. . N

oral JJ 4_p
health NN 4_p
of IN N
an DT N
economically RB N
disadvantaged JJ N
rural JJ N
population NN N
in IN N
Andhra NNP N
Pradesh NNP N
, , N
India NNP N
who WP N
were VBD N
primarily RB N
users NNS N
of IN N
traditional JJ N
materials NNS N
. . N

150 CD 3_p
of IN N
the DT N
original JJ N
study NN N
population NN N
. . N

-DOCSTART- -X- O O 3056498

Sixty NNP 3_p
women NNS N
with IN N
climacteric JJ N
complaints NNS N
who WP N
had VBD N
not RB 4_p
menstruated VBN 4_p
for IN N
at IN N
least JJS N
1 CD N
year NN N
climacteric JJ N
complaints NNS N
in IN N
postmenopausal JJ N
women NNS N
-DOCSTART- -X- O O 2107116

gastrostomy NN 4_p
: : N
This DT N
study NN N
compared VBN N
operative JJ 4_p
gastrostomy NN 4_p
( ( 4_p
OG NNP 4_p
) ) 4_p
( ( N
by IN N
surgeons NNS N
) ) N
with IN N
endoscopic NN 4_p
gastrostomy NN 4_p
( ( 4_p
PEG NNP 4_p
) ) 4_p
( ( N
by IN N
physicians NNS N
) ) N
Patients NNS N
were VBD N
assessed VBN N
for IN N
complications NNS N
, , N
mortality NN N
, , N
tube NN N
function NN N
, , N
and CC N
cost NN N
. . N

Groups NNP N
were VBD N
equally RB N
matched VBN N
for IN N
indications NNS N
and CC N
underlying JJ N
disease NN N
. . N

Fifty-seven NNP 3_p
had VBD N
OG NNP 4_p
and CC N
64 CD 3_p
had VBD N
attempted VBN N
PEG NNP 4_p
. . N

-DOCSTART- -X- O O 8162628

patients NNS N
with IN N
ischemic JJ 4_p
heart NN 4_p
disease NN 4_p
. . N

14 CD 3_p
randomized JJ N
patients NNS N
with IN N
stable JJ N
ischemic JJ N
heart NN N
disease NN N
-DOCSTART- -X- O O 7824501

bronchial JJ 4_p
hyperreactivity NN 4_p
bronchial JJ 4_p
hyperresponsiveness NN 4_p
evaluation NN N
model NN N
bronchial JJ 4_p
hyperresponsiveness NN 4_p
. . 4_p

-DOCSTART- -X- O O 11791023

1999 CD N
MONICA NNP N
sample NN N
from IN N
northern JJ N
Sweden NNP N
. . N

MONICA NNP N
sample NN N
of IN N
6000 CD N
subjects NNS N
from IN N
a DT N
geographically RB N
defined VBN N
population NN N
in IN N
northern JJ N
Sweden NNP N
, , N
regarding VBG N
indications NNS N
for IN N
treatment NN N
, , N
target VB N
blood NN N
pressure NN N
and CC N
risk NN N
distribution NN N
. . N

drug-treated JJ 4_p
hypertension NN 4_p
. . N

untreated JJ N
subjects NNS N
low- JJ N
medium- NN N
high- NN N
very-high-risk JJ N
group NN N
. . N

those DT N
aged VBN 1_p
45-54 CD 1_p
subjects NNS 1_p
aged VBN 1_p
below IN 1_p
60 CD 1_p
-DOCSTART- -X- O O 17069543

childhood/adolescent JJ 1_p
pervasive JJ 4_p
developmental NN 4_p
disorder NN 4_p
. . N

Eleven NNP 3_p
patients NNS N
with IN N
a DT N
diagnosis NN N
of IN N
either DT N
autism NN 4_p
, , N
Asperger NNP 4_p
's POS 4_p
syndrome NN 4_p
, , N
or CC N
PDD NNP 4_p
not RB N
otherwise RB N
specified VBN N
( ( N
PDD-NOS NNP 4_p
) ) N
and CC N
aged VBN N
6-14 CD 1_p
years NNS 1_p
-DOCSTART- -X- O O 15358853

patients NNS 4_p
with IN 4_p
symptomatic JJ 4_p
peripheral JJ 4_p
arterial JJ 4_p
disease NN 4_p
73 CD 3_p
patients NNS 3_p
were VBD 4_p
assigned VBN 4_p
to TO 4_p
CT NNP 4_p
angiography NN 4_p
, , 4_p
and CC 4_p
72 CD 3_p
were VBD 4_p
assigned VBN 4_p
to TO 4_p
DSA NNP 4_p
. . N

patients NNS N
with IN N
symptomatic JJ N
peripheral JJ N
arterial JJ N
disease NN N
. . N

-DOCSTART- -X- O O 22332211

participants NNS N
participants NNS N
Eyes NNP N
All DT N
eyes NNS N
Participants NNS N
with IN N
2 CD N
study NN N
eyes NNS N
423 CD 3_p
participants NNS N
with IN N
1 CD 4_p
study NN 4_p
eye NN 4_p
112 CD 3_p
participants NNS N
with IN N
2 CD 4_p
study NN 4_p
eyes NNS 4_p
-DOCSTART- -X- O O 15492353

children NNS 4_p
with IN 4_p
autistic JJ 4_p
and CC 4_p
other JJ 4_p
pervasive JJ 4_p
developmental NN 4_p
disorders NNS 4_p
. . 4_p

children NNS 1_p
with IN N
autism NN 4_p
and CC 4_p
other JJ 4_p
pervasive JJ 4_p
developmental NN 4_p
disorders NNS 4_p
( ( 4_p
PDD NNP 4_p
) ) N
. . N

79 CD 3_p
children NNS 1_p
who WP N
were VBD N
aged VBN 1_p
5 CD 1_p
to TO 1_p
12 CD 1_p
years NNS 1_p
and CC N
had VBD N
PDD NNP 4_p
. . N

PDD NNP N
in IN N
children NNS N
. . N

-DOCSTART- -X- O O 3131904

female JJ 4_p
patients NNS 4_p
undergoing VBG 4_p
curative JJ 4_p
adjuvant JJ 4_p
irradiation NN 4_p
following VBG 4_p
breast NN 4_p
cancer NN 4_p
] NNP 4_p
50 CD N
patients NNS N
submitted VBN N
to TO N
curative VB N
adjuvant JJ N
irradiation NN N
following VBG N
surgery NN N
for IN N
mammary JJ N
carcinoma NN N
. . N

patients NNS N
with IN N
irradiations NNS N
of IN N
the DT N
thoracic NN N
wall NN N
and CC N
the DT N
regional JJ N
lymph NN N
nodes NNS N
. . N

-DOCSTART- -X- O O 25282520

homozygous JJ 4_p
familial JJ 4_p
hypercholesterolaemia NN 4_p
Homozygous NNP 4_p
familial JJ 4_p
hypercholesterolaemia NN 4_p
ten JJ N
countries NNS N
in IN N
North NNP N
America NNP N
, , N
Europe NNP N
, , N
the DT N
Middle NNP N
East NNP N
, , N
and CC N
South NNP N
Africa NNP N
. . N

50 CD 3_p
eligible JJ N
patients NNS N
( ( 1_p
aged VBN 1_p
≥12 CD 1_p
years NNS 1_p
) ) 1_p
with IN N
homozygous JJ N
familial JJ N
hypercholesterolaemia NN 4_p
, , N
on IN N
stable JJ N
lipid-regulating JJ N
therapy NN N
for IN N
at IN N
least JJS N
4 CD N
weeks NNS N
, , N
and CC N
not RB N
receiving VBG N
lipoprotein JJ N
apheresis NN N
, , N
were VBD N
randomly RB N
allocated VBN N
by IN N
a DT N
computer-generated JJ N
randomisation NN N
sequence NN N
in IN N
a DT N
2:1 CD N
ratio NN N
to TO N
receive VB N
subcutaneous JJ N
evolocumab NNS N
420 CD N
mg NN N
or CC N
placebo NN N
every DT N
4 CD N
weeks NNS N
for IN N
12 CD N
weeks NNS N
system NN N
. . N

Patients NNS N
, , N
study NN N
personnel NNS N
, , N
and CC N
the DT N
funder NN N
were VBD N
masked VBN N
to TO N
treatment NN N
and CC N
to TO N
the DT N
efficacy NN N
results NNS N
by IN N
the DT N
central JJ N
laboratory NN N
not RB N
returning VBG N
LDL NNP N
cholesterol NN N
or CC N
any DT N
lipid JJ N
results NNS N
to TO N
the DT N
clinical JJ N
sites NNS N
after IN N
the DT N
baseline NN N
visit NN N
the DT N
50 CD N
eligible JJ N
patients NNS N
randomly RB N
assigned VBN N
to TO N
the DT N
two CD N
treatment NN N
groups NNS N
, , N
49 CD 3_p
actually RB N
received VBD N
the DT N
study NN N
drug NN N
and CC N
completed VBD N
the DT N
study NN N
( ( N
16 CD N
in IN N
the DT N
placebo NN N
group NN N
and CC N
33 CD N
in IN N
the DT N
evolocumab NN N
group NN N
) ) N
INTERPRETATION NNP 4_p
In IN 4_p
patients NNS 4_p
with IN 4_p
homozygous JJ 4_p
familial JJ 4_p
hypercholesterolaemia NN 4_p
-DOCSTART- -X- O O 25441055

late-life JJ 4_p
depression NN 4_p
geriatric JJ 4_p
depression NN 4_p
Older JJR 1_p
participants NNS 1_p
completed VBD N
baseline JJ N
measures NNS N
of IN N
memory NN N
and CC N
executive NN N
function NN N
, , N
health NN N
, , N
and CC N
baseline NN N
and CC N
post-treatment JJ N
Hamilton NNP 4_p
Depression NNP 4_p
Scales NNP 4_p
( ( 4_p
HAM-D NNP 4_p
) ) 4_p
in IN N
a DT N
12-week JJ N
trial NN N
comparing VBG N
psychotherapies NNS N
( ( N
problem-solving JJ N
vs. FW N
supportive NN 3_p
; : 3_p
N NNP 3_p
= NNP 3_p
46 CD 3_p
) ) N
response NN 4_p
for IN 4_p
older JJR 4_p
patients NNS 4_p
exhibiting VBG 4_p
executive JJ 4_p
dysfunction NN 4_p
in IN 4_p
depression NN 4_p
decision-making NN 4_p
in IN 4_p
geriatric JJ 4_p
depression NN 4_p
-DOCSTART- -X- O O 9842079

Smokers NNP 4_p
recruited VBD N
from IN N
among IN N
the DT N
health NN N
centre NN N
users NNS N
through IN N
the DT N
preventive JJ N
activities NNS N
and CC N
health NN N
promotion NN N
programme NN N
. . N

54 CD 3_p
patients NNS N
were VBD N
included VBN N
, , N
with IN N
6 CD 3_p
losses NNS N
. . N

21 CD 3_p
MI NNP N
group NN N
27 CD 3_p
AI NNP N
group NN N
. . N

-DOCSTART- -X- O O 16275661

patients NNS N
with IN N
persistent JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
: : N
AF NNP 4_p
patients NNS N
with IN N
effective JJ N
rhythm NNS N
control NN N
patients NNS N
treated VBN N
with IN N
rate NN N
control NN N
. . N

266 CD 3_p
AF NNP N
patients NNS N
randomized VBD N
to TO N
rhythm VB N
control NN N
in IN N
the DT N
RACE NNP N
study NN N
, , N
49 CD 3_p
patients NNS N
turned VBD N
to TO N
long-term JJ N
sinus NN N
rhythm NN N
and CC N
were VBD N
continuously RB N
treated VBN N
with IN N
oral JJ N
anticoagulation NN N
. . N

256 CD 3_p
rate-control JJ N
patients NNS N
of IN N
RACE NNP N
patients NNS N
who WP N
remained VBD N
on IN N
warfarin NN N
-DOCSTART- -X- O O 10211492

after IN N
rubber NN N
band NN N
ligation NN N
of IN N
hemorrhoids NNS 4_p
: : N
After IN N
hemorrhoidal JJ 4_p
banding NN 4_p
, , N
patients NNS N
115 CD 3_p
patients NNS N
studied VBN N
-DOCSTART- -X- O O 9669262

women NNS 4_p
after IN 4_p
myocardial JJ 4_p
infarction NN 4_p
: : 4_p
women NNS 4_p
with IN 4_p
average JJ 4_p
cholesterol NN 4_p
levels NNS 4_p
after IN 4_p
myocardial JJ 4_p
infarction NN 4_p
( ( 4_p
MI NNP 4_p
) ) 4_p
. . 4_p

coronary JJ 4_p
heart NN 4_p
disease NN 4_p
( ( 4_p
CHD NNP 4_p
) ) 4_p
in IN 4_p
women NNS 4_p
; : 4_p
in IN 4_p
particular JJ 4_p
, , 4_p
those DT 4_p
with IN 4_p
CHD NNP 4_p
and CC 4_p
average JJ 4_p
cholesterol NN 4_p
levels NNS 4_p
. . 4_p

576 CD N
postmenopausal NN N
women NNS N
, , N
between IN N
3 CD N
and CC N
20 CD N
months NNS N
after IN N
MI NNP N
, , N
with IN N
a DT N
total JJ N
cholesterol NN N
level NN N
< VBD N
240 CD N
mg/dl NN N
and CC N
a DT N
low JJ N
density NN N
lipoprotein NN N
cholesterol NN N
level NN N
115 CD N
to TO N
174 CD N
mg/dl NNS N
The DT N
3,583 CD N
men NNS N
in IN N
the DT N
CARE NNP N
trial NN N
men NNS N
and CC N
women NNS N
. . N

post-MI JJ N
women NNS N
with IN N
average JJ N
cholesterol NN N
levels NNS N
. . N

-DOCSTART- -X- O O 15093843

atrial JJ 4_p
fibrillation NN 4_p
or CC N
flutter NN 4_p
( ( 4_p
AFF NNP 4_p
) ) 4_p
over IN N
450 CD 3_p
patients NNS N
. . N

Seventy-eight JJ 3_p
patients NNS N
with IN N
AFF NNP 4_p
and CC N
a DT N
ventricular JJ N
rate NN N
of IN N
> NNP N
/= NNP N
120 CD N
beats NNS N
per IN N
minute NN N
were VBD N
enrolled VBN N
. . N

One CD 3_p
patient NN N
in IN N
the DT N
placebo NN N
group NN N
-DOCSTART- -X- O O 8450514

Antinuclear JJ 4_p
antibodies NNS 4_p
-DOCSTART- -X- O O 8828933

extended VBN 4_p
wear NN 4_p
rigid JJ 4_p
gas NN 4_p
permeable JJ 4_p
contact NN 4_p
lenses NNS 4_p
. . N

single-center JJ 4_p
, , 4_p
controlled VBN 4_p
, , 4_p
double-masked JJ 4_p
study NN 4_p
of IN N
39 CD 3_p
RGP NNP 4_p
lens VBZ 4_p
wearers NNS 4_p
. . N

RGP NNP N
lenses VBZ N
-DOCSTART- -X- O O 18761646

markedly RB N
obese JJ N
adolescents NNS 1_p
with IN N
normal JJ 4_p
glucose JJ 4_p
tolerance NN 4_p
. . N

28 CD N
obese JJ 4_p
[ JJ 4_p
mean NN 4_p
body NN 4_p
mass NN 4_p
index NN 4_p
( ( 4_p
BMI NNP 4_p
) ) 4_p
: : 4_p
40.3 CD 4_p
+/- JJ 4_p
5.7 CD 4_p
kg/m NN 4_p
( ( 4_p
2 CD 4_p
) ) 4_p
] NN N
, , N
insulin-resistant JJ 4_p
[ JJ 4_p
homeostasis NN 4_p
model NN 4_p
assessment JJ 4_p
- : 4_p
insulin NN 4_p
resistance NN 4_p
: : 4_p
7.6 CD 4_p
+/- JJ 4_p
2.8 CD 4_p
and CC N
whole JJ 4_p
body NN 4_p
insulin JJ 4_p
sensitivity NN 4_p
index NN 4_p
( ( 4_p
WBISI NNP 4_p
) ) 4_p
: : 4_p
1.5 CD 4_p
+/- JJ 4_p
0.7 CD 4_p
] JJ 4_p
adolescents NNS N
( ( N
age NN N
15.0 CD 1_p
+/- JJ 1_p
1.3 CD 1_p
yr NN 1_p
) ) N
randomized VBD 4_p
to TO 4_p
MET NNP 4_p
( ( 4_p
n JJ 4_p
= NN 4_p
15 CD 4_p
, , 4_p
dose JJ 4_p
1500 CD 4_p
mg JJ 4_p
daily JJ 4_p
) ) 4_p
or CC 4_p
placebo NN 4_p
( ( 4_p
n JJ N
= NNP N
13 CD N
) ) N
. . N

obese JJ 4_p
children NNS N
with IN N
NGT NNP 4_p
-DOCSTART- -X- O O 23113962

118 CD N
lesions NNS N
in IN N
lung NN N
, , N
liver NN N
and CC N
lymph NN N
nodes NNS N
were VBD N
selected VBN N
from IN N
30 CD N
patients NNS N
enrolled VBN N
in IN N
early JJ N
phase NN N
clinical JJ N
trials NNS N
. . N

-DOCSTART- -X- O O 4016785

lymphoblastoid JJ 4_p
interferon NN 4_p
. . N

patients NNS N
-DOCSTART- -X- O O 20522464

acute JJ 4_p
moderate NN 4_p
to TO 4_p
severe VB 4_p
asthma NN 4_p
in IN N
children NNS 1_p
between IN N
5 CD 1_p
and CC 1_p
15 CD 1_p
years NNS 1_p
of IN N
age NN N
: : N
acute JJ 4_p
moderate NN 4_p
to TO 4_p
severe VB 4_p
asthma NN 4_p
. . N

Emergency NNP N
room/outpatient NN N
paediatric NN N
services NNS N
of IN N
a DT N
tertiary JJ N
care NN N
hospital NN N
. . N

Children NNP 1_p
aged VBD N
5-15 CD 1_p
years NNS 1_p
( ( N
without IN N
prior RB N
use NN N
of IN N
montelukast NN N
) ) N
with IN N
acute JJ 4_p
moderate NN 4_p
to TO 4_p
severe VB 4_p
asthma JJ 4_p
exacerbation NN 4_p
, , N
as IN N
defined VBN N
using VBG N
Modified NNP N
Pulmonary NNP N
Index NNP N
Score NNP N
( ( N
MPIS NNP N
) ) N
> VBD N
or CC N
=9 NNS N
, , N
were VBD N
enrolled VBN N
. . N

117 CD 3_p
children NNS 1_p
( ( N
60 CD 3_p
in IN N
montelukast NN N
group NN N
and CC N
57 CD 3_p
in IN N
placebo NN N
group NN N
) ) N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

children NNS 1_p
with IN N
acute JJ 4_p
moderate NN 4_p
to TO 4_p
severe VB 4_p
asthma NN 4_p
. . N

-DOCSTART- -X- O O 11013280

patients NNS 4_p
with IN 4_p
advanced JJ 4_p
non-small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
advanced JJ 4_p
non-small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
( ( 4_p
NSCLC NNP 4_p
) ) 4_p
. . 4_p

Between NNP N
January NNP N
1995 CD N
and CC N
April NNP N
1996 CD N
, , N
414 CD N
patients NNS N
with IN N
stage NN N
IIIB NNP N
or CC N
IV NNP N
NSCLC NNP N
were VBD N
randomized VBN N
to TO N
received VB N
either RB N
a DT N
control NN N
arm NN N
of IN N
high-dose JJ N
cisplatin NN N
( ( N
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
or CC N
a DT N
combination NN N
of IN N
paclitaxel NN N
( ( N
175 CD N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
3-hour JJ N
infusion NN N
) ) N
and CC N
cisplatin NN N
( ( N
80 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
every DT N
21 CD N
days NNS N
. . N

-DOCSTART- -X- O O 404962

purulent NN 4_p
meningitis NN 4_p
. . N

86 CD 3_p
pediatric JJ 1_p
and CC N
adult NN 1_p
patients NNS N
( ( N
41 CD 3_p
Haemophilus NNP 3_p
influenzae NN 3_p
, , N
22 CD 3_p
Streptococcus NNP 3_p
pneumoniae NN 3_p
, , N
13 CD 3_p
Neisseria NNP 3_p
meningitidis NN 3_p
, , N
and CC N
10 CD 3_p
of IN N
unknown JJ N
etiology NN N
) ) N
. . N

H. NNP N
influenzae NN 4_p
patients NNS N
patients NNS N
with IN N
H. NNP N
influenzae NN 4_p
. . N

-DOCSTART- -X- O O 15305197

UK NNP 4_p
genetic JJ 4_p
risk NN 4_p
counselling NN 4_p
services NNS 4_p
for IN 4_p
familial JJ 4_p
cancer NN 4_p
: : 4_p
50 CD N
new JJ N
clinic JJ N
attendees NNS N
, , N
referred VBD N
for IN N
cancer NN N
genetic JJ N
counselling NN N
to TO N
five CD N
UK NNP N
centres NNS N
. . N

The DT N
centres NNS N
represented VBD N
England NNP N
, , N
Scotland NNP N
and CC N
Wales NNP N
, , N
and CC N
were VBD N
randomly RB N
selected VBN N
from IN N
groups NNS N
ranked VBN N
by IN N
different JJ N
levels NNS N
of IN N
clinical JJ N
activity NN N
in IN N
cancer NN N
genetics NNS N
practice NN N
. . N

A DT N
total NN N
of IN N
256 CD N
unaffected JJ N
adults NNS N
fulfilled VBD N
the DT N
study NN N
criteria NNS N
. . N

-DOCSTART- -X- O O 24799074

conducted VBN N
in IN N
24 CD 3_p
male NN 2_p
healthy JJ 4_p
volunteers NNS 4_p
via IN 4_p
peroral JJ 4_p
route NN 4_p
. . N

-DOCSTART- -X- O O 6376144

adult NN 4_p
asthma NN 4_p
: : 4_p
Sixteen NNP 4_p
young JJ 4_p
adult NN 4_p
sufferers NNS 4_p
from IN 4_p
extrinsic JJ 4_p
paroxysmal JJ 4_p
asthma NN 4_p
with IN 4_p
pollen JJ 4_p
hypersensitivity NN 4_p
took VBD 4_p
part NN 4_p
in IN 4_p
a DT 4_p
therapeutic JJ 4_p
trial NN 4_p
of IN 4_p
the DT 4_p
synthetic JJ 4_p
anticholinergic NN 4_p
agent NN 4_p
oxitropium NN 4_p
bromide NN 4_p
administered VBN 4_p
by IN 4_p
a DT 4_p
metered VBN 4_p
dose NN 4_p
inhaler NN 4_p
. . 4_p

-DOCSTART- -X- O O 11815321

normal JJ 4_p
pregnancy NN 4_p
. . N

several JJ N
mammalian JJ N
species NNS N
. . N

pregnant JJ 4_p
women NNS 2_p
pregnant JJ 4_p
women NNS 2_p
with IN N
abnormally RB N
increased VBN 4_p
3-HIA JJ 4_p
excretion NN 4_p
. . N

Twenty-six NNP 3_p
pregnant JJ 4_p
women NNS 2_p
with IN N
increased JJ 4_p
3-HIA JJ 4_p
excretion NN 4_p
were VBD N
studied VBN N
in IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
trial NN N
; : N
normal JJ N
pregnancy NN N
-DOCSTART- -X- O O 25670541

locally RB 4_p
advanced JJ 4_p
head NN 4_p
and CC 4_p
neck NN 4_p
cancer NN 4_p
: : N
locally RB 4_p
advanced JJ 4_p
head NN 4_p
and CC 4_p
neck NN 4_p
cancer NN 4_p
. . N

Three CD 3_p
hundred VBD 3_p
eighty-four JJ 3_p
patients NNS 3_p
with IN 3_p
stage NN 3_p
III NNP 3_p
( ( N
6 CD N
% NN N
) ) N
and CC N
IV NNP N
( ( N
94 CD N
% NN N
) ) N
oropharyngeal NN N
( ( N
59.4 CD N
% NN N
) ) N
, , N
hypopharyngeal NN N
( ( N
32.3 CD N
% NN N
) ) N
, , N
and CC N
oral JJ N
cavity NN N
( ( N
8.3 CD N
% NN N
) ) N
cancer NN N
limited VBN 4_p
to TO 4_p
oropharyngeal VB 4_p
cancer NN 4_p
-DOCSTART- -X- O O 12478408

renal JJ 4_p
transplantation NN 4_p
. . 4_p

( ( N
CMV NNP N
) ) N
disease NN N
after IN N
renal JJ N
transplantation NN N
( ( N
RTx NNP N
) ) N
. . N

total NN N
of IN N
38 CD N
patients NNS N
was VBD N
randomized VBN N
to TO N
3-month JJ N
treatment NN N
with IN N
either DT N
oral JJ N
ganciclovir NN N
( ( N
1 CD N
g NN N
t.i.d. NN N
n=14 RB N
, , N
GAN NNP N
group NN N
) ) N
or CC N
oral JJ N
valacyclovir NN N
( ( N
2 CD N
g NN N
q.i.d. NN N
n=12 RB N
, , N
VAL NNP N
group NN N
) ) N
-DOCSTART- -X- O O 17909199

treatment NN N
of IN N
recurrent NN 4_p
or CC 4_p
refractory NN 4_p
non JJ 4_p
small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
. . N

All DT N
patients NNS N
had VBD N
histologically RB 4_p
confirmed VBN 4_p
nonsquamous JJ 4_p
NSCLC NNP 4_p
that WDT N
had VBD N
progressed VBN N
during IN N
or CC N
after IN N
one CD N
platinum-based JJ N
regimen NNS N
. . N

One CD 3_p
hundred VBD 3_p
twenty NN 3_p
patients NNS 3_p
-DOCSTART- -X- O O 16644334

patients NNS N
with IN N
atrial JJ 4_p
fibrillation NN 4_p
. . N

after IN 4_p
conversion NN 4_p
to TO 4_p
sinus VB 4_p
rhythm NN 4_p
. . N

patients NNS N
with IN N
atrial JJ 4_p
fibrillation NN 4_p
Patients NNPS N
who WP N
had VBD N
symptomatic JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
for IN N
> $ N
48 CD N
hours NNS N
but CC N
< $ N
6 CD N
months NNS N
were VBD N
eligible JJ N
Patients NNS N
were VBD N
admitted VBN N
to TO N
a DT N
hospital NN N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
azimilide JJ N
125 CD N
mg NN N
or CC N
a DT N
matched JJ N
placebo NN N
twice RB N
daily RB N
for IN N
3 CD N
days NNS N
and CC N
then RB N
once RB N
daily JJ N
. . N

Patients NNS N
who WP N
were VBD N
in IN N
sinus NN N
rhythm NN N
spontaneously RB N
or CC N
had VBD N
sinus VBN N
rhythm NNS N
restored VBN N
by IN N
electric JJ N
cardioversion NN N
on IN N
day NN N
4 CD N
were VBD N
discharged VBN N
from IN N
the DT N
hospital NN N
. . N

patients NNS N
with IN N
structural JJ 4_p
heart NN 4_p
disease NN 4_p
. . N

446 CD 3_p
patients NNS N
were VBD N
randomized VBN N
in IN N
the DT N
study NN N
; : N
314 CD 3_p
were VBD N
in IN N
the DT N
subgroup NN N
with IN N
structural JJ 4_p
heart NN 4_p
disease NN 4_p
. . N

patients NNS N
with IN N
structural JJ 4_p
heart NN 4_p
disease NN 4_p
who WP N
were VBD N
in IN N
atrial JJ 4_p
fibrillation NN 4_p
and CC N
converted VBD 4_p
to TO 4_p
sinus VB 4_p
rhythm NN 4_p
. . N

-DOCSTART- -X- O O 1659236

methadone NN N
maintenance NN N
heroin VB 4_p
addicts NNS 4_p
waiting VBG N
for IN N
treatment NN N
in IN N
standard JJ N
comprehensive JJ N
methadone NN N
maintenance NN N
programs NNS N
. . N

New NNP N
York NNP N
City NNP N
. . N

A NNP N
sample NN N
of IN N
301 CD 3_p
volunteer NN N
subjects NNS N
recruited VBN N
from IN N
the DT N
waiting VBG N
list NN N
for IN N
treatment NN N
in IN N
the DT N
Beth NNP N
Israel NNP N
methadone NN N
program NN N
persons NNS N
awaiting VBG N
entry NN N
into IN N
comprehensive JJ N
treatment NN N
-DOCSTART- -X- O O 9607867

adult VB 1_p
male JJ 2_p
subjects NNS N
-DOCSTART- -X- O O 9660035

healthy JJ N
volunteers NNS N
. . N

Twenty CD 3_p
volunteers NNS N
were VBD N
given VBN N
single JJ N
doses NNS N
of IN N
fluoxetine JJ N
20 CD N
mg NN N
or CC N
an DT N
identical JJ N
placebo NN N
daily RB N
for IN N
28 CD N
days NNS N
prior RB N
to TO N
receiving VBG N
a DT N
single JJ N
10 CD N
mg JJ N
oral JJ N
dose NN N
of IN N
zolmitriptan NN N
. . N

Sixteen JJ 3_p
volunteers NNS N
completed VBD N
the DT N
two CD N
treatment NN N
phases NNS N
. . N

patients NNS N
treated VBN N
concurrently RB N
with IN N
selective JJ N
serotonin NNS 4_p
reuptake VBP 4_p
inhibitors NNS 4_p
-DOCSTART- -X- O O 10338217

patients NNS 4_p
with IN 4_p
bone NN 4_p
marrow NN 4_p
transplantation NN 4_p
( ( 4_p
BMT NNP 4_p
) ) 4_p
. . N

patients NNS 4_p
undergoing JJ 4_p
BMT NNP 4_p
. . N

66 CD 3_p
patients NNS 3_p
with IN N
43 CD 3_p
hematologic NNS N
and CC N
23 CD 3_p
solid JJ N
malignancies NNS N
( ( N
21 CD 3_p
breast NN N
carcinomas NN N
) ) N
Patients NNS 4_p
with IN 4_p
hematologic JJ 4_p
malignancies NNS 4_p
Patients NNS N
with IN N
solid JJ N
malignancies NNS N
( ( N
n JJ N
= NNP N
23 CD N
) ) N
14 CD 3_p
in-hospital JJ N
deaths NNS N
without IN N
relationship NN 4_p
to TO 4_p
GLN NNP 4_p
administration NN 4_p
. . 4_p

1 CD 3_p
of IN 3_p
10 CD 3_p
hematologic JJ N
patients NNS N
receiving VBG N
GLN NNP N
-DOCSTART- -X- O O 9190129

older JJR 4_p
subjects NNS 4_p
. . 4_p

healthy JJ N
older JJR N
subjects NNS N
Twenty-two JJ N
volunteers NNS N
over IN N
60 CD N
years NNS N
of IN N
age NN N
an DT N
experimental JJ N
group NN N
of IN N
13 CD N
older JJR N
subjects NNS N
( ( N
3 CD N
men NNS N
and CC N
10 CD N
women NNS N
, , N
mean JJ N
age NN N
63.5 CD N
+/- JJ N
3 CD N
years NNS N
) ) N
while IN N
the DT N
remaining VBG N
9 CD N
subjects NNS N
( ( N
3 CD N
men NNS N
and CC N
6 CD N
women NNS N
, , N
mean JJ N
age NN N
64.2 CD N
+/- JJ N
4 CD N
years NNS N
) ) N
served VBD N
as IN N
inactive JJ N
control NN N
group NN N
. . N

healthy JJ N
elderly JJ N
people NNS N
. . N

-DOCSTART- -X- O O 15573541

Operators NNS N
in IN N
complex JJ N
event-driven JJ N
domains NNS N
48 CD 3_p
participants NNS N
performed VBD N
a DT N
visually RB 4_p
demanding VBG 4_p
air NN 4_p
traffic NN 4_p
control NN 4_p
( ( 4_p
ATC NNP 4_p
) ) 4_p
task NN 4_p
. . N

-DOCSTART- -X- O O 19562475

parent-reported JJ N
autism NN 4_p
symptoms NNS 4_p
in IN N
school-age JJ 1_p
children NNS 1_p
with IN N
high-functioning JJ N
autism NN 4_p
. . N

parent-reported JJ N
autism NN 4_p
symptoms NNS N
. . N

Nineteen JJ 3_p
children NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
and CC N
an DT N
anxiety NN N
disorder NN N
( ( 1_p
7-11 CD 1_p
years NNS 1_p
old JJ 1_p
) ) N
were VBD N
randomly RB N
assigned VBN N
-DOCSTART- -X- O O 20569998

elderly JJ 1_p
oncologic JJ 4_p
hypertensive JJ 4_p
patients NNS N
: : N
Elderly JJ N
neoplastic JJ 4_p
patients NNS N
hypertension NN 4_p
and CC N
hyperuricemia NN 4_p
hypertensive JJ 4_p
neoplastic JJ 4_p
elderly JJ 1_p
patients NNS N
. . N

Seventy NNP 3_p
patients NNS N
with IN N
cancer NN 4_p
hypertension NN 4_p
and CC N
hyperuricemia NN 4_p
in IN N
elderly JJ N
patients NNS N
under IN N
chemotherapeutic JJ 4_p
treatment NN 4_p
. . N

-DOCSTART- -X- O O 417361

patients NNS 4_p
with IN 4_p
organic JJ 4_p
dementia NN 4_p
. . 4_p

eight CD 3_p
patients NNS 4_p
in IN 4_p
the DT 4_p
presenile JJ 1_p
age NN 4_p
who WP 4_p
displayed VBD 4_p
symptoms NNS 4_p
of IN 4_p
moderate JJ 4_p
dementia NN 4_p
. . 4_p

-DOCSTART- -X- O O 2085344

weaned JJ N
alcoholics NNS 4_p
. . N

Five CD 3_p
hundred JJ 3_p
and CC 3_p
sixty-nine JJ 3_p
alcoholics NNS 4_p
One CD 3_p
hundred CD 3_p
and CC 3_p
eighty-one JJ 3_p
patients NNS N
in IN N
the DT N
CA NNP N
group NN N
versus VBD N
175 CD 3_p
in IN N
the DT N
placebo NN 4_p
group NN 4_p
completed VBD N
the DT N
three-month JJ N
study NN N
. . N

-DOCSTART- -X- O O 21996146

patients NNS N
having VBG N
coronary JJ N
stent JJ N
implantation NN N
treated VBN N
with IN N
prasugrel NN N
. . N

patients NNS N
with IN N
acute JJ N
coronary JJ N
syndromes NNS N
undergoing VBG N
percutaneous JJ N
coronary JJ N
intervention NN N
. . N

total JJ N
298 CD N
consecutive JJ N
patients NNS N
68 CD N
± JJ N
10 CD N
years NNS N
old JJ N
( ( N
31 CD N
% NN N
> JJ N
75 CD N
years NNS N
old JJ N
) ) N
underwent JJ N
stent JJ N
implantation NN N
and CC N
received VBD N
prasugrel JJ N
therapy NN N
. . N

Patients NNS N
≥75 CD N
years NNS N
old JJ N
and CC N
with IN N
body NN N
weight JJ N
≤60 NNP N
-DOCSTART- -X- O O 15541087

Twenty NNP N
patients NNS N
with IN N
seborrhoeic JJ N
dermatitis NN N
were VBD N
included VBN N
in IN N
this DT N
study NN N
, , N
11 CD N
patients NNS N
in IN N
the DT N
pimecrolimus JJ N
1 CD N
% NN N
cream NN N
group NN N
and CC N
nine CD N
patients NNS N
in IN N
the DT N
betamethasone NN N
17-valerate JJ N
0.1 CD N
% NN N
cream NN N
group NN N
. . N

-DOCSTART- -X- O O 24928832

metastatic JJ 4_p
or CC 4_p
recurrent JJ 4_p
squamous JJ 4_p
cell NN 4_p
carcinoma NN 4_p
of IN 4_p
the DT 4_p
head NN 4_p
and CC 4_p
neck NN 4_p
. . N

recurrent NN 4_p
or CC 4_p
metastatic JJ 4_p
( ( 4_p
R/M NNP 4_p
) ) 4_p
head NN 4_p
and CC 4_p
neck NN 4_p
squamous JJ 4_p
cell NN 4_p
carcinoma NN 4_p
( ( 4_p
HNSCC NNP 4_p
) ) 4_p
patients NNS 4_p
, , N
whose WP$ N
disease NN 4_p
has VBZ 4_p
progressed VBN 4_p
after IN 4_p
platinum-containing JJ 4_p
therapy NN 4_p
. . N

43 CD N
centers NNS N
; : N
124 CD 3_p
patients NNS 3_p
A DT N
total NN N
of IN N
121 CD 3_p
patients NNS 3_p
were VBD N
treated VBN N
( ( N
61 CD 3_p
afatinib NN 3_p
, , N
60 CD 3_p
cetuximab NN 3_p
) ) N
and CC N
68 CD 3_p
crossed VBN 3_p
over IN 3_p
to TO 3_p
stage VB 3_p
II NNP 3_p
( ( N
32 CD 3_p
and CC N
36 CD 3_p
respectively RB N
) ) N
. . N

in IN N
R/M NNP N
HNSCC NNP N
-DOCSTART- -X- O O 25082565

patients NNS N
with IN N
non-small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
after IN N
failure NN N
of IN N
first-line JJ N
chemotherapy NN N
: : N
patients NNS N
with IN N
non-small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
( ( 4_p
NSCLC NNP 4_p
) ) 4_p
patients NNS N
with IN N
advanced JJ 4_p
NSCLC NNP 4_p
, , N
EGFR NNP N
wild-type NN N
or CC N
unknown JJ N
, , N
PS NNP N
0-2 CD N
, , N
in IN N
whom WP N
initial JJ N
cisplatin-based JJ N
chemotherapy NN N
had VBD N
failed VBN N
147 CD 3_p
patients NNS N
were VBD N
randomized VBN N
( ( N
median JJ N
age NN N
: : N
60±8 CD 1_p
years NNS 1_p
, , 1_p
PS NNP N
0/1/2 CD N
: : N
44/83/20 CD N
patients NNS N
; : N
males NNS 2_p
: : N
78 CD N
% NN N
) ) N
-DOCSTART- -X- O O 14970775

palatal-anterior JJ N
superior JJ N
alveolar JJ N
injection NN N
40 CD 3_p
subjects NNS N
-DOCSTART- -X- O O 9101947

inguinal JJ 4_p
hernia NN 4_p
repair NN 4_p
-DOCSTART- -X- O O 24505318

internet NN N
use NN N
Korean JJ N
adolescents NNS 1_p
: : N
57,857 CD 3_p
middle JJ N
and CC N
high JJ N
school NN N
students NNS N
( ( N
13-18 CD 1_p
year NN 1_p
olds NNS 1_p
) ) N
from IN N
a DT N
Korean NNP N
nationally RB N
representative JJ N
survey NN N
, , N
which WDT N
was VBD N
surveyed VBN N
in IN N
2009 CD N
. . N

Female JJ 2_p
students NNS N
in IN N
girls NNS N
' POS N
schools NNS N
adolescents NNS 1_p
-DOCSTART- -X- O O 6119875

patients NNS N
with IN N
myocardial JJ 4_p
infarction NN 4_p
patients NNS N
with IN N
suspected JJ N
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
In IN N
the DT N
first JJ N
study NN N
388 CD 3_p
patients NNS 3_p
with IN N
suspected JJ N
acute JJ N
myocardial JJ N
infarction NN N
473 CD 3_p
patients NNS 3_p
with IN N
suspected JJ N
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
Patients NNS N
-DOCSTART- -X- O O 26046796

pancreatic JJ 4_p
cancer NN 4_p
with IN 4_p
epidermal JJ 4_p
growth NN N
factor NN N
receptor NN N
mutations NNS N
: : N
Eighty-eight JJ 3_p
chemotherapy-naïve JJ 4_p
metastatic JJ 4_p
pancreatic JJ 4_p
cancer NN 4_p
patients NNS 4_p
were VBD N
randomized VBN N
for IN N
treatment NN N
with IN N
gemcitabine NN 4_p
or CC 4_p
gemcitabine NN 4_p
plus CC 4_p
erlotinib NN 4_p
in IN N
patients NNS 4_p
with IN 4_p
EGFR NNP 4_p
mutations NNS 4_p
than IN 4_p
in IN 4_p
those DT 4_p
without IN 4_p
EGFR NNP 4_p
mutations NNS 4_p
treating VBG 4_p
metastatic JJ 4_p
pancreatic JJ 4_p
cancer NN 4_p
patients NNS 4_p
, , 4_p
especially RB 4_p
those DT 4_p
with IN 4_p
EGFR NNP 4_p
mutations NNS 4_p
-DOCSTART- -X- O O 15839875

chronic JJ 4_p
suppurative JJ 4_p
otitis NN 4_p
media NNS 4_p
: : 4_p
a DT 4_p
randomized NN 4_p
controlled VBN 4_p
trial NN 4_p
. . N

-DOCSTART- -X- O O 21424566

Two CD N
groups NNS N
of IN N
40 CD 3_p
consecutive JJ N
asymptomatic JJ N
patients NNS N
aged VBN 1_p
between IN 1_p
48 CD 1_p
and CC 1_p
72 CD 1_p
years NNS 1_p
underwent JJ N
CT NNP N
colonography NN N
. . N

-DOCSTART- -X- O O 22678947

mild JJ 4_p
cognitive JJ 4_p
impairment NN 4_p
: : 4_p
Individuals NNS N
with IN N
amnestic JJ 4_p
mild NNS 4_p
cognitive JJ 4_p
impairment NN 4_p
( ( 4_p
MCI NNP 4_p
) ) 4_p
individuals NNS N
with IN N
amnestic JJ 4_p
MCI NNP 4_p
. . 4_p

Forty NNP 3_p
individuals NNS N
with IN N
single JJ 4_p
domain NN 4_p
amnestic JJ 4_p
MCI NNP 4_p
and CC N
their PRP$ N
program NN N
partners NNS N
were VBD N
randomized VBN N
-DOCSTART- -X- O O 18073312

obese JJ N
humans NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
mellitus JJ N
humans NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
mellitus VBP N
; : N
The DT N
study NN N
was VBD N
performed VBN N
at IN N
Ohio NNP N
State NNP N
University NNP N
's POS N
General NNP N
Clinical NNP N
Research NNP N
Center NNP N
. . N

There EX N
were VBD N
18 CD N
obese JJ N
, , N
mildly RB N
diabetic JJ N
humans NNS N
included VBD N
in IN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 1408861

first-time JJ 4_p
adolescent NN 1_p
mothers NNS N
and CC 4_p
their PRP$ 4_p
infants NNS 1_p
. . N

adolescent JJ 1_p
mothers NNS 2_p
( ( 1_p
17 CD 1_p
years NNS 1_p
old JJ 1_p
or CC 1_p
younger JJR 1_p
) ) 1_p
and CC 1_p
their PRP$ 1_p
infants NNS 1_p
, , 1_p
243 CD 3_p
mother-infant JJ N
pairs NNS N
were VBD 4_p
randomly RB 4_p
assigned VBN 4_p
two CD N
groups NNS N
. . N

All DT N
of IN N
the DT N
mothers NNS N
were VBD N
unwed JJ N
, , N
on IN N
Medicaid NNP N
, , N
and CC N
black JJ N
. . N

control NN N
group NN N
experimental JJ N
group NN N
-DOCSTART- -X- O O 18565251

osteoarthritis NN 4_p
of IN 4_p
the DT 4_p
ankle NN 4_p
. . N

patients NNS N
with IN N
osteoarthritis NN 4_p
( ( N
OA NNP 4_p
) ) N
of IN N
the DT N
ankle NN N
. . N

43 CD N
ankles NNS N
( ( N
30 CD 3_p
patients NNS N
) ) N
with IN N
radiographic JJ 4_p
Kellgren NNP 4_p
Lawrence NNP 4_p
grade VBD 4_p
III NNP 4_p
OA NNP 4_p
-DOCSTART- -X- O O 25516338

African JJ N
Americans NNPS N
From IN N
the DT N
PointBreak NNP N
Study NNP N
: : N
in IN N
Patients NNP N
With IN N
Stage NNP 4_p
IIIB/IV NNP 4_p
Nonsquamous NNP 4_p
Non-Small-Cell NNP 4_p
Lung NNP 4_p
Cancer NNP 4_p
INTRODUCTION NNP N
African JJ N
Americans NNPS N
have VBP N
a DT N
greater JJR N
incidence NN N
of IN N
lung NN 4_p
cancer NN 4_p
than IN N
whites NNS N
10 CD N
% NN N
of IN N
the DT N
patients NNS N
were VBD N
African JJ N
American NNP N
analyzed VBN N
: : N
African JJ N
Americans NNPS N
versus VBP N
whites NNS N
for IN N
PemCBev NNP 4_p
; : N
PemCBev NNP 4_p
versus NN N
PacCBev NNP 4_p
in IN N
African NNP N
Americans NNPS N
; : N
and CC N
academic JJ N
versus NN N
community NN N
settings NNS N
for IN N
African JJ N
Americans NNPS N
. . N

RESULTS NNP N
Of IN N
939 CD N
intent-to-treat NN N
( ( N
ITT NNP N
) ) N
patients NNS N
, , N
94 CD N
were VBD N
African JJ N
American NNP N
and CC N
805 CD N
were VBD N
white JJ N
. . N

African-American JJ N
differences NNS N
between IN N
African JJ N
Americans NNPS N
and CC N
result NN N
, , N
for IN N
African JJ N
Americans NNPS N
arm NN N
. . N

For IN N
African JJ N
Americans NNPS N
outcomes NNS N
data NNS N
for IN N
African JJ N
-DOCSTART- -X- O O 17009251

hip NN 4_p
and CC 4_p
knee VB 4_p
joint JJ 4_p
replacement NN 4_p
in IN N
the DT N
Women NNP 2_p
's POS 2_p
Health NNP N
Initiative NNP N
. . N

data NNS N
from IN N
the DT N
Women NNP 2_p
's POS 2_p
Health NNP N
Initiative NNP N
placebo-controlled JJ N
, , N
double-blind JJ N
, , N
randomized JJ N
trials NNS N
. . N

Community-dwelling JJ 4_p
women NNS 2_p
ages VBZ N
50-79 JJ 1_p
years NNS 1_p
were VBD N
enrolled VBN N
at IN N
40 CD N
US NNP N
clinics NNS N
. . N

Women NNS 2_p
with IN N
prior JJ N
arthroplasty NNS N
were VBD N
excluded VBN N
, , N
yielding VBG N
a DT N
sample JJ N
size NN N
of IN N
26,321 CD 3_p
subjects NNS N
. . N

Women NNS N
who WP 4_p
had VBD 4_p
had VBN 4_p
hysterectomies NNS 4_p
Those DT 4_p
who WP 4_p
had VBD 4_p
not RB 4_p
had VBN 4_p
hysterectomies NNS 4_p
women NNS 2_p
-DOCSTART- -X- O O 21909698

Patients NNPS N
above IN N
18 CD 1_p
years NNS 1_p
with IN N
a DT N
rectal JJ 4_p
cancer NN 4_p
, , N
able JJ 4_p
to TO 4_p
give VB 4_p
informed JJ 4_p
consent NN 4_p
, , N
and CC N
scheduled VBD 4_p
for IN 4_p
an DT 4_p
anterior JJ 4_p
resection NN 4_p
were VBD N
eligible JJ N
for IN N
the DT N
study NN N
. . N

leak NN 4_p
. . N

RESULTS NNP N
Five CD 3_p
hundred VBD 3_p
twenty-nine NN 3_p
patients NNS N
were VBD N
randomised VBN N
( ( N
58 CD N
% NN N
-DOCSTART- -X- O O 23801256

autistic JJ 4_p
disorders NNS 4_p
patients NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . N

Fifty NNP 3_p
nine CD 3_p
children NNS 1_p
and CC N
adolescents NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
-DOCSTART- -X- O O 16571852

2862 CD 3_p
eligible JJ N
overweight NN 4_p
and CC 4_p
obese JJ 4_p
( ( 4_p
BMI NNP 4_p
= VBZ 4_p
27 CD 4_p
to TO 4_p
40 CD 4_p
kg/m2 NNS 4_p
) ) 4_p
members NNS N
from IN N
four CD N
regions NNS N
of IN N
Kaiser NNP N
Permanente NNP N
's POS N
integrated JJ N
health NN N
care NN N
delivery NN N
system NN N
participants NNS N
Subjects NNS N
in IN N
the DT N
tailored VBN N
expert NN N
system NN N
subjects NNS N
in IN N
the DT N
information-only JJ N
condition NN N
Participants NNS N
36 CD N
% NN N
of IN N
enrollees NNS N
were VBD N
African-American JJ N
, , N
with IN N
enrollment NN N
rates NNS N
higher RBR N
than IN N
the DT N
general JJ N
proportion NN N
of IN N
African JJ N
Americans NNPS N
in IN N
any DT N
of IN N
the DT N
study NN N
regions NNS N
. . N

-DOCSTART- -X- O O 6849742

six CD 3_p
subjects NNS N
who WP N
received VBD N
either DT N
placebo NN N
, , N
practolol VBP N
50 CD N
mg NN N
, , N
practolol VBP N
200 CD N
mg NN N
, , N
propranolol VBP N
10 CD N
mg NN N
or CC N
propranolol VB N
40 CD N
mg. NN N
-DOCSTART- -X- O O 26224825

adult NN 1_p
patients NNS N
with IN N
a DT N
dorsally RB N
displaced JJ N
fracture NN N
of IN N
the DT N
distal JJ N
radius NN N
: : N
patients NNS N
with IN N
dorsally-displaced JJ 4_p
fractures NNS 4_p
of IN 4_p
the DT 4_p
distal JJ 4_p
radius NN 4_p
. . N

18 CD N
trauma NN 4_p
centres NNS N
in IN N
the DT N
United NNP N
Kingdom NNP N
. . N

Data NNP N
from IN N
460 CD 3_p
patients NNS N
were VBD N
available JJ N
for IN N
analysis NN N
patients NNS N
treated VBN N
with IN N
locking-plate JJ N
fixation NN N
over IN N
those DT N
treated VBN N
with IN N
K-wires NNP N
. . N

-DOCSTART- -X- O O 1291393

One CD 3_p
hundred VBD 3_p
maxillary JJ N
premolar JJ N
teeth NNS N
ten VB N
groups NNS N
. . N

Each DT N
group NN N
-DOCSTART- -X- O O 3818024

Seven NNP N
healthy JJ N
subjects NNS N
patients NNS N
with IN N
ischaemic JJ N
heart NN N
disease NN N
. . N

-DOCSTART- -X- O O 20434046

chronically RB 4_p
hospitalized VBN 4_p
, , N
disabled JJ 4_p
patients NNS N
with IN N
stroke NN 4_p
. . N

chronically RB N
hospitalized VBN N
, , N
disabled VBD N
, , N
elderly JJ 1_p
patients NNS N
after IN N
stroke NN N
. . N

Duration NN N
of IN N
hospitalization NN N
was VBD N
more JJR N
than IN N
1 CD N
year NN N
because IN N
of IN N
insufficiency NN N
of IN N
nursing NN N
homes NNS N
. . N

elderly JJ N
patients NNS N
who WP N
are VBP N
chronically RB N
hospitalized VBN N
and CC N
disabled VBN N
as IN N
a DT N
result NN N
of IN N
hemiparesis NN 4_p
after IN N
stroke NN N
. . N

Patients NNS N
with IN N
stroke NN N
chronically RB N
hospitalized VBN N
patients NNS N
poststroke VBD N
-DOCSTART- -X- O O 26082615

hypertensive JJ 4_p
patients NNS 4_p
inadequately RB N
controlled VBN N
by IN N
fimasartan JJ N
monotherapy NN N
. . N

patients NNS N
whose WP$ N
BP NNP N
goal NN N
was VBD N
not RB N
achieved VBN N
after IN N
4 CD N
weeks NNS N
of IN N
treatment NN N
with IN N
once-daily JJ N
fimasartan JJ N
60 CD N
mg. JJ N
Patients NNPS N
with IN N
sitting VBG N
diastolic JJ 4_p
blood NN 4_p
pressure NN 4_p
( ( 4_p
siDBP NN 4_p
) ) 4_p
≥90 VBZ N
mmHg NN N
with IN N
4 CD N
weeks NNS N
of IN N
once-daily JJ N
fimasartan JJ N
60 CD N
mg NNS N
the DT N
263 CD 3_p
randomized JJ N
patients NNS N
, , N
256 CD 3_p
patients NNS N
who WP N
had VBD N
available JJ N
efficacy NN N
data NNS N
were VBD N
analyzed VBN N
-DOCSTART- -X- O O 3065176

[ JJ 4_p
Vulvovaginal NNP 4_p
Candida NNP 4_p
mycoses VBZ 4_p
-- : 4_p
treatment NN 4_p
-DOCSTART- -X- O O 3715614

cancer NN 4_p
of IN 4_p
the DT 4_p
thyroid JJ 4_p
gland NN 4_p
] NN 4_p
-DOCSTART- -X- O O 24689172

Chinese JJ N
ring-necked JJ N
pheasants NNS N
( ( N
Phasianus NNP N
colchicus NN N
) ) N
. . N

game NN 4_p
farm-reared JJ 4_p
pheasants NNS 4_p
in IN 4_p
the DT 4_p
United NNP 4_p
States NNPS 4_p
. . 4_p

Chinese JJ N
ring-necked JJ N
pheasants NNS N
Pheasant JJ N
chicks NNS N
( ( N
approximately RB N
1 CD N
day-old JJ N
; : N
n CC 3_p
= VB 3_p
160 CD 3_p
) ) N
Chinese JJ N
ring-necked JJ N
pheasants NNS N
. . N

-DOCSTART- -X- O O 20017819

dogs NNS 4_p
. . 4_p

healthy JJ 4_p
dogs NNS 4_p
. . 4_p

Nine NNP 4_p
adult NN 4_p
dogs NNS 4_p
( ( 4_p
beagle NN 4_p
and CC 4_p
beagle NN 4_p
cross NN 4_p
breeds NNS 4_p
) ) 4_p
, , 4_p
four CD 4_p
males NNS 4_p
and CC 4_p
five CD 4_p
females NNS 4_p
. . 4_p

-DOCSTART- -X- O O 3541596

mild JJ 4_p
hypertension NN 4_p
mild JJ 4_p
diastolic JJ 4_p
hypertension NN 4_p
( ( N
range NN N
: : N
95 CD N
to TO N
105 CD N
mm NNS N
Hg NNP N
) ) N
Fifty-six JJ 3_p
patients NNS N
were VBD N
enrolled VBN N
-DOCSTART- -X- O O 15746480

outpatient JJ N
youth NN N
with IN N
autistic JJ N
disorder NN N
: : N
youth NN N
with IN N
developmental JJ N
disabilities NNS N
. . N

eight CD 4_p
outpatients NNS 4_p
who WP 4_p
participated VBD 4_p
in IN 4_p
an DT 4_p
ongoing JJ 4_p
placebo-controlled JJ 4_p
study NN 4_p
of IN 4_p
valproate NN 4_p
for IN 4_p
aggression NN 4_p
in IN 4_p
autism NN 4_p
. . 4_p

-DOCSTART- -X- O O 8644646

Fifty-nine NNP N
episodes NNS N
of IN N
atrial JJ 4_p
flutter NN 4_p
in IN N
54 CD 3_p
patients NNS N
who WP N
failed VBD N
to TO N
terminate VB N
with IN N
an DT N
intravenous JJ N
infusion NN N
of IN N
ibutilide NN N
, , N
procainamide NN N
, , N
or CC N
placebo VB N
alone JJ N
underwent JJ N
attempts NNS N
at IN N
pacing VBG N
termination NN N
using VBG N
a DT N
standard JJ N
protocol NN N
of IN N
burst JJ N
atrial JJ N
overdrive JJ N
pacing NN N
. . N

-DOCSTART- -X- O O 15535495

One CD 3_p
hundred VBD 3_p
anaesthetized JJ N
patients NNS N
( ( N
ASA NNP N
1-2 CD N
, , N
aged VBD N
18 CD 1_p
to TO 1_p
80 CD 1_p
years NNS 1_p
) ) N
-DOCSTART- -X- O O 22740508

chronic JJ 4_p
heart NN 4_p
failure NN 4_p
: : 4_p
two CD N
large JJ N
populations NNS N
of IN N
patients NNS N
with IN N
HF NNP N
. . N

1457 CD 3_p
patients NNS 3_p
enrolled VBN N
in IN N
the DT N
Controlled NNP 4_p
Rosuvastatin NNP 4_p
Multinational NNP 4_p
Trial NNP 4_p
in IN 4_p
HF NNP 4_p
( ( 4_p
CORONA NNP 4_p
) ) N
and CC N
1233 CD 3_p
patients NNS 3_p
enrolled VBN N
in IN N
the DT N
GISSI-Heart NNP N
Failure NNP N
trial NN N
( ( N
GISSI-HF NNP N
) ) N
. . N

patients NNS 4_p
with IN 4_p
chronic JJ 4_p
HF NNP 4_p
-DOCSTART- -X- O O 21418212

toddlers NNS 4_p
with IN 4_p
early JJ 4_p
autism NN 4_p
symptoms NNS 4_p
. . 4_p

Sixty-two JJ N
children NNS N
( ( N
51 CD N
boys NNS N
and CC N
11 CD N
girls NNS N
; : N
M NNP N
age NN N
= VBD N
20 CD N
months NNS N
; : N
SD NNP N
= NNP N
2.6 CD N
) ) N
who WP N
met VBD N
criteria NNS N
for IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
) ) N
and CC N
their PRP$ N
parents NNS N
participated VBN N
in IN N
the DT N
study NN N
. . N

. . N

Parents NNS N
of IN N
children NNS N
who WP N
evidence NN N
higher JJR N
object JJ N
interest NN N
-DOCSTART- -X- O O 25527253

patients NNS 4_p
with IN 4_p
spinal JJ 4_p
cord NN 4_p
injury NN 4_p
and CC 4_p
major JJ 4_p
depression NN 4_p
: : 4_p
pain NN 4_p
( ( 4_p
secondary JJ 4_p
aim NN 4_p
) ) 4_p
in IN 4_p
individuals NNS 4_p
with IN 4_p
spinal JJ 4_p
cord NN 4_p
injury NN 4_p
( ( 4_p
SCI NNP 4_p
) ) 4_p
enrolled VBD 4_p
in IN 4_p
a DT 4_p
randomized NN 4_p
controlled VBN 4_p
trial NN 4_p
( ( 4_p
RCT NNP 4_p
) ) 4_p
on IN 4_p
the DT 4_p
efficacy NN 4_p
of IN 4_p
venlafaxine NN 4_p
XR NN 4_p
for IN 4_p
major JJ 4_p
depressive JJ 4_p
disorder NN 4_p
( ( 4_p
MDD NNP 4_p
) ) 4_p
Six NNP N
Departments NNP N
of IN N
Physical NNP N
Medicine NNP N
and CC N
Rehabilitation NNP N
in IN N
university-based JJ N
medical JJ N
schools NNS N
. . N

Individuals NNS N
( ( 3_p
N=123 NNP 3_p
) ) N
with IN N
SCI NNP N
and CC N
major JJ N
depression NN N
between IN N
18 CD 1_p
and CC 1_p
64 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
, , N
at IN N
least JJS N
1 CD N
month NN N
post-SCI NN N
who WP N
also RB N
reported VBD N
pain NN N
. . N

-DOCSTART- -X- O O 1927197

gastroesophageal JJ 4_p
malignancy NN 4_p
. . 4_p

300 CD 3_p
consecutive JJ N
patients NNS N
, , N
including VBG N
256 CD 3_p
with IN N
esophageal NN 4_p
or CC 4_p
gastric JJ 4_p
carcinomas NN 4_p
. . N

patients NNS N
with IN N
carcinoma NN 4_p
-DOCSTART- -X- O O 24292519

patients NNS N
with IN N
standard-risk JJ 4_p
disease NN 4_p
following VBG N
haploidentical JJ 4_p
transplantation NN 4_p
: : N
patients NNS N
receiving VBG N
hematopoietic JJ N
SCT NNP N
without IN N
ex JJ N
vivo FW N
T-cell-depletion NN N
from IN N
haploidentical JJ N
donors NNS N
, , N
224 CD 3_p
patients NNS 3_p
with IN N
standard-risk JJ 4_p
hematological JJ 4_p
malignancy NN 4_p
One CD 3_p
hundred CD 3_p
and CC 3_p
twelve VB 3_p
patients NNS 3_p
-DOCSTART- -X- O O 16548702

breast VB 4_p
cancer NN 4_p
risk NN 4_p
134 CD 3_p
young JJ 1_p
adult NN 1_p
women NNS 2_p
, , N
6 CD 3_p
variables NNS N
-DOCSTART- -X- O O 23775967

patients NNS N
with IN N
lymphoma NN N
and CC N
resolved VBD N
hepatitis NN N
B NNP N
. . N

patients NNS N
with IN N
lymphoma NN N
and CC N
resolved VBD N
hepatitis NN N
B NNP N
Eighty NNP N
patients NNS N
with IN N
CD20 NNP N
( ( N
+ NNP N
) ) N
lymphoma NN N
and CC N
resolved VBD N
hepatitis NN N
B NNP N
Fifty-eight JJ N
patients NNS N
one CD N
patient NN N
seven CD N
patients NNS N
control NN N
group NN N
Four CD N
patients NNS N
control NN N
group NN N
patients NNS N
with IN N
lymphoma NN N
and CC N
resolved VBD N
hepatitis NN N
B NNP N
. . N

-DOCSTART- -X- O O 10200837

children NNS 4_p
with IN 4_p
autism NN 4_p
: : 4_p
persons NNS N
with IN N
autism NN N
Twelve NNP N
children NNS N
with IN N
autism NN N
-DOCSTART- -X- O O 3180669

37 CD 3_p
non-atopic JJ 4_p
patients NNS 4_p
referred VBD 4_p
for IN 4_p
intravenous JJ 4_p
urography NN 4_p
. . N

Nineteen JJ 3_p
patients NNS N
18 CD 3_p
patients NNS N
non-atopic JJ 4_p
patients NNS 4_p
undergoing VBG 4_p
intravenous JJ 4_p
urography NN 4_p
. . N

-DOCSTART- -X- O O 8045623

cervical JJ 4_p
spondylosis NN 4_p
. . N

Two CD 3_p
hundred JJ 3_p
cases NNS N
of IN N
cervical JJ 4_p
spondylosis NN 4_p
were VBD N
studied VBN N
-DOCSTART- -X- O O 8311760

Does NNP N
wavelength VB N
matter NN N
when WRB N
photocoagulating VBG N
eyes NNS N
with IN N
macular JJ N
degeneration NN N
or CC N
diabetic JJ N
retinopathy NN N
? . N
-DOCSTART- -X- O O 11488317

adult JJ 1_p
asthmatic JJ 4_p
patients NNS N
. . N

adult NN N
asthmatic JJ N
patients NNS N
Twenty NNP 3_p
adult NN N
patients NNS N
with IN N
asthma NNS N
were VBD N
studied VBN N
. . N

no DT N
cardiovascular JJ N
disease NN N
or CC N
medication NN N
. . N

-DOCSTART- -X- O O 8338088

colonoscopy NN 4_p
or CC 4_p
sigmoidoscopy JJ 4_p
preparation NN 4_p
. . 4_p

One CD N
hundred VBD N
thirteen JJ N
patients NNS N
-DOCSTART- -X- O O 10463847

childhood NN 4_p
severe JJ 4_p
cryptogenic/idiopathic NN 4_p
generalised VBD 4_p
epilepsy NN 4_p
72 CD N
children NNS N
with IN N
no DT N
evidence NN N
of IN N
brain NN N
damage NN N
, , N
starting VBG N
epilepsy NN N
between IN N
1 CD N
and CC N
10 CD N
years NNS N
, , N
with IN N
two CD N
or CC N
more JJR N
types NNS N
of IN N
generalised JJ N
seizures NNS N
. . N

excluded VBD N
patients NNS N
with IN N
infantile JJ N
spasms NNS N
or CC N
typical JJ N
absences NNS N
. . N

-DOCSTART- -X- O O 10860330

randomly RB 4_p
selected VBN 4_p
subjects NNS 4_p
for IN N
cavity NN 4_p
preparation NN 4_p
with IN N
conventional JJ N
air NN N
turbine/bur IN N
dental JJ N
surgery NN N
or CC N
an DT N
Er NNP N
, , N
Cr NNP N
: : N
YSGG PRP$ N
laser-powered JJ N
system NN N
using VBG N
a DT N
split-mouth JJ N
design NN N
. . N

Sixty-seven JJ 3_p
subjects NNS N
completed VBD N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 12020338

microvascular JJ N
complications NNS N
of IN N
type NN 4_p
1 CD 4_p
diabetes NNS 4_p
mellitus RB 4_p
. . N

microvascular JJ N
complications NNS N
of IN N
type NN 4_p
1 CD 4_p
diabetes NNS 4_p
mellitus RB 4_p
. . N

type NN N
1 CD N
diabetes NNS N
mellitus NN N
-DOCSTART- -X- O O 7977921

older JJR 1_p
adults NNS 1_p
: : N
older JJR N
adults NNS N
From IN N
a DT N
random JJ N
sample NN N
of IN N
health NN N
maintenance NN N
organization NN N
( ( N
HMO NNP N
) ) N
enrollees VBZ N
65 CD N
years NNS N
and CC N
older JJR N
, , N
1559 CD 3_p
ambulatory NN N
seniors NNS N
ambulatory NN 4_p
HMO NNP 4_p
enrollees NNS 4_p
-DOCSTART- -X- O O 3624669

20 CD 3_p
men NNS 2_p
with IN N
ventricular JJ 4_p
tachycardia NN 4_p
. . N

patient NN N
both DT N
with IN N
placebo NN 4_p
and CC N
with IN N
active JJ 4_p
pyridostigmine NN 4_p
. . 4_p

-DOCSTART- -X- O O 7208897

Breast NNP 4_p
cancer NN 4_p
screening VBG 4_p
Sweden NNP 4_p
. . 4_p

Four CD N
population-based JJ N
breast NN N
cancer NN N
screening VBG N
projects NNS N
are VBP N
in IN N
progress NN N
in IN N
Sweden NNP N
-DOCSTART- -X- O O 2764265

trauma NN 4_p
patients NNS N
] VBP N
50 CD 3_p
posttraumatic JJ 4_p
intensive-care JJ 4_p
patients NNS N
with IN N
medium NN N
grade NN N
lesions NNS 4_p
( ( N
ISS NNP 4_p
criteria NNS 4_p
) ) N
, , N
the DT N
patients NNS N
who WP N
are VBP N
at IN N
particularly RB N
high JJ N
infection NN 4_p
exposure NN N
risk NN N
, , N
e.g NN N
. . N

through IN N
reintervention NN 4_p
surgery NN 4_p
, , N
haemorrhage NN 4_p
complications NNS 4_p
or CC N
extensive JJ N
diagnostic JJ 4_p
interventions NNS 4_p
. . N

-DOCSTART- -X- O O 22795327

glioma NN 4_p
risk NN 4_p
in IN N
Han NNP N
Chinese NNP N
. . N

glioma JJ N
susceptibility NN N
10 CD N
tag NN N
single JJ N
nucleotide JJ N
polymorphisms NN N
( ( N
tSNPs NN N
) ) N
in IN N
seven CD N
genes NNS N
associated VBN N
with IN N
glioma NN 4_p
susceptibility NN N
in IN N
a DT N
Han NNP N
Chinese NNP N
population NN N
, , N
including VBG N
301 CD 3_p
glioma NN N
cases NNS N
and CC N
302 CD 3_p
controls NNS N
, , N
using VBG N
a DT N
multiplexed JJ N
single JJ N
nucleotide NN N
polymorphism NN N
( ( N
SNP NNP N
) ) N
MassEXTEND NNP N
assay NN N
. . N

-DOCSTART- -X- O O 22628369

METHODS NNP N
Participants NNP N
( ( N
n JJ 3_p
= NNP 3_p
80 CD 3_p
) ) N
were VBD N
recruited VBN N
from IN N
a DT N
hospital NN N
clinic NN N
in IN N
Chandigarh NNP N
, , N
India NNP N
, , N
and CC N
randomized VBD N
to TO N
a DT N
3-month JJ N
group NN N
intervention NN N
or CC N
individual JJ N
enhanced JJ N
standard NN N
of IN N
care NN N
followed VBN N
by IN N
crossover NN N
of IN N
condition NN N
and CC N
assessed VBD N
over IN N
6 CD N
months NNS N
. . N

-DOCSTART- -X- O O 3119086

autistic JJ 4_p
symptoms NNS 4_p
. . N

-DOCSTART- -X- O O 18592368

autistic JJ 4_p
children NNS 1_p
: : N
pre-school JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
. . N

children NNS 1_p
with IN N
autism NN 4_p
. . N

-DOCSTART- -X- O O 10073522

tubal JJ 4_p
pregnancy NN 4_p
. . 4_p

-DOCSTART- -X- O O 18357902

below-knee NN 4_p
amputees NNS 4_p
] VBP N
younger JJR 1_p
population NN N
below-knee NN 4_p
amputees NNS 4_p
, , N
secondary JJ N
to TO N
war NN 4_p
wounding VBG 4_p
. . N

Forty NNP 3_p
below-knee NN 4_p
amputees NNS 4_p
( ( N
after IN 4_p
war NN 4_p
wounding NN 4_p
) ) N
, , N
average JJ N
age NN N
35.6 CD 1_p
+/- JJ 1_p
10.6 CD 1_p
years NNS N
, , N
that WDT N
were VBD N
included VBN N
in IN N
primary JJ N
rehabilitation NN N
program NN N
with IN N
prosthetics NNS N
, , N
were VBD N
examined VBN N
. . N

amputated VBN N
and CC N
non-amputated JJ N
limbs NNS N
in IN N
war NN 4_p
wounded VBD 4_p
below-knee JJ 4_p
amputees NNS 4_p
. . 4_p

-DOCSTART- -X- O O 3174738

nicotine JJ N
chewing VBG N
gum NN N
in IN N
humans NNS N
. . N

nine CD 3_p
cigarette NN 4_p
smokers NNS 4_p
who WP N
had VBD N
been VBN N
abstinent JJ N
from IN N
tobacco NN N
for IN N
12 CD N
hr NN N
. . N

-DOCSTART- -X- O O 2192505

[ JJ N
Cisapride NNP 4_p
for IN N
the DT N
treatment NN N
of IN N
irritable JJ 4_p
stomach NN 4_p
-- : N
results NNS N
of IN N
2 CD N
multicenter NN N
studies NNS N
] VBP N
-DOCSTART- -X- O O 16794570

influenza NN N
A NNP N
, , N
Parkinson NNP N
's POS N
disease NN N
( ( N
PD NNP N
) ) N
, , N
and CC N
acute NN N
or CC N
chronic JJ N
drug-induced JJ N
dyskinesia NN N
. . N

normal JJ 4_p
subjects NNS N
. . N

14 CD 3_p
healthy JJ 4_p
subjects NNS N
-DOCSTART- -X- O O 7080985

three CD N
groups NNS N
of IN N
30 CD 3_p
patients NNS N
with IN N
uncomplicated JJ N
urinary JJ 4_p
infections NNS 4_p
] VBP N
. . N

-DOCSTART- -X- O O 9413463

liver-transplant JJ 4_p
recipients NNS N
. . N

orthotopic NN N
liver JJ N
transplantation NN N
. . N

Between NNP N
December NNP N
, , N
1993 CD N
, , N
and CC N
April NNP N
, , N
1995 CD N
, , N
304 CD 3_p
liver-transplant JJ N
recipients NNS N
Seronegative JJ N
recipients NNS N
of IN N
seronegative JJ 4_p
livers NNS 4_p
orthotopic NN N
liver NN 4_p
transplantation NN 4_p
. . N

-DOCSTART- -X- O O 11450816

autistic JJ 4_p
disorder NN 4_p
: : 4_p
Twenty-eight JJ 3_p
children NNS 1_p
( ( N
27 CD 3_p
boys NNS N
) ) N
ages VBZ 1_p
3 CD 1_p
to TO 1_p
11 CD 1_p
years NNS 1_p
( ( N
M NNP N
= NNP N
5.8 CD N
) ) N
with IN N
a DT N
primary JJ N
diagnosis NN N
of IN N
autistic JJ N
disorder NN N
received VBD N
either CC N
placebo NN N
or CC N
lamotrigine JJ N
twice JJ N
daily RB N
. . N

-DOCSTART- -X- O O 17286730

patient JJ 4_p
experience NN N
patient JJ N
views NNS N
of IN N
community NN N
hospital NN N
care NN N
. . N

A DT N
sample NN N
of IN N
13 CD 3_p
patients NNS N
randomized VBN N
to TO N
the DT N
community NN N
hospital NN N
arm NN N
of IN N
the DT N
RCT NNP N
joined VBD N
the DT N
qualitative JJ N
study NN N
. . N

patients NNS N
. . N

patients NNS N
patient JJ N
-DOCSTART- -X- O O 19035420

Efficacy NN N
of IN N
wrist NN N
working VBG N
splints NNS N
in IN N
patients NNS N
with IN N
rheumatoid JJ N
arthritis NN N
: : N
controlled VBN 4_p
trial NN 4_p
among IN 4_p
33 CD 3_p
RA NNP 3_p
patients NNS 3_p
with IN 4_p
wrist JJ 4_p
arthritis NN 4_p
. . N

Patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
the DT N
splinting VBG N
group NN N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
or CC N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
16 CD N
) ) N
. . N

Patients NNS 4_p
in IN 4_p
the DT 4_p
splinting NN 4_p
group NN 4_p
RA NNP N
patients NNS N
with IN N
wrist JJ N
arthritis NN N
. . N

-DOCSTART- -X- O O 11804430

PCOS NNP 4_p
patients NNS 4_p
after IN N
CYP17a NNP N
inhibitor NN N
. . N

PCOS NNP N
patients NNS N
. . N

Alexandria NNP N
IVF/ICSI NNP N
center NN N
. . N

Ninety-seven JJ N
insulin-resistant JJ N
PCOS NNP N
patients NNS N
undergoing VBG N
ovulation NN N
induction NN N
using VBG N
clomiphene JJ N
citrate NN N
PCOS NNP N
patients NNS N
-DOCSTART- -X- O O 10757250

healthy JJ N
subjects NNS N
receiving VBG N
sertraline NN N
and CC N
lorazepam NN N
. . N

Patients NNS N
suffering VBG N
from IN N
some DT N
psychiatric JJ N
and CC N
neurological JJ N
disorders NNS N
patients NNS N
with IN N
schizophrenia NN N
. . N

Twenty NNP N
healthy JJ N
subjects NNS N
-DOCSTART- -X- O O 15800226

patients NNS N
with IN N
transient JJ N
ischemic JJ N
attack NN N
or CC N
stroke NN N
caused VBN N
by IN N
angiographically RB N
verified VBN N
50 CD N
to TO N
99 CD N
percent NN N
stenosis NN N
of IN N
a DT N
major JJ N
intracranial JJ N
artery NN N
After IN N
569 CD N
patients NNS N
had VBD N
undergone JJ N
randomization NN N
, , N
enrollment NN N
was VBD N
stopped VBN N
because IN N
of IN N
concerns NNS N
about IN N
the DT N
safety NN N
of IN N
the DT N
patients NNS N
who WP N
had VBD N
been VBN N
assigned VBN N
to TO N
receive VB N
warfarin NN N
. . N

patients NNS 4_p
with IN 4_p
intracranial JJ 4_p
arterial JJ 4_p
stenosis NN 4_p
. . 4_p

-DOCSTART- -X- O O 10563544

ulcerative JJ 4_p
colitis NN 4_p
( ( 4_p
UC NNP 4_p
) ) 4_p
Ten NNP N
healthy JJ N
volunteers NNS N
, , N
and CC N
seven CD N
with IN N
UC NNP N
in IN N
symptomatic JJ N
remission NN N
took VBD N
part NN N
; : N
all DT N
were VBD N
non-smokers NNS N
. . N

17 CD N
subjects NNS N
17 CD N
subjects NNS N
normal JJ N
subjects NNS N
and CC N
patients NNS N
with IN N
UC NNP N
. . N

-DOCSTART- -X- O O 21869698

employed NNS N
depressed JJ 4_p
patients NNS N
: : N
employed JJ N
patients NNS N
with IN N
major JJ 4_p
depressive JJ 4_p
disorder NN 4_p
( ( 4_p
MDD NNP 4_p
) ) 4_p
. . N

Gainfully NNP N
employed VBD N
( ( N
≥20 NNP N
h/wk NN N
) ) N
male NN N
and CC N
female JJ N
outpatients NNS N
with IN N
MDD NNP N
were VBD N
randomly RB N
assigned VBN N
( ( N
2:1 CD N
ratio NN N
) ) N
to TO N
12 CD N
weeks NNS N
of IN N
double-blind JJ N
treatment NN N
with IN N
desvenlafaxine JJ N
50 CD N
mg/d NN N
or CC N
placebo NN N
population NN N
. . N

A DT N
predefined JJ N
, , N
modified VBD N
ITT NNP N
population NN N
( ( N
ie JJ N
, , N
those DT N
in IN N
the DT N
ITT NNP N
population NN N
with IN N
baseline JJ N
HAM-D₁₇ NNP N
was VBD N
efficacious JJ N
for IN N
treating VBG N
MDD NNP N
in IN N
-DOCSTART- -X- O O 10441604

neonatal JJ 4_p
seizures NNS 4_p
. . 4_p

neonates NNS N
admitted VBN N
to TO N
an DT N
intensive JJ N
care NN N
unit NN N
. . N

59 CD N
neonates NNS N
with IN N
seizures NNS N
that WDT N
were VBD N
confirmed VBN N
by IN N
electroencephalography NN N
. . N

neonates NNS N
30 CD N
neonates NNS N
assigned VBN N
to TO N
receive VB N
phenobarbital NN N
29 CD N
neonates NNS N
assigned VBN N
to TO N
receive VB N
phenytoin NN N
neonates NNS N
. . N

-DOCSTART- -X- O O 17297382

HIV-positive JJ 4_p
men NNS 2_p
. . N

men NNS 2_p
men NNS 2_p
. . N

36 CD 3_p
HIV-positive JJ 4_p
men NNS 2_p
. . N

KY NNP N
Jelly NNP N
users NNS N
. . N

HIV-positive JJ 4_p
male JJ 2_p
population NN N
. . N

-DOCSTART- -X- O O 11034934

4159 CD 3_p
patients NNS 4_p
with IN 4_p
myocardial JJ 4_p
infarction NN 4_p
and CC 4_p
average JJ 4_p
LDL NNP 4_p
concentrations NNS 4_p
at IN 4_p
baseline NN 4_p
( ( 4_p
115 CD 4_p
to TO 4_p
174 CD 4_p
mg/dL NNS 4_p
, , 4_p
mean VBP 4_p
139 CD 4_p
mg/dL NN 4_p
) ) 4_p
. . N

patients NNS 4_p
who WP 4_p
had VBD 4_p
either CC 4_p
a DT 4_p
myocardial JJ 4_p
infarction NN 4_p
or CC 4_p
coronary JJ 4_p
death NN 4_p
( ( N
cases NNS N
, , N
n=418 NN 3_p
) ) N
patients NNS 4_p
who WP 4_p
did VBD 4_p
not RB 4_p
have VB 4_p
a DT 4_p
cardiovascular JJ 4_p
event NN 4_p
( ( N
control NN N
subjects VBZ N
, , N
n=370 NN 3_p
) ) N
-DOCSTART- -X- O O 7499684

patients NNS 4_p
with IN 4_p
a DT 4_p
history NN 4_p
of IN 4_p
seasonal JJ 4_p
allergic JJ 4_p
rhinitis NN 4_p
. . N

susceptible JJ 4_p
individuals NNS 4_p
eight CD 3_p
subjects NNS 3_p
with IN N
a DT N
history NN N
of IN N
seasonal JJ N
allergic JJ N
rhinitis NN N
, , N
who WP N
were VBD N
tested VBN N
out IN N
of IN N
season NN N
Another DT 3_p
group NN 3_p
of IN 3_p
eight CD 3_p
subjects NNS N
with IN N
a DT N
history NN N
of IN N
seasonal JJ N
allergic JJ N
rhinitis NN N
-DOCSTART- -X- O O 10685722

essential JJ 4_p
hypertension NN 4_p
. . N

446 CD 3_p
hypertensive JJ 4_p
patients NNS N
( ( N
mean JJ 1_p
age NN 1_p
: : 1_p
55.8 CD 1_p
+/- JJ 1_p
11.0 CD 1_p
years NNS 1_p
) ) N
-DOCSTART- -X- O O 24216497

healthy JJ N
dogs NNS N
undergoing VBG N
elective JJ 4_p
surgery NN 4_p
. . N

premedicated VBN N
healthy JJ N
dogs NNS N
undergoing VBG N
elective JJ 4_p
tibial JJ 4_p
plateau NN 4_p
leveling VBG 4_p
osteotomy NN 4_p
( ( 4_p
TPLO NNP 4_p
) ) 4_p
. . N

Nineteen JJ 3_p
client-owned JJ 3_p
dogs NNS N
Ten CD N
dogs NNS N
were VBD N
anesthetized VBN N
with IN N
sevoflurane NN N
and CC N
nine CD N
dogs NNS N
were VBD N
anesthetized VBN N
with IN N
isoflurane NN N
. . N

premedicated VBN N
healthy JJ N
dogs NNS N
undergoing VBG N
an DT N
elective JJ N
surgical JJ N
procedure NN N
. . N

-DOCSTART- -X- O O 19544653

chronic JJ 4_p
hepatitis NN 4_p
B NNP 4_p
of IN N
20 CD 3_p
patients NNS N
] JJ N
chronic JJ 4_p
hepatitis NN 4_p
B NNP 4_p
. . N

42 CD 3_p
patients NNS N
with IN N
chronic JJ 4_p
hepatitis NN 4_p
B NNP 4_p
patients NNS N
with IN N
chronic JJ 4_p
hepatitis NN 4_p
B NNP 4_p
-DOCSTART- -X- O O 10957888

mild JJ N
pneumonia NN 4_p
. . N

Eighty-six JJ 3_p
male JJ 2_p
patients NNS N
, , N
doing VBG N
their PRP$ N
obligatory JJ N
military JJ N
service NN N
, , N
ranging VBG N
between IN N
19 CD 1_p
and CC 1_p
24 CD 1_p
years NNS 1_p
of IN N
age NN N
( ( N
mean JJ N
20 CD N
) ) N
Seventy-eight JJ 3_p
patients NNS N
were VBD N
able JJ N
to TO N
be VB N
evaluated VBN N
for IN N
efficacy NN N
-DOCSTART- -X- O O 20680681

breast NN 4_p
cancer NN 4_p
patients NNS N
. . N

191 CD 3_p
patients NNS N
with IN N
T2-4 NNP 4_p
N0-1 NNP 4_p
breast NN 4_p
cancer NN 4_p
enrolled VBN N
in IN N
a DT N
randomized JJ N
trial NN N
-DOCSTART- -X- O O 6885201

healthy JJ N
volunteers NNS N
. . N

12 CD 3_p
healthy JJ N
volunteers NNS N
-DOCSTART- -X- O O 23586852

school-aged JJ N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
: : N
children NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
. . N

participants NNS N
. . N

Six CD N
children NNS N
children NNS N
with IN N
ASD NNP N
. . N

-DOCSTART- -X- O O 19207322

injection NN 4_p
comfort NN 4_p
cohesive JJ 4_p
hyaluronic JJ 4_p
acid NN 4_p
filler NN 4_p
three CD N
centers NNS N
enrolled VBD N
60 CD 3_p
subjects NNS N
, , N
injected VBN N
with IN N
both DT N
products NNS N
, , N
randomly RB N
assigned VBN N
to TO N
left VBD N
or CC N
right JJ N
nasolabial JJ N
fold NN N
. . N

Subjects NNS N
used VBD N
a DT N
visual JJ N
analog NN N
scale NN N
( ( N
0-10 JJ N
) ) N
for IN N
pain NN 4_p
assessment NN 4_p
. . N

-DOCSTART- -X- O O 23127528

pancreatic JJ 4_p
cancer NN 4_p
( ( 4_p
PC NN 4_p
) ) 4_p
. . N

90 CD 3_p
patients NNS N
with IN N
PC NNP 4_p
undergoing VBG N
gemcitabine JJ 4_p
therapy NN 4_p
. . N

-DOCSTART- -X- O O 15764958

antiretroviral-naive JJ 4_p
HIV-infected JJ 4_p
adults NNS 1_p
: : N
antiretroviral-naive JJ 4_p
patients NNS N
over IN N
48 CD N
weeks NNS N
. . N

-DOCSTART- -X- O O 26691535

pre-school JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
: : N
152 CD 3_p
pre-school JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
-DOCSTART- -X- O O 21552726

children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
children NNS N
with IN N
Autism NNP N
Spectrum NNP N
Disorders NNP N
11 CD N
children NNS N
diagnosed VBN N
with IN N
Autism NNP N
( ( N
n=6 NN N
) ) N
and CC N
Asperger NNP N
syndrome VBP N
( ( N
n=5 NN N
) ) N
by IN N
a DT N
multidisciplinary JJ N
team NN N
, , N
that WDT N
attended VBD N
specialized JJ N
speech-language JJ N
pathology NN N
therapy NN N
at IN N
the DT N
institution NN N
were VBD N
the DT N
study NN N
was VBD N
carried VBN N
out RP N
. . N

children NNS N
with IN N
Asperger NNP N
syndrome NN N
children NNS N
with IN N
autism NN N
. . N

children NNS N
with IN N
Autism NNP N
Spectrum NNP N
Disorders NNP N
. . N

-DOCSTART- -X- O O 9185746

liver NN N
function NN N
with IN N
fewer JJR N
side NN N
effects NNS N
. . N

subjects NNS N
with IN N
normal JJ N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
and CC N
severely RB N
impaired JJ N
liver NN N
function NN N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
( ( N
study NN N
I PRP N
) ) N
. . N

15 CD N
individuals NNS N
with IN N
normal JJ N
liver NN N
function NN N
and CC N
45 CD N
patients NNS N
with IN N
cirrhosis NN N
( ( N
15 CD N
Child NNP N
A NNP N
, , N
15 CD N
Child NNP N
B NNP N
, , N
and CC N
15 CD N
Child NNP N
C NNP N
) ) N
. . N

-DOCSTART- -X- O O 9095512

random JJ N
blood NN N
samples NNS N
various JJ N
ethnic JJ N
groups NNS N
in IN N
KwaZulu-Natal NNP N
, , N
South NNP N
Africa NNP N
, , N
and CC N
with IN N
samples NNS N
of IN N
selected VBN N
red JJ N
cell NN N
phenotypes NNS N
. . N

-DOCSTART- -X- O O 20472253

A NNP N
total NN N
of IN N
78 CD 3_p
boys NNS 1_p
age NN 1_p
13-15 CD 1_p
years NNS 1_p
with IN N
a DT N
mean JJ 4_p
body NN 4_p
fat JJ 4_p
percentage NN 4_p
of IN 4_p
30 CD 4_p
% NN 4_p
+/-9 JJ 4_p
% NN 4_p
normotensive JJ 4_p
and CC 4_p
normolipidemic JJ 4_p
slightly RB N
overweight JJ N
adolescent NN N
boys NNS N
. . N

-DOCSTART- -X- O O 19958431

Forty NNP 3_p
five CD 3_p
patients NNS N
with IN N
melasma NNS 4_p
were VBD N
randomly RB N
assigned VBN N
into IN N
three CD N
groups NNS N
of IN N
fifteen JJ N
patients NNS N
each DT N
. . N

melasma NN N
. . N

-DOCSTART- -X- O O 24277510

patients NNS N
with IN N
HCC NNP 4_p
smaller JJR N
than IN N
4 CD N
cm NN N
. . N

hepatocellular JJ 4_p
carcinoma NN 4_p
( ( N
HCC NNP N
) ) N
≤ VBD N
4 CD N
cm NN N
, , N
in IN N
patients NNS N
with IN N
liver JJ 4_p
cirrhosis NN 4_p
METHODS NNP N
Thirty NNP N
patients NNS N
with IN N
single JJ N
HCC NNP N
≤ NNP N
4 CD N
cm NN N
in IN N
diameter NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
treatments NNS N
: : N
15 CD N
patients NNS N
were VBD N
treated VBN N
with IN N
source NN N
; : N
15 CD N
patients NNS N
were VBD N
treated VBN N
with IN N
electrode NN N
documented VBN N
in IN N
13 CD N
patients NNS N
-DOCSTART- -X- O O 17152183

HIV-positive JJ 4_p
homosexual JJ N
men NNS 2_p
: : N
mildly RB N
symptomatic JJ N
HIV-positive JJ 4_p
homosexual JJ N
and CC N
bisexual JJ N
men NNS N
. . N

Participants NNS N
were VBD N
recruited VBN N
largely RB N
during IN N
the DT N
era NN N
prior RB N
to TO N
highly RB N
active JJ N
antiretroviral JJ N
therapy NN N
( ( N
HAART NNP N
; : N
1992-1997 JJ N
) ) N
. . N

Men NNPS 2_p
a DT N
psychoeducational JJ N
seminar NN N
group NN N
( ( N
n JJ N
= NNP N
46 CD N
) ) N
. . N

Men NNP 2_p
in IN N
the DT N
CBSM NNP N
group NN N
HIV-positive JJ N
homosexual JJ N
and CC N
bisexual JJ N
men NNS N
. . N

-DOCSTART- -X- O O 17899340

witnesses NNS 4_p
witness NN N
participants NNS N
-DOCSTART- -X- O O 6686808

antacids NNS N
on IN N
intragastric JJ N
pH NN N
in IN N
healthy JJ 4_p
subjects NNS 4_p
and CC N
duodenal JJ 4_p
ulcer NN 4_p
patients NNS N
. . N

in IN N
healthy JJ N
subjects NNS N
with IN N
MAO NNP N
less JJR N
than IN N
30 CD N
mmol/h NN N
and CC N
in IN N
duodenal JJ 4_p
ulcer NN 4_p
patients NNS N
with IN N
MAO NNP N
greater JJR N
than IN N
35 CD N
mmol/h NN N
. . N

healthy JJ N
subjects NNS N
duodenal JJ 4_p
ulcer NN 4_p
patients NNS N
-DOCSTART- -X- O O 50611

rapid JJ 4_p
radiation NN 4_p
treatment NN 4_p
normal JJ N
human JJ N
skin NN N
reactions NNS N
to TO N
two CD N
different JJ N
rapid JJ N
radiotherapy NN N
schedules NNS N
of IN N
2 CD N
sessions NNS N
per IN N
day NN N
and CC N
evaluated VBD N
their PRP$ N
effectiveness NN N
in IN N
relief NN N
of IN N
pain NN N
and CC N
local JJ N
tumor NN N
control NN N
. . N

Patients NNS N
were VBD N
randomized VBN N
to TO N
three CD N
treatment NN N
groups NNS N
: : N
SCHEDULE VB N
A NNP N
( ( N
control NN N
) ) N
: : N
conventional JJ N
one CD N
treatment NN N
per IN N
day NN N
regimen NNS N
totalling VBG N
3,760 CD N
rads NNS N
in IN N
22-23 JJ N
days NNS N
; : N
SCHEDULE NNP N
B NNP N
: : N
2 CD N
sessions NNS N
per IN N
day NN N
totalling VBG N
3,440 CD N
rads NNS N
in IN N
10-11 JJ N
days NNS N
; : N
and CC N
SCHEDULE NNP N
C NNP N
: : N
2 CD N
sessions NNS N
per IN N
day NN N
totalling VBG N
3,568 CD N
rads NNS N
in IN N
10-11 JJ N
days NNS N
. . N

-DOCSTART- -X- O O 26448791

Physician NNP 4_p
Practice NNP 4_p
Autism NNP 4_p
Spectrum NNP 4_p
Disorders NNP 4_p
. . 4_p

The DT N
CHICA NNP 4_p
( ( 4_p
Child NNP 4_p
Health NNP 4_p
Improvement NNP 4_p
through IN 4_p
Computer NNP 4_p
Automation NNP 4_p
) ) N
system NN N
, , N
a DT N
CDSS NNP N
, , N
was VBD N
enhanced VBN N
with IN N
a DT N
module NN N
to TO N
improve VB N
management NN N
of IN N
autism NN 4_p
in IN N
2 CD N
of IN N
the DT N
4 CD N
community NN N
pediatric JJ N
clinics NNS N
using VBG N
the DT N
system NN N
. . N

pediatric JJ 4_p
users NNS 4_p
cross-sectional JJ N
surveys NNS N
between IN N
November NNP N
2010 CD N
and CC N
January NNP N
2013 CD N
. . N

A DT N
total NN N
of IN N
45 CD 3_p
, , N
39 CD 3_p
, , N
and CC N
42 CD 3_p
pediatricians NNS N
responded VBD N
at IN N
each DT N
time NN N
point NN N
, , N
respectively RB N
, , N
a DT N
95-100 CD N
% NN N
response NN N
rate NN N
. . N

-DOCSTART- -X- O O 20004739

children NNS 1_p
undergoing VBG N
hematopoietic JJ 4_p
stem NN 4_p
cell NN 4_p
transplantation NN 4_p
( ( 4_p
" JJ 4_p
PNTREE NNP 4_p
" NN 4_p
) ) 4_p
: : N
Children NNP 1_p
undergoing VBG N
hematopoietic JJ 4_p
stem NN 4_p
cell NN 4_p
transplantation NN 4_p
( ( 4_p
HSCT NNP 4_p
) ) 4_p
children NNS 1_p
undergoing VBG N
allogeneic NN 4_p
HSCT NNP 4_p
. . N

children NNS 1_p
undergoing VBG N
HSCT NNP 4_p
-DOCSTART- -X- O O 4752239

enterobiasis NN 4_p
: : 4_p
paediatric JJ 4_p
community NN N
. . N

-DOCSTART- -X- O O 14977031

Body NNP 4_p
asymmetry NN 4_p
conjugate VBP 4_p
lateral JJ 4_p
eye NN 4_p
movement NN 4_p
( ( 4_p
CLEM NNP 4_p
) ) 4_p
authors NNS N
control NN 4_p
( ( 4_p
symmetric JJ 4_p
) ) 4_p
condition NN 4_p
participant NN N
participants NNS N
-DOCSTART- -X- O O 11699803

autism NN 4_p
. . N

autistic JJ 4_p
disorder NN 4_p
. . 4_p

Fifty-six JJ 3_p
subjects NNS N
with IN N
autistic JJ 4_p
disorder NN 4_p
-DOCSTART- -X- O O 24740733

patients NNS N
before IN N
and CC N
after IN N
parotid JJ 4_p
gland NN 4_p
tumor NN 4_p
surgery NN 4_p
: : N
17 CD 3_p
patients NNS N
with IN N
benign JJ 4_p
( ( N
n JJ N
= NNP N
13 CD 3_p
) ) N
and CC N
malignant JJ 4_p
( ( N
n JJ N
= NNP N
4 CD 3_p
) ) N
tumors NNS 4_p
. . N

patients NNS N
with IN N
small JJ 4_p
( ( 4_p
1.5-2.4 JJ 4_p
cm NN 4_p
) ) 4_p
benign NN 4_p
tumors NNS 4_p
located VBN 4_p
in IN 4_p
superficial JJ 4_p
lobes NNS 4_p
. . N

Patients NNS N
with IN N
medium NN 4_p
size NN 4_p
( ( 4_p
2.5-3.4 JJ 4_p
cm NN 4_p
) ) 4_p
malignant NN 4_p
tumors NNS 4_p
in IN 4_p
both DT 4_p
lobes NNS 4_p
patients NNS N
with IN N
benign JJ 4_p
tumors NNS 4_p
-DOCSTART- -X- O O 12564610

patients NNS N
with IN N
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
: : N
435 CD 3_p
adults NNS 1_p
with IN N
stable JJ 4_p
, , 4_p
symptomatic JJ 4_p
, , 4_p
smoking-related JJ 4_p
COPD NNP 4_p
were VBD N
randomized VBN N
79 CD 3_p
patients NNS N
with IN N
serious JJ 4_p
adverse JJ 4_p
events NNS 4_p
( ( N
SAEs NNP 4_p
) ) N
, , N
43 CD 3_p
( ( N
14.8 CD N
% NN N
) ) N
in IN N
the DT N
sibenadet NN 4_p
pMDI NN 4_p
group NN N
and CC N
36 CD 3_p
( ( N
24.8 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN 4_p
group NN N
. . N

-DOCSTART- -X- O O 20199680

prostate NN 4_p
cancer NN 4_p
men NNS 2_p
's POS 2_p
( ( N
45-70 CD 1_p
years NNS 1_p
) ) N
Internet NNP N
access NN N
and CC N
their PRP$ N
willingness NN N
to TO N
use VB N
a DT N
web- JJ N
vs. FW N
a DT N
print-based JJ N
tool NN N
. . N

men NNS N
's POS N
informed VBN N
decision NN N
making VBG N
-DOCSTART- -X- O O 24885187

patients NNS 4_p
with IN 4_p
large JJ 4_p
or CC 4_p
locally RB 4_p
advanced JJ 4_p
HER2-positive NNP 4_p
( ( 4_p
HER2+ NNP 4_p
) ) 4_p
breast NN 4_p
cancers NNS 4_p
core NN 4_p
biopsy NN 4_p
samples NNS 4_p
from IN 4_p
27 CD 4_p
HER2+ NNP 4_p
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
enrolled VBN 4_p
in IN 4_p
a DT 4_p
preoperative JJ 4_p
clinical JJ 4_p
trial NN 4_p
using VBG 4_p
trastuzumab NN 4_p
, , 4_p
nab-paclitaxel JJ 4_p
and CC 4_p
carboplatin JJ 4_p
combination NN 4_p
therapy NN 4_p
( ( 4_p
BrUOG NNP 4_p
BR-211B NNP 4_p
( ( 4_p
NCT00617942 NNP 4_p
) ) 4_p
) ) 4_p
. . N

18 CD N
weeks NNS N
of IN N
treatment NN N
-DOCSTART- -X- O O 1799472

non-Hodgkin NN 4_p
's POS 4_p
lymphoma NN 4_p
: : N
Non-Hodgkin NNP 4_p
's POS 4_p
Lymphoma NNP 4_p
Cooperative NNP N
Study NNP N
Group NNP N
. . N

70 CD 3_p
NHL NNP N
patients NNS N
who WP N
received VBD N
either CC N
chlorambucil NN N
( ( N
CB NNP N
; : N
10 CD N
mg/day NN N
) ) N
or CC N
CB NNP N
plus CC N
interferon JJ N
alfa-2b NN N
( ( N
5 CD N
million CD N
units NNS N
( ( N
MU NNP N
) ) N
/m2 VBD N
subcutaneously RB N
three CD N
times NNS N
a DT N
week NN N
) ) N
. . N

63 CD 3_p
evaluable JJ N
patients NNS N
patients NNS N
receiving VBG N
no DT 4_p
maintenance NN 4_p
therapy NN 4_p
patients NNS N
on IN N
no DT 4_p
maintenance NN 4_p
therapy NN 4_p
. . N

-DOCSTART- -X- O O 12790985

35 CD 3_p
consecutive JJ N
patients NNS N
presenting VBG N
with IN N
acute NN 4_p
thrombosed VBN 4_p
circumferential JJ 4_p
prolapsed JJ 4_p
haemorrhoids NNS 4_p
. . N

Thirty NNP 3_p
patients NNS N
patients NNS N
stapled JJ 3_p
group NN 3_p
patients NNS N
More JJR N
patients NNS N
in IN N
the DT N
conventional JJ 4_p
group NN 4_p
complained VBD N
of IN N
persistent JJ N
symptoms NNS N
of IN N
pain NN N
, , N
bleeding NN N
and CC N
discharge NN N
at IN N
2 CD N
week NN N
and CC N
6 CD N
week NN N
review NN N
with IN N
20 CD N
% NN N
requiring VBG N
readmission NN N
compared VBN N
with IN N
none NN N
in IN N
the DT N
stapled JJ N
group NN N
. . N

two CD N
patients NNS N
from IN N
each DT N
group NN N
had VBD N
ultrasonic JJ N
evidence NN N
-DOCSTART- -X- O O 22459310

Treating NNP 4_p
to TO 4_p
New NNP 4_p
Targets NNP 4_p
[ NNP 4_p
TNT NNP 4_p
] NNP 4_p
study NN 4_p
) ) 4_p
Treating NNP N
to TO N
New NNP N
Targets NNP N
( ( N
TNT NNP N
) ) N
trial NN N
10,001 CD N
TNT NNP N
participants NNS N
, , N
9,376 CD N
had VBD N
estimated VBN N
glomerular JJ N
filtration NN N
rate NN N
( ( N
eGFR NN N
) ) N
measurements NNS N
at IN N
baseline NN N
and CC N
1 CD N
year NN N
and CC N
were VBD N
included VBN N
in IN N
this DT N
analysis NN N
. . N

-DOCSTART- -X- O O 23361389

older JJR 1_p
, , N
undernourished JJ 4_p
, , N
community-dwelling JJ N
individuals NNS N
in IN N
primary JJ N
care NN N
: : N
older JJR N
, , N
community-dwelling JJ N
individuals NNS N
. . N

older JJR N
, , N
undernourished JJ 4_p
, , N
community-dwelling JJ N
individuals NNS N
. . N

146 CD 3_p
non-institutionalized JJ 4_p
, , 4_p
undernourished JJ 4_p
individuals NNS N
aged VBN 1_p
≥65 CD 1_p
years NNS 1_p
in IN N
primary JJ N
care NN N
functioning NN N
in IN N
older JJR N
, , N
undernourished JJ N
, , N
community-dwelling JJ N
individuals NNS N
-DOCSTART- -X- O O 15274666

Helicobacter NNP 4_p
pylori JJ 4_p
eradication NN 4_p
in IN 4_p
children NNS 1_p
and CC 4_p
adolescents NNS 1_p
children NNS 1_p
and CC N
adolescents NNS 1_p
. . N

Helicobacter NNP 4_p
pylori NN 4_p
infected VBD N
10-21 JJ 1_p
year NN N
olds NNS N
were VBD N
offered VBN N
treatment NN N
, , N
individuals NNS N
with IN N
abdominal JJ 4_p
pain NN 4_p
underwent JJ N
upper JJ N
endoscopy NN N
and CC N
those DT N
with IN N
peptic JJ 4_p
ulcers NNS 4_p
were VBD N
excluded VBN N
. . N

131 CD 3_p
individuals NNS N
were VBD N
randomized VBN N
, , N
of IN N
whom WP N
31 CD 3_p
( ( 3_p
24 CD 3_p
% NN 3_p
) ) 3_p
had VBD N
undergone JJ N
upper JJ N
endoscopy NN N
. . N

Full NNP N
compliance NN N
was VBD N
achieved VBN N
in IN N
93 CD N
% NN N
( ( N
122 CD N
of IN N
131 CD N
) ) N
. . N

children NNS 1_p
and CC N
adolescents NNS 1_p
. . N

children NNS 1_p
. . N

-DOCSTART- -X- O O 16253098

chronic JJ 4_p
periodontitis NN 4_p
. . N

patients NNS N
submitted VBN N
to TO N
different JJ N
treatments NNS N
of IN N
chronic JJ 4_p
periodontitis NN 4_p
and CC N
their PRP$ N
association NN N
with IN N
clinical JJ N
parameters NNS N
. . N

Sixty NNP 3_p
patients NNS N
were VBD N
assigned VBN N
-DOCSTART- -X- O O 10832774

patients NNS N
with IN N
autistic JJ 4_p
disorder NN 4_p
: : N
the DT N
Autism NNP N
RUPP NNP N
Network NNP N
. . N

uncommunicative JJ N
and CC N
extremely RB N
heterogeneous JJ N
in IN N
problem NN N
presentation NN N
children/adolescents NNS 1_p
. . N

uncomplicated JJ N
autism NN 4_p
without IN N
secondary JJ N
symptoms NNS N
as IN N
a DT N
CGI-S NNP N
of IN N
3 CD N
, , N
mildly RB N
ill JJ N
. . N

nonverbal JJ N
, , N
lower JJR N
functioning NN N
, , N
sometimes RB N
noncompliant JJ N
subjects NNS N
low-end JJ N
IQs NNP N
-DOCSTART- -X- O O 24768960

endometriosis NN 4_p
Endometriosis NNP 4_p
and CC N
pelvic JJ 4_p
pain NN 4_p
clinic NN N
at IN N
a DT N
university NN N
teaching VBG N
hospital NN N
. . N

Women NNP 2_p
of IN N
reproductive JJ N
age NN N
with IN N
pelvic JJ 4_p
pain NN 4_p
and CC N
visually RB N
proved JJ N
endometriosis NN 4_p
. . N

-DOCSTART- -X- O O 15169706

risperidone-treated JJ N
youths NNS N
with IN N
autism NN N
: : N
63 CD N
children NNS N
and CC N
adolescents NNS N
with IN N
autism NN N
treated VBN N
with IN N
risperidone NN N
for IN N
6 CD N
months NNS N
. . N

-DOCSTART- -X- O O 25644584

psoriatic JJ 4_p
arthritis NN 4_p
patients NNS N
patients NNS 4_p
with IN 4_p
psoriatic JJ 4_p
arthritis NN 4_p
, , 4_p
in IN 4_p
stable JJ 4_p
low JJ 4_p
disease NN 4_p
state NN 4_p
. . 4_p

Seventy-two JJ 3_p
patients NNS N
were VBD N
invited VBN N
to TO N
participate VB N
, , N
of IN N
which WDT N
57 CD 3_p
were VBD N
found VBN N
to TO N
be VB N
eligible JJ N
. . N

-DOCSTART- -X- O O 6151482

3837 CD 3_p
patients NNS N
with IN N
a DT N
recent JJ N
myocardial JJ N
infarction NN N
. . N

-DOCSTART- -X- O O 12236273

UK NNP N
registered JJ N
population NN N
aged VBD N
over IN 1_p
65 CD 1_p
years NNS 1_p
in IN N
east JJ N
London NNP N
practices NNS N
. . N

East NNP N
London NNP N
and CC N
Essex NNP N
network NN N
of IN N
researchers NNS N
( ( N
ELENoR NNP N
) ) N
. . N

Participants NNS N
were VBD N
1,820 CD 3_p
low-risk JJ N
patients NNS N
aged VBD N
65 CD 1_p
to TO 1_p
74 CD 1_p
years NNS N
who WP N
had VBD N
not RB 4_p
previously RB 4_p
been VBN 4_p
in IN 4_p
a DT 4_p
recall NN 4_p
system NN 4_p
for IN 4_p
influenza JJ 4_p
immunisation NN 4_p
at IN N
their PRP$ N
general JJ N
practice NN N
. . N

patients NNS N
making VBG N
a DT N
telephone NN N
appointment NN N
low-risk JJ 4_p
older JJR 4_p
population NN N
in IN N
inner-city JJ N
areas NNS N
-DOCSTART- -X- O O 21238531

dentine JJ 4_p
hypersensitivity NN 4_p
: : 4_p
Fifty-one CD 3_p
patients NNS N
participated VBN N
in IN N
this DT N
study NN N
for IN N
a DT N
total NN N
of IN N
174 CD N
teeth NNS N
. . N

-DOCSTART- -X- O O 23931247

abdominal JJ 4_p
hysterectomies NNS 4_p
. . N

total JJ N
abdominal JJ 4_p
hysterectomy NN 4_p
operations NNS N
. . N

We PRP N
conducted VBD N
this DT N
randomized VBN N
controlled VBD N
clinical JJ N
study NN N
on IN N
61 CD 3_p
patients NNS N
. . N

The DT N
study NN N
was VBD N
conducted VBN N
in IN N
the DT N
operation NN N
room NN N
, , N
post-anesthesia JJ N
care NN N
unit NN N
, , N
and CC N
inpatient JJ N
clinic NN N
. . N

61 CD N
patients NNS N
into IN N
control NN N
group NN N
( ( N
group NN N
C NNP N
) ) N
, , N
block NN N
group NN N
( ( N
group NN N
B NNP N
) ) N
and CC N
dexketoprofen-block JJ N
group NN N
( ( N
group NN N
DB NNP N
) ) N
-DOCSTART- -X- O O 1326734

previously RB N
untreated JJ N
patients NNS N
with IN N
extensive JJ 4_p
small JJ 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
. . N

One CD 3_p
hundred CD 3_p
and CC 3_p
eleven RB 3_p
previously RB N
untreated JJ N
patients NNS N
with IN N
extensive JJ 4_p
small JJ 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
Ninety-six JJ 3_p
patients NNS 3_p
were VBD N
evaluable JJ N
for IN N
response NN N
and CC N
toxicity NN N
and CC N
additional JJ N
12 CD 3_p
patients NNS 3_p
for IN N
toxicity NN N
only RB N
. . N

-DOCSTART- -X- O O 12057986

diabetic JJ 4_p
patients NNS N
undergoing VBG N
percutaneous JJ 4_p
coronary JJ 4_p
intervention NN 4_p
: : N
diabetic JJ N
patients NNS N
undergoing VBG N
percutaneous JJ N
coronary JJ N
intervention NN N
( ( N
PCI NNP N
) ) N
. . N

In IN N
18 CD N
countries NNS N
, , N
4809 CD 3_p
patients NNS N
undergoing VBG N
PCI NNP N
with IN N
stent JJ 4_p
implantation NN 4_p
diabetic JJ 4_p
patients NNS 4_p
undergoing VBG 4_p
PCI NNP 4_p
diabetic JJ N
patients NNS N
. . N

-DOCSTART- -X- O O 11134799

A DT N
randomized JJ N
trial NN N
in IN N
simultaneous JJ 4_p
pancreas-kidney JJ 4_p
transplantation NN 4_p
: : N
-DOCSTART- -X- O O 24214165

children NNS 1_p
with IN N
autism NN 4_p
: : N
children NNS N
with IN N
autism NN N
, , N
ages VBZ 1_p
4-8 CD 1_p
years NNS 1_p
children NNS 1_p
in IN N
the DT N
treatment NN N
group NN N
( ( N
n JJ 3_p
= NNP 3_p
17 CD 3_p
) ) N
Usual NNP N
Care NNP N
control NN N
group NN N
( ( 3_p
n JJ 3_p
= NNP 3_p
15 CD 3_p
) ) 3_p
. . N

children NNS 1_p
with IN N
autism NN 4_p
. . N

-DOCSTART- -X- O O 9002920

persons NNS N
with IN N
disabilities NNS 4_p
. . N

44 CD 3_p
adults NNS 1_p
with IN N
severe JJ 4_p
disabilities NNS 4_p
-DOCSTART- -X- O O 18376682

Post-laparoscopic NNP 4_p
cholecystectomy NN 4_p
pain NN 4_p
: : N
Postoperative NNP 4_p
pain NN 4_p
after IN 4_p
laparoscopic NN 4_p
cholecystectomy NN 4_p
( ( 4_p
LC NNP 4_p
) ) 4_p
Two CD 3_p
hundred VBD 3_p
patients NNS N
with IN N
similar JJ N
demographics NNS N
undergoing JJ N
elective JJ N
LC NNP N
four CD 3_p
groups NNS 3_p
of IN 3_p
50 CD 3_p
patients NNS 3_p
each DT 3_p
patients NNS N
parietal JJ 4_p
( ( 4_p
somatic JJ 4_p
) ) 4_p
abdominal JJ 4_p
pain NN 4_p
. . N

Patients NNS N
in IN N
each DT N
group NN N
all DT N
patients NNS N
-DOCSTART- -X- O O 9042119

salbutamol-treated JJ 4_p
inpatients NNS 4_p
with IN 4_p
acute JJ 4_p
bronchiolitis NN 4_p
: : 4_p
children NNS N
admitted VBN N
to TO N
the DT N
hospital NN N
with IN N
bronchiolitis NN N
treated VBN N
with IN N
nebulized JJ N
salbutamol NN N
. . N

participants NNS N
, , N
children NNS N
aged VBD N
6 CD N
weeks NNS N
to TO N
15 CD N
months NNS N
, , N
admitted VBN N
with IN N
first-time JJ N
wheezing NN N
, , N
were VBD N
eligible JJ N
if IN N
their PRP$ N
oxygen NN N
saturation NN N
was VBD N
less JJR N
than IN N
95 CD N
% NN N
on IN N
admission NN N
to TO N
the DT N
hospital NN N
and CC N
their PRP$ N
Respiratory NNP N
Distress NNP N
Assessment NNP N
Instrument NNP N
( ( N
RDAI NNP N
) ) N
score NN N
was VBD N
greater JJR N
than IN N
6 CD N
. . N

Patients NNS N
were VBD N
excluded VBN N
if IN N
they PRP N
had VBD N
any DT N
one CD N
of IN N
the DT N
following NN N
: : N
an DT N
underlying JJ N
disease NN N
that WDT N
might MD N
affect VB N
cardiopulmonary JJ N
status NN N
, , N
asthma NN N
, , N
recent JJ N
treatment NN N
with IN N
steroids NNS N
( ( N
within IN N
2 CD N
weeks NNS N
) ) N
, , N
or CC N
any DT N
history NN N
of IN N
adverse JJ N
reaction NN N
to TO N
steroids NNS N
. . N

children NNS N
hospitalized VBN N
with IN N
bronchiolitis NN N
-DOCSTART- -X- O O 3370523

outpatient JJ N
burn NN 4_p
dressing VBG N
. . N

outpatient NN N
burns NNS 4_p
. . N

two CD N
treatment NN N
groups NNS N
were VBD N
closely RB N
matched VBN N
in IN N
age NN N
, , N
sex NN N
, , N
per IN N
cent NN N
of IN N
BSA NNP N
burned VBD 4_p
, , N
and CC N
in IN N
burn JJ 4_p
severity NN N
and CC N
locations NNS N
. . N

outpatient NN N
burns NNS 4_p
-DOCSTART- -X- O O 1486965

nocturnal JJ 4_p
asthma NN 4_p
: : 4_p
multicentre JJ N
French JJ N
Multicentre NNP N
Study NNP N
Group NNP N
. . N

Ninety NNP N
six CD N
patients NNS N
with IN N
nocturnal JJ N
asthma NN N
, , N
( ( N
forced JJ N
expiratory NN N
volume NN N
in IN N
one CD N
second NN N
( ( N
FEV1 NNP N
) ) N
60-90 CD N
% NN N
of IN N
predicted JJ N
value NN N
, , N
reversibility NN N
> NN N
or CC N
= VB N
15 CD N
% NN N
, , N
at IN N
least JJS N
two CD N
nocturnal JJ N
awakenings NNS N
per IN N
week NN N
) ) N
multicentre NN N
patients NNS N
with IN N
nocturnal JJ N
asthma NN N
. . N

-DOCSTART- -X- O O 21396848

transrectal JJ 4_p
prostate NN 4_p
biopsy NN 4_p
: : N
transrectal JJ 4_p
prostate NN 4_p
biopsy NN 4_p
( ( N
TPB NNP 4_p
) ) N
patients NNS N
receiving VBG N
perianal-intrarectal JJ N
lidocaine-prilocaine NN N
( ( N
PILP NNP N
) ) N
cream NN N
before IN N
PPNB NNP N
. . N

Three NNP 3_p
hundred VBD 3_p
consecutive JJ N
patients NNS N
scheduled VBN N
for IN N
US-guided JJ N
TPB NNP 4_p
-DOCSTART- -X- O O 11132252

children NNS 4_p
with IN 4_p
autism NN 4_p
: : N
children NNS 1_p
aged VBD 1_p
2 CD 1_p
to TO 1_p
7 CD 1_p
years NNS 1_p
95 CD 3_p
participants NNS N
children NNS N
with IN N
autism NN 4_p
. . N

children NNS N
with IN N
autism NN 4_p
. . N

-DOCSTART- -X- O O 15002089

after IN 4_p
end-to-side JJ 4_p
neurorrhaphy NN 4_p
. . 4_p

after IN 4_p
end-to-side JJ 4_p
neurorrhaphy NN 4_p
Four CD N
groups NNS N
( ( N
n=4 JJ N
for IN N
each DT N
group NN N
) ) N
were VBD N
used VBN N
: : N
end-to-end JJ N
coaptation NN N
( ( N
six CD N
months NNS N
postoperatively RB N
) ) N
, , N
end-to-side JJ N
coaptation NN N
( ( N
four CD N
months NNS N
and CC N
six CD N
months NNS N
postoperatively RB N
) ) N
and CC N
normal JJ N
control NN N
. . N

-DOCSTART- -X- O O 10707032

non-diabetic JJ 4_p
men NNS N
with IN N
hypertension NN 4_p
, , 4_p
hypertriglyceridaemia NN 4_p
and CC 4_p
central JJ 4_p
fat JJ 4_p
distribution NN 4_p
: : N
non-diabetic JJ 4_p
obese JJ 4_p
subjects NNS 4_p
with IN 4_p
a DT 4_p
central JJ 4_p
fat JJ 4_p
distribution NN 4_p
non-diabetic JJ 4_p
men NNS 2_p
( ( N
n=168 NN 3_p
) ) N
with IN N
a DT N
fasting VBG 4_p
plasma NN 4_p
triglyceride JJ 4_p
concentration NN 4_p
> NN 4_p
or CC 4_p
=1.7 NN 4_p
and CC 4_p
< NN 4_p
or CC 4_p
=6.5 NN 4_p
mmol/l NN 4_p
, , 4_p
high JJ 4_p
blood NN 4_p
pressure NN 4_p
( ( 4_p
systolic JJ 4_p
> NN 4_p
or CC 4_p
=140 NN 4_p
and CC 4_p
< NN 4_p
or CC 4_p
=180 VB 4_p
and/or JJ 4_p
diastolic JJ 4_p
> NN 4_p
or CC 4_p
=90 NN 4_p
and CC 4_p
< NN 4_p
or CC 4_p
=105 NN 4_p
mmHg NN 4_p
, , N
or CC N
treatment NN 4_p
for IN 4_p
hypertension NN 4_p
) ) N
and CC N
a DT 4_p
waist-to-hip JJ 4_p
ratio NN 4_p
> NN 4_p
or CC 4_p
=0.95 NN 4_p
. . 4_p

non-diabetic JJ 4_p
subjects NNS 4_p
with IN 4_p
a DT 4_p
central JJ 4_p
fat JJ 4_p
distribution NN 4_p
. . N

-DOCSTART- -X- O O 25234479

autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . 4_p

autism-spectrum JJ 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
12 CD 3_p
children NNS 1_p
with IN N
ASD NNP N
and CC N
19 CD 3_p
control NN N
participants NNS N
ASD NNP 4_p
. . 4_p

-DOCSTART- -X- O O 8499152

320 CD 4_p
multiple JJ 4_p
myeloma NN 4_p
( ( 4_p
MM NNP 4_p
) ) 4_p
patients NNS 4_p
entering VBG 4_p
the DT 4_p
German JJ 4_p
Myeloma NNP 4_p
Treatment NNP 4_p
Group NNP 4_p
( ( 4_p
GMTG NNP 4_p
) ) 4_p
trial NN 4_p
MM01 NNP 4_p
poor JJ 4_p
prognosis NN 4_p
patients NNS 4_p
( ( 4_p
50 CD 4_p
% NN 4_p
TRS NNP 4_p
: : 4_p
16 CD 4_p
months NNS 4_p
) ) 4_p
characterised VBN 4_p
by IN 4_p
pretreatment JJ 4_p
platelets NNS 4_p
of IN 4_p
< NN 4_p
or CC 4_p
= $ 4_p
150,000 CD 4_p
Patients NNS N
lacking VBG N
both DT N
risk NN N
factors NNS N
-DOCSTART- -X- O O 12824973

patients NNS 4_p
who WP 4_p
previously RB 4_p
were VBD 4_p
clomiphene JJ 4_p
citrate NN 4_p
resistant NN 4_p
. . 4_p

Forty-eight NNP N
patients NNS N
from IN N
a DT N
private JJ N
tertiary JJ N
infertility NN N
clinic NN N
patients NNS N
who WP N
previously RB N
were VBD N
resistant JJ N
to TO N
clomiphene VB N
citrate NN N
. . N

-DOCSTART- -X- O O 8708224

patients NNS N
with IN N
unilateral JJ 4_p
lung NN 4_p
pathology NN 4_p
. . N

patients NNS N
with IN N
unilateral JJ 4_p
lung NN 4_p
pathology NN 4_p
Thirty-nine JJ 3_p
patients NNS N
with IN N
unilateral JJ 4_p
lung NN 4_p
pathology NN 4_p
-DOCSTART- -X- O O 10619912

Gastric JJ 4_p
carcinoma NN 4_p
: : N
Gastric NNP 4_p
carcinoma NN 4_p
diffuse NN N
and CC N
intestinal JJ N
. . N

85 CD N
biopsy NN N
samples NNS N
from IN N
patients NNS N
with IN N
gastric JJ 4_p
adenocarcinoma NN 4_p
. . N

control NN N
group NN N
consisted VBD N
of IN N
40 CD N
specimens NNS N
from IN N
normal JJ N
gastric JJ N
mucosa NN N
. . N

-DOCSTART- -X- O O 10741842

low-income JJ N
urban JJ N
children NNS 1_p
: : N
low-income JJ N
urban JJ N
population NN N
in IN N
Seattle/King NNP N
County NNP N
, , N
Washington NNP N
, , N
as RB N
well RB N
as IN N
caregiver NN N
knowledge NN N
caretakers NNS N
of IN N
children NNS 1_p
aged VBN N
4-12 CD 1_p
years NNS N
with IN N
persistent JJ N
asthma NN 4_p
living NN N
in IN N
households NNS N
with IN N
incomes NNS N
less JJR N
than IN N
200 CD N
% NN N
of IN N
poverty NN N
. . N

children NNS 1_p
and CC N
their PRP$ N
caregivers NNS N
are VBP N
participants NNS N
in IN N
the DT N
ongoing JJ N
Seattle-King JJ N
County NNP N
Healthy NNP N
Homes NNP N
Project NNP N
, , N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
an DT N
intervention NN N
to TO N
empower VB N
low-income JJ N
families NNS N
to TO N
reduce VB N
exposure NN N
to TO N
indoor VB N
asthma JJ 4_p
triggers NNS N
. . N

the DT N
first JJ N
112 CD 3_p
enrolled JJ N
households NNS N
. . N

low-income JJ N
urban JJ N
children NNS 1_p
with IN N
asthma NN 4_p
-DOCSTART- -X- O O 24201232

children NNS 1_p
with IN N
autism NN 4_p
: : N
Forty NNP 3_p
outpatients NNS N
aged VBD 1_p
4 CD 1_p
to12 NN 1_p
years NNS 1_p
, , N
who WP N
were VBD N
diagnosed VBN N
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
based VBN N
on IN N
the DT N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
Fourth NNP N
Edition NNP N
, , N
Text NNP N
Revision NNP N
criteria NNS N
-DOCSTART- -X- O O 3594511

arterial JJ 4_p
hypertensive JJ 4_p
patients NNS N
. . N

49 CD 3_p
hypertensive JJ 4_p
patients NNS N
( ( N
WHO NNP N
I-II NNP N
) ) N
, , N
divided VBD N
into IN N
three CD 3_p
parallel JJ N
randomized VBN N
groups NNS N
, , N
were VBD N
studied VBN N
over IN N
a DT N
6 CD N
months NNS N
period NN N
. . N

hypertensive JJ 4_p
subjects NNS N
with IN N
metabolic JJ 4_p
coronary JJ 4_p
risk NN 4_p
factors NNS N
. . N

-DOCSTART- -X- O O 17722826

early JJ 4_p
peripheral JJ 4_p
facial JJ 4_p
paralysis NN 4_p
] NN 4_p
peripheral JJ 4_p
facial JJ 4_p
paralysis NN 4_p
. . 4_p

Fifty-two JJ 4_p
cases NNS 4_p
facial JJ 4_p
paralysis NN 4_p
. . 4_p

-DOCSTART- -X- O O 24981013

body NN 4_p
image NN 4_p
threat NN 4_p
. . 4_p

Women NNP 2_p
( ( N
N=123 NNP 3_p
) ) N
were VBD N
randomized VBN N
into IN N
an DT N
individual-threat JJ N
, , N
group-threat JJ N
or CC N
no-threat JJ N
condition NN N
. . N

women NNS 2_p
. . N

-DOCSTART- -X- O O 15616772

patients NNS N
with IN N
locally RB N
advanced JJ N
gastric JJ 4_p
cancer NN 4_p
. . 4_p

gastric JJ 4_p
cancer NN 4_p
patients NNS N
advanced JJ N
gastric JJ 4_p
cancer NN 4_p
. . 4_p

patients NNS N
with IN N
locally RB N
advanced VBN N
resectable JJ 4_p
gastric JJ 4_p
cancer NN 4_p
. . 4_p

156 CD 3_p
patients NNS N
with IN N
stage NN 4_p
III NNP 4_p
or CC 4_p
IV NNP 4_p
gastric JJ 4_p
cancer NN 4_p
who WP N
had VBD N
undergone JJ N
curative JJ 4_p
resection NN 4_p
patients NNS N
with IN N
pT2/T3 JJ 4_p
primary JJ 4_p
tumors NNS 4_p
patients NNS N
with IN N
intestinal-type JJ 4_p
but CC 4_p
not RB 4_p
diffuse-type JJ 4_p
cancer NN 4_p
. . 4_p

limited JJ N
number NN N
of IN N
patients NNS N
gastric JJ 4_p
cancer NN 4_p
patients NNS N
after IN N
curative JJ 4_p
gastrectomy NN 4_p
; : N
in IN N
particular JJ N
, , N
in IN N
patients NNS N
with IN N
pT2/T3 JJ 4_p
tumors NNS 4_p
and CC 4_p
intestinal-type JJ 4_p
primary JJ 4_p
tumors NNS 4_p
. . 4_p

-DOCSTART- -X- O O 16555138

autism NN 4_p
: : 4_p
autism NN 4_p
15 CD N
children NNS N
aged VBN N
2-16 CD N
years NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
. . N

-DOCSTART- -X- O O 12182253

postoperative JJ 4_p
dental NN 4_p
pain NN 4_p
. . 4_p

patients NNS N
experiencing VBG N
acute JJ 4_p
pain NN 4_p
. . 4_p

patients NNS N
with IN N
postoperative JJ 4_p
dental NN 4_p
pain NN 4_p
. . N

A DT N
total NN N
of IN N
498 CD 3_p
patients NNS N
( ( N
219 CD 3_p
men NNS 2_p
, , N
279 CD 3_p
women NNS 2_p
; : N
mean JJ N
age NN N
, , N
21.5 CD 1_p
years NNS N
) ) N
participated VBD N
in IN N
this DT N
study NN N
. . N

-DOCSTART- -X- O O 17961229

Canadian JJ N
lactating VBG N
women NNS 2_p
exposed VBN N
to TO N
high JJ N
levels NNS N
of IN N
folate NN 4_p
Canada NNP N
reproducing VBG 4_p
women NNS 2_p
. . N

women NNS 2_p
with IN N
high JJ 4_p
blood NN 4_p
folate NN 4_p
values NNS 4_p
well-educated JJ N
lactating VBG N
Canadian JJ N
women NNS 2_p
exposed VBN N
to TO N
high JJ N
levels NNS N
of IN N
synthetic JJ 4_p
folate NN 4_p
. . N

sample NN N
of IN N
predominantly RB N
university-educated JJ N
lactating VBG N
women NNS 2_p
( ( 1_p
32 CD 1_p
+/- JJ 1_p
4 CD 1_p
yr NN 1_p
) ) 1_p
at IN N
4- JJ N
( ( N
n JJ N
= NNP N
53 CD 3_p
) ) N
and CC N
16-wk JJ N
postpartum NN N
( ( N
n JJ N
= NNP N
55 CD 3_p
) ) N
. . N

-DOCSTART- -X- O O 2199180

Fifty-nine JJ 4_p
consecutive JJ 4_p
patients NNS 4_p
( ( 4_p
19 CD 4_p
men NNS 4_p
, , 4_p
40 CD 4_p
women NNS 4_p
, , 4_p
mean JJ 4_p
age NN 4_p
60.8 CD 4_p
[ JJ 4_p
27-80 JJ 4_p
] NNP 4_p
years NNS 4_p
) ) 4_p
with IN 4_p
primary JJ 4_p
osteoporosis NN 4_p
-DOCSTART- -X- O O 11836674

management NN 4_p
of IN 4_p
unresectable JJ 4_p
malignant JJ 4_p
mesothelioma NN 4_p
Malignant NNP 4_p
mesothelioma NN 4_p
patients NNS N
with IN N
unresectable JJ N
disease NN N
. . N

mesothelioma NN N
. . N

-DOCSTART- -X- O O 17046466

childhood NN 1_p
lymphoblastic JJ 4_p
leukaemia NN 4_p
: : N
childhood NN 1_p
lymphoblastic JJ 4_p
leukaemia NN 4_p
childhood NN N
lymphoblastic JJ N
leukaemia NN N
. . N

Consecutive JJ N
children NNS 1_p
with IN N
lymphoblastic JJ 4_p
leukaemia NN N
diagnosed VBN N
in IN N
the DT N
UK NNP N
and CC N
Ireland NNP N
between IN N
April NNP N
, , N
1997 CD N
, , N
and CC N
June NNP N
, , N
2002 CD N
-DOCSTART- -X- O O 17179098

patients NNS N
with IN N
advanced JJ 4_p
or CC 4_p
recurrent JJ 4_p
breast NN 4_p
cancer NN 4_p
. . N

patients NNS N
with IN N
advanced JJ 4_p
or CC 4_p
recurrent JJ 4_p
breast NN 4_p
cancer NN 4_p
. . N

221 CD 3_p
patients NNS N
were VBD N
assessable JJ N
. . N

patients NNS N
who WP N
were VBD N
premenopausal NN 4_p
, , N
had VBD N
no DT 4_p
prior JJ 4_p
therapy NN 4_p
, , N
and CC N
were VBD N
stage NN N
IV NNP N
at IN N
diagnosis NN N
with IN N
an DT N
intact JJ 4_p
primary JJ 4_p
tumor NN 4_p
. . N

patients NNS N
who WP N
had VBD N
not RB 4_p
received VBN 4_p
prior JJ 4_p
therapy NN 4_p
. . N

-DOCSTART- -X- O O 18062520

patients NNS N
undergoing VBG 4_p
surgical JJ 4_p
procedures NNS 4_p
under IN 4_p
regional JJ 4_p
anaesthesia NN 4_p
. . N

Forty NNP 3_p
adult JJ N
American JJ N
Society NNP N
of IN N
Anaesthesiologists NNP N
( ( N
ASA NNP N
) ) N
grade VBD N
1-111 JJ N
patients NNS N
, , N
aged VBN N
between IN N
40-65 JJ 1_p
years NNS 1_p
undergoing VBG 4_p
surgery NN 4_p
under IN 4_p
regional JJ 4_p
anaesthesia NN 4_p
( ( 4_p
sub-arachnoid JJ 4_p
block NN 4_p
) ) N
were VBD N
included VBN N
. . N

-DOCSTART- -X- O O 20712132

acute JJ 4_p
abacterial JJ 4_p
otitis NN 4_p
externa NN 4_p
. . N

105 CD 3_p
patients NNS N
diagnosed VBN N
with IN N
acute JJ 4_p
abacterial JJ 4_p
otitis NN 4_p
externa NN 4_p
were VBD N
included VBN N
and CC N
randomized VBN N
-DOCSTART- -X- O O 11701672

healthy JJ N
men NNS N
: : N
GHD NNP 1_p
adults NNS 1_p
healthy JJ 2_p
nonobese JJ 2_p
males NNS 2_p
-DOCSTART- -X- O O 19109835

donor JJ N
hepatic JJ N
transection NN N
: : N
Twenty-four CD N
living NN N
liver NN N
donors NNS N
( ( N
n JJ N
= VBP N
12 CD N
for IN N
each DT N
group NN N
) ) N
-DOCSTART- -X- O O 14625812

interferon NN 4_p
alpha NN 4_p
monotherapy NN 4_p
relapsers NNS 4_p
with IN N
chronic JJ 4_p
hepatitis NN 4_p
C. NNP 4_p
interferon NN 4_p
monotherapy NN 4_p
relapsers NNS 4_p
with IN N
chronic JJ 4_p
hepatitis NN 4_p
C. NNP 4_p
Interferon NNP 4_p
alpha NN 4_p
monotherapy NN 4_p
relapsers NNS 4_p
with IN N
chronic JJ 4_p
hepatitis NN 4_p
C NNP 4_p
Only JJ N
patients NNS N
with IN N
negative JJ 4_p
HCV NNP 4_p
RNA NNP 4_p
at IN N
week NN N
10 CD N
continued VBD N
treatment NN N
. . N

Thirty-seven JJ 3_p
patients NNS N
were VBD N
enrolled VBN N
, , N
19 CD 3_p
( ( N
6 CD 3_p
females NNS 2_p
, , N
median JJ N
age NN N
43 CD 1_p
) ) N
in IN N
the DT N
24 CD N
week NN N
and CC N
18 CD 3_p
( ( N
5 CD 3_p
females NNS 2_p
, , N
median JJ N
age NN N
40 CD 1_p
) ) N
in IN N
the DT N
48 CD N
week NN N
treatment NN N
arm NN N
. . N

Baseline JJ N
characteristics NNS N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

Three CD 3_p
patients NNS N
discontinued VBN N
treatment NN N
early JJ N
( ( N
two CD N
due JJ N
to TO N
moderate VB N
adverse JJ N
events NNS N
, , N
one CD N
due JJ N
to TO N
non-compliance NN N
) ) N
. . N

relapsers NNS 4_p
with IN 4_p
chronic JJ 4_p
hepatitis NN 4_p
C NNP 4_p
-DOCSTART- -X- O O 26279073

Women NNP 2_p
with IN N
Polycystic NNP 4_p
Ovary NNP 4_p
Syndrome NNP 4_p
: : N
women NNS 2_p
with IN N
polycystic JJ 4_p
ovary JJ 4_p
syndrome NN 4_p
( ( 4_p
PCOS NNP 4_p
) ) 4_p
. . N

64 CD 3_p
women NNS 2_p
with IN N
PCOS NNP 4_p
were VBD N
randomized VBN N
supplementation NN N
among IN N
-DOCSTART- -X- O O 21354925

postoperative JJ 4_p
patient-controlled JJ 4_p
analgesia NN 4_p
thoracotomy NN 4_p
. . N

A NNP N
consecutive JJ N
series NN N
of IN N
100 CD 3_p
patients NNS 3_p
undergoing JJ N
thoracoscope-assisted JJ 4_p
thoracotomy NN 4_p
-DOCSTART- -X- O O 24384588

antiretroviral JJ 4_p
initiation NN 4_p
A5224s NNP N
was VBD N
a DT N
sub-study NN N
of IN N
A5202 NNP N
, , N
a DT N
prospective JJ N
trial NN N
of IN N
1857 CD N
ART-naive JJ N
participants NNS N
randomized VBN N
to TO N
blinded VBN N
abacavir-lamivudine NN N
( ( N
ABC/3TC NNP N
) ) N
or CC N
tenofovir JJ N
DF-emtricitabine NNP N
( ( N
TDF/FTC NNP N
) ) N
with IN N
open-label JJ N
efavirenz NN N
( ( N
EFV NNP N
) ) N
or CC N
atazanavir-ritonavir JJ N
( ( N
ATV/r NNP N
) ) N
. . N

269 CD N
participants NNS N
: : N
85 CD N
% NN N
men NNS N
, , N
47 CD N
% NN N
white JJ N
non-Hispanic JJ N
, , N
median JJ N
age NN N
38 CD N
years NNS N
, , N
HIV-1 NNP N
RNA NNP N
4.6 CD N
log10 NN N
copies/ml NN N
, , N
and CC N
CD4 NNP N
cell VBP N
count NN N
233 CD N
cells/μl NN N
-DOCSTART- -X- O O 12080735

patients NNS 4_p
with IN 4_p
herpes NNS 4_p
zoster NN 4_p
] NN N
. . N

-DOCSTART- -X- O O 16492716

human JJ 4_p
oesophagus NN 4_p
eight CD 3_p
healthy JJ 4_p
volunteers NNS N
( ( N
seven CD 3_p
males NNS 2_p
; : N
mean JJ 1_p
age NN 1_p
32 CD 1_p
years NNS 1_p
) ) N
-DOCSTART- -X- O O 17505452

endometrial JJ 4_p
cancer NN 4_p
] NNP 4_p
patients NNS 4_p
with IN 4_p
endometrial JJ 4_p
cancer NN 4_p
. . 4_p

80 CD 3_p
patients NNS 3_p
randomly RB N
assigned VBN N
to TO N
laparoscopic VB 4_p
lymphadenectomy NN 4_p
and CC 4_p
to TO 4_p
abdominal JJ 4_p
lymphadenectomy NN 4_p
in IN 4_p
the DT 4_p
treatment NN 4_p
of IN 4_p
endometrial JJ 4_p
cancer NN 4_p
. . N

Forty NNP 3_p
patients NNS 3_p
-DOCSTART- -X- O O 7889896

children NNS 1_p
suffering VBG 4_p
from IN 4_p
severe JJ 4_p
protein-energy JJ 4_p
malnutrition NN 4_p
. . 4_p

hospital NN N
of IN N
children NNS N
suffering VBG N
from IN N
severe JJ N
protein-energy JJ N
malnutrition NN N
( ( N
PEM NNP 4_p
) ) N
. . N

group NN N
( ( N
short- JJ N
versus IN N
long-stay NN N
) ) N
and CC N
one CD N
repeated VBN N
measures NNS N
factor NN N
( ( N
admission NN N
, , N
then RB N
12 CD N
, , N
18 CD N
, , N
24 CD N
, , N
30 CD N
and CC N
36 CD N
months NNS N
post-admission NN N
) ) N
SETTING NNP N
Primary NNP N
health NN N
care NN N
, , N
Kingston NNP N
, , N
Jamaica NNP N
. . N

SUBJECTS NNP N
n JJ N
= NNP N
81 CD 3_p
; : N
mean JJ N
age NN N
11 CD 1_p
months NNS 1_p
; : N
79 CD N
contribute VBP N
longitudinal JJ N
data NNS N
; : N
44 CD N
every DT N
measurement NN N
. . N

-DOCSTART- -X- O O 24338168

patients NNS N
with IN N
advanced JJ 4_p
bladder NN 4_p
cancer NN 4_p
: : N
patients NNS N
with IN N
advanced JJ 4_p
bladder NN 4_p
cancer NN 4_p
. . N

One CD 3_p
hundred CD 3_p
and CC 3_p
twenty RB 3_p
untreated JJ N
patients NNS N
with IN N
stage NN 4_p
III/IV NNP 4_p
bladder NN 4_p
cancer NN 4_p
92 CD 3_p
males NNS 2_p
and CC N
28 CD 3_p
females NNS 3_p
included VBN N
in IN N
the DT N
study NN N
had VBD N
a DT N
median JJ 1_p
age NN 1_p
of IN 1_p
62 CD 1_p
years NNS 1_p
( ( N
range VB N
40-85 CD 1_p
years NNS 1_p
) ) N
. . N

-DOCSTART- -X- O O 12241713

patients NNS N
with IN N
limb JJ N
ischaemia NN N
patients NNS N
with IN N
ischaemic JJ N
limbs NNS N
because IN N
of IN N
peripheral JJ N
arterial JJ N
disease NN N
. . N

25 CD N
patients NNS N
( ( N
group NN N
A DT N
) ) N
with IN N
unilateral JJ N
ischaemia NN N
of IN N
the DT N
leg NN N
22 CD N
patients NNS N
( ( N
group NN N
B NNP N
) ) N
with IN N
bilateral JJ N
leg NN N
ischaemia NN N
Two CD N
patients NNS N
were VBD N
excluded VBN N
from IN N
group NN N
B NNP N
after IN N
randomisation NN N
. . N

group NN N
B NNP N
patients NNS N
group NN N
A DT N
patients NNS N
. . N

Two CD N
patients NNS N
-DOCSTART- -X- O O 18339093

children NNS 1_p
with IN N
autism NN 4_p
: : N
Children NNP 1_p
who WP N
have VBP N
a DT N
combination NN N
of IN N
language NN 4_p
and CC 4_p
developmental JJ 4_p
disabilities NNS 4_p
with IN N
autism NN 4_p
Participants NNS N
were VBD N
two CD N
groups NNS N
of IN N
children NNS 1_p
with IN N
autism NN 4_p
, , N
aged VBD N
between IN N
3 CD 1_p
and CC N
7 CD 1_p
years NNS N
. . N

-DOCSTART- -X- O O 14668075

smoking VBG 4_p
cessation NN 4_p
total NN N
of IN N
1,524 CD 3_p
smokers NNS 3_p
( ( N
649 CD 2_p
men NNS 2_p
and CC N
875 CD 2_p
women NNS 2_p
) ) N
of IN N
average JJ 1_p
age NN 1_p
45.1 CD 1_p
years NNS 1_p
-DOCSTART- -X- O O 23815478

speech NN N
Humans NNS 4_p
people NNS N
-DOCSTART- -X- O O 16791814

International NNP N
Czech NNP N
and CC N
Slovak NNP N
patients NNS N
with IN N
differentiated JJ 4_p
thyroid NN 4_p
cancer NN 4_p
. . N

Slovak NNP N
patients NNS N
with IN N
differentiated JJ 4_p
thyroid NN 4_p
cancer NN 4_p
in IN N
Slovak NNP N
and CC N
Czech NNP N
hospitals NNS N
. . N

From NNP N
September NNP N
1991 CD N
to TO N
October NNP N
2005 CD N
in IN N
the DT N
Department NNP N
of IN N
Nuclear NNP N
Medicine NNP N
in IN N
Ostrava NNP N
357 CD 3_p
patients NNS N
from IN N
the DT N
Slovak NNP N
Republic NNP N
with IN N
differentiated VBN 4_p
thyroid NN 4_p
cancers NNS 4_p
( ( 4_p
follicular JJ 4_p
and CC 4_p
papillary JJ 4_p
) ) 4_p
underwent NN N
complex JJ N
therapy NN N
. . N

They PRP N
were VBD N
diagnosed VBN N
and CC N
operated VBN N
due JJ N
to TO N
the DT N
cancer NN N
( ( N
near-total JJ N
thyroidectomy NN N
and CC N
removal NN N
of IN N
lymph JJ N
node JJ N
metastases NNS N
) ) N
in IN N
Slovak NNP N
hospitals NNS N
. . N

Then RB N
they PRP N
were VBD N
sent VBN N
to TO N
the DT N
Department NNP N
of IN N
Nuclear NNP N
Medicine NNP N
in IN N
Ostrava NNP N
in IN N
the DT N
Czech NNP N
Republic NNP N
. . N

Slovak NNP N
Republic NNP N
, , N
in IN N
the DT N
University NNP N
Hospital NNP N
in IN N
Martin NNP N
. . N

-DOCSTART- -X- O O 2831788

hypertension NN 4_p
. . N

59 CD 3_p
mild NN 4_p
to TO 4_p
moderate VB 4_p
hypertensives NNS 4_p
-DOCSTART- -X- O O 11069570

atopic NN 4_p
eczema NN 4_p
. . 4_p

allergic JJ 4_p
inflammation NN 4_p
at IN 4_p
an DT 4_p
early JJ 4_p
age NN 4_p
A NNP N
total NN N
of IN N
27 CD N
infants NNS N
, , N
mean JJ N
age NN N
4.6 CD N
months NNS N
, , N
who WP N
manifested VBD N
atopic JJ N
eczema NN N
during IN N
exclusive JJ N
breast-feeding NN N
and CC N
who WP N
have VBP N
had VBN N
no DT N
exposure NN N
to TO N
any DT N
infant NN N
or CC N
substitute NN N
formula NN N
infants NNS N
-DOCSTART- -X- O O 8964276

patients NNS N
with IN N
newly RB N
diagnosed VBN N
or CC N
recurrent JJ N
epilepsy NN N
. . N

patients NNS N
with IN N
untreated JJ N
, , N
newly RB N
diagnosed VBN N
or CC N
recurrent JJ N
partial JJ N
and/or NN N
generalised VBD N
tonic-clonic JJ N
seizures NNS N
patients NNS N
on IN N
CBZ NNP N
600 CD N
-DOCSTART- -X- O O 21040167

post-transplant JJ 4_p
. . N

patients NNS N
achieving VBG N
tacrolimus JJ N
whole-blood JJ N
concentrations NNS N
of IN N
≥10 NNP N
ng/mL NN N
within IN N
3 CD N
days NNS N
of IN N
kidney NN 4_p
transplantation NN 4_p
, , N
after IN N
randomization NN N
either RB N
to TO N
standard VB N
dosing VBG N
( ( N
control VB N
group NN N
) ) N
or CC N
post-transplantation NN N
dosing NN N
guided VBN N
by IN N
a DT N
2-hour JJ N
( ( N
C NNP N
( ( N
2 CD N
) ) N
) ) N
level NN N
following VBG N
a DT N
preoperative JJ N
tacrolimus NN N
dose NN N
( ( N
T2 NNP N
group NN N
) ) N
monitoring NN N
. . N

Participants NNS N
received VBD N
concomitant JJ N
mycophenolate NN N
mofetil NN N
and CC N
steroids NNS N
RESULTS NNP N
Ninety NNP N
patients NNS N
were VBD N
recruited VBN N
, , N
of IN N
which WDT N
84 CD N
were VBD N
included VBN N
in IN N
the DT N
analysis NN N
( ( N
control NN N
group NN N
n=43 VBD N
; : N
T2 NNP N
group NN N
-DOCSTART- -X- O O 24213956

Forty-three JJ 4_p
chronic JJ 4_p
stroke NN 4_p
patients NNS 4_p
with IN 4_p
mild JJ 4_p
to TO 4_p
moderate VB 4_p
upper JJ 4_p
extremity NN 4_p
impairment NN 4_p
-DOCSTART- -X- O O 25062129

contact NN 4_p
lenses VBZ 4_p
worn VBP N
for IN N
10 CD N
hours NNS N
single JJ N
use NN N
( ( N
DD NNP N
) ) N
and CC N
7 CD N
days NNS N
of IN N
extended JJ 4_p
wear NN 4_p
( ( 4_p
EW NNP 4_p
) ) 4_p
. . N

Two CD N
similar JJ N
study NN N
populations NNS N
( ( N
DD NNP N
, , N
n JJ N
= VBP N
55 CD 3_p
; : N
EW NNP N
, , N
n JJ N
= NNP N
53 CD 3_p
) ) N
four CD N
study NN N
sites NNS N
. . N

-DOCSTART- -X- O O 21531178

community-dwelling JJ 4_p
older JJR 1_p
Black NNP 4_p
adults NNS 1_p
. . 4_p

community-dwelling JJ 4_p
older JJR 1_p
Black NNP 4_p
adults NNS 1_p
. . N

Churches NNP N
and CC N
community-based JJ N
organizations NNS N
. . N

Men NNP 2_p
and CC N
women NNS 2_p
( ( N
n JJ N
= NNP N
110 CD 3_p
) ) N
50 CD 1_p
years NNS 1_p
old JJ 1_p
and CC 1_p
older JJR 1_p
from IN 4_p
3 CD 4_p
south JJ 4_p
Florida NNP 4_p
counties NNS 4_p
. . N

-DOCSTART- -X- O O 14716650

postoperative JJ 4_p
pain NN 4_p
relief NN N
after IN N
total JJ 4_p
knee NN 4_p
arthroplasty NN 4_p
. . N

total JJ 4_p
knee NN 4_p
arthroplasty NN 4_p
. . N

Patients NNS N
were VBD N
randomly RB N
enrolled VBN N
into IN N
patient-controlled JJ N
anesthesia NN N
( ( N
PCA NNP N
) ) N
alone RB N
, , N
PCA NNP N
plus CC N
TENS NNP N
, , N
or CC N
PCA NNP N
plus CC N
sham JJ N
TENS NNP N
. . N

-DOCSTART- -X- O O 1412152

bleeding NN 4_p
or CC N
blood NN 4_p
product NN 4_p
requirements NNS 4_p
associated VBN N
with IN N
cardiopulmonary JJ 4_p
bypass NN 4_p
. . N

92 CD 3_p
patients NNS N
with IN N
overt JJ 4_p
bleeding NN 4_p
and CC N
a DT N
prolonged JJ 4_p
bleeding NN 4_p
time NN 4_p
. . N

patients NNS N
with IN N
excessive JJ N
immediate JJ N
postoperative JJ N
bleeding NN N
. . N

-DOCSTART- -X- O O 16354710

hip JJ 4_p
fracture NN 4_p
: : N
acute NN 4_p
trauma NN 4_p
ward NN 4_p
. . N

elderly JJ 1_p
women NNS 2_p
with IN N
hip JJ 4_p
fracture NN 4_p
. . N

Thirty-eight NNP 3_p
bedded VBD N
acute JJ N
trauma NN N
ward NN N
in IN N
a DT N
teaching JJ N
hospital NN N
. . N

All DT N
but CC N
11 CD 3_p
of IN 3_p
344 CD 3_p
consecutive JJ N
admissions NNS N
with IN N
acute JJ N
nonpathological JJ N
hip NN N
fracture NN N
were VBD N
approached VBN N
. . N

Three CD 3_p
hundred VBD 3_p
and CC 3_p
eighteen JJ 3_p
( ( 3_p
93 CD 3_p
% NN 3_p
) ) 3_p
agreed VBD N
to TO N
inclusion NN N
. . N

Sixteen NNP 3_p
were VBD 4_p
ineligible JJ 4_p
across IN N
the DT N
UK NNP N
. . N

-DOCSTART- -X- O O 25577772

patients NNS 4_p
with IN 4_p
diabetes NNS 4_p
mellitus NNS 4_p
. . N

type NN 4_p
2 CD 4_p
diabetes NNS 4_p
( ( 4_p
T2DM NNP 4_p
) ) 4_p
Standard NNP N
echocardiography NN N
was VBD N
performed VBN N
on IN N
849 CD 3_p
people NNS N
with IN N
T2DM NNP N
( ( N
median JJ 1_p
age NN 1_p
65years CD 1_p
, , N
40 CD N
% NN N
female NN 2_p
, , N
median JJ N
duration NN N
of IN N
diabetes NNS 4_p
5.5years CD N
) ) N
. . N

people NNS N
with IN N
T2DM NNP 4_p
. . N

-DOCSTART- -X- O O 9676351

young JJ 4_p
asthmatics NNS 4_p
] VBP 4_p
Nineteen JJ 1_p
asthmatics NNS 1_p
aged VBD 1_p
6 CD 1_p
to TO 1_p
12 CD 1_p
years NNS 1_p
young JJ N
asthmatics NNS N
patients NNS N
who WP N
have VBP N
difficulty NN N
in IN N
swallowing VBG N
large JJ N
dosage NN N
forms NNS N
. . N

-DOCSTART- -X- O O 19563641

men NNS 2_p
receiving VBG N
therapy NN N
for IN N
prostate NN 4_p
cancer NN 4_p
. . N

men NNS 2_p
receiving VBG N
androgen NN 4_p
deprivation NN 4_p
for IN N
their PRP$ N
prostate NN N
cancer NN N
. . N

195 CD 3_p
men NNS 2_p
( ( N
65 CD N
subjects NNS N
per IN N
arm NN N
) ) N
undergoing NN N
treatment NN N
for IN N
prostate NN 4_p
cancer NN 4_p
involving VBG 4_p
ADT NNP 4_p
in IN N
the DT N
cities NNS N
of IN N
Perth NNP N
and CC N
Brisbane NNP N
in IN N
Australia NNP N
. . N

-DOCSTART- -X- O O 1423955

patients NNS 4_p
with IN 4_p
atrial JJ 4_p
fibrillation NN 4_p
or CC 4_p
atrial JJ 4_p
flutter NN 4_p
. . 4_p

patients NNS 4_p
in IN 4_p
atrial JJ 4_p
fibrillation NN 4_p
and/or IN 4_p
atrial JJ 4_p
flutter NN 4_p
. . 4_p

32 CD N
patients NNS N
with IN N
atrial JJ N
fibrillation NN N
or CC N
atrial JJ N
flutter NN N
( ( N
mean JJ N
+/- NN N
SD NNP N
age NN N
, , N
66 CD N
+/- JJ N
7 CD N
years NNS N
; : N
mean VB N
baseline JJ N
heart NN N
rate NN N
, , N
131 CD N
+/- JJ N
10 CD N
beats NNS N
per IN N
minute NN N
) ) N
after IN N
20 CD N
mg NN N
or CC N
20 CD N
mg NN N
followed VBN N
by IN N
25-mg JJ N
bolus NN N
doses NNS N
and CC N
a DT N
10 CD N
and CC N
15 CD N
mg/hr NN N
infusion NN N
for IN N
24 CD N
hours NNS N
Thirty NNP N
of IN N
32 CD N
patients NNS N
patients NNS N
with IN N
atrial JJ N
fibrillation NN N
or CC N
atrial JJ N
flutter NN N
-DOCSTART- -X- O O 9757955

women NNS 2_p
women NNS N
receiving VBG N
depot NN 4_p
medroxyprogesterone NN 4_p
injections NNS N
. . N

-DOCSTART- -X- O O 16435344

plantar NN 4_p
fasciitis NN 4_p
North JJ N
American JJ N
confirmatory NN N
study NN N
. . N

recalcitrant JJ 4_p
chronic JJ 4_p
plantar NN 4_p
fasciitis NN 4_p
four CD 3_p
outpatient NN 3_p
orthopedic NN N
clinics NNS N
. . N

The DT N
patients NNS N
, , N
114 CD 3_p
adult NN 1_p
subjects NNS 1_p
with IN N
chronic JJ 4_p
plantar NN 4_p
fasciitis NN 4_p
, , 4_p
recalcitrant JJ 4_p
to TO 4_p
conservative JJ 4_p
therapies NNS 4_p
for IN N
at IN N
least JJS N
6 CD N
months NNS N
-DOCSTART- -X- O O 8733449

chronic JJ 4_p
suppurative JJ 4_p
otitis NN 4_p
media NNS 4_p
. . N

Active NNP 4_p
chronic JJ 4_p
suppurative NN 4_p
otitis NN 4_p
media NNS 4_p
patients NNS N
are VBP N
being VBG N
considered VBN N
for IN N
surgical JJ N
treatment NN N
. . N

discharging VBG 4_p
ears NNS 4_p
. . N

Fifty-two JJ 3_p
patients NNS N
were VBD N
selected VBN N
chronic JJ 4_p
suppurative NN 4_p
otitis NN 4_p
media NNS 4_p
. . N

active JJ 4_p
chronic JJ 4_p
suppurative NN 4_p
otitis NN 4_p
media NNS 4_p
-DOCSTART- -X- O O 23128568

race-discordant JJ N
patient-provider JJ N
African JJ N
American JJ N
patients NNS N
and CC N
white JJ N
health NN N
care NN N
providers NNS N
99 CD 3_p
African JJ N
American JJ N
patients NNS N
with IN N
hypertension NN 4_p
-DOCSTART- -X- O O 6410450

in IN 4_p
man NN 4_p
animals NNS N
and CC N
man NN N
. . N

animals NNS N
in IN N
man NN N
-DOCSTART- -X- O O 2663585

patients NNS 4_p
with IN 4_p
congestive JJ 4_p
heart NN 4_p
failure NN 4_p
. . 4_p

patients NNS N
with IN N
congestive JJ N
heart NN N
failure NN N
97 CD N
patients NNS N
( ( N
aged VBN N
31-83 CD N
years NNS N
) ) N
belonging VBG N
to TO N
NYHA NNP N
class NN N
II NNP N
and CC N
III NNP N
with IN N
congestive JJ N
heart NN N
failure NN N
of IN N
different JJ N
aetiology NN N
, , N
but CC N
without IN N
any DT N
complex JJ N
ventricular NN N
arrhythmias NN N
in IN N
basal NN N
conditions NNS N
( ( N
couplets NNS N
with IN N
R'-R NNP N
" NNP N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
400 CD N
msec NNS N
, , N
ventricular JJ N
tachycardia NN N
, , N
R NNP N
on IN N
T NNP N
phenomena NN N
) ) N
. . N

-DOCSTART- -X- O O 6384285

study NN N
of IN N
selenium NN N
sulfide NN N
in IN N
tinea NN N
versicolor NN N
. . N

tinea NN N
versicolor NN N
. . N

treatment NN N
groups NNS N
-DOCSTART- -X- O O 20413513

hyperglycemia NN 4_p
in IN 4_p
patients NNS 4_p
with IN 4_p
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
inadequately RB 4_p
controlled VBN 4_p
by IN 4_p
metformin NN 4_p
monotherapy NN 4_p
. . 4_p

patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
exhibiting VBG N
inadequate JJ N
glycemic NNS N
control NN N
( ( N
A1C NNP N
7-11 CD N
% NN N
) ) N
. . N

302 CD 4_p
patients NNS 4_p
with IN 4_p
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
( ( 4_p
mean JJ 4_p
A1C NNP 4_p
8.3 CD 4_p
% NN 4_p
) ) 4_p
on IN 4_p
metformin NN 4_p
monotherapy NN 4_p
( ( 4_p
mean JJ 4_p
1.5 CD 4_p
g/day NN 4_p
) ) 4_p
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
who WP N
had VBD N
inadequate JJ N
glycemic NNS N
control NN N
with IN N
metformin NN N
alone RB N
. . N

type NN N
2 CD N
diabetes NNS N
. . N

-DOCSTART- -X- O O 23776270

brown-egg NN N
laying NN N
hens NNS N
. . N

total NN N
of IN N
five CD 3_p
hundred JJ 3_p
forty NN 3_p
19-wk-old JJ 1_p
HyLine NNP N
Brown NNP N
hens NNS N
were VBD N
used VBN N
to TO N
study VB N
-DOCSTART- -X- O O 25017958

laparoscopic JJ 4_p
transabdominal JJ 4_p
preperitoneal NN 4_p
( ( 4_p
TAPP NNP 4_p
) ) 4_p
versus NN 4_p
Lichtenstein NNP 4_p
tension NN 4_p
free JJ 4_p
inguinal JJ 4_p
hernia NN 4_p
repair NN 4_p
: : 4_p
complications NNS 4_p
of IN 4_p
laparoscopic JJ 4_p
transabdominal JJ 4_p
preperitoneal NN 4_p
( ( 4_p
TAPP NNP 4_p
) ) 4_p
and CC 4_p
Lichtenstein NNP 4_p
tension NN 4_p
free JJ 4_p
hernia NN 4_p
repair NN 4_p
. . 4_p

A NNP N
total NN N
of IN N
120 CD 3_p
patients NNS N
who WP N
went VBD N
inguinal JJ 4_p
hernia NN 4_p
repair NN 4_p
at IN N
Shahid NNP N
Sadoughi NNP N
university NN N
training VBG N
hospital NN N
from IN N
April NNP N
2011 CD N
to TO N
August NNP N
2013 CD N
-DOCSTART- -X- O O 18582177

children NNS N
with IN N
autism NN N
and CC N
irritable JJ N
behavior NN N
. . N

children NNS 4_p
with IN 4_p
autism NN 4_p
and CC 4_p
irritable JJ 4_p
behavior NN 4_p
. . 4_p

Thirty-eight JJ N
children NNS N
, , N
ages VBZ N
5-17 CD N
years NNS N
with IN N
autism NN N
and CC N
severe JJ N
behavioral JJ N
disturbance NN N
This DT N
sample NN N
of IN N
38 CD N
was VBD N
a DT N
subset NN N
of IN N
101 CD N
subjects NNS N
who WP N
participated VBD N
in IN N
the DT N
clinical JJ N
trial NN N
; : N
63 CD N
were VBD N
unable JJ N
to TO N
perform VB N
the DT N
cognitive JJ N
tasks NNS N
. . N

Twenty-nine JJ N
boys NNS N
and CC N
9 CD N
girls NNS N
with IN N
autism NN N
and CC N
severe JJ N
behavioral JJ N
disturbance NN N
and CC N
a DT N
mental JJ N
age NN N
> NNP N
or=18 JJ N
months NNS N
completed VBN N
the DT N
cognitive JJ N
part NN N
of IN N
the DT N
study NN N
. . N

children NNS N
with IN N
autism NN N
-DOCSTART- -X- O O 24246210

overactive JJ 4_p
bladder NN 4_p
. . 4_p

patients NNS 1_p
with IN 1_p
overactive JJ 1_p
bladder NN 1_p
( ( 1_p
OAB NNP 1_p
) ) 1_p
. . 1_p

patients NNS N
with IN N
continuous JJ N
OAB NNP N
symptoms NNS N
for IN N
≥ JJ N
3 CD N
months NNS N
, , N
daily JJ N
mean VBP N
voiding VBG N
frequency NN N
( ( N
DMVF NNP N
) ) N
≥ VBD N
8 CD N
, , N
and CC N
daily JJ N
mean JJ N
urgency NN N
or CC N
urgency NN N
incontinence NN N
frequency NN N
-DOCSTART- -X- O O 4407133

Letter NN N
: : N
Cephaloridine NN N
and CC N
gentamicin NN N
in IN N
prophylaxis NN 4_p
of IN N
surgical JJ 4_p
wound NN 4_p
infection NN 4_p
. . N

-DOCSTART- -X- O O 11932900

recurrent NN 4_p
or CC 4_p
persistent JJ 4_p
nasopharyngeal NN 4_p
carcinomas NN 4_p
after IN 4_p
radiotherapy NN 4_p
residual JJ N
nasopharyngeal NN N
carcinomas NN N
( ( N
NPC NNP 4_p
) ) N
Thirty NNP 3_p
six CD 3_p
NPC NNP N
patients NNS N
underwent JJ N
head NN N
and CC N
neck NN N
CT NNP N
, , N
Tc-MIBI NNP N
SPECT NNP N
, , N
and CC N
FDG-PET NNP N
four CD N
months NNS N
after IN N
radiotherapy NN N
36 CD N
patients NNS N
. . N

No DT N
patients NNS N
had VBD N
multiple JJ N
foci NN N
of IN N
NPC NNP N
. . N

-DOCSTART- -X- O O 12031821

patients NNS 4_p
with IN 4_p
coronary JJ 4_p
heart NN 4_p
disease NN 4_p
. . N

patients NNS 4_p
with IN 4_p
coronary JJ 4_p
heart NN 4_p
disease NN 4_p
( ( 4_p
CHD NNP 4_p
) ) 4_p
Fifty-eight JJ 3_p
patients NNS 3_p
-DOCSTART- -X- O O 12810472

recurrent NN 4_p
chronic JJ 4_p
hyperplastic JJ 4_p
sinusitis NN 4_p
with IN 4_p
nasal JJ 4_p
polyposis NN 4_p
. . 4_p

One CD 4_p
hundred JJ 4_p
seventy NN 4_p
patients NNS 4_p
with IN 4_p
bilateral JJ 4_p
obstructive CD 4_p
or CC 4_p
minimally RB 4_p
obstructive JJ 4_p
chronic JJ 4_p
hyperplastic JJ 4_p
sinusitis NN 4_p
with IN 4_p
nasal JJ 4_p
polyposis NN 4_p
. . 4_p

All DT N
patients NNS N
were VBD N
surgically RB N
treated VBN N
in IN N
the DT N
ENT NNP N
Department NNP N
, , N
University NNP N
of IN N
Siena NNP N
Medical NNP N
School NNP N
. . N

One CD N
month NN N
after IN N
surgery NN N
1 CD N
patients NNS N
patients NNS N
treated VBN N
with IN N
furosemide NN N
or CC N
mometasone NN N
patients NNS N
who WP N
did VBD N
not RB N
receive VB N
any DT N
treatment NN N
chronic JJ N
hyperplastic JJ N
sinusitis NN N
with IN N
nasal JJ N
polyposis NN N
. . N

-DOCSTART- -X- O O 5410150

prolonged JJ N
complete JJ N
remission NN N
in IN N
acute JJ 4_p
leukemia NN 4_p
of IN N
childhood NN 1_p
. . N

-DOCSTART- -X- O O 8639070

cognitive JJ N
functioning NN N
patients NNS 4_p
with IN 4_p
MS NNP 4_p
. . 4_p

A NNP N
total NN N
of IN N
45 CD N
ambulatory JJ N
patients NNS N
with IN N
MS NNP N
and CC N
severe JJ N
fatigue NN N
-DOCSTART- -X- O O 12635578

perennial JJ 4_p
allergic JJ 4_p
rhinitis NN 4_p
. . 4_p

patients NNS N
with IN N
allergic JJ 4_p
rhinitis NN 4_p
32 CD 3_p
subjects NNS N
with IN N
perennial JJ 4_p
allergic JJ 4_p
rhinitis NN 4_p
and CC N
randomized VBD N
them PRP N
in IN N
a DT N
double-blinded JJ N
, , N
cross-over JJ N
fashion NN N
patients NNS N
with IN N
perennial JJ 4_p
allergic JJ 4_p
rhinitis NN 4_p
-DOCSTART- -X- O O 16007391

Japanese JJ N
smokers NNS N
: : N
Japanese JJ N
smokers NNS N
. . N

eight CD N
male JJ N
habitual JJ N
smokers NNS N
Japanese JJ 4_p
habitual JJ 4_p
smokers NNS 4_p
. . 4_p

-DOCSTART- -X- O O 17880325

myocardial JJ 4_p
infarction NN 4_p
in IN N
patients NNS N
with IN N
non-ST JJ N
elevation NN N
acute NN 4_p
coronary JJ 4_p
syndromes NNS 4_p
: : N
non-ST JJ 4_p
elevation NN 4_p
acute NN 4_p
coronary JJ 4_p
syndromes NNS 4_p
( ( 4_p
NSTE NNP 4_p
ACS NNP 4_p
) ) 4_p
. . 4_p

we PRP N
evaluated VBD N
26,466 CD 3_p
NSTE NNP N
ACS NNP N
patients NNS N
from IN N
the DT N
Global NNP N
Use NNP N
of IN N
Strategies NNPS N
to TO N
Open VB N
Occluded NNP N
Arteries NNPS N
in IN N
Acute NNP N
Coronary NNP N
Syndromes NNP N
( ( N
GUSTO-IIb NNP N
) ) N
, , N
Platelet NNP N
Glycoprotein NNP N
IIb/IIIa NNP N
in IN N
Unstable JJ N
Angina NNP N
: : N
-DOCSTART- -X- O O 8318411

metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
: : N
67 CD 3_p
patients NNS N
with IN N
systemic JJ 4_p
breast NN 4_p
cancer NN 4_p
treated VBN 4_p
by IN 4_p
chemotherapy NN 4_p
; : N
55 CD 3_p
were VBD N
assessable JJ 4_p
by IN 4_p
UICC NNP 4_p
criteria NNS 4_p
and CC N
the DT N
response NN N
index NN N
( ( N
96 CD N
% NN N
of IN N
all DT N
UICC NNP N
assessable JJ N
patients NNS N
) ) N
. . N

patients NNS N
-DOCSTART- -X- O O 10945514

treatment NN N
of IN N
chronic JJ 4_p
pain NN 4_p
. . N

469 CD 3_p
patients NNS N
469 CD 3_p
patients NNS N
, , N
255 CD 3_p
( ( N
54.4 CD N
% NN N
) ) N
were VBD N
female JJ 2_p
and CC N
214 CD 3_p
( ( N
45.6 CD N
% NN N
) ) N
were VBD N
male JJ 2_p
. . N

mean JJ N
age NN N
was VBD N
51.1 CD 1_p
years NNS 1_p
. . N

Types NNS N
of IN N
chronic NN 4_p
pain NN 4_p
included VBD N
back RB 4_p
( ( N
214 CD N
; : N
45.6 CD N
% NN N
) ) N
, , N
arthritic JJ 4_p
( ( N
145 CD N
; : N
30.9 CD N
% NN N
) ) N
, , N
other JJ 4_p
musculoskeletal NN 4_p
( ( N
65 CD N
; : N
13.9 CD N
% NN N
) ) N
, , N
cancer NN 4_p
( ( N
6 CD N
; : N
1.3 CD N
% NN N
) ) N
, , N
diabetic JJ 4_p
neuropathic NN 4_p
( ( N
3 CD N
; : N
0.6 CD N
% NN N
) ) N
, , N
postherpetic JJ 4_p
neuralgic NN 4_p
( ( N
5 CD N
; : N
1.1 CD N
% NN N
) ) N
, , N
other JJ 4_p
neurologic NN 4_p
( ( N
21 CD N
; : N
4.5 CD N
% NN N
) ) N
, , N
and CC N
other JJ N
unclassified JJ 4_p
chronic JJ 4_p
pain NN 4_p
( ( N
10 CD N
; : N
2.1 CD N
% NN N
) ) N
-DOCSTART- -X- O O 15943172

obese JJ N
patients NNS N
. . N

One CD N
hundred CD N
and CC N
five CD N
obese JJ N
[ NN N
Body NNP N
Mass NNP N
Index NNP N
( ( N
BMI NNP N
) ) N
> VBD N
or CC N
= $ N
30 CD N
] JJ N
patients NNS N
participated VBN N
in IN N
the DT N
study NN N
. . N

62 CD N
took VBD N
part NN N
in IN N
the DT N
treatment NN N
program NN N
and CC N
43 CD N
served VBD N
as IN N
controls NNS N
. . N

obesity NN 4_p
unit NN 4_p
's POS 4_p
waiting VBG 4_p
list NN 4_p
Fifty-seven NNP N
( ( N
92 CD N
% NN N
) ) N
patients NNS N
completed VBN N
treatment NN N
. . N

-DOCSTART- -X- O O 3073441

auricular JJ 4_p
fibrillation NN 4_p
] NN 4_p
-DOCSTART- -X- O O 18470779

disruptive JJ 4_p
behavior NN 4_p
problems NNS 4_p
youth VB 1_p
participating VBG N
in IN N
a DT N
school NN 4_p
mental JJ 4_p
health NN 4_p
program NN 4_p
in IN 4_p
an DT 4_p
underserved JJ 4_p
community NN 4_p
in IN 4_p
the DT 4_p
Appalachian JJ 4_p
region NN 4_p
. . N

117 CD 3_p
children NNS 1_p
in IN 1_p
kindergarten VBN 1_p
through IN 1_p
6th CD 1_p
grade NN 1_p
including VBG N
91 CD 3_p
children NNS 1_p
( ( N
78 CD N
% NN N
male NN 2_p
) ) N
from IN N
5 CD N
schools NNS N
who WP N
were VBD N
consecutively RB N
referred VBN N
to TO N
the DT N
intervention NN N
program NN N
and CC N
26 CD 3_p
children NNS 1_p
( ( N
73 CD N
% NN N
male NN 2_p
) ) N
from IN N
3 CD N
schools NNS N
in IN N
which WDT N
program NN N
implementation NN N
was VBD N
delayed VBN N
for IN N
1 CD N
year NN N
. . N

-DOCSTART- -X- O O 6350097

Patients NNS N
with IN N
endoscopically RB 4_p
documented VBN N
duodenal JJ 4_p
ulcer NN 4_p
69 CD 3_p
patients NNS N
in IN N
each DT N
group NN N
114 CD 3_p
patients NNS N
with IN N
healed JJ N
ulcer NN 4_p
-DOCSTART- -X- O O 14711190

a DT N
randomized JJ N
, , N
double-blind JJ N
study NN N
design NN N
, , N
group NN N
1 CD N
( ( N
12 CD 4_p
patients NNS N
; : N
7 CD 4_p
males NNS 4_p
, , N
5 CD 4_p
females NNS 4_p
) ) N
with IN N
serum JJ 4_p
LDL-C JJ 4_p
levels NNS 4_p
higher JJR N
than IN N
170 CD N
mg/dL NN N
and CC N
without IN N
any DT N
other JJ N
risk NN N
factor NN N
for IN N
atherosclerosis NN 4_p
received VBD N
three CD N
months NNS N
of IN N
20 CD N
mg/day JJ N
atorvastatin FW N
treatment NN N
while IN N
group NN N
11 CD N
( ( N
8 CD 4_p
males NNS 4_p
, , N
4 CD 4_p
females NNS 4_p
) ) N
with IN N
the DT N
same JJ N
characteristics NNS N
received VBD N
80 CD N
mg/day NN N
. . N

-DOCSTART- -X- O O 11961446

acute JJ 4_p
hematogenous JJ 4_p
bone NN 4_p
and CC 4_p
joint JJ 4_p
infection NN 4_p
in IN 4_p
children NNS 1_p
: : 4_p
Thirty-three JJ 3_p
cases NNS N
of IN N
acute JJ N
hematogenous JJ N
bone NN N
or CC N
joint JJ N
infection NN N
in IN N
children NNS N
children NNS N
with IN N
blood-borne JJ N
musculoskeletal JJ 4_p
infection NN 4_p
. . N

-DOCSTART- -X- O O 12197822

Should MD N
we PRP N
debrief VB N
and CC N
counsel NN N
people NNS N
who WP N
have VBP N
had VBN N
psychological JJ N
shock NN N
? . N
-DOCSTART- -X- O O 18217284

children NNS 1_p
after IN N
adenotonsillectomy JJ 4_p
] NN N
-DOCSTART- -X- O O 23483320

100 CD 3_p
patients NNS N
experiencing VBG N
primary JJ 4_p
TKA NNP 4_p
-DOCSTART- -X- O O 3544187

duodenal JJ 4_p
ulcer NN 4_p
duodenal JJ 4_p
ulcer NN 4_p
. . N

171 CD 3_p
patients NNS N
with IN N
endoscopically RB N
confirmed VBN N
duodenal JJ 4_p
ulcers NNS 4_p
. . N

two CD N
treatment NN N
groups NNS N
-DOCSTART- -X- O O 4157501

myocardial JJ 4_p
infarction NN 4_p
. . 4_p

-DOCSTART- -X- O O 23587455

Eighty NNP N
patients NNS N
undergoing VBG N
gynecological JJ N
tumor NN N
resection NN N
RESULTS VB N
A DT N
total NN N
of IN N
79 CD N
patients NNS N
were VBD N
evaluated VBN N
-DOCSTART- -X- O O 11379334

patients NNS N
undergoing VBG N
H. NNP N
pylori JJ N
eradication NN N
. . N

One CD 3_p
hundred CD 3_p
and CC 3_p
ninety-three JJ 3_p
( ( 3_p
193 CD 3_p
) ) 3_p
H. NNP 4_p
pylori-positive JJ 4_p
patients NNS 4_p
Group NNP 4_p
A NNP 4_p
( ( N
N NNP N
= NNP N
64 CD 3_p
) ) N
: : N
Group NNP 4_p
B NNP 4_p
( ( N
N NNP N
= NNP N
64 CD 3_p
) ) 3_p
: : N
Group NNP 4_p
C NNP 4_p
( ( N
N NNP N
= NNP N
65 CD 3_p
) ) N
: : N
All DT N
patients NNS N
One CD N
hundred CD N
and CC N
eighty-eight JJ N
out IN N
of IN N
the DT N
193 CD N
H. NNP N
pylori-positive JJ N
patients NNS N
( ( N
96 CD N
% NN N
) ) N
completed VBD N
therapy NN N
. . N

193 CD N
enrolled JJ N
subjects NNS N
-DOCSTART- -X- O O 12044624

patients NNS 4_p
with IN 4_p
critical JJ 4_p
limb NN 4_p
ischaemia NN 4_p
: : 4_p
patients NNS N
with IN N
allodynia NN 4_p
, , N
hyperalgesia NN 4_p
and CC N
hyperpathia NN 4_p
secondary JJ 4_p
to TO 4_p
critical JJ 4_p
limb NN 4_p
ischaemia NN 4_p
. . N

Thirty-five JJ 3_p
patients NNS N
completed VBD N
the DT N
study NN N
, , N
18 CD N
17 CD N
-DOCSTART- -X- O O 20486273

older JJR 1_p
patients NNS N
with IN N
diabetes NNS 4_p
: : N
elderly JJ 1_p
patients NNS N
patients NNS N
with IN N
diabetes NNS N
. . N

elderly JJ 1_p
patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
. . N

Eleven NNP 3_p
thousand VBP 3_p
one CD 3_p
hundred CD 3_p
and CC 3_p
forty JJ 3_p
patients NNS N
aged VBN 1_p
at IN 1_p
least JJS 1_p
55 CD 1_p
years NNS 1_p
with IN N
type NN 4_p
2 CD 4_p
diabetes NNS 4_p
( ( N
mean JJ 1_p
66+/-6 CD 1_p
years NNS 1_p
) ) N
subgroups NNS N
according VBG N
to TO N
age NN N
: : N
below IN N
65 CD N
, , N
65-74 JJ N
and CC N
at IN N
least JJS N
75 CD N
years NNS N
. . N

patients NNS N
of IN N
at IN N
least JJS N
75 CD N
years NNS N
with IN N
type NN N
2 CD N
diabetes NNS N
. . N

older JJR N
patients NNS N
in IN N
this DT N
age NN N
group NN N
-DOCSTART- -X- O O 10499652

heparin NN 4_p
pretreated VBN 4_p
patients NNS N
. . N

Thirty NNP 3_p
patients NNS N
scheduled VBN N
for IN N
elective JJ 4_p
myocardial JJ 4_p
revascularization NN 4_p
and CC N
having VBG N
undergone JJ N
preoperative JJ 4_p
heparin NN 4_p
treatment NN 4_p
heparin NN 4_p
pretreated JJ 4_p
patients NNS N
; : N
-DOCSTART- -X- O O 20406576

children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . N

children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASDs NNP N
) ) N
. . N

72 CD 3_p
Danish JJ N
children NNS N
( ( N
aged VBN 1_p
4 CD 1_p
years NNS 1_p
to TO 1_p
10 CD 1_p
years NNS 1_p
11 CD 1_p
months NNS 1_p
) ) N
assigned VBD N
to TO N
diet VB N
( ( N
A DT N
) ) N
or CC N
non-diet JJ N
( ( N
B NNP N
) ) N
groups NNS N
by IN N
stratified JJ N
randomisation NN N
. . N

26 CD 3_p
diet JJ 3_p
children NNS 3_p
and CC N
29 CD 3_p
controls NNS 3_p
children NNS N
diagnosed VBN N
with IN N
ASD NNP N
. . N

-DOCSTART- -X- O O 24973545

parents NNS N
of IN N
disabled JJ 4_p
children NNS 4_p
. . N

parents NNS N
of IN N
disabled JJ N
children NNS N
parents NNS N
of IN N
a DT N
child NN N
with IN N
a DT N
disability NN 4_p
or CC 4_p
autistic JJ 4_p
spectrum NN 4_p
condition NN 4_p
. . N

comprising VBG N
an DT N
intervention NN N
group NN N
( ( N
n=48 CC 3_p
) ) N
and CC N
comparator NN N
( ( N
no DT N
intervention NN N
) ) N
group NN N
( ( N
n=28 RB 3_p
) ) N
was VBD N
used VBN N
parents NNS N
who WP N
do VBP N
not RB N
have VB N
English NNP N
as IN N
a DT N
first JJ N
language NN N
-DOCSTART- -X- O O 15356657

children NNS 1_p
with IN N
acute JJ 4_p
lymphoblastic JJ 4_p
leukemia NN 4_p
in IN N
first JJ N
bone NN N
marrow NN N
relapse NN N
. . N

relapsed JJ N
acute NN 4_p
lymphoblastic JJ 4_p
leukemia NN 4_p
( ( N
ALL DT 4_p
) ) N
. . N

45 CD 3_p
patients NNS N
with IN N
ALL NNP N
in IN N
first JJ N
bone NN N
marrow NN N
relapse NN N
enrolled VBD N
-DOCSTART- -X- O O 24964689

Thai NNP 4_p
hypertensive JJ 4_p
population NN N
: : N
people NNS N
living VBG N
with IN N
hypertension NN 4_p
. . N

Forty-four NNP 3_p
subjects NNS N
, , N
aged VBD N
35 CD 1_p
to TO 1_p
59-year-old JJ 1_p
, , N
with IN N
hypertension NN 4_p
in IN N
Nakhon NNP 4_p
Pathom NNP 4_p
Province NNP 4_p
, , 4_p
Thailand NNP 4_p
-DOCSTART- -X- O O 17700083

children NNS N
with IN N
autism NN 4_p
and CC 4_p
developmental JJ 4_p
delay NN 4_p
. . N

young JJ 1_p
children NNS 1_p
with IN N
disabilities NNS N
and CC N
coping VBG N
abilities NNS N
of IN N
their PRP$ N
families NNS N
and CC N
( ( N
2 CD N
) ) N
describe VB N
the DT N
characteristics NNS N
of IN N
children NNS N
and CC N
families NNS N
who WP N
benefit VBP N
most RBS N
from IN N
the DT N
intervention NN N
. . N

Fifty-nine JJ 3_p
children NNS N
, , N
aged VBN 1_p
3-5 CD 1_p
years NNS 1_p
, , N
with IN N
no DT N
cerebral JJ N
palsy NN N
A DT N
special JJ N
education NN N
teacher NN N
provided VBD N
40 CD N
visits NNS N
over IN N
12 CD N
months NNS N
working VBG N
with IN N
the DT N
families NNS N
-DOCSTART- -X- O O 22011217

patients NNS N
affected VBN N
by IN N
acne NN 4_p
and CC N
polycystic JJ 4_p
ovary JJ 4_p
syndrome NN 4_p
: : 4_p
few JJ N
patients NNS N
, , N
especially RB N
women NNS 2_p
In IN N
women NNS 2_p
with IN N
acne NN 4_p
and CC N
proven JJ N
PCOS NNP N
therapy NN N
with IN N
estroprogestins NNS N
( ( N
EPs NNP N
) ) N
women NNS 2_p
affected VBN N
by IN N
mild NN 4_p
to TO 4_p
severe VB 4_p
acne NN 4_p
and CC N
polycystic JJ 4_p
ovary JJ 4_p
syndrome NN 4_p
( ( 4_p
PCOS NNP 4_p
) ) 4_p
. . N

Fifty-nine JJ 3_p
women NNS 2_p
were VBD N
randomized VBN N
women NNS 2_p
with IN N
acne NN 4_p
-DOCSTART- -X- O O 23229426

TKA NNP 4_p
we PRP N
enrolled VBD N
151 CD 3_p
patients NNS N
undergoing JJ N
TKA NNP 4_p
. . N

Group NNP N
A NNP N
( ( N
n=76 JJ 3_p
patients NNS N
) ) N
Control NNP N
Group NNP N
B NNP N
( ( N
n=75 JJ 3_p
patients NNS N
) ) N
-DOCSTART- -X- O O 3112261

outpatient JJ N
oral JJ 4_p
surgery NN 4_p
. . N

16 CD 3_p
healthy JJ 4_p
patients NNS N
requiring VBG 4_p
removal NN 4_p
of IN 4_p
bilateral JJ 4_p
symmetrically-impacted JJ 4_p
mandibular JJ 4_p
third JJ 4_p
molars NNS 4_p
-DOCSTART- -X- O O 6344196

rheumatoid JJ 4_p
arthritis NN 4_p
. . N

( ( N
n JJ N
= NNP N
20 CD 3_p
) ) N
( ( N
m JJ N
= NNP N
19 CD 3_p
) ) N
patients NNS N
with IN N
rheumatoid JJ 4_p
arthritis NN 4_p
of IN N
mild-moderate JJ 4_p
activity NN 4_p
. . N

-DOCSTART- -X- O O 12239448

hepatocellular JJ 4_p
carcinoma NN 4_p
. . N

hepatocellular JJ 4_p
carcinoma NN 4_p
Twenty NNP 3_p
patients NNS N
with IN N
hepatocellular JJ 4_p
carcinoma NN 4_p
measuring VBG 4_p
< $ 4_p
25 CD 4_p
mm NN 4_p
-DOCSTART- -X- O O 8570775

autism NN 4_p
: : N
children NNS 1_p
children NNS 1_p
children NNS N
autistic JJ 4_p
children NNS 1_p
-DOCSTART- -X- O O 9864127

healthy JJ 4_p
adult NN 4_p
volunteers NNS 4_p
with IN 4_p
and CC 4_p
without IN 4_p
the DT 4_p
Morgan NNP 4_p
therapeutic JJ 4_p
lens NNS 4_p
( ( 4_p
MTL NNP 4_p
) ) 4_p
. . 4_p

healthy JJ N
volunteers NNS N
who WP N
were VBD N
at IN N
least JJS N
18 CD N
years NNS N
of IN N
age NN N
. . N

Both DT N
eyes NNS N
of IN N
each DT N
volunteer NN N
treatment NN N
groups NNS N
and CC N
the DT N
volunteers NNS N
. . N

The DT N
volunteers NNS N
Sixty-three JJ N
volunteers NNS N
were VBD N
recruited VBN N
into IN N
the DT N
study NN N
, , N
with IN N
61 CD N
entered VBN N
in IN N
the DT N
final JJ N
analysis NN N
. . N

-DOCSTART- -X- O O 21430242

46 CD 4_p
healthy JJ 4_p
adults NNS 4_p
( ( 4_p
16 CD 4_p
males NNS 4_p
, , 4_p
30 CD 4_p
females NNS 4_p
; : 4_p
age NN 4_p
31-66 JJ 4_p
y NN 4_p
) ) 4_p
. . 4_p

Fecal JJ N
SCFA NNP N
levels NNS N
varied VBD N
widely RB N
among IN N
participants NNS N
at IN N
entry NN N
( ( N
butyrate JJ N
concentrations NNS N
: : N
3.5-32.6 JJ N
mmol/kg NN N
; : N
butyrate JJ N
excretions NNS N
: : N
0.3-18.2 JJ N
mmol/48 NN N
h NN N
) ) N
. . N

-DOCSTART- -X- O O 23084676

infertile JJ 4_p
women NNS 4_p
undergoing VBG 4_p
laparoscopic JJ 4_p
stripping NN 4_p
of IN 4_p
bilateral JJ 4_p
endometriomas NN 4_p
. . 4_p

University NNP 4_p
teaching NN 4_p
hospital NN 4_p
. . 4_p

100 CD N
patients NNS N
with IN N
bilateral JJ N
endometriomas NN N
. . N

-DOCSTART- -X- O O 16824559

autism NN 4_p
autism NN 4_p
Compared VBN 4_p
to TO 4_p
ten VB 4_p
IQ- NNP 4_p
and CC 4_p
age-matched JJ 4_p
healthy JJ 4_p
controls NNS 4_p
, , 4_p
eight CD 4_p
participants NNS 4_p
with IN 4_p
autism NN 4_p
-DOCSTART- -X- O O 22026323

young JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
Forty-seven JJ 3_p
children NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
and CC N
wait-list JJ N
control NN N
groups NNS N
. . N

-DOCSTART- -X- O O 8750409

Measuring VBG 4_p
the DT 4_p
impact NN 4_p
of IN 4_p
patient JJ 4_p
counseling NN 4_p
in IN 4_p
the DT 4_p
outpatient JJ 4_p
pharmacy NN 4_p
setting NN 4_p
: : 4_p
the DT 4_p
research NN 4_p
design NN 4_p
of IN 4_p
the DT 4_p
Kaiser NNP 4_p
Permanente/USC NNP 4_p
patient NN 4_p
consultation NN 4_p
study NN 4_p
. . 4_p

outpatient JJ N
pharmacy NN N
setting VBG N
. . N

The DT N
study NN N
was VBD N
conducted VBN N
in IN N
pharmacies NNS N
operated VBN N
by IN N
the DT N
Southern NNP N
California NNP N
region NN N
Kaiser NNP N
Permanente NNP N
Medical NNP N
Care NNP N
Program NNP N
. . N

-DOCSTART- -X- O O 4908199

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
ergotamine JJ 4_p
tartrate NN 4_p
. . N

-DOCSTART- -X- O O 24061784

children NNS N
and CC N
adolescents NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
: : N
children NNS N
and CC N
adolescents NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

children NNS 4_p
and CC 4_p
adolescents NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
and CC 4_p
prominent JJ 4_p
repetitive JJ 4_p
behavior NN 4_p
. . 4_p

149 CD N
children NNS N
and CC N
adolescents NNS N
5 CD N
to TO N
17 CD N
years NNS N
of IN N
age NN N
( ( N
mean JJ N
[ NNP N
SD NNP N
] NNP N
age NN N
, , N
9.4 CD N
[ NN N
3.1 CD N
] CD N
years NNS N
) ) N
from IN N
6 CD N
academic JJ N
centers NNS N
Participants NNS N
had VBD N
autistic JJ N
disorder NN N
, , N
Asperger NNP N
syndrome NN N
, , N
or CC N
pervasive JJ N
developmental JJ N
disorder NN N
, , N
not RB N
otherwise RB N
specified VBN N
; : N
had VBD N
illness JJ N
severity NN N
ratings NNS N
that WDT N
were VBD N
moderate JJ N
or CC N
more JJR N
than IN N
moderate VB N
on IN N
the DT N
Clinical JJ N
Global NNP N
Impression-Severity NNP N
scale NN N
; : N
and CC N
scored VBD N
moderate JJ N
or CC N
more JJR N
than IN N
moderate VB N
on IN N
compulsive JJ N
behaviors NNS N
measured VBN N
with IN N
the DT N
modified JJ N
Children NNP N
's POS N
Yale-Brown JJ N
Obsessive-Compulsive JJ N
Scale NNP N
. . N

children NNS N
and CC N
adolescents NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

-DOCSTART- -X- O O 19512937

HIV-infected JJ 4_p
patients NNS 4_p
initiating VBG 4_p
antiretroviral JJ 4_p
therapy NN 4_p
( ( 4_p
ART NNP 4_p
) ) 4_p
106 CD 3_p
ART-naive JJ 4_p
HIV-infected JJ 4_p
subjects NNS 4_p
who WP N
were VBD N
randomized VBN N
to TO N
receive VB N
efavirenz NN N
( ( N
EFV NNP N
) ) N
+ FW N
zidovudine/lamivudine NN N
( ( N
n JJ N
= NNP N
32 CD 3_p
) ) N
or CC N
lopinavir/ritonavir NN N
( ( N
LPV/r NNP N
) ) N
+ VBP N
zidovudine/lamivudine JJ N
induction NN N
( ( N
n JJ N
= NNP N
74 CD 3_p
) ) N
for IN N
24-48 JJ N
weeks NNS N
followed VBN N
by IN N
LPV/r NNP N
monotherapy NN N
. . N

Subjects NNS 4_p
with IN 4_p
lower JJR 4_p
baseline NN 4_p
CD4 NNP 4_p
T NNP 4_p
cell NN 4_p
count NN 4_p
, , N
non-black JJ N
race NN N
, , N
and CC N
higher JJR N
baseline NN N
glucose NN N
ART-naive JJ 4_p
subjects NNS N
-DOCSTART- -X- O O 8623957

patients NNS N
undergoing JJ N
outpatient JJ 4_p
gynecological JJ 4_p
laparoscopy NN 4_p
. . N

90 CD N
ASA NNP N
grade NN N
I PRP N
or CC N
11 CD N
women NNS 2_p
undergoing VBG N
outpatient JJ N
gynecological JJ N
laparoscopy NN N
. . N

-DOCSTART- -X- O O 1415973

patients NNS N
who WP 4_p
require VBP 4_p
long-term JJ 4_p
ventilation NN 4_p
in IN 4_p
the DT 4_p
Intensive NNP 4_p
Care NNP 4_p
Unit NNP 4_p
. . N

Twenty-four CD 3_p
patients NNS N
predicted VBN N
to TO N
require VB 4_p
artificial JJ 4_p
ventilation NN 4_p
for IN 4_p
at IN 4_p
least JJS 4_p
48 CD 4_p
h NNS 4_p
-DOCSTART- -X- O O 15948916

children NNS 1_p
with IN N
Asperger NNP 4_p
Syndrome NNP 4_p
. . 4_p

children NNS 1_p
with IN N
Asperger NNP 4_p
Syndrome NNP 4_p
it PRP N
was VBD N
not RB N
possible JJ N
to TO N
recruit VB N
the DT N
target NN N
of IN N
60 CD 3_p
patients NNS N
. . N

-DOCSTART- -X- O O 3954130

normal JJ 4_p
subjects NNS N
and CC N
postoperative JJ N
patients NNS N
. . N

Critically NNP 4_p
ill JJ 4_p
patients NNS N
seven CD 3_p
normal JJ 4_p
, , 4_p
healthy JJ 4_p
male NN 2_p
subjects NNS N
and CC N
eight CD 3_p
male NN 2_p
patients NNS N
who WP N
had VBD N
undergone JJ N
upper JJ N
abdominal JJ N
surgery NN N
2-4 JJ N
days NNS N
previously RB N
-DOCSTART- -X- O O 3434628

hyperactive JJ 4_p
and CC N
autistic JJ 4_p
children NNS 1_p
. . N

Twenty-one CD 3_p
attention NN 4_p
deficit NN 4_p
disorder NN 4_p
with IN N
hyperactivity NN 4_p
and CC N
seven CD 3_p
autistic JJ 4_p
children NNS 1_p
known JJ N
hyperserotoninemic JJ 4_p
autistic NN 4_p
and CC N
attention NN 4_p
deficit NN 4_p
disorder NN 4_p
children NNS 1_p
-DOCSTART- -X- O O 22904179

Adult NNP 1_p
height NN N
in IN N
short JJ N
children NNS 1_p
born VBN N
SGA NNP 4_p
treated VBD N
with IN N
growth NN N
hormone NN N
and CC N
gonadotropin NN N
releasing VBG N
hormone NN N
analog NN N
: : N
short JJ 4_p
children NNS 4_p
born VBP 4_p
small JJ 4_p
for IN 4_p
gestational JJ 4_p
age NN 4_p
( ( 4_p
SGA NNP 4_p
) ) 4_p
. . N

expectation NN N
included VBD N
121 CD N
short JJ N
SGA NNP N
children NNS N
( ( N
60 CD N
boys NNS N
) ) N
at IN N
least JJS N
8 CD N
yr NN N
of IN N
age NN N
performed VBD N
intention-to-treat JJ N
analyses NNS N
on IN N
all DT N
children NNS N
and CC N
uncensored JJ N
case NN N
analyses VBZ N
on IN N
84 CD N
children NNS N
who WP N
reached VBD N
AH NNP N
RESULTS NNP N
Short NNP N
SGA NNP N
children NNS N
in IN N
short JJ N
SGA NNP N
children NNS N
, , N
particularly RB N
with IN N
GH NNP N
2 CD N
mg/m NN N
( ( N
2 CD N
) ) N
· NN N
d NN N
during IN N
puberty NN N
-DOCSTART- -X- O O 1334639

pigs NNS N
with IN 4_p
and CC 4_p
without IN 4_p
passively RB 4_p
acquired VBN 4_p
maternal JJ 4_p
antibody NN 4_p
Pigs NNS 4_p
pigs NNS N
inoculated VBD N
with IN N
strain NN N
Bartha NNP N
or CC N
with IN N
the DT N
inactivated JJ N
vaccine NN N
-DOCSTART- -X- O O 12882611

Twenty-six NNP 3_p
patients NNS N
with IN N
knee NN 4_p
disorders NNS 4_p
requiring VBG 4_p
arthroscopy NN 4_p
-DOCSTART- -X- O O 19594501

manic JJ N
patients NNS N
who WP N
did VBD N
not RB N
respond VB N
to TO N
an DT N
initial JJ N
adequate JJ N
trial NN N
of IN N
lithium NN N
. . N

( ( N
n JJ N
= NNP N
45 CD N
) ) N
-DOCSTART- -X- O O 7704288

obese JJ 4_p
, , N
insulin JJ 4_p
resistant NN 4_p
, , N
normoglycemic JJ 4_p
, , N
hypertensive JJ 4_p
men NNS N
. . N

6 CD 3_p
obese JJ 4_p
insulin NN 4_p
resistant NN 4_p
, , N
normoglycemic JJ 4_p
hypertensive JJ 4_p
men NNS 2_p
were VBD N
investigated VBN N
( ( N
age NN N
49 CD 1_p
+/- JJ 1_p
2 CD 1_p
years NNS N
, , N
BMI NNP N
27.6 CD N
+/- JJ N
1.2 CD N
, , N
mean JJ N
+/- JJ N
SEM NNP N
) ) N
. . N

-DOCSTART- -X- O O 23192919

contrast-induced JJ 4_p
acute JJ 4_p
kidney NN 4_p
injury NN 4_p
in IN 4_p
acute JJ 4_p
ST-segment-elevation NNP 4_p
myocardial JJ 4_p
infarction NN 4_p
: : 4_p
substudy NN N
from IN N
the DT N
HORIZONS-AMI NNP N
trial NN N
. . N

Contrast-induced NNP N
acute NN N
kidney NN N
injury NN N
( ( N
CI-AKI NNP N
) ) N
patients NNS N
at IN N
risk NN N
for IN N
CI-AKI NNP N
trial NN N
database NN N
of IN N
patients NNS N
with IN N
ST-segment-elevation NNP N
myocardial JJ N
infarction NN N
979 CD N
ST-segment-elevation JJ N
myocardial JJ N
infarction NN N
patients NNS N
enrolled VBN N
in IN N
the DT N
Harmonizing NNP N
Outcomes NNP N
with IN N
Revascularization NNP N
and CC N
Stents NNP N
in IN N
Acute NNP N
Myocardial NNP N
Infarction NNP N
( ( N
HORIZONS-AMI NNP N
) ) N
trial NN N
occurred VBD N
in IN N
131 CD N
patients NNS N
( ( N
13.3 CD N
% NN N
) ) N
identify VB N
patients NNS N
who WP N
are VBP N
at IN N
risk NN N
for IN N
developing VBG N
CI-AKI NNP N
after IN N
primary JJ N
percutaneous JJ N
coronary JJ N
intervention NN N
in IN N
ST-segment-elevation NNP N
myocardial JJ N
infarction NN N
-DOCSTART- -X- O O 10437192

obstinate JJ 4_p
heart NN 4_p
failure NN 4_p
-DOCSTART- -X- O O 25691677

men NNS 2_p
with IN N
locally RB 4_p
advanced JJ 4_p
prostate NN 4_p
cancer NN 4_p
. . N

NCIC NNP 4_p
Clinical NNP 4_p
Trials NNP 4_p
Group NNP 4_p
PR.3/Medical NNP 4_p
Research NNP 4_p
Council NNP 4_p
PR07/Intergroup NNP 4_p
T94-0110 NNP 4_p
patients NNS N
with IN N
locally RB N
advanced JJ 4_p
prostate NN 4_p
cancer NN 4_p
. . N

Patients NNS N
with IN N
T3-4 NNP N
, , N
N0/Nx NNP N
, , N
M0 NNP N
prostate NN N
cancer NN N
or CC N
T1-2 JJ N
disease NN N
with IN N
either DT N
prostate-specific JJ N
antigen NN N
( ( N
PSA NNP N
) ) N
of IN N
more JJR N
than IN N
40 CD N
μg/L NN N
or CC N
PSA NNP N
of IN N
20 CD N
to TO N
40 CD N
μg/L NNS N
plus CC N
Gleason NNP N
score NN N
of IN N
8 CD N
to TO N
10 CD N
RESULTS NNP N
One CD 3_p
thousand CD 3_p
two CD 3_p
hundred VBD 3_p
five CD 3_p
patients NNS 3_p
of IN N
men NNS 2_p
with IN N
locally RB 4_p
advanced JJ 4_p
prostate NN 4_p
cancer NN 4_p
-DOCSTART- -X- O O 10442506

platelet NN N
function NN N
in IN N
patients NNS N
with IN N
mild JJ N
to TO N
moderate VB N
hypertension NN 4_p
. . N

patients NNS N
with IN N
mild JJ N
to TO N
moderate VB N
arterial JJ 4_p
hypertension NN 4_p
. . N

24 CD 3_p
patients NNS N
( ( N
2 CD N
groups NNS N
of IN N
12 CD 3_p
patients NNS N
each DT N
) ) N
. . N

hypertensive JJ 4_p
patients NNS N
-DOCSTART- -X- O O 12599844

patients NNS N
with IN N
diabetes NNS 4_p
mellitus NNS 4_p
in IN N
the DT N
LIFE-study NNP N
] NNP N
patients NNS N
with IN N
hypertension NN N
and CC N
diabetes VBZ N
diabetic JJ N
patients NNS N
. . N

A NNP N
total NN N
of IN N
1195 CD 3_p
patients NNS N
in IN N
the DT N
LIFE-study NNP N
had VBD N
diabetes NNS N
patients NNS N
had VBD N
ECG-verified JJ N
left JJ N
ventricular NN N
hypertrophy NN N
, , N
mean JJ N
age NN N
67 CD 1_p
years NNS N
, , N
blood NN N
pressure NN N
177/96 CD N
mmHg NN N
after IN N
two CD N
weeks NNS N
placebo JJ N
run-in JJ N
period NN N
. . N

Patients NNS N
were VBD N
followed VBN N
for IN N
at IN N
least JJS N
four CD N
years NNS N
( ( N
mean JJ N
4.7 CD N
years NNS N
) ) N
. . N

patients NNS N
with IN N
hypertension NN 4_p
and CC N
diabetes NNS N
. . N

-DOCSTART- -X- O O 17297323

porcine JJ N
model NN N
of IN N
lavage-induced JJ 4_p
acute NN 4_p
lung NN 4_p
injury NN 4_p
: : N
lavage-induced JJ N
porcine NN N
lung NN N
injury NN N
33 CD 3_p
healthy JJ N
female NN 2_p
pigs NNS N
, , N
weighing VBG N
52 CD N
+/- JJ N
4.1 CD N
kg NN N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
four CD N
groups NNS N
: : N
group NN N
1 CD N
group NN N
2 CD N
group NN N
3 CD N
group NN N
4 CD N
-DOCSTART- -X- O O 24201696

functionally RB 4_p
impaired JJ 4_p
older JJR 4_p
adults NNS 4_p
older JJR N
people NNS N
. . N

Community-dwelling JJ N
people NNS N
aged VBN N
≥ JJ N
65 CD N
years NNS N
with IN N
functional JJ N
impairment NN N
RESULTS VB N
A DT N
total NN N
of IN N
170 CD N
participants NNS N
( ( N
n JJ N
= $ N
86 CD N
perindopril NN N
, , N
n JJ N
= FW N
84 CD N
placebo NN N
) ) N
randomized VBN N
. . N

Mean JJ N
age NN N
was VBD N
75.7 CD N
( ( N
standard JJ N
deviation NN N
[ NNP N
SD NNP N
] NNP N
6.8 CD N
) ) N
years NNS N
in IN N
functionally RB N
impaired JJ N
older JJR N
people NNS N
-DOCSTART- -X- O O 2182521

patients NNS N
with IN N
diffuse NN 4_p
histiocytic JJ 4_p
lymphoma NN 4_p
. . N

-DOCSTART- -X- O O 18802161

depression NN 4_p
among IN 4_p
low-income JJ 4_p
patients NNS 4_p
with IN 4_p
cancer NN 4_p
. . 4_p

Patients NNPS 4_p
With IN 4_p
Cancer NNP 4_p
Study NNP N
patients NNS N
included VBD N
472 CD N
low-income JJ N
, , N
predominantly RB N
female JJ N
Hispanic JJ N
patients NNS N
with IN N
cancer NN N
age NN N
> VBD N
or= JJ N
18 CD N
years NNS N
with IN N
major JJ N
depression NN N
( ( N
49 CD N
% NN N
) ) N
, , N
dysthymia NN N
( ( N
5 CD N
% NN N
) ) N
, , N
or CC N
both DT N
( ( N
46 CD N
% NN N
) ) N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
intervention NN N
( ( N
n JJ N
= NNP N
242 CD N
) ) N
or CC N
enhanced VBN N
usual JJ N
care NN N
( ( N
EUC NNP N
; : N
n CC N
= VB N
230 CD N
) ) N
. . N

patients NNS N
with IN N
depressive JJ N
disorders NNS N
in IN N
a DT N
low-income JJ N
, , N
predominantly RB N
Hispanic JJ N
population NN N
in IN N
public JJ N
sector NN N
oncology NN N
clinics NNS N
. . N

-DOCSTART- -X- O O 21036891

patients NNS N
with IN N
stable JJ 4_p
systolic JJ 4_p
heart NN 4_p
failure NN 4_p
: : 4_p
systolic JJ 4_p
HF NNP 4_p
patients NNS N
Forty-five JJ 3_p
HF NNP 4_p
patients NNS N
( ( N
New NNP N
York NNP N
Heart NNP N
Association NNP N
class NN N
II-III NNP N
) ) N
-DOCSTART- -X- O O 22112544

10 CD N
geographically-dispersed JJ N
screening NN N
centers NNS N
participating VBG N
in IN N
the DT N
ongoing JJ N
Prostate NNP 4_p
, , 4_p
Lung NNP 4_p
, , 4_p
Colorectal NNP 4_p
, , 4_p
and CC 4_p
Ovarian JJ 4_p
Cancer NNP 4_p
Screening NNP N
Trial NNP N
. . N

64,554 CD 3_p
participants NNS 3_p
( ( N
aged VBN 1_p
55-74 NN 1_p
) ) 1_p
Of IN N
these DT N
, , N
39,385 CD 3_p
participants NNS N
returned VBN N
for IN N
repeat NN N
screening NN N
. . N

patients NNS N
with IN N
inadequate JJ N
FSG NNP N
-DOCSTART- -X- O O 23045243

patients NNS N
with IN N
knee JJ N
osteoarthritis NN N
. . N

patients NNS N
with IN N
tibiofemoral JJ N
( ( N
TF NNP N
) ) N
osteoarthritis NN N
( ( N
OA NNP N
) ) N
. . N

167 CD N
patients NNS N
with IN N
knee JJ N
OA NNP N
. . N

-DOCSTART- -X- O O 792738

rheumatic JJ 4_p
arthropathies NNS 4_p
( ( 4_p
inflammatory NN 4_p
and CC 4_p
degenerative NN 4_p
) ) 4_p
] NN 4_p
patients NNS N
suffering VBG N
from IN N
inflammatory NN N
and CC N
degenerative JJ N
rheumatic JJ N
arthropathies NNS N
. . N

30 CD N
subjects NNS N
using VBG N
the DT N
controlled JJ N
experiment NN N
technique NN N
according VBG N
to TO N
the DT N
" NN N
between IN N
patient JJ N
" NNP N
pattern NN N
, , N
attributing VBG N
parsalmide NN N
and CC N
indomethacin NN N
at IN N
random NN N
to TO N
two CD N
groups NNS N
. . N

-DOCSTART- -X- O O 19193781

metastatic JJ N
and/or NN N
unresectable JJ N
malignant JJ 4_p
gastrointestinal JJ 4_p
stromal JJ 4_p
tumors NNS 4_p
. . N

patients NNS N
with IN N
CD117 NNP N
( ( N
+ NNP N
) ) N
unresectable JJ N
and/or JJ N
metastatic JJ N
malignant JJ N
gastrointestinal JJ N
stromal NN N
tumors NNS N
( ( N
GISTs NNP 4_p
) ) N
. . N

patients NNS N
with IN N
progressive JJ N
disease NN N
on IN N
a DT N
lower JJR N
dose NN N
. . N

European JJ N
Organization NNP N
for IN N
Research NNP N
and CC N
Treatment NNP N
of IN N
Cancer NNP N
( ( N
n JJ N
= NNP N
946 CD 3_p
) ) N
and CC N
the DT N
other JJ N
by IN N
the DT N
Southwest NNP N
Oncology NNP N
Group NNP N
( ( N
n JJ N
= NNP N
746 CD 3_p
) ) N
. . N

-DOCSTART- -X- O O 24077211

rats NNS N
. . N

controlled VBD N
animal JJ N
( ( N
CCI NNP N
) ) N
rat VBP N
model NN N
METHODS NNP N
Sprague-Dawley NNP N
rats NNS N
weighting VBG N
260 CD N
- : N
320 CD N
( ( N
vector NN N
) ) N
. . N

( ( N
ELISA NNP N
) ) N
. . N

Animals NNS N
were VBD N
sacrificed VBN N
and CC N
the DT N
L4-5 NNP N
lumbar NN N
segment NN N
of IN N
the DT N
spinal JJ N
cord NN N
was VBD N
removed VBN N
for IN N
determination NN N
of IN N
green JJ N
fluorescent NN N
protein NN N
( ( N
GFP NNP N
) ) N
expression NN N
pain NN N
-DOCSTART- -X- O O 26609668

Participants NNS N
included VBD N
504 CD 3_p
overweight NN 4_p
and CC 4_p
obese JJ 4_p
adults NNS 1_p
seeking VBG N
weight JJ N
loss NN N
treatment NN N
. . N

sample NN N
was VBD N
84.92 CD 3_p
% NN 3_p
female NN 2_p
and CC N
73.61 CD 3_p
% NN 3_p
white JJ N
, , N
with IN N
a DT N
mean NN N
( ( N
± NNP N
SD NNP N
) ) N
age NN 1_p
of IN 1_p
47.35 CD 1_p
± JJ 1_p
9.75 CD 1_p
years NNS 1_p
included VBD N
previous JJ 4_p
attempts NNS 4_p
to TO 4_p
lose VB 4_p
50-79 JJ 4_p
lbs NN 4_p
, , N
age NN N
, , N
not RB 4_p
possessing VBG 4_p
health NN 4_p
insurance NN 4_p
, , N
and CC N
BES NNP N
, , N
BDI NNP N
, , N
and CC N
HSS NNP N
scores NNS N
-DOCSTART- -X- O O 23773380

sentinel JJ 4_p
lymph JJ 4_p
node-positive JJ 4_p
patients NNS N
patients NNS N
with IN N
sentinel JJ 4_p
lymph JJ 4_p
node-positive JJ 4_p
( ( 4_p
SLN+ NNP 4_p
) ) 4_p
primary VBP 4_p
invasive JJ 4_p
breast NN 4_p
cancer NN 4_p
. . 4_p

patients NNS N
with IN N
SLN+ NNP 4_p
breast NN 4_p
cancer NN 4_p
. . N

Patients NNPS N
with IN N
SLN+ NNP 4_p
primary JJ 4_p
breast NN 4_p
cancer NN 4_p
474 CD 3_p
SLN+ NN 4_p
patients NNS 4_p
patients NNS N
were VBD N
premenopausal JJ 4_p
( ( N
34 CD N
% NN N
vs. FW N
27 CD N
% NN N
; : N
P NNP N
= NNP N
.095 NNP N
) ) N
and CC N
had VBD N
pT2-3 NN N
tumors NNS N
patients NNS N
with IN N
known JJ N
human JJ N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
type VBD 4_p
2 CD 4_p
positive JJ 4_p
tumor NN 4_p
( ( N
12 CD N
% NN N
vs. FW N
17 CD N
% NN N
, , N
P NNP N
= NNP N
.066 NNP N
) ) N
premenopausal NN 4_p
patients NNS N
and CC N
patients NNS N
with IN N
larger JJR 4_p
( ( 4_p
pT2-3 NN 4_p
) ) 4_p
tumors NNS 4_p
. . N

-DOCSTART- -X- O O 20817247

newborn JJ 1_p
infants NNS 1_p
: : N
infants NNS 1_p
admitted VBN N
to TO N
hospital VB N
neonates NNS 1_p
acute JJ 4_p
noxious JJ 4_p
procedure NN N
newborn JJ 4_p
infants NNS 1_p
. . N

59 CD 3_p
newborn JJ 4_p
infants NNS 1_p
at IN N
University NNP N
College NNP N
Hospital NNP N
( ( N
London NNP N
, , N
UK NNP N
) ) N
29 CD N
infants NNS N
significantly RB N
affect JJ N
activity NN N
noxious JJ N
events NNS N
in IN N
-DOCSTART- -X- O O 11508634

Seattle NNP 4_p
Minority NNP 4_p
Youth NNP 1_p
Health NNP 4_p
Project NNP 4_p
. . N

youth NN 1_p
, , N
parents NNS 1_p
, , N
and CC N
key JJ N
neighborhood NN N
leaders NNS N
four CD N
intervention NN N
and CC N
six CD 3_p
control NN N
neighborhoods NNS N
in IN N
Seattle NNP N
. . N

neighborhood NN N
residents NNS N
to TO N
serve VB N
as IN N
a DT N
community NN N
action NN N
board NN N
. . N

-DOCSTART- -X- O O 23749007

breast NN 4_p
cancer NN 4_p
: : N
patients NNS 4_p
, , 4_p
especially RB 4_p
those DT 4_p
with IN 4_p
big JJ 4_p
tumours NNS 4_p
. . N

prospective JJ 4_p
randomized VBN 4_p
control NN 4_p
trial NN 4_p
of IN 4_p
modified JJ 4_p
radical JJ 4_p
mastectomy NN 4_p
performed VBD 4_p
for IN 4_p
breast NN 4_p
cancer NN 4_p
in IN 4_p
Pusat NNP 4_p
Perubatan NNP 4_p
Universiti NNP 4_p
Kebangsaan NNP 4_p
Malaysia NNP 4_p
( ( 4_p
PPUKM NNP 4_p
) ) 4_p
between IN 4_p
1st CD 4_p
June NNP 4_p
2007 CD 4_p
to TO 4_p
31st CD 4_p
December NNP 4_p
2008 CD 4_p
. . N

Patients NNS N
were VBD N
randomized VBN N
in IN N
two CD N
groups NNS N
: : N
group NN N
A NNP N
( ( N
n JJ N
= NNP N
20 CD 3_p
) ) N
underwent NN 4_p
modified VBD 4_p
radical JJ 4_p
mastectomy NN 4_p
using VBG 4_p
ultracision NN 4_p
( ( 4_p
UC NNP 4_p
) ) 4_p
and CC N
group NN N
B NNP N
( ( N
n JJ 3_p
= NNP 3_p
20 CD 3_p
) ) N
with IN N
the DT 4_p
conventional JJ 4_p
electrocautery NN 4_p
( ( 4_p
EC NNP 4_p
) ) 4_p
method NN 4_p
. . N

RESULTS VB N
A DT N
total NN N
of IN N
40 CD 3_p
patients NNS N
were VBD N
involved VBN N
in IN N
this DT N
study NN N
The DT N
majority NN N
of IN N
patients NNS N
were VBD N
Malay NNP N
( ( N
55 CD N
% NN N
) ) N
followed VBN N
by IN N
Chinese NNP N
( ( N
35 CD N
% NN N
) ) N
, , N
Indian JJ N
( ( N
5 CD N
% NN N
) ) N
and CC N
others NNS N
( ( N
5 CD N
% NN N
) ) N
-DOCSTART- -X- O O 22882961

general JJ N
population NN N
. . N

Swiss JJ N
population NN N
Population-based JJ N
cross-sectional JJ N
studies NNS N
conducted VBN N
in IN N
1984-1986 JJ N
( ( N
N=3300 NNP 3_p
) ) N
, , N
1988-1989 JJ 4_p
( ( 4_p
N=3331 NNP N
) ) N
, , N
1992-1993 JJ 4_p
( ( 4_p
N=3133 NNP N
) ) 4_p
and CC N
2003-2006 JJ 4_p
( ( 4_p
N=6170 NNP N
) ) 4_p
and CC N
restricted VBN N
to TO N
age NN 1_p
group NN 1_p
35-75 CD 1_p
years NNS 1_p
. . N

age NN 1_p
group NN 1_p
35 CD 1_p
to TO 1_p
75 CD 1_p
-DOCSTART- -X- O O 24716680

patients NNS N
with IN N
heart NN 4_p
failure NN 4_p
patients NNS N
with IN N
heart NN 4_p
failure NN 4_p
and CC 4_p
a DT 4_p
preserved JJ 4_p
left NN 4_p
ventricular JJ 4_p
ejection NN 4_p
fraction NN 4_p
. . N

3445 CD 3_p
patients NNS N
with IN N
symptomatic JJ 4_p
heart NN 4_p
failure NN 4_p
and CC 4_p
a DT 4_p
left JJ 4_p
ventricular JJ 4_p
ejection NN 4_p
fraction NN 4_p
of IN 4_p
45 CD 4_p
% NN 4_p
or CC 4_p
more JJR 4_p
In IN N
patients NNS N
with IN N
heart NN N
failure NN N
and CC N
a DT N
preserved JJ N
ejection NN N
fraction NN N
-DOCSTART- -X- O O 12183788

[ JJ N
Local NNP N
treatment NN N
of IN N
periarthropathies NNS 4_p
local JJ N
treatment NN N
for IN N
periarthropathies NNS 4_p
periarthropathies NNS 4_p
of IN N
different JJ N
localizations NNS N
. . N

-DOCSTART- -X- O O 8614420

conservative JJ N
surgery NN N
for IN N
early-stage JJ N
breast NN 4_p
cancer NN 4_p
. . N

Patients NNPS N
with IN N
early-stage JJ N
breast NN 4_p
cancer NN 4_p
who WP N
are VBP N
at IN N
substantial JJ N
risk NN N
for IN N
systemic JJ N
metastases NNS 4_p
Two CD 3_p
hundred VBD 3_p
forty-four JJ 3_p
patients NNS N
with IN N
stage NN N
I PRP N
or CC N
II NNP N
breast NN 4_p
cancer NN 4_p
who WP N
were VBD N
at IN N
substantial JJ N
risk NN N
for IN N
distant JJ N
metastases NNS 4_p
All DT N
had VBD N
had VBN N
breast-conserving JJ N
surgery NN N
. . N

patients NNS N
ar VBP N
substantial JJ N
risk NN N
for IN N
systemic JJ N
metastases NNS 4_p
-DOCSTART- -X- O O 9788422

following VBG N
total JJ 4_p
hip JJ 4_p
replacement NN 4_p
: : N
Between NNP N
1995 CD N
and CC N
1996 CD N
, , N
100 CD 3_p
patients NNS 3_p
were VBD N
randomized VBN N
to TO N
receive VB N
a DT N
prophylactic JJ N
therapy NN N
for IN N
prevention NN N
of IN N
heterotopic NN 4_p
ossification NN 4_p
. . N

One CD N
hundred VBD N
patients NNS N
receiving VBG N
no DT N
prophylactic JJ N
therapy NN N
after IN N
total JJ N
hip NN N
arthroplasty NN N
between IN N
1988 CD N
and CC N
1992 CD N
were VBD N
analyzed VBN N
and CC N
defined VBN N
as IN N
the DT N
historical JJ N
control NN N
group NN N
. . N

-DOCSTART- -X- O O 8884623

in IN N
patients NNS N
subjected VBN N
to TO N
craniotomy VB 4_p
for IN 4_p
cerebral JJ 4_p
tumors NNS 4_p
. . N

Twenty CD 3_p
patients NNS N
subjected VBN N
to TO N
craniotomy VB 4_p
for IN 4_p
supratentorial JJ 4_p
cerebral JJ 4_p
tumors NNS 4_p
randomized VBN N
five CD 3_p
patients NNS N
. . N

-DOCSTART- -X- O O 10223244

prostate NN 4_p
carcinoma NN 4_p
. . N

25 CD 3_p
matched JJ N
primary NN 4_p
and CC 4_p
metastatic JJ 4_p
prostate NN 4_p
tumors NNS 4_p
. . 4_p

Twenty-five JJ 3_p
cases NNS N
were VBD N
selected VBN N
from IN N
the DT N
surgical JJ N
pathology NN N
files NNS N
of IN N
the DT N
Mayo NNP N
Clinic NNP N
from IN N
patients NNS N
who WP N
had VBD N
undergone JJ N
radical JJ N
retropubic NN N
prostatectomy NN N
and CC N
bilateral JJ N
lymphadenectomy NN N
between IN N
1987-1991 JJ N
. . N

All DT N
patients NNS N
had VBD N
regional JJ 4_p
lymph NN 4_p
node NN 4_p
metastases NNS 4_p
at IN N
the DT N
time NN N
of IN N
surgery NN N
. . N

24 CD 3_p
informative JJ N
cases NNS N
-DOCSTART- -X- O O 15914128

healthy JJ 4_p
women NNS 2_p
were VBD N
randomized VBN N
to TO N
EE VB N
20 CD N
microg/DRSP NN N
3 CD N
mg NN N
or CC N
EE NNP N
20 CD N
microg/DSG NN N
150 CD N
microg NN N
for IN N
seven CD N
cycles NNS N
. . N

-DOCSTART- -X- O O 20221773

humans NNS N
: : N
exhaustive VBP N
cycling VBG N
exercise NN N
ten JJ N
fit JJ N
male NN N
human JJ N
subjects NNS N
. . N

-DOCSTART- -X- O O 21545527

patients NNS N
undergoing VBG N
an DT N
allogeneic JJ 4_p
hematopoietic JJ 4_p
stem NN 4_p
cell NN 4_p
transplantation NN 4_p
: : N
Forty-seven NNP 3_p
patients NNS N
undergoing VBG N
an DT N
allogeneic JJ 4_p
HSCT NNP 4_p
patients NNS 4_p
undergoing VBG 4_p
an DT 4_p
allogeneic JJ 4_p
HSCT NNP 4_p
. . N

-DOCSTART- -X- O O 7044324

human JJ 4_p
tungiasis NN 4_p
-DOCSTART- -X- O O 7825420

glaucoma NN 4_p
patients NNS 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
glaucoma NN 4_p
or CC 4_p
ocular JJ 4_p
hypertension NN 4_p
. . 4_p

total NN 4_p
of IN 4_p
89 CD 4_p
patients NNS 4_p
were VBD 4_p
enrolled VBN 4_p
, , 4_p
and CC 4_p
71 CD 4_p
completed VBD 4_p
the DT 4_p
10-week JJ 4_p
treatment NN 4_p
period NN 4_p
. . 4_p

-DOCSTART- -X- O O 16381993

30 CD 3_p
men NNS 2_p
with IN N
abdominal JJ 4_p
obesity NN 4_p
, , N
aged VBN 1_p
48-66 CD 1_p
years NNS 1_p
-DOCSTART- -X- O O 21233425

adult NN 4_p
health NN 4_p
: : 4_p
enrolled VBD 4_p
infants NNS 4_p
from IN 4_p
1972 CD 4_p
to TO 4_p
1977 CD 4_p
at IN 4_p
the DT 4_p
Frank NNP 4_p
Porter NNP 4_p
Graham NNP 4_p
Child NNP 4_p
Development NNP 4_p
Institute NNP 4_p
in IN 4_p
Chapel NNP 4_p
Hill NNP 4_p
, , 4_p
North NNP 4_p
Carolina NNP 4_p
randomized VBD N
111 CD N
infants NNS N
to TO N
receive VB N
an DT N
intensive JJ N
early JJ N
education NN N
program NN N
or CC N
nutritional JJ N
supplements NNS N
and CC N
parental JJ N
counseling NN N
alone RB N
; : N
participants NNS N
have VBP N
been VBN N
followed VBN N
to TO N
the DT N
present JJ N
day NN N
. . N

when WRB N
participants NNS N
were VBD N
aged VBN N
21 CD N
years NNS N
-DOCSTART- -X- O O 11994052

clomiphene NN 4_p
resistant JJ 4_p
polycystic JJ 4_p
ovary JJ 4_p
syndrome NN 4_p
clomiphene NN 4_p
resistant JJ 4_p
infertile JJ 4_p
women NNS 2_p
with IN N
polycystic JJ 4_p
ovary JJ 4_p
syndrome NN 4_p
( ( N
PCOS NNP 4_p
) ) N
in IN N
an DT N
infertility NN N
clinic NN N
. . N

clomiphene NN 4_p
resistant JJ 4_p
women NNS 2_p
with IN N
PCOS NNP 4_p
. . N

Twelve NNP 3_p
women NNS 2_p
completed VBD N
the DT N
metformin NN N
arm NN N
and CC N
14 CD 3_p
the DT N
placebo NN N
arm NN N
. . N

clomiphene VB 4_p
resistant JJ 4_p
infertile JJ 4_p
women NNS 2_p
with IN N
PCOS NNP 4_p
-DOCSTART- -X- O O 9327193

elderly JJ 4_p
patients NNS 4_p
with IN 4_p
heart NN 4_p
failure NN 4_p
. . 4_p

elderly JJ N
patients NNS N
with IN N
heart NN N
failure NN N
. . N

at IN N
a DT N
single JJ N
centre NN N
patients NNS N
being VBG N
selected VBN N
for IN N
inclusion NN N
from IN N
the DT N
outpatient JJ N
population NN N
. . N

Sixty-one CD N
patients NNS N
-DOCSTART- -X- O O 25497243

suspected JJ 4_p
coronary JJ 4_p
heart NN 4_p
disease NN 4_p
. . N

patients NNS N
with IN N
suspected JJ 4_p
CHD NNP 4_p
( ( 4_p
pretest JJS 4_p
likelihood RB 4_p
10 CD 4_p
% NN 4_p
-90 NNP 4_p
% NN 4_p
) ) 4_p
requiring VBG 4_p
further JJ 4_p
investigation NN 4_p
. . N

A DT N
total NN N
of IN N
1,200 CD 3_p
patients NNS N
will MD N
be VB N
randomized VBN N
patients NNS N
with IN N
suspected JJ 4_p
CHD NNP 4_p
-DOCSTART- -X- O O 2871945

chemotherapy NN N
for IN N
advanced JJ N
solid JJ N
tumors NNS N
: : N
227 CD N
patients NNS N
with IN N
breast NN N
, , N
colorectal NN N
, , N
lung NN N
and CC N
other JJ N
solid JJ N
forms NNS N
of IN N
cancer NN N
. . N

MPA NNP N
( ( N
117 CD N
patients NNS N
) ) N
placebo NN N
( ( N
110 CD N
patients NNS N
) ) N
. . N

-DOCSTART- -X- O O 12241650

Laser NNP N
treatment NN N
of IN N
childhood NN N
haemangioma NN N
: : N
progress NN N
or CC N
not RB N
? . N
-DOCSTART- -X- O O 12780755

children NNS 1_p
being VBG N
treated VBN N
for IN N
acute JJ 4_p
lymphoblastic JJ 4_p
leukaemia NN 4_p
. . N

Children NNP 1_p
were VBD N
investigated VBN N
who WP N
were VBD N
receiving VBG N
glucocorticoid JJ N
treatment NN N
for IN N
acute JJ 4_p
lymphoblastic JJ 4_p
leukaemia NN 4_p
( ( 4_p
ALL DT 4_p
) ) 4_p
. . N

children NNS 1_p
Nineteen NNP 3_p
children NNS 1_p
( ( N
8 CD 3_p
male NN 2_p
, , N
11 CD 3_p
female NN 2_p
) ) N
with IN N
a DT N
median JJ N
age NN N
5.9 CD 1_p
years NNS 1_p
( ( N
range VB N
2.6-13 CD 1_p
years NNS N
) ) N
were VBD N
recruited VBN N
into IN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 20090434

postoperative JJ 4_p
pain NN 4_p
in IN N
children NNS 1_p
after IN N
tonsillectomy NN 4_p
. . N

children NNS 1_p
undergoing VBG N
outpatient JJ N
tonsillectomy NN N
. . N

Children NNP N
6 CD 1_p
to TO 1_p
15 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
Parents NNS N
-DOCSTART- -X- O O 12108616

children NNS N
with IN N
autism NN N
and CC N
pervasive JJ N
developmental JJ N
disorder NN N
. . N

children NNS N
with IN N
autism/pervasive JJ N
developmental JJ N
disorder NN N
( ( N
PDD NNP N
) ) N
and CC N
chronic JJ N
diarrhea NN N
. . N

children NNS N
with IN N
autism/PDD NN N
and CC N
various JJ N
GI NNP N
conditions NNS N
Children NNP N
with IN N
chronic NN N
, , N
active JJ N
diarrhea NN N
Children NNP N
with IN N
no DT N
GI NNP N
problems NNS N
children NNS N
with IN N
autism/PDD NN N
and CC N
chronic JJ N
diarrhea NN N
-DOCSTART- -X- O O 12739123

acute JJ N
appendicitis NN N
in IN N
women NNS N
of IN N
reproductive JJ N
age NN N
. . N

acute JJ N
appendicitis NN N
in IN N
women NNS N
of IN N
reproductive JJ N
age NN N
1991-1992 JJ N
. . N

Female JJ N
patients NNS N
between IN N
16 CD N
and CC N
45 CD N
years NNS N
suspected JJ N
acute JJ N
appendicitis NN N
. . N

-DOCSTART- -X- O O 15482502

children NNS 4_p
with IN 4_p
autism NN 4_p
: : 4_p
Twenty-eight JJ N
children NNS N
with IN N
autism NN N
stratified VBD N
for IN N
age NN N
and CC N
baseline NN N
severity NN N
. . N

-DOCSTART- -X- O O 17433718

persons NNS N
with IN N
and CC N
without IN N
autism NN 4_p
. . N

individuals NNS N
with IN N
autism NN 4_p
persons NNS N
with IN N
autism NN 4_p
. . N

Individuals NNS N
with IN N
autism NN 4_p
-DOCSTART- -X- O O 16957425

large JJ N
population NN N
of IN N
hypertensive JJ N
patients NNS N
. . N

cardiovascular JJ N
target NN N
organ JJ N
damage NN N
and CC N
metabolic JJ N
profile NN N
in IN N
520 CD 3_p
hypertensive JJ N
patients NNS N
. . N

patients NNS N
hypertensive JJ 4_p
patients NNS 4_p
-DOCSTART- -X- O O 24336330

from IN 4_p
mouse NN 4_p
model NN 4_p
experiments NNS 4_p
Using VBG 4_p
a DT 4_p
randomised JJ 4_p
tamoxifen NN 4_p
trial NN 4_p
cohort NN 4_p
including VBG N
in IN N
total JJ N
564 CD 3_p
invasive JJ N
breast NN 4_p
carcinomas NN 4_p
Further NNP N
, , N
in IN 4_p
a DT 4_p
mouse NN 4_p
model NN 4_p
that IN N
mouse NN N
-DOCSTART- -X- O O 25456370

patients NNS 4_p
with IN 4_p
tuberous JJ 4_p
sclerosis NN 4_p
complex NN 4_p
: : N
patients NNS N
with IN N
subependymal JJ 4_p
giant NN 4_p
cell NN 4_p
astrocytoma NN 4_p
( ( 4_p
SEGA NNP 4_p
) ) 4_p
associated VBN N
with IN N
tuberous JJ 4_p
sclerosis NN 4_p
complex NN 4_p
data NNS N
( ( N
up IN N
to TO N
Jan NNP N
11 CD N
, , N
2013 CD N
) ) N
in IN N
patients NNS N
with IN N
tuberous JJ 4_p
sclerosis NN 4_p
complex NN 4_p
who WP 4_p
had VBD 4_p
SEGA NNP 4_p
that WDT 4_p
was VBD 4_p
growing VBG 4_p
and CC 4_p
needed VBN 4_p
treatment NN 4_p
included VBD N
all DT N
patients NNS N
who WP N
had VBD N
been VBN N
assigned VBN N
everolimus RBR N
during IN N
the DT N
double-blind NN N
, , N
randomised VBD N
phase NN N
of IN N
the DT N
trial NN N
and CC N
those DT N
patients NNS N
who WP N
crossed VBD N
over IN N
from IN N
the DT N
placebo NN N
group NN N
to TO N
receive VB N
everolimus NN N
during IN N
the DT N
randomised JJ N
phase NN N
or CC N
at IN N
the DT N
start NN N
of IN N
the DT N
extension NN N
phase NN N
the DT N
original JJ N
117 CD 3_p
randomly RB N
assigned VBN N
patients NNS N
, , N
111 CD 3_p
were VBD N
given VBN N
everolimus NNS N
between IN N
Aug NNP N
20 CD N
, , N
2009 CD N
, , N
and CC N
Jan NNP N
11 CD N
, , N
2013 CD N
everolimus NN N
in IN N
patients NNS N
who WP N
have VBP N
few JJ N
treatment NN N
options NNS N
and CC N
who WP N
need VBP N
continued VBN N
treatment NN N
for IN N
tuberous JJ 4_p
sclerosis NN 4_p
-DOCSTART- -X- O O 18702754

post-operative JJ N
pain NN N
management NN N
. . N

Thirty-eight NNP N
patients NNS N
with IN N
post-operative JJ N
pain NN N
following VBG N
hip NN N
replacement NN N
surgery NN N
-DOCSTART- -X- O O 23747131

multicenter NN N
, , N
open-label JJ N
, , N
pilot NN N
study NN N
enrolling VBG N
consecutive JJ N
non-ulcer JJ 4_p
dyspepsia NN 4_p
patients NNS N
with IN N
H. NNP 4_p
pylori FW 4_p
infection NN 4_p
never RB N
previously RB N
treated VBN N
for IN N
the DT N
infection NN N
. . N

270 CD 3_p
patients NNS N
were VBD N
enrolled VBN N
, , N
but CC N
13 CD 3_p
patients NNS N
early RB N
interrupted VBN N
treatment NN N
-DOCSTART- -X- O O 15915547

healthy JJ N
volunteers NNS N
. . N

nine CD N
healthy JJ N
normotensive JJ N
volunteers NNS N
( ( N
age NN 1_p
27 CD 1_p
+/- JJ 1_p
3 CD 1_p
y NN 1_p
, , N
BMI NNP N
23.3 CD N
+/- JJ N
2.0 CD N
kg NN N
m NN N
( ( N
-2 NNP N
) ) N
; : N
mean JJ N
+/- JJ N
SD NNP N
) ) N
-randomly RB N
-DOCSTART- -X- O O 21106341

resuscitation NN 4_p
-- : 4_p
head JJ 4_p
blunt NN N
head NN N
injury NN N
patients NNS N
. . N

air NN N
and CC N
land NN N
emergency NN N
medical JJ N
services NNS N
and CC N
2 CD N
trauma NN N
centers NNS N
serving VBG N
a DT N
population NN N
of IN N
4 CD 3_p
million CD 3_p
people NNS 3_p
. . 3_p

study NN N
population NN N
consisted VBD N
of IN N
head NN N
injured VBN N
, , N
blunt VB N
trauma JJ N
adult NN 4_p
patients NNS N
with IN N
a DT N
Glasgow NNP 4_p
Coma NNP 4_p
Scale NNP N
of IN N
lower JJR N
than IN N
9 CD N
. . N

132 CD 3_p
eligible JJ 3_p
patients NNS 3_p
, , N
113 CD 3_p
were VBD N
randomized VBN N
. . N

Nineteen NNP N
eligible JJ N
patients NNS N
blunt NN 4_p
trauma NN 4_p
patients NNS 4_p
with IN 4_p
head JJ 4_p
injuries NNS 4_p
; : 4_p
-DOCSTART- -X- O O 25451017

irritability NN 4_p
in IN 4_p
autism NN 4_p
. . N

Participants NNS N
included VBD N
40 CD 3_p
outpatient JJ 3_p
children NNS 1_p
and CC N
adolescents NNS 1_p
with IN N
autism NN N
. . N

Eighteen JJ 3_p
patients NNS 3_p
in IN N
the DT N
placebo NN N
group NN N
16 CD 3_p
patients NNS 3_p
in IN N
the DT N
buspirone NN N
group NN N
in IN 4_p
individuals NNS 4_p
with IN 4_p
autism NN 4_p
-DOCSTART- -X- O O 15922817

Korean JJ N
patients NNS N
with IN N
mild JJ 4_p
to TO 4_p
moderate VB 4_p
hypertension NN 4_p
. . N

Korea NNP N
. . N

Korean JJ 4_p
patients NNS 4_p
with IN N
mild JJ 4_p
to TO 4_p
moderate VB 4_p
hypertension NN 4_p
. . N

Eligible JJ N
patients NNS N
were VBD N
Korean NNP N
, , N
aged VBD 1_p
18 CD 1_p
to TO 1_p
75 CD 1_p
years NNS 1_p
, , N
had VBD N
hypertension NN 4_p
, , N
and CC N
were VBD 4_p
either RB 4_p
taking VBG 4_p
antihypertensive JJ 4_p
medications NNS 4_p
or CC 4_p
had VBD 4_p
a DT 4_p
documented VBN 4_p
sitting VBG 4_p
diastolic JJ 4_p
blood NN 4_p
pressure NN 4_p
of IN 4_p
90 CD 4_p
to TO 4_p
109 CD 4_p
mm NN 4_p
Hg NNP 4_p
. . N

One CD 3_p
hundred VBD 3_p
eighteen JJ 3_p
patients NNS N
were VBD N
enrolled VBN N
. . N

-DOCSTART- -X- O O 9351754

laparoscopic NN 4_p
tubal JJ 4_p
sterilization NN 4_p
patients NNS N
undergoing VBG N
laparoscopic JJ 4_p
tubal JJ 4_p
sterilization NN 4_p
with IN N
silastic JJ N
bands NNS N
. . N

One CD 3_p
hundred VBD 3_p
five CD 3_p
women NNS 2_p
undergoing VBG N
laparoscopic NN 4_p
tubal JJ 4_p
sterilization NN 4_p
with IN N
silastic JJ N
bands NNS N
-DOCSTART- -X- O O 15653006

urogenital JJ 4_p
atrophy NN 4_p
in IN N
postmenopausal JJ 4_p
women NNS 2_p
on IN 4_p
hormone NN 4_p
therapy NN 4_p
. . N

27 CD 3_p
women NNS 2_p
with IN N
climacteric JJ 4_p
symptoms NNS 4_p
and CC N
atrophic JJ 4_p
vaginitis NN 4_p
receive VB N
HT NNP N
plus CC N
local JJ N
estriol NN N
or CC N
placebo NN N
. . N

-DOCSTART- -X- O O 12410073

autism NN 4_p
. . 4_p

autism NN 4_p
Eighty-five JJ 3_p
children NNS 3_p
with IN N
autism NN N
without IN N
other JJ N
medical JJ N
conditions NNS N
and CC N
not RB N
taking VBG N
other JJ N
psychotropic NN N
medications NNS N
participated VBD N
( ( N
ages NNS 1_p
between IN 1_p
3 CD 1_p
and CC 1_p
12 CD 1_p
years NNS 1_p
, , N
mean JJ N
IQ NNP N
= NNP N
55 CD N
) ) N
. . N

children NNS 1_p
with IN N
and CC N
without IN N
gastrointestinal JJ 4_p
problems NNS 4_p
-DOCSTART- -X- O O 9683043

Hypertensive JJ 4_p
patients NNS N
Subjects NNS N
with IN N
a DT N
difference NN N
of IN N
> NN N
or CC N
= $ N
20 CD N
mm NN N
Hg NNP N
systolic NN N
or CC N
> NN N
or CC N
= $ N
10 CD N
mm NN N
Hg NNP N
diastolic VBZ N
BP NNP N
between IN N
CBP NNP N
and CC N
awake VB N
ABP NNP N
or CC N
CBP NNP N
and CC N
HBP NNP N
A DT N
total NN N
of IN N
189 CD 3_p
patients NNS N
completed VBD N
the DT N
study NN N
( ( N
79 CD 3_p
on IN N
stable JJ N
antihypertensive JJ N
treatment NN N
) ) N
. . N

-DOCSTART- -X- O O 24676906

nutritional JJ N
deficiency-based JJ N
autism NN 4_p
in IN N
Oman NNP N
. . N

redox NN 4_p
and CC 4_p
methylation NN 4_p
metabolites NNS 4_p
, , N
as RB N
well RB N
as IN N
the DT N
level NN N
of IN N
protein JJ N
homocysteinylation NN N
and CC N
hair JJ N
mercury NN N
levels NNS N
, , N
in IN N
autistic JJ 4_p
and CC 4_p
neurotypical JJ 4_p
control NN 4_p
Omani NNP N
children NNS N
, , N
who WP N
were VBD N
previously RB N
shown VBN N
to TO N
exhibit VB N
significant JJ N
nutritional JJ N
deficiencies NNS N
in IN N
serum NN N
folate NN N
and CC N
vitamin NN N
B₁₂ NNP N
glutathione NN N
in IN N
autistic JJ 4_p
subjects NNS N
activity NN N
. . N

Autistic JJ N
males NNS 2_p
than IN N
females NNS 2_p
hair NN N
of IN N
autistic JJ 4_p
subjects NNS N
vs. FW N
control NN N
subjects NNS N
Thus RB N
, , N
autism NN 4_p
in IN N
Oman NNP N
-DOCSTART- -X- O O 2128415

obese JJ 4_p
men NNS 2_p
. . N

22 CD 3_p
obese JJ 4_p
men NNS 2_p
and CC N
10 CD 3_p
normal JJ 4_p
controls NNS N
seven CD 3_p
male JJ N
patients NNS N
with IN N
subclinical JJ 4_p
hypothyroidism NN 4_p
obese JJ 4_p
subjects NNS N
after IN N
substantial JJ N
weight JJ N
loss NN N
. . N

control NN N
and CC N
obese JJ 4_p
men NNS N
. . N

obese JJ 4_p
men NNS N
hypothyroid JJ 4_p
men NNS N
obese JJ 4_p
subjects NNS N
. . N

-DOCSTART- -X- O O 8614301

Eskimo NNP 4_p
diet NN 4_p
. . N

Healthy JJ N
men NNS 2_p
and CC 2_p
women NNS 2_p
( ( N
134 CD N
) ) N
-DOCSTART- -X- O O 22079053

judo NN 4_p
athletes NNS 4_p
' POS N
judo NN N
athletes NNS N
in IN N
a DT N
top JJ N
10 CD N
national-ranked JJ N
team NN N
. . N

18 CD 3_p
athletes NNS 3_p
of IN N
both DT 2_p
sexes NNS 2_p
from IN N
a DT N
judo NN N
team NN N
currently RB N
competing VBG N
on IN N
a DT N
national JJ N
level NN N
. . N

national JJ 1_p
level NN 1_p
judo NN N
athletes NNS N
-DOCSTART- -X- O O 11322670

hospitalized JJ N
elderly JJ 1_p
patients NNS 1_p
-- : N
a DT N
elderly JJ 1_p
hospitalized JJ N
patients NNS N
. . N

patients NNS N
aged VBN N
75 CD 1_p
years NNS 1_p
and CC 1_p
older JJR 1_p
on IN N
four CD N
or CC N
more JJR N
medicines NNS N
who WP N
had VBD N
been VBN N
discharged VBN N
from IN N
three CD N
acute JJ N
general JJ N
and CC N
one CD N
long-stay JJ N
hospital NN N
to TO N
a DT N
pharmacy NN N
intervention NN N
or CC N
usual JJ N
care NN N
. . N

we PRP N
recruited VBD N
362 CD 3_p
patients NNS 3_p
, , N
of IN N
whom WP N
181 CD 3_p
were VBD 3_p
randomized VBN 3_p
to TO 3_p
each DT 3_p
group NN 3_p
. . N

We PRP N
collected VBD N
hospital NN N
and CC N
general JJ N
practice NN N
data NNS N
on IN N
at IN 3_p
least JJS 3_p
91 CD 3_p
and CC N
72 CD 3_p
% NN 3_p
of IN 3_p
patients NNS 3_p
respectively RB N
at IN N
each DT N
follow-up JJ N
point NN N
and CC N
interviewed VBD N
between IN 3_p
43 CD 3_p
and CC N
90 CD 3_p
% NN 3_p
of IN 3_p
the DT 3_p
study NN 3_p
subjects NNS 3_p
. . N

-DOCSTART- -X- O O 21616612

tropical JJ N
hair NN N
sheep NN N
. . N

sheep NN N
Barbados NNP N
Black NNP N
Belly NNP N
ewes FW N
( ( N
n=34 NN N
) ) N
and CC N
ewe JJ N
lambs NN N
( ( N
n=35 JJ N
; : N
37.5±0.9 CD N
kg NN N
) ) N
in IN N
ewe NN N
lambs NNS N
than IN N
ewes NN N
animals NNS N
. . N

In IN N
Experiment JJ N
2 CD N
, , N
lactating VBG N
ewes NN N
from IN N
experiment JJ N
1 CD N
( ( N
n=61 NN N
) ) N
60-85 JJ N
days NNS N
postpartum NN N
observed VBN N
in IN N
ewes NN N
productivity NN N
in IN N
tropical JJ N
breeds NNS N
of IN N
sheep NN N
-DOCSTART- -X- O O 18783414

single-implant JJ N
crown JJ N
single-implant JJ N
crown NN N
restorations NNS N
METHODS NNP N
Altogether NNP N
, , N
35 CD N
consecutive JJ N
patients NNS N
were VBD N
provided VBN N
with IN N
41 CD N
turned VBD N
single JJ N
Brånemark NNP N
System NNP N
implants NNS N
( ( N
Nobel NNP N
Biocare NNP N
AB NNP N
) ) N
in IN N
the DT N
partially RB N
edentulous JJ N
upper JJ N
jaw NN N
. . N

By IN N
random NN N
, , N
15 CD N
and CC N
20 CD N
patients NNS N
were VBD N
provided VBN N
with IN N
18 CD N
test NN N
and CC N
23 CD N
control NN N
implant JJ N
crowns NNS N
, , N
respectively RB N
-DOCSTART- -X- O O 11536065

nasal JJ 4_p
allergen JJ 4_p
17 CD 3_p
patients NNS N
with IN N
anamnestic JJ N
known VBN N
rhinokonjunktivitis NN 4_p
( ( N
6 CD N
f NN N
, , N
11 CD N
m NN N
) ) N
had VBD N
a DT N
pricktest NN N
and CC N
then RB N
a DT N
nasal JJ N
provocation NN N
testing VBG N
with IN N
an DT N
allergen NN N
which WDT N
provoked VBD N
a DT N
reaction NN N
on IN N
the DT N
skin NN N
. . N

7 CD 3_p
patients NNS N
a DT N
positive JJ N
reaction NN N
, , N
within IN N
7 CD N
patient NN N
a DT N
negative JJ N
reaction NN N
, , N
3 CD N
patients NNS N
had VBD N
a DT N
unspecific JJ N
nasal NN N
hyperreactivity NN N
. . N

6 CD N
of IN N
the DT N
7 CD N
patients NNS N
with IN N
positive JJ N
reaction NN N
in IN N
aR NN N
of IN N
the DT N
7 CD N
results NNS N
with IN N
negative JJ N
reaction NN N
-DOCSTART- -X- O O 11374137

spontaneous JJ 4_p
pneumothorax NN 4_p
] NNP 4_p
Spontaneous JJ N
pneumothorax NN N
( ( N
SP NNP N
) ) N
young JJ N
, , N
thin JJ N
and CC N
otherwise RB N
healthy JJ N
males NNS N
. . N

40 CD N
patients NNS N
admitted VBN N
in IN N
a DT N
five-year JJ N
period NN N
, , N
with IN N
a DT N
SP NNP N
-DOCSTART- -X- O O 18566882

children NNS 1_p
with IN N
high JJ 4_p
functioning VBG 4_p
autism NN 4_p
and CC N
Asperger NNP 4_p
Syndrome NNP 4_p
. . N

for IN N
6-11 JJ 1_p
year NN N
olds NNS N
with IN N
high JJ 4_p
functioning VBG 4_p
autism NN 4_p
and CC N
Asperger NNP 4_p
Syndrome NNP 4_p
. . N

Children NNP N
1 CD N
h/week NN N
over IN N
18 CD N
weeks NNS N
. . N

other JJ N
groups NNS N
on IN N
autism-specific JJ N
social JJ N
interaction NN N
scores NNS N
LEGO NNP N
and CC N
SULP NNP N
groups NNS N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

SULP NNP N
and CC N
LEGO NNP N
groups NNS N
-DOCSTART- -X- O O 20881754

in IN N
patients NNS N
with IN N
gastroesophageal JJ 4_p
reflux JJ 4_p
disease NN 4_p
. . N

patients NNS N
with IN N
gastroesophageal JJ 4_p
reflux NN 4_p
disease NN 4_p
( ( 4_p
GERD NNP 4_p
) ) 4_p
. . 4_p

39 CD 3_p
patients NNS N
with IN N
delayed JJ 4_p
gastric NN 4_p
emptying NN 4_p
( ( 4_p
DGE NNP 4_p
) ) 4_p
from IN N
2 CD N
studies NNS N
( ( N
n JJ 3_p
= NNP 3_p
84 CD 3_p
) ) N
All PDT N
the DT N
84 CD 3_p
patients NNS N
were VBD N
classified VBN N
at IN N
baseline NN N
with IN N
DGE NNP 4_p
( ( N
gastric JJ N
retention NN N
> VBD N
6.3 CD N
% NN N
at IN N
4 CD N
hours NNS N
) ) N
or CC N
normal JJ 4_p
gastric JJ 4_p
emptying NN 4_p
. . N

subgroup NN N
of IN N
diabetic JJ 4_p
patients NNS N
with IN N
DGE NNP 4_p
( ( N
n JJ N
= NNP N
10 CD 3_p
) ) N
patients NNS N
with IN N
GERD NNP 4_p
with IN N
DGE NNP 4_p
. . N

-DOCSTART- -X- O O 24986270

allergic JJ 4_p
rhinitis NN 4_p
: : 4_p
Allergic NNP 4_p
rhinitis NN 4_p
undergraduate JJ N
nursing NN N
students NNS N
with IN N
allergic JJ 4_p
rhinitis NN 4_p
over IN N
a DT N
3-month JJ N
follow-up NN N
249 CD 3_p
participants NNS N
recruited VBN N
from IN N
one CD N
university NN N
in IN N
Hong NNP N
Kong NNP N
. . N

240 CD 3_p
participants NNS N
completed VBD N
the DT N
trial NN N
, , N
with IN N
9 CD N
( ( N
3.6 CD N
% NN N
) ) N
drop-outs NN N
. . N

-DOCSTART- -X- O O 15681940

heparin-resistant JJ N
patients NNS N
scheduled VBN 4_p
to TO 4_p
undergo VB 4_p
cardiac JJ 4_p
surgery NN 4_p
necessitating VBG 4_p
cardiopulmonary JJ 4_p
bypass NN 4_p
. . N

heparin NN N
resistant JJ N
patients NNS N
undergoing VBG N
cardiac JJ N
surgery NN N
. . N

heparin-resistant JJ N
patients NNS N
undergoing VBG N
cardiac JJ 4_p
surgery NN 4_p
with IN N
cardiopulmonary JJ N
bypass NN N
. . N

Heparin NNP N
resistance NN N
was VBD N
diagnosed VBN N
when WRB N
the DT N
activated VBN N
clotting NN N
time NN N
was VBD N
less JJR N
than IN N
480 CD N
s NNS N
after IN N
400 CD N
U/kg NNP N
heparin NN N
. . N

Fifty-four JJ 3_p
heparin-resistant JJ N
patients NNS N
were VBD N
randomized VBN N
. . N

heparin-resistant JJ N
patients NNS N
. . N

heparin-resistant JJ N
patients NNS N
-DOCSTART- -X- O O 22999292

children NNS N
with IN N
autistic JJ 4_p
disorder NN 4_p
: : N
children NNS 1_p
with IN N
autism NN 4_p
. . N

Children NNP N
with IN N
autism NN 4_p
-DOCSTART- -X- O O 25920470

post-stroke JJ 4_p
subjects NNS 4_p
: : N
conducted VBN N
in IN N
the DT N
occupational JJ N
therapy NN N
unit NN N
of IN N
a DT N
rehabilitation NN N
Institute NNP N
. . N

A DT N
convenience NN N
sample NN N
of IN N
35 CD N
stroke NN N
subjects NNS N
( ( N
mean JJ N
poststroke NN N
duration NN N
, , N
28.76 CD N
weeks NNS N
) ) N
Thirty-two JJ 3_p
participants NNS N
completed VBD N
the DT N
entire JJ N
study NN N
protocol NN N
. . N

side NN 4_p
in IN 4_p
poststroke NN 4_p
hemiparetic JJ 4_p
subjects NNS 4_p
-DOCSTART- -X- O O 24217336

maternal JJ 4_p
mental JJ 4_p
health NN 4_p
after IN N
a DT N
child NN 4_p
's POS 4_p
diagnosis NN 4_p
of IN 4_p
autism NN 4_p
spectrum JJ 4_p
disorder NN 4_p
: : N
mothers NNS N
of IN N
children NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
autism NN N
clinic NN N
and CC N
6 CD N
community-based JJ N
early JJ N
intervention NN N
programs NNS N
that WDT N
primarily RB N
serve VBP N
low-income JJ N
families NNS N
. . N

Participants NNS N
were VBD N
mothers NNS 2_p
of IN N
122 CD 3_p
young JJ 3_p
children NNS 3_p
( ( N
mean JJ N
age NN N
, , N
34 CD N
months NNS N
) ) N
who WP N
recently RB N
received VBD N
a DT N
diagnosis NN N
of IN N
ASD NNP N
. . N

Fifty-nine JJ 3_p
mothers NNS N
-DOCSTART- -X- O O 16567604

patients NNS N
with IN N
chronic JJ 4_p
illness NN 4_p
. . N

heterogeneous JJ N
cohort NN N
of IN N
patients NNS N
with IN N
chronic JJ 4_p
illness NN 4_p
initially RB N
exposed VBD N
to TO N
a DT N
multidisciplinary JJ N
, , N
home-based JJ N
intervention NN N
( ( N
HBI NNP N
) ) N
( ( N
n JJ N
= NNP N
260 CD 3_p
) ) N
or CC N
to TO N
usual JJ N
postdischarge NN N
care NN N
( ( N
n JJ N
= NNP N
268 CD 3_p
) ) N
. . N

patients NNS N
with IN N
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
-DOCSTART- -X- O O 21664059

after IN 4_p
radiotherapy NN 4_p
for IN N
prostate NN 4_p
cancer NN 4_p
. . N

512 CD 3_p
patients NNS N
( ( N
conformally RB N
treated VBN N
to TO N
68 CD N
Gy NNP N
[ NNP N
n VBD N
= $ N
284 CD 3_p
] NNP N
and CC N
78 CD N
Gy NNP N
[ NNP N
n VBD N
= $ N
228 CD 3_p
] NN N
) ) N
with IN N
complete JJ N
follow-up NN N
at IN N
3 CD N
years NNS N
after IN N
radiotherapy NN N
were VBD N
studied VBN N
. . N

-DOCSTART- -X- O O 22115710

patients NNS N
with IN N
diabetic JJ 4_p
macular JJ 4_p
edema NN 4_p
. . N

Fifty NNP N
eyes NNS N
among IN N
50 CD N
patients NNS N
with IN N
DME NNP N
, , N
retinal JJ N
thickness NN N
≥ VBD N
300 CD N
microns NNS N
and CC N
best-corrected JJ N
visual JJ N
acuity NN N
( ( N
BCVA NNP N
) ) N
20/40 CD N
to TO N
20/200 CD N
-DOCSTART- -X- O O 14650571

menopause NN 4_p
menopausal NN 4_p
hot JJ 4_p
flushes NNS 4_p
, , N
sleep JJ 4_p
disturbances NNS 4_p
, , N
and CC N
mood NN 4_p
changes NNS 4_p
. . N

experimental JJ N
acupuncture NN N
treatment NN N
group NN N
acupuncture NN N
treatment NN N
group NN N
experimental JJ N
acupuncture NN N
treatment NN N
group NN N
experimental JJ N
acupuncture NN N
treatment NN N
group NN N
and CC N
the DT N
comparison NN N
acupuncture NN N
treatment NN N
group NN N
-DOCSTART- -X- O O 8217692

HIV NNP 4_p
. . N

-DOCSTART- -X- O O 16173223

sedation NN 4_p
of IN 4_p
autistic JJ 4_p
patients NNS 4_p
during IN 4_p
dental JJ 4_p
treatment NN 4_p
. . 4_p

sedating VBG N
autistic JJ N
patients NNS N
during IN N
dental JJ N
treatment NN N
. . N

13 CD 3_p
subjects NNS N
aged VBD N
5.8 CD 1_p
to TO 1_p
14.7 CD 1_p
years NNS 1_p
. . N

autistic JJ N
patients NNS N
-DOCSTART- -X- O O 20560900

Dose-response JJ 4_p
relationship NN 4_p
of IN 4_p
sertindole NN 4_p
and CC 4_p
haloperidol NN 4_p
using VBG 4_p
the DT 4_p
pharmacopsychometric JJ 4_p
triangle NN 4_p
. . N

Selected NNP 4_p
Positive NNP 4_p
and CC 4_p
Negative NNP 4_p
Syndrome NNP 4_p
Scale NNP 4_p
( ( 4_p
PANSS NNP 4_p
) ) 4_p
subscales NNS N
and CC N
the DT N
Simpson-Angus JJ N
scale NN N
-DOCSTART- -X- O O 21636141

post-menopausal JJ 4_p
women NNS 2_p
with IN N
high JJ 4_p
levels NNS 4_p
in IN 4_p
serum JJ 4_p
LDL-cholesterol NNP 4_p
. . N

-DOCSTART- -X- O O 23228924

patients NNS 4_p
treated VBN 4_p
with IN 4_p
anthracycline-based JJ 4_p
chemotherapy NN 4_p
. . N

patients NNS 4_p
treated VBN 4_p
with IN 4_p
anthracyclines NNS 4_p
. . N

42 CD 3_p
patients NNS 3_p
treated VBN 4_p
with IN 4_p
anthracyclines NNS 4_p
. . N

healthy JJ 4_p
volunteers NNS 4_p
. . N

21 CD 3_p
men NNS 2_p
and CC N
21 CD 3_p
women NNS 2_p
with IN N
a DT N
mean JJ N
age NN 1_p
of IN 1_p
55 CD 1_p
± JJ 1_p
17 CD 1_p
years NNS 1_p
, , N
who WP 4_p
presented VBD 4_p
a DT 4_p
median NN 4_p
of IN 4_p
84 CD 4_p
months NNS 4_p
after IN 4_p
chemotherapy NN 4_p
with IN 4_p
a DT 4_p
cumulative JJ 4_p
anthracycline NN 4_p
exposure NN 4_p
of IN 4_p
282 CD 4_p
± JJ 4_p
65 CD 4_p
mg/m NN 4_p
( ( 4_p
2 CD 4_p
) ) 4_p
and CC N
a DT 4_p
mean NN 4_p
left VBD 4_p
ventricular JJ 4_p
ejection NN 4_p
fraction NN 4_p
of IN 4_p
52 CD 4_p
± JJ N
12 CD N
% NN N
elevated VBN 4_p
in IN 4_p
patients NNS 4_p
with IN 4_p
previous JJ 4_p
anthracycline NN 4_p
treatment NN 4_p
-DOCSTART- -X- O O 24406481

overweight NN 4_p
and CC 4_p
obese JJ 4_p
subjects NNS 4_p
with IN 4_p
cardiovascular JJ 4_p
disease NN 4_p
. . N

overweight JJ 4_p
and CC 4_p
obese JJ 4_p
subjects NNS 4_p
receiving VBG 4_p
long-term JJ 4_p
sibutramine NN 4_p
treatment NN 4_p
with IN 4_p
diet JJ 4_p
and CC 4_p
exercise NN 4_p
. . N

A DT N
total NN N
of IN N
9804 CD 3_p
male NN 2_p
and CC N
female JJ 2_p
subjects NNS N
, , N
aged VBD 1_p
55 CD 1_p
years NNS 1_p
or CC 1_p
older JJR 1_p
, , N
with IN N
a DT N
body NN N
mass NN N
index NN N
of IN N
27-45 JJ N
kg NNS N
m NN N
( ( N
-2 NN N
) ) N
were VBD N
included VBN N
in IN N
this DT N
current JJ N
subanalysis NN N
were VBD N
required VBN N
to TO N
have VB N
a DT N
history NN N
of IN N
cardiovascular JJ 4_p
disease NN 4_p
and/or VBD N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
mellitus VBP 4_p
with IN N
at IN N
least JJS N
one CD N
cardiovascular NN N
risk NN N
factor NN N
( ( N
hypertension NN 4_p
, , N
dyslipidemia NN 4_p
, , N
current JJ N
smoking NN N
or CC N
diabetic JJ N
nephropathy NN N
) ) N
to TO N
be VB N
harmful JJ 4_p
in IN 4_p
this DT 4_p
obese JJ 4_p
elderly JJ 4_p
cardiovascular NN 4_p
-DOCSTART- -X- O O 17717526

men NNS 2_p
treated VBN N
for IN N
symptomatic JJ 4_p
benign NN 4_p
prostatic JJ 4_p
hyperplasia NN 4_p
. . N

men NNS 2_p
with IN N
lower JJR 4_p
urinary JJ 4_p
tract NN 4_p
symptoms NNS 4_p
associated VBN N
with IN N
benign JJ 4_p
prostatic JJ 4_p
hyperplasia NN 4_p
( ( 4_p
BPH NNP 4_p
) ) 4_p
. . N

men NNS 2_p
aged VBN 1_p
> NN 1_p
or CC 1_p
= $ 1_p
50 CD 1_p
years NNS 1_p
372 CD 3_p
patients NNS N
355 CD N
completing VBG N
the DT N
study NN N
. . N

At IN N
baseline NN N
, , N
64 CD N
% NN N
of IN N
the DT N
patients NNS N
reported VBD N
erectile JJ 4_p
dysfunction NN 4_p
( ( 4_p
ED NNP 4_p
) ) 4_p
and CC N
63 CD N
% NN N
reported VBD N
ejaculatory JJ 4_p
dysfunction NN 4_p
( ( 4_p
EjD NNP 4_p
) ) 4_p
. . N

-DOCSTART- -X- O O 21996342

included VBD N
132 CD 3_p
patients NNS N
with IN N
grass JJ 4_p
pollen-induced JJ 4_p
rhinoconjunctivitis NN 4_p
patients NNS N
received VBD N
6 CD N
weekly JJ N
patches NNS N
-DOCSTART- -X- O O 15509022

nematode JJ 4_p
parasites NNS 4_p
of IN N
small JJ N
ruminants NNS N
on IN N
government NN N
breeding NN N
farms NNS N
in IN N
Sabah NNP N
, , N
East NNP N
Malaysia NNP N
. . N

Government-owned JJ N
small-ruminant JJ N
breeding NN N
farms NNS N
eastern JJ N
Malaysian JJ N
state NN N
of IN N
Sabah NNP N
nematode JJ 4_p
parasite NN 4_p
Haemonchus NNP 4_p
contortus NN 4_p
. . N

sheep NN N
and CC N
goats NNS N
on IN N
all DT N
farms NNS N
. . N

-DOCSTART- -X- O O 15965438

severe VB 4_p
atopic NN 4_p
dermatitis NN 4_p
in IN 4_p
adults NNS 4_p
: : 4_p
59 CD N
patients NNS N
with IN N
moderate JJ N
to TO N
severe VB N
atopic NN N
dermatitis NN N
Forty-seven JJ N
patients NNS N
completed VBD N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 19833962

nociceptive JJ N
processing NN N
in IN N
the DT N
spinal JJ N
cord NN N
. . N

decreased VBN N
pain NN N
responses NNS N
under IN N
placebo NN N
-DOCSTART- -X- O O 19135077

Autism NNP N
spectrum NN N
disorders NNS N
. . N

individuals NNS N
with IN N
an DT N
Autism NNP N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
adolescents NNS N
with IN N
ASDs NNP N
individuals NNS N
with IN N
Autism NNP N
adolescents NNS N
with IN N
ASDs NNP N
to TO N
controls VB N
matched VBN N
on IN N
sex NN N
, , N
age NN N
and CC N
IQ NNP N
individuals NNS N
with IN N
ASDs NNP N
individuals NNS N
with IN N
ASDs NNP N
ASDs NNP N
-DOCSTART- -X- O O 12447025

hyperactive JJ 4_p
and CC 4_p
impulsive JJ 4_p
children NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
. . N

-DOCSTART- -X- O O 1884668

opioid JJ 4_p
physical JJ 4_p
dependence NN 4_p
in IN N
heroin NN 4_p
addicts NNS 4_p
. . N

long-term JJ N
heroin NN 4_p
addicts NNS 4_p
Patients NNS N
who WP N
received VBD N
placebo NN N
( ( N
n JJ N
= NNP N
18 CD 3_p
) ) N
Patients NNS N
who WP N
received VBD N
naloxone NN N
( ( N
n JJ N
= NNP N
58 CD 3_p
) ) N
-DOCSTART- -X- O O 25344395

polymyositis NN 4_p
and CC 4_p
dermatomyositis NN 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
polymyositis NN 4_p
( ( 4_p
PM NNP 4_p
) ) 4_p
and CC 4_p
dermatomyositis NN 4_p
( ( 4_p
DM NNP 4_p
) ) 4_p
. . N

13 CD 3_p
patients NNS N
with IN 4_p
PM NNP 4_p
and CC 4_p
DM NNP 4_p
completed VBD 4_p
patients NNS N
with IN N
PM NNP N
and CC N
DM NNP N
. . N

-DOCSTART- -X- O O 8208469

patients NNS N
undergoing VBG N
breast JJ N
reconstruction NN N
with IN N
the DT N
abdominal JJ N
wall NN N
. . N

breast NN N
reconstruction NN N
by IN N
transposition NN N
of IN N
rectus NN N
abdominis NN N
myocutaneous JJ N
flap NN N
From IN N
October NNP N
1990 CD N
to TO N
March NNP N
1992 CD N
38 CD N
patients NNS N
were VBD N
recruited VBN N
: : N
20 CD N
patients NNS N
in IN N
the DT N
antibiotic JJ N
prophylaxis NN N
arm NN N
and CC N
18 CD N
patients NNS N
in IN N
the DT N
control NN N
group NN N
. . N

-DOCSTART- -X- O O 20228284

Half NN N
of IN N
the DT N
participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
conscious-processing-condition NN N
( ( N
i.e. FW N
consciously RB 4_p
thinking VBG 4_p
about IN 4_p
the DT 4_p
information NN 4_p
they PRP 4_p
read VBP 4_p
in IN 4_p
the DT 4_p
case NN 4_p
description NN 4_p
) ) 4_p
, , 4_p
the DT 4_p
other JJ 4_p
half NN 4_p
to TO 4_p
the DT 4_p
unconscious-processing JJ 4_p
condition NN 4_p
( ( 4_p
i.e. FW 4_p
performing VBG N
an DT N
unrelated JJ N
distracter NN N
task NN N
) ) N
. . N

-DOCSTART- -X- O O 7761011

group NN N
A NNP N
patients NNS N
group NN N
B NNP N
patients NNS N
44 CD 3_p
patients NNS N
, , N
both DT N
male NN 2_p
and CC N
female NN 2_p
, , N
classified VBD N
as IN N
ASA NNP N
II NNP N
and CC N
III NNP N
. . N

group NN N
A NNP N
patients NNS N
-DOCSTART- -X- O O 2187009

autistic JJ 4_p
children NNS 1_p
autistic JJ 4_p
subjects NNS N
7 CD 3_p
subjects NNS N
-DOCSTART- -X- O O 12120773

caries NNS 4_p
removal VBP 4_p
techniques NNS 4_p
on IN 4_p
human JJ 4_p
dentin NN 4_p
. . 4_p

different JJ N
caries NNS N
removal VBP N
techniques NNS N
on IN N
human JJ N
dentin NN N
topography NN N
. . N

Thirty-six NNP N
extracted VBD N
human JJ N
carious JJ N
mandibular NN N
molars NNS N
six CD N
groups NNS N
according VBG N
to TO N
caries NNS N
removal NN N
technique NN N
. . N

-DOCSTART- -X- O O 21664757

final-year JJ N
medical JJ N
students NNS N
. . N

Students NNS 1_p
( ( 1_p
176 CD 3_p
; : 1_p
25.35±1.03 CD 1_p
years NNS 1_p
, , 1_p
63 CD 1_p
% NN 1_p
female NN 2_p
) ) N
to TO N
44 CD 3_p
four-person JJ 3_p
teams NNS 3_p
of IN N
all DT N
groups NNS N
administering VBG N
simulated JJ N
adult NN N
CPR NNP N
-DOCSTART- -X- O O 15985559

patients NNS N
treated VBN N
for IN N
Helicobacter NNP 4_p
pylori JJ 4_p
infection NN 4_p
. . N

795 CD 3_p
adults NNS 1_p
with IN N
preneoplastic JJ 4_p
gastric JJ 4_p
lesions NNS 4_p
was VBD N
randomised VBN N
to TO N
receive VB N
anti-H JJ N
pylori NN N
treatment NN N
Ninety NNP N
seven CD N
per IN N
cent NN N
of IN N
subjects NNS N
were VBD N
H NNP N
pylori JJ N
positive JJ N
at IN N
baseline NN N
, , N
and CC N
53 CD N
% NN N
were VBD N
positive JJ N
at IN N
12 CD N
years NNS N
. . N

patients NNS N
with IN N
preneoplastic JJ 4_p
gastric JJ 4_p
lesions NNS 4_p
-DOCSTART- -X- O O 19188136

stage NN N
IIIB/IV NNP N
non-small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
( ( N
NSCLC NNP N
) ) N
. . N

stage NN 4_p
IIIB/IV NNP 4_p
non-small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
( ( 4_p
NSCLC NNP 4_p
) ) 4_p
. . N

A DT N
total NN N
of IN N
168 CD 3_p
patients NNS 3_p
with IN N
previously RB N
untreated VBN N
stage NN N
IIIB/IV NNP N
NSCLC NNP N
were VBD N
advanced JJ 4_p
NSCLC NNP 4_p
. . N

-DOCSTART- -X- O O 20697791

young JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
: : N
autism NN 4_p
. . 4_p

children NNS 1_p
with IN N
autism NN N
Six NNP 3_p
boys NNS 2_p
were VBD N
matched VBN N
across IN N
various JJ N
features NNS N
( ( N
i.e. FW N
age NN N
, , N
language NN N
, , N
autism NN N
severity NN N
) ) N
-DOCSTART- -X- O O 22465608

Prospective NNP 4_p
study NN 4_p
of IN 4_p
104 CD 4_p
consecutive JJ 4_p
patients NNS 4_p
undergoing VBG 4_p
coronary JJ 4_p
angiography NN 4_p
who WP 4_p
were VBD 4_p
randomized VBN 4_p
-DOCSTART- -X- O O 2141092

Should MD N
angioplasty VB N
be VB N
deferred VBN N
after IN N
infarction NN N
? . N
-DOCSTART- -X- O O 23613224

cardiac JJ 4_p
rehabilitation NN 4_p
: : 4_p
Ninety NNP 3_p
participants NNS N
with IN N
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
( ( N
80 CD 3_p
men/10 NN 2_p
women NNS 2_p
, , N
mean JJ N
age NN 1_p
57 CD 1_p
± JJ 1_p
8 CD 1_p
years NNS 1_p
) ) N
RESULTS NNP N
Eighty-three JJ 3_p
participants NNS N
( ( N
92 CD N
% NN N
) ) N
completed VBD N
the DT N
intervention NN N
without IN N
any DT N
severe JJ N
adverse JJ N
events NNS N
-DOCSTART- -X- O O 22485232

patients NNS N
with IN N
severe JJ 4_p
acute NN 4_p
pancreatitis NN 4_p
. . N

patients NNS N
with IN N
severe JJ 4_p
acute NN 4_p
pancreatitis NN 4_p
( ( 4_p
SAP NNP 4_p
) ) 4_p
. . N

71 CD 3_p
patients NNS 3_p
with IN N
confirmed VBN N
severe JJ 4_p
acute NN 4_p
pancreatitis NN 4_p
from IN N
March NNP N
2009 CD N
to TO N
September NNP N
2011 CD N
in IN N
the DT N
Department NNP N
of IN N
Critical NNP N
Care NNP N
Medicine NNP N
of IN N
Huizhou NNP N
Municipal NNP N
Central NNP N
Hospital NNP N
, , N
Guangdong NNP N
, , N
China NNP N
patients NNS N
with IN N
severe JJ N
acute NN N
pancreatitis NN N
. . N

-DOCSTART- -X- O O 7572690

patients NNS N
with IN N
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
( ( 4_p
CAD NNP 4_p
) ) 4_p
. . 4_p

total NN N
of IN N
4,444 CD 3_p
patients NNS N
with IN N
angina JJ 4_p
pectoris NN 4_p
or CC N
previous JJ N
myocardial JJ 4_p
infarction NN 4_p
and CC N
serum VB 4_p
cholesterol NN 4_p
levels NNS 4_p
of IN N
213-310 JJ N
mg/dl NN N
( ( N
5.5-8.0 JJ N
mmol/liter NN N
) ) N
while IN N
treated VBN N
with IN N
a DT N
lipid-lowering JJ N
diet NN N
256 CD 3_p
patients NNS N
women NNS 2_p
and CC N
patients NNS N
of IN N
both DT 2_p
sexes NNS 2_p
-DOCSTART- -X- O O 5573167

autistic JJ N
children NNS 1_p
engaged VBN N
in IN N
self-stimulatory JJ 4_p
behavior NN 4_p
. . N

-DOCSTART- -X- O O 12084138

needle JJ N
exchangers NNS N
needle JJ N
exchange NN N
clients NNS N
. . N

Rhode NNP N
Island NNP N
, , N
USA NNP N
. . N

Between NNP N
2/98 CD N
and CC N
10/99 CD N
, , N
we PRP N
recruited VBD N
187 CD 3_p
AUDIT-positive JJ 3_p
( ( 3_p
> JJ 3_p
8 CD 3_p
) ) 3_p
active JJ 3_p
injection NN 3_p
drug NN 3_p
users NNS 3_p
. . N

injection NN N
drug NN N
users NNS N
with IN N
drinking NN N
problems NNS N
. . N

-DOCSTART- -X- O O 18678836

operable JJ N
breast NN 4_p
cancer NN 4_p
with IN N
0 CD N
to TO N
3 CD N
positive JJ N
axillary JJ N
nodes NNS N
: : N
metastatic JJ N
breast NN N
cancer NN N
. . N

operable JJ 4_p
breast NN 4_p
cancer NN 4_p
. . N

Women NNP 2_p
with IN N
invasive JJ 4_p
breast NN 4_p
cancer NN 4_p
were VBD N
eligible JJ N
if IN N
there EX N
were VBD N
one CD N
to TO N
three CD N
positive JJ N
lymph NN N
nodes NNS N
or CC N
if IN N
the DT N
node-negative JJ N
tumor NN N
was VBD N
greater JJR N
than IN N
1 CD N
cm NN N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
after IN N
surgery NN N
patients NNS N
with IN N
estrogen JJ N
receptor NN N
( ( N
ER NNP N
) ) N
and/or VBP N
progesterone NN N
receptor NN N
( ( N
PR NNP N
) ) N
-positive JJ N
tumors NNS N
. . N

2,882 CD 3_p
eligible JJ N
patients NNS N
enrolled VBN N
. . N

-DOCSTART- -X- O O 7003882

[ JJ 4_p
Median NNP 4_p
and CC 4_p
mediolateral JJ 4_p
episiotomy NN 4_p
] NN 4_p
. . 4_p

-DOCSTART- -X- O O 3732715

patients NNS 4_p
with IN 4_p
syndrome JJ 4_p
X NNP 4_p
] NNP 4_p
Patients NNS 4_p
with IN 4_p
angina JJ 4_p
pectoris NN 4_p
, , 4_p
exercise NN 4_p
induced VBN 4_p
myocardial JJ 4_p
ischemia NN 4_p
, , N
normal JJ 4_p
coronary JJ 4_p
arteries NNS 4_p
and CC 4_p
no DT 4_p
evidence NN 4_p
of IN 4_p
epicardial JJ 4_p
spasm NN 4_p
, , N
i.e NN N
. . N

patients NNS 4_p
with IN 4_p
syndrome JJ 4_p
x NN 4_p
13 CD 3_p
patients NNS 3_p
who WP N
showed VBD N
the DT N
above JJ N
set NN N
of IN N
findings NNS N
. . N

-DOCSTART- -X- O O 12005275

migraine NN 4_p
in IN N
adolescents NNS 1_p
: : N
adolescent JJ N
migraineurs NNS N
. . N

Patients NNS N
aged VBD N
12 CD 1_p
to TO 1_p
17 CD 1_p
years NNS 1_p
received VBD N
rizatriptan JJ N
5 CD N
mg NN N
( ( N
n JJ N
= NNP N
149 CD 3_p
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
147 CD 3_p
) ) N
adolescents NNS N
for IN N
the DT N
treatment NN N
of IN N
a DT N
migraine JJ N
attack NN 4_p
. . N

-DOCSTART- -X- O O 15973098

hemorrhoidectomy NN 4_p
: : N
134 CD 3_p
patients NNS N
were VBD N
included VBN N
at IN N
7 CD N
hospital NN N
centers NNS N
. . N

-DOCSTART- -X- O O 24472253

children NNS 1_p
with IN N
autism NN 4_p
: : N
young JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
. . N

A NNP N
total NN N
of IN N
61 CD 3_p
children NNS N
( ( N
48 CD 3_p
males NNS 3_p
) ) N
with IN N
autism NN 4_p
, , 1_p
29 CD 1_p
to TO 1_p
60 CD 1_p
months NNS 1_p
of IN 1_p
age NN 1_p
, , 1_p
had VBD N
earlier RBR N
been VBN N
randomized VBN N
either RB N
to TO N
8 CD N
weeks NNS N
of IN N
preschool-based JJ 4_p
social JJ 4_p
communication NN 4_p
treatment NN 4_p
in IN N
addition NN N
to TO N
standard JJ N
preschool NN N
program NN N
( ( N
n JJ N
= NNP N
34 CD N
) ) N
or CC N
to TO N
standard JJ N
preschool NN N
program NN N
only RB N
( ( N
n JJ N
= NNP N
27 CD N
) ) N
. . N

-DOCSTART- -X- O O 10337847

Caregivers NNP N
( ( N
n JJ N
= NNP N
77 CD 4_p
) ) 4_p
of IN N
the DT N
cognitively RB 4_p
impaired JJ 4_p
living NN N
at IN N
home NN N
-DOCSTART- -X- O O 26016867

overweight JJ 4_p
men NNS 2_p
. . N

in IN 1_p
overweight JJ 4_p
men NNS 2_p
. . N

A DT N
total NN N
of IN N
47 CD 3_p
men NNS 3_p
with IN N
a DT N
mean JJ N
± NN N
SD NNP N
age NN 1_p
of IN 1_p
46.5 CD 1_p
± JJ 1_p
5.1 CD 1_p
y NN 1_p
, , 1_p
who WP N
were VBD N
overweight JJ 4_p
[ NNP N
body NN N
mass NN N
index NN N
( ( N
in IN N
kg/m NN N
( ( N
2 CD N
) ) N
) ) N
from IN N
25 CD N
to TO N
30 CD N
] NNS N
but CC N
otherwise RB N
healthy JJ N
in IN N
overweight JJ 4_p
adults NNS 1_p
the DT N
Australian JJ N
New NNP N
Zealand NNP N
-DOCSTART- -X- O O 12049860

venous JJ 4_p
thromboembolism NN 4_p
after IN 4_p
elective JJ 4_p
hip-replacement JJ 4_p
surgery NN 4_p
: : N
we PRP N
randomly VBP N
assigned JJ N
2275 CD 3_p
consecutive JJ 3_p
patients NNS 3_p
aged VBN N
18 CD 1_p
years NNS 1_p
or CC 1_p
older JJR 1_p
who WP N
were VBD N
undergoing VBG N
elective JJ N
hip-replacement JJ 4_p
surgery NN 4_p
to TO N
receive VB N
postoperative JJ N
subcutaneous JJ N
injections NNS N
of IN N
either DT N
2.5 CD N
mg NN N
fondaparinux NN N
once RB N
daily JJ N
or CC N
30 CD N
mg NNS N
enoxaparin JJ N
twice RB N
daily RB N
. . N

-DOCSTART- -X- O O 7598920

ASA NNP 4_p
I PRP 4_p
and CC 4_p
II NNP 4_p
patients NNS 4_p
. . N

patients NNS N
receiving VBG N
a DT N
bolus NN N
dose NN N
of IN N
either CC N
eltanolone NN N
or CC N
propofol NN N
. . N

40 CD N
ASA NNP N
status NN N
I PRP N
and CC N
II NNP N
patients NNS N
scheduled VBN 4_p
for IN 4_p
elective JJ 4_p
surgery NN 4_p
. . N

Patients NNPS N
were VBD N
premedicated VBN N
with IN N
oral JJ N
temazepam NN N
20 CD N
mg. NN N
Patients NNPS N
receiving VBG N
either CC N
eltanolone NN N
or CC N
propofol NN N
patients NNS N
receiving VBG N
eltanolone NN N
. . N

-DOCSTART- -X- O O 6124226

Neuroleptics NNS 4_p
and CC 4_p
depression NN 4_p
. . 4_p

-DOCSTART- -X- O O 16879519

rocuronium NN N
under IN N
stable JJ N
nitrous JJ N
oxide-fentanyl JJ N
or CC N
nitrous JJ N
oxide-sevoflurane JJ N
anesthesia NN 4_p
in IN N
children NNS 1_p
. . N

children NNS 1_p
anesthetized VBN N
with IN N
nitrous JJ N
oxide NN N
( ( N
N2O NNP N
) ) N
and CC N
fentanyl $ N
or CC N
with IN N
N2O NNP N
and CC N
sevoflurane NN N
. . N

Twenty-four JJ 3_p
children NNS 1_p
( ( N
3-11 CD 1_p
years NNS 1_p
old JJ 1_p
, , N
ASA NNP 4_p
PS NNP 4_p
I PRP 4_p
or CC 4_p
II NNP 4_p
) ) N
were VBD N
randomized VBN N
-DOCSTART- -X- O O 23027887

patients NNS N
with IN N
rheumatoid JJ 4_p
arthritis NN 4_p
and CC 4_p
an DT 4_p
inadequate JJ 4_p
response NN 4_p
to TO 4_p
1 CD 4_p
or CC 4_p
more JJR 4_p
tumor JJ 4_p
necrosis NN 4_p
factor NN 4_p
inhibitors NNS 4_p
: : N
patients NNS N
with IN N
rheumatoid JJ 4_p
arthritis NN 4_p
( ( 4_p
RA NNP 4_p
) ) 4_p
who WP N
had VBD N
an DT N
inadequate JJ 4_p
response NN 4_p
to TO 4_p
tumor VB 4_p
necrosis NN 4_p
factor NN 4_p
( ( 4_p
TNF NNP 4_p
) ) 4_p
inhibitors NNS 4_p
. . N

Patients NNPS N
in IN N
REFLEX NNP N
PBO-randomized JJ N
patients NNS N
480 CD 3_p
patients NNS N
received VBD N
≥ JJ N
1 CD N
RTX NNP N
course NN N
-DOCSTART- -X- O O 23782653

Home-based JJ N
reach-to-grasp JJ N
training NN N
for IN N
people NNS N
after IN 4_p
stroke NN 4_p
: : N
study NN N
protocol NN N
people NNS N
with IN N
stroke NN 4_p
50 CD 3_p
individuals NNS N
with IN N
upper-limb JJ 4_p
motor NN 4_p
impairment NN 4_p
after IN N
stroke NN 4_p
. . N

Participants NNS N
will MD N
be VB N
recruited VBN N
after IN 4_p
discharge NN 4_p
from IN 4_p
hospital NN 4_p
and CC 4_p
up RB 4_p
to TO 4_p
12 CD 4_p
months NNS 4_p
post-stroke RB 4_p
from IN N
hospital NN N
stroke NN 4_p
services NNS N
and CC N
community NN N
therapy-provider NN N
services NNS N
. . N

Participants NNS N
Participants NNS N
Participants NNS N
-DOCSTART- -X- O O 18556619

sexually RB 4_p
transmitted VBN 4_p
infections NNS 4_p
From IN N
January NNP N
2002 CD N
through IN N
December NNP N
2004 CD N
, , N
600 CD 3_p
patients NNS N
with IN N
Neisseria NNP N
gonorrhoeae NN N
or CC N
Chlamydia NNP N
trachomatis NN N
were VBD N
recruited VBN N
from IN N
STI NNP N
clinics NNS N
urban JJ N
, , N
minority NN N
patients NNS N
-DOCSTART- -X- O O 16651950

wound NN N
closure NN N
dermal JJ 4_p
closure NN 4_p
of IN 4_p
the DT 4_p
Pfannenstiel NNP 4_p
incision NN 4_p
during IN N
nonemergent JJ N
cesarean JJ 4_p
delivery NN N
surgery NN N
produces VBZ N
enrolled VBD N
195 CD 3_p
patients NNS N
, , N
of IN N
whom WP N
188 CD 3_p
were VBD N
eligible JJ N
for IN N
analysis NN N
. . N

-DOCSTART- -X- O O 2248073

major JJ N
depression NN 4_p
. . N

75 CD 3_p
outpatients NNS N
. . N

moclobemide NN N
( ( N
25 CD 3_p
patients NNS N
) ) N
Imipramine NNP N
( ( N
25 CD 3_p
patients NNS N
) ) N
25 CD 3_p
patients NNS N
-DOCSTART- -X- O O 21224870

tetanus NN 4_p
toxoid JJ 4_p
immunization NN 4_p
vitamin NN 4_p
D NNP 4_p
supplementation NN 4_p
. . N

Vitamin NNP N
D NNP N
deficiency NN N
in IN N
lupus JJ N
erythematosus NN N
patients NNS N
. . N

In IN N
all DT N
, , N
32 CD 3_p
individuals NNS N
were VBD N
randomized VBN N
in IN N
a DT N
placebo NN N
controlled VBN N
, , N
double-blind JJ N
setting NN N
-DOCSTART- -X- O O 11210885

laryngectomy NN 4_p
female JJ 2_p
laryngectomees NNS 4_p
and/or VBP N
laryngectomees NNS 4_p
with IN 4_p
a DT 4_p
hypotonic JJ 4_p
pharyngoesophageal NN 4_p
( ( 4_p
PE NNP 4_p
) ) 4_p
segment NN 4_p
six CD 3_p
laryngectomees NNS 4_p
. . N

speech JJ 4_p
intelligibility NN 4_p
measurements NNS 4_p
with IN N
12 CD N
listeners NNS N
female JJ 2_p
laryngectomees NNS 4_p
with IN 4_p
a DT 4_p
hypotonic JJ 4_p
PE NNP 4_p
segment NN 4_p
male NN 2_p
laryngectomees NNS 4_p
-DOCSTART- -X- O O 15309442

urinary JJ 4_p
excretion NN 4_p
of IN 4_p
ferulic JJ 4_p
acid NN 4_p
in IN 4_p
humans NNS 4_p
Scandinavian JJ N
18 CD N
postmenopausal JJ N
women NNS N
after IN N
a DT N
dietary JJ N
intake NN N
of IN N
rye NN N
bran NN N
or CC N
an DT N
inert JJ N
wheat NN N
bran NN N
( ( N
control NN N
) ) N
in IN N
a DT N
crossover NN N
study NN N
( ( N
2 CD N
x RB N
6 CD N
weeks NNS N
with IN N
4 CD N
weeks NNS N
washout NN N
) ) N
-DOCSTART- -X- O O 25284194

patients NNS 4_p
with IN 4_p
Chagas NNP 4_p
heart NN 4_p
disease NN 4_p
patients NNS 4_p
with IN 4_p
chagasic JJ 4_p
cardiopathy NN 4_p
. . N

( ( N
1 CD N
) ) N
a DT 4_p
Chagas NNP 4_p
disease NN 4_p
diagnosis NN 4_p
confirmed VBN 4_p
by IN 4_p
serology NN 4_p
; : N
( ( N
2 CD N
) ) N
segmental NN N
, , N
mild NN 4_p
or CC 4_p
moderate VB 4_p
global JJ 4_p
left NN 4_p
ventricular JJ 4_p
systolic JJ 4_p
dysfunction NN 4_p
; : 4_p
and CC N
( ( N
3 CD N
) ) N
age NN 1_p
between IN 1_p
18 CD 1_p
and CC 1_p
65 CD 1_p
years NNS 1_p
. . N

exclusion NN N
criteria NNS N
are VBP N
as IN N
follows VBZ N
: : N
( ( N
1 CD N
) ) N
pregnancy NN N
, , N
( ( N
2 CD N
) ) N
diabetes VBZ 4_p
mellitus NN 4_p
, , 4_p
( ( N
3 CD N
) ) N
tobacco NN 4_p
use NN 4_p
, , 4_p
( ( N
4 CD N
) ) N
alcohol NN 4_p
abuse NN 4_p
, , N
( ( N
5 CD N
) ) N
evidence NN 4_p
of IN 4_p
nonchagasic JJ 4_p
heart NN 4_p
disease NN 4_p
, , N
( ( N
6 CD N
) ) N
depression NN 4_p
, , N
( ( N
7 CD N
) ) N
dysphagia NN 4_p
with IN N
evidence NN N
of IN N
food NN N
residues NNS N
in IN N
the DT N
esophagus NN N
, , N
( ( N
8 CD N
) ) N
dysphagia NN N
with IN N
weight JJ N
loss NN N
higher JJR N
than IN N
15 CD N
% NN N
of IN N
usual JJ N
weight NN N
in IN N
the DT N
last JJ N
four CD N
months NNS N
and/or RB N
( ( N
9 CD N
) ) N
conditions NNS N
that WDT N
may MD N
result VB N
in IN N
low JJ N
protocol NN N
adherence NN N
. . N

-DOCSTART- -X- O O 15947531

obese JJ 4_p
patients NNS N
with IN N
heart NN 4_p
failure NN 4_p
: : N
obese JJ 4_p
patients NNS N
with IN N
heart NN 4_p
failure NN 4_p
obese JJ 4_p
patients NNS N
with IN N
ejection NN N
fractions NNS N
< VBP N
or CC N
=40 CD N
% NN N
. . N

Twenty-one JJ 3_p
consecutive JJ N
obese JJ 4_p
patients NNS N
with IN N
heart NN 4_p
failure NN 4_p
were VBD N
recruited VBN N
. . N

-DOCSTART- -X- O O 789390

coronary JJ 4_p
heart NN 4_p
disease NN 4_p
. . 4_p

-DOCSTART- -X- O O 18812446

peripheral JJ 4_p
pulmonary JJ 4_p
lesions NNS 4_p
: : 4_p
Two CD N
hundred VBD N
two CD N
patients NNS N
with IN N
PPLs NNP N
and CC N
positive JJ N
EBUS NNP N
findings NNS N
were VBD N
enrolled VBN N
. . N

A DT N
total NN N
of IN N
182 CD N
patients NNS N
( ( N
94 CD N
in IN N
the DT N
EBUS NNP N
CDPs NNP N
group NN N
and CC N
88 CD N
in IN N
the DT N
EBUS-TBNA JJ N
plus CC N
CDPs NNP N
group NN N
) ) N
were VBD N
analyzed VBN N
. . N

-DOCSTART- -X- O O 1492408

pre-eclampsia NN 4_p
. . 4_p

Pre-Eclampsia NNP N
of IN N
Pregnancy NNP N
. . N

group NN N
of IN N
primiparous JJ N
and CC N
multiparous JJ N
pregnant JJ N
women NNS N
. . N

Some DT 4_p
of IN 4_p
these DT 4_p
women NNS 4_p
had VBD 4_p
personal JJ 4_p
or CC 4_p
family NN 4_p
histories NNS 4_p
of IN 4_p
hypertension NN 4_p
( ( 4_p
21 CD 4_p
% NN 4_p
) ) 4_p
. . 4_p

Only RB N
those DT N
patients NNS N
who WP N
received VBD N
prenatal JJ N
care NN N
at IN N
the DT N
Central NNP N
Maternity NNP N
Hospital NNP N
for IN N
Luanda NNP N
hypertension NN N
of IN N
pregnancy NN N
. . N

eclampsia NN N
-DOCSTART- -X- O O 15829494

patients NNS N
with IN N
advanced JJ 4_p
melanoma NN 4_p
: : N
patients NNS N
with IN N
advanced JJ 4_p
melanoma NN 4_p
. . N

From NNP N
January NNP N
2000 CD N
to TO N
April NNP N
2002 CD N
, , N
132 CD 3_p
patients NNS N
were VBD N
enrolled VBN N
on IN N
the DT N
study NN N
. . N

Patient NNP N
and CC N
tumor NN N
characteristics NNS N
Patients NNS N
with IN N
cerebral JJ 4_p
metastases NNS 4_p
were VBD N
included VBN N
. . N

-DOCSTART- -X- O O 21785368

cardiovascular JJ 4_p
risks NNS 4_p
in IN N
managers NNS N
: : N
managers NNS N
-- : N
was VBD N
145 CD 3_p
managers NNS N
from IN N
8 CD N
organizations NNS N
-DOCSTART- -X- O O 7035637

71 CD 3_p
normal JJ N
children NNS 1_p
in IN N
three CD N
age NN N
groups NNS N
: : N
36 CD 1_p
to TO 1_p
72 CD 1_p
months NNS 1_p
, , 1_p
15 CD 1_p
to TO 1_p
18 CD 1_p
months NNS 1_p
, , N
and CC N
6 CD 1_p
to TO 1_p
8 CD 1_p
months NNS 1_p
. . N

three CD N
age NN N
groups NNS N
. . N

-DOCSTART- -X- O O 8871414

depression NN 4_p
. . N

150 CD 3_p
outpatients NNS N
with IN N
major JJ 4_p
depression NN 4_p
to TO N
a DT N
treatment NN N
focused VBN N
exclusively RB N
on IN N
the DT N
behavioral JJ N
activation NN N
( ( N
BA NNP N
) ) N
component NN N
of IN N
CT NNP N
-DOCSTART- -X- O O 25475363

Children NNP 1_p
with IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorder NNP 4_p
Who NNP N
are VBP N
Minimally NNP N
Verbal NNP N
. . N

school-aged JJ N
children NNS 1_p
with IN N
autism NN 4_p
who WP N
have VBP N
limited VBN N
communication NN N
skills NNS N
Sixty-one JJ 3_p
children NNS N
with IN N
autism NN 4_p
age NN 1_p
5-8 JJ 1_p
with IN N
minimal JJ N
spontaneous JJ N
communication NN N
received VBD N
a DT N
6-month JJ N
social JJ N
communication NN N
intervention NN N
including VBG N
parent NN N
training NN N
. . N

Parent-child JJ N
play NN N
interactions NNS N
Parents NNS N
Children NNP 1_p
's POS 1_p
parents NNS N
' POS N
implementation NN N
children NNS 1_p
's POS 1_p
social JJ N
engagement NN N
. . N

-DOCSTART- -X- O O 3085131

human JJ N
cigarette NN 4_p
smoking NN 4_p
normal JJ 4_p
volunteers NNS N
. . N

-DOCSTART- -X- O O 18080171

in IN N
children NNS N
and CC N
adolescents NNS N
with IN N
AD NNP N
Autistic JJ N
Disorder NNP N
( ( N
AD NNP N
) ) N
A DT N
total NN N
of IN N
30 CD N
subjects NNS N
, , N
between IN N
the DT N
ages NNS N
of IN N
8 CD N
and CC N
18 CD N
with IN N
AD NNP N
based VBN N
on IN N
DSM NNP N
IV NNP N
criteria NNS N
, , N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

children NNS N
with IN N
AD NNP N
. . N

-DOCSTART- -X- O O 11956614

Endometrial JJ N
cytodiagnosis NN N
cytological JJ N
screening NN N
for IN N
endometrial JJ N
cancer NN N
315 CD 3_p
women NNS 3_p
( ( N
premenopause IN N
251 CD 3_p
, , N
postmenopause RB N
64 CD 3_p
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
who WP N
underwent VBP N
the DT N
endometrial JJ N
cytological JJ N
screening NN N
with IN N
either CC N
the DT N
softcyte NN N
or CC N
the DT N
endocyte NN N
. . N

screening VBG N
for IN N
endometrial JJ N
cancer NN N
. . N

-DOCSTART- -X- O O 10476617

preeclampsia NN 4_p
. . N

pregnant JJ 4_p
women NNS 2_p
with IN N
a DT N
high JJ N
risk NN N
of IN N
preeclampsia NN 4_p
Forty NNP 3_p
pregnant JJ 4_p
women NNS 2_p
preeclampsia NN 4_p
in IN N
high-risk JJ N
pregnant JJ N
women NNS N
. . N

-DOCSTART- -X- O O 24268858

chronic JJ 4_p
central JJ 4_p
serous JJ 4_p
chorioretinopathy NN 4_p
: : 4_p
Thirty-four JJ N
eyes NNS N
of IN N
32 CD N
patients NNS N
with IN N
chronic JJ N
CSC NNP N
with IN N
> NNP N
6 CD N
months NNS N
' POS N
duration NN N
of IN N
symptoms NNS N
or CC N
recurrent JJ N
CSC NNP N
were VBD N
randomly RB N
placed VBN N
into IN N
the DT N
low-fluence JJ N
PDT NNP N
group NN N
( ( N
n JJ N
= NNP N
18 CD N
) ) N
or CC N
the DT N
ranibizumab NN N
group NN N
( ( N
n JJ N
= NNP N
16 CD N
) ) N
. . N

16 CD N
eyes NNS N
2 CD N
eyes NNS N
-DOCSTART- -X- O O 11888754

241 CD 3_p
consecutive JJ N
patients NNS N
undergoing VBG N
elective JJ 4_p
coronary JJ 4_p
artery NN 4_p
bypass NN 4_p
grafting VBG 4_p
were VBD N
randomly RB N
allocated VBN N
into IN N
three CD N
groups NNS N
. . N

Group1 NNP 3_p
( ( 3_p
n=77 NN 3_p
) ) 3_p
Group NNP 3_p
2 CD 3_p
( ( 3_p
n=72 NN 3_p
) ) 3_p
Group NNP 3_p
3 CD 3_p
( ( 3_p
n=92 NN 3_p
) ) 3_p
-DOCSTART- -X- O O 3075724

control NN N
subjects NNS N
and CC N
depressed JJ 4_p
patients NNS N
. . N

depressed JJ N
and CC N
control JJ N
subjects NNS N
. . N

two CD N
groups NNS N
of IN N
8 CD 3_p
patients NNS N
-DOCSTART- -X- O O 21148662

paroxysmal JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
with IN 4_p
hypertension NN 4_p
Japanese JJ 4_p
Rhythm NNP 4_p
Management NNP 4_p
Trial NNP 4_p
II NNP 4_p
for IN 4_p
Atrial NNP 4_p
Fibrillation NNP 4_p
( ( 4_p
J-RHYTHM NNP 4_p
II NNP 4_p
study NN 4_p
) ) 4_p
The DT N
study NN N
enrolled VBD N
318 CD 3_p
patients NNS N
( ( N
66 CD 1_p
years NNS 1_p
, , N
male/female JJ 2_p
219/99 CD 3_p
, , N
158 CD 3_p
in IN N
the DT N
ARB NNP N
group NN N
and CC N
160 CD 3_p
in IN N
the DT N
CCB NNP N
group NN N
) ) N
treated VBD N
at IN N
48 CD N
sites NNS N
throughout IN N
Japan NNP N
. . N

At IN 4_p
baseline NN 4_p
, , 4_p
the DT 4_p
frequency NN 4_p
of IN 4_p
AF NNP 4_p
episodes NNS 4_p
( ( 4_p
days/month NN 4_p
) ) 4_p
was VBD 4_p
3.8 CD 4_p
± JJ 4_p
5.0 CD 4_p
in IN 4_p
the DT 4_p
ARB NNP 4_p
group NN 4_p
vs. FW 4_p
4.8 CD N
± $ N
6.3 CD N
in IN N
the DT N
CCB NNP N
group NN N
In IN 4_p
patients NNS 4_p
with IN 4_p
paroxysmal JJ 4_p
AF NNP 4_p
and CC 4_p
hypertension NN 4_p
-DOCSTART- -X- O O 21063747

Italian JJ 4_p
and CC 4_p
US JJ 4_p
American JJ 4_p
context NN 4_p
sensitivity NN 4_p
and CC 4_p
Fear NNP 4_p
of IN 4_p
Isolation NNP 4_p
. . N

Easterners NNS N
Westerners NNS N
. . N

two CD N
different JJ 4_p
Western JJ 4_p
cultures NNS 4_p
. . N

Testing VBG 4_p
Italian JJ 4_p
( ( 4_p
IT NNP 4_p
) ) 4_p
and CC 4_p
US JJ 4_p
American NNP 4_p
( ( 4_p
US NNP 4_p
) ) 4_p
adults NNS 1_p
US JJ 4_p
participants NNS 4_p
. . N

Eastern NNP N
populations NNS N
-DOCSTART- -X- O O 3337028

infants NNS N
fed VBN N
iron-fortified JJ N
beikost NN N
with IN N
meat NN N
. . N

two CD N
groups NNS N
of IN N
healthy JJ N
term NN N
infants NNS N
who WP N
received VBD N
meat-containing JJ N
baby NN N
foods NNS N
fortified VBN N
with IN N
ferrous JJ N
sulphate NN N
( ( N
2 CD N
mg NN N
Fe/100 NNP N
g NN N
) ) N
. . N

healthy JJ N
term NN N
infants NNS N
-DOCSTART- -X- O O 2865615

intravenous JJ N
infusion NN N
due JJ N
to TO N
phlebitis VB 4_p
and CC 4_p
extravasation NN 4_p
. . N

skin NN N
of IN N
patients NNS N
patients NNS N
with IN N
active JJ N
patches NNS N
-DOCSTART- -X- O O 26382998

infants NNS 1_p
with IN N
bronchiolitis NN 4_p
( ( 4_p
BIDS NNP 4_p
) ) 4_p
: : N
children NNS 1_p
with IN N
lower JJR 4_p
respiratory NN 4_p
tract JJ 4_p
infections NNS 4_p
. . N

infants NNS 1_p
aged VBN 1_p
6 CD 1_p
weeks NNS 1_p
to TO 1_p
12 CD 1_p
months NNS 1_p
of IN 1_p
age NN 1_p
with IN N
physician-diagnosed JJ N
bronchiolitis NN 4_p
newly RB N
admitted VBN N
into IN N
eight CD N
paediatric JJ N
hospital NN N
units NNS N
in IN N
the DT N
UK NNP N
( ( N
the DT N
Bronchiolitis NNP N
of IN N
Infancy NNP N
Discharge NNP N
Study NNP N
[ NNP N
BIDS NNP N
] NNP N
) ) N
. . N

308 CD 3_p
infants NNS 3_p
of IN N
infants NNS 1_p
with IN N
bronchiolitis NN 4_p
-DOCSTART- -X- O O 16360994

day-only JJ N
angiography NN 4_p
procedures NNS 4_p
-- : N
a DT N
patients NNS N
with IN N
cardiovascular JJ 4_p
disease NN 4_p
Sixty-five JJ 3_p
day-only JJ N
patients NNS N
with IN N
renal JJ 4_p
impairment NN 4_p
( ( 4_p
mean JJ 4_p
serum NN 4_p
creatinine NN 4_p
concentration NN 4_p
0.16+/-0.03 NNP 4_p
mmol/l NN 4_p
) ) 4_p
due JJ N
to TO N
undergo JJ 4_p
coronary JJ 4_p
or CC 4_p
peripheral JJ 4_p
angiography NN 4_p
and/or NN 4_p
stenting VBG 4_p
60 CD 3_p
patients NNS N
with IN N
complete JJ N
data NNS N
day-stay JJ N
patients NNS N
with IN N
mild-to-moderate JJ 4_p
chronic JJ 4_p
renal JJ 4_p
impairment NN 4_p
undergoing VBG 4_p
angiography NN 4_p
and/or NN 4_p
intervention NN 4_p
-DOCSTART- -X- O O 3098997

marrow NN 4_p
transplant NN 4_p
recipients NNS 4_p
receiving VBG 4_p
total JJ 4_p
parenteral JJ 4_p
nutrition NN 4_p
. . 4_p

30 CD N
patients NNS N
undergoing JJ N
marrow JJ N
transplantation NN N
for IN N
acute NN N
leukemia NN N
-DOCSTART- -X- O O 526820

tube NN 4_p
spacer NN 4_p
-DOCSTART- -X- O O 18318721

mild NN 4_p
to TO 4_p
moderate VB 4_p
facial JJ 4_p
photodamage NN 4_p
. . N

Ten NNP 3_p
subjects VBZ 3_p
( ( 1_p
ages IN 1_p
35-63 NNP 1_p
) ) 1_p
with IN N
facial JJ 4_p
dyschromia NN 4_p
and CC 4_p
rhytides NNS 4_p
Ten NNP 3_p
female JJ 2_p
subjects NNS N
with IN N
mild NN 4_p
to TO 4_p
moderate VB 4_p
facial JJ 4_p
photodamage NN 4_p
Nine NNP 3_p
of IN 3_p
10 CD 3_p
patients NNS 3_p
completed VBD 3_p
the DT 3_p
trial NN 3_p
; : N
facial JJ N
photodamage NN N
-DOCSTART- -X- O O 16076379

hyperphosphatemia NN 4_p
in IN 4_p
hemodialysis NN 4_p
patients NNS 4_p
in IN N
Japan NNP 4_p
. . N

86 CD 3_p
hemodialysis NN 4_p
patients NNS N
in IN N
Japan NNP N
. . N

Of IN N
the DT N
86 CD N
patients NNS N
, , N
62 CD 3_p
finished VBD N
the DT N
study NN N
without IN N
a DT N
change NN N
of IN N
dosage NN N
and CC N
their PRP$ N
data NNS N
were VBD N
analyzed VBN N
( ( N
group NN N
A NNP N
, , N
N=16 NNP 3_p
; : N
group NN N
B NNP N
, , N
N=26 NNP 3_p
; : N
group NN N
C NNP N
, , N
N=20 NNP 3_p
) ) N
. . N

-DOCSTART- -X- O O 15894964

patients NNS N
with IN N
chronic JJ 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
: : N
100 CD 3_p
patients NNS N
with IN N
chronic JJ 4_p
CAD NNP 4_p
, , N
60 CD 3_p
of IN N
whom WP N
were VBD N
chronic JJ 4_p
smokers NNS 4_p
. . N

60 CD 3_p
of IN N
100 CD N
patients NNS N
( ( N
30 CD N
of IN N
whom WP N
were VBD N
smokers NNS 4_p
) ) N
and CC N
in IN N
24 CD 3_p
healthy JJ N
controls NNS N
. . N

Smokers NNS 4_p
( ( N
n JJ N
= NNP N
20 CD 3_p
) ) N
matched VBN N
for IN N
age NN N
, , N
myocardial JJ N
ischemia NN N
, , N
and CC N
other JJ N
risk NN N
factors NNS N
with IN N
20 CD 3_p
nonsmokers NNS 4_p
patients NNS N
with IN N
chronic JJ 4_p
CAD NNP 4_p
. . N

-DOCSTART- -X- O O 10671339

stem NN 4_p
cell NN 4_p
transplant NN 4_p
patients NNS N
. . N

117 CD 3_p
patients NNS N
who WP N
had VBD N
undergone JJ 4_p
stem NN 4_p
cell NN 4_p
transplantation NN 4_p
( ( N
SCT NNP 4_p
) ) N
. . N

subgroup NN N
of IN N
allogeneic JJ N
SCT NNP N
patients NNS N
autologous JJ N
SCT NNP N
patients NNS N
with IN N
breast JJ N
cancer NN N
SCT NNP 4_p
patients NNS 4_p
-DOCSTART- -X- O O 2474103

patients NNS N
with IN N
essential JJ 4_p
hypertension NN 4_p
. . N

patients NNS N
with IN N
essential JJ N
hypertension NN N
-DOCSTART- -X- O O 24280031

autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . 4_p

28 CD 3_p
adults NNS 1_p
diagnosed VBN N
with IN N
either DT 4_p
autistic JJ 4_p
disorder NN 4_p
( ( 4_p
high-functioning JJ 4_p
) ) 4_p
or CC 4_p
Asperger NNP 4_p
's POS 4_p
disorder NN 4_p
completed VBD N
-DOCSTART- -X- O O 12559222

severe JJ 4_p
low-output JJ 4_p
heart NN 4_p
failure NN 4_p
: : N
patients NNS N
with IN N
low-output JJ N
heart NN N
failure NN N
. . N

203 CD 3_p
patients NNS N
with IN N
severe JJ N
heart NN N
failure NN N
-DOCSTART- -X- O O 17393618

in IN N
patients NNS N
undergoing JJ N
chemotherapy NN 4_p
. . N

patients NNS N
undergoing JJ N
chemotherapy NN 4_p
. . N

patients NNS N
undergoing JJ N
chemotherapy NN 4_p
. . N

patients NNS N
undergoing JJ N
chemotherapy NN 4_p
. . N

-DOCSTART- -X- O O 17979862

infants NNS 1_p
with IN N
Down NNP 4_p
syndrome NN 4_p
. . N

infants NNS 1_p
with IN N
Down NNP 4_p
syndrome NN 4_p
( ( N
DS NNP 4_p
) ) N
. . N

The DT N
first JJ N
cohort NN N
included VBD N
30 CD 3_p
infants NNS 1_p
with IN N
DS NNP 4_p
( ( N
17 CD 3_p
males NNS 2_p
, , N
13 CD 3_p
females NNS 2_p
; : N
mean JJ N
age NN N
10 CD 1_p
mo NN 1_p
[ NNP N
SD NNP N
1.9 CD N
mo NN N
] NN N
) ) N
A DT N
control NN 4_p
( ( 4_p
C NNP 4_p
) ) 4_p
group NN 4_p
from IN N
another DT N
study NN N
, , N
who WP N
did VBD N
not RB N
receive VB N
treadmill NN N
training NN N
, , N
served VBD N
as IN N
the DT N
control NN N
( ( N
eight CD 3_p
males NNS 2_p
, , N
seven CD 3_p
females NNS 2_p
; : N
mean JJ N
age NN N
10.4 CD 1_p
mo NN 1_p
[ NNP N
SD NNP N
2.2 CD N
mo NN N
] NN N
) ) N
. . N

infants NNS 1_p
with IN N
DS NNP 4_p
. . N

-DOCSTART- -X- O O 2644391

patients NNS N
and CC N
their PRP$ N
partners NNS N
with IN N
bacterial JJ N
vaginosis NN N
. . N

male JJ N
partners NNS N
of IN N
women NNS N
with IN N
bacterial JJ N
vaginosis NN N
patients NNS N
with IN N
bacterial JJ N
vaginosis NN N
. . N

sexual JJ N
partner NN N
of IN N
women NNS N
with IN N
bacterial JJ N
vaginosis NN N
-DOCSTART- -X- O O 15602505

in IN N
childhood NN 1_p
and CC 1_p
adolescent JJ 1_p
autism NN 4_p
. . N

children NNS N
with IN N
autism NN N
. . N

repetitive JJ N
behaviors NNS N
in IN N
childhood NN N
and CC N
adolescent JJ N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
( ( N
ASDs NNP 4_p
) ) N
. . N

45 CD 3_p
child NN 1_p
or CC 1_p
adolescent JJ 1_p
patients NNS N
with IN N
ASD NNP 4_p
were VBD N
randomized VBN N
into IN N
two CD N
acute JJ N
8-week JJ N
phases NNS N
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
crossover NN N
study NN N
of IN N
liquid JJ N
fluoxetine NN N
. . N

repetitive JJ N
behaviors NNS N
-DOCSTART- -X- O O 10902449

transurethral JJ N
resections NNS N
] VBP N
short JJ N
procedures NNS N
for IN N
transurethral JJ N
resection NN N
Fifty-seven NNP 3_p
patients NNS N
scheduled VBN N
for IN N
transurethral JJ N
resection NN N
of IN N
the DT N
prostate NN N
or CC N
a DT N
vesical JJ 4_p
tumor NN 4_p
. . N

Patients NNS N
were VBD N
ASA NNP N
I-III NNP N
, , N
over IN N
55 CD 1_p
years NNS N
of IN N
age NN N
-DOCSTART- -X- O O 25572620

adult JJ 1_p
cancer NN 4_p
survivors NNS 4_p
. . N

( ( N
conducted VBN N
2010-2013 CD N
) ) N
adult NN 1_p
cancer NN 4_p
survivors NNS N
who WP N
regularly RB N
smoked VBD N
cigarettes NNS N
. . N

Adult NNP N
onset VBD N
cancer NN 4_p
survivors NNS N
in IN N
Memphis NNP N
, , N
Tennessee NNP N
( ( N
n=427 UH 3_p
, , N
67 CD N
% NN N
female NN 2_p
, , N
60 CD N
% NN N
Caucasian JJ N
) ) N
cancer NN 4_p
survivors NNS N
-DOCSTART- -X- O O 19713225

venous JJ N
thrombosis NN N
: : N
patients NNS 4_p
with IN 4_p
venous JJ 4_p
thrombosis NN 4_p
Cases NNP N
who WP N
had VBD N
a DT N
first JJ N
venous JJ N
thrombosis NN N
( ( N
n=515 JJ N
) ) N
and CC N
matched VBN N
controls NNS N
( ( N
n=1,505 NN N
) ) N
were VBD N
identified VBN N
from IN N
a DT N
population-based JJ N
, , N
nested JJ N
, , N
case-cohort JJ N
study NN N
( ( N
the DT N
HUNT NNP N
2 CD N
study NN N
) ) N
comprising VBG N
71 CD N
% NN N
( ( N
n=66,140 JJ N
) ) N
of IN N
the DT N
adult NN N
residents NNS N
of IN N
Nord-Trøndelag NNP N
County NNP N
in IN N
Norway NNP N
for IN N
subjects NNS N
with IN N
concentrations NNS N
of IN N
C-reactive JJ N
protein NN N
in IN N
the DT N
highest JJS N
quintile NN N
in IN N
subjects NNS N
who WP N
experienced VBD N
venous JJ N
thrombosis NN N
within IN N
a DT N
year NN N
after IN N
blood NN N
sampling VBG N
subsequent JJ N
venous JJ N
thrombosis NN N
. . N

Blood NNP N
pressure NN N
to TO N
venous JJ N
thrombosis NN N
-DOCSTART- -X- O O 22510874

acute JJ 4_p
myeloid JJ 4_p
leukemia NN 4_p
patients NNS 4_p
. . 4_p

newly RB N
diagnosed VBN N
AML NNP N
patients NNS N
from IN N
2 CD 3_p
large JJ N
study NN N
groups NNS N
( ( N
the DT N
German JJ N
AML NNP N
Cooperative NNP N
Group NNP N
and CC N
the DT N
Dutch-Belgian JJ N
Hematology NNP N
Oncology NNP N
Cooperative NNP N
group NN N
) ) N
. . N

261 CD 3_p
patients NNS 3_p
from IN 3_p
a DT 3_p
third JJ 3_p
cohort NN 3_p
. . N

-DOCSTART- -X- O O 7841058

cancer NN 4_p
patients NNS N
: : N
cancer NN 4_p
patients NNS N
A DT N
total NN N
of IN N
117 CD 3_p
patients NNS N
newly RB N
referred VBN N
to TO N
a DT N
medical JJ N
oncology NN N
clinic NN N
who WP N
were VBD N
to TO N
be VB N
given VBN N
'bad CD N
news NN N
' POS N
-DOCSTART- -X- O O 20051135

in IN N
patients NNS N
> JJ 1_p
or=12 CD 1_p
years NNS 1_p
old JJ 1_p
with IN N
mild-to-moderate JJ 4_p
persistent JJ 4_p
asthma NN 4_p
. . N

1233 CD 3_p
patients NNS N
were VBD N
randomized VBN N
. . N

-DOCSTART- -X- O O 3122275

human JJ 4_p
circulation NN 4_p
. . N

Twenty NNP 3_p
healthy JJ N
subjects NNS N
participated VBN N
-DOCSTART- -X- O O 8837189

210 CD 3_p
ASA NNP 4_p
I PRP 4_p
or CC 4_p
II NNP 4_p
patients NNS 4_p
undergoing VBG 4_p
cesarean JJ 4_p
delivery NN 4_p
, , N
who WP N
were VBD N
randomly RB 4_p
assigned VBN 4_p
to TO 4_p
six CD 4_p
groups NNS 4_p
. . N

-DOCSTART- -X- O O 17597498

young JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
sensory JJ 4_p
impairment NN 4_p
in IN 4_p
young JJ 4_p
children NNS 4_p
Thirteen NNP 3_p
children NNS 3_p
with IN 4_p
autism NN 4_p
between IN 1_p
the DT 1_p
ages NNS 1_p
of IN 1_p
three CD 1_p
and CC 1_p
six CD 1_p
children NNS N
with IN N
bowel NN N
and CC N
sleep JJ N
abnormalities NNS N
-DOCSTART- -X- O O 22035883

Between NNP N
March NNP N
2008 CD N
and CC N
February NNP N
2011,157 CD 3_p
patients NNS N
who WP N
had VBD N
tubal JJ 4_p
EP NNP 4_p
diagnosed VBN N
by IN N
a DT N
non-laparoscopic JJ N
approach NN N
and CC N
were VBD N
hemodynamically RB N
stable JJ N
were VBD N
enrolled VBN N
in IN N
a DT N
prospective JJ N
study NN N
in IN N
Qassim NNP N
, , N
Saudi NNP N
Arabia NNP N
. . N

-DOCSTART- -X- O O 23614586

Chinese JJ N
schoolchildren NNS 1_p
. . N

rural JJ N
schools NNS N
in IN N
Linxiang NNP N
City NNP N
District NNP N
, , N
Hunan NNP N
province NN N
, , N
China NNP N
1718 CD 3_p
children NNS 1_p
, , N
9 CD 1_p
to TO 1_p
10 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
, , N
in IN N
38 CD N
schools NNS N
over IN N
the DT N
course NN N
of IN N
1 CD N
school NN N
year NN N
. . N

-DOCSTART- -X- O O 12738312

head-and-neck JJ 4_p
cancer NN 4_p
patients NNS N
. . N

patients NNS N
with IN N
head-and-neck JJ 4_p
squamous JJ 4_p
cell NN 4_p
carcinomas NN 4_p
. . N

65 CD 3_p
patients NNS 3_p
with IN N
head-and-neck JJ 4_p
squamous JJ 4_p
cell NN 4_p
carcinoma NN 4_p
nodal JJ N
metastasis NN N
Fifty-four CD 3_p
patients NNS 3_p
had VBD N
sufficient JJ N
tumor NN N
cells NNS N
for IN N
comet JJ N
analysis NN N
-DOCSTART- -X- O O 10554799

in IN N
patients NNS N
with IN N
haematological JJ 4_p
malignancies NNS 4_p
. . N

Adults NNS 1_p
with IN N
haematological JJ N
malignancies NNS N
receiving VBG N
chemotherapy NN N
or CC N
bone NN N
marrow NN N
transplants NNS N
more RBR N
patients NNS N
receiving VBG N
flu NN N
required VBN N
amphotericin NN N
B NNP N
-DOCSTART- -X- O O 25612845

healthy JJ N
volunteers NNS N
. . N

included VBD N
36 CD 3_p
healthy JJ N
male NN 2_p
volunteers NNS 2_p
-DOCSTART- -X- O O 12058842

children NNS 1_p
with IN N
autism NN 4_p
. . N

Twenty NNP 3_p
children NNS 1_p
with IN N
autism NN 4_p
( ( N
mean JJ 1_p
age NN 1_p
, , 1_p
5 CD 1_p
years NNS 1_p
) ) 1_p
were VBD N
recruited VBN N
for IN N
the DT N
study NN N
from IN N
a DT N
school NN N
for IN N
children NNS 1_p
with IN N
autism NN 4_p
. . N

imitation NN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
or CC N
contingently RB N
responsive JJ N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
-DOCSTART- -X- O O 5322596

candida NN N
in IN N
hospital JJ N
in-patients NNS N
-DOCSTART- -X- O O 10790473

three-year-old JJ 4_p
children NNS 4_p
in IN 4_p
relation NN 4_p
to TO 4_p
otitis VB 4_p
media NNS 4_p
in IN 4_p
their PRP$ 4_p
first JJ 4_p
three CD 4_p
years NNS 4_p
of IN 4_p
life NN 4_p
. . 4_p

We PRP N
enrolled VBD N
6350 CD N
healthy JJ N
infants NNS N
by IN N
2 CD N
months NNS N
of IN N
age NN N
who WP N
presented VBD N
for IN N
primary JJ N
care NN N
at IN N
1 CD N
of IN N
2 CD N
urban JJ N
hospitals NNS N
or CC N
1 CD N
of IN N
2 CD N
small JJ N
town/rural JJ N
and CC N
4 CD N
suburban JJ N
private JJ N
pediatric JJ N
practices NNS N
. . N

Children NNP N
who WP N
met VBD N
specified VBN N
minimum JJ N
criteria NNS N
regarding VBG N
the DT N
persistence NN N
of IN N
MEE NNP N
became VBD N
eligible JJ N
for IN N
a DT N
clinical JJ N
trial NN N
From IN N
among IN N
those DT N
remaining VBG N
, , N
we PRP N
selected VBD N
randomly RB N
, , N
within IN N
sociodemographic JJ N
strata NNS N
, , N
a DT N
sample NN N
of IN N
241 CD N
children NNS N
who WP N
represented VBD N
a DT N
spectrum NN N
of IN N
MEE NNP N
experience NN N
from IN N
having VBG N
no DT N
MEE NNP N
to TO N
having VBG N
MEE NNP N
whose WP$ N
cumulative JJ N
duration NN N
fell VBD N
just RB N
short RB N
of IN N
meeting VBG N
randomization NN N
criteria NNS N
. . N

In IN N
subjects NNS N
so RB N
selected VBN N
, , N
the DT N
estimated JJ N
duration NN N
of IN N
MEE NNP N
ranged VBD N
from IN N
none NN N
to TO N
65.6 CD N
% NN N
of IN N
the DT N
first JJ N
year NN N
of IN N
life NN N
and CC N
44.8 CD N
% NN N
of IN N
the DT N
first JJ N
3 CD N
years NNS N
of IN N
life NN N
. . N

241 CD N
children NNS N
persistent JJ N
early-life JJ N
MEE NNP N
-DOCSTART- -X- O O 23343686

University NNP N
Hospital NNP N
. . N

35 CD N
patients NNS N
with IN N
chronic JJ N
stable JJ N
coronary JJ N
artery NN N
disease NN N
. . N

in IN N
patients NNS N
with IN N
chronic JJ N
coronary JJ N
artery NN N
disease NN N
-DOCSTART- -X- O O 3586567

surgery NN N
of IN N
the DT N
thyroid JJ N
gland NN N
. . N

76 CD 3_p
consecutive JJ N
patients NNS N
who WP N
came VBD N
for IN N
scheduled VBN N
thyroid NN 4_p
surgery NN N
. . N

patients NNS N
in IN N
the DT N
treatment NN N
group NN N
( ( N
n JJ N
= NNP N
39 CD N
) ) N
and CC N
control NN N
group NN N
( ( N
n JJ N
= NNP N
37 CD N
) ) N
-DOCSTART- -X- O O 3114351

angina JJ 4_p
pectoris NN 4_p
: : N
12 CD 3_p
patients NNS N
with IN N
chronic JJ N
stable JJ N
angina NN N
receiving VBG N
treatment NN N
with IN N
beta-adrenergic JJ N
blocking NN N
or CC N
calcium NN N
channel NNS N
blocking VBG N
agents NNS N
. . N

-DOCSTART- -X- O O 19660462

Norfloxacin NNP N
modulates VBZ N
the DT N
inflammatory JJ N
response NN N
and CC N
directly RB N
affects VBZ N
neutrophils NNS N
in IN N
patients NNS N
with IN N
decompensated JJ 4_p
cirrhosis NN 4_p
. . N

Patients NNPS N
with IN N
cirrhosis NN 4_p
undergoing VBG N
selective JJ N
intestinal JJ N
decontamination NN N
with IN N
norfloxacin JJ N
Thirty-one CD 3_p
patients NNS N
with IN N
cirrhosis NN 4_p
receiving VBG N
norfloxacin NN N
( ( N
400 CD N
mg/day NN N
) ) N
were VBD N
included VBN N
. . N

Fifty-nine JJ N
ascitic JJ N
fluid NN N
samples NNS N
patients NNS N
with IN N
cirrhosis NN 4_p
. . N

-DOCSTART- -X- O O 17852958

the DT N
elderly JJ 1_p
visually RB 4_p
impaired VBN 4_p
. . N

the DT N
elderly JJ N
with IN N
age-related JJ 4_p
macular JJ 4_p
degeneration NN 4_p
A DT N
total NN N
of IN N
229 CD 3_p
persons NNS N
were VBD N
randomized VBN N
to TO N
the DT N
study NN N
elderly JJ N
with IN N
decreased JJ N
vision NN N
-DOCSTART- -X- O O 20061334

acromegalic JJ 4_p
patients NNS 4_p
with IN 4_p
macroadenomas JJ 4_p
newly RB 4_p
diagnosed VBN 4_p
acromegalic JJ 4_p
patients NNS 4_p
with IN 4_p
macroadenomas NN 4_p
. . N

pool NN N
of IN N
108 CD 3_p
patients NNS 3_p
49 CD 3_p
patients NNS 3_p
in IN 3_p
each DT 3_p
group NN 3_p
patients NNS 4_p
with IN 4_p
GH-secreting NNP 4_p
pituitary JJ 4_p
macroadenomas NN 4_p
. . N

-DOCSTART- -X- O O 19407805

subjects NNS N
with IN N
prehypertension NN N
. . N

untreated JJ N
hypertensive JJ N
patients NNS N
and CC N
high-risk JJ N
pregnant JJ N
women NNS N
. . N

prehypertension NN N
. . N

244 CD N
subjects NNS N
with IN N
prehypertension NN N
, , N
43.0 CD N
+/- JJ N
13.0 CD N
years NNS N
of IN N
age NN N
prehypertensive JJ N
subjects NNS N
. . N

subjects NNS N
at IN N
elevated JJ N
risk NN N
of IN N
developing VBG N
hypertension NN N
. . N

-DOCSTART- -X- O O 21260940

overactive JJ 4_p
bladder NN 4_p
in IN 4_p
females NNS 4_p
: : 4_p
-DOCSTART- -X- O O 15816586

patients NNS N
Seventy-five JJ N
patients NNS N
undergoing VBG N
open JJ N
hernia NN N
repair NN N
as IN N
day NN N
care NN N
surgery NN N
-DOCSTART- -X- O O 15013543

orthognathic JJ 4_p
surgery NN N
. . N

temporomandibular JJ 4_p
joint NN 4_p
( ( 4_p
TMJ NNP 4_p
) ) 4_p
after IN N
bilateral JJ 4_p
sagittal JJ 4_p
split NN 4_p
osteotomy NN 4_p
of IN N
the DT N
mandible JJ N
for IN N
orthognathic JJ 4_p
surgery NN N
A NNP N
total NN N
of IN N
28 CD 3_p
patients NNS N
with IN N
mandibular JJ 4_p
retrognathism NN 4_p
had VBD N
bilateral JJ 4_p
sagittal JJ 4_p
split NN 4_p
osteotomies NNS 4_p
for IN N
mandibular JJ N
advancement NN N
. . N

14 CD 3_p
patients NNS N
( ( N
28 CD 3_p
TMJ NNP 4_p
) ) N
15/28 CD 3_p
TMJs NNP 4_p
( ( N
54 CD N
% NN N
) ) N
that WDT N
had VBD N
not RB N
been VBN N
positioned VBN N
changed VBD N
28 CD 3_p
that WDT N
had VBD N
been VBN N
positioned VBN N
, , N
changes NNS N
were VBD N
found VBN N
in IN N
only RB N
3 CD 3_p
TMJs NNP 4_p
( ( N
11 CD N
% NN N
) ) N
postoperatively RB N
. . N

-DOCSTART- -X- O O 21892106

patients NNS 4_p
with IN 4_p
non-small JJ 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
not RB 4_p
suitable JJ 4_p
for IN 4_p
curative JJ 4_p
therapy NN 4_p
: : 4_p
Patients NNPS 1_p
were VBD 1_p
eligible JJ 1_p
if IN 1_p
they PRP 1_p
had VBD 1_p
stage VBN 1_p
I-IIIB NNP 1_p
NSCLC NNP 1_p
, , 1_p
unsuitable JJ 1_p
for IN 1_p
curative JJ 1_p
therapy NN 1_p
, , 1_p
or CC 1_p
stage NN 1_p
IV NNP 1_p
with IN 1_p
a DT 1_p
PET-detected JJ 1_p
extracranial JJ 1_p
solitary JJ 1_p
metastasis NN 1_p
. . 1_p

Eighty-four JJ 1_p
patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
. . 1_p

-DOCSTART- -X- O O 16562630

muscle NN 4_p
fatigue NN 4_p
. . N

Seven NNP 3_p
paraplegic JJ N
subjects NNS N
participated VBN N
-DOCSTART- -X- O O 24662947

patients NNS 4_p
with IN 4_p
advanced JJ 4_p
head NN 4_p
and CC 4_p
neck NN 4_p
carcinoma NN 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
advanced JJ 4_p
head NN 4_p
and CC 4_p
neck NN 4_p
squamous JJ 4_p
cell NN 4_p
carcinoma NN 4_p
or CC 4_p
nasopharyngeal JJ 4_p
carcinoma NN 4_p
. . 4_p

Patients NNS 4_p
with IN 4_p
locally RB 4_p
advanced JJ 4_p
or CC 4_p
metastatic JJ 4_p
head NN 4_p
and CC 4_p
neck NN 4_p
squamous JJ 4_p
cell NN 4_p
carcinoma NN 4_p
or CC 4_p
nasopharyngeal JJ 4_p
carcinoma NN 4_p
not RB 4_p
suitable JJ 4_p
for IN 4_p
operation NN 4_p
or CC 4_p
radiotherapy NN 4_p
One CD 3_p
hundred CD 3_p
and CC 3_p
thirty-six JJ 3_p
eligible JJ N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
. . N

patients NNS 4_p
with IN 4_p
advanced JJ 4_p
head NN 4_p
and CC 4_p
neck NN 4_p
squamous JJ 4_p
cell NN 4_p
carcinoma NN 4_p
or CC 4_p
nasopharyngeal JJ 4_p
carcinoma NN 4_p
. . 4_p

-DOCSTART- -X- O O 11414348

adolescent JJ 1_p
adolescents NNS 1_p
who WP N
receive VBP N
treatment NN N
for IN N
alcohol NN 4_p
and CC 4_p
drug NN 4_p
problems NNS 4_p
. . N

A NNP N
cohort NN N
of IN N
youth NN 1_p
( ( N
N NNP N
= NNP N
162 CD 3_p
, , N
60 CD N
% NN N
male NN N
) ) N
treated VBD N
during IN N
adolescence NN 1_p
( ( N
mean JJ N
age NN N
= VBD N
16 CD 1_p
years NNS 1_p
) ) 1_p
was VBD N
followed VBN N
into IN N
young JJ 1_p
adulthood NN 1_p
Participants NNS N
( ( N
14-18 CD 1_p
years NNS 1_p
old JJ 1_p
) ) N
were VBD N
consecutive JJ N
admissions NNS N
to TO N
inpatient VB N
adolescent JJ N
alcohol NN N
and CC N
drug NN N
treatment NN N
centers NNS N
in IN N
San NNP N
Diego NNP N
that WDT N
were VBD N
abstinence NN N
focused VBN N
and CC N
based VBN N
on IN N
the DT N
12-step JJ N
approach NN N
. . N

-DOCSTART- -X- O O 1730427

Stage NN 4_p
II NNP 4_p
carcinoma NN 4_p
of IN 4_p
the DT 4_p
ovary JJ 4_p
: : N
Ninety-three JJ 3_p
women NNS 2_p
with IN N
FIGO NNP 4_p
stage NN 4_p
II NNP 4_p
epithelial JJ 4_p
ovarian JJ 4_p
carcinoma NN 4_p
forty-five JJ 3_p
women NNS 2_p
treated VBN N
with IN N
melphalan NN N
forty-eight JJ 3_p
women NNS 2_p
treated VBN 4_p
with IN 4_p
intraperitoneal JJ 4_p
phosphorus NN 4_p
-DOCSTART- -X- O O 26002536

novices NNS 4_p
Totally RB N
39 CD 3_p
medical JJ N
students NNS N
and CC N
physician JJ N
assistant NN N
students NNS N
novice JJ 4_p
trainee NN 4_p
. . N

-DOCSTART- -X- O O 15468367

osteoarthritis NN 4_p
of IN 4_p
the DT 4_p
knee NN 4_p
: : 4_p
primary JJ N
osteoarthritis NN N
( ( N
OA NNP N
) ) N
of IN N
the DT N
knee NN N
total NN N
of IN N
622 CD N
men NNS N
and CC N
women NNS N
with IN N
radiological JJ N
evidence NN N
of IN N
primary JJ N
knee NN N
OA NNP N
and CC N
mild VB N
to TO N
severe VB N
symptoms NNS N
patients NNS 4_p
with IN 4_p
OA NNP 4_p
-DOCSTART- -X- O O 11783270

56 CD 3_p
old JJ 1_p
subjects NNS N
randomized VBN N
into IN N
3 CD N
groups NNS N
. . N

-DOCSTART- -X- O O 24324379

children NNS 1_p
with IN N
autism NN 4_p
. . N

children NNS 1_p
with IN N
autism NN 4_p
. . N

children NNS 1_p
with IN N
autism NN 4_p
Four CD 3_p
children NNS 1_p
with IN N
autism NN 4_p
children NNS 1_p
children NNS 1_p
-DOCSTART- -X- O O 3030386

hypertensive JJ 4_p
patients NNS 4_p
treated VBN N
with IN N
bendrofluazide NN N
. . N

hypertensive JJ 4_p
patients NNS N
on IN N
treatment NN N
with IN N
a DT N
diuretic JJ N
. . N

13 CD 3_p
hypertensive JJ N
patients NNS N
on IN N
treatment NN N
with IN N
bendrofluazide JJ N
5 CD N
mg JJ N
daily RB N
hypertensive JJ N
patients NNS N
receiving VBG N
treatment NN N
with IN N
diuretics NNS N
-DOCSTART- -X- O O 2286596

hospitalized JJ N
patients NNS N
with IN N
lower JJR N
respiratory NN N
tract JJ N
infections NNS N
. . N

121 CD N
patients NNS N
was VBD N
studied VBN N
; : N
92 CD N
were VBD N
clinically RB N
evaluable JJ N
. . N

59 CD N
patients NNS N
were VBD N
treated VBN N
with IN N
ofloxacin NN N
and CC N
33 CD N
with IN N
the DT N
comparator NN N
drug NN N
. . N

-DOCSTART- -X- O O 347921

IPPB NNP N
for IN N
the DT N
treatment NN N
of IN N
croup NN 4_p
: : N
Twenty CD 3_p
patients NNS 3_p
( ( N
aged VBN 1_p
4 CD 1_p
months NNS 1_p
to TO 1_p
5 CD 1_p
years NNS 1_p
) ) N
hospitalized VBD N
with IN N
acute JJ N
croup NN N
and CC N
persistent JJ N
inspiratory NN N
stridor NN N
at IN N
rest NN N
acute JJ N
signs NNS N
of IN N
croup NN 4_p
. . N

-DOCSTART- -X- O O 23865673

from IN N
160 CD 3_p
pregnant JJ N
women NNS 2_p
attending VBG N
high-risk JJ 4_p
maternity NN 4_p
clinics NNS N
at IN N
a DT N
tertiary JJ N
care NN N
facility NN N
-DOCSTART- -X- O O 22690882

web-based JJ N
tailored JJ N
smoking NN 4_p
cessation NN 4_p
advice NN N
reports NNS N
Participants NNS N
were VBD N
allocated VBN N
randomly RB N
to TO N
one CD N
of IN N
two CD N
groups NNS N
Participants NNS N
( ( N
n IN N
= NNP N
1758 CD N
) ) N
were VBD N
visitors NNS N
to TO N
the DT N
QUIT NNP N
website NN N
who WP N
were VBD N
based VBN N
in IN N
the DT N
United NNP N
Kingdom NNP N
, , N
aged VBD N
18 CD N
years NNS N
or CC N
over RB N
and CC N
who WP N
smoked VBD N
cigarettes NNS N
or CC N
hand-rolled JJ N
tobacco NN N
The DT N
intervention NN N
group NN N
the DT N
control NN N
group NN N
outcomes NNS N
. . N

Intervention NN N
participants NNS N
materials NNS N
than IN N
control NN N
participants NNS N
-DOCSTART- -X- O O 10649829

adult NN 1_p
autistic JJ 4_p
disorder NN 4_p
. . N

repetitive JJ N
behaviors NNS N
in IN N
adult NN 1_p
autistic JJ 4_p
patients NNS N
. . N

Eleven NNP 3_p
adult NN 1_p
patients NNS N
with IN N
autism NN 4_p
or CC N
Asperger NNP 4_p
's POS 4_p
disorder NN 4_p
were VBD N
randomized VBN N
-DOCSTART- -X- O O 16329017

12 CD 2_p
endoscopy NN 2_p
trainees NNS 2_p
, , 2_p
10 CD 2_p
surgeons NNS 2_p
and CC 2_p
two CD 2_p
medical JJ 2_p
gastroenterologists NNS 2_p
, , 2_p
all DT 2_p
with IN 2_p
experience NN 2_p
in IN 2_p
gastroscopy NN 2_p
but CC 2_p
with IN 2_p
no DT 2_p
specific JJ 2_p
colonoscopy NN 2_p
experience NN 2_p
-DOCSTART- -X- O O 19207781

atrial JJ 4_p
fibrillation NN 4_p
( ( 4_p
AF NNP 4_p
) ) 4_p
ablation NN 4_p
. . N

One CD 3_p
hundred VBD 3_p
seventy-five JJ 3_p
patients NNS 3_p
, , N
57.1 CD N
% NN N
paroxysmal JJ N
AF NNP N
, , N
78.5 CD N
% NN N
male NN 2_p
, , N
underwent JJ N
AF NNP 4_p
ablation NN 4_p
and CC 4_p
esophagoscopy $ 4_p
24 CD N
hours NNS N
thereafter RB N
. . N

-DOCSTART- -X- O O 2885887

Noradrenergic NNP N
mechanisms NNS N
in IN N
akathisia NN 4_p
: : N
treatment NN N
with IN N
propranolol NN 4_p
and CC 4_p
clonidine NN 4_p
. . N

-DOCSTART- -X- O O 20504165

HIV-infected NNP N
adults NNS N
with IN N
a DT N
toll-like JJ N
receptor NN N
9 CD N
agonist NN N
adjuvant NN N
: : N
Persons NNP N
infected VBD N
with IN N
human JJ N
immunodeficiency NN N
virus NN N
( ( N
HIV NNP N
) ) N
HIV-infected NNP N
adults NNS N
. . N

HIV-positive JJ N
patients NNS N
Ninety-seven JJ N
participants NNS N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 23896590

AHA NNP N
paper NN N
cardiac NN N
arrest NN N
record NN N
. . N

16 CD 3_p
anaesthesiology NN N
residents NNS N
-DOCSTART- -X- O O 11377310

patients NNS N
undergoing JJ N
transurethral JJ 4_p
resection NN 4_p
of IN 4_p
the DT 4_p
prostate NN 4_p
( ( N
TURP NNP 4_p
) ) N
. . N

Fifty-six NNP 3_p
male NN 2_p
patients NNS N
( ( N
mean JJ N
age NN N
71.2 CD 1_p
+/- JJ 1_p
8.2 CD 1_p
years NNS N
) ) N
scheduled VBD N
for IN N
TURP NNP 4_p
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

27 CD 3_p
patients NNS N
29 CD 3_p
patients NNS N
-DOCSTART- -X- O O 17391914

autism NN N
. . N

unfamiliar JJ N
child NN N
with IN N
autism NN N
. . N

Children NNP N
( ( N
N=296 NNP N
; : N
M NNP N
age=10.21 IN N
years NNS N
) ) N
unfamiliar JJ N
child NN N
with IN N
autism NN N
teacher NN 4_p
hypothetical JJ N
mother NN N
hypothetical JJ N
father NN N
hypothetical JJ N
" NNP N
doctor NN N
. . N

" JJ N
Fifth-graders NNS N
-DOCSTART- -X- O O 18588611

150 CD 3_p
nulliparas NNS 4_p
with IN N
a DT N
gestational JJ N
age NN N
of IN N
39-41 JJ N
weeks NNS N
of IN N
pregnancy NN 4_p
and CC N
a DT N
Bishop NNP 4_p
score NN 4_p
of IN 4_p
< NN 4_p
or CC 4_p
=5 NN 4_p
. . N

-DOCSTART- -X- O O 20001837

autistic JJ 4_p
children NNS 1_p
's POS 1_p
behavior NN N
. . N

behavioral JJ N
and CC N
emotional JJ N
disturbances NNS N
in IN N
Thai NNP N
autistic JJ N
children NNS N
. . N

The DT N
study NN N
was VBD N
conducted VBN N
at IN N
the DT N
Rehabilitation NNP N
Centre NNP N
of IN N
the DT N
Thai NNP N
Red NNP N
Cross NNP N
Society NNP N
. . N

A NNP N
total NN N
of IN N
60 CD 3_p
autistic JJ 4_p
children NNS N
between IN N
the DT N
ages NNS N
of IN N
3 CD 1_p
and CC 1_p
10 CD 1_p
completed VBD N
this DT N
study NN N
. . N

Sixty NNP 3_p
( ( 3_p
60 CD 3_p
) ) 3_p
autistic JJ 4_p
children NNS N
, , N
mean JJ N
age NN N
4.67 CD 1_p
+/- JJ 1_p
1.82 CD 1_p
, , N
were VBD N
recruited VBN N
. . N

Thailand NNP N
. . N

-DOCSTART- -X- O O 17967671

pediatric JJ 4_p
cardiac JJ 4_p
patients NNS 4_p
. . 4_p

pediatric JJ N
cardiac JJ N
surgery NN N
. . N

50 CD N
pediatric JJ N
patients NNS N
( ( N
18 CD N
girls NNS N
, , N
32 CD N
boys NNS N
) ) N
, , N
aged VBD N
4 CD N
months NNS N
to TO N
15 CD N
years NNS N
, , N
undergoing VBG N
elective JJ N
repair NN N
of IN N
congenital JJ N
heart NN N
disease NN N
. . N

-DOCSTART- -X- O O 17929164

patients NNS N
with IN N
autistic JJ 4_p
disorder NN 4_p
. . N

About IN N
40 CD 3_p
children NNS 1_p
between IN N
the DT N
ages NNS N
three CD 1_p
and CC 1_p
11 CD 1_p
years NNS 1_p
( ( N
inclusive JJ N
) ) N
with IN N
a DT N
DSM NNP N
IV NNP N
clinical JJ N
diagnosis NN N
of IN N
autism NN 4_p
and CC N
who WP N
were VBD N
outpatients NNS N
from IN N
a DT N
specialty NN N
clinic NN N
for IN N
children NNS 1_p
were VBD N
recruited VBN N
. . N

children NNS 1_p
presented VBN N
with IN N
a DT N
chief JJ N
complaint NN N
of IN N
severely RB N
disruptive JJ N
symptoms NNS N
related VBN N
to TO N
autistic JJ 4_p
disorder NN 4_p
. . N

-DOCSTART- -X- O O 19081412

primary JJ N
stenting NN N
of IN N
totally RB N
occluded JJ 4_p
native JJ 4_p
coronary JJ 4_p
arteries NNS 4_p
: : N
total JJ 4_p
coronary JJ 4_p
occlusions NNS 4_p
patients NNS N
enrolled VBN N
in IN N
the DT N
Primary NNP N
Stenting NNP N
of IN N
Totally NNP 4_p
Occluded NNP 4_p
Native NNP 4_p
Coronary NNP 4_p
Arteries NNP 4_p
II NNP N
study NN N
. . N

Patients NNPS N
with IN N
totally RB 4_p
occluded JJ 4_p
coronary JJ 4_p
arteries NNS 4_p
( ( N
100 CD 3_p
patients NNS N
) ) N
bare-metal JJ N
BxVelocity NNP N
stents NNS N
( ( N
BMSs NNP N
) ) N
( ( N
Cordis NNP N
) ) N
( ( N
100 CD 3_p
patients NNS N
) ) N
-DOCSTART- -X- O O 16181530

patients NNS N
with IN N
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
at IN N
the DT N
stable JJ 4_p
phase NN 4_p
] NNP N
. . N

patients NNS N
with IN N
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
( ( 4_p
COPD NNP 4_p
) ) 4_p
at IN N
the DT N
stable JJ 4_p
phase NN 4_p
. . N

Thirty-six JJ 3_p
patients NNS N
with IN N
COPD NNP 4_p
patients NNS N
with IN N
COPD NNP 4_p
in IN N
the DT N
stable JJ N
phase NN N
. . N

-DOCSTART- -X- O O 16399263

sensory/motor-based JJ N
functional JJ N
knowledge NN N
of IN N
man-made JJ N
objects NNS N
: : N
participants NNS N
Participants NNS 4_p
participants NNS N
' POS N
Participants NNS N
Participants NNS N
-DOCSTART- -X- O O 7205145

radioimmunoassay VB N
. . N

radioimmunoassay NN N
-DOCSTART- -X- O O 9935005

Thirty NNP 3_p
patients NNS 4_p
undergoing VBG 4_p
primary JJ 4_p
ICD NNP 4_p
implantation NN 4_p
or CC 4_p
pulse JJ 4_p
generator NN 4_p
replacement NN 4_p
14 CD 3_p
patients NNS N
-DOCSTART- -X- O O 9601831

myofascial JJ 4_p
pain NN 4_p
dysfunction NN 4_p
( ( N
MPD NNP N
) ) N
10 CD 3_p
patients NNS N
with IN N
MPD NNP 4_p
with IN N
subthreshold JJ N
TENS NNP N
( ( N
frequency NN N
35 CD N
Hz NNP N
, , N
pulse RB N
width VBZ N
100 CD N
milliseconds NNS N
, , N
modulation NN N
50 CD N
% NN N
) ) N
compared VBN N
with IN N
sham NN N
TENS NNP N
at IN N
8 CD N
visits NNS N
over IN N
14 CD N
weeks NNS N
. . N

-DOCSTART- -X- O O 1622739

patients NNS 4_p
with IN 4_p
advanced JJ 4_p
cancer NN 4_p
. . 4_p

Eighteen JJ 4_p
patients NNS 4_p
of IN 4_p
colorectal JJ 4_p
cancer NN 4_p
with IN 4_p
metastases NNS 4_p
to TO 4_p
the DT 4_p
liver NN 4_p
or CC 4_p
lung NN 4_p
or CC 4_p
of IN 4_p
unresectable JJ 4_p
hepatoma NN 4_p
Of IN 4_p
18 CD 4_p
patients NNS 4_p
12 CD 4_p
were VBD 4_p
evaluable JJ 4_p
for IN 4_p
their PRP$ 4_p
response NN 4_p
to TO 4_p
therapy NN 4_p
. . 4_p

-DOCSTART- -X- O O 8069156

asthma NN 4_p
and CC 4_p
bronchitis NN 4_p
. . N

-DOCSTART- -X- O O 9493479

healthy JJ 4_p
volunteers NNS 4_p
with IN 4_p
neurasthenic JJ 4_p
complaints NNS 4_p
. . 4_p

Sixty-four CD 3_p
healthy JJ 3_p
volunteers NNS 3_p
( ( N
aged VBN 1_p
40 CD 1_p
to TO 1_p
65 CD 1_p
years NNS 1_p
) ) 1_p
, , N
selected VBN N
on IN N
the DT N
basis NN N
of IN N
fulfilling VBG N
the DT N
ICD-10 NNP N
F48.0 NNP N
criteria NNS 4_p
for IN 4_p
neurasthenia NN 4_p
-DOCSTART- -X- O O 19681862

discoid JJ 4_p
lupus NN 4_p
erythematosus NN 4_p
. . 4_p

patients NNS N
with IN N
therapy-resistant JJ N
discoid NN N
lupus NN N
erythematosus NN N
( ( N
DLE NNP N
) ) N
. . N

Thirty-seven JJ N
patients NNS N
with IN N
at IN N
least JJS N
one CD N
newly RB N
developed VBN N
DLE NNP N
lesion NN N
-DOCSTART- -X- O O 23385110

older JJR 1_p
adults NNS 1_p
: : N
older JJR 1_p
adults NNS 1_p
who WP N
are VBP N
inexperienced VBN 4_p
wheelchair JJ 4_p
users NNS 4_p
. . N

Participants NNS N
( ( N
N=20 NNP 3_p
) ) N
who WP N
were VBD N
community-living JJ N
older JJR 1_p
adults NNS 1_p
at IN 1_p
least JJS 1_p
65 CD 1_p
years NNS 1_p
old JJ 1_p
( ( N
mean JJ N
age NN N
, , N
70y CD 1_p
) ) N
, , N
50 CD N
% NN N
women NNS 2_p
, , N
and CC N
who WP N
had VBD N
no DT N
experience NN N
of IN N
using VBG N
a DT N
wheelchair NN N
among IN N
older JJR N
adults NNS N
who WP N
are VBP N
inexperienced VBN N
wheelchair JJ N
users NNS N
-DOCSTART- -X- O O 10555930

airway NN N
responses NNS N
to TO N
allergen VB N
. . N

airway NN N
responses NNS N
to TO N
inhaled VB N
allergen NN N
. . N

Eight NNP 3_p
male NN 2_p
volunteers NNS N
with IN N
allergic JJ 4_p
asthma NN 4_p
. . N

-DOCSTART- -X- O O 7726441

gynecologic JJ 4_p
surgery NN 4_p
. . 4_p

recovery NN 4_p
from IN 4_p
anesthesia NN 4_p
. . 4_p

120 CD 4_p
female JJ 4_p
patients NNS 4_p
( ( 4_p
ASA NNP 4_p
physical JJ 4_p
status NN 4_p
I PRP 4_p
) ) 4_p
undergoing VBG 4_p
gynecologic JJ 4_p
surgery NN 4_p
. . 4_p

-DOCSTART- -X- O O 3519095

healthy JJ 4_p
subjects NNS N
. . N

10 CD 3_p
adult NN 1_p
healthy JJ 4_p
subjects NNS N
-DOCSTART- -X- O O 7285032

essential JJ 4_p
arterial JJ 4_p
hypertension NN 4_p
; : 4_p
prazosin NN 4_p
in IN 4_p
comparison NN 4_p
with IN 4_p
propranolol JJ 4_p
] NN N
-DOCSTART- -X- O O 8033763

drug NN 4_p
preferences NNS 4_p
: : N
normal JJ 4_p
volunteers NNS N
'non-choosers NNS N
' POS N
never RB N
chose JJ N
drug NN N
, , N
whereas IN N
'choosers NNS N
' POS N
always RB N
chose JJ N
drug NN N
. . N

males NNS 2_p
and/or IN N
full-time JJ N
students NNS N
-DOCSTART- -X- O O 2808984

10 CD 3_p
consecutive JJ N
patients NNS N
with IN N
a DT N
minute NN N
ventilation-sensing NN N
, , N
rate-modulating JJ N
ventricular JJ N
pacemaker NN N
implanted VBN N
for IN N
complete JJ N
heart NN N
block NN N
. . N

All DT N
patients NNS N
had VBD N
paroxysmal JJ 4_p
( ( N
seven CD 3_p
patients NNS N
) ) N
or CC N
chronic JJ N
( ( N
three CD 3_p
patients NNS N
) ) N
atrial JJ 4_p
fibrillation NN 4_p
and CC N
were VBD N
referred VBN N
for IN N
catheter JJR N
ablation NN N
of IN N
the DT N
atrioventricular JJ N
junction NN N
. . N

-DOCSTART- -X- O O 8126502

patients NNS N
with IN N
Parkinson NNP 4_p
's POS 4_p
disease NN 4_p
. . N

12 CD N
patients NNS N
with IN N
Parkinson NNP 4_p
's POS 4_p
disease NN 4_p
and CC N
motor NN 4_p
fluctuations NNS 4_p
-DOCSTART- -X- O O 22968615

infectious JJ 4_p
and CC 4_p
inflammatory JJ 4_p
complications NNS 4_p
after IN N
oral JJ 4_p
surgery NN 4_p
procedures NNS N
] VBP N
prevention NN N
and CC N
treatment NN N
of IN N
infectious JJ N
and CC N
inflammatory JJ N
complications NNS N
after IN N
oral JJ N
surgery NN N
procedures NNS N
. . N

outpatient JJ N
-DOCSTART- -X- O O 12437457

of IN N
multiple JJ 4_p
actinic JJ 4_p
keratoses NNS 4_p
. . N

A DT N
specialized JJ N
outpatient NN N
dermatology NN N
clinic NN N
within IN N
a DT N
state-funded JJ N
hospital NN N
in IN N
Germany NNP N
. . N

PATIENTS VB N
The DT N
study NN N
population NN N
was VBD N
aged VBN N
45 CD 1_p
to TO 1_p
85 CD 1_p
years NNS N
. . N

Of IN N
52 CD 3_p
patients NNS N
screened VBD N
, , N
36 CD N
men NNS 2_p
and CC 2_p
women NNS 2_p
with IN N
AK NNP N
confirmed VBN N
by IN N
histological JJ N
diagnosis NN N
were VBD N
enrolled VBN N
. . N

Patients NNS N
were VBD N
excluded VBN N
from IN N
the DT N
study NN N
if IN N
they PRP N
did VBD N
not RB N
have VB N
a DT N
histological JJ N
diagnosis NN N
for IN N
AK NNP N
, , N
if IN N
they PRP N
were VBD N
older JJR N
than IN N
85 CD N
years NNS N
, , N
or CC N
if IN N
they PRP N
did VBD N
not RB N
comply VB N
with IN N
the DT N
protocol NN N
. . N

All DT N
patients NNS N
had VBD N
responded VBN N
to TO N
a DT N
notice NN N
asking VBG N
for IN N
volunteers NNS N
. . N

by IN N
patients NNS N
treated VBN N
with IN N
imiquimod NN N
-DOCSTART- -X- O O 23524367

24 CD 3_p
healthy JJ N
students NNS N
( ( N
17 CD 3_p
men NNS 2_p
and CC N
7 CD 3_p
women NNS 2_p
) ) N
who WP N
stretched VBD 4_p
their PRP$ 4_p
right JJ 4_p
hamstrings NNS 4_p
for IN N
durations NNS N
of IN N
20 CD N
, , N
60 CD N
-DOCSTART- -X- O O 17623816

patients NNS N
with IN N
coronary JJ N
artery NN N
disease NN N
and CC N
normal JJ N
glucose JJ N
tolerance NN N
. . N

patients NNS 4_p
with IN 4_p
documented JJ 4_p
stable JJ 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
and CC 4_p
normal JJ 4_p
glucose JJ 4_p
tolerance NN 4_p
. . 4_p

54 CD 4_p
patients NNS 4_p
with IN 4_p
normal JJ 4_p
fasting VBG 4_p
glucose JJ 4_p
levels NNS 4_p
, , 4_p
18 CD 4_p
showed VBD 4_p
impaired JJ 4_p
glucose JJ 4_p
tolerance NN 4_p
and CC 4_p
36 CD 4_p
patients NNS 4_p
with IN 4_p
normal JJ 4_p
glucose JJ 4_p
tolerance NN 4_p
were VBD 4_p
randomized VBN 4_p
patients NNS N
with IN N
coronary JJ N
artery NN N
disease NN N
. . N

normoglycemic JJ 4_p
individuals NNS 4_p
with IN 4_p
stable JJ 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
. . 4_p

-DOCSTART- -X- O O 7865492

patients NNS N
with IN N
duodenal JJ 4_p
ulcer NN 4_p
( ( 4_p
Du NNP 4_p
) ) 4_p
upon IN N
190 CD 3_p
patients NNS N
with IN N
DU NNP 4_p
. . N

Seventy NNP 3_p
three CD 3_p
patients NNS N
two CD N
groups NNS N
31 CD 3_p
patients NNS N
42 CD 3_p
patients NNS N
with IN N
H. NNP 4_p
pylori FW 4_p
patients NNS N
with IN N
DU NNP 4_p
-DOCSTART- -X- O O 5575706

bursitis NN 4_p
and CC 4_p
other JJ 4_p
foot NN 4_p
disorders NNS 4_p
. . 4_p

-DOCSTART- -X- O O 21304253

patients NNS N
with IN N
overactive JJ 4_p
bladder NN 4_p
associated VBN 4_p
with IN 4_p
benign JJ 4_p
prostatic JJ 4_p
hyperplasia NN 4_p
: : N
total NN N
of IN N
100 CD 3_p
patients NNS N
with IN N
benign JJ 4_p
prostatic JJ 4_p
hyperplasia NN 4_p
( ( 4_p
BPH NNP 4_p
) ) 4_p
and CC 4_p
overactive JJ 4_p
bladder NN 4_p
( ( 4_p
OAB NNP 4_p
) ) 4_p
symptoms NNS 4_p
( ( N
BPH/OAB NNP 4_p
) ) N
, , N
enrolled VBN N
between IN N
June NNP N
2006 CD N
to TO N
March NNP N
2008 CD N
-DOCSTART- -X- O O 20113305

women NNS 4_p
with IN 4_p
borderline JJ 4_p
personality NN 4_p
disorder NN 4_p
. . 4_p

women NNS 4_p
meeting VBG 4_p
criteria NNS 4_p
for IN 4_p
borderline NN 4_p
personality NN 4_p
disorder NN 4_p
( ( 4_p
BPD NNP 4_p
) ) 4_p
. . 4_p

73 CD N
female JJ N
subjects NNS N
meeting VBG N
criteria NNS N
for IN N
BPD NNP N
-DOCSTART- -X- O O 9322632

Two CD 3_p
hundred VBD 3_p
patients NNS 3_p
with IN N
indications NNS 4_p
for IN 4_p
induction NN 4_p
of IN 4_p
labor NN 4_p
and CC 4_p
unfavorable JJ 4_p
cervical JJ 4_p
examinations NNS 4_p
Of IN N
the DT N
200 CD 3_p
patients NNS N
enrolled VBD N
, , N
99 CD 3_p
were VBD N
randomized VBN N
to TO N
misoprostol VB 3_p
and CC N
101 CD 3_p
to TO N
dinoprostone VB 3_p
. . N

38 CD N
patients NNS N
( ( N
19.3 CD N
% NN N
) ) N
had VBD N
cesarean JJ 4_p
deliveries NNS 4_p
. . N

-DOCSTART- -X- O O 18704672

children NNS 1_p
diagnosed VBN 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
individuals NNS N
diagnosed VBN N
with IN N
autism NN 4_p
45 CD 3_p
children NNS 1_p
diagnosed VBN N
with IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorder NNP 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
ages VBZ N
7-14 CD 1_p
-DOCSTART- -X- O O 23619951

higher-functioning JJ N
autism NN N
adolescent JJ N
boys NNS N
. . N

higher-functioning JJ N
autism NN N
adolescent VB N
boys NNS N
Participants NNS N
were VBD N
seventh- JJ N
, , N
eighth- JJ N
and CC N
ninth-grade JJ N
students NNS N
( ( N
N NNP N
= NNP N
395 CD N
) ) N
from IN N
regular JJ N
classes NNS N
in IN N
a DT N
mainstream JJ N
school NN N
. . N

Two-eighth-grade JJ N
classes NNS N
for IN N
adolescent NN N
students NNS N
in IN N
inclusive JJ N
educational JJ N
environments NNS N
-DOCSTART- -X- O O 9170524

colorectal JJ 4_p
cancer NN 4_p
] NNP N
26 CD 3_p
cases NNS N
composed VBN N
of IN N
11 CD 3_p
cases NNS N
of IN N
arm NN N
A NNP N
and CC N
15 CD 3_p
cases NNS N
of IN N
arm NN N
B NNP N
advanced JJ 4_p
colorectal JJ 4_p
carcinoma NN 4_p
. . 4_p

-DOCSTART- -X- O O 18067498

prospective JJ 4_p
blood NN 4_p
donors NNS 4_p
: : N
Participants NNS N
were VBD N
randomly RB N
assigned VBN N
-DOCSTART- -X- O O 2195532

bronchial JJ N
provocation NN N
with IN N
methacholine JJ N
] NN N
A DT N
bronchial JJ N
provocation NN N
challenge NN N
test NN N
was VBD N
conducted VBN N
with IN N
30 CD 3_p
subjects NNS 4_p
using VBG N
metacholin NN N
. . N

-DOCSTART- -X- O O 7699494

patient-controlled JJ 4_p
sedation NN 4_p
with IN 4_p
midazolam NN 4_p
. . 4_p

26 CD 3_p
patients NNS N
undergoing JJ N
bilateral JJ 4_p
lower JJR 4_p
third JJ 4_p
molar JJ 4_p
surgery NN 4_p
at IN N
two CD N
visits NNS N
-DOCSTART- -X- O O 25256627

children NNS 1_p
with IN N
an DT N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
: : N
People NNPS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
( ( 4_p
ASDs NNP 4_p
) ) 4_p
children NNS 1_p
with IN N
ASD NNP 4_p
. . N

children NNS 1_p
with IN N
ASD NNP 4_p
( ( N
n JJ N
= NN N
121 CD 3_p
, , N
8-12 CD 1_p
years NNS 1_p
, , N
IQ NNP N
> NNP N
80 CD N
) ) N
children NNS N
with IN N
ASD NNP 4_p
. . N

-DOCSTART- -X- O O 6756508

postmenopausal JJ 4_p
women NNS 2_p
with IN N
advanced JJ 4_p
breast NN 4_p
cancer NN 4_p
. . N

Eighty-eight JJ 3_p
postmenopausal JJ N
women NNS N
with IN N
metastatic JJ N
breast NN N
cancer NN N
, , N
in IN N
whom WP N
estrogen NN 4_p
receptors NNS 4_p
( ( 4_p
ER NNP 4_p
) ) 4_p
were VBD 4_p
positive JJ 4_p
or CC 4_p
unknown JJ 4_p
Patients NNS N
with IN N
known JJ N
ER NNP N
negative JJ N
status NN N
were VBD N
not RB N
studied VBN N
. . N

postmenopausal NN N
patients NNS N
with IN N
advanced JJ N
breast NN N
cancer NN N
. . N

-DOCSTART- -X- O O 15591456

colon NN 4_p
carcinoma NN 4_p
patients NNS 4_p
233 CD 3_p
colon NN 4_p
cancer NN 4_p
specimens NNS N
from IN N
patients NNS N
who WP N
were VBD N
registered VBN N
in IN N
a DT N
prospective JJ N
adjuvant NN N
immunochemotherapy NN N
clinical JJ N
trial NN N
. . N

-DOCSTART- -X- O O 19948568

toddlers NNS 1_p
with IN N
autism NN 4_p
: : N
toddlers NNS 1_p
diagnosed VBN N
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
. . N

Forty-eight JJ 3_p
children NNS 1_p
diagnosed VBN N
with IN N
ASD NNP 4_p
between IN N
18 CD 1_p
and CC 1_p
30 CD 1_p
months NNS 1_p
of IN 1_p
age NN 1_p
toddlers NNS 1_p
with IN N
ASD NNP 4_p
-DOCSTART- -X- O O 11472320

patients NNS N
with IN N
non-ulcer JJ 4_p
dyspepsia NN 4_p
. . N

non-ulcer JJ 4_p
dyspepsia NN 4_p
patients NNS N
. . N

129 CD 3_p
H. NNP N
pylori NN 4_p
infected VBD 4_p
patients NNS N
with IN N
severe JJ 4_p
epigastric JJ 4_p
pain NN 4_p
, , N
without IN 4_p
gastro-oesophageal JJ 4_p
reflux NN 4_p
symptoms NNS N
124 CD 3_p
such JJ N
patients NNS N
to TO N
receive VB N
identical-appearing JJ N
placebos NNS N
. . N

non-infected JJ 4_p
patients NNS N
patients NNS N
with IN N
non-ulcer JJ 4_p
dyspepsia NN 4_p
H. NNP N
pylori-infected JJ 4_p
patients NNS N
-DOCSTART- -X- O O 24352377

autism NN 4_p
individuals NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
( ( 4_p
ASD NNP 4_p
) ) N
University NNP N
of IN N
Tokyo NNP N
Hospital NNP N
total NN 3_p
of IN 3_p
40 CD 3_p
highly RB N
functioning VBG N
men NNS 2_p
with IN N
ASD NNP N
-DOCSTART- -X- O O 21142736

35 CD 4_p
women NNS 4_p
with IN 4_p
axillary JJ 4_p
hair NN 4_p
-DOCSTART- -X- O O 11837240

Pacifier NNP N
as IN N
a DT N
risk NN N
factor NN N
for IN N
acute NN 4_p
otitis NN 4_p
media NNS 4_p
. . N

-DOCSTART- -X- O O 19701647

normal JJ N
humans NNS N
. . N

11 CD 3_p
healthy JJ 3_p
subjects NNS 3_p
. . N

healthy JJ 4_p
humans NNS 4_p
-DOCSTART- -X- O O 18684258

atrial JJ 4_p
fibrillation NN 4_p
: : N
patients NNS N
with IN N
AF NNP N
. . N

Patients NNS 4_p
with IN 4_p
persistent JJ 4_p
AF NNP 4_p
or CC 4_p
AF NNP 4_p
induced VBD 4_p
during IN 4_p
a DT 4_p
routine JJ 4_p
electrophysiology NN 4_p
study NN 4_p
( ( N
EPS NNP N
) ) N
patients NNS N
with IN N
induced JJ N
AF NNP N
AF NNP N
in IN N
patients NNS N
-DOCSTART- -X- O O 9349928

heart NN 4_p
transplant NN 4_p
recipients NNS 4_p
. . 4_p

heart-transplant JJ N
recipients NNS N
. . N

Twenty NNP 3_p
heart-transplant JJ N
recipients NNS N
were VBD N
randomised VBN N
into IN N
either CC N
a DT N
treated JJ N
or CC N
a DT N
placebo NN N
group NN N
. . N

one CD N
patient NN N
in IN N
the DT N
ticlopidine NN N
group NN N
was VBD N
withdrawn VBN N
because IN N
of IN N
a DT N
major JJ N
fall NN N
in IN N
cyclosporin JJ N
blood NN N
level NN N
within IN N
3 CD N
days NNS N
of IN N
treatment NN N
. . N

-DOCSTART- -X- O O 7134226

in IN N
12 CD 3_p
patients NNS N
with IN N
atherosclerotic JJ 4_p
disease NN 4_p
-DOCSTART- -X- O O 3076138

arterial JJ 4_p
hypertension NN 4_p
. . 4_p

-DOCSTART- -X- O O 3962622

eye NN N
surgery NN N
. . N

105 CD 3_p
patients NNS N
admitted VBN N
for IN N
cataract NN 4_p
surgery NN N
control NN N
group NN N
( ( N
n JJ N
= NNP N
99 CD 3_p
) ) N
-DOCSTART- -X- O O 2698934

crossover NN 4_p
multicentre NN 4_p
study NN 4_p
. . 4_p

66 CD 4_p
uncomplicated JJ 4_p
essential JJ 4_p
hypertensives NNS 4_p
, , 4_p
with IN 4_p
diastolic JJ 4_p
blood NN 4_p
pressure NN 4_p
of IN 4_p
greater JJR 4_p
than IN 4_p
100 CD 4_p
and CC 4_p
less JJR 4_p
than IN 4_p
115 CD 4_p
mmHg NN 4_p
. . 4_p

uncomplicated JJ N
essential JJ N
hypertensives NNS N
. . N

-DOCSTART- -X- O O 12067044

low-fat JJ 4_p
( ( 4_p
20 CD 4_p
% NN 4_p
energy NN 4_p
) ) 4_p
dietary JJ 4_p
pattern NN 4_p
Data NNP N
from IN N
13,277 CD 3_p
postmenopausal JJ 4_p
women NNS 2_p
randomly RB N
assigned VBN N
to TO N
the DT N
low-fat JJ N
intervention NN N
arm NN N
of IN N
the DT N
Women NNP 2_p
's POS N
Health NNP N
Initiative NNP N
Dietary NNP N
Modification NNP N
Trial NNP N
. . N

Year NNP N
1 CD N
program NN N
participation NN N
( ( N
degree NN N
of IN N
attending VBG N
group NN N
sessions NNS N
and CC N
submitting VBG N
fat JJ N
scores NNS N
) ) N
and CC N
adherence NN N
to TO N
the DT N
low-fat JJ N
dietary JJ N
pattern NN N
-DOCSTART- -X- O O 21552085

young JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . N

young JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . N

young JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . N

-DOCSTART- -X- O O 9796041

pertussis NN 4_p
vaccine NN 4_p
efficacy NN 4_p
trial NN 4_p
in IN 4_p
Germany NNP 4_p
DT NNP N
vaccine NN N
recipients NNS N
. . N

subjects NNS N
in IN N
each DT N
vaccine NN N
group NN N
at IN N
approximately RB N
3-month JJ N
intervals NNS N
-DOCSTART- -X- O O 12423984

Zambian JJ 4_p
children NNS 1_p
with IN N
cryptosporidiosis NN 4_p
: : N
Cryptosporidiosis NNP 4_p
in IN N
children NNS 1_p
in IN N
developing VBG 4_p
countries NNS 4_p
Zambian JJ 4_p
children NNS 1_p
with IN N
diarrhoea NN 4_p
due JJ 4_p
to TO 4_p
Cryptosporidium NNP 4_p
parvum NN 4_p
. . N

Children NNP 1_p
with IN N
cryptosporidial JJ 4_p
diarrhoea NNS 4_p
who WP N
were VBD N
admitted VBN N
to TO N
the DT N
University NNP N
Teaching NNP N
Hospital NNP N
, , N
Lusaka NNP N
, , N
Zambia NNP N
, , N
between IN N
November NNP N
, , N
2000 CD N
, , N
and CC N
July NNP N
, , N
2001 CD N
, , N
and CC N
whose WP$ N
parents NNS N
consented VBD N
to TO N
their PRP$ N
having VBG N
an DT N
HIV JJ N
test NN N
were VBD N
randomly RB N
assigned VBN N
nitazoxanide RB N
( ( N
100 CD N
mg NN N
twice RB N
daily RB N
orally RB N
for IN N
3 CD N
days NNS N
) ) N
or CC N
placebo NN N
. . N

C NNP 4_p
parvum NN 4_p
or CC N
co-infected JJ N
at IN N
baseline NN N
. . N

50 CD 3_p
HIV-seropositive JJ N
and CC N
50 CD 3_p
HIV-seronegative JJ N
children NNS 1_p
-DOCSTART- -X- O O 18248651

children NNS 1_p
and CC N
adolescents NNS 1_p
with IN N
GH NNP 4_p
and CC 4_p
cortisol JJ 4_p
insufficiency NN 4_p
. . N

young JJ 1_p
GH NNP 4_p
deficient NN 4_p
patients NNS N
children NNS 1_p
and CC N
adolescents NNS 1_p
with IN N
GH NNP 4_p
and/or VBP 4_p
cortisol JJ 4_p
deficiency NN 4_p
. . N

A NNP N
total NN N
of IN N
20 CD 3_p
patients NNS 3_p
( ( 1_p
2-18 CD 1_p
years NNS 1_p
) ) N
fasted VBD N
for IN N
14 CD N
h NN N
( ( N
22.00-12.00 JJ N
h NN N
) ) N
on IN N
two CD N
occasions NNS N
Fourteen NNP 1_p
had VBD N
pituitary JJ 4_p
hormone NN 4_p
deficiency NN 4_p
( ( 4_p
PHD NNP 4_p
) ) 4_p
including VBG N
GH NNP 4_p
deficiency NN 4_p
( ( 4_p
GHD NNP 4_p
) ) 4_p
. . N

Of IN N
the DT N
14 CD 3_p
patients NNS N
, , N
seven CD 3_p
were VBD N
ACTH NNP N
sufficient NN N
( ( N
PHDC+ NNP N
) ) N
and CC N
seven CD 3_p
ACTH NNP 4_p
deficient NN 4_p
( ( 4_p
PHDC- NNP 4_p
) ) 4_p
. . N

Six NNP 3_p
had VBD N
primary JJ 4_p
adrenal JJ 4_p
failure NN 4_p
( ( 4_p
PAF NNP 4_p
) ) 4_p
. . N

patients NNS N
with IN N
PHDC- NNP 4_p
. . N

children NNS 1_p
and CC N
adolescents NNS 1_p
Patients NNS N
with IN N
PHD NNP 4_p
-DOCSTART- -X- O O 8908288

laryngeal JJ N
cancer NN N
. . N

120 CD N
newly RB N
identified VBN N
cases NNS N
of IN N
laryngeal JJ N
squamous JJ N
cell NN N
carcinoma NN N
who WP N
were VBD N
registered VBN N
at IN N
10 CD N
participating VBG N
institutions NNS N
between IN N
November NNP N
1984 CD N
and CC N
October NNP N
1989 CD N
. . N

Of IN N
the DT N
initial JJ N
120 CD N
cases NNS N
, , N
11 CD N
cases NNS N
were VBD N
disqualified VBN N
( ( N
3 CD N
cases NNS N
of IN N
double JJ N
cancer NN N
and CC N
8 CD N
of IN N
incomplete JJ N
primary JJ N
therapy NN N
) ) N
and CC N
the DT N
remaining VBG N
109 CD N
were VBD N
used VBN N
for IN N
evaluation NN N
. . N

-DOCSTART- -X- O O 23995030

panic JJ 4_p
disorder NN 4_p
and CC 4_p
noncardiac JJ 4_p
chest NN 4_p
pain NN 4_p
. . 4_p

individuals NNS N
with IN N
panic JJ 4_p
disorder NN 4_p
( ( 4_p
PD NNP 4_p
) ) 4_p
with IN 4_p
a DT 4_p
chief JJ 4_p
complaint NN 4_p
of IN 4_p
noncardiac JJ 4_p
chest NN 4_p
pain NN 4_p
. . N

69 CD 3_p
patients NNS 3_p
-DOCSTART- -X- O O 2183734

Treatment NN N
of IN N
renal JJ 4_p
failure NN 4_p
associated VBN N
with IN N
multiple JJ 4_p
myeloma NN 4_p
. . N

patients NNS N
with IN N
multiple JJ N
myeloma NN N
Twenty-one CD 3_p
patients NNS N
with IN N
active JJ N
myeloma NN 4_p
and CC N
progressive JJ N
renal JJ N
failure NN N
Of IN N
5 CD 3_p
patients NNS N
who WP N
were VBD N
oliguric JJ N
and CC N
undergoing JJ N
dialysis NN N
at IN N
presentation NN N
Of IN N
16 CD 3_p
polyuric JJ N
patients NNS N
-DOCSTART- -X- O O 19415341

cancer-related JJ 4_p
fatigue NN 4_p
: : N
cancer-related JJ 4_p
fatigue NN 4_p
. . N

Eligible JJ N
adults NNS 1_p
with IN N
cancer NN 4_p
Two CD 3_p
hundred VBD 3_p
ninety NN 3_p
patients NNS N
were VBD N
accrued VBN N
to TO N
this DT N
trial NN N
. . N

cancer-related JJ 4_p
fatigue NN 4_p
. . N

-DOCSTART- -X- O O 16124442

HIV-infected NNP 4_p
Thai NNP 4_p
patients NNS 4_p
. . N

HIV NNP 4_p
infection NN N
in IN N
Thai NNP 1_p
adults NNS 1_p
was VBD N
conducted VBN N
in IN N
3 CD N
hospitals NNS N
in IN N
northern JJ N
Thailand NNP N
during IN N
2002 CD N
to TO N
2003 CD N
. . N

HIV-infected JJ 4_p
Thai NNP N
adults NNS 1_p
who WP N
had VBD N
never RB N
received VBN N
anti-retrovirals NNS N
, , N
had VBD N
a DT N
Karnofski NNP N
Performance NNP N
Score NNP N
( ( N
KPS NNP N
) ) N
of IN N
> NN N
or CC N
= $ N
70 CD N
, , N
and CC N
had VBD N
no DT N
opportunistic JJ N
infections NNS 4_p
. . N

60 CD 3_p
evaluable JJ 3_p
subjects NNS 3_p
, , N
40 CD 3_p
in IN N
the DT N
SH NNP N
group NN N
and CC N
20 CD 3_p
in IN N
the DT N
placebo NN N
group NN N
-DOCSTART- -X- O O 21450630

patients NNS N
with IN N
claudication NN 4_p
. . N

patients NNS N
with IN N
claudication NN N
. . N

Sixty-eight JJ 3_p
patients NNS N
with IN N
peripheral JJ 4_p
obstructive JJ 4_p
arterial JJ 4_p
disease NN 4_p
and CC N
intermittent JJ 4_p
claudication NN 4_p
( ( N
Fontaine NNP N
stage NN N
II NNP N
) ) N
profiles NNS N
in IN N
patients NNS N
with IN N
claudication NN N
-DOCSTART- -X- O O 24781567

elderly JJ 4_p
patients NNS 4_p
undergoing VBG 4_p
hip JJ 4_p
fracture NN 4_p
repair NN 4_p
. . 4_p

patients NNS N
undergoing VBG N
hip JJ N
fracture NN N
repair NN N
under IN N
spinal JJ N
anesthesia NN N
to TO N
light NN N
( ( N
BIS NNP N
> NNP N
80 CD N
) ) N
or CC N
deep JJ N
( ( N
BIS NNP N
approximately RB N
50 CD N
) ) N
sedation NN N
. . N

-DOCSTART- -X- O O 9315428

IHD NNP 4_p
. . 4_p

Ischemic NNP N
Heart NNP N
disease NN N
. . N

Ischemic NNP N
Heart NNP N
Disease NNP N
patients NNS N
with IN N
a DT N
previous JJ N
myocardial JJ N
infarction NN N
or CC N
unstable JJ N
angina-ischemic JJ N
heart NN N
disease NN N
( ( N
IHD NNP N
) ) N
. . N

9014 CD N
patients NNS N
from IN N
85 CD N
centers NNS N
in IN N
Australia NNP N
and CC N
New NNP N
Zealand NNP N
. . N

-DOCSTART- -X- O O 19371522

migraine NN N
headache NN N
. . N

Patients NNS N
with IN N
headaches NNS N
All DT N
44 CD N
patients NNS N
migraine NN N
patients NNS N
-DOCSTART- -X- O O 24146455

of IN N
mild NN 4_p
or CC 4_p
mild NN 4_p
to TO 4_p
moderate VB 4_p
erectile JJ 4_p
dysfunction NN 4_p
in IN 4_p
Thai NNP 4_p
male NN 2_p
among IN N
Thai NNP N
male NN 2_p
of IN 4_p
mild NN 4_p
and CC 4_p
mild NN 4_p
to TO 4_p
moderate VB 4_p
ED NNP 4_p
in IN 4_p
Thai NNP 4_p
patients NNS 4_p
of IN N
63 CD 3_p
patients NNS 3_p
with IN N
mild JJ 4_p
or CC 4_p
mild JJ 4_p
to TO 4_p
moderate VB 4_p
ED NNP 4_p
were VBD 4_p
randomized VBN 4_p
-DOCSTART- -X- O O 23925092

Japanese JJ 4_p
Elderly NNP 1_p
Diabetes NNPS 4_p
Intervention NNP N
Trial NNP N
( ( N
J-EDIT NNP N
) ) N
] NN N
-DOCSTART- -X- O O 18278302

Ten CD 3_p
ceramic JJ 3_p
blocks NNS 3_p
( ( 3_p
6x6x6 CD 3_p
mm NN 3_p
) ) 3_p
were VBD 3_p
fabricated VBN 3_p
and CC 3_p
randomly RB 3_p
assigned VBN 3_p
to TO 3_p
2 CD 3_p
groups NNS 3_p
( ( 3_p
n=5 NN 3_p
) ) 3_p
, , 3_p
according VBG 3_p
to TO 3_p
the DT 3_p
conditioning NN 3_p
method NN 3_p
: : 3_p
G1- JJ 3_p
10 CD 3_p
% NN 3_p
hydrofluoric JJ 3_p
acid NN 3_p
application NN 3_p
for IN 3_p
2 CD 3_p
min NN 3_p
plus CC 3_p
rinsing NN 3_p
and CC 3_p
drying NN 3_p
, , 3_p
followed VBN 3_p
by IN 3_p
silane NN 3_p
application NN 3_p
for IN 3_p
30 CD 3_p
s NNS N
; : N
G2- NNP N
-DOCSTART- -X- O O 12823122

Hungarian JJ N
asthmatics NNS 4_p
. . N

119 CD 3_p
asthmatics NNS N
were VBD N
randomized VBN N
the DT N
subjects NNS N
were VBD N
regularly RB N
controlled VBN N
asthmatics NNS N
-DOCSTART- -X- O O 7789678

20 CD 3_p
heparinized JJ 4_p
dogs NNS N
-DOCSTART- -X- O O 23984944

participants NNS N
undertook VBP N
an DT N
active JJ N
object NN 4_p
location NN 4_p
memory NN 4_p
task NN 4_p
within IN N
a DT N
virtual JJ N
house NN N
in IN N
which WDT N
each DT N
room NN N
was VBD N
associated VBN N
with IN N
a DT N
different JJ N
schedule NN N
of IN N
task-irrelevant JJ N
emotional JJ N
events NNS N
. . N

participants NNS N
participants NNS N
-DOCSTART- -X- O O 15012924

patients NNS N
with IN N
chronic JJ N
heart NN N
failure NN N
patients NNS N
with IN N
chronic JJ N
heart NN N
failure NN N
( ( N
CHF NNP N
) ) N
patients NNS N
with IN N
CHF NNP N
. . N

Patients NNPS N
with IN N
stable JJ N
CHF NNP N
( ( N
NYHA NNP N
II/III NNP N
; : N
59 CD N
( ( N
11 CD N
) ) N
years NNS N
) ) N
-DOCSTART- -X- O O 17618948

14 CD 3_p
patients NNS N
with IN N
colonic JJ 4_p
cancer NN 4_p
-DOCSTART- -X- O O 19998583

healthy JJ N
volunteers NNS N
. . N

24 CD 3_p
healthy JJ N
volunteers NNS N
under IN 4_p
fasting VBG 4_p
conditions NNS N
. . N

-DOCSTART- -X- O O 24738609

Severe NNP N
, , N
Chronic NNP 4_p
Low NNP 4_p
Back NNP 4_p
Pain NNP 4_p
With IN 4_p
a DT 4_p
Neuropathic JJ 4_p
Component NN 4_p
: : N
severe JJ 4_p
, , 4_p
chronic JJ 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
with IN 4_p
a DT 4_p
neuropathic JJ 4_p
component NN 4_p
. . 4_p

Eligible JJ N
patients NNS N
had VBD N
painDETECT VBN N
" JJ N
unclear JJ N
" NN N
or CC N
" VB N
positive JJ N
" NNP N
ratings NNS N
and CC N
average JJ N
pain NN N
intensity NN N
≥ VBP N
6 CD N
( ( N
11-point JJ N
NRS-3 NNP N
[ NNP N
average JJ N
3-day JJ N
pain NN N
intensity NN N
] NN N
) ) N
at IN N
baseline NN N
favorable JJ N
treatment NN N
option NN N
for IN N
severe JJ 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
with IN N
-DOCSTART- -X- O O 9308064

children NNS N
undergoing VBG N
myringotomy NN N
. . N

70 CD N
% NN N
of IN N
children NNS N
bilateral JJ N
myringotomy NNS N
and CC N
tube VB N
placement NN N
( ( N
BM NNP N
& CC N
T NNP N
) ) N
. . N

Forty NNP N
three CD N
ASA NNP N
I PRP N
or CC N
II NNP N
children NNS N
age NN N
six CD N
months NNS N
or CC N
older JJR N
scheduled VBN N
for IN N
elective JJ N
BM NNP N
& CC N
T NNP N
children NNS N
receiving VBG N
rescue NN N
analgesia NN N
. . N

children NNS N
undergoing VBG N
BM NNP N
& CC N
T NNP N
. . N

-DOCSTART- -X- O O 24435893

Alzheimer NNP 4_p
's POS 4_p
disease NN 4_p
: : 4_p
Danish NNP N
patients NNS 4_p
with IN 4_p
Alzheimer NNP 4_p
's POS 4_p
disease NN 4_p
and CC 4_p
their PRP$ 4_p
primary JJ 4_p
caregivers NNS 4_p
. . N

Primary NNP N
care NN N
and CC N
memory NN N
clinics NNS N
in IN N
five CD N
Danish JJ N
districts NNS N
. . N

330 CD 3_p
community-dwelling JJ N
patients NNS N
and CC N
their PRP$ N
primary JJ N
caregivers NNS N
. . N

patients NNS N
and CC N
caregivers NNS N
with IN N
special JJ N
needs NNS N
-DOCSTART- -X- O O 23444169

healthy JJ N
adult NN N
subjects NNS N
. . N

Under IN N
fasting VBG N
conditions NNS N
, , N
24 CD N
healthy JJ N
Egyptian JJ N
male NN N
volunteers NNS N
-DOCSTART- -X- O O 22721929

patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
and CC N
high-normal JJ 4_p
body NN 4_p
lead JJ 4_p
burdens NNS 4_p
. . N

type NN 4_p
2 CD 4_p
diabetic JJ 4_p
patients NNS N
University NNP N
medical JJ N
center NN N
; : N
50 CD N
patients NNS N
( ( N
serum JJ N
creatinine NN N
, , N
1.5-3.9 JJ N
mg/dL NN N
) ) N
with IN N
high-normal JJ N
body NN N
lead JJ N
burden NN N
( ( N
≥80- JJ N
< NN N
600 CD N
μg NN N
) ) N
for IN N
Chinese JJ N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
control NN N
group NN N
. . N

17 CD N
( ( N
68 CD N
% NN N
) ) N
control-group NN N
patients NNS N
and CC N
9 CD N
( ( N
36 CD N
% NN N
) ) N
treatment-group NN N
patients NNS N
nephropathy NN N
in IN N
type NN N
2 CD N
diabetic JJ N
patients NNS N
with IN N
high-normal JJ N
body NN N
lead JJ N
-DOCSTART- -X- O O 10871578

bone NN 4_p
marrow NN 4_p
transplantation NN 4_p
patients NNS N
. . N

patients NNS N
undergoing VBG N
BMT NNP N
Twenty-four JJ 3_p
BMT NNP N
patients NNS N
patients NNS 4_p
undergoing VBG 4_p
high-dose JJ 4_p
chemotherapy NN 4_p
-DOCSTART- -X- O O 7815983

intestinal JJ 4_p
absorption NN 4_p
of IN 4_p
fructose NN 4_p
25 CD 3_p
healthy JJ 4_p
controls NNS 4_p
-DOCSTART- -X- O O 16208798

three CD N
power NN N
toothbrushes NNS N
. . N

After IN N
refraining VBG N
from IN N
all DT N
oral JJ N
hygiene NN N
procedures NNS N
for IN N
23-25 JJ N
hours NNS N
, , N
subjects NNS N
received VBD N
an DT N
oral JJ N
tissue NN N
examination NN N
A DT N
total NN N
of IN N
79 CD 3_p
subjects NNS N
( ( N
28 CD 3_p
males NNS 2_p
and CC N
51 CD 3_p
females NNS 2_p
) ) N
were VBD N
enrolled VBN N
and CC N
completed VBN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 12496956

adults NNS 1_p
with IN N
autistic JJ 4_p
and CC 4_p
Asperger NNP 4_p
's POS 4_p
disorders NNS 4_p
. . N

autism NN 4_p
spectrum NN 4_p
patients NNS N
. . N

15 CD N
adults NNS N
with IN N
autism NN N
or CC N
Asperger NNP N
's POS N
disorder NN N
-DOCSTART- -X- O O 7910732

Two CD 4_p
groups NNS 4_p
of IN 4_p
12 CD 3_p
severe JJ 4_p
agoraphobics NNS 4_p
were VBD 4_p
treated VBN 4_p
12 CD 3_p
received VBD N
4 CD N
sessions NNS N
of IN N
'associative JJ N
therapy NN N
' '' N
-DOCSTART- -X- O O 11981150

breast NN 4_p
cancer NN 4_p
surgery NN 4_p
. . 4_p

female JJ N
patients NNS N
. . N

adult NN N
patients NNS N
undergoing VBG N
breast NN N
cancer NN N
surgery NN N
. . N

Sixty-eight JJ N
women NNS N
premedicated VBN N
with IN N
midazolam NNS N
patients NNS N
after IN N
breast NN N
cancer NN N
surgery NN N
with IN N
general JJ N
anesthesia NN N
. . N

-DOCSTART- -X- O O 17516971

premenopausal NN 4_p
and CC 4_p
postmenopausal JJ 4_p
women NNS 2_p
prior RB N
to TO N
outpatient VB 4_p
resectoscopy NN 4_p
. . N

Norwegian JJ N
university NN N
teaching VBG N
hospital NN N
. . N

Premenopausal NNP 4_p
and CC 4_p
postmenopausal JJ 4_p
women NNS 2_p
referred VBD N
to TO N
outpatient VB 4_p
resectoscopy NN 4_p
. . N

-DOCSTART- -X- O O 17984242

healthy JJ 4_p
men NNS 2_p
. . N

Twenty-four CD 2_p
healthy JJ N
males NNS 2_p
( ( N
age NN 1_p
, , 1_p
35-48 CD 1_p
years NNS 1_p
) ) N
participated VBD N
in IN N
the DT N
study NN N
. . N

healthy JJ 4_p
men NNS 2_p
-DOCSTART- -X- O O 3859359

central JJ 4_p
nervous JJ 4_p
system NN 4_p
relapse NN 4_p
in IN N
children NNS 1_p
with IN N
acute JJ 4_p
lymphocytic JJ 4_p
leukemia NN 4_p
. . N

Eighty-seven JJ 3_p
children NNS N
with IN N
central JJ 4_p
nervous JJ 4_p
system NN 4_p
( ( 4_p
CNS NNP 4_p
) ) 4_p
leukemia NN 4_p
-DOCSTART- -X- O O 8123267

outpatient JJ 4_p
anesthesia NN 4_p
: : N
postoperative JJ N
recovery NN N
of IN N
patients NNS N
following VBG N
the DT N
use NN N
of IN N
either DT N
propofol-nitrous JJ N
oxide NN N
( ( N
N2O NNP N
) ) N
or CC N
enflurane-N2O JJ N
for IN N
maintenance NN N
of IN N
outpatient JJ 4_p
anesthesia NN 4_p
. . N

University NNP N
hospital NN N
outpatient NN 4_p
surgery NN N
center NN N
. . N

61 CD 3_p
ASA NNP 4_p
physical JJ 4_p
status NN 4_p
I PRP 4_p
and CC 4_p
II NNP 4_p
, , N
healthy JJ 4_p
female NN 2_p
outpatients NNS 4_p
undergoing VBG N
laparoscopic NN 4_p
surgery NN 4_p
. . N

-DOCSTART- -X- O O 23365106

obese JJ 4_p
adults NNS 4_p
on IN 4_p
a DT 4_p
weight JJ 4_p
loss NN 4_p
diet NN 4_p
. . 4_p

cardiovascular JJ N
disease NN N
in IN N
obese JJ N
individuals NNS N
. . N

obese JJ N
participants NNS N
on IN N
a DT N
weight JJ N
loss NN N
diet NN N
25 CD N
% NN N
energy NN N
weight VBD 4_p
loss NN 4_p
diet NN 4_p
alone RB 4_p
( ( 4_p
WL NNP 4_p
) ) 4_p
( ( 4_p
n JJ 4_p
= NNP 4_p
12 CD 4_p
) ) 4_p
WL NNP N
plus CC N
4 CD N
g/d NN N
Omacor NNP N
( ( N
46 CD N
% NN N
EPA NNP N
and CC N
38 CD N
% NN N
DHA NNP N
) ) N
supplementation NN N
( ( N
WL+FAEE NNP N
) ) N
( ( N
n JJ N
= NNP N
13 CD N
) ) N
obese JJ N
adults NNS N
. . N

obese JJ 4_p
adults NNS 4_p
. . 4_p

-DOCSTART- -X- O O 16981667

MRC NNP 4_p
AML10 NNP N
trial NN 4_p
. . N

-DOCSTART- -X- O O 7906128

elderly JJ N
population NN N
setting NN N
was VBD N
a DT N
270,000 CD N
member NN N
group-model JJ N
PPGP NNP N
in IN N
Colorado NNP N
, , N
from IN N
1990 CD N
to TO N
1991 CD N
. . N

Participants NNS N
included VBD N
91 CD N
physicians NNS N
, , N
62 CD N
men NNS N
and CC N
29 CD N
women NNS N
; : N
median JJ N
age NN N
was VBD N
38.7 CD N
years NNS N
. . N

-DOCSTART- -X- O O 18391640

middle-aged JJ 1_p
and CC N
older JJR 1_p
adults NNS 1_p
. . N

decreased JJ 4_p
central JJ 4_p
arterial JJ 4_p
compliance NN 4_p
in IN N
young JJ 1_p
men NNS N
. . N

older JJR N
adults NNS N
with IN N
reduced JJ 4_p
baseline NN 4_p
arterial JJ 4_p
compliance NN 4_p
. . N

middle-aged JJ N
and CC N
older JJR N
adults NNS N
. . N

37 CD 3_p
healthy JJ 4_p
, , N
sedentary JJ 4_p
men NNS 2_p
and CC N
women NNS 2_p
( ( N
52+/-2 JJ 1_p
years NNS 1_p
) ) N
performed VBD N
13 CD N
weeks NNS N
of IN N
ST NNP N
( ( N
n=13 NN N
) ) N
, , N
ST+aerobic NNP N
exercise NN N
( ( N
n=12 JJ N
) ) N
or CC N
stretching VBG N
exercises NNS N
Participants NNS N
were VBD N
rigorously RB N
screened VBN N
for IN N
cardiovascular JJ 4_p
disease NN 4_p
and CC N
underwent JJ N
pre-post JJ N
testing NN N
for IN N
carotid JJ 4_p
arterial JJ 4_p
compliance NN 4_p
( ( N
via IN N
simultaneous JJ N
ultrasound NN N
and CC N
applanation NN N
tonometry NN N
) ) N
, , N
carotid-femoral JJ N
pulse NN N
wave NN N
velocity NN N
, , N
plasma JJ N
endothelin-1 NN N
and CC N
angiotensin NN N
II NNP N
concentrations NNS N
and CC N
carotid JJ N
artery NN N
vasoreactivity NN N
( ( N
cold JJ N
pressor NN N
test NN N
) ) N
middle-aged JJ N
and CC N
older JJR N
adults NNS N
. . N

-DOCSTART- -X- O O 19682342

iron NN N
deficiency NN N
anemia NN 4_p
in IN N
heavy JJ N
uterine JJ 4_p
bleeding NN 4_p
: : N
477 CD 3_p
women NNS 2_p
with IN N
anemia NN 4_p
, , 4_p
iron NN 4_p
deficiency NN 4_p
, , 4_p
and CC 4_p
heavy JJ 4_p
uterine JJ 4_p
bleeding NN 4_p
were VBD N
assigned VBN N
patients NNS N
with IN N
iron NN N
deficiency NN N
anemia NN N
due JJ N
to TO N
heavy JJ N
uterine JJ N
bleeding NN N
-DOCSTART- -X- O O 24488157

children NNS 1_p
with IN N
ASD NNP 4_p
: : N
70 CD 3_p
children NNS 1_p
with IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorder NNP 4_p
. . N

-DOCSTART- -X- O O 19852790

children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
: : N
children NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
( ( 4_p
ASD NNP 4_p
) ) N
ages VBZ 1_p
3-8 JJ 1_p
years NNS 1_p
. . N

Phase NNP N
1 CD N
involved VBD N
65 CD 3_p
children NNS 1_p
with IN N
ASD NNP 4_p
who WP N
received VBD N
one CD N
round NN N
of IN N
DMSA NNP N
( ( N
3 CD N
days NNS N
) ) N
. . N

Participants NNS N
who WP N
had VBD N
high JJ 4_p
urinary JJ 4_p
excretion NN 4_p
of IN 4_p
toxic JJ 4_p
metals NNS 4_p
were VBD N
selected VBN N
to TO N
continue VB N
on IN N
to TO N
phase VB N
2 CD N
. . N

phase NN N
2 CD N
, , N
49 CD 3_p
participants NNS N
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
double-blind JJ N
design NN N
to TO N
receive VB N
an DT N
additional JJ N
6 CD N
rounds NNS N
of IN N
either DT N
DMSA NNP N
or CC N
placebo NN N
. . N

children NNS 1_p
with IN N
ASD NNP 4_p
who WP N
have VBP N
high JJ 4_p
urinary JJ 4_p
excretion NN 4_p
of IN 4_p
toxic JJ 4_p
metals NNS 4_p
-DOCSTART- -X- O O 2834996

naturally RB N
occurring VBG N
common JJ 4_p
colds NNS 4_p
. . N

patients NNS N
with IN N
naturally RB 4_p
occurring VBG 4_p
common JJ 4_p
colds NNS 4_p
of IN N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
48 CD N
h NNS N
duration NN N
10-MU JJ N
( ( N
n JJ N
= NNP N
74 CD 3_p
) ) N
, , N
20-MU JJ N
( ( N
n JJ N
= NNP N
74 CD 3_p
) ) N
, , N
and CC N
placebo NN N
( ( N
n JJ N
= NNP N
72 CD 3_p
) ) N
groups NNS N
-DOCSTART- -X- O O 7956382

pulmonary JJ 4_p
function NN 4_p
following VBG 4_p
coronary JJ 4_p
artery JJ 4_p
bypass NN 4_p
graft NN 4_p
surgery NN 4_p
. . 4_p

prospective JJ N
, , N
randomized VBN N
, , N
controlled VBD N
study NN N
of IN N
patients NNS N
following VBG N
coronary JJ N
artery JJ N
bypass NN N
graft NN N
( ( N
CABG NNP N
) ) N
surgery NN N
with IN N
the DT N
right NN N
or CC N
left VBD N
internal JJ N
thoracic NN N
artery NN N
( ( N
ITA NNP N
) ) N
. . N

Forty-five JJ N
male JJ N
patients NNS N
( ( N
mean JJ N
age NN N
, , N
57 CD N
+/- JJ N
6 CD N
years NNS N
) ) N
were VBD N
randomly RB N
assigned VBN N
TENS NNP N
group NN N
-DOCSTART- -X- O O 23494559

individuals NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

individuals NNS N
with IN N
high JJ N
functioning VBG N
Autism NNP N
Spectrum NNP N
Disorders NNP N
. . N

twenty-two JJ N
youth NN N
, , N
ages VBZ N
16-19 JJ N
, , N
were VBD N
evaluated VBN N
during IN N
two CD N
employment NN N
interviews NNS N
. . N

-DOCSTART- -X- O O 21793626

diabetic JJ 4_p
rats NNS N
. . N

diabetic JJ 4_p
rats NNS 4_p
. . N

Thirty NNP 3_p
male NN 2_p
rats NNS N
-DOCSTART- -X- O O 19353317

distal JJ 4_p
femoral JJ 4_p
fractures NNS 4_p
: : N
distal JJ 4_p
femoral JJ 4_p
fractures NNS 4_p
From IN N
September NNP N
2002 CD N
to TO N
December NNP N
2004 CD N
, , N
68 CD 3_p
closed VBD N
fractures NNS 4_p
of IN 4_p
the DT 4_p
distal JJ 4_p
femur NN 4_p
were VBD N
treated VBN N
by IN N
bridge NN N
plate NN N
osteosynthesis NN N
using VBG N
DCS NNP N
in IN N
31 CD 3_p
and CC N
RIMSN NNP N
in IN N
37 CD 3_p
. . N

distal JJ 4_p
femoral JJ 4_p
fractures NNS 4_p
. . N

-DOCSTART- -X- O O 14616133

seasonal JJ 4_p
allergic JJ 4_p
rhinitis NN 4_p
. . N

-DOCSTART- -X- O O 8741469

Sixteen JJ 3_p
patients NNS N
scheduled VBN 4_p
for IN 4_p
gastrectomy NN 4_p
were VBD N
studied VBN N
. . N

patients NNS N
receiving VBG N
intraoperative JJ N
epidural JJ N
block NN N
. . N

-DOCSTART- -X- O O 20636866

radiation-induced JJ N
skin NN N
disease NN N
Subjects NNPS N
who WP N
were VBD N
undergoing VBG N
a DT N
planned JJ N
course NN N
of IN N
radiation NN N
therapy NN N
after IN N
breast-conserving JJ N
surgery NN N
-DOCSTART- -X- O O 17054808

cataract VB 4_p
surgery NN 4_p
under IN 4_p
total JJ 4_p
intravenous JJ 4_p
anaesthesia NN 4_p
, , 4_p
local JJ 4_p
anaesthesia NN 4_p
under IN 4_p
sedation NN 4_p
or CC 4_p
local JJ 4_p
anaesthesia NN 4_p
alone RB 4_p
: : N
-DOCSTART- -X- O O 14609821

persistent JJ 4_p
corneal JJ 4_p
epithelial JJ 4_p
defects NNS 4_p
. . 4_p

persistent JJ 4_p
corneal JJ 4_p
epithelial JJ 4_p
defects NNS 4_p
. . 4_p

60 CD N
eyes NNS N
of IN N
59 CD N
patients NNS N
-DOCSTART- -X- O O 3896455

advanced JJ 4_p
breast NN 4_p
cancer NN 4_p
. . N

155 CD 3_p
consecutive JJ N
patients NNS N
with IN N
Stage NNP N
IV NNP N
breast NN N
cancer NN N
randomly RB N
allocated VBN N
to TO N
receive VB N
either DT N
( ( N
1 CD N
) ) N
vincristin NN N
( ( N
V NNP N
) ) N
1.2 CD N
mg/m2 NN N
( ( N
maximum JJ N
dose NN N
, , N
2 CD N
mg NN N
) ) N
, , N
Adriamycin NNP N
( ( N
A NNP N
) ) N
( ( N
doxorubicin NN N
) ) N
40 CD N
mg/m2 NN N
, , N
and CC N
cyclophosphamide NN N
( ( N
C NNP N
) ) N
500 CD N
mg/m2 NN N
, , N
all DT N
intravenously RB N
on IN N
day NN N
1 CD N
, , N
every DT N
4 CD N
weeks NNS N
, , N
in IN N
combination NN N
with IN N
medroxyprogesteron NN N
acetate NN N
( ( N
MPA NNP N
) ) N
600 CD N
mg NN N
orally RB N
on IN N
days NNS N
1 CD N
through IN N
14 CD N
, , N
500 CD N
mg NNS N
intramuscularly RB N
on IN N
days NNS N
1 CD N
through IN N
28 CD N
, , N
and CC N
twice RB N
weekly JJ N
afterwards NNS N
( ( N
combined VBN N
chemoendocrine NN N
approach NN N
) ) N
or CC N
( ( N
2 CD N
) ) N
the DT N
same JJ N
combination NN N
chemotherapy NN N
( ( N
VAC NNP N
) ) N
for IN N
three CD N
cycles NNS N
alternating VBG N
with IN N
MPA NNP N
in IN N
the DT N
above-mentioned JJ N
dosage NN N
during IN N
8 CD N
weeks NNS N
( ( N
alternating VBG N
chemoendocrine VB N
approach NN N
) ) N
patients NNS N
with IN N
more JJR N
than IN N
one CD N
metastatic JJ N
site NN N
estrogen NN N
receptor NN N
( ( N
ER NNP N
) ) N
-negative JJ N
patients NNS N
patients NNS N
younger JJR N
than IN N
51 CD N
years NNS N
of IN N
age NN N
patients NNS N
with IN N
a DT N
disease-free JJ N
interval NN N
of IN N
1 CD N
year NN N
or CC N
less JJR N
. . N

Patients NNS N
with IN N
these DT N
parameters NNS N
probably RB N
belong RB N
to TO N
the DT N
same JJ N
population NN N
. . N

-DOCSTART- -X- O O 12485538

children NNS 1_p
with IN N
autism NN 4_p
. . N

-DOCSTART- -X- O O 21425723

perineal NN 4_p
pain NN 4_p
after IN N
perineorrhaphy NN N
: : N
Thailand NNP N
. . N

postpartum NN N
perineal NN N
pain NN N
after IN N
perineorrhaphy NN N
. . N

One NNP N
hundred VBD N
women NNS 3_p
who WP N
gave VBD N
birth NN N
vaginally RB N
with IN N
episiotomy NN N
and CC N
a DT N
second- JJ 4_p
or CC 4_p
third-degree JJ 4_p
tear NN 4_p
-DOCSTART- -X- O O 22311204

autism NN N
spectrum NN N
disorder NN N
children NNS N
with IN N
ASD NNP N
high JJ N
functioning NN N
children NNS N
with IN N
ASD NNP N
. . N

children NNS N
with IN N
autism NN N
-DOCSTART- -X- O O 6761890

Platelet NNP 4_p
inhibitory NN 4_p
drugs NNS 4_p
: : 4_p
platelet NN 4_p
deposition NN 4_p
in IN 4_p
human JJ 4_p
thrombi NN 4_p
Dacron NNP N
arterial JJ N
grafts NN N
27 CD 3_p
patients NNS 3_p
-DOCSTART- -X- O O 8673938

gingival NN 4_p
status NN N
of IN N
adolescents NNS 1_p
. . 4_p

gingival NN N
status NN N
of IN N
11- JJ 1_p
to TO 1_p
15-year-old JJ 1_p
children NNS 1_p
attending VBG N
a DT N
school NN N
in IN N
Rio NNP N
de IN N
Janeiro NNP N
, , N
Brazil NNP N
. . N

control VB N
( ( N
C NNP N
) ) N
and CC N
treatment NN N
( ( N
T NNP N
) ) N
groups NNS N
, , N
n JJ N
= NN N
53 CD 3_p
and CC N
n JJ N
= NN N
57 CD 3_p
subjects NNS N
matched VBN N
at IN N
baseline NN N
on IN N
age NN N
, , N
salivary JJ N
levels NNS N
of IN N
mutans NNS N
streptococci VBP N
, , N
and CC N
caries NNS N
scores NNS N
. . N

-DOCSTART- -X- O O 22038637

high-risk JJ 4_p
cardiac JJ 4_p
surgery NN 4_p
patients NNS 4_p
] VBP N
EuroSCORE-stratified JJ N
high-risk JJ N
cardiac NN N
surgery NN N
patients NNS N
with IN N
a DT N
score NN N
≥8 NN N
with IN N
104 CD N
patients NNS N
either CC N
without IN N
prophylactic JJ N
IABP NNP N
insertion NN N
( ( N
group NN N
A NNP N
, , N
n=52 NN N
) ) N
or CC N
with IN N
IABP NNP N
( ( N
group NN N
B NNP N
, , N
n=52 NN N
) ) N
RESULTS VB N
The DT N
median JJ N
age NN N
of IN N
the DT N
patients NNS N
was VBD N
74 CD 1_p
years NNS N
and CC N
43 CD N
% NN N
of IN N
participants NNS N
were VBD N
females NNS N
insertion NN N
in IN N
EuroSCORE-stratified JJ N
high-risk JJ N
-DOCSTART- -X- O O 24417452

children NNS 1_p
with IN N
disabilities NNS 4_p
. . N

children NNS 1_p
with IN N
intellectual JJ N
and CC N
developmental JJ N
disabilities NNS N
who WP N
exhibit VBP N
limitations NNS N
in IN N
daily JJ N
time NN N
management NN N
. . N

Participating VBG N
children NNS 1_p
( ( N
n JJ N
= NNP N
47 CD 3_p
) ) N
( ( 1_p
F17/M30 NNP N
) ) N
were VBD N
aged VBN 1_p
6-11 JJ 1_p
with IN N
ADHD NNP 4_p
, , 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
, , 4_p
mild NN 4_p
or CC 4_p
moderate JJ 4_p
intellectual JJ 4_p
disability NN 4_p
, , 4_p
spina NN 4_p
bifida NN 4_p
, , 4_p
and CC 4_p
cerebral JJ 4_p
palsy NN 4_p
. . N

In IN N
total JJ N
10 CD 3_p
children NNS 3_p
( ( N
21.3 CD N
% NN N
) ) N
, , N
five CD 3_p
from IN N
each DT N
group NN N
, , N
dropped VBD N
out RP N
, , N
leaving VBG N
37 CD 3_p
children NNS N
in IN N
the DT N
data NN N
analysis NN N
. . N

children NNS N
with IN N
intellectual JJ N
and CC N
developmental JJ N
disabilities NNS N
-DOCSTART- -X- O O 21044518

children NNS N
with IN N
learning VBG N
disabilities NNS N
] NNP N
children NNS 4_p
with IN 4_p
learning VBG 4_p
disabilities NNS 4_p
( ( 4_p
LD NNP 4_p
) ) N
. . N

children NNS N
with IN N
LD NNP N
. . N

85 CD 1_p
children NNS 1_p
with IN 1_p
LD NNP 1_p
, , 1_p
with IN 1_p
age NN 1_p
range NN 1_p
between IN 1_p
8 CD 1_p
years NNS 1_p
and CC 1_p
10 CD 1_p
years NNS 1_p
( ( 1_p
age NN 1_p
, , 1_p
M=111.02 NNP 1_p
, , 1_p
SD=9.6 NNP 1_p
) ) 1_p
, , 1_p
whose WP$ 1_p
spelling VBG 1_p
performance NN 1_p
was VBD 1_p
two CD 1_p
years NNS 1_p
below IN 1_p
grade JJ 1_p
level NN 1_p
. . 1_p

-DOCSTART- -X- O O 8106772

patients NNS 4_p
with IN 4_p
advanced JJ 4_p
human JJ 4_p
immunodeficiency NN 4_p
virus NN 4_p
disease NN 4_p
: : 4_p
patients NNS N
with IN N
human JJ N
immunodeficiency NN N
virus NN N
( ( N
HIV NNP N
) ) N
disease NN N
, , N
absolute JJ N
CD4 NNP N
lymphocyte NN N
count NN N
of IN N
< $ N
200/microL CD N
( ( N
or CC N
prior RB N
AIDS-defining NNP N
opportunistic JJ N
infection NN N
) ) N
, , N
and CC N
the DT N
presence NN N
of IN N
serum NN N
IgG NNP N
to TO N
Toxoplasma NNP N
gondii NN N
. . N

218 CD N
patients NNS N
taking VBG N
trimethoprim-sulfamethoxazole JJ N
117 CD N
taking VBG N
aerosolized JJ N
pentamidine NN N
HIV-infected JJ N
patients NNS N
-DOCSTART- -X- O O 23104718

patients NNS N
with IN N
chronic JJ 4_p
xerostomia NN 4_p
following VBG N
treatment NN N
of IN N
head NN 4_p
and CC 4_p
neck NN 4_p
cancer NN 4_p
. . N

head NN 4_p
and CC 4_p
neck NN 4_p
cancer NN 4_p
chronic JJ 4_p
xerostomia NN 4_p
total NN N
of IN N
145 CD 3_p
patients NNS N
with IN N
chronic JJ 4_p
radiation-induced JJ 4_p
xerostomia NN 4_p
> $ N
18 CD N
months NNS N
after IN N
treatments NNS N
were VBD N
recruited VBN N
from IN N
seven CD N
UK NNP N
cancer NN N
centres NNS N
. . N

patients NNS N
suffering VBG N
from IN N
chronic JJ 4_p
radiation-induced JJ 4_p
xerostomia NN 4_p
. . 4_p

-DOCSTART- -X- O O 6360688

70 CD 3_p
patients NNS N
. . N

70 CD 3_p
patients NNS N
hospitalized VBN N
in IN N
the DT N
Coronary NNP N
Care NNP N
Unit NNP N
for IN N
unstable JJ 4_p
angina NN 4_p
, , N
defined VBN N
as IN N
recent JJ N
( ( N
less JJR N
than IN N
one CD N
month NN N
) ) N
appearance NN N
or CC N
aggravation NN N
of IN N
spontaneous JJ N
chest NN 4_p
pains NNS 4_p
. . 4_p

Among IN N
the DT N
70 CD 3_p
patients NNS N
, , N
24 CD 3_p
had VBD N
angina VBN 4_p
only RB N
at IN N
rest NN N
. . N

patients NNS N
have VBP N
been VBN N
divided VBN N
into IN N
two CD N
groups NNS N
according VBG N
to TO N
ST-T JJ N
changes NNS N
during IN N
chest NN 4_p
pain NN 4_p
: : N
29 CD 3_p
with IN N
ST NNP N
elevation NN N
( ( N
group NN N
A NNP N
) ) N
and CC N
41 CD 3_p
with IN N
other JJ N
repolarization NN 4_p
abnormalities NNS 4_p
( ( 4_p
group NN 4_p
B NNP 4_p
) ) 4_p
. . N

24 CD 3_p
patients NNS N
with IN N
angina JJ 4_p
exclusively RB N
at IN N
rest NN N
unstable JJ N
angina NNS 4_p
in IN N
patients NNS N
with IN N
angina NN 4_p
which WDT N
is VBZ N
exclusively RB N
spontaneous JJ N
. . N

-DOCSTART- -X- O O 21067912

advanced JJ 4_p
colorectal JJ 4_p
cancer NN 4_p
patients NNS 4_p
. . N

advanced JJ 4_p
colorectal JJ 4_p
cancer NN 4_p
( ( 4_p
ACC NNP 4_p
) ) 4_p
patients NNS 4_p
treated VBN 4_p
in IN 4_p
the DT 4_p
phase NN 4_p
III NNP 4_p
CAIRO2 NNP 4_p
study NN 4_p
. . N

Seven NNP 3_p
hundred VBD 3_p
and CC 3_p
fifty JJ 3_p
five CD 3_p
previously RB N
untreated JJ N
ACC NNP N
patients NNS N
Seven NNP 3_p
hundred CD 3_p
and CC 3_p
thirty VB 3_p
two CD 3_p
patients NNS 3_p
were VBD 3_p
evaluable JJ 3_p
-DOCSTART- -X- O O 14616872

allergic JJ 4_p
reaction NN 4_p
-- : N
a DT N
case NN N
series NN N
. . N

first JJ N
six CD 3_p
subjects NNS N
Peanut-allergic JJ 4_p
subjects NNS N
food-allergic JJ 4_p
consumers NNS N
-DOCSTART- -X- O O 12422941

methamphetamine NN 4_p
craving NN 4_p
. . N

population NN N
of IN N
methamphetamine NN N
users NNS N
. . N

-DOCSTART- -X- O O 25957107

cardiovascular JJ 4_p
dysfunction NN 4_p
associated VBN N
with IN N
a DT N
sedentary JJ N
lifestyle NN N
. . N

60-day JJ N
bed NN N
rest NN N
. . N

Fourteen NNP 3_p
healthy JJ N
men NNS 2_p
-DOCSTART- -X- O O 10078672

healthy JJ 4_p
volunteers NNS N
. . N

healthy JJ N
, , N
non-drug-abusing JJ 4_p
volunteers NNS N
. . N

Ten NNP 3_p
healthy JJ N
volunteers NNS N
-DOCSTART- -X- O O 24070810

acute JJ N
seasonal JJ N
allergic JJ N
conjunctivitis NN N
. . N

Eighteen JJ N
subjects NNS N
( ( N
mean JJ N
age NN N
, , N
29.5±11.0 CD N
years NNS N
) ) N
allergic VBP N
to TO N
grass VB N
pollen NN N
and CC N
symptoms NNS N
of IN N
allergic JJ N
conjunctivitis NN N
challenge NN N
. . N

Signs NNP N
of IN N
allergic JJ N
conjunctivitis NN N
-DOCSTART- -X- O O 12131309

transrectal JJ 4_p
ultrasound NN 4_p
guided VBD 4_p
prostate NN 4_p
biopsy NN 4_p
100 CD 4_p
consecutive JJ N
patients NNS N
with IN N
sterile JJ 4_p
urine JJ 4_p
cultures NNS 4_p
underwent JJ N
transrectal JJ 4_p
ultrasound NN 4_p
guided VBD 4_p
prostate NN 4_p
biopsy NN 4_p
. . N

-DOCSTART- -X- O O 8034784

32 CD 4_p
subjects NNS 4_p
. . 4_p

-DOCSTART- -X- O O 19941058

autism NN 4_p
. . N

individuals NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP 4_p
) ) N
individuals NNS N
with IN N
autism NN N
13 CD 3_p
individuals NNS N
with IN N
ASD NNP N
. . N

-DOCSTART- -X- O O 24916506

chronic JJ 4_p
lymphocytic JJ 4_p
leukemia NN 4_p
. . N

patient JJ N
outcomes NNS N
in IN N
chronic JJ 4_p
lymphocytic JJ 4_p
leukemia NN 4_p
( ( N
CLL NNP 4_p
) ) N
. . N

patients NNS N
who WP N
will MD N
benefit VB N
from IN N
immunochemotherapy NN N
over IN N
chemotherapy NN N
alone RB N
has VBZ N
not RB N
been VBN N
determined VBN N
. . N

We PRP N
assessed VBD N
genome-wide JJ N
expression NN N
of IN N
300 CD 3_p
pretreatment NN N
specimens NNS N
from IN N
a DT N
subset NN N
of IN N
552 CD 3_p
patients NNS N
in IN N
REACH NNP N
, , N
a DT N
study NN N
of IN N
FC NNP N
or CC N
R-FC NNP N
in IN N
relapsed JJ N
CLL NNP 4_p
. . N

An DT N
independent JJ N
test NN N
set NN N
was VBD N
derived VBN N
from IN N
282 CD N
pretreatment NN N
specimens NNS N
from IN N
CLL8 NNP N
, , N
a DT N
study NN N
of IN N
FC NNP N
or CC N
R-FC NNP N
in IN N
treatment-naïve JJ N
patients NNS N
. . N

for IN N
CLL NNP N
patients NNS N
-DOCSTART- -X- O O 18752063

children NNS 1_p
with IN N
pervasive JJ 4_p
developmental NN 4_p
disorders NNS 4_p
and CC 4_p
hyperactivity NN 4_p
. . N

children NNS 1_p
with IN N
pervasive JJ 4_p
developmental NN 4_p
disorders NNS 4_p
and CC 4_p
hyperactivity NN 4_p
RUPP NNP N
Autism NNP 4_p
Network NNP N
data NNS N
. . N

Participants NNS N
were VBD N
33 CD 3_p
children NNS 1_p
( ( N
29 CD 2_p
boys NNS 2_p
) ) N
between IN 1_p
the DT 1_p
ages NNS 1_p
of IN 1_p
5 CD 1_p
and CC 1_p
13 CD 1_p
years NNS 1_p
children NNS 1_p
with IN N
PDD NNP 4_p
and CC 4_p
hyperactivity NN 4_p
. . N

-DOCSTART- -X- O O 25694364

Students NNP 4_p
with IN 4_p
ASD NNP 4_p
. . 4_p

school-aged JJ 1_p
children NNS 1_p
with IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorder NNP 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
. . 4_p

students NNS N
school-aged JJ 1_p
children NNS 1_p
meeting VBG N
educational JJ N
criteria NNS N
for IN N
autism NN 4_p
( ( N
N NNP N
= NNP N
31 CD N
) ) N
. . N

-DOCSTART- -X- O O 17958625

treatment NN 4_p
of IN 4_p
pyoderma NN 4_p
in IN 4_p
Bamako NNP 4_p
, , 4_p
Mali NNP 4_p
: : 4_p
Pyoderma NNP 4_p
( ( 4_p
bacterial JJ 4_p
superficial NN 4_p
skin NN 4_p
infection NN 4_p
) ) 4_p
tropical JJ 4_p
developing VBG 4_p
countries NNS 4_p
. . 4_p

In IN N
Bamako NNP N
, , N
132 CD N
patients NNS N
with IN N
pyoderma NN N
, , N
diagnosed VBN N
and CC N
graded VBN N
as IN N
" NN N
severe JJ N
" NN N
on IN N
clinical JJ N
grounds NNS N
severe JJ 4_p
pyoderma NN 4_p
in IN 4_p
Mali NNP 4_p
. . 4_p

-DOCSTART- -X- O O 10361382

during IN 4_p
starvation NN 4_p
in IN 4_p
humans NNS 4_p
. . 4_p

starving VBG 4_p
subjects NNS 4_p
. . N

28 CD 3_p
normal JJ 4_p
men NNS N
( ( N
age NN 1_p
27-35 CD 1_p
years NNS 1_p
) ) N
within IN N
10 CD N
% NN N
of IN N
their PRP$ N
ideal NN N
body NN N
weight NN N
. . N

They PRP N
were VBD N
randomly RB N
divided VBN N
into IN N
4 CD N
groups NNS N
of IN N
7 CD N
. . N

-DOCSTART- -X- O O 9799143

150 CD 3_p
patients NNS N
with IN N
gallbladder JJ 4_p
lithiasis NN 4_p
who WP N
underwent JJ N
laparoscopy NN 4_p
-DOCSTART- -X- O O 24930179

participants NNS 4_p
verbally RB 4_p
estimated VBD 4_p
the DT 4_p
metric JJ 4_p
distances NNS 4_p
between IN 4_p
themselves PRP 4_p
and CC 4_p
targets NNS 4_p
, , 4_p
or CC 4_p
they PRP 4_p
threw VBD 4_p
a DT 4_p
beanbag NN 4_p
to TO 4_p
targets NNS 4_p
. . N

trainees NNS 4_p
that IN 4_p
their PRP$ 4_p
training NN 4_p
-DOCSTART- -X- O O 19182698

randomized NN N
, , N
blinded VBD N
trial NN N
in IN N
217 CD 3_p
postmenopausal JJ 4_p
women NNS 2_p
with IN N
hot JJ 4_p
flushes NNS 4_p
randomized VBD N
to TO N
5 CD N
or CC N
10 CD N
g/day NN N
of IN N
MF101 NNP N
or CC N
placebo NN N
for IN N
12 CD N
weeks NNS N
. . N

-DOCSTART- -X- O O 25659440

simultaneous JJ 4_p
bilateral JJ 4_p
total NN 4_p
knee NN 4_p
arthroplasty NN 4_p
: : N
after IN N
simultaneous JJ 4_p
bilateral JJ 4_p
total NN 4_p
knee NN 4_p
arthroplasty NN 4_p
( ( 4_p
TKA NNP 4_p
) ) 4_p
. . N

patients NNS N
-DOCSTART- -X- O O 1593244

one CD 4_p
nicotine NN 4_p
transdermal NN 4_p
system NN 4_p
( ( 4_p
Nicoderm NNP 4_p
, , 4_p
Marion NNP 4_p
Merrell NNP 4_p
Dow NNP 4_p
Inc NNP 4_p
, , 4_p
Kansas NNP 4_p
City NNP 4_p
, , 4_p
Mo NNP 4_p
, , 4_p
and CC 4_p
ALZA NNP 4_p
Corporation NNP 4_p
, , 4_p
Palo NNP 4_p
Alto NNP 4_p
, , 4_p
Calif NNP 4_p
) ) 4_p
in IN 4_p
a DT 4_p
population NN 4_p
who WP 4_p
were VBD 4_p
allowed VBN 4_p
to TO 4_p
continue VB 4_p
smoking VBG 4_p
. . 4_p

186 CD N
subjects NNS N
completing VBG N
the DT N
study NN N
-DOCSTART- -X- O O 7593698

plaque NN 4_p
and CC 4_p
gingivitis NN 4_p
. . 4_p

70 CD 3_p
subjects NNS 3_p
with IN N
gingivitis NN 4_p
All DT N
participants NNS N
had VBD N
at IN N
least JJS N
20 CD N
natural JJ N
teeth NNS N
with IN N
no DT N
probing VBG N
depths NNS N
greater JJR N
than IN N
3 CD N
mm NNS N
and CC N
a DT N
plaque JJ N
index NN N
of IN N
2 CD N
or CC N
more JJR N
at IN N
baseline NN N
. . N

-DOCSTART- -X- O O 21366734

2166 CD N
women NNS N
, , N
aged VBD N
20-59 JJ N
, , N
with IN N
recent JJ N
low-grade JJ N
cervical JJ N
cytology NN N
taken VBN N
within IN N
the DT N
NHS NNP N
Cervical NNP N
Screening NNP N
Programmes NNP N
in IN N
Scotland NNP N
and CC N
England NNP N
, , N
and CC N
managed VBN N
by IN N
6-monthly JJ N
cytology NN N
in IN N
primary JJ N
care NN N
. . N

'on-time JJ N
attendees NNS N
' POS N
'late '' N
attendees NNS N
' POS N
or CC N
'non-attendees NNS N
' POS N
in IN N
younger JJR N
women NNS N
, , N
those DT N
without IN N
post-secondary JJ N
education NN N
, , N
and CC N
non-users NNS N
of IN N
prescribed JJ N
contraception NN N
among IN N
women NNS N
who WP N
were VBD N
younger JJR N
, , N
smokers NNS N
and CC N
had VBD N
negative JJ N
cytology NN N
in IN N
women NNS N
who WP N
were VBD N
younger JJR N
, , N
smokers NNS N
, , N
had VBD N
children NNS N
and CC N
attended VBD N
late RB N
be VB N
young JJ N
, , N
smoke NN N
, , N
lack NN N
post-secondary JJ N
education NN N
, , N
and CC N
have VBP N
defaulted VBN N
from IN N
a DT N
previous JJ N
surveillance NN N
appointment NN N
-DOCSTART- -X- O O 3220672

primary JJ 4_p
open-angle JJ 4_p
glaucoma NN 4_p
-- : N
results NNS N
black JJ N
Jamaican JJ N
population NN N
. . N

48 CD N
eyes NNS N
of IN N
30 CD 3_p
black JJ N
Jamaican JJ N
patients NNS N
with IN N
primary JJ 4_p
open-angle JJ 4_p
glaucoma NN 4_p
. . N

All DT N
eyes NNS N
had VBD N
uncontrolled VBN 4_p
intra-ocular JJ 4_p
pressures NNS 4_p
( ( 4_p
greater JJR 4_p
than IN 4_p
or CC 4_p
equal JJ 4_p
to TO 4_p
22 CD 4_p
mm NNS 4_p
Hg NNP 4_p
) ) 4_p
despite IN N
medical JJ N
therapy NN N
. . N

Jamaican NNP N
glaucoma NN 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 19531038

Paediatric NNP 4_p
Intensive NNP 4_p
Care NNP 4_p
Unit NNP 4_p
of IN 4_p
Padua NNP 4_p
Hospital NNP 4_p
. . 4_p

It PRP N
considered VBD N
patients NNS N
of IN N
0-36 JJ N
months NNS N
, , N
not RB N
premature NN N
, , N
treated VBN N
with IN N
inotropic JJ N
infusion NN N
with IN N
monitoring NN N
of IN N
blood NN N
pressure NN N
. . N

Hospital NNP 4_p
Research NNP 4_p
Ethics NNP 4_p
committee NN 4_p
parents NNS N
The DT N
sample NN N
comprised VBD N
30 CD N
patients NNS N
of IN N
age NN N
between IN N
1 CD N
and CC N
27 CD N
months NNS N
, , N
of IN N
whom WP N
13 CD N
( ( N
43 CD N
% NN N
) ) N
were VBD N
male JJ N
. . N

They PRP N
were VBD N
all DT N
affected VBN N
by IN N
cardiac NN N
, , N
respiratory NN N
or CC N
infective JJ N
pathology NN N
, , N
all DT N
of IN N
them PRP N
intubated VBN N
and CC N
on IN N
artificial JJ N
respiratory NN N
support NN N
, , N
sedated VBN N
and CC N
infused VBN N
with IN N
dopamine NN N
. . N

The DT 4_p
study NN 4_p
was VBD 4_p
conducted VBN 4_p
on IN 4_p
a DT 4_p
limited JJ 4_p
sample NN 4_p
; : 4_p
-DOCSTART- -X- O O 19608530

human JJ N
tears NNS N
and CC N
saliva NN N
. . N

tears NNS N
and CC N
saliva NN N
of IN N
healthy JJ 4_p
individuals NNS N
. . N

The DT N
subjects NNS N
( ( N
n JJ 3_p
= NNP 3_p
45 CD 3_p
) ) N
-DOCSTART- -X- O O 24112670

rib NN 4_p
fractures NNS 4_p
. . N

pulmonary JJ 4_p
morbidity NN 4_p
after IN N
rib NN 4_p
fractures NNS 4_p
all DT N
patients NNS N
with IN N
rib JJ 4_p
fractures NNS 4_p
who WP N
received VBD N
ketorolac NN N
< $ N
4 CD N
days NNS N
after IN N
injury NN N
compared VBN N
with IN N
a DT N
random JJ N
sample NN N
of IN N
those DT N
who WP N
did VBD N
not RB N
. . N

202 CD 3_p
patients NNS N
who WP N
received VBD N
ketorolac NN N
and CC N
417 CD 3_p
who WP N
did VBD N
not RB N
patients NNS N
with IN N
rib JJ 4_p
fractures NNS 4_p
-DOCSTART- -X- O O 1793881

Thirty NNP 3_p
ASA NNP 4_p
I-II NNP 4_p
adult NN N
patients NNS N
undergoing VBG N
selective JJ N
surgery NN N
-DOCSTART- -X- O O 6364880

12 CD 3_p
adult NN 4_p
volunteers NNS 4_p
( ( 4_p
6 CD 3_p
atopics NNS 4_p
, , 4_p
6 CD 3_p
non-atopics NNS 4_p
) ) 4_p
. . 4_p

-DOCSTART- -X- O O 20431290

stroke-free JJ 4_p
individuals NNS 4_p
over IN 4_p
2 CD 4_p
years NNS 4_p
. . 4_p

total NN 4_p
of IN 4_p
227 CD 4_p
subjects NNS 4_p
227 CD 4_p
randomized JJ 4_p
subjects NNS 4_p
, , 4_p
33 CD 4_p
( ( 4_p
14.5 CD 4_p
% NN 4_p
) ) 4_p
had VBD 4_p
SBI VBN 4_p
at IN 4_p
baseline NN 4_p
. . 4_p

-DOCSTART- -X- O O 7831455

schizophrenic JJ 4_p
children NNS 1_p
: : N
19 CD 3_p
schizophrenic JJ 4_p
children NNS 1_p
, , N
16 CD 3_p
males NNS 2_p
and CC N
3 CD 3_p
females NNS 2_p
, , N
mean JJ 1_p
age NN 1_p
8.9 CD 1_p
years NNS 1_p
( ( N
range VB N
5.5-11.7 NNP 1_p
) ) N
Schizophrenic JJ 4_p
children NNS 1_p
-DOCSTART- -X- O O 20456192

migraine NN 4_p
pain NN 4_p
. . 4_p

migraineurs NNS N
. . N

23 CD 3_p
migraineurs NNS N
showing VBG N
pain NN N
at IN N
pressure NN N
on IN N
scalp NN N
arteries NNS N
patients NNS N
experiencing VBG N
scalp JJ N
arterial JJ N
tenderness NN N
. . N

-DOCSTART- -X- O O 17479312

laparoscopic NN N
adrenalectomy NN N
( ( N
LA NNP N
) ) N
From IN N
January NNP N
2004 CD N
to TO N
January NNP N
2006 CD N
, , N
50 CD N
patients NNS N
( ( N
pts NNS N
) ) N
undergoing VBG N
LA NNP N
-DOCSTART- -X- O O 3314516

human JJ N
pregnancy NN 4_p
. . N

32 CD 3_p
gravid JJ 4_p
women NNS 2_p
undergoing VBG N
elective JJ 4_p
cesarean JJ 4_p
section NN 4_p
at IN N
term NN N
. . N

-DOCSTART- -X- O O 8268649

patients NNS 4_p
receiving VBG 4_p
hemodialysis NN 4_p
or CC 4_p
peritoneal JJ 4_p
dialysis NN 4_p
. . N

dialysis NN 4_p
patients NNS N
26 CD 3_p
hemodialysis NN 4_p
patients NNS N
and CC N
10 CD 3_p
peritoneal JJ 4_p
dialysis NN 4_p
( ( 4_p
CAPD NNP 4_p
) ) 4_p
patients NNS N
and CC N
compared VBN N
the DT N
results NNS N
with IN N
those DT N
from IN N
66 CD 3_p
age NN N
matched VBD N
control NN N
subjects NNS N
. . N

three CD N
groups NNS N
-DOCSTART- -X- O O 18056791

Sixteen NNP 3_p
male JJ 2_p
subjects NNS N
-DOCSTART- -X- O O 6352035

surgical JJ N
patients NNS N
with IN N
serious JJ 4_p
systemic JJ 4_p
infection NN 4_p
. . N

patients NNS N
with IN N
serious JJ 4_p
systemic JJ 4_p
infection NN 4_p
. . 4_p

Thirty-seven JJ 3_p
surgical JJ N
patients NNS N
were VBD N
evaluated VBN N
for IN N
efficacy NN N
and CC N
46 CD 3_p
patients NNS N
were VBD N
evaluated VBN N
for IN N
toxicity NN N
. . N

patients NNS N
who WP N
have VBP N
serious JJ 4_p
infections NNS 4_p
after IN 4_p
surgery NN 4_p
. . 4_p

-DOCSTART- -X- O O 17366257

community-based JJ 4_p
substance NN 4_p
abuse NN 4_p
clinicians NNS 4_p
Motivational NNP N
Interviewing NNP N
( ( N
MI NNP N
) ) N
. . N

13 CD N
clinicians NNS N
received VBD N
live JJ N
supervision NN N
via IN N
telephone NN N
during IN N
5 CD N
counseling VBG N
sessions NNS N
conducted VBN N
at IN N
their PRP$ N
community NN N
treatment NN N
facilities NNS N
. . N

MI NNP N
community NN N
clinicians NNS N
-DOCSTART- -X- O O 2224810

Recombinant JJ 4_p
human JJ 4_p
erythropoietin NN 4_p
. . 4_p

-DOCSTART- -X- O O 17950167

adolescent JJ 1_p
physical JJ N
activity NN N
adolescents NNS N
participating VBG N
in IN N
a DT N
health NN 4_p
behavior NN 4_p
intervention NN 4_p
. . N

Participants NNS N
were VBD N
adolescent JJ N
girls NNS 2_p
and CC N
boys NNS 2_p
( ( N
N NNP N
= NNP N
878 CD 3_p
) ) N
aged VBN N
11-15 CD 1_p
years NNS N
on IN N
entry NN N
. . N

adolescents NNS N
-DOCSTART- -X- O O 1359809

patients NNS N
undergoing JJ N
abdominal JJ 4_p
hysterectomy NN 4_p
. . N

patients NNS N
anesthetized VBN N
with IN N
thiopental JJ N
, , N
fentanyl JJ N
, , N
nitrous JJ N
oxide NN N
, , N
and CC N
oxygen NN N
. . N

14 CD N
women NNS N
undergoing VBG N
abdominal JJ N
hysterectomy NN N
. . N

20 CD N
patients NNS N
were VBD N
included VBN N
-DOCSTART- -X- O O 17178774

chronic JJ 4_p
midportion NN 4_p
Achilles NNP 4_p
tendinopathy NN 4_p
: : N
chronic JJ 4_p
midportion NN 4_p
Achilles NNP 4_p
tendinopathy NN 4_p
. . N

Sports NNP N
Medical NNP N
Department NNP N
, , N
The DT N
Hague NNP N
Medical NNP N
Centre NNP N
, , N
The DT N
Netherlands NNP N
. . N

Inclusion NNP N
criteria NNS N
were VBD N
: : N
age NN 1_p
18-70 CD 1_p
years NNS 1_p
, , N
active JJ 4_p
participation NN 4_p
in IN 4_p
sports NNS 4_p
, , N
and CC N
tendon VB 4_p
pain NN 4_p
localised VBN 4_p
at IN 4_p
2-7 JJ 4_p
cm NN 4_p
from IN 4_p
distal JJ 4_p
insertion NN 4_p
. . N

Exclusion NN N
criteria NNS N
were VBD N
: : N
insertional JJ N
disorders NNS N
, , N
partial JJ N
or CC N
complete JJ N
ruptures NNS N
, , N
or CC N
systemic JJ N
illness NN N
. . N

70 CD N
tendons NNS N
were VBD N
included VBN N
eccentric JJ N
group NN N
from IN N
50.1 CD N
to TO N
68.8 CD N
( ( N
p NN N
= RB N
0.001 CD N
) ) N
night NN N
splint NN N
group NN N
from IN N
49.4 CD N
to TO N
67.0 CD N
( ( N
p NN N
< RB N
0.001 CD N
) ) N
. . N

-DOCSTART- -X- O O 288486

acute JJ 4_p
myelogenous JJ 4_p
leukemia NN 4_p
. . 4_p

Twenty-seven JJ N
patients NNS N
receiving VBG N
a DT N
standard JJ N
cytosine NN N
arabinoside NN N
and CC N
daunorubicin JJ N
regimen NNS N
as IN N
induction NN N
of IN N
reinduction NN N
therapy NN N
of IN N
acute JJ N
myelogenous JJ N
leukemia NN N
Treatment NN N
groups NNS N
were VBD N
comparable JJ N
with IN N
respect NN N
to TO N
age NN N
and CC N
baseline NN N
granulocyte NN N
counts NNS N
. . N

-DOCSTART- -X- O O 3307842

after IN N
radiation NN N
therapy NN N
for IN N
breast NN N
cancer NN N
. . N

519 CD N
disease-free JJ N
breast NN N
cancer NN N
patients NNS N
7 CD N
to TO N
12 CD N
years NNS N
after IN N
primary JJ N
treatment NN N
. . N

-DOCSTART- -X- O O 9428861

patients NNS 4_p
undergoing VBG 4_p
cholecystectomy NN 4_p
. . N

24 CD 3_p
patients NNS N
undergoing JJ N
cholecystectomy NN N
. . N

Ten CD N
patients NNS N
The DT N
placebo NN N
group NN N
patients NNS N
cholecystectomized JJ N
patients NNS N
. . N

-DOCSTART- -X- O O 24749259

patients NNS N
with IN N
spontaneous JJ 4_p
breathing NN 4_p
after IN 4_p
abdominal JJ 4_p
surgery NN 4_p
. . N

-DOCSTART- -X- O O 17156222

90 CD 3_p
patients NNS 3_p
scheduled VBN N
for IN N
minor JJ 4_p
gynaecological JJ 4_p
( ( 4_p
hysteroscopy NN 4_p
) ) 4_p
or CC 4_p
urological JJ 4_p
( ( 4_p
ureteroscopy JJ 4_p
) ) 4_p
procedures NNS 4_p
planned VBN N
to TO N
last JJ N
1-2 JJ N
h NN N
under IN N
sevoflurane NN 4_p
anaesthesia NN 4_p
with IN N
spontaneous JJ N
ventilation NN N
of IN N
the DT N
lungs NNS N
via IN N
a DT N
laryngeal JJ N
mask NN N
airway NN N
. . N

patients NNS N
who WP N
experienced VBD N
postoperative JJ 4_p
nausea NN 4_p
and CC 4_p
vomiting NN 4_p
in IN N
the DT N
first JJ N
24 CD N
h NN N
( ( N
30 CD N
% NN N
and CC N
27 CD N
% NN N
for IN N
the DT N
midazolam NN N
and CC N
ondansetron NN N
groups NNS N
, , N
respectively RB N
) ) N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

patients NNS N
' POS N
underlying JJ N
risks NNS N
( ( N
midazolam JJ N
group NN N
: : N
p NN N
= VBZ N
0.018 CD N
; : N
ondansetron VBN N
group NN N
: : N
p NN N
= VBZ N
0.017 CD N
) ) N
. . N

-DOCSTART- -X- O O 20837163

hypertensive JJ 4_p
patients NNS N
Diagnosed VBD N
hypertensive JJ 4_p
patients NNS N
Five CD 3_p
hundred VBD 3_p
participants NNS N
were VBD N
enrolled VBN N
and CC N
baseline JJ N
characteristics NNS N
include VBP N
a DT N
mean JJ N
age NN N
of IN N
60.0 CD 1_p
years NNS 1_p
; : N
57.6 CD N
% NN N
female NN 2_p
; : N
and CC N
77.6 CD N
% NN N
white JJ N
. . N

37.7 CD N
% NN N
participants NNS N
had VBD N
uncontrolled VBN 4_p
blood NN 4_p
pressure NN 4_p
; : N
the DT N
mean NN N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
was VBD N
in IN N
the DT N
obese JJ N
range NN N
( ( N
32.4 CD N
) ) N
and CC N
21.8 CD N
% NN N
had VBD N
diabetes NNS 4_p
. . N

-DOCSTART- -X- O O 6341410

87 CD 3_p
volunteers NNS N
who WP N
wanted VBD N
to TO N
quit VB N
cigarette NN 4_p
smoking NN 4_p
individuals NNS N
-DOCSTART- -X- O O 22446996

patients NNS N
with IN N
acute JJ N
coronary JJ N
syndrome NN N
in IN N
the DT N
PROVE NNP N
IT-TIMI NNP N
22 CD N
trial NN N
. . N

large JJ N
cohort NN N
of IN N
patients NNS N
presenting VBG N
across IN N
the DT N
spectrum NN N
of IN N
ACS NNP N
. . N

( ( N
n JJ N
= NNP N
3,761 CD N
) ) N
patients NNS N
randomized VBN N
to TO N
atorvastatin VB N
80 CD N
mg NN N
or CC N
pravastatin NN N
40 CD N
mg NN N
after IN N
ACS NNP N
in IN N
patients NNS N
with IN N
elevated JJ N
baseline NN N
PlGF NNP N
-DOCSTART- -X- O O 8436747

patients NNS 4_p
with IN 4_p
congestive JJ 4_p
heart NN 4_p
failure NN 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
congestive JJ 4_p
heart NN 4_p
failure NN 4_p
. . 4_p

patients NNS N
with IN N
congestive JJ N
heart NN N
failure NN N
. . N

13 CD N
patients NNS N
with IN N
congestive JJ N
heart NN N
failure NN N
long-term JJ N
treatment NN N
of IN N
patients NNS N
having VBG N
congestive JJ N
heart NN N
failure NN N
patients NNS N
with IN N
ischemic JJ N
heart NN N
disease NN N
patients NNS N
with IN N
congestive JJ N
heart NN N
failure NN N
. . N

-DOCSTART- -X- O O 18339046

Thirteen NNP 3_p
emmetropic JJ 4_p
subjects NNS N
-DOCSTART- -X- O O 1336890

early JJ N
post-menopausal JJ N
women NNS N
. . N

spontaneous JJ N
calcanean JJ N
bone NN N
loss NN N
occurring VBG N
in IN N
healthy JJ N
early JJ N
post-menopausal JJ N
women NNS N
-DOCSTART- -X- O O 22349989

In IN 4_p
SUSTAIN NNP 4_p
, , 4_p
172 CD N
patients NNS 4_p
with IN 4_p
low JJ 4_p
levels NNS 4_p
of IN 4_p
HDL-C NNP 4_p
will MD 4_p
be VB 4_p
randomized VBN 4_p
In IN N
ASSURE NNP N
, , N
310 CD 3_p
patients NNS N
with IN N
angiographic JJ 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
and CC N
low JJ N
HDL-C NNP N
levels NNS N
will MD N
be VB N
randomized VBN N
-DOCSTART- -X- O O 2949396

patients NNS N
with IN N
transient JJ 4_p
ischaemic JJ 4_p
attacks NNS 4_p
. . N

25 CD 3_p
male JJ 2_p
patients NNS N
with IN N
transient JJ 4_p
ischaemic JJ 4_p
attacks NNS 4_p
( ( 4_p
TIA NNP 4_p
) ) 4_p
. . N

In IN N
addition NN N
, , N
the DT N
same JJ N
parameters NNS N
were VBD N
studied VBN N
in IN N
a DT N
group NN N
of IN N
20 CD 3_p
healthy JJ N
males NNS 2_p
of IN N
matched JJ N
age NN N
. . N

-DOCSTART- -X- O O 24550145

children NNS 1_p
with IN N
ASD NNP 4_p
who WP N
received VBD 4_p
targeted VBN 4_p
social JJ 4_p
communication NN 4_p
interventions NNS 4_p
. . N

40 CD 3_p
children NNS 1_p
who WP N
were VBD N
participants NNS N
in IN N
a DT N
randomized NN 4_p
controlled VBD 4_p
early JJ 4_p
intervention NN 4_p
trial NN N
( ( N
Kasari NNP N
et RB N
al RB N
. . N

) ) N
from IN 1_p
early JJ 1_p
childhood NN 1_p
( ( 1_p
2-5 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
) ) 1_p
to TO 1_p
elementary JJ 1_p
school NN 1_p
age NN 1_p
( ( 1_p
8-10 CD 1_p
years NNS 1_p
) ) 1_p
-DOCSTART- -X- O O 22669453

AJCC/UICC NNP N
stage NN N
II NNP N
colorectal NN N
cancer NN N
. . N

patients NNS N
with IN N
American JJ N
Joint NNP N
Committee NNP N
on IN N
Cancer/Union NNP N
for IN N
International NNP N
Cancer NNP N
Control NNP N
( ( N
AJCC/UICC NNP N
) ) N
stage NN N
II NNP N
disease NN N
. . N

Tumors NNPS N
of IN N
120 CD N
randomly RB N
selected VBN N
patients NNS N
with IN N
AJCC/UICC NNP N
stage NN N
II NNP N
disease NN N
were VBD N
retrospectively RB N
reviewed VBN N
tumor NN N
growth NN N
pattern NN N
( ( N
expanding VBG N
vs. IN N
infiltrating VBG N
) ) N
outcome NN N
in IN N
patients NNS N
with IN N
AJCC/UICC NNP N
stage NN N
II NNP N
colorectal NN N
cancer NN N
-DOCSTART- -X- O O 22160347

toddlers NNS 1_p
with IN N
autism NN 4_p
. . N

parent NN N
children NNS 1_p
with IN N
autism NN 4_p
based VBN N
on IN N
the DT N
TEACCH NNP N
model NN N
. . N

Twenty JJ 3_p
families NNS 3_p
child NN 1_p
and CC N
parent NN N
-DOCSTART- -X- O O 24919961

Positive NNP N
Parenting NNP N
adapted VBD N
to TO N
Autism NNP 4_p
( ( N
VIPP-AUTI NNP N
) ) N
with IN N
78 CD 3_p
primary JJ 3_p
caregivers NNS 3_p
and CC N
their PRP$ N
child NN 1_p
( ( 1_p
16-61 JJ 1_p
months NNS 1_p
) ) 1_p
with IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorder NNP 4_p
. . N

-DOCSTART- -X- O O 19516150

overweight JJ 4_p
Latina NNP 4_p
adolescents NNS 1_p
. . N

overweight JJ N
Latina NNP N
adolescent NN N
females NNS 2_p
. . N

41 CD 3_p
overweight JJ 4_p
Latina NNP N
girls NNS 2_p
( ( N
15.2 CD 1_p
+/- JJ 1_p
1.1 CD 1_p
yr NN 1_p
) ) N
overweight JJ 4_p
Latina NNP N
girls NNS 2_p
. . N

-DOCSTART- -X- O O 18243378

sheep JJ 4_p
production NN 4_p
in IN 4_p
Ethiopia NNP 4_p
. . 4_p

three CD N
genotypes NNS N
of IN N
sheep NN N
in IN N
a DT N
2 CD N
x NN N
2 CD N
x JJ N
3 CD N
factorial JJ N
experiment NN N
conducted VBN N
at IN N
Debre NNP N
Berhan NNP N
research NN N
station NN N
in IN N
the DT N
central JJ 4_p
highlands NNS 4_p
of IN 4_p
Ethiopia NNP 4_p
. . N

three CD N
genotypes NNS N
: : N
indigenous JJ N
Menz NNP N
( ( N
n=40 NN 3_p
) ) N
, , N
50 CD N
% NN N
Awassi NNP N
x NNP N
50 CD N
% NN N
Menz NNP N
crosses VBZ N
( ( N
n=38 NN N
) ) N
and CC N
75 CD N
% NN N
Awassi NNP N
x NNP N
25 CD N
% NN N
Menz NNP N
crosses VBZ N
( ( N
n=31 JJ 3_p
) ) N
. . N

sheep JJ N
-DOCSTART- -X- O O 12238830

atrial JJ N
fibrillation NN N
after IN N
coronary JJ N
artery NN N
bypass NN N
grafting NN N
patients NNS N
after IN 4_p
coronary JJ 4_p
operations NNS 4_p
. . N

Two CD 3_p
hundred VBD 3_p
seven CD 3_p
consecutive JJ N
coronary JJ N
artery NN N
bypass NN N
patients NNS N
( ( N
mean JJ N
age NN N
62 CD N
+/- JJ N
11 CD N
years NNS N
) ) N
All DT N
patients NNS N
with IN N
an DT N
ejection NN N
fraction NN N
less JJR N
than IN N
0.40 CD N
were VBD N
excluded VBN N
. . N

-DOCSTART- -X- O O 24231167

children NNS 1_p
with IN N
autism NN N
spectrum NN N
disorders NNS N
and CC N
serious JJ N
behavioral JJ N
problems NNS N
. . N

206 CD 3_p
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
who WP N
participated VBD N
in IN N
2 CD N
risperidone NN N
trials NNS N
. . N

-DOCSTART- -X- O O 17603862

lateral JJ 4_p
epicondylitis NN 4_p
. . 4_p

tennis NN 4_p
elbow NN 4_p
. . 4_p

tennis NN 4_p
elbow NN 4_p
Fifty NNP N
patients NNS N
who WP N
had VBD N
tennis NN N
elbow NN N
participated VBD N
in IN N
the DT N
study NN N
-DOCSTART- -X- O O 15890448

chorioptic JJ 4_p
mange NN 4_p
in IN N
alpacas NN N
. . N

naturally RB N
infested VBN N
alpacas NN N
Thirty NNP 3_p
alpacas NN N
, , N
all DT N
positive JJ N
for IN N
Chorioptes NNP N
sp NN N
. . N

mite NN N
, , N
were VBD N
randomly RB N
allocated VBN N
to TO N
two CD N
treatment NN N
groups NNS N
in IN N
Study NNP N
1 CD N
. . N

In IN N
Study NNP N
2 CD N
, , N
one CD N
group NN N
of IN N
19 CD 3_p
alpacas NNS N
received VBD N
four CD N
administrations NNS N
at IN N
weekly JJ N
interval NN N
of IN N
topical JJ N
eprinomectin NN N
at IN N
the DT N
dose JJ N
rate NN N
of IN N
500mug/kg CD N
, , N
and CC N
response NN N
to TO N
treatment NN N
was VBD N
monitored VBN N
by IN N
mite JJ N
counts NNS N
. . N

Chorioptes NNPS 4_p
mite JJ 4_p
burden NN 4_p
in IN N
alpacas NN N
. . N

-DOCSTART- -X- O O 1778354

type NN 4_p
2 CD 4_p
( ( 4_p
non-insulin-dependent JJ 4_p
) ) 4_p
diabetes VBZ 4_p
mellitus VBN 4_p
of IN N
6,956 CD N
47-49-year-old JJ N
Malmö NNP N
males NNS N
, , N
a DT N
series NN N
of IN N
41 CD N
subjects NNS N
with IN N
early-stage JJ N
Type NNP N
2 CD N
( ( N
non-insulin-dependent JJ N
) ) N
diabetes VBZ N
mellitus JJ N
and CC N
181 CD N
subjects NNS N
with IN N
impaired JJ N
glucose JJ N
tolerance NN N
-DOCSTART- -X- O O 10408075

umbilical JJ 4_p
cord NN 4_p
complications NNS 4_p
] VBP 4_p
A NNP N
low-risk JJ N
population NN N
of IN N
4196 CD N
cases NNS N
was VBD N
selected VBN N
in IN N
which WDT N
cord NN N
complications NNS N
have VBP N
been VBN N
recognized VBN N
in IN N
34.3 CD N
% NN N
. . N

Cases VBZ 4_p
with IN 4_p
cord NN 4_p
complications NNS 4_p
and CC 4_p
controls NNS 4_p
were VBD 4_p
paired VBN 4_p
25 CD N
pairs NNS N
were VBD N
randomly RB N
selected VBN N
. . N

-DOCSTART- -X- O O 16095446

paediatric JJ 4_p
cuffed NN 4_p
tracheal NN 4_p
tubes NNS 4_p
50 CD 3_p
children NNS 1_p
undergoing VBG N
general JJ 4_p
anaesthesia NN 4_p
with IN 4_p
tracheal JJ 4_p
intubation NN 4_p
and CC 4_p
standardized JJ 4_p
anaesthesia NN 4_p
technique NN 4_p
( ( N
including VBG N
66 CD N
% NN N
N2O NNP N
in IN N
O2 NNP N
) ) N
and CC N
ventilator JJ N
settings NNS N
. . N

-DOCSTART- -X- O O 20447774

prostate NN N
cancer NN N
. . N

patients NNS 4_p
with IN 4_p
high-risk JJ 4_p
prostate NN 4_p
cancer NN 4_p
. . 4_p

Between NNP N
January NNP N
2003 CD N
and CC N
December NNP N
2007 CD N
, , N
168 CD N
patients NNS N
All DT 1_p
patients NNS 1_p
had VBD 1_p
undergone RP 1_p
a DT 1_p
9-month JJ 1_p
course NN 1_p
of IN 1_p
total JJ 1_p
androgen NN 1_p
deprivation NN 1_p
, , 1_p
with IN 1_p
radiotherapy NN 1_p
starting VBG 1_p
2 CD 1_p
months NNS 1_p
after IN 1_p
initiation NN 1_p
of IN 1_p
the DT 1_p
total JJ 1_p
androgen NN 1_p
deprivation NN 1_p
. . 1_p

-DOCSTART- -X- O O 18572078

patients NNS N
with IN N
relapsing-remitting JJ 4_p
multiple JJ 4_p
sclerosis NN 4_p
: : N
a DT N
multicentre NN 4_p
patients NNS N
with IN N
relapsing-remitting JJ N
multiple JJ N
sclerosis NN N
The DT N
study NN N
was VBD N
done VBN N
in IN N
51 CD 4_p
centres NNS 4_p
in IN 4_p
nine CD 4_p
countries NNS 4_p
. . 4_p

Inclusion NN N
criteria NNS N
were VBD N
one CD 4_p
or CC 4_p
more JJR 4_p
relapses NNS 4_p
in IN 4_p
the DT 4_p
year NN 4_p
before IN 4_p
entry NN 4_p
and CC 4_p
at IN 4_p
least JJS 4_p
one CD 4_p
gadolinium NN 4_p
enhancing NN 4_p
( ( 4_p
GdE NNP 4_p
) ) 4_p
lesion NN 4_p
on IN 4_p
screening VBG 4_p
MRI NNP 4_p
. . 4_p

Of IN N
720 CD N
patients NNS N
screened VBD N
, , N
306 CD 3_p
eligible JJ N
patients NNS N
were VBD N
enrolled VBN N
. . N

Patients NNS N
, , N
aged VBN N
18-50 CD 1_p
years NNS N
In IN N
patients NNS N
with IN N
relapsing-remitting JJ N
multiple JJ N
sclerosis NN N
-DOCSTART- -X- O O 2973215

non-Q-wave JJ 4_p
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
. . N

non-Q-wave JJ 4_p
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
( ( 4_p
AMI NNP 4_p
) ) 4_p
non-Q-wave JJ N
AMI NNP N
confirmed VBN N
by IN N
creatine NN N
kinase-MB NN N
( ( N
CK-MB NNP N
) ) N
544 CD N
patients NNS N
patients NNS N
( ( N
65 CD N
vs RB N
60 CD N
years NNS N
-DOCSTART- -X- O O 21989146

Helicobacter NNP N
pylori NN N
. . N

Helicobacter NNP N
pylori NN N
( ( N
HP NNP N
) ) N
HP-infected JJ 4_p
patients NNS 4_p
. . 4_p

treatment-naive JJ N
patients NNS N
. . N

Patients NNPS N
with IN N
a DT N
diagnosis NN N
of IN N
HP NNP N
gastritis NN N
or CC N
peptic JJ N
ulcer JJ N
disease NN N
confirmed VBD N
using VBG N
endoscopy NN N
and CC N
stool NN N
antigen NN N
testing VBG N
were VBD N
eligible JJ N
for IN N
inclusion NN N
in IN N
this DT N
study NN N
. . N

patients NNS N
Patients NNS N
HP NNP N
in IN N
treatment-naive JJ N
patients NNS N
. . N

-DOCSTART- -X- O O 16483029

erectile JJ 4_p
dysfunction NN 4_p
: : 4_p
Men NNP 2_p
with IN N
erectile JJ 4_p
dysfunction NN 4_p
were VBD N
randomized VBN N
into IN N
two CD 3_p
groups NNS 3_p
of IN 3_p
25 CD 3_p
each DT 3_p
. . N

25 CD 3_p
men NNS 2_p
erectile JJ 4_p
dysfunction NN 4_p
. . N

-DOCSTART- -X- O O 9532967

short-term JJ 4_p
memory NN 4_p
random NN N
interval JJ N
repetition NN N
central JJ 4_p
executive NN 4_p
-DOCSTART- -X- O O 15283485

Chronic NNP 4_p
rhinosinusitis NN 4_p
( ( 4_p
CRS NNP 4_p
) ) 4_p
CRS NNP 4_p
post-functional JJ N
endoscopic NN N
sinus NN N
surgery NN N
patients NNS N
who WP N
presented VBD N
for IN N
their PRP$ N
initial JJ N
visitfrom NN N
1996 CD N
to TO N
1998 CD N
. . N

200 CD 3_p
randomly RB N
selected VBN N
patients NNS N
Eighty-nine JJ 3_p
( ( 3_p
59.3 CD 3_p
% NN 3_p
) ) 3_p
women NNS N
and CC N
61 CD 3_p
( ( 3_p
40.7 CD 3_p
% NN 3_p
) ) 3_p
men NNS N
patients NNS N
with IN N
CRS NNP 4_p
-DOCSTART- -X- O O 22578685

patients NNS N
after IN N
open-chamber JJ 4_p
cardiac JJ 4_p
surgery NN 4_p
patients NNS N
undergoing VBG 4_p
open-chamber JJ 4_p
( ( 4_p
left-sided JJ 4_p
) ) 4_p
cardiac NN 4_p
surgery NN 4_p
who WP N
were VBD N
assigned VBN N
carbon NN N
dioxide NN N
insufflation NN N
or CC N
placebo NN N
( ( N
control VB N
group NN N
) ) N
in IN N
addition NN N
to TO N
standardized VB N
mechanical JJ N
deairing VBG N
maneuvers NNS N
. . N

One CD 3_p
hundred VBD 3_p
twenty-five JJ 3_p
patients NNS N
underwent JJ N
surgery NN N
Factors NNS N
most RBS N
strongly RB N
associated VBN N
with IN N
neurocognitive JJ N
decline NN N
were VBD N
hypercholesterolemia JJ N
, , N
aortic JJ N
atheroma NN N
grade NN N
, , N
and CC N
coronary JJ N
artery NN N
disease NN N
. . N

The DT N
most RBS N
important JJ N
factor NN N
is VBZ N
atheromatous JJ 4_p
vascular JJ 4_p
disease NN 4_p
. . N

-DOCSTART- -X- O O 24732169

postmenopausal JJ 4_p
women NNS 2_p
with IN N
chronic JJ 4_p
venous JJ 4_p
insufficiency NN 4_p
: : N
postmenopausal JJ 4_p
women NNS N
with IN N
chronic JJ 4_p
venous JJ 4_p
insufficiency NN 4_p
( ( 4_p
CVI NNP 4_p
) ) 4_p
. . N

Consecutive JJ N
postmenopausal NN N
women NNS N
( ( N
N=130 NNP N
; : N
mean JJ N
age NN N
± NNP N
SD NNP N
, , N
65.44±14.7y CD N
) ) N
with IN N
mild JJ N
CVI NNP N
-DOCSTART- -X- O O 7092002

40 CD 4_p
patients NNS 4_p
to TO 4_p
evaluate VB 4_p
the DT 4_p
need NN 4_p
for IN 4_p
antibiotics NNS 4_p
in IN 4_p
acute JJ 4_p
exacerbations NNS 4_p
of IN 4_p
chronic JJ 4_p
bronchitis NN 4_p
. . 4_p

All DT N
patients NNS N
were VBD N
sufficiently RB N
ill VBN N
to TO N
require VB N
hospitalization NN N
although IN N
none NN N
needed VBD N
ventilatory JJ N
support NN N
; : N
the DT N
presence NN N
of IN N
pneumonia NN N
was VBD N
excluded VBN N
. . N

moderately RB N
ill JJ N
patients NNS N
with IN N
exacerbations NNS N
of IN N
chronic JJ N
bronchitis NN N
. . N

-DOCSTART- -X- O O 2871744

acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
: : 4_p
A DT N
total NN N
of IN N
269 CD 3_p
patients NNS N
, , N
who WP N
presented VBD N
with IN N
symptoms NNS 4_p
and CC 4_p
electrocardiographic JJ 4_p
signs NNS 4_p
suggesting VBG 4_p
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
were VBD N
randomized VBN N
to TO N
acute VB N
intravenous JJ N
and CC N
subsequent JJ N
oral JJ N
therapy NN N
with IN N
propranolol NN N
( ( N
n JJ N
= NNP N
134 CD N
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
135 CD N
) ) N
. . N

patients NNS N
with IN N
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
-DOCSTART- -X- O O 15358872

Parent NNP 4_p
management NN 4_p
training NN 4_p
and CC 4_p
Asperger NNP 4_p
syndrome NN 4_p
: : 4_p
parent NN 4_p
based VBN 4_p
Asperger NNP 4_p
syndrome NN 4_p
. . N

parents NNS N
of IN N
a DT N
child NN 1_p
with IN N
Asperger NNP 4_p
syndrome NN 4_p
. . N

-DOCSTART- -X- O O 11384820

percutaneous JJ N
coronary JJ N
interventions NNS N
( ( N
PCI NNP N
) ) N
. . N

99 CD N
post-percutaneous JJ N
coronary JJ N
interventions NNS N
( ( N
PCI NNP N
) ) N
patients NNS N
patients NNS N
following VBG N
PCI NNP N
. . N

-DOCSTART- -X- O O 8123947

patients NNS 4_p
receiving VBG 4_p
intravenous JJ 4_p
antibiotics NNS 4_p
: : 4_p
specific JJ N
for IN N
a DT N
patient NN 3_p
group NN 3_p
receiving VBG N
prolonged JJ N
courses NNS N
of IN N
i.v NN N
. . N

antibiotics NNS N
. . N

Patients NNPS N
with IN N
cystic JJ N
fibrosis NN N
receiving VBG N
intermittent JJ N
i.v NN N
. . N

antibiotics NNS N
patients NNS N
requiring VBG N
longer JJR N
term NN N
i.v NN N
. . N

access NN N
. . N

-DOCSTART- -X- O O 21034619

patients NNS 4_p
with IN 4_p
chronic JJ 4_p
severe JJ 4_p
hepatitis NN 4_p
. . 4_p

patients NNS N
with IN N
chronic JJ N
severe JJ 4_p
hepatitis NN 4_p
Eighty-five JJ 3_p
cases NNS 3_p
with IN N
chronic JJ N
severe JJ 4_p
hepatitis NN 4_p
treatment NN 4_p
plus CC 4_p
medical JJ 4_p
ozone NN 4_p
therapy NN 4_p
for IN 4_p
-DOCSTART- -X- O O 18845704

Thirty-one JJ 3_p
men NNS 2_p
and CC 2_p
women NNS 2_p
, , N
age NN 1_p
19-50 JJ 1_p
y NN 1_p
and CC N
body NN 4_p
mass NN 4_p
index NN 4_p
27-33 JJ 4_p
kg/m NN 4_p
( ( 4_p
2 CD 4_p
) ) 4_p
Two CD N
of IN N
the DT N
3 CD N
subjects NNS N
in IN N
the DT N
MCT NNP 4_p
oil NN 4_p
group NN N
6 CD N
subjects NNS N
had VBD N
the DT N
metabolic JJ 4_p
syndrome NN 4_p
at IN N
baseline NN N
; : N
2 CD N
subjects VBZ N
no RB N
longer RBR N
had VBD N
metabolic JJ N
syndrome NN N
at IN N
endpoint NN N
, , N
1 CD N
person NN N
developed VBD N
metabolic JJ 4_p
syndrome NN 4_p
, , N
and CC N
4 CD N
subjects NNS N
did VBD N
not RB N
have VB N
any DT N
change NN N
in IN N
their PRP$ N
metabolic JJ N
syndrome NN N
status NN N
. . N

-DOCSTART- -X- O O 3550340

patients NNS 4_p
with IN 4_p
squamous JJ 4_p
cell NN 4_p
carcinoma NN 4_p
of IN 4_p
the DT 4_p
head NN 4_p
and CC 4_p
neck NN 4_p
. . 4_p

Eighty-three JJ N
patients NNS N
with IN N
advanced JJ N
disease NN N
were VBD N
entered VBN N
into IN N
the DT N
first JJ N
study NN N
( ( N
43/chemotherapy CD N
; : N
40/control CD N
) ) N
, , N
and CC N
60 CD N
into IN N
the DT N
second JJ N
Patient JJ N
randomization NN N
was VBD N
stratified VBN N
by IN N
stage NN N
( ( N
III/IV NNP N
) ) N
and CC N
site NN N
-DOCSTART- -X- O O 17901881

amblyopia NN N
. . N

51 CD N
participants NNS N
with IN N
amblyopia NN N
( ( N
strabismic JJ N
n=17 NN N
; : N
anisometropic CC N
n=10 VBP N
; : N
combined VBN N
n=24 NN N
) ) N
, , N
mean JJ N
age NN N
10 CD N
years NNS N
8 CD N
months NNS N
. . N

The DT N
amblyopia NN N
was VBD N
defined VBN N
as IN N
severe/moderate NN N
( ( N
< JJ N
0.250 CD N
logMAR NN N
) ) N
, , N
n=41 RB N
or CC N
mild VB N
( ( N
> CD N
or CC N
= VB N
0.250 CD N
logMAR NN N
) ) N
, , N
n=10 RB N
. . N

subgroup NN N
with IN N
severe/moderate NN N
amblyopia NN N
( ( N
0.074+/-0.036 JJ N
) ) N
-DOCSTART- -X- O O 22695168

Ten CD 3_p
females NNS 2_p
ran VBD N
barefoot NN N
over IN N
a DT N
force NN N
plate NN N
in IN N
three CD N
conditions NNS N
: : N
no DT N
heel NN N
lifts NNS N
( ( N
NHL NNP N
) ) N
, , N
with IN N
12 CD N
mm NNS N
heel JJ N
lifts NNS N
( ( N
12HL CD N
) ) N
and CC N
with IN N
18 CD N
mm NNS N
heel JJ N
lifts NNS N
( ( N
18HL CD N
) ) N
. . N

-DOCSTART- -X- O O 7887018

healthy JJ 4_p
volunteers NNS 4_p
vaccinated VBD 4_p
with IN 4_p
BCG NNP 4_p
plus CC 4_p
killed VBN 4_p
leishmanial JJ 4_p
promastigotes NNS 4_p
: : N
208 CD 3_p
initially RB N
PPD NNP N
and CC N
leishmanin JJ N
skin-test JJ N
negative JJ N
volunteers NNS N
68 CD 3_p
received VBD N
BCG NNP N
plus CC N
Venezuelan NNP 4_p
vaccinees NNS 4_p
non-endemic JJ N
( ( N
British JJ N
) ) N
volunteers NNS N
. . N

-DOCSTART- -X- O O 12569977

mild JJ 4_p
asthma JJ 4_p
patients NNS 4_p
: : 4_p
mite-allergic JJ N
asthma NN N
. . N

mite JJ 4_p
monosensitive NN 4_p
, , 4_p
mild JJ 4_p
asthma NN 4_p
patients NNS 4_p
. . 4_p

26 CD N
asthma JJ N
patients NNS N
who WP N
randomly VBP N
received VBN N
vaccination NN N
or CC N
placebo NN N
for IN N
1 CD N
year NN N
. . N

mild JJ 4_p
asthma JJ 4_p
patients NNS 4_p
-DOCSTART- -X- O O 16712638

young JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
: : N
young JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
. . N

Participants NNPS N
were VBD N
58 CD 3_p
children NNS 1_p
with IN N
autism NN 4_p
aged VBN N
3 CD 1_p
and CC 1_p
4 CD 1_p
years NNS 1_p
( ( N
46 CD 3_p
boys NNS 2_p
) ) N
. . N

young JJ N
children NNS N
with IN N
autism NN N
. . N

-DOCSTART- -X- O O 22616853

persistent JJ N
insomnia NN 4_p
in IN N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
: : N
sleep JJ N
disorders NNS N
in IN N
children NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
One CD 3_p
hundred CD 3_p
and CC 3_p
sixty JJ 3_p
children NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
, , N
aged VBN 1_p
4-10 CD 1_p
years NNS 1_p
, , N
suffering VBG N
from IN N
sleep JJ 4_p
onset NN 4_p
insomnia NN 4_p
and CC 4_p
impaired JJ 4_p
sleep JJ 4_p
maintenance NN 4_p
-DOCSTART- -X- O O 16671415

traumatic JJ N
brain NN N
injury NN N
: : N
patients NNS N
with IN N
traumatic JJ N
brain NN N
injury NN N
and CC N
raised VBD N
intracranial JJ N
pressure NN N
that WDT N
does VBZ N
not RB N
respond VB N
to TO N
initial JJ N
treatment NN N
measures NNS N
. . N

-DOCSTART- -X- O O 17434069

screening VBG 4_p
mammography NN 4_p
patients NNS 4_p
. . 4_p

women NNS 4_p
who WP 4_p
present VBP 4_p
for IN 4_p
screening VBG 4_p
mammography NN 4_p
. . N

A NNP N
total NN N
of IN N
198 CD 3_p
English-speaking JJ 3_p
women NNS 3_p
, , N
with IN N
no DT N
personal JJ N
or CC N
family NN N
history NN N
of IN N
breast NN 4_p
cancer NN 4_p
, , N
were VBD N
recruited VBN N
and CC N
randomized VBN N
to TO N
four CD N
groups NNS N
when WRB N
they PRP N
presented VBD N
to TO N
the DT N
clinic NN N
for IN N
a DT N
screening NN 4_p
mammogram NN 4_p
. . N

-DOCSTART- -X- O O 7053590

One CD 3_p
hundred CD 3_p
and CC 3_p
ten VB 3_p
consecutive JJ N
patients NNS N
were VBD N
evaluated VBN N
. . N

premalignant JJ N
changes NNS N
of IN N
the DT N
cervix NN N
uteri NN N
-DOCSTART- -X- O O 26315981

Children NNP 1_p
With IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorder NNP 4_p
. . N

children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) N
. . N

children NNS 1_p
with IN N
attention NN N
deficit NN N
hyperactivity NN 4_p
disorder NN N
children NNS N
with IN N
ASD NNP N
Sixty-two JJ 3_p
subjects NNS N
( ( N
boys NNS 2_p
, , N
N=53 NNP N
; : N
girls NNS 2_p
, , N
N=9 NNP N
; : N
mean JJ N
age=8.5 CD 1_p
years NNS 1_p
[ JJ N
SD=2.25 NNP N
] NN N
) ) N
children NNS 1_p
with IN N
ASD NNP 4_p
. . N

-DOCSTART- -X- O O 9562733

patients NNS N
with IN N
cerebral JJ N
ischaemia NN N
of IN N
arterial JJ N
origin NN N
planned VBN N
to TO N
enroll VB N
4500 CD N
patients NNS N
with IN N
a DT N
mean JJ N
follow-up NN N
of IN N
three CD N
years NNS N
. . N

international JJ N
, , N
multicentre JJ N
study NN N
in IN N
which WDT N
60-80 JJ N
hospitals NNS N
in IN N
the DT N
Netherlands NNP N
and CC N
other JJ N
countries NNS N
in IN N
Europe NNP N
and CC N
Australia NNP N
will MD N
participate VB N
. . N

-DOCSTART- -X- O O 25973096

ischemia/reperfusion NN 4_p
cerebral JJ 4_p
injury NN 4_p
. . N

neurosurgery NN 4_p
. . N

inpatient JJ N
ischemia/reperfusion NN 4_p
cerebral JJ 4_p
injury NN 4_p
during IN N
cerebral JJ N
or CC N
neural JJ N
surgeries NNS N
. . N

Chinese JJ N
patient NN N
population NN N
surgical JJ N
patients NNS N
under IN N
clinical JJ N
conditions NNS N
experiencing VBG N
substantial JJ 4_p
cerebral JJ 4_p
vasodilation NN 4_p
. . N

-DOCSTART- -X- O O 18341602

Fifteen NNP 3_p
patients NNS 3_p
, , N
each DT N
with IN N
a DT N
pair NN N
of IN N
contralateral JJ 4_p
class-II JJ 4_p
proximal JJ 4_p
furcation NN 4_p
involvements NNS 4_p
, , N
presenting VBG 4_p
probing VBG 4_p
depths NNS 4_p
( ( 4_p
PDs NNP 4_p
) ) 4_p
> VBP 4_p
/=5 JJ 4_p
mm NN 4_p
and CC N
bleeding NN 4_p
on IN 4_p
probing VBG 4_p
( ( 4_p
BOP NNP 4_p
) ) 4_p
were VBD N
selected VBN N
. . N

-DOCSTART- -X- O O 3545842

patients NNS 4_p
with IN 4_p
acute NN 4_p
severe JJ 4_p
pulmonary JJ 4_p
embolism NN 4_p
( ( 4_p
PE NNP 4_p
) ) 4_p
. . 4_p

PE NNP N
was VBD N
less JJR N
than IN N
5 CD N
days NNS N
old JJ N
133 CD N
patients NNS N
two CD N
patients NNS N
died VBD N
before IN N
treatment NN N
and CC N
two CD N
were VBD N
excluded VBN N
retrospectively RB N
, , N
leaving VBG N
129 CD N
patients NNS N
for IN N
final JJ N
analysis NN N
two CD N
groups NNS N
-DOCSTART- -X- O O 3307414

glomerular JJ 4_p
diseases NNS 4_p
: : N
glomerulonephritis NN 4_p
29 CD 3_p
GN NNP 3_p
patients NNS N
with IN N
normal JJ 4_p
renal JJ 4_p
function NN 4_p
( ( N
17 CD 3_p
membranoproliferative NN N
GN NNP N
, , N
12 CD 3_p
IgA NNP N
GN NNP N
) ) N
-DOCSTART- -X- O O 11550726

therapists NNS 4_p
therapists NNS N
disclosing VBG N
personal JJ N
information NN N
during IN N
psychotherapy NN N
. . N

therapists NNS N
at IN N
a DT N
university NN N
counseling NN N
center NN N
one CD N
client NN N
another DT N
client NN N
. . N

quality NN N
of IN N
the DT N
therapeutic JJ N
relationship NN N
and CC N
the DT N
outcome NN N
of IN N
treatment NN N
. . N

-DOCSTART- -X- O O 10525558

( ( 4_p
COPD NNP 4_p
) ) 4_p
. . 4_p

One CD 4_p
hundred CD 4_p
and CC 4_p
forty VB 4_p
four CD 4_p
patients NNS 4_p
with IN 4_p
moderate JJ 4_p
or CC 4_p
severe JJ 4_p
COPD NNP 4_p
patients NNS N
receiving VBG N
combination NN N
treatment NN N
-DOCSTART- -X- O O 2947151

chronic JJ 4_p
coronary JJ 4_p
insufficiency NN 4_p
] NNP 4_p
29 CD 3_p
male JJ 2_p
patients NNS N
with IN N
coronary JJ 4_p
insufficiency NN 4_p
who WP N
had VBD N
persistent JJ 4_p
ST NNP 4_p
depression NN 4_p
on IN N
exercise NN N
tolerance NN N
test NN N
( ( N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
1 CD N
mm NN N
) ) N
, , N
despite IN N
treatment NN N
with IN N
nifedipine JJ N
40 CD N
mg JJ N
per IN N
day NN N
. . N

-DOCSTART- -X- O O 15678729

Postoperative JJ N
Fifty NNP 3_p
ASA NNP 4_p
I-II JJ 4_p
patients NNS 4_p
after IN 4_p
spinal JJ 4_p
anaesthesia NN 4_p
. . N

-DOCSTART- -X- O O 25798575

advanced JJ 4_p
, , 4_p
life-limiting JJ 4_p
illness NN 4_p
: : 4_p
patients NNS 4_p
with IN 4_p
limited JJ 4_p
prognosis NN 4_p
patients NNS 4_p
with IN 4_p
limited JJ 4_p
life NN 4_p
expectancy NN 4_p
. . N

patients NNS 4_p
in IN 4_p
the DT 4_p
palliative JJ 4_p
care NN 4_p
setting VBG 4_p
. . N

Eligibility NNP N
included VBD N
adults NNS 1_p
with IN N
an DT N
estimated JJ N
life NN N
expectancy NN N
of IN N
between IN N
1 CD N
month NN N
and CC N
1 CD N
year NN N
, , N
statin NN N
therapy NN N
for IN N
3 CD N
months NNS N
or CC N
more JJR N
for IN N
primary JJ N
or CC N
secondary JJ N
prevention NN N
of IN N
cardiovascular JJ 4_p
disease NN 4_p
, , N
recent JJ N
deterioration NN N
in IN N
functional JJ N
status NN N
, , N
and CC N
no DT N
recent JJ 4_p
active JJ 4_p
cardiovascular JJ 4_p
disease NN 4_p
. . N

conducted VBN N
from IN N
June NNP N
3 CD N
, , N
2011 CD N
, , N
to TO N
May NNP N
2 CD N
, , N
2013 CD N
. . N

A DT N
total NN N
of IN N
381 CD 3_p
patients NNS N
were VBD N
enrolled VBN N
; : N
Mean NNP 1_p
( ( 1_p
SD NNP 1_p
) ) 1_p
age NN 1_p
was VBD 1_p
74.1 CD 1_p
( ( 1_p
11.6 CD 1_p
) ) 1_p
years NNS 1_p
, , N
22.0 CD N
% NN N
of IN N
the DT N
participants NNS N
were VBD N
cognitively RB N
impaired VBN N
, , N
and CC N
48.8 CD N
% NN N
had VBD N
cancer NN N
. . N

-DOCSTART- -X- O O 3940160

[ IN N
The DT 4_p
use NN 4_p
of IN 4_p
cephalosporins NNS 4_p
in IN 4_p
hospital NN 4_p
practice NN 4_p
] NN N
-DOCSTART- -X- O O 9230829

patients NNS N
with IN N
small JJ N
choroidal NNS N
melanoma NN N
. . N

patients NNS N
with IN N
small JJ N
choroidal NNS N
melanoma NN N
. . N

From IN N
December NNP N
1986 CD N
to TO N
August NNP N
1989 CD N
, , N
patients NNS N
with IN N
small JJ N
choroidal NN N
melanoma NN N
, , N
not RB N
large JJ N
enough RB N
to TO N
be VB N
eligible JJ N
for IN N
the DT N
COMS NNP N
clinical JJ N
trials NNS N
A DT N
total NN N
of IN N
204 CD N
patients NNS N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

Otherwise NNP N
healthy JJ N
patients NNS N
, , N
average JJ N
age NN N
of IN N
60 CD N
years NNS N
, , N
without IN N
a DT N
previous JJ N
diagnosis NN N
of IN N
malignant JJ N
disease NN N
who WP N
have VBP N
small JJ N
choroidal JJ N
lesions NNS N
judged VBD N
to TO N
be VB N
melanoma VBN N
-DOCSTART- -X- O O 2108990

treatment NN 4_p
in IN 4_p
an DT 4_p
IVF NNP 4_p
programme NN 4_p
. . 4_p

IVF NNP N
programme NN N
HCG NNP N
( ( N
193 CD N
transfers NNS N
) ) N
against IN N
placebo NN N
( ( N
194 CD N
transfers NNS N
) ) N
. . N

IVF NNP 4_p
programme NN 4_p
. . 4_p

-DOCSTART- -X- O O 10778276

subject NN 4_p
's POS 4_p
fist NN 4_p
clenching NN 4_p
20 CD N
female JJ N
and CC N
20 CD N
male JJ N
students NNS N
( ( N
ages NNS N
: : N
17-34 CD N
years NNS N
) ) N
-DOCSTART- -X- O O 8015504

Twenty-six JJ N
postmenopausal JJ N
women NNS N
-DOCSTART- -X- O O 20218011

16 CD 3_p
normal JJ 4_p
adult NN 1_p
male NN 2_p
volunteers NNS N
digoxin NN N
. . N

-DOCSTART- -X- O O 9553664

postmastectomy NN 4_p
lymphedema NN 4_p
. . N

patients NNS N
affected VBN N
by IN N
postmastectomy JJ 4_p
lymphedema NN 4_p
patients NNS N
with IN N
postmastectomy JJ 4_p
lymphedema NN 4_p
. . N

Patients NNPS N
with IN N
monolateral JJ 4_p
postmastectomy NN 4_p
lymphedema NN 4_p
Eighty NNP 3_p
patients NNS N
-DOCSTART- -X- O O 7964693

progressive JJ 4_p
supranuclear JJ 4_p
palsy NN 4_p
: : N
progressive JJ 4_p
supranuclear JJ 4_p
palsy NN 4_p
( ( N
PSP NNP N
) ) N
patients NNS N
enrolled VBN N
in IN N
these DT N
studies NNS N
-DOCSTART- -X- O O 8155449

50 CD 3_p
patients NNS N
allocated VBD N
randomly RB N
to TO N
undergo VB N
anaesthesia NN N
with IN N
either DT N
artificial JJ N
ventilation NN N
with IN N
isoflurane NN N
and CC N
nitrous JJ N
oxide NN N
in IN N
oxygen NN N
and CC N
atracurium NN N
( ( N
group NN N
A NNP N
) ) N
or CC N
spontaneous JJ N
ventilation NN N
with IN N
isoflurane NN N
and CC N
nitrous JJ N
oxide NN N
in IN N
oxygen NN N
( ( N
group NN N
B NNP N
) ) N
. . N

-DOCSTART- -X- O O 19995250

women NNS 2_p
who WP N
seek VBP N
reduction NN 4_p
mammaplasty NN 4_p
have VBP N
pathological JJ N
degrees NNS N
of IN N
anxiety NN 4_p
or CC N
depression NN 4_p
, , N
or CC N
both DT N
. . N

Eighty-two JJ 3_p
patients NNS N
were VBD N
randomised VBN N
, , N
40 CD N
to TO N
have VB N
the DT N
operation NN N
, , N
and CC N
42 CD N
patients NNS N
to TO N
conservative JJ N
treatment NN N
. . N

Twenty-nine JJ N
patients NNS N
in IN N
the DT N
operated JJ N
group NN N
and CC N
35 CD N
patients NNS N
in IN N
the DT N
conservative JJ N
group NN N
-DOCSTART- -X- O O 16940738

third JJ 4_p
stage NN 4_p
of IN 4_p
labor NN 4_p
. . N

Three CD 3_p
hundred VBD 3_p
and CC 3_p
fifty-five JJ 3_p
women NNS 2_p
third JJ 4_p
stage NN 4_p
of IN 4_p
labor NN 4_p
-DOCSTART- -X- O O 8712092

patients NNS N
with IN N
prostatic JJ 4_p
cancer NN 4_p
] NN N
124 CD 3_p
patients NNS N
with IN N
prostatic JJ N
cancer NN 4_p
( ( N
stage NN N
C NNP N
, , N
D NNP N
) ) N
. . N

patients NNS N
with IN N
prostatic JJ N
cancer NN 4_p
-DOCSTART- -X- O O 7559252

five CD 3_p
normal JJ 4_p
subjects NNS N
-DOCSTART- -X- O O 16238797

asthma NN 4_p
. . N

patients NNS 4_p
with IN 4_p
mild JJ 4_p
asthma NNS 4_p
patients NNS 4_p
with IN 4_p
asthma NN 4_p
. . 4_p

-DOCSTART- -X- O O 22808053

patients NNS 4_p
with IN 4_p
colon NN 4_p
adenomas NN 4_p
: : N
adults NNS 1_p
with IN N
polyps NNS N
Sixteen NNP 3_p
adults NNS 1_p
with IN N
adenomas NN 4_p
detected VBN 4_p
and CC 4_p
removed VBN 4_p
at IN 4_p
screening VBG 4_p
colonoscopy NN 4_p
-DOCSTART- -X- O O 15824212

endotoxemia NN 4_p
20 CD 3_p
healthy JJ 4_p
, , N
male JJ 2_p
subjects NNS N
-DOCSTART- -X- O O 24237999

rheumatoid JJ 4_p
arthritis NN 4_p
patients NNS N
treated VBN N
with IN N
etanercept JJ N
monotherapy NN N
: : N
etanercept-treated JJ 4_p
patients NNS 4_p
with IN N
rheumatoid JJ 4_p
arthritis NN 4_p
( ( 4_p
RA NNP 4_p
) ) 4_p
. . N

Data NNP N
from IN N
an DT N
RCT NNP N
( ( N
Trial NNP N
of IN N
Etanercept NNP N
and CC N
Methotrexate NNP N
with IN N
Radiographic NNP N
Patient NNP N
Outcomes NNP N
[ NNP N
TEMPO NNP N
] NNP N
; : N
n=682 CC 3_p
) ) N
and CC N
an DT N
observational JJ N
registry NN N
( ( N
Rheumatoid NNP N
Arthritis NNP N
DMARD NNP N
Intervention NNP N
and CC N
Utilization NNP N
Study NNP N
[ NNP N
RADIUS NNP N
II NNP N
] NNP N
; : N
n=4341 CC N
) ) N
patients NNS N
initiating VBG N
etanercept NN N
( ( N
monotherapy NN N
or CC N
with IN N
methotrexate NN N
) ) N
. . N

RESULTS JJ N
Patients NNS N
from IN N
TEMPO NNP N
and CC N
RADIUS NNP N
II NNP N
who WP N
received VBD N
etanercept JJ N
monotherapy NN N
more JJR N
patients NNS N
with IN N
lower JJR N
baseline NN N
CDAI NNP N
scores VBZ N
-DOCSTART- -X- O O 23104956

hemodialysis NN 4_p
. . N

hemodialysis NN 4_p
( ( 4_p
HD NNP 4_p
) ) 4_p
Totally RB 3_p
21 CD 3_p
clinically RB 3_p
stable JJ 3_p
chronic JJ 3_p
HD NNP 3_p
patients NNS 3_p
dysfunction NN 4_p
in IN 4_p
end-stage JJ 4_p
renal JJ 4_p
disease NN 4_p
-DOCSTART- -X- O O 20633669

patients NNS N
with IN N
hip JJ 4_p
osteoarthritis NN 4_p
: : N
patients NNS N
with IN N
hip NN 4_p
osteoarthritis NN 4_p
( ( 4_p
OA NNP 4_p
) ) 4_p
. . N

patients NNS N
from IN 4_p
hospitals NNS 4_p
, , N
primary JJ N
health NN N
care NN N
and CC N
advertisement NN N
, , N
Oslo NNP N
, , N
Norway NNP N
. . N

109 CD 3_p
patients NNS N
with IN N
radiographic JJ 4_p
and CC 4_p
symptomatic JJ 4_p
hip NN 4_p
OA NNP 4_p
with IN N
mild NN N
to TO N
moderate VB N
symptoms NNS N
. . N

-DOCSTART- -X- O O 3286673

normal JJ 4_p
subjects NNS 4_p
and CC 4_p
patients NNS 4_p
with IN 4_p
type JJ 4_p
1 CD 4_p
diabetes NNS 4_p
. . 4_p

seven CD N
normal JJ N
men NNS N
and CC N
nine CD N
insulin-dependent NN N
( ( N
type JJ N
1 CD N
) ) N
diabetic JJ N
patients NNS N
. . N

normal JJ N
men NNS N
diabetic JJ N
patients NNS N
normal JJ N
men NNS N
insulin-dependent JJ N
diabetic JJ N
patients NNS N
-DOCSTART- -X- O O 22682024

nets NNS 4_p
in IN 4_p
a DT 4_p
malaria NN 4_p
endemic JJ 4_p
area NN 4_p
of IN 4_p
central JJ 4_p
India NNP 4_p
and CC N
malaria NN N
incidence NN N
in IN N
a DT N
tribal NN N
dominated VBN N
malaria NNS 3_p
endemic JJ 3_p
area NN 4_p
in IN N
Chhattisgarh NNP N
state NN N
, , N
central JJ N
India NNP N
the DT 3_p
community NN 3_p
phase NN N
( ( N
September NNP N
2006 CD N
to TO N
August NNP N
2007 CD N
) ) N
, , N
16 CD 3_p
malaria NNS 3_p
endemic JJ 3_p
villages NNS 3_p
in IN N
district NN N
Kanker NNP N
the DT N
community NN 3_p
in IN N
the DT N
study NN N
villages NNS N
setting NN N
of IN N
-DOCSTART- -X- O O 11369627

allogeneic JJ 4_p
marrow NN 4_p
transplantation NN 4_p
compared VBN 4_p
with IN 4_p
blood NN 4_p
stem NN 4_p
cell NN 4_p
transplantation NN 4_p
. . 4_p

recipients NNS N
of IN N
blood NN N
stem NN N
cells NNS N
recipients NNS N
of IN N
marrow NN N
. . N

115 CD N
patients NNS N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
allogeneic JJ N
marrow NN N
or CC N
filgrastim-mobilized JJ N
blood NN N
stem NN N
cell NN N
transplantation NN N
. . N

-DOCSTART- -X- O O 9704200

Twenty-nine JJ 3_p
patients NNS N
undergoing VBG N
cholecystectomy NN N
because IN N
of IN N
chronic JJ 4_p
calculous JJ 4_p
cholecystitis NN 4_p
were VBD N
randomised VBN N
to TO N
receive VB N
phenylbutazone NN N
10 CD N
mg/kg NN N
intramuscularly RB N
or CC N
a DT N
control NN N
injection NN N
-DOCSTART- -X- O O 24372367

children NNS 1_p
with IN N
cancer NN 4_p
: : N
children NNS 1_p
with IN N
cancer NN 4_p
. . N

children NNS N
with IN N
cancer NN 4_p
. . N

children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN N
these DT N
effects NNS N
Participants NNPS N
being VBG N
treated VBN N
were VBD N
recruited VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
from IN N
September NNP N
2011-February JJ N
2013 CD N
in IN N
Taiwan NNP N
. . N

children NNS 1_p
with IN N
cancer NN 4_p
-DOCSTART- -X- O O 26446239

Metastatic NNP N
Non-Small NNP N
Cell NNP N
Lung NNP N
Cancer NNP N
Following NNP N
Disease NNP N
Progression NNP N
On IN N
or CC N
After IN N
Platinum-Based JJ N
Chemotherapy NNP N
. . N

patients NNS N
with IN N
metastatic JJ 4_p
non-small NN 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
( ( 4_p
NSCLC NNP 4_p
) ) 4_p
with IN N
disease NN N
progression NN N
on IN N
or CC N
after IN N
platinum-based JJ N
chemotherapy NN N
. . N

Patients NNS N
with IN N
epidermal JJ 4_p
growth NN 4_p
factor NN 4_p
receptor NN 4_p
or CC N
anaplastic JJ 4_p
lymphoma NN 4_p
kinase NN 4_p
genomic JJ 4_p
tumor NN 4_p
aberrations NNS 4_p
1,253 CD 3_p
patients NNS 3_p
with IN N
metastatic JJ N
NSCLC NNP N
previously RB N
treated VBD N
with IN N
a DT N
platinum-based JJ N
combination NN N
therapy NN N
. . N

treatment NN N
of IN N
patients NNS N
with IN N
metastatic JJ 4_p
non-small NN 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
whose WP$ N
disease NN N
has VBZ N
progressed VBN N
on IN N
or CC N
after IN N
platinum-based JJ N
chemotherapy NN N
safety NN N
in IN N
patients NNS N
with IN N
squamous JJ 4_p
cell NN 4_p
tumors NNS 4_p
treatment NN 1_p
in IN 1_p
elderly JJ 1_p
patients NNS 1_p
effects NNS N
in IN N
patients NNS N
with IN N
tumors NNS 4_p
harboring VBG 4_p
epidermal JJ 4_p
growth NN 4_p
factor NN 4_p
receptor NN 4_p
or CC N
anaplastic JJ N
lymphoma NN N
kinase NN N
genomic JJ N
tumor NN N
aberrations NNS N
-DOCSTART- -X- O O 19080323

patients NNS N
with IN N
non-small JJ N
cell NN N
lung NN N
cancer NN N
after IN N
antiangiogenesis NN N
therapy NN N
. . N

Patients NNPS N
of IN N
non-small JJ N
cell NN N
lung NN N
cancer NN N
( ( N
NSCLC NNP N
) ) N
treated VBD N
with IN N
chemotherapy NN N
with IN N
or CC N
without IN N
Endostar NNP N
-DOCSTART- -X- O O 15623221

growing VBG N
turkeys NNS N
of IN N
different JJ N
ages NNS N
. . N

growing VBG N
turkeys NNS N
at IN N
4 CD 1_p
, , 1_p
8 CD 1_p
and CC 1_p
12 CD 1_p
weeks NNS 1_p
of IN N
age NN N
. . N

-DOCSTART- -X- O O 7679164

exercise NN 4_p
in IN N
humans NNS N
. . N

eight CD 3_p
volunteers NNS 4_p
undergoing VBG N
physical JJ 4_p
stress NN 4_p
on IN N
an DT N
ergometric JJ N
bicycle NN N
. . N

-DOCSTART- -X- O O 8600885

hospitalized JJ 4_p
patients NNS 4_p
with IN 4_p
ocular JJ 4_p
hypertension NN 4_p
or CC 4_p
glaucoma NN 4_p
. . 4_p

Patients NNS 4_p
in IN 4_p
group NN 4_p
1 CD 4_p
( ( 4_p
n=9 NN 4_p
) ) 4_p
Patients NNS N
in IN N
group NN N
2 CD N
( ( N
n=10 NN N
) ) N
-DOCSTART- -X- O O 17208334

acne JJ 4_p
vulgaris NN 4_p
. . N

Patients NNPS 1_p
12 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
and CC 1_p
older JJR 1_p
with IN N
acne JJ 4_p
vulgaris NN 4_p
( ( N
N NNP 3_p
= NNP 3_p
3010 CD 3_p
) ) N
participated VBN N
-DOCSTART- -X- O O 22698563

coronary JJ 4_p
artery NN 4_p
bypass NN 4_p
graft NN N
surgery NN N
: : N
Forty CD 3_p
patients NNS N
were VBD N
randomized VBN N
-DOCSTART- -X- O O 17165495

Graves NNP 4_p
' POS 4_p
disease NN 4_p
] NNP N
Graves NNP 4_p
' POS 4_p
disease NN 4_p
( ( N
GD NNP 4_p
) ) N
Sixty NNP 3_p
cases NNS N
of IN N
GD NNP N
were VBD N
randomly RB N
divided VBN N
Graves NNP N
' POS N
disease NN N
-DOCSTART- -X- O O 11246578

Work-related JJ 4_p
stress NN 4_p
and CC 4_p
early JJ 4_p
atherosclerosis NN 4_p
. . 4_p

early JJ 4_p
atherosclerosis NN 4_p
Four CD 3_p
hundred VBD 3_p
sixty-seven JJ 3_p
members NNS N
of IN N
an DT N
occupational JJ N
cohort NN N
( ( N
total JJ N
N NNP N
= NNP N
573 CD 3_p
) ) N
were VBD N
examined VBN N
via IN N
questionnaires NNS N
and CC N
B-mode NNP N
ultrasound NN N
. . N

women NNS 2_p
, , 2_p
stress NN N
men NNS 2_p
with IN N
greater JJR N
work-related JJ 4_p
stress NN 4_p
-DOCSTART- -X- O O 22917554

pulmonary JJ 4_p
arterial JJ 4_p
hypertension NN 4_p
in IN 4_p
children NNS 4_p
. . 4_p

children NNS 1_p
. . 1_p

children NNS 1_p
with IN 1_p
PAH NNP 1_p
. . 1_p

29 CD N
children NNS N
treated VBN N
with IN N
inhaled JJ N
treprostinil NN N
for IN N
≥6 JJ N
weeks NNS N
was VBD N
performed VBN N
in IN N
4 CD N
patients NNS N
targeted JJ N
PAH NNP N
therapy NN N
in IN N
children NNS N
warranted VBN N
in IN N
pediatric JJ N
patients NNS N
with IN N
-DOCSTART- -X- O O 15955950

writer NN N
's POS N
cramp NN N
dystonia NN N
: : N
Ten CD N
patients NNS N
with IN N
writer NN N
's POS N
cramp NN N
-DOCSTART- -X- O O 7527107

patients NNS 4_p
with IN 4_p
mild-to-moderate JJ 4_p
essential JJ 4_p
hypertension NN 4_p
. . 4_p

205 CD N
patients NNS N
from IN N
16 CD N
investigators NNS N
. . N

-DOCSTART- -X- O O 26398887

Type NNP N
2 CD N
Diabetic NNP 4_p
Patients NNPS N
Poorly NNP N
Controlled VBN N
by IN N
Statins NNP N
. . N

DM NNP 4_p
subjects NNS 4_p
who WP 4_p
had VBD 4_p
failed VBN 4_p
to TO 4_p
achieve VB 4_p
the DT 4_p
optimal JJ 4_p
LDL-C NNP 4_p
targets NNS 4_p
. . N

T2DM NNP 4_p
patients NNS 4_p
with IN 4_p
insufficient JJ 4_p
statin NN 4_p
response NN 4_p
. . 4_p

-DOCSTART- -X- O O 10703628

occupational JJ 4_p
irritant JJ 4_p
contact NN 4_p
dermatitis NN 4_p
. . N

2 CD 3_p
panels NNS 3_p
of IN N
25 CD 3_p
hospital NN 3_p
nurses NNS N
with IN N
mild JJ N
signs NNS N
of IN N
skin JJ 4_p
irritation NN 4_p
-DOCSTART- -X- O O 8376441

dynamic JJ 4_p
hip NN 4_p
screw NN 4_p
and CC N
the DT N
gamma NN 4_p
locking VBG 4_p
nail NN 4_p
. . N

200 CD 3_p
petrochanteric JJ 4_p
femoral JJ 4_p
fractures NNS 4_p
in IN N
elderly JJ 1_p
patients NNS N
. . N

-DOCSTART- -X- O O 12377836

sleep JJ 4_p
apnea/hypopnea NN 4_p
syndrome NN 4_p
. . 4_p

sleep JJ 4_p
apnea/hypopnea NN 4_p
syndrome NN 4_p
( ( 4_p
SAHS NNP 4_p
) ) 4_p
Fifty-five JJ 3_p
patients NNS 3_p
suspected VBN N
of IN N
having VBG N
SAHS NNP N
and CC N
living VBG N
within IN N
30 CD N
km NN N
of IN N
our PRP$ N
laboratory NN N
. . N

Patients NNPS N
were VBD N
studied VBN N
first RB N
in IN N
their PRP$ N
homes NNS N
-DOCSTART- -X- O O 16731878

new JJ N
admissions NNS N
. . N

individuals NNS 4_p
in IN 4_p
the DT 4_p
transitional JJ 4_p
period NN 4_p
following VBG 4_p
a DT 4_p
return NN 4_p
to TO 4_p
the DT 4_p
community NN 4_p
. . N

individuals NNS N
newly RB 4_p
admitted VBN 4_p
to TO 4_p
nursing VBG 4_p
homes NNS 4_p
and CC N
worked VBD N
with IN N
a DT N
family NN N
caregiver NN N
to TO N
develop VB N
and CC N
implement VB N
a DT N
nursing NN N
home NN N
discharge NN N
plan NN N
. . N

intervention NN N
group NN N
( ( N
n JJ 3_p
= NNP 3_p
33 CD 3_p
) ) N
control NN N
group NN N
( ( N
n JJ 3_p
= NNP 3_p
29 CD 3_p
) ) N
-DOCSTART- -X- O O 15472677

post-ERCP JJ N
pancreatitis NN N
: : N
post-ERCP JJ N
pancreatitis NN N
. . N

Patients NNPS N
A DT N
total NN N
of IN N
246 CD N
patients NNS N
were VBD N
randomized VBN N
( ( N
116 CD N
pure-cut JJ N
current JJ N
, , N
130 CD N
blend NN N
current JJ N
) ) N
. . N

-DOCSTART- -X- O O 15987536

subarachnoid JJ 4_p
hemorrhage NN 4_p
: : 4_p
patients NNS N
with IN N
acute JJ 4_p
nontraumatic JJ 4_p
subarachnoid NN 4_p
hemorrhage NN 4_p
( ( 4_p
SAH NNP 4_p
) ) 4_p
42 CD 3_p
patients NNS N
participating VBG N
in IN N
the DT N
enoxaparin JJ N
trial NN N
for IN N
acute NN 4_p
aneurysmal JJ 4_p
SAH NNP 4_p
at IN N
four CD N
time NN N
points NNS N
: : N
1 CD N
) ) N
at IN N
hospital JJ N
admission NN N
; : N
2 CD N
) ) N
12 CD N
to TO N
24 CD N
hours NNS N
after IN N
aneurysm JJ N
surgery NN N
but CC N
before IN N
initiation NN N
of IN N
enoxaparin JJ N
therapy NN N
; : N
3 CD N
) ) N
3 CD N
hours NNS N
after IN N
the DT N
first JJ N
dose NN N
; : N
and CC N
4 CD N
) ) N
at IN N
the DT N
conclusion NN N
of IN N
treatment NN N
. . N

-DOCSTART- -X- O O 11348533

human JJ 4_p
African JJ 4_p
trypanosomiasis NN 4_p
. . 4_p

588 CD N
patients NNS N
under IN N
treatment NN N
with IN N
melarsoprol NN N
. . N

38 CD N
encephalopathy JJ N
cases NNS N
Nine JJ N
patients NNS N
were VBD N
attributed VBN N
to TO N
the DT N
convulsion NN N
type NN N
-DOCSTART- -X- O O 22377512

in IN N
patients NNS N
with IN N
bipolar JJ 4_p
I PRP 4_p
disorder VBP 4_p
after IN N
an DT N
acute JJ 4_p
manic NN 4_p
or CC 4_p
mixed JJ 4_p
episode NN 4_p
. . N

in IN N
patients NNS N
with IN N
bipolar JJ 4_p
I PRP 4_p
disorder VBP 4_p
. . N

clinically RB 4_p
stable JJ 4_p
patients NNS N
with IN N
this DT N
disorder NN N
. . N

Patients NNPS N
( ( N
n=766 JJ 3_p
) ) N
, , N
aged VBD N
18 CD 1_p
to TO 1_p
65 CD 1_p
years NNS 1_p
inclusive JJ N
, , N
with IN N
current JJ 4_p
manic NN 4_p
or CC 4_p
mixed JJ 4_p
episodes NNS 4_p
were VBD N
initially RB N
randomized VBN N
Patients NNS N
on IN N
paliperidone NN N
ER NNP N
who WP N
achieved VBD N
remission NN N
to TO N
patients NNS N
not RB N
previously RB N
stabilized VBN N
on IN N
paliperidone NN N
ER NNP N
. . N

in IN N
patients NNS N
with IN N
bipolar JJ 4_p
I PRP 4_p
disorder VBP 4_p
. . N

-DOCSTART- -X- O O 20592840

multi-site JJ 4_p
swine NN 4_p
production NN 4_p
system NN 4_p
during IN 4_p
an DT 4_p
outbreak NN 4_p
of IN 4_p
systemic JJ 4_p
porcine NN 4_p
circovirus NN 4_p
associated VBN 4_p
disease NN 4_p
. . 4_p

2 CD 3_p
cohorts NNS 3_p
of IN N
finisher NN N
pigs NNS N
in IN N
a DT N
multi-site JJ N
swine NN N
production NN N
system NN N
located VBN N
in IN N
southern JJ N
Ontario NNP N
. . N

2 CD N
cohorts NNS N
. . N

pigs NNS N
herd NN N
experiencing VBG N
an DT N
outbreak NN N
of IN N
PCVAD NNP N
-DOCSTART- -X- O O 8434135

dairy NN 4_p
cows NNS 4_p
at IN 4_p
parturition NN 4_p
. . 4_p

dairy VB 4_p
cows NNS 4_p
during IN 4_p
the DT 4_p
last JJ 4_p
seven CD 4_p
weeks NNS 4_p
of IN 4_p
pregnancy NN 4_p
Ten CD N
monozygotic JJ N
twin NN N
pairs NNS N
of IN N
pregnant JJ N
cows NNS N
( ( N
five CD N
pairs NNS N
of IN N
parity NN N
1 CD N
or CC N
2 CD N
, , N
and CC N
five CD N
pairs NNS N
of IN N
parity NN N
3 CD N
or CC N
more JJR N
) ) N
cows NNS N
fed VBP N
the DT N
anion NN N
diet NN N
cows NNS N
fed VBP N
the DT N
cation NN N
diet NN N
. . N

-DOCSTART- -X- O O 22156967

black JJ N
MSM NNP N
: : N
black JJ N
MSM NNP N
New NNP N
York NNP N
City NNP N
Participants NNP N
( ( N
n JJ N
= NNP N
283 CD 3_p
) ) N
reporting NN N
at IN N
least JJS N
two CD N
sexual JJ N
partners NNS N
and CC N
unprotected JJ N
anal JJ N
intercourse NN N
with IN N
a DT N
man NN N
in IN N
the DT N
past JJ N
3 CD N
months NNS N
black JJ N
MSM NNP N
in IN N
the DT N
USA NNP N
-DOCSTART- -X- O O 9393424

implant JJ 4_p
integration NN 4_p
at IN N
stage NN 4_p
II NNP 4_p
uncovering NN 4_p
surgery NN 4_p
. . N

30 CD N
Department NNP N
of IN N
Veterans NNP N
Affairs NNP N
medical JJ N
centers NNS N
and CC N
two CD N
dental JJ N
schools NNS N
initiated VBD N
a DT N
long-term JJ N
clinical JJ N
study NN N
to TO N
investigate VB N
the DT N
clinical JJ N
performance NN N
of IN N
implants NNS 4_p
within IN 4_p
the DT 4_p
Spectra-System NNP 4_p
( ( N
Core-Vent JJ N
Corporation NNP N
, , N
Las NNP N
Vegas NNP N
, , N
NV NNP N
) ) N
. . N

crestal JJ N
incision NN N
was VBD N
used VBN N
for IN N
1,705 CD 3_p
implants NNS 3_p
( ( N
381 CD 3_p
patients NNS 3_p
) ) N
and CC N
the DT N
remote JJ N
incision NN N
for IN N
593 CD 3_p
implants NNS 3_p
( ( N
141 CD 3_p
patients NNS 3_p
) ) N
. . N

-DOCSTART- -X- O O 25579054

schizophrenia NN 4_p
. . 4_p

-DOCSTART- -X- O O 20124059

total JJ 4_p
hip NN 4_p
arthroplasty NN 4_p
: : N
Minimally NNP N
invasive JJ N
total NN N
hip NN N
arthroplasty NN N
Twenty NNP 3_p
randomized VBD N
patients NNS N
who WP N
underwent VBP N
a DT N
primary JJ 4_p
total JJ 4_p
hip NN 4_p
replacement NN 4_p
with IN N
use NN N
of IN N
a DT N
minimally RB N
invasive JJ N
modified VBN N
Watson-Jones JJ N
approach NN N
( ( N
minimally RB N
invasive JJ N
group NN N
) ) N
were VBD N
compared VBN N
with IN N
a DT N
group NN N
of IN N
twenty NN 3_p
patients NNS N
who WP N
underwent VBD N
a DT N
total JJ N
hip NN N
arthroplasty NN N
with IN N
use NN N
of IN N
a DT N
standard JJ N
transgluteal NN N
Hardinge NNP N
approach NN N
( ( N
standard JJ N
group NN N
) ) N
. . N

patients NNS N
who WP N
underwent VBD N
a DT N
total JJ 4_p
hip NN 4_p
arthroplasty NN 4_p
through IN N
a DT N
minimally RB N
invasive JJ N
Watson-Jones NNS N
approach NN N
standard JJ 4_p
transgluteal NN 4_p
approach NN 4_p
. . N

-DOCSTART- -X- O O 12378396

lunar JJ 4_p
stent NN 4_p
MOONLIGHT NNP N
( ( N
Multicenter NNP N
Objective NNP N
ObservatioNal NNP N
Lunar NNP N
Iridiumoxide NNP N
intimal JJ N
GrowtH NNP N
Trial NNP N
) ) N
study NN N
Between IN N
March NNP N
2001 CD N
and CC N
November NNP N
2001 CD N
, , N
87 CD 3_p
patients NNS N
with IN N
99 CD N
lesions NNS 4_p
were VBD N
enrolled VBN N
in IN N
this DT N
study NN N
-DOCSTART- -X- O O 8892490

patients NNS N
after IN N
a DT N
myocardial JJ N
infarction NN N
: : N
post-hospital JJ N
data NNS N
myocardial JJ 4_p
infarction NN 4_p
( ( 4_p
MI NNP 4_p
) ) N
patients NNS 4_p
admitted VBN 4_p
for IN 4_p
the DT 4_p
first JJ 4_p
MI NNP 4_p
with IN 4_p
recurrent JJ 4_p
MI NNP 4_p
patients NNS 4_p
. . N

An DT N
inception NN N
cohort NN N
of IN N
patients NNS 4_p
enrolled VBN 4_p
in IN 4_p
the DT 4_p
Beta-Blocker NNP 4_p
in IN 4_p
Heart NNP 4_p
Attack NNP 4_p
Trial NNP 4_p
( ( N
n JJ N
= NN N
2830 CD 3_p
) ) N
was VBD N
included VBN N
. . N

in-hospital JJ N
and CC N
post-hospital JJ N
data NNS N
) ) N
-DOCSTART- -X- O O 19705924

antihistaminic NN N
( ( N
H1 NNP N
) ) N
effect NN N
of IN N
bilastine NN N
. . N

studies NNS N
in IN N
healthy JJ 4_p
adult NN 1_p
subjects NNS N
. . N

In IN N
the DT N
single-dose JJ N
studies NNS N
, , N
a DT N
total NN N
of IN N
183 CD 3_p
subjects NNS N
received VBD N
oral JJ N
doses NNS N
of IN N
bilastine NN N
In IN N
the DT N
multiple-dose JJ N
studies NNS N
, , N
127 CD 3_p
healthy JJ 4_p
subjects NNS N
received VBD N
bilastine JJ N
-DOCSTART- -X- O O 9818688

Twenty-six JJ 3_p
patients NNS N
with IN N
relapsed JJ 4_p
Hodgkin NNP 4_p
's POS 4_p
disease NN 4_p
Their PRP$ N
median JJ N
age NN N
was VBD N
31 CD 1_p
years NNS N
( ( N
range NN N
, , N
22-59 JJ N
) ) N
and CC N
14 CD 2_p
patients NNS N
were VBD N
males NNS 2_p
and CC N
12 CD 2_p
were VBD N
females NNS 2_p
. . N

Patients NNS N
were VBD N
pretreated VBN N
with IN N
a DT N
median NN N
of IN N
eight CD N
cycles NNS N
of IN N
cytotoxic NN N
chemotherapy NN N
, , N
while IN N
18 CD 3_p
patients NNS N
had VBD N
undergone JJ N
extended JJ N
field NN N
irradiation NN N
. . N

patients NNS N
with IN N
Hodgkin NNP 4_p
's POS 4_p
disease NN 4_p
-DOCSTART- -X- O O 18632218

oral JJ N
cancer NN N
screening NN N
in IN N
the DT N
developing NN N
world NN N
population-based JJ N
screening NN N
project NN N
in IN N
India NNP N
. . N

oral JJ N
cancer NN N
mortality NN N
in IN N
high-risk JJ N
individuals NNS N
in IN N
India NNP N
. . N

96,517 CD N
eligible JJ N
subjects NNS N
, , N
87,655 CD N
were VBD N
screened VBN N
, , N
8688 CD N
individuals NNS N
never RB N
received VBD N
the DT N
invitation NN N
and CC N
174 CD N
refused VBD N
screening NN N
. . N

5143 CD N
screen-positives NNS N
-DOCSTART- -X- O O 9116082

Confounding VBG N
by IN N
indication NN N
? . N
-DOCSTART- -X- O O 16377918

Japanese JJ N
familial JJ 4_p
hypercholesterolemia NN 4_p
. . N

familial JJ 4_p
hypercholesterolemia NN 4_p
( ( 4_p
FH NNP 4_p
) ) 4_p
24 CD 3_p
initial JJ N
patients NNS N
, , N
17 CD 3_p
heterozygous JJ 4_p
FH NNP 4_p
patients NNS N
( ( N
age NN N
: : N
54.1 CD 1_p
years NNS N
; : N
5 CD 3_p
males NNS 2_p
) ) N
Fifteen JJ 3_p
patients NNS N
completed VBD N
the DT N
trial NN N
-DOCSTART- -X- O O 17140502

pregnant JJ N
women NNS 2_p
. . N

The DT N
participants NNS N
were VBD N
primary JJ 4_p
antenatal JJ 4_p
care NN 4_p
providers NNS 4_p
-- : N
family NN N
physicians NNS N
, , N
obstetricians NNS N
, , N
and CC N
midwives NNS N
-- : N
from IN N
four CD N
diverse NN N
communities NNS N
in IN N
Ontario NNP N
. . N

In IN N
total JJ N
, , N
227 CD 3_p
pregnant JJ N
women NNS 2_p
were VBD N
recruited VBN N
: : N
98 CD 3_p
in IN N
the DT N
ALPHA NNP N
group NN N
and CC N
129 CD 3_p
in IN N
the DT N
control NN N
group NN N
. . N

-DOCSTART- -X- O O 11981066

patients NNS N
with IN N
chronic JJ 4_p
glomerulonephritis NN 4_p
. . 4_p

patients NNS N
with IN N
chronic JJ 4_p
glomerulonephritis NN 4_p
( ( 4_p
CGN NNP 4_p
) ) 4_p
40 CD 3_p
normotensive JJ N
hypercholesterolemic JJ 4_p
patients NNS N
with IN N
CGN NNP 4_p
Subjects NNS N
comprised VBD N
24 CD 3_p
men NNS 2_p
and CC N
16 CD 3_p
women NNS 2_p
, , N
with IN N
a DT N
mean JJ N
age NN N
of IN N
40.8+/-14.4 JJ 1_p
years NNS N
; : N
27 CD 3_p
had VBD N
IgA NNP 4_p
nephropathy JJ 4_p
and CC N
13 CD 3_p
had VBD N
non-IgA JJ 4_p
proliferative JJ 4_p
glomerulonephritis NN 4_p
. . N

patients NNS N
with IN N
CGN NNP 4_p
and CC N
hypercholesterolaemia NN 4_p
. . N

-DOCSTART- -X- O O 10509459

minimally RB N
invasive JJ N
surgery NN N
. . N

minimally RB N
invasive JJ N
surgery NN N
( ( N
MIS NNP N
) ) N
experienced JJ N
surgeons NNS N
Twenty CD 3_p
surgeons NNS N
were VBD N
presented VBN N
objects NNS N
in IN N
a DT N
random NN N
order NN N
, , N
with IN N
participants NNS N
blinded VBN N
as IN N
to TO N
their PRP$ N
identity NN N
. . N

surgeons NNS N
-DOCSTART- -X- O O 10606880

12 CD 4_p
healthy JJ 4_p
male NN 4_p
volunteers NNS 4_p
Six CD N
participants NNS N
-DOCSTART- -X- O O 16249417

surgical JJ N
wound NN N
infection NN N
: : N
patients NNS N
following VBG N
colorectal JJ N
surgery NN N
. . N

300 CD N
patients NNS N
aged VBD N
18 CD N
to TO N
80 CD N
years NNS N
who WP N
underwent VBP N
elective JJ N
colorectal NN N
surgery NN N
in IN N
14 CD N
Spanish JJ N
hospitals NNS N
from IN N
March NNP N
1 CD N
, , N
2003 CD N
, , N
to TO N
October NNP N
31 CD N
, , N
2004 CD N
. . N

patients NNS N
undergoing VBG N
colon NN N
or CC N
rectal JJ N
surgery NN N
. . N

-DOCSTART- -X- O O 25238860

patients NNS 4_p
with IN 4_p
Multiple NNP 4_p
Sclerosis NNP 4_p
based VBN 4_p
on IN 4_p
the DT 4_p
model NN 4_p
of IN 4_p
the DT 4_p
ICF NNP 4_p
. . N

MS NNP 4_p
patients NNS N
according VBG N
to TO N
the DT N
ICF NNP N
Forty NNP 3_p
patients NNS N
with IN N
MS NNP N
were VBD N
randomised VBN N
in IN N
an DT N
intervention NN N
( ( N
IG NNP N
) ) N
- : N
and CC N
a DT N
control NN N
group NN N
( ( N
CG NNP N
) ) N
. . N

-DOCSTART- -X- O O 24898318

adolescent JJ 1_p
social JJ N
competence NN N
and CC N
behavior NN N
: : N
youth NN 1_p
5th-8th JJ 1_p
grade NN 1_p
children NNS 1_p
. . N

Children NNP 1_p
( ( N
N NNP N
= NNP N
131 CD 3_p
) ) N
were VBD N
recruited VBN N
through IN N
referral JJ N
by IN N
school NN N
counselors NNS N
and CC N
school-based JJ N
recruitment NN N
and CC N
then RB N
screened VBD N
for IN N
low JJ N
social JJ N
competence NN N
. . N

-DOCSTART- -X- O O 10969304

human JJ N
volunteers NNS N
. . N

American NNP 4_p
Society NNP 4_p
of IN 4_p
Anesthesiologists NNP 4_p
physical JJ 4_p
status NN 4_p
1 CD 4_p
( ( N
n JJ N
= NNP N
17 CD 3_p
) ) N
volunteers NNS N
-DOCSTART- -X- O O 21327867

insulin NN 4_p
resistance NN 4_p
Sixteen NNP N
overweight MD N
to TO N
obese VB N
adults NNS N
( ( N
BMI NNP N
30.6 CD N
± NNP N
0.8 CD N
; : N
67.2 CD N
± IN N
4.0 CD N
years NNS N
of IN N
age NN N
) ) N
with IN N
either DT N
impaired JJ N
fasting NN N
glucose NN N
, , N
or CC N
impaired VBD N
glucose JJ N
tolerance NN N
completed VBD N
one CD N
of IN N
two CD N
lifestyle JJ N
interventions NNS N
: : N
DIWL NNP N
( ( N
n JJ N
= NNP N
8 CD N
) ) N
-DOCSTART- -X- O O 8792266

children NNS 1_p
with IN N
autism NN 4_p
. . N

Eighty NNP 3_p
children NNS 1_p
, , N
3-17 JJ 1_p
years NNS N
of IN N
age NN N
, , N
with IN N
autism NN 4_p
or CC N
Asperger NNP 4_p
syndrome NN 4_p
and CC N
mild NN 4_p
to TO 4_p
severe VB 4_p
distress NN 4_p
in IN 4_p
the DT 4_p
presence NN 4_p
of IN 4_p
some DT 4_p
sounds NNS 4_p
children NNS 1_p
with IN N
autism NN 4_p
and CC N
sound JJ 4_p
sensitivity NN 4_p
-DOCSTART- -X- O O 7072873

over IN 4_p
1,200 CD 4_p
respondents NNS 4_p
, , 4_p
people NNS 4_p
assigned VBD 4_p
memory NN 4_p
aids NNS 4_p
reported VBD 4_p
over IN 4_p
50 CD 4_p
per IN 4_p
cent NN 4_p
more JJR 4_p
symptom JJ 4_p
episodes NNS 4_p
than IN 4_p
those DT 4_p
not RB 4_p
assigned JJ 4_p
memory NN 4_p
aids NNS 4_p
. . 4_p

-DOCSTART- -X- O O 10594396

patients NNS N
with IN N
moderately RB N
severe JJ N
reflux NN 4_p
oesophagitis NN 4_p
. . N

133 CD 3_p
patients NNS N
-DOCSTART- -X- O O 24675714

overweight JJ 4_p
subjects NNS N
overweight NN 4_p
or CC 4_p
obese JJ 4_p
adults NNS 1_p
in IN N
eight CD N
centers NNS N
across IN N
Europe NNP N
. . N

256 CD 3_p
adults NNS 3_p
( ( N
body NN N
mass NN N
index NN N
> VBD N
27 CD N
kg NNS N
m NN N
( ( N
- : N
) ) N
( ( N
2 CD N
) ) N
) ) N
maintenance NN N
in IN N
overweight NN 4_p
and CC 4_p
obese JJ 4_p
adults NNS N
-DOCSTART- -X- O O 11828556

Seventy-two JJ 3_p
patients NNS 3_p
with IN 4_p
a DT 4_p
carpal JJ 4_p
tunnel NN 4_p
syndrome NN 4_p
were VBD 4_p
individually RB 4_p
randomized VBN 4_p
into IN 4_p
the DT 4_p
trial NN 4_p
( ( 4_p
limited JJ 4_p
incision NN 4_p
CTR NNP 4_p
) ) 4_p
( ( 4_p
n=36 JJ 4_p
) ) 4_p
and CC 4_p
control NN 4_p
group NN 4_p
( ( 4_p
traditional JJ 4_p
technique NN 4_p
CTR NNP 4_p
) ) 4_p
( ( 4_p
n=36 JJ 4_p
) ) 4_p
. . N

In IN N
the DT N
trial NN 4_p
group NN 4_p
, , 4_p
skin FW 4_p
incision NN 4_p
parallel NN 4_p
to TO 4_p
the DT 4_p
thenar NN 4_p
crease NN 4_p
was VBD 4_p
made VBN 4_p
up RP 4_p
to TO 4_p
2.5 CD 4_p
cm NN 4_p
in IN 4_p
length NN 4_p
, , 4_p
under IN 4_p
an DT 4_p
operating NN 4_p
microscope NN 4_p
and CC 4_p
endoscopic JJ 4_p
transillumination NN 4_p
. . N

Skin NNP N
incision NN N
in IN N
the DT N
control NN N
group NN N
began VBD N
at IN N
the DT N
distal JJ N
border NN N
of IN N
the DT N
carpal JJ N
ligament NN N
, , N
followed VBD N
the DT N
longitudinal JJ N
crease NN N
of IN N
the DT N
palm NN N
, , N
and CC N
crossed VBD N
the DT N
base NN N
of IN N
the DT N
palm NN N
in IN N
a DT N
zigzag JJ N
fashion NN N
. . N

Three CD N
months NNS N
after IN N
surgery NN N
-DOCSTART- -X- O O 18166533

16-community JJ N
trial NN N
to TO N
promote VB N
judicious JJ N
antibiotic JJ N
use NN N
in IN N
Massachusetts NNP N
. . N

young JJ N
children NNS N
commercially RB N
and CC N
Medicaid-insured JJ N
children NNS N
. . N

community-level JJ N
, , N
cluster-randomized JJ N
trial NN N
in IN N
16 CD 3_p
nonoverlapping VBG N
Massachusetts NNP N
communities NNS N
, , N
studied VBN N
from IN N
1998 CD N
to TO N
2003 CD N
. . N

children NNS 1_p
who WP 1_p
were VBD 1_p
aged VBN 1_p
3 CD 1_p
to TO 1_p
< VB 1_p
72 CD 1_p
months NNS 1_p
, , N
resided VBN N
in IN N
study NN N
communities NNS N
, , N
and CC N
were VBD N
insured VBN N
by IN N
a DT N
participating VBG N
commercial JJ N
health NN N
plan NN N
or CC N
Medicaid NNP N
. . N

223,135 CD 3_p
person-years NNS N
of IN N
observation NN N
. . N

Medicaid-insured JJ N
children NNS N
-DOCSTART- -X- O O 11074150

awake JJ N
resting NN N
tobacco NN N
smokers NNS N
. . N

Eleven NNP N
healthy JJ N
tobacco NN N
smoking VBG N
adult NN N
male NN N
volunteers NNS N
of IN N
mixed JJ N
race NN N
-DOCSTART- -X- O O 3132778

colon NN 4_p
surgery NN 4_p
] NN 4_p
-DOCSTART- -X- O O 24526141

Dural NNP 4_p
Arteriovenous NNP 4_p
Fistula NNP 4_p
. . 4_p

dural JJ N
arteriovenous JJ N
fistula NN N
( ( N
DAVF NNP N
) ) N
in IN N
the DT N
transverse NN N
sinus NN N
. . N

Nine NNP N
patients NNS N
underwent JJ 4_p
NCE NNP 4_p
4D CD 4_p
MRA NNP 4_p
. . N

All DT N
patients NNS N
also RB N
underwent JJ N
digital JJ N
subtraction NN N
angiography NN N
( ( N
DSA NNP N
) ) N
Among IN N
seven CD N
patients NNS N
with IN N
patent NN N
DAVFs NNP N
of IN N
three CD N
patients NNS N
with IN N
CVR NNP N
-DOCSTART- -X- O O 6844471

chronic JJ N
bronchitis NN N
and CC N
emphysema NN N
: : N
patients NNS N
disabled VBN N
by IN N
chronic JJ N
obstructive JJ N
airways NNS N
disease NN N
giving VBG N
rise NN N
to TO N
dyspnoea VB N
. . N

Forty-three JJ 3_p
men NNS 2_p
and CC 3_p
22 CD 3_p
women NNS 2_p
with IN N
severe JJ 4_p
COAD NNP 4_p
-DOCSTART- -X- O O 24673076

42 CD N
cases NNS N
of IN N
autism NN 4_p
] NNP 4_p
autism NN 4_p
. . N

Eighty-four JJ 3_p
children NNS 1_p
of IN N
autism NN 4_p
were VBD N
randomly RB N
divided VBN N
into IN N
a DT N
tongue JJ N
acupuncture NN N
group NN N
( ( N
group NN N
A NNP N
) ) N
and CC N
a DT N
conventional JJ N
training NN N
group NN N
( ( N
group NN N
B NNP N
) ) N
, , N
42 CD N
cases NNS N
in IN N
each DT N
group NN N
. . N

autism NN 4_p
. . N

-DOCSTART- -X- O O 2015394

patients NNS N
with IN N
chronic JJ 4_p
myeloid NN 4_p
leukemia NN 4_p
in IN 4_p
the DT 4_p
chronic JJ 4_p
phase NN 4_p
: : N
patients NNS N
with IN N
chronic JJ 4_p
myeloid NN 4_p
leukemia NN 4_p
treated VBN 4_p
by IN 4_p
allogeneic JJ 4_p
marrow NN 4_p
transplantation NN 4_p
while IN 4_p
in IN 4_p
the DT 4_p
chronic JJ 4_p
phase NN 4_p
. . N

Fifty-seven JJ 3_p
patients NNS N
patients NNS N
receiving VBG N
the DT N
higher JJR N
dose NN N
of IN N
total JJ N
body NN N
irradiation NN N
-DOCSTART- -X- O O 23410851

AIDS-affected JJ N
children NNS N
living VBG N
in IN N
AIDS-impacted JJ N
communities NNS N
: : N
southwestern JJ N
Uganda NNP N
. . N

AIDS-affected JJ N
children NNS N
in IN N
communities NNS N
heavily RB N
impacted VBN N
by IN N
HIV/AIDS NNP N
in IN N
Uganda NNP N
. . N

a DT N
treatment NN N
condition NN N
( ( N
n=179 JJ N
) ) N
and CC N
a DT N
control NN N
condition NN N
( ( N
n=118 JJ N
) ) N
children NNS N
with IN N
poor JJ N
mental JJ N
health NN N
functioning VBG N
living NN N
in IN N
communities NNS N
affected VBN N
by IN N
HIV/AIDS NNP N
children NNS N
living VBG N
in IN N
resource JJ N
poor JJ N
AIDS-impacted JJ N
communities NNS N
. . N

-DOCSTART- -X- O O 19022794

analgesia NN 4_p
after IN 4_p
craniotomy NN 4_p
. . 4_p

82 CD N
patients NNS N
undergoing JJ N
elective JJ N
craniotomies NNS N
. . N

-DOCSTART- -X- O O 18409186

to TO 4_p
what WP 4_p
extent VB 4_p
the DT 4_p
percentage NN 4_p
of IN 4_p
prostate NN 4_p
cancers NNS 4_p
( ( 4_p
PCs NNS 4_p
) ) 4_p
detected VBN 4_p
in IN 4_p
men NNS 4_p
with IN 4_p
these DT 4_p
suspicious JJ 4_p
findings NNS 4_p
varies NNS 4_p
between IN 4_p
examiners NNS 4_p
. . 4_p

7,280 CD N
men NNS N
underwent VBD N
a DT N
PSA-determination NN N
and CC N
DRE NNP N
of IN N
whom WP N
2,102 CD 3_p
underwent JJ N
prostate NN N
biopsy NN N
( ( N
biopsy JJ N
indication NN N
PSA NNP N
> NNP N
or CC N
= $ N
4.0 CD N
ng/ml JJ N
and/or RB N
suspicious JJ N
DRE NNP N
and/or NN N
TRUS NNP N
) ) N
. . N

2,102 CD 3_p
men NNS 2_p
biopsied VBD N
, , N
443 CD 3_p
PCs NNS N
were VBD N
detected VBN N
( ( N
PPV NNP N
= RB N
21 CD N
% NN N
) ) N
men NNS 2_p
with IN 2_p
a DT 2_p
suspicious JJ 4_p
DRE NNP 4_p
-DOCSTART- -X- O O 18353086

non-melanoma JJ N
skin NN N
cancer NN N
non-melanoma JJ N
skin NN N
cancer NN N
. . N

16 CD N
lesions NNS N
, , N
either RB N
superficial JJ N
basal NN N
cell NN N
carcinoma NN N
( ( N
BCC NNP N
) ) N
or CC N
Bowen NNP N
's POS N
disease NN N
( ( N
BD NNP N
) ) N
. . N

-DOCSTART- -X- O O 1488874

Oscillatory NN 4_p
potentials NNS N
, , N
retinopathy NN 4_p
, , N
and CC N
long-term JJ N
glucose NN N
control NN N
in IN N
insulin-dependent JJ 4_p
diabetes NNS 4_p
. . N

insulin-dependent JJ 4_p
diabetes NNS 4_p
. . N

45 CD 3_p
patients NNS N
Oslo NNP N
-DOCSTART- -X- O O 16109116

migraine NN 4_p
. . N

patients NNS 4_p
receiving VBG 4_p
topiramate NN 4_p
( ( 4_p
TPM NNP 4_p
) ) 4_p
100 CD 4_p
mg/d NN 4_p
in IN 4_p
two CD 4_p
divided JJ 4_p
doses NNS 4_p
for IN 4_p
migraine JJ 4_p
prevention NN 4_p
similar JJ 4_p
protocols NNS 4_p
and CC 4_p
study NN 4_p
populations NNS 4_p
. . N

intent-to-treat NN 4_p
( ( 4_p
ITT NNP 4_p
) ) 4_p
and CC 4_p
study-completer JJ 4_p
populations NNS 4_p
migraine NN 4_p
headache NN 4_p
in IN N
adults NNS 1_p
. . N

-DOCSTART- -X- O O 7907677

patients NNS N
with IN N
atrial JJ 4_p
fibrillation NN 4_p
715 CD 3_p
patients NNS N
aged VBN N
75 CD 1_p
years NNS 1_p
or CC 1_p
less JJR 1_p
and CC N
385 CD 3_p
patients NNS N
older JJR 1_p
than IN 1_p
75 CD 1_p
; : N
-DOCSTART- -X- O O 11378833

postmenopausal JJ 4_p
women NNS 2_p
. . 4_p

normotensive JJ 4_p
postmenopausal NN 4_p
women NNS 2_p
receiving VBG 4_p
a DT 4_p
fixed JJ 4_p
mid-range JJ 4_p
daily JJ 4_p
dose NN 4_p
of IN 4_p
conjugated JJ 4_p
equine NN 4_p
oestrogen NN 4_p
( ( 4_p
CEE NNP 4_p
) ) 4_p
. . N

Twenty NNP N
normotensive JJ 4_p
postmenopausal NN 4_p
women NNS N
( ( N
median JJ 1_p
age NN 1_p
53 CD 1_p
years NNS 1_p
) ) N
-DOCSTART- -X- O O 3089050

Seventy-three JJ 3_p
patients NNS N
undergoing VBG N
elective JJ 4_p
perianal JJ 4_p
surgery NN 4_p
-DOCSTART- -X- O O 8689462

inflammatory JJ 4_p
knee NN 4_p
osteoarthritis NN 4_p
. . N

inflammatory JJ 4_p
knee NN 4_p
osteoarthritis NN 4_p
. . N

rheumatology NN N
outpatient NN N
department NN N
. . N

63 CD 3_p
patients NNS 3_p
( ( N
24 CD 2_p
male NN 2_p
, , N
39 CD 2_p
female NN 2_p
, , N
mean JJ N
age NN 1_p
70.5 CD 1_p
years NNS 1_p
) ) N
with IN N
bilateral JJ 4_p
symptomatic JJ 4_p
knee NN 4_p
osteoarthritis NN 4_p
with IN 4_p
effusion NN 4_p
. . N

two CD N
groups NNS N
were VBD N
comparable JJ N
at IN N
entry NN N
high JJ N
drop-out NN N
rate NN N
symptomatic JJ 4_p
knee NN 4_p
osteoarthritis NN 4_p
-DOCSTART- -X- O O 18395723

menopausal NN 4_p
symptoms NNS 4_p
in IN 4_p
women NNS 4_p
treated VBN 4_p
with IN 4_p
soy JJ 4_p
isoflavones NNS 4_p
. . 4_p

women NNS 4_p
who WP 4_p
do VBP 4_p
and CC 4_p
who WP 4_p
do VBP 4_p
not RB 4_p
produce VB 4_p
equol NN 4_p
96 CD 4_p
healthy JJ 4_p
menopausal NN 4_p
women NNS 4_p
. . 4_p

-DOCSTART- -X- O O 21975231

acute JJ 4_p
ST NNP 4_p
elevation NN 4_p
myocardial JJ 4_p
infarction NN 4_p
. . N

acute JJ 4_p
ST-elevation NNP 4_p
myocardial JJ 4_p
infarction NN 4_p
( ( 4_p
STEMI NNP 4_p
) ) 4_p
Eight VBD 3_p
patients NNS 3_p
with IN N
a DT N
diagnosis NN 4_p
of IN 4_p
acute JJ 4_p
STEMI NNP 4_p
and CC 4_p
duration NN 4_p
of IN 4_p
symptoms NNS 4_p
of IN 4_p
? . 4_p
24 CD 4_p
hours NNS 4_p
that WDT 4_p
were VBD 4_p
perfused VBN 4_p
successfully RB 4_p
through IN 4_p
primary JJ 4_p
percutaneous JJ 4_p
coronary JJ 4_p
intervention NN 4_p
( ( 4_p
PPCI NNP 4_p
) ) 4_p
with IN 4_p
a DT 4_p
LVEF NNP 4_p
of IN 4_p
? . 4_p
45 CD 4_p
% NN N
the DT 4_p
Instituto NNP 4_p
Nacional NNP 4_p
de FW 4_p
Cardiología NNP 4_p
Ignacio NNP 4_p
Chávez NNP 4_p
of IN N
acute JJ 4_p
STEMI NNP 4_p
-DOCSTART- -X- O O 16198776

onychomycosis NN 4_p
: : N
Minneapolis NNP N
Veterans NNP N
Affairs NNP N
Medical NNP N
Center NNP N
. . N

The DT N
main JJ N
inclusion NN N
criteria NNS N
for IN N
participants NNS N
were VBD N
a DT N
positive JJ 4_p
dermatophyte NN 4_p
culture NN 4_p
and CC 4_p
at IN 4_p
least JJS 4_p
25 CD 4_p
% NN 4_p
distal JJ 4_p
subungual JJ 4_p
clinical JJ 4_p
involvement NN 4_p
. . N

Six CD 3_p
hundred VBD 3_p
eighteen JJ 3_p
volunteers NNS N
were VBD N
screened VBN N
; : N
306 CD 3_p
were VBD N
randomized VBN N
. . N

The DT N
study NN N
population NN N
primarily RB N
consisted VBN N
of IN 1_p
older JJR 1_p
men NNS 2_p
with IN N
severe JJ 4_p
onychomycosis NN 4_p
. . N

-DOCSTART- -X- O O 9071556

children NNS 1_p
with IN N
atopic NN 4_p
dermatitis NN 4_p
. . N

children NNS 1_p
. . N

children NNS 1_p
with IN N
atopic NN 4_p
dermatitis NN 4_p
. . N

children NNS 1_p
with IN N
atopic NN 4_p
dermatitis NN 4_p
-DOCSTART- -X- O O 8091822

patients NNS 4_p
with IN 4_p
stable JJ 4_p
angina NNS 4_p
and CC 4_p
angiographically RB 4_p
proven JJ 4_p
relevant JJ 4_p
coronary JJ 4_p
stenosis NN 4_p
i.v NN 4_p
. . 4_p

application NN 4_p
of IN 4_p
0.75 CD 4_p
mg/kg NN 4_p
-DOCSTART- -X- O O 20637249

children NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
. . N

autistic JJ 4_p
disorder NN 4_p
. . N

Forty NNP 3_p
children NNS N
between IN N
the DT N
ages NNS 1_p
of IN 1_p
4 CD 1_p
and CC 1_p
12 CD 1_p
years NNS 1_p
with IN N
a DT N
DSM NNP 4_p
IV NNP 4_p
clinical JJ 4_p
diagnosis NN 4_p
of IN 4_p
autism NN 4_p
who WP N
were VBD N
outpatients NNS N
from IN N
a DT N
specialty NN N
clinic NN N
for IN N
children NNS N
were VBD N
recruited VBN N
. . N

children NNS N
severely RB 4_p
disruptive JJ 4_p
symptoms NNS 4_p
related VBN N
to TO N
autistic JJ 4_p
disorder NN 4_p
. . N

children NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
. . N

-DOCSTART- -X- O O 24839882

minimally RB N
verbal JJ N
children NNS 1_p
with IN N
autism NN 4_p
: : N
school-aged JJ 1_p
, , 1_p
minimally RB N
verbal JJ N
children NNS N
with IN N
autism NN 4_p
. . N

A NNP N
total NN N
of IN N
61 CD 3_p
minimally RB N
verbal JJ N
children NNS 1_p
with IN N
autism NN N
, , N
aged VBD 1_p
5 CD 1_p
to TO 1_p
8 CD 1_p
years NNS 1_p
Minimally NNP N
verbal JJ N
school-aged JJ 1_p
children NNS 1_p
-DOCSTART- -X- O O 11064610

patients NNS 4_p
undergoing VBG 4_p
coronary JJ 4_p
artery NN 4_p
bypass NN 4_p
surgery NN 4_p
. . 4_p

patients NNS 4_p
undergoing VBG 4_p
coronary JJ 4_p
artery NN 4_p
bypass NN 4_p
graft NN 4_p
surgery NN 4_p
( ( 4_p
CABG NNP 4_p
) ) 4_p
. . 4_p

Sixty JJ N
patients NNS N
( ( N
age NN N
40-73 CD N
yr NN N
, , N
56 CD N
male NN N
) ) N
were VBD N
assigned VBN N
randomly RB N
to TO N
receive VB N
alfentanil NN N
, , N
fentanyl NN N
or CC N
sufentanil NN N
and CC N
propofol NN N
patients NNS N
undergoing VBG N
CABG NNP N
-DOCSTART- -X- O O 10816058

paediatric JJ N
heart NN N
surgery NN N
. . N

Children NNP N
children NNS N
. . N

19 CD N
children NNS N
were VBD N
randomized VBN N
to TO N
heparin-coated JJ N
paediatric JJ N
patient NN N
-DOCSTART- -X- O O 21120480

patients NNS N
with IN N
advanced JJ 4_p
solid JJ 4_p
tumours NN 4_p
: : N
METHODS NNP N
Sixty NNP 3_p
patients NNS 3_p
-DOCSTART- -X- O O 9697788

population-based JJ N
screening NN N
study NN N
. . N

prostate NN 4_p
cancer NN 4_p
and CC 4_p
benign JJ 4_p
conditions NNS 4_p
of IN 4_p
the DT 4_p
prostate NN 4_p
( ( N
Rotterdam NNP N
section NN N
of IN N
the DT N
European NNP N
Randomized NNP N
Study NNP N
of IN N
Screening NNP N
for IN N
Prostate NNP N
Cancer NNP N
) ) N
10,865 CD N
men NNS N
have VBP N
been VBN N
screened VBN N
biopsy NN N
results NNS N
of IN N
1202 CD N
men NNS N
with IN N
PSA NNP 4_p
levels NNS 4_p
of IN N
4 CD N
ng/mL NNS N
or CC N
more JJR N
1202 CD 3_p
men NNS N
studied VBD N
, , N
361 CD N
cases NNS N
of IN N
prostate NN N
cancer NN N
-DOCSTART- -X- O O 20584070

patients NNS N
with IN N
mild JJ 4_p
to TO 4_p
moderate VB 4_p
chronic JJ 4_p
kidney NN 4_p
disease NN 4_p
. . N

patients NNS N
with IN N
chronic JJ 4_p
kidney NN 4_p
disease NN 4_p
( ( 4_p
CKD NNP 4_p
) ) 4_p
. . 4_p

patients NNS N
with IN N
mild JJ 4_p
CKD NNP 4_p
. . N

Thirty NNP 4_p
CKD NNP 4_p
patients NNS 4_p
with IN N
mild JJ 4_p
to TO 4_p
moderate VB 4_p
renal JJ 4_p
insufficiency NN 4_p
( ( N
20 CD 2_p
men NNS 2_p
and CC 2_p
10 CD 2_p
women NNS 2_p
; : N
mean JJ N
age NN N
, , N
37 CD 1_p
years NNS 1_p
; : 1_p
estimated VBN 1_p
glomerular JJ 1_p
filtration NN 1_p
rate NN 1_p
( ( 1_p
eGFR NN 1_p
) ) 1_p
> VBZ 1_p
60 CD 1_p
mL NN 1_p
min NN 1_p
( ( 1_p
-1 NNP 1_p
) ) 1_p
and CC 1_p
blood NN 1_p
pressure NN 1_p
> VBZ 1_p
130/85 CD 1_p
mmHg NN 1_p
) ) 1_p
were VBD 1_p
included VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

-DOCSTART- -X- O O 20538165

patients NNS N
with IN N
acute JJ 4_p
coronary JJ 4_p
syndrome NN 4_p
. . N

patients NNS N
with IN N
acute JJ 4_p
coronary JJ 4_p
syndrome NN 4_p
( ( N
ACS NNP 4_p
) ) N
. . N

ACS NNP 4_p
patients NNS N
undergoing VBG 4_p
cardiac JJ 4_p
catheterization NN 4_p
with IN N
> NNP 4_p
or=1 VBP 4_p
nonobstructive JJ 4_p
native JJ 4_p
coronary JJ 4_p
artery NN 4_p
atheroma NN 4_p
28 CD 3_p
patients NNS N
In IN N
ACS NNP 4_p
patients NNS N
patients NNS N
presenting VBG N
with IN N
ACS NNP 4_p
. . N

-DOCSTART- -X- O O 25047312

children NNS 1_p
two CD N
matched JJ N
groups NNS N
of IN N
30 CD 3_p
children NNS N
referred VBD N
to TO N
our PRP$ N
ED NNP 4_p
between IN 4_p
2010 CD 4_p
and CC 4_p
2011 CD 4_p
. . N

Mean JJ 1_p
age NN 1_p
was VBD 1_p
6.18 CD 1_p
± JJ 1_p
2.88 CD 1_p
years NNS 1_p
and CC N
31 CD 3_p
patients NNS N
( ( N
51.7 CD N
% NN N
) ) N
were VBD N
male JJ 2_p
-DOCSTART- -X- O O 10634838

ill JJ 4_p
preterm JJ 4_p
infants NNS 1_p
. . N

100 CD 3_p
preterm JJ N
infants NNS N
, , N
weighing VBG N
less JJR N
than IN N
1750 CD N
g NN N
at IN N
birth NN N
and CC N
requiring VBG N
ventilatory JJ N
support NN N
and CC N
parenteral JJ N
nutrition NN N
ill JJ N
preterm JJ N
infants NNS N
requiring VBG N
parenteral JJ N
nutrition NN N
. . N

-DOCSTART- -X- O O 23605805

administration NN 4_p
. . N

Eighteen NNP 3_p
healthy JJ 4_p
volunteers NNS N
-DOCSTART- -X- O O 7706148

children NNS 4_p
with IN 4_p
autism NN 4_p
3 CD 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
children NNS N
children NNS N
with IN N
autism NN N
-DOCSTART- -X- O O 25681235

transcatheter NN 4_p
aortic JJ 4_p
valve NN 4_p
replacement NN 4_p
: : 4_p
moderate JJ 4_p
and CC 4_p
severe JJ 4_p
paravalvular JJ 4_p
aortic JJ 4_p
regurgitation NN 4_p
Placement NNP 4_p
of IN 4_p
Aortic NNP 4_p
Transcatheter NNP 4_p
Valves NNP 4_p
( ( 4_p
PARTNER NNP 4_p
) ) 4_p
I PRP 4_p
and CC 4_p
PARTNER NNP 4_p
II NNP 4_p
trials NNS 4_p
consortium NN N
of IN N
echocardiography NN N
core NN N
laboratory NN N
directors NNS N
randomly JJ N
chosen NN N
subset NN N
of IN N
the DT N
randomized JJ N
patients NNS N
in IN N
the DT N
PARTNER NNP N
IIB NNP N
trial NN N
using VBG N
a DT N
multiwindow NN N
, , N
multiparametric JJ N
approach NN N
. . N

RESULTS NNP N
Only RB N
87 CD 3_p
patients NNS N
assessed VBN N
for IN N
PAR NNP 4_p
by IN N
the DT N
consortium NN N
could MD N
be VB N
paired VBN N
with IN N
readings NNS N
by IN N
the DT N
PARTNER NNP N
IIB NNP N
core NN N
laboratory NN N
-DOCSTART- -X- O O 15994720

children NNS 1_p
with IN N
autism NN 4_p
. . N

risperidone NN N
in IN N
children NNS 1_p
ages NNS N
5 CD 1_p
to TO 1_p
17 CD 1_p
years NNS 1_p
with IN N
autism NN 4_p
accompanied VBN N
by IN N
severe JJ N
tantrums NNS N
, , N
aggression NN N
, , N
and/or JJ N
self-injurious JJ N
behavior NN N
who WP N
showed VBD N
a DT N
positive JJ N
response NN N
in IN N
an DT N
earlier JJR N
8-week JJ N
trial NN N
. . N

Part NNP N
I PRP N
included VBD N
63 CD 3_p
children NNS N
. . N

Part NNP N
II NNP N
included VBD N
32 CD 3_p
patients NNS N
. . N

children NNS N
with IN N
autism NN N
characterized VBN N
by IN N
tantrums NNS N
, , N
aggression NN N
, , N
and/or JJ N
self-injurious JJ N
behavior NN N
. . N

-DOCSTART- -X- O O 16214437

ST-elevation NNP 4_p
myocardial JJ 4_p
infarction NN 4_p
in IN N
patients NNS N
treated VBN N
with IN N
thrombolytic JJ N
therapy NN N
. . N

120 CD N
patients NNS N
who WP N
had VBD N
ST-elevation NNP 4_p
myocardial JJ 4_p
infarction NN 4_p
that WDT N
was VBD N
treated VBN N
within IN N
12 CD N
hours NNS N
from IN N
symptom JJ N
onset VBN N
-DOCSTART- -X- O O 7488285

polyarteritis NN N
nodosa NN N
and CC N
Churg-Strauss NNP N
syndrome NN N
patients NNS N
with IN N
factors NNS N
predicting VBG N
poor JJ N
prognosis NN N
. . N

sixty-two JJ N
patients NNS N
. . N

severe JJ 4_p
polyarteritis NN 4_p
nodosa NN 4_p
( ( 4_p
PAN NNP 4_p
) ) 4_p
and CC 4_p
Churg-Strauss JJ 4_p
syndrome NN 4_p
( ( 4_p
CSS NNP 4_p
) ) 4_p
62 CD 3_p
patients NNS 3_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
prednisone NN N
plus CC N
cyclophosphamide NN N
( ( N
intravenous JJ N
bolus NN N
) ) N
( ( N
group NN N
A NNP N
; : N
n JJ N
= NNP N
28 CD N
) ) N
or CC N
prednisone JJ N
plus CC N
cyclophosphamide JJ N
( ( N
intravenous JJ N
bolus NN N
) ) N
plus CC N
plasma JJ N
exchanges NNS N
( ( N
group NN N
B NNP N
; : N
n CC N
= VB N
34 CD N
) ) N
as IN N
first-line JJ N
treatment NN N
for IN N
severe JJ N
PAN NNP N
or CC N
CSS NNP N
. . N

-DOCSTART- -X- O O 1722167

finasteride-treated JJ 4_p
subjects NNS 4_p
and CC N
male JJ N
pseudohermaphrodites NNS 4_p
with IN N
inherited JJ 4_p
5 CD 4_p
alpha-reductase JJ 4_p
deficiency NN 4_p
. . N

Male JJ 4_p
pseudohermaphrodites NNS 4_p
( ( 4_p
MPHs NNP 4_p
) ) 4_p
with IN 4_p
inherited JJ 4_p
5 CD 4_p
alpha-reductase JJ 4_p
deficiency NN 4_p
and CC 4_p
decreased VBD 4_p
dihydrotestosterone NN 4_p
production NN 4_p
The DT N
5 CD N
alpha-steroid JJ N
metabolite NN N
profile NN N
in IN N
the DT N
MPHs NNP N
was VBD N
compared VBN N
with IN N
that DT N
of IN N
men NNS 4_p
with IN 4_p
benign JJ 4_p
prostatic JJ 4_p
hyperplasia NN 4_p
-DOCSTART- -X- O O 21859314

. . N

Forty NNP 3_p
human JJ N
third JJ N
molars NNS N
-DOCSTART- -X- O O 2231203

chronic JJ 4_p
inflammatory NN 4_p
bowel NN 4_p
disease NN 4_p
. . 4_p

-DOCSTART- -X- O O 22924950

Cutaneous NNP 4_p
Lymphoma NNP 4_p
Task NNP N
Force NNP N
phase NN N
III NNP N
randomized VBD N
clinical JJ N
trial NN N
early JJ N
stages NNS N
of IN N
mycosis NN 4_p
fungoides NNS 4_p
. . N

patients NNS N
treated VBN N
with IN N
PUVA NNP N
alone RB N
or CC N
PUVA NNP N
and CC N
bexarotene NN N
. . N

in IN N
patients NNS N
with IN N
stage NN N
IB NNP N
and CC N
IIA NNP N
mycosis NN N
fungoides NNS N
( ( N
MF NNP N
) ) N
after IN N
93 CD N
of IN N
145 CD N
required JJ N
patients NNS N
the DT N
93 CD N
randomized JJ N
patients NNS N
, , N
87 CD N
started VBD N
treatment NN N
, , N
41 CD N
received VBD N
PUVA NNP N
and CC N
46 CD N
received VBD N
PUVA NNP N
+ NNP N
bexarotene NN N
-DOCSTART- -X- O O 17356056

eosinophilic JJ 4_p
and CC 4_p
non-eosinophilic JJ 4_p
asthma NN 4_p
. . N

12 CD 3_p
patients NNS 3_p
with IN N
symptomatic JJ 4_p
eosinophilic JJ 4_p
asthma NN 4_p
, , N
11 CD 3_p
patients NNS 3_p
with IN N
non-eosinophilic JJ 4_p
asthma NN 4_p
and CC N
10 CD 3_p
healthy JJ 4_p
controls NNS 4_p
. . N

patients NNS N
with IN N
non-eosinophilic JJ N
asthma NN N
and CC N
6 CD 3_p
different JJ 3_p
patients NNS 3_p
with IN N
eosinophilic JJ N
asthma NN N
Patients NNS N
with IN N
non-eosinophilic JJ N
asthma NN N
Non-eosinophilic JJ N
and CC N
eosinophilic JJ N
asthma NN N
groups NNS N
-DOCSTART- -X- O O 2180462

post-operative JJ 4_p
infective JJ 4_p
complications NNS 4_p
following VBG 4_p
emergency NN 4_p
abdominal JJ 4_p
surgery NN 4_p
. . 4_p

57 CD 3_p
patients NNS N
undergoing JJ N
emergency NN N
abdominal JJ N
surgery NN N
, , N
prospectively RB N
a DT N
further JJ N
63 CD 3_p
patients NNS N
undergoing JJ N
emergency NN N
abdominal JJ N
surgery NN N
The DT N
total NN N
of IN N
120 CD 3_p
patients NNS N
studied VBN N
-DOCSTART- -X- O O 16792607

combined JJ N
spinal JJ N
epidural JJ N
anaesthesia NN N
. . N

116 CD 4_p
parturients NNS 4_p
undergoing JJ 4_p
elective JJ 4_p
Caesarean JJ 4_p
section NN 4_p
to TO 4_p
receive VB 4_p
anaesthesia NN 4_p
using VBG 4_p
one CD 4_p
of IN 4_p
these DT 4_p
techniques NNS 4_p
. . 4_p

-DOCSTART- -X- O O 8604728

patients NNS 4_p
with IN 4_p
poor JJ 4_p
prognoses NNS 4_p
, , 4_p
to TO 4_p
determine VB 4_p
risk NN 4_p
factors NNS 4_p
for IN 4_p
surgical JJ 4_p
failure NN 4_p
and CC 4_p
to TO 4_p
examine VB 4_p
the DT 4_p
relationship NN 4_p
of IN 4_p
intraocular JJ 4_p
pressure NN 4_p
and CC 4_p
visual JJ 4_p
function NN 4_p
. . 4_p

213 CD N
patients NNS N
with IN N
previous JJ N
cataract NN N
surgery NN N
or CC N
previous JJ N
failed VBD N
filtering VBG N
surgery NN N
eyes NNS N
after IN N
previous JJ N
cataract NN N
surgery NN N
or CC N
unsuccessful JJ N
filtering NN N
surgery NN N
-DOCSTART- -X- O O 8056005

patients NNS N
with IN N
moderate JJ 4_p
coronary JJ 4_p
disease NN 4_p
. . N

348 CD 3_p
patients NNS N
with IN N
moderate JJ 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
, , 4_p
standardized VBD N
coronary JJ N
angiograms NNS N
were VBD N
taken VBN N
3 CD N
years NNS N
apart RB N
-DOCSTART- -X- O O 20367417

distal JJ 4_p
radial JJ 4_p
fractures NNS 4_p
. . 4_p

nonoperated JJ 4_p
distal JJ 4_p
radial NN 4_p
fractures NNS 4_p
One CD N
third NN N
of IN N
the DT N
patients NNS N
of IN N
the DT N
international JJ N
trial NN N
were VBD N
treated VBN N
at IN N
Linköping NNP N
University NNP N
Hospital NNP N
our PRP$ N
27 CD N
patients NNS N
in IN N
distal JJ N
radial JJ N
fractures NNS N
. . N

-DOCSTART- -X- O O 17998493

acute NN 4_p
uncomplicated JJ 4_p
cystitis NN 4_p
in IN N
women NNS 2_p
. . N

338 CD 3_p
women NNS 2_p
aged VBD 1_p
18 CD 1_p
to TO 1_p
45 CD 1_p
years NNS 1_p
with IN N
acute NN 4_p
uncomplicated JJ 4_p
cystitis NN 4_p
acute JJ 4_p
cystitis NN 4_p
in IN N
women NNS 2_p
. . N

-DOCSTART- -X- O O 24652860

health-related JJ 4_p
quality NN 4_p
of IN 4_p
life NN 4_p
, , 4_p
body NN 4_p
composition NN 4_p
, , 4_p
and CC 4_p
function NN 4_p
of IN 4_p
older JJR 4_p
adults NNS 4_p
. . N

function NN N
in IN N
older JJR 1_p
adults NNS 1_p
. . N

Fifty JJ 3_p
participants NNS 3_p
were VBD N
randomized VBN N
the DT 4_p
PCS NNP 4_p
in IN N
older JJR N
adults NNS N
-DOCSTART- -X- O O 7964960

nausea NN 4_p
and CC N
vomiting NN 4_p
associated VBN N
with IN N
fractionated JJ 4_p
total-body JJ 4_p
irradiation NN 4_p
. . N

total-body JJ 4_p
irradiation NN 4_p
( ( 4_p
TBI NNP 4_p
) ) 4_p
-induced VBD 4_p
nausea NN 4_p
and CC 4_p
vomiting NN 4_p
. . N

Twenty NNP 3_p
patients NNS N
who WP N
received VBD N
4 CD N
days NNS N
of IN N
TBI NNP N
as IN N
part NN N
of IN N
their PRP$ N
preparative JJ N
regimen NNS N
before IN N
bone NN N
marrow NN N
transplantation NN N
-DOCSTART- -X- O O 25534295

very RB 4_p
platinum-sensitive JJ 4_p
ovarian JJ 4_p
cancer NN 4_p
patients NNS 4_p
: : 4_p
subset JJ 4_p
analysis NN 4_p
of IN 4_p
the DT 4_p
CALYPSO NNP 4_p
phase NN 4_p
III NNP 4_p
trial NN 4_p
. . N

patients NNS 4_p
with IN 4_p
very RB 4_p
platinum-sensitive JJ 4_p
recurrent NN 4_p
ovarian JJ 4_p
cancer NN 4_p
( ( 4_p
ROC NNP 4_p
) ) 4_p
enrolled VBD 4_p
in IN 4_p
the DT 4_p
phase NN 4_p
III NNP 4_p
CALYPSO NNP 4_p
trial NN 4_p
. . 4_p

The DT N
international JJ N
non-inferiority JJ N
trial NN N
enrolled VBD N
women NNS N
with IN N
ROC NNP N
that WDT N
relapsed VBD N
> $ N
6 CD N
months NNS N
following VBG N
first- JJ N
or CC N
second-line JJ N
platinum- JJ N
and CC N
paclitaxel-based JJ N
therapies NNS N
. . N

patients NNS N
with IN N
a DT N
TFI NNP N
> NNP N
24 CD N
months NNS N
A DT N
total NN 3_p
of IN 3_p
259 CD 3_p
very RB N
platinum-sensitive JJ 4_p
patients NNS 4_p
were VBD 4_p
included VBN 4_p
( ( 4_p
n=131 UH N
, , 4_p
CD NNP 4_p
; : 4_p
n=128 RB N
, , 4_p
CP NNP 4_p
) ) 4_p
. . N

patients NNS 4_p
with IN 4_p
very RB 4_p
platinum-sensitive JJ 4_p
ROC NNP 4_p
. . 4_p

-DOCSTART- -X- O O 10094243

patients NNS N
with IN N
panic JJ 4_p
disorder NN 4_p
and CC N
in IN N
social JJ 4_p
phobics NNS 4_p
Twenty-nine JJ 3_p
patients NNS 3_p
received VBD N
epinephrine JJ N
, , N
ten JJ 3_p
patients NNS 3_p
received VBD N
placebo NN N
. . N

-DOCSTART- -X- O O 11547366

Forty-eight NNP 3_p
matched VBD N
pairs NNS N
of IN N
osteoarthritic JJ 4_p
knees NNS N
from IN N
patients NNS N
who WP N
underwent VBP N
primary JJ N
total JJ N
knee NN N
arthroplasty NN N
with IN N
a DT N
round-on-round NN N
, , N
Apollo NNP N
Knee NNP N
System NNP N
Patients NNS N
were VBD N
matched VBN N
for IN N
patient JJ N
factors NNS N
, , N
preoperative JJ N
deformities NNS 4_p
, , N
cruciate JJ N
salvage NN N
or CC N
sacrifice NN N
, , N
and CC N
surgical JJ N
technique NN N
. . N

elderly JJ 1_p
patients NNS N
( ( N
> JJ 1_p
70 CD 1_p
years NNS N
old JJ N
) ) N
-DOCSTART- -X- O O 11978277

symptomatic JJ 4_p
endometriosis NN 4_p
: : N
endometriosis NN 4_p
patients NNS N
of IN N
a DT N
12-month JJ N
course NN N
of IN N
GnRH NNP N
agonist VBP N
alone RB N
or CC N
with IN N
one CD N
of IN N
three CD N
" JJ N
add-back JJ N
" NN N
regimens NNS N
. . N

All DT N
patients NNS N
had VBD N
received VBN N
monthly JJ N
leuprolide NN N
acetate NN N
201 CD 3_p
patients NNS N
enrolled VBN N
in IN N
the DT N
initial JJ N
trial NN N
, , N
123 CD 3_p
completed VBN N
at IN N
least JJS N
280 CD N
days NNS N
of IN N
therapy NN N
and CC N
entered VBD N
the DT N
follow-up JJ N
period NN N
. . N

symptomatic JJ 4_p
endometriosis NN 4_p
patients NNS N
-DOCSTART- -X- O O 9772108

modification NN 4_p
of IN 4_p
agonist-antagonist JJ 4_p
electromyographic JJ 4_p
activity NN 4_p
for IN 4_p
rapid JJ 4_p
movement NN 4_p
inhibition NN 4_p
. . N

Subjects NNS 4_p
made VBD 4_p
a DT 4_p
fast JJ 4_p
elbow NN 4_p
extension NN 4_p
movement NN 4_p
to TO 4_p
designated VBN 4_p
target NN 4_p
in IN 4_p
response NN 4_p
to TO 4_p
a DT 4_p
go JJ 4_p
signal NN 4_p
. . N

-DOCSTART- -X- O O 23880333

adults NNS 1_p
with IN N
high-functioning JJ 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
: : N
Adults NNP 1_p
with IN N
high-functioning JJ 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
have VBP N
difficulties NNS N
in IN N
social JJ N
communication NN N
; : N
adults NNS 1_p
with IN N
ASD NNP 4_p
children NNS 1_p
with IN N
ASD NNP 4_p
. . N

adults NNS 1_p
with IN N
ASD NNP 4_p
. . N

The DT N
participants NNS N
will MD N
be VB N
60 CD 3_p
adults NNS 3_p
with IN N
ASD NNP 4_p
; : N
30 CD 3_p
will MD 3_p
be VB 3_p
assigned VBN 3_p
to TO 3_p
a DT 3_p
CBT NNP 3_p
group NN 3_p
and CC N
30 CD 3_p
to TO 3_p
a DT 3_p
waitlist NN 3_p
control NN 3_p
group NN 3_p
. . N

-DOCSTART- -X- O O 17848325

septate JJ 4_p
uterus NN 4_p
: : N
Endoscopic NNP N
gynecology NN N
units NNS N
at IN N
tertiary JJ N
care NN N
university NN N
hospitals NNS N
. . N

One CD 3_p
hundred-sixty JJ 3_p
patients NNS N
with IN N
septate JJ 4_p
uterus NNS 4_p
and CC N
a DT N
history NN N
of IN N
recurrent JJ N
abortion NN N
or CC N
primary JJ N
infertility NN 4_p
undergoing VBG N
hysteroscopic NN N
metroplasty NN N
from IN N
2001 CD N
to TO N
2005 CD N
. . N

-DOCSTART- -X- O O 7640140

healthy JJ N
male NN N
and CC N
female JJ N
volunteers NNS N
: : N
male NN N
and CC N
female JJ N
healthy JJ N
volunteers NNS N
. . N

Ten CD 3_p
males NNS 2_p
and CC N
nine CD 3_p
females NNS 2_p
( ( N
age NN N
range NN N
20-33 CD N
years NNS N
) ) N
-DOCSTART- -X- O O 21433319

patients NNS N
with IN N
initial JJ N
symptoms NNS N
of IN N
prostatic JJ N
adenoma NN N
and CC N
risk NN N
of IN N
its PRP$ N
progression NN N
] NN N
multicenter NN N
, , N
open-population NN N
50 CD 3_p
patients NNS 3_p
with IN N
initial JJ N
symptoms NNS N
of IN N
prostatic JJ 4_p
adenoma NN 4_p
( ( 4_p
PA NNP 4_p
) ) 4_p
in IN N
comparison NN N
with IN N
50 CD 3_p
matched JJ 3_p
controls NNS 3_p
. . N

-DOCSTART- -X- O O 16326121

nine CD N
subjects NNS N
( ( N
eight CD N
men NNS N
and CC N
one CD N
woman NN N
; : N
mean JJ N
age+/-SD NN N
: : N
31.3+/-11.0 JJ N
yr NN N
) ) N
with IN N
mild JJ N
intermittent JJ N
allergic NN N
asthma NN N
, , N
never RB N
treated VBN N
with IN N
regular JJ N
beta2-agonists NNS N
or CC N
inhaled JJ N
corticosteroids NNS N
. . N

all DT N
subjects NNS N
had VBD N
shown VBN N
a DT N
positive JJ N
early JJ N
airway NN N
response NN N
( ( N
EAR NNP N
) ) N
to TO N
allergen VB N
. . N

-DOCSTART- -X- O O 9196141

Hodgkin NNP 4_p
's POS 4_p
disease NN 4_p
. . N

chemotherapy NN 4_p
in IN N
nonbulky JJ N
involved JJ N
field NN N
( ( N
IF/BF NNP N
) ) N
and CC N
noninvolved VBN N
extended-field NN N
( ( N
EF/IF NNP N
) ) N
sites VBZ N
in IN N
patients NNS N
with IN N
intermediate-stage JJ N
Hodgkin NNP 4_p
's POS 4_p
disease NN 4_p
( ( N
HD NNP 4_p
) ) N
. . N

HD NNP 4_p
patients NNS N
in IN N
stage NN 4_p
I PRP 4_p
to TO 4_p
IIIA NNP 4_p
with IN N
a DT N
large JJ 4_p
mediastinal JJ 4_p
mass NN 4_p
, , N
E NNP 4_p
stage NN 4_p
, , N
or CC N
massive JJ 4_p
spleen JJ 4_p
involvement NN 4_p
146 CD 3_p
patients NNS N
who WP N
responded VBD N
to TO N
chemotherapy VB 4_p
were VBD N
randomized VBN N
to TO N
receive VB N
20 CD N
Gy NNP N
( ( N
70 CD 3_p
patients NNS N
) ) N
or CC N
40 CD N
Gy NNP N
( ( N
76 CD 3_p
patients NNS N
) ) N
of IN N
EF NNP N
irradiation NN N
in IN N
all DT N
fields NNS N
outside IN N
bulky JJ N
disease NN N
sites NNS N
. . N

A DT N
cohort NN N
of IN N
111 CD 3_p
patients NNS N
who WP N
fulfilled VBD N
the DT N
same JJ N
inclusion NN N
criteria NNS N
in IN N
the DT N
subsequent JJ N
trial NN N
HD5 NNP N
( ( N
1988 CD N
to TO N
1993 CD N
) ) N
were VBD N
treated VBN N
with IN N
30 CD N
Gy NNP N
. . N

modern JJ N
polychemotherapy NN 4_p
in IN N
patients NNS N
with IN N
intermediate-stage JJ 4_p
HD NNP 4_p
. . N

-DOCSTART- -X- O O 19590075

H5N1 NNP 4_p
subtype NN 4_p
avian JJ 4_p
influenza NN 4_p
virus NN 4_p
recombinant JJ 4_p
protein-based JJ 4_p
vaccine NN 4_p
. . N

farmed JJ N
poultry NN N
and CC N
free-living JJ N
birds NNS N
commercial JJ N
chicken NN N
industry NN N
pBCX NN 4_p
vector NN 4_p
-DOCSTART- -X- O O 15039684

Children NNP 4_p
younger JJR 4_p
than IN 4_p
16 CD 4_p
years NNS 4_p
and CC 4_p
experiencing VBG 4_p
moderate JJ 4_p
to TO 4_p
severe VB 4_p
blunt NN 4_p
head JJ 4_p
injury NN 4_p
group NN 4_p
. . 4_p

One CD N
hundred VBD N
two CD N
patients NNS N
were VBD N
enrolled VBN N
, , N
with IN N
a DT N
median JJ N
age NN N
of IN N
6.1 CD N
years NNS N
. . N

Sixty-eight JJ N
percent NN N
were VBD N
boys NNS N
. . N

2 CD N
treatment NN N
groups NNS N
3 CD N
( ( N
7 CD N
% NN N
) ) N
of IN N
46 CD 3_p
patients NNS N
3 CD N
( ( N
5 CD N
% NN N
) ) N
of IN N
56 CD 3_p
patients NNS N
groups NNS N
( ( N
seizure JJ N
rate NN N
increased VBN N
by IN N
1.5 CD N
% NN N
in IN N
the DT N
phenytoin NN N
group NN N
) ) N
children NNS N
may MD N
be VB N
much RB N
-DOCSTART- -X- O O 23052635

of IN N
520 CD 3_p
patients NNS N
with IN N
osteoarthritis NN 4_p
who WP N
underwent VBD 4_p
computer-navigated JJ 4_p
total JJ 4_p
knee NN 4_p
arthroplasty NN 4_p
for IN 4_p
one CD 4_p
knee NN 4_p
and CC N
conventional JJ 4_p
total JJ 4_p
knee NN 4_p
arthroplasty NN 4_p
for IN 4_p
the DT 4_p
other JJ 4_p
were VBD N
452 CD 3_p
women NNS 2_p
( ( 2_p
904 CD 2_p
knees NNS 2_p
) ) N
and CC N
sixty-eight JJ 3_p
men NNS 2_p
( ( 2_p
136 CD 2_p
knees NNS 2_p
) ) N
with IN N
a DT N
mean JJ 1_p
age NN 1_p
of IN 1_p
sixty-eight JJ 1_p
years NNS 1_p
( ( N
range NN N
, , N
forty-nine JJ N
to TO N
eighty-eight JJ N
years NNS N
) ) N
at IN N
the DT N
time NN N
of IN N
the DT N
index NN N
arthroplasty NN N
the DT N
knees NNS N
that WDT N
underwent VBD N
computer-navigated JJ N
total JJ N
knee NN N
arthroplasty NN N
and CC N
those DT N
that WDT N
underwent JJ N
conventional JJ N
total JJ N
knee NN N
arthroplasty NN N
-DOCSTART- -X- O O 19968217

total JJ 4_p
hip JJ 4_p
replacement NN 4_p
: : N
a DT N
randomized JJ N
prospective JJ N
study NN N
. . N

From IN N
2004 CD N
to TO N
2008 CD N
, , N
81 CD 3_p
patients NNS N
seeking VBG N
elective JJ N
THRs NNP 4_p
were VBD N
randomly RB N
assigned VBN N
into IN N
a DT N
standard JJ N
rehabilitation NN N
group NN N
or CC N
an DT N
early JJ N
rehabilitation NN N
group NN N
. . N

standard JJ N
group NN N
included VBD N
restrictions NNS N
to TO N
avoid VB N
hip NN N
flexion NN N
> VBD N
90 CD N
degrees NNS N
and CC N
avoidance NN N
of IN N
riding VBG N
in IN N
a DT N
car NN N
for IN N
the DT N
first JJ N
postoperative JJ N
month NN N
. . N

The DT N
early JJ N
group NN N
had VBD N
no DT N
flexion NN N
or CC N
car NN N
riding NN N
restrictions NNS N
. . N

Forty-three JJ 3_p
patients NNS N
were VBD N
in IN N
the DT N
standard JJ N
group NN N
and CC N
38 CD 3_p
patients NNS N
were VBD N
in IN N
the DT N
early JJ N
group NN N
. . N

no DT N
significant JJ N
demographic JJ N
differences NNS N
between IN N
the DT N
2 CD N
groups NNS N
. . N

-DOCSTART- -X- O O 25056444

Prior JJ N
experience NN N
with IN N
a DT N
pain NN 4_p
stimulus NN 4_p
Healthy NNP N
normotensive JJ N
undergraduates NNS 1_p
( ( N
66 CD 3_p
women NNS 2_p
, , N
68 CD 3_p
men NNS 2_p
) ) N
who WP N
either DT N
did VBD N
or CC N
did VBD N
not RB N
report VB N
prior JJ N
experience NN N
with IN N
pain NN N
from IN N
submerging VBG N
a DT N
limb NN N
in IN N
cold JJ N
water NN N
were VBD N
enrolled VBN N
. . N

context NN N
, , N
prior JJ N
experience NN N
with IN N
the DT N
pain NN 4_p
stimulus NN 4_p
-DOCSTART- -X- O O 2218657

acute JJ 4_p
otitis NN 4_p
media NNS 4_p
in IN N
infants NNS 1_p
and CC 1_p
children NNS 1_p
. . N

377 CD 3_p
infants NNS 1_p
and CC 1_p
children NNS 1_p
with IN N
acute NN 4_p
otitis NN 4_p
media NNS 4_p
( ( 4_p
AOM NNP 4_p
) ) 4_p
received VBD N
a DT N
10-day JJ N
course NN N
of IN N
an DT N
oral JJ N
suspension NN N
-DOCSTART- -X- O O 19853700

management NN N
of IN N
atrial JJ 4_p
fibrillation NN 4_p
complicating VBG N
coronary JJ N
artery NN N
bypass NN N
grafting NN N
: : N
management NN N
of IN N
atrial JJ N
fibrillation NN N
( ( N
AF NNP 4_p
) ) N
complicating VBG N
coronary JJ N
artery NN N
bypass NN N
grafting NN N
( ( N
CABG NNP N
) ) N
post-CABG JJ N
AF NNP N
in IN N
the DT N
PREVENT-IV NNP N
trial NN N
geographic JJ N
region NN N
type NN N
of IN N
site NN N
. . N

patients NNS N
who WP N
developed VBD N
post-CABG JJ 4_p
AF NNP 4_p
( ( N
663 CD 3_p
) ) N
with IN N
those DT N
who WP N
did VBD N
not RB N
( ( N
2,131 CD 3_p
) ) N
. . N

patients NNS N
with IN N
post-CABG JJ N
patients NNS N
without IN N
AF NNP N
patients NNS N
with IN N
AF NNP N
-DOCSTART- -X- O O 18462303

herpes NNS 4_p
simplex JJ 4_p
labialis NN 4_p
. . 4_p

herpes NNS 4_p
simplex JJ 4_p
labialis NN 4_p
( ( N
HSL NNP N
) ) N
international JJ N
, , N
multicentre JJ N
enrolled VBD N
728 CD 3_p
subjects NNS N
with IN N
a DT N
history NN N
of IN N
recurrent NN N
HSL NNP 4_p
. . N

351 CD 3_p
-DOCSTART- -X- O O 19092729

scleral JJ 4_p
buckling NN 4_p
surgery NN 4_p
. . 4_p

Patients NNS N
undergoing VBG N
scleral JJ 4_p
buckle NN 4_p
surgery NN 4_p
over IN N
18 CD N
months NNS N
116 CD 3_p
patients NNS 3_p
were VBD N
recruited VBN N
, , N
58 CD 3_p
to TO N
each DT N
treatment NN N
arm NN N
. . N

-DOCSTART- -X- O O 18606053

acute JJ 4_p
bacterial JJ 4_p
otitis NN 4_p
externa NN 4_p
. . N

patients NNS 4_p
with IN 4_p
acute JJ 4_p
bacterial JJ 4_p
otitis NN 4_p
externa NN 4_p
( ( 4_p
AOE NNP 4_p
) ) 4_p
multi-center JJ 4_p
clinical JJ 4_p
trial NN 4_p
in IN 4_p
ear NN 4_p
, , 4_p
nose RB 4_p
, , 4_p
and CC 4_p
throat NN 4_p
( ( 4_p
ENT NNP 4_p
) ) 4_p
specialist NN 4_p
practices NNS 4_p
338 CD 3_p
patients NNS N
aged VBN 1_p
18-76 NNS 1_p
who WP N
had VBD N
a DT N
previous JJ N
episode NN 4_p
of IN 4_p
otitis NN 4_p
externa NN 4_p
within IN N
the DT N
last JJ N
year NN N
patients NNS 4_p
with IN 4_p
AOE NNP 4_p
-DOCSTART- -X- O O 19301089

postmenopausal JJ 4_p
osteoporosis NN 4_p
: : 4_p
postmenopausal JJ 4_p
women NNS 4_p
with IN 4_p
osteoporosis NN 4_p
. . 4_p

61 CD N
postmenopausal JJ N
women NNS N
with IN N
osteoporosis NN N
. . N

-DOCSTART- -X- O O 2741888

postprandial JJ 4_p
esophageal JJ 4_p
acid NN N
exposure NN N
. . N

gastroesophageal NN 4_p
reflux NN 4_p
( ( N
GER NNP 4_p
) ) N
. . N

10 CD 3_p
normal JJ N
subjects NNS N
and CC N
10 CD 3_p
GER NNP N
patients NNS N
following VBG N
low JJ N
and CC N
high JJ N
fat NN N
meals NNS N
eaten VBP N
in IN N
two CD N
body NN N
positions NNS N
. . N

-DOCSTART- -X- O O 1479049

hyperactive JJ 4_p
and CC 4_p
impulsive JJ 4_p
children NNS 4_p
with IN 4_p
autistic JJ 4_p
disorder NN 4_p
. . 4_p

autistic JJ N
children NNS N
autistic JJ N
children NNS N
Eight NNP N
male NN N
children NNS N
( ( N
8.1 CD N
+/- JJ N
2.8 CD N
years NNS N
) ) N
with IN N
autistic JJ N
disorder NN N
, , N
diagnosed VBN N
by IN N
DSM-III-R NNP N
criteria NNS N
Subjects NNS N
were VBD N
included VBN N
in IN N
the DT N
study NN N
if IN N
they PRP N
had VBD N
inattention NN N
, , N
impulsivity NN N
, , N
and CC N
hyperactivity NN N
that WDT N
was VBD N
excessive JJ N
for IN N
their PRP$ N
developmental JJ N
level NN N
. . N

Subjects NNS N
had VBD N
not RB N
tolerated VBN N
or CC N
responded VBN N
to TO N
other JJ N
psychopharmacologic JJ N
treatments NNS N
( ( N
neuroleptics NNS N
, , N
methylphenidate NN N
, , N
or CC N
desipramine NN N
) ) N
. . N

children NNS 4_p
with IN 4_p
autistic JJ 4_p
disorder NN 4_p
. . 4_p

-DOCSTART- -X- O O 2188165

hypertension NN 4_p
emergencies NNS 4_p
] VBP N
hypertensive JJ 4_p
emergencies NNS 4_p
. . N

During IN N
hypertensive JJ 4_p
crises NNS 4_p
( ( 4_p
systolic JJ 4_p
blood NN 4_p
pressure NN 4_p
exceeding VBG 4_p
200 CD 4_p
mmHg NN 4_p
and CC 4_p
diastolic JJ 4_p
blood NN 4_p
pressure NN 4_p
exceeding VBG 4_p
115 CD 4_p
mmHg NN 4_p
) ) N
forty NN 3_p
hypertensive JJ 4_p
patients NNS N
hypertensive JJ 4_p
emergencies NNS 4_p
. . N

-DOCSTART- -X- O O 1741218

lactating VBG N
women NNS 2_p
. . N

Twenty-three JJ 3_p
women NNS 4_p
who WP N
were VBD N
exclusively RB N
breast-feeding VBG N
their PRP$ N
infants NNS N
were VBD N
randomly RB N
assigned VBN N
breast-feeding JJ N
mothers NNS N
. . N

-DOCSTART- -X- O O 3608343

oral JJ N
ketoprofen NN N
. . N

8 CD 3_p
healthy JJ 4_p
male NN 2_p
volunteers NNS N
, , N
mean JJ N
age NN N
27.2 CD 1_p
years NNS N
14 CD N
blood NN N
and CC N
4 CD N
urine JJ N
samples NNS N
-DOCSTART- -X- O O 22136317

Japanese JJ N
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
subgroup NN N
of IN N
postmenopausal NN N
, , N
estrogen VBP N
receptor-positive JJ N
Japanese JJ N
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
from IN N
the DT N
Pre-Operative JJ N
" NNP N
Arimidex NNP N
" NNP N
Compared NNP N
with IN N
Tamoxifen NNP N
trial NN N
Patients NNS N
with IN N
large JJ N
, , N
potentially RB N
operable JJ N
, , N
locally-advanced JJ 3_p
breast NN 3_p
cancer NN 3_p
-DOCSTART- -X- O O 22412171

chronic JJ 4_p
stroke NN 4_p
patients NNS 4_p
. . N

A NNP 4_p
total NN 4_p
of IN 4_p
41 CD 3_p
chronic JJ 3_p
stroke NN 3_p
patients NNS 3_p
received VBD 4_p
excitatory JJ 4_p
TBS NNP 4_p
to TO 4_p
the DT 4_p
ipsilesional NN 4_p
hemisphere NN 4_p
or CC 4_p
inhibitory NN 4_p
TBS NNP 4_p
to TO 4_p
the DT 4_p
contralesional NN 4_p
hemisphere NN 4_p
in IN 4_p
2 CD 4_p
centers NNS 4_p
; : 4_p
-DOCSTART- -X- O O 12452980

paediatric JJ 1_p
liver JJ 4_p
transplantation NN 4_p
. . 4_p

group NN N
of IN N
children NNS 1_p
post VBN N
liver JJ N
transplantation NN N
gingival JJ 4_p
overgrowth NN 4_p
in IN N
children NNS 1_p
receiving VBG N
FK506 NNP N
Seventy-nine JJ 3_p
children NNS 1_p
( ( 1_p
aged VBN 1_p
15-196 CD 1_p
months NNS 1_p
) ) 1_p
undergoing VBG N
liver JJ N
transplantation NN N
at IN N
Birmingham NNP N
Children NNP N
's POS N
Hospital NNP N
between IN N
October NNP N
1998 CD N
and CC N
October NNP N
2000 CD N
Fifty-two JJ 4_p
patients NNS 4_p
Eighteen JJ N
children NNS 1_p
41 CD 3_p
children NNS 1_p
receiving VBG N
cyclosporin NN N
alone RB N
, , N
26 CD 3_p
exhibited VBD N
gingival NN 4_p
overgrowth NN 4_p
compared VBN N
to TO N
zero CD 3_p
of IN 3_p
20 CD 3_p
patients NNS 3_p
receiving VBG N
tacrolimus JJ N
alone RB N
. . N

children NNS 1_p
treated VBN N
with IN N
immunosuppression NN N
liver JJ N
transplantation NN N
in IN N
children NNS 1_p
-DOCSTART- -X- O O 10097996

assessing VBG N
theory NN N
of IN N
mind NN N
in IN N
normal JJ N
children NNS N
and CC N
children NNS N
with IN N
pervasive JJ 4_p
developmental NN 4_p
disorders NNS 4_p
. . N

normal JJ N
children NNS N
and CC N
children NNS N
with IN N
pervasive JJ 4_p
developmental NN 4_p
disorders NNS 4_p
( ( 4_p
PDDs NNP 4_p
) ) 4_p
. . 4_p

normal JJ N
children NNS N
( ( N
n JJ N
= NNP N
70 CD 3_p
) ) N
young JJ 1_p
children NNS 1_p
older JJR 1_p
children NNS 1_p
normal JJ N
children NNS 1_p
( ( N
n JJ N
= NNP N
12 CD 3_p
) ) N
sample NN N
of IN N
children NNS 1_p
with IN N
PDDs NNP 4_p
( ( N
n JJ N
= NNP N
10 CD 3_p
) ) N
children NNS 1_p
with IN N
PDDs NNP 4_p
( ( N
n JJ N
= NNP N
20 CD 3_p
) ) N
children NNS 1_p
with IN N
other JJ N
psychiatric JJ 4_p
disorders NNS 4_p
( ( N
e.g. NN N
children NNS 1_p
with IN N
Attention-deficit NNP 4_p
Hyperactivity NNP 4_p
Disorder NNP 4_p
; : N
n CC N
= VB N
32 CD 3_p
) ) N
-DOCSTART- -X- O O 6337497

one CD N
eye NN N
of IN N
each DT N
of IN N
48 CD 3_p
patients NNS N
with IN N
ocular JJ 4_p
hypertension NN 4_p
. . N

-DOCSTART- -X- O O 9437974

130 CD N
patients NNS N
with IN N
inferior JJ N
alveolar JJ N
nerve NN N
( ( N
IAN NNP N
) ) N
and CC N
lingual JJ N
nerve NN N
( ( N
LN NNP N
) ) N
injuries NNS N
. . N

IAN NNP N
patients NNS N
the DT N
IAN NNP N
and CC N
LN NNP N
patient JJ N
populations NNS N
. . N

patients NNS 4_p
with IN 4_p
IAN NNP 4_p
injuries NNS 4_p
. . 4_p

-DOCSTART- -X- O O 22565413

hematologic JJ 4_p
cancer NN 4_p
patients NNS N
. . N

hematologic JJ 4_p
cancer NN 4_p
patients NNS N
hematologic VB 4_p
cancer NN 4_p
patients NNS N
online VBP N
. . N

One CD 3_p
hundred VBD 3_p
eighty-six JJ 3_p
registrants NNS 3_p
One CD 3_p
hundred VBD 3_p
eleven JJ 3_p
patients NNS 3_p
-DOCSTART- -X- O O 8712112

acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
395 CD 3_p
patients NNS N
with IN N
acute JJ N
myocardial JJ N
infarction NN N
( ( N
AMI NNP 4_p
) ) N
138 CD 3_p
patients NNS N
with IN N
anterior JJ N
wall NN N
AMI NNP N
257 CD 3_p
patients NNS N
with IN N
nonanterior JJ N
wall NN N
AMI NNP N
patients NNS N
with IN N
anterior JJ N
wall NN N
AMI NNP N
-DOCSTART- -X- O O 24330473

Parkinson NNP 4_p
's POS 4_p
disease NN 4_p
: : N
Forty-five NNP 3_p
women NNS 2_p
and CC 2_p
men NNS 2_p
, , N
aged VBN 1_p
50-79 CD 1_p
years NNS 1_p
, , N
were VBD N
recruited VBN N
. . N

Twenty-nine NN 3_p
of IN N
them PRP N
were VBD N
blindly RB N
randomised VBN N
to TO N
tactile VB N
massage NN N
( ( N
TM NNP N
) ) N
and CC N
16 CD 3_p
of IN N
them PRP N
to TO N
the DT N
control NN N
group NN N
, , N
rest NN N
to TO N
music NN N
( ( N
RTM NNP N
) ) N
-DOCSTART- -X- O O 8893393

patients NNS 4_p
with IN 4_p
HIV-1 NNP 4_p
infection NN 4_p
in IN N
12 CD 3_p
patients NNS N
with IN N
human JJ 4_p
immunodeficiency NN 4_p
virus NN 4_p
type-1 NN 4_p
( ( N
HIV-1 NNP 4_p
) ) N
infection NN N
3-12 JJ N
months NNS N
after IN N
initiation NN N
of IN N
antiretroviral JJ N
therapy NN N
. . N

HIV-1 NNP 4_p
infection NN N
. . N

-DOCSTART- -X- O O 11045790

superficial JJ 4_p
bladder NN 4_p
cancer NN 4_p
superficial JJ N
bladder NN N
cancer NN N
. . N

total NN N
of IN N
99 CD N
subjects NNS N
with IN N
resected JJ N
superficial JJ N
bladder NN N
cancer NN N
( ( N
pTa NN N
, , N
pT1 NN N
) ) N
bladder NN N
cancer NN N
. . N

-DOCSTART- -X- O O 10374155

Primary JJ N
capsulectomy NN N
, , N
anterior JJ N
vitrectomy NN N
, , N
lensectomy NN N
, , N
and CC N
posterior JJ N
chamber NN N
lens NNS N
implantation NN N
in IN N
children NNS 1_p
: : N
childhood NN 1_p
cataract NN 4_p
. . N

45 CD N
eyes NNS N
38 CD N
eyes NNS N
were VBD N
included VBN N
All DT N
eyes NNS N
had VBD N
lensectomy NN N
and CC N
posterior JJ N
chamber NN N
intraocular JJ N
lens NNS N
( ( N
PC NNP N
IOL NNP N
) ) N
implantation NN N
. . N

children NNS 1_p
. . N

-DOCSTART- -X- O O 15274670

animals NNS N
and CC N
healthy JJ 4_p
humans NNS 4_p
. . 4_p

Twenty-nine JJ 3_p
patients NNS N
( ( N
6 CD 3_p
type NN N
1 CD N
and CC N
23 CD 3_p
type NN N
2 CD N
) ) N
with IN N
gastroparesis NN 4_p
at IN N
baseline NN N
and CC N
after IN N
treatment NN N
with IN N
KC NNP N
11458 CD N
in IN N
a DT N
dose NN N
of IN N
8 CD N
mg NNS N
t.d.s. NN N
or CC N
placebo NN N
for IN N
8 CD N
days NNS N
. . N

-DOCSTART- -X- O O 12538120

minimally RB N
invasive JJ N
mitral-valve JJ 4_p
operations NNS 4_p
. . N

patients NNS N
with IN N
peripheral JJ N
vessel NN N
disease NN N
. . N

20 CD 3_p
patients NNS N
were VBD N
prospectively RB N
randomized VBN N
into IN N
2 CD N
groups NNS N
, , N
to TO N
undergo VB N
either RB N
standard JJ N
femoral NN N
( ( N
group NN N
A NNP N
) ) N
or CC N
direct JJ N
aortic JJ N
cannulation NN N
( ( N
group NN N
B NNP N
) ) N
. . N

-DOCSTART- -X- O O 15327617

sublingual JJ 4_p
and CC 4_p
vaginal JJ 4_p
misoprostol NN 4_p
in IN 4_p
second JJ 4_p
trimester NN 4_p
termination NN 4_p
of IN 4_p
pregnancy NN 4_p
. . N

second JJ 4_p
trimester NN 4_p
medical JJ 4_p
abortion NN 4_p
. . 4_p

Tertiary JJ N
referral JJ N
unit NN N
and CC N
a DT N
teaching JJ N
hospital NN N
. . N

Two CD 3_p
hundred VBD 3_p
and CC 3_p
twenty-four JJ 3_p
women NNS 3_p
at IN N
12 CD N
to TO N
20 CD N
weeks NNS N
of IN N
gestation NN N
. . N

-DOCSTART- -X- O O 9820191

Basal NNP 4_p
cell NN 4_p
carcinoma NN 4_p
of IN 4_p
the DT 4_p
face NN 4_p
: : N
surgery NN N
or CC N
radiotherapy NN N
-DOCSTART- -X- O O 17595435

premature JJ N
infants NNS N
. . N

low-birth-weight JJ N
infants NNS N
122 CD N
low-birth-weight JJ N
infants NNS N
. . N

Premature NN N
infants NNS N
< VBP N
or=32 JJ N
weeks NNS N
, , N
< NNP N
or=1850 MD N
g VB N
, , N
and CC N
receiving VBG N
parenteral JJ N
amino NN N
acids NNS N
at IN N
1.5 CD N
g/kg/d NN N
for IN N
an DT N
extended JJ N
period NN N
( ( N
> JJ N
24 CD N
hours NNS N
) ) N
, , N
or CC N
3 CD N
g/kg/d NN N
for IN N
a DT N
short JJ N
( ( N
5 CD N
hour NN N
) ) N
, , N
extended VBD N
( ( N
24 CD N
hour NN N
) ) N
, , N
or CC N
prolonged VBN N
( ( N
3-5 JJ N
days NNS N
) ) N
duration NN N
30 CD 4_p
infants NNS 4_p
, , 4_p
matched VBN 4_p
for IN 4_p
birth NN 4_p
weight NN 4_p
and CC 4_p
gestational JJ 4_p
age NN 4_p
, , 4_p
receiving VBG 4_p
PN NNP 4_p
during IN 4_p
the DT 4_p
first JJ 4_p
5 CD 4_p
days NNS 4_p
after IN 4_p
birth NN 4_p
Infants NNS N
with IN N
large JJ N
patent NN N
ductus NN N
arteriosus NN N
( ( N
PDA NNP N
) ) N
Low-birth-weight JJ N
infants NNS N
-DOCSTART- -X- O O 21978765

ovarian JJ 4_p
cancer NN 4_p
. . N

ovarian JJ 4_p
cancer NN 4_p
( ( 4_p
OC NNP 4_p
) ) 4_p
. . 4_p

Patients NNPS 4_p
with IN 4_p
stage JJ 4_p
IC-IV JJ 4_p
OC NNP 4_p
Patients NNS 4_p
with IN 4_p
complete JJ 4_p
response NN 4_p
( ( 4_p
CR NNP 4_p
) ) 4_p
toxicity NN 4_p
. . N

PD NNP N
or CC N
death NN N
in IN N
636 CD 3_p
patients NNS N
by IN N
820 CD 3_p
of IN N
919 CD 3_p
patients NNS N
enrolled VBD N
; : N
352 CD 3_p
patients NNS N
with IN N
CR NNP N
whereas NNS N
155 CD 3_p
patients NNS N
without IN N
CR NNP N
-DOCSTART- -X- O O 16911649

adenoidectomy NN 4_p
: : N
adenoidectomy NN N
among IN N
children NNS 1_p
< VBP 1_p
6 CD 1_p
years NNS 1_p
of IN N
age NN N
. . N

Kanta-Hame JJ N
Central NNP N
Hospital NNP N
, , N
a DT N
district NN N
referral NN N
center NN N
in IN N
Finland NNP N
. . N

93 CD 3_p
children NNS 1_p
undergoing JJ N
outpatient JJ N
adenoidectomy NN N
. . N

patients NNS N
with IN N
extensive JJ 4_p
adenoids NNS 4_p
and/or VBP N
profuse RB 4_p
intraoperative JJ 4_p
bleeding NN 4_p
. . N

adenoidectomy NN N
among IN N
children NNS 1_p
. . N

-DOCSTART- -X- O O 20843746

ovarian JJ 4_p
stimulation NN 4_p
for IN 4_p
IVF NNP 4_p
. . 4_p

prior RB N
to TO N
IVF NNP N
in IN N
1509 CD N
patients NNS N
of IN N
1509 CD N
patients NNS N
-DOCSTART- -X- O O 7595712

extensive JJ N
small-cell NN N
lung NN 4_p
cancer NN 4_p
: : N
previously RB N
untreated JJ N
patients NNS N
with IN N
extensive-stage JJ N
small-cell JJ 4_p
carcinoma NN 4_p
of IN 4_p
the DT 4_p
lung NN 4_p
( ( 4_p
SCLC NNP 4_p
) ) 4_p
. . N

Patients NNPS N
with IN N
extensive JJ N
SCLC NNP N
with IN N
a DT N
Karnofsky NNP N
performance NN N
score NN N
( ( N
KPS NNP N
) ) N
> VBD N
or CC N
= $ N
50 CD N
and CC N
adequate JJ N
renal JJ N
function NN N
and CC N
bone NN N
marrow NN N
reserve NN N
were VBD N
eligible JJ N
. . N

Patients NNS N
with IN N
CNS NNP N
metastases NNS N
were VBD N
eligible JJ N
From NNP N
May NNP N
1989 CD N
through IN N
March NNP N
1993 CD N
, , N
171 CD 3_p
patients NNS N
were VBD N
randomized VBN N
( ( N
84 CD N
to TO N
VP NNP N
and CC N
87 CD N
to TO N
VIP NNP N
) ) N
. . N

All DT N
patients NNS N
were VBD N
assessable JJ N
for IN N
survival NN N
; : N
163 CD 3_p
were VBD N
fully RB N
assessable JJ N
for IN N
response NN N
and CC N
162 CD 3_p
for IN N
toxicity NN N
. . N

patients NNS N
with IN N
extensive JJ N
SCLC NNP N
. . N

-DOCSTART- -X- O O 8487344

Abdominal NNP N
surgical JJ N
wound NN N
trauma NN N
patients NNS N
requiring VBG N
abdominal JJ N
exploration NN N
. . N

Five CD N
hundred VBD N
ninety-two JJ N
patients NNS N
were VBD N
evaluated VBN N
: : N
283 CD N
received VBD N
ampicillin/sulbactam NN N
and CC N
309 CD N
received VBD N
cefoxitin NN N
. . N

-DOCSTART- -X- O O 24147543

40 CD N
lesions NNS N
of IN N
actinic JJ 4_p
keratosis NN 4_p
in IN N
Japanese JJ N
patients NNS N
. . N

12 CD N
, , N
15 CD N
and CC N
13 CD N
Japanese JJ N
actinic JJ 4_p
keratosis NN 4_p
( ( 4_p
AK NNP 4_p
) ) 4_p
lesions NNS N
Most JJS N
Japanese JJ N
AK NNP N
lesions NNS N
-DOCSTART- -X- O O 22488107

patients NNS N
with IN N
sickle JJ 4_p
cell NN 4_p
disease NN 4_p
. . N

patients NNS N
with IN N
SCD NNP 4_p
to TO N
quality NN N
of IN N
life NN N
inpatients NNS N
with IN N
SCD NNP 4_p
. . N

-DOCSTART- -X- O O 25101527

Norway NNP N
: : N
multisite JJ 4_p
Patients NNS N
from IN N
six CD N
psychiatric JJ N
clinics NNS N
in IN N
Southern NNP N
Norway NNP N
( ( N
N NNP 3_p
= NNP 3_p
259 CD 3_p
) ) N
-DOCSTART- -X- O O 22585469

for IN N
tracheal JJ 4_p
intubation NN 4_p
under IN N
general JJ 4_p
anesthesia NN 4_p
a DT N
simulated JJ N
difficult JJ N
airway NN N
METHODS NNP N
Ninety-four JJ 3_p
subjects NNS N
successfully RB N
completed VBD N
the DT N
trial NN N
in IN N
a DT N
simulated JJ N
difficult JJ N
airway NN N
-DOCSTART- -X- O O 20603436

cetuximab-treated JJ N
patients NNS N
with IN N
advanced JJ 4_p
colorectal JJ 4_p
cancer NN 4_p
( ( 4_p
ACRC NNP 4_p
) ) 4_p
-- : N
results NNS N
cetuximab-treated JJ 4_p
patients NNS 4_p
with IN N
ACRC NNP 4_p
. . N

five CD 3_p
hundred VBD 3_p
and CC 3_p
seventy-two JJ 3_p
patients NNS 3_p
were VBD N
included VBN N
; : N
41 CD 1_p
% NN 1_p
were VBD 1_p
≥ JJ 1_p
65 CD 1_p
years NNS 1_p
and CC N
25 CD N
% NN N
had VBD N
comorbidities NNS N
at IN N
randomization NN N
0.13 CD N
) ) N
. . N

Elderly JJ 1_p
patients NNS 1_p
0.005 CD N
) ) N
. . N

Patients NNS N
with IN N
greater JJR N
comorbidity NN N
OS NNP N
. . N

For IN N
patients NNS N
with IN N
-DOCSTART- -X- O O 18096070

horses NNS N
. . N

9 CD 3_p
exercise-conditioned JJ N
horses NNS N
on IN N
2 CD N
separate JJ N
occasions NNS N
horse NN N
. . N

-DOCSTART- -X- O O 20357382

hyperglycemic JJ 4_p
patients NNS 4_p
with IN N
non-ST JJ N
elevation NN N
acute NN 4_p
coronary JJ 4_p
syndrome NN 4_p
. . N

patients NNS N
with IN N
diabetes NNS 4_p
receiving VBG N
standard JJ N
treatment NN N
for IN N
diabetes NNS N
and CC N
randomized VBN N
to TO N
ranolazine VB N
or CC N
placebo VB N
within IN N
the DT N
MERLIN-TIMI-36 NNP N
( ( N
MERLIN NNP N
) ) N
study NN N
. . N

patients NNS N
with IN N
diabetes NNS N
and CC N
A1C NNP N
of IN N
> NNP N
or=8-10 JJ N
% NN N
at IN N
randomization NN N
( ( N
n JJ N
= NNP N
171 CD N
) ) N
placebo-adjusted JJ N
( ( N
n JJ N
= NNP N
182 CD N
) ) N
patients NNS N
with IN N
FPG NNP N
of IN N
150-400 JJ N
mg/dl NN N
at IN N
randomization NN N
, , N
ranolazine NN N
( ( N
n JJ N
= NNP N
131 CD N
) ) N
placebo NN N
( ( N
n JJ N
= NNP N
147 CD N
) ) N
patients NNS N
with IN N
cardiovascular JJ N
disease NN N
and CC N
poorly RB N
controlled VBN N
diabetes NNS N
. . N

-DOCSTART- -X- O O 23768813

schizophrenia NN 4_p
: : 4_p
in IN N
schizophrenia NN N
in IN N
schizophrenia NN N
patients NNS N
with IN N
negative JJ N
symptoms NNS N
who WP N
were VBD N
receiving VBG N
second JJ N
generation NN N
antipsychotics NNS N
. . N

Forty-three JJ N
subjects NNS N
-DOCSTART- -X- O O 14656280

ovarian JJ 4_p
cancer NN 4_p
patients NNS 4_p
with IN 4_p
a DT 4_p
pathologically RB 4_p
complete JJ 4_p
remission NN 4_p
after IN 4_p
platinum-based JJ 4_p
intravenous JJ 4_p
chemotherapy NN 4_p
. . 4_p

patients NNS N
who WP N
achieve VBP N
a DT N
pathological JJ N
complete JJ N
remission NN N
( ( N
pCR NN N
) ) N
at IN N
second-look NN N
surgery NN N
but CC N
in IN N
whom WP N
a DT N
high JJ N
rate NN N
of IN N
relapses NNS N
still RB N
occurs VBZ N
. . N

Between JJ N
1988 CD N
and CC N
1997 CD N
, , N
153 CD N
patients NNS N
in IN N
pCR JJ N
following VBG N
platinum-based JJ N
intravenous JJ N
CT NNP N
includes VBZ N
16 CD N
patients NNS N
who WP N
were VBD N
not RB N
eligible JJ N
and CC N
17 CD N
patients NNS N
who WP N
had VBD N
protocol NN N
violations NNS N
. . N

two CD N
groups NNS N
were VBD N
well RB N
balanced VBN N
in IN N
terms NNS N
of IN N
age NN N
( ( N
median JJ N
= VBZ N
55 CD N
years NNS N
) ) N
, , N
performance NN N
status NN N
( ( N
78 CD N
% NN N
P.S NNP N
. . N

O NNP N
) ) N
, , N
FIGO NNP N
stage NN N
( ( N
96 CD N
% NN N
stage NN N
III NNP N
) ) N
, , N
histology NN N
( ( N
serous JJ N
in IN N
66 CD N
% NN N
) ) N
, , N
grade VBD N
( ( N
2 CD N
or CC N
3 CD N
in IN N
80 CD N
% NN N
) ) N
, , N
and CC N
residuum NN N
before RB N
intravenous JJ N
CT NNP N
( ( N
> $ N
1 CD N
cm NN N
in IN N
40 CD N
% NN N
) ) N
. . N

-DOCSTART- -X- O O 21038654

non-nephrotic JJ 4_p
syndrome JJ 4_p
IgA NNP 4_p
nephropathy NN 4_p
non-nephrotic JJ 4_p
syndrome NN 4_p
IgA NNP 4_p
nephropathy NN 4_p
( ( 4_p
IgAN NNP 4_p
) ) 4_p
. . N

Seventy NNP 3_p
primary JJ 4_p
IgAN NNP 4_p
patients NNS N
-DOCSTART- -X- O O 8752254

postmenopausal JJ 4_p
bone NN 4_p
loss NN 4_p
. . N

postmenopausal JJ 4_p
osteoporosis NN 4_p
. . N

groups NNS N
of IN N
20 CD 3_p
, , N
60 CD 3_p
women NNS 2_p
Patients NNPS N
who WP N
received VBD 4_p
calcium NN 4_p
alone RB N
-DOCSTART- -X- O O 25822242

toddlers NNS 1_p
with IN N
autism NN 4_p
. . N

two CD N
parent-mediated JJ N
interventions NNS N
toddlers NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
. . N

86 CD 3_p
toddlers NNS 1_p
( ( 1_p
range VB 1_p
22-36 JJ 1_p
months NNS 1_p
) ) 1_p
with IN N
ASD NNP 4_p
and CC N
their PRP$ N
primary JJ N
caregiver NN N
. . N

Caregiver-child JJ N
dyads NNS N
-DOCSTART- -X- O O 9039228

39 CD 3_p
patients NNS N
with IN N
marginal JJ 4_p
zone NN 4_p
B NNP 4_p
cell NN 4_p
lymphoma NN 4_p
( ( 4_p
MZBCL NNP 4_p
) ) 4_p
of IN N
the DT N
parotid NN N
glands NNS N
( ( N
stages NNS N
I PRP N
or CC N
II NNP N
) ) N
were VBD N
studied VBN N
. . N

-DOCSTART- -X- O O 15741848

High NNP N
schools NNS N
( ( N
N=24 NNP N
) ) N
paired VBD N
on IN N
enrollment NN N
size NN N
, , N
racial JJ N
composition NN N
, , N
urban JJ N
or CC N
rural JJ N
location NN N
, , N
and CC N
class NN N
structure NN N
were VBD N
randomized VBN N
into IN N
control NN N
( ( N
N=12 NNP N
) ) N
or CC N
experimental JJ N
( ( N
N=12 NNP N
) ) N
groups NNS N
. . N

Of IN N
the DT N
4044 CD 3_p
girls NNS 2_p
enrolled VBD N
and CC N
eligible JJ N
, , N
2087 CD 3_p
( ( 3_p
51.6 CD 3_p
% NN 3_p
) ) N
participated VBD N
in IN N
the DT N
measurement JJ N
component NN N
of IN N
the DT N
study NN N
. . N

1038 CD 3_p
girls NNS 2_p
in IN N
the DT N
control NN N
group NN N
and CC N
1049 CD 3_p
girls NNS 2_p
in IN N
the DT N
experimental JJ N
group NN N
. . N

black JJ N
and CC N
white JJ N
adolescent JJ 1_p
girls NNS 2_p
. . N

black JJ N
and CC N
white JJ N
adolescent JJ 1_p
girls NNS 2_p
. . N

-DOCSTART- -X- O O 23104617

social JJ N
disability NN N
in IN N
autism NN N
spectrum NN N
disorder NN N
: : N
Research NNP N
Units NNP N
on IN N
Pediatric NNP N
Psychopharmacology NNP N
( ( N
RUPP NNP N
) ) N
Autism NNP N
Network NNP N
trials NNS N
. . N

autism NN N
spectrum NN N
disorders NNS N
data NNS N
from IN N
two CD N
federally-funded JJ N
, , N
multi-site JJ N
, , N
randomized JJ N
trials NNS N
with IN N
risperidone NN N
. . N

Study NNP N
1 CD N
included VBD N
52 CD N
subjects NNS N
assigned VBN N
to TO N
placebo VB N
and CC N
49 CD N
subjects NNS N
to TO N
risperidone VB N
under IN N
double-blind JJ N
conditions NNS N
. . N

Study NNP N
2 CD N
included VBD N
49 CD N
subjects NNS N
assigned VBN N
to TO N
risperidone VB N
only RB N
and CC N
75 CD N
subjects NNS N
assigned VBN N
to TO N
risperidone VB N
plus JJ N
parent NN N
training NN N
. . N

-DOCSTART- -X- O O 16541481

adults NNS 1_p
with IN N
established VBN N
rheumatoid NN 4_p
arthritis NN 4_p
: : 4_p
patients NNS N
with IN N
disease NN 4_p
modifying VBG 4_p
antirheumatic JJ 4_p
drug NN 4_p
( ( 4_p
DMARD NNP 4_p
) ) 4_p
refractory NN 4_p
rheumatoid JJ 4_p
arthritis NN 4_p
( ( 4_p
RA NNP 4_p
) ) 4_p
. . N

714 CD 3_p
patients NNS N
who WP N
received VBD N
etanercept RB N
in IN N
one CD N
of IN N
7 CD N
initial JJ N
trials NNS N
or CC N
a DT N
longterm JJ N
extension NN N
. . N

581 CD 3_p
patients NNS N
who WP N
enrolled VBD N
in IN N
the DT N
extension NN N
. . N

714 CD 3_p
patients NNS N
enrolled VBN N
in IN N
the DT N
initial JJ N
trials NNS N
, , N
581 CD 3_p
( ( N
81 CD N
% NN N
) ) N
enrolled VBN N
in IN N
the DT N
extension NN N
, , N
and CC N
388 CD 3_p
( ( N
54 CD N
% NN N
) ) N
patients NNS N
are VBP N
continuing VBG N
to TO N
receive VB N
etanercept JJ N
therapy NN N
. . N

356 CD 3_p
patients NNS N
who WP N
completed VBD N
6 CD N
years NNS N
of IN N
etanercept JJ N
treatment NN N
167 CD 3_p
patients NNS N
who WP N
completed VBD N
Year NNP N
7 CD N
. . N

patients NNS N
with IN N
RA NNP 4_p
in IN N
general JJ N
. . N

-DOCSTART- -X- O O 23782128

children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
and CC 4_p
ADHD NNP 4_p
symptoms NNS 4_p
. . N

24 CD 3_p
children NNS N
( ( N
19 CD 3_p
boys NNS 2_p
; : N
5 CD 3_p
girls NNS 2_p
) ) N
who WP N
met VBD N
American NNP N
Psychiatric NNP N
Association NNP N
, , N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
4th CD N
ed NN N
. . N

elementary JJ 1_p
school-age NN 1_p
, , N
community-based JJ N
children NNS N
( ( N
mean JJ N
chronological JJ N
age=8.8 NN 1_p
years NNS 1_p
, , N
SD=1.7 NNP N
; : N
mean JJ N
intelligence NN N
quotient NN N
[ NNP N
IQ NNP N
] NNP N
=85 NNP N
; : N
SD=16.8 NNP N
) ) N
. . N

children NNS 1_p
with IN N
ASD NNP 4_p
and CC N
significant JJ 4_p
ADHD NNP 4_p
symptoms NNS 4_p
. . N

-DOCSTART- -X- O O 18501909

pelvic JJ 4_p
inflammatory JJ 4_p
disease NN 4_p
( ( 4_p
PID NNP 4_p
) ) 4_p
. . N

43 CD 3_p
participants NNS N
, , N
40 CD 3_p
were VBD N
randomized VBN N
to TO N
tissue VB N
sampling VBG N
. . N

PID NNP 4_p
. . N

-DOCSTART- -X- O O 11205419

users NNS N
of IN N
ecstasy NN 4_p
. . N

humans NNS N
Two CD N
groups NNS N
of IN N
21 CD N
males NNS 2_p
with IN N
moderate JJ 4_p
and CC 4_p
heavy JJ 4_p
recreational JJ 4_p
use NN 4_p
of IN 4_p
MDMA NNP 4_p
, , 4_p
respectively RB 4_p
, , N
and CC N
a DT N
control NN N
group NN N
of IN N
20 CD N
males NNS N
without IN N
use NN N
of IN N
MDMA NNP N
were VBD N
compared VBN N
. . N

same JJ N
subculture NN N
. . N

-DOCSTART- -X- O O 15914517

outpatients NNS N
( ( 3_p
N NNP 3_p
= NNP 3_p
7 CD 3_p
) ) 3_p
Study NNP 4_p
patients NNS 4_p
took VBD 4_p
each DT 4_p
drug NN 4_p
for IN 4_p
five CD 4_p
3-week JJ 4_p
periods NNS 4_p
, , N
with IN 4_p
international JJ 4_p
normalized VBN 4_p
ratio NN 4_p
( ( 4_p
INR NNP 4_p
) ) 4_p
measurements VBZ 4_p
taken VBN 4_p
twice RB 4_p
per IN 4_p
period NN 4_p
. . N

-DOCSTART- -X- O O 4938245

Persistent JJ 4_p
phenothiazine NN 4_p
dyskinesia NN 4_p
Six CD 3_p
patients NNS N
with IN N
persistent JJ 4_p
phenothiazine NN 4_p
dyskinesia NN 4_p
-DOCSTART- -X- O O 25532076

patients NNS N
with IN N
acute JJ 4_p
manic NN 4_p
or CC 4_p
mixed JJ 4_p
episodes NNS 4_p
associated VBN 4_p
with IN 4_p
bipolar JJ 4_p
I PRP 4_p
disorder VBP 4_p
. . N

treatment NN N
with IN N
cariprazine JJ 4_p
3-12mg/day JJ 4_p
( ( N
n=158 JJ 3_p
) ) N
or CC N
placebo NN N
( ( N
n=154 JJ 3_p
) ) N
. . N

-DOCSTART- -X- O O 15278032

randomized JJ 4_p
prospective JJ 4_p
analysis NN 4_p
of IN 4_p
121 CD 3_p
consecutive JJ 4_p
inguinal JJ 4_p
hernia NN 4_p
repairs NNS 4_p
was VBD 4_p
performed VBN 4_p
over IN 4_p
a DT 4_p
12-month JJ 4_p
period NN 4_p
. . 4_p

Male JJ 2_p
well-informed JJ 4_p
patients NNS 4_p
with IN 4_p
primary JJ 4_p
monolateral JJ 4_p
inguinal JJ 4_p
hernia NN 4_p
( ( 4_p
ASA NNP 4_p
I-II NNP 4_p
) ) 4_p
2 CD N
groups NNS N
group NN N
A DT N
( ( N
TAPP NNP N
) ) N
( ( N
median JJ N
age NN N
47+/-7 JJ N
years NNS N
, , N
57 CD N
patients NNS N
) ) N
, , N
group NN N
B NNP N
open JJ N
mesh NN N
herniorrhaphy NN N
( ( N
45+/-6 JJ N
years NNS N
, , N
64 CD N
patients NNS N
) ) N
. . N

patients NNS N
with IN N
a DT N
low JJ N
ASA NNP N
index NN N
and CC N
busy JJ N
job/sport NN N
activity NN N
. . N

-DOCSTART- -X- O O 9040453

244 CD 3_p
individuals NNS N
with IN N
isolated JJ 4_p
systolic JJ 4_p
hypertension NN 4_p
( ( N
> CD 1_p
or CC 1_p
= $ 1_p
60 CD 1_p
years NNS 1_p
) ) 1_p
enrolled VBD N
in IN N
the DT N
placebo-controlled JJ N
Systolic NNP 4_p
Hypertension NNP 4_p
in IN N
europe JJ N
Trial NNP N
. . N

At IN N
entry NN N
, , N
systolic/diastolic JJ N
pressures NNS N
averaged VBD N
176/86 CD N
mm NN N
Hg NNP N
in IN N
the DT N
clinic NN N
and CC N
149/80 CD N
mm NN N
Hg NNP N
on IN N
24-hour JJ N
ambulatory JJ N
monitoring NN N
. . N

-DOCSTART- -X- O O 4353587

postoperative JJ 4_p
cytostatic JJ 4_p
medication NN 4_p
in IN N
patients NNS N
with IN 4_p
operable JJ 4_p
carcinoma NN 4_p
of IN 4_p
the DT 4_p
lung NN 4_p
. . N

-DOCSTART- -X- O O 19968048

melatonin NN N
on IN N
sleep NN 4_p
problems NNS 4_p
in IN N
children NNS 1_p
participants NNS N
for IN N
2 CD N
weeks NNS N
All DT N
participants NNS N
12 CD 3_p
of IN N
18 CD 3_p
subjects NNS N
who WP N
completed VBD N
the DT N
study NN N
( ( N
11 CD 3_p
males NNS N
, , N
age NN N
range NN N
2 CD 1_p
to TO 1_p
15.25 CD 1_p
years NNS 1_p
, , N
mean JJ N
5.47 CD N
, , N
SD NNP N
3.6 CD N
) ) N
. . N

Five CD 3_p
participants NNS N
Eight CD 3_p
out IN N
of IN N
12 CD 3_p
had VBD N
melatonin VBN N
first RB N
-DOCSTART- -X- O O 25432493

robot-assisted JJ 4_p
radical JJ 4_p
prostatectomy NN 4_p
. . 4_p

robot-assisted JJ N
radical JJ N
prostatectomy NN N
( ( N
RARP NNP N
) ) N
158 CD 3_p
patients NNS N
who WP N
underwent VBP N
RARP NNP N
for IN N
clinically RB N
localized VBN N
prostate NN 4_p
cancer NN 4_p
by IN N
a DT N
single JJ N
surgeon NN N
at IN N
our PRP$ N
institute NN N
from IN N
March NNP N
2012 CD N
to TO N
January NNP N
2013 CD N
. . N

( ( N
n JJ N
= NNP N
79 CD 3_p
) ) N
( ( N
n JJ N
= NNP N
79 CD N
) ) N
-DOCSTART- -X- O O 11077389

untreated JJ N
irreversible JJ N
pulpitis NN 4_p
. . N

untreated JJ N
teeth NNS N
diagnosed VBN N
with IN N
irreversible JJ N
pulpitis NN N
. . N

Forty NNP 3_p
emergency NN N
patients NNS N
participated VBD N
, , N
and CC N
each DT N
had VBD N
a DT N
clinical JJ N
diagnosis NN N
of IN N
an DT N
irreversible JJ N
pulpitis NN N
. . N

-DOCSTART- -X- O O 8815984

treatment NN 4_p
of IN 4_p
second JJ 4_p
degree NN 4_p
burns NNS 4_p
. . 4_p

Burns NNS N
are VBP N
common JJ N
in IN N
Vietnam NNP N
Vietnam-Sweden JJ N
hospital NN N
at IN N
Uong NNP N
Bi NNP N
in IN N
northern JJ N
Vietnam NNP N
. . N

20 CD 3_p
patients NNS N
with IN N
second JJ N
degree NN N
burns NNS N
were VBD N
treated VBN N
with IN N
the DT N
extract NN N
of IN N
the DT N
Choerospondias NNP N
axillaris NN N
and CC N
19 CD 3_p
with IN N
saline JJ N
gauze NN N
. . N

second JJ N
degree NN N
burns NNS N
both DT N
children NNS 1_p
and CC N
adults NNS 1_p
. . N

-DOCSTART- -X- O O 16908870

preschoolers NNS N
with IN N
ASD NNP 4_p
. . N

36 CD 3_p
preschoolers NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
. . N

-DOCSTART- -X- O O 3816105

Adult NNP 4_p
inpatients NNS 4_p
who WP 4_p
had VBD 4_p
received VBN 4_p
warfarin JJ 4_p
sodium NN 4_p
10 CD 4_p
mg JJ 4_p
daily RB 4_p
for IN 4_p
less JJR 4_p
than IN 4_p
three CD 4_p
days NNS 4_p
were VBD 4_p
eligible JJ 4_p
for IN 4_p
the DT 4_p
study NN 4_p
. . 4_p

total NN N
of IN N
54 CD N
patients NNS N
met VBD N
the DT N
study NN N
criteria NNS N
-DOCSTART- -X- O O 25885180

toxin NN 4_p
removal NN 4_p
: : N
maintenance NN 4_p
hemodialysis NN 4_p
( ( 4_p
HD NNP 4_p
) ) 4_p
patients NNS 4_p
. . 4_p

Only RB 4_p
stable JJ 4_p
HD NNP 4_p
patients NNS 4_p
will MD N
be VB N
recruited VBN N
where WRB N
20 CD 3_p
study NN N
subjects NNS N
-DOCSTART- -X- O O 23893101

adolescents NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
. . 1_p

adolescents NNS 1_p
with IN 1_p
higher-functioning JJ 1_p
ASD NNP 1_p
. . 1_p

58 CD N
participants NNS N
aged VBN N
11-16 JJ N
years-old JJ N
adolescents NNS 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

-DOCSTART- -X- O O 10968308

older JJR 1_p
population NN 1_p
's POS 1_p
Multiple NNP N
sites NNS N
of IN N
care NN N
in IN N
San NNP N
Francisco NNP N
, , N
California NNP N
. . N

Patients NNPS N
aged VBD 1_p
65 CD 1_p
or CC 1_p
older JJR 1_p
of IN N
primary JJ N
care NN N
physicians NNS N
in IN N
a DT N
large JJ N
provider NN N
organization NN N
bearing VBG N
financial JJ N
risk NN N
for IN N
their PRP$ N
care NN N
( ( N
n JJ N
= NN N
6409 CD 3_p
) ) N
. . N

-DOCSTART- -X- O O 16585808

registered JJ 4_p
nurses NNS 4_p
. . 4_p

health NN N
care NN N
professionals NNS N
. . N

mail NN N
and CC N
telephone NN N
survey NN N
of IN N
49,605 CD N
registered JJ N
nurses NNS N
for IN N
the DT N
2000 CD N
National NNP N
Sample NNP N
Survey NNP N
of IN N
Registered NNP N
Nurses NNP N
-DOCSTART- -X- O O 20084587

families NNS N
with IN N
a DT N
handicapped JJ N
child NN 1_p
, , N
which WDT N
has VBZ N
already RB N
been VBN N
successfully RB N
evaluated VBN N
in IN N
its PRP$ N
country NN N
of IN N
origin NN N
, , N
Australia NNP N
. . N

several JJ N
Social NNP N
Pediatric NNP N
Centers NNP N
( ( N
SPCs NNP N
) ) N
and CC N
further JJ N
clinics/institutions NNS N
in IN N
Germany NNP N
( ( N
3-7 JJ N
families NNS N
per IN N
training NN N
) ) N
-DOCSTART- -X- O O 23680243

women NNS 2_p
with IN N
type JJ 4_p
1 CD 4_p
diabetes NNS 4_p
: : N
in IN 4_p
pregnant JJ 4_p
type NN 4_p
1 CD 4_p
diabetic JJ 4_p
patient NN 4_p
A NNP N
retrospective JJ N
observational NN N
study NN N
included VBD N
thirty-four JJ 3_p
pregnant JJ 4_p
type NN 4_p
1 CD 4_p
diabetic JJ 4_p
patients NNS 4_p
. . N

CSII NNP N
treated VBD N
group NN N
( ( N
n=14 CC 3_p
) ) N
and CC N
MDI NNP N
treated VBD N
group NN N
( ( N
n=20 RB 3_p
) ) N
. . N

pregnant JJ 4_p
type NN 4_p
1 CD 4_p
diabetic JJ 4_p
patients NNS N
-DOCSTART- -X- O O 15886667

primary JJ 4_p
and CC 4_p
repeat VB 4_p
lower JJR 4_p
extremity NN 4_p
amputation NN 4_p
: : 4_p
African JJ N
Americans NNPS N
Randomly NNP N
selected VBD N
medical JJ N
records NNS N
were VBD N
reviewed VBN N
for IN N
248 CD 3_p
African JJ 3_p
American NNP 3_p
, , N
30 CD 3_p
Hispanic NNP 3_p
, , N
and CC N
235 CD 3_p
white JJ 3_p
or CC 3_p
other-race JJ 3_p
patients NNS 3_p
undergoing VBG 4_p
above- JJ 4_p
or CC 4_p
below-knee JJ 4_p
amputation NN 4_p
between IN N
1995 CD N
and CC N
2003 CD N
at IN N
three CD N
Chicago NNP N
teaching VBG N
hospitals NNS N
. . N

African JJ N
American JJ N
amputees NNS N
. . N

-DOCSTART- -X- O O 25561389

patients NNS 4_p
' POS 4_p
anxiety NN 4_p
level NN 4_p
patients NNS 4_p
' POS 4_p
anxiety NN 4_p
levels NNS 4_p
patients NNS 4_p
' POS 4_p
anxiety NN 4_p
level NN 4_p
. . N

333 CD 3_p
patients NNS 3_p
patients NNS 4_p
undergoing VBG 4_p
third JJ 4_p
molar JJ 4_p
surgery NN 4_p
. . N

-DOCSTART- -X- O O 1682643

whooping JJ 4_p
cough NN 4_p
. . N

three CD N
Swedish JJ N
hospitals NNS N
. . N

73 CD 3_p
children NNS 1_p
aged VBD 1_p
less JJR 1_p
than IN 1_p
36 CD 1_p
months NNS 1_p
who WP N
were VBD N
admitted VBN N
with IN N
a DT N
clinical JJ N
diagnosis NN N
of IN N
whooping JJ 4_p
cough NN 4_p
. . N

47 CD 3_p
children NNS 1_p
with IN N
less JJR 4_p
than IN 4_p
or CC 4_p
equal JJ 4_p
to TO 4_p
14 CD 4_p
days NNS 4_p
of IN 4_p
disease NN 4_p
before IN 4_p
therapy NN 4_p
. . N

-DOCSTART- -X- O O 19886920

adult NN 1_p
subjects NNS N
with IN N
a DT N
history NN N
of IN N
moderate-severe JJ 4_p
grass NN 4_p
pollen NN 4_p
induced VBD 4_p
rhinoconjunctivitis NN 4_p
inadequately RB 4_p
controlled VBN 4_p
by IN 4_p
symptomatic JJ 4_p
medications NNS 4_p
. . N

Subjects NNS N
-DOCSTART- -X- O O 4949377

Miotics NNS 4_p
in IN 4_p
cataract NN 4_p
surgery NN 4_p
. . 4_p

-DOCSTART- -X- O O 9303285

20 CD N
adult NN N
surgical JJ N
patients NNS N
during IN N
propofol-nitrous JJ N
oxide NN N
and CC N
isoflurane NN N
( ( N
1 CD N
MAC NNP N
) ) N
-nitrous JJ N
oxide JJ N
anaesthesia NN N
. . N

-DOCSTART- -X- O O 12925182

rats NNS N
. . N

rat NN N
. . N

Thirty-seven NNP 3_p
male NN 2_p
Wistar NNP N
rats NNS N
-DOCSTART- -X- O O 6938012

prostate NN 4_p
cancer NN 4_p
follow-up NN 4_p
of IN 4_p
212 CD 4_p
randomized JJ 4_p
patients NNS 4_p
. . 4_p

Two CD N
hundred VBD N
and CC N
twelve JJ N
patients NNS N
treated VBN N
for IN N
prostatic JJ N
cancer NN N
grade NN N
I PRP N
or CC N
II NNP N
were VBD N
The DT N
patients NNS N
were VBD N
part NN N
of IN N
a DT N
multicentre NN N
study NN N
in IN N
the DT N
Stockholm NNP N
area NN N
and CC N
had VBD N
been VBN N
randomized VBN N
to TO N
treatment NN N
with IN N
either DT N
estramustine JJ N
phosphate NN N
( ( N
Estracyt NNP N
) ) N
or CC N
polyestradiol JJ N
phosphate NN N
and CC N
ethinyl JJ N
estradiol NN N
. . N

-DOCSTART- -X- O O 12123333

breast NN 4_p
cancer NN 4_p
patients NNS 4_p
: : 4_p
postmenopausal JJ 4_p
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
postmenopausal NN N
patients NNS N
with IN N
a DT N
history NN N
of IN N
breast NN N
cancer NN N
. . N

Seventy-one NNP N
postmenopausal NN N
patients NNS N
patients NNS N
with IN N
a DT N
history NN N
of IN N
breast NN N
cancer NN N
-DOCSTART- -X- O O 14660988

depression NN 4_p
after IN 4_p
admission NN 4_p
for IN 4_p
a DT 4_p
cardiac JJ 4_p
condition NN 4_p
: : N
cardiac JJ N
patients NNS N
depression NN N
in IN N
patients NNS N
hospitalized VBN N
in IN N
South NNP N
Australia NNP N
for IN N
a DT N
range NN N
of IN N
cardiac JJ N
conditions NNS N
The DT N
subgroup NN N
identified VBD N
as IN N
depressed VBN N
was VBD N
entered VBN N
into IN N
the DT N
nested JJ N
IDACC NNP N
trial NN N
1455 CD 3_p
participants NNS N
screened VBN N
were VBD N
classified VBN N
as IN N
depression NN N
cases NNS N
Australian JJ N
setting NN N
hospitalized JJ N
cardiac JJ N
patients NNS N
. . N

depression NN N
in IN N
cardiac JJ N
patients NNS N
-DOCSTART- -X- O O 18972730

chronic JJ 4_p
nonspecific NN 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
patient NN N
] NN N
chronic JJ 4_p
nonspecific NN 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
patient NN N
. . N

Three CD 3_p
hundred VBD 3_p
and CC 3_p
five CD 3_p
cases NNS N
chronic JJ 4_p
nonspecific NN 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
patient NN N
-DOCSTART- -X- O O 19127179

12 CD 3_p
male JJ 2_p
team-sport NN N
players NNS N
participants NNS N
-DOCSTART- -X- O O 10089089

severely RB N
neutropenic JJ N
patients NNS N
. . N

fever NN 4_p
in IN 4_p
neutropenic JJ 4_p
patients NNS 4_p
. . 4_p

patients NNS N
who WP N
experienced VBD N
a DT N
total NN N
of IN N
247 CD N
febrile JJ N
episodes NNS N
All DT N
247 CD N
episodes NNS N
were VBD N
evaluable JJ N
febrile JJ N
neutropenic JJ N
patients NNS N
. . N

-DOCSTART- -X- O O 9683400

oxidation NN N
in IN N
subjects NNS N
with IN N
impaired JJ 4_p
glucose JJ 4_p
tolerance NN 4_p
. . N

29 CD 3_p
subjects NNS N
with IN N
impaired JJ N
glucose JJ N
tolerance NN N
. . N

subjects NNS N
with IN N
impaired JJ N
glucose JJ N
tolerance NN N
-DOCSTART- -X- O O 11068835

50 CD 3_p
cirrhotic JJ 4_p
patients NNS N
. . N

esophageal JJ 4_p
varices NNS 4_p
. . 4_p

41 CD 3_p
patients NNS N
. . N

Nine CD 3_p
patients NNS N
showed VBD N
negative JJ 4_p
MRA NNP 4_p
results NNS 4_p
. . 4_p

-DOCSTART- -X- O O 12424317

Global JJ N
contour NN N
saliency NN N
Our PRP$ N
visual JJ N
system NN N
can MD N
link VB N
components NNS N
of IN N
contours NNS N
and CC N
segregate JJ N
contours NNS N
from IN N
complex JJ N
backgrounds NNS N
based VBN N
on IN N
geometric JJ N
grouping NN N
rules NNS N
. . N

This DT N
is VBZ N
an DT N
important JJ N
intermediate JJ N
step NN N
in IN N
object JJ N
recognition NN N
. . N

The DT N
substrate NN N
for IN N
contour JJ N
integration NN N
may MD N
be VB N
based VBN N
on IN N
contextual JJ N
interactions NNS N
and CC N
intrinsic JJ N
horizontal NN N
connections NNS N
seen VBN N
in IN N
primary JJ N
visual JJ N
cortex NN N
( ( N
V1 NNP N
) ) N
. . N

We PRP N
examined VBD N
the DT N
perceptual JJ N
rules NNS N
governing VBG N
contour NN N
saliency NN N
to TO N
determine VB N
whether IN N
the DT N
spatial JJ N
extents NNS N
of IN N
contextual JJ N
interactions NNS N
and CC N
horizontal JJ N
connections NNS N
match VBP N
those DT N
mediating JJ N
saliency NN N
. . N

To TO N
quantify VB N
these DT N
rules NNS N
, , N
we PRP N
used VBD N
stimuli NNS N
composed VBN N
of IN N
randomly RB N
oriented VBN N
nonoverlapping JJ N
line NN N
segments NNS N
. . N

Salient NN N
contours NN N
within IN N
this DT N
complex JJ N
background NN N
were VBD N
formed VBN N
by IN N
colinear JJ N
alignment NN N
of IN N
nearby JJ N
segments NNS N
. . N

Contour NNP N
detectability NN N
was VBD N
measured VBN N
using VBG N
a DT N
2-interval-forced-choice JJ N
design NN N
. . N

-DOCSTART- -X- O O 9546119

therapy NN N
for IN N
Helicobacter NNP 4_p
pylori JJ 4_p
eradication NN N
. . N

H. NNP 4_p
pylori-positive JJ 4_p
patients NNS N
with IN N
gastric JJ 4_p
or CC 4_p
duodenal JJ 4_p
ulcers NNS 4_p
or CC 4_p
erosive JJ 4_p
gastritis NN 4_p
, , N
treated VBN N
after IN N
failure NN N
of IN N
dual JJ N
therapy NN N
( ( N
proton-pump-inhibitors NNS N
or CC N
ranitidine VB N
plus CC N
amoxicillin VB N
) ) N
or CC N
for IN N
the DT N
first JJ N
time NN N
. . N

total NN N
of IN N
71 CD 3_p
patients NNS N
were VBD N
treated VBN N
by IN N
quadruple JJ N
therapy NN N
, , N
and CC N
42 CD 3_p
patients NNS N
were VBD N
treated VBN N
by IN N
triple JJ N
therapy NN N
. . N

-DOCSTART- -X- O O 2540788

small JJ N
cell NN N
lung NN N
cancer NN N
: : N
610 CD N
patients NNS N
with IN N
small JJ N
cell NN N
lung NN N
cancer NN N
196 CD N
( ( N
32.1 CD N
% NN N
) ) N
had VBD N
limited VBN N
disease NN N
and CC N
414 CD N
( ( N
67.9 CD N
% NN N
) ) N
extensive JJ N
disease NN N
. . N

-DOCSTART- -X- O O 2544249

Wilms NNP 4_p
' POS 4_p
tumor NN 4_p
. . 4_p

National NNP N
Wilms NNP 4_p
' POS 4_p
Tumor NNP 4_p
National NNP N
Wilms NNP N
' POS N
Tumor NNP N
low-risk JJ N
patients NNS N
those DT N
at IN N
high JJ N
risk NN N
for IN N
relapse NN N
. . N

Eligible JJ N
patients NNS N
( ( N
1439 CD 3_p
) ) N
stage NN N
( ( N
I-IV NNP N
) ) N
and CC N
histology NN N
( ( N
favorable JJ N
[ NN N
FH NNP N
] NNP N
or CC N
unfavorable JJ N
[ JJ N
UH NNP N
] NNP N
) ) N
, , N
and CC N
contributed VBD N
data NNS N
to TO N
survival VB N
and CC N
relapse-free JJ N
survival NN N
( ( N
RFS NNP N
) ) N
analyses VBZ N
. . N

Four-year JJ N
( ( N
postnephrectomy NN N
) ) N
survival NN N
percentages NNS N
high-risk JJ N
patients NNS N
-DOCSTART- -X- O O 22892323

patients NNS 4_p
with IN 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
. . 4_p

Coronary NNP 4_p
artery NN 4_p
disease NN 4_p
patients NNS 4_p
whose WP$ 4_p
LDL-C JJ 4_p
≥ NN 4_p
70 CD 4_p
mg/dL NN 4_p
after IN 4_p
treatment NN 4_p
with IN 4_p
atorvastatin JJ 4_p
10 CD 4_p
mg/day NN 4_p
or CC 4_p
rosuvastatin VB 4_p
2.5 CD 4_p
mg/day NN 4_p
-DOCSTART- -X- O O 9786491

healthy JJ 4_p
volunteers NNS 4_p
: : 4_p
-DOCSTART- -X- O O 20226548

patients NNS N
with IN N
heparin-induced JJ N
thrombocytopenia NN N
( ( N
HIT NNP N
) ) N
. . N

patients NNS N
undergoing VBG N
elective JJ N
PCI NNP N
. . N

140 CD N
patients NNS N
bolus NN N
) ) N
, , N
138 CD N
patients NNS N
were VBD N
analyzed VBN N
effect NN N
in IN N
patients NNS N
undergoing VBG N
elective JJ N
PCI NNP N
-DOCSTART- -X- O O 24634631

sleep NN 4_p
disturbances NNS 4_p
elderly JJ 1_p
population NN N
undergoing VBG N
fast-track JJ N
total JJ N
hip NN N
and CC N
knee NN 4_p
arthroplasty NN 4_p
( ( N
THA/TKA NNP N
) ) N
with IN N
length NN N
of IN N
stay NN N
< IN N
3 CD N
days NNS N
. . N

Twenty NNP 3_p
patients NNS N
( ( N
≥ JJ 1_p
60 CD 1_p
years NNS 1_p
) ) N
undergoing VBG N
THA NNP N
or CC N
TKA NNP N
in IN N
a DT N
standardized JJ N
setup NN N
with IN N
spinal JJ N
anesthesia NN N
and CC N
multimodal JJ N
opioid-sparing JJ N
postoperative JJ N
analgesia NN N
were VBD N
included VBN N
-DOCSTART- -X- O O 1853794

bacteriuria NN N
in IN N
elderly JJ N
women NNS N
. . N

bacteriuria NN N
in IN N
a DT N
group NN N
of IN N
non-catheterized JJ N
elderly JJ N
women NNS N
Thirty-one JJ N
women NNS N
received VBD N
single-dose JJ N
treatment NN N
and CC N
22 CD N
conventional-dose JJ N
treatment NN N
. . N

selected VBN N
elderly JJ N
women NNS N
with IN N
bacteriuria NN N
-DOCSTART- -X- O O 23660099

patients NNS N
suffering VBG N
from IN N
severe JJ 4_p
acute NN 4_p
pancreatitis NN 4_p
] NNP N
patients NNS N
with IN N
severe JJ 4_p
acute NN 4_p
pancreatitis NN 4_p
( ( 4_p
ASP NNP 4_p
) ) 4_p
. . N

Seventy NNP 3_p
SAP NNP N
cases NNS N
admitted VBD N
from IN N
January NNP N
2005 CD N
to TO N
October NNP N
2012 CD N
were VBD N
randomly RB N
assigned VBN N
parenteral JJ N
nutrition NN N
( ( N
PN NNP N
) ) N
group NN N
( ( N
n=22 NN N
) ) N
, , N
EN NNP N
group NN N
( ( N
n=25 CC N
) ) N
and CC N
bifidobacterium NN N
added VBD N
EN NNP N
( ( N
P+EN NNP N
) ) N
group NN N
( ( N
n=23 RB N
) ) N
. . N

-DOCSTART- -X- O O 8521712

premenopausal JJ 4_p
women NNS 4_p
. . 4_p

premenopausal JJ N
women NNS N
22 CD N
premenopausal JJ N
women NNS N
, , N
age NN N
32.6 CD N
( ( N
range JJ N
20-45 CD N
years NNS N
) ) N
-DOCSTART- -X- O O 9507846

false-negative JJ N
sextant JJ N
prostate NN N
biopsies NNS N
. . N

false-negative JJ N
sextant JJ N
prostate NN N
biopsies NNS N
in IN N
patients NNS N
undergoing VBG N
radical JJ N
prostatectomy NN N
. . N

A NNP N
total NN N
of IN N
118 CD N
patients NNS N
with IN N
biopsy NN N
proved VBN N
prostate JJ N
cancer NN N
118 CD N
patients NNS N
-DOCSTART- -X- O O 20875504

postsurgical JJ 4_p
orthopedic JJ 4_p
patients NNS 4_p
: : N
postsurgical JJ 4_p
orthopedic JJ 4_p
patients NNS N
Patients NNPS N
( ( N
N=60 NNP 3_p
) ) N
admitted VBD N
to TO N
our PRP$ N
department NN N
postorthopedic NN N
surgery NN N
Exclusion NN N
criteria NNS N
were VBD N
age NN 1_p
18 CD 1_p
years NNS 1_p
or CC 1_p
younger JJR 1_p
and CC 1_p
90 CD 1_p
years NNS 1_p
or CC 1_p
older JJR 1_p
, , N
Mini-Mental JJ N
State NNP N
Examination NNP N
score NN N
of IN N
21 CD N
of IN N
30 CD N
or CC N
lower JJR N
, , N
no DT N
ambulating VBG N
order NN N
, , N
advanced JJ N
vision NN N
impairment NN N
, , N
malignancy NN N
, , N
pneumonia NN N
, , N
or CC N
heart NN N
failure NN N
. . N

conventional JJ N
physiotherapy NN N
. . N

postsurgical JJ N
orthopedic JJ N
patients NNS N
. . N

nonneurologic JJ N
patients NNS N
. . N

-DOCSTART- -X- O O 17003665

hyperactivity NN 4_p
in IN 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
: : N
attention-deficit/hyperactivity NN 4_p
disorder NN 4_p
( ( 4_p
ADHD NNP 4_p
) ) 4_p
symptoms NNS 4_p
in IN N
children NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
. . N

Children NNP 1_p
ages VBZ 1_p
5 CD 1_p
to TO 1_p
15 CD 1_p
with IN N
ASD NNP N
and CC N
prominent JJ N
ADHD NNP N
symptoms NNS N
In IN N
2004-2005 JJ N
, , N
12 CD 3_p
boys NNS 2_p
and CC N
4 CD 3_p
girls NNS 2_p
( ( N
7 CD N
with IN N
autistic JJ N
disorder NN N
, , N
1 CD N
Asperger NNP N
's POS N
, , N
8 CD N
pervasive JJ N
developmental NN N
disorder NN N
not RB N
otherwise RB N
specified VBN N
) ) N
hyperactivity NN N
in IN N
some DT N
children NNS 1_p
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

-DOCSTART- -X- O O 19011453

acute NN 4_p
mania NN 4_p
. . N

-DOCSTART- -X- O O 15528779

falls NNS N
among IN N
at-risk JJ N
elders NNS N
. . N

elderly JJ 1_p
persons NNS 1_p
incidence NN 4_p
of IN 4_p
falls NNS 4_p
and CC 4_p
the DT 4_p
time NN 4_p
to TO 4_p
first VB 4_p
fall NN 4_p
among IN 4_p
a DT 4_p
clinically RB 4_p
defined JJ 4_p
population NN 4_p
of IN 4_p
elderly JJ 4_p
men NNS 4_p
and CC 4_p
women NNS 4_p
. . 4_p

The DT N
participants NNS N
were VBD N
294 CD N
men NNS N
and CC N
women NNS N
, , N
aged VBD N
60 CD N
years NNS N
or CC N
older JJR N
, , N
who WP N
had VBD N
either CC N
a DT N
hospital JJ N
admission NN N
or CC N
bed NN N
rest NN N
for IN N
2 CD N
days NNS N
or CC N
more JJR N
within IN N
the DT N
previous JJ N
month NN N
. . N

among IN N
elderly JJ N
men NNS N
and CC N
women NNS N
recovering VBG N
from IN N
recent JJ N
hospitalizations NNS N
, , N
bed VBD N
rest NN N
, , N
or CC N
both DT N
who WP N
have VBP N
low JJ N
levels NNS N
of IN N
physical JJ N
functioning NN N
. . N

-DOCSTART- -X- O O 19333040

patients NNS N
undergoing VBG N
low JJ N
anterior JJ N
resection NN N
with IN N
total JJ N
mesorectal JJ N
excision NN N
for IN N
primary JJ 4_p
rectal JJ 4_p
cancer NN 4_p
patients NNS N
undergoing VBG N
low JJ N
anterior JJ N
resection NN N
Forty NNP 3_p
patients NNS N
after IN N
elective JJ 4_p
sphincter-saving JJ 4_p
low JJ 4_p
anterior JJ 4_p
resection NN 4_p
a DT N
total NN N
of IN N
41 CD N
patients NNS N
were VBD N
screened VBN N
and CC N
34 CD 3_p
patients NNS N
were VBD N
randomized VBN N
. . N

Eighteen JJ 3_p
patients NNS N
were VBD N
randomized VBN N
to TO N
the DT N
stoma NN N
group NN N
and CC N
16 CD 3_p
patients NNS N
to TO N
the DT N
nonstoma NN N
group NN N
patients NNS N
undergoing VBG N
low JJ N
anterior JJ N
resection NN N
. . N

patients NNS N
undergoing VBG N
low JJ N
anterior JJ 4_p
resection NN 4_p
-DOCSTART- -X- O O 17762804

recovery NN N
from IN N
low JJ 4_p
back RB 4_p
pain NN 4_p
work-related JJ 4_p
low JJ 4_p
back RB 4_p
disorder NN 4_p
( ( N
WR-LBD NNP 4_p
) ) N
active JJ 4_p
industrial JJ 4_p
workers NNS 4_p
with IN N
low JJ 4_p
back RB 4_p
disorders NNS 4_p
433 CD 3_p
actively RB N
employed VBN N
hourly RB N
union NN N
workers NNS N
who WP N
had VBD N
a DT N
recent JJ N
diagnosis NN N
of IN N
a DT N
WR-LBD JJ N
: : N
1 CD N
) ) N
those DT N
who WP N
wore VBP N
a DT N
specially RB N
designed VBN N
back RP N
support NN N
plus CC N
received JJ N
education NN N
on IN N
back JJ N
health NN N
; : N
and CC N
2 CD N
) ) N
those DT N
who WP N
received VBD N
education NN N
on IN N
back JJ N
health NN N
only RB N
. . N

industrial JJ N
workers NNS N
who WP N
work VBP N
in IN N
psychosocial JJ N
environments NNS N
and CC N
perform VB N
manual JJ N
material NN N
handling VBG N
tasks NNS N
similar JJ N
to TO N
those DT N
found VBN N
in IN N
parts NNS N
distribution NN N
centers NNS N
. . N

-DOCSTART- -X- O O 22471381

criminal JJ 4_p
suspects NNS 4_p
short-sightedness NN 4_p
during IN 4_p
police NNS 4_p
interrogation NN 4_p
participants NNS N
( ( N
N NNP N
= NNP N
81 CD N
) ) N
criminal JJ N
and CC N
unethical JJ N
behaviors NNS N
Experiment JJ N
2 CD N
( ( N
N NNP N
= NNP N
143 CD N
) ) N
-DOCSTART- -X- O O 17331237

major JJ 4_p
depressive JJ 4_p
disorder NN 4_p
Depressive NNP N
disorder NN N
depressive JJ N
disorder NN N
depressive JJ N
disorder NN N
primary JJ N
care NN N
in IN N
the DT N
Netherlands NNP N
Forty NNP 3_p
general JJ N
practices NNS N
patients NNS N
who WP N
are VBP N
diagnosed VBN N
with IN N
moderate JJ N
to TO N
severe JJ N
depression NN N
, , N
based VBN N
on IN N
DSM-IV NNP N
criteria NNS N
, , N
and CC N
stratified VBD N
according VBG N
to TO N
comorbid VB N
chronic JJ N
physical JJ N
illness NN N
. . N

patients NNS N
with IN N
a DT N
depressive JJ N
disorder NN N
major JJ N
depressive JJ N
disorder NN N
-DOCSTART- -X- O O 18953651

postmenopausal JJ 4_p
women NNS 2_p
who WP N
receive VBP N
endocrine NN N
treatment NN N
for IN N
highly RB N
endocrine-responsive JJ N
, , N
node-positive JJ N
breast NN 4_p
cancer NN 4_p
Breast NNP 4_p
Cancer NNP 4_p
Study NNP N
Group NNP N
postmenopausal JJ 4_p
women NNS 1_p
with IN N
highly RB N
endocrine JJ N
responsive JJ N
breast NN 4_p
cancer NN 4_p
. . N

12-93 JJ 3_p
, , N
postmenopausal JJ 4_p
women NNS 3_p
with IN N
node-positive JJ N
, , N
estrogen JJ N
receptor NN N
( ( N
ER NNP N
) ) N
-positive CD N
or CC N
ER-negative JJ N
, , N
operable JJ N
breast NN 4_p
cancer NN 4_p
893 CD 3_p
patients NNS N
with IN N
endocrine-responsive JJ 4_p
disease NN 4_p
, , N
and CC N
according VBG N
to TO N
prospectively RB N
defined JJ N
categories NNS N
of IN N
ER NNP N
, , N
age NN N
and CC N
nodal JJ N
status NN N
. . N

postmenopausal JJ 4_p
women NNS 3_p
with IN N
endocrine-responsive JJ N
breast NN 4_p
cancer NN 4_p
-DOCSTART- -X- O O 8276557

major JJ 4_p
surgery NN 4_p
: : N
Italian JJ N
Study NNP N
Group NNP N
. . N

One CD 3_p
thousand CD 3_p
one CD 3_p
hundred CD 3_p
and CC 3_p
twenty-two JJ 3_p
patients NNS 3_p
( ( N
533 CD 3_p
males NNS N
and CC N
589 CD 3_p
females NNS N
; : N
mean JJ 1_p
age NN 1_p
62.2 CD 1_p
+/- JJ 1_p
11.4 CD 1_p
yrs NN 1_p
) ) N
were VBD N
enrolled VBN N
in IN N
a DT N
multicentre NN N
controlled VBN N
study NN N
-DOCSTART- -X- O O 25045936

Thirty-seven JJ 3_p
men NNS 2_p
and CC N
women NNS 2_p
classified VBN N
with IN N
MetS NNP 4_p
-DOCSTART- -X- O O 26214440

80 CD 3_p
patients NNS N
with IN N
trigeminal JJ 4_p
neuralgia NNS 4_p
. . N

-DOCSTART- -X- O O 14655885

patients NNS 4_p
with IN 4_p
chronic JJ 4_p
proximal JJ 4_p
plantar NN 4_p
fasciitis NN 4_p
: : 4_p
chronically RB 4_p
painful JJ 4_p
proximal JJ 4_p
plantar NN 4_p
fasciitis NN 4_p
Forty-seven JJ 4_p
patients NNS 4_p
( ( 4_p
49 CD 4_p
feet NNS 4_p
) ) 4_p
with IN 4_p
a DT 4_p
previously RB 4_p
unsuccessful JJ 4_p
nonsurgical JJ 4_p
treatment NN 4_p
of IN 4_p
at IN 4_p
least JJS 4_p
6 CD 4_p
months NNS 4_p
were VBD 4_p
randomized VBN 4_p
to TO 4_p
two CD 4_p
groups NNS 4_p
. . 4_p

Group NNP N
1 CD N
( ( N
25 CD N
heels NNS N
) ) N
group NN N
2 CD N
( ( N
24 CD N
heels NNS N
) ) N
-DOCSTART- -X- O O 21226576

acute NN 4_p
otitis NN 4_p
media NNS 4_p
in IN 4_p
children NNS 4_p
under IN 4_p
2 CD 4_p
years NNS 4_p
of IN 4_p
age NN 4_p
. . 4_p

children NNS N
younger JJR N
than IN N
2 CD N
years NNS N
of IN N
age NN N
with IN N
acute JJ N
otitis NN N
media NNS N
. . N

291 CD N
children NNS N
6 CD N
to TO N
23 CD N
months NNS N
of IN N
age NN N
, , N
with IN N
acute JJ N
otitis NN N
media NNS N
diagnosed VBN N
with IN N
the DT N
use NN N
of IN N
stringent NN N
criteria NNS N
children NNS N
6 CD N
to TO N
23 CD N
months NNS N
of IN N
age NN N
with IN N
acute JJ N
otitis NN N
media NNS N
-DOCSTART- -X- O O 7881703

Fourteen NNP 3_p
healthy JJ N
, , N
non-smoking JJ N
, , N
Caucasian JJ N
male NN 2_p
volunteers NNS N
-DOCSTART- -X- O O 20537413

older JJR 1_p
adults NNS 1_p
. . 1_p

older JJR 1_p
adults NNS 1_p
older JJR 1_p
adults NNS 1_p
60 CD 3_p
older JJR 1_p
adults NNS 1_p
( ( 1_p
mean JJ 1_p
± NNP 1_p
SD NNP 1_p
age NN 1_p
: : 1_p
68.7 CD 1_p
± $ 1_p
6.1 CD 1_p
years NNS 1_p
) ) 1_p
an DT N
older JJR 1_p
adult NN 1_p
exercise NN N
program NN N
-DOCSTART- -X- O O 12541005

pre-school JJ 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
. . N

pre-school JJ 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
. . N

Twenty-four CD 3_p
children NNS 3_p
meeting VBG 4_p
ICD-10 NNP 4_p
criteria NNS 4_p
for IN 4_p
childhood NN 4_p
autism NN 4_p
( ( 1_p
mean JJ 1_p
age NN 1_p
= VBD 1_p
23 CD 1_p
months NNS 1_p
) ) 1_p
parent NN N
training NN N
group NN N
three CD N
parents NNS N
in IN N
the DT N
local JJ N
services NNS N
group NN N
pre-school JJ N
children NNS N
with IN N
autism NN N
-DOCSTART- -X- O O 25806587

Resistance NNP 4_p
Exercise NNP 4_p
. . 4_p

young JJ 1_p
resistance-trained JJ N
males NNS 2_p
. . N

12 CD 3_p
resistance-trained JJ N
males NNS 2_p
performed VBD N
6 CD N
conditions NNS N
in IN N
random NN N
counterbalanced VBN N
order NN N
: : N
rest NN N
( ( N
R NNP N
) ) N
, , N
low-intensity NN N
( ( N
LIRE NNP N
: : N
30 CD N
% NN N
1RM CD N
) ) N
and CC N
moderate-intensity NN N
( ( N
MIRE NNP N
: : N
70 CD N
% NN N
1RM CD N
) ) N
resistance NN N
exercise NN N
with IN N
or CC N
without IN N
PVO NNP N
. . N

-DOCSTART- -X- O O 6992570

granulocytopenic JJ 4_p
patients NNS N
. . N

granulocytopenic JJ 4_p
patients NNS N
. . N

Patients NNS N
were VBD N
stratified VBN N
into IN N
two CD 3_p
groups NNS N
: : N
favorable-prognosis NN N
, , N
group NN 3_p
1 CD 3_p
( ( N
carcinoma NN 4_p
, , N
lymphoma NN 4_p
, , N
multiple JJ 4_p
myeloma NN 4_p
) ) N
, , N
or CC N
unfavorable-prognosis NN N
, , N
group NN 3_p
2 CD 3_p
( ( N
acute JJ 4_p
leukemia NN 4_p
, , N
bone NN 4_p
marrow NN 4_p
transplantation NN 4_p
) ) N
, , N
based VBN N
on IN N
anticipated JJ N
duration NN N
of IN N
granulocytopenia NN 4_p
. . N

-DOCSTART- -X- O O 9564194

multisite JJ N
clinical JJ N
trials NNS N
. . N

multisite NN N
clinical JJ N
trial NN N
results NNS N
interrater JJ N
reliability NN N
training NN N
sessions NNS N
Phase NNP N
II NNP N
multisite RB N
clinical JJ N
drug NN N
trial NN N
. . N

-DOCSTART- -X- O O 8141163

white JJ N
and CC N
black JJ N
normotensive JJ N
subjects NNS N
: : N
Twelve NNP 3_p
normotensive JJ 3_p
white JJ 3_p
and CC N
12 CD 3_p
normotensive JJ 3_p
black JJ 3_p
men NNS 3_p
whites NNS N
blacks NNS N
. . N

salt-sensitive JJ N
hypertension NN N
in IN N
blacks NNS N
. . N

-DOCSTART- -X- O O 20952020

patients NNS 4_p
with IN 4_p
prostate JJ 4_p
cancer NN 4_p
. . 4_p

men NNS 2_p
with IN N
prostate NN 4_p
cancer NN 4_p
-DOCSTART- -X- O O 25459500

children NNS N
after IN 4_p
tetralogy NN 4_p
of IN 4_p
Fallot NNP 4_p
repair NN 4_p
. . N

Twenty-nine JJ 3_p
children NNS 1_p
( ( 1_p
age NN 1_p
range NN 1_p
, , 1_p
5-18 CD 1_p
years NNS 1_p
) ) 1_p
with IN N
repaired VBN N
TOF NNP N
and CC N
44 CD N
healthy JJ N
controls NNS N
Children NNP N
with IN 4_p
repaired VBN 4_p
TOF NNP 4_p
normal JJ N
, , N
children NNS N
with IN N
repaired JJ 4_p
TOF NNP 4_p
exhibit NN 4_p
RV NNP 4_p
dilatation NN 4_p
and CC 4_p
subtle NN 4_p
-DOCSTART- -X- O O 22777592

Sixty-seven JJ 3_p
patients NNS N
with IN N
bacterial JJ 4_p
vaginosis NN 4_p
( ( 4_p
BV NNP 4_p
) ) N
, , N
50 CD 3_p
with IN N
intermediate JJ N
flora NNS N
and CC N
42 CD 3_p
with IN N
normal JJ N
vaginal JJ 4_p
flora NNS 4_p
were VBD N
enrolled VBN N
-DOCSTART- -X- O O 25659828

children NNS 1_p
with IN N
partial JJ 4_p
epilepsy NN 4_p
. . N

weight JJ 4_p
loss NN 4_p
in IN N
children NNS 1_p
children NNS 1_p
with IN N
partial JJ N
epilepsy NN N
. . N

children NNS 1_p
with IN N
partial JJ N
epilepsy NN N
179 CD 3_p
children NNS 1_p
( ( N
93 CD 3_p
male NN 2_p
, , N
86 CD 3_p
female NN 2_p
; : N
age NN 1_p
6-18 CD 1_p
years NNS 1_p
) ) 1_p
loss NN N
. . N

Weight NNP N
loss NN N
-DOCSTART- -X- O O 19502023

patients NNS N
undergoing VBG 4_p
ambulatory JJ 4_p
cosmetic JJ 4_p
surgery NN 4_p
. . 4_p

postoperative JJ 4_p
nausea NN 4_p
and CC 4_p
vomiting NN 4_p
( ( N
PONV NNP 4_p
) ) N
. . N

Academic NNP N
hospital NN N
. . N

126 CD 3_p
ASA NNP 4_p
physical JJ 4_p
status NN 4_p
I PRP 4_p
and CC 4_p
II NNP 4_p
patients NNS 4_p
undergoing VBG 4_p
outpatient JJ 4_p
plastic NN 4_p
surgery NN 4_p
with IN N
three CD 4_p
or CC 4_p
more JJR 4_p
risk NN 4_p
factors NNS 4_p
for IN 4_p
PONV NNP 4_p
. . N

patients NNS N
at IN N
high JJ N
risk NN N
for IN N
PONV NNP N
undergoing JJ N
outpatient NN N
plastic NN N
surgery NN N
-DOCSTART- -X- O O 11378004

patients NNS 4_p
with IN 4_p
chronic JJ 4_p
heart NN 4_p
failure NN 4_p
. . N

-DOCSTART- -X- O O 17174704

Between NNP N
1999 CD N
and CC N
2002 CD N
, , N
1397 CD 3_p
antiretroviral-treatment-naive JJ 4_p
patients NNS N
, , N
presenting VBG N
at IN N
18 CD N
clinical JJ N
trial NN N
units NNS N
with IN N
80 CD N
research NN N
sites NNS N
in IN N
the DT N
USA NNP N
1397 CD 3_p
patients NNS N
were VBD N
assessed VBN N
for IN N
the DT N
composite JJ N
endpoint NN N
. . N

388 CD 3_p
participants NNS N
developed VBD N
the DT N
composite JJ N
endpoint NN N
, , N
302 CD 3_p
developed VBD N
AIDS NNP 4_p
or CC N
died VBN N
, , N
and CC N
188 CD 3_p
died VBD N
. . N

treatment-naive JJ N
patients NNS N
with IN N
HIV NNP 4_p
. . N

-DOCSTART- -X- O O 22634446

persistent JJ 4_p
genital JJ 4_p
warts NNS 4_p
. . N

recurrent JJ 4_p
genital JJ 4_p
warts NNS 4_p
conducted VBN N
independently RB N
in IN N
Australia NNP N
and CC N
China NNP N
. . N

Of IN N
33 CD N
protocol NN N
compliant NN N
Brisbane NNP N
recipients NNS N
of IN N
placebo NN N
immunotherapy NN N
Among IN N
102 CD N
protocol NN N
compliant NN N
Brisbane NNP N
recipients NNS N
of IN N
VLP NNP N
immunotherapy NN N
± JJ N
7 CD N
% NN N
) ) N
. . N

Of IN N
52 CD N
protocol NN N
compliant NN N
placebo NN N
immunotherapy NN N
recipients NNS N
in IN N
observed VBN N
for IN N
the DT N
168 CD N
Wenzhou NNP N
protocol NN N
compliant JJ N
subjects NNS N
who WP N
also RB N
received VBD N
VLP NNP N
immunotherapy NN N
of IN N
recurrent JJ N
genital JJ N
warts NNS N
in IN N
patients NNS N
for IN N
whom WP N
destructive JJ N
therapy NN N
is VBZ N
unsuccessful JJ N
-DOCSTART- -X- O O 8509099

condylomata NNS 4_p
acuminata NNS 4_p
following VBG 4_p
cryotherapy NN 4_p
97 CD 3_p
patients NNS 3_p
with IN 3_p
recurrent JJ 3_p
condylomata NN 3_p
acuminata NN 3_p
. . 4_p

36 CD 4_p
and CC 4_p
37 CD 4_p
patients NNS 4_p
, , 4_p
respectively RB 4_p
, , 4_p
completed VBD 4_p
the DT 4_p
study NN 4_p
population NN 4_p
of IN 4_p
patients NNS 4_p
with IN 4_p
recurrent JJ 4_p
condylomata NNS 4_p
. . N

-DOCSTART- -X- O O 24988118

children NNS 1_p
and CC 1_p
young JJ 1_p
adults NNS 1_p
with IN N
HIV NNP 4_p
: : N
HIV-infected JJ 4_p
patients NNS N
HIV-infected JJ 4_p
subjects NNS 4_p
. . N

perinatally RB 4_p
acquired VBN 4_p
HIV NNP 4_p
( ( 4_p
PHIV NNP 4_p
) ) 4_p
-infected VBD 4_p
subjects NNS 4_p
or CC N
behaviorally RB 4_p
acquired VBN 4_p
HIV NNP 4_p
( ( 4_p
BHIV NNP 4_p
) ) 4_p
-infected VBD 4_p
subjects NNS 4_p
( ( N
5.0-24.9 CD 1_p
years NNS 1_p
) ) N
. . N

Fifty-eight JJ 3_p
subjects NNS 3_p
enrolled VBN 3_p
( ( N
67 CD 2_p
% NN 2_p
male NN 2_p
, , N
85 CD 3_p
% NN 3_p
African JJ 3_p
American NNP 3_p
and CC N
64 CD 3_p
% NN 3_p
BHIV NNP N
) ) N
and CC N
50 CD 3_p
completed VBN 3_p
with IN 3_p
no DT 3_p
safety NN 3_p
concerns NNS 3_p
. . N

-DOCSTART- -X- O O 21097567

hospital NN N
emergency NN N
department NN N
. . N

patients NNS N
in IN N
a DT N
hospital NN N
emergency NN N
department NN N
. . N

Twenty-five JJ 3_p
patients NNS N
were VBD N
allocated VBN N
randomly RB N
either DT N
to TO N
a DT N
TAMS NNP N
group NN N
or CC N
to TO N
an DT N
on-scene JJ N
directed NN N
( ( N
OSD NNP N
) ) N
group NN N
. . N

12 CD 3_p
were VBD N
intubated VBN N
-DOCSTART- -X- O O 10360656

advanced JJ 4_p
colorectal JJ 4_p
cancer NN 4_p
. . N

patients NNS N
with IN N
unresectable JJ N
, , N
advanced JJ 4_p
colorectal JJ 4_p
carcinoma NN 4_p
. . N

Forty-nine JJ 3_p
chemotherapy-naive JJ 4_p
patients NNS N
were VBD N
randomized VBN N
-DOCSTART- -X- O O 6143667

hypertensive JJ 4_p
non-diabetic JJ 4_p
patients NNS 4_p
. . 4_p

13 CD 4_p
hypertensive JJ 4_p
patients NNS 4_p
. . 4_p

-DOCSTART- -X- O O 3098341

postmenopausal JJ 4_p
women NNS 4_p
. . 4_p

three CD N
groups NNS N
of IN N
postmenopausal JJ N
women NNS N
given VBN N
0.025 CD N
mg NNS N
, , N
0.05 CD N
mg NN N
, , N
or CC N
0.1 CD N
mg NNS N
transdermal JJ N
oestradiol JJ N
daily RB N
. . N

-DOCSTART- -X- O O 17276750

inattention NN 4_p
and CC 4_p
hyperactivity NN 4_p
in IN N
pervasive JJ 4_p
developmental JJ 4_p
disorders NNS 4_p
: : N
children NNS N
who WP N
have VBP N
pervasive JJ 4_p
developmental NN 4_p
disorders NNS 4_p
( ( 4_p
PDD NNP 4_p
) ) 4_p
and CC N
significant JJ 4_p
hyperactive-inattentive JJ 4_p
symptoms NNS 4_p
. . N

Sixty-six JJ 3_p
children NNS 1_p
( ( N
mean JJ 1_p
age NN 1_p
7.5 CD 1_p
y NN 1_p
) ) N
with IN N
autistic JJ 4_p
disorder NN 4_p
, , 4_p
Asperger NNP 4_p
's POS 4_p
disorder NN 4_p
, , 4_p
and CC 4_p
PDD NNP 4_p
not RB N
otherwise RB N
specified VBN N
children NNS 1_p
with IN N
PDD NNP 4_p
. . N

-DOCSTART- -X- O O 21412846

chronic JJ N
schizophrenia NN 4_p
: : N
patients NNS 4_p
with IN 4_p
chronic JJ 4_p
schizophrenia NN 4_p
patients NNS N
with IN N
chronic JJ 4_p
schizophrenia NN 4_p
. . N

Eligible JJ N
participants NNS N
in IN N
the DT N
study NN N
were VBD N
51 CD 3_p
patients NNS 3_p
with IN N
chronic JJ 4_p
schizophrenia NN 4_p
with IN N
ages NNS 1_p
ranging VBG 1_p
from IN 1_p
20 CD 1_p
to TO 1_p
45 CD 1_p
years NNS 1_p
. . N

All DT N
participants NNS N
were VBD N
inpatients NNS 4_p
, , N
in IN 4_p
the DT 4_p
active JJ 4_p
phase NN 4_p
of IN 4_p
illness NN 4_p
, , N
and CC N
met VBD 4_p
DSM-IV-TR NNP 4_p
criteria NNS 4_p
for IN 4_p
schizophrenia NN 4_p
. . N

Patients NNS N
were VBD N
randomly RB N
allocated VBN N
serum NN N
of IN N
schizophrenic JJ N
patients NNS N
-DOCSTART- -X- O O 8801151

retained JJ 4_p
placenta NN 4_p
. . 4_p

women NNS 2_p
with IN N
retained JJ N
placenta NN N
. . N

( ( N
10 CD 3_p
women NNS 3_p
, , 3_p
group NN N
1 CD N
) ) N
( ( N
11 CD 3_p
women NNS 3_p
, , N
group NN N
2 CD N
) ) N
( ( N
7 CD 3_p
women NNS 3_p
, , N
group NN N
3 CD N
) ) N
Nine NNP 3_p
women NNS 2_p
( ( N
group NN N
4 CD N
, , N
controls NNS N
) ) N
underwent VBP N
manual JJ N
removal NN N
of IN N
the DT N
retained JJ N
placenta NN N
. . N

-DOCSTART- -X- O O 15606733

basal NN N
cell NN N
carcinoma NN N
. . N

basal NN N
cell NN N
carcinoma NN N
Subjects NNP N
applied VBD N
study NN N
cream NN N
to TO N
one CD N
biopsy-confirmed JJ N
basal NN N
cell NN N
carcinoma NN N
tumor NN N
vehicle-controlled JJ N
, , N
double-blind JJ N
study NN N
. . N

basal NN N
cell NN N
carcinoma NN N
before IN N
Mohs NNP N
micrographic JJ N
surgery NN N
. . N

-DOCSTART- -X- O O 24473220

field NN N
experiment NN N
in IN N
Sweden NNP N
. . N

individuals NNS N
on IN N
long-term JJ N
sickness NN 4_p
absence NN 4_p
. . N

by IN N
the DT N
Public NNP N
Employment NNP N
Service NNP N
and CC N
the DT N
Social NNP N
Insurance NNP N
Agency NNP N
in IN N
Sweden NNP N
during IN N
2008-2010 JJ N
, , N
in IN N
which WDT N
over IN 3_p
4000 CD 3_p
participants NNS 3_p
were VBD N
randomly RB N
offered VBN N
private JJ N
and CC N
public JJ 4_p
rehabilitation NN 4_p
. . N

individuals NNS N
-DOCSTART- -X- O O 26053242

Carpal NNP 4_p
Tunnel NNP 4_p
Syndrome NNP 4_p
. . N

30 CD 3_p
predominantly RB N
sensory JJ N
neuropathy JJ N
CTS NNP 4_p
patients NNS N
, , N
as IN N
confirmed VBN N
by IN N
a DT N
nerve NN 4_p
conduction NN 4_p
study NN 4_p
. . N

patients NNS 4_p
with IN 4_p
CTS NNP 4_p
. . 4_p

-DOCSTART- -X- O O 15486373

COPD NNP 4_p
patients NNS 4_p
: : 4_p
subjects NNS 4_p
with IN 4_p
COPD NNP 4_p
participants NNS N
with IN N
mild-to-moderate JJ N
COPD NNP N
. . N

1,116 CD N
participants NNS N
in IN N
10 CD N
centers NNS N
over IN N
> $ N
3.5 CD N
to TO N
4.5 CD N
years NNS N
. . N

A DT N
total NN N
of IN N
1,116 CD N
smokers NNS N
or CC N
recent JJ N
ex-smokers NNS N
with IN N
mild-to-moderate JJ N
COPD NNP N
( ( N
age NN N
range NN N
, , N
40 CD N
to TO N
69 CD N
years NNS N
; : N
mean JJ N
age NN N
, , N
56.3 CD N
years NNS N
; : N
37.2 CD N
% NN N
female NN N
) ) N
. . N

Older JJR N
men NNS N
middle-aged JJ N
to TO N
elderly JJ N
persons NNS N
with IN N
COPD NNP N
. . N

-DOCSTART- -X- O O 20004758

high-impact JJ N
unilateral JJ N
intervention NN N
. . N

Healthy NNP N
premenopausal NN N
women NNS N
61 CD N
women NNS N
( ( N
age NN N
33.6+/-11.1 CD N
years NNS N
) ) N
completed VBD N
the DT N
intervention NN N
. . N

premenopausal JJ 4_p
women NNS 4_p
-DOCSTART- -X- O O 11839712

proximal JJ N
stomach NN N
in IN N
humans NNS N
. . N

Eleven NNP 3_p
healthy JJ 4_p
male NN 2_p
volunteers NNS N
. . N

-DOCSTART- -X- O O 15523323

advanced JJ 4_p
heart NN 4_p
failure NN 4_p
. . 4_p

74 CD 4_p
patients NNS 4_p
with IN N
chronic JJ 4_p
heart NN 4_p
failure NN 4_p
DD NNP N
genotype NN N
. . N

ACE NNP N
genotype NN N
ID NNP N
or CC N
II NNP N
subgroups NNS N
. . N

-DOCSTART- -X- O O 20973712

two CD N
studies NNS N
of IN N
aripiprazole NN N
in IN N
the DT N
treatment NN N
of IN N
irritability NN 4_p
associated VBN N
with IN N
autistic JJ 4_p
disorder NN 4_p
. . N

two CD N
8-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
multicenter JJ N
trials NNS N
children NNS N
and CC N
adolescents NNS N
with IN N
autistic JJ 4_p
disorder NN 4_p
-DOCSTART- -X- O O 25367544

toddlers NNS 1_p
with IN N
autism NN 4_p
: : N
82 CD 3_p
children NNS 1_p
diagnosed VBN N
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
at IN N
16 CD 1_p
to TO 1_p
20 CD 1_p
months NNS 1_p
. . N

-DOCSTART- -X- O O 9066329

young JJ 1_p
children NNS 1_p
during IN N
general JJ N
anesthesia NN 4_p
. . 4_p

young JJ 1_p
children NNS 1_p
. . N

patients NNS N
Full-term NNP 1_p
newborns NNS 1_p
and CC 1_p
children NNS 1_p
( ( N
n JJ N
= NNP N
488 CD 3_p
) ) 4_p
through IN N
8 CD N
yr NN N
of IN N
age NN N
who WP N
required VBD N
general JJ 4_p
anesthesia NN 4_p
and CC 4_p
tracheal JJ 4_p
intubation NN 4_p
young JJ 1_p
children NNS 1_p
. . N

full-term JJ 1_p
newborns NNS 1_p
and CC 1_p
children NNS 1_p
during IN N
anesthesia NN 4_p
. . N

-DOCSTART- -X- O O 9951491

patients NNS N
with IN N
seasonal JJ 4_p
allergic JJ 4_p
conjunctivitis NN 4_p
. . N

A DT N
total NN N
of IN N
135 CD 3_p
patients NNS N
with IN N
signs NNS N
and CC N
symptoms NNS N
of IN N
seasonal JJ 4_p
allergic JJ 4_p
conjunctivitis NN 4_p
participated VBD N
. . N

-DOCSTART- -X- O O 17519714

digital JJ 3_p
nerve NN 3_p
blocks NNS 3_p
: : 3_p
From IN 4_p
March NNP 4_p
of IN 4_p
1999 CD 4_p
to TO 4_p
March NNP 4_p
of IN 4_p
2001 CD 4_p
, , 4_p
70 CD 4_p
adult NN 4_p
patients NNS 4_p
who WP 4_p
underwent VBP 4_p
immediate JJ 4_p
reconstruction NN 4_p
for IN 4_p
traumatic JJ 4_p
injuries NNS 4_p
of IN 4_p
the DT 4_p
digits NNS 4_p
digital JJ 3_p
nerve NN 3_p
blocks NNS 3_p
. . 3_p

-DOCSTART- -X- O O 8473426

patients NNS N
with IN N
and CC N
without IN N
polycystic JJ 4_p
ovaries NNS 4_p
undergoing VBG N
in-vitro JJ N
fertilization NN N
. . N

76 CD 3_p
patients NNS N
with IN N
polycystic JJ 4_p
ovaries NNS 4_p
( ( N
PCO NNP N
) ) N
diagnosed VBD N
on IN N
pre-treatment JJ N
ultrasound JJ N
scan NN N
, , N
and CC N
76 CD 3_p
control NN 4_p
patients NNS N
who WP N
had VBD N
normal JJ N
ovaries NNS N
and CC N
were VBD N
matched VBN N
for IN N
age NN N
, , N
cause NN N
of IN N
infertility NN N
and CC N
stimulation NN N
regimen NNS N
. . N

patients NNS N
with IN N
PCO NNP 4_p
PCO NNP 4_p
group NN N
group NN 4_p
with IN 4_p
normal JJ 4_p
ovaries NNS 4_p
. . N

Patients NNS N
with IN N
and CC N
without IN N
PCO NNP 4_p
undergoing VBG N
IVF NNP N
-DOCSTART- -X- O O 184069

blood NN 4_p
lymphocyte JJ 4_p
population NN 4_p
in IN 4_p
mammary JJ 4_p
carcinoma NN 4_p
. . N

-DOCSTART- -X- O O 12006271

Between NNP N
October NNP N
15 CD N
, , N
1996 CD N
, , N
and CC N
March NNP N
24 CD N
, , N
1999 CD N
, , N
104 CD 3_p
patients NNS N
at IN N
13 CD N
centers NNS N
were VBD N
prospectively RB N
randomized VBN N
cerebral JJ 4_p
AVM NNP 4_p
-DOCSTART- -X- O O 7649753

The DT 4_p
three CD 4_p
data NNS 4_p
sources NNS 4_p
for IN 4_p
the DT 4_p
study NN 4_p
were VBD 4_p
( ( 4_p
1 CD 4_p
) ) 4_p
the DT 4_p
generic JJ 4_p
screen NN 4_p
results NNS 4_p
of IN 4_p
a DT 4_p
3 CD 4_p
percent NN 4_p
random JJ 4_p
sample NN 4_p
of IN 4_p
Medicare NNP 4_p
beneficiaries NNS 4_p
age NN 4_p
65 CD 4_p
years NNS 4_p
or CC 4_p
older JJR 4_p
who WP 4_p
were VBD 4_p
admitted VBN 4_p
to TO 4_p
California NNP 4_p
hospitals NNS 4_p
between IN 4_p
1 CD 4_p
July NNP 4_p
1987 CD 4_p
and CC 4_p
30 CD 4_p
June NNP 4_p
1988 CD 4_p
( ( 4_p
n JJ 4_p
= $ 4_p
20,136 CD 4_p
patients NNS 4_p
) ) 4_p
; : 4_p
( ( 4_p
2 CD 4_p
) ) 4_p
the DT 4_p
1987 CD 4_p
and CC 4_p
1988 CD 4_p
California NNP 4_p
Medicare NNP 4_p
Provided VBD 4_p
Analysis NNP 4_p
and CC 4_p
Review NNP 4_p
( ( 4_p
MEDPAR NNP 4_p
) ) 4_p
data NN 4_p
files NNS 4_p
; : 4_p
and CC 4_p
( ( 4_p
3 CD 4_p
) ) 4_p
the DT 4_p
American NNP 4_p
Hospital NNP 4_p
Association NNP 4_p
( ( 4_p
AHA NNP 4_p
) ) 4_p
1988 CD 4_p
Annual NNP 4_p
Survey NNP 4_p
of IN 4_p
Hospitals NNP 4_p
. . 4_p

-DOCSTART- -X- O O 18679829

Three CD N
hundred VBD N
and CC N
seventy JJ N
nine CD N
women NNS N
( ( N
260 CD N
with IN N
a DT N
family NN N
history NN N
of IN N
breast NN N
cancer NN N
; : N
119 CD N
with IN N
breast NN N
cancer NN N
) ) N
from IN N
The DT N
Royal NNP N
Marsden NNP N
NHS NNP N
Foundation NNP N
Trust NNP N
-DOCSTART- -X- O O 15937908

postmenopausal JJ 4_p
women NNS 2_p
with IN N
advanced JJ 4_p
breast NN 4_p
carcinoma NN 4_p
who WP N
had VBD N
disease NN N
progression NN N
after IN N
receipt NN N
of IN N
previous JJ N
endocrine NN N
treatment NN N
. . N

319 CD 3_p
( ( N
74.5 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
fulvestrant JJ N
group NN N
and CC N
322 CD 3_p
( ( N
76.1 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
anastrozole JJ N
group NN N
postmenopausal JJ 4_p
women NNS 2_p
with IN N
advanced JJ 4_p
breast NN 4_p
carcinoma NN 4_p
. . N

-DOCSTART- -X- O O 7954555

drug NN N
therapy NN N
of IN N
myocardial JJ 4_p
ischemia NN 4_p
during IN 4_p
the DT 4_p
peri-PTCA JJ 4_p
period NN 4_p
. . N

peri-PTCA JJ 4_p
( ( 4_p
percutaneous JJ 4_p
transluminal JJ 4_p
coronary JJ 4_p
angioplasty NN 4_p
) ) 4_p
30 CD N
patients NNS N
. . N

30 CD N
patients NNS N
. . N

-DOCSTART- -X- O O 24104513

preschoolers NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . 4_p

children NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
Two CD N
matched VBD N
groups NNS N
of IN N
18 CD 3_p
children NNS 1_p
each DT N
participated VBN N
in IN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 22951426

patients NNS N
with IN N
a DT N
presumptive JJ N
diagnosis NN N
of IN N
acute JJ 4_p
pyelonephritis NN 4_p
patients NNS N
. . N

patients NNS N
who WP N
satisfied VBD N
the DT N
criteria NNS N
for IN N
switch NN N
therapy NN N
group NN N
A NNP N
group NN N
B NNP N
Eighty-two JJ 3_p
patients NNS N
were VBD N
enrolled VBN N
; : N
41 CD 3_p
( ( N
50 CD N
% NN N
) ) N
patients NNS N
in IN N
group NN N
A NNP N
and CC N
41 CD 3_p
( ( N
50 CD N
% NN N
) ) N
patients NNS N
in IN N
group NN N
B NNP N
were VBD N
evaluated VBN N
. . N

-DOCSTART- -X- O O 23111617

social JJ N
behavior NN N
in IN N
children NNS 1_p
with IN N
autism NN 4_p
. . N

4- JJ N
to TO N
12-year-old JJ N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
; : N
N NNP N
= NNP N
24 CD N
) ) N
-DOCSTART- -X- O O 19621686

esophageal JJ 4_p
carcinoma NN 4_p
in IN 4_p
Asians NNPS 4_p
. . 4_p

in IN N
Asian JJ N
people NNS N
Patients NNS 4_p
of IN 4_p
resectable JJ 4_p
esophageal JJ 4_p
cancer NN 4_p
of IN 4_p
comparable JJ 4_p
stage NN 4_p
Discharged VBN N
patients NNS N
Up IN N
to TO N
December NNP N
2006 CD N
, , N
eighty-seven JJ 3_p
patients NNS 3_p
of IN 3_p
stage NN 3_p
II NNP 3_p
and CC 3_p
III NNP 3_p
, , N
including VBG N
71 CD 3_p
patients NNS 3_p
of IN 3_p
middle JJ 3_p
third JJ 3_p
lesions NNS 3_p
and CC N
16 CD 3_p
lower JJR 3_p
third JJ 3_p
lesions NNS 3_p
were VBD 3_p
enrolled VBN 3_p
. . N

-DOCSTART- -X- O O 18711222

chronic JJ 4_p
kidney NN 4_p
disease NN 4_p
with IN N
outcomes NNS N
in IN N
chronic JJ 4_p
heart NN 4_p
failure NN 4_p
: : N
patients NNS N
with IN N
heart NN 4_p
failure NN 4_p
( ( N
HF NNP 4_p
) ) N
. . N

HF NNP 4_p
patients NNS N
Of IN N
7788 CD 3_p
patients NNS N
in IN N
the DT N
Digitalis NNP N
Investigation NNP N
Group NNP N
trial NN N
, , N
3527 CD 3_p
had VBD N
CKD NNP 4_p
, , N
defined VBN N
by IN N
an DT N
estimated VBN N
glomerular JJ N
filtration NN N
rate NN N
( ( N
GFR NNP N
) ) N
< VBD N
60 CD N
ml/min/1.73 NNS N
m NN N
( ( N
2 CD N
) ) N
body NN N
surface JJ N
area NN N
( ( N
BSA NNP N
) ) N
. . N

ambulatory JJ 4_p
patients NNS N
with IN N
chronic JJ 4_p
HF NNP 4_p
-DOCSTART- -X- O O 22275153

patients NNS 4_p
with IN 4_p
overactive JJ 4_p
bladder NN 4_p
. . 4_p

patients NNS N
with IN N
overactive JJ N
bladder NN N
( ( N
OAB NNP N
) ) N
symptoms NNS N
. . N

patients NNS N
with IN N
OAB NNP N
symptoms NNS N
. . N

Twenty-six JJ N
patients NNS N
The DT N
mean JJ N
age NN N
was VBD N
67 CD N
years NNS N
and CC N
mean JJ N
BMI NNP N
was VBD N
28.3 CD N
kg/m NN N
( ( N
2 CD N
) ) N
CONCLUSION NNP N
Rectal NNP N
-DOCSTART- -X- O O 21938889

inpatients NNS 4_p
in IN 4_p
physical JJ 4_p
rehabilitation NN 4_p
. . 4_p

35 CD 3_p
hospitalized JJ N
patients NNS N
in IN N
physical JJ 4_p
rehabilitation NN 4_p
. . N

All DT N
participants NNS N
were VBD N
diagnosed VBN N
with IN N
a DT N
neurologic JJ 4_p
disorder NN 4_p
or CC N
had VBD N
recently RB N
undergone JJ N
orthopedic JJ 4_p
surgery NN 4_p
. . N

inpatients NNS N
in IN N
physical JJ 4_p
rehabilitation NN 4_p
. . N

-DOCSTART- -X- O O 6849726

mouse NN N
and CC N
man NN 2_p
mice NN N
and CC N
man NN 2_p
10 CD 3_p
volunteers NNS 3_p
. . N

mice NN N
man NN N
. . N

-DOCSTART- -X- O O 21543343

young JJ 1_p
people NNS N
with IN N
familial JJ 4_p
adenomatous JJ 4_p
polyposis NN 4_p
. . N

colorectal JJ 4_p
cancer NN 4_p
Familial NNP N
adenomatous JJ N
polyposis NN N
( ( N
FAP NNP N
) ) N
FAP NNP N
patients NNS N
from IN N
10 CD 1_p
to TO 1_p
21 CD 1_p
years NNS 1_p
of IN N
age NN N
. . N

A DT N
total NN N
of IN N
206 CD N
randomized JJ N
FAP NNP N
patients NNS N
commenced VBD N
intervention NN N
, , N
of IN N
whom WP N
133 CD N
had VBD N
at IN N
least JJS N
one CD N
follow-up JJ N
endoscopy NN N
and CC N
were VBD N
therefore RB N
included VBN N
in IN N
the DT N
primary JJ N
analysis NN N
-DOCSTART- -X- O O 15894770

patients NNS 4_p
with IN 4_p
non-valvar JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
. . 4_p

patients NNS N
taking VBG N
part NN N
in IN N
the DT N
SPAF NNP N
( ( N
stroke JJ N
prevention NN N
in IN N
atrial JJ N
fibrillation NN N
) ) N
study NN N
. . N

1321 CD N
participants NNS N
in IN N
the DT N
SPAF NNP N
III NNP N
study NN N
1321 CD N
patients NNS N
with IN N
atrial JJ N
fibrillation NN N
( ( N
AF NNP N
) ) N
, , N
331 CD N
( ( N
25 CD N
% NN N
) ) N
had VBD N
a DT N
documented JJ N
history NN N
of IN N
clinical JJ N
heart NN N
failure NN N
, , N
of IN N
which WDT N
168 CD N
cases NNS N
were VBD N
related VBN N
to TO N
a DT N
new JJ N
or CC N
recurrent JJ N
episode NN N
of IN N
acute NN N
decompensated VBN N
heart NN N
failure NN N
occurring VBG N
within IN N
the DT N
preceding VBG N
three CD N
months NNS N
. . N

Patients NNS N
with IN N
severe JJ N
LV NNP N
dysfunction NN N
on IN N
two CD N
dimensional JJ N
echocardiography NN N
and CC N
low JJ N
fractional JJ N
shortening NN N
Patients NNS N
with IN N
acute NN N
or CC N
recent JJ N
decompensated VBN N
features NNS N
-DOCSTART- -X- O O 23463854

Hawaiian JJ 4_p
youth NN 4_p
and CC 4_p
communities NNS 4_p
. . 4_p

communities NNS N
on IN N
Hawai'i NNP N
Island NNP N
university-based JJ N
research NN N
team NN N
school-based JJ 4_p
substance NN 4_p
use NN 4_p
prevention NN 4_p
curriculum NN 4_p
students NNS N
and CC N
community NN N
-DOCSTART- -X- O O 17477785

home-visit JJ N
invitation NN N
increase NN N
Pap NNP N
smear JJ N
screening NN N
in IN N
Samliem NNP N
, , N
Khon NNP N
Kaen NNP N
, , N
Thailand NNP N
cervical JJ 4_p
cancer NN 4_p
screening VBG N
in IN N
women NNS 2_p
between IN N
35 CD 1_p
and CC 1_p
60 CD 1_p
years NNS N
of IN N
age NN N
. . N

randomly RB N
recruited VBD N
304 CD 3_p
women NNS 2_p
from IN N
the DT N
Samliem NNP N
inner-city NN N
community NN N
, , N
Khon NNP N
Kaen NNP N
, , N
Northeast NNP N
Thailand NNP N
, , N
and CC N
assigned VBD N
participants NNS N
58 CD 3_p
of IN N
158 CD 3_p
women NNS 2_p
in IN N
the DT N
intervention NN N
zone NN N
and CC N
46 CD 3_p
of IN N
146 CD 3_p
in IN N
the DT N
control NN N
zone NN N
were VBD N
excluded VBN N
from IN N
the DT N
study NN N
because IN N
of IN N
having VBG N
had VBD N
a DT N
Pap NNP N
smear NN N
within IN N
5 CD N
years NNS N
, , N
but CC N
these DT N
were VBD N
included VBN N
in IN N
the DT N
final JJ N
analysis NN N
. . N

100 CD 3_p
women NNS 2_p
in IN N
the DT N
intervention NN N
group NN N
100 CD 3_p
women NNS 2_p
in IN N
the DT N
control NN N
group NN N
-DOCSTART- -X- O O 12651635

patients NNS N
treated VBN N
with IN N
aspirin NN N
until IN N
surgery NN 4_p
. . N

in IN N
patients NNS N
treated VBN N
with IN N
aspirin NN N
until IN N
the DT N
day NN N
before IN N
surgery NN 4_p
. . N

Eighty JJ 3_p
patients NNS 3_p
were VBD N
included VBN N
and CC N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
one CD N
group NN N
received VBD N
tranexamic JJ N
acid NN N
30 CD N
mg/kg NN N
, , N
and CC N
one CD N
group NN N
received VBD N
placebo NN N
( ( N
0.9 CD N
% NN N
NaCl NNP N
) ) N
as IN N
a DT N
bolus JJ N
injection NN N
before IN N
CPB NNP N
. . N

The DT 3_p
patients NNS 3_p
in IN 3_p
the DT 3_p
tranexamic JJ 3_p
acid NN 3_p
group NN 3_p
the DT 3_p
patients NNS 3_p
in IN 3_p
the DT 3_p
placebo NN 3_p
group NN 3_p
patients NNS N
receiving VBG N
tranexamic JJ N
acid NN N
. . N

-DOCSTART- -X- O O 18270751

young JJ 4_p
normoalbuminuric JJ 4_p
and CC 4_p
normotensive JJ 4_p
patients NNS 4_p
with IN 4_p
type JJ 4_p
1 CD 4_p
diabetes NNS 4_p
13 CD N
patients NNS N
aged VBN N
24 CD N
years NNS N
at IN N
baseline NN N
type NN N
1 CD N
diabetes VBZ N
patients NNS N
. . N

-DOCSTART- -X- O O 19459553

During IN N
orthopaedic JJ 4_p
surgery NN 4_p
of IN N
the DT N
limb NN N
three CD 3_p
parallel JJ 3_p
groups NNS 3_p
in IN N
30 CD 3_p
patients NNS N
-DOCSTART- -X- O O 7814306

adults NNS 4_p
with IN 4_p
both DT 4_p
autism NN 4_p
and CC 4_p
mental JJ 4_p
retardation NN 4_p
. . 4_p

6 CD 4_p
adults NNS 4_p
with IN 4_p
both DT 4_p
autism NN 4_p
and CC 4_p
moderate VB 4_p
to TO 4_p
profound VB 4_p
mental JJ 4_p
retardation NN 4_p
. . 4_p

6 CD N
participants NNS N
adults NNS N
with IN N
both DT N
autism NN N
and CC N
mental JJ N
retardation NN N
-DOCSTART- -X- O O 15978926

patients NNS 4_p
unfit JJ 4_p
for IN 4_p
open JJ 4_p
repair NN 4_p
of IN 4_p
abdominal JJ 4_p
aortic JJ 4_p
aneurysm NN 4_p
( ( N
EVAR NNP N
trial NN N
2 CD N
) ) N
: : N
patients NNS N
of IN N
poor JJ N
health NN N
status NN N
considered VBN N
unfit NN 4_p
for IN 4_p
major JJ 4_p
surgery NN 4_p
. . N

patients NNS N
unfit JJ N
for IN N
open JJ N
repair NN N
of IN N
aortic JJ N
aneurysm NN N
. . N

338 CD 3_p
patients NNS 3_p
aged VBN 1_p
60 CD 1_p
years NNS 1_p
or CC 1_p
older JJR 1_p
who WP N
had VBD N
aneurysms NNS 4_p
of IN 4_p
at IN 4_p
least JJS 4_p
5.5 CD 4_p
cm NN 4_p
in IN 4_p
diameter NN 4_p
and CC N
who WP N
had VBD N
been VBN N
referred VBN N
to TO N
one CD N
of IN N
31 CD N
hospitals NNS N
in IN N
the DT N
UK NNP N
. . N

197 CD N
patients NNS N
-DOCSTART- -X- O O 7481533

patients NNS N
with IN N
pedunculated JJ 4_p
and CC 4_p
small JJ 4_p
sessile NN 4_p
tubular NN 4_p
and CC 4_p
tubulovillous JJ 4_p
adenomas NN 4_p
. . N

After IN N
initial JJ 4_p
colonoscopic NN 4_p
polypectomy NN 4_p
patients NNS N
age NN 1_p
above IN 1_p
60 CD 1_p
years NNS 1_p
and CC N
male JJ 2_p
gender NN N
-DOCSTART- -X- O O 14599236

Modeling VBG N
hippocampal NN 4_p
and CC 4_p
neocortical JJ 4_p
contributions NNS 4_p
to TO N
recognition VB 4_p
memory NN 4_p
: : N
a DT N
complementary-learning-systems JJ N
approach NN N
. . N

computational JJ N
neural-network JJ N
model NN N
-DOCSTART- -X- O O 9241341

post-cesarean JJ 4_p
section NN 4_p
( ( 4_p
CS NNP 4_p
) ) 4_p
morphine VB N
self-administered JJ N
by IN N
the DT N
patient NN N
via IN N
the DT N
patient-controlled JJ N
analgesia NN N
device NN N
( ( N
PCA NNP N
) ) N
Forty-two JJ N
patients NNS N
scheduled VBN N
for IN N
elective JJ N
CS NNP N
All DT N
patients NNS N
received VBD N
-DOCSTART- -X- O O 2188871

intrahepatic JJ 4_p
cholestasis NN 4_p
. . 4_p

multicenter NN N
cholestatic JJ N
patients NNS N
with IN N
chronic JJ N
liver NN N
disease NN N
. . N

220 CD N
inpatients NNS N
( ( N
26 CD N
% NN N
chronic JJ N
active JJ N
hepatitis NN N
, , N
68 CD N
% NN N
cirrhosis NN N
, , N
6 CD N
% NN N
primary JJ N
biliary JJ N
cirrhosis NN N
) ) N
with IN N
stable JJ N
( ( N
1 CD N
month NN N
or CC N
more JJR N
) ) N
at IN N
least JJS N
twofold JJ N
increases NNS N
in IN N
serum JJ N
total NN N
and CC N
conjugated VBD N
bilirubin NN N
and CC N
alkaline JJ N
phosphatase NN N
volunteered VBD N
for IN N
the DT N
trial NN N
. . N

-DOCSTART- -X- O O 11013775

shoulder NN N
arthroscopy NN N
] NNP N
Thirty-two JJ N
patients NNS N
with IN N
impingement JJ N
syndrome JJ N
underwent JJ N
subacromial JJ N
decompression NN N
in IN N
the DT N
course NN N
of IN N
arthroscopic JJ N
shoulder NN N
surgery NN N
. . N

-DOCSTART- -X- O O 22342106

children NNS 1_p
with IN N
autism NN 4_p
. . N

children NNS 1_p
with IN N
autism NN 4_p
. . N

NAC NNP N
in IN N
children NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
. . N

Thirty-three JJ 3_p
subjects NNS N
( ( N
31 CD 3_p
male NN 2_p
subjects NNS N
, , N
2 CD 3_p
female JJ 2_p
subjects NNS N
; : N
aged VBN N
3.2-10.7 CD 1_p
years NNS 1_p
) ) N
were VBD N
randomized VBN N
in IN N
the DT N
study NN N
. . N

14 CD 3_p
subjects NNS N
in IN N
the DT N
NAC NNP N
group NN N
and CC N
15 CD 3_p
in IN N
the DT N
placebo NN N
group NN N
. . N

children NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
. . N

-DOCSTART- -X- O O 22265360

children NNS 4_p
with IN 4_p
pervasive JJ 4_p
developmental NN 4_p
disorders NNS 4_p
and CC 4_p
serious JJ 4_p
behavioral JJ 4_p
problems NNS 4_p
. . 4_p

Children NNP N
with IN N
Pervasive NNP N
Developmental NNP N
Disorders NNP N
( ( N
PDDs NNP N
) ) N
124 CD N
children NNS N
( ( N
4 CD N
through IN N
13 CD N
years NNS N
of IN N
age NN N
) ) N
with IN N
PDDs NNP N
and CC N
serious JJ N
behavioral JJ N
problems NNS N
to TO N
medication VB N
alone RB N
( ( N
MED NNP N
; : N
n CC N
= $ N
49 CD N
; : N
risperidone NN N
0.5 CD N
to TO N
3.5 CD N
mg/day NN N
; : N
Parents NNS N
of IN N
children NNS N
in IN N
COMB NNP N
received VBD N
an DT N
average NN N
of IN N
11.4 CD N
PT NNP N
sessions NNS N
. . N

Seventeen JJ N
subjects NNS N
did VBD N
not RB N
have VB N
a DT N
post-randomization NN N
Vineland NNP N
assessment NN N
. . N

Children NNP N
With IN N
Pervasive NNP N
Developmental NNP N
Disorders NNP N
; : N
-DOCSTART- -X- O O 18429536

female JJ 2_p
nurses VBZ N
in IN N
hospital JJ N
settings NNS N
females NNS 2_p
-DOCSTART- -X- O O 11085402

tracing VBG N
subjects NNS 4_p
in IN 4_p
epidemiologic JJ 4_p
studies NNS 4_p
. . N

tracing VBG N
subjects NNS N
in IN N
epidemiologic JJ N
studies NNS N
. . N

two CD N
World NNP N
Wide NNP N
Web-based JJ N
directories NNS N
( ( N
Canada411 NNP N
and CC N
InfoSpace NNP N
Canada NNP N
) ) N
346 CD 3_p
adults NNS 1_p
randomly RB N
selected VBN N
from IN N
respondents NNS N
in IN N
an DT N
ongoing JJ N
cohort NN N
study NN N
. . N

subjects NNS N
in IN N
epidemiologic JJ N
studies NNS N
. . N

-DOCSTART- -X- O O 14622630

hypertension NN 4_p
hypertensive JJ 4_p
patients NNS N
. . N

patients NNS N
One CD 3_p
hundred CD 3_p
and CC 3_p
seven CD 3_p
subjects NNS N
between IN N
the DT N
ages NNS N
of IN N
26 CD 1_p
and CC 1_p
80 CD 1_p
participated VBN N
in IN N
-DOCSTART- -X- O O 22008443

tetralogy NN 4_p
of IN 4_p
Fallot NNP 4_p
( ( 4_p
TOF NNP 4_p
) ) 4_p
. . 4_p

TOF NNP N
patients NNS N
receiving VBG N
cardioplegia NN N
. . N

From IN N
January NNP N
2008 CD N
to TO N
June NNP N
2010 CD N
, , N
80 CD N
consecutive JJ N
children NNS N
undergoing VBG N
correction NN N
of IN N
TOF NNP N
protection NN N
in IN N
children NNS N
undergoing VBG N
correction NN N
of IN N
tetralogy NN N
-DOCSTART- -X- O O 23980121

in IN N
Ghana NNP N
. . N

( ( N
CPAP NNP N
) ) N
effectively RB N
decreases VBZ N
respiratory JJ N
rate NN N
in IN N
children NNS 1_p
presenting VBG N
to TO N
Ghanaian NNP N
district NN N
hospitals NNS N
with IN N
respiratory NN 4_p
distress NN 4_p
. . N

Nurses NNS N
trained VBN N
by IN N
US NNP N
study NN N
personnel NNS N
( ( N
first-generation NN N
) ) N
and CC N
nurses NNS N
trained VBN N
by IN N
Ghanaian JJ N
nurses NNS N
after IN N
the DT N
study NN N
( ( N
second-generation NN N
) ) N
were VBD N
evaluated VBN N
on IN N
CPAP NNP N
knowledge NN N
and CC N
skills NNS N
. . N

Twenty-eight JJ 3_p
nurses NNS N
participated VBN N
in IN N
the DT N
study NN N
, , N
9 CD 3_p
first-generation NN N
and CC N
19 CD 3_p
second-generation NN N
. . N

-DOCSTART- -X- O O 1991872

Forty-four CD 4_p
patients NNS 4_p
, , 4_p
surgically RB 4_p
treated VBN 4_p
for IN 4_p
advanced JJ 4_p
periodontal JJ 4_p
disease NN 4_p
-DOCSTART- -X- O O 24335055

healthy JJ N
postmenopausal NN 4_p
women NNS 2_p
. . N

Seventy-six NNP 3_p
healthy JJ N
postmenopausal NN 4_p
women NNS 1_p
RESULTS NNP N
Seventy-one JJ N
women NNS N
with IN N
a DT N
mean JJ N
± NN N
SD NNP N
age NN N
of IN N
58.8 CD N
± JJ N
-DOCSTART- -X- O O 12687510

patients NNS N
with IN N
rheumatoid JJ 4_p
arthritis NN 4_p
receiving VBG 4_p
outpatient JJ 4_p
clinical JJ 4_p
nurse NN 4_p
specialist NN 4_p
care NN 4_p
, , 4_p
inpatient NN 4_p
care NN 4_p
, , 4_p
or CC 4_p
day NN 4_p
patient JJ 4_p
team NN 4_p
care NN 4_p
. . N

patients NNS N
with IN N
rheumatoid JJ N
arthritis NN N
( ( N
RA NNP N
) ) N
. . N

210 CD 3_p
RA NNP N
patients NNS N
who WP N
participated VBD N
in IN N
a DT N
randomized JJ N
trial NN N
The DT N
questionnaire NN N
was VBD N
returned VBN N
by IN N
174 CD 3_p
patients NNS 3_p
( ( 3_p
83 CD 3_p
% NN 3_p
) ) 3_p
. . N

RA NNP N
patients NNS N
. . N

-DOCSTART- -X- O O 14999992

exuding VBG N
wounds NNS N
. . N

exuding VBG N
wounds NNS N
greater JJR N
than IN N
2.5 CD N
x JJ N
2.5 CD N
cm NN N
. . N

target NN N
population NN N
was VBD N
300 CD N
control NN N
and CC N
300 CD N
test NN N
subjects NNS N
across IN N
three CD N
sites NNS N
in IN N
the DT N
UK NNP N
, , N
but CC N
recruitment JJ N
difficulties NNS N
resulted VBD N
in IN N
only RB N
125 CD N
patients NNS N
being VBG N
evaluable JJ N
. . N

-DOCSTART- -X- O O 1394200

patients NNS 4_p
undergoing JJ 4_p
surgery NN 4_p
for IN 4_p
colorectal JJ 4_p
cancer NN 4_p
. . 4_p

patients NNS N
undergoing VBG N
surgery NN N
for IN N
colorectal JJ N
cancer NN N
Patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
control VB N
( ( N
n JJ N
= NNP N
13 CD N
) ) N
or CC N
treatment NN N
groups NNS N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
. . N

-DOCSTART- -X- O O 1444872

patients NNS N
with IN N
unstable JJ N
angina NN N
. . N

Fifty-six JJ N
patients NNS N
with IN N
unstable JJ N
angina NN N
, , N
mean JJ N
age NN N
of IN N
55.4 CD N
+/- JJ N
8.5 CD N
, , N
41 CD N
men NNS N
and CC N
15 CD N
women NNS N
-DOCSTART- -X- O O 19127003

adolescents NNS 1_p
: : 1_p
students NNS 4_p
with IN N
TBI NNP 4_p
returning VBG N
to TO N
school NN N
. . N

adolescents NNS 1_p
adolescents NNS 1_p
with IN N
traumatic JJ 4_p
brain NN 4_p
injury NN 4_p
( ( N
TBI NNP 4_p
) ) N
-DOCSTART- -X- O O 23531317

17 CD 3_p
metabolic JJ 4_p
syndrome NN 4_p
( ( N
MetS NNP 4_p
) ) N
and CC N
15 CD 3_p
healthy JJ N
subjects NNS N
inhaled VBN N
filtered JJ N
air NN N
( ( N
FA NNP N
) ) N
or CC N
DE NNP N
exposure NN N
in IN N
two-hour JJ N
sessions NNS N
on IN N
different JJ N
days NNS N
with IN N
a DT N
minimum JJ N
2-week JJ N
washout NN N
period NN N
. . N

-DOCSTART- -X- O O 19111789

dysfunctional JJ 4_p
uterine JJ 4_p
bleeding NN 4_p
among IN 4_p
women NNS 4_p
agreeing VBG 4_p
to TO 4_p
obtain VB 4_p
surgical JJ 4_p
treatment NN 4_p
. . 4_p

dysfunctional JJ N
uterine JJ N
bleeding NN N
( ( N
DUB NNP N
) ) N
of IN N
women NNS N
who WP N
agreed VBD N
to TO N
obtain VB N
surgical JJ N
treatment NN N
; : N
We PRP N
collected VBD N
baseline NN N
data NNS N
on IN N
DUB NNP N
symptoms NNS N
and CC N
aspects NNS N
of IN N
the DT N
financial JJ N
and CC N
quality-of-life JJ N
burden NN N
for IN N
237 CD N
women NNS N
agreeing VBG N
to TO N
surgery VB N
for IN N
DUB NNP N
in IN N
a DT N
randomized JJ N
trial NN N
comparing VBG N
hysterectomy NN N
with IN N
endometrial JJ N
ablation NN N
. . N

-DOCSTART- -X- O O 26449882

consumers NNS N
101 CD 3_p
subjects NNS N
subjects NNS N
scoring VBG N
high JJ N
on IN N
autistic-like JJ 4_p
traits NNS 4_p
-DOCSTART- -X- O O 12452403

severe JJ N
irritable JJ N
bowel NN N
syndrome NN N
: : N
Patients NNS N
with IN N
severe JJ N
irritable JJ N
bowel NN N
syndrome NN N
18 CD N
patients NNS N
( ( N
study VB N
I PRP N
) ) N
24 CD N
patients NNS N
( ( N
study VB N
II NNP N
) ) N
. . N

-DOCSTART- -X- O O 10861653

pre-core NN 4_p
mutant NN 4_p
chronic JJ 4_p
hepatitis NN 4_p
B NNP 4_p
infection NN 4_p
pre-core JJ 4_p
mutant NN 4_p
of IN 4_p
hepatitis NN 4_p
B NNP 4_p
virus NN 4_p
( ( 4_p
HBV NNP 4_p
) ) 4_p
infection NN 4_p
Mediterranean NNP N
Europe NNP N
and CC N
in IN N
Asia NNP N
. . N

pre-core JJ N
mutant NN N
HBV NNP N
patients NNS N
with IN N
this DT N
variant NN N
patients NNS N
with IN N
pre-core JJ N
mutant NN N
hepatitis NN N
B NNP N
. . N

patients NNS N
with IN N
chronic JJ N
hepatitis NN N
B NNP N
, , N
including VBG N
those DT N
with IN N
pre-core JJ N
mutant JJ N
HBV NNP N
infection NN N
. . N

-DOCSTART- -X- O O 16691061

HIV-infected JJ N
women NNS N
. . N

HIV-infected JJ N
women NNS N
. . N

in IN N
sexually RB N
abstinent JJ N
and CC N
active JJ N
HIV-infected JJ N
women NNS N
. . N

Fifty-nine JJ N
HIV-infected JJ N
women NNS N
Sexually NNP N
abstinent JJ N
women NNS N
HIV-infected JJ N
women NNS N
and CC N
their PRP$ N
male JJ N
partners NNS N
. . N

-DOCSTART- -X- O O 24371832

subjects NNS 4_p
with IN 4_p
metabolic JJ 4_p
syndrome NN 4_p
. . N

subjects NNS 4_p
with IN 4_p
metabolic JJ 4_p
syndrome NN 4_p
( ( 4_p
MS NNP 4_p
) ) 4_p
. . 4_p

Participants NNS 4_p
with IN 4_p
MS NNP 4_p
( ( N
n JJ 3_p
= NNP 3_p
54 CD 3_p
) ) N
Forty-two JJ 3_p
subjects NNS 3_p
completed VBD N
the DT N
study NN N
( ( N
placebo NN N
, , N
n JJ 3_p
= VBP 3_p
19 CD 3_p
; : N
WGP NNP N
, , N
n JJ 3_p
= NNP 3_p
23 CD 3_p
) ) N
subjects NNS 4_p
with IN 4_p
MS NNP 4_p
-DOCSTART- -X- O O 25912520

Elementary NNP N
School NNP N
Children NNP 1_p
: : N
ethnically RB N
diverse JJ N
children NNS 1_p
in IN N
Texas NNP N
. . N

2012-2013 JJ N
school NN N
year NN N
. . N

A DT N
total NN N
of IN N
107 CD 3_p
children NNS 1_p
in IN N
fourth JJ N
and CC N
fifth JJ N
grade NN N
consented VBN N
. . N

There EX N
was VBD N
an DT N
attrition NN N
rate NN N
of IN N
8.8 CD N
% NN N
with IN N
a DT N
final JJ N
sample NN N
size NN N
of IN N
44 CD 3_p
children NNS 1_p
in IN N
three CD N
intervention NN N
schools NNS N
, , N
and CC N
a DT N
sample NN N
of IN N
50 CD 3_p
children NNS 1_p
in IN N
three CD N
comparison NN N
schools NNS N
. . N

in-school NN N
or CC N
afterschool JJ N
program NN N
. . N

among IN N
children NNS N
in IN N
elementary JJ N
school NN N
-DOCSTART- -X- O O 11781402

anti-herpes NNS 4_p
virus JJ N
therapy NN N
in IN N
MS NNP 4_p
. . N

patients NNS N
with IN N
relapsing-remitting JJ N
MS NNP 4_p
in IN N
a DT N
phase NN N
2 CD N
Patients NNPS N
were VBD N
eligible JJ N
for IN N
the DT N
study NN N
if IN N
they PRP N
had VBD N
had VBN N
two CD N
or CC N
more JJR N
MS JJ 4_p
relapses NNS N
in IN N
the DT N
2-year JJ N
period NN N
before IN N
enrollment NN N
. . N

Seventy JJ 3_p
patients NNS N
with IN N
Expanded NNP N
Disability NNP N
Status NNP N
Scale NNP N
scores NNS N
of IN N
0 CD N
to TO N
5.5 CD N
patients NNS N
with IN N
relapsing-remitting JJ N
MS NNP 4_p
who WP N
had VBD N
two CD N
or CC N
more JJR N
relapses NNS N
during IN N
the DT N
previous JJ N
2-year JJ N
period NN N
. . N

patients NNS N
with IN N
MS NNP 4_p
and CC N
high JJ N
levels NNS N
of IN N
MRI-evident JJ 4_p
disease NN 4_p
activity NN 4_p
. . N

-DOCSTART- -X- O O 7036799

60 CD 3_p
healthy JJ 4_p
patients NNS 4_p
undergoing VBG 4_p
lower JJR 4_p
abdominal JJ 4_p
surgery NN 4_p
. . N

-DOCSTART- -X- O O 12384805

stage NN 4_p
III NNP 4_p
melanoma NN 4_p
. . N

stage NN 4_p
III NNP 4_p
( ( 4_p
regional JJ 4_p
lymph NN 4_p
nodes NNS 4_p
) ) 4_p
melanoma NN 4_p
. . N

patients NNS N
without IN N
any DT N
detectable JJ N
metastases NNS 4_p
Eighty-eight JJ 3_p
patients NNS N
determined VBD N
as IN N
eligible JJ N
for IN N
treatment NN N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 23754339

children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . N

parents NNS N
of IN N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
Eighty NNP N
children NNS N
, , N
ages VBZ N
2-10 CD N
years NNS N
, , N
with IN N
ASD NNP N
and CC N
sleep JJ N
onset NN N
delay NN N
completed VBD N
the DT N
study NN N
. . N

ASD NNP N
-DOCSTART- -X- O O 25560349

90 CD 3_p
women NNS 2_p
who WP N
had VBD N
undergone JJ 4_p
cesarean JJ 4_p
operation NN 4_p
in IN N
Amir-al-Momenin NNP N
hospital NN N
( ( N
Gerash NNP N
, , N
Iran NNP N
) ) N
. . N

participants NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
each DT N
containing VBG N
45 CD 3_p
patients NNS 3_p
. . N

The DT N
participants NNS N
' POS N
mean JJ N
age NN N
was VBD N
27.56±4.20 CD 1_p
in IN N
the DT N
aloe NN N
vera NN N
group NN N
and CC N
26.62±4.88 CD 1_p
in IN N
the DT N
control NN N
group NN N
the DT N
women NNS 2_p
-DOCSTART- -X- O O 16750325

patients NNS N
with IN N
locally RB 4_p
advanced JJ 4_p
noninflammatory JJ 4_p
breast NN 4_p
cancer NN 4_p
. . N

patients NNS N
with IN N
locally RB 4_p
advanced JJ 4_p
breast NN 4_p
cancer NN 4_p
treated VBN N
with IN N
chemotherapy NN N
and CC N
mastectomy NN N
. . N

Between NNP N
1985 CD N
and CC N
1989 CD N
, , N
200 CD 3_p
patients NNS N
with IN N
clinical JJ N
Stage NNP 4_p
III NNP 4_p
noninflammatory JJ 4_p
breast NN 4_p
cancer NN 4_p
Of IN N
the DT N
179 CD 3_p
patients NNS N
treated VBN N
with IN N
mastectomy NN N
after IN N
neoadjuvant JJ N
chemotherapy NN N
, , N
108 CD 3_p
participated VBN N
-DOCSTART- -X- O O 8090084

patients NNS N
with IN N
multiple JJ 4_p
sclerosis NN 4_p
. . N

24 CD 3_p
patients NNS N
with IN N
clinically RB N
definite JJ N
multiple JJ 4_p
sclerosis NN 4_p
and CC N
in IN N
36 CD 3_p
healthy JJ 4_p
control NN 4_p
subjects NNS N
. . N

-DOCSTART- -X- O O 10643677

male NN 2_p
, , N
obese JJ 4_p
subjects NNS N
. . N

Twelve NNP 3_p
male NN 2_p
, , N
obese JJ 4_p
subjects NNS N
( ( N
age NN N
36.3+/-5.1 CD 1_p
y NN N
; : N
body NN N
weight VBD N
94.6+/-13.9 CD N
kg NN N
; : N
body NN N
mass NN N
index NN N
, , N
BMI NNP N
30.8+/-3.0 NNP N
kg/m2 NN N
) ) N
and CC N
in IN N
an DT N
additional JJ N
study NN N
15 CD 3_p
lean JJ N
, , N
well-trained JJ N
subjects NNS N
( ( N
age NN N
36.2+/-7.2 CD 1_p
y NN N
; : N
body NN N
weight VBD N
72.2+/-5.9 JJ N
kg NN N
; : N
BMI NNP N
22.3+/-1.7 CD N
kg/m2 NN N
) ) N
participated VBD N
. . N

subjects NNS N
were VBD N
randomly RB N
assigned VBN N
-DOCSTART- -X- O O 24630545

frozen JJ 4_p
shoulder NN 4_p
. . N

frozen JJ 4_p
shoulder NN 4_p
. . N

All DT N
primary JJ N
care NN N
referrals NNS N
of IN N
frozen JJ 4_p
shoulder NN 4_p
to TO N
our PRP$ N
physiotherapy NN N
department NN N
were VBD N
included VBN N
during IN N
a DT N
12-month JJ N
period NN N
. . N

Of IN N
these DT N
referrals NNS N
, , N
17 CD N
% NN N
met VBD N
the DT N
inclusion NN N
criteria NNS N
for IN N
primary JJ 4_p
idiopathic JJ 4_p
frozen JJ 4_p
shoulder NN 4_p
. . N

75 CD 3_p
patients NNS N
frozen JJ 4_p
shoulder NN 4_p
-DOCSTART- -X- O O 352099

deep JJ 4_p
vein NN 4_p
thrombosis NN 4_p
. . N

42 CD 3_p
medical JJ 3_p
patients NNS 3_p
with IN 4_p
a DT 4_p
history NN 4_p
of IN 4_p
deep JJ 4_p
vein NN 4_p
thrombosis NN 4_p
of IN 4_p
less JJR 4_p
than IN 4_p
five CD 4_p
days NNS 4_p
Only JJ N
patients NNS N
with IN N
extensive JJ N
thromboses NNS N
were VBD N
included VBN N
. . N

occurred VBD N
in IN N
71.4 CD N
% NN N
of IN N
21 CD N
patients NNS N
treated VBN N
with IN N
streptokinase NN N
21 CD N
heparin-treated JJ N
patients NNS N
. . N

patients NNS N
with IN N
acute JJ N
deep JJ N
vein NN N
thrombosis NN N
with IN N
proximal JJ N
extension NN N
of IN N
the DT N
thrombus NN N
beyond IN N
the DT N
calf NN N
veins NNS N
-DOCSTART- -X- O O 19565731

Eighty-four JJ 3_p
cases NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
3 CD 3_p
groups NNS 3_p
, , N
28 CD 3_p
cases NNS N
in IN N
each DT N
group NN N
. . N

-DOCSTART- -X- O O 26148018

children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . N

74 CD 3_p
children NNS 1_p
with IN N
ASD NNP N
with IN N
severe JJ N
maladaptive JJ 4_p
behaviour NN 4_p
and CC N
increased VBD N
urinary JJ 4_p
I-FABP NNP 4_p
. . N

Subjects NNS 4_p
were VBD 4_p
randomised VBN 4_p
to TO 4_p
receive VB 4_p
gluten-casein NN 4_p
or CC 4_p
a DT 4_p
placebo NN 4_p
for IN 4_p
seven CD 4_p
days NNS 4_p
. . N

-DOCSTART- -X- O O 21593282

Thirty-two NNP 4_p
healthy JJ 4_p
, , 4_p
opioid-naive JJ 4_p
adults NNS 4_p
-DOCSTART- -X- O O 12642847

48 CD 4_p
healthy JJ 4_p
volunteers NNS 4_p
( ( 4_p
24 CD 4_p
men NNS 2_p
and CC 4_p
24 CD 4_p
women NNS 2_p
) ) 4_p
. . 4_p

-DOCSTART- -X- O O 8394956

chronic JJ N
alcoholics NNS 4_p
. . N

alcoholics NNS 4_p
who WP N
took VBD N
their PRP$ N
assigned JJ N
medication NN N
( ( N
lithium NN N
or CC N
placebo NN N
) ) N
for IN N
the DT N
first JJ N
6 CD N
months NNS N
after IN N
discharge NN N
from IN N
an DT N
inpatient JJ N
rehabilitation NN N
program NN N
alcoholics NNS 4_p
who WP N
took VBD N
their PRP$ N
medication NN N
erratically RB N
or CC N
not RB N
at IN N
all DT N
. . N

Attendance NN N
at IN N
Alcoholics NNP 4_p
Anonymous NNP N
( ( N
AA NNP N
) ) N
meetings NNS N
-DOCSTART- -X- O O 16887481

gastric JJ N
cancer NN N
of IN N
the DT N
cardia NN N
or CC N
subcardia NN N
: : N
gastric JJ N
cancer NN N
of IN N
the DT N
cardia NN N
or CC N
subcardia NN N
. . N

Between NNP N
July NNP N
, , N
1995 CD N
, , N
and CC N
December NNP N
, , N
2003 CD N
, , N
167 CD N
patients NNS N
were VBD N
enrolled VBN N
from IN N
27 CD N
Japanese JJ N
hospitals NNS N
The DT 4_p
projected JJ 4_p
sample NN 4_p
size NN 4_p
was VBD 4_p
302 CD 4_p
. . 4_p

After IN 4_p
the DT 4_p
first JJ 4_p
interim JJ 4_p
analysis NN 4_p
, , 4_p
the DT 4_p
predicted JJ 4_p
probability NN 4_p
of IN 4_p
LTA NNP 4_p
having VBG 4_p
a DT 4_p
significantly RB 4_p
better RBR 4_p
overall JJ 4_p
survival NN 4_p
than IN 4_p
TH NNP 4_p
at IN 4_p
the DT 4_p
final JJ 4_p
analysis NN 4_p
was VBD 4_p
only RB 4_p
3.65 CD 4_p
% NN 4_p
, , 4_p
and CC 4_p
the DT 4_p
trial NN 4_p
was VBD 4_p
closed VBN 4_p
immediately RB 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
cancer NN 4_p
of IN 4_p
the DT 4_p
cardia NN 4_p
or CC 4_p
subcardia NN 4_p
-DOCSTART- -X- O O 1426893

acute JJ 4_p
posttransfusion NN 4_p
hepatitis NN 4_p
C NNP 4_p
: : 4_p
-DOCSTART- -X- O O 7892971

paediatric JJ 4_p
tonsillectomy NN 4_p
. . N

forty-two JJ 3_p
children NNS 1_p
scheduled VBN N
for IN N
elective JJ N
adenotonsillectomy NN N
children NNS 1_p
children NNS 1_p
having VBG N
tonsillectomy NN 4_p
. . N

-DOCSTART- -X- O O 6134039

bacterial JJ 4_p
meningitis NN 4_p
in IN 4_p
children NNS 4_p
. . 4_p

78 CD 4_p
patients NNS 4_p
with IN 4_p
bacterial JJ 4_p
meningitis NN 4_p
were VBD 4_p
evaluated VBN 4_p
-DOCSTART- -X- O O 18555063

Anxiety NN 4_p
sensitivity NN 4_p
later JJ 4_p
anxiety NN 4_p
symptoms NNS 4_p
and CC 4_p
syndromes NNS 4_p
. . N

anxiety NN 4_p
sensitivity NN 4_p
( ( N
AS NNP N
) ) N
anxiety NN 4_p
symptoms NNS 4_p
and CC 4_p
panic NN 4_p
anxiety NN 4_p
psychopathology NN 4_p
anxiety NN 4_p
symptoms NNS 4_p
. . 4_p

-DOCSTART- -X- O O 21809679

[ NN N
Use NNP 4_p
of IN 4_p
Tachocomb NNP 4_p
for IN 4_p
prevention NN 4_p
of IN 4_p
postoperative JJ 4_p
lymphatic JJ 4_p
leaks NNS 4_p
in IN 4_p
the DT 4_p
abdomen NNS 4_p
] VBP N
-DOCSTART- -X- O O 11931782

cytomegalovirus NN 4_p
retinitis NN 4_p
in IN 4_p
patients NNS 4_p
with IN 4_p
AIDS NNP 4_p
. . 4_p

patients NNS N
with IN N
acquired JJ N
immunodeficiency NN N
syndrome NN N
( ( N
AIDS NNP N
) ) N
. . N

two CD N
doses NNS N
( ( N
165-microg/injection JJ N
[ NN N
35 CD N
eyes NNS N
, , N
30 CD 3_p
patients NNS N
] JJ N
and CC N
330-microg/injection JJ N
[ NN N
153 CD N
eyes NNS N
, , N
120 CD 3_p
patients NNS N
] JJ N
) ) N
-DOCSTART- -X- O O 22526891

One NNP 3_p
hundred VBD 3_p
and CC 3_p
eighty JJ 3_p
randomly RB N
selected VBN N
healthy JJ 4_p
volunteers NNS N
( ( N
ASA NNP N
I PRP N
) ) N
-DOCSTART- -X- O O 8137583

ovarian JJ 4_p
cancer NN 4_p
patients NNS N
. . N

8 CD 3_p
patients NNS N
( ( N
age NN N
43-65 CD 1_p
years NNS N
) ) N
with IN N
ovarian JJ N
cancer NN N
. . N

-DOCSTART- -X- O O 8976475

chronic JJ 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
: : N
chronic JJ 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
( ( N
CLBP NNP N
) ) N
. . N

Primary NNP N
contact NN N
, , N
college NN N
out-patient JJ N
clinic NN N
. . N

174 CD 3_p
patients NNS N
aged VBN N
20-60 JJ 1_p
yr NNS N
-DOCSTART- -X- O O 21949005

children NNS 1_p
with IN N
autism NN 4_p
: : N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . N

51 CD 3_p
children NNS 1_p
aged VBN 1_p
2 CD 1_p
years NNS 1_p
0 CD 1_p
months NNS 1_p
to TO 1_p
4 CD 1_p
years NNS 1_p
11 CD 1_p
months NNS 1_p
. . N

children NNS 1_p
with IN N
autism NN 4_p
. . N

children NNS 1_p
's POS 1_p
-DOCSTART- -X- O O 15224627

social JJ 4_p
phobia NN 4_p
: : N
patients NNS N
and CC N
controls NNS N
A DT N
total NN N
of IN N
32 CD 3_p
social JJ N
phobics NNS N
and CC N
32 CD 3_p
controls NNS N
Social NNP N
phobics NNS N
social JJ N
phobics NNS N
-DOCSTART- -X- O O 2586565

patients NNS 4_p
with IN 4_p
alcoholic JJ 4_p
cirrhosis NN 4_p
and CC 4_p
massive JJ 4_p
ascites NNS 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
alcoholic JJ 4_p
cirrhosis NN 4_p
299 CD N
men NNS N
with IN N
alcoholic JJ N
cirrhosis NN N
, , N
who WP N
had VBD N
persistent NN N
or CC N
recurrent NN N
severe JJ N
ascites VBZ N
despite IN N
a DT N
standard JJ N
medical JJ N
regimen NNS N
, , N
to TO N
receive VB N
either RB N
intensive JJ N
medical JJ N
treatment NN N
or CC N
peritoneovenous JJ N
( ( N
LeVeen NNP N
) ) N
shunting VBG N
. . N

Group NNP N
1 CD N
had VBD N
normal JJ N
or CC N
mildly RB N
abnormal JJ N
results NNS N
on IN N
liver-function NN N
tests NNS N
, , N
Group NNP N
2 CD N
had VBD N
more RBR N
severe JJ N
liver NN N
dysfunction NN N
or CC N
previous JJ N
complications NNS N
, , N
and CC N
Group NNP N
3 CD N
had VBD N
severe JJ N
prerenal JJ N
azotemia NN N
without IN N
kidney NN N
disease NN N
. . N

medical JJ N
patients NNS N
surgical JJ N
patients NNS N
medical JJ N
and CC N
surgical JJ N
patients NNS N
. . N

-DOCSTART- -X- O O 15691793

regional JJ N
acute NN N
hospital NN N
. . N

A DT N
total NN N
of IN N
60 CD 3_p
consecutive JJ N
men NNS 2_p
admitted VBN N
from IN N
a DT N
waiting VBG N
list NN N
for IN N
surgery NN N
for IN N
benign JJ 4_p
prostatic JJ 4_p
hyperplasia NN 4_p
( ( 4_p
BPH NNP 4_p
) ) 4_p
Data NNP N
analysis NN N
was VBD N
based VBN N
on IN N
51 CD 3_p
patients NNS 3_p
. . N

-DOCSTART- -X- O O 21822764

children NNS 1_p
with IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorders NNP 4_p
( ( 4_p
ASD NNP 4_p
) ) N
. . N

two CD 3_p
groups NNS 3_p
of IN N
children NNS 1_p
children NNS 1_p
with IN N
ASD NNP N
-DOCSTART- -X- O O 3146231

[ JJ N
Complaints NNS N
in IN N
the DT N
postoperative JJ N
phase NN N
related VBN N
to TO N
anesthetics NNS 4_p
] NNP N
headache NN N
, , N
nausea NN N
, , N
vomiting NN N
, , N
and CC N
analgesic JJ N
requirement NN N
during IN N
the DT N
first JJ N
postoperative JJ N
24 CD N
h NN N
women NNS 2_p
men NNS 2_p
. . N

patients NNS N
in IN N
the DT N
postoperative JJ 4_p
phase NN 4_p
-DOCSTART- -X- O O 24679062

patients NNS 4_p
undergoing JJ 4_p
noncardiac JJ 4_p
surgery NN 4_p
. . 4_p

patients NNS 4_p
undergoing JJ 4_p
noncardiac JJ 4_p
surgery NN 4_p
patients NNS 4_p
who WP 4_p
are VBP 4_p
already RB 4_p
on IN 4_p
an DT 4_p
aspirin JJ 4_p
regimen NNS 4_p
and CC 4_p
among IN 4_p
those DT 4_p
who WP 4_p
are VBP 4_p
not RB 4_p
. . 4_p

10,010 CD N
patients NNS N
who WP N
were VBD N
preparing VBG N
to TO N
undergo VB N
noncardiac JJ N
surgery NN N
and CC N
were VBD N
at IN N
risk NN N
for IN N
vascular JJ N
complications NNS N
-DOCSTART- -X- O O 7540705

patients NNS N
with IN N
benign JJ N
prostatic JJ N
hyperplasia NN N
. . N

Beta-sitosterol NNP 4_p
Study NNP 4_p
Group NNP 4_p
. . 4_p

randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
multicentre NN N
study NN N
, , N
200 CD N
patients NNS N
( ( N
recruited VBN N
between IN N
April NNP N
and CC N
October NNP N
1993 CD N
) ) N
with IN N
symptomatic JJ N
benign NN N
prostatic JJ N
hyperplasia NN N
were VBD N
treated VBN N
-DOCSTART- -X- O O 17175376

risk NN 4_p
of IN 4_p
lung NN 4_p
cancer NN 4_p
. . 4_p

susceptibility NN 4_p
to TO 4_p
lung NN 4_p
cancer NN 4_p
. . 4_p

hospital-based JJ N
case-control NN N
study NN N
CA NNP 4_p
repeat NN 4_p
polymorphism NN 4_p
in IN 4_p
the DT 4_p
EGFR NNP 4_p
gene NN 4_p
with IN 4_p
risk NN 4_p
of IN 4_p
lung NN 4_p
cancer NN 4_p
in IN 4_p
a DT 4_p
Korean JJ 4_p
population NN 4_p
. . 4_p

-DOCSTART- -X- O O 22845070

adults NNS 1_p
and CC N
children NNS 1_p
Participants NNS N
adults NNS N
majority NN N
of IN N
adults NNS N
and CC N
a DT N
sizeable JJ N
proportion NN N
of IN N
4- JJ 1_p
to TO 1_p
6-year-olds NNS 1_p
. . N

both DT N
age NN N
groups NNS N
children NNS N
as RB N
young JJ N
as IN N
4 CD N
children NNS N
-DOCSTART- -X- O O 8589555

human JJ N
embryo JJ N
culture NN N
. . N

Pronuclear-stage JJ N
human JJ N
embryos NN N
Human JJ N
embryos NN N
from IN N
seven CD 3_p
patients NNS N
Murine NNP N
embryos JJ N
Human NNP N
embryos NN N
-DOCSTART- -X- O O 6764321

treatment NN 4_p
of IN 4_p
primary JJ 4_p
open JJ 4_p
angle NN 4_p
glaucoma NN 4_p
. . 4_p

-DOCSTART- -X- O O 10492627

operable JJ 4_p
gastric JJ 4_p
cancer NN 4_p
: : 4_p
Dutch JJ 4_p
patients NNS N
with IN N
operable JJ N
gastric JJ N
cancer NN N
. . N

Patients NNS N
younger JJR N
than IN N
75 CD N
years NNS N
of IN N
age NN N
with IN N
a DT N
good JJ N
physical NN N
and CC N
mental JJ N
condition NN N
and CC N
a DT N
histologically RB N
proven JJ N
adenocarcinoma NN N
of IN N
the DT N
stomach NN N
without IN N
clinical JJ N
or CC N
radiographic JJ N
( ( N
computed JJ N
tomography NN N
scan NN N
) ) N
evidence NN N
of IN N
distant JJ N
metastases NNS N
Early JJ N
gastric JJ N
cancer NN N
or CC N
cardia VB N
carcinoma NN N
were VBD N
excluded VBN N
. . N

56 CD N
eligible JJ N
and CC N
evaluable JJ N
patients NNS N
were VBD N
entered VBN N
: : N
-DOCSTART- -X- O O 14763475

refractive JJ 4_p
surgery NN 4_p
. . N

corneal NN 4_p
pain NN 4_p
after IN N
refractive JJ N
surgery NN N
Thirty NNP 3_p
patients NNS N
-DOCSTART- -X- O O 7259216

22 CD 4_p
patients NNS 4_p
with IN 4_p
alopecia JJ 4_p
areata NNS 4_p
to TO 4_p
whom WP 4_p
either DT 4_p
DNCB NNP 4_p
or CC 4_p
croton VB 4_p
oil NN 4_p
was VBD 4_p
applied VBN 4_p
topically RB 4_p
. . 4_p

-DOCSTART- -X- O O 23890774

urban JJ 4_p
youth NN 4_p
: : 4_p
predominately RB 4_p
low-income JJ 4_p
and CC 4_p
ethnic JJ 4_p
minority NN 4_p
urban JJ 4_p
youth NN 4_p
. . 4_p

14 CD N
Chicago NNP N
public JJ N
schools NNS N
. . N

6-year JJ 4_p
period NN 4_p
of IN 4_p
program NN 4_p
implementation NN 4_p
for IN 4_p
a DT 4_p
cohort NN 4_p
of IN 4_p
youth NN 4_p
in IN 4_p
each DT 4_p
school NN 4_p
, , 4_p
followed VBD 4_p
from IN 4_p
grades NNS 4_p
3 CD 4_p
to TO 4_p
8 CD 4_p
. . 4_p

health NN N
of IN N
youth NN N
in IN N
low-income JJ N
, , N
urban JJ N
settings NNS N
-DOCSTART- -X- O O 22985336

neuropathic JJ 4_p
diabetic JJ 4_p
foot NN 4_p
ulcers NNS 4_p
. . 4_p

healing NN 4_p
of IN 4_p
neuropathic JJ 4_p
diabetic JJ 4_p
foot NN 4_p
ulcers NNS 4_p
( ( 4_p
NDFU NNP 4_p
) ) 4_p
63 CD 3_p
Caucasians NNPS 3_p
, , N
type RB 4_p
2 CD 4_p
diabetic JJ 4_p
patients NNS 4_p
followed VBD N
up RP N
in IN N
the DT N
diabetic JJ N
foot NN N
outpatient NN N
clinic NN N
treatment NN N
-DOCSTART- -X- O O 991148

advanced JJ 4_p
acute NN 4_p
leukemia NN 4_p
in IN N
children NNS 1_p
. . N

children NNS 1_p
with IN N
acute JJ 4_p
leukemia NN 4_p
in IN 4_p
relapse NN 4_p
. . N

-DOCSTART- -X- O O 2859779

21 CD 4_p
patients NNS 4_p
with IN 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
who WP 4_p
were VBD 4_p
receiving VBG 4_p
placebo NN 4_p
, , 4_p
acebutolol NN 4_p
, , 4_p
and CC 4_p
propranolol NN 4_p
in IN 4_p
a DT 4_p
double-blind NN 4_p
26 CD N
patients NNS N
with IN N
chronic JJ N
angina NNS N
pectoris VBP N
13 CD N
patients NNS N
with IN N
stable JJ N
angina NNS N
pectoris VBP N
patients NNS N
with IN N
coronary JJ N
disease NN N
and CC N
a DT N
wide JJ N
range NN N
of IN N
ejection NN N
fractions NNS N
reduced VBN N
resting NN N
left VBD N
ventricular JJ N
function NN N
. . N

-DOCSTART- -X- O O 20839989

dogs NNS N
. . N

dogs NNS N
undergoing VBG N
elective JJ N
orchiectomy NN N
or CC N
ovariohysterectomy NN N
. . N

46 CD 3_p
dogs NNS 3_p
housed VBN N
in IN N
animal NN N
shelters NNS N
and CC N
undergoing VBG N
elective JJ N
orchiectomy NN N
or CC N
ovariohysterectomy NN N
. . N

dogs NNS N
undergoing VBG N
surgery NN N
. . N

-DOCSTART- -X- O O 19675193

adults NNS 1_p
with IN N
type JJ 4_p
1 CD 4_p
diabetes NNS 4_p
. . N

intensively RB 1_p
treated VBN 1_p
adults NNS 1_p
with IN N
type JJ 4_p
1 CD 4_p
diabetes NNS 4_p
. . N

83 CD 1_p
of IN 1_p
86 CD 1_p
individuals NNS 1_p
> JJ 1_p
or=25 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
with IN 1_p
type JJ 1_p
1 CD 1_p
diabetes NNS 1_p
who WP 1_p
used VBD 1_p
CGM NNP 1_p
as IN 1_p
part NN 1_p
of IN 1_p
a DT 1_p
6-month JJ 1_p
randomized JJ 1_p
clinical JJ 1_p
trial NN 1_p
in IN 1_p
a DT 1_p
subsequent JJ 1_p
6-month JJ 1_p
extension NN 1_p
study NN 1_p
. . 1_p

intensively RB N
treated VBN N
adults NNS 1_p
with IN N
type JJ 4_p
1 CD 4_p
diabetes NNS 4_p
-DOCSTART- -X- O O 22670827

in IN N
children NNS 1_p
LMA-Unique NNP N
in IN N
60 CD 3_p
children NNS N
undergoing JJ 4_p
surgery NN 4_p
-DOCSTART- -X- O O 8568534

plantar NN 4_p
flexor NN 4_p
spasticity NN 4_p
in IN N
patients NNS N
with IN N
traumatic JJ 4_p
brain NN 4_p
injury NN 4_p
. . N

Thirty-four CD 3_p
volunteer NN 4_p
adult NN 4_p
patients NNS 4_p
with IN 4_p
traumatic JJ 4_p
brain NN 4_p
injuries NNS 4_p
participated VBD 4_p
. . 4_p

There EX N
were VBD N
28 CD 3_p
males NNS N
and CC N
6 CD 3_p
females NNS N
; : N
the DT N
mean JJ N
age NN N
was VBD N
30.3 CD N
years NNS N
. . N

Twenty-six JJ 3_p
subjects NNS N
returned VBN N
to TO N
have VB N
the DT N
second JJ N
ankle NN N
tested VBN N
, , N
resulting VBG N
in IN N
60 CD 3_p
ankles NNS N
-DOCSTART- -X- O O 17997772

Patients NNS N
with IN N
a DT N
chalazion NN N
136 CD N
consecutive JJ N
patients NNS N
were VBD N
enrolled VBN N
into IN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 3690941

dental JJ 4_p
pain NN 4_p
. . N

120 CD 3_p
patients NNS N
suffering VBG N
from IN N
pain NN N
as IN N
a DT N
result NN N
of IN N
oral JJ N
surgery NN N
-DOCSTART- -X- O O 22926008

African-Americans NNPS N
. . N

African-American JJ N
patients NNS N
attending VBG N
a DT N
primary-care JJ N
provider NN N
visit NN N
to TO N
compare VB N
efficacy NN N
of IN N
a DT N
computer-delivered JJ N
tailored JJ N
intervention NN N
to TO N
increase VB N
colorectal JJ N
cancer NN N
( ( N
CRC NNP N
) ) N
screening NN N
( ( N
n JJ N
= NNP N
273 CD N
) ) N
with IN N
non-tailored JJ N
print NN N
material-an JJ N
American JJ N
Cancer NNP N
Society NNP N
brochure NN N
on IN N
CRC NNP N
screening NN N
( ( N
n JJ N
= NNP N
283 CD N
) ) N
. . N

-DOCSTART- -X- O O 9427455

infants NNS 1_p
healthy JJ 4_p
infants NNS 1_p
. . N

The DT N
Pa NNP N
group NN N
( ( N
n JJ N
= NNP N
101 CD 3_p
) ) N
had VBD N
a DT N
clearly RB N
lower JJR N
incidence NN N
of IN N
both DT N
local JJ 4_p
and CC 4_p
systemic JJ 4_p
adverse JJ 4_p
events NNS 4_p
than IN N
the DT N
Pw NNP N
group NN N
( ( N
n JJ N
= NNP N
100 CD 3_p
) ) N
. . N

-DOCSTART- -X- O O 2968595

hypercholesterolemia NN 4_p
] NN N
24 CD 3_p
patients NNS N
with IN N
familial JJ 4_p
hypercholesterolemia NN 4_p
. . N

heterozygous JJ 4_p
familial JJ 4_p
hypercholesterolemia NN 4_p
. . N

-DOCSTART- -X- O O 8840371

women NNS 4_p
versus IN 4_p
men NNS 4_p
. . 4_p

Nuclear JJ N
medicine NN N
laboratory NN N
in IN N
a DT N
university-affiliated JJ N
hospital NN N
. . N

Consecutive JJ N
patients NNS N
who WP N
were VBD N
referred VBN N
for IN N
evaluation NN N
of IN N
known VBN N
or CC N
suspected VBN N
coronary JJ N
artery NN N
disease NN N
. . N

Patients NNS N
were VBD N
judged VBN N
not RB N
to TO N
be VB N
able JJ N
to TO N
exercise VB N
adequately RB N
. . N

men NNS N
and CC N
women NNS N
. . N

women NNS N
and CC N
men NNS N
. . N

-DOCSTART- -X- O O 17717132

the DT N
spectrum NN N
of IN N
acute JJ N
coronary JJ N
syndromes NNS N
. . N

acute JJ N
coronary JJ N
syndromes NNS N
( ( N
ACS NNP N
) ) N
. . N

3225 CD N
patients NNS N
with IN N
ACS NNP N
. . N

-DOCSTART- -X- O O 21072224

the DT N
gambia NN N
and CC N
Tanzania NNP N
: : N
randomly RB N
selected VBN N
children NNS 1_p
aged VBN N
0-5 CD 1_p
years NNS 1_p
from IN N
48 CD N
Gambian JJ N
and CC N
36 CD N
Tanzanian JJ N
communities NNS N
. . N

The DT N
Gambia NNP N
Tanzania NNP N
. . N

in IN N
Tanzania NNP N
in IN N
Tanzania NNP N
In IN N
The DT N
Gambia NNP N
in IN N
The DT N
Gambia NNP N
in IN N
The DT N
Gambia NNP N
-DOCSTART- -X- O O 15960694

impact NN 4_p
on IN 4_p
nurse JJ 4_p
practices NNS 4_p
. . 4_p

home NN N
health NN N
nurses NNS N
caring VBG N
for IN N
heart NN N
failure NN N
( ( N
HF NNP N
) ) N
patients NNS N
. . N

Information NNP N
on IN N
nurse NN N
practices NNS N
was VBD N
abstracted VBN N
from IN N
the DT N
clinical JJ N
records NNS N
of IN N
patients NNS N
admitted VBN N
between IN N
June NNP N
2000 CD N
and CC N
November NNP N
2001 CD N
to TO N
the DT N
care NN N
of IN N
354 CD N
study NN N
nurses NNS N
at IN N
a DT N
large JJ N
, , N
urban JJ N
, , N
nonprofit JJ N
home NN N
care NN N
agency NN N
. . N

home NN 4_p
health NN 4_p
nurses NNS 4_p
-DOCSTART- -X- O O 22006202

patients NNS N
with IN N
active JJ N
rheumatoid NN N
arthritis NN N
and CC N
an DT N
inadequate JJ N
response NN N
to TO N
methotrexate VB N
alone RB N
. . N

active JJ N
rheumatoid NN N
arthritis NN N
( ( N
RA NNP N
) ) N
in IN N
patients NNS N
receiving VBG N
a DT N
stable JJ N
background NN N
regimen NNS N
of IN N
methotrexate NN N
( ( N
MTX NNP N
) ) N
who WP N
have VBP N
an DT N
inadequate JJ N
response NN N
to TO N
MTX NNP N
monotherapy NN N
. . N

patients NNS N
with IN N
active JJ N
RA NNP N
( ( N
n JJ N
= NNP N
507 CD N
) ) N
CONCLUSION NNP N
In IN N
patients NNS N
with IN N
active JJ N
RA NNP N
in IN N
whom WP N
the DT N
response NN N
to TO N
MTX NNP N
has VBZ N
been VBN N
inadequate JJ N
-DOCSTART- -X- O O 16939848

paclitaxel-induced JJ N
paclitaxel-induced JJ N
Thirty-two JJ 3_p
patients NNS N
undergoing VBG N
six CD N
courses NNS N
of IN N
paclitaxel-based JJ N
chemotherapy NN 4_p
patients NNS N
with IN N
cancer NN 4_p
-DOCSTART- -X- O O 7974179

carcinoma NN 4_p
of IN 4_p
the DT 4_p
uterine JJ 4_p
cervix NN 4_p
. . N

carcinoma NN 4_p
of IN 4_p
the DT 4_p
uterine JJ 4_p
cervix NN 4_p
. . N

Between NNP N
January NNP N
1983 CD N
and CC N
February NNP N
1989 CD N
, , N
a DT N
total NN N
of IN N
165 CD 3_p
patients NNS N
with IN N
carcinoma NN 4_p
of IN 4_p
the DT 4_p
uterine JJ 4_p
cervix NN 4_p
was VBD N
entered VBN N
in IN N
a DT N
prospective JJ N
randomized NN N
study NN N
concerning VBG N
the DT N
point NN N
A NNP N
dose NN N
of IN N
HDR NNP N
therapy NN N
( ( N
6 CD N
Gy/fraction NNP N
vs FW N
7.5 CD N
Gy/fraction NNP N
) ) N
and CC N
external JJ N
irradiation NN N
dose NN N
at IN N
Department NNP N
of IN N
Radiation NNP N
Therapy NNP N
, , N
The DT N
Center NNP N
for IN N
Adult NNP N
Diseases NNP N
, , N
Osaka NNP N
. . N

UICC NNP N
[ VBD N
20 CD N
] JJ N
stage NN N
distribution NN N
of IN N
patients NNS N
was VBD N
as IN N
follows VBZ N
: : N
stage NN N
IA NNP N
= NNP N
4 CD 3_p
, , N
stage NN N
IB NNP N
= NNP N
33 CD 3_p
, , N
stage NN N
IIA NNP N
= NNP N
18 CD 3_p
, , N
stage NN N
IIB NNP N
= NNP N
38 CD 3_p
, , N
stage NN N
III NNP N
= NNP N
57 CD 3_p
, , N
stage NN N
IV NNP N
= VBZ N
15 CD 3_p
. . N

-DOCSTART- -X- O O 9553982

infants NNS N
with IN N
atopic JJ N
dermatitis NN N
. . N

Atopic NNP N
Child NNP N
. . N

ETAC NNP N
( ( N
Early JJ N
Treatment NN N
of IN N
the DT N
Atopic NNP N
Child NNP N
) ) N
, , N
a DT N
multi-centre JJ N
predominantly RB N
European JJ N
study NN N
to TO N
investigate VB N
the DT N
potential NN N
for IN N
cetirizine NN N
to TO N
prevent VB N
the DT N
development NN N
of IN N
asthma NN N
in IN N
infants NNS N
with IN N
atopic NN N
dermatitis NN N
817 CD N
children NNS N
large JJ N
cohort NN N
of IN N
1-2 JJ N
years NNS N
olds VBZ N
with IN N
already RB N
established VBN N
atopic NN N
dermatitis NN N
, , N
resident NN N
in IN N
different JJ N
countries NNS N
and CC N
in IN N
different JJ N
environments NNS N
. . N

infants NNS N
with IN N
atopic NN N
dermatitis NN N
infants NNS N
-DOCSTART- -X- O O 19686304

elementary JJ 1_p
school NN 1_p
students NNS N
' POS N
4th CD 1_p
grade NN 1_p
student NN N
assessment NN N
of IN N
their PRP$ N
sun NN N
protection NN N
behaviors NNS N
. . N

Fall NN N
of IN N
2006 CD N
for IN N
the DT N
Sun NNP N
Protection NNP N
for IN N
Florida NNP N
's POS N
Children NNP N
( ( N
SPF NNP N
) ) N
project NN N
. . N

Hillsborough NNP N
County NNP N
Schools NNP N
, , N
Florida NNP N
. . N

students NNS N
students NNS N
Students NNS N
-DOCSTART- -X- O O 23647761

patients NNS N
with IN N
oesophageal JJ 4_p
cancer NN 4_p
patients NNS N
with IN N
incurable JJ N
oesophageal JJ 4_p
cancer NN 4_p
. . N

41 CD 3_p
Patients NNPS N
-DOCSTART- -X- O O 24785600

endometrial JJ 4_p
polyps NNS 4_p
121 CD N
women NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
polyp VB N
removal NN N
-DOCSTART- -X- O O 24965333

static JJ 4_p
magnetic JJ 4_p
field-exposed JJ 4_p
rat NN 4_p
. . 4_p

static JJ 4_p
magnetic JJ 4_p
field NN 4_p
( ( 4_p
SMF NNP 4_p
) ) 4_p
-exposed VBD 4_p
rats NNS 4_p
. . 4_p

Rats NNS N
SMF-exposed JJ 4_p
rats NNS 4_p
. . N

-DOCSTART- -X- O O 1445476

patients NNS N
with IN N
congestive JJ 4_p
heart NN 4_p
failure NN 4_p
. . N

60 CD 3_p
patients NNS N
with IN N
mild JJ 4_p
to TO N
moderate VB 4_p
( ( 4_p
II NNP 4_p
and CC 4_p
III NNP 4_p
NYHA NNP 4_p
class NN 4_p
) ) 4_p
congestive JJ 4_p
heart NN 4_p
failure NN 4_p
. . N

The DT N
group NN N
was VBD N
made VBN N
up IN N
of IN N
men NNS 2_p
and CC N
women NNS 2_p
aged VBD N
between IN 1_p
48 CD 1_p
and CC 1_p
73 CD 1_p
years NNS 1_p
in IN N
chronic JJ 4_p
treatment NN 4_p
with IN N
digitalis NN N
and CC N
diuretics NNS N
for IN N
at IN N
least JJS N
3 CD N
months NNS N
and CC N
who WP N
still RB N
displayed VBD N
symptoms NNS N
. . N

patients NNS N
with IN N
congestive JJ 4_p
heart NN 4_p
failure NN 4_p
-DOCSTART- -X- O O 15673801

Wegener NNP N
's POS N
granulomatosis NN N
. . N

patients NNS N
with IN N
Wegener NNP N
's POS N
granulomatosis NN N
have VBP N
disease NN N
flares NNS N
after IN N
conventional JJ N
medications NNS N
are VBP N
tapered VBN N
. . N

in IN N
180 CD N
patients NNS N
with IN N
Wegener NNP N
's POS N
granulomatosis NN N
. . N

Of IN N
the DT N
174 CD N
patients NNS N
who WP N
could MD N
be VB N
evaluated VBN N
, , N
126 CD N
( ( N
72.4 CD N
percent NN N
) ) N
had VBD N
a DT N
sustained VBN N
remission NN N
, , N
but CC N
only RB N
86 CD N
( ( N
49.4 CD N
percent NN N
) ) N
remained VBD N
in IN N
remission NN N
for IN N
the DT N
remainder NN N
of IN N
the DT N
trial NN N
. . N

maintenance NN N
of IN N
remission NN N
in IN N
patients NNS N
with IN N
Wegener NNP N
's POS N
granulomatosis NN N
. . N

-DOCSTART- -X- O O 22438600

first-year JJ N
pharmacy NN N
students NNS N
. . N

pharmacy NN N
student NN N
first-year JJ N
students NNS N
Students NNS N
students NNS N
-DOCSTART- -X- O O 23065684

Prostate NNP N
, , N
Lung NNP N
, , N
Colorectal NNP N
and CC N
Ovarian NNP N
( ( N
PLCO NNP N
) ) N
Trial NNP N
all DT 4_p
cancers NNS 4_p
showing VBG 4_p
a DT 4_p
positive JJ 4_p
screen NN 4_p
result NN 4_p
earlier RBR 4_p
with IN 4_p
ROCA NNP 4_p
than IN 4_p
under IN 4_p
the DT 4_p
PLCO NNP 4_p
such JJ N
women NNS N
132 CD N
intervention NN N
arm NN N
ovarian JJ N
cancer NN N
deaths NNS N
versus VBP N
119 CD N
in IN N
usual JJ N
care NN N
-DOCSTART- -X- O O 12653895

hepatocellular JJ 4_p
carcinoma NN 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
curative JJ 4_p
resection NN 4_p
of IN 4_p
HCC NNP 4_p
; : 4_p
818 CD N
days NNS N
, , N
21 CD 3_p
patients NNS N
received VBD N
one CD N
dose NN N
and CC N
19 CD 3_p
received VBD N
four CD N
doses NNS N
, , N
with IN N
10 CD N
( ( N
47.6 CD N
% NN N
) ) N
and CC N
eight CD N
( ( N
42.1 CD N
% NN N
) ) N
recurrences NNS N
, , N
respectively RB N
. . N

two CD N
groups NNS N
. . N

-DOCSTART- -X- O O 20635521

children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . 4_p

children NNS 1_p
with IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorders NNP 4_p
( ( 4_p
ASD NNP 4_p
) ) N
. . N

Participants NNS N
were VBD N
50 CD 3_p
children NNS 1_p
with IN N
ASD NNP 4_p
, , N
age NN 1_p
range NN 1_p
3 CD 1_p
to TO 1_p
5 CD 1_p
years NNS 1_p
, , N
who WP N
had VBD N
previously RB N
been VBN N
evaluated VBN N
on IN N
standard JJ N
tests NNS N
of IN N
language NN N
and CC N
level NN N
of IN N
functioning VBG N
. . N

Children NNP 1_p
with IN N
ASD NNP 4_p
-DOCSTART- -X- O O 25253808

weaned JJ 4_p
piglets NNS 4_p
. . 4_p

gastrointestinal JJ N
tract NN N
of IN N
piglets NNS N
. . N

A DT N
total NN N
of IN N
96 CD 3_p
purebred JJ N
Landrace NNP N
piglets NNS N
were VBD N
weaned VBN N
at IN N
the DT N
age NN 1_p
of IN 1_p
26 CD 1_p
± JJ 1_p
1 CD 1_p
d NN 1_p
. . N

Piglets NNS N
( ( N
4 CD 3_p
males NNS 2_p
and CC N
4 CD 3_p
females NNS 2_p
per IN N
treatment NN N
group NN N
) ) N
immune JJ N
system NN N
-DOCSTART- -X- O O 3342655

hypoxemia NN 4_p
we PRP N
studied VBD N
20 CD 3_p
healthy JJ 4_p
men NNS 2_p
, , N
aged VBD 1_p
20 CD 1_p
to TO 1_p
34 CD 1_p
years NNS 1_p
, , N
using VBG N
a DT N
tight-fitting JJ N
face NN N
mask NN N
and CC N
an DT N
isocapnic JJ N
partial NN N
rebreathing NN N
system NN N
( ( N
a DT N
modified VBN N
anesthesia NN N
machine NN N
) ) N
-DOCSTART- -X- O O 25818246

social JJ 4_p
anxiety NN 4_p
in IN 4_p
autistic JJ 4_p
adults NNS N
. . N

social JJ 4_p
anxiety NN 4_p
in IN 4_p
autistic JJ 4_p
adults NNS 4_p
commenced VBD 4_p
in IN 4_p
the DT 4_p
spring NN 4_p
of IN 4_p
2014 CD 4_p
. . N

MDMA NNP 4_p
has VBZ 4_p
been VBN 4_p
administered VBN 4_p
to TO N
over IN N
1133 CD 3_p
individuals NNS 3_p
for IN N
research NN N
purposes NNS N
-DOCSTART- -X- O O 10235220

chronic JJ 4_p
anti-HBe-positive JJ 4_p
hepatitis NN 4_p
B NNP 4_p
Seventy-two JJ 3_p
consecutive JJ N
anti-HBe-positive JJ N
chronic NN N
hepatitis NN N
B NNP N
patients NNS N
( ( N
59 CD 3_p
male NN 2_p
and CC N
13 CD 3_p
female NN 2_p
, , N
median JJ N
age NN N
41 CD 1_p
yr NN 1_p
) ) N
stratified VBN N
by IN N
sex NN N
and CC N
histology NN N
-DOCSTART- -X- O O 1286738

hereditary JJ 4_p
androgenic JJ 4_p
alopecia NN 4_p
in IN N
young JJ 1_p
males NNS 2_p
. . N

young JJ 1_p
males NNS 2_p
with IN N
hereditary JJ N
androgenic JJ 4_p
alopecia NN 4_p
. . N

alopecia VBN 4_p
with IN N
a DT N
mild NN N
to TO N
moderate VB N
perifollicular JJ N
inflammation NN N
zone NN N
. . N

20 CD 3_p
subjects NNS N
who WP N
received VBD N
two CD N
tablets NNS N
of IN N
ViviScal NNP N
once RB N
daily RB N
and CC N
20 CD 3_p
who WP N
received VBD N
two CD N
tablets NNS N
of IN N
fish JJ N
extract NN N
once RB N
daily JJ N
for IN N
6 CD N
months NNS N
. . N

The DT N
mean JJ N
patient NN N
age NN N
and CC N
mean JJ N
duration NN N
and CC N
severity NN N
of IN N
baldness NN N
Most JJS N
patients NNS N
had VBD N
been VBN N
treated VBN N
with IN N
long-term JJ N
topical JJ N
2 CD N
% NN N
minoxidil NN N
for IN N
1 CD N
year NN N
or CC N
more JJR N
three CD 3_p
patients NNS N
withdrew VBD N
from IN N
the DT N
study NN N
before IN N
the DT N
fourth JJ N
month NN N
due JJ N
to TO N
lack VB N
of IN N
therapeutic JJ N
effect NN N
. . N

-DOCSTART- -X- O O 23716409

in IN N
Bangladesh NNP 4_p
: : N
Randomly RB 4_p
selected VBN 4_p
households NNS 4_p
( ( N
N NNP N
= NNP N
452 CD 3_p
) ) N
in IN N
rural JJ 4_p
Bangladesh NNP 4_p
. . N

-DOCSTART- -X- O O 19243606

patients NNS 4_p
with IN 4_p
unresectable JJ 4_p
pancreatic JJ 4_p
adenocarcinoma NN 4_p
. . 4_p

Advanced NNP 4_p
pancreatic JJ 4_p
cancer NN 4_p
Patients NNS 4_p
with IN 4_p
histological/cytological JJ 4_p
proven NN 4_p
inoperable JJ 4_p
adenocarcinoma NN 4_p
of IN 4_p
the DT 4_p
head NN 4_p
of IN 4_p
pancreas NNS 4_p
were VBD 4_p
randomised VBN 4_p
to TO 4_p
receive VB 4_p
KAb NNP 4_p
201 CD 4_p
Between NNP 4_p
February NNP 4_p
2003 CD 4_p
and CC 4_p
July NNP 4_p
2005 CD 4_p
, , 4_p
25 CD 4_p
patients NNS 4_p
were VBD 4_p
enrolled VBN 4_p
. . 4_p

Nineteen JJ 4_p
patients NNS 4_p
were VBD 4_p
randomised VBN 4_p
, , 4_p
9 CD 4_p
to TO 4_p
the DT 4_p
intravenous JJ 4_p
and CC 4_p
10 CD 4_p
to TO 4_p
the DT 4_p
intra-arterial JJ 4_p
arms NNS 4_p
. . 4_p

-DOCSTART- -X- O O 26510263

Cardiopulmonary JJ 4_p
bypass NN 4_p
( ( 4_p
CPB NNP 4_p
) ) 4_p
patients NNS N
having VBG N
CBR NNP N
Forty NNP 3_p
patients NNS 3_p
undergoing VBG N
elective JJ N
CPB NNP N
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
propofol NN N
or CC N
isoflurane NN N
for IN N
maintenance NN N
of IN N
anaesthesia NN N
. . N

the DT N
propofol NN N
group NN N
the DT N
isoflurane NN N
group NN N
, , N
the DT N
propofol NN N
group NN N
hours NNS N
, , N
patients NNS N
on IN N
propofol NN N
than IN N
patients NNS N
on IN N
isoflurane NN N
-DOCSTART- -X- O O 14596755

men NNS 2_p
with IN N
lower JJR N
urinary JJ N
tract NN N
symptoms NNS N
related VBN N
to TO N
benign VB 4_p
prostatic JJ 4_p
enlargement NN 4_p
. . 4_p

177 CD 3_p
( ( N
out IN N
of IN N
755 CD 3_p
) ) N
patients NNS N
refused VBD N
randomisation NN N
-DOCSTART- -X- O O 24530652

healthy JJ N
female NN 2_p
volunteers NNS N
using VBG N
an DT N
objective JJ N
implicit JJ N
measure NN N
of IN N
social JJ N
motivational JJ N
behavior NN N
: : N
avoidance NN N
tendencies NNS N
angry JJ N
faces VBZ N
healthy JJ N
females NNS 2_p
. . N

-DOCSTART- -X- O O 8411891

cataract NN 4_p
extraction NN 4_p
with IN 4_p
lens JJ 4_p
implantation NN 4_p
. . 4_p

participation NN N
of IN N
medical JJ N
statisticians NNS N
A DT N
total NN N
of IN N
190 CD N
patients NNS N
with IN N
ICCE NNP N
and CC N
ACL NNP N
and CC N
170 CD N
patients NNS N
with IN N
ECCE NNP N
and CC N
PCL NNP N
were VBD N
followed VBN N
up RP N
for IN N
2 CD N
years NNS N
. . N

patients NNS N
with IN N
an DT N
intact JJ N
iris JJ N
diaphragm NN N
. . N

-DOCSTART- -X- O O 7047002

Thirty-one CD 3_p
patients NNS N
scheduled VBN N
for IN N
long-term JJ N
( ( N
24 CD N
weeks NNS N
) ) N
treatment NN N
with IN N
prednisone NN N
in IN N
comparatively RB N
high JJ N
doses NNS N
-DOCSTART- -X- O O 22151475

acute NN 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
with IN N
severe JJ N
disability NN N
: : N
patients NNS 4_p
with IN 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
In IN N
Korea NNP 4_p
Participants NNS 4_p
with IN 4_p
acute NN 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
and CC 4_p
severe JJ 4_p
functional JJ 4_p
disability NN 4_p
, , N
defined VBD N
as IN N
an DT N
Oswestry NNP N
Disability NNP N
Index NNP N
( ( N
ODI NNP N
) ) N
value NN N
> $ N
60 CD N
% NN N
-DOCSTART- -X- O O 9129469

lactational JJ N
amenorrhea NN N
in IN N
Honduran NNP N
women NNS N
. . N

postpartum NN N
low-income JJ N
Honduran NNP N
women NNS N
who WP N
had VBD N
breast-fed VBN N
fully RB N
for IN N
4 CD N
mo NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
-DOCSTART- -X- O O 8731496

60 CD 3_p
unfit JJ N
male NN 2_p
university NN N
undergraduate JJ N
students NNS N
with IN N
no DT N
previous JJ N
training NN N
in IN N
stress JJ N
management NN N
-DOCSTART- -X- O O 25854713

Borderline NNP 4_p
or CC 4_p
Mildly RB 4_p
Increased VBD 4_p
Left NNP 4_p
Ventricular NNP 4_p
Wall NNP 4_p
Thickness NNP 4_p
. . 4_p

advanced JJ N
CA NNP N
. . N

Patients NNP 4_p
with IN 4_p
presumptive JJ 4_p
diagnosis NN 4_p
of IN 4_p
CA NNP 4_p
and CC 4_p
mean VB 4_p
left JJR 4_p
ventricular NN 4_p
wall NN 4_p
thickness NN 4_p
( ( 4_p
LVWT NNP 4_p
) ) 4_p
≤14 VBP 4_p
mm NNS 4_p
were VBD 4_p
recruited VBN 4_p
LS NNP N
) ) N
] NN N
. . N

Among IN N
119 CD 3_p
patients NNS N
included VBD N
, , N
47 CD 3_p
were VBD N
finally RB N
diagnosed VBN N
with IN N
CA NNP 4_p
in IN 4_p
patients NNS 4_p
with IN 4_p
less JJR 4_p
advanced JJ 4_p
CA NNP 4_p
-DOCSTART- -X- O O 18946011

persons NNS 4_p
using VBG 4_p
interdental JJ 4_p
brushing NN 4_p
than IN 4_p
in IN 4_p
those DT 4_p
flossing NN 4_p
smokers NNS 4_p
-DOCSTART- -X- O O 8132701

malignant JJ 4_p
melanoma NN 4_p
. . N

malignant JJ N
melanoma NN N
. . N

patients NNS N
with IN N
high-risk JJ 4_p
melanoma NN 4_p
the DT N
patients NNS N
had VBD N
lesions NNS 4_p
greater JJR 4_p
than IN 4_p
1.70 CD 4_p
mm JJ 4_p
thick NN 4_p
and CC 4_p
TNM NNP 4_p
stage NN 4_p
IB NNP 4_p
or CC 4_p
stage NN 4_p
II NNP 4_p
disease NN 4_p
. . N

coumarin-treated JJ N
group NN N
of IN N
13 CD N
patients NNS N
, , N
and CC N
10 CD N
recurrences NNS N
in IN N
the DT N
placebo-treated JJ N
group NN N
of IN N
14 CD N
patients NNS N
-DOCSTART- -X- O O 23870440

teacher-student JJ 4_p
interaction NN 4_p
A DT N
total NN N
of IN N
24 CD 3_p
schools NNS N
. . N

Third- CD N
and CC N
fourth-grade JJ N
teachers NNS N
in IN N
treatment NN N
schools NNS N
( ( N
n=132 NN 3_p
) ) N
received VBD N
training NN N
in IN N
the DT N
RC NNP N
approach NN N
, , N
whereas JJ N
teachers NNS N
in IN N
control NN N
schools NNS N
( ( N
n=107 NN 3_p
) ) N
-DOCSTART- -X- O O 7011331

serotonin-migraine JJ 4_p
30 CD 3_p
patients NNS N
30 CD 3_p
patients NNS 3_p
receiving VBG N
3 CD N
x JJ N
0.5 CD N
mg NN N
or CC N
placebo JJ N
daily RB N
-DOCSTART- -X- O O 20488452

Third- JJ 1_p
and CC 1_p
fourth-grade JJ 1_p
students NNS 1_p
in IN N
a DT N
comparing NN N
symbols NNS N
group NN N
-DOCSTART- -X- O O 22989372

subjects NNS N
with IN N
asthma NN N
allergic JJ N
asthma NN N
. . N

27 CD 4_p
patients NNS 4_p
aged VBD 4_p
18 CD 4_p
to TO 4_p
40 CD 4_p
years NNS 4_p
with IN 4_p
positive JJ 4_p
skin-prick JJ 4_p
tests NNS 4_p
and CC 4_p
mild JJ 4_p
asthma JJ 4_p
in IN N
diseased JJ N
volunteers NNS N
-DOCSTART- -X- O O 17608965

outpatient JJ 4_p
surgical JJ 4_p
procedures NNS 4_p
. . N

under IN N
general JJ 4_p
anaesthesia NN 4_p
. . N

One CD 3_p
hundred VBD 3_p
ASA NNP 4_p
I-II NNP 4_p
patients NNS 4_p
, , N
aged VBN N
18-60 JJ 1_p
yr NN 1_p
undergoing VBG N
elective JJ 4_p
minor JJ 4_p
surgery NN 4_p
-DOCSTART- -X- O O 11015817

patients NNS 4_p
in IN 4_p
state NN 4_p
hospitals NNS 4_p
. . N

long-term JJ 4_p
state NN 4_p
hospital NN 4_p
inpatients NNS 4_p
in IN N
Connecticut NNP N
. . N

people NNS 4_p
experiencing VBG 4_p
lengthy JJ 4_p
hospitalizations NNS 4_p
. . N

Long-stay JJ N
patients NNS N
with IN N
schizophrenia NN N
in IN N
a DT N
state NN N
hospital NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
begin VB N
open-label JJ N
clozapine NN N
( ( N
n JJ N
= NNP N
138 CD 3_p
) ) N
or CC N
to TO N
continue VB N
receiving VBG N
conventional JJ N
antipsychotic JJ N
medications NNS N
( ( N
n JJ N
= NNP N
89 CD 3_p
) ) N
. . N

-DOCSTART- -X- O O 25887586

total JJ 4_p
hip NN 4_p
arthroplasty NN 4_p
. . N

postoperative JJ 4_p
patients NNS N
Forty-eight JJ 3_p
patients NNS N
undergoing VBG N
THA NNP N
resection NN N
in IN N
arthroplasty JJ 4_p
using VBG 4_p
the DT 4_p
posterolateral JJ 4_p
approach NN 4_p
-DOCSTART- -X- O O 10682031

patients NNS 4_p
with IN 4_p
nosocomial JJ 4_p
pneumonia NN 4_p
: : N
intubated JJ 4_p
and CC 4_p
mechanically RB 4_p
ventilated JJ 4_p
patients NNS 4_p
with IN N
nosocomial JJ 4_p
pneumonia NN 4_p
. . N

Thirty-eight NNP 3_p
mechanically RB 4_p
ventilated VBD 4_p
patients NNS 4_p
with IN 4_p
documented JJ 4_p
nosocomial JJ 4_p
pneumonia NN 4_p
were VBD N
included VBN N
. . N

Respiratory NNP N
tolerance NN N
was VBD N
good JJ N
in IN N
all DT N
but CC N
two CD N
patients NNS N
. . N

ventilated JJ 4_p
patients NNS 4_p
with IN 4_p
documented JJ 4_p
nosocomial JJ 4_p
pneumonia NN 4_p
. . N

-DOCSTART- -X- O O 663366

after IN 4_p
electric JJ 4_p
cardioversion NN 4_p
] NN 4_p
-DOCSTART- -X- O O 9647338

patients NNS N
with IN N
definite JJ 4_p
diabetic JJ 4_p
autonomic JJ 4_p
neuropathy NN 4_p
over IN 4_p
a DT 4_p
period NN 4_p
of IN 4_p
2 CD 4_p
years NNS 4_p
. . N

35 CD 3_p
patients NNS N
35 CD 3_p
controls NNS 4_p
with IN 4_p
diabetes NNS 4_p
mellitus NNS 4_p
, , 4_p
of IN 4_p
similar JJ 4_p
age NN 4_p
, , 4_p
gender NN 4_p
, , 4_p
and CC 4_p
glycemic JJ 4_p
control NN 4_p
. . 4_p

patients NNS N
with IN N
definite JJ N
DAN NNP N
-DOCSTART- -X- O O 25119339

LBW NNP 4_p
infants NNS 1_p
. . N

285 CD 3_p
low-birth-weight JJ 4_p
infants NNS N
( ( N
2,000-2,500 JJ N
g NN N
) ) N
-DOCSTART- -X- O O 12579266

laryngeal JJ 4_p
squamous JJ 4_p
cell NN 4_p
carcinomas NN 4_p
patients NNS N
with IN N
laryngeal JJ N
squamous JJ N
cell NN N
carcinoma NN N
( ( N
LSCC NNP 4_p
) ) N
36.7 CD N
% NN N
( ( N
37 CD 3_p
of IN N
102 CD 3_p
) ) N
patients NNS N
-DOCSTART- -X- O O 21931984

participants NNS 4_p
were VBD 4_p
required VBN 4_p
to TO 4_p
locomote VB 4_p
in IN 4_p
the DT 4_p
dark NN 4_p
to TO 4_p
a DT 4_p
lit NN 4_p
target NN 4_p
in IN 4_p
three CD 4_p
different JJ 4_p
conditions NNS 4_p
: : 4_p
monocular JJ 4_p
vision/target NN 4_p
with IN 4_p
image NN 4_p
size NN 4_p
, , 4_p
binocular JJ 4_p
vision/target NN 4_p
with IN 4_p
image NN 4_p
size NN 4_p
, , 4_p
and CC 4_p
binocular JJ 4_p
vision/point-light JJ 4_p
target NN 4_p
( ( 4_p
without IN 4_p
image NN 4_p
size NN 4_p
) ) 4_p
. . 4_p

participants NNS N
-DOCSTART- -X- O O 15267097

saltwater NN 4_p
crocodile NN 4_p
( ( N
Crocodylus NNP 4_p
porosus NN 4_p
) ) N
. . N

-DOCSTART- -X- O O 1894676

scaphoid NN 4_p
fractures NNS 4_p
fractures NNS 4_p
of IN 4_p
the DT 4_p
carpal JJ 4_p
scaphoid NN 4_p
. . N

392 CD 3_p
fresh JJ N
fractures NNS N
292 CD 3_p
fractures NNS N
-DOCSTART- -X- O O 15688961

toothbrushes NNS N
periodontal JJ 4_p
diseases NNS 4_p
. . N

Twenty NNP 3_p
patients NNS N
had VBD N
one CD N
side NN N
of IN N
their PRP$ N
mouths NNS N
brushed VBN N
with IN N
a DT N
toothbrush NN N
containing VBG N
the DT N
antimicrobial JJ N
agent NN N
( ( N
experimental JJ N
side NN N
) ) N
, , N
and CC N
the DT N
other JJ N
side NN N
with IN N
a DT N
toothbrush NN N
containing VBG N
no DT N
agent NN N
( ( N
control NN N
) ) N
. . N

-DOCSTART- -X- O O 25193142

Parent NN 1_p
and CC 1_p
family NN 1_p
outcomes NNS 1_p
of IN N
PEERS NNS N
: : N
a DT N
social JJ N
skills NNS N
intervention NN N
for IN N
adolescents NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . N

child NN 1_p
with IN N
an DT N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) N
family NN N
parent NN 1_p
adolescents NNS 1_p
with IN N
high-functioning JJ N
ASD NNP 4_p
. . N

parents NNS 1_p
in IN N
the DT N
PEERS NNP N
experimental JJ N
group NN N
-DOCSTART- -X- O O 8227803

hypertensive JJ 4_p
patients NNS 4_p
with IN 4_p
stable JJ 4_p
angina NN 4_p
hypertensive JJ N
patients NNS N
with IN N
stable JJ N
angina NNS N
30 CD 3_p
hypertensive JJ N
patients NNS N
( ( N
20 CD 3_p
with IN 3_p
and CC 3_p
10 CD 3_p
without IN 3_p
stable JJ 3_p
angina NN 3_p
) ) N
. . N

-DOCSTART- -X- O O 21276573

selected VBN 4_p
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
congestive JJ 4_p
heart NN 4_p
failure NN 4_p
. . 4_p

88 CD 1_p
consecutive JJ 1_p
patients NNS 1_p
who WP 1_p
met VBD 1_p
the DT 1_p
CRT NNP 1_p
implantation NN 1_p
criteria NNS 1_p
in IN 1_p
our PRP$ 1_p
hospital NN 1_p
between IN 1_p
28 CD 1_p
November NNP 1_p
2007 CD 1_p
and CC 1_p
30 CD 1_p
December NNP 1_p
2009 CD 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO 1_p
two CD 1_p
groups NNS 1_p
. . 1_p

Forty-four CD N
patients NNS N
underwent JJ N
CRT NNP N
device NN N
implantation NN N
using VBG N
Overlay NNP N
Ref NNP N
44 CD 1_p
patients NNS 1_p
were VBD 1_p
conventionally RB 1_p
implanted VBN 1_p
( ( 1_p
control VB 1_p
group NN 1_p
) ) 1_p
. . 1_p

-DOCSTART- -X- O O 23642776

healthy JJ 4_p
institutionalized VBN N
elderly JJ 1_p
humans NNS N
. . N

elderly JJ 1_p
healthy JJ N
institutionalized JJ N
elderly RB N
. . N

62 CD 3_p
subjects NNS N
aged VBN N
65-96 CD 1_p
years NNS N
healthy JJ 4_p
elderly JJ 1_p
subjects NNS N
. . N

healthy JJ 4_p
elderly JJ 1_p
people NNS N
. . N

-DOCSTART- -X- O O 11237545

unexplained JJ N
syncope NN N
: : N
vasovagal JJ N
syncope NN N
. . N

patients NNS N
with IN N
unexplained JJ N
syncope NN N
and CC N
healthy JJ N
controls NNS N
. . N

Forty-eight NNP N
patients NNS N
with IN N
unexplained JJ N
syncope NN N
and CC N
negative JJ N
passive JJ N
head-up NN N
tilt NN N
at IN N
70 CD N
degrees NNS N
for IN N
40 CD N
min NN N
, , N
and CC N
14 CD N
healthy JJ N
controls NNS N
negative JJ N
passive JJ N
head-up NN N
tilt NN N
-DOCSTART- -X- O O 7032533

type NN N
IV NNP N
hyperlipoproteinemia NN N
. . N

group NN N
of IN N
30 CD N
patients NNS N
with IN N
a DT N
type NN N
IV NNP N
hyperlipoproteinemia NN N
. . N

type NN N
IV NNP N
hyperlipoproteinemia NN N
-DOCSTART- -X- O O 25760553

neuropsychiatric JJ 4_p
disorders NNS 4_p
later RB N
in IN N
childhood NN 1_p
: : N
Seventy-five JJ 3_p
infants NNS 1_p
who WP N
were VBD N
randomized VBN 4_p
to TO 4_p
receive VB 4_p
Lactobacillus NNP 4_p
rhamnosus NN 4_p
GG NNP 4_p
( ( 4_p
ATCC NNP 4_p
53103 CD 4_p
) ) N
or CC 4_p
placebo NN 4_p
during IN 4_p
the DT 4_p
first JJ 4_p
6 CD N
mo NN N
of IN N
life NN N
were VBD N
followed-up JJ N
for IN N
13 CD N
y NN N
. . N

development NN N
later RB N
in IN N
childhood NN 1_p
-DOCSTART- -X- O O 17662102

patients NNS N
with IN N
hepatitis NN 4_p
B NNP 4_p
e VBZ 4_p
antigen-negative JJ 4_p
chronic JJ 4_p
hepatitis NN 4_p
B NNP 4_p
. . N

chronic JJ 4_p
hepatitis NN 4_p
B NNP 4_p
( ( N
CHB NNP 4_p
) ) N
. . N

Thirteen NNP 3_p
patients NNS N
with IN N
HBeAg-negative JJ 4_p
CHB NNP 4_p
HBeAg-negative JJ 4_p
CHB NNP 4_p
-DOCSTART- -X- O O 22320409

phacoemulsification NN 4_p
. . N

80 CD 3_p
American JJ N
Society NNP N
of IN N
Anesthesiology NNP N
grade VBD N
I-II NNP N
patients NNS N
who WP N
underwent JJ N
phacoemulsification NN N
with IN N
local JJ N
anesthesia NN N
under IN N
sedation NN N
. . N

four CD N
groups NNS N
( ( N
20 CD 3_p
patients NNS N
for IN N
each DT N
) ) N
: : N
-DOCSTART- -X- O O 7966066

patients NNS N
with IN N
rheumatoid JJ 4_p
arthritis NN 4_p
. . N

patients NNS N
with IN N
rheumatoid JJ 4_p
arthritis NN 4_p
( ( 4_p
RA NNP 4_p
) ) 4_p
. . N

patients NNS N
with IN N
RA NNP N
. . N

Patients NNPS N
( ( N
n JJ N
= NNP N
48 CD 3_p
) ) N
enrolled VBN N
at IN N
the DT N
beginning NN N
of IN N
our PRP$ N
study NN N
patients NNS N
with IN N
RA NNP 4_p
patients NNS N
with IN N
RA NNP 4_p
. . N

-DOCSTART- -X- O O 9088586

pulmonary JJ 4_p
vascular NN 4_p
bed NN 4_p
in IN N
man NN 2_p
. . N

oedema NNS 4_p
in IN N
patients NNS N
with IN N
hypoxic JJ 4_p
cor NN 4_p
pulmonale NN 4_p
. . N

Eight NNP 3_p
normal JJ N
volunteers NNS N
were VBD N
studied VBN N
-DOCSTART- -X- O O 3541602

hypertension NN 4_p
and CC 4_p
lipid JJ 4_p
levels NNS 4_p
. . 4_p

patients NNS N
with IN N
mild JJ N
to TO N
moderate VB N
hypertension NN N
. . N

31 CD N
patients NNS N
after IN N
a DT N
four-week JJ N
placebo NN N
washout IN N
period NN N
. . N

-DOCSTART- -X- O O 9474454

Fifty NNP 3_p
patients NNS N
with IN N
blepharitis NN 4_p
, , N
conjuctivitis NN 4_p
, , N
or CC N
blepharoconjunctivitis NN 4_p
-DOCSTART- -X- O O 16181541

vertebral JJ 4_p
basilar JJ 4_p
artery NN 4_p
ischemic JJ 4_p
vertigo NN 4_p
] NN N
Ninety NNP 3_p
patients NNS N
with IN N
VBIV NNP N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
; : N
Another DT N
45 CD N
patients NNS N
( ( N
control VB N
group NN N
) ) N
-DOCSTART- -X- O O 24708422

fully RB 4_p
edentulous JJ 4_p
patients NNS 4_p
. . N

Fifty-nine NNP 3_p
patients NNS 3_p
( ( N
72 CD N
jaws NNS N
) ) N
with IN N
edentulous JJ 4_p
maxillas NNS 4_p
and/ VBP 4_p
or CC 4_p
mandibles NNS 4_p
, , 4_p
were VBD N
consecutively RB N
recruited VBN N
and CC N
randomly RB N
assigned VBN N
-DOCSTART- -X- O O 2139523

advanced JJ 4_p
breast NN 4_p
cancer NN 4_p
: : N
From IN N
January NNP N
1985 CD N
to TO N
September NNP N
1988 CD N
, , N
60 CD 3_p
women NNS 2_p
with IN N
advanced JJ 4_p
breast NN 4_p
cancer NN 4_p
were VBD N
randomized VBN N
in IN N
two CD N
arms NNS N
All DT N
patients NNS N
were VBD N
post-menopausal JJ 4_p
, , N
previously RB N
untreated VBN N
with IN N
hormone NN N
therapy NN N
, , N
and CC N
with IN N
tumor NN N
receptor NN N
status NN N
determined VBD N
immediately RB N
before IN N
randomization NN N
; : N
all DT N
had VBD N
objectively RB N
evaluable JJ 4_p
lesions NNS 4_p
. . N

Thirty-one NN 3_p
and CC N
29 CD 3_p
patients NNS N
were VBD N
included VBN N
respectively RB N
in IN N
arms NNS N
A NNP N
and CC N
B NNP N
. . N

-DOCSTART- -X- O O 3341795

patient NN N
with IN N
chronic JJ 4_p
stasis NN 4_p
ulcers NNS 4_p
. . N

-DOCSTART- -X- O O 17443855

Shouldice NNP 4_p
, , 4_p
Lichtenstein NNP 4_p
and CC 4_p
transabdominal JJ 4_p
preperitoneal NN 4_p
hernia NN 4_p
repairs NNS N
. . N

Some DT N
280 CD 3_p
men NNS 2_p
with IN N
a DT N
primary JJ 4_p
hernia NN 4_p
were VBD N
randomized VBN N
-DOCSTART- -X- O O 16948927

children NNS 1_p
with IN N
autism NN 4_p
: : N
children NNS 1_p
with IN N
autism NN 4_p
. . N

children NNS 1_p
with IN N
autism NN 4_p
40 CD 3_p
consecutive JJ N
children NNS 1_p
with IN N
autism NN 4_p
, , N
whose WP$ N
ages NNS 1_p
ranged VBD 1_p
from IN 1_p
2 CD 1_p
to TO 1_p
9 CD 1_p
years NNS 1_p
, , N
who WP N
were VBD N
receiving VBG N
either CC N
risperidone NN N
or CC N
placebo VB N
given VBN N
orally RB N
at IN N
a DT N
dose NN N
of IN N
1 CD N
mg/day NN N
for IN N
6 CD N
months NNS N
. . N

40 CD 3_p
children NNS 1_p
enrolled VBD N
children NNS 1_p
with IN N
autism NN 4_p
-DOCSTART- -X- O O 20815045

in IN 4_p
diabetic JJ 4_p
patients NNS 4_p
: : N
in IN 4_p
diabetic JJ 4_p
patients NNS 4_p
after IN 4_p
sirolimus-eluting JJ 4_p
stent NN 4_p
( ( 4_p
SES NNP 4_p
) ) 4_p
or CC N
paclitaxel-eluting JJ 4_p
stent NN 4_p
( ( 4_p
PES NNP 4_p
) ) 4_p
implantation NN 4_p
Diabetic NNP 4_p
patients NNS N
with IN N
de FW N
novo FW N
coronary JJ N
lesions NNS N
( ( 3_p
169 CD 3_p
patients NNS 3_p
with IN N
190 CD N
lesions NNS N
) ) N
-DOCSTART- -X- O O 25801058

pharmacokinetics NNS N
of IN N
simvastatin NN N
. . N

of IN N
statins NNS N
in IN N
dyslipidemia NN 4_p
patients NNS N
in IN N
China NNP N
study NN N
in IN N
healthy JJ 4_p
Chinese NNP N
-DOCSTART- -X- O O 20940688

patients NNS N
undergoing VBG N
oral JJ N
surgery NN N
. . N

One CD N
hundred-fifty JJ N
dental JJ N
patients NNS N
-DOCSTART- -X- O O 2105256

severely RB N
malnourished VBN 4_p
cirrhotics NNS 4_p
. . N

Thirty-five JJ 3_p
severely RB N
malnourished VBN 4_p
cirrhotic JJ 4_p
patients NNS N
Both DT N
groups NNS N
were VBD N
homogeneous JJ N
regarding VBG N
age NN N
, , N
sex NN N
distribution NN N
, , N
etiology NN N
of IN N
liver JJ N
cirrhosis NN N
, , N
history NN N
of IN N
previous JJ N
complications NNS N
, , N
clinical JJ N
status NN N
, , N
liver RB N
and CC N
renal JJ N
function NN N
, , N
modified VBD N
Child NNP N
's POS N
score NN N
, , N
and CC N
nutritional JJ N
status NN N
at IN N
admission NN N
. . N

severely RB N
malnourished JJ 4_p
cirrhotics NNS 4_p
. . N

-DOCSTART- -X- O O 4716523

duodenal JJ 4_p
ulcer NN 4_p
. . N

-DOCSTART- -X- O O 25797097

group NN N
of IN N
21 CD 3_p
participants NNS N
underwent JJ N
two CD N
days NNS N
of IN N
training NN N
and CC N
were VBD N
then RB N
asked VBN N
to TO N
categorize VB N
40 CD N
newly RB N
learned VBN N
words NNS N
and CC N
a DT N
set NN N
of IN N
matched NNS N
familiar JJ N
words NNS N
as IN N
living NN N
or CC N
nonliving NN N
in IN N
an DT N
MRI NNP N
scanner NN N
. . N

-DOCSTART- -X- O O 9316683

inpatient JJ 4_p
treatment NN 4_p
of IN 4_p
cocaine NN 4_p
dependence NN 4_p
. . 4_p

cocaine NN 4_p
addiction NN 4_p
. . 4_p

66 CD N
recently RB N
abstinent JJ N
cocaine-dependent JJ N
patients NNS N
on IN N
an DT N
inpatient JJ N
substance NN N
abuse NN N
treatment NN N
unit NN N
utilizing VBG N
an DT N
intensive JJ N
12-step JJ N
milieu-oriented JJ N
psychosocial JJ N
therapy NN N
. . N

-DOCSTART- -X- O O 1835619

patients NNS N
with IN N
resectable JJ N
gastric JJ N
cancer NN N
: : N
386 CD 4_p
Japanese JJ 4_p
patients NNS 4_p
with IN 4_p
resectable JJ 4_p
gastric JJ 4_p
cancer NN 4_p
. . 4_p

264 CD N
patients NNS N
with IN N
curatively RB N
resected VBN N
cancer NN N
264 CD N
patients NNS N
patients NNS N
with IN N
a DT N
curatively RB N
resected VBN N
gastric JJ N
cancer NN N
-DOCSTART- -X- O O 17519148

oral JJ 4_p
contraceptive NN 4_p
( ( 4_p
OC NNP 4_p
) ) 4_p
Women NNP 2_p
, , N
aged VBD 1_p
18-34 CD 1_p
years NNS 1_p
, , N
with IN 4_p
no DT 4_p
contraindications NNS 4_p
to TO 4_p
the DT 4_p
use NN 4_p
of IN 4_p
combined JJ 4_p
OCs NNP 4_p
, , 4_p
were VBD 4_p
randomized VBN 4_p
to TO 4_p
three CD 4_p
cycles NNS 4_p
of IN 4_p
treatment NN 4_p
with IN 4_p
a DT 4_p
CVR NNP 4_p
delivering NN 4_p
NES/EE NNP 4_p
( ( 4_p
150/15 CD 4_p
microg/day NN 4_p
) ) 4_p
or CC 4_p
a DT 4_p
combined JJ 4_p
OC NNP 4_p
providing VBG 4_p
LNG NNP 4_p
and CC 4_p
EE NNP 4_p
( ( 4_p
150/30 CD 4_p
microg NN 4_p
per IN 4_p
tablet NN 4_p
) ) 4_p
Of IN N
47 CD 3_p
women NNS 2_p
randomized VBN N
, , N
45 CD 3_p
completed VBD N
the DT N
study NN N
( ( N
CVR NNP N
: : N
23 CD N
; : N
OC NNP N
: : N
22 CD N
) ) N
. . N

-DOCSTART- -X- O O 9495616

4 CD 3_p
groups NNS 3_p
of IN N
10 CD 3_p
subjects NNS N
. . N

volunteers NNS N
A DT N
group NN N
of IN N
10 CD 3_p
subjects NNS N
had VBD N
plaque VBN 4_p
scored VBN N
-DOCSTART- -X- O O 6425480

children NNS 1_p
with IN N
cystic JJ 4_p
fibrosis NN 4_p
. . N

11 CD N
malnourished JJ 4_p
children NNS N
( ( N
age NN N
10 CD N
to TO N
17 CD N
years NNS N
) ) N
with IN N
cystic JJ 4_p
fibrosis NN 4_p
, , N
before IN N
and CC N
after IN N
improvement NN N
of IN N
nutritional JJ N
status NN N
with IN N
supplemental JJ N
parenteral JJ N
nutrients NNS N
for IN N
1 CD N
month NN N
. . N

-DOCSTART- -X- O O 21998264

Twenty-five JJ 3_p
sedentary JJ N
healthy JJ N
subjects NNS N
-DOCSTART- -X- O O 19433686

patients NNS N
with IN N
stage NN 4_p
III NNP 4_p
melanoma NN 4_p
. . N

1,256 CD 3_p
patients NNS N
with IN N
stage NN 4_p
III NNP 4_p
melanoma NN 4_p
were VBD N
randomly RB N
assigned VBN N
after IN 4_p
full JJ 4_p
lymphadenectomy NN 4_p
-DOCSTART- -X- O O 26209587

patients NNS 4_p
with IN 4_p
open-angle JJ 4_p
glaucoma NN 4_p
or CC 4_p
ocular JJ 4_p
hypertension NN 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
open-angle JJ 4_p
glaucoma NN 4_p
or CC 4_p
ocular JJ 4_p
hypertension NN 4_p
. . 4_p

randomised VBD N
298 CD 3_p
patients NNS 3_p
, , N
of IN N
whom WP N
292 CD 3_p
( ( N
98 CD N
% NN N
) ) N
completed VBD N
the DT N
study NN N
-DOCSTART- -X- O O 11292279

54 CD 3_p
healthy JJ N
volunteers NNS N
to TO N
Persons NNPS N
with IN N
one CD N
or CC N
two CD N
long JJ N
( ( N
l NN N
) ) N
5HTTLPR CD 4_p
alleles NNS 4_p
5HTTLPR CD 4_p
genotype NN 4_p
. . N

-DOCSTART- -X- O O 19508318

children NNS 1_p
with IN N
autism NN 4_p
and CC 4_p
developmental JJ 4_p
delay NN 4_p
children NNS 1_p
with IN N
developmental JJ 4_p
problems NNS 4_p
. . N

Participants VBZ N
A DT N
total NN N
of IN N
59 CD 3_p
children NNS N
, , N
aged VBN N
3-5 CD 1_p
years NNS 1_p
, , N
attending VBG N
two CD N
early JJ N
childhood NN N
intervention NN N
centres NNS N
in IN N
Melbourne NNP N
, , N
Australia NNP N
. . N

Half NNP N
of IN N
the DT N
subjects NNS N
Fifty-four JJ 3_p
children NNS 1_p
-DOCSTART- -X- O O 22198983

recovery NN N
enhancement NN N
after IN N
stroke VBD N
2 CD N
to TO N
60 CD 3_p
patients NNS N
3 CD N
to TO N
30 CD N
days NNS N
after IN N
ischemic JJ 4_p
or CC 4_p
hemorrhagic JJ 4_p
stroke NN 4_p
RESULTS NNP N
Sixty NNP 3_p
patients NNS N
were VBD N
recruited VBN N
at IN N
mean NN N
of IN N
8 CD N
days NNS N
( ( N
SD NNP N
± NNP N
5 CD N
) ) N
post NN N
ictus NN N
, , N
with IN N
mean JJ 1_p
age NN 1_p
71 CD 1_p
years NNS 1_p
( ( 1_p
± JJ 1_p
12 CD 1_p
years NNS 1_p
) ) N
and CC N
53 CD N
% NN N
men NNS 2_p
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
baseline NN N
in IN N
G-CSF-treated JJ N
patients NNS N
cells NNS N
in IN N
patients NNS N
with IN N
ischemic JJ N
stroke NN N
-DOCSTART- -X- O O 16797292

posttransplant JJ 4_p
hypertension NN 4_p
in IN 4_p
kidney NN 4_p
allograft NN 4_p
recipients NNS 4_p
. . 4_p

kidney NN 1_p
recipients NNS 1_p
. . 1_p

Thirty-two JJ 4_p
patients NNS 4_p
on IN 4_p
antihypertensive JJ 4_p
treatment NN 4_p
completed VBD 4_p
the DT 4_p
study NN 4_p
. . 4_p

kidney NN 4_p
allograft NN 4_p
recipients NNS 4_p
-DOCSTART- -X- O O 20726255

=2 VB 1_p
month-old JJ 1_p
children NNS N
. . N

1200 CD 3_p
healthy JJ N
children NNS 1_p
of IN N
2-5 JJ 1_p
months NNS 1_p
old JJ 1_p
in IN N
Jiangsu NNP N
province NN N
were VBD N
administered VBN N
OPV NNP 4_p
( ( 4_p
HDC NNP 4_p
) ) 4_p
vaccine NN 4_p
and CC N
control NN N
vaccines NNS N
. . N

the DT N
children NNS N
> VBP N
or CC N
=2 JJ N
months NNS N
old JJ N
. . N

-DOCSTART- -X- O O 21135366

high-risk JJ N
patients NNS N
with IN N
recent JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
: : N
stable JJ 4_p
patients NNS 4_p
with IN 4_p
low JJ 4_p
ejection NN 4_p
fraction NN 4_p
late RB 4_p
after IN 4_p
myocardial JJ 4_p
infarction NN 4_p
Outpatients NNS 4_p
with IN 4_p
recent JJ 4_p
( ( 4_p
6 CD 4_p
to TO 4_p
40 CD 4_p
days NNS 4_p
) ) 4_p
acute VBP 4_p
myocardial JJ 4_p
infarction NN 4_p
, , 4_p
left VBD 4_p
ventricular JJ 4_p
dysfunction NN 4_p
( ( 4_p
ejection JJ 4_p
fraction NN 4_p
< VBD 4_p
35 CD 4_p
% NN 4_p
) ) 4_p
, , 4_p
and CC 4_p
low JJ 4_p
heart NN 4_p
rate NN 4_p
variability NN 4_p
ICD NNP N
patients NNS N
ICD NNP N
patients NNS N
patients NNS N
patients NNS 4_p
receiving VBG 4_p
ICDs NNP 4_p
early RB 4_p
after IN 4_p
myocardial JJ 4_p
infarction NN 4_p
-DOCSTART- -X- O O 21090563

patients NNS N
with IN N
advanced JJ N
melanoma NN 4_p
. . N

Treatment-naïve CD N
or CC N
previously RB N
treated VBN N
patients NNS N
with IN N
unresectable JJ N
stage NN N
III/IV NNP N
melanoma NN N
( ( N
n JJ N
= NNP N
115 CD N
) ) N
received VBD N
open-label JJ N
ipilimumab NN N
( ( N
10 CD N
mg/kg NN N
every DT N
3 CD N
weeks NNS N
for IN N
four CD N
doses NNS N
) ) N
-DOCSTART- -X- O O 555487

coronary-prone NN 4_p
( ( 4_p
Type NNP 4_p
A NNP 4_p
) ) 4_p
managers NNS 4_p
. . 4_p

type NN N
A DT N
intervention NN N
project NN N
for IN N
healthy JJ N
managers NNS N
manifestations NNS N
of IN N
clinical JJ N
CHD NNP N
) ) N
all DT N
three CD N
groups NNS N
-DOCSTART- -X- O O 18714238

cardiovascular JJ N
and CC N
cardiorespiratory JJ N
cardiovascular NN N
and CC N
cardiorespiratory NN N
adaptations NNS N
in IN N
college NN N
athletes NNS N
and CC N
compared VBN N
two CD N
concurrent JJ N
exercise NN N
( ( N
CE NNP N
) ) N
protocols NNS N
. . N

performed VBN N
on IN N
30 CD 3_p
women NNS 2_p
( ( N
mean JJ N
age NN N
19.6 CD 1_p
years NNS N
) ) N
and CC N
20 CD 3_p
men NNS 2_p
( ( N
20.4 CD 1_p
years NNS N
) ) N
. . N

-DOCSTART- -X- O O 19054570

bipolar JJ 4_p
1 CD 4_p
disorder NN 4_p
. . N

patients NNS N
with IN N
manic JJ N
and CC N
mixed JJ N
mood NN 4_p
episodes NNS 4_p
patients NNS N
presenting VBG N
with IN N
a DT N
mixed JJ N
index NN N
episode NN N
who WP N
were VBD N
enrolled VBN N
in IN N
a DT N
larger JJR N
double-blind NN N
, , N
placebo-controlled JJ N
trial NN N
. . N

Patients NNS N
who WP N
met VBD N
remission NN N
criteria NNS N
at IN N
2 CD N
consecutive JJ N
weekly JJ N
visits NNS N
during IN N
6 CD N
to TO N
12 CD N
weeks NNS N
of IN N
open-label JJ N
olanzapine JJ N
treatment NN N
121 CD 3_p
of IN N
304 CD 3_p
patients NNS N
patients NNS N
presenting VBG N
with IN N
a DT N
mixed JJ 4_p
index NN 4_p
episode NN 4_p
of IN N
bipolar NN 4_p
I PRP 4_p
disorder VBP 4_p
. . N

-DOCSTART- -X- O O 20159310

subjects NNS N
with IN N
chronic JJ N
psoriasis NN N
. . N

36 CD N
subjects NNS N
with IN N
chronic JJ N
plaque NN N
psoriasis NN N
. . N

-DOCSTART- -X- O O 8179563

gynaecological JJ 4_p
day-case NN 4_p
surgery NN 4_p
. . N

day-case JJ 4_p
gynaecological JJ 4_p
procedures NNS 4_p
was VBD N
evaluated VBN N
in IN N
55 CD 3_p
healthy JJ 4_p
volunteers NNS 4_p
in IN N
a DT N
single JJ N
blinded JJ N
fashion NN N
. . N

-DOCSTART- -X- O O 1815520

20 CD 3_p
healthy JJ 4_p
male NN 2_p
volunteers NNS N
. . N

One CD 3_p
subject NN N
was VBD N
identified VBN N
to TO N
be VB N
a DT N
poor JJ 4_p
metabolizer NN 4_p
. . N

-DOCSTART- -X- O O 8512622

adult NN 4_p
males NNS 4_p
. . 4_p

( ( 4_p
EEG NNP 4_p
) ) 4_p
activity NN 4_p
in IN 4_p
21 CD 4_p
healthy JJ 4_p
, , 4_p
adult JJ 4_p
males NNS 4_p
( ( 4_p
X NNP 4_p
= VBZ 4_p
22.7 CD 4_p
years NNS 4_p
) ) 4_p
. . 4_p

-DOCSTART- -X- O O 9713225

malignant JJ N
dysphagia NN N
. . N

Patients NNS N
with IN N
inoperable JJ N
carcinoma NN N
of IN N
the DT N
oesophagus NN N
Fourteen JJ 4_p
patients NNS 4_p
were VBD 4_p
randomised VBN 4_p
to TO 4_p
receive VB 4_p
laser NN 4_p
only RB 4_p
, , 4_p
and CC 4_p
12 CD 4_p
to TO 4_p
receive VB 4_p
laser NN 4_p
followed VBN 4_p
by IN 4_p
brachytherapy NN 4_p
. . 4_p

-DOCSTART- -X- O O 12663340

patients NNS N
with IN N
severe JJ 4_p
acute JJ 4_p
respiratory NN 4_p
distress JJ 4_p
syndrome NN 4_p
: : N
adult NN 1_p
patients NNS N
with IN N
acute JJ 4_p
respiratory NN 4_p
distress NN 4_p
syndrome NN 4_p
( ( 4_p
ARDS NNP 4_p
) ) 4_p
. . N

40 CD 3_p
ARDS NNP 4_p
patients NNS N
Patients NNS N
were VBD N
randomized VBN N
-DOCSTART- -X- O O 3675403

following VBG 4_p
cholecystectomy NN 4_p
. . 4_p

after IN 4_p
cholecystectomy NN 4_p
. . 4_p

-DOCSTART- -X- O O 26151440

siblings NNS N
of IN N
children NNS N
with IN N
special JJ 4_p
needs NNS 4_p
. . N

Siblings NNS N
of IN N
children NNS 1_p
with IN N
a DT N
disability NN 4_p
siblings NNS N
of IN N
children NNS N
with IN N
disabilities NNS 4_p
and CC 4_p
chronic JJ 4_p
health NN 4_p
conditions NNS 4_p
. . N

Fifty-six JJ 3_p
children NNS N
aged VBN 1_p
7-12 CD 1_p
-DOCSTART- -X- O O 25963425

metastatic JJ 4_p
colorectal JJ 4_p
cancer NN 4_p
. . 4_p

metastatic JJ 4_p
colorectal NN 4_p
cancer NN 4_p
( ( 4_p
mCRC NN 4_p
) ) 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
mCRC NN 4_p
patients NNS 4_p
with IN 4_p
mCRC NN 4_p
. . N

-DOCSTART- -X- O O 23381483

adults NNS 1_p
with IN N
autism NN 4_p
People NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
high-functioning JJ N
adults NNS 1_p
with IN N
ASD NNP 4_p
matched VBN N
controls NNS N
ASD NNP 4_p
adults NNS 1_p
adults NNS 1_p
with IN N
ASD NNP 4_p
. . N

adult NN 1_p
individuals NNS N
with IN N
ASD NNP 4_p
. . N

-DOCSTART- -X- O O 23360819

DiOGenes NNP 4_p
study NN 4_p
. . 4_p

overweight JJ 4_p
European JJ N
adults NNS N
participating VBG N
in IN N
the DT N
Diet NNP 4_p
Obesity NNP 4_p
and CC 4_p
Genes NNP 4_p
study NN 4_p
. . N

twenty-four JJ 3_p
candidate NN 3_p
genes NNS 3_p
were VBD 3_p
investigated VBN 3_p
-DOCSTART- -X- O O 22480794

hemodialysis NN 4_p
patients NNS N
: : N
hemodialysis NN 4_p
( ( 4_p
HD NNP 4_p
) ) 4_p
patients NNS N
. . N

HD NNP 4_p
patients NNS 4_p
. . 4_p

HD NNP 4_p
patients NNS N
undergoing JJ N
periprocedure NN N
bridging VBG N
anticoagulation NN 4_p
. . N

29 CD 3_p
eligible JJ N
and CC N
consenting VBG N
patients NNS N
in IN N
HD NNP N
patients NNS N
-DOCSTART- -X- O O 16452103

patients NNS 4_p
with IN 4_p
persistent JJ 4_p
arm NN 4_p
pain NN 4_p
. . 4_p

placebo NN N
controls NNS N
. . N

270 CD N
adults NNS N
with IN N
arm NN N
pain NN N
due JJ N
to TO N
repetitive VB N
use NN N
that WDT N
had VBD N
lasted VBN N
at IN N
least JJS N
three CD N
months NNS N
despite IN N
treatment NN N
and CC N
who WP N
scored VBD N
> NNP N
or CC N
=3 VBN N
on IN N
a DT N
10 CD N
point NN N
pain NN N
scale NN N
. . N

-DOCSTART- -X- O O 8179165

studied VBN N
in IN N
67 CD 3_p
patients NNS N
undergoing JJ N
colorectal JJ 4_p
surgery NN 4_p
under IN N
continuous JJ 4_p
epidural JJ 4_p
anaesthesia NN 4_p
and CC N
light JJ 4_p
general JJ 4_p
anaesthesia NN 4_p
using VBG N
propofol NN N
, , N
halothane NN N
, , N
and CC N
midazolam/fentanyl NN N
. . N

-DOCSTART- -X- O O 11319711

type NN 4_p
2 CD 4_p
diabetes NNS 4_p
: : 4_p
type VB 4_p
2 CD 4_p
diabetes NNS 4_p
subjects NNS 4_p
8 CD N
patients NNS N
, , N
5 CD N
of IN N
whom WP N
were VBD N
insulin-requiring JJ N
. . N

type NN N
2 CD N
diabetes NNS N
group NN N
normal JJ N
nondiabetic JJ N
subjects NNS N
-DOCSTART- -X- O O 8282676

Naltrexone NN N
in IN N
autistic JJ 4_p
children NNS 1_p
: : N
naltrexone NN N
in IN N
autistic JJ 4_p
children NNS 1_p
Forty-one CD 3_p
children NNS 1_p
, , N
all DT N
inpatients NNS 4_p
, , N
ages VBZ N
2.9 CD 1_p
to TO 1_p
7.8 CD 1_p
years NNS 1_p
, , N
completed VBD N
the DT N
study NN N
. . N

hyperactivity NN 4_p
children NNS N
with IN N
moderate JJ 4_p
to TO 4_p
severe VB 4_p
self-injurious JJ 4_p
behavior NN 4_p
. . N

-DOCSTART- -X- O O 22587862

community-living JJ N
older NN 1_p
persons NNS 1_p
: : N
-DOCSTART- -X- O O 15119720

Bitewing NNP N
film NN N
quality NN N
: : N
Four NNP N
bitewing VBG N
films NNS N
right NN N
and CC N
left VBD N
premolar JJ N
and CC N
molar JJ N
regions NNS N
of IN N
45 CD 3_p
dental JJ N
students NNS N
360 CD N
films NNS N
-DOCSTART- -X- O O 21802739

geriatric JJ 4_p
depression NN 4_p
Thirty-eight JJ 3_p
patients NNS N
treatment NN N
of IN N
late-life JJ 4_p
depression NN 4_p
. . N

A NNP N
small JJ N
and CC N
predominantly RB N
White NNP N
sample NN N
-DOCSTART- -X- O O 1857873

infusion NN 4_p
time NN 4_p
acute JJ 4_p
toxicity NN 4_p
of IN 4_p
amphotericin NN 4_p
B NNP 4_p
: : N
-DOCSTART- -X- O O 18215978

HIV-infected JJ 4_p
subjects NNS N
with IN N
prior JJ N
nucleoside JJ N
analog NN N
experience NN N
. . N

283 CD 3_p
nucleoside-experienced JJ N
HIV-infected JJ 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 3877292

20 CD 3_p
patients NNS 3_p
. . N

-DOCSTART- -X- O O 9532999

third JJ N
stage NN N
of IN N
labour NN N
. . N

20 CD 1_p
women NNS 1_p
randomly RB 1_p
allocated VBN 1_p
into IN 1_p
two CD 1_p
groups NNS 1_p
of IN 1_p
10 CD 1_p
. . 1_p

third JJ N
stage NN N
of IN N
labour JJ N
-DOCSTART- -X- O O 9751681

patients NNS N
with IN N
sick JJ 4_p
sinus NN 4_p
syndrome NN 4_p
. . N

patients NNS N
with IN N
sick JJ 4_p
sinus NN 4_p
syndrome NN 4_p
patients NNS N
with IN N
sick JJ 4_p
sinus NN 4_p
syndrome NN 4_p
. . N

Two CD 3_p
hundred VBD 3_p
twenty-five JJ 3_p
consecutive JJ N
patients NNS N
with IN N
sick JJ 4_p
sinus NN 4_p
syndrome NN 4_p
and CC N
intact JJ N
AV NNP N
conduction NN N
patients NNS N
patients NNS N
with IN N
sick JJ 4_p
sinus NN 4_p
syndrome NN 4_p
-DOCSTART- -X- O O 19958945

Patients NNPS N
undergoing VBG N
mini-incision JJ 4_p
thyroidectomy NN 4_p
under IN N
local JJ 4_p
anesthesia NN 4_p
Recruitment NNP N
led VBD N
to TO N
22 CD 3_p
patients NNS N
in IN N
group NN N
1 CD N
and CC N
25 CD 3_p
patients NNS N
in IN N
group NN N
2 CD N
. . N

-DOCSTART- -X- O O 26208985

children NNS 1_p
with IN N
autism NN 4_p
. . N

autistic JJ 4_p
disorder NN 4_p
( ( 4_p
AD NNP 4_p
) ) 4_p
44 CD 3_p
outpatients NNS N
of IN N
both DT 2_p
genders NNS 2_p
aged VBN N
4-12 CD 1_p
years NNS 1_p
with IN N
a DT N
diagnosis NN N
of IN N
AD NNP 4_p
and CC N
a DT N
score NN N
of IN N
≥12 NN N
on IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist-Community NNP N
( ( N
ABC-C NNP N
) ) N
irritability NN N
subscale NN N
were VBD N
included VBN N
groups NNS N
. . N

Twenty CD 3_p
patients NNS 3_p
-DOCSTART- -X- O O 26205311

valve JJ 4_p
replacement NN 4_p
surgery NN 4_p
. . 4_p

Patients NNPS 4_p
with IN 4_p
rheumatic JJ 4_p
heart NN 4_p
disease NN 4_p
undergoing VBG 4_p
valve JJ 4_p
replacement NN 4_p
surgery NN 4_p
-DOCSTART- -X- O O 11104595

severely RB N
malnourished VBN N
head NN 4_p
and CC 4_p
neck NN 4_p
cancer NN 4_p
patients NNS N
: : N
malnourished VBN N
head NN 4_p
and CC 4_p
neck NN 4_p
cancer NN 4_p
patients NNS N
undergoing VBG N
surgery NN N
. . N

49 CD 3_p
Malnourished NNP N
( ( N
weight JJ N
loss NN N
> VBZ N
10 CD N
% NN N
) ) N
head NN 4_p
and CC 4_p
neck NN 4_p
cancer NN 4_p
patients NNS N
who WP N
were VBD N
included VBN N
in IN N
a DT N
nutrition NN N
intervention NN N
trial NN N
patients NNS N
-DOCSTART- -X- O O 9394942

young JJ N
autistic JJ N
children NNS N
: : N
young JJ N
autistic JJ N
children NNS N
Eleven NNP 4_p
children NNS 4_p
with IN 4_p
autistic JJ 4_p
disorder NN 4_p
, , 4_p
aged VBD 4_p
3.0 CD 4_p
to TO 4_p
8.3 CD 4_p
years NNS 4_p
24 CD N
children NNS N
-DOCSTART- -X- O O 7851604

Women NNP 2_p
undergoing VBG N
controlled JJ N
ovarian JJ 4_p
stimulation NN 4_p
for IN N
assisted JJ N
conception NN N
-DOCSTART- -X- O O 15181401

patients NNS N
with IN N
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
. . N

University NNP N
Hospital NNP N
, , N
cardiac JJ N
surgical JJ N
operative NN N
theatre NN N
. . N

42 CD 3_p
patients NNS N
with IN N
coronary JJ N
artery NN N
disease NN N
, , N
scheduled VBN N
to TO N
undergo VB N
coronary JJ N
surgery NN N
. . N

INCLUSION NNP N
CRITERIA NNP N
severe JJ 4_p
coronary JJ 4_p
stenosis NN 4_p
of IN 4_p
anterior JJ 4_p
descending VBG 4_p
coronary JJ 4_p
artery NN 4_p
; : N
no DT 4_p
collateral NN 4_p
flow NN 4_p
on IN 4_p
angiography NN 4_p
; : N
at IN 4_p
least JJS 4_p
two CD 4_p
normokinetic JJ 4_p
segments NNS 4_p
in IN 4_p
the DT 4_p
myocardial JJ 4_p
region NN 4_p
supplied VBN 4_p
by IN 4_p
the DT 4_p
vessel NN 4_p
being VBG 4_p
bypassed VBN 4_p
. . N

-DOCSTART- -X- O O 22527308

blepharitis NN 4_p
of IN N
acute NN N
eyelid JJ N
diseases NNS N
like IN N
blepharitis NN N
in IN N
patients NNS N
diagnosed VBN N
with IN N
blepharitis NN N
this DT N
multi-center NN N
in IN N
197 CD N
patients NNS N
( ( N
ITT NNP N
( ( N
intention-to-treat-group JJ N
) ) N
; : N
mean JJ N
age NN N
56 CD N
± JJ N
18 CD N
years NNS N
, , N
56 CD N
% NN N
female NN N
, , N
active JJ N
drug NN N
: : N
vehicle NN N
= IN N
97:100 CD N
) ) N
-DOCSTART- -X- O O 24934732

nephrectomy NN 4_p
for IN 4_p
kidney NN 4_p
donation NN 4_p
. . 4_p

Our PRP$ N
center NN N
initiated VBD N
such PDT N
a DT N
trial NN N
in IN N
January NNP N
2011 CD N
, , N
following VBG N
subjects NNS N
randomized VBN N
to TO N
LESS-DN NNP N
versus NN N
LDN NNP N
from IN N
surgery NN N
through IN N
5 CD N
years NNS N
postdonation NN N
. . N

One CD 3_p
hundred JJ 3_p
subjects NNS N
( ( N
49 CD N
LESS-DN NNP N
, , N
51 CD N
LDN NNP N
) ) N
underwent NN N
surgery NN N
; : N
donor CC N
demographics NNS N
were VBD N
similar JJ N
between IN N
groups NNS N
, , N
and CC N
included VBD N
a DT N
predominance NN N
of IN N
female JJ N
, , N
living-unrelated JJ N
donors NNS N
, , N
mean JJ N
age NN N
of IN N
47 CD 1_p
years NNS 1_p
who WP N
underwent VBP N
left VBN N
donor JJ N
nephrectomy NN N
. . N

Operative JJ N
parameters NNS N
( ( N
overall JJ N
time NN N
, , N
time NN N
to TO N
extraction NN N
, , N
warm JJ N
ischemia NN 4_p
time NN N
, , N
blood NN 4_p
loss NN 4_p
) ) N
were VBD N
similar JJ N
between IN N
groups NNS N
. . N

-DOCSTART- -X- O O 8053586

craniotomy NN N
. . N

Thirty NNP N
patients NNS N
scheduled VBN N
for IN N
craniotomy NN N
were VBD N
assigned VBN N
to TO N
either VB N
a DT N
normothermic JJ N
or CC N
mildly RB N
hypothermic JJ N
group NN N
. . N

craniotomy NN N
-DOCSTART- -X- O O 11918753

human JJ 4_p
essential JJ 4_p
hypertension NN 4_p
. . 4_p

human JJ 4_p
subjects NNS 4_p
with IN 4_p
essential JJ 4_p
hypertension NN 4_p
. . 4_p

Twenty NNP N
male NN N
, , N
white JJ N
patients NNS N
( ( N
27 CD N
+/- JJ N
1 CD N
years NNS N
) ) N
with IN N
mild JJ N
essential JJ N
hypertension NN N
( ( N
143 CD N
+/- JJ N
11/95 CD N
+/- JJ N
6 CD N
mm NN N
Hg NNP N
) ) N
-DOCSTART- -X- O O 14514742

children NNS 1_p
undergoing VBG N
automated VBN 4_p
peritoneal JJ 4_p
dialysis NN 4_p
. . N

pediatric JJ 1_p
patients NNS N
undergoing VBG N
peritoneal JJ 4_p
dialysis NN 4_p
( ( N
PD NNP 4_p
) ) N
. . N

28 CD 3_p
children NNS 1_p
( ( N
age NN N
, , N
6 CD 1_p
mo NN 1_p
to TO 1_p
15 CD 1_p
yr NN 1_p
) ) N
undergoing NN N
automated VBN 4_p
PD NNP 4_p
( ( N
APD NNP 4_p
) ) N
. . N

children NNS 1_p
undergoing VBG N
APD NNP 4_p
-DOCSTART- -X- O O 22586827

Forty-five JJ 3_p
( ( N
45 CD 3_p
) ) N
female NN 2_p
subjects NNS N
, , N
between IN N
the DT N
ages NNS N
of IN N
18 CD 1_p
and CC 1_p
40 CD 1_p
years NNS 1_p
no-treatment JJ N
control NN N
, , N
the DT N
treatment-control NN N
( ( N
table JJ N
stabilization NN N
) ) N
, , N
and CC N
the DT N
experimental JJ N
( ( N
PostureJac NNP N
) ) N
group NN N
. . N

PostureJac NNP N
group NN N
no-treatment JJ N
control NN N
( ( N
p=.001 NN N
) ) N
and CC N
the DT N
treatment-control NN N
( ( N
p=.004 NN N
) ) N
groups NNS N
-DOCSTART- -X- O O 25187485

smoking VBG 4_p
cessation NN 4_p
42 CD 3_p
healthy JJ N
volunteers NNS N
of IN N
540 CD 3_p
smokers NNS 4_p
in IN N
smokers NNS 4_p
-DOCSTART- -X- O O 15482080

cocaine-abusing JJ 4_p
homeless JJ N
persons NNS N
: : N
cocaine-dependent JJ 4_p
homeless NN N
persons NNS N
who WP N
participated VBD N
in IN N
a DT N
clinical JJ N
trial NN N
that WDT N
compared VBN N
day NN N
treatment NN N
only RB N
( ( N
DT NNP N
, , N
n JJ N
= NNP N
69 CD 3_p
) ) N
with IN N
day NN N
treatment NN N
plus CC N
abstinent-contingent JJ N
housing NN N
and CC N
work NN N
( ( N
DT+ NNP N
, , N
n JJ N
= NNP N
72 CD 3_p
) ) 3_p
. . N

-DOCSTART- -X- O O 15449150

lung NN 4_p
adenocarcinoma NN 4_p
patients NNS 4_p
with IN 4_p
lung NN 4_p
adenocarcinoma NN 4_p
prospective JJ N
study NN N
on IN N
30 CD N
patients NNS N
with IN N
lung NN N
adenocarcinoma NN N
, , N
divided VBN N
into IN N
two CD N
groups NNS N
of IN N
15 CD N
patients NNS N
each DT N
. . N

-DOCSTART- -X- O O 24662027

cats NNS N
. . N

neutropenic JJ 4_p
animals NNS 4_p
. . N

FIV-infected NNP 4_p
( ( N
n=14 NN 3_p
) ) N
, , N
FIV-uninfected JJ 4_p
healthy JJ 4_p
cats NNS 4_p
( ( N
n=19 NN 3_p
) ) N
, , N
and CC N
in IN N
HuG-CSF-induced NNP N
neutropenic JJ N
cats NNS N
( ( N
n=4 NN N
) ) N
. . N

both DT N
FIV-uninfected JJ 4_p
and CC N
FIV-infected JJ 4_p
cats NNS 4_p
all DT N
HuG-CSF-treated JJ 4_p
cats NNS 4_p
in IN 4_p
feline JJ 4_p
patients NNS 4_p
-DOCSTART- -X- O O 8156515

remission NN N
induction NN N
therapy NN N
for IN N
acute JJ 4_p
leukemia NN 4_p
patients NNS N
undergoing JJ N
remission NN N
induction NN N
therapy NN N
for IN N
acute JJ 4_p
leukemia NN 4_p
. . N

Adults NNP N
with IN N
acute JJ N
leukemia NN N
undergoing VBG N
remission NN N
induction NN N
chemotherapy NN N
36 CD 3_p
patients NNS 3_p
41 CD 3_p
patients NNS 3_p
patients NNS N
undergoing JJ N
remission NN N
induction NN N
chemotherapy NN N
for IN N
acute JJ N
leukemia NN N
. . N

-DOCSTART- -X- O O 1889248

healthy JJ 4_p
subjects NNS N
who WP N
received VBD N
D53 NNP N
immunostimulant NN N
. . N

Twelve VB 3_p
nonsmoking VBG 4_p
healthy JJ 4_p
subjects NNS N
respiratory JJ 4_p
tract JJ 4_p
infection NN 4_p
. . N

-DOCSTART- -X- O O 22727707

clozapine-treated JJ N
patients NNS N
with IN N
schizophrenia NN 4_p
: : N
in IN N
clozapine-treated JJ N
patients NNS N
with IN N
schizophrenia NN N
trial NN N
, , N
clozapine-treated JJ N
patients NNS N
with IN N
schizophrenia NN N
eight CD N
. . N

Nineteen JJ N
patients NNS N
completed VBD N
the DT N
study NN N
the DT N
rosiglitazone NN N
group NN N
( ( N
n=9 CC N
) ) N
and CC N
the DT N
placebo NN N
group NN N
( ( N
n=10 RB N
) ) N
in IN N
clozapine-treated JJ N
patients NNS N
with IN N
schizophrenia NN N
in IN N
patients NNS N
with IN N
schizophrenia NN N
-DOCSTART- -X- O O 25519880

moderate JJ N
endemicity NN N
areas NNS N
in IN N
western JJ N
Côte NNP N
d'Ivoire NN N
: : N
the DT N
tropics NNS N
and CC N
subtropics NNS N
in IN N
four CD N
provinces NNS N
in IN N
western JJ N
Côte NNP N
d'Ivoire NN N
d'Ivoire NN N
. . N

A DT N
total NN 3_p
of IN 3_p
12,110 CD 3_p
children NNS 3_p
, , N
aged VBN 1_p
13-14 CD 1_p
years NNS 1_p
, , N
from IN N
264 CD N
villages NNS N
were VBD N
screened VBN N
for IN N
S. NNP N
mansoni NNP N
using VBG N
duplicate JJ N
Kato-Katz NNP 4_p
thick NN 4_p
smears NNS 4_p
from IN 4_p
single JJ 4_p
stool NN 4_p
samples NNS 4_p
. . N

Among IN N
the DT N
schools NNS N
with IN N
a DT N
S. NNP N
mansoni NN N
prevalence NN N
of IN N
10-24 JJ N
% NN N
, , N
75 CD N
schools NNS N
were VBD N
selected VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
treatment NN N
arms NNS N
. . N

In IN N
each DT N
school NN N
, , N
three CD N
stool NN N
samples NNS N
are VBP N
being VBG N
collected VBN N
from IN N
100 CD 3_p
children NNS 3_p
aged VBN 1_p
9-12 CD 1_p
years NNS 1_p
annually RB N
and CC N
one CD N
stool NN N
sample NN N
from IN N
100 CD 3_p
first-year JJ 3_p
students NNS 3_p
at IN N
baseline NN N
and CC N
in IN N
the DT N
final JJ N
year NN N
and CC N
subjected VBN N
to TO N
duplicate VB N
Kato-Katz NNP N
thick JJ N
smears NNS N
-DOCSTART- -X- O O 22066521

parenting NN 1_p
and CC 1_p
children NNS 1_p
: : N
Helping NNP N
HAND NNP N
. . N

children NNS 1_p
and CC N
parents NNS 1_p
5- JJ 1_p
to TO 1_p
8-year-old JJ 1_p
children NNS 1_p
in IN N
primary JJ N
care NN N
clinics NNS N
. . N

children NNS 1_p
with IN N
body NN 4_p
mass NN 4_p
index NN 4_p
85-99 CD N
% NN N
tile NN N
and CC N
their PRP$ N
parents NNS 1_p
. . N

Forty NNP 3_p
parent-child JJ 3_p
dyads NNS N
enrolled VBD N
: : N
82.5 CD N
% NN N
were VBD N
Hispanic NNP N
, , N
80 CD N
% NN N
had VBD N
a DT N
girl NN 2_p
and CC N
65 CD N
% NN N
reported VBD N
income NN N
≤ NNP N
$ $ N
30 CD N
, , N
000/year CD N
-DOCSTART- -X- O O 24089423

adults NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
: : N
adults NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
adults NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
and CC N
intelligence NN N
within IN N
the DT N
normal JJ N
range NN N
: : N
groups NNS 3_p
of IN 3_p
6-8 JJ 3_p
patients NNS 3_p
. . N

68 CD 3_p
psychiatric JJ N
patients NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
-DOCSTART- -X- O O 14550686

heroin NN 4_p
dependence NN 4_p
. . N

Western JJ N
countries NNS N
. . N

Twenty-five JJ 3_p
opioid-dependent JJ 4_p
patients NNS 4_p
on IN N
intravenous JJ N
( ( N
IV NNP N
) ) N
heroin NN N
or CC N
IV NNP N
methadone CD N
maintenance NN N
treatment NN N
16 CD 3_p
subjects NNS 3_p
-DOCSTART- -X- O O 11786587

Four NNP 3_p
hundred VBD 3_p
sixty-nine JJ 3_p
assessable JJ N
advanced JJ N
cancer NN N
patients NNS N
were VBD N
randomized VBN N
to TO N
( ( N
1 CD N
) ) N
oral JJ N
megestrol NN N
acetate VBP N
800 CD N
mg/d NN N
liquid NN N
suspension NN N
plus CC N
placebo NN N
, , N
( ( N
2 CD N
) ) N
oral JJ N
dronabinol $ N
2.5 CD N
mg NN N
twice RB N
a DT N
day NN N
plus CC N
placebo NN N
, , N
or CC N
( ( N
3 CD N
) ) N
both DT N
agents NNS N
. . N

Eligible JJ 4_p
patients NNS 4_p
acknowledged VBD 4_p
that IN 4_p
loss NN 4_p
of IN 4_p
appetite NN 4_p
or CC 4_p
weight NN 4_p
was VBD 4_p
a DT 4_p
problem NN 4_p
and CC 4_p
reported VBD 4_p
the DT 4_p
loss NN 4_p
of IN 4_p
5 CD 4_p
pounds NNS 4_p
or CC 4_p
more JJR 4_p
during IN 4_p
2 CD 4_p
months NNS 4_p
and/or IN 4_p
a DT 4_p
daily JJ 4_p
intake NN 4_p
of IN 4_p
less JJR 4_p
than IN 4_p
20 CD 4_p
calories/kg NN 4_p
of IN 4_p
body NN 4_p
weight NN 4_p
. . N

megestrol NN N
acetate-treated JJ N
patients NNS N
dronabinol-treated JJ N
patients NNS N
: : N
megestrol JJ N
acetate-treated JJ N
and CC N
combination-treated JJ N
patients NNS N
. . N

men NNS 2_p
who WP N
received VBD N
megestrol NN N
acetate NN N
. . N

advanced JJ N
cancer NN N
patients NNS N
-DOCSTART- -X- O O 19155827

Adults NNP N
with IN N
long-term JJ N
indwelling VBG N
catheters NNS N
that WDT N
required VBD N
changing VBG N
every DT N
3 CD N
weeks NNS N
or CC N
less JJR N
, , N
living NN N
in IN N
the DT N
community NN N
, , N
and CC N
requiring VBG N
supportive JJ N
or CC N
continuing VBG N
care NN N
were VBD N
recruited VBN N
. . N

One CD 1_p
hundred VBD 1_p
twelve VB 1_p
potential JJ 1_p
participants NNS 1_p
were VBD 1_p
screened VBN 1_p
; : 1_p
73 CD 1_p
were VBD 1_p
enrolled VBN 1_p
, , 1_p
randomized VBN 1_p
, , 1_p
and CC 1_p
included VBD 1_p
53 CD N
completed VBD N
16 CD N
terminated VBD N
early JJ N
-DOCSTART- -X- O O 17535502

informal JJ N
caregivers NNS N
of IN N
heart NN 4_p
failure NN 4_p
patients NNS 4_p
. . N

informal JJ N
caregivers NNS N
of IN N
patients NNS N
with IN N
heart NN N
failure NN N
. . N

60 CD 3_p
caregiver/patient NN 3_p
dyads NNS 3_p
in IN N
a DT N
cross-sectional JJ N
design NN N
. . N

Patients NNS 4_p
with IN 4_p
chronic JJ 4_p
stable JJ 4_p
heart NN 4_p
failure NN 4_p
were VBD N
recruited VBN N
from IN N
out-patient JJ N
clinics NNS N
. . N

informal JJ N
caregivers NNS N
of IN N
heart NN N
failure NN N
patients NNS N
. . N

-DOCSTART- -X- O O 7739439

treatment NN 4_p
of IN 4_p
bone NN 4_p
infections NNS 4_p
] NNP 4_p
33 CD 4_p
patients NNS 4_p
suffering VBG 4_p
from IN 4_p
osteomyelitis NN 4_p
. . 4_p

17 CD N
patients NNS N
, , N
a DT N
through IN N
drainage NN N
with IN N
sterile JJ N
physiologic JJ N
solution NN N
was VBD N
applied VBN N
, , N
while IN N
in IN N
the DT N
second JJ N
group NN N
, , N
16 CD N
patients NNS N
, , N
antibiotic JJ N
was VBD N
added VBN N
to TO N
the DT N
sterile JJ N
physiologic JJ N
solution NN N
. . N

-DOCSTART- -X- O O 25580916

in IN 4_p
autism NN 4_p
: : N
participants NNS 1_p
were VBD 1_p
referred VBN 1_p
outpatients NNS 1_p
between IN 1_p
4 CD 1_p
and CC 1_p
12 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
with IN N
the DT 4_p
diagnosis NN 4_p
of IN 4_p
ADs NNP 4_p
and CC N
a DT 4_p
score NN 4_p
of IN 4_p
more JJR 4_p
than IN 4_p
12 CD 4_p
on IN 4_p
Aberrant JJ 4_p
Behavior NNP 4_p
Checklist-Community NNP 4_p
( ( 4_p
ABC-C NNP 4_p
) ) 4_p
Irritability NNP 4_p
subscale NN 4_p
score NN 4_p
. . N

Forty NNP 3_p
patients NNS N
completed VBD N
the DT N
10-week JJ 3_p
trial NN N
. . N

-DOCSTART- -X- O O 8129324

55 CD N
premature NN N
infants NNS N
weighing VBG N
less JJR N
than IN N
1501 CD N
g NN N
at IN N
birth NN N
were VBD N
selected VBN N
randomly RB N
at IN N
their PRP$ N
initial JJ N
eye NN N
examination NN N
. . N

42 CD N
patients NNS N
. . N

premature JJ N
infants NNS N
. . N

-DOCSTART- -X- O O 24225475

patients NNS 4_p
with IN 4_p
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
: : 4_p
patients NNS N
with IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
( ( N
COPD NNP N
) ) N
patients NNS 4_p
with IN 4_p
COPD NNP 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
COPD NNP 4_p
. . 4_p

-DOCSTART- -X- O O 11323998

root JJ 4_p
canal JJ 4_p
filling NN 4_p
materials NNS N
for IN N
primary JJ 4_p
molars NNS 4_p
: : N
primary JJ 4_p
molars NNS 4_p
-DOCSTART- -X- O O 15304592

Huntington NNP 4_p
disease NN 4_p
. . N

Huntington NNP 4_p
disease NN 4_p
( ( N
HD NNP 4_p
) ) N
60 CD 3_p
HD NNP 4_p
patients NNS N
HD NNP 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 9672054

adults NNS N
with IN N
autistic JJ 4_p
disorder NN 4_p
and CC N
other JJ N
pervasive JJ N
developmental NN N
disorders NNS N
. . N

autism NN 4_p
. . 4_p

patients NNS N
with IN N
autism NN 4_p
. . N

Thirty-one CD 3_p
adults NNS 1_p
( ( N
age NN N
[ VBZ N
mean+/-SD JJ N
] NNP N
, , N
28.1+/-7.3 JJ N
years NNS N
) ) N
with IN N
autistic JJ 4_p
disorder NN 4_p
( ( N
n=17 JJ N
) ) N
or CC N
pervasive JJ N
developmental JJ N
disorder NN N
not RB N
otherwise RB N
specified VBN N
( ( N
n=14 JJ 3_p
) ) N
participated VBD N
in IN N
a DT N
12-week JJ N
double-blind NN N
, , N
placebo-controlled JJ N
trial NN N
of IN N
risperidone NN N
. . N

autism NN 4_p
in IN N
adults NNS 1_p
. . N

-DOCSTART- -X- O O 8338943

after IN 4_p
bone NN 4_p
marrow NN 4_p
transplantation NN 4_p
by IN 4_p
pentoxifylline NN 4_p
: : N
bone NN 4_p
marrow NN 4_p
transplantation NN 4_p
( ( 4_p
BMT NNP 4_p
) ) 4_p
. . 4_p

patients NNS N
undergoing JJ N
BMT NNP 4_p
. . N

140 CD 3_p
patients NNS N
undergoing VBG N
either CC N
allogeneic NN N
( ( N
n JJ N
= NNP N
51 CD 3_p
) ) N
or CC N
autologous JJ N
BMT NNP 4_p
( ( N
n JJ N
= NNP N
89 CD 3_p
) ) N
. . N

after IN N
BMT NNP 4_p
. . N

-DOCSTART- -X- O O 3447334

5-fluorouracil JJ 4_p
and CC 4_p
filtration NN 4_p
surgery NN 4_p
. . 4_p

postoperative JJ N
blebs NN N
5-FU JJ N
group NN N
. . N

-DOCSTART- -X- O O 10482855

Inhibition NN 4_p
of IN 4_p
the DT 4_p
seasonal JJ 4_p
IgE NNP 4_p
increase NN 4_p
to TO 4_p
Dactylis NNP 4_p
glomerata NNS 4_p
-DOCSTART- -X- O O 18837418

diffuse NN 4_p
lung NN 4_p
disease NN 4_p
. . N

diffuse NN 4_p
parenchymal JJ 4_p
lung NN 4_p
disease NN 4_p
( ( 4_p
DPLD NNP 4_p
) ) N
. . N

95 CD 3_p
patients NNS N
who WP N
underwent VBP N
fluoroscopy NN N
guided VBD N
TBLB NNP N
over IN N
a DT N
two CD N
year NN N
period NN N
. . N

Patients NNS N
with IN N
a DT N
lung NN 4_p
mass NN 4_p
or CC N
solitary JJ N
lung NN 4_p
nodule NN 4_p
undergoing VBG N
TBLB NNP N
were VBD N
excluded VBN N
. . N

patients NNS N
with IN N
DPLD NNP 4_p
74 CD 3_p
out IN N
of IN N
95 CD 3_p
patients NNS N
( ( N
78 CD 3_p
% NN 3_p
) ) N
Jumbo NNP N
forcep NN N
while IN N
the DT N
smaller JJR N
forcep NN N
was VBD N
diagnostic JJ N
in IN N
62 CD 3_p
out IN N
of IN N
95 CD 3_p
patients NNS N
( ( N
65 CD 3_p
% NN 3_p
) ) N
. . N

diffuse NN 4_p
infiltrative JJ 4_p
lung NN 4_p
disease NN 4_p
. . N

-DOCSTART- -X- O O 21785360

consent NN N
for IN N
data NNS N
sharing VBG N
in IN N
genome JJ 4_p
research NN 4_p
. . N

323 CD 3_p
eligible JJ N
adult NN 1_p
participants NNS N
being VBG N
recruited VBN N
into IN N
one CD N
of IN N
six CD N
genome JJ N
studies NNS N
at IN N
Baylor NNP N
College NNP N
of IN N
Medicine NNP N
in IN N
Houston NNP N
, , N
Texas NNP N
, , N
between IN N
January NNP N
2008 CD N
and CC N
August NNP N
2009 CD N
. . N

Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
experimental JJ N
consent NN N
documents NNS N
( ( N
traditional JJ N
, , N
n JJ N
= VBP N
110 CD 3_p
; : N
binary JJ N
, , N
n JJ N
= VBP N
103 CD N
; : N
and CC N
tiered VBD N
, , N
n JJ N
= NNP N
110 CD N
) ) N
. . N

-DOCSTART- -X- O O 25619686

Breast NNP 4_p
Cancer NNP 4_p
Radiation NNP N
Therapy NNP N
. . N

A NNP N
total NN N
of IN N
248 CD 3_p
patients NNS N
with IN N
breast JJ 4_p
cancer NN 4_p
Patients NNS N
-DOCSTART- -X- O O 7896655

young JJ 1_p
autistic JJ 4_p
children NNS 4_p
: : N
autism NN 4_p
. . 4_p

Thirteen NNP 3_p
children NNS N
with IN N
autistic JJ 4_p
disorder NN 4_p
, , N
aged VBD 1_p
3.4 CD 1_p
to TO 1_p
8.3 CD 1_p
years NNS 1_p
( ( N
mean VB N
5.4 CD N
) ) N
, , N
were VBD N
studied VBN N
in IN N
home NN N
, , N
school NN N
, , N
and CC N
outpatient JJ N
laboratory NN N
. . N

young JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
. . N

-DOCSTART- -X- O O 2374275

non-insulin-dependent JJ 4_p
diabetes NNS 4_p
mellitus NN 4_p
. . 4_p

dyslipidemic JJ 4_p
patients NNS 4_p
with IN 4_p
non-insulin-dependent JJ 4_p
diabetes NNS 4_p
mellitus VBP 4_p
, , 4_p
13 CD 4_p
patients NNS 4_p
were VBD 4_p
treated VBN 4_p
in IN 4_p
a DT 4_p
randomized JJ 4_p
crossover NN 4_p
trial NN 4_p
. . 4_p

patients NNS N
patients NNS N
with IN N
non-insulin-dependent JJ N
diabetes NNS N
mellitus NN N
. . N

-DOCSTART- -X- O O 1997878

Sinemet NNP 4_p
CR NNP 4_p
in IN 4_p
Parkinson NNP 4_p
's POS 4_p
disease NN 4_p
. . 4_p

-DOCSTART- -X- O O 384024

patients NNS N
with IN N
acute JJ 4_p
ureteral JJ 4_p
colic NN 4_p
. . N

81 CD 3_p
patients NNS N
with IN N
acute JJ 4_p
ureteral JJ 4_p
colic NN 4_p
and CC N
the DT N
confirmed JJ N
presence NN N
of IN N
a DT N
calculus NN N
. . N

randomized JJ N
double-blind JJ N
comparison NN N
of IN N
intramuscular JJ N
2 CD N
and CC N
4 CD N
mg. NN N
butorphanol NN N
and CC N
80 CD N
mg. NNS N
meperidine NN N
was VBD N
used VBN N
. . N

-DOCSTART- -X- O O 11098982

critically RB N
ill JJ N
patients NNS N
: : N
percutaneous JJ 4_p
dilational JJ 4_p
tracheostomy NN 4_p
( ( 4_p
PDT NNP 4_p
) ) 4_p
in IN N
critically RB N
ill JJ N
patients NNS N
. . N

Trauma NNP N
and CC N
general JJ N
intensive JJ N
care NN N
units NNS N
of IN N
a DT N
university NN N
tertiary JJ N
teaching NN N
hospital NN N
, , N
which WDT N
is VBZ N
also RB N
a DT N
level NN N
1 CD N
trauma NN N
center NN N
. . N

One CD N
hundred VBN N
critically RB N
ill JJ N
patients NNS N
with IN N
an DT N
indication NN N
for IN N
PDT NNP N
. . N

Patients NNPS N
experiencing VBG N
PDT NNP 4_p
patients NNS N
undergoing VBG N
PDT NNP N
percutaneous JJ 4_p
tracheostomy NN 4_p
in IN N
critically RB N
ill JJ N
patients NNS N
. . N

-DOCSTART- -X- O O 21445888

sheep JJ 4_p
fed NN 4_p
on IN 4_p
finger NN 4_p
millet NN 4_p
straw NN 4_p
( ( 4_p
Eleucine NNP 4_p
coracana NN 4_p
) ) 4_p
-based VBD 4_p
diet JJ 4_p
Nellore NNP 4_p
rams NNS 4_p
fed VBP 4_p
on IN 4_p
a DT 4_p
finger NN 4_p
millet NN 4_p
straw NN 4_p
( ( 4_p
FMS NNP 4_p
) ) 4_p
-based VBD 4_p
diet JJ 4_p
. . 4_p

Thirty-six JJ N
Nellore NNP N
sheep NN N
nutrients NNS N
in IN N
sheep JJ N
fed NN N
on IN N
an DT N
FMS-based JJ N
-DOCSTART- -X- O O 24012722

memory-based JJ 4_p
automaticity NN 4_p
: : 4_p
Participants NNS 4_p
-DOCSTART- -X- O O 26036434

postmenopausal JJ 4_p
women NNS 2_p
with IN N
osteopenia NN 4_p
: : N
81 CD 3_p
postmenopausal NN 4_p
osteopenic JJ 4_p
women NNS 2_p
to TO N
1-yr JJ N
nightly RB N
treatment NN 4_p
with IN 4_p
melatonin NN 4_p
1 CD 4_p
mg NN 4_p
( ( 4_p
N NNP 4_p
= NNP 4_p
20 CD 4_p
) ) 4_p
, , 4_p
3 CD 4_p
mg NN 4_p
( ( 4_p
N NNP 4_p
= NNP 4_p
20 CD 4_p
) ) 4_p
, , 4_p
or CC 4_p
placebo NN 4_p
( ( 4_p
N NNP 4_p
= NNP 4_p
41 CD 4_p
) ) 4_p
. . N

Mean NNP 1_p
age NN 1_p
of IN 1_p
the DT 1_p
study NN 1_p
subjects NNS 1_p
was VBD 1_p
63 CD 1_p
( ( 1_p
range VB 1_p
56-73 NNP 1_p
) ) 1_p
yr NN 1_p
. . N

-DOCSTART- -X- O O 15656360

Lasik NNP 4_p
surgery NN 4_p
] NN 4_p
conjunctival JJ 4_p
bleeding NN 4_p
during IN N
Lasik NNP N
surgery NN N
. . N

One CD 3_p
hundred VBN 3_p
cases NNS N
( ( N
200 CD N
eyes NNS N
) ) N
conjunctival JJ 4_p
bleeding NN 4_p
. . N

-DOCSTART- -X- O O 23828383

cervical JJ 4_p
cancer NN 4_p
patients NNS N
before IN N
and CC N
after IN N
treatment NN N
. . N

cervical JJ 4_p
cancer NN 4_p
patients NNS N
104 CD 3_p
cervical JJ 4_p
cancer NN 4_p
patients NNS N
selected VBN N
for IN N
the DT N
present JJ N
study NN N
, , N
54 CD 3_p
and CC N
50 CD 3_p
patients NNS N
were VBD N
treated VBN N
with IN N
chemo- JJ N
and CC N
radiotherapy NN N
respectively RB N
. . N

cervical JJ 4_p
cancer NN 4_p
patients NNS N
patients NNS N
treated VBN N
with IN N
chemotherapy NN 4_p
. . N

cervical JJ 4_p
cancer NN 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 12792318

Fifty-eight JJ N
patients NNS N
with IN N
posterior JJ N
benign NN N
paroxysmal JJ N
positional JJ N
vertigo NN N
-DOCSTART- -X- O O 23806094

skin NN 4_p
cancer NN 4_p
prevention NN N
for IN N
children NNS 1_p
: : N
family NN N
study NN N
. . N

parents NNS 1_p
and CC N
their PRP$ N
children NNS 1_p
Families NNS N
were VBD N
recruited VBN N
through IN N
schools NNS N
and CC N
community NN N
centers NNS N
and CC N
were VBD N
included VBN N
if IN N
there EX N
was VBD N
1 CD N
child NN N
in IN N
Grades NNP 4_p
1-3 JJ 4_p
at IN 4_p
moderate JJ 4_p
to TO 4_p
high JJ 4_p
risk NN 4_p
for IN 4_p
skin JJ 4_p
cancer NN 4_p
. . N

tailored JJ N
intervention NN N
, , N
in IN N
which WDT N
they PRP N
received VBD N
personalized JJ N
skin NN N
cancer NN N
education NN N
through IN N
the DT N
mail NN N
; : N
or CC N
a DT N
control NN N
group NN N
who WP N
received VBD N
generic JJ N
skin NN N
cancer NN N
information NN N
materials NNS N
. . N

Parents NNS N
Tailored VBN N
group NN N
participants NNS N
families NNS N
skin JJ N
cancer NN N
prevention NN N
practices NNS N
in IN N
young JJ 1_p
children NNS 1_p
. . N

-DOCSTART- -X- O O 21598839

proactive JJ N
learning NN N
in IN N
hypnosis NN 4_p
, , 4_p
post-hypnotic JJ 4_p
suggestion NN 4_p
, , 4_p
and CC 4_p
academic JJ 4_p
performance NN 4_p
. . 4_p

Participants NNS N
( ( N
N NNP N
= NNP N
56 CD 3_p
) ) N
control NN N
group NN N
treatment NN N
group NN N
. . N

-DOCSTART- -X- O O 1721246

patients NNS N
with IN N
cough NN 4_p
associated VBN 4_p
with IN 4_p
captopril NN 4_p
and CC 4_p
enalapril NN 4_p
. . N

10 CD 3_p
hypertensive JJ 4_p
patients NNS N
receiving VBG N
ACE NNP N
inhibitors NNS N
. . N

Of IN N
these DT N
patients NNS N
, , N
five CD 3_p
had VBD N
reported VBN N
cough NN 4_p
with IN N
ACE NNP N
inhibitors NNS N
. . N

BK NNP N
caused VBD N
cough NN N
at IN N
13.4 CD N
+/- JJ N
1.2 CD N
( ( N
-log NNP N
M NNP N
) ) N
in IN N
5 CD 3_p
patients NNS N
with IN N
cough NN N
associated VBN N
with IN N
ACE NNP N
inhibitors NNS N
, , N
but CC N
it PRP N
did VBD N
not RB N
cause VB N
cough NN N
at IN N
concentrations NNS N
up RB N
to TO N
10 CD N
( ( N
-5 NN N
) ) N
M NNP N
in IN N
other JJ N
5 CD 3_p
patients NNS N
. . N

5 CD 3_p
patients NNS N
were VBD N
free JJ N
from IN N
cough NN N
symptoms NNS N
, , N
and CC N
BK NNP N
did VBD N
not RB N
cause VB N
cough NN N
up RB N
to TO N
10 CD N
( ( N
-5 NN N
) ) N
M NNP N
in IN N
these DT N
patients NNS N
, , N
except IN N
for IN N
one CD N
who WP N
coughed VBD N
at IN N
10 CD N
( ( N
-9 NN N
) ) N
M NNP N
hypertensive JJ N
patients NNS N
receiving VBG N
ACE NNP N
inhibitors NNS N
. . N

-DOCSTART- -X- O O 14616279

urinary JJ N
incontinent NN N
elderly JJ N
women NNS N
. . N

elderly JJ N
women NNS N
urinary JJ N
incontinence NN N
in IN N
elderly JJ N
women NNS N
. . N

Postmenopausal NNP N
women NNS N
( ( N
age NN N
65 CD N
years NNS N
or CC N
older JJR N
) ) N
Twenty-four JJ N
women NNS N
treated VBN N
with IN N
ES NNP N
and CC N
11 CD N
women NNS N
treated VBN N
with IN N
Kegel NNP N
exercises NNS N
elderly JJ N
women NNS N
-DOCSTART- -X- O O 18054932

Sixty-one CD 3_p
patients NNS N
-DOCSTART- -X- O O 12823129

asthmatic JJ 4_p
children NNS N
. . N

asthmatic JJ 4_p
children NNS N
One CD N
hundred CD N
and CC N
fifty-five JJ N
children NNS N
were VBD N
investigated VBN N
, , N
122 CD N
of IN N
them PRP N
asthmatic JJ N
and CC N
33 CD N
nonallergic NN N
. . N

Japanese JJ N
children NNS N
childhood NN N
asthma NN N
-DOCSTART- -X- O O 24840596

children NNS N
with IN N
autism NN 4_p
. . N

children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) N
. . N

two CD N
groups NNS N
of IN N
children NNS 1_p
, , N
matched VBD N
according VBG N
to TO N
age NN N
, , N
sex NN N
and CC N
mean JJ N
length NN N
of IN N
utterance NN N
-DOCSTART- -X- O O 20683712

vitamin JJ 4_p
D-deficient JJ 4_p
non-western JJ N
immigrants NNS N
: : N
non-western JJ N
immigrants NNS N
. . N

trial NN N
in IN N
11 CD N
general JJ N
practices NNS N
in IN N
The DT N
Netherlands NNP N
. . N

Non-western JJ N
immigrants NNS N
, , N
aged VBN N
18-65 CD N
years NNS N
( ( N
n JJ N
= NNP N
232 CD N
) ) N
and CC N
serum $ N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
< $ N
25 CD N
analysis NN N
included VBD N
treating VBG N
vitamin NN N
D NNP N
deficiency NN N
in IN N
-DOCSTART- -X- O O 15477567

Effects NNS N
of IN N
brain-penetrating JJ 4_p
ACE NNP 4_p
inhibitors NNS 4_p
on IN N
Alzheimer NNP 4_p
disease NN 4_p
progression NN N
. . N

-DOCSTART- -X- O O 8780429

geriatric JJ 4_p
depression NN 4_p
. . 4_p

elderly JJ 4_p
patients NNS 4_p
with IN 4_p
depression NN 4_p
and CC 4_p
in IN 4_p
normal JJ 4_p
subjects NNS 4_p
Two CD N
established VBD N
hyperintensity NN N
rating NN N
systems NNS N
MRI NNP N
brain NN N
scans NNS N
of IN N
48 CD N
elderly JJ N
patients NNS N
with IN N
depression NN N
diagnosed VBN N
according VBG N
to TO N
DSM-III-R NNP N
with IN N
the DT N
scans NNS N
of IN N
39 CD N
normal JJ N
elderly JJ N
subjects NNS N
. . N

Elderly NNP N
depressed VBD N
patients NNS N
-DOCSTART- -X- O O 1358607

ASA NNP 4_p
Class NNP 4_p
I-III NNP 4_p
female JJ 2_p
patients NNS 4_p
about IN 4_p
to TO 4_p
undergo VB 4_p
major JJ 4_p
abdominal JJ 4_p
gynaecological JJ 4_p
surgery NN 4_p
or CC 4_p
vaginal JJ 4_p
hysterectomy NN 4_p
. . N

-DOCSTART- -X- O O 1697487

speech NN 4_p
therapy NN 4_p
. . N

-DOCSTART- -X- O O 9950438

stage NN 4_p
II NNP 4_p
and CC 4_p
stage NN 4_p
III NNP 4_p
human JJ 4_p
colon NN 4_p
cancer NN 4_p
: : N
254 CD 3_p
patients NNS N
with IN N
colon NN N
cancer NN N
were VBD N
randomly RB N
assigned VBN N
postoperative JJ N
ASI NNP N
or CC N
no DT N
adjuvant JJ N
treatment NN N
. . N

patients NNS N
with IN N
stage NN N
II NNP N
disease NN N
stage NN N
II NNP N
colon NN N
cancer NN N
. . N

-DOCSTART- -X- O O 1904908

bulimia NN 4_p
nervosa NN 4_p
Ninety-one CD N
female JJ N
bulimic JJ 4_p
outpatients NNS N
depressed JJ 4_p
and CC 4_p
nondepressed JJ 4_p
Sixty-eight JJ 3_p
patients NNS N
who WP N
completed VBD N
the DT N
study NN N
-DOCSTART- -X- O O 18672629

adults NNS N
in IN N
adults NNS N
46 CD N
adults NNS N
ASA NNP N
I-II NNP N
, , N
undergoing VBG N
elective JJ N
gynecological NN N
or CC N
general JJ N
surgery NN N
with IN N
balanced JJ N
general JJ N
anesthesia NN N
-DOCSTART- -X- O O 17224353

chronic JJ 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
Sixty-one CD 4_p
patients NNS 4_p
( ( 4_p
mean JJ 4_p
age NN 4_p
, , 4_p
41 CD 4_p
years NNS 4_p
) ) 4_p
with IN 4_p
nonspecific JJ 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
were VBD 4_p
randomized VBN 4_p
patients NNS N
with IN N
chronic JJ N
low JJ N
back RB N
pain NN N
. . N

-DOCSTART- -X- O O 21618513

colorectal JJ 4_p
adenoma NN 4_p
recurrence NN 4_p
colorectal JJ 4_p
neoplasms NNS 4_p
in IN N
some DT N
human JJ N
studies NNS N
. . N

1,859 CD N
participants NNS N
of IN N
the DT N
Polyp NNP N
Prevention NNP N
Trial NNP N
. . N

in IN N
women NNS 2_p
. . 2_p

-DOCSTART- -X- O O 16870004

twelve NN 3_p
healthy JJ 4_p
, , N
consenting VBG N
subjects NNS N
-DOCSTART- -X- O O 9751554

military JJ N
paratroopers NNS 4_p
' POS N
Army NNP N
paratrooper IN N
training NN N
. . N

777 CD 4_p
volunteers NNS N
from IN N
the DT N
U.S. NNP N
Army NNP N
Airborne NNP N
School NNP N
, , N
Fort NNP N
Benning NNP N
, , N
Ga. NNP N
745 CD 4_p
completed VBD N
all DT N
study NN N
requirements NNS N
( ( N
369 CD 4_p
brace-wearers NNS 4_p
and CC N
376 CD 4_p
non-brace-wearers NNS 4_p
) ) N
. . N

during IN N
parachute JJ N
training NN N
-DOCSTART- -X- O O 6850464

humans NNS N
. . N

a DT N
randomized JJ N
study NN N
of IN N
patients NNS N
with IN N
gastric JJ N
, , N
pancreatic JJ N
and CC N
colorectal JJ N
cancer NN N
a DT N
randomized JJ N
study NN N
of IN N
patients NNS N
with IN N
resectable JJ N
cancer NN N
of IN N
the DT N
colon NN N
of IN N
patients NNS N
with IN N
malignant JJ N
melanoma NN N
and CC N
stage NN N
IV NNP N
carcinoma NN N
of IN N
the DT N
breast NN N
of IN N
patients NNS N
with IN N
advanced JJ N
gastrointestinal JJ N
cancer NN N
selective JJ N
stimulation NN N
of IN N
the DT N
immune NN N
system NN N
with IN N
NED NNP N
137 CD N
-DOCSTART- -X- O O 12492271

soleus JJ 4_p
Thirty NNP 4_p
subjects NNS 4_p
activity NN N
and CC N
rehabilitation NN N
. . N

-DOCSTART- -X- O O 9855086

patients NNS N
with IN N
peptic JJ 4_p
ulcer NN 4_p
bleeding NN 4_p
: : N
Twelve NNP N
Helicobacter NNP 4_p
pylori NN 4_p
( ( 4_p
+ NNP 4_p
) ) 4_p
patients NNS 4_p
and CC N
12 CD N
H. NNP 4_p
pylori NN 4_p
( ( 4_p
- : 4_p
) ) 4_p
subjects NNS 4_p
were VBD N
included VBN N
. . N

peptic JJ 4_p
ulcer NN 4_p
bleeding NN 4_p
-DOCSTART- -X- O O 8435382

patients NNS N
with IN N
cirrhosis NN 4_p
and CC 4_p
ascites NNS 4_p
. . N

seven CD 3_p
patients NNS N
with IN N
cirrhosis NN 4_p
and CC 4_p
tense NN 4_p
ascites NNS 4_p
. . N

Patients NNS N
patients NNS N
with IN N
cirrhosis NN 4_p
and CC 4_p
ascites NNS 4_p
. . N

-DOCSTART- -X- O O 17491486

periodontal JJ 4_p
disease NN 4_p
and CC N
the DT N
risk NN N
of IN N
preterm JJ N
birth NN N
. . N

-DOCSTART- -X- O O 16730541

150 CD N
consecutive JJ N
adult NN N
patients NNS N
undergoing VBG N
tonsillectomy NN N
. . N

Indications NNS N
included VBD N
chronic JJ 4_p
tonsillitis NN 4_p
and CC N
obstructive JJ 4_p
sleep NN 4_p
apnea NN 4_p
syndrome NN 4_p
. . 4_p

Exclusion NN N
criteria NNS N
included VBD N
peritonsillar JJ 4_p
abscess NN 4_p
history NN N
, , N
bleeding VBG 4_p
disorders NNS 4_p
, , N
and CC N
any DT N
other JJ N
procedure NN N
together RB N
with IN N
tonsillectomy NN 4_p
. . N

-DOCSTART- -X- O O 22683613

patients NNS N
with IN N
multiple JJ 4_p
myeloma NNS 4_p
and CC N
low JJ 4_p
peripheral JJ 4_p
blood NN 4_p
CD34 NNP 4_p
( ( 4_p
+ NNP 4_p
) ) 4_p
cell NN 4_p
count NN 4_p
: : N
patients NNS N
with IN N
multiple JJ 4_p
myeloma NN 4_p
. . N

patients NNS N
with IN N
multiple JJ 4_p
myeloma NN 4_p
, , N
stratified VBN 4_p
by IN 4_p
preapheresis NN 4_p
PB NNP 4_p
CD34 NNP 4_p
( ( 4_p
+ NNP 4_p
) ) 4_p
cell NN 4_p
count NN 4_p
: : 4_p
< JJ 4_p
10 CD 4_p
, , 4_p
< FW 4_p
15 CD 4_p
, , 4_p
< FW 4_p
20 CD 4_p
, , 4_p
and CC 4_p
≥20 NNP 4_p
cells/μL NN 4_p
-DOCSTART- -X- O O 24027014

colorectal JJ 4_p
cancer NN 4_p
screening VBG 4_p
among IN N
Iranian JJ N
health NN N
club NN N
members NNS 3_p
: : N
Twelve NNP 3_p
health NN N
clubs NNS N
of IN N
a DT N
municipal JJ N
district NN N
in IN N
Tehran NNP N
were VBD N
randomized VBN N
A DT N
total NN 3_p
of IN 3_p
360 CD 3_p
members NNS 3_p
aged VBN 1_p
50 CD 1_p
and CC 1_p
older JJR 1_p
from IN N
12 CD 3_p
health NN N
clubs NNS N
completed VBD N
a DT N
baseline NN N
survey NN N
. . N

-DOCSTART- -X- O O 2494948

for IN N
patients NNS N
with IN N
noncuratively RB 4_p
resected VBN 4_p
colorectal JJ 4_p
carcinoma NN 4_p
54 CD 3_p
institutions NNS 4_p
in IN 4_p
the DT 4_p
Kyushu NNP 4_p
and CC 4_p
Chugoku NNP 4_p
areas NNS 4_p
of IN 4_p
Japan NNP 4_p
. . N

The DT N
criteria NNS N
for IN N
patient JJ N
selection NN N
were VBD N
as IN N
follows VBZ N
: : N
1 CD N
) ) N
Age NNP 1_p
of IN 1_p
75 CD 1_p
years NNS N
or CC N
less JJR N
and CC N
not RB N
accompanied VBN N
by IN N
any DT N
serious JJ N
disease NN N
. . N

2 CD N
) ) N
Macroscopic NNP N
diagnosis NN N
as IN N
being VBG N
noncuratively RB N
resected VBN N
on IN N
completion NN N
of IN N
the DT N
surgical JJ N
procedure NN N
. . N

3 CD N
) ) N
Definitive JJ N
diagnosis NN N
of IN N
colorectal JJ 4_p
carcinomas NN 4_p
, , N
histologically RB N
. . N

4 CD N
) ) N
No DT N
synchronous JJ N
or CC N
metachronous JJ N
double JJ N
cancer NN N
. . N

MMC NNP N
group NN N
-DOCSTART- -X- O O 18397386

patients NNS N
with IN N
HCV NNP 4_p
genotype NN 4_p
1 CD 4_p
infection NN 4_p
treated VBN N
with IN N
peginterferon NN N
alpha-2a JJ N
plus CC N
ribavirin JJ N
. . N

patients NNS N
with IN N
chronic JJ 4_p
hepatitis NN 4_p
C NNP 4_p
treatment-naive JJ N
patients NNS N
with IN N
HCV NNP 4_p
genotype NN 4_p
1 CD 4_p
infection NN 4_p
enrolled VBN N
in IN N
a DT N
large JJ N
expanded JJ N
access NN N
programme NN N
. . N

Eight NNP 3_p
hundred VBD 3_p
and CC 3_p
ninety-one JJ 3_p
patients NNS N
treated VBD N
for IN N
48 CD N
weeks NNS N
with IN N
an DT N
initial JJ N
ribavirin NN N
dose NN N
of IN N
800 CD N
or CC N
1000/1200 CD N
mg/day NNS N
genotype JJ N
1 CD N
patients NNS N
. . N

-DOCSTART- -X- O O 12748567

benign VB N
paroxysmal JJ N
positional JJ N
vertigo NN N
in IN N
the DT N
elderly JJ N
. . N

benign JJ N
positional JJ N
paroxysmal NN N
vertigo NN N
( ( N
BPPV NNP N
) ) N
in IN N
elderly JJ N
persons NNS N
. . N

Forty-seven JJ N
patients NNS N
( ( N
> JJ N
/=70 CD N
years NNS N
old JJ N
) ) N
with IN N
the DT N
diagnosis NN N
of IN N
unilateral JJ N
posterior JJ N
semicircular JJ N
canal NN N
BPPV NNP N
BPPV NNP N
in IN N
the DT N
elderly JJ N
. . N

-DOCSTART- -X- O O 7859140

zidovudine NN 4_p
( ( 4_p
AZT NNP 4_p
) ) 4_p
-treated VBD 4_p
asymptomatic JJ 4_p
HIV-infected JJ 4_p
subjects NNS 4_p
with IN 4_p
200-500 JJ 4_p
CD4 NNP 4_p
cells/mm3 NN 4_p
: : N
zidovudine NN N
( ( N
AZT NNP N
) ) N
-treated VBD N
asymptomatic JJ N
human JJ 4_p
immunodeficiency NN 4_p
virus NN 4_p
( ( 4_p
HIV NNP 4_p
) ) 4_p
-infected VBD 4_p
subjects NNS N
with IN N
200-500 JJ N
CD4 NNP N
cells/mm3 NN N
at IN N
entry NN N
. . N

352 CD 3_p
subjects NNS N
were VBD N
prestratified VBN N
by IN N
prior JJ N
AZT NNP N
use NN N
-DOCSTART- -X- O O 25286703

facet JJ 4_p
joint NN 4_p
related VBD 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
] NN 4_p
facet-joint NN 4_p
related VBN 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
. . N

20 CD 3_p
patients NNS N
with IN N
facet-joint JJ 4_p
pain NN 4_p
-DOCSTART- -X- O O 9894936

recurrent JJ 4_p
herpetic JJ 4_p
ocular JJ 4_p
infection NN 4_p
. . 4_p

Twenty NNP N
patients NNS N
with IN N
herpes NNS N
simplex JJ N
virus IN N
1-related JJ N
recurrent NN N
keratitis/keratouveitis NN N
-DOCSTART- -X- O O 15055365

children NNS 1_p
with IN 4_p
and CC 4_p
without IN 4_p
autism NN 4_p
. . N

children NNS N
with IN N
and CC N
without IN N
autism NN N
Children NNP N
with IN N
autism NN N
and CC N
typically RB N
developed JJ N
children NNS N
participated VBN N
Children NNP N
with IN N
autism NN N
typically RB N
developed JJ N
children NNS N
children NNS N
with IN N
autism NN N
children NNS N
with IN N
autism NN N
. . N

-DOCSTART- -X- O O 18686184

study NN N
enrolled VBD N
263 CD 3_p
healthy JJ 4_p
smokers NNS 4_p
( ( N
M NNP N
( ( N
age NN N
) ) N
= VBZ N
49 CD 1_p
years NNS N
) ) N
who WP 4_p
smoked VBD 4_p
a DT 4_p
mean NN 4_p
of IN 4_p
24 CD 4_p
cigarettes/day NN 4_p
, , 4_p
with IN 4_p
a DT 4_p
mean NN 4_p
of IN 4_p
31 CD 4_p
pack-years NNS 4_p
. . N

-DOCSTART- -X- O O 15608043

caudal JJ N
route NN N
in IN N
children NNS N
. . N

children NNS N
. . N

Ninety-nine JJ 3_p
ASA NNP N
I-II NNP N
children NNS N
less JJR 1_p
than IN 1_p
10 CD 1_p
yr JJ N
old JJ N
scheduled VBN N
for IN N
elective JJ N
sub-umbilical JJ 4_p
surgery NN 4_p
-DOCSTART- -X- O O 24113340

children NNS 1_p
showing VBG N
low-functioning JJ N
autism NN 4_p
. . N

children NNS 4_p
with IN 4_p
low-functioning JJ 4_p
autism NN 4_p
children NNS 1_p
with IN N
autism NN 4_p
-DOCSTART- -X- O O 3287907

postoperative JJ N
pain NN N
. . N

moderate JJ N
or CC N
severe JJ N
postoperative JJ N
pain NN N
. . N

A DT N
final JJ N
patient NN N
population NN N
of IN N
149 CD N
subjects NNS N
Sixty CD N
patients NNS N
patients NNS N
with IN N
postoperative JJ N
pain NN N
. . N

-DOCSTART- -X- O O 25450124

depressed JJ 4_p
spinal JJ 4_p
cord NN 4_p
injury NN 4_p
trial NN N
participants NNS N
. . N

people NNS N
with IN N
spinal JJ 4_p
cord NN 4_p
injury NN 4_p
( ( 4_p
SCI NNP 4_p
) ) 4_p
diagnosed VBD N
with IN N
major JJ 4_p
depressive JJ 4_p
disorder NN 4_p
( ( 4_p
MDD NNP 4_p
) ) N
Of IN N
the DT N
133 CD 3_p
persons NNS N
who WP N
were VBD N
randomized VBN N
into IN N
the DT N
Project NN N
to TO N
Improve VB N
Symptoms NNP N
and CC N
Mood NNP N
after IN N
Spinal NNP 4_p
Cord NNP 4_p
Injury NNP 4_p
randomized VBD N
controlled VBN N
trial NN N
, , N
124 CD 3_p
participated VBN N
in IN N
this DT N
study NN N
. . N

All DT N
participants NNS N
were VBD N
between IN N
the DT N
ages NNS N
of IN N
18 CD 1_p
and CC N
64 CD 1_p
years NNS N
, , N
at IN N
least JJS N
1 CD N
month NN N
post-SCI NN N
, , N
met VBD N
the DT N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
4th CD N
edition NN N
, , N
criteria NNS N
for IN N
MDD NNP N
, , N
and CC N
completed VBD N
the DT N
core NN N
measures NNS N
used VBN N
in IN N
this DT N
study NN N
. . N

participants NNS N
' POS N
trial NN N
participants NNS N
. . N

participants NNS N
' POS N
those DT N
with IN N
incomplete JJ 4_p
injuries NNS 4_p
. . N

people NNS N
with IN N
SCI NNP 4_p
. . N

-DOCSTART- -X- O O 19564877

obese JJ 4_p
subjects NNS N
. . N

69 CD 3_p
obese JJ 3_p
healthy JJ 3_p
adults NNS 3_p
received VBD N
a DT N
hypocaloric JJ 4_p
diet NN 4_p
well-selected JJ N
population NN N
. . N

-DOCSTART- -X- O O 9761783

healthy JJ N
men NNS 2_p
and CC N
women NNS 2_p
from IN N
five CD N
European JJ N
countries NNS N
: : N
France NNP N
, , N
Ireland NNP N
, , N
The DT N
Netherlands NNP N
, , N
Spain NNP N
, , N
and CC N
the DT N
U.K NNP N
. . N

Volunteers NNS N
, , N
aged VBD N
25 CD 1_p
45 CD 1_p
, , N
all DT N
nonsmokers NNS N
-DOCSTART- -X- O O 26135372

Patients NNP N
with IN N
Juvenile NNP 1_p
Idiopathic NNP 4_p
Arthritis NNP 4_p
: : N
A DT N
Randomized NNP N
Controlled NNP N
Trial NNP N
. . N

patients NNS N
with IN N
juvenile JJ 1_p
idiopathic JJ 4_p
arthritis NN 4_p
. . N

30 CD 3_p
children NNS 1_p
with IN N
polyarticular JJ 4_p
juvenile NN 4_p
idiopathic JJ 4_p
arthritis NN 4_p
patients NNS N
with IN N
juvenile JJ 1_p
idiopathic JJ 4_p
arthritis NN 4_p
. . N

-DOCSTART- -X- O O 9405728

after IN 4_p
GnRH NNP 4_p
agonist NN 4_p
treatment NN 4_p
. . 4_p

hormone NN 4_p
replacement NN 4_p
therapy NN 4_p
28 CD N
patients NNS N
treated VBD N
for IN N
6 CD N
months NNS N
with IN N
a DT N
GnRH NNP N
agonist NN N
. . N

postmenopausal JJ N
women NNS N
with IN N
high JJ N
bone NN N
turnover NN N
treated VBN N
with IN N
HRT NNP N
. . N

women NNS N
with IN N
ovarian JJ N
deficiency NN N
. . N

-DOCSTART- -X- O O 11422660

type NN 4_p
2 CD 4_p
diabetic JJ 4_p
patients NNS 4_p
Six NNP N
male NN N
and CC N
female JJ N
type NN N
2 CD N
diabetic JJ N
patients NNS N
[ JJ N
DM2 NNP N
; : N
age NN N
54 CD N
+/- JJ N
10 CD N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
years NNS N
; : N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
25.6 CD N
+/- JJ N
2.9 CD N
kg NN N
m NN N
( ( N
-2 NNP N
) ) N
] NN N
treated VBN N
with IN N
diet JJ N
or CC N
one CD N
oral JJ N
hypoglycaemic JJ N
agent NN N
and CC N
six CD N
age- JJ N
and CC N
BMI-matched JJ N
control NN N
subjects NNS N
( ( N
Ctr NNP N
) ) N
. . N

-DOCSTART- -X- O O 8832526

II NNP 4_p
type NN 4_p
mixed JJ 4_p
essential JJ 4_p
cryoglobulinemia NN 4_p
. . 4_p

Thirty-three JJ N
patients NNS N
with IN N
II NNP N
type NN N
mixed JJ N
essential JJ N
cryoglobulinemia NN N
( ( N
MEC NNP N
) ) N
were VBD N
randomized VBN N
II NNP N
type NN N
mixed JJ N
essential JJ N
cryoglobulinemia NN N
. . N

-DOCSTART- -X- O O 23095369

WHO NNP 4_p
type VBP 4_p
I PRP 4_p
anovulation VBP 4_p
infertility NN 4_p
: : N
women NNS 2_p
with IN N
HH NNP N
. . N

35 CD 3_p
HH NNP N
women NNS 2_p
( ( N
aged VBN N
25-36 CD N
yr NN N
) ) N
attending VBG N
our PRP$ N
Center NNP N
. . N

Eighteen JJ 3_p
patients NNS N
received VBD N
150 CD N
IU NNP N
hMG-HP NN N
( ( N
150 CD N
IU NNP N
FSH NNP N
+ VBD N
150 CD N
IU NNP N
LH-like NNP N
activity NN N
) ) N
and CC N
seventeen JJ 3_p
received VBD N
150IU CD N
r-hFSH/75IU JJ N
rhLH NNS N
development NN N
in IN N
HH NNP N
-DOCSTART- -X- O O 12704402

hyperinsulinemic JJ 4_p
subjects NNS 4_p
. . 4_p

subjects NNS N
with IN N
hyperinsulinemia NN 4_p
. . N

A DT N
total NN N
of IN N
36 CD 3_p
obese JJ 4_p
nondiabetic JJ N
volunteers NNS N
with IN N
hyperinsulinemia NN 4_p
( ( N
10 CD 3_p
males/26 NN 2_p
females NNS 2_p
, , N
aged VBD N
34-65 JJ 1_p
y NN N
, , N
BMI NNP N
28-43 CD N
kg/m NN N
( ( N
2 CD N
) ) N
, , N
fasting VBG N
insulin JJ N
12-45 JJ N
mU/l NN N
) ) N
. . N

subjects NNS N
with IN N
hyperinsulinemia PDT 4_p
-DOCSTART- -X- O O 7643653

assessment NN N
of IN N
catheter-tip JJ 4_p
PO2 NNP N
sensor NN N
: : N
standard JJ N
catheters NNS 4_p
catheter NN 4_p
surface NN N
. . N

success NN N
rate NN N
for IN N
catheter NN 4_p
insertion NN N
is VBZ N
57 CD N
% NN N
for IN N
138 CD 3_p
standard NN 3_p
and CC N
50 CD N
% NN N
for IN N
74 CD 3_p
laser-cut JJ 3_p
catheters NNS 4_p
studied VBN N
. . N

-DOCSTART- -X- O O 11343038

children NNS 1_p
with IN N
autism NN 4_p
. . N

children NNS 1_p
with IN N
autism NN 4_p
. . 4_p

Sixty NNP 3_p
subjects VBZ N
with IN N
autism NN 4_p
-DOCSTART- -X- O O 11140546

heavier JJR N
women NNS 2_p
heavier JJR N
women NNS 2_p
women NNS 2_p
with IN N
anemia NN 4_p
due JJ N
to TO N
bleeding VBG 4_p
from IN N
uterine JJ 4_p
leiomyomata NN 4_p
. . N

Patients NNS N
were VBD N
divided VBN N
into IN N
weight NN N
quartiles NNS N
according VBG N
to TO N
their PRP$ N
baseline NN N
weight NN N
in IN N
kilograms NNS N
: : N
46- JJ N
< NN N
64 CD N
, , N
64- JJ N
< NN N
72 CD N
, , N
72- JJ N
< NN N
89 CD N
, , N
89-159 JJ N
( ( N
pounds-102- JJ N
< NN N
140 CD N
, , N
140- JJ N
< NN N
159 CD N
, , N
159- JJ N
< NN N
196 CD N
, , N
196-350 JJ N
) ) N
. . N

Heavier NNP N
women NNS 2_p
-DOCSTART- -X- O O 17631392

patients NNS N
with IN N
osteoarthritis NN 4_p
. . N

osteoarthritis NN 4_p
( ( 4_p
OA NNP 4_p
) ) 4_p
of IN 4_p
the DT 4_p
hip NN 4_p
and CC 4_p
knee NN 4_p
. . N

548 CD 3_p
patients NNS 3_p
( ( N
median JJ N
age NN N
63 CD N
years NNS N
) ) N
with IN N
OA NNP 4_p
of IN 4_p
the DT 4_p
hip NN 4_p
or CC 4_p
knee NN 4_p
were VBD N
randomized VBN N
OA NNP 4_p
of IN 4_p
the DT 4_p
hip NN 4_p
and CC 4_p
knee NN 4_p
. . N

-DOCSTART- -X- O O 1751081

39 CD N
patients NNS N
being VBG N
treated VBN N
with IN N
high JJ N
flux JJ N
dialysis NN N
. . N

patients NNS N
being VBG N
maintained VBN N
on IN N
high JJ N
flux JJ N
dialysis NN N
. . N

-DOCSTART- -X- O O 11159256

complex JJ 4_p
regional JJ 4_p
pain NN 4_p
syndrome NN 4_p
I PRP N
patients NNS N
pretreated VBN 4_p
with IN 4_p
spinal JJ 4_p
cord NN 4_p
stimulation NN 4_p
: : N
Forty-three JJ 3_p
patients NNS N
with IN N
peripheral JJ 4_p
neuropathic JJ 4_p
pain NN 4_p
, , N
exclusively RB N
pain NN 4_p
reduced VBN 4_p
by IN 4_p
spinal JJ 4_p
cord NN 4_p
stimulation NN 4_p
( ( 4_p
SCS NNP 4_p
) ) 4_p
, , N
were VBD N
switched VBN N
into IN N
a DT N
painful JJ 4_p
state NN 4_p
after IN 4_p
SCS NNP 4_p
inactivation NN 4_p
. . N

-DOCSTART- -X- O O 16386890

patients NNS N
treated VBN N
in IN N
the DT N
CHART NNP N
trial NN N
of IN N
accelerated JJ N
radiotherapy NN N
in IN N
head NN N
and CC N
neck NN N
cancer NN N
. . N

402 CD N
patients NNS N
-DOCSTART- -X- O O 4025245

nonclient JJ N
school NN N
population NN N
undergoing VBG N
mass NN N
inoculation NN N
against IN N
rubella NN N
. . N

Fifty-one CD N
girls NNS N
-DOCSTART- -X- O O 8015776

drainage NN N
of IN N
subretinal JJ 4_p
fluid NN 4_p
: : N
50 CD 3_p
consecutive JJ N
eyes NNS N
-DOCSTART- -X- O O 3557014

duodenal JJ 4_p
ulcer NN 4_p
283 CD 3_p
patients NNS N
with IN N
active JJ N
duodenal JJ 4_p
ulcer NN 4_p
to TO N
compare VB N
possible JJ N
factors NNS N
that WDT N
may MD N
affect VB N
healing NN N
and CC N
relapse NN N
in IN N
patients NNS N
treated VBN N
with IN N
a DT N
potent JJ N
antisecretory NN 4_p
agent NN 4_p
, , 4_p
cimetidine NN 4_p
, , 4_p
or CC N
a DT N
site-protective JJ 4_p
and CC 4_p
cytoprotective JJ 4_p
agent NN 4_p
, , N
sucralfate NN N
. . N

both DT N
groups NNS N
patients NNS N
with IN N
healed JJ N
ulcers NNS 4_p
, , N
238 CD 3_p
participated VBN N
patients NNS N
-DOCSTART- -X- O O 25533997

non-comorbid JJ N
boys NNS 2_p
with IN N
ADHD NNP 4_p
and CC N
with IN N
ASD NNP 4_p
. . N

Age-matched JJ N
boys NNS 2_p
with IN N
ADHD NNP 4_p
( ( N
18 CD N
) ) N
, , N
ASD NNP 4_p
( ( N
19 CD N
) ) N
and CC N
healthy JJ 4_p
controls NNS 4_p
( ( N
25 CD N
) ) N
ASD NNP 4_p
boys VBZ 2_p
ADHD NNP 4_p
boys VBZ 2_p
-DOCSTART- -X- O O 10568568

patients NNS N
with IN N
severe JJ N
Raynaud NNP N
's POS N
syndrome NN N
: : N
Patients NNPS N
with IN N
Raynaud NNP N
's POS N
syndrome NN N
healthy JJ N
volunteers NNS N
and CC N
patients NNS N
with IN N
primary JJ N
Raynaud NNP N
's POS N
syndrome NN N
. . N

20 CD N
patients NNS N
with IN N
severe JJ N
Raynaud NNP N
's POS N
syndrome NN N
, , N
and CC N
ten RB N
healthy JJ N
volunteers NNS N
. . N

primary JJ N
Raynaud NNP N
's POS N
syndrome NN N
-DOCSTART- -X- O O 25296247

postcraniotomy NN N
emergence NN 4_p
hypertension NN 4_p
: : N
hypertension NN 4_p
after IN N
craniotomy NN N
Fifty-two JJ 3_p
subjects NNS 3_p
brain NN N
tumor NN N
resection NN N
( ( N
40 CD 3_p
subjects NNS N
finally RB N
analyzed VBN N
) ) N
. . N

those DT N
patients NNS N
carrying VBG N
a DT N
preoperative JJ N
diagnosis NN N
of IN N
hypertension NN 4_p
-DOCSTART- -X- O O 16603337

young JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
. . N

Children NNP 1_p
with IN N
autism NN 4_p
three CD 3_p
young JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
and CC N
their PRP$ N
mothers NNS N
. . N

young JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
parents NNS N
. . N

-DOCSTART- -X- O O 21484217

mandibular JJ 4_p
third JJ 4_p
molar JJ 4_p
surgery NN 4_p
. . N

mandibular JJ 4_p
third JJ 4_p
molar JJ 4_p
surgery NN 4_p
. . N

Twenty NNP 3_p
healthy JJ N
patients NNS N
with IN 4_p
bilateral JJ 4_p
, , 4_p
symmetrically RB 4_p
impacted JJ 4_p
mandibular JJ 4_p
third JJ 4_p
molars NNS 4_p
-DOCSTART- -X- O O 11396751

children NNS 4_p
undergoing VBG 4_p
genitourinary JJ 4_p
surgery NN 4_p
. . 4_p

children NNS N
undergoing VBG N
genitourinary JJ N
surgery NN N
Thirty NNP N
children NNS N
, , N
aged VBD N
2 CD N
to TO N
8 CD N
years NNS N
, , N
scheduled VBN N
for IN N
genitourinary JJ N
surgery NN N
-DOCSTART- -X- O O 7620474

anorexia JJ 4_p
nervosa NN 4_p
. . N

anorexia JJ 4_p
nervosa NN 4_p
29 CD 3_p
inpatients NNS N
. . N

both DT 4_p
groups NNS N
cisapride NN 4_p
group NN N
; : N
cisapride NN 4_p
group NN N
-DOCSTART- -X- O O 16299669

fleas NNS 4_p
on IN N
cats NNS 4_p
. . N

cats NNS N
Eighty NNP 3_p
cats NNS N
were VBD N
randomly RB N
allocated VBN N
Kansas NNP 4_p
1 CD 4_p
flea NN 4_p
strain NN N
. . N

cats NN N
cats NNS N
-DOCSTART- -X- O O 8640699

postmenopausal NN 4_p
patients NNS N
with IN N
metastatic JJ 4_p
breast NN 4_p
carcinoma NN 4_p
: : N
Breast NNP 4_p
cancer NN 4_p
patients NNS N
with IN 4_p
prior JJ 4_p
response NN 4_p
to TO 4_p
endocrine VB 4_p
therapy NN 4_p
post NN N
menopausal NN N
patients NNS N
who WP N
had VBD N
disease NN N
progression NN N
after IN N
receiving VBG N
antiestrogen NN N
therapy NN N
either DT N
for IN N
metastatic JJ N
disease NN N
or CC N
as IN N
adjuvant JJ N
therapy NN N
. . N

In IN N
2 CD N
multiinstitutional JJ N
prospective JJ N
trials NNS N
, , N
683 CD 3_p
postmenopausal NN N
patients NNS N
postmenopausal NN 4_p
patients NNS N
with IN N
metastatic JJ 4_p
breast NN 4_p
carcinoma NN 4_p
-DOCSTART- -X- O O 22989921

psychosis NN 4_p
first JJ 4_p
episode NN 4_p
psychosis NN 4_p
. . N

untreated JJ N
psychosis NN N
( ( N
DUP NNP N
) ) N
First NNP N
Episode NNP N
Psychosis NNP N
( ( N
FEP NNP N
) ) N
patients NNS N
Seventy-seven NNP 3_p
consecutively RB N
admitted VBD N
, , N
drug-naïve JJ N
patients NNS N
with IN N
FEP NNP N
of IN N
untreated JJ N
negative JJ N
symptoms NNS N
( ( N
DUNS NNP N
) ) N
or CC N
a DT N
short JJ N
duration NN N
of IN N
untreated JJ N
positive JJ N
symptoms NNS N
( ( N
DUPS NNP N
) ) N
of IN N
FEP NNP N
patients NNS N
-DOCSTART- -X- O O 18561117

502 CD 3_p
adults NNS N
with IN N
seasonal JJ 4_p
allergic JJ 4_p
rhinitis NN 4_p
of IN N
at IN N
least JJS N
2 CD N
years NNS N
' POS N
duration NN N
. . N

patients NNS N
underwent VBP N
between IN N
one CD N
and CC N
five CD N
priming NN N
sessions NNS N
with IN N
exposure NN N
to TO N
3,500 CD N
grains/m NN N
( ( N
3 CD N
) ) N
( ( N
+/-500 JJ N
) ) N
of IN N
ragweed NN N
pollen NN N
in IN N
an DT N
environmental JJ N
exposure NN N
chamber NN N
. . N

Patients NNS N
-DOCSTART- -X- O O 8436638

periodontal JJ 4_p
infections NNS 4_p
with IN 4_p
systemic JJ 4_p
antimicrobial JJ 4_p
agents NNS 4_p
Patients NNS N
who WP N
had VBD N
high JJ 4_p
proportions NNS 4_p
of IN 4_p
spirochetes NNS 4_p
, , 4_p
i.e. FW 4_p
> FW 4_p
20 CD 4_p
% NN 4_p
, , 4_p
in IN 4_p
plaques NNS 4_p
removed VBN 4_p
from IN 4_p
diseased JJ 4_p
periodontal NN 4_p
sites NNS 4_p
18 CD 3_p
patients NNS N
-DOCSTART- -X- O O 24628747

acute JJ 4_p
extremity NN 4_p
pain NN 4_p
after IN N
emergency NN N
department NN N
discharge NN N
. . N

patients NNS N
discharged VBN N
from IN N
the DT N
emergency NN N
department NN N
( ( N
ED NNP N
) ) N
. . N

patients NNS N
with IN N
acute JJ 4_p
extremity NN 4_p
pain NN 4_p
who WP N
were VBD N
discharged VBN N
home NN N
from IN N
the DT N
ED NNP N
-DOCSTART- -X- O O 24761456

emergency NN N
physicians NNS N
( ( N
EPs NNP N
) ) N
Ninety-five JJ 3_p
physicians NNS N
were VBD N
randomized VBN N
. . N

Eighty-two JJ 3_p
physicians NNS N
completed VBD N
the DT N
experiment NN N
, , N
for IN N
a DT N
response NN N
rate NN N
of IN N
86 CD N
% NN N
. . N

Physicians NNPS N
-DOCSTART- -X- O O 12085177

patients NNS N
with IN N
advanced JJ 4_p
gastric JJ 4_p
cancer NN 4_p
: : N
patients NNS N
with IN N
non-resectable JJ 4_p
gastric JJ 4_p
and CC 4_p
gastro-oesophageal JJ 4_p
adenocarcinoma NN 4_p
. . N

Three CD 3_p
hundred VBD 3_p
and CC 3_p
sixty-nine JJ 3_p
patients NNS N
with IN N
histological JJ 4_p
proof NN 4_p
of IN 4_p
adenocarcinoma NN 4_p
, , N
who WP N
had VBD N
received VBN N
no RB N
more RBR N
than IN N
a DT N
single JJ N
regimen NN N
of IN N
5-fluorouracil-based JJ N
chemotherapy NN N
pre-defined JJ N
sub-group NN N
of IN N
123 CD 3_p
patients NNS N
who WP N
had VBD N
received VBN N
prior RB N
chemotherapy NN N
patients NNS N
who WP N
had VBD N
previously RB N
received VBN N
chemotherapy NN N
. . N

-DOCSTART- -X- O O 25934164

levonorgestrel NN 4_p
intrauterine JJ 4_p
contraceptive NN 4_p
( ( 4_p
LNG20 NNP 4_p
) ) 4_p
Nulliparous NNP N
and CC N
parous JJ N
women NNS 2_p
aged VBN N
16-45 JJ 1_p
years NNS 1_p
at IN N
enrollment NN N
with IN N
regular JJ N
menstrual JJ N
cycles NNS N
and CC N
requesting VBG N
contraception NN N
were VBD N
enrolled VBN N
in IN N
an DT N
open-label JJ N
Women NNP 2_p
aged VBD N
36-45 CD 1_p
years NNS N
received VBD N
LNG20 NNP N
for IN N
safety NN N
evaluation NN N
only RB N
. . N

total NN N
of IN N
1600 CD 3_p
women NNS 2_p
aged VBN 1_p
16-35 CD 1_p
years NNS 1_p
and CC N
151 CD 3_p
women NNS 2_p
aged VBN 1_p
36-45 CD 1_p
years NNS 1_p
agreed VBD N
to TO N
LNG20 NNP N
placement NN N
, , N
including VBG N
1011 CD N
( ( N
57.7 CD N
% NN N
) ) N
nulliparous JJ N
and CC N
438 CD 3_p
( ( N
25.1 CD N
% NN N
) ) N
obese JJ N
women NNS 2_p
. . N

Successful JJ N
placement NN N
occurred VBD N
in IN N
1714 CD 3_p
( ( N
97.9 CD N
% NN N
) ) N
women NNS 2_p
. . N

Six NNP N
pregnancies NNS N
occurred VBD N
, , N
four CD N
of IN N
which WDT N
were VBD N
ectopic NNS N
. . N

women NNS 2_p
who WP N
discontinued VBD N
LNG20 NNP N
and CC N
desired VBD N
pregnancy NN N
10 CD N
( ( N
0.6 CD N
% NN N
) ) N
women NNS 2_p
. . N

26 CD N
( ( N
1.5 CD N
% NN N
) ) N
LNG20 NNP N
nulliparous JJ N
and CC N
parous JJ N
women NNS 2_p
. . N

-DOCSTART- -X- O O 11207836

septic JJ 4_p
shock NN 4_p
. . N

older JJR 1_p
people NNS N
septic JJ 4_p
shock NN 4_p
patients NNS N
. . N

Patients NNPS N
with IN N
septic JJ 4_p
shock NN 4_p
who WP N
were VBD N
enrolled VBN N
in IN N
the DT N
placebo NN N
limb NN N
of IN N
the DT N
North JJ N
American JJ N
Sepsis NNP N
Trial NNP N
( ( N
NORASEPT NNP N
II NNP N
) ) N
Nine NNP 3_p
hundred VBD 3_p
and CC 3_p
thirty JJ 3_p
patients NNS N
presenting VBG N
to TO N
hospital VB N
within IN N
12 CD N
hours NNS N
of IN N
the DT N
onset NN N
of IN N
septic JJ 4_p
shock NN 4_p
. . N

population NN N
was VBD N
broken VBN N
down RP N
into IN N
five CD N
age NN N
groups NNS N
as IN N
follows VBZ N
: : N
less JJR 1_p
than IN 1_p
50 CD 1_p
years NNS 1_p
( ( N
group NN N
one CD N
) ) N
, , N
50 CD 1_p
to TO 1_p
64 CD 1_p
years NNS 1_p
( ( N
group NN N
two CD N
) ) N
, , N
65 CD 1_p
to TO 1_p
74 CD 1_p
years NNS 1_p
( ( N
group NN N
three CD N
) ) N
, , N
75 CD 1_p
to TO 1_p
84 CD 1_p
years NNS 1_p
( ( N
group NN N
four CD N
) ) N
, , N
and CC N
85 CD 1_p
or CC 1_p
older JJR 1_p
( ( N
group NN N
five CD N
) ) N
. . N

930 CD 3_p
patients NNS N
. . N

patients NNS N
' POS N
mean JJ N
age NN N
( ( N
+/- JJ N
SD NNP N
) ) N
was VBD N
59 CD 1_p
+/- JJ 1_p
17 CD 1_p
years NNS 1_p
( ( N
range NN N
, , N
18 CD N
to TO N
102 CD N
) ) N
. . N

280 CD 3_p
patients NNS N
in IN N
group NN N
one CD N
, , N
242 CD 3_p
in IN N
group NN N
two CD N
, , N
210 CD 3_p
in IN N
group NN N
three CD N
, , N
150 CD 3_p
in IN N
group NN N
four CD N
, , N
and CC N
48 CD 3_p
in IN N
group NN N
five CD N
. . N

-DOCSTART- -X- O O 1548248

autism NN 4_p
. . N

Autistic JJ 4_p
individuals NNS N
often RB N
exhibit VBP N
hyperarousal JJ 4_p
behaviors NNS 4_p
( ( N
e.g. NN N
stereotyped VBD N
body NN N
movements NNS N
, , N
self-stimulation NN N
, , N
hypervigilance NN N
, , N
and CC N
hyperactivity NN N
) ) N
hyperarousal JJ 4_p
behaviors NNS N
associated VBN N
with IN N
autism NN 4_p
. . N

nine CD 3_p
autistic JJ 4_p
males NNS N
( ( N
aged VBN N
5 CD N
to TO N
33 CD N
years NNS N
) ) N
. . N

some DT N
autistic JJ 4_p
subjects NNS N
. . N

larger JJR N
autistic JJ 4_p
population NN N
-DOCSTART- -X- O O 25323335

hypoxemic JJ 4_p
COPD NNP 4_p
patients NNS 4_p
: : 4_p
METHODS NNP N
Forty-three JJ 3_p
patients NNS 3_p
with IN N
severe JJ N
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
( ( N
COPD NNP N
, , N
age NN 1_p
60 CD 1_p
± JJ 1_p
9 CD 1_p
years NNS 1_p
, , N
FEV1 NNP N
37 CD N
± VBD N
16 CD N
% NN N
pred VBN N
. . N

) ) N
and CC N
indications NNS N
for IN N
LTOT NNP N
were VBD N
recruited VBN N
during IN N
pulmonary JJ N
rehabilitation NN N
for IN N
this DT N
cross-over NN N
study NN N
exercise NN N
in IN N
patients NNS N
with IN N
severe JJ N
-DOCSTART- -X- O O 12505565

patients NNS N
with IN N
chronic JJ N
kidney NN N
disease NN N
patients NNS N
with IN N
mild JJ N
renal JJ N
impairment NN N
patients NNS N
who WP N
underwent VBP N
percutaneous JJ N
coronary JJ N
intervention NN N
( ( N
PCI NNP N
) ) N
. . N

patients NNS N
enrolled VBN N
in IN N
the DT N
Enhanced NNP N
Suppression NNP N
of IN N
the DT N
Platelet NNP N
IIb/IIIa NNP N
Receptor NNP N
with IN N
Integrilin NNP N
Therapy NNP N
( ( N
ESPRIT NNP N
) ) N
trial NN N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
placebo VB N
or CC N
eptifibatide VB N
Patients NNS N
with IN N
CrCl NNP N
< NNP N
60 CD N
ml/min NN N
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
older JJR N
, , N
women NNS N
patients NNS N
with IN N
mild JJ N
renal JJ N
impairment NN N
. . N

-DOCSTART- -X- O O 24660272

treatment NN N
of IN N
periodontitis NN 4_p
: : N
subjects NNS N
with IN N
chronic JJ 4_p
periodontitis NN 4_p
30 CD 3_p
subjects NNS N
with IN N
moderate JJ N
to TO N
advanced JJ N
periodontitis NN 4_p
13 CD 3_p
test NN 3_p
and CC N
15 CD 3_p
control NN 3_p
subjects NNS N
subjects NNS N
with IN N
moderate JJ N
to TO N
advanced JJ N
periodontitis NN 4_p
. . N

-DOCSTART- -X- O O 23905378

rheumatoid JJ N
arthritis NN N
patients NNS N
of IN N
Shen NNP N
deficiency NN N
and CC N
cold JJ N
invading NN N
syndrome NN N
by IN N
RA NNP N
patients NNS N
of IN N
Shen NNP N
deficiency NN N
and CC N
cold JJ N
invading NN N
syndrome NN N
in IN N
the DT N
treatment NN N
group NN N
( ( N
120 CD N
cases NNS N
) ) N
were VBD N
treated VBN N
with IN N
BQZD NNP N
and CC N
MTX NNP N
( ( N
10 CD N
mg/week NN N
) ) N
control NN N
group NN N
( ( N
120 CD N
cases NNS N
) ) N
were VBD N
treated VBN N
with IN N
MTX NNP N
( ( N
10 CD N
mg/week NN N
) ) N
alone RB N
. . N

RA NNP N
patients NNS N
of IN N
Shen NNP N
deficiency NN N
and CC N
cold JJ N
invading NN N
syndrome NN N
. . N

-DOCSTART- -X- O O 8752181

228 CD 3_p
patients NNS N
( ( N
development NN N
set VBN N
) ) N
with IN N
symptoms NNS N
compatible JJ N
with IN N
AMI NNP 4_p
and CC N
tested VBN N
in IN N
a DT N
similar JJ N
group NN N
of IN N
223 CD 3_p
patients NNS N
( ( N
test NN N
set VBN N
) ) N
from IN N
the DT N
Thrombolysis NNP N
and CC N
Angioplasty NNP N
in IN N
Myocardial NNP N
Infarction NNP N
( ( N
TAMI-5 NNP N
) ) N
Trial NNP N
. . N

-DOCSTART- -X- O O 22967497

paroxysmal JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
-- : 4_p
a DT 4_p
atrial JJ N
fibrillation NN N
Eligible JJ N
patients NNS N
will MD N
present VB N
AF NNP N
lasting VBG N
less JJR N
than IN N
43 CD N
hours NNS N
, , N
will MD N
be VB N
in IN N
stable JJ N
cardio-pulmonary JJ N
condition NN N
and CC N
will MD N
have VB N
no DT N
prior JJ N
history NN N
of IN N
advanced JJ N
heart NN N
failure NN N
or CC N
significant JJ N
valvular JJ N
disease NN N
. . N

sample JJ N
size NN N
of IN N
80 CD N
patients NNS N
was VBD N
calculated VBN N
-DOCSTART- -X- O O 22511135

adults NNS 4_p
with IN 4_p
acute JJ 4_p
respiratory NN 4_p
distress NN 4_p
syndrome NN 4_p
. . 4_p

Sixteen NNP 4_p
consecutive JJ 4_p
patients NNS 4_p
within IN 4_p
the DT 4_p
first JJ 4_p
48 CD 4_p
hrs NN 4_p
of IN 4_p
mainly RB 4_p
pulmonary JJ 4_p
acute NN 4_p
respiratory NN 4_p
distress JJ 4_p
syndrome NN 4_p
. . 4_p

In IN N
patients NNS N
with IN N
mainly RB N
pulmonary JJ N
acute NN N
respiratory NN N
distress NN N
syndrome NN N
-DOCSTART- -X- O O 24599830

patients NNS 4_p
with IN 4_p
chronic JJ 4_p
kidney NN 4_p
disease NN 4_p
. . N

patients NNS 4_p
with IN 4_p
chronic JJ 4_p
kidney NN 4_p
disease NN 4_p
( ( N
CKD NNP 4_p
) ) N
not RB N
on IN N
dialysis NN N
non-dialysis JJ 4_p
CKD NNP 4_p
patients NNS 4_p
. . N

subgroup NN N
of IN N
patients NNS N
from IN N
a DT N
study NN N
that WDT N
evaluated VBD N
the DT N
impact NN N
of IN N
two CD N
phosphorus NN N
binder NN N
regimens NNS N
on IN N
hard JJ N
outcomes NNS N
in IN N
CKD NNP N
. . N

Patients NNS N
( ( N
n JJ N
= NNP N
113 CD 3_p
) ) N
with IN N
stage NN N
3-4 JJ N
CKD NNP N
and CC N
evidence NN N
of IN N
CAC NNP 4_p
on IN N
a DT N
phosphorus-restricted JJ N
diet NN N
CKD NNP 4_p
patients NNS N
-DOCSTART- -X- O O 15642753

low-income JJ N
African JJ N
American JJ N
families NNS N
of IN N
young JJ N
children NNS 1_p
with IN N
asthma NN 4_p
. . N

Of IN N
55 CD 3_p
families NNS N
, , N
71 CD 3_p
% NN 3_p
completed VBD N
the DT N
program NN N
low-income JJ N
families NNS N
-DOCSTART- -X- O O 9267377

UTI NNP 4_p
-DOCSTART- -X- O O 8323420

dependent NN 4_p
and CC 4_p
nondependent JJ 4_p
harmful JJ 4_p
drinkers NNS 4_p
. . 4_p

patients NNS N
with IN N
dependent JJ N
or CC N
harmful JJ N
drinking NN N
behaviors NNS N
. . N

83 CD N
first- JJ N
, , N
second- JJ N
, , N
and CC N
third-year JJ N
medical JJ N
residents NNS N
to TO N
receive VB N
or CC N
not RB N
to TO N
receive VB N
diagnostic JJ N
information NN N
and CC N
counseling VBG N
directives NNS N
on IN N
214 CD N
patients NNS N
who WP N
reported VBD N
at IN N
least JJS N
one CD N
symptom NN N
of IN N
alcohol NN N
impairment NN N
as IN N
defined VBN N
in IN N
the DT N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
Third NNP N
Edition NNP N
. . N

female JJ N
patients NNS N
, , N
patients NNS N
with IN N
inactive JJ N
disorders NNS N
, , N
and CC N
nondependent NN N
but CC N
harmful JJ N
drinkers NNS N
. . N

-DOCSTART- -X- O O 20304413

severely JJ 1_p
obese JJ 1_p
adolescents NNS 1_p
. . 1_p

severely RB 1_p
obese JJ 1_p
adolescents NNS 1_p
. . 1_p

Forty-six JJ 3_p
subjects NNS N
( ( N
24 CD 3_p
HPLC NNP N
, , N
22 CD 3_p
in IN N
low JJ N
fat NN N
) ) N
initiated VBD N
and CC N
33 CD 3_p
subjects NNS N
completed VBD N
the DT N
intervention NN N
; : N
severely JJ 1_p
obese JJ 1_p
adolescents NNS 1_p
. . 1_p

-DOCSTART- -X- O O 17171539

anxiety NN 4_p
disorders NNS 4_p
in IN N
children NNS 1_p
with IN N
high JJ 4_p
functioning VBG 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
: : N
47 CD 3_p
children NNS 1_p
with IN N
comorbid NN N
anxiety NN N
disorders NNS N
and CC N
High NNP 4_p
Functioning NNP 4_p
Autism NNP 4_p
Spectrum NNP 4_p
Disorder NNP 4_p
( ( 4_p
HFA NNP 4_p
) ) N
HFA NNP N
children NNS 1_p
-DOCSTART- -X- O O 11554235

children NNS 1_p
receiving VBG N
combined JJ N
cancer NN 4_p
chemotherapy NN 4_p
. . N

adults NNS 1_p
and CC N
children NNS 1_p
receiving VBG N
cancer NN 4_p
chemotherapy NN 4_p
. . N

children NNS 1_p
receiving VBG N
highly RB 4_p
emetogenic JJ 4_p
chemotherapy NN 4_p
for IN N
various JJ N
malignancies NNS 4_p
. . N

total NN N
of IN N
51 CD 3_p
children NNS N
( ( N
mean JJ N
age NN N
: : N
7.7 CD 1_p
+/- NN 1_p
4.8 CD 1_p
year NN 1_p
) ) N
were VBD N
studied VBN N
children NNS 1_p
receiving VBG N
highly RB 4_p
emetogenic JJ 4_p
chemotherapy NN 4_p
. . N

-DOCSTART- -X- O O 18249478

healthy JJ N
unvaccinated JJ N
individuals NNS N
. . N

healthy JJ 4_p
unvaccinated JJ 4_p
individuals NNS 4_p
. . 4_p

healthy JJ N
unvaccinated JJ N
individuals NNS N
. . N

-DOCSTART- -X- O O 18795522

40 CD 3_p
non-carious JJ 4_p
human JJ 4_p
premolars NNS 4_p
-DOCSTART- -X- O O 15233698

patients NNS N
with IN N
non-erosive JJ 4_p
reflux NN 4_p
disease NN 4_p
. . N

patients NNS 4_p
with IN 4_p
reflux NN 4_p
symptoms NNS 4_p
patients NNS N
with IN N
non-erosive JJ 4_p
reflux NN 4_p
disease NN 4_p
. . N

multicentre NN N
Adults NNS 1_p
with IN N
a DT N
history NN N
of IN N
reflux NN 4_p
symptoms NNS N
, , N
a DT N
negative JJ N
endoscopy NN N
, , N
and CC N
> NNP N
or CC N
= VB N
3 CD N
days NNS N
of IN N
moderate JJ N
to TO N
very RB N
severe JJ N
heartburn NN 4_p
in IN N
the DT N
7 CD N
days NNS N
before IN N
enrollment NN N
( ( N
N NNP N
= NNP N
535 CD N
) ) N
Patients NNS N
with IN N
complete JJ N
symptom NN N
relief NN N
then RB N
entered VBD N
the DT N
on-demand JJ N
phase NN N
. . N

non-erosive JJ 4_p
reflux NN 4_p
disease NN 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 9862848

esophageal JJ 4_p
variceal JJ 4_p
hemorrhage NN 4_p
: : 4_p
Esophageal NNP 4_p
variceal JJ 4_p
hemorrhage NN 4_p
( ( 4_p
EVH NNP 4_p
) ) 4_p
patients NNS N
with IN N
EVH NNP N
. . N

incidence NN N
of IN N
variceal NN N
rebleeding NN N
( ( N
41.9 CD N
% NN N
vs. FW N
42.9 CD N
% NN N
) ) N
, , N
variceal JJ N
obliteration NN N
( ( N
41.9 CD N
% NN N
vs. FW N
40.0 CD N
% NN N
) ) N
, , N
hospital JJ N
days NNS N
, , N
blood NN N
transfusions NNS N
, , N
shunt NN N
requirements NNS N
, , N
and CC N
survival NN N
( ( N
71.0 CD N
% NN N
vs. FW N
60.0 CD N
% NN N
) ) N
-DOCSTART- -X- O O 11816482

A NNP N
total NN N
of IN N
465 CD 3_p
patients NNS N
with IN N
primary JJ N
and CC N
multiple JJ N
or CC N
recurrent NN N
, , N
stages VBZ N
Ta NNP N
and CC N
T1 NNP N
superficial JJ 4_p
bladder NN 4_p
cancer NN 4_p
-DOCSTART- -X- O O 15238023

impoverished JJ 4_p
relational-encoding NN 4_p
and CC N
distinctiveness NN 4_p
heuristic JJ 4_p
accounts NNS 4_p
. . N

participants NNS N
were VBD N
given VBN N
inclusion NN 4_p
recall NN 4_p
instructions NNS 4_p
to TO N
report VB N
studied JJ N
items NNS N
as RB N
well RB N
as IN N
related JJ N
items NNS N
-DOCSTART- -X- O O 18971406

beneficiaries NNS 4_p
with IN 4_p
mental JJ 4_p
illness NN 4_p
: : 4_p
Cash NNP N
and CC N
Counseling NNP N
Demonstration NNP N
and CC N
Evaluation NNP N
( ( N
CCDE NNP N
) ) N
programs NNS N
in IN N
New NNP N
Jersey NNP N
, , N
Arkansas NNP N
, , N
and CC N
Florida NNP N
those DT N
with IN N
a DT N
diagnosis NN N
of IN N
mental JJ N
illness NN N
. . N

nonelderly RB N
Medicaid NNP N
beneficiaries NNS N
in IN N
New NNP N
Jersey NNP N
with IN N
a DT N
diagnosis NN N
of IN N
mental JJ N
illness NN N
and CC N
compared VBN N
and CC N
contrasted VBN N
the DT N
experiences NNS N
of IN N
those DT N
in IN N
New NNP N
Jersey NNP N
's POS N
CCDE NNP N
program NN N
( ( N
N=109 NNP N
) ) N
and CC N
those DT N
who WP N
received VBD N
services NNS N
provided VBN N
by IN N
an DT N
agency NN N
( ( N
N=119 NNP N
) ) N
. . N

persons NNS N
with IN N
a DT N
diagnosis NN N
of IN N
mental JJ N
illness NN N
. . N

-DOCSTART- -X- O O 1999025

686 CD 3_p
patients NNS N
with IN N
stable JJ 4_p
angina NNS 4_p
myocardial JJ 4_p
infarction NN 4_p
accompanied VBN N
by IN N
serum NN N
enzyme NN N
elevations NNS N
with IN N
or CC N
without IN N
electrocardiographic JJ N
-DOCSTART- -X- O O 2162258

mild NN 4_p
to TO 4_p
moderate VB 4_p
essential JJ 4_p
hypertension NN 4_p
. . 4_p

Hypertensive JJ 4_p
patients NNS 4_p
5 CD N
mg NN N
of IN N
enalapril NN N
( ( N
n JJ N
= NNP N
50 CD N
) ) N
or CC N
10 CD N
mg NN N
of IN N
lisinopril NN N
( ( N
n JJ N
= NNP N
47 CD N
) ) N
daily RB N
. . N

two CD 3_p
treatment NN N
groups NNS N
mild NN N
to TO N
moderate VB N
uncomplicated JJ N
essential JJ N
hypertension NN 4_p
. . N

-DOCSTART- -X- O O 19910194

elderly JJ 1_p
patients NNS 1_p
with IN N
early-stage JJ N
breast NN 4_p
cancer NN 4_p
: : N
patients NNS N
with IN N
early-stage JJ N
breast NN 4_p
cancer NN 4_p
. . N

Between JJ N
2001 CD N
and CC N
2005 CD N
, , N
749 CD N
women NNS 2_p
aged VBN N
55-75 JJ 1_p
years NNS 1_p
with IN N
infiltrating VBG N
breast NN 4_p
carcinoma NN 4_p
-DOCSTART- -X- O O 1634173

grade NN 4_p
1 CD 4_p
and CC N
2 CD 4_p
hemorrhoids NNS 4_p
. . N

80 CD 3_p
patients NNS N
with IN N
first JJ N
and CC N
second JJ N
degree NN N
hemorrhoids NNS N
; : N
first JJ 4_p
and CC 4_p
second JJ 4_p
degree NN 4_p
hemorrhoids NNS 4_p
-DOCSTART- -X- O O 24164087

. . N

One CD 3_p
hundred VBD 3_p
patients NNS N
scheduled VBN N
for IN N
lobectomy NN N
-DOCSTART- -X- O O 9690266

Lead-exposed JJ 4_p
Children NNP 4_p
( ( 4_p
TLC NNP 4_p
) ) 4_p
toddlers NNS 4_p
. . 4_p

young JJ N
children NNS N
Lead-Exposed JJ N
Children NNP N
lead-exposed JJ N
children NNS N
Baltimore NNP N
, , N
Cincinnati NNP N
and CC N
Columbus NNP N
, , N
Newark NNP N
and CC N
Philadelphia NNP N
. . N

Children NNP N
were VBD N
eligible JJ N
for IN N
TLC NNP N
if IN N
they PRP N
were VBD N
between IN N
12 CD N
and CC N
33 CD N
months NNS N
of IN N
age NN N
, , N
had VBD N
a DT N
confirmed VBN N
blood NN N
lead NN N
concentration NN N
between IN N
20 CD N
and CC N
44 CD N
micrograms/dL NN N
and CC N
lived VBD N
in IN N
a DT N
residence NN N
suitable JJ N
for IN N
lead JJ N
dust NN N
reduction NN N
. . N

children NNS N
A DT N
total NN N
of IN N
1854 CD N
children NNS N
were VBD N
evaluated VBN N
and CC N
780 CD N
children NNS N
were VBD N
randomised VBN N
between IN N
August NNP N
1994 CD N
and CC N
January NNP N
1997 CD N
. . N

The DT N
mean JJ N
age NN N
of IN N
randomised JJ N
children NNS N
was VBD N
24 CD N
months NNS N
and CC N
mean VB N
blood NN N
lead JJ N
level NN N
26 CD N
micrograms/dL NN N
. . N

Three-quarters NNS N
were VBD N
African-American JJ N
. . N

Most JJS N
children NNS N
had VBD N
poor JJ N
, , N
single JJ N
mothers NNS N
who WP N
had VBD N
completed VBN N
12 CD N
or CC N
fewer JJR N
years NNS N
of IN N
school NN N
and CC N
who WP N
lived VBD N
in IN N
older JJR N
, , N
poorly RB N
maintained VBD N
residences NNS N
. . N

-DOCSTART- -X- O O 20822543

3-5 JJ 4_p
year NN 4_p
old JJ 4_p
children NNS 4_p
attending VBG 4_p
long RB 4_p
day NN 4_p
care NN 4_p
services NNS 4_p
: : 4_p
Young NNP 4_p
children NNS 4_p
young JJ N
children NNS N
children NNS N
attending VBG N
long RB N
day NN N
care NN N
services NNS N
. . N

Three CD N
hundred VBD N
children NNS N
aged VBN N
between IN N
3-5 CD N
years NNS N
from IN N
twenty NN N
randomly RB N
selected VBN N
long RB N
day NN N
care NN N
services NNS N
in IN N
the DT N
Hunter NNP N
Region NNP N
of IN N
New NNP N
South NNP N
Wales NNP N
, , N
Australia NNP N
young JJ N
children NNS N
in IN N
long JJ N
day NN N
care NN N
settings NNS N
. . N

Australian NNP N
New NNP N
Zealand NNP N
Clinical NNP N
Trials NNP N
Registry NNP N
-DOCSTART- -X- O O 25714521

after IN 4_p
treatment NN 4_p
of IN 4_p
ruptured JJ 4_p
intracranial JJ 4_p
aneurysms NN 4_p
Acute NNP 4_p
hydrocephalus NN 4_p
A NNP N
total NN N
of IN N
471 CD 3_p
patients NNS 3_p
who WP N
were VBD N
part NN 4_p
of IN 4_p
a DT 4_p
prospective JJ 4_p
, , 4_p
randomized VBN 4_p
, , 4_p
controlled VBN 4_p
trial NN 4_p
from IN 4_p
2003 CD 4_p
to TO 4_p
2007 CD 4_p
were VBD 4_p
retrospectively RB 4_p
reviewed VBN 4_p
. . N

patients NNS 4_p
treated VBN 4_p
by IN 4_p
endovascular JJ 4_p
or CC 4_p
microsurgical JJ 4_p
means NNS 4_p
. . N

shunt-dependent JJ 4_p
hydrocephalus NN 4_p
-DOCSTART- -X- O O 17078451

psoriasis NN 4_p
vulgaris NN 4_p
clinical JJ N
report NN N
of IN N
60 CD 3_p
cases NNS N
. . N

-DOCSTART- -X- O O 16177585

patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
. . N

Forty-two NNP 3_p
diabetic JJ 4_p
patients NNS N
-DOCSTART- -X- O O 8667967

Tight-fitting JJ 4_p
underwear JJ 4_p
and CC 4_p
sperm JJ 4_p
quality NN 4_p
. . N

-DOCSTART- -X- O O 8498878

autistic JJ 4_p
disorder NN 4_p
. . 4_p

12 CD 4_p
autistic JJ 4_p
subjects NNS 4_p
12 CD 4_p
different JJ 4_p
subjects NNS 4_p
A DT N
referral JJ N
sample NN N
of IN N
30 CD N
male NN N
and CC N
female JJ N
autistic JJ N
patients NNS N
were VBD N
enrolled VBN N
, , N
and CC N
24 CD N
completed VBD N
the DT N
study NN N
. . N

autistic JJ N
disorder NN N
-DOCSTART- -X- O O 11154142

healthy JJ 4_p
postmenopausal NN 4_p
women NNS 2_p
. . N

25 CD 3_p
healthy JJ 4_p
postmenopausal NN 4_p
women NNS 2_p
( ( N
52.5 CD 1_p
+/- JJ 1_p
2.8 CD 1_p
years NNS N
) ) N
postmenopausal JJ 4_p
women NNS 2_p
-DOCSTART- -X- O O 22277317

percutaneous JJ N
coronary JJ N
intervention NN N
in IN N
chronic JJ N
total JJ N
occlusion NN N
-- : N
CAtholic NNP N
Total NNP N
Occlusion NNP N
Study NNP N
( ( N
CATOS NNP N
) ) N
trial NN N
. . N

chronic JJ N
total JJ N
occlusion NN N
( ( N
CTO NNP N
) ) N
. . N

in IN N
patients NNS N
with IN N
CTO NNP N
lesion NN N
with IN N
a DT N
reference NN N
vessel NN N
diameter NN N
≥ VBD N
2.5mm CD N
option NN N
in IN N
patients NNS N
undergoing VBG N
PCI NNP N
for IN N
CTO NNP N
with IN N
DESs NNP N
-DOCSTART- -X- O O 18443393

functional JJ 4_p
memory NN 4_p
disorder NN 4_p
. . N

-DOCSTART- -X- O O 12636954

pregnant JJ 4_p
smokers NNS 4_p
. . N

One CD 3_p
hundred VBD 3_p
forty-two NN 3_p
pregnant NN 4_p
, , N
predominantly RB N
Hispanic JJ N
women NNS 2_p
-DOCSTART- -X- O O 939970

Forty-one CD 3_p
consecutive JJ N
patients NNS N
with IN N
supratentorial JJ 4_p
primary JJ 4_p
brain NN 4_p
tumors NNS 4_p
( ( N
38 CD 3_p
Grade NNP 4_p
III NNP 4_p
and CC 4_p
IV NNP 4_p
astrocytomas RB 4_p
, , N
one CD 3_p
giant-cell NN 4_p
astrocytoma NN 4_p
, , N
and CC N
two CD 3_p
cases NNS N
with IN N
insufficient JJ N
tissue NN N
for IN N
diagnosis NN N
) ) N
within IN N
2 CD N
weeks NNS N
of IN N
surgery NN N
-DOCSTART- -X- O O 22050796

Laryngeal NNP 4_p
Mask NNP 4_p
Airway NNP 4_p
insertion NN 4_p
. . N

Laryngeal NNP N
Mask NNP N
Airway NNP N
( ( N
LMA NNP 4_p
) ) N
insertion NN N
. . N

120 CD 3_p
ASA NNP N
physical JJ N
status NN N
1 CD N
and CC N
2 CD N
patients NNS N
undergoing JJ N
elective JJ N
orthopedic JJ 4_p
surgeries NNS 4_p
. . N

Group NNP N
A NNP N
patients NNS N
Group NNP N
B NNP N
patients NNS N
Group NNP N
C NNP N
, , N
patients NNS N
Group NNP N
D NNP N
, , N
patients NNS N
LMA NNP N
insertion NN N
-DOCSTART- -X- O O 11360574

relieving VBG N
neuroendocrino-immunological JJ 4_p
effect NN 4_p
65 CD 3_p
patients NNS N
took VBD N
prednisone NN N
, , N
and CC N
were VBD N
randomly RB N
divided VBN N
into IN N
Fufang NNP N
prednisone NN N
group NN N
( ( N
mixture NN N
of IN N
prednisone NN N
and CC N
EB NNP N
) ) N
and CC N
prednisone NN N
group NN N
. . N

-DOCSTART- -X- O O 21463068

methadone-maintained JJ N
cocaine NN N
abusers NNS N
patients NNS N
in IN N
methadone JJ N
maintenance NN N
. . N

methadone-maintained JJ N
, , N
cocaine-dependent JJ N
patients NNS N
( ( N
N NNP N
= NNP N
193 CD N
) ) N
with IN N
and CC N
without IN N
concurrent JJ N
AD NNP N
Patients NNS N
with IN N
and CC N
without IN N
concurrent JJ N
AD NNP N
cocaine-using JJ N
methadone NN N
patients NNS N
-DOCSTART- -X- O O 10685169

second JJ 4_p
intention NN 4_p
wound IN 4_p
healing VBG 4_p
in IN N
horses NNS N
. . N

horses NNS N
. . N

four CD 3_p
horses NNS N
, , N
each DT N
with IN N
wounds NNS N
Four CD N
adult NN N
Standardbred NNP N
geldings NNS N
. . N

four CD N
horses NNS N
, , N
giving VBG N
a DT N
total NN N
of IN N
64 CD N
wounds NNS N
. . N

horses NNS N
. . N

-DOCSTART- -X- O O 9512674

multicenter NN 4_p
, , 4_p
double-blind NN 4_p
, , 4_p
randomized VBN 4_p
, , 4_p
parallel-group JJ 4_p
study NN 4_p
. . 4_p

cisplatin NN 4_p
chemotherapy NN 4_p
( ( 4_p
> CD 4_p
or CC 4_p
= VB 4_p
60 CD 4_p
mg/m2 NN 4_p
) ) 4_p
. . 4_p

40 CD N
% NN N
and CC N
49 CD N
% NN N
of IN N
patients NNS N
in IN N
Cycles NNP N
2 CD N
and CC N
3 CD N
, , N
respectively RB N
, , N
for IN N
the DT N
10 CD N
micrograms/kg NN N
group NN N
, , N
and CC N
in IN N
42 CD N
% NN N
and CC N
38 CD N
% NN N
of IN N
patients NNS N
in IN N
Cycles NNP N
2 CD N
and CC N
3 CD N
, , N
respectively RB N
, , N
for IN N
the DT N
40 CD N
micrograms/kg NN N
group NN N
. . N

high-dose JJ 4_p
cisplatin-based JJ 4_p
chemotherapy NN 4_p
. . 4_p

-DOCSTART- -X- O O 23539079

sprint NN 4_p
acceleration NN 4_p
ability NN 4_p
. . 4_p

athletes NNS 4_p
Twenty-one CD 3_p
physically RB 4_p
active JJ 4_p
men NNS 2_p
-DOCSTART- -X- O O 11863211

COPD NNP 4_p
patients NNS 4_p
. . N

-DOCSTART- -X- O O 2067508

Sixty NNP 3_p
adult NN 1_p
patients NNS N
, , N
ASA NNP N
Classes NNP N
I PRP N
& CC N
II NNP N
-DOCSTART- -X- O O 26573368

typically RB N
developing VBG N
adolescent JJ 1_p
schoolchildren NN 1_p
. . N

typically RB N
developing VBG N
UK NNP N
adolescents NNS 1_p
aged VBN 1_p
13-16 CD 1_p
years NNS 1_p
( ( N
n RB 3_p
196 CD 3_p
) ) N
. . N

-DOCSTART- -X- O O 21432861

in IN 4_p
human JJ 4_p
plasma NN 4_p
analyte NN N
and CC N
the DT N
IS NNP N
organic JJ N
phase NN N
each DT N
formulation NN N
was VBD N
administered VBN N
-DOCSTART- -X- O O 8792262

children NNS 1_p
with IN N
a DT N
pervasive JJ 4_p
development NN 4_p
disorder NN 4_p
. . N

children NNS 1_p
with IN N
autism NN 4_p
or CC N
a DT N
related JJ 4_p
pervasive JJ 4_p
developmental NN 4_p
disorder NN 4_p
( ( 4_p
PDD NNP 4_p
) ) 4_p
children NNS 1_p
with IN N
PDD NNP 4_p
-DOCSTART- -X- O O 9229263

autistic JJ 4_p
children NNS 1_p
's POS 1_p
-DOCSTART- -X- O O 23870503

postmenopausal NN 4_p
women NNS 4_p
vitamin NN 4_p
D NNP 4_p
insufficiency NN 4_p
( ( 4_p
VDI NNP 4_p
) ) 4_p
. . 4_p

Postmenopausal NNP N
women NNS N
. . N

609 CD N
postmenopausal JJ N
women NNS N
with IN N
a DT N
mean JJ N
age NN N
of IN N
61 CD N
( ( N
sd JJ N
6 CD N
years NNS N
) ) N
, , N
of IN N
whom WP N
113 CD N
( ( N
19 CD N
% NN N
) ) N
had VBD N
VDI NNP N
. . N

-DOCSTART- -X- O O 16522696

patients NNS N
with IN N
euvolemic JJ 4_p
or CC 4_p
hypervolemic JJ 4_p
hyponatremia NN 4_p
. . N

abnormality NN N
among IN N
hospitalized JJ 4_p
patients NNS 4_p
. . N

patients NNS N
with IN N
euvolemic JJ 4_p
or CC N
hypervolemic JJ 4_p
hyponatremia NN 4_p
. . N

at IN N
a DT N
hospital NN N
. . N

Seventy-four JJ 3_p
patients NNS N
( ( N
average JJ N
baseline NN N
serum NN N
[ NNP N
Na NNP N
( ( N
+ NNP N
) ) N
] NN N
, , N
115 CD N
to TO N
< VB N
130 CD N
mEq/liter NN N
) ) N
were VBD N
studied VBN N
. . N

-DOCSTART- -X- O O 22983407

caries NNS 4_p
deep JJ 4_p
caries NNS 4_p
lesions NNS 4_p
Inclusion NN N
criteria NNS N
were VBD N
as IN N
follows VBZ N
: : N
patients NNS N
with IN N
permanent JJ 4_p
molars NNS 4_p
presenting VBG 4_p
deep JJ 4_p
caries NNS 4_p
lesions NNS 4_p
( ( 4_p
lesion NN 4_p
affecting VBG 4_p
≥ JJ 4_p
1/2 CD 4_p
of IN 4_p
the DT 4_p
dentin NN 4_p
on IN 4_p
radiographic JJ 4_p
examination NN 4_p
) ) N
, , N
positive JJ N
response NN N
to TO N
a DT N
cold JJ N
test NN N
, , N
absence NN N
of IN N
spontaneous JJ N
pain NN N
, , N
negative JJ N
sensitivity NN N
to TO N
percussion NN N
, , N
and CC N
absence NN N
of IN N
periapical JJ N
lesions NNS N
( ( N
radiographic JJ N
examination NN N
) ) N
baseline NN N
, , N
299 CD 3_p
treatments NNS N
were VBD N
executed VBN N
: : N
147 CD N
period NN N
, , N
213 CD N
teeth NNS N
had VBD N
been VBN N
evaluated VBN N
-DOCSTART- -X- O O 25912590

posttonsillectomy NN 4_p
pain NN 4_p
Post-tonsillectomy JJ 4_p
pain NN 4_p
72 CD 3_p
ASA NNP N
I-II JJ N
patients NNS N
between IN 1_p
3 CD 1_p
and CC 1_p
12 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
, , N
scheduled VBN N
to TO N
undergo VB N
tonsillectomy NN N
were VBD N
enrolled VBN N
children NNS 1_p
. . N

-DOCSTART- -X- O O 20965956

cardiac JJ N
surgery NN N
with IN N
cardiopulmonary JJ 4_p
bypass NN 4_p
patients NNS N
undergoing VBG N
cardiac JJ 4_p
surgery NN 4_p
with IN 4_p
cardiopulmonary JJ 4_p
bypass NN 4_p
( ( 4_p
CPB NNP 4_p
) ) 4_p
Pericardial NNP N
blood NN N
of IN N
13 CD 3_p
patients NNS N
patients NNS N
undergoing VBG N
cardiac JJ N
surgery NN N
with IN N
CPB NNP N
-DOCSTART- -X- O O 19622708

cancer NN 4_p
patients NNS N
cancer NN 4_p
patients NNS N
. . N

newly RB N
diagnosed VBN N
breast NN 4_p
cancer NN 4_p
patients NNS N
( ( N
n JJ N
= NNP N
45 CD 3_p
) ) N
with IN N
clinically RB 4_p
significant JJ 4_p
depressive JJ 4_p
symptoms NNS 4_p
cancer NN 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 25643864

High-Functioning NNP 4_p
Children NNP 1_p
with IN N
ASD NNP 4_p
. . N

43 CD 3_p
children NNS 1_p
, , N
ages VBZ 1_p
7-12 CD 1_p
years NNS 1_p
with IN N
high-functioning JJ 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
HFASD NNP 4_p
) ) N
-DOCSTART- -X- O O 12050494

patients NNS N
with IN N
superficial JJ 4_p
bladder NN 4_p
tumors NNS 4_p
. . N

superficial JJ 4_p
bladder NN 4_p
carcinoma NNS 4_p
A NNP N
total NN N
of IN N
301 CD 3_p
patients NNS N
underwent JJ N
transurethral JJ 4_p
resection NN 4_p
of IN 4_p
bladder NN 4_p
tumors NNS 4_p
with IN N
white JJ N
light NN N
or CC N
fluorescence NN N
diagnosis NN N
. . N

A DT N
total NN N
of IN N
191 CD 3_p
patients NNS N
with IN N
superficial JJ 4_p
bladder NN 4_p
carcinoma NN 4_p
were VBD N
available JJ N
-DOCSTART- -X- O O 16337719

in IN N
naive JJ 4_p
and CC 4_p
pre-immunized JJ 4_p
subjects NNS 4_p
. . N

A DT N
total NN N
of IN N
86 CD 3_p
healthy JJ 4_p
subjects NNS N
-DOCSTART- -X- O O 12567169

external JJ 4_p
genital NN 4_p
and CC 4_p
perianal JJ 4_p
warts NNS 4_p
in IN N
different JJ N
patient JJ N
populations NNS N
. . N

patients NNS N
' POS N
demographic JJ N
variables NNS N
external JJ 4_p
genital NN 4_p
and CC 4_p
perianal JJ 4_p
warts NNS 4_p
. . N

Male NNP 2_p
and CC N
female JJ 2_p
immunocompetent NN 4_p
patients NNS N
subgroups NNS N
based VBN N
on IN N
variables NNS N
of IN N
gender NN N
, , N
baseline JJ N
wart NN 4_p
area NN N
, , N
duration NN N
of IN N
current JJ N
outbreak NN N
of IN N
warts NNS 4_p
, , N
previous JJ N
wart NN N
treatment NN N
, , N
and CC N
tobacco NN N
use NN N
. . N

external JJ N
genital NN 4_p
and CC 4_p
perianal JJ 4_p
warts NNS 4_p
-DOCSTART- -X- O O 11072681

irritable JJ 4_p
bowel NN 4_p
syndrome NN 4_p
] NN N
-DOCSTART- -X- O O 350565

hepatic JJ N
amoebiasis NN N
. . N

31 CD N
patients NNS N
with IN N
hepatic JJ N
amoebiasis NN N
. . N

Only RB N
those DT N
with IN N
unequivocal JJ N
clinical JJ N
, , N
radiological JJ N
and CC N
laboratory JJ N
evidence NN N
of IN N
hepatic JJ N
amoebiasis NN N
15 CD N
patients NNS N
received VBN N
metronidazole JJ N
and CC N
16 CD N
tinidazole NN N
, , N
in IN N
random JJ N
order NN N
. . N

hepatic JJ N
amoebiasis NN N
in IN N
Bangladesh NNP N
-DOCSTART- -X- O O 1697914

benign JJ 4_p
prostatic JJ 4_p
hypertrophy NN 4_p
. . N

270 CD 3_p
patients NNS N
with IN N
benign JJ 3_p
prostatic JJ 3_p
hypertrophy NN 3_p
patients NNS N
with IN N
benign JJ 3_p
prostatic JJ 3_p
hypertrophy NN 3_p
. . N

-DOCSTART- -X- O O 24022375

nursing NN 4_p
home NN 4_p
patients NNS 4_p
: : N
nursing JJ N
home NN N
patients NNS N
. . N

624 CD 3_p
nursing NN N
home NN N
patients NNS N
with IN N
dementia NN 4_p
, , N
446 CD 3_p
completed VBD N
follow-up JJ N
assessments NNS N
. . N

-DOCSTART- -X- O O 3630589

Forty NNP 1_p
women NNS 1_p
, , 1_p
aged VBN 1_p
26-40 CD 1_p
years NNS 1_p
gastric JJ N
contents NNS N
and CC N
pH NN N
before IN N
general JJ N
anaesthesia NN N
. . N

-DOCSTART- -X- O O 17252578

Does NNP N
ambient VBD N
light JJ N
contribute NN N
to TO N
the DT N
therapeutic JJ N
effects NNS N
of IN N
topical JJ N
photodynamic JJ N
therapy NN N
( ( N
PDT NNP N
) ) N
using VBG N
aminolevulinic JJ N
acid NN N
HCl NNP N
( ( N
ALA NNP N
) ) N
? . N
-DOCSTART- -X- O O 19672771

patients NNS N
with IN N
hairy JJ N
cell NN N
leukemia NN N
: : N
a DT N
multicenter NN N
phase NN N
III NNP N
trial NN N
( ( N
SAKK NNP N
32/98 CD N
) ) N
. . N

One CD N
hundred VBD N
patients NNS N
-DOCSTART- -X- O O 24146058

feline NN 4_p
osteoarthritis NN 4_p
. . N

feline NN 4_p
osteoarthritis NN 4_p
( ( 4_p
OA NNP 4_p
) ) 4_p
Cats NNPS 1_p
over IN 1_p
eight CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
with IN N
clinical JJ 4_p
signs NNS 4_p
of IN 4_p
chronic JJ 4_p
OA NNP 4_p
were VBD N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
Cats NNPS N
cats NNS N
-DOCSTART- -X- O O 15810908

pharmacokinetic JJ N
( ( N
PK NNP N
) ) N
BDDrFVIII NNP N
formulations NNS N
in IN N
patients NNS N
with IN N
haemophilia PDT 4_p
A DT 4_p
series NN N
of IN N
blood NN N
samples NNS N
were VBD N
collected VBN N
over IN N
a DT N
period NN N
of IN N
48 CD N
h NN N
after IN N
i.v NN N
. . N

administration NN N
of IN N
each DT N
of IN N
the DT N
FVIII NNP N
preparations NNS N
. . N

-DOCSTART- -X- O O 24345974

young JJ 1_p
swimmers NNS N
swimmers NNS N
young JJ 1_p
swimmers NNS N
An DT N
experimental JJ N
group NN N
( ( 3_p
n JJ 3_p
= NNP 3_p
20 CD 3_p
) ) N
and CC N
a DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
20 CD 3_p
) ) N
of IN N
young JJ 1_p
male NN 2_p
swimmers NNS N
with IN N
the DT N
same JJ N
characteristics NNS N
( ( N
age NN N
, , N
body NN N
mass NN N
, , N
height NN N
, , N
training NN N
volume NN N
, , N
and CC N
maturational JJ N
state NN N
) ) N
were VBD N
evaluated VBN N
. . N

-DOCSTART- -X- O O 11395821

overweight JJ 4_p
patients NNS N
. . N

overweight JJ N
patients NNS N
. . N

A NNP N
group NN N
of IN N
106 CD 3_p
patients NNS N
with IN N
a DT N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
> VBD N
26.4 CD N
, , N
representing VBG N
the DT N
upper JJ N
quintile NN N
of IN N
500 CD N
prospectively RB N
randomized JJ N
patients NNS N
overweight JJ N
patients NNS N
overweight NN N
and CC N
normal-weight JJ N
patients NNS N
. . N

-DOCSTART- -X- O O 9235679

patients NNS N
who WP N
had VBD N
received VBN N
a DT N
hip NN 4_p
replacement NN 4_p
. . N

258 CD N
patients NNS N
were VBD N
evaluated VBN N
. . N

-DOCSTART- -X- O O 16772718

short JJ 1_p
children NNS 1_p
born VBP 1_p
small JJ 1_p
for IN 1_p
gestational JJ 1_p
age NN 1_p
: : 1_p
short JJ 1_p
children NNS 1_p
born VBP 1_p
small JJ 1_p
for IN 1_p
gestational JJ 1_p
age NN 1_p
SGA NNP 1_p
58 CD 3_p
growth-retarded JJ 1_p
SGA NNP 1_p
children NNS 1_p
aged VBN 1_p
2-5 CD 1_p
years NNS 1_p
were VBD 1_p
randomized VBN 1_p
-DOCSTART- -X- O O 8421029

knee JJ 4_p
replacement NN 4_p
under IN 4_p
tourniquet NN 4_p
. . 4_p

32 CD 3_p
knee JJ 4_p
replacement NN 4_p
operations NNS 4_p
-DOCSTART- -X- O O 21048092

high-risk JJ N
patients NNS N
receiving VBG N
goal-directed JJ N
fluid NN N
therapy NN N
undergoing VBG N
major JJ N
abdominal JJ N
surgery NN N
. . N

patients NNS N
undergoing VBG N
major JJ N
abdominal JJ N
surgery NN N
in IN N
patients NNS N
undergoing VBG N
major JJ N
abdominal JJ N
surgery NN N
in IN N
patients NNS N
who WP N
were VBD N
at IN N
increased VBN N
risk NN N
by IN N
virtue NN N
of IN N
a DT N
reduced VBN N
METHODS NNP N
Patients NNPS N
undergoing VBG N
elective JJ N
major JJ N
colorectal NN N
or CC N
urological JJ N
surgery NN N
who WP N
had VBD N
an DT N
AT NNP N
of IN N
< NNP N
11 CD N
mL NN N
· NN N
kg NN N
( ( N
-1 NNP N
) ) N
· VBP N
min NN N
( ( N
-1 JJ N
) ) N
or CC N
an DT N
AT NNP N
of IN N
11 CD N
to TO N
14 CD N
mL NNS N
· JJ N
kg NN N
( ( N
-1 NNP N
) ) N
· VBP N
min NN N
( ( N
-1 NNP N
) ) N
with IN N
a DT N
history NN N
of IN N
ischemic JJ N
heart NN N
disease NN N
were VBD N
recruited VBN N
Survey NNP N
. . N

RESULTS NNP N
One CD N
hundred VBD N
twenty-four JJ N
patients NNS N
were VBD N
recruited VBN N
over IN N
a DT N
23-month JJ N
fluid NN N
therapy NN N
in IN N
elective JJ N
surgical JJ N
-DOCSTART- -X- O O 3277760

six CD 4_p
umbilical JJ 4_p
cord NN 4_p
care NN 4_p
regimens VBZ 4_p
. . 4_p

Two CD 4_p
hundred VBD 4_p
and CC 4_p
seventy VB 4_p
one CD 4_p
infants NNS 4_p
were VBD 4_p
enrolled VBN 4_p
in IN 4_p
a DT 4_p
study NN 4_p
to TO 4_p
compare VB 4_p
six CD 4_p
different JJ 4_p
methods NNS 4_p
of IN 4_p
treating VBG 4_p
the DT 4_p
umbilical JJ 4_p
cord NN 4_p
. . 4_p

-DOCSTART- -X- O O 19718941

church-attending JJ N
African-American JJ N
men NNS 2_p
. . N

among IN N
African-American JJ N
men NNS 2_p
; : N
African-American JJ N
men NNS 2_p
who WP N
attend VBP N
church NN N
Churches NNP N
-DOCSTART- -X- O O 19682100

antiretroviral-naïve JJ N
HIV-infected JJ 4_p
patients NNS N
treated VBN N
with IN N
first-line JJ N
lopinavir/ritonavir NN N
monotherapy NN N
in IN N
the DT N
MONARK NNP N
trial NN N
. . N

. . N

MONotherapy NNP N
AntiRetroviral NNP N
Kaletra NNP N
( ( N
MONARK NNP N
) ) N
is VBZ N
the DT N
first JJ N
randomized JJ N
trial NN N
comparing VBG N
lopinavir/ritonavir JJ N
monotherapy NN N
to TO N
triple VB N
combination NN N
therapy NN N
with IN N
zidovudine/lamivudine NN N
and CC N
lopinavir/ritonavir NN N
in IN N
antiretroviral-naïve JJ N
patients NNS N
of IN N
136 CD N
antiretroviral-naïve JJ N
patients NNS N
, , N
with IN N
a DT N
CD4 NNP N
cell NN N
count NN N
above IN N
100 CD N
cells/microL NN N
and CC N
a DT N
plasma NN N
HIV NNP N
RNA NNP N
below IN N
100,000 CD N
HIV-1 JJ N
RNA NNP N
copies/mL NN N
53 CD N
) ) N
. . N

We PRP N
focus VBP N
here RB N
on IN N
patients NNS N
in IN N
the DT N
lopinavir/ritonavir NN N
monotherapy NN N
arm NN N
followed VBD N
to TO N
week NN N
96 CD N
-DOCSTART- -X- O O 14989068

90 CD 3_p
patients NNS N
with IN N
IgAN NNP 4_p
of IN 4_p
deficiency NN 4_p
of IN 4_p
Yin NNP 4_p
with IN N
damp-heat JJ 4_p
symptom NN 4_p
-DOCSTART- -X- O O 7829176

scleral JJ 4_p
buckling NN 4_p
surgery NN 4_p
. . N

scleral JJ 4_p
buckling NN 4_p
procedures NNS 4_p
. . N

60 CD 3_p
patients NNS N
. . N

Thirty JJ 3_p
patients NNS N
scleral JJ N
buckling NN N
procedures NNS N
. . N

-DOCSTART- -X- O O 21047588

European NNP N
Randomized NNP N
Study NNP N
of IN N
Screening NNP 4_p
for IN 4_p
Prostate NNP 4_p
Cancer NNP 4_p
. . N

participating VBG N
in IN N
the DT N
European NNP N
Randomized NNP N
Study NNP N
of IN N
Screening NNP N
for IN N
Prostate NNP N
Cancer NNP N
( ( N
ERSPC NNP N
) ) N
. . N

56,653 CD 3_p
screened JJ N
men NNS 2_p
in IN N
the DT N
ERSPC NNP N
centres NNS N
of IN N
Finland NNP N
, , N
Italy NNP N
, , N
Netherlands NNP N
, , N
Sweden NNP N
and CC N
Switzerland NNP N
, , N
who WP N
underwent VBD N
3-7 JJ N
screening NN N
rounds NNS N
at IN N
2-4 JJ N
year NN N
interval NN N
. . N

Data NNP N
for IN N
prostate NN N
cancer NN N
were VBD N
obtained VBN N
from IN N
the DT N
ERSPC NNP N
central JJ N
database NN N
. . N

Data NNP N
for IN N
high JJ N
grade NN N
PIN NNP 4_p
and CC N
LSPC NNP 4_p
were VBD N
gathered VBN N
from IN N
each DT N
ERSPC NNP N
centre NN N
. . N

men NNS N
. . N

-DOCSTART- -X- O O 3900301

715 CD 3_p
eligible JJ N
patients NNS N
with IN N
all DT N
types NNS N
of IN N
malignant JJ 4_p
lymphoma NN 4_p
( ( N
ML NNP N
) ) N
. . N

281 CD 3_p
evaluable JJ N
patients NNS N
with IN N
favorable JJ N
histologic JJ N
types NNS N
of IN N
ML NNP 4_p
388 CD 3_p
evaluable JJ N
patients NNS N
with IN N
unfavorable JJ N
histologic JJ N
types NNS N
of IN N
ML NNP N
-DOCSTART- -X- O O 3287226

patients NNS N
operated VBN N
on IN N
for IN N
hip NN N
prosthesis NN N
] NNP N
211 CD N
patients NNS N
of IN N
both DT N
sexes NNS N
candidates NNS N
to TO N
receive VB N
total JJ N
hip NN N
arthroplasty NN N
and CC N
presenting NN N
at IN N
least JJS N
one CD N
major JJ N
thromboembolic NN N
risk NN N
factor NN N
patients NNS N
undergoing VBG N
major JJ N
orthopaedic JJ N
surgery NN N
. . N

-DOCSTART- -X- O O 21610189

adults NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
individuals NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
( ( 4_p
a DT 4_p
) ) 4_p
215 CD 4_p
supported VBN 4_p
employees NNS 4_p
who WP 4_p
were VBD 4_p
in IN 4_p
sheltered JJ 4_p
workshops NNS 4_p
prior RB 4_p
to TO 4_p
entering VBG 4_p
supported JJ 4_p
employment NN 4_p
and CC 4_p
( ( 4_p
b NN 4_p
) ) 4_p
215 CD 4_p
supported VBN 4_p
employees NNS 4_p
who WP 4_p
were VBD 4_p
not RB 4_p
in IN 4_p
sheltered JJ 4_p
workshops NNS 4_p
. . 4_p

individuals NNS N
with IN N
ASD NNP N
-DOCSTART- -X- O O 24930546

total JJ 4_p
hip NN 4_p
replacement NN 4_p
with IN 4_p
resurfacing VBG 4_p
Metal-on-metal NNP 4_p
( ( 4_p
MOM NNP 4_p
) ) 4_p
total JJ N
hip NN N
arthroplasties NNS N
52 CD N
hips NNS N
in IN N
52 CD 3_p
patients NNS N
( ( N
median JJ N
age NN N
60 CD 1_p
( ( N
51-64 JJ 1_p
) ) N
years NNS N
, , N
30 CD 1_p
women NNS 1_p
) ) N
-DOCSTART- -X- O O 21118369

septic JJ 4_p
patients NNS N
critical JJ N
care NN N
patients NNS N
with IN N
severe JJ 4_p
sepsis NN 4_p
. . 4_p

Forty-four CD 3_p
patients NNS N
with IN N
severe JJ 4_p
sepsis NN 4_p
or CC 4_p
septic JJ 4_p
shock NN 4_p
-DOCSTART- -X- O O 16527796

epistaxis VBP N
. . N

Subjects NNPS N
comprised VBD N
131 CD 3_p
adult NN 1_p
patients NNS N
who WP 4_p
under-went JJ 4_p
NTI NNP 4_p
. . N

Subjects NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
a DT N
) ) N
NTI NNP N
under IN N
CTSC NNP N
guidance NN N
( ( N
G NNP N
[ NNP N
+ NNP N
] NNP N
group NN N
) ) N
epistaxis NN N
. . N

-DOCSTART- -X- O O 7010662

certain JJ 4_p
disorders NNS 4_p
observed VBN 4_p
in IN 4_p
infantile JJ 4_p
autism NN 4_p
-DOCSTART- -X- O O 14713377

children NNS N
with IN N
Developmental NNP 4_p
Coordination NNP 4_p
Disorder NNP 4_p
: : N
parents NNS N
and CC N
teachers NNS N
. . N

Children NNP N
with IN N
Developmental NNP 4_p
Coordination NNP 4_p
Disorder NNP 4_p
( ( 4_p
DCD NNP 4_p
) ) 4_p
parents NNS N
and CC N
teachers NNS N
children NNS N
with IN N
DCD NNP N
; : N
children NNS N
with IN N
DCD NNP N
Thirty-one CD 3_p
children NNS N
with IN N
DCD NNP N
aged VBD N
7 CD 1_p
to TO 1_p
9 CD 1_p
years NNS 1_p
participated VBN N
in IN N
the DT N
study NN N
. . N

teachers NNS N
and CC N
parents NNS N
27 CD 3_p
children NNS N
teachers NNS N
and CC N
parents NNS N
-DOCSTART- -X- O O 2474057

737 CD N
patients NNS N
with IN N
aggressive JJ N
malignant JJ N
lymphoma NN N
. . N

From IN N
July NNP N
1984 CD N
to TO N
September NNP N
1987 CD N
, , N
737 CD N
patients NNS N
with IN N
aggressive JJ N
malignant JJ N
lymphoma NN N
( ( N
ML NNP N
) ) N
Four CD 1_p
hundred VBD 1_p
forty-two JJ 1_p
patients NNS 1_p
-DOCSTART- -X- O O 12900807

type NN 4_p
2 CD 4_p
diabetic JJ 4_p
patients NNS 4_p
: : 4_p
45 CD 4_p
patients NNS 4_p
with IN 4_p
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
mellitus FW 4_p
( ( 4_p
DM NNP 4_p
) ) 4_p
Forty-five JJ N
patients NNS N
with IN N
type JJ N
2 CD N
DM NNP N
initially RB N
were VBD N
compared VBN N
with IN N
15 CD N
healthy JJ N
controls NNS N
matched VBN N
for IN N
age NN N
and CC N
sex NN N
. . N

type JJ N
2 CD N
DM NNP N
healthy JJ N
individuals NNS N
-DOCSTART- -X- O O 25087908

youth NN 1_p
diagnosed VBN N
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
: : N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
. . 4_p

youth NN N
with IN N
ASD NNP 4_p
. . N

two CD 4_p
Australian JJ 4_p
university NN 4_p
sites NNS 4_p
between IN 4_p
February NNP 4_p
2009 CD 4_p
and CC 4_p
January NNP 4_p
2012 CD 4_p
, , 4_p
50 CD 3_p
male NN 2_p
participants NNS N
aged VBN N
between IN N
12 CD 1_p
and CC 1_p
18 CD 1_p
years NNS 1_p
, , N
with IN N
Autistic NNP 4_p
or CC 4_p
Asperger NNP 4_p
's POS 4_p
Disorder NNP 4_p
-DOCSTART- -X- O O 19781408

patients NNS N
with IN N
coronary JJ N
heart NN N
disease NN N
( ( N
CHD NNP N
) ) N
or CC N
CHD NNP N
risk NN N
equivalents NNS N
( ( N
clinical JJ N
trials.gov NN N
NCT00685776 NNP N
) ) N
. . N

Eligible JJ N
patients NNS N
at IN N
National NNP N
Cholesterol NNP N
Education NNP N
Program-Adult NNP N
Treatment NNP N
Panel NNP N
III NNP N
LDL-C NNP N
treatment NN N
goal NN N
on IN N
a DT N
statin NN N
, , N
with IN N
or CC N
without IN N
other JJ N
lipid-modifying JJ N
medications NNS N
total NN N
of IN N
2,757 CD N
patients NNS N
were VBD N
screened VBN N
at IN N
153 CD N
centers NNS N
in IN N
20 CD N
countries NNS N
, , N
and CC N
1,623 CD N
patients NNS N
were VBD N
randomized VBN N
-DOCSTART- -X- O O 25589191

for IN N
EGFR NNP 4_p
mutation-positive JJ 4_p
lung NN 4_p
adenocarcinoma NN 4_p
( ( 4_p
LUX-Lung JJ 4_p
3 CD 4_p
and CC N
LUX-Lung NNP 4_p
6 CD 4_p
) ) N
: : N
patients NNS 4_p
with IN 4_p
EGFR NNP 4_p
mutation-positive JJ 4_p
lung NN 4_p
adenocarcinoma NN 4_p
Previously RB N
untreated VBD N
patients NNS N
with IN N
EGFR NNP N
mutation-positive JJ N
stage NN N
IIIB NNP N
or CC N
IV NNP N
lung NN N
adenocarcinoma NN 4_p
were VBD N
enrolled VBN N
in IN N
LUX-Lung NNP N
3 CD N
( ( N
n=345 NN 3_p
) ) N
and CC N
LUX-Lung JJ N
6 CD N
( ( N
n=364 NN 3_p
) ) N
. . N

population NN N
345 CD 3_p
patients NNS N
patients NNS 4_p
with IN 4_p
EGFR NNP 4_p
229 CD 3_p
patients NNS 3_p
in IN N
LUX-Lung NNP N
3 CD N
239 CD 3_p
patients NNS 3_p
in IN N
LUX-Lung NNP N
patients NNS 4_p
with IN 4_p
del19 JJ 4_p
EGFR NNP 4_p
mutations NNS 4_p
. . N

patients NNS 4_p
with IN 4_p
Leu858Arg NNP 4_p
EGFR NNP 4_p
mutations NNS 4_p
-DOCSTART- -X- O O 11265037

unstable JJ N
trochanteric JJ N
hip NN N
fractures NNS N
: : N
analysis NN N
of IN N
218 CD N
fractures NNS N
. . N

retrospective JJ N
radiographic JJ N
review NN N
of IN N
218 CD N
unstable JJ N
fractures NNS N
-DOCSTART- -X- O O 8419816

104 CD 3_p
patients NNS N
with IN N
H. NNP 4_p
pylori FW 4_p
infection NN 4_p
and CC N
recurrent JJ 4_p
duodenal JJ 4_p
ulcer NN 4_p
52 CD 3_p
patients NNS N
given VBN N
antibiotics NNS N
patients NNS N
with IN N
recurrent JJ 4_p
duodenal JJ 4_p
ulcer NN 4_p
-DOCSTART- -X- O O 18635304

80 CD 3_p
adults NNS 1_p
were VBD N
randomly RB N
assigned VBN N
-DOCSTART- -X- O O 25690266

patients NNS N
requesting VBG N
same-day JJ N
consultations NNS N
in IN N
general JJ N
practice NN N
. . N

GP-led NNP 4_p
telephone NN 4_p
triage NN 4_p
( ( 4_p
GPT NNP 4_p
) ) 4_p
nurse-led JJ 4_p
computer-supported JJ 4_p
telephone NN 4_p
triage NN 4_p
( ( 4_p
NT NNP 4_p
) ) N
General NNP N
practices NNS N
( ( N
n JJ N
= NNP N
42 CD N
) ) N
in IN N
four CD N
regions NNS N
of IN N
England NNP N
PARTICIPANTS JJ N
Patients NNPS N
requesting VBG N
same-day JJ N
consultations NNS N
RESULTS NNP N
Of IN N
20,990 CD 3_p
eligible JJ N
randomised VBN N
patients NNS N
( ( N
UC NNP N
n RB N
= JJ N
7283 CD N
; : N
GPT NNP N
n IN N
= JJ N
6695 CD N
; : N
NT NNP N
n IN 3_p
= NNP 3_p
7012 CD 3_p
) ) N
, , N
primary JJ N
outcome NN N
data NNS N
were VBD N
analysed VBN N
for IN N
-DOCSTART- -X- O O 8141223

Maternal NNP N
erythropoietin NN N
in IN N
singleton NN 4_p
pregnancies NNS 4_p
: : N
97 CD 3_p
patients NNS N
with IN N
a DT N
first-trimester JJ N
hemoglobin NN N
level NN N
> NN N
or CC N
= $ N
14.0 CD N
gm/dl NN N
( ( N
hematinic JJ N
group NN N
, , N
n RB N
= VBZ N
53 CD 3_p
) ) N
or CC N
a DT N
placebo NN N
( ( N
n JJ N
= NNP N
44 CD 3_p
) ) N
. . N

-DOCSTART- -X- O O 12531809

patients NNS 4_p
with IN 4_p
standard-risk JJ 4_p
acute JJ 4_p
lymphoblastic JJ 4_p
leukemia NN 4_p
: : 4_p
childhood NN 4_p
acute NN 4_p
lymphoblastic JJ 4_p
leukemia NN 4_p
( ( 4_p
ALL DT 4_p
) ) 4_p
more JJR N
than IN N
1000 CD N
subjects NNS N
Children NNP N
with IN N
National NNP N
Cancer NNP N
Institute NNP N
standard-risk NN N
ALL NNP N
-DOCSTART- -X- O O 24105031

Thai NNP N
beef NN N
cattle NNS N
-- : N
nitrogen DT N
utilization NN N
, , N
blood NN 4_p
biochemistry NN 4_p
, , N
and CC N
hematology NN N
. . N

Four CD N
Thai NNP N
male NN 2_p
native JJ N
beef NN N
cattle NNS N
, , N
initial JJ 4_p
body NN 4_p
weight NN 4_p
( ( 4_p
BW NNP 4_p
) ) 4_p
of IN 4_p
100 CD 4_p
± JJ 4_p
3.0 CD 4_p
kg NNS 4_p
in IN N
Thai NNP N
native JJ N
beef NN N
cattle NNS N
fed VBP N
on IN N
rice NN N
straw NN N
-DOCSTART- -X- O O 3830804

primary JJ N
digestive JJ N
localizations NNS N
of IN N
non-Hodgkin NN 4_p
's POS 4_p
lymphoma NN 4_p
] NN 4_p
chemotherapy JJ N
treatment NN N
in IN N
82 CD 3_p
patients NNS N
presenting VBG N
with IN N
primary JJ 4_p
digestive JJ 4_p
lymphoma NN 4_p
and CC N
included VBD N
in IN N
a DT N
study NN N
conducted VBN N
between IN N
October NNP N
1977 CD N
and CC N
October NNP N
1985 CD N
. . N

31 CD 3_p
gastric JJ 4_p
lymphoma NN 4_p
, , N
18 CD 3_p
small JJ 4_p
intestinal JJ 4_p
lymphomas NN 4_p
, , N
and CC N
19 CD 3_p
with IN N
multiple JJ 4_p
involvement NN 4_p
: : N
63 CD N
patients NNS N
had VBD N
had VBN N
a DT N
surgical JJ N
staging NN N
with IN N
total JJ N
tumor NN N
resection NN N
in IN N
15 CD N
cases NNS N
. . N

Nineteen JJ 3_p
patients NNS N
with IN N
limited JJ 4_p
disease NN 4_p
( ( 4_p
ID NNP 4_p
and CC 4_p
IID NNP 4_p
) ) 4_p
Twenty-seven JJ 3_p
stage NN 4_p
IIID NNP 4_p
and CC N
thirty-six JJ 3_p
stage NN 4_p
IV NNP 4_p
Low JJ N
grade NN N
lymphomas NN N
( ( N
16 CD N
patients NNS N
) ) N
Intermediate NNP N
( ( N
56 CD N
patients NNS N
) ) N
and CC N
high JJ N
grade NN N
( ( N
10 CD N
patients NNS N
) ) N
lymphomas VBP N
100 CD N
( ( N
51 CD N
patients NNS N
) ) N
with IN N
17 CD N
patients NNS N
in IN N
relapse NN N
within IN N
6 CD N
to TO N
40 CD N
months NNS N
. . N

-DOCSTART- -X- O O 15793648

Patients NNS 4_p
with IN 4_p
Grade NNP 4_p
III NNP 4_p
hemorrhoids NNS 4_p
who WP 4_p
were VBD 4_p
employed VBN 4_p
during IN 4_p
the DT 4_p
trial NN 4_p
period NN 4_p
Over IN N
a DT N
20-month JJ N
period NN N
, , N
88 CD N
patients NNS N
were VBD N
recruited VBN N
. . N

-DOCSTART- -X- O O 16378639

Twenty NNP 3_p
eyes NNS 3_p
of IN 3_p
20 CD 3_p
consecutive JJ 3_p
patients NNS 3_p
( ( N
spherical JJ N
equivalent NN N
[ NNP N
SE NNP N
] NNP N
, , N
-2.01+/-1.36 NNP N
diopters NNS N
[ NNP N
D NNP N
] NNP N
) ) N
treated VBD N
with IN N
wavefront-guided JJ N
Zyoptix NNP N
Ablation NNP N
Refinement NNP N
software NN N
( ( N
ZAR NNP N
) ) N
LASIK NNP N
and CC N
20 CD 3_p
eyes NNS 3_p
of IN N
20 CD 3_p
consecutive JJ 3_p
patients NNS 3_p
( ( N
SE NNP N
, , N
-1.81+/-1.21 NNP N
D NNP N
) ) N
treated VBD N
with IN N
standard JJ N
Planoscan NNP N
LASIK NNP N
, , N
both DT N
for IN N
residual JJ 4_p
refractive JJ 4_p
error NN 4_p
enhancement NN 4_p
. . N

-DOCSTART- -X- O O 6751144

the DT N
elderly JJ 1_p
. . N

after IN N
upper JJ N
abdominal JJ N
surgery NN N
. . N

20 CD 3_p
patients NNS N
aged VBD 1_p
61 CD 1_p
to TO 1_p
78 CD 1_p
years NNS 1_p
. . N

elderly JJ N
patients NNS N
undergoing VBG 4_p
upper JJ 4_p
abdominal JJ 4_p
surgery NN 4_p
-DOCSTART- -X- O O 19595104

large JJ 4_p
hepatocellular JJ 4_p
carcinoma NN 4_p
] NNP 4_p
hepatocellular JJ 4_p
carcinoma NN 4_p
( ( 4_p
HCC NNP 4_p
) ) 4_p
. . 4_p

Sixty-eight JJ 3_p
patients NNS N
with IN N
unresectable JJ N
HCC NNP N
patients NNS 4_p
with IN 4_p
multiple JJ 4_p
lesions NNS 4_p
-DOCSTART- -X- O O 22582764

preschoolers NNS 1_p
with IN N
autism NN 4_p
. . N

children NNS 1_p
with IN N
an DT N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
attend VBP 4_p
public JJ 4_p
preschools NNS 4_p
public JJ 4_p
preschool NN 4_p
teachers NNS 4_p
Sixteen NNP 3_p
dyads NNS N
( ( N
preschoolers NNS 1_p
with IN N
ASD NNP 4_p
and CC N
the DT N
public JJ N
school NN N
teachers NNS N
who WP N
worked VBD N
in IN N
the DT N
child NN N
's POS N
classroom NN N
) ) N
teachers NNS 4_p
children NNS 1_p
with IN N
ASD NNP 4_p
in IN N
a DT N
public JJ 4_p
preschool NN 4_p
-DOCSTART- -X- O O 8571077

among IN N
hypercholesterolaemic JJ 4_p
, , N
postmenopausal JJ 4_p
women NNS 2_p
. . N

Hypercholesterolaemic NNP 4_p
, , N
postmenopausal JJ 4_p
women NNS 4_p
non-smoking JJ 4_p
, , N
hypercholesterolaemic JJ 4_p
, , N
postmenopausal JJ 4_p
women NNS 4_p
-DOCSTART- -X- O O 20966820

One CD 3_p
hundred VBD 3_p
twenty-five JJ 3_p
volunteers NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
treatment NN 3_p
( ( 3_p
n JJ 3_p
= NNP 3_p
100 CD 3_p
) ) 3_p
or CC N
control VB 3_p
group NN 3_p
( ( 3_p
n JJ 3_p
= NNP 3_p
25 CD 3_p
) ) 3_p
after IN N
examination NN N
by IN N
the DT N
team NN N
neurologist NN N
to TO N
ensure VB N
a DT N
diagnosis NN N
of IN N
migraine NN 4_p
headache NN 4_p
. . N

100 CD 3_p
patients NNS N
in IN N
the DT N
treatment NN N
group NN N
-DOCSTART- -X- O O 7873425

baroreflex JJ 4_p
control NN 4_p
of IN 4_p
heart NN 4_p
rate NN 4_p
in IN 4_p
humans NNS 4_p
. . N

-DOCSTART- -X- O O 24897394

Postpartum NNP 4_p
hemorrhage NN 4_p
89 CD 3_p
pregnant JJ N
women NNS 2_p
to TO N
whom WP N
oxytocin NN N
was VBD N
administered VBN N
after IN N
placenta JJ N
separation NN N
were VBD N
studied VBN N
in IN N
Group NNP N
1 CD N
, , N
89 CD 3_p
pregnant JJ 3_p
women NNS 2_p
were VBD N
included VBN N
in IN N
Group NNP N
2 CD N
, , N
and CC N
oxytocin NN N
was VBD N
administered VBN N
after IN N
delivery NN N
of IN N
the DT N
shoulder NN N
. . N

-DOCSTART- -X- O O 25515056

Guillian-Barre NNP 4_p
syndrome NN 4_p
. . 4_p

plasma JJ 4_p
exchange NN 4_p
( ( 4_p
PE NNP 4_p
) ) 4_p
and CC N
intravenous JJ 4_p
immunoglobulin NN 4_p
( ( 4_p
IVIg NNP 4_p
) ) 4_p
for IN N
Guillian-Barre NNP 4_p
Syndrome NNP 4_p
( ( 4_p
GBS NNP 4_p
) ) 4_p
. . N

64 CD 3_p
adult NN 1_p
patients NNS 1_p
with IN N
GBS NNP 4_p
for IN 4_p
PE NNP 4_p
and CC N
IVIg NNP 4_p
treatment NN 4_p
, , N
respectively RB N
, , N
and CC N
nerve NN 4_p
function NN 4_p
reduce VB 4_p
the DT 4_p
GBS NNP 4_p
patients NNS 4_p
' POS N
rehabilitation NN 4_p
of IN 4_p
patients NNS 4_p
-DOCSTART- -X- O O 19901118

postmenopausal JJ 4_p
women NNS 2_p
in IN N
a DT N
substudy NN N
of IN N
the DT N
women NNS N
's POS N
health NN N
initiative NN N
randomized VBN N
trial NN N
. . N

diverse JJ N
racial/ethnic JJ N
populations NNS N
subsample NN N
of IN N
the DT N
Women NNP N
's POS N
Health NNP N
Initiative NNP N
( ( N
WHI NNP N
) ) N
clinical JJ N
trial NN N
participants NNS N
. . N

women NNS 2_p
random JJ N
sample NN N
of IN 3_p
435 CD 3_p
racially RB 3_p
and CC 3_p
ethnically RB 3_p
diverse JJ 3_p
participants NNS 3_p
from IN N
15 CD N
of IN N
40 CD N
WHI NNP N
clinics NNS N
. . N

women NNS 2_p
age NN 1_p
60 CD 1_p
to TO 1_p
79 CD 1_p
years NNS 1_p
-DOCSTART- -X- O O 12709801

acute JJ 4_p
bacterial JJ 4_p
maxillary JJ 4_p
sinusitis NN 4_p
in IN N
adults NNS 1_p
. . 1_p

outpatients NNS N
with IN N
both DT N
clinical JJ N
signs NNS N
and CC N
symptoms NNS N
and CC N
radiographic JJ N
evidence NN N
of IN N
acute JJ 4_p
sinusitis NN 4_p
452 CD 3_p
patients NNS N
considered VBN N
valid JJ N
for IN N
clinical JJ N
efficacy NN N
-DOCSTART- -X- O O 19691092

patients NNS N
with IN N
localized JJ 4_p
prostate NN 4_p
cancer NN 4_p
: : N
From IN N
December NNP N
1997 CD N
through IN N
February NNP N
2003 CD N
, , N
244 CD 3_p
men NNS 3_p
with IN N
newly RB N
diagnosed VBN N
localized JJ 4_p
prostate NN 4_p
cancer NN 4_p
-DOCSTART- -X- O O 21309696

children NNS 4_p
and CC 4_p
adolescents NNS 4_p
with IN 4_p
autism NN 4_p
: : 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
. . 4_p

sample NN 4_p
of IN 4_p
children NNS 4_p
and CC 4_p
adolescents NNS 4_p
with IN 4_p
ASD NNP 4_p
. . 4_p

Thirty-four JJ 4_p
children NNS 4_p
and CC 4_p
adolescents NNS 4_p
with IN 4_p
ASD NNP 4_p
( ( 4_p
age NN 4_p
range NN 4_p
8-17 CD 4_p
years NNS 4_p
; : 4_p
IQ NNP 4_p
> NNP 4_p
75 CD 4_p
) ) 4_p
were VBD 4_p
enrolled VBN 4_p
-DOCSTART- -X- O O 24557758

patients NNS N
undergoing JJ N
retinal JJ 4_p
angiography NN 4_p
. . N

diabetic JJ 4_p
and CC 4_p
nondiabetic JJ 4_p
patients NNS N
undergoing VBG N
retinal JJ N
angiography NN N
by IN N
comparing VBG N
it PRP N
with IN N
usually RB N
administered VBN N
eyedrops NNS N
( ( N
tropicamide VB N
1 CD N
% NN N
and CC N
phenylephrine VB N
10 CD N
% NN N
) ) N
total NN N
of IN N
154 CD N
eyes NNS N
of IN N
77 CD 3_p
patients NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
2 CD N
groups NNS N
: : N
diabetic JJ 4_p
patients NNS 4_p
diabetic JJ 4_p
and CC 4_p
nondiabetic JJ 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 11435682

acute JJ 4_p
phase NN 4_p
of IN N
stroke NN 4_p
. . N

acute JJ N
stroke NN N
patients NNS N
One CD 3_p
hundred CD 3_p
and CC 3_p
twenty-nine JJ 3_p
patients NNS N
examined VBD N
within IN N
a DT N
median NN N
of IN N
72 CD N
h NN N
, , N
lying VBG N
on IN N
the DT N
left JJ N
side NN N
resulted VBD N
in IN N
slightly RB N
lower JJR N
SaO NNP N
( ( N
2 CD N
) ) N
than IN N
lying VBG N
on IN N
the DT N
right JJ N
side NN N
, , N
which WDT N
was VBD N
statistically RB N
significant JJ N
in IN N
the DT N
patients NNS N
with IN N
a DT N
right NN N
( ( N
n JJ N
= NNP N
66 CD N
) ) N
, , N
but CC N
not RB N
left VBD N
, , N
hemiparesis NN N
. . N

-DOCSTART- -X- O O 14749563

severely RB 4_p
burned JJ 4_p
children NNS 1_p
. . N

Thirty-five JJ 3_p
children NNS 3_p
with IN N
> NN N
or CC N
=40 CD N
% NN N
total JJ N
body NN N
surface NN N
area NN N
burns NNS N
were VBD N
randomized VBN N
-DOCSTART- -X- O O 10380161

humans NNS N
exposed VBN 4_p
to TO 4_p
2.0 CD 4_p
ppm NNS 4_p
nitrogen JJ 4_p
dioxide NN 4_p
. . N

8 CD 3_p
healthy JJ N
volunteers NNS N
were VBD N
exposed VBN 4_p
to TO 4_p
2.0 CD 4_p
ppm NN 4_p
NO2 NNP 4_p
and CC 4_p
to TO 4_p
filtered VB 4_p
air NN 4_p
for IN 4_p
4 CD 4_p
h NNS 4_p
while IN N
undergoing VBG N
intermittent JJ 4_p
moderate JJ 4_p
exercise NN 4_p
. . N

-DOCSTART- -X- O O 1960378

Treatment NN N
of IN N
hepatitis NN N
B NNP N
virus NN N
infection NN N
with IN N
interferon NN N
. . N

patients NNS N
with IN N
HBe NNP N
antigen-positive JJ N
disease NN N
acquired VBD N
in IN N
adult NN N
life NN N
Twenty-one CD N
pretreatment JJ N
variables NNS N
were VBD N
assessed VBN N
for IN N
their PRP$ N
significance NN N
in IN N
response NN N
prediction NN N
using VBG N
data NNS N
from IN N
114 CD N
patients NNS N
given VBN N
alpha-interferon NNS N
for IN N
chronic JJ N
hepatitis NN N
B NNP N
virus NN N
infection NN N
. . N

patients NNS N
-DOCSTART- -X- O O 9652612

acute NN 4_p
and CC 4_p
gangrenous JJ 4_p
cholecystitis NN 4_p
. . N

acute JJ 4_p
cholecystitis NN 4_p
. . N

patients NNS N
with IN N
acute JJ 4_p
cholecystitis NN 4_p
. . N

63 CD 3_p
of IN N
68 CD 3_p
consecutive JJ N
patients NNS N
who WP N
met VBD N
criteria NNS N
for IN N
acute JJ 4_p
cholecystitis NN 4_p
were VBD N
randomly RB N
assigned VBN N
OC NNP N
( ( N
31 CD 3_p
patients NNS N
) ) N
or CC N
LC NNP N
( ( N
32 CD 3_p
patients NNS N
) ) N
. . N

-DOCSTART- -X- O O 17666359

HBV-carrying NNP 4_p
renal JJ 4_p
transplant NN 4_p
recipients NNS 4_p
] VBP N
kidney NN 4_p
transplant NN 4_p
( ( 4_p
KT NNP 4_p
) ) 4_p
recipients VBZ 4_p
carrying VBG 4_p
hepatitis NN 4_p
B NNP 4_p
Virus NNP 4_p
( ( 4_p
HBV NNP 4_p
) ) 4_p
. . 4_p

109 CD 3_p
patients NNS 3_p
with IN N
HBV NNP N
HBV-carrying NNP 4_p
renal JJ 4_p
transplant NN 4_p
recipients NNS 4_p
-DOCSTART- -X- O O 15358441

postmenopausal JJ 4_p
women NNS 2_p
. . N

Twenty NNP 3_p
six CD 3_p
postmenopausal JJ 4_p
women NNS 2_p
with IN N
climacteric JJ 4_p
symptoms NNS 4_p
were VBD N
two CD N
groups NNS N
; : N
one CD N
group NN N
who WP N
displayed VBD N
a DT N
significant JJ N
variance NN N
in IN N
negative JJ 4_p
mood NN 4_p
symptoms NNS 4_p
during IN N
HRT NNP N
( ( N
cyclicity NN N
) ) N
and CC N
one CD N
group NN N
with IN N
no DT N
cyclical JJ N
changes NNS N
in IN N
negative JJ 4_p
mood NN 4_p
symptoms NNS 4_p
during IN N
treatment NN N
. . N

Women NNP N
expressing VBG N
cyclicity NN N
in IN N
negative JJ 4_p
mood NN 4_p
symptoms NNS 4_p
-DOCSTART- -X- O O 10075386

hypertensive JJ 4_p
patients NNS 4_p
: : 4_p
36 CD 4_p
never-treated JJ 4_p
mild NN 4_p
to TO 4_p
moderate VB 4_p
hypertensive JJ 4_p
patients NNS 4_p
. . 4_p

-DOCSTART- -X- O O 15154956

larger JJR 4_p
patient JJ 4_p
population NN 4_p
. . 4_p

Nine NNP 4_p
hundred VBD 4_p
patient JJ N
aged VBN N
< NN 1_p
80 CD 1_p
, , N
with IN N
diabetes NNS 4_p
of IN N
> NN N
or CC N
=1 JJ N
year NN N
known VBN N
duration NN N
, , N
treated VBN N
by IN N
either DT N
diet JJ N
alone NN N
or CC N
diet JJ N
and CC N
oral JJ N
agents NNS N
, , N
will MD N
be VB N
recruited VBN N
in IN N
15 CD N
centres NNS N
and CC N
followed VBD N
for IN N
4 CD N
years NNS N
. . N

-DOCSTART- -X- O O 25453593

Breastfeeding NNP 4_p
( ( 4_p
BF NNP 4_p
) ) 4_p
mothers NNS 2_p
enrolled VBD N
mothers NNS 2_p
were VBD N
randomised VBN N
to TO N
an DT N
intervention NN N
( ( N
IG NNP N
, , N
n JJ N
= VBP N
18 CD 3_p
; : N
6 CD N
BF NNP N
) ) N
or CC N
control VB N
group NN N
( ( N
CG NNP N
, , N
n JJ N
= VBP N
18 CD N
; : N
6 CD N
BF NNP N
) ) N
. . N

IG JJ N
differences NNS N
were VBD N
observed VBN N
-DOCSTART- -X- O O 18321372

patients NNS N
with IN N
liver JJ N
metastases NNS N
from IN N
colorectal JJ N
cancer NN N
150 CD N
patients NNS N
will MD N
be VB N
included VBN N
and CC N
randomized VBN N
intraoperatively RB N
after IN N
surgical JJ N
exploration NN N
just RB N
prior RB N
to TO N
resection NN N
. . N

-DOCSTART- -X- O O 22640463

on IN N
senior JJ N
medical JJ N
students NNS 4_p
volunteer NN N
senior JJ 4_p
medical JJ 4_p
students NNS 4_p
. . N

-DOCSTART- -X- O O 3960619

preterm JJ 4_p
infants NNS 1_p
. . N

Preterm NNP N
infants NNS 1_p
preterm NN 4_p
infant NN 1_p
. . N

Two CD N
groups NNS N
of IN N
five CD 3_p
preterm JJ N
infants NNS N
-DOCSTART- -X- O O 15960148

hyperphosphatemic JJ N
patients NNS N
with IN N
end-stage JJ N
renal JJ N
disease NN N
. . N

patients NNS N
receiving VBG N
long-term JJ N
dialysis NN N
treatment NN N
. . N

patients NNS N
with IN N
end-stage JJ N
renal JJ N
disease NN N
( ( N
ESRD NNP N
) ) N
. . N

Chinese JJ N
patients NNS N
with IN N
ESRD NNP N
. . N

male NN N
and CC N
female JJ N
hemodialysis NN N
patients NNS N
n=73 CC N
) ) N
n=30 CC N
) ) N
n=31 CC N
; : N
Chinese JJ N
patients NNS N
with IN N
ESRD NNP N
. . N

-DOCSTART- -X- O O 7803065

older JJR 1_p
adults NNS 1_p
: : 1_p
the DT 1_p
elderly JJ 1_p
older JJR 1_p
adults NNS 1_p
older JJR N
adults NNS N
whose WP$ N
health NN 4_p
behaviors NNS 4_p
put VBD 4_p
them PRP 4_p
at IN 4_p
risk NN 4_p
1988 CD 4_p
the DT 4_p
Health NNP 4_p
Care NNP 4_p
Financing NNP 4_p
Administration NNP 4_p
older JJR 1_p
adults NNS 1_p
. . 1_p

one CD N
of IN N
the DT N
five CD N
demonstration NN N
sites NNS N
. . N

Over IN N
1,900 CD 3_p
community-dwelling JJ 3_p
Medicare NNP 3_p
beneficiaries NNS 3_p
who WP N
receive VBP N
their PRP$ N
health NN N
care NN N
through IN N
fee-for-service JJ N
providers NNS N
were VBD N
enrolled VBN N
in IN N
the DT N
demonstration NN N
. . N

Nine NNP 3_p
hundred-seventy-three NN 3_p
of IN N
the DT N
experimental JJ N
subjects NNS N
and CC N
938 CD N
of IN N
the DT N
control NN N
subjects VBZ N
completed VBN 4_p
a DT 4_p
lengthy JJ 4_p
telephone NN 4_p
interview NN 4_p
, , 4_p
which WDT 4_p
determined VBD 4_p
each DT 4_p
person NN 4_p
's POS 4_p
use NN 4_p
of IN 4_p
preventive JJ 4_p
services NNS 4_p
and CC 4_p
practices NNS 4_p
. . N

Although IN N
all DT N
973 CD N
experimental JJ N
subjects NNS N
were VBD N
invited VBN N
by IN N
letter NN N
and CC N
follow-up JJ N
telephone NN N
calls VBZ N
to TO N
attend VB N
these DT N
free-of-charge JJ N
, , N
Medicare-provided JJ N
sessions NNS N
, , N
not RB N
everyone NN N
attended VBD N
-DOCSTART- -X- O O 22124576

young JJ N
adults NNS N
with IN N
childhood-onset JJ N
growth NN N
hormone NN N
deficiency NN N
. . N

young JJ N
adults NNS N
with IN N
childhood-onset JJ N
GH NNP N
deficiency NN N
In IN N
young JJ N
adults NNS N
with IN N
childhood-onset JJ N
growth NN N
hormone NN N
deficiency NN N
( ( N
CO NNP N
GHD NNP N
) ) N
Patients NNPS N
( ( N
n JJ N
= VBZ N
160 CD N
; : N
mean JJ N
age NN N
, , N
21.2 CD N
years NNS N
; : N
63 CD N
% NN N
males NNS N
) ) N
with IN N
CO NNP N
-DOCSTART- -X- O O 6367857

women NNS 2_p
with IN 4_p
operable JJ 4_p
breast NN 4_p
cancer NN 4_p
with IN 4_p
histologically RB 4_p
positive JJ 4_p
axillary JJ 4_p
lymph NN 4_p
nodes NNS 4_p
. . 4_p

patients NNS N
with IN N
a DT N
68-month JJ N
median JJ N
follow-up NN N
172 CD 3_p
receiving VBG N
CMFVP NNP N
186 CD 3_p
women NNS N
given VBN N
L-PAM NNP N
women NNS N
who WP N
were VBD N
premenopausal NN 4_p
-DOCSTART- -X- O O 17302075

pediatric JJ N
anesthesia NN N
: : N
patients NNS N
were VBD N
24 CD N
children NNS N
undergoing VBG N
tonsillectomy NN N
and CC N
adenoidectomy NN N
. . N

-DOCSTART- -X- O O 8472567

medical JJ 4_p
intensive JJ 4_p
care NN 4_p
unit NN 4_p
patients NNS 4_p
. . 4_p

critically RB 4_p
ill JJ 4_p
patients NNS 4_p
; : 4_p
The DT N
medical JJ N
intensive JJ N
care NN N
unit NN N
( ( N
ICU NNP N
) ) N
of IN N
a DT N
university NN N
hospital NN N
located VBN N
in IN N
a DT N
large JJ N
metropolitan JJ N
area NN N
. . N

A DT N
total NN N
of IN N
100 CD N
patients NNS N
who WP N
were VBD N
admitted VBN N
to TO N
the DT N
medical JJ N
ICU NNP N
, , N
required VBD N
arterial JJ N
line NN N
monitoring NN N
for IN N
clinical JJ N
purposes NNS N
, , N
and CC N
were VBD N
managed VBN N
by IN N
the DT N
ICU NNP N
medical JJ N
service NN N
. . N

Exclusion NNP N
criteria NNS N
included VBD N
active JJ N
bleeding NN N
or CC N
chronic JJ N
renal JJ N
failure NN N
at IN N
the DT N
time NN N
of IN N
ICU NNP N
admission NN N
. . N

critically RB N
ill JJ N
patients NNS N
critically RB N
ill JJ N
patients NNS N
-DOCSTART- -X- O O 24101715

children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . N

children NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
A DT N
total NN N
of IN N
32 CD 3_p
children NNS 3_p
aged VBN N
9-13 CD 1_p
years NNS 1_p
Child NN N
and CC N
parent NN N
groups NNS N
Children NNP 4_p
met VBD 4_p
diagnostic JJ 4_p
criteria NNS 4_p
for IN 4_p
1-6 JJ 4_p
anxiety NN 4_p
disorders NNS 4_p
( ( 4_p
median JJ 4_p
3 CD 4_p
) ) 4_p
. . 4_p

UK NNP N
child NN N
and CC N
adolescent JJ N
mental NN N
health NN N
services NNS N
-DOCSTART- -X- O O 17276748

pervasive JJ N
developmental NN N
disorders NNS N
( ( N
PDD NNP N
) ) N
children NNS N
with IN N
PDD NNP N
. . N

83 CD N
youngsters NNS N
with IN N
PDD NNP N
. . N

children NNS N
with IN N
PDD NNP N
-DOCSTART- -X- O O 22574591

acute NN N
exacerbated VBD N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
patients NNS N
] VBP N
acute NN N
exacerbated VBD N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
( ( N
COPD NNP N
) ) N
patients NNS N
. . N

Seventy-nine JJ N
patients NNS N
with IN N
acute JJ N
exacerbated VBN N
COPD NNP N
acute NN 4_p
exacerbated VBN 4_p
COPD NNP 4_p
patients NNS 4_p
. . 4_p

-DOCSTART- -X- O O 16200817

inflammatory JJ 4_p
biomarkers NNS 4_p
in IN 4_p
atopic NN 4_p
asthma NN 4_p
. . 4_p

Fourteen NNP 3_p
atopic NN 3_p
patients NNS 3_p
with IN N
mild-to-moderate JJ N
asthma NN N
( ( N
forced JJ N
expiratory NN N
volume NN N
in IN N
1 CD N
second NN N
of IN N
76 CD N
% NN N
) ) N
corticosteroid-treatedatopic JJ 4_p
asthmatic JJ 4_p
patients NNS 4_p
. . 4_p

-DOCSTART- -X- O O 7676782

termination NN 4_p
of IN N
pregnancy NN 4_p
. . 4_p

Sixty NNP 3_p
unpremedicated VBD N
, , N
Asa NNP N
1-2 JJ N
women NNS N
-DOCSTART- -X- O O 20149953

40-year-old JJ 1_p
women NNS 2_p
. . N

321 CD 3_p
women NNS 2_p
aged VBN 1_p
38-45 CD 1_p
years NNS 1_p
was VBD N
conducted VBN N
. . N

Women NNP 2_p
in IN N
the DT N
intervention NN N
group NN N
-DOCSTART- -X- O O 3287999

Forty NNP 3_p
patients NNS N
scheduled VBN N
to TO N
undergo VB N
thoracotomy NN 4_p
-DOCSTART- -X- O O 1642441

ventricular JJ N
arrhythmia NN N
] NNP N
18 CD N
adult NN N
patients NNS N
( ( N
7 CD N
women NNS N
and CC N
11 CD N
men NNS N
) ) N
aged VBD N
50 CD N
+/- JJ N
7 CD N
patients NNS N
with IN N
more JJR N
than IN N
100 CD N
premature JJ N
ventricular JJ N
contractions NNS N
( ( N
PVC NNP N
) ) N
per IN N
hour NN N
in IN N
two CD N
24 CD N
hour NN N
Holter NNP N
records NNS N
obtained VBN N
at IN N
an DT N
interval NN N
of IN N
7 CD N
days NNS N
population NN N
with IN N
a DT N
low JJ N
risk NN N
of IN N
serious JJ N
rhythm JJ N
events NNS N
-DOCSTART- -X- O O 19814586

patients NNS N
with IN N
cancer NN 4_p
. . N

opioid-tolerant JJ N
patients NNS N
with IN N
cancer NN N
. . N

conducted VBN N
in IN N
opioid-tolerant JJ 4_p
male NN 2_p
and CC 2_p
female JJ 2_p
patients NNS N
( ( N
aged VBN 1_p
> NN 1_p
or CC 1_p
=17 CD 1_p
years NNS 1_p
) ) N
with IN N
BTcP NNP N
. . N

131 CD 3_p
patients NNS N
entered VBD N
the DT N
titration NN N
phase NN N
, , N
of IN N
whom WP N
61 CD 3_p
were VBD N
included VBN N
in IN N
the DT N
primary JJ N
efficacy NN N
analysis NN N
. . N

opioid-tolerant JJ N
patients NNS N
with IN N
cancer NN N
. . N

-DOCSTART- -X- O O 24320862

interscalene JJ 4_p
block NN 4_p
. . 4_p

-DOCSTART- -X- O O 20932687

nonresectable JJ 4_p
rectal JJ 4_p
cancer NN 4_p
: : N
locally RB 4_p
advanced JJ 4_p
rectal JJ 4_p
cancer NN 4_p
Patients NNP N
( ( N
N NNP N
= NNP N
207 CD 3_p
) ) N
with IN N
nonresectable JJ 4_p
rectal JJ 4_p
cancer NN 4_p
were VBD N
randomized VBN N
to TO N
preoperative VB N
CRT NNP N
or CC N
RT NNP N
( ( N
2 CD N
Gy NNP N
× VBD N
25 CD N
± NNP N
5-fluorouracil/leucovorin JJ N
) ) N
the DT N
105 CD 3_p
patients NNS N
alive JJ N
in IN N
Norway NNP N
and CC N
Sweden NNP N
after IN N
4 CD N
to TO N
12 CD N
years NNS N
of IN N
follow-up NN N
, , N
78 CD N
( ( N
74 CD N
% NN N
) ) N
Of IN N
44 CD N
patients NNS N
in IN N
the DT N
CRT NNP N
group NN N
for IN N
locally RB N
advanced JJ N
rectal JJ N
cancer NN N
-DOCSTART- -X- O O 25022248

autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . 4_p

Individuals NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
children NNS 1_p
with IN N
ASD NNP 4_p
and CC N
typically-developing NN 4_p
( ( 4_p
TD NNP 4_p
) ) 4_p
controls VBZ 4_p
. . N

Thirty-one CD 3_p
children NNS N
with IN N
ASD NNP 4_p
and CC N
31 CD N
age NN N
and CC N
IQ NNP N
matched VBD N
TD NNP N
children NNS N
( ( 1_p
average JJ 1_p
age NN 1_p
= JJ 1_p
12 CD 1_p
years NNS 1_p
) ) N
ASD NNP 4_p
-DOCSTART- -X- O O 23678498

families NNS N
in IN N
challenging VBG N
contexts NN N
: : N
France NNP N
children NNS N
being VBG N
referred VBN N
for IN N
mental JJ N
health NN N
problems NNS N
. . N

families NNS N
living VBG N
in IN N
vulnerable JJ N
contexts NN N
. . N

440 CD N
women NNS N
and CC N
their PRP$ N
families NNS N
, , N
took VBD N
place NN N
in IN N
Paris NNP N
and CC N
its PRP$ N
inner JJ N
suburbs NNS N
from IN N
2006 CD N
to TO N
2011 CD N
. . N

To TO N
be VB N
eligible JJ N
for IN N
inclusion NN N
, , N
women NNS N
had VBD N
to TO N
be VB N
( ( N
i NN N
) ) N
under IN N
26 CD N
years NNS N
old JJ N
, , N
( ( N
ii NN N
) ) N
less JJR N
that IN N
27 CD N
weeks NNS N
pregnant JJ N
, , N
( ( N
iii NN N
) ) N
sufficiently RB N
fluent VBN N
in IN N
French JJ N
to TO N
give VB N
truly NN N
informed JJ N
consent NN N
to TO N
participate VB N
in IN N
the DT N
study NN N
and CC N
benefit NN N
from IN N
the DT N
intervention NN N
and CC N
( ( N
iv NN N
) ) N
presenting VBG N
with IN N
one CD N
or CC N
more JJR N
of IN N
the DT N
following JJ N
social JJ N
vulnerability NN N
factors NNS N
: : N
low JJ N
income NN N
, , N
low JJ N
educational JJ N
level NN N
, , N
and/or RB N
intending VBG N
to TO N
bring VB N
up RP N
the DT N
child NN N
without IN N
the DT N
child NN N
's POS N
father NN N
. . N

-DOCSTART- -X- O O 15769967

cardiovascular JJ 4_p
events NNS 4_p
and CC N
cancer NN 4_p
: : N
cancer NN 4_p
and CC N
cardiovascular JJ 4_p
events NNS 4_p
. . N

cancer NN 4_p
, , N
cancer NN N
death NN N
, , N
and CC N
major JJ N
cardiovascular JJ 4_p
events NNS 4_p
. . N

international JJ N
patients NNS N
at IN 1_p
least JJS 1_p
55 CD 1_p
years NNS 1_p
old JJ 1_p
with IN N
vascular JJ 4_p
disease NN 4_p
or CC 4_p
diabetes VBZ 4_p
mellitus NN 4_p
was VBD N
extended VBN N
( ( N
HOPE-The NNP N
Ongoing NNP N
Outcomes NNP N
[ NNP N
HOPE-TOO NNP N
] NNP N
) ) N
between IN N
April NNP N
16 CD N
, , N
1999 CD N
, , N
and CC N
May NNP N
26 CD N
, , N
2003 CD N
. . N

267 CD N
HOPE NNP N
centers NNS N
that WDT N
had VBD N
enrolled VBN N
9541 CD 3_p
patients NNS N
, , N
174 CD N
centers NNS N
participated VBN N
in IN N
the DT N
HOPE-TOO NNP N
trial NN N
. . N

7030 CD 3_p
patients NNS N
enrolled VBN N
at IN N
these DT N
centers NNS N
, , N
916 CD 3_p
were VBD N
deceased VBN N
at IN N
the DT N
beginning NN N
of IN N
the DT N
extension NN N
, , N
1382 CD 3_p
refused VBD N
participation NN N
, , N
3994 CD 3_p
continued VBD N
to TO N
take VB N
the DT N
study NN N
intervention NN N
, , N
and CC N
738 CD 3_p
agreed VBD N
to TO N
passive VB N
follow-up NN N
. . N

patients NNS N
with IN N
vascular JJ 4_p
disease NN 4_p
or CC 4_p
diabetes VBZ 4_p
mellitus NNS 4_p
-DOCSTART- -X- O O 20386431

advanced JJ 4_p
pancreatic JJ 4_p
cancer NN 4_p
patients NNS 4_p
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
pancreatic JJ 4_p
cancer NN 4_p
( ( 4_p
APC NNP 4_p
) ) 4_p
. . N

cohort NN N
of IN N
39 CD 3_p
patients NNS 3_p
with IN N
APC NNP N
, , N
without IN N
thrombosis NN 4_p
, , 4_p
receiving VBG 4_p
chemotherapy NN 4_p
APC NNP 4_p
patients NNS 4_p
treated VBD 4_p
-DOCSTART- -X- O O 21575074

primary JJ 1_p
school-aged JJ 1_p
children NNS 1_p
with IN 4_p
pragmatic JJ 4_p
language NN 4_p
impairment NN 4_p
: : N
children NNS 1_p
with IN 4_p
specific JJ 4_p
language NN 4_p
impairment NN 4_p
. . N

Children NNP 1_p
with IN N
pragmatic JJ 4_p
language NN 4_p
impairment NN 4_p
( ( 4_p
CwPLI NNP 4_p
) ) 4_p
CwPLI NNP 4_p
children NNS 1_p
with IN N
specific JJ 4_p
language NN 4_p
impairment NN 4_p
( ( 4_p
CwSLI NNP 4_p
) ) 4_p
. . N

Primary NNP N
school-aged JJ N
CwPLI NNP N
( ( 3_p
n= JJ 3_p
59 CD 3_p
) ) 3_p
and CC N
CwSLI NNP N
( ( 3_p
n= JJ 3_p
12 CD 3_p
) ) 3_p
were VBD N
recruited VBN N
from IN N
speech NN N
and CC N
language NN N
therapists NNS N
. . N

CwPLI NNP N
and CC N
CwSLI NNP N
-DOCSTART- -X- O O 709549

advanced JJ 4_p
carcinoma NN 4_p
of IN 4_p
the DT 4_p
cervix NN 4_p
. . 4_p

-DOCSTART- -X- O O 16540862

patients NNS N
with IN N
low JJ 4_p
back RB 4_p
pain NN 4_p
: : N
low JJ 4_p
back RB 4_p
pain NN 4_p
in IN N
managed VBN N
care NN N
patients NNS N
receiving VBG N
medical JJ N
or CC N
chiropractic JJ N
care NN N
. . N

low VB 4_p
back RB 4_p
pain NN 4_p
patients NNS N
A NNP N
total NN N
of IN N
681 CD 3_p
low JJ 4_p
back RB 4_p
pain NN 4_p
patients NNS N
presenting VBG N
to TO N
a DT N
managed-care JJ N
facility NN N
681 CD 3_p
patients NNS N
, , N
610 CD 3_p
( ( N
89.6 CD N
% NN N
) ) N
were VBD N
followed VBN N
through IN N
18 CD N
months NNS N
. . N

-DOCSTART- -X- O O 8098276

patients NNS N
with IN N
chronic JJ 4_p
heart NN 4_p
failure NN 4_p
: : N
patients NNS N
with IN N
chronic JJ N
heart NN N
failure NN N
. . N

Nineteen NNP 3_p
patients NNS N
entered VBD N
the DT N
study NN N
. . N

Three CD 3_p
patients NNS N
had VBD N
ischemic JJ 4_p
heart NN 4_p
disease NN 4_p
, , N
13 CD N
had VBD N
dilated VBN 4_p
cardiomyopathy NN 4_p
, , N
and CC N
three CD N
had VBD N
valvular JJ 4_p
disease NN 4_p
; : 4_p
16 CD N
patients NNS N
were VBD N
in IN N
New NNP N
York NNP N
Heart NNP N
Association NNP N
class NN N
II NNP N
, , N
and CC N
three CD N
patients NNS N
were VBD N
in IN N
New NNP N
York NNP N
Heart NNP N
Association NNP N
class NN N
III NNP N
. . N

patients NNS N
with IN N
atrial JJ 4_p
fibrillation NN 4_p
patients NNS N
with IN N
sinus JJ 4_p
rhythm NN 4_p
. . N

Patients NNS N
with IN N
mild-to-moderate JJ 4_p
heart NN 4_p
failure NN 4_p
with IN N
sinus NN 4_p
rhythm NN 4_p
those DT N
with IN N
atrial JJ 4_p
fibrillation NN 4_p
because IN N
of IN N
its PRP$ N
frequent JJ N
induction NN N
of IN N
tachycardia NN 4_p
-DOCSTART- -X- O O 21171314

patients NNS 4_p
with IN 4_p
advanced JJ 4_p
larynx NN 4_p
cancer NN 4_p
] NNP N
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
larynx NN 4_p
cancer NN 4_p
. . N

112 CD 3_p
patients NNS 3_p
with IN N
advanced JJ 4_p
larynx NN 4_p
cancer NN 4_p
after IN 4_p
radical JJ 4_p
surgical JJ 4_p
treatment NN 4_p
. . N

Patients NNS 4_p
with IN 4_p
close JJ 4_p
surgical JJ 4_p
margins NNS 4_p
-DOCSTART- -X- O O 8841156

patients NNS N
with IN N
hematologic JJ 4_p
malignancies NNS 4_p
. . N

patients NNS N
with IN N
hematologic JJ 4_p
malignancies NNS 4_p
. . N

Seventy NNP 3_p
immunocompromised VBD 4_p
febrile JJ 4_p
patients NNS N
with IN N
hematologic JJ 4_p
malignancies NNS 4_p
vancomycin JJ N
therapeutic JJ N
drug NN N
monitoring NN N
group NN N
-DOCSTART- -X- O O 15477492

Recurrent JJ 4_p
tuberculosis NN 4_p
in IN N
the DT N
United NNP N
States NNPS N
and CC N
Canada NNP N
: : N
active JJ 4_p
tuberculosis NN 4_p
after IN 4_p
treatment NN 4_p
( ( N
n JJ N
= NNP N
1,075 CD 3_p
) ) N
human JJ 4_p
immunodeficiency NN 4_p
virus-infected JJ 4_p
tuberculosis NN 4_p
( ( N
n JJ N
= NNP N
169 CD 3_p
) ) N
. . N

85 CD 3_p
patients NNS N
having VBG 4_p
a DT 4_p
positive JJ 4_p
culture NN 4_p
after IN 4_p
completing VBG 4_p
treatment NN 4_p
recurrent NN 4_p
tuberculosis NN 4_p
in IN N
the DT N
United NNP N
States NNPS N
and CC N
Canada NNP N
-DOCSTART- -X- O O 16283087

children NNS 1_p
with IN N
autistic JJ 4_p
spectrum NN 4_p
disorders NNS 4_p
. . N

children NNS N
with IN N
autistic JJ N
spectrum NN N
disorders NNS N
Ten CD 3_p
children NNS 1_p
were VBD N
trained VBN N
on IN N
theory NN N
of IN N
mind NN N
, , N
whilst WP N
ten EX 3_p
were VBD N
trained VBN N
in IN N
executive JJ N
function NN N
. . N

Seven JJ 3_p
children NNS N
were VBD N
assigned VBN N
to TO N
a DT N
control NN N
group NN N
, , N
receiving VBG N
no DT N
intervention NN N
. . N

-DOCSTART- -X- O O 3001523

severely RB N
immunocompromised JJ N
patients NNS N
. . N

varicella-zoster JJ N
virus NN N
infection NN N
in IN N
severely RB N
immunocompromised JJ N
patients NNS N
who WP N
presented VBD N
within IN N
72 CD N
hours NNS N
of IN N
onset NN N
of IN N
the DT N
infection NN N
. . N

Eleven JJ N
patients NNS N
were VBD N
treated VBN N
in IN N
each DT N
group NN N
. . N

immunocompromised JJ N
patients NNS N
. . N

-DOCSTART- -X- O O 11701433

growth NN N
hormone-deficient JJ N
women NNS N
. . N

GH-deficient NNP N
( ( N
GHD NNP N
) ) N
women NNS N
In IN N
two CD N
separate JJ N
studies NNS N
, , N
eight CD N
GHD NNP N
women NNS N
GHD NNP N
women NNS N
GHD NNP N
women NNS N
-DOCSTART- -X- O O 26156941

healthcare JJ N
workers NNS N
. . N

200 CD 3_p
female NN 2_p
healthcare NN N
workers NNS N
( ( N
age NN 1_p
: : 1_p
42.0 CD 1_p
, , N
body NN N
mass NN N
index NN N
: : N
24.1 CD N
, , N
average JJ N
pain NN N
intensity NN N
: : N
3.1 CD N
on IN N
a DT N
scale NN N
of IN N
0 CD N
to TO N
10 CD N
, , N
average JJ N
WRPE NNP N
: : N
3.6 CD N
on IN N
a DT N
scale NN N
of IN N
0 CD N
to TO N
10 CD N
) ) N
from IN N
18 CD N
departments NNS N
at IN N
three CD N
participating VBG N
hospitals NNS N
. . N

Participants NNS N
were VBD N
randomly RB N
allocated VBN N
at IN N
the DT N
cluster NN N
level NN N
in IN N
healthcare JJ N
workers NNS N
-DOCSTART- -X- O O 17572835

patients NNS N
with IN N
osteoporosis NN 4_p
: : N
80 CD 3_p
postmenopausal JJ 4_p
women NNS N
with IN N
osteoporosis NN 4_p
postmenopausal JJ 4_p
women NNS N
Eighty NNP 3_p
postmenopausal JJ 4_p
women NNS N
with IN N
osteoporosis NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
38 CD 3_p
) ) N
or CC N
an DT N
exercise NN N
group NN N
( ( N
n JJ N
= NNP N
42 CD 3_p
) ) N
. . N

patients NNS N
with IN N
osteoporosis NN N
. . N

-DOCSTART- -X- O O 16229958

early JJ N
adolescent NN N
and CC N
peer NN N
Students NNS N
( ( N
n=2453 NN N
) ) N
in IN N
the DT N
seven CD N
middle JJ N
schools NNS N
in IN N
one CD N
school NN N
district NN N
were VBD N
assessed VBN N
at IN N
school NN N
at IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
the DT N
sixth JJ N
, , N
seventh JJ N
, , N
eighth JJ N
grade NN N
and CC N
beginning NN N
of IN N
the DT N
9th CD N
grade NN N
. . N

Self-reported JJ 4_p
smoking NN 4_p
and CC 4_p
drinking NN 4_p
and CC 4_p
the DT 4_p
number NN 4_p
of IN 4_p
substance NN 4_p
using VBG 4_p
friends NNS 4_p
were VBD 4_p
assessed VBN 4_p
5 CD 4_p
times NNS 4_p
over IN 4_p
3 CD 4_p
years NNS 4_p
. . 4_p

-DOCSTART- -X- O O 17045894

heart NN 4_p
failure NN 4_p
patients NNS 4_p
. . 4_p

heart NN 4_p
failure NN 4_p
patients NNS 4_p
patients NNS N
surviving VBG N
myocardial JJ N
infarction NN N
. . N

humans NNS N
. . N

Patients NNPS N
with IN N
post-myocardial JJ N
infarction NN N
left VBD N
ventricular JJ N
dysfunction NN N
patients NNS N
with IN N
stable JJ N
congestive JJ N
heart NN N
failure NN N
. . N

-DOCSTART- -X- O O 23075031

sleep JJ 4_p
need NN 4_p
of IN 4_p
sedentary JJ 4_p
young JJ 4_p
adults NNS 4_p
. . 4_p

sedentary JJ 4_p
adults NNS 4_p
Twelve NNP N
healthy JJ N
volunteers NNS N
( ( N
25.2 CD N
± RB N
4.0 CD N
years NNS N
, , N
9 CD N
females NNS N
, , N
[ NNP N
Vdot NNP N
] NNP N
O NNP N
( ( N
2 CD N
) ) N
max NN N
35.4 CD N
± NN N
8.8 CD N
ml· NN N
kg NN N
( ( N
-1 NNP N
) ) N
· VBP N
min NN N
( ( N
-1 NNP N
) ) N
) ) N
-DOCSTART- -X- O O 12424783

early-stage JJ 4_p
breast NN 4_p
cancer NN 4_p
. . N

women NNS 2_p
with IN N
early-stage JJ 4_p
breast NN 4_p
cancer NN 4_p
was VBD N
tested VBN N
a DT N
three-group JJ N
, , N
three-phase JJ N
randomized JJ N
clinical JJ N
trial NN N
of IN N
a DT N
sample NN N
of IN N
125 CD 3_p
women NNS 2_p
. . N

-DOCSTART- -X- O O 16864886

parasite JJ 4_p
burden NN 4_p
finishing VBG N
heifers NNS N
1,862 CD 3_p
yearling VBG N
heifers NNS N
feedlot NN N
heifers NNS N
-DOCSTART- -X- O O 22610128

children NNS 1_p
with IN N
cerebral JJ 4_p
palsy NN 4_p
: : N
children NNS 1_p
with IN N
cerebral JJ 4_p
palsy NN 4_p
. . N

Children NNP 1_p
between IN N
4 CD 1_p
and CC 1_p
18 CD 1_p
years NNS 1_p
old JJ 1_p
with IN N
cerebral JJ N
palsy NN N
. . N

Thirty-eight JJ 3_p
children NNS 1_p
participated VBN N
. . N

cerebral JJ 4_p
palsy NN 4_p
children NNS 1_p
-DOCSTART- -X- O O 24200220

lung NN 4_p
cancer NN 4_p
. . N

patients NNS 4_p
treated VBN 4_p
with IN 4_p
photon NN 4_p
SBRT NNP 4_p
for IN N
lung NN 4_p
cancer NN 4_p
with IN 4_p
tumors NNS 4_p
within IN 4_p
< JJ 4_p
2.5cm CD 4_p
of IN 4_p
the DT 4_p
CW NNP 4_p
. . N

260 CD 3_p
cases NNS N
; : N
of IN N
these DT N
, , N
chronic NN 4_p
grade NN 4_p
≥ VBD 4_p
2 CD 4_p
CW NNP 4_p
pain NN 4_p
was VBD N
identified VBN N
in IN N
23 CD N
patients NNS N
then RB N
selected VBD N
10 CD 3_p
representative JJ 3_p
patients NNS 3_p
from IN N
this DT N
group NN N
and CC N
generated VBD N
proton NN N
SBRT NNP N
treatment NN N
plans NNS N
-DOCSTART- -X- O O 3516395

acute JJ 4_p
myelogenous JJ 4_p
leukemia NN 4_p
in IN 4_p
relapse NN 4_p
: : N
a DT N
Leukemia NNP N
Intergroup NNP N
Study NNP N
. . N

Patients NNS N
with IN N
acute JJ 4_p
myelogenous JJ 4_p
leukemia NN 4_p
in IN 4_p
relapse NN 4_p
who WP N
were VBD N
ineligible JJ 4_p
for IN 4_p
further JJ 4_p
anthracycline NN 4_p
therapy NN 4_p
either CC N
because IN N
they PRP N
were VBD N
judged VBN N
to TO N
be VB N
anthracycline JJ 4_p
resistant NN 4_p
or CC N
had VBD 4_p
received VBN 4_p
the DT 4_p
maximum JJ 4_p
doses NNS 4_p
three CD N
of IN N
25 CD 3_p
patients NNS N
given VBN N
high-dose JJ N
cytarabine NN N
and CC N
three CD N
of IN N
23 CD 3_p
given VBN N
amsacrine NN N
-DOCSTART- -X- O O 22617366

irritable JJ 4_p
bowel NN 4_p
syndrome NN 4_p
. . 4_p

patients NNS N
with IN N
irritable JJ N
bowel NN N
syndrome NN N
( ( N
IBS NNP N
) ) N
IBS NNP 4_p
patients NNS 4_p
. . 4_p

Patients NNPS N
with IN N
IBS NNP N
according VBG N
to TO N
the DT N
Rome NNP N
II NNP N
criteria NNS N
-DOCSTART- -X- O O 25542917

120 CD 3_p
participants NNS N
received VBD N
a DT N
1 CD N
week NN N
supply NN N
of IN N
nicotine JJ 4_p
inhalers NNS 4_p
and CC N
1 CD N
week NN N
of IN N
nicotine JJ N
lozenges NNS N
Menthol NNP 4_p
cigarette NN 4_p
smokers NNS 4_p
nonmenthol JJ 4_p
smokers NNS 4_p
. . 4_p

-DOCSTART- -X- O O 3553277

asthma NN 4_p
. . N

231 CD 3_p
patients NNS N
with IN N
chronic JJ 4_p
reversible JJ 4_p
obstructive JJ 4_p
airway NN 4_p
disease NN 4_p
half NN 3_p
preferred VBD N
using VBG N
the DT N
powder NN N
. . N

-DOCSTART- -X- O O 19696287

hypervascular JJ 4_p
hepatocellular JJ 4_p
carcinoma NN 4_p
The DT N
study NN N
included VBD N
149 CD 3_p
patients NNS 3_p
, , N
among IN N
whom WP N
36 CD 3_p
patients NNS 3_p
with IN N
hypervascular JJ 4_p
hepatocellular JJ 4_p
carcinoma NN 4_p
were VBD N
identified VBN N
. . N

-DOCSTART- -X- O O 16840576

aging VBG N
humans NNS N
. . N

aging VBG N
adults NNS N
. . N

Twenty-six JJ N
sedentary JJ N
but CC N
healthy JJ N
middle-aged JJ N
and CC N
older JJR N
subjects NNS N
intervention NN N
group NN N
( ( N
52 CD N
+/- JJ N
2 CD N
yr NN N
, , N
3 CD N
men NNS N
, , N
10 CD N
women NNS N
) ) N
a DT N
control NN N
group NN N
( ( N
53 CD N
+/- JJ N
2 CD N
yr NN N
, , N
4 CD N
men NNS N
, , N
9 CD N
women NNS N
) ) N
At IN N
baseline NN N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
blood NN N
pressure NN N
, , N
cardiac JJ N
output NN N
, , N
basal JJ N
femoral JJ N
blood NN N
flow NN N
( ( N
via IN N
Doppler NNP N
ultrasound NN N
) ) N
, , N
vascular JJ N
conductance NN N
, , N
and CC N
vascular JJ N
resistance NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

healthy JJ 4_p
middle-aged JJ 4_p
and CC 4_p
older JJR 4_p
adults NNS 4_p
. . 4_p

-DOCSTART- -X- O O 12576957

in IN 4_p
patients NNS 4_p
with IN 4_p
acute JJ 4_p
respiratory NN 4_p
distress NN 4_p
syndrome NN 4_p
. . 4_p

acute JJ 4_p
respiratory NN 4_p
distress JJ 4_p
syndrome JJ 4_p
patients NNS 4_p
acute JJ 4_p
respiratory NN 4_p
distress JJ 4_p
syndrome JJ 4_p
patients NNS 4_p
Intensive JJ N
Care NNP N
Unit NNP N
of IN N
the DT N
Ohio NNP N
State NNP N
University NNP N
Medical NNP N
Center NNP N
. . N

A DT N
total NN N
of IN N
67 CD N
patients NNS N
were VBD N
enrolled VBN N
who WP N
met VBD N
defined VBN N
criteria NNS N
for IN N
acute NN N
lung NN N
injury/acute NN N
respiratory NN N
distress JJ N
syndrome NN N
. . N

-DOCSTART- -X- O O 18322606

chronic JJ 4_p
hepatitis NN 4_p
B NNP 4_p
patients NNS N
] NNP N
chronic JJ 4_p
hepatitis NN 4_p
B NNP 4_p
patients NNS N
with IN N
liver JJ 4_p
fibrosis NN 4_p
. . N

57 CD 3_p
chronic NN 4_p
hepatitis NN 4_p
B NNP 4_p
patients NNS N
with IN N
liver JJ 4_p
fibrosis NN 4_p
liver JJ 4_p
fibrosis NN 4_p
in IN N
chronic JJ 4_p
hepatitis NN 4_p
B NNP 4_p
patients NNS N
-DOCSTART- -X- O O 24067301

adults NNS 1_p
with IN N
asperger JJ 4_p
syndrome NN 4_p
. . N

healthy JJ 4_p
men NNS 4_p
. . 4_p

individuals NNS N
with IN N
Asperger NNP N
syndrome NN N
( ( N
AS IN N
) ) N
adults NNS N
with IN N
AS NNP N
individuals NNS N
with IN N
AS NNP N
. . N

-DOCSTART- -X- O O 16730335

treatment NN N
on IN N
prolactin NN N
levels NNS N
in IN N
children NNS N
with IN N
autism NN N
. . N

children NNS N
and CC N
adolescents NNS N
with IN N
autism NN N
. . N

Patients NNPS N
with IN N
autism NN N
( ( N
N NNP N
= NNP N
101 CD N
, , N
5-17 CD N
years NNS N
of IN N
age NN N
) ) N
63 CD N
then RB N
took VBD N
part NN N
in IN N
a DT N
4-month JJ N
open-label JJ N
follow-up JJ N
phase NN N
. . N

children NNS N
with IN N
autism NN N
. . N

children NNS N
and CC N
adolescents NNS N
-DOCSTART- -X- O O 25526831

early JJ 1_p
adolescents NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
and CC 4_p
clinical JJ 4_p
anxiety NN 4_p
: : N
preteens NNS 1_p
with IN N
ASD NNP 4_p
early JJ 1_p
adolescents NNS 1_p
with IN N
ASD NNP 4_p
and CC 4_p
clinical JJ 4_p
anxiety NN 4_p
. . N

Thirty-three JJ 3_p
adolescents NNS 1_p
( ( 1_p
11-15 CD 1_p
years NNS 1_p
old JJ 1_p
) ) 1_p
-DOCSTART- -X- O O 1880321

steroid-dependent JJ 4_p
asthma NN 4_p
. . N

subjects NNS N
with IN N
corticosteroid-requiring JJ N
asthma NN 4_p
. . N

Ten CD 3_p
subjects NNS 3_p
completed VBD N
the DT N
study NN N
. . N

subjects NNS N
with IN N
steroid-dependent JJ N
asthma NN 4_p
. . N

-DOCSTART- -X- O O 21131142

4 CD 3_p
psychologically RB N
and CC N
physically RB N
healthy JJ 4_p
hallucinogen-using NN 4_p
adults NNS 1_p
. . N

pressure NN N
. . N

Participant NNP N
-DOCSTART- -X- O O 17482439

21 CD 3_p
healthy JJ 4_p
subjects NNS N
with IN N
different JJ 4_p
fitness NN 4_p
levels NNS 4_p
. . N

-DOCSTART- -X- O O 19109542

Ten CD N
patients NNS N
with IN N
chronic JJ N
stroke NN N
( ( N
7 CD N
males NNS N
; : N
mean JJ N
age NN N
, , N
61.4+/-3.02 JJ N
years NNS N
; : N
age NN N
range NN N
, , N
48 CD N
to TO N
79 CD N
years NNS N
; : N
mean JJ N
time NN N
since IN N
stroke NN N
, , N
28.5 CD N
months NNS N
; : N
range NN N
, , N
13 CD N
to TO N
42 CD N
months NNS N
) ) N
exhibiting VBG N
stable JJ N
, , N
affected JJ N
arm NN N
motor NN N
deficits NNS N
-DOCSTART- -X- O O 12590404

severe JJ 4_p
depression NN 4_p
: : N
multicentre NN N
study NN N
was VBD N
conducted VBN N
in IN N
86 CD 3_p
severely RB N
depressed JJ N
inpatients NNS N
( ( N
> JJ N
or= RB N
25 CD N
on IN N
the DT N
17-item JJ N
Hamilton NNP N
depression NN 4_p
rating NN N
scale NN N
[ NNP N
HAMD NNP N
] NNP N
total JJ N
score NN N
) ) N
86 CD 3_p
patients NNS N
-DOCSTART- -X- O O 20576092

patients NNS 4_p
with IN 4_p
early JJ 4_p
rheumatoid NN 4_p
arthritis NN 4_p
: : 4_p
rheumatoid NN 4_p
arthritis NN 4_p
( ( 4_p
RA NNP 4_p
) ) 4_p
patients NNS 4_p
with IN 4_p
early JJ 4_p
RA NNP 4_p
initially RB 4_p
treated VBD 4_p
with IN 4_p
a DT 4_p
combination NN 4_p
of IN 4_p
three CD 4_p
disease-modifying JJ 4_p
antirheumatic JJ 4_p
drugs NNS 4_p
( ( 4_p
DMARDs NNP 4_p
) ) 4_p
or CC 4_p
a DT 4_p
single JJ 4_p
DMARD NNP 4_p
. . 4_p

199 CD N
patients NNS N
with IN N
early JJ N
active JJ N
RA NNP N
RA JJ N
patients NNS N
. . N

-DOCSTART- -X- O O 23510984

Patients NNPS N
with IN N
mutant JJ 4_p
KRAS NNP 4_p
metastatic JJ 4_p
adenocarcinoma NN 4_p
of IN 4_p
the DT 4_p
colon NN 4_p
or CC 4_p
rectum VB 4_p
refractory NN 4_p
to TO N
fluoropyrimidine- JJ N
and CC N
oxaliplatin-based JJ N
chemotherapy NN N
155 CD 3_p
patients NNS N
were VBD N
randomized VBN N
. . N

-DOCSTART- -X- O O 11570022

mammography NN N
. . N

Participants NNS N
were VBD N
1908 CD N
women NNS N
aged VBD N
50 CD N
to TO N
75 CD N
years NNS N
continuously RB N
enrolled VBD N
in IN N
a DT N
large JJ N
group-model JJ N
HMO NNP N
during IN N
the DT N
study NN N
who WP N
underwent VBD N
a DT N
bilateral JJ N
mammogram NN N
during IN N
the DT N
first JJ N
quarter NN N
of IN N
1994 CD N
and CC N
no DT N
subsequent JJ N
mammogram NN N
during IN N
the DT N
next JJ N
18 CD N
to TO N
21 CD N
months NNS N
. . N

-DOCSTART- -X- O O 7995325

healthy JJ 4_p
women NNS 4_p
and CC 4_p
in IN 4_p
women NNS 4_p
with IN 4_p
primary JJ 4_p
Raynaud NNP 4_p
's POS 4_p
phenomenon NN 4_p
. . 4_p

healthy JJ N
women NNS N
patients NNS N
with IN N
Raynaud NNP N
's POS N
phenomenon NN N
17 CD N
healthy JJ N
normotensive JJ N
women NNS N
and CC N
in IN N
12 CD N
women NNS N
with IN N
Raynaud NNP N
's POS N
phenomenon NN N
. . N

-DOCSTART- -X- O O 12666946

adult NN N
periodontitis NN N
; : N
adult NN N
periodontitis NN N
. . N

Eighty NNP 4_p
teeth VBZ 4_p
in IN 4_p
18 CD 4_p
patients NNS 4_p
adult NN 4_p
periodontitis NN 4_p
. . 4_p

-DOCSTART- -X- O O 24714816

adults NNS 1_p
with IN N
Down NNP 4_p
syndrome NN 4_p
. . N

sedentary JJ N
adults NNS 1_p
with IN N
Down NNP 4_p
syndrome NN 4_p
( ( 4_p
DS NNP 4_p
) ) 4_p
. . N

40 CD 3_p
male NN 2_p
adults NNS 1_p
with IN N
DS NNP N
were VBD N
recruited VBN N
for IN N
the DT N
trial NN N
through IN N
different JJ N
community NN N
support NN N
groups NNS N
for IN N
people NNS 4_p
with IN 4_p
intellectual JJ 4_p
disabilities NNS 4_p
. . N

All DT N
participants NNS 4_p
had VBD 4_p
medical JJ 4_p
approval NN 4_p
for IN 4_p
participation NN 4_p
in IN 4_p
physical JJ 4_p
activity NN 4_p
. . N

Twenty-four CD 3_p
adults NNS 1_p
control NN N
group NN N
included VBD N
16 CD N
age- JJ 1_p
, , N
gender- JJ 2_p
, , N
and CC N
BMI-matched NNP N
adults NNS 1_p
with IN N
DS NNP 4_p
. . N

sedentary JJ N
adults NNS 1_p
with IN N
DS NNP 4_p
. . N

-DOCSTART- -X- O O 19330493

hypertensive JJ 4_p
patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
and CC N
microalbuminuria NNS 4_p
. . N

Patients NNPS N
with IN N
diabetes NNS 4_p
complicated VBN N
by IN N
hypertension NN 4_p
and CC N
microalbuminuria NNS 4_p
Patients NNPS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
, , N
mild-to-moderate JJ N
hypertension NN 4_p
( ( N
diastolic JJ N
blood NN N
pressure NN N
85-105 JJ N
mmHg NN N
, , N
systolic JJ N
blood NN N
pressure NN N
< VBZ N
160 CD N
mmHg NN N
, , N
and CC N
24-hour JJ N
mean JJ N
systolic JJ N
blood NN N
pressure NN N
> VBZ N
130 CD N
mmHg NN N
) ) N
, , N
and CC N
microalbuminuria NNS 4_p
-DOCSTART- -X- O O 9006598

care NN 4_p
givers NNS 4_p
' POS 4_p
satisfaction NN 4_p
with IN 4_p
information NN 4_p
received VBN 4_p
during IN 4_p
hospitalization NN 4_p
. . 4_p

new JJ 4_p
patients NNS 4_p
and CC 4_p
maintain NN 4_p
or CC 4_p
increase VB 4_p
patient JJ 4_p
volume NN 4_p
. . 4_p

Family NNP N
care NN N
givers NNS N
-DOCSTART- -X- O O 24534270

in IN 4_p
overweight JJ 4_p
adults NNS 4_p
: : 4_p
stiffness NN N
in IN N
sedentary JJ N
, , N
overweight JJ N
individuals NNS N
. . N

Seventy-seven JJ N
individuals NNS N
( ( N
19 CD N
men NNS N
, , N
58 CD N
women NNS N
; : N
age NN N
, , N
30-55 CD N
years NNS N
) ) N
groups NNS N
; : N
two CD N
groups NNS N
completed VBD N
30 CD N
minutes NNS N
of IN N
accumulated JJ N
walking VBG N
with IN N
either DT N
monthly JJ N
or CC N
weekly JJ N
telephone NN N
support NN N
; : N
the DT N
third JJ N
group NN N
( ( N
control NN N
) ) N
performed VBD N
stretching VBG N
exercises NNS N
The DT N
walking VBG N
groups NNS N
in IN N
overweight JJ N
individuals NNS N
-DOCSTART- -X- O O 3963358

50 CD 3_p
patients NNS N
were VBD N
investigated VBN N
during IN N
induction NN N
of IN N
anaesthesia NN 4_p
and CC N
infrarenal JJ 4_p
aortic JJ 4_p
bypass NN 4_p
surgery NN 4_p
. . N

26 CD 3_p
were VBD N
operated VBN N
on IN N
under IN N
neuroleptanaesthesia NN 4_p
( ( N
NA NNP N
group NN N
) ) N
and CC N
24 CD 3_p
under IN N
continuous JJ N
epidural JJ N
combined VBN N
with IN N
a DT N
light JJ 4_p
general JJ 4_p
anaesthesia NN 4_p
( ( N
epidural JJ N
group NN N
) ) N
. . N

-DOCSTART- -X- O O 7554709

healthy JJ N
male NN N
volunteers NNS N
. . N

-DOCSTART- -X- O O 23405947

advanced JJ 4_p
heart NN 4_p
failure NN 4_p
. . N

Heart NNP 4_p
Failure NNP 4_p
In IN N
patients NNS N
admitted VBN N
to TO N
the DT N
hospital NN N
with IN N
acute JJ 4_p
HF NNP 4_p
, , N
both DT N
ventricles NNS N
were VBD N
evaluated VBN N
by IN N
echocardiography NN N
on IN N
admission NN N
, , N
at IN N
discharge NN N
, , N
and CC N
at IN N
3 CD N
months NNS N
. . N

-DOCSTART- -X- O O 24104511

children NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
192 CD 3_p
students NNS 3_p
from IN 3_p
47 CD 3_p
kindergarten-through-second-grade JJ 3_p
autism NN N
support NN 3_p
classrooms NNS 3_p
participating VBG N
in IN N
a DT N
year-long JJ N
behavioral JJ N
intervention NN N
study NN N
Children NNP 1_p
's POS 1_p
-DOCSTART- -X- O O 16030275

acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
Patients NNPS N
with IN N
AMI NNP 4_p
who WP N
were VBD N
admitted VBN N
to TO N
76 CD N
acute NN N
care NN N
hospitals NNS N
in IN N
Quebec NNP N
that WDT N
treated VBD N
at IN N
least JJS N
30 CD N
AMI NNP N
patients NNS N
per IN N
year NN N
between IN N
April NNP N
1 CD N
, , N
1999 CD N
, , N
and CC N
March NNP N
31 CD N
, , N
2003 CD N
. . N

rapid JJ N
( ( N
immediate JJ N
; : N
n CC N
= $ N
38 CD N
hospitals NNS N
and CC N
2533 CD 3_p
patients NNS N
) ) N
or CC N
delayed VBN N
( ( N
14 CD N
months NNS N
; : N
n CC N
= $ N
38 CD N
hospitals NNS N
and CC N
3142 CD 3_p
patients NNS N
) ) N
patients NNS N
with IN N
AMI NNP N
. . N

-DOCSTART- -X- O O 15994014

hypertrophic JJ 4_p
scars NNS 4_p
after IN 4_p
burn JJ 4_p
injury NN 4_p
76 CD N
burn NN 4_p
scars NNS 4_p
in IN N
60 CD 3_p
patients NNS 3_p
were VBD N
-DOCSTART- -X- O O 2208619

hookworm NN 4_p
, , N
Ascaris NNP 4_p
and CC N
Trichuris NNP 4_p
infection NN 4_p
340 CD 3_p
cases NNS N
of IN N
hookworm NN 4_p
infection NN 4_p
, , N
196 CD 3_p
cases NNS N
of IN N
ascariasis NN 4_p
and CC N
178 CD 3_p
cases NNS N
of IN N
trichuriasis NN 4_p
were VBD N
treated VBN N
with IN N
an DT N
anthelmintic JJ N
, , N
oxibendazole JJ N
, , N
15mg/kg.d CD N
x JJ N
3d CD N
; : N
102 CD N
, , N
70 CD N
and CC N
66 CD N
cases NNS N
of IN N
respective JJ 4_p
infections NNS 4_p
were VBD N
treated VBN N
with IN N
pyrantel NN N
10mg/kg.d CD N
x NN N
3d CD N
and CC N
108 CD N
, , N
74 CD N
and CC N
63 CD N
cases NNS N
took VBD N
placebo NN N
-DOCSTART- -X- O O 15453848

A DT N
total NN N
of IN N
119 CD 3_p
patients NNS N
, , N
aged VBN N
61-86 CD 1_p
years NNS 1_p
, , N
underwent JJ N
cataract NN 4_p
surgery NN 4_p
with IN 4_p
phacoemulsification NN 4_p
performed VBN N
by IN N
a DT N
single JJ N
surgeon NN N
. . N

-DOCSTART- -X- O O 12199005

obstructive JJ 4_p
sleep NN 4_p
apnoea NN 4_p
and CC 4_p
snoring VBG 4_p
obstructive JJ N
sleep JJ N
apnoea NN N
syndrome NN N
( ( N
OSAS NNP N
) ) N
. . N

Nineteen NNP 3_p
patients NNS N
using VBG N
a DT N
MAS NNP N
for IN N
symptomatic JJ N
OSAS NNP N
underwent NN N
polysomnography NN N
, , N
with IN N
MAS NNP N
use NN N
randomised VBD N
to TO N
one CD N
half NN N
of IN N
the DT N
night NN N
. . N

snoring VBG N
and CC N
OSAS NNP N
Fifteen JJ N
patients NNS N
( ( N
79 CD N
% NN N
) ) N
-DOCSTART- -X- O O 9558860

32 CD 3_p
patients NNS N
undergoing JJ N
elective JJ 4_p
cardiac NN 4_p
surgery NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
hypothermia NN 4_p
( ( N
n JJ 3_p
= NNP 3_p
16 CD 3_p
) ) N
or CC N
normothermia NN 4_p
( ( N
n JJ N
= NNP N
16 CD N
) ) N
. . N

-DOCSTART- -X- O O 22513516

cardiac JJ N
surgery NN N
patients NNS N
. . N

76 CD N
patients NNS N
undergoing JJ N
elective JJ N
on-pump JJ N
cardiac NN N
surgery NN N
patients NNS N
undergoing VBG N
cardiovascular JJ N
surgery NN N
. . N

-DOCSTART- -X- O O 9735531

autistic JJ N
individuals NNS N
Eighteen NNP N
autistic JJ N
individuals NNS N
, , N
ranging VBG N
in IN N
age NN N
from IN N
7 CD N
to TO N
18 CD N
years NNS N
autistic JJ N
individuals NNS N
. . N

-DOCSTART- -X- O O 10439497

hypertensive JJ N
and CC N
hypercholesterolaemic JJ N
patients NNS N
patients NNS N
who WP N
were VBD N
also RB N
encouraged VBN N
to TO N
improve VB N
their PRP$ N
lifestyle NN N
. . N

Fifty-four JJ N
general JJ N
practice NN N
surgeries NNS N
in IN N
Norway NNP N
. . N

Hypertensive JJ N
patients NNS N
, , N
210 CD N
females NNS N
and CC N
160 CD N
males NNS N
, , N
treated VBD N
or CC N
untreated JJ N
with IN N
antihypertensive JJ N
drugs NNS N
with IN N
a DT N
sitting VBG N
diastolic JJ N
blood NN N
pressure NN N
between IN N
95 CD N
and CC N
115 CD N
mmHg NN N
and CC N
a DT N
serum JJ N
total NN N
cholesterol NN N
between IN N
6.5 CD N
mmol/l NNS N
( ( N
7.0 CD N
for IN N
those DT N
age NN N
60-67 JJ N
years NNS N
) ) N
and CC N
9.0 CD N
mmol/l NN N
. . N

hypertensive JJ N
and CC N
hypercholesterolaemic JJ N
patients NNS N
. . N

-DOCSTART- -X- O O 25348544

implant JJ 4_p
overdentures NNS 4_p
. . N

edentulous JJ N
participants NNS N
with IN N
removable JJ N
complete JJ N
overdentures NNS N
attached VBN N
to TO N
1 CD N
or CC N
2 CD N
mandibular JJ N
implants NNS N
. . N

86 CD 3_p
participants NNS N
( ( 1_p
mean JJ 1_p
age NN 1_p
, , 1_p
67 CD 1_p
y NN 1_p
) ) 1_p
-DOCSTART- -X- O O 12143780

patients NNS 4_p
with IN 4_p
severe JJ 4_p
chronic JJ 4_p
non-specific JJ 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
. . 4_p

-DOCSTART- -X- O O 10594393

ulcerative JJ 4_p
colitis NN 4_p
. . N

patients NNS 4_p
with IN 4_p
poor JJ 4_p
pouch JJ 4_p
function NN 4_p
Twenty NNP 3_p
ulcerative JJ 4_p
colitis NN 4_p
patients NNS N
with IN N
poor JJ 4_p
pouch JJ 4_p
function NN 4_p
( ( N
score NN N
> VBZ N
4 CD N
on IN N
a DT N
12-point JJ N
score NN N
) ) N
total NN N
of IN N
16 CD 3_p
patients NNS N
completed VBD N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 23873901

exudative JJ N
age-related JJ N
macular JJ N
degeneration NN N
. . N

choroidal JJ N
neovascularisation NN N
( ( N
CNV NNP N
) ) N
. . N

eyes NNS N
with IN N
new-onset JJ N
CNV NNP N
. . N

total NN N
of IN N
56 CD N
patients NNS N
were VBD N
enrolled VBN N
in IN N
patients NNS N
with IN N
CNV NNP N
-DOCSTART- -X- O O 21887489

children NNS 1_p
and CC N
adolescents NNS 1_p
with IN N
juvenile JJ 4_p
idiopathic JJ 4_p
arthritis NN 4_p
. . N

children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN N
juvenile JJ 4_p
idiopathic JJ 4_p
arthritis NN 4_p
( ( 4_p
JIA NNP 4_p
) ) 4_p
. . N

patients NNS N
with IN N
JIA NNP 4_p
aged VBD N
between IN 1_p
8 CD 1_p
and CC 1_p
17 CD 1_p
years NNS 1_p
and CC N
healthy JJ N
controls NNS N
was VBD N
used VBN N
. . N

Fifty-two JJ 3_p
patients NNS N
and CC N
48 CD N
controls NNS N
were VBD N
included VBN N
with IN N
a DT N
mean JJ N
age NN N
of IN N
12.13 CD 1_p
± JJ 1_p
2.92 CD 1_p
and CC 1_p
11.27 CD 1_p
± JJ 1_p
1.59 CD 1_p
years NNS 1_p
, , N
respectively RB N
. . N

The DT N
mean JJ N
disease NN N
duration NN N
was VBD N
that IN N
only JJ N
depression NN N
was VBD N
related VBN N
to TO N
-DOCSTART- -X- O O 2508567

colorectal JJ 4_p
carcinoma NN 4_p
( ( N
second JJ N
study NN N
) ) N
: : N
non-curatively RB 4_p
resected JJ 4_p
patients NNS N
. . N

Japan NNP N
] NNP N
non-curatively RB 4_p
resected VBN 4_p
colorectal JJ 4_p
carcinoma NN 4_p
patients NNS 4_p
as IN N
a DT N
collaborative JJ 4_p
study NN 4_p
at IN N
428 CD N
institutes NNS N
in IN N
Japan NNP N
from IN N
Jan. NNP N
1984 CD N
to TO N
Dec. NNP N
1985 CD N
. . N

1,138 CD 3_p
patients NNS N
were VBD N
entered VBN N
in IN N
this DT N
study NN N
556 CD 3_p
cases NNS N
( ( N
colon NN N
carcinoma NN N
regimen NNS N
C NNP N
: : N
148 CD 3_p
, , N
D NNP N
: : N
185 CD 3_p
cases NNS N
, , N
rectal JJ N
carcinoma NN N
regimen NNS N
C NNP N
: : N
94 CD 3_p
, , N
D NNP N
: : N
129 CD 3_p
cases NNS N
) ) N
-DOCSTART- -X- O O 6108264

110 CD 3_p
patients NNS N
suffering VBG N
from IN N
hay NN 4_p
fever NN 4_p
( ( N
confirmed VBN N
by IN N
skin NN N
tests NNS N
) ) N
-DOCSTART- -X- O O 1302807

vaginal JJ 4_p
candidosis NN 4_p
: : 4_p
vaginal JJ 4_p
candidosis NN 4_p
. . N

treatment NN N
of IN N
vaginal JJ 4_p
candidosis NN 4_p
in IN N
a DT N
randomized JJ N
study NN N
in IN N
Finland NNP N
. . N

-DOCSTART- -X- O O 16379508

children NNS 2_p
, , 2_p
adolescents NNS 2_p
, , 2_p
and CC 2_p
adults NNS 2_p
with IN 2_p
mental JJ 2_p
retardation NN 2_p
and CC 2_p
pervasive JJ 2_p
developmental NN 2_p
disorders NNS 2_p
. . 2_p

children NNS 1_p
, , 1_p
adolescents NNS 1_p
, , 1_p
and CC 1_p
adults NNS 1_p
with IN 1_p
mental JJ 1_p
retardation NN 1_p
( ( 1_p
MR NNP 1_p
) ) 1_p
and CC 1_p
pervasive JJ 1_p
developmental NN 1_p
disorders NNS 1_p
( ( 1_p
PDD NNP 1_p
) ) 1_p
. . 1_p

children NNS 4_p
, , 4_p
adolescents NNS 4_p
, , 4_p
and CC 4_p
adults NNS 4_p
with IN 4_p
MR NNP 4_p
and CC 4_p
PDDs NNP 4_p
21-subject JJ 4_p
subset NN 4_p
during IN 4_p
the DT 4_p
course NN 4_p
of IN 4_p
a DT 4_p
double-blind JJ 4_p
, , 4_p
placebo-controlled JJ 4_p
trial NN 4_p
. . 4_p

children NNS N
and CC N
adolescents NNS N
( ( N
n=10 NN N
) ) N
, , N
mean JJ N
age NN N
of IN N
12.5 CD N
years NNS N
adults NNS N
, , N
mean JJ N
age NN N
of IN N
35.3 CD N
years NNS N
-DOCSTART- -X- O O 24679061

patients NNS 4_p
undergoing JJ 4_p
noncardiac JJ 4_p
surgery NN 4_p
. . 4_p

noncardiac JJ N
surgery NN N
. . N

patients NNS 4_p
with IN 4_p
, , 4_p
or CC 4_p
at IN 4_p
risk NN 4_p
for IN 4_p
, , 4_p
atherosclerotic JJ 4_p
disease NN 4_p
who WP 4_p
were VBD 4_p
undergoing VBG 4_p
noncardiac JJ 4_p
surgery NN 4_p
. . 4_p

10,010 CD N
patients NNS N
at IN N
135 CD N
centers NNS N
in IN N
23 CD N
countries NNS N
were VBD N
enrolled VBN N
. . N

329 CD N
patients NNS N
patients NNS 4_p
undergoing JJ 4_p
noncardiac JJ 4_p
surgery NN 4_p
-DOCSTART- -X- O O 15817848

young JJ 2_p
women NNS 2_p
young JJ 1_p
, , N
healthy JJ 1_p
women NNS 1_p
. . N

Subjects NNS N
were VBD N
155 CD 3_p
young JJ N
( ( N
aged VBN N
18-30 CD 1_p
y NN 1_p
) ) N
, , N
healthy JJ 4_p
, , 4_p
normal-weight JJ 4_p
women NNS N
with IN N
intake NN N
of IN N
dietary JJ N
calcium NN N
< VBZ N
800 CD N
mg/d NN N
and CC N
energy NN N
intake VBP N
< CD N
/= JJ N
2200 CD N
kcal/d NN N
. . N

One CD 3_p
hundred VBD 3_p
thirty-five JJ 3_p
women NNS N
completed VBD N
the DT N
trial NN N
. . N

young JJ 1_p
, , N
healthy JJ 1_p
women NNS 1_p
-DOCSTART- -X- O O 10448447

chronic JJ N
depression NN N
among IN N
women NNS N
in IN N
an DT N
inner JJ N
city NN N
. . N

remission NN N
from IN N
depression NN N
. . N

remission NN N
of IN N
chronic JJ N
depression NN N
-DOCSTART- -X- O O 24103072

recipients NNS N
of IN N
extended JJ N
criteria NNS N
donor JJ N
kidneys NNS N
. . N

Patients NNS N
in IN N
the DT N
BENEFIT-EXT NNP N
study NN N
received VBD N
extended JJ N
criteria NNS N
donor JJ N
kidneys NNS N
Patients NNS 4_p
who WP 4_p
remained VBD 4_p
on IN 4_p
assigned JJ 4_p
therapy NN 4_p
through IN 4_p
year NN 4_p
3 CD 4_p
were VBD 4_p
eligible JJ 4_p
to TO 4_p
enter VB 4_p
a DT 4_p
long-term JJ 4_p
extension NN 4_p
( ( 4_p
LTE NNP 4_p
) ) 4_p
study NN 4_p
. . 4_p

Three CD N
hundred VBD N
four CD N
patients NNS N
entered VBD N
the DT N
LTE NNP N
( ( N
n JJ N
= $ N
104 CD N
MI NNP N
; : N
n CC N
= $ N
113 CD N
LI NNP N
; : N
n CC N
= $ N
87 CD N
CsA NNP N
) ) N
, , N
and CC N
260 CD N
continued VBD N
treatment NN N
through IN N
n CC N
= $ N
100 CD N
n CC N
= $ N
1 CD N
CsA NNP N
) ) N
; : N
two CD N
of IN N
three CD N
PTLD NNP N
cases NNS N
in IN N
the DT N
LI NNP N
group NN N
were VBD N
in IN N
patients NNS N
who WP N
were VBD N
-DOCSTART- -X- O O 17073957

high-risk JJ N
individuals NNS N
. . N

Three CD N
hundred VBD N
sixty-six JJ N
patients NNS N
undergoing VBG N
elective JJ N
cardiac JJ N
surgery NN N
with IN N
full JJ N
median JJ N
sternotomy NN N
and CC N
having VBG N
body NN N
surface JJ N
area NN N
( ( N
BSA NNP N
) ) N
less JJR N
than IN N
1.5 CD N
m NN N
( ( N
2 CD N
) ) N
following VBG N
median JJ N
sternotomy NN N
in IN N
high-risk JJ N
patients NNS N
with IN N
little JJ N
body NN N
mass NN N
. . N

-DOCSTART- -X- O O 21767149

40 CD N
women NNS N
with IN N
laparoscopically RB N
confirmed VBN N
endometriosis NN N
. . N

The DT N
trial NN N
was VBD N
conducted VBN N
at IN N
a DT N
private JJ N
CHM NNP N
clinic NN N
in IN N
Hove NNP N
( ( N
U.K. NNP N
) ) N
and CC N
at IN N
a DT N
National NNP N
Health NNP N
Service NNP N
outpatient NN N
clinic NN N
in IN N
London NNP N
( ( N
U.K. NNP N
) ) N
. . N

Twenty-eight NNP N
( ( N
28 CD N
) ) N
women NNS N
completed VBD N
the DT N
trial NN N
. . N

-DOCSTART- -X- O O 7936339

surgery NN N
of IN N
the DT N
abdominal JJ N
aorta NN N
] NNP N
Twenty-five JJ N
patients NNS N
undergoing VBG N
excision NN N
of IN N
an DT N
aortic JJ N
abdominal JJ N
aneurysm NN N
-DOCSTART- -X- O O 21787048

nonverbal JJ N
children NNS 1_p
nonverbal JJ N
children NNS 1_p
with IN N
autism NN 4_p
following VBG N
classroom-based JJ N
intervention NN N
( ( N
Picture NNP N
Exchange NNP N
Communication NNP N
System NNP N
[ NNP N
PECS NNP N
] NNP N
training NN N
) ) N
84 CD 3_p
children NNS 1_p
from IN N
15 CD N
schools NNS N
participated VBN N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
They PRP N
were VBD N
aged VBN N
4-10 JJ 1_p
years NNS 1_p
( ( N
73 CD 3_p
boys NNS 2_p
) ) N
. . N

children NNS N
who WP N
could MD N
talk VB N
-DOCSTART- -X- O O 14996144

bipolar JJ 4_p
type NN 4_p
II NNP 4_p
or CC 4_p
bipolar JJ 4_p
NOS NNP 4_p
major JJ 4_p
depression NN 4_p
- : 4_p
low JJ 4_p
manic JJ 4_p
switch NN 4_p
rate NN 4_p
. . N

bipolar JJ 4_p
type NN 4_p
II NNP 4_p
( ( N
BP NNP 4_p
II NNP 4_p
) ) N
major JJ N
depressive JJ N
episode NN N
( ( N
MDE NNP N
) ) N
As IN N
part NN N
of IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
relapse-prevention NN N
study NN N
of IN N
fluoxetine JJ N
monotherapy NN N
in IN N
BP NNP 4_p
II NNP 4_p
MDE NNP N
, , N
37 CD 3_p
patients NNS N
BP NNP 4_p
II NNP 4_p
MDE NNP 4_p
. . N

-DOCSTART- -X- O O 15746053

patients NNS N
with IN N
solid JJ N
tumors NNS N
. . N

fasted JJ N
patients NNS N
Twenty-five JJ N
patients NNS N
-DOCSTART- -X- O O 7048172

16 CD 3_p
patients NNS N
with IN N
relapsing VBG 4_p
non-Hodgkin NN 4_p
's POS 4_p
malignant JJ 4_p
lymphomas NN 4_p
considered VBN N
as IN N
clinical JJ N
stage NN N
I PRP N
or CC N
II NNP N
5 CD 3_p
of IN N
them PRP N
were VBD N
included VBN N
in IN N
a DT N
randomized JJ N
trial NN N
11 CD 3_p
were VBD N
systematically RB N
treated VBN N
by IN N
BCG NNP N
-DOCSTART- -X- O O 23811316

adults NNS N
with IN N
chronic JJ N
spinal JJ N
cord NN N
injury NN N
. . N

untrained JJ N
adults NNS N
with IN N
chronic JJ N
spinal JJ N
cord NN N
injury NN N
( ( N
SCI NNP N
) ) N
. . N

Male NNP N
adults NNS N
with IN N
complete JJ N
SCI NNP N
at IN N
or CC N
below IN N
the DT N
fifth JJ N
thoracic NN N
level NN N
( ( N
T5 NNP N
) ) N
( ( N
N=17 NNP N
) ) N
volunteered VBD N
for IN N
this DT N
study NN N
. . N

intervention NN N
( ( N
n=9 JJ N
) ) N
or CC N
control NN N
( ( N
n=8 JJ N
) ) N
group NN N
antioxidant NN N
defense NN N
system NN N
in IN N
adults NNS N
with IN N
chronic JJ N
SCI NNP N
-DOCSTART- -X- O O 21635675

healthy JJ 4_p
subjects NNS N
. . N

in IN N
healthy JJ N
, , N
lean JJ N
males NNS N
in IN N
healthy JJ N
males NNS N
-DOCSTART- -X- O O 24366350

Households NNS N
with IN N
young JJ 1_p
children NNS 1_p
and CC N
use NN N
of IN N
freely RB N
distributed VBN N
bednets NNS N
in IN N
rural JJ N
Madagascar NNP N
. . N

children NNS 1_p
in IN N
Madagascar NNP N
. . N

bednet NN N
distribution NN N
programs NNS N
young JJ 1_p
children NNS 1_p
. . N

free JJ N
bednet NN N
distribution NN N
program NN N
in IN N
Madagascar NNP N
from IN N
2007-2008 JJ N
. . N

children NNS N
560 CD 3_p
households NNS N
in IN N
the DT N
study NN N
child NN N
under IN 1_p
5 CD 1_p
years NNS 1_p
of IN N
age NN N
children NNS N
-DOCSTART- -X- O O 22800470

smokers NNS 4_p
and CC N
non-smokers NNS 4_p
: : N
were VBD N
32 CD 3_p
smokers NNS 3_p
and CC 3_p
33 CD 3_p
non-smokers NNS 3_p
without IN N
any DT N
evidence NN N
of IN N
premalignant JJ 4_p
oral JJ 4_p
lesions NNS 4_p
-DOCSTART- -X- O O 20519346

90 CD N
patients NNS N
( ( N
78 CD N
women NNS N
; : N
median JJ N
age NN N
, , N
52 CD N
yr NN N
; : N
range NN N
, , N
22-83 JJ N
) ) N
with IN N
a DT N
nontoxic JJ N
nodular JJ N
goiter NN N
( ( N
median JJ N
size NN N
, , N
63 CD N
ml NN N
; : N
range NN N
, , N
25-379 JJ N
ml NN N
) ) N
were VBD N
randomized VBN N
-DOCSTART- -X- O O 17472838

postponing VBG 4_p
dialysis NN 4_p
in IN N
the DT N
elderly JJ 1_p
: : N
Italian JJ N
uremic JJ N
patients NNS N
without IN N
diabetes NNS 4_p
older JJR 1_p
than IN 1_p
70 CD 1_p
years NNS 1_p
with IN N
glomerular JJ 4_p
filtration NN 4_p
rate NN 4_p
of IN 4_p
5 CD 4_p
to TO 4_p
7 CD 4_p
mL/min NN 4_p
( ( 4_p
0.08 CD 4_p
to TO 4_p
0.12 CD 4_p
mL/s NN 4_p
) ) 4_p
. . N

56 CD 3_p
patients NNS 3_p
elderly JJ 1_p
patients NNS 1_p
without IN N
diabetes NNS 4_p
. . N

-DOCSTART- -X- O O 22595172

preterm JJ N
infants NNS N
. . N

preterm JJ 1_p
infants NNS 1_p
of IN N
longer JJR 4_p
Kangaroo NNP 4_p
Care NNP 4_p
( ( 4_p
30 CD 4_p
minutes NNS 4_p
, , 4_p
KC30 NNP 4_p
) ) 4_p
and CC N
shorter JJR 4_p
KC NNP 4_p
( ( 4_p
15 CD 4_p
minutes NNS 4_p
, , 4_p
KC15 NNP 4_p
) ) 4_p
before IN 4_p
and CC 4_p
throughout IN 4_p
heel NN 4_p
stick NNS 4_p
compared VBN 4_p
with IN 4_p
incubator NN 4_p
care NN 4_p
( ( 4_p
IC NNP 4_p
) ) 4_p
. . N

26 CD 3_p
infants NNS 1_p
. . N

preterm JJ 1_p
infants NNS 1_p
. . 1_p

-DOCSTART- -X- O O 22789149

Four CD N
clinician JJ N
members NNS N
of IN N
the DT N
American NNP N
Academy NNP N
of IN N
Family NNP N
Physicians NNP N
National NNP N
Research NNP N
Network NNP N
participated VBN N
by IN N
enrolling VBG N
194 CD 3_p
patients NNS 3_p
into IN N
a DT N
randomized JJ N
patient NN N
trial NN N
and CC N
29 CD N
physicians NNS N
into IN N
a DT N
non-randomized JJ N
clinician JJ N
trial NN N
of IN N
respective JJ N
interventions NNS N
. . N

-DOCSTART- -X- O O 12742556

hirsutism NN N
. . N

hirsutism NN N
. . N

Women NNP N
with IN N
hirsutism NN N
, , N
as IN N
defined VBN N
by IN N
a DT N
minimum JJ N
Ferriman-Gallwey JJ N
score NN N
of IN N
10 CD N
47 CD N
women NNS N
enrolled VBD N
hirsutism NN N
. . N

-DOCSTART- -X- O O 18082528

abdominal JJ 4_p
aortic JJ 4_p
aneurysm NN 4_p
. . 4_p

abdominal JJ N
aortic JJ N
aneurysms NNS N
( ( N
AAAs NNP N
) ) N
in IN N
patients NNS N
at IN N
risk NN N
146 CD N
patients NNS N
( ( N
mean JJ N
age NN N
69 CD N
+/- JJ N
10 CD N
years NNS N
; : N
127 CD N
men NNS N
) ) N
patients NNS N
with IN N
AAAs NNP N
confirmed VBN N
by IN N
CT NNP N
. . N

-DOCSTART- -X- O O 26266420

a DT N
Chinese JJ 4_p
hypertensive JJ 4_p
population NN 4_p
. . N

A DT 1_p
total NN N
of IN N
480 CD 3_p
subjects NNS N
aged VBN 1_p
28-75 CD 1_p
were VBD 1_p
enrolled VBN N
in IN N
this DT N
study NN N
from IN N
September NNP N
2005-December JJ N
2005 CD N
from IN N
six CD N
hospitals NNS N
in IN N
different JJ N
Chinese JJ N
regions NNS N
. . 1_p

-DOCSTART- -X- O O 8787889

Twelve NNP 4_p
healthy JJ 4_p
male NN 4_p
volunteers NNS 4_p
Both DT N
antibiotics NNS N
were VBD N
well RB N
tolerated VBN N
in IN N
this DT N
single-dose JJ N
administration NN N
study NN N
. . N

Both DT N
drugs NNS N
had VBD N
rather RB N
short JJ N
biological JJ N
elimination NN N
half-lives NNS N
and CC N
a DT N
predominantly RB N
renal JJ N
route NN N
of IN N
elimination NN N
. . N

-DOCSTART- -X- O O 25841244

patients NNS 4_p
with IN 4_p
ischaemic JJ 4_p
left VBD 4_p
ventricular JJ 4_p
dysfunction NN 4_p
. . 4_p

-DOCSTART- -X- O O 17511685

after IN N
liver JJ 4_p
transplantation NN 4_p
-- : N
a DT N
after IN N
liver JJ 4_p
transplantation NN 4_p
( ( 4_p
LT NNP 4_p
) ) 4_p
Between NNP N
February NNP N
2000 CD N
and CC N
August NNP N
2004 CD N
, , N
110 CD 3_p
patients NNS N
after IN 4_p
LT NNP 4_p
All DT N
patients NNS N
received VBD N
methylprednisolon NN N
for IN N
14 CD N
days NNS N
after IN N
LT NNP N
. . N

after IN N
LT NNP 4_p
-DOCSTART- -X- O O 16595217

in IN 4_p
patients NNS 4_p
with IN 4_p
borderline JJ 4_p
semen NNS 4_p
: : 4_p
patients NNS 4_p
with IN 4_p
borderline JJ 4_p
semen NNS 4_p
A DT N
university NN N
medical JJ N
center NN N
in IN N
The DT N
Netherlands NNP N
. . N

One CD 3_p
hundred VBN 3_p
six CD 3_p
couples NNS 3_p
with IN N
borderline JJ 4_p
semen NNS 4_p
who WP N
were VBD N
undergoing VBG N
IVF NNP N
and CC N
ICSI NNP N
on IN N
sibling VBG N
oocytes NNS N
. . N

In IN 3_p
78 CD 3_p
patients NNS 3_p
2 CD 3_p
patients NNS 3_p
Patients NNS N
of IN N
the DT N
IVF+ NNP N
IVF- NNP N
group NN N
. . N

101 CD 3_p
patients NNS 3_p
patients NNS 4_p
with IN 4_p
borderline JJ 4_p
semen NNS 4_p
: : N
-DOCSTART- -X- O O 23241003

patients NNS N
with IN N
systolic JJ 4_p
heart NN 4_p
failure NN 4_p
left JJ 4_p
heart NN 4_p
failure NN 4_p
patients NNS N
with IN N
left JJ 4_p
systolic JJ 4_p
heart NN 4_p
failure NN 4_p
. . N

106 CD 3_p
patients NNS N
were VBD N
randomized VBN N
1:1 CD N
to TO N
sildenafil VB N
( ( N
n=53 NN 3_p
) ) N
or CC N
placebo NN N
( ( N
n=53 JJ 3_p
) ) N
. . N

Patients NNS N
received VBD N
sildenafil JJ N
25 CD N
mg NN N
twice RB N
a DT N
day NN N
or CC N
matching VBG N
placebo NN N
for IN N
the DT N
first JJ N
2 CD N
weeks NNS N
and CC N
50 CD N
mg NN N
3 CD N
times NNS N
a DT N
week NN N
for IN N
the DT N
remainder NN N
of IN N
the DT N
trial NN N
. . N

left JJ N
heart NN N
failure NN N
patients NNS N
-DOCSTART- -X- O O 20145986

caregiver RB 4_p
toddlers NNS 1_p
with IN N
autism NN 4_p
. . N

caregivers NNS N
and CC N
toddlers NNS 1_p
with IN N
autism NN 4_p
. . N

24 CD 3_p
caregiver-mediated JJ N
sessions NNS N
toddlers NNS 1_p
with IN N
autism NN 4_p
. . N

-DOCSTART- -X- O O 12233894

postmenopausal JJ 4_p
women NNS 2_p
stratified VBN N
by IN N
Helicobacter NNP 4_p
pylori NN 4_p
status NN N
. . N

healthy JJ 4_p
postmenopausal NN 4_p
women NNS 2_p
stratified VBN N
by IN N
Helicobacter NNP 4_p
pylori NN 4_p
status NN N
. . N

-DOCSTART- -X- O O 20204691

autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
: : N
children NNS 1_p
with IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorder NNP 4_p
. . 4_p

43 CD 3_p
children NNS N
, , N
aged VBN N
3-8 CD 1_p
years NNS 1_p
. . N

-DOCSTART- -X- O O 22550938

dyspnoea NN 4_p
in IN N
primary JJ N
care NN N
. . N

heart NN N
failure NN N
in IN N
primary JJ N
care NN N
B-type NNP 4_p
natriuretic JJ 4_p
peptide NN 4_p
( ( 4_p
BNP NNP 4_p
) ) 4_p
levels NNS 4_p
. . N

Twenty-nine JJ 3_p
primary JJ N
care NN N
physicians NNS N
in IN N
Switzerland NNP N
and CC N
Germany NNP N
coordinated VBN N
by IN N
the DT N
University NNP N
Hospital NNP N
Basel NNP N
, , N
Switzerland NNP N
. . N

total NN N
of IN N
323 CD 3_p
consecutive JJ N
patients NNS N
presenting VBG N
with IN N
dyspnoea NN 4_p
. . N

-DOCSTART- -X- O O 8930174

21 CD N
salt-replete JJ N
normal-to-high JJ N
renin NN N
hypertensive JJ N
patients NNS N
. . N

-DOCSTART- -X- O O 6740101

United NNP N
States NNPS N
children NNS 1_p
two CD 1_p
months NNS 1_p
of IN N
age NN N
439 CD 3_p
children NNS 1_p
at IN 1_p
two CD 1_p
, , 1_p
four CD 1_p
, , 1_p
and CC 1_p
six CD 1_p
months NNS 1_p
of IN 1_p
age NN 1_p
and CC N
from IN N
85 CD 3_p
children NNS 1_p
at IN 1_p
18 CD 1_p
and CC 1_p
20 CD 1_p
months NNS 1_p
of IN 1_p
age NN 1_p
-DOCSTART- -X- O O 15200727

42 CD N
patients NNS N
Participants NNS 4_p
were VBD 4_p
randomly RB 4_p
assigned VBN 4_p
to TO 4_p
treatment NN 4_p
nursing NN N
modality NN N
for IN N
chronic JJ N
pain NN N
sufferers NNS N
. . N

-DOCSTART- -X- O O 3108794

high-risk JJ 4_p
head NN 4_p
and CC 4_p
neck NN 4_p
surgery NN 4_p
: : N
Patients NNS N
who WP N
undergo VBP N
major JJ N
contaminated VBN N
surgery NN N
of IN N
the DT N
head NN N
and CC N
neck NN N
Patients NNS N
who WP N
were VBD N
identified VBN N
as IN N
requiring VBG N
pedicled VBD N
flap JJ N
reconstruction NN N
were VBD N
potential JJ N
candidates NNS N
for IN N
the DT N
study NN N
. . N

One CD 3_p
hundred VBD 3_p
nine CD 3_p
patients NNS N
were VBD N
evaluable JJ N
. . N

-DOCSTART- -X- O O 16472981

recurrent NN 4_p
aphthous JJ 4_p
stomatitis NN 4_p
( ( 4_p
RAS NNP 4_p
) ) 4_p
Thirty NNP 3_p
subjects NNS N
( ( N
8 CD 3_p
men NNS 2_p
and CC N
22 CD 3_p
women NNS 2_p
) ) N
who WP N
had VBD N
minor JJ N
RAS NNP N
at IN N
least JJS N
once RB N
a DT N
month NN N
-DOCSTART- -X- O O 19135235

in IN 4_p
cesarean-delivered JJ 4_p
children NNS 1_p
Allergic NNP 4_p
children NNS N
1223 CD 3_p
mothers NNS 3_p
with IN N
infants NNS 1_p
at IN N
high JJ 4_p
risk NN 4_p
for IN 4_p
allergy NN 4_p
last JJ N
month NN N
of IN N
pregnancy NN N
and CC N
their PRP$ N
infants NNS 1_p
to TO N
receive VB N
it PRP N
from IN N
birth NN N
until IN N
age NN 1_p
6 CD 1_p
months NNS 1_p
. . N

Of IN N
the DT N
1018 CD 3_p
intent-to-treat NN 3_p
infants NNS N
, , N
891 CD 3_p
( ( 3_p
88 CD 3_p
% NN 3_p
) ) 3_p
attended VBD 3_p
the DT N
5-year JJ N
visit NN N
. . N

high-risk JJ 4_p
mothers NNS N
and CC N
children NNS N
. . N

-DOCSTART- -X- O O 16904652

15 CD 3_p
adult NN 1_p
subjects NNS N
diagnosed VBN N
with IN N
autism NN 4_p
or CC 4_p
Asperger NNP 4_p
's POS 4_p
disorder NN 4_p
, , N
and CC N
comprehension NN N
of IN N
affective JJ N
speech NN N
( ( N
happy JJ N
, , N
indifferent JJ N
, , N
angry JJ N
, , N
and CC N
sad NN N
) ) N
-DOCSTART- -X- O O 21997224

displaced JJ 4_p
femoral JJ 4_p
neck NN 4_p
fractures NNS 4_p
in IN 4_p
the DT 4_p
elderly JJ 4_p
: : 4_p
elderly JJ N
patients NNS N
with IN N
displaced JJ N
femoral JJ N
neck NN N
fractures NNS N
. . N

at IN N
a DT N
university NN N
hospital NN N
in IN N
Norway NNP N
; : N
166 CD N
patients NNS N
, , N
124 CD N
( ( N
75 CD N
% NN N
) ) N
women NNS N
with IN N
a DT N
mean JJ N
age NN N
of IN N
82 CD N
years NNS N
-DOCSTART- -X- O O 8403910

pregnant VB 4_p
and CC N
non-pregnant JJ 4_p
women NNS 2_p
. . N

nine CD 3_p
non-pregnant JJ 4_p
and CC N
36 CD 3_p
pregnant JJ 4_p
women NNS 2_p
. . N

36 CD 3_p
pregnant JJ 4_p
women NNS 2_p
non-pregnant JJ 4_p
and CC N
pregnant JJ 4_p
women NNS 2_p
-DOCSTART- -X- O O 21704300

for IN N
patients NNS N
undergoing VBG N
coronary JJ N
artery NN N
bypass NN N
graft NN N
surgery NN N
for IN N
patients NNS N
undergoing VBG 4_p
isolated JJ 4_p
coronary JJ 4_p
artery NN 4_p
bypass NN 4_p
graft NN 4_p
surgery NN 4_p
from IN N
2000 CD N
to TO N
2008 CD N
for IN N
patients NNS N
who WP N
received VBD N
preoperative JJ N
β-blockers NNS N
with IN N
those DT N
of IN N
patients NNS N
who WP N
did VBD N
not RB N
had VBD N
12,855 CD 3_p
patients NNS N
, , N
of IN N
whom WP N
7,967 CD N
( ( N
62.0 CD N
% NN N
) ) N
were VBD N
treated VBN N
preoperatively RB N
with IN N
β-blockers NNS N
-DOCSTART- -X- O O 22676466

rural JJ N
women NNS 2_p
living VBG 4_p
with IN 4_p
AIDS NNP 4_p
in IN 4_p
India NNP 4_p
: : N
68 CD 3_p
rural JJ N
women NNS 2_p
living VBG 4_p
with IN 4_p
AIDS NNP 4_p
Two CD N
high JJ N
prevalence NN N
HIV/AIDS NNP N
villages NNS N
in IN N
rural JJ N
Andhra NNP N
Pradesh NNP N
, , N
which WDT N
were VBD N
demographically RB N
alike JJ N
and CC N
served VBN N
by IN N
distinct JJ N
Public NNP N
Health NNP N
Centers NNP N
, , N
were VBD N
selected VBN N
randomly RB N
from IN N
a DT N
total NN N
of IN N
16 CD N
villages NNS N
. . N

women NNS 2_p
living VBG 4_p
with IN 4_p
AIDS NNP 4_p
-DOCSTART- -X- O O 11476129

autistic JJ 4_p
disorder NN 4_p
: : 4_p
autism NN 4_p
Individuals NNS N
with IN N
a DT N
DSM-IV JJ N
diagnosis NN N
of IN N
autistic JJ N
disorder NN N
( ( N
mean JJ N
age NN N
, , N
16.3 CD N
years NNS N
; : N
range NN N
, , N
10-36 JJ N
years NNS N
) ) N
were VBD N
randomly RB N
assigned VBN N
, , N
by IN N
using VBG N
a DT N
Latin NNP N
square NN N
design NN N
, , N
to TO N
the DT N
following JJ N
7-week JJ N
trials NNS N
: : N
placebo NN N
, , N
clomipramine NN N
( ( N
mean JJ N
daily RB N
dose RB N
, , N
128.4 CD N
mg NN N
; : N
range NN N
, , N
100-150 JJ N
mg NN N
) ) N
, , N
or CC N
haloperidol NN N
( ( N
mean JJ N
daily RB N
dose RB N
, , N
1.3 CD N
mg NN N
; : N
range NN N
, , N
1-1.5 JJ N
mg NN N
) ) N
. . N

Data NNP N
on IN N
36 CD 3_p
subjects NNS N
were VBD N
analyzed VBN N
-DOCSTART- -X- O O 23296213

individuals NNS N
with IN N
serious JJ 4_p
mental JJ 4_p
illness NN 4_p
( ( 4_p
SMI NNP 4_p
) ) 4_p
receiving VBG 4_p
antipsychotic JJ 4_p
drug NN 4_p
therapy NN 4_p
. . N

individuals NNS N
with IN N
SMI NNP 4_p
over IN N
8 CD N
weeks NNS N
. . N

30 CD 3_p
individuals NNS N
( ( N
BMI NNP N
≥ VBZ N
28 CD N
kg/m NN N
( ( N
2 CD N
) ) N
) ) N
for IN N
individuals NNS N
with IN N
SMI NNP N
in IN N
patients NNS N
taking VBG N
antipsychotic JJ 4_p
medications NNS 4_p
; : N
-DOCSTART- -X- O O 8964113

chronic JJ 4_p
cigarette NN 4_p
smokers NNS 4_p
. . 4_p

chronic JJ N
cigarette NN N
smokers NNS N
. . N

a DT N
cross-sectional JJ N
comparison NN N
of IN N
smokers NNS N
and CC N
control NN N
subjects NNS N
heavy JJ N
smokers NNS N
moderate JJ 4_p
smokers NNS 4_p
nonsmokers NNS 4_p
. . N

smokers NNS N
-DOCSTART- -X- O O 15821644

cardiopulmonary JJ 4_p
bypass NN 4_p
patients NNS N
undergoing VBG N
coronary JJ 4_p
artery NN 4_p
bypass NN 4_p
grafting NN N
. . N

Blood NNP N
samples NNS N
from IN N
41 CD 3_p
patients NNS N
cardiopulmonary JJ 4_p
bypass NN 4_p
. . N

patients NNS N
subjected VBN N
to TO N
cardiopulmonary JJ 4_p
bypass NN 4_p
. . N

-DOCSTART- -X- O O 8957368

symptomatic JJ 4_p
malignant JJ 4_p
pleural JJ 4_p
effusion NN 4_p
. . 4_p

malignant JJ 4_p
pleural JJ 4_p
effusion NN 4_p
. . N

From IN N
September NNP N
1993 CD N
to TO N
November NNP N
1995 CD N
, , N
57 CD 3_p
patients NNS N
Patients NNS N
with IN N
poor JJ 4_p
general JJ 4_p
condition NN 4_p
( ( N
Karnofsky NNP N
score RB N
less JJR N
than IN N
30 CD N
% NN N
) ) N
, , N
poor JJ 4_p
pulmonary JJ 4_p
function NN 4_p
( ( N
forced JJ N
expiratory NN N
volume NN N
in IN N
1 CD N
second NN N
less JJR N
than IN N
0.5 CD N
L NNP N
) ) N
, , N
or CC N
trapped VBN 4_p
lungs NNS 4_p
were VBD N
excluded VBN N
from IN N
this DT N
study NN N
. . N

patients NNS N
who WP N
do VBP N
not RB N
have VB N
trapped VBN 4_p
lungs NNS 4_p
. . N

-DOCSTART- -X- O O 25260191

toddlers NNS 1_p
at IN N
high JJ 4_p
risk NN 4_p
for IN 4_p
autism NN 4_p
. . N

parent-mediated JJ N
toddlers NNS 1_p
at IN N
high JJ 4_p
risk NN 4_p
for IN 4_p
an DT 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
. . 4_p

Participants NNS N
included VBD N
caregivers NNS N
and CC N
their PRP$ N
66 CD 3_p
toddlers NNS 3_p
at IN N
high JJ N
risk NN N
for IN N
ASD NNP 4_p
. . N

Caregivers NNS N
-DOCSTART- -X- O O 23862237

type NN 4_p
III NNP 4_p
prostatitis NN 4_p
] NNP 4_p
242 CD 3_p
patients NNS 3_p
with IN N
type JJ 4_p
III NNP 4_p
prostatitis NN 4_p
diagnosed VBN N
by IN N
the DT N
NIH NNP N
criteria NNS N
All PDT N
the DT N
242 CD 3_p
patients NNS 3_p
completed VBD N
the DT N
treatment NN N
. . N

-DOCSTART- -X- O O 19910815

elite JJ 4_p
junior JJ 4_p
soccer NN 4_p
players NNS 4_p
. . 4_p

male JJ 2_p
elite JJ N
junior JJ N
soccer NN N
players NNS N
. . N

Twenty NNP N
highly RB N
trained VBD N
soccer NN N
players NNS N
( ( N
age NN N
18.3 CD 1_p
+/- JJ 1_p
0.6 CD 1_p
years NNS 1_p
, , N
height VBD N
177 CD N
+/- JJ N
4 CD N
cm NN N
, , N
body NN N
mass VBD N
71.4 CD N
+/- JJ N
6.9 CD N
kg NN N
, , N
sum NN N
skinfolds NNS N
48.1 CD N
+/- JJ N
11.4 CD N
mm NN N
) ) N
, , N
members NNS N
of IN N
a DT N
professional JJ N
soccer NN N
academy NN N
young JJ N
elite JJ N
soccer NN N
players NNS N
-DOCSTART- -X- O O 8403942

aortocoronary JJ 4_p
bypass NN 4_p
patency NN 4_p
patients NNS 4_p
after IN 4_p
aortocoronary JJ 4_p
bypass NN 4_p
( ( 4_p
ACB NNP 4_p
) ) 4_p
surgery NN 4_p
. . 4_p

52 CD 3_p
patients NNS N
ACB NNP N
's POS N
with IN N
intraoperative JJ N
blood NN N
flow NN N
rates NNS N
-DOCSTART- -X- O O 17178532

children NNS 4_p
with IN 4_p
autism NN 4_p
: : 4_p
children NNS 1_p
with IN N
autism NN 4_p
20 CD 3_p
children NNS 1_p
with IN N
autism NN 4_p
participating VBG N
in IN N
a DT N
randomised JJ N
placebo-controlled JJ N
trial NN N
of IN N
risperidone NN N
for IN N
disruptive JJ N
behaviours NNS N
. . N

-DOCSTART- -X- O O 7010528

patients NNS 4_p
with IN 4_p
gastric JJ 4_p
ulcer NN 4_p
. . 4_p

Patients NNS 4_p
with IN 4_p
benign JJ 4_p
gastric JJ 4_p
ulcer NN 4_p
Fifty NNP 4_p
two CD 4_p
patients NNS 4_p
entered VBD 4_p
the DT 4_p
trial NN 4_p
, , 4_p
and CC 4_p
12 CD 4_p
were VBD 4_p
withdrawn VBN 4_p
. . 4_p

peptic JJ 4_p
ulcer NN 4_p
. . 4_p

-DOCSTART- -X- O O 16596465

children NNS 4_p
, , 4_p
adolescents NNS 4_p
and CC 4_p
adults NNS 4_p
with IN 4_p
mental JJ 4_p
retardation NN 4_p
. . 4_p

destructive JJ N
Forty NNP 4_p
subjects NNS 4_p
, , 4_p
aged VBN 4_p
8-56 CD 4_p
years NNS 4_p
( ( 4_p
mean=22 NN 4_p
) ) 4_p
, , 4_p
all DT 4_p
with IN 4_p
mental JJ 4_p
retardation NN 4_p
and CC 4_p
36 CD 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
participated VBD 4_p
-DOCSTART- -X- O O 20484002

children NNS 1_p
with IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorders NNP 4_p
( ( N
ASD NNP 4_p
) ) N
. . N

47 CD 3_p
preschool NN 1_p
and CC 1_p
K-1 JJ 1_p
students NNS 1_p
in IN N
ASD NNP 4_p
classrooms NNS N
participated VBD N
from IN N
Los NNP N
Angeles NNP N
Unified NNP N
School NNP N
District NNP N
. . N

children NNS N
with IN N
ASD NNP 4_p
and CC N
other JJ N
special JJ 4_p
needs NNS 4_p
. . N

-DOCSTART- -X- O O 9182738

80 CD 4_p
teeth NNS 4_p
with IN 4_p
5 CD 4_p
to TO 4_p
12 CD 4_p
mm NNS 4_p
probing VBG 4_p
depths NNS 4_p
in IN 4_p
15 CD 4_p
patients NNS 4_p
. . 4_p

groups NNS N
of IN N
4 CD N
teeth NNS N
-DOCSTART- -X- O O 14605954

after IN 4_p
hemorrhoidectomy NN 4_p
: : 4_p
after IN N
hemorrhoidectomy NN N
. . N

112 CD N
consecutive JJ N
patients NNS N
after IN N
hemorrhoidectomy NN N
after IN N
hemorrhoidectomy NN N
. . N

after IN N
hemorrhoidectomy NN N
-DOCSTART- -X- O O 24732316

endometrial JJ 4_p
cancer NN 4_p
467 CD 3_p
women NNS 2_p
with IN N
type JJ 4_p
1 CD 4_p
or CC 4_p
2 CD 4_p
endometrial JJ 4_p
cancer NN 4_p
and CC N
582 CD N
age-matched JJ N
controls NNS N
. . N

tumor NN 4_p
specimens NNS N
of IN N
46 CD 3_p
women NNS N
with IN N
type JJ 4_p
1 CD 4_p
endometrial JJ 4_p
cancer NN 4_p
enrolled VBN N
in IN N
RTOG NNP N
trials NNS N
9708 CD N
and CC N
9905. CD N
for IN N
patients NNS N
with IN N
the DT N
variant NN 4_p
and CC 4_p
wild-type JJ 4_p
alleles NNS 4_p
-DOCSTART- -X- O O 2881132

preterm JJ 4_p
labour NN 4_p
. . N

pregnant JJ 4_p
women NNS 2_p
4122 CD 3_p
women NNS N
at IN N
27-31 JJ N
weeks NNS N
' POS N
gestation NN N
69 CD 3_p
women NNS N
. . N

pregnant JJ 4_p
women NNS N
with IN N
group-B JJ 4_p
streptococci NN 4_p
in IN N
the DT N
urine NN N
-DOCSTART- -X- O O 15304616

chorea NNS 4_p
in IN 4_p
Huntington NNP 4_p
's POS 4_p
disease NN 4_p
: : N
-DOCSTART- -X- O O 24275895

depression NN 4_p
in IN 4_p
Parkinson NNP 4_p
's POS 4_p
disease NN 4_p
. . 4_p

people NNS N
with IN N
Parkinson NNP N
's POS N
disease NN N
( ( N
PD NNP N
) ) N
after IN N
their PRP$ N
participation NN N
in IN N
an DT N
NIH-sponsored JJ N
, , N
randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
cognitive-behavioral JJ N
treatment NN N
for IN N
depression NN N
. . N

-DOCSTART- -X- O O 9529556

Pruritus NNP 4_p
in IN N
HIV-1+ NNP 4_p
patients NNS N
patients NNS N
on IN N
four CD 4_p
different JJ 4_p
forms NNS 4_p
of IN 4_p
therapy NN 4_p
for IN N
their PRP$ N
pruritus NN 4_p
. . N

Patients NNS N
on IN N
pentoxifylline NN N
-DOCSTART- -X- O O 15446660

Chomsky NNP N
's POS N
principle NN N
of IN N
Full NNP N
Interpretation NNP N
. . N

88 CD 3_p
adult JJ 1_p
Japanese JJ 4_p
speakers NNS N
-DOCSTART- -X- O O 11060324

" NNP 4_p
cytoreduction NN 4_p
nephrectomy NN 4_p
in IN 4_p
metastatic JJ 4_p
renal JJ 4_p
cancer NN 4_p
: : 4_p
Southwest NNP 4_p
Oncology NNP 4_p
Group NNP 4_p
Trial NNP 4_p
8949 CD N
" NN N
-DOCSTART- -X- O O 17974096

septic JJ 4_p
acute NN 4_p
lung NN 4_p
injury NN 4_p
patients NNS N
with IN N
septic JJ 4_p
acute NN 4_p
lung NN 4_p
injury NN 4_p
( ( 4_p
ALI NNP 4_p
) ) 4_p
-DOCSTART- -X- O O 19040172

dually RB N
eligible JJ N
beneficiaries NNS N
. . N

Florida NNP N
Medicare NNP N
beneficiaries NNS N
who WP N
are VBP N
also RB N
enrolled VBN N
in IN N
Medicaid NNP N
and CC N
have VBP N
congestive JJ N
heart NN N
failure NN N
( ( N
CHF NNP N
) ) N
, , N
diabetes VBZ N
, , N
or CC N
coronary JJ N
artery NN N
disease NN N
( ( N
CAD NNP N
) ) N
. . N

33,000 CD N
enrollees NNS N
. . N

beneficiaries NNS N
with IN N
CHF NNP N
who WP N
resided VBD N
in IN N
high-cost NN N
South NNP N
Florida NNP N
counties NNS N
-DOCSTART- -X- O O 2165088

mild NN 4_p
or CC 4_p
moderate JJ 4_p
essential JJ 4_p
hypertension NN 4_p
: : N
Five CD 3_p
hundred JJ 3_p
and CC 3_p
fifty-nine JJ 3_p
hypertensive JJ N
outpatients NNS 4_p
with IN 4_p
diastolic JJ 4_p
blood NN 4_p
pressure NN 4_p
between IN 4_p
95 CD 4_p
and CC 4_p
110 CD 4_p
mmHg NN 4_p
subjects NNS N
-DOCSTART- -X- O O 7692028

very RB 4_p
low JJ 4_p
birth NN 4_p
weight NN 4_p
infants NNS 4_p
: : 4_p
very RB 4_p
low JJ 4_p
birth NN 4_p
weight NN 4_p
( ( 4_p
< CD 4_p
or CC 4_p
= VB 4_p
1500 CD 4_p
gm NN 4_p
) ) 4_p
infants NNS 4_p
. . 4_p

Eight NNP N
sites NNS N
, , N
heterogeneous JJ N
for IN N
sociodemographic JJ N
and CC N
health NN N
care NN N
use NN N
. . N

Infants NNS N
( ( N
N NNP N
= NNP N
280 CD N
) ) N
born VBN N
weighing VBG N
< NN N
or CC N
= NN N
1500 CD N
gm NN N
and CC N
selected VBN N
for IN N
the DT N
Infant NNP N
Health NNP N
and CC N
Development NNP N
Program NNP N
. . N

geographic JJ N
distance NN N
from IN N
the DT N
day NN N
care NN N
center NN N
. . N

36 CD N
months NNS N
of IN N
age NN N
( ( N
corrected VBN N
for IN N
gestational JJ N
age NN N
when WRB N
final JJ N
assessments NNS N
were VBD N
completed VBN N
) ) N
. . N

very RB N
low JJ N
birth NN N
weight NN N
children NNS N
-DOCSTART- -X- O O 18522171

malignant JJ 4_p
brain NN 4_p
gliomas NN 4_p
malignantly-converted JJ 4_p
brain NN 4_p
gliomas NN 4_p
-DOCSTART- -X- O O 15937606

women NNS 2_p
experiencing VBG N
vaginal JJ 4_p
and CC 4_p
Caesarean JJ 4_p
births NNS N
. . N

vaginal JJ 4_p
delivery NN 4_p
Caesarean JJ N
section NN N
. . N

3 CD N
Montreal NNP N
hospitals NNS N
in IN N
1990-1991 JJ N
. . N

999 CD 3_p
trial NN N
participants NNS N
for IN N
whom WP N
follow-up JJ N
data NNS N
were VBD N
available JJ N
, , N
135 CD 3_p
delivered VBN N
by IN N
Caesarean NNP N
section NN N
( ( N
CS NNP N
) ) N
, , N
and CC N
864 CD 3_p
had VBD N
a DT N
vaginal JJ N
birth NN N
( ( N
VB NNP N
) ) N
. . N

Primiparous JJ N
women NNS 2_p
Multiparous JJ N
women NNS 2_p
those DT N
who WP N
had VBD N
an DT N
episiotomy NN N
with IN N
or CC N
without IN N
forceps NNS N
. . N

-DOCSTART- -X- O O 20038728

patients NNS N
with IN N
hormone JJ 4_p
receptor-positive JJ 4_p
breast NN 4_p
cancer NN 4_p
: : N
patients NNS N
with IN N
breast JJ 4_p
cancer NN 4_p
. . N

menopausal JJ 4_p
women NNS N
. . N

Fifty NNP 3_p
patients NNS N
patients NNS N
with IN N
breast JJ 4_p
cancer NN 4_p
. . N

-DOCSTART- -X- O O 2068469

biliary JJ N
and CC N
gastric JJ N
surgery NN N
. . N

80 CD 3_p
patients NNS N
undergoing JJ N
biliary JJ N
or CC N
gastric JJ N
surgery NN N
. . N

biliary JJ N
and CC N
gastric JJ N
surgery NN N
. . N

-DOCSTART- -X- O O 24467617

pre-pubertal JJ 1_p
female JJ 2_p
dogs NNS N
: : N
pre-pubertal JJ 1_p
female JJ 2_p
dogs NNS N
with IN N
deslorelin JJ 4_p
acetate NN 4_p
implants NNS 4_p
Sicilian JJ N
hound NN N
female JJ 2_p
dogs NNS N
( ( N
24 CD 3_p
) ) N
-DOCSTART- -X- O O 12816740

chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
. . N

59 CD 3_p
patients NNS N
with IN N
COPD NNP 4_p
randomized VBD N
-DOCSTART- -X- O O 16146466

lipopolysaccharide-induced JJ 4_p
acute NN 4_p
lung NN 4_p
injury NN 4_p
acute JJ 4_p
lung NN 4_p
injury NN 4_p
. . N

rat NN 4_p
72 CD 3_p
rats NNS 3_p
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
HBO NNP N
or CC N
air NN N
treatment NN N
. . N

rats NNS 4_p
rats NNS 4_p
septic JJ 4_p
rats NNS 4_p
. . N

-DOCSTART- -X- O O 25530107

PARTICIPANTS NNP N
16 CD 3_p
patients NNS 3_p
with IN N
intradialytic JJ 4_p
hypertension NN 4_p
-DOCSTART- -X- O O 5980490

Alcoholism NN 4_p
, , 4_p
avoidance NN 4_p
learning NN 4_p
and CC 4_p
emotional JJ 4_p
responsiveness NN 4_p
. . N

-DOCSTART- -X- O O 7617857

postmenopausal JJ 4_p
women NNS 4_p
undergoing VBG 4_p
continuous JJ 4_p
combined VBN 4_p
hormonal JJ 4_p
replacement NN 4_p
therapy NN 4_p
( ( 4_p
HRT NNP 4_p
) ) 4_p
. . 4_p

41 CD 4_p
postmenopausal JJ 4_p
women NNS 4_p
obtained VBN 4_p
before IN 4_p
and CC 4_p
1 CD 4_p
year NN 4_p
after IN 4_p
the DT 4_p
initiation NN 4_p
of IN 4_p
HRT NNP 4_p
subjects NNS N
undergoing VBG N
continuous JJ N
combined VBN N
HRT NNP N
-DOCSTART- -X- O O 11297722

restricting- JJ 4_p
and CC 4_p
restricting-purging-type JJ 4_p
anorexia NN 4_p
nervosa NN 4_p
. . 4_p

35 CD N
patients NNS N
with IN N
restricting-type JJ N
anorexia NN N
nervosa NN N
. . N

Anorexics NNS N
patients NNS 4_p
with IN 4_p
anorexia JJ 4_p
nervosa NN 4_p
-DOCSTART- -X- O O 8297739

patients NNS 4_p
with IN 4_p
advanced JJ 4_p
breast NN 4_p
cancer NN 4_p
. . 4_p

62 CD 3_p
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
breast NN 4_p
cancer NN 4_p
-DOCSTART- -X- O O 15080019

patient-controlled JJ N
analgesia NN N
environment NN N
. . N

374 CD 3_p
patients NNS N
using VBG N
opioid JJ N
PCA NNP N
, , N
but CC N
otherwise RB N
considered VBN N
to TO N
be VB N
low JJ N
risk NN N
for IN N
PONV NNP 4_p
-DOCSTART- -X- O O 11253439

skin JJ 4_p
cancers NNS 4_p
among IN N
beachgoers NNS N
in IN N
southeastern JJ N
New NNP N
England NNP N
. . N

representative JJ N
sample NN N
( ( N
N NNP N
= NNP N
2,324 CD 3_p
) ) N
of IN N
beachgoers NNS N
in IN N
Southeastern NNP N
New NNP N
England NNP N
during IN N
the DT N
summer NN N
of IN N
1995 CD N
. . N

-DOCSTART- -X- O O 16214598

patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
in IN N
the DT N
PROactive NNP N
Study NNP N
Patients NNPS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
high-risk JJ N
patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
. . N

5238 CD 3_p
patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
who WP N
had VBD N
evidence NN N
of IN N
macrovascular JJ 4_p
disease NN 4_p
. . N

patients NNS N
from IN N
primary-care JJ N
practices NNS N
and CC N
hospitals NNS N
. . N

514 CD 3_p
of IN N
2605 CD 3_p
patients NNS N
patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
who WP N
have VBP N
a DT N
high JJ N
risk NN N
of IN N
macrovascular JJ 4_p
events NNS 4_p
. . N

-DOCSTART- -X- O O 2371368

schizophrenia NN 4_p
and CC N
schizoaffective JJ 4_p
disorder NN 4_p
: : N
acutely RB N
exacerbating VBG N
schizophrenic JJ 4_p
or CC N
schizoaffective JJ 4_p
patients NNS N
111 CD 3_p
patients NNS 3_p
-DOCSTART- -X- O O 12093332

after IN 4_p
carotid JJ 4_p
endarterectomy NN 4_p
: : N
Ninety-five JJ N
consecutive JJ N
primary JJ N
carotid NN 4_p
endarterectomies NNS 4_p
were VBD N
performed VBN N
in IN N
a DT N
prospective JJ N
randomized VBN N
fashion NN N
in IN N
92 CD 3_p
patients NNS N
. . N

Fifty-one CD N
procedures NNS N
-DOCSTART- -X- O O 17621027

head JJ 4_p
injury NN 4_p
Eight NNP 3_p
hundred VBD 3_p
sixty-one JJ 3_p
patients NNS 3_p
with IN N
severe JJ 4_p
traumatic JJ 4_p
brain NN 4_p
injury NN 4_p
who WP N
were VBD N
admitted VBN N
to TO N
86 CD N
centers NNS N
-DOCSTART- -X- O O 20031809

women NNS 2_p
with IN N
coronary JJ 4_p
disease NN 4_p
: : N
coronary JJ 4_p
heart NN 4_p
disease NN 4_p
in IN N
women NNS N
. . N

women NNS 2_p
women NNS N
coronary JJ N
patients NNS N
. . N

Two CD 3_p
hundred VBD 3_p
thirty-seven JJ 3_p
consecutive JJ N
women NNS N
patients NNS N
, , N
aged VBD N
75 CD 1_p
years NNS 1_p
or CC N
younger JJR N
, , N
hospitalized VBN N
for IN N
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
, , N
coronary JJ 4_p
artery NN 4_p
bypass NN 4_p
grafting NN 4_p
, , N
or CC N
percutaneous JJ 4_p
coronary JJ 4_p
intervention NN 4_p
women NNS 2_p
with IN N
coronary JJ 4_p
heart NN 4_p
disease NN 4_p
-DOCSTART- -X- O O 24887304

patients NNS 4_p
with IN 4_p
diabetes NNS 4_p
mellitus NNS 4_p
and CC 4_p
stable JJ 4_p
angina NN 4_p
. . N

-DOCSTART- -X- O O 2461017

total JJ 4_p
hip NN 4_p
replacement NN 4_p
. . N

10 CD 3_p
patients NNS N
undergoing JJ N
total JJ N
hip NN N
replacement NN N
( ( N
THR NNP 4_p
) ) N
patients NNS N
undergoing JJ 4_p
THR NNP 4_p
. . N

100 CD 3_p
patients NNS N
were VBD N
randomized VBN N
. . N

patients NNS N
undergoing JJ N
total JJ N
hip NN N
replacement NN N
-DOCSTART- -X- O O 23975885

patients NNS N
with IN N
treated JJ N
HIV NNP 4_p
infection NN 4_p
: : N
Thirty-one JJ N
subjects NNS N
with IN N
an DT N
ART-suppressed JJ N
plasma NN N
HIV NNP N
RNA NNP N
level NN N
of IN N
< $ N
40 CD N
copies/mL NN N
and CC N
a DT N
CD4 NNP N
( ( N
+ NNP N
) ) N
T-cell NNP N
count NN N
of IN N
≥350 NNP N
cells/mm NN N
( ( N
3 CD N
) ) N
for IN N
≥1 JJ N
year NN N
among IN N
patients NNS N
receiving VBG N
treatment NN N
for IN N
HIV NNP N
infection NN N
-DOCSTART- -X- O O 23045537

underserved JJ 4_p
population NN 4_p
. . 4_p

low-income JJ 4_p
, , 4_p
uninsured JJ 4_p
, , 4_p
and CC 4_p
minority NN 4_p
populations NNS 4_p
. . 4_p

patients NNS N
with IN N
abnormal JJ N
screening VBG N
tests NNS N
in IN N
a DT N
medically RB N
underserved JJ N
patient JJ N
population NN N
. . N

Denver NNP N
Health NNP N
, , N
the DT N
safety-net JJ N
health NN N
care NN N
system NN N
serving VBG N
Denver NNP N
, , N
is VBZ N
one CD N
of IN N
10 CD N
performance NN N
sites NNS N
participating VBG N
in IN N
the DT N
Patient NNP N
Navigation NNP N
Research NNP N
Program NNP N
. . N

993 CD N
eligible JJ N
subjects NNS N
with IN N
abnormal JJ N
screening VBG N
tests NNS N
randomized VBD N
to TO N
navigation NN N
and CC N
no-navigation NN N
( ( N
control NN N
) ) N
arms NNS N
and CC N
analyzed VBD N
, , N
628 CD N
had VBD N
abnormal JJ N
breast NN N
screens NNS N
( ( N
66 CD N
abnormal RB N
clinical JJ N
breast NN N
examinations NNS N
, , N
304 CD N
BIRADS NNP N
0 CD N
, , N
200 CD N
BIRADS NNP N
3 CD N
, , N
58 CD N
BIRADS NNP N
4 CD N
or CC N
5 CD N
) ) N
whereas VBD N
235 CD N
had VBD N
abnormal JJ N
colorectal NN N
and CC N
130 CD N
had VBD N
abnormal JJ N
prostate NN N
screens NNS N
. . N

Participant JJ 4_p
demographics NNS 4_p
included VBD 4_p
72 CD 4_p
% NN 4_p
minority NN 4_p
, , 4_p
49 CD 4_p
% NN 4_p
with IN 4_p
annual JJ 4_p
household JJ 4_p
income NN 4_p
less JJR 4_p
than IN 4_p
$ $ 4_p
10,000 CD 4_p
, , 4_p
and CC 4_p
36 CD 4_p
% NN 4_p
uninsured JJ 4_p
. . 4_p

medically RB N
underserved JJ N
population NN N
. . N

-DOCSTART- -X- O O 2405107

patients NNS N
with IN N
metastatic JJ 4_p
colorectal JJ 4_p
cancer NN 4_p
. . N

One CD 3_p
hundred VBD 3_p
twenty-two JJ 3_p
chemotherapy-naive JJ N
patients NNS N
with IN N
histologically RB N
confirmed VBN N
colorectal JJ 4_p
adenocarcinoma NN 4_p
In IN N
both DT N
groups NNS N
, , N
patients NNS N
received VBD N
continuous JJ N
infusion NN N
FU NNP N
1,000 CD N
mg/m2/d NN N
for IN N
5 CD N
consecutive JJ N
days NNS N
every DT N
4 CD N
weeks NNS N
. . N

patients NNS N
with IN N
advanced JJ 4_p
colorectal JJ 4_p
carcinoma NN 4_p
. . N

-DOCSTART- -X- O O 21432860

nondiabetic JJ 4_p
patients NNS N
with IN N
stage NN 4_p
I PRP 4_p
or CC 4_p
II NNP 4_p
chronic JJ 4_p
kidney NN 4_p
disease NN 4_p
. . N

Thirty NNP 3_p
nondiabetic JJ 4_p
stage NN 4_p
I PRP 4_p
or CC 4_p
II NNP 4_p
CKD NNP 4_p
patients NNS 4_p
who WP N
had VBD N
already RB N
been VBN N
treated VBN N
with IN N
angiotensin NN N
II NNP N
receptor NN N
blockers NNS N
Patients NNPS N
2 CD N
groups NNS N
; : N
nondiabetic JJ 4_p
hypertensive JJ 4_p
CKD NNP 4_p
patients NNS 4_p
-DOCSTART- -X- O O 22118062

children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . N

high JJ 4_p
functioning VBG 4_p
children NNS 4_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
in IN N
general JJ N
education NN N
classrooms NNS N
. . N

conditions NNS N
. . N

Sixty NNP N
children NNS N
participated VBD N
from IN N
56 CD N
classrooms NNS N
in IN N
30 CD N
schools NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
-DOCSTART- -X- O O 7235205

asthmatics NNS 4_p
. . N

13 CD 3_p
asthmatic JJ 4_p
patients NNS N
after IN N
single JJ N
and CC N
multiple JJ N
oral JJ N
dosage NN N
of IN N
a DT N
microcrystalline JJ N
theophylline NN N
tablet NN N
( ( N
Nuelin NNP N
) ) N
and CC N
a DT N
sustained-release JJ N
preparation NN N
( ( N
Nuelin NNP N
Retard NNP N
) ) N
-DOCSTART- -X- O O 10947757

during IN N
minor JJ N
elective JJ N
surgery NN N
. . N

Forty NNP N
adult NN N
patients NNS N
, , N
ASA NNP N
I-II NNP N
-DOCSTART- -X- O O 24694748

twin JJ 4_p
premature NN 1_p
infants NNS 1_p
: : N
preterm NN N
twins NNS N
One CD 3_p
hundred VBD 3_p
premature NN 3_p
twins NNS 3_p
( ( N
50 CD 3_p
sets NNS N
) ) N
born VBP N
between IN N
26 CD N
weeks NNS N
' POS N
and CC N
34 CD N
weeks NNS N
' POS N
gestation NN N
undergoing VBG N
heel NN N
blood NN N
sampling VBG N
measure NN N
for IN N
twin JJ 4_p
premature NN 1_p
infants NNS 1_p
-DOCSTART- -X- O O 22492697

hypopharyngeal NN 4_p
squamous JJ 4_p
cell NN 4_p
carcinoma NN 4_p
: : 4_p
larynx-preservation JJ 4_p
approach NN 4_p
to TO 4_p
immediate VB 4_p
surgery NN 4_p
in IN 4_p
hypopharynx NN 4_p
and CC 4_p
lateral JJ 4_p
epilarynx NN 4_p
squamous JJ 4_p
cell NN 4_p
carcinoma NN 4_p
. . N

Two CD 3_p
hundred CD 3_p
and CC 3_p
two CD 3_p
patients NNS 3_p
on IN N
194 CD 3_p
eligible JJ N
patients NNS N
-DOCSTART- -X- O O 20976617

children NNS 1_p
with IN N
autism NN 4_p
: : N
children NNS 1_p
with IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorders NNP 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
8-13 JJ 1_p
year NN 1_p
old JJ 1_p
children NNS 1_p
with IN N
ASD NNP N
and CC N
normal JJ N
IQs NNP N
( ( N
n JJ N
= NNP N
40 CD N
) ) N
-DOCSTART- -X- O O 26040302

type NN 4_p
2 CD 4_p
diabetes NNS 4_p
inadequately RB N
controlled VBN N
on IN N
basal NN N
insulin NN N
: : N
Patients NNPS N
inadequately RB N
controlled VBN N
[ NN N
glycated VBN N
haemoglobin NN N
( ( N
HbA1c NNP N
) ) N
> VBD N
7 CD N
to TO N
≤10 VB N
% NN N
( ( N
> JJ N
53 CD N
to TO N
≤86 VB N
mmol/mol NN N
) ) N
] NN N
on IN N
basal NN N
insulin NN N
( ( N
glargine NN N
, , N
detemir NN N
, , N
NPH NNP N
) ) N
were VBD N
randomized VBN N
to TO N
empagliflozin VB N
10 CD N
mg NN N
( ( N
n JJ N
= NNP N
169 CD 3_p
) ) N
, , N
empagliflozin $ N
25 CD N
mg NN N
( ( N
n JJ N
= NNP N
155 CD 3_p
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
170 CD 3_p
) ) N
-DOCSTART- -X- O O 16880243

patients NNS N
with IN N
breast JJ 4_p
cancer NN 4_p
metastatic NN N
to TO N
bone NN N
: : N
breast NN 4_p
cancer NN 4_p
patients NNS N
with IN N
newly RB N
diagnosed VBN N
bone NN 4_p
metastases NNS 4_p
. . N

Patients NNS N
diagnosed VBD N
with IN N
bone NN 4_p
metastases NNS 4_p
< VBP N
or CC N
= VBP N
6 CD N
weeks NNS N
prior RB N
to TO N
first JJ N
visit NN N
312 CD 3_p
patients NNS N
enrolled VBD N
Breast NNP 4_p
cancer NN 4_p
patients NNS N
with IN N
newly RB N
diagnosed VBN N
bone NN 4_p
metastases NNS 4_p
-DOCSTART- -X- O O 341733

postoperative JJ 4_p
wound NN 4_p
infection NN 4_p
in IN 4_p
elective JJ 4_p
colon NN 4_p
surgery NN 4_p
. . 4_p

-DOCSTART- -X- O O 7936969

junior JJ 1_p
high JJ 1_p
school NN 1_p
girls NNS 2_p
' POS N
volleyball NN N
performance NN N
. . N

72 CD 3_p
seventh-grade JJ 1_p
girls NNS 2_p
' POS N
-DOCSTART- -X- O O 7673658

chronic JJ 4_p
schizophrenic JJ 4_p
patients NNS N
: : N
cyproheptadine JJ N
augmentation NN N
of IN N
ongoing VBG N
haloperidol NN N
treatment NN N
40 CD 3_p
chronic JJ N
schizophrenic JJ N
in-patients NNS N
. . N

chronic JJ N
schizophrenic JJ N
patients NNS N
who WP N
are VBP N
intolerant JJ N
of IN N
extrapyramidal JJ N
side NN N
effects NNS N
of IN N
conventional JJ N
antipsychotics NNS N
. . N

-DOCSTART- -X- O O 10832773

autism NN 4_p
: : 4_p
-DOCSTART- -X- O O 20673857

males NNS 2_p
with IN N
latent JJ 4_p
myofascial JJ 4_p
trigger NN 4_p
points NNS 4_p
. . N

Thirty NNP 3_p
physically RB 4_p
active JJ 4_p
males NNS N
with IN N
tight JJ 4_p
hamstrings NNS 4_p
and CC 4_p
at IN 4_p
least JJS 4_p
one CD 4_p
latent NN 4_p
MTrP NNP 4_p
on IN 4_p
muscles NNS 4_p
innervated VBN 4_p
by IN 4_p
the DT 4_p
lumbosacral JJ 4_p
, , 4_p
sciatic JJ 4_p
, , 4_p
tibial JJ 4_p
and CC 4_p
common JJ 4_p
peroneal JJ 4_p
nerves NNS 4_p
. . N

young JJ 1_p
and CC N
physically RB 4_p
active JJ 4_p
males NNS 2_p
-DOCSTART- -X- O O 9825232

patients NNS 4_p
with IN 4_p
migraine NN 4_p
. . 4_p

Forty-one CD N
migraine JJ N
subjects NNS N
( ( N
26 CD N
males NNS N
, , N
15 CD N
females NNS N
) ) N
, , N
mean JJ N
age NN N
36 CD N
+/- JJ N
2 CD N
years NNS N
( ( N
range VB N
36-39 CD N
years NNS N
) ) N
, , N
and CC N
20 CD N
healthy JJ N
control NN N
subjects NNS N
( ( N
14 CD N
males NNS N
, , N
six CD N
females NNS N
) ) N
, , N
mean JJ N
age NN N
36 CD N
+/- JJ N
2 CD N
years NNS N
( ( N
range VB N
36-39 CD N
years NNS N
) ) N
patients NNS N
without IN N
hypertension NN N
and CC N
other JJ N
cardiovascular JJ N
disease NN N
. . N

-DOCSTART- -X- O O 18417969

Hispanic JJ N
cancer NN 4_p
patients NNS N
and CC N
their PRP$ N
family NN N
members NNS N
previously RB N
registered VBN N
in IN N
local JJ N
cancer NN 4_p
registries NNS N
in IN N
Texas NNP N
. . N

Hispanics NNPS N
to TO N
the DT N
Cancer NNP 4_p
Genetics NNP N
Network NNP N
national JJ N
cancer NN 4_p
genetics NNS N
registry NN N
. . N

South NNP N
Texas NNP N
cancer NN 4_p
registries NNS N
, , N
444 CD 3_p
Hispanic JJ N
men NNS 2_p
and CC N
women NNS 2_p
were VBD N
randomly RB N
assigned VBN N
154 CD 3_p
individuals NNS N
joined VBD N
the DT N
Cancer NNP 4_p
Genetics NNP N
Network NNP N
. . N

-DOCSTART- -X- O O 18337049

home-based JJ N
telehealth NN N
intervention NN N
nurse JJ N
and CC N
patient JJ N
Subjects NNPS N
randomized NN N
controlled VBD N
clinical JJ N
trial NN N
Telephone NNP N
( ( N
n=14 NN 3_p
) ) N
and CC N
videophone NN N
( ( N
n=14 JJ 3_p
) ) N
interactions NNS N
Nurses NNPS N
Patients NNS N
-DOCSTART- -X- O O 4459905

pain NN 4_p
-DOCSTART- -X- O O 2990708

Twenty-eight JJ 3_p
newly RB N
diagnosed VBN N
patients NNS N
with IN N
small JJ 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
patients NNS N
with IN N
extensive JJ N
disease NN N
; : N
-DOCSTART- -X- O O 2493733

paroxysmal JJ N
atrial JJ N
fibrillation NN N
or CC N
flutter NN N
to TO N
sinus VB 4_p
rhythm NN 4_p
. . N

40 CD 3_p
patients NNS N
with IN N
paroxysmal JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
( ( N
AF NNP N
) ) N
or CC N
atrial JJ N
flutter NN N
( ( N
AFI NNP N
) ) N
. . N

20 CD 3_p
patients NNS N
receiving VBG N
flecainide RB N
, , N
14 CD 3_p
of IN N
17 CD 3_p
( ( N
82 CD N
% NN N
) ) N
with IN N
AF NNP N
converted VBD N
to TO N
sinus VB 4_p
rhythm NN 4_p
, , N
but CC N
in IN N
3 CD N
patients NNS N
with IN N
AFI NNP N
flecainide NN N
failed VBD N
. . N

-DOCSTART- -X- O O 23266440

breast NN 4_p
cancer NN 4_p
pre- JJ 4_p
and CC 4_p
postmenopausal JJ 4_p
women NNS 2_p
. . N

of IN N
693 CD 3_p
overweight/obese JJ 4_p
women NNS 2_p
aged VBN N
≥21years NNS 1_p
diagnosed VBD N
with IN N
any DT N
early JJ 4_p
stage NN 4_p
breast NN 4_p
cancer NN 4_p
( ( N
stages NNS N
I PRP N
[ VBP N
≥1cm JJ N
] NNP N
-III NN N
) ) N
within IN N
the DT N
previous JJ N
five CD N
years NNS N
survival NN N
. . N

Participants NNS N
were VBD N
recruited VBN N
between IN N
2010 CD N
and CC N
2012 CD N
at IN N
four CD N
sites NNS N
, , N
had VBD N
completed VBN N
initial JJ N
therapies NNS N
, , N
and CC N
had VBD N
a DT N
body NN N
mass NN N
index NN N
between IN N
25 CD N
and CC N
45kg/m CD N
( ( N
2 CD N
) ) N
for IN N
overweight NN 4_p
or CC 4_p
obese JJ 4_p
breast NN 4_p
cancer NN 4_p
survivors NNS N
-DOCSTART- -X- O O 17438178

recurrent NN N
aphthous JJ 4_p
stomatitis NN 4_p
. . N

Forty-nine JJ 3_p
volunteers NNS N
who WP N
passed VBD N
the DT N
initial JJ N
assessment NN N
for IN N
recurrent NN N
aphthous JJ 4_p
stomatitis NN 4_p
entered VBD N
a DT N
pretrial JJ N
phase NN N
in IN N
which WDT N
their PRP$ N
eligibility NN N
for IN N
the DT N
trial NN N
phase NN N
of IN N
the DT N
study NN N
was VBD N
assessed VBN N
. . N

Sixteen JJ 3_p
subjects NNS N
were VBD N
deemed VBN N
ineligible JJ N
26 CD 3_p
subjects NNS N
-DOCSTART- -X- O O 21639806

breast-cancer JJ N
prevention NN N
in IN N
postmenopausal JJ N
women NNS N
. . N

patients NNS 4_p
with IN 4_p
early-stage JJ 4_p
breast NN 4_p
cancer NN 4_p
. . 4_p

eligible JJ N
postmenopausal NN N
women NNS N
35 CD N
years NNS N
of IN N
age NN N
or CC N
older JJR N
had VBD N
at IN N
least JJS N
one CD N
of IN N
the DT N
following JJ N
risk NN N
factors NNS N
: : N
60 CD N
years NNS N
of IN N
age NN N
or CC N
older JJR N
; : N
Gail NNP N
5-year JJ N
risk NN N
score NN N
greater JJR N
than IN N
1.66 CD N
% NN N
( ( N
chances NNS N
in IN N
100 CD N
of IN N
invasive JJ N
breast NN N
cancer NN N
developing VBG N
within IN N
5 CD N
years NNS N
) ) N
; : N
prior JJ N
atypical JJ N
ductal NN N
or CC N
lobular JJ N
hyperplasia NN N
or CC N
lobular JJ N
carcinoma NN N
in IN N
situ NN N
; : N
or CC N
ductal JJ N
carcinoma NN N
in IN N
situ NN N
with IN N
mastectomy NN N
. . N

total NN N
of IN N
4560 CD N
women NNS N
for IN N
whom WP N
the DT N
median JJ N
age NN N
was VBD N
62.5 CD N
years NNS N
and CC N
the DT N
median JJ N
Gail NNP N
risk NN N
score NN N
was VBD N
2.3 CD N
% NN N
invasive JJ N
breast NN N
cancers NNS N
in IN N
postmenopausal JJ N
women NNS N
who WP N
were VBD N
at IN N
moderately RB N
increased VBN N
risk NN N
for IN N
breast NN N
cancer NN N
. . N

-DOCSTART- -X- O O 22743137

Six CD N
hundred CD N
and CC N
twelve VB N
infertile JJ N
women NNS N
candidates NNS N
for IN N
intrauterine JJ N
insemination NN N
( ( N
IUI NNP N
) ) N
randomized VBN N
women NNS N
-DOCSTART- -X- O O 16920077

children NNS N
with IN N
autism NN 4_p
: : N
childhood VB N
neurodevelopmental JJ 4_p
disorders NNS 4_p
. . 4_p

13 CD 3_p
children NNS N
( ( N
aged VBN 1_p
5 CD 1_p
to TO 1_p
17 CD 1_p
years NNS 1_p
) ) N
with IN N
autistic JJ N
disorders NNS N
accompanied VBN N
by IN N
severe JJ 4_p
tantrums NNS 4_p
, , 4_p
aggression NN 4_p
, , 4_p
or CC 4_p
self-injurious JJ 4_p
behavior NN 4_p
. . N

children NNS N
with IN N
autism NN N
. . N

-DOCSTART- -X- O O 20661580

patients NNS N
with IN N
endometriosis NN 4_p
. . N

after IN N
treatment NN N
of IN N
144 CD 3_p
infertile JJ 4_p
women NNS 2_p
in IN N
their PRP$ N
reproductive JJ N
age NN N
by IN N
laparoscopy NN N
( ( N
whose WP$ N
endometriosis NN N
was VBD N
confirmed VBN N
by IN N
prior JJ N
laparoscopy NN N
) ) N
( ( N
47 CD 3_p
cases NNS N
) ) N
who WP N
received VBD N
letrozole NN N
for IN N
2 CD N
months NNS N
, , N
group NN N
2 CD N
( ( N
40 CD N
patients NNS N
) ) N
who WP N
were VBD N
prescribed VBN N
triptorelin NN N
for IN N
2 CD N
months NNS N
and CC N
group NN N
3 CD N
who WP N
were VBD N
57 CD N
patients NNS N
in IN N
the DT N
control NN N
group NN N
and CC N
did VBD N
not RB N
receive VB N
any DT N
medication NN N
. . N

-DOCSTART- -X- O O 23469597

middle-and-late JJ 4_p
stage NN 4_p
tumor NN 4_p
patients NNS N
receiving VBG 4_p
chemotherapy NN 4_p
] NN N
middle-and-late JJ 4_p
stage NN 4_p
tumor NN 4_p
patients NNS N
receiving VBG N
chemotherapy NN N
. . N

Recruited VBD N
60 CD 3_p
patients NNS N
were VBD N
randomly RB N
assigned VBN N
middle-and-late JJ 4_p
stage NN 4_p
tumor NN 4_p
patients NNS N
receiving VBG N
chemotherapy NN N
-DOCSTART- -X- O O 3430295

tinea NN 4_p
pedis NN 4_p
. . N

Twenty-nine JJ 3_p
patients NNS N
with IN N
mycologically RB N
proven VBN N
tinea NN 4_p
pedis NNS 4_p
-DOCSTART- -X- O O 23127292

patients NNS N
with IN N
node-negative JJ 4_p
breast NN 4_p
cancer NN 4_p
: : N
1113 CD 3_p
patients NNS N
participating VBG N
node-negative JJ 4_p
breast NN 4_p
cancer NN 4_p
. . N

-DOCSTART- -X- O O 9205768

patients NNS N
with IN N
duodenal JJ 4_p
ulcer NN 4_p
. . N

two CD N
parallel JJ N
groups NNS N
patients NNS N
with IN N
duodenal JJ N
ulcer NN N
. . N

Thirty JJ N
patients NNS N
were VBD N
included VBN N
, , N
divided VBN N
into IN N
two CD 3_p
groups NNS 3_p
of IN 3_p
15 CD 3_p
, , N
to TO N
whom WP N
one CD N
of IN N
the DT N
study NN N
therapies NNS N
was VBD N
administered VBN N
based VBN N
on IN N
a DT N
randomization NN N
code NN N
. . N

-DOCSTART- -X- O O 25083601

family NN N
carers NNS N
of IN N
people NNS N
with IN N
dementia NN 4_p
Family NNP 4_p
carers NNS 4_p
of IN 4_p
people NNS 4_p
with IN 4_p
dementia NN 4_p
METHODS NNP N
260 CD 3_p
family NN N
carers NNS N
from IN N
NHS NNP N
dementia NN 4_p
services NNS N
RESULTS NNP N
Data NNP N
were VBD N
available JJ N
for IN N
187 CD 3_p
carers NNS N
( ( N
71.9 CD N
% NN N
) ) N
-DOCSTART- -X- O O 17634259

resistance NN N
type NN N
exercise NN N
in IN N
males NNS 2_p
. . N

human JJ N
Seven NNP 3_p
healthy JJ N
, , N
untrained JJ N
men NNS 2_p
( ( 1_p
22.5 CD 1_p
+/- JJ 1_p
0.9 CD 1_p
y NN 1_p
) ) 1_p
-DOCSTART- -X- O O 16508555

patients NNS N
with IN N
nonspecific JJ N
low JJ 4_p
back RB 4_p
pain NN 4_p
. . N

patients NNS N
with IN N
low JJ 4_p
back RB 4_p
pain NN 4_p
. . N

442 CD 3_p
patients NNS N
with IN N
low JJ 4_p
back RB 4_p
pain NN 4_p
were VBD N
used VBN N
. . N

( ( N
sub NN N
) ) N
acute NN N
and CC N
chronic JJ N
patients NNS N
with IN N
low JJ 4_p
back RB 4_p
pain NN 4_p
. . N

-DOCSTART- -X- O O 12793516

480 CD 3_p
subjects NNS 4_p
with IN 4_p
a DT 4_p
history NN 4_p
of IN 4_p
repeated VBN 4_p
parasuicide NN 4_p
Most JJS 4_p
patients NNS 4_p
had VBD 4_p
significant JJ 4_p
anxiety NN 4_p
and CC 4_p
depressive JJ 4_p
disturbance NN 4_p
with IN 4_p
42 CD 4_p
% NN 4_p
having VBG 4_p
a DT 4_p
personality NN 4_p
disorder NN 4_p
. . N

-DOCSTART- -X- O O 7674231

patients NNS N
with IN N
rheumatic JJ 4_p
disease NN 4_p
attending VBG N
the DT N
outpatient NN N
clinic NN N
for IN N
rheumatic JJ 4_p
diseases NNS 4_p
. . N

Twenty-four CD 3_p
patients NNS N
with IN N
chronic JJ 4_p
arthritis NN 4_p
[ VBD N
20 CD 3_p
with IN N
rheumatoid JJ 4_p
arthritis NN 4_p
( ( 4_p
RA NNP 4_p
) ) 4_p
and CC N
4 CD 3_p
with IN N
psoriatic JJ 4_p
arthritis NN 4_p
( ( 4_p
PsA NNP 4_p
) ) 4_p
] NN N
This DT N
finding NN N
was VBD N
confirmed VBN N
in IN N
a DT N
further JJ N
series NN N
of IN N
39 CD 3_p
patients NNS N
. . N

-DOCSTART- -X- O O 12718385

patients NNS N
with IN N
superficial JJ N
bladder NN N
cancer NN N
. . N

superficial JJ N
bladder NN N
cancer NN N
following VBG N
transurethral JJ N
resection NN N
. . N

Sixty-three JJ N
patients NNS N
were VBD N
randomized VBN N
patients NNS N
enrolled VBN N
were VBD N
elderly JJ N
people NNS N
( ( N
mean JJ N
age NN N
, , N
71 CD N
years NNS N
) ) N
. . N

patients NNS N
with IN N
pulmonary JJ N
tuberculosis NN N
or CC N
aged VBN N
patients NNS N
with IN N
primary JJ N
bladder NN N
tumors NNS N
-DOCSTART- -X- O O 25820842

humans NNS N
. . N

humans NNS N
. . N

Ten CD 3_p
healthy JJ N
male NN 2_p
volunteers NNS N
with IN N
prior JJ 4_p
experience NN 4_p
with IN 4_p
psychedelics NNS 4_p
human JJ N
-DOCSTART- -X- O O 17868242

farmers NNS 4_p
, , 4_p
insurers NNS 4_p
, , 4_p
and CC 4_p
other JJ 4_p
stakeholders NNS 4_p
. . N

Farms NNP N
( ( N
316 CD N
) ) N
located VBN N
in IN N
a DT N
9-county JJ N
area NN N
of IN N
northwestern JJ N
Iowa NNP N
were VBD N
recruited VBN N
and CC N
randomized VBN N
into IN N
intervention NN N
and CC N
control NN N
cohorts NNS N
. . N

-DOCSTART- -X- O O 24885551

Borderline NNP 4_p
Personality NNP 4_p
Disorder NNP 4_p
( ( 4_p
BPD NNP 4_p
) ) 4_p
Seventy NNP N
patients NNS N
, , N
aged VBD 1_p
18 CD 1_p
to TO 1_p
45 CD 1_p
years NNS 1_p
with IN N
a DT N
primary JJ N
diagnosis NN N
of IN N
BPD NNP N
, , N
showing VBG N
a DT N
chronic JJ N
pattern NN N
of IN N
parasuicidal JJ N
gestures NNS N
and/or IN N
reporting VBG N
high JJ N
degrees NNS N
of IN N
severity NN N
of IN N
other JJ N
borderline NN N
symptoms NNS N
, , N
are VBP N
randomly RB N
allocated VBN N
to TO N
the DT N
control NN N
and CC N
intervention NN N
groups NNS N
. . N

Subjects NNS N
in IN N
the DT N
control NN N
group NN N
receive VBP N
standard JJ N
outpatient NN N
DBT NNP N
, , N
provided VBD N
in IN N
one CD N
of IN N
three CD N
regular JJ N
mental JJ N
health NN N
settings NNS N
in IN N
GGZ NNP 4_p
Rivierduinen NNP 4_p
. . N

Subjects NNS N
in IN N
the DT N
intervention NN N
group NN N
receive VBP N
12 CD N
weeks NNS N
of IN N
intensified JJ N
inpatient NN N
DBT NNP N
plus CC N
six CD N
months NNS N
of IN N
standard JJ N
DBT NNP N
, , N
provided VBN N
in IN N
the DT N
Center NNP N
for IN N
Personality NNP 4_p
Disorders NNP 4_p
Jelgersma NNP 4_p
DISCUSSION NNP N
Highly NNP 4_p
suicidal JJ 4_p
outpatient NN 4_p
patients NNS N
-DOCSTART- -X- O O 6734073

continuous JJ 4_p
ambulatory JJ 4_p
peritoneal JJ 4_p
dialysis NN 4_p
( ( N
CAPD NNP 4_p
) ) N
. . N

in IN N
six CD 3_p
patients NNS N
on IN N
continuous JJ 4_p
ambulatory JJ 4_p
peritoneal JJ 4_p
dialysis NN 4_p
ambulatory JJ N
peritoneal JJ N
dialysis NN N
. . N

-DOCSTART- -X- O O 22080631

intensive JJ 4_p
care NN 4_p
unit NN 4_p
survivors NNS 4_p
: : N
patients NNS N
who WP N
survive VBP 4_p
medical JJ 4_p
and CC 4_p
surgical JJ 4_p
general JJ 4_p
intensive JJ 4_p
care NN 4_p
unit NN 4_p
care NN 4_p
21 CD 3_p
general JJ 3_p
medical/surgical JJ N
intensive JJ N
care NN N
unit NN N
survivors NNS N
( ( N
8 CD 3_p
controls NNS N
and CC N
13 CD N
intervention NN N
patients NNS N
) ) N
with IN N
either DT N
cognitive NN N
or CC N
functional JJ N
impairment NN N
at IN N
hospital JJ N
discharge NN N
. . N

Patients NNPS N
tolerated VBD N
the DT N
program NN N
with IN N
only RB N
one CD N
adverse JJ N
event NN N
reported VBD N
. . N

intensive JJ 4_p
care NN 4_p
unit NN 4_p
survivors NNS 4_p
-DOCSTART- -X- O O 17481800

chronic JJ 4_p
hypotension NN 4_p
. . N

50 CD 3_p
hypotensive JJ 4_p
persons NNS N
-DOCSTART- -X- O O 24214840

providers NNS 4_p
' POS 4_p
in-office NN 4_p
use NN 4_p
of IN 4_p
CDC NNP 4_p
gynecologic JJ 4_p
cancer NN 4_p
materials NNS 4_p
and CC 4_p
their PRP$ 4_p
recognition NN 4_p
of IN 4_p
the DT 4_p
symptoms NNS 4_p
highlighted VBN 4_p
in IN 4_p
the DT 4_p
materials NNS 4_p
. . 4_p

data NNS N
from IN N
a DT N
national JJ N
2012 CD N
survey NN N
of IN N
US NNP N
primary JJ N
care NN N
physicians NNS N
, , N
nurse JJ 3_p
practitioners NNS 3_p
, , N
and CC N
gynecologists NNS N
( ( N
N NNP N
= NNP N
1,380 CD 3_p
) ) N
and CC N
health NN N
care NN N
providers NNS N
-DOCSTART- -X- O O 2768768

healthy JJ N
older JJR 1_p
men NNS 2_p
and CC 2_p
women NNS 2_p
. . N

101 CD 3_p
older JJR 1_p
men NNS N
and CC N
women NNS N
( ( N
mean JJ N
age NN N
= VBD N
67 CD N
years NNS N
) ) N
. . N

-DOCSTART- -X- O O 12356631

human JJ N
treatment NN 4_p
of IN 4_p
de FW 4_p
novo FW 4_p
coronary JJ 4_p
lesions NNS 4_p
. . N

A NNP N
total NN N
of IN N
122 CD 3_p
( ( N
qDES JJ 3_p
66 CD 3_p
, , N
BMS NNP 3_p
56 CD 3_p
) ) N
patients NNS N
atherosclerotic JJ 4_p
disease NN 4_p
. . N

-DOCSTART- -X- O O 6988462

Seventy-seven JJ 3_p
consecutive JJ N
biopsies NNS N
a DT N
single JJ N
operator NN N
. . N

-DOCSTART- -X- O O 24266855

patients NNS N
receiving VBG 4_p
sirolimus NN 4_p
and CC 4_p
corticosteroids NNS 4_p
: : N
420 CD 3_p
de FW 4_p
novo FW 4_p
renal JJ 4_p
allograft NN 4_p
recipients NNS N
at IN N
49 CD N
European JJ N
transplant NN N
centers NNS N
. . N

357 CD 3_p
patients NNS N
-DOCSTART- -X- O O 9419170

patients NNS N
with IN N
advanced JJ 4_p
human JJ 4_p
immunodeficiency NN 4_p
virus NN 4_p
disease NN 4_p
. . N

310 CD 4_p
patients NNS N
entering VBG N
a DT N
controlled JJ N
trial NN N
of IN N
prophylaxis NN N
with IN N
valaciclovir JJ N
versus NN N
acyclovir NN N
. . N

-DOCSTART- -X- O O 18161643

transition NN N
from IN N
residential JJ 4_p
to TO 4_p
outpatient JJ 4_p
addiction NN 4_p
Four CD N
residential JJ N
addiction NN N
treatment NN N
centers NNS N
A DT N
total NN N
of IN N
282 CD 3_p
participants NNS N
( ( N
100 CD 3_p
women NNS 2_p
, , N
182 CD 3_p
men NNS 2_p
) ) N
with IN N
substance NN N
use NN N
disorders NNS N
were VBD N
included VBN N
in IN N
this DT N
secondary JJ N
analysis NN N
. . N

-DOCSTART- -X- O O 26746121

Young NNP 1_p
Children NNP 1_p
with IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorder NNP 4_p
: : N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
. . N

Children NNP 1_p
2-6 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
with IN N
ASD NNP 4_p
( ( N
N NNP N
= NNP N
166 CD 3_p
) ) N
young JJ 1_p
children NNS 1_p
with IN N
ASD NNP 4_p
-DOCSTART- -X- O O 24859114

overweight JJ N
adults NNS 1_p
participating VBG N
in IN N
a DT N
12-mo JJ N
randomized JJ N
trial NN N
testing VBG N
energy-restricted JJ N
diets NNS 4_p
differing VBG N
in IN N
GL NNP N
. . 1_p

-DOCSTART- -X- O O 24327720

African JJ N
Americans NNPS N
: : N
African JJ N
Americans NNPS N
have VBP N
a DT N
disproportionate JJ N
burden NN N
of IN N
inflammation-associated JJ N
chronic JJ N
diseases NNS N
328 CD N
African JJ N
Americans NNPS N
( ( N
median JJ N
age NN N
, , N
51 CD N
years NNS N
) ) N
of IN N
public JJ N
housing NN N
communities NNS N
in IN N
Boston NNP N
, , N
MA NNP N
, , N
who WP N
were VBD N
enrolled VBN N
over RP N
three CD N
consecutive JJ N
winter NN N
periods NNS N
( ( N
2007-2010 JJ N
) ) N
. . N

of IN N
cancer NN N
health NN N
disparities NNS N
in IN N
African JJ N
Americans NNPS N
-DOCSTART- -X- O O 17241298

Helicobacter NNP 4_p
pylori JJ 4_p
eradication NN 4_p
: : N
Korea NNP N
. . N

After IN N
upper JJ 4_p
gastrointestinal JJ 4_p
endoscopy NN 4_p
, , N
H. NNP 4_p
pylori-infected JJ 4_p
patients NNS N
with IN N
a DT N
gastric JJ 4_p
ulcer NN 4_p
and/or VBZ 4_p
a DT 4_p
duodenal JJ 4_p
ulcer NN 4_p
total NN N
of IN N
598 CD 3_p
patients NNS N
were VBD N
enrolled VBN N
; : N
H. NNP 4_p
pylori NN 4_p
in IN N
Korea NNP N
. . N

-DOCSTART- -X- O O 6123810

catamenial JJ 4_p
epilepsy NN 4_p
. . N

14 CD 3_p
of IN N
18 CD 3_p
patients NNS N
who WP N
received VBD N
both DT N
treatments NNS N
-DOCSTART- -X- O O 18989547

in IN N
children NNS 1_p
. . N

a DT N
pediatric JJ N
intensive JJ N
care NN N
unit NN N
( ( N
PICU NNP N
) ) N
. . N

enrolled VBD N
children NNS 1_p
aged VBN 1_p
28 CD 1_p
days NNS 1_p
to TO 1_p
4 CD 1_p
years NNS 1_p
who WP N
were VBD N
admitted VBN N
to TO N
a DT N
PICU NNP 4_p
between IN N
October NNP N
of IN N
2005 CD N
and CC N
June NNP N
of IN N
2007 CD N
and CC N
put VB N
on IN N
mechanical JJ N
ventilation NN N
( ( N
MV NNP N
) ) N
for IN N
more JJR N
than IN N
48 CD N
hours NNS N
. . N

Children NNP 1_p
were VBD N
excluded VBN N
if IN N
they PRP N
had VBD N
undergone JJ N
tracheotomy NN N
or CC N
had VBD N
chronic JJ 4_p
respiratory NN 4_p
diseases NNS 4_p
. . 4_p

children NNS 1_p
studied VBN N
here RB N
-DOCSTART- -X- O O 10207709

25 CD N
couples NNS 4_p
-DOCSTART- -X- O O 1541306

children NNS 1_p
with IN N
severe JJ N
falciparum NN 4_p
malaria NN 4_p
. . N

11 CD 3_p
Karen NNP 4_p
children NNS N
aged VBD N
between IN 1_p
1.7 CD 1_p
and CC 1_p
11 CD 1_p
y NN 1_p
with IN N
severe JJ N
falciparum NN 4_p
malaria NN 4_p
. . N

Eight CD 3_p
of IN N
the DT N
children NNS N
were VBD N
comatose JJ N
. . N

9 CD N
further JJ N
children NNS N
with IN N
severe JJ N
malaria NNS N
of IN N
similar JJ N
age NN N
range NN N
( ( N
four CD N
of IN N
whom WP N
were VBD N
unconscious JJ N
) ) N
children NNS N
with IN N
severe JJ N
malaria NNS N
; : N
-DOCSTART- -X- O O 22434360

patients NNS N
with IN N
recurrent NN N
or CC N
metastatic JJ N
head NN 4_p
and CC 4_p
neck NN 4_p
cancer NN 4_p
: : N
Recurrent NNP N
or CC N
metastatic JJ N
squamous JJ 4_p
cell NN 4_p
carcinoma NN 4_p
of IN N
the DT N
head NN N
and CC N
neck NN N
( ( N
SCCHN NNP N
) ) N
patients NNS N
with IN N
recurrent NN N
or CC N
metastatic JJ N
SCCHN NNP 4_p
and CC N
no DT N
prior JJ N
systemic JJ N
therapy NN N
for IN N
metastatic JJ N
disease NN N
were VBD N
randomized VBN N
to TO N
pemetrexed VB N
( ( N
500 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
plus CC N
cisplatin NN N
( ( N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
; : N
n CC N
= VB N
398 CD N
) ) N
or CC N
placebo JJ N
plus CC N
cisplatin NN N
( ( N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
; : N
n CC N
= VB N
397 CD N
) ) N
patients NNS N
with IN N
oropharyngeal JJ 4_p
cancers NNS 4_p
-DOCSTART- -X- O O 23303244

volunteers NNS N
. . N

Single NNP N
university NN N
hospital NN N
. . N

Ten CD N
male NN N
volunteers NNS N
aged VBN N
18-28 JJ N
( ( N
mean JJ N
22 CD N
) ) N
years NNS N
. . N

-DOCSTART- -X- O O 24694924

autism NN 4_p
traits NNS 4_p
. . 4_p

Thus NNP N
, , N
40 CD 3_p
heterosexual JJ 4_p
males NNS 2_p
believed VBN N
that IN N
they PRP N
were VBD N
touched VBN N
by IN N
either CC N
a DT N
man NN 2_p
or CC N
a DT N
woman NN 2_p
, , N
although IN N
in IN N
fact NN N
an DT N
identical JJ N
pattern NN N
of IN N
touch NN N
was VBD N
always RB N
given VBN N
by IN N
the DT N
same JJ N
female JJ 2_p
experimenter NN N
blind NN N
to TO N
condition NN N
type NN N
in IN 4_p
individuals NNS 4_p
with IN 4_p
autistic JJ 4_p
traits NNS 4_p
-DOCSTART- -X- O O 9670112

patients NNS N
after IN 4_p
myocardial JJ 4_p
infarction NN 4_p
male NN N
patients NNS N
after IN N
myocardial JJ N
infarction NN N
( ( N
MI NNP N
) ) N
aged VBD 1_p
between IN 1_p
38 CD 1_p
and CC 1_p
61 CD 1_p
. . N

the DT N
training NN 3_p
group NN 3_p
( ( N
n JJ N
= NNP N
21 CD 3_p
) ) N
, , N
staying VBG 4_p
in IN 4_p
Cardiac NNP 4_p
Rehabilitation NNP 4_p
Department NNP 4_p
and CC 4_p
the DT 4_p
control NN 3_p
group NN 3_p
( ( 3_p
n JJ 3_p
= NNP 3_p
11 CD 3_p
) ) N
The DT N
training NN N
group NN N
MI NNP N
patients NNS N
-DOCSTART- -X- O O 20152225

patients NNS N
with IN N
symptomatic JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
after IN N
atrioventricular JJ N
node JJ N
ablation NN N
. . N

patients NNS N
with IN N
advanced JJ 4_p
heart NN 4_p
failure NN 4_p
, , N
intraventricular JJ 4_p
conduction NN 4_p
delay NN 4_p
, , 4_p
and CC N
atrial JJ 4_p
fibrillation NN 4_p
( ( 4_p
AF NNP 4_p
) ) 4_p
post-atrioventricular NN 4_p
( ( 4_p
AV NNP 4_p
) ) 4_p
node NN 4_p
ablation NN 4_p
. . N

Patients NNS N
with IN N
refractory JJ N
AF NNP 4_p
underwent NN N
AV NNP N
node CC N
ablation NN N
108 CD 3_p
patients NNS N
. . N

-DOCSTART- -X- O O 16266472

Chinese JJ 4_p
patients NNS 4_p
with IN 4_p
essential JJ 4_p
hypertension NN 4_p
. . 4_p

105 CD 4_p
patients NNS 4_p
with IN 4_p
mild JJ 4_p
or CC 4_p
moderate JJ 4_p
essential JJ 4_p
hypertension NN 4_p
Only RB N
those DT N
patients NNS N
who WP N
have VBP N
finished VBN N
8 CD N
weeks NNS N
of IN N
active JJ N
treatment NN N
in IN N
both DT N
groups NNS N
were VBD N
included VBN N
into IN N
the DT N
final JJ N
analysis NN N
. . N

One CD N
hundred VBD N
one CD N
patients NNS N
( ( N
51 CD N
in IN N
enalapril NN N
group NN N
and CC N
50 CD N
in IN N
indapamide JJ N
group NN N
) ) N
completed VBD N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 15891326

active JJ N
compression-decompression NN N
cardiopulmonary JJ N
resuscitation NN N
. . N

patients NNS N
ventilated VBN N
with IN N
an DT N
endotracheal JJ N
tube NN N
( ( N
ETT NNP N
) ) N
during IN N
active JJ N
compression-decompression NN N
cardiopulmonary JJ N
resuscitation NN N
. . N

active JJ N
compression-decompression NN N
cardiopulmonary JJ N
resuscitation NN N
in IN N
13 CD N
out-of-hospital JJ N
cardiac JJ N
arrest NN N
patients NNS N
-DOCSTART- -X- O O 17579182

children NNS N
and CC N
young JJ N
adults NNS N
receiving VBG N
hematopoietic JJ N
stem-cell JJ N
transplantation NN N
hematopoietic JJ N
stem-cell JJ N
transplantation NN N
( ( N
HSCT NNP N
) ) N
recipients NNS N
. . N

178 CD N
patients NNS N
( ( N
89 CD N
in IN N
each DT N
arm NN N
) ) N
, , N
receiving VBG N
unmanipulated JJ N
HSCT NNP N
from IN N
either CC N
a DT N
relative NN N
or CC N
an DT N
unrelated JJ N
donor NN N
-DOCSTART- -X- O O 8133853

very-low-birth-weight JJ 4_p
infants NNS 1_p
. . N

premature JJ 4_p
infants NNS 1_p
. . N

2416 CD 3_p
infants NNS 1_p
were VBD N
stratified VBN N
according VBG N
to TO N
birth NN N
weight NN N
( ( N
501 CD N
to TO N
1000 CD N
g NN N
and CC N
1001 CD N
to TO N
1500 CD N
g NN N
) ) N
Control NN N
infants NNS N
Infants NNS 1_p
weighing VBG N
501 CD N
to TO N
1000 CD N
g NN N
at IN N
birth NN N
very-low-birth-weight JJ N
infants NNS 1_p
. . N

-DOCSTART- -X- O O 22465904

obsessive-compulsive JJ N
disorder NN N
: : N
Twelve CD N
patients NNS N
were VBD N
given VBN N
fluoxetine NN N
( ( N
20 CD N
mg/d NN N
) ) N
plus CC N
zinc NN N
( ( N
440 CD N
mg/d NN N
) ) N
and CC N
11 CD N
patients NNS N
were VBD N
given VBN N
fluoxetine JJ N
plus CC N
placebo NN N
for IN N
8 CD N
wk NNS N
-DOCSTART- -X- O O 24534682

volunteers NNS 3_p
prospective JJ 4_p
Le NNP 4_p
Fort NNP 4_p
I PRP 4_p
osteotomy VBP 4_p
patients NNS N
-DOCSTART- -X- O O 15279417

18 CD 3_p
patients NNS 3_p
( ( N
36 CD N
eyes NNS N
) ) N
with IN N
recently RB N
primary JJ 4_p
open JJ 4_p
angle NN 4_p
glaucoma NN 4_p
. . N

control NN N
group NN N
( ( N
4 CD 3_p
patients NNS 3_p
) ) N
who WP N
was VBD N
instilled VBN N
with IN N
natural JJ 4_p
tears NNS 4_p
( ( N
with IN N
different JJ N
preservative NN N
) ) N
. . N

-DOCSTART- -X- O O 16503545

nasopharyngeal JJ 4_p
carcinoma NN 4_p
] NNP N
terminal JJ 4_p
nasopharyngeal JJ 4_p
carcinoma NN 4_p
( ( 4_p
NPC NNP 4_p
) ) 4_p
. . N

180 CD 3_p
patients NNS N
with IN N
NPC NNP 4_p
terminal JJ 4_p
NPC NNP 4_p
-DOCSTART- -X- O O 1977089

European NNP N
multicentre NN N
trial NN N
. . N

230 CD 3_p
patients NNS N
with IN N
endoscopically RB N
documented VBN N
gastric NN 4_p
( ( N
71 CD 3_p
) ) N
or CC N
duodenal JJ 4_p
( ( N
159 CD 3_p
) ) N
ulcers NNS 4_p
. . N

Gastric NNP 4_p
ulcer JJ 4_p
patients NNS N
who WP N
satisfied VBD N
all DT N
criteria NNS N
for IN N
inclusion NN N
and CC N
exclusion NN N
treatment NN N
of IN N
duodenal JJ 4_p
and CC 4_p
gastric JJ 4_p
ulceration NN 4_p
. . 4_p

-DOCSTART- -X- O O 24675775

modified VBN N
eggs NNS N
and CC N
an DT N
egg-yolk NN N
based VBN N
beverage NN N
on IN N
serum NN 4_p
lutein NN 4_p
and CC 4_p
zeaxanthin JJ 4_p
concentrations NNS 4_p
eggs NNS N
One CD 3_p
hundred VBD 3_p
healthy JJ 4_p
volunteers NNS N
were VBD N
recruited VBN N
and CC N
randomized VBN N
into IN N
5 CD N
groups NNS N
for IN N
90 CD N
days NNS N
. . N

-DOCSTART- -X- O O 20500784

individuals NNS N
with IN N
ASD NNP 4_p
. . N

autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
people NNS N
with IN N
ASD NNP 4_p
37 CD 3_p
participants NNS N
( ( N
22 CD 2_p
male NN 2_p
, , 2_p
15 CD 2_p
female NN 2_p
) ) N
, , N
ages VBZ 1_p
17-39 JJ 1_p
( ( 1_p
M NNP 1_p
= NNP 1_p
31.49 CD 1_p
) ) 1_p
years NNS 1_p
at IN N
the DT N
beginning NN N
of IN N
the DT N
programme NN N
) ) N
diagnosed VBD N
with IN N
an DT N
ASD NNP 4_p
and CC N
a DT N
group NN N
of IN N
34 CD 3_p
adults NNS 3_p
with IN N
ASD NNP 4_p
as IN N
control NN N
group NN N
( ( N
waiting VBG N
list NN N
) ) N
( ( N
19 CD 2_p
male NN 2_p
, , 2_p
15 CD 2_p
female NN 2_p
) ) N
, , N
ages VBZ 1_p
24-38 JJ 1_p
( ( N
M NNP N
= VBZ N
30 CD N
at IN N
programme JJ N
initiation NN N
) ) N
years NNS N
. . N

individuals NNS N
with IN N
ASD NNP 4_p
adults NNS 1_p
with IN N
ASD NNP 4_p
. . N

-DOCSTART- -X- O O 20513659

high JJ 4_p
autism NN 4_p
spectrum JJ 4_p
quotient NN 4_p
adult NN 4_p
of IN 4_p
normal JJ 4_p
intelligence NN 4_p
low- JJ N
and CC N
high-scoring JJ N
individuals NNS N
on IN N
the DT N
Autism NNP N
Spectrum NNP N
Quotient NNP N
Fifteen NNP N
low-scoring JJ N
individuals NNS N
and CC N
14 CD N
high-scoring JJ N
individuals NNS N
derived VBN N
from IN N
a DT N
normal JJ N
population NN N
participated VBD N
in IN N
the DT N
study NN N
. . N

Autism NNP N
Spectrum NNP N
Quotient NNP N
autistic JJ N
individuals NNS N
-DOCSTART- -X- O O 1818543

refractory NN 4_p
rheumatoid NN 4_p
arthritis NN 4_p
. . N

Fifty-two JJ 3_p
patients NNS N
with IN 4_p
severe JJ 4_p
rheumatoid NN 4_p
arthritis NN 4_p
( ( 4_p
RA NNP 4_p
) ) 4_p
from IN 4_p
four CD 4_p
Australian JJ 4_p
centres NNS 4_p
Seven NNP N
CSA NNP N
recipients NNS N
( ( N
three CD N
gastrointestinal NN N
symptoms NNS N
, , N
two CD N
neurological JJ N
symptoms NNS N
, , N
two CD N
other JJ N
) ) N
and CC N
12 CD N
AZA NNP N
recipients NNS N
( ( N
six CD N
gastrointestinal NN N
symptoms NNS N
, , N
four CD N
inefficacy NN N
, , N
two CD N
other JJ N
) ) N
withdrew VBD N
from IN N
treatment NN N
prematurely RB N
. . N

severely RB N
affected JJ N
patients NNS N
with IN N
RA NNP N
-DOCSTART- -X- O O 20526599

Adult NNP N
patients NNS N
who WP N
underwent VBP N
laparotomy NN N
for IN N
bowel NN N
resection NN N
scheduled VBN N
for IN N
opioid-based JJ N
intravenous JJ N
patient-controlled JJ N
analgesia NN N
received VBD N
oral JJ N
alvimopan NN N
or CC N
placebo NN N
preoperatively RB N
and CC N
twice RB N
daily RB N
postoperatively RB N
until IN N
hospital JJ N
discharge NN N
or CC N
for IN N
7 CD N
postoperative JJ N
days NNS N
. . N

patients NNS N
undergoing VBG N
bowel JJ N
resection NN N
. . N

-DOCSTART- -X- O O 17947289

Children NNP 4_p
with IN 4_p
autism NN 4_p
's POS 4_p
Thirty-five JJ 3_p
children NNS 3_p
diagnosed VBN N
with IN N
autism NN 4_p
-DOCSTART- -X- O O 20440639

toddlers NNS 1_p
with IN N
autism NN 4_p
: : N
. . N

Seventy-five JJ N
toddlers NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
65 CD N
autism NN N
, , N
10 CD N
PDD-NOS NN N
, , N
mean JJ N
age NN N
= VBD N
34.4 CD N
months NNS N
, , N
SD NNP N
= NNP N
6.2 CD N
) ) N
sample NN N
of IN N
67 CD N
children NNS N
-DOCSTART- -X- O O 16767966

general JJ N
surgical JJ N
adult NN N
patient JJ N
population NN N
. . N

surgical JJ N
patients NNS N
A NNP N
total NN N
of IN N
700 CD N
adult NN N
surgical JJ N
patients NNS N
who WP N
planned VBD N
to TO N
have VB N
surgery NN N
under IN N
general JJ N
anesthesia NN N
general JJ N
surgical JJ N
adult NN N
patient JJ N
population NN N
. . N

-DOCSTART- -X- O O 21800228

urban JJ 4_p
African JJ 4_p
American JJ 4_p
boys NNS 4_p
. . N

sample NN N
of IN N
urban JJ N
, , N
low-income JJ N
, , N
African JJ N
American NNP N
boys NN N
. . N

urban JJ N
African JJ N
American JJ N
boys NNS N
. . N

-DOCSTART- -X- O O 2577555

liver NN N
surgery NN N
II NNP N
-- : N
regional JJ N
chemotherapy NN N
] NN N
657 CD 3_p
cases NNS N
of IN N
primary JJ N
and CC N
secondary JJ N
liver NN N
only RB N
malignancies VBZ N
. . N

colorectal JJ N
liver NN N
metastases NNS N
. . N

unresectable JJ N
colorectal JJ N
liver NN N
metastases NNS N
. . N

-DOCSTART- -X- O O 23019005

Sensitivity NN N
to TO N
musical JJ N
structure NN N
in IN N
the DT N
human JJ N
brain NN N
. . N

brain-damaged JJ 4_p
patients NNS N
individual-subject JJ N
fMRI NN N
analyses NNS N
-DOCSTART- -X- O O 20329618

patients NNS N
with IN N
oligospermia JJ N
] NN N
patients NNS N
with IN N
oligospermia NN N
( ( N
OSM NNP N
) ) N
. . N

Seventy-two JJ N
OSM NNP N
patients NNS N
patients NNS 4_p
with IN 4_p
OSM NNP 4_p
. . 4_p

-DOCSTART- -X- O O 24315475

in IN N
patients NNS N
with IN N
a DT N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
< VBD N
23.0 CD N
kg/m NN N
( ( N
2 CD N
) ) N
. . N

One CD 3_p
hundred CD 3_p
and CC 3_p
twenty JJ 3_p
consecutive JJ N
patients NNS N
with IN N
a DT N
BMI NNP N
< NNP N
23.0 CD N
kg/m NN N
( ( N
2 CD N
) ) N
and CC N
a DT N
low JJ N
calcium NN N
load NN N
undergoing VBG N
retrospective JJ N
electrocardiogram NN N
( ( N
ECG NNP N
) ) N
-gated VBD N
dual-source JJ N
CCTA NNP 4_p
agent NN N
doses NNS N
in IN N
CCTA NNP N
in IN N
patients NNS N
with IN N
a DT N
low JJ N
BMI NNP N
< NN N
23.0 CD N
kg/m NN N
( ( N
2 CD N
) ) N
and CC N
-DOCSTART- -X- O O 20048611

linear JJ N
surgical JJ N
incisions NNS N
: : N
Patients NNPS N
undergoing VBG N
Wise-pattern JJ 4_p
breast NN 4_p
reduction NN 4_p
or CC 4_p
abdominal JJ 4_p
procedures NNS 4_p
Of IN N
59 CD 3_p
patients NNS N
, , N
eight CD N
were VBD N
excluded VBN N
from IN N
randomization NN N
Fifty-one CD 3_p
patients NNS N
( ( N
breast NN N
, , N
n JJ N
= VBP N
24 CD N
; : N
abdomen NNS N
, , N
n JJ N
= NNP N
27 CD N
) ) N
-DOCSTART- -X- O O 8798245

children NNS 1_p
male JJ 2_p
relatives NNS 2_p
. . N

children NNS 1_p
family NN N
members NNS N
. . N

Parents NNS 1_p
of IN N
381 CD 3_p
girls NNS 2_p
and CC N
375 CD 3_p
boys NNS 2_p
age NN 1_p
8-12 JJ 1_p
y NN 1_p
completed VBN N
family NN N
history NN N
questionnaires NNS N
. . N

children NNS N
-DOCSTART- -X- O O 25871593

children NNS 1_p
with IN N
autism NN 4_p
. . N

children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
. . 4_p

Twenty-two JJ 3_p
children NNS N
with IN N
ASD NNP 4_p
and CC N
22 CD N
typically RB N
developing VBG N
children NNS 1_p
, , N
ages VBZ 1_p
6-12 JJ 1_p
yr NN 1_p
Participants NNS N
participants NNS N
. . N

in IN N
children NNS 1_p
with IN N
ASD NNP 4_p
-DOCSTART- -X- O O 7505498

Sandostatin NNP N
prophylaxis NN 4_p
for IN N
preservation NN 4_p
injury NN 4_p
after IN N
pancreas JJ 4_p
transplantation NN 4_p
. . N

-DOCSTART- -X- O O 1911498

nine CD N
healthy JJ N
volunteers NNS N
major JJ 4_p
abdominal JJ 4_p
surgery NN 4_p
. . 4_p

-DOCSTART- -X- O O 21145428

Right RB 4_p
ventricular JJ 4_p
pacing VBG 4_p
in IN 4_p
MADIT-II NNP 4_p
: : 4_p
-DOCSTART- -X- O O 20657150

Tensile IN N
bond NN N
strength NN N
of IN N
a DT N
lithium-disilicate JJ N
pressed JJ N
glass NN N
ceramic NN N
to TO N
dentin VB N
adhesive JJ N
and CC N
ceramic JJ N
Sixty NNP N
7x3 CD N
mm NN N
pressed VBN N
ceramic JJ N
discs NN N
of IN N
IPS NNP N
e.max NN N
dentin NN N
surface NN N
treatments NNS N
-DOCSTART- -X- O O 19301691

patients NNS 4_p
with IN 4_p
vascular JJ 4_p
disease NN 4_p
or CC 4_p
high-risk JJ 4_p
diabetes NNS 4_p
-DOCSTART- -X- O O 10194485

healthy JJ 4_p
volunteers NNS 4_p
and CC 4_p
patients NNS 4_p
who WP 4_p
are VBP 4_p
post-thrombotic JJ 4_p
. . 4_p

Deep NNP N
vein NN N
thrombosis NN N
( ( N
DVT NNP N
) ) N
morbidity NN N
and CC N
mortality NN N
in IN N
patients NNS N
who WP N
are VBP N
hospitalized VBN N
. . N

healthy JJ N
volunteers NNS N
and CC N
patients NNS N
with IN N
severe JJ N
post-thrombotic JJ N
venous JJ N
disease NN N
. . N

Twenty-two NNP N
lower JJR N
extremities NNS N
from IN N
healthy JJ N
volunteers NNS N
and CC N
11 CD N
lower JJR N
extremities NNS N
from IN N
patients NNS N
with IN N
class NN N
4 CD N
to TO N
class NN N
6 CD N
post-thrombotic JJ N
chronic JJ N
venous JJ N
insufficiency NN N
were VBD N
studied VBN N
. . N

Patients NNS N
with IN N
post-thrombotic JJ N
venous JJ N
disease NN N
healthy JJ N
volunteers NNS N
and CC N
in IN N
patients NNS N
who WP N
were VBD N
post-thrombotic JJ N
. . N

-DOCSTART- -X- O O 21721430

Siriraj NNP N
Asthma NNP 4_p
Control NNP N
Siriraj NNP N
Hospital NNP N
. . N

20 CD 3_p
randomized JJ N
asthmatic JJ 4_p
patients NNS N
in IN N
the DT N
clinic NN N
including VBG N
the DT N
record NN N
of IN N
3 CD N
visits NNS N
for IN N
each DT N
subject NN N
. . N

20 CD 3_p
patients NNS N
with IN N
age NN 1_p
29-73 CD 1_p
years NNS 1_p
Thai NNP N
asthmatic JJ 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 11194696

Increasing VBG N
the DT N
reach NN N
of IN N
health NN N
sponsorship NN N
: : N
using VBG N
a DT N
" JJ N
sponsorship NN N
kit NN N
" NN N
to TO N
promote VB N
health NN N
. . N

Australia NNP N
Healthway NNP N
staff NN N
Healthway NNP N
staff NN N
-DOCSTART- -X- O O 24234676

children NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . 4_p

Thirty-four JJ N
children NNS N
, , N
with IN N
autism NN N
spectrum NN N
disorders NNS N
, , N
ages VBZ N
4-14 CD N
years NNS N
-DOCSTART- -X- O O 24807158

Poor NNP 4_p
prognosis NN 4_p
patients NNS 4_p
with IN 4_p
inoperable JJ 4_p
locally RB 4_p
advanced JJ 4_p
NSCLC NNP 4_p
and CC 4_p
large JJ 4_p
tumors NNS 4_p
Poor NNP 4_p
prognosis NN 4_p
patients NNS N
with IN N
bulky JJ N
stage NN N
III NNP N
locally RB N
advanced VBD N
non-small-cell JJ N
lung NN N
cancer NN N
poor JJ N
prognosis NN N
patients NNS N
A DT N
total NN N
of IN N
188 CD 3_p
poor JJ N
prognosis NN N
patients NNS N
recruited VBN N
patients NNS N
with IN N
tumors NNS N
larger JJR N
than IN N
7 CD N
cm NN N
( ( N
N NNP N
= NNP N
108 CD 3_p
) ) N
versus NN N
tumors NNS N
7 CD N
cm NN N
or CC N
smaller JJR N
( ( N
N NNP N
= NNP N
76 CD 3_p
) ) N
. . N

patients NNS N
with IN N
poor JJ 4_p
prognosis NN 4_p
and CC N
inoperable JJ 4_p
locally RB 4_p
advanced JJ 4_p
non-small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
-DOCSTART- -X- O O 23760519

after IN N
pediatric JJ N
umbilical JJ N
hernia NN N
repair NN N
. . N

Tertiary-referral JJ 4_p
urban JJ 4_p
children NNS 4_p
's POS 4_p
hospital NN 4_p
. . 4_p

Eligible JJ N
children NNS N
3 CD N
to TO N
12 CD N
years NNS N
of IN N
age NN N
undergoing JJ N
elective JJ N
umbilical JJ N
hernia NN N
repair NN N
from IN N
November NNP N
16 CD N
, , N
2009 CD N
, , N
through IN N
May NNP N
31 CD N
, , N
2011 CD N
. . N

-DOCSTART- -X- O O 18288059

NSCLC NNP N
high JJ N
performance NN N
status NN N
patients NNS N
who WP N
have VBP N
relapsed VBN N
after IN N
their PRP$ N
first-line JJ N
chemotherapy NN N
. . N

300 CD N
patients NNS N
will MD N
be VB N
randomized VBN N
-DOCSTART- -X- O O 6958487

hay NN 4_p
fever NN 4_p
93 CD 3_p
patients NNS N
with IN N
seasonal JJ 4_p
allergic JJ 4_p
rhinitis NN 4_p
All DT N
patients NNS N
were VBD N
sensitive JJ N
to TO N
either DT N
birch NN N
or CC N
grass NN N
pollen NN N
, , N
their PRP$ N
sensitivity NN N
being VBG N
confirmed VBN N
by IN N
a DT N
skin NN N
prick NN N
test NN N
. . N

-DOCSTART- -X- O O 25492271

patients NNS 4_p
with IN 4_p
thalassaemia NN 4_p
with IN 4_p
moderate-to-severe JJ 4_p
myocardial JJ 4_p
iron NN 4_p
deposition NN 4_p
: : N
Twenty CD 3_p
patients NNS 3_p
Department NNP 4_p
of IN 4_p
Pediatric NNP 4_p
and CC 4_p
Child NNP 4_p
Health NNP 4_p
, , N
Aga NNP N
Khan NNP N
University NNP N
Hospital NNP N
, , N
Karachi NNP N
, , N
Pakistan NNP N
. . N

The DT N
Aga NNP N
Khan NNP N
University NNP N
-DOCSTART- -X- O O 8877260

participants NNS 4_p
in IN 4_p
the DT 4_p
Appropriate NNP 4_p
Blood NNP 4_p
Pressure NNP 4_p
Control NNP 4_p
in IN 4_p
Diabetes NNP 4_p
trial NN 4_p
. . 4_p

two CD 4_p
study NN 4_p
populations NNS 4_p
: : 4_p
a DT 4_p
hypertensive JJ 4_p
one NN 4_p
( ( 4_p
diastolic JJ 4_p
blood NN 4_p
pressure NN 4_p
of IN 4_p
> NN 4_p
or CC 4_p
= $ 4_p
90.0 CD 4_p
mm NN 4_p
Hg NNP 4_p
at IN 4_p
the DT 4_p
time NN 4_p
of IN 4_p
randomization NN 4_p
) ) 4_p
and CC 4_p
a DT 4_p
normotensive JJ 4_p
one NN 4_p
( ( 4_p
diastolic JJ 4_p
blood NN 4_p
pressure NN 4_p
of IN 4_p
80.0-89.0 JJ 4_p
mm NN 4_p
Hg NNP 4_p
at IN 4_p
the DT 4_p
time NN 4_p
of IN 4_p
randomization NN 4_p
) ) 4_p
. . 4_p

950 CD N
men NNS N
and CC N
women NNS N
aged VBN N
40-74 JJ N
years NNS N
There EX N
were VBD N
470 CD N
randomized JJ N
participants NNS N
in IN N
the DT N
hypertensive JJ N
population NN N
and CC N
480 CD N
randomized JJ N
participants NNS N
in IN N
the DT N
normotensive JJ N
population NN N
. . N

randomized JJ N
patients NNS N
-DOCSTART- -X- O O 10714690

premature JJ 4_p
infants NNS 1_p
with IN N
heavily RB 4_p
pigmented VBN 4_p
irides NNS 4_p
. . N

premature NN N
infants NNS N
with IN N
heavily RB N
pigmented VBN N
irides NNS N
Twenty-eight JJ 3_p
consecutive JJ N
babies NNS 1_p
with IN N
dark JJ N
irides NNS N
and CC N
birthweight NN N
< NN N
1600 CD N
g NN N
referred VBD N
for IN N
screening VBG N
for IN N
retinopathy NN N
of IN N
prematurity NN N
comprised VBD N
the DT N
study NN N
population NN N
. . N

-DOCSTART- -X- O O 15310639

children NNS 1_p
. . 4_p

children NNS 1_p
undergoing VBG 4_p
genito-urinary JJ 4_p
surgery NN 4_p
. . 4_p

80 CD 3_p
boys NNS N
aged VBN N
two CD 1_p
to TO 1_p
eight CD 1_p
years NNS N
scheduled VBN N
for IN N
surgical JJ N
repair NN N
of IN N
hypospadias NNS N
were VBD N
allocated VBN N
randomly RB N
caudal JJ N
0.25 CD N
% NN N
plain NN N
bupivacaine NN N
0.5 CD N
mL.kg NN N
( ( N
-1 NN N
) ) N
( ( N
Group NNP N
I PRP N
) ) N
0.25 CD N
% NN N
plain NN N
bupivacaine NN N
0.5 CD N
mL.kg NN N
( ( N
-1 NNP N
) ) N
with IN N
neostigmine NN N
( ( N
Groups NNP N
II-IV NNP N
) ) N
-DOCSTART- -X- O O 23808817

cancer NN 4_p
patients NNS 4_p
treated VBN 4_p
with IN 4_p
autologous JJ 4_p
stem NN 4_p
cell NN 4_p
transplantation NN 4_p
: : N
cancer NN 4_p
patients NNS 4_p
treated VBN 4_p
with IN 4_p
autologous JJ 4_p
stem NN 4_p
cell NN 4_p
transplantation NN 4_p
whereas RB N
extended VBN N
care NN N
patients NNS N
RESULTS NNP N
Thirty-seven JJ 3_p
patients NNS 3_p
consented VBN N
to TO N
participate VB N
in IN N
the DT N
study NN N
( ( N
54 CD 3_p
% NN 3_p
male NN 2_p
; : N
mean JJ 1_p
age NN 1_p
58.7 CD 1_p
± JJ 1_p
9.5 CD 1_p
years NNS 1_p
; : 1_p
median JJ 4_p
body NN 4_p
mass NN 4_p
index NN 4_p
26.8 CD 4_p
kg NN 4_p
m NN 4_p
( ( 4_p
-2 NNP 4_p
) ) N
, , N
range VBP 4_p
16.4-47.6 JJ 4_p
kg NN 4_p
m NN 4_p
( ( 4_p
-2 NNP 4_p
) ) 4_p
) ) 4_p
; : N
33 CD 3_p
patients NNS N
completed VBD N
the DT N
study NN N
and CC N
28 CD 3_p
patients NNS 3_p
returned VBD N
the DT N
questionnaire NN N
( ( N
response NN N
rate NN N
= VBD N
85 CD N
% NN N
) ) N
difference NN 4_p
= NNP 4_p
0.56 CD 4_p
) ) N
. . N

CONCLUSIONS NNP N
Cancer NNP 4_p
patients NNS 4_p
treated VBD 4_p
with IN 4_p
autologous JJ 4_p
stem NN 4_p
cell NN 4_p
extended JJ 4_p
nutrition NN 4_p
care NN 4_p
. . N

Extended NNP N
-DOCSTART- -X- O O 10678548

patients NNS N
with IN N
chronic JJ 4_p
renal JJ 4_p
disease NN 4_p
. . N

patients NNS N
exhibiting VBG N
a DT N
progressive JJ 4_p
decline NN 4_p
in IN 4_p
renal JJ 4_p
function NN 4_p
because IN N
of IN N
chronic JJ 4_p
renal JJ 4_p
disease NN 4_p
. . N

group NN N
of IN N
patients NNS N
with IN N
progressive JJ N
chronic JJ N
renal JJ N
failure NN N
( ( N
creatinine JJ N
clearance NN N
20-45 JJ N
ml/min NN N
) ) N
either CC N
with IN N
or CC N
without IN N
proteinuria NNS N
and CC N
hypertension NN N
. . N

( ( N
n JJ N
= NNP N
22 CD 3_p
) ) N
; : N
( ( N
n JJ N
= NNP N
42 CD 3_p
) ) N
; : N
( ( N
n JJ N
= NNP N
44 CD 3_p
) ) N
patients NNS N
with IN N
moderate JJ N
chronic JJ N
renal JJ N
failure NN N
. . N

-DOCSTART- -X- O O 10971307

vasopressin NN 4_p
secretion NN 4_p
in IN 4_p
man NN 2_p
. . 4_p

healthy JJ 4_p
subjects NNS 4_p
. . N

24 CD 3_p
healthy JJ N
volunteers NNS N
. . N

-DOCSTART- -X- O O 22020134

healthy JJ 4_p
young JJ 1_p
adults NNS 1_p
. . N

Sixty-five JJ 3_p
healthy JJ 4_p
adults NNS 1_p
aged VBD 1_p
18-29yrs JJ 1_p
-DOCSTART- -X- O O 21846665

parents NNS N
of IN N
children NNS N
with IN N
autism NN N
: : N
a DT N
parent NN 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
. . 4_p

parents NNS 4_p
of IN 4_p
young JJ 4_p
children NNS 4_p
on IN 4_p
the DT 4_p
autism NN 4_p
spectrum NN 4_p
Parents NNS 4_p
Parents NNS 4_p
young JJ 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
. . 4_p

-DOCSTART- -X- O O 20705223

endothelial JJ N
dysfunction NN N
in IN N
healthy JJ N
humans NNS N
. . N

endothelial JJ N
function NN N
in IN N
lean JJ N
healthy JJ N
humans NNS N
. . N

Forty-three JJ N
normal-weight JJ N
healthy JJ N
volunteers NNS N
were VBD N
recruited VBN N
( ( N
mean JJ N
age NN N
29 CD N
years NNS N
; : N
18 CD N
women NNS N
) ) N
. . N

Subjects NNS N
normal-weight JJ N
healthy JJ N
young JJ N
subjects NNS N
-DOCSTART- -X- O O 10741095

subjects NNS 4_p
with IN 4_p
mild-to-moderate JJ 4_p
asthma NN 4_p
. . 4_p

subjects NNS 4_p
with IN 4_p
mild-to-moderate JJ 4_p
asthma NN 4_p
, , 4_p
three CD 4_p
groups NNS 4_p
of IN 4_p
11 CD 4_p
patients NNS 4_p
-DOCSTART- -X- O O 26153884

Excessive NNP 4_p
Weight NNP 4_p
Gain NNP 4_p
in IN N
Adolescents NNP 1_p
. . 1_p

non-active JJ N
video NN N
gaming VBG N
adolescents NNS 1_p
who WP N
primarily RB N
were VBD N
of IN N
healthy JJ N
weight NN N
. . N

270 CD 3_p
gaming NN N
( ( N
i.e NN N
. . N

≥ CC N
2 CD N
hours/week JJ N
non-active JJ N
video NN N
game NN N
time NN N
) ) N
adolescents NNS 1_p
randomly RB N
to TO N
an DT N
intervention NN N
group NN N
( ( N
n JJ 3_p
= NNP 3_p
140 CD 3_p
) ) N
( ( N
receiving VBG N
active JJ N
video NN N
games NNS N
and CC N
encouragement NN N
to TO N
play VB N
) ) N
or CC N
a DT N
waiting-list JJ N
control NN N
group NN N
( ( N
n JJ N
= NNP N
130 CD 3_p
) ) N
The DT N
control NN N
group NN N
The DT N
intervention NN N
group NN N
showed VBD 1_p
that IN 1_p
14 CD 1_p
% NN 1_p
of IN 1_p
the DT 1_p
adolescents NNS 1_p
anthropometrics NNS N
in IN N
a DT N
group NN N
of IN N
'excessive JJ N
' POS N
non-active JJ N
video NN N
gamers NNS N
( ( N
mean JJ N
~ VBP N
14 CD N
hours/week NN N
) ) N
who WP N
primarily RB N
were VBD N
of IN N
healthy JJ N
-DOCSTART- -X- O O 20058059

children NNS 1_p
having VBG N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . N

second JJ 1_p
to TO 1_p
fifth VB 1_p
grade JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . 4_p

CFT NNP N
group NN N
DTC NNP N
group NN N
-DOCSTART- -X- O O 8722072

patients NNS N
with IN N
insulin-dependent JJ 4_p
diabetes NNS 4_p
mellitus FW 4_p
( ( N
IDDM NNP 4_p
) ) N
in IN N
the DT N
Diabetes NNP N
Control NNP N
and CC N
Complications NNP N
Trial NNP N
( ( N
DCCT NNP N
) ) N
. . N

29 CD 3_p
DCCT NNP N
clinics NNS N
-DOCSTART- -X- O O 2182235

1,615 CD N
angiographic JJ N
readings NNS N
in IN N
240 CD 3_p
patients NNS N
with IN N
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
Half NNP N
of IN N
these DT N
patients NNS N
-DOCSTART- -X- O O 12243889

canine JJ 4_p
Canine NNP 4_p
parvoviral JJ 4_p
enteritis NN 4_p
dogs NNS 4_p
parvoviral JJ 4_p
enteritis NN 4_p
in IN 4_p
dogs NNS 4_p
. . N

beagle NN N
pups NNS 4_p
( ( 1_p
8-9 JJ 1_p
weeks NNS N
) ) N
; : N
Fourteen JJ 3_p
animals NNS N
were VBD N
inoculated VBN N
with IN N
virulent JJ 4_p
canine NN 4_p
parvovirus NN 4_p
; : N
10 CD 3_p
animals NNS N
that WDT N
developed VBD N
clinical JJ N
signs NNS N
thereby RB N
meeting VBG N
the DT N
inclusion NN N
criteria NNS N
were VBD N
admitted VBN N
to TO N
the DT N
treatment NN N
phase NN N
dogs NNS 4_p
with IN N
parvoviral JJ 4_p
enteritis NN 4_p
-DOCSTART- -X- O O 25319807

in IN 4_p
melanoma NN 4_p
patients NNS 4_p
with IN 4_p
high JJ 4_p
serum NN 4_p
MMP-8 NNP 4_p
levels NNS 4_p
melanoma NN 4_p
from IN 3_p
460 CD 3_p
patients NNS 3_p
with IN N
stage JJ 4_p
IIB-IIIC JJ 4_p
melanoma NN 4_p
were VBD 4_p
analyzed VBN 4_p
for IN 4_p
MMP-8 NNP 4_p
months NNS 4_p
in IN 4_p
patients NNS 4_p
with IN 4_p
high JJ 4_p
MMP-8 JJ 4_p
levels NNS 4_p
survival NN 4_p
for IN 4_p
patients NNS 4_p
with IN 4_p
high JJ 4_p
MMP-8 NNP 4_p
-DOCSTART- -X- O O 15764256

54 CD N
patients NNS N
with IN N
biopsy-proven JJ N
chronic JJ 4_p
glomerulonephritis NN 4_p
, , N
hypertension NN 4_p
and CC N
normal JJ N
or CC N
slightly RB N
impaired JJ 4_p
kidney NN 4_p
function NN 4_p
. . N

-DOCSTART- -X- O O 3745846

gastroesophageal JJ N
reflux NN N
. . N

23 CD 3_p
patients NNS 3_p
with IN N
gastroesophageal JJ 4_p
reflux NN 4_p
. . N

Group NNP N
I PRP N
patients NNS N
with IN N
delayed JJ N
or CC N
normal JJ N
GE NNP N
-DOCSTART- -X- O O 18453793

outpatient JJ N
setting NN N
. . N

patients NNS N
with IN N
hypertension NN 4_p
. . N

A DT 4_p
total NN 4_p
of IN 4_p
1367 CD 3_p
patients NNS 4_p
participated VBN 4_p
in IN 4_p
the DT 4_p
study NN 4_p
; : 4_p
mean JJ 4_p
age NN 4_p
was VBD 4_p
52.5 CD 1_p
years NNS 1_p
, , 4_p
40.8 CD 4_p
% NN 4_p
were VBD 4_p
male JJ 2_p
, , 4_p
76.5 CD 4_p
% NN 4_p
were VBD 4_p
black JJ 4_p
, , 4_p
50.8 CD 4_p
% NN 4_p
graduated VBN 4_p
from IN 4_p
high JJ 4_p
school NN 4_p
, , 4_p
26 CD 4_p
% NN 4_p
were VBD 4_p
married VBN 4_p
, , 4_p
and CC 4_p
54.1 CD 4_p
% NN 4_p
had VBD 4_p
income NN 4_p
< NNP 4_p
$ $ 4_p
5,000 CD 4_p
. . 4_p

primarily RB N
low-income JJ N
, , N
minority NN N
patients NNS N
with IN N
hypertension NN N
outpatient JJ N
settings NNS N
patient NN N
groups NNS N
. . N

-DOCSTART- -X- O O 1788685

chronic JJ 4_p
venous JJ 4_p
insufficiency NN 4_p
] NNP 4_p
-DOCSTART- -X- O O 18420953

patients NNS N
with IN N
Fisher NNP 4_p
grade NN 4_p
III NNP 4_p
subarachnoid JJ 4_p
hemorrhage NN 4_p
: : 4_p
patients NNS N
with IN N
ruptured JJ N
aneurysms NNS N
. . N

One CD 3_p
hundred CD 3_p
and CC 3_p
seventy JJ 3_p
patients NNS 3_p
with IN N
Fisher NNP 4_p
Grade NNP 4_p
III NNP 4_p
subarachnoid JJ 4_p
hemorrhage NN 4_p
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

patients NNS N
with IN N
Fisher NNP 4_p
grade NN 4_p
III NNP 4_p
subarachnoid NN 4_p
hemorrhage NN 4_p
. . N

-DOCSTART- -X- O O 19535468

children NNS 1_p
with IN N
autism NN 4_p
child NN 1_p
responsiveness NN N
in IN N
children NNS 1_p
with IN N
autism NN 4_p
during IN N
joint JJ N
engagement NN N
episodes NNS N
. . N

( ( N
n JJ N
= NNP N
10 CD 3_p
) ) N
children NNS 1_p
with IN N
autism NN 4_p
. . N

-DOCSTART- -X- O O 10759619

volunteers NNS 4_p
. . N

steady-state JJ N
conditions NNS N
in IN N
volunteers NNS N
. . N

12 CD 3_p
healthy JJ 4_p
volunteers NNS N
over IN N
6 CD N
days NNS N
. . N

-DOCSTART- -X- O O 19931151

pain NN 4_p
associated VBN 4_p
with IN 4_p
intramuscular JJ 4_p
injection NN 4_p
of IN 4_p
palivizumab NN 4_p
( ( 4_p
synagis NN 4_p
) ) 4_p
. . N

Infants NNS 1_p
receive VBP N
many JJ N
painful JJ N
immunizations NNS N
before IN N
they PRP N
are VBP N
2 CD N
years NNS N
old JJ N
. . N

pain NN 4_p
of IN 4_p
intramuscular JJ 4_p
palivizumab NNS 4_p
-DOCSTART- -X- O O 25294277

schizophrenia NN 4_p
: : 4_p
people NNS 4_p
with IN 4_p
schizophrenia NN 4_p
1,049 CD 3_p
patients NNS 3_p
were VBD N
included VBN N
in IN N
the DT N
initial JJ N
cluster NN N
analysis NN N
. . N

-DOCSTART- -X- O O 3314599

following VBG N
thoracotomy NN 4_p
: : N
-DOCSTART- -X- O O 25907208

0.5 CD 4_p
% NN 4_p
eye NN 4_p
drops NNS 4_p
on IN 4_p
patient NN 4_p
's POS 4_p
comfort NN 4_p
during IN 4_p
instillation NN 4_p
. . N

-DOCSTART- -X- O O 23713303

chronic JJ 4_p
tension-type JJ 4_p
headache NN 4_p
chronic JJ 4_p
tension-type JJ 4_p
headache NN 4_p
( ( 4_p
CTTH NNP 4_p
) ) 4_p
. . N

Two CD 3_p
hundred VBD 3_p
and CC 3_p
eighty-eight JJ 3_p
cases NNS N
CTTH NNP 4_p
-DOCSTART- -X- O O 12401759

type NN N
1 CD N
diabetes NNS N
for IN N
patients NNS N
with IN N
long-standing JJ N
poor JJ N
glycemic JJ N
control NN N
. . N

type JJ 4_p
1 CD 4_p
diabetic JJ 4_p
patients NNS N
with IN N
long-standing JJ N
poor JJ 4_p
glycemic JJ 4_p
control NN 4_p
. . N

A NNP 4_p
total NN 4_p
of IN 4_p
79 CD 4_p
patients NNS 4_p
in IN 4_p
11 CD 4_p
Dutch NN 4_p
centers NNS 4_p
patients NNS N
with IN N
a DT N
history NN N
of IN N
long-term JJ N
poor JJ 4_p
glycemic JJ 4_p
control NN 4_p
. . N

-DOCSTART- -X- O O 19415409

healthy JJ 4_p
subjects NNS N
. . N

Thirteen NNP 3_p
healthy JJ 4_p
human JJ N
volunteers NNS N
( ( N
6 CD 2_p
men NNS 2_p
and CC 2_p
7 CD 2_p
women NNS 2_p
, , N
aged VBN 1_p
20-28 CD 1_p
years NNS 1_p
) ) 1_p
-DOCSTART- -X- O O 10071998

in IN 4_p
vitro JJ 4_p
fertilization NN 4_p
: : 4_p
women NNS 2_p
undergoing VBG N
ultrasonically RB 4_p
guided VBN 4_p
oocyte NN 4_p
retrieval NN 4_p
. . N

Seventy-eight JJ 3_p
women NNS 2_p
-DOCSTART- -X- O O 11143509

49 CD N
patients NNS N
who WP N
underwent JJ N
gastrectomy NN N
with IN N
Longmire-Interposition NNP N
with IN N
( ( N
n JJ N
= NNP N
33 CD N
) ) N
or CC N
without IN N
( ( N
n JJ N
= NNP N
16 CD N
) ) N
an DT N
additional JJ N
pouch NN N
and CC N
46 CD N
patients NNS N
with IN N
a DT N
Roux-en-Y-reconstruction NN N
-DOCSTART- -X- O O 23716291

three CD 4_p
readers NNS 4_p
at IN 4_p
different JJ 4_p
levels NNS 4_p
of IN 4_p
training NN 4_p
or CC 4_p
at IN 4_p
different JJ 4_p
points NNS 4_p
of IN 4_p
the DT 4_p
learning VBG 4_p
curve NN 4_p
proposed VBN 4_p
by IN 4_p
the DT 4_p
international JJ 4_p
guidelines NNS 4_p
. . N

Three NNP 4_p
radiologists VBZ 4_p
in IN 4_p
training VBG 4_p
with IN 4_p
different JJ 4_p
levels NNS 4_p
of IN 4_p
experience NN 4_p
in IN 4_p
MDCT-CA NNP 4_p
The DT N
trainee NN N
radiologists VBZ N
-DOCSTART- -X- O O 12504399

uncomplicated JJ 4_p
malaria NNS 4_p
: : N
sub-Saharan JJ N
Africa NNP N
. . N

children NNS 1_p
from IN N
Kampala NNP N
, , N
Uganda NNP N
. . N

healthy JJ N
children NNS N
aged VBD N
6 CD 1_p
months NNS 1_p
to TO 1_p
5 CD 1_p
years NNS 1_p
316 CD 3_p
participants NNS N
-DOCSTART- -X- O O 22006695

individuals NNS N
with IN N
chronic JJ 4_p
stroke NN 4_p
bulbospinal JJ N
contributions NNS N
to TO N
maximum VB N
joint JJ N
torque NN N
generation NN N
in IN N
11 CD 3_p
individuals NNS N
with IN N
stroke NN 4_p
and CC N
10 CD 3_p
individuals NNS 3_p
without IN 4_p
stroke NN 4_p
. . N

-DOCSTART- -X- O O 6455048

osteoporotic JJ 4_p
backache NN 4_p
22 CD 4_p
postmenopausal JJ 1_p
women NNS 2_p
with IN N
backache NN 4_p
and CC 4_p
a DT 4_p
halisteretic JJ 4_p
spine NN 4_p
with IN 4_p
crush JJ 4_p
fracture NN 4_p
( ( 4_p
s NN 4_p
) ) 4_p
, , N
12 CD 4_p
women NNS 2_p
completed VBD N
a DT N
12-week JJ N
therapy NN N
with IN N
sodium NN N
fluoride NN N
, , N
calcium NN N
and CC N
calciferol NN N
-DOCSTART- -X- O O 10808042

adult NN 1_p
autistic JJ 4_p
disorders NNS 4_p
. . N

adult NN N
autistic JJ N
patients NNS N
and CC N
matched VBD N
normal JJ N
controls NNS N
. . N

11 CD N
adult NN N
patients NNS N
with IN N
autism NN N
or CC N
Asperger NNP N
's POS N
disorder NN N
were VBD N
compared VBN N
with IN N
nine CD N
matched JJ N
controls NNS N
. . N

autistic JJ N
patients NNS N
-DOCSTART- -X- O O 8940983

vaccines NNS N
after IN N
a DT N
primary JJ N
vaccination NN N
series NN N
in IN N
Philippine NNP N
infants NNS 1_p
. . N

in IN N
174 CD 3_p
Philippine JJ N
infants NNS N
after IN N
a DT N
primary JJ 4_p
vaccination NN 4_p
series NN N
. . N

Philippine JJ N
infants NNS N
. . N

-DOCSTART- -X- O O 15689088

infants NNS 1_p
primed VBN N
at IN N
birth NN N
with IN N
hepatitis NN 4_p
B NNP 4_p
vaccine NN N
. . N

infants NNS 1_p
primed VBN N
at IN N
birth NN N
with IN N
hepatitis NN 4_p
B NNP 4_p
vaccine NN N
. . N

150 CD 3_p
healthy JJ N
, , N
full-term JJ N
infants NNS 1_p
-DOCSTART- -X- O O 9049582

healthy JJ 4_p
volunteers NNS N
. . N

healthy JJ 4_p
male NN 2_p
volunteers NNS N
two CD N
groups NNS N
of IN N
subjects NNS N
( ( N
each DT N
containing VBG N
six CD 3_p
subjects NNS N
taking VBG N
the DT N
drug NN N
and CC N
three CD 3_p
taking VBG N
placebo NN N
) ) N
receiving VBG N
3 CD N
, , N
60 CD N
and CC N
300 CD N
mg NN N
or CC N
15 CD N
, , N
60 CD N
and CC N
450 CD N
mg NN N
YM17E NNP N
, , N
respectively RB N
. . N

small JJ N
number NN N
of IN N
subjects NNS N
-DOCSTART- -X- O O 18665413

subjects NNS 4_p
with IN 4_p
coronary JJ 4_p
heart NN 4_p
disease NN 4_p
using VBG 4_p
multiple JJ 4_p
medications NNS 4_p
. . N

coronary JJ 4_p
heart NN 4_p
disease NN 4_p
( ( 4_p
CHD NNP 4_p
) ) 4_p
subjects NNS 4_p
with IN 4_p
CHD NNP 4_p
using VBG 4_p
multiple JJ 4_p
drugs NNS 4_p
for IN 4_p
this DT 4_p
condition NN 4_p
. . N

Inclusion NNP 4_p
criteria NNS 4_p
were VBD 4_p
myocardial JJ 4_p
infarction NN 4_p
or CC N
unstable JJ 4_p
ischemic JJ 4_p
attack NN 4_p
, , N
age NN 1_p
under IN 1_p
70 CD 1_p
years NNS 1_p
, , N
use NN 4_p
of IN 4_p
betablockers NNS 4_p
and CC 4_p
presence NN 4_p
of IN 4_p
sinus NN 4_p
rhythm NN 4_p
. . N

CHD NNP 4_p
patients NNS 4_p
. . N

-DOCSTART- -X- O O 11819768

Austrain NNP 4_p
Czech JJ 4_p
German NNP 4_p
gastric NN 4_p
cancer NN 4_p
subgroup NN 4_p
of IN 4_p
individuals NNS 4_p
with IN 4_p
an DT 4_p
increased VBN 4_p
risk NN 4_p
for IN 4_p
this DT 4_p
fatal JJ 4_p
disease NN 4_p
. . 4_p

Men NN 4_p
between IN 4_p
55 CD 4_p
and CC 4_p
65 CD 4_p
years NNS 4_p
of IN 4_p
age NN 4_p
with IN 4_p
a DT 4_p
gastric JJ 4_p
cancer NN 4_p
phenotype NN 4_p
of IN 4_p
Helicobacter NNP 4_p
pylori FW 4_p
gastritis NN 4_p
are VBP 4_p
randomized VBN 4_p
Since IN N
March NNP N
1998 CD N
, , N
1524 CD N
target NN N
patients NNS N
have VBP N
been VBN N
screened VBN N
, , N
279 CD N
patients NNS N
( ( N
18.3 CD N
% NN N
) ) N
had VBD N
a DT N
corpus NN N
dominant JJ N
type NN N
of IN N
H. NNP N
pylori FW N
gastritis NN N
, , N
and CC N
167 CD N
of IN N
those DT N
were VBD N
randomized VBN N
-DOCSTART- -X- O O 6624525

arthrography NN 4_p
of IN N
the DT N
knee NN N
. . N

double JJ N
contrast NN N
knee NN N
arthrography NN 4_p
, , N
190 CD 3_p
and CC N
184 CD 3_p
patients NNS N
each DT N
. . N

-DOCSTART- -X- O O 23888359

childhood NN 1_p
autism NN 4_p
: : 4_p
38 CD N
male JJ 1_p
youths NNS 1_p
( ( 1_p
7-16 CD 1_p
years NNS 1_p
old JJ 1_p
) ) 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
young JJ 1_p
individuals NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
-DOCSTART- -X- O O 20830241

Four CD 3_p
healthy JJ 4_p
volunteers NNS N
with IN N
significant JJ 4_p
erythema NN 4_p
and CC 4_p
telangiectasia NN 4_p
on IN 4_p
the DT 4_p
face NN 4_p
of IN N
telangiectasias NN N
-DOCSTART- -X- O O 2015149

310 CD 3_p
patients NNS 3_p
undergoing JJ N
anaesthesia JJ 4_p
. . N

-DOCSTART- -X- O O 22920273

Canada NNP N
. . N

first-trimester JJ 4_p
abortion NN 4_p
Consenting NNP N
women NNS 2_p
choosing VBG N
to TO N
use VB N
an DT 4_p
IUD NNP 4_p
after IN 4_p
an DT 4_p
abortion NN 4_p
for IN 4_p
a DT 4_p
pregnancy NN 4_p
of IN 4_p
less JJR 4_p
than IN 4_p
12 CD 4_p
weeks NNS 4_p
of IN 4_p
gestation NN 4_p
-DOCSTART- -X- O O 12653872

hypertensive JJ N
patients NNS N
with IN N
echolucent JJ N
plaques NNS N
in IN N
the DT N
carotid NN N
artery NN N
. . N

high-risk JJ 4_p
hypertensive JJ 4_p
men NNS 4_p
patients NNS N
with IN N
carotid JJ N
artery NN N
plaques NNS N
. . N

usual JJ N
care NN N
group NN N
17 CD N
of IN N
32 CD N
( ( N
53 CD N
% NN N
) ) N
patients NNS N
with IN N
echolucent JJ N
plaques NNS N
at IN N
baseline NN N
-DOCSTART- -X- O O 19803237

acute JJ 4_p
gouty NN 4_p
arthritis NN 4_p
] NNP 4_p
acute JJ 4_p
gouty NN 4_p
arthritis NN 4_p
. . 4_p

Sixty NNP 3_p
cases NNS 3_p
-DOCSTART- -X- O O 2014078

Prophylactic JJ 4_p
amnioinfusion NN 4_p
in IN 4_p
pregnancies NNS 4_p
complicated VBN 4_p
by IN 4_p
oligohydramnios NNS 4_p
: : 4_p
term NN 4_p
and CC 4_p
post-dates NNS 4_p
pregnancies NNS 4_p
with IN 4_p
decreased JJ 4_p
amniotic JJ 4_p
fluid NN 4_p
volume NN 4_p
. . 4_p

Patients NNS N
receiving VBG N
prophylactic JJ N
amnioinfusion NN N
-DOCSTART- -X- O O 17912634

multinational JJ 4_p
postmenopausal JJ 4_p
women NNS 4_p
with IN 4_p
HR+ NNP 4_p
breast NN 4_p
cancer NN 4_p
ineligible JJ 4_p
for IN 4_p
breast-conserving JJ 4_p
surgery NN 4_p
. . 4_p

postmenopausal JJ N
women NNS N
with IN N
HR+ NNP N
locally RB N
advanced VBD N
breast NN N
cancer NN N
. . N

-DOCSTART- -X- O O 23361105

following VBG 4_p
cardiac JJ 4_p
surgery NN 4_p
: : 4_p
cardiopulmonary JJ 4_p
bypass NN 4_p
( ( 4_p
CPB NNP 4_p
) ) 4_p
Patients NNS 3_p
( ( 3_p
N NNP 3_p
= NNP 3_p
115 CD 3_p
) ) 3_p
in IN N
patients NNS N
undergoing VBG N
CPB NNP N
-DOCSTART- -X- O O 4448416

haemorrhagic JJ 4_p
diathesis NN 4_p
of IN 4_p
fulminant JJ 4_p
hepatic JJ 4_p
failure NN 4_p
. . N

fulminant JJ 4_p
hepatic JJ 4_p
failure NN 4_p
nine CD N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
treatment NN N
with IN N
either DT N
concentrate NN N
alone RB N
or CC N
concentrate VB N
plus CC N
heparin VB N
. . N

-DOCSTART- -X- O O 10755175

children NNS 1_p
with IN 1_p
autism NN 1_p
: : 1_p
16 CD 3_p
children NNS 3_p
with IN N
autism NN 3_p
parents NNS N
child NN N
-DOCSTART- -X- O O 6650773

Bovine NNP 4_p
carotid NN 4_p
artery NN 4_p
heterografts NNS 4_p
versus VBP N
polytetrafluoroethylene JJ 4_p
grafts NNS N
. . N

diabetic JJ 4_p
patients NNS N
nondiabetic JJ 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 24263699

older JJR 1_p
adults NNS 1_p
with IN N
and CC N
without IN 4_p
glaucoma NN N
. . N

conducted VBN N
from IN N
2005-2009 CD N
involved JJ N
126 CD 3_p
patients NNS N
with IN N
glaucoma NN 4_p
and CC N
49 CD 3_p
without IN 4_p
glaucoma NN 4_p
recruited VBN N
from IN N
the DT N
Glaucoma NNP N
and CC N
Comprehensive NNP N
Eye NNP N
Clinics NNP N
at IN N
Washington NNP N
University NNP N
, , N
St NNP N
Louis NNP N
, , N
Missouri NNP N
. . N

aged VBN N
55 CD 1_p
to TO 1_p
90 CD 1_p
years NNS 1_p
A DT N
total NN N
of IN N
166 CD 3_p
eligible JJ N
patients NNS N
refused VBD N
participation NN N
. . N

older JJR 1_p
adults NNS 1_p
-DOCSTART- -X- O O 9398110

patients NNS N
with IN N
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
. . N

40 CD 3_p
patients NNS N
with IN N
AMI NNP 4_p
within IN N
12 CD N
hours NNS N
after IN N
the DT N
onset NN N
of IN N
the DT N
symptom NN N
and CC N
who WP N
randomly VBP N
received VBN N
early JJ N
treatment NN N
with IN N
either CC N
the DT N
ACE NNP N
inhibitor NN N
imidapril NN N
or CC N
a DT N
placebo NN N
( ( N
20 CD 3_p
patients NNS N
in IN N
the DT N
imidapril NN N
group NN N
and CC N
20 CD 3_p
in IN N
the DT N
placebo NN N
group NN N
) ) N
. . N

-DOCSTART- -X- O O 20394631

acne JJ N
vulgaris NN N
: : N
Eighty NNP 3_p
patients NNS N
( ( N
38 CD 3_p
males NNS 4_p
and CC N
42 CD 3_p
females NNS 4_p
, , N
mean JJ 1_p
+/- JJ 1_p
SD NNP 1_p
age NN 1_p
19.7 CD 1_p
+/- JJ 1_p
5.9 CD 1_p
years NNS 1_p
) ) 1_p
-DOCSTART- -X- O O 17324094

underserved JJ N
women NNS 2_p
participating VBG N
in IN N
an DT N
intervention NN N
designed VBN N
to TO N
increase VB N
mammography NN N
use NN N
. . N

897 CD 3_p
women NNS 2_p
from IN N
three CD N
racial JJ N
groups NNS N
( ( N
white JJ N
, , N
African JJ N
American NNP N
, , N
Native JJ N
American NNP N
) ) N
living NN N
in IN N
a DT N
rural JJ N
county NN N
in IN N
North NNP N
Carolina NNP N
. . N

815 CD 3_p
women NNS 2_p
; : N
775 CD 3_p
women NNS 2_p
provided VBD N
data NNS N
-DOCSTART- -X- O O 9399611

hypertensive JJ 4_p
patients NNS N
in IN N
a DT N
rural JJ 4_p
setting NN 4_p
. . N

patients NNS N
who WP N
were VBD N
monitored VBN N
by IN N
specially RB N
trained VBN N
community NN N
pharmacists NNS N
in IN N
a DT N
group NN N
medical JJ N
practice NN N
. . N

25 CD 3_p
patients NNS N
control NN N
group NN N
of IN N
26 CD 3_p
patients NNS N
-DOCSTART- -X- O O 16596861

adults NNS 1_p
with IN N
coronary JJ 4_p
heart NN 4_p
disease NN 4_p
. . N

-DOCSTART- -X- O O 1723467

obese JJ 4_p
patients NNS N
. . N

mildly RB 4_p
or CC 4_p
transiently RB 4_p
hypertensive JJ 4_p
nondiabetic JJ 4_p
obese JJ 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 1827602

age NN N
of IN N
onset NN N
in IN N
panic JJ 4_p
disorder NN 4_p
Groups NNP N
the DT N
sample NN N
of IN N
the DT N
cross-national JJ N
collaborative NN N
panic NN N
study NN N
( ( N
CNCPS NNP N
) ) N
Patients NNS N
who WP N
developed VBD N
avoidance NN N
behavior NN N
before IN N
the DT N
full JJ 4_p
syndrome NN 4_p
of IN N
panic JJ 4_p
disorder NN 4_p
Patients NNS N
-DOCSTART- -X- O O 8520804

in IN 4_p
man NN 2_p
. . 4_p

Eighteen NNP 3_p
healthy JJ N
volunteers NNS N
-DOCSTART- -X- O O 21720441

34 CD 3_p
, , N
lean JJ 4_p
or CC 4_p
overweight/obese JJ 4_p
adults NNS 1_p
revealed VBD N
the DT N
obese JJ N
than IN N
the DT N
lean JJ N
and CC N
overweight JJ N
among IN N
overweight JJ N
and CC N
obese JJ N
individuals NNS N
-DOCSTART- -X- O O 16889080

patients NNS N
with IN N
prostatic JJ 4_p
adenoma NN 4_p
multicenter NN N
patients NNS N
with IN N
prostatic JJ 4_p
adenoma NN 4_p
. . N

-DOCSTART- -X- O O 23361064

focal JJ 4_p
hand NN 4_p
dystonia NN 4_p
. . N

Patients NNS N
with IN N
writer NN 4_p
's POS 4_p
cramp NN 4_p
patients NNS N
with IN N
dystonia NN 4_p
patients NNS N
with IN N
writer NN 4_p
's POS 4_p
cramp NN 4_p
. . N

Fourteen JJ 3_p
patients NNS N
affected VBN N
by IN N
writer NN N
's POS N
cramp NN N
in IN N
the DT N
right JJ N
hand NN N
and CC N
17 CD 3_p
age- JJ N
and CC N
gender-matched JJ N
healthy JJ N
subjects NNS N
were VBD N
recruited VBN N
for IN N
the DT N
study NN N
. . N

Patients NNS N
with IN N
writer NN 4_p
's POS 4_p
cramp NN 4_p
-DOCSTART- -X- O O 21632816

critically RB 4_p
ill JJ 4_p
children NNS 1_p
. . N

Twenty-five JJ N
percent NN N
of IN N
the DT N
children NNS 1_p
with IN N
IIT NNP N
experienced VBD N
hypoglycemia NN 4_p
We PRP N
studied VBD N
369 CD 3_p
patients NNS N
who WP N
stayed VBD N
in IN N
PICU NNP N
for IN N
at IN N
least JJS N
3 CD N
d NN N
( ( N
study VB N
1 CD N
) ) N
and CC N
126 CD 3_p
patients NNS N
in IN N
a DT N
nested JJ N
case-control NN N
study NN N
( ( N
study VB N
2 CD N
) ) N
. . N

-DOCSTART- -X- O O 11788219

coronary JJ 4_p
brachytherapy NN 4_p
with IN 4_p
gamma JJ 4_p
irradiation NN 4_p
. . 4_p

in-stent JJ N
restenosis NN N
Washington NNP N
Radiation NNP N
for IN N
In-Stent NNP N
Restenosis NNP N
Trial NNP N
( ( N
WRIST NNP N
) ) N
. . N

patients NNS N
enrolled VBN N
in IN N
WRIST NNP N
. . N

randomized VBD N
130 CD N
patients NNS N
to TO N
double-blinded JJ N
therapy NN N
with IN N
gamma JJ N
irradiation NN N
( ( N
iridium-192 JJ N
[ NNP N
( ( N
192 CD N
) ) N
Ir NNP N
] NNP N
) ) N
versus NN N
placebo NN N
after IN N
interventional JJ N
treatment NN N
of IN N
diffuse NN N
in-stent JJ N
restenosis NN N
. . N

-DOCSTART- -X- O O 17404792

patients NNS N
with IN N
swallowing VBG 4_p
disorders NNS 4_p
as IN 4_p
a DT 4_p
nutrition NN 4_p
support NN 4_p
or CC N
a DT N
decompressant NN N
of IN N
gastrointestine NN 4_p
, , N
perioperative JJ N
complications NNS N
associated VBN N
with IN N
PEG NNP N
have VBP N
not RB N
decreased VBN N
, , N
especially RB N
peristomal JJ N
infections NNS N
. . N

pigs NNS 4_p
under IN 4_p
general JJ 4_p
anesthesia NN 4_p
thirty JJ 3_p
patients NNS N
with IN N
prior JJ N
consent NN N
-DOCSTART- -X- O O 19808281

heart NN 4_p
failure NN 4_p
outpatients NNS 4_p
: : N
patients NNS N
under IN N
cardiologists NNS N
' POS N
care NN N
over IN N
long-term JJ N
follow-up NN N
One CD 3_p
hundred VBD 3_p
seventeen JJ 3_p
patients NNS N
were VBD N
randomized VBN N
to TO N
usual JJ N
care NN N
, , N
and CC N
233 CD 3_p
to TO N
additional JJ N
intervention NN N
. . N

patients NNS N
under IN N
the DT N
supervision NN N
of IN N
a DT N
cardiologist NN N
-DOCSTART- -X- O O 3535021

duodenal JJ N
ulceration NN N
. . N

multi-clinic JJ 4_p
study NN 4_p
comparing VBG 4_p
the DT 4_p
therapeutic JJ 4_p
efficacy NN 4_p
and CC 4_p
degree NN 4_p
of IN 4_p
oral JJ 4_p
staining NN 4_p
of IN 4_p
new JJ 4_p
colloidal JJ 4_p
bismuth NN 4_p
subcitrate NN 4_p
( ( 4_p
CBS NNP 4_p
) ) 4_p
coated VBD 4_p
tablets NNS 4_p
over IN 4_p
4 CD 4_p
weeks NNS 4_p
of IN 4_p
treatment NN 4_p
in IN 4_p
patients NNS 4_p
suffering VBG 4_p
from IN 4_p
duodenal JJ 4_p
ulceration NN 4_p
9 CD N
clinics NNS N
in IN N
the DT N
Netherlands NNP N
, , N
Belgium NNP N
, , N
Ireland NNP N
, , N
the DT N
United NNP N
Kingdom NNP N
, , N
and CC N
Italy NNP N
. . N

94 CD N
patients NNS N
treated VBN N
with IN N
CBS NNP N
coated VBD N
tablets NNS N
and CC N
95 CD N
patients NNS N
treated VBN N
with IN N
CBS NNP N
chewing VBG N
tablets NNS N
-DOCSTART- -X- O O 7118776

patients NNS 4_p
with IN 4_p
mixed JJ 4_p
aerobic NNS 4_p
-- : 4_p
anaerobic JJ 4_p
infections NNS 4_p
. . N

-DOCSTART- -X- O O 10607234

patients NNS N
with IN N
chronic JJ N
hepatitis NN N
B NNP N
. . N

Caucasian JJ N
patients NNS N
chronic JJ N
active JJ N
hepatitis NN N
B NNP N
( ( N
CAHB NNP N
) ) N
Asian JJ N
patients NNS N
10 CD N
Chinese JJ N
patients NNS N
with IN N
histologically RB N
proven VBN N
CAHB NNP N
and CC N
seven CD N
healthy JJ N
Chinese JJ N
individuals NNS N
. . N

Chinese JJ N
CAHB NNP N
patients NNS N
Caucasian JJ N
patients NNS N
with IN N
CAHB NNP N
-DOCSTART- -X- O O 23512255

extensor NN N
mechanism NN N
power NN N
following VBG N
total JJ 4_p
knee JJ 4_p
arthroplasty NN 4_p
. . N

patients NNS N
by IN N
direct JJ N
physical JJ N
testing NN N
. . N

212 CD 3_p
TKA JJ 4_p
patients NNS N
-DOCSTART- -X- O O 9931687

patients NNS 4_p
with IN 4_p
surgical JJ 4_p
interventions NNS 4_p
and CC 4_p
total JJ 4_p
parenteral JJ 4_p
nutrition NN 4_p
34 CD 3_p
patients NNS N
have VBP N
been VBN N
included VBN N
( ( N
with IN N
glutamine NN 4_p
: : N
n JJ N
= $ N
18 CD 3_p
; : N
without IN 4_p
glutamine NN 4_p
: : N
n JJ N
= NNP N
16 CD 3_p
) ) N
. . N

Patients NNS 4_p
with IN 4_p
glutamine JJ 4_p
substitution NN 4_p
-DOCSTART- -X- O O 6148163

Graves NNP 4_p
' POS 4_p
disease NN 4_p
This DT N
study NN N
was VBD N
carried VBN N
out RP N
on IN N
55 CD 3_p
patients NNS N
, , N
who WP N
were VBD N
either RB N
treated VBN N
for IN N
six CD N
( ( N
n JJ N
= NNP N
16 CD 3_p
) ) N
or CC N
18 CD N
months NNS N
( ( N
n JJ N
= NNP N
39 CD 3_p
) ) N
and CC N
followed VBD N
up RP N
for IN N
an DT N
additional JJ N
two-year JJ N
period NN N
. . N

TSAb NNP N
was VBD N
determined VBN N
on IN N
whole JJ N
serum NN N
in IN N
29 CD 3_p
patients NNS N
before IN N
and CC N
at IN N
the DT N
end NN N
of IN N
treatment NN N
, , N
and CC N
in IN N
26 CD 3_p
patients NNS N
at IN N
the DT N
end NN N
of IN N
treatment NN N
only RB N
. . N

TSAb NNP N
determined VBD N
again RB N
during IN N
follow-up NN N
was VBD N
negative JJ N
in IN N
each DT N
of IN N
the DT N
18 CD 3_p
patients NNS N
in IN N
remission NN N
, , N
and CC N
positive JJ N
in IN N
8/10 CD 3_p
patients NNS N
at IN N
the DT N
time NN N
of IN N
relapse NN N
, , N
whatever WDT N
its PRP$ N
level NN N
at IN N
the DT N
end NN N
of IN N
the DT N
drug NN N
course NN N
. . N

-DOCSTART- -X- O O 12482473

antidepressant VB 4_p
treatment NN 4_p
with IN N
amitritpyline NN 4_p
-DOCSTART- -X- O O 12568856

infertile JJ 4_p
patients NNS N
: : N
One CD 3_p
hundred VBN 3_p
eighty-nine JJ 3_p
infertile JJ 4_p
women NNS 2_p
undergoing VBG N
outpatient JJ N
hysteroscopy NN N
. . N

group NN N
B NNP N
group NN N
A NNP N
. . N

patients NNS N
. . N

-DOCSTART- -X- O O 25252600

Patients NNS N
presenting VBG N
within IN N
6 CD 4_p
h NN 4_p
of IN 4_p
onset NN 4_p
of IN 4_p
STEMI NNP 4_p
and CC 4_p
undergoing JJ 4_p
planned VBN 4_p
primary JJ 4_p
PCI NNP 4_p
( ( 4_p
P-PCI NNP 4_p
) ) 4_p
with IN 4_p
TIMI NNP 4_p
0/1 CD 4_p
flow NN 4_p
in IN 4_p
the DT 4_p
infarct-related JJ 4_p
artery NN 4_p
( ( 4_p
IRA NNP 4_p
) ) 4_p
and CC N
no DT 4_p
significant JJ 4_p
bystander NN 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
on IN 4_p
angiography NN 4_p
, , 4_p
are VBP 4_p
randomised VBN 4_p
into IN 4_p
one CD 4_p
of IN 4_p
three CD 4_p
groups NNS 4_p
: : 4_p
PCI NNP 4_p
with IN 4_p
adjunctive JJ 4_p
pharmacotherapy NN 4_p
( ( 4_p
intracoronary JJ 4_p
adenosine NN 4_p
or CC 4_p
SNP NNP 4_p
) ) 4_p
or CC 4_p
control NN 4_p
( ( 4_p
standard JJ 4_p
PCI NNP 4_p
) ) 4_p
. . N

All DT N
receive VBP N
Bivalirudin NNP 4_p
anticoagulation NN 4_p
and CC N
thrombus JJ 4_p
aspiration NN 4_p
. . N

240 CD 3_p
patients NNS 3_p
( ( N
powered VBN N
at IN N
80 CD N
% NN N
to TO N
detect VB N
a DT N
5 CD N
% NN N
absolute JJ N
reduction NN N
in IN N
IS NNP N
) ) N
. . N

-DOCSTART- -X- O O 22050040

for IN N
moderate JJ N
to TO N
severe VB N
facial JJ N
erythema NN N
of IN N
rosacea NN N
: : N
BACKGROUND NNP N
Erythema NNP 4_p
of IN 4_p
rosacea NN 4_p
In IN N
study NN N
A NNP N
, , N
122 CD 3_p
subjects NNS 3_p
were VBD N
randomized VBN N
to TO N
receive VB N
a DT N
single JJ N
application NN N
of IN N
BT NNP N
0·07 CD N
% NN N
, , N
0·18 CD N
% NN N
, , N
0·5 CD N
% NN N
or CC N
vehicle NN N
. . N

In IN N
study NN N
B NNP N
( ( N
4-week JJ N
treatment NN N
and CC N
4-week JJ N
follow-up NN N
) ) N
, , N
269 CD 3_p
subjects NNS 3_p
treatment NN N
of IN N
moderate JJ N
to TO N
severe VB N
erythema NN N
-DOCSTART- -X- O O 16119805

transurethral JJ N
resection NN N
of IN N
superficial JJ N
bladder NN N
cancer NN N
] NNP N
prophylactic JJ N
intravesical JJ N
instillation NN N
of IN N
pirarubicin NN N
( ( N
THP NNP N
) ) N
prior RB N
to TO N
transurethral JJ N
resection NN N
( ( N
TUR NNP N
) ) N
of IN N
superficial JJ N
bladder NN N
cancer NN N
. . N

63 CD N
patients NNS N
superficial JJ N
bladder NN N
cancer NN N
. . N

-DOCSTART- -X- O O 17322624

patients NNS N
with IN N
symptomatic JJ 4_p
paroxysmal JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
and/or NN 4_p
flutter NN 4_p
monitored VBD N
with IN N
trans-telephonic JJ N
electrocardiography NN N
: : N
patients NNS N
with IN N
paroxysmal JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
or CC 4_p
flutter NN 4_p
( ( 4_p
PAF/PAFL NNP 4_p
) ) 4_p
experiencing VBG N
2 CD N
or CC N
more JJR N
episodes NNS N
of IN N
symptomatic JJ 4_p
PAF/PAFL NNP 4_p
during IN N
a DT N
28-day JJ N
observation NN N
period NN N
to TO N
determine VB N
the DT N
dose-response JJ N
effect NN N
and CC N
safety NN N
of IN N
flecainide NN N
. . N

143 CD 3_p
patients NNS N
at IN N
30 CD N
centers NNS N
123 CD 3_p
patients NNS N
patients NNS N
with IN N
PAF/PAFL NNP 4_p
. . N

-DOCSTART- -X- O O 22273828

children NNS 4_p
: : 4_p
strabismus NN 4_p
surgery NN 4_p
in IN 4_p
children NNS 4_p
. . 4_p

The DT N
operating NN N
theatre NN N
suite NN N
and CC N
day NN N
care NN N
unit NN N
of IN N
Seoul NNP N
National NNP N
University NNP N
Hospital NNP N
. . N

405 CD N
paediatric JJ N
patients NNS N
( ( N
aged VBN N
4-12 CD N
years NNS N
) ) N
undergoing VBG N
strabismus JJ N
surgery NN N
-DOCSTART- -X- O O 9834207

granulocyte JJ N
colony-stimulating JJ N
factor NN N
therapy NN N
after IN N
autologous JJ N
blood NN N
stem NN N
cell NN N
transplantation NN N
in IN N
children NNS 1_p
: : N
Japanese JJ N
Cooperative NNP N
Study NNP N
Group NNP N
of IN N
PBSCT NNP N
. . N

74 CD 3_p
children NNS 1_p
who WP N
were VBD N
scheduled VBN N
to TO N
undergo VB N
high-dose JJ 4_p
chemotherapy NN 4_p
followed VBN N
by IN N
autologous JJ 4_p
peripheral JJ 4_p
blood NN 4_p
stem NN 4_p
cell NN 4_p
transplantation NN 4_p
( ( 4_p
PBSCT NNP 4_p
) ) 4_p
The DT N
diagnosis NN N
included VBD N
acute JJ 4_p
lymphoblastic JJ 4_p
leukemia NN 4_p
( ( N
ALL DT N
) ) N
( ( N
n JJ N
= NNP N
27 CD 3_p
) ) N
, , N
neuroblastoma FW 4_p
( ( N
n JJ N
= NNP N
29 CD 3_p
) ) N
, , N
and CC N
miscellaneous JJ 4_p
solid JJ 4_p
tumors NNS 4_p
( ( N
n JJ N
= NNP N
18 CD 3_p
) ) N
. . N

Eligibility NNP N
criteria NNS N
included VBD N
( ( N
1 CD N
) ) N
primary NN 4_p
PBSCT NNP 4_p
, , N
( ( N
2 CD N
) ) N
chemotherapy-responsive JJ 4_p
disease NN 4_p
, , N
and CC N
( ( N
3 CD N
) ) N
collected VBN 4_p
cell NN 4_p
number NN 4_p
> $ 4_p
1 CD 4_p
x $ 4_p
10 CD 4_p
( ( 4_p
5 CD 4_p
) ) 4_p
colony-forming NN 4_p
unit-granulocyte-macrophage JJ 4_p
( ( 4_p
CFU-GM NNP 4_p
) ) 4_p
/kg NN 4_p
and CC 4_p
> $ 4_p
1 CD 4_p
x $ 4_p
10 CD 4_p
( ( 4_p
6 CD 4_p
) ) 4_p
CD34 NNP 4_p
( ( 4_p
+ NNP 4_p
) ) 4_p
cells/kg VBP 4_p
patient NN N
's POS N
body NN N
weight NN N
. . N

11 CD 3_p
patients NNS N
were VBD N
excluded VBN N
due JJ N
to TO N
disease VB N
progression NN N
before IN N
PBSCT NNP 4_p
( ( N
n JJ N
= NNP N
6 CD 3_p
) ) N
or CC N
a DT N
low JJ N
number NN N
of IN N
harvested JJ N
cells NNS N
( ( N
n JJ N
= NNP N
5 CD N
) ) 3_p
, , N
leaving VBG N
63 CD 3_p
patients NNS N
for IN N
analysis NN N
; : N
32 CD 3_p
patients NNS N
Five CD 3_p
patients NNS N
( ( N
two CD 3_p
in IN N
the DT N
treatment NN N
group NN N
and CC N
three CD 3_p
in IN N
the DT N
control NN N
group NN N
) ) N
were VBD N
subsequently RB N
removed VBN N
due JJ N
to TO N
protocol VB N
violations NNS N
. . N

PBSCT NNP N
. . N

G-CSF NNP N
therapy NN N
in IN N
children NNS 1_p
undergoing VBG N
PBSCT NNP 4_p
-DOCSTART- -X- O O 17113685

299 CD N
older JJR N
men NNS N
-DOCSTART- -X- O O 6365881

multi-centre JJ N
studies NNS N
. . N

West NNP N
Germany NNP N
and CC N
involving VBG N
80 CD 3_p
patients NNS N
serious JJ 4_p
systemic JJ 4_p
infections NNS 4_p
. . N

large JJ N
collaborative NN N
study NN N
involving VBG N
15 CD N
centres NNS N
, , N
254 CD 3_p
patients NNS N
were VBD N
enrolled VBN N
. . N

-DOCSTART- -X- O O 23102530

End-expiratory JJ 4_p
lung NN 4_p
volume NN 4_p
20 CD 3_p
patients NNS 3_p
postcardiac JJ 3_p
surgery NN 3_p
. . N

-DOCSTART- -X- O O 16437191

osteoporosis NN 4_p
multi-center JJ N
Consecutive JJ N
post-menopausal JJ N
women NNS N
aged VBN 1_p
50 CD 1_p
years NNS 1_p
to TO 1_p
86 CD 1_p
years NNS 1_p
starting VBG N
treatment NN N
with IN N
raloxifene NN N
according VBG N
to TO N
daily JJ N
practice NN N
were VBD N
enrolled VBN N
from IN N
126 CD N
primary JJ N
care NN N
offices NNS N
in IN N
Spain NNP N
. . N

women NNS 2_p
A DT N
total NN N
of IN N
745 CD 3_p
post-menopausal JJ N
women NNS N
( ( N
group NN N
A NNP N
, , N
n=366 RB 3_p
; : N
group NN N
B NNP N
n=379 NN N
) ) N
, , N
with IN N
a DT N
mean JJ 1_p
age NN 1_p
of IN 1_p
62 CD 1_p
years NNS 1_p
young JJ N
post-menopausal JJ 4_p
women NNS N
suffering VBG N
osteoporosis NN N
-DOCSTART- -X- O O 22537359

autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . 4_p

in IN N
brains NNS N
of IN N
patients NNS N
with IN N
autism NN N
exploration NN N
. . N

Twenty NNP N
children NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
age NN N
4-12 CD N
years NNS N
RESULTS NNP N
Eighteen JJ N
participants NNS N
( ( N
10 CD N
mecamylamine NN N
, , N
8 CD N
placebo NN N
) ) N
completed VBD N
the DT N
study NN N
-DOCSTART- -X- O O 19155155

gastric JJ 4_p
cancer NN 4_p
patients NNS N
: : N
cancer NN 4_p
patients NNS N
gastric JJ N
cancer NN N
patients NNS N
. . N

121 CD 3_p
gastric JJ 4_p
cancer NN 4_p
patients NNS N
attending VBG N
inpatient JJ N
rehabilitation NN N
after IN N
surgical JJ N
treatment NN N
-DOCSTART- -X- O O 24490842

the DT N
athlete NN N
. . N

A DT N
total NN N
of IN N
97 CD 3_p
college-aged JJ 1_p
students NNS 1_p
( ( 1_p
age NN 1_p
= VBZ 1_p
20.65 CD 1_p
± JJ 1_p
4.38 CD 1_p
years NNS 1_p
) ) 1_p
, , N
most JJS N
with IN N
little JJ N
to TO N
no DT N
experience NN N
with IN N
psychological JJ 4_p
strategies NNS 4_p
. . N

-DOCSTART- -X- O O 23349254

rowers NNS 4_p
. . 4_p

rowers NNS 4_p
subjected VBN 4_p
to TO 4_p
exhaustive VB 4_p
exercise NN 4_p
. . 4_p

study NN N
included VBD N
18 CD N
members NNS N
of IN N
the DT N
Polish JJ N
Rowing NNP N
Team NNP N
. . N

-DOCSTART- -X- O O 12358871

general JJ 4_p
practitioners NNS 4_p
( ( 4_p
GPs NNP 4_p
) ) 4_p
for IN 4_p
patients NNS 4_p
with IN 4_p
diabetes NNS 4_p
. . N

Cluster NNP N
randomized VBD N
controlled VBN N
trial NN N
with IN N
124 CD 3_p
practices NNS 3_p
and CC N
185 CD 3_p
GPs NNP N
in IN N
The DT N
Netherlands NNP N
. . N

1410 CD 3_p
consultations NNS N
with IN N
Type NNP 4_p
2 CD 4_p
diabetic JJ 4_p
patients NNS 4_p
at IN N
baseline NN N
and CC N
1449 CD N
consultations NNS N
-DOCSTART- -X- O O 9322152

FK NNP N
506- JJ N
versus NN N
cyclosporine NN N
A-treated JJ N
heart NN 4_p
transplant NN 4_p
recipients NNS 4_p
: : N
-DOCSTART- -X- O O 18855271

hypertensive JJ 4_p
patients NNS 4_p
with IN 4_p
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
. . N

hypertensive JJ 4_p
type-2 JJ 4_p
diabetic JJ 4_p
patients NNS N
hypertensive JJ 4_p
type-2 JJ 4_p
diabetic JJ 4_p
patients NNS N
. . N

Forty NNP 3_p
type-2 JJ 4_p
diabetic JJ 4_p
patients NNS N
with IN N
never-treated JJ N
hypertension NN 4_p
-DOCSTART- -X- O O 10091821

patients NNS N
with IN N
left JJ 4_p
ventricular JJ 4_p
dysfunction NN 4_p
. . N

patients NNS N
with IN N
left JJ N
ventricular JJ N
dysfunction NN N
. . N

patients NNS N
with IN N
left JJ N
ventricular JJ N
dysfunction NN N
. . N

6,781 CD 3_p
patients NNS N
randomized VBN N
into IN N
the DT N
Studies NNPS N
of IN N
Left NNP N
Ventricular NNP N
Dysfunction NNP N
trials NNS N
. . N

-DOCSTART- -X- O O 23623047

patients NNS N
with IN N
stable JJ 4_p
angina JJ 4_p
pectoris NN 4_p
. . N

One CD 3_p
hundred VBD 3_p
hypertensive JJ 4_p
patients NNS N
with IN N
stable JJ 4_p
angina NNS 4_p
pectoris NNS 4_p
who WP N
underwent VBP N
elective JJ N
percutaneous JJ N
coronary JJ N
intervention NN N
volume NN N
in IN N
patients NNS N
with IN N
stable JJ N
angina NNS N
pectoris NN N
-DOCSTART- -X- O O 15534261

cognition NN N
in IN N
the DT N
elderly JJ N
: : N
Participants NNS N
in IN N
the DT N
Age-Related JJ N
Eye NNP N
Disease NNP N
Study NNP N
2,166 CD N
elderly JJ N
persons NNS N
after IN N
a DT N
median NN N
of IN N
6.9 CD N
years NNS N
of IN N
treatment NN N
. . N

-DOCSTART- -X- O O 17331650

second-degree JJ 4_p
burns NNS 4_p
. . N

burn NN 4_p
patients NNS 4_p
second-degree JJ 4_p
burn NN 4_p
wounds NNS 4_p
. . N

Seventy-two JJ 3_p
cases NNS N
of IN N
patients NNS N
with IN N
acute JJ 4_p
second-degree JJ 4_p
burns NNS 4_p
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

patients NNS N
with IN N
less JJR N
than IN N
30 CD N
% NN N
TBSA NNP N
covered VBD N
with IN N
xenogenic JJ N
acellular JJ N
dermal NN N
matrix NN N
. . N

patients NNS N
with IN N
less JJR N
than IN N
30 CD N
% NN N
TBSA NNP N
covered VBD N
with IN N
betadine JJ N
ointment NN N
gauzes NNS N
. . N

patients NNS N
with IN N
more JJR N
than IN N
30 CD N
% NN N
TBSA NNP N
covered VBD N
with IN N
porcine JJ N
acellular JJ N
dermal NN N
matrix NN N
. . N

patients NNS N
with IN N
more JJR N
than IN N
30 CD N
% NN N
TBSA NNP N
covered VBD N
with IN N
betadine JJ N
ointment NN N
gauzes NNS N
. . N

second-degree JJ 4_p
burn NN 4_p
wound NN 4_p
-DOCSTART- -X- O O 12505733

apical JJ N
defibrillation NN N
paddle NN N
of IN N
importance NN N
Twenty NNP N
sequential NN N
anaesthetised VBD N
patients NNS N
-DOCSTART- -X- O O 15916851

acute JJ 4_p
stroke NN 4_p
patients NNS N
. . N

acute JJ 4_p
atherosclerotic JJ 4_p
ischemic JJ 4_p
stroke NN 4_p
patients NNS N
60 CD 3_p
acute JJ N
atherosclerotic JJ N
stroke NN 4_p
patients NNS N
and CC N
matched VBN N
control NN N
subjects NNS N
. . N

All DT N
patients NNS N
were VBD N
examined VBN N
within IN N
72 CD N
h NN N
after IN N
stroke NN 4_p
onset NN N
. . N

patients NNS N
with IN N
acute JJ N
atherosclerotic JJ N
ischemic JJ N
stroke NN 4_p
. . N

-DOCSTART- -X- O O 20356587

hyperinsulinemic JJ N
women NNS 2_p
with IN N
polycystic JJ 4_p
ovary JJ 4_p
syndrome NN 4_p
. . N

PCOS NNP 4_p
women NNS N
29 CD 3_p
women NNS 2_p
PCOS NNP N
women NNS 2_p
PCOS NNP 4_p
patients NNS N
-DOCSTART- -X- O O 9058626

primary JJ 4_p
biliary JJ 4_p
cirrhosis NN 4_p
: : 4_p
Twenty-four JJ 3_p
patients NNS N
with IN N
primary JJ N
biliary JJ N
cirrhosis NN N
and CC N
17 CD N
healthy JJ N
subjects NNS N
were VBD N
studied VBN N
. . N

Primary JJ N
biliary JJ N
cirrhosis NN N
patients NNS N
primary JJ 4_p
biliary JJ 4_p
cirrhosis NN 4_p
patients NNS N
healthy JJ 4_p
subjects NNS 4_p
-DOCSTART- -X- O O 20109864

ventricular JJ 4_p
tachycardia NN 4_p
before IN N
defibrillator NN 4_p
implantation NN 4_p
in IN N
patients NNS N
with IN N
coronary JJ 4_p
heart NN 4_p
disease NN 4_p
( ( 4_p
VTACH NNP 4_p
) ) 4_p
: : N
patients NNS N
with IN N
ventricular JJ 4_p
tachycardia NN 4_p
( ( 4_p
VT NNP 4_p
) ) 4_p
and CC N
a DT N
history NN N
of IN N
myocardial JJ 4_p
infarction NN 4_p
The DT N
Ventricular NNP 4_p
Tachycardia NNP 4_p
Ablation NNP 4_p
in IN 4_p
Coronary NNP 4_p
Heart NNP 4_p
Disease NNP 4_p
( ( 4_p
VTACH NNP 4_p
) ) 4_p
study NN N
was VBD N
a DT N
prospective JJ N
, , N
open JJ N
, , N
randomised VBD N
controlled VBN N
trial NN N
, , N
undertaken VBN N
in IN N
16 CD N
centres NNS N
in IN N
four CD N
European JJ N
countries NNS N
. . N

Patients NNS N
aged VBN N
18-80 CD 1_p
years NNS 1_p
were VBD N
eligible JJ N
for IN N
enrolment NN N
if IN N
they PRP N
had VBD N
stable JJ 4_p
VT NNP 4_p
, , N
previous JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
, , N
and CC N
reduced VBD 4_p
left-ventricular JJ 4_p
ejection NN 4_p
fraction NN 4_p
( ( 4_p
LVEF NNP 4_p
; : 4_p
< NNP 4_p
or=50 IN 4_p
% NN 4_p
) ) 4_p
. . N

110 CD 3_p
patients NNS N
were VBD N
randomly RB N
allocated VBN N
in IN N
a DT N
1:1 CD N
ratio NN N
107 CD 3_p
patients NNS N
were VBD N
included VBN N
in IN N
the DT N
ITT NNP N
population NN N
( ( N
ablation NN N
group NN N
, , N
n=52 RB N
; : N
control NN N
group NN N
, , N
n=55 RB N
) ) N
. . N

Nine JJ 3_p
patients NNS N
died VBD N
during IN N
the DT N
study NN N
( ( N
ablation NN N
group NN N
, , N
five CD N
; : N
control NN N
group NN N
, , N
four CD N
) ) N
. . N

patients NNS N
with IN N
stable JJ 4_p
VT NNP 4_p
, , N
previous JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
, , N
and CC N
reduced VBD 4_p
LVEF NNP 4_p
. . N

-DOCSTART- -X- O O 24447434

postmenopausal NN 4_p
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
with IN 4_p
previous JJ 4_p
exposure NN 4_p
to TO 4_p
endocrine VB 4_p
therapy NN 4_p
primary JJ 4_p
tumor NN 4_p
tissue NN 4_p
from IN N
patients NNS N
who WP N
participated VBD N
in IN N
a DT N
randomized JJ N
trial NN N
of IN N
adjuvant JJ N
tamoxifen NN N
( ( N
1-3 CD N
years NNS N
) ) N
versus NN N
observation NN N
. . N

CONCLUSIONS JJ N
Patients NNPS N
whose WP$ N
tumor NN 4_p
expresses VBZ N
p-p70S6K JJ N
, , N
as IN N
a DT N
marker NN N
of IN N
downstream NN N
PI3K NNP N
and/or NN N
MAPK NNP N
pathway NN N
activation NN N
-DOCSTART- -X- O O 22982948

participants NNS N
performed VBD N
a DT N
self-timed JJ N
30 CD N
minute NN N
brisk NN 4_p
walk VBP 4_p
in IN N
two CD N
different JJ N
environments NNS N
, , N
park NN N
and CC N
urban JJ N
sample NN N
of IN N
40 CD 3_p
healthy JJ 4_p
adults NNS 1_p
was VBD N
recruited VBN N
: : N
16 CD 2_p
males NNS 2_p
, , N
24 CD 2_p
females NNS 2_p
, , N
mean JJ 1_p
age NN 1_p
22.9 CD 1_p
( ( 1_p
5.5 CD 1_p
) ) 1_p
years NNS 1_p
steps/min NN N
. . N

Participants NNS N
-DOCSTART- -X- O O 23257173

non-hyperlipidaemic JJ 4_p
primary JJ 4_p
hypertension NN 4_p
. . N

hypercholesterolaemic JJ 4_p
hypertensive JJ 4_p
subjects NNS N
hypertensive JJ 4_p
subjects NNS N
with IN N
lower JJR 4_p
plasma NN 4_p
cholesterol NN 4_p
Fourteen JJ N
non-hyperlipidaemic JJ N
primary JJ N
hypertensive JJ N
subjects NNS N
( ( N
10 CD 2_p
men NNS 2_p
; : N
overall JJ N
mean±SD NN 1_p
age NN 1_p
58±12 CD 1_p
years NNS 1_p
) ) N
that IN N
, , N
in IN N
non-hyperlipidaemic JJ N
subjects NNS N
with IN N
primary JJ N
hypertension NN N
-DOCSTART- -X- O O 9917050

bradycardia NN 4_p
and CC N
emetic JJ 4_p
symptoms NNS 4_p
in IN N
otoplasty NN N
. . N

Fifty NNP 3_p
otoplasty JJ 4_p
patients NNS N
were VBD N
studied VBN N
; : N
-DOCSTART- -X- O O 24286965

acute JJ 4_p
coronary JJ 4_p
syndrome NN 4_p
. . N

Diabetes NNP 4_p
mellitus NN 4_p
cardiovascular JJ 4_p
disease NN 4_p
. . 4_p

hospitalized JJ 4_p
patients NNS 4_p
with IN 4_p
acute JJ 4_p
coronary JJ 4_p
syndrome NN 4_p
16 CD 3_p
patients NNS N
with IN N
acute JJ 4_p
coronary JJ 4_p
artery NN 4_p
syndrome NN 4_p
, , N
a DT N
capillary JJ N
or CC N
venous JJ N
blood NN N
glucose NN N
≥ VBD N
140 CD N
mg/dl NN N
, , N
and CC N
treatment NN N
with IN N
a DT N
continuous JJ N
infusion NN N
of IN N
fast JJ N
acting VBG N
human JJ N
insulin NN N
-DOCSTART- -X- O O 23547660

COPD NNP N
patients NNS N
. . N

study NN N
. . N

Participants NNS N
can MD N
use VB N
any DT N
background NN N
treatment NN N
for IN N
COPD NNP N
except IN N
inhaled JJ N
anticholinergic JJ N
agents NNS N
. . N

The DT N
study NN N
encompasses VBZ N
a DT N
wide JJ N
range NN N
of IN N
COPD NNP N
patients NNS N
, , N
e.g FW N
. . N

patients NNS N
with IN N
stable JJ N
cardiac JJ N
diseases NNS N
including VBG N
arrhythmia NN N
can MD N
be VB N
included VBN N
. . N

Clinical JJ N
sites NNS N
are VBP N
international JJ N
and CC N
include VBP N
both DT N
primary JJ N
care NN N
as RB N
well RB N
as IN N
specialists NNS N
RESULTS NNP N
To TO N
date NN N
, , N
over IN N
17,000 CD N
participants NNS N
have VBP N
been VBN N
randomized VBN N
from IN N
over IN N
1200 CD N
sites NNS N
in IN N
50 CD N
countries NNS N
-DOCSTART- -X- O O 43164

A DT 4_p
double-blind JJ 4_p
crossover NN 4_p
comparison NN 4_p
of IN 4_p
pindolol NN 4_p
, , 4_p
metoprolol NN 4_p
, , 4_p
atenolol NN 4_p
and CC 4_p
labetalol NN 4_p
in IN 4_p
mild NN 4_p
to TO 4_p
moderate VB 4_p
hypertension NN 4_p
. . 4_p

-DOCSTART- -X- O O 1370735

orthotopic NN 4_p
liver NN 4_p
transplantation NN 4_p
. . 4_p

orthotopic JJ N
liver NN N
transplantation NN N
From IN N
November NNP N
1989 CD N
to TO N
June NNP N
1990 CD N
, , N
13 CD 3_p
patients NNS N
23 CD 3_p
patients NNS N
-DOCSTART- -X- O O 9172668

treatment NN N
course NN N
of IN N
avascular JJ 4_p
femur NNS 4_p
head VBP 4_p
necrosis NN 4_p
after IN N
femoral JJ 4_p
core NN 4_p
decompression NN 4_p
] NNP N
. . N

vascular JJ 4_p
femoral JJ 4_p
head NN 4_p
necrosis NN 4_p
is VBZ N
a DT N
serious JJ N
illness NN N
, , N
especially RB N
when WRB N
appearing VBG N
in IN N
patients NNS N
aged VBD N
30 CD 1_p
to TO 1_p
50 CD 1_p
years NNS 1_p
. . N

high-dose JJ N
steroids NNS N
, , N
abuse NN N
of IN N
alcohol NN N
, , N
defect NN 4_p
of IN 4_p
bone NN 4_p
marrow NN 4_p
and CC N
trauma NN 4_p
of IN 4_p
the DT 4_p
hip NN 4_p
. . N

between IN N
the DT N
curable JJ N
stage NN N
IIc NNP N
and CC N
the DT N
stage NN N
III NNP N
, , N
showing VBG N
the DT N
beginning NN N
of IN N
breakdown NN 4_p
of IN 4_p
the DT 4_p
femoral JJ 4_p
head NN 4_p
. . N

-DOCSTART- -X- O O 14519754

nonmelanoma JJ 4_p
skin NN 4_p
cancer NN 4_p
Nutritional JJ N
Prevention NN N
of IN N
Cancer NNP N
Trial NNP N
was VBD N
a DT N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
prevent VB N
nonmelanoma JJ 4_p
skin JJ 4_p
cancer NN 4_p
among IN N
1312 CD 3_p
patients NNS N
from IN N
the DT N
Eastern NNP 4_p
United NNP 4_p
States NNPS 4_p
who WP N
had VBD N
previously RB 4_p
had VBN 4_p
this DT 4_p
disease NN 4_p
. . N

-DOCSTART- -X- O O 22402015

auditory JJ N
processing NN N
disorders NNS N
( ( N
APD NNP N
) ) N
listeners NNS N
with IN N
APD NNP N
. . N

normal-hearing JJ N
participants NNS N
of IN N
varying VBG N
ages NNS N
33 CD N
adults NNS N
and CC N
30 CD N
children NNS N
( ( N
aged VBN N
8-11 CD N
years NNS N
) ) N
with IN N
no DT N
known JJ N
history NN N
of IN N
listening VBG N
difficulties NNS N
Adult NN N
participants NNS N
child NN N
participants NNS N
. . N

-DOCSTART- -X- O O 12951131

individuals NNS N
with IN N
autism NN 4_p
and CC N
other JJ N
developmental JJ N
disabilities NNS N
. . N

individuals NNS 4_p
with IN 4_p
developmental JJ 4_p
disabilities NNS 4_p
persons NNS 4_p
with IN 4_p
developmental JJ 4_p
disabilities NNS 4_p
. . 4_p

-DOCSTART- -X- O O 22712208

[ NNP N
Medical NNP 4_p
safety NN 4_p
and CC N
staff NN N
mental JJ N
health NN N
] NNP N
nurses NNS 4_p
with IN 4_p
rapidly RB 4_p
rotating VBG 4_p
shifts NNS 4_p
. . N

night-shift JJ 4_p
workers NNS 4_p
. . N

-DOCSTART- -X- O O 10992834

neuromuscular JJ 4_p
block NN 4_p
at IN 4_p
the DT 4_p
laryngeal NN 4_p
muscles NNS 4_p
surface NN 4_p
laryngeal NN 4_p
electromyography NN 4_p
neuromuscular JJ N
block NN N
neuromuscular JJ N
block NN N
neuromuscular JJ N
block NN N
at IN N
the DT N
larynx NN N
. . N

-DOCSTART- -X- O O 26485385

Patients NNS 4_p
Undergoing VBG 4_p
Surgical JJ 4_p
Removal NNP 4_p
of IN 4_p
an DT 4_p
Odontogenic NNP 4_p
Maxillary NNP 4_p
Cyst NNP 4_p
. . N

the DT 4_p
first JJ 4_p
24 CD 4_p
hours NNS 4_p
after IN 4_p
odontogenic JJ 4_p
maxillary JJ 4_p
cyst NN 4_p
removal NN 4_p
under IN 4_p
general JJ 4_p
anesthesia NN 4_p
patients NNS 4_p
scheduled VBN 4_p
for IN 4_p
surgical JJ 4_p
removal NN 4_p
of IN 4_p
an DT 4_p
odontogenic JJ 4_p
maxillary JJ 4_p
cyst NN 4_p
under IN 4_p
general JJ 4_p
anesthesia NN 4_p
48 CD 3_p
eligible JJ 3_p
patients NNS 3_p
-DOCSTART- -X- O O 12151468

children NNS 1_p
with IN N
autism NN 4_p
and CC N
serious JJ N
behavioral JJ 4_p
problems NNS 4_p
. . 4_p

treatment NN N
of IN N
autistic JJ 4_p
disorder NN 4_p
accompanied VBN N
by IN N
severe JJ N
tantrums NNS N
, , N
aggression NN N
, , N
or CC N
self-injurious JJ N
behavior NN N
in IN N
children NNS 1_p
5 CD N
to TO N
17 CD N
years NNS N
old JJ N
. . N

A DT N
total NN N
of IN N
101 CD 3_p
children NNS N
( ( N
82 CD 3_p
boys NNS N
and CC N
19 CD 3_p
girls NNS N
; : N
mean VB N
[ IN N
+/-SD JJ N
] NNP N
age NN N
, , N
8.8+/-2.7 CD N
years NNS N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
risperidone NN N
( ( N
49 CD 3_p
children NNS N
) ) N
or CC N
placebo NN N
( ( N
52 CD N
) ) N
children NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
. . N

-DOCSTART- -X- O O 6516935

junior JJ N
high JJ N
school NN N
students NNS N
. . N

Fifty-nine JJ 3_p
junior JJ N
high JJ N
school NN N
students NNS N
who WP N
volunteered VBD N
to TO N
participate VB N
in IN N
treatment NN N
for IN N
interpersonal JJ N
anxiety NN 4_p
( ( N
RET NNP N
) ) N
, , N
rational-emotive JJ N
therapy NN N
with IN N
imagery NN N
( ( N
REI NNP N
) ) N
, , N
relationship-oriented JJ N
counseling NN N
( ( N
ROC NNP N
) ) N
, , N
and CC N
waiting-list JJ N
control NN N
( ( N
WLC NNP N
) ) N
groups NNS N
. . N

-DOCSTART- -X- O O 7956629

patients NNS N
with IN N
type NN 4_p
I PRP 4_p
diabetes VBZ 4_p
. . N

10 CD 3_p
adult NN 1_p
type NN 4_p
I PRP 4_p
diabetic JJ 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 20730486

4,724 CD 3_p
patients NNS N
took VBD N
part NN N
in IN N
IES NNP N
, , N
and CC N
206 CD 3_p
patients NNS N
were VBD N
included VBN N
in IN N
a DT N
bone NN N
sub-study NN N
. . N

-DOCSTART- -X- O O 1849786

patients NNS 4_p
with IN 4_p
extensive JJ 4_p
non-small NN 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
. . 4_p

87 CD 3_p
patients NNS 4_p
with IN 4_p
inoperable JJ 4_p
, , 4_p
extensive JJ 4_p
non-small NN 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
( ( 4_p
NSCLC NNP 4_p
) ) 4_p
-DOCSTART- -X- O O 12426230

septic JJ 4_p
shock NN 4_p
: : 4_p
adrenal JJ 4_p
insufficiency NN 4_p
in IN N
septic JJ 4_p
shock NN 4_p
40 CD 3_p
patients NNS N
with IN N
septic JJ 4_p
shock NN 4_p
-DOCSTART- -X- O O 18783079

[ VB 4_p
The DT 4_p
CARESS-in-AMI NNP 4_p
trial NN 4_p
] NN 4_p
-DOCSTART- -X- O O 23827399

patients NNS N
with IN N
previous JJ N
coronary JJ N
artery NN N
bypass NN N
grafting NN N
( ( N
from IN N
the DT N
j-Cypher JJ N
Registry NNP N
) ) N
. . N

patients NNS N
who WP N
had VBD N
previously RB N
undergone JJ N
coronary JJ N
artery NN N
bypass NN N
grafting NN N
( ( N
CABG NNP N
) ) N
in IN N
the DT N
drug-eluting JJ N
stent NN N
era NN N
. . N

12,812 CD N
patients NNS N
who WP N
had VBD N
undergone JJ N
sirolimus-eluting JJ N
stent NN N
implantation NN N
in IN N
the DT N
j-Cypher JJ N
registry NN N
, , N
919 CD N
( ( N
7.2 CD N
% NN N
) ) N
had VBD N
a DT N
history NN N
of IN N
CABG NNP N
and CC N
had VBD N
significantly RB N
higher JJR N
crude JJ N
5-year JJ N
mortality NN N
( ( N
19.9 CD N
% NN N
vs JJ N
14.0 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
in IN N
patients NNS N
with IN N
previous JJ N
CABG NNP N
the DT N
patients NNS N
with IN N
previous JJ N
CABG NNP N
Among IN N
the DT N
patients NNS N
with IN N
previous JJ N
-DOCSTART- -X- O O 22038501

patients NNS N
undergoing VBG N
standard JJ N
versus NN N
extended VBD N
lymphadenectomy NN N
in IN N
radical JJ 4_p
PD NNP 4_p
for IN N
pancreatic JJ 4_p
cancer NN 4_p
March NNP N
2000 CD N
to TO N
May NNP N
2003 CD N
, , N
112 CD 3_p
patients NNS N
with IN N
potentially RB N
curable JJ N
pancreatic JJ 4_p
head NN 4_p
cancer NN 4_p
were VBD N
enrolled VBN N
and CC N
intraoperatively RB N
randomized VBN N
to TO N
a DT N
standard NN N
or CC N
extended JJ N
lymphadenectomy NN N
group NN N
. . N

A DT 3_p
hundred CD 3_p
and CC 3_p
one CD 3_p
eligible JJ N
patients NNS N
were VBD N
analyzed VBN N
. . N

Demographic NNP N
and CC N
histopathological JJ N
characteristics NNS N
of IN N
the DT N
two CD N
groups NNS N
were VBD N
similar JJ N
. . N

patients NNS N
with IN N
resectable JJ 4_p
pancreatic JJ 4_p
head NN 4_p
cancer NN 4_p
-DOCSTART- -X- O O 16733916

136 CD 3_p
postmenopausal JJ 4_p
women NNS 2_p
-DOCSTART- -X- O O 10470636

transurethral JJ N
procedures NNS N
. . N

elderly JJ 1_p
males NNS 2_p
undergoing VBG 4_p
elective JJ 4_p
transurethral JJ 4_p
resection NN 4_p
of IN 4_p
the DT 4_p
prostate NN 4_p
. . N

Teaching NNP N
hospital NN N
. . N

21 CD 3_p
ASA NNP 4_p
physical JJ 4_p
status NN 4_p
I PRP 4_p
, , 4_p
II NNP 4_p
, , 4_p
and CC 4_p
III NNP 4_p
patients NNS 4_p
at IN 1_p
least JJS 1_p
18 CD 1_p
years NNS N
of IN N
age NN N
, , N
undergoing VBG N
transurethral JJ N
surgery NN N
. . N

-DOCSTART- -X- O O 12713767

patients NNS 4_p
with IN 4_p
primary JJ 4_p
hypercholesterolemia NN 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
primary JJ 4_p
hypercholesterolemia NN 4_p
. . 4_p

827 CD N
patients NNS N
with IN N
baseline JJ N
low-density NN N
lipoprotein NN N
cholesterol NN N
( ( N
LDL-C NNP N
) ) N
> NN N
or CC N
=3.36 VB N
mmol/l NN N
( ( N
130 CD N
mg/dl NN N
) ) N
to TO N
< VB N
or CC N
=6.47 VB N
mmol/l NN N
( ( N
250 CD N
mg/dl NN N
) ) N
and CC N
triglycerides VBZ N
< NN N
or CC N
=3.95 VB N
mmol/l NN N
( ( N
350 CD N
mg/dl NN N
) ) N
-DOCSTART- -X- O O 21753062

humans NNS N
. . N

Sixty-one CD 3_p
healthy JJ N
adults NNS 1_p
consumed VBD N
each DT N
of IN N
3 CD N
diets NNS N
for IN N
3 CD N
wk NN N
-DOCSTART- -X- O O 1516345

intravenous JJ 4_p
digital JJ 4_p
subtraction NN 4_p
angiography NN 4_p
for IN N
peripheral JJ 4_p
vascular JJ 4_p
disease NN 4_p
. . N

-DOCSTART- -X- O O 6366124

non-Hodgkin NN 4_p
's POS 4_p
lymphomas NN 4_p
. . N

Between NNP N
July NNP N
1 CD N
, , N
1971 CD N
and CC N
December NNP N
31 CD N
, , N
1978 CD N
, , N
150 CD 3_p
patients NNS N
with IN N
favorable JJ N
subtypes NNS N
of IN N
non-Hodgkin NN 4_p
's POS 4_p
lymphoma NN 4_p
[ NNP N
nodular JJ N
poorly RB N
differentiated VBN N
lymphocytic JJ N
( ( N
NLPD NNP N
) ) N
, , N
nodular JJ N
mixed JJ N
, , N
or CC N
diffuse RB N
well RB N
differentiated VBN N
lymphocytic JJ N
] NNS N
clinical JJ N
trials NNS N
at IN N
Stanford NNP N
University NNP N
. . N

-DOCSTART- -X- O O 12065558

anthracycline-pretreated JJ 4_p
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
breast NN 4_p
cancer NN 4_p
: : N
metastatic JJ N
breast NN N
cancer NN N
anthracycline-pretreated JJ 4_p
patients NNS 4_p
with IN 4_p
MBC NNP 4_p
. . N

women NNS 2_p
with IN N
anthracycline-pretreated JJ 4_p
MBC NNP 4_p
. . N

-DOCSTART- -X- O O 23630033

type JJ N
2 CD N
diabetes NNS N
inadequately RB N
controlled VBN N
on IN N
metformin NN N
monotherapy NN N
. . N

subjects NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
mellitus NN N
who WP N
have VBP N
inadequate JJ N
glycemic NNS N
control NN N
on IN N
metformin NN N
monotherapy NN N
. . N

-DOCSTART- -X- O O 8378411

patients NNS 4_p
with IN 4_p
dementia NN 4_p
and CC 4_p
depression NN 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
dementia NN 4_p
and CC 4_p
mild JJ 4_p
depression NN 4_p
( ( 4_p
DSM-III-R NNP 4_p
290.21 CD 4_p
) ) 4_p
127 CD N
patients NNS N
-DOCSTART- -X- O O 24626980

children NNS 1_p
with IN N
disorders NNS 4_p
of IN 4_p
the DT 4_p
autism NN 4_p
spectrum NN 4_p
. . N

children NNS N
with IN N
Autism NNP N
Spectrum NNP N
Disorders NNP N
21 CD N
children NNS N
with IN N
Autism NNP N
Spectrum NNP 4_p
Disorder NNP N
diagnoses NNS N
-DOCSTART- -X- O O 17624203

Asian JJ 4_p
males NNS 2_p
with IN N
erectile JJ 4_p
dysfunction NN 4_p
and CC N
cardiovascular JJ 4_p
risk NN 4_p
. . N

Asian JJ N
males NNS 2_p
with IN N
erectile JJ 4_p
dysfunction NN 4_p
( ( N
ED NNP 4_p
) ) N
and CC N
one CD N
or CC N
more JJR N
of IN N
the DT N
co-morbidities NNS N
, , N
mild-to-moderate JJ N
hypertension NN 4_p
, , N
dyslipidemia NN 4_p
, , N
and CC N
diabetes NNS 4_p
. . N

One CD 3_p
hundred CD 3_p
and CC 3_p
fifty VB 3_p
five CD 3_p
male JJ 3_p
subjects NNS N
-DOCSTART- -X- O O 18957505

subjects NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
. . N

type NN N
2 CD N
diabetes NNS N
mellitus FW N
( ( N
T2DM NNP N
) ) N
General NNP N
Clinical NNP N
Research NNP N
Centers NNPS N
at IN N
two CD N
University NNP N
Hospitals NNP N
. . N

Forty-one JJ N
subjects NNS N
with IN N
T2DM NNP N
-DOCSTART- -X- O O 21548512

acne JJ 4_p
vulgaris NN 4_p
: : N
moderate JJ 4_p
acne NNS 4_p
vulgaris NNS 4_p
( ( N
240 CD 3_p
patients NNS N
) ) N
in IN N
both DT N
intention-to-treat JJ N
and CC N
per-protocol JJ N
populations NNS N
. . N

moderate JJ 4_p
acne NN 4_p
vulgaris NN 4_p
-DOCSTART- -X- O O 17196973

readers NNS N
with IN N
autism NN 4_p
Individuals NNS N
with IN N
autism NN N
16 CD 4_p
normally RB 4_p
developing VBG 4_p
adolescents NNS N
and CC N
16 CD 4_p
adolescents NNS N
with IN N
autism NN 4_p
readers NNS N
with IN N
autism NN 3_p
-DOCSTART- -X- O O 18541792

optic JJ 4_p
neuritis NN 4_p
: : N
optic JJ 4_p
neuritis NN 4_p
Subjects NNPS N
in IN N
the DT N
Optic NNP N
Neuritis NNP N
Treatment NNP N
Trial NNP N
, , N
who WP N
were VBD N
enrolled VBN N
between IN N
July NNP N
1 CD N
, , N
1988 CD N
, , N
and CC N
June NNP N
30 CD N
, , N
1991 CD N
, , N
were VBD N
followed VBN N
up RP N
prospectively RB N
for IN N
15 CD N
years NNS N
, , N
with IN N
the DT N
final JJ N
examination NN N
in IN N
2006 CD N
. . N

Neurologic NNP N
and CC N
ophthalmologic JJ N
examinations NNS N
at IN N
13 CD N
clinical JJ N
sites NNS N
. . N

Three CD 3_p
hundred VBD 3_p
eighty-nine JJ 3_p
subjects NNS N
with IN N
acute JJ 4_p
optic JJ 4_p
neuritis NN 4_p
. . N

-DOCSTART- -X- O O 12546485

children NNS 4_p
with IN 4_p
intellectual JJ 4_p
disabilities NNS 4_p
. . 4_p

parents NNS 4_p
and CC 4_p
Prelinguistic NNP 4_p
Milieu NNP 4_p
Teaching NNP 4_p
for IN 4_p
the DT 4_p
children NNS 4_p
( ( 4_p
RPMT NNP 4_p
) ) 4_p
. . 4_p

Thirty-nine JJ N
prelinguistic JJ N
toddlers NNS N
with IN N
intellectual JJ N
disabilities NNS N
and CC N
their PRP$ N
primary JJ N
caregivers NNS N
participated VBD N
in IN N
this DT N
study NN N
. . N

-DOCSTART- -X- O O 10807619

patients NNS N
with IN N
moderate JJ 4_p
to TO 4_p
severe VB 4_p
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
: : N
patients NNS N
with IN N
moderate JJ 4_p
to TO 4_p
severe VB 4_p
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
. . N

Eighteen NNP N
UK NNP N
hospitals NNS N
. . N

751 CD N
men NNS 2_p
and CC N
women NNS 2_p
aged VBD 1_p
between IN 1_p
40 CD 1_p
and CC 1_p
75 CD 1_p
years NNS 1_p
with IN N
mean NN N
forced JJ N
expiratory NN N
volume NN N
in IN N
one CD N
second NN N
( ( N
FEV NNP N
( ( N
1 CD N
) ) N
) ) N
50 CD N
% NN N
of IN N
predicted VBN N
normal JJ N
. . N

patients NNS N
with IN N
moderate JJ 4_p
to TO 4_p
severe VB 4_p
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
. . N

-DOCSTART- -X- O O 20608027

patients NNS N
with IN N
chronic JJ 4_p
heart NN 4_p
failure NN 4_p
] NNP N
patients NNS N
with IN N
chronic JJ 4_p
heart NN 4_p
failure NN 4_p
( ( 4_p
CHF NNP 4_p
) ) 4_p
. . N

52 CD 3_p
male JJ 2_p
patients NNS N
with IN N
postinfarction NN N
cardiosclerosis NN N
( ( N
PICS NNP N
) ) N
who WP N
have VBP N
developed VBN N
CHF NNP 4_p
have VBP N
been VBN N
observed VBN N
. . N

The DT N
age NN N
of IN N
the DT N
patients NNS N
varied VBD N
from IN N
38 CD 1_p
till NN 1_p
60 CD 1_p
. . N

CHF NNP 4_p
patients NNS N
-DOCSTART- -X- O O 19606510

children NNS 1_p
with IN N
autistic JJ 4_p
spectrum NN 4_p
disorders NNS 4_p
. . N

children NNS 1_p
with IN N
Autistic NNP 4_p
Spectrum NNP 4_p
Disorders NNP 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
. . N

Thirty-two JJ 3_p
children NNS 1_p
with IN N
ASD NNP 4_p
treatment NN N
group NN N
control NN N
group NN N
children NNS 1_p
with IN N
ASD NNP 4_p
. . N

-DOCSTART- -X- O O 17207470

children NNS 4_p
with IN 4_p
autistic JJ 4_p
spectrum NN 4_p
disorders NNS 4_p
. . 4_p

parents NNS N
of IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
) ) N
. . N

Data NNP N
from IN N
diet JJ N
diaries NNS N
of IN N
children NNS N
( ( N
3-8 CD N
years NNS N
) ) N
with IN N
ASD NNP N
( ( N
n JJ N
= NNP N
62 CD N
) ) N
were VBD N
analyzed VBN N
children NNS N
-DOCSTART- -X- O O 15131557

Occluded NNP N
Native NNP N
Coronary NNP N
Arteries NNP N
( ( N
PRISON NNP N
) ) N
total JJ N
coronary JJ N
occlusions NNS N
balloon NN N
angioplasty NN N
chronic JJ 4_p
total JJ 4_p
occlusions NNS 4_p
. . N

200 CD 3_p
patients NNS N
were VBD N
enrolled VBN N
. . N

chronic JJ N
total JJ N
occlusions NNS N
-DOCSTART- -X- O O 18303031

advanced JJ 4_p
hepatocellular JJ 4_p
carcinoma NN 4_p
: : 4_p
French JJ N
clinical JJ N
trials NNS N
. . N

Cancer NNP 4_p
of IN 4_p
the DT 4_p
Liver NNP 4_p
Italian JJ 4_p
Program NNP 4_p
( ( 4_p
CLIP NNP 4_p
) ) 4_p
Barcelona NNP 4_p
Clinic NNP 4_p
Liver NNP 4_p
Cancer NNP 4_p
group NN 4_p
( ( 4_p
BCLC NNP 4_p
) ) 4_p
] NN N
patients NNS 4_p
with IN 4_p
hepatocellular JJ 4_p
carcinoma NN 4_p
( ( 4_p
HCC NNP 4_p
) ) 4_p
French JJ N
patients NNS N
with IN N
HCC NNP N
whose WP$ N
main JJ N
etiology NN N
is VBZ N
alcoholic JJ N
cirrhosis NN N
. . N

We PRP 4_p
have VBP 4_p
pooled VBN 4_p
two CD 4_p
randomized JJ 4_p
clinical JJ 4_p
trials NNS 4_p
in IN 4_p
palliative JJ 4_p
condition NN 4_p
from IN 4_p
the DT 4_p
Fédération NNP 4_p
Francophone NNP 4_p
de FW 4_p
Cancerologie NNP 4_p
Digestive NNP 4_p
. . N

They PRP N
had VBD N
included VBN N
416 CD 3_p
and CC 3_p
122 CD 3_p
patients NNS 3_p
included VBD 3_p
538 CD 3_p
patients NNS 3_p
-DOCSTART- -X- O O 18040663

young JJ 1_p
people NNS 1_p
with IN N
type JJ 4_p
1 CD 4_p
diabetes NNS 4_p
. . N

One CD 3_p
hundred CD 3_p
and CC 3_p
twenty-six JJ 3_p
patients NNS 3_p
fulfilled VBD N
the DT N
eligibility NN N
criteria NNS N
( ( N
type NN N
1 CD N
diabetes NNS N
for IN N
> NN N
1 CD N
year NN N
; : N
on IN N
conventional JJ N
insulin NN N
therapy NN N
( ( N
CIT NNP N
) ) N
; : N
aged VBN 1_p
between IN 1_p
8 CD 1_p
and CC 1_p
18 CD 1_p
years NNS 1_p
) ) N
, , N
of IN N
whom WP N
92 CD N
enrolled VBD N
. . N

-DOCSTART- -X- O O 10410152

nausea NN 4_p
, , 4_p
vomiting VBG 4_p
and CC 4_p
appetite JJ 4_p
loss NN 4_p
in IN 4_p
remission NN 4_p
induction NN 4_p
chemotherapy NN 4_p
of IN 4_p
acute JJ 4_p
myeloid NN 4_p
leukemia NN 4_p
-- : 4_p
a DT 4_p
acute JJ 4_p
myeloid NN 4_p
leukemia NN 4_p
granisetron NN N
alone RB N
and CC N
combination NN N
with IN N
granisetron NN N
plus CC N
methylprednisolone NN N
. . N

combination NN N
group NN N
. . N

The DT N
single JJ N
and CC N
combination NN N
groups NNS N
comprised VBD N
14 CD N
and CC N
13 CD N
patients NNS N
, , N
respectively RB N
, , N
and CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
background NN N
of IN N
both DT N
groups NNS N
. . N

-DOCSTART- -X- O O 21083385

persons NNS N
with IN N
cystic JJ N
fibrosis NN N
and CC N
the DT N
G551D-CFTR NNP N
mutation NN N
. . N

39 CD N
adults NNS N
with IN N
cystic JJ N
fibrosis NN N
and CC N
at IN N
least JJS N
one CD N
G551D-CFTR JJ N
allele NN N
treat VB N
cystic JJ N
fibrosis NN N
. . N

-DOCSTART- -X- O O 4077545

pediatric JJ N
asthma NN 4_p
. . N

children NNS 1_p
with IN N
asthma NN 4_p
are VBP N
able JJ N
to TO N
acquire VB N
the DT N
asthma NN 4_p
knowledge NN N
and CC N
skills NNS N
presented VBN N
in IN N
a DT N
self-management JJ N
training NN N
program NN N
conducted VBN N
by IN N
the DT N
American NNP N
Lung NNP N
Association NNP N
of IN N
Utah NNP N
preschool NN 1_p
( ( 1_p
ages VBZ 1_p
2-5 CD 1_p
) ) 1_p
one CD N
or CC N
both DT N
parents NNS 1_p
child NN 1_p
and CC 1_p
parent NN 1_p
( ( 1_p
s NN 1_p
) ) 1_p
. . N

( ( N
ages IN 1_p
6-14 NN 1_p
) ) N
child NN 1_p
and CC 1_p
parent NN 1_p
( ( 1_p
s PRP 1_p
) ) 1_p
Private JJ N
physicians NNS N
referred VBD N
21 CD 3_p
preschool NN 1_p
children NNS 1_p
and CC N
38 CD 1_p
school-age JJ 1_p
children NNS 1_p
into IN N
the DT N
program NN N
. . N

school-age JJ 1_p
children NNS 1_p
preschool NN 1_p
children NNS 1_p
-DOCSTART- -X- O O 8101194

patients NNS N
with IN N
essential JJ 4_p
hypertension NN 4_p
. . N

group NN N
of IN N
16 CD 3_p
essential JJ N
hypertensive JJ N
patients NNS N
. . N

-DOCSTART- -X- O O 16911869

patients NNS N
with IN N
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
. . N

patients NNS N
with IN N
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
( ( 4_p
COPD NNP 4_p
) ) 4_p
. . N

patients NNS N
with IN N
COPD NNP 4_p
. . N

204 CD 3_p
patients NNS N
patients NNS N
with IN N
COPD NNP 4_p
. . N

-DOCSTART- -X- O O 21419391

child JJ 1_p
anxiety NN 4_p
for IN N
children NNS 1_p
from IN N
grades NNS N
4 CD N
to TO N
6 CD N
, , N
using VBG N
random JJ N
assignment NN N
at IN N
the DT N
school-level NN N
children NNS 1_p
with IN N
anxiety NN 4_p
symptoms NNS N
( ( N
N=191 NNP 3_p
, , N
mean JJ N
age=10.1 NN 1_p
) ) N
as IN N
screened VBN N
with IN N
self NN N
, , N
parent NN N
, , N
and CC N
teacher-reports NNS N
; : N
the DT N
second JJ N
study NN N
took VBD N
a DT N
universal JJ N
approach NN N
with IN N
full JJ N
classrooms NNS N
of IN N
children NNS N
participating VBG N
( ( N
N=253 NNP 3_p
, , N
mean JJ N
age=9.8 NN 1_p
) ) N
. . N

of IN N
children NNS N
with IN N
high-anxiety NN N
symptoms NNS N
-DOCSTART- -X- O O 23839319

extracorporeal NN 4_p
shock NN 4_p
wave VBP 4_p
lithotripsy NN 4_p
( ( 4_p
ESWL NNP 4_p
) ) 4_p
. . 4_p

Patients NNPS N
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
. . N

enrolled VBD N
228 CD 3_p
patients NNS N
-DOCSTART- -X- O O 22638779

Patients NNP N
scheduled VBD N
to TO N
undergo VB N
ESD NNP N
for IN N
early JJ 4_p
gastric JJ 4_p
cancer NN 4_p
or CC 4_p
adenoma NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
sedation NN N
with IN N
midazolam NN N
or CC N
propofol NN N
, , N
and CC N
consciousness JJ N
level NN N
was VBD N
evaluated VBN N
by IN N
bispectral JJ N
index NN N
( ( N
BIS NNP N
) ) N
monitoring NN N
. . N

we PRP N
178 CD 3_p
patients NNS N
patients NNS N
after IN N
ESD NNP N
-DOCSTART- -X- O O 12168688

autistic JJ 4_p
syndromes NNS 4_p
. . 4_p

children NNS 1_p
with IN N
autistic JJ 4_p
syndromes NNS 4_p
and CC N
urinary JJ 4_p
peptide NN 4_p
abnormalities NNS 4_p
. . 4_p

diet JJ N
and CC N
control NN N
group NN N
with IN N
10 CD 3_p
children NNS 1_p
in IN N
each DT N
group NN N
participated VBD N
. . N

-DOCSTART- -X- O O 15897822

chronic JJ 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
: : 4_p
chronic JJ 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
( ( 4_p
cLBP NN 4_p
) ) N
. . N

204 CD 3_p
patients NNS N
with IN N
cLBP NNS N
whose WP$ N
Oswestry NNP N
Disability NNP N
Index NNP N
( ( N
ODI NNP N
) ) N
was VBD N
at IN N
least JJS N
16 CD N
% NN N
, , N
102 CD N
were VBD N
randomized VBN N
into IN N
a DT N
combined JJ N
manipulative JJ N
treatment NN N
, , N
exercise NN N
, , N
and CC N
physician JJ N
consultation NN N
group NN N
( ( N
i.e. FW N
a DT N
combination NN N
group NN N
) ) N
, , N
and CC N
102 CD N
to TO N
a DT N
consultation NN N
alone RB N
group NN N
. . N

patients NNS N
with IN N
cLBP NN 4_p
. . N

-DOCSTART- -X- O O 16802487

prolonged JJ 4_p
anaesthesia NN 4_p
for IN N
acoustic JJ 4_p
neuroma NN 4_p
surgery NN 4_p
: : N
33 CD 3_p
patients NNS N
acoustic JJ 4_p
neuroma NN 4_p
surgery NN 4_p
. . N

acoustic JJ 4_p
neuroma NN 4_p
surgery NN N
. . N

-DOCSTART- -X- O O 20164800

patients NNS N
suffering VBG N
from IN N
intractable JJ 4_p
periorbital NN 4_p
pain NN 4_p
after IN N
acute JJ 4_p
angle JJ 4_p
closure NN 4_p
glaucoma NN 4_p
( ( N
AACG NNP N
) ) N
. . N

19 CD 3_p
patients NNS N
suffering VBG N
from IN N
periorbital JJ N
pain NN N
after IN N
an DT N
AACG NNP 4_p
attack NN N
-DOCSTART- -X- O O 5378631

post-rotational JJ 4_p
turning VBG 4_p
sensation NN 4_p
and CC 4_p
nystagmus NN 4_p
. . 4_p

-DOCSTART- -X- O O 14650863

thrombotic JJ 4_p
disorders NNS 4_p
. . 4_p

venous JJ 4_p
thromboembolism NN 4_p
( ( 4_p
VTE NNP 4_p
) ) 4_p
in IN N
the DT N
orthopedic JJ N
surgical JJ N
setting NN N
. . N

acute JJ 4_p
coronary JJ 4_p
syndromes NNS 4_p
-DOCSTART- -X- O O 15196300

glyceryltrinitrate NN 4_p
induced VBN 4_p
migraine NN 4_p
. . N

Twelve CD 3_p
patients NNS N
with IN N
migraine NN 4_p
without IN 4_p
aura NN 4_p
were VBD N
included VBN N
in IN N
a DT N
randomized JJ N
double JJ N
blind NN N
crossover NN N
study NN N
. . N

-DOCSTART- -X- O O 2271374

12 CD 3_p
young JJ 1_p
healthy JJ 4_p
male NN 2_p
volunteers NNS N
. . N

-DOCSTART- -X- O O 6859471

healthy JJ N
volunteers NNS N
. . N

-DOCSTART- -X- O O 9105060

asthma NN 4_p
asthma JJ 4_p
79 CD N
asthma NN 4_p
patients NNS 4_p
requiring VBG N
high JJ N
doses NNS N
( ( N
1,500 CD N
microg/d NN N
or CC N
more JJR N
) ) N
of IN N
inhaled JJ 4_p
beclomethasone NN 4_p
dipropionate NN 4_p
( ( N
BDI NNP N
) ) N
for IN N
clinical JJ N
control NN N
( ( N
duration NN N
of IN N
asthma NN N
, , N
11.0 CD N
+/- JJ N
3.1 CD N
yr NN N
; : N
duration NN N
of IN N
BDI NNP N
treatment NN N
, , N
0.5 CD N
+/- JJ N
0.3 CD N
yr NN N
; : N
FEV1 NNP N
percentage NN N
of IN N
predicted VBN N
, , N
80.7 CD N
+/- JJ N
2.0 CD N
% NN N
) ) N
. . N

asthma JJ 4_p
-DOCSTART- -X- O O 18415946

commercial JJ 4_p
beef NN 4_p
cattle NNS 4_p
at IN 4_p
housing NN 4_p
. . 4_p

commercial JJ N
beef NN N
cattle NNS N
with IN N
three CD N
fluke NNS N
and CC N
worm VB N
combination NN N
products NNS N
with IN N
different JJ N
administration NN N
profiles NNS N
. . N

Young NNP 1_p
beef NN 1_p
cattle NNS 1_p
( ( N
n JJ N
= NNP N
270 CD 3_p
) ) N
weighing VBG N
approximately RB N
400 CD N
kg NNS N
were VBD N
allocated VBN N
to TO N
batches NNS N
of IN N
five CD N
-DOCSTART- -X- O O 18029492

trained JJ N
men NNS N
Trained VBN N
men NNS N
( ( N
n JJ N
= VBZ N
41 CD N
; : N
34 CD N
+/- JJ N
5 CD N
y NN N
; : N
maximum JJ N
oxygen NN N
uptake JJ N
= JJ N
55 CD N
+/- JJ N
7 CD N
mL NN N
x NN N
kg NN N
( ( N
-1 NNP N
) ) N
x VBP N
min NN N
( ( N
-1 NNP N
) ) N
) ) N
from IN N
a DT N
homogenous JJ N
police NN N
Special JJ N
Forces NNS N
unit NN N
inadequate JJ N
mean JJ N
daily JJ N
fruit NN N
and CC N
vegetable JJ N
consumption NN N
( ( N
3.2 CD N
+/- JJ N
1.2 CD N
servings NNS N
) ) N
. . N

group NN N
of IN N
trained JJ N
men NNS N
over IN N
28 CD N
wk NNS N
. . N

-DOCSTART- -X- O O 22923209

Autism NNP 4_p
spectrum JJ 4_p
disorder NN 4_p
children NNS N
with IN N
autism NN N
over IN N
100 CD N
healthy JJ N
adults NNS N
general JJ N
population NN N
. . N

-DOCSTART- -X- O O 3134815

premature JJ 4_p
labor NN 4_p
associated VBN 4_p
with IN 4_p
premature JJ 4_p
rupture NN 4_p
of IN 4_p
the DT 4_p
membranes NNS 4_p
. . N

preterm JJ 4_p
labor NN 4_p
after IN 4_p
membrane JJ 4_p
rupture NN 4_p
. . N

One CD 3_p
hundred VBD 3_p
nine CD 3_p
women NNS 3_p
participated VBD N
over IN N
a DT N
26-month JJ N
interval NN N
. . N

-DOCSTART- -X- O O 11056317

to TO N
prevent VB N
breast NN 4_p
cancer NN 4_p
. . N

Italian JJ 4_p
Tamoxifen NNP 4_p
Prevention NNP 4_p
Study NNP 4_p
. . N

-DOCSTART- -X- O O 8655293

HIV NNP 4_p
seropositive JJ 4_p
subjects NNS N
with IN N
elevated JJ N
TNF NNP N
. . N

HIV-seropositive JJ 4_p
patients NNS N
persons NNS N
with IN N
elevated JJ N
TNF-alpha NNP N
. . N

Six NNP 3_p
HIV-seropositive JJ 4_p
subjects NNS N
with IN N
elevated JJ N
amounts NNS N
of IN N
TNF-alpha NNP N
in IN N
plasma NN N
at IN N
least JJS N
at IN N
two CD N
occasions NNS N
-DOCSTART- -X- O O 11922398

post-hemorrhoidectomy JJ N
status NN N
: : N
chronic JJ N
venous JJ N
insufficiency NN N
. . N

non-surgical JJ N
patients NNS N
with IN N
acute JJ 4_p
uncomplicated JJ 4_p
hemorrhoids NNS 4_p
. . N

post-hemorrhoidectomy JJ 4_p
patients NNS N
. . N

30 CD 3_p
patients NNS N
were VBD N
randomized VBN N
-DOCSTART- -X- O O 25178668

patients NNS 4_p
with IN 4_p
ST NNP 4_p
elevation NN 4_p
acute NN 4_p
myocardial JJ 4_p
infarction NN 4_p
( ( N
MICAMI-TICLO NNP N
trial NN N
) ) N
patients NNS N
with IN N
ACS NNP 4_p
. . N

patients NNS N
presenting VBG N
with IN N
ST-segment JJ N
elevation NN N
myocardial JJ 4_p
infarction NN 4_p
( ( 4_p
STEMI NNP 4_p
) ) 4_p
Ninety-two JJ 3_p
patients NNS N
presenting VBG N
with IN N
STEMI NNP N
Of IN N
the DT N
92 CD 3_p
randomized JJ 3_p
patients NNS 3_p
, , N
70 CD 3_p
patients NNS 3_p
were VBD N
analyzed VBN N
. . N

Mean JJ 1_p
age NN 1_p
of IN 1_p
patients NNS 1_p
was VBD 1_p
58.8±10 CD 1_p
years NNS 1_p
. . N

Patients NNS N
presented VBN N
with IN N
a DT N
mean JJ N
ischemic JJ N
time NN N
of IN N
4.4±2.6 CD N
hours NNS N
loading NN N
in IN N
patients NNS N
presenting VBG N
with IN N
-DOCSTART- -X- O O 384574

patients NNS N
with IN N
hepatic JJ 4_p
metastases NNS 4_p
from IN N
colorectal JJ 4_p
cancer NN 4_p
: : N
74 CD 3_p
patients NNS N
with IN N
hepatic JJ 4_p
metastases NNS 4_p
from IN N
colorectal JJ 4_p
cancer NN 4_p
were VBD N
randomized VBN N
to TO N
either DT N
intra-arterial JJ N
hepatic JJ N
artery NN N
infusion NN N
with IN N
5-fluorouracil JJ N
( ( N
5-FU JJ N
) ) N
or CC N
systemic JJ N
chemotherapy NN N
with IN N
5-FU JJ N
. . N

patients NNS N
with IN N
hepatic JJ N
metastases NNS N
. . N

-DOCSTART- -X- O O 11978262

patients NNS 4_p
with IN 4_p
mild JJ 4_p
or CC 4_p
borderline JJ 4_p
hypertension NN 4_p
: : 4_p
A DT N
total NN N
of IN N
18 CD N
hypertensive JJ N
and CC N
hyperinsulinemic JJ N
( ( N
= JJ N
10 CD N
U/mL NNP N
or CC N
more JJR N
) ) N
men NNS N
and CC N
women NNS N
completed VBD N
the DT N
trial NN N
. . N

patients NNS N
with IN N
hypertension NN N
-DOCSTART- -X- O O 21190079

breast NN 4_p
cancer NN 4_p
patients NNS N
investigated VBD N
a DT N
cohort NN N
of IN N
278 CD 3_p
patients NNS N
from IN N
the DT N
GeparTrio NNP N
trial NN N
-DOCSTART- -X- O O 11318056

isochronous JJ 4_p
tapping NN 4_p
: : N
Isochronous JJ 4_p
serial JJ 4_p
interval NN 4_p
production NN 4_p
( ( 4_p
ISIP NNP 4_p
) ) N
Men NNP 2_p
and CC N
women NNS 2_p
, , N
22-36 JJ 1_p
years NNS 1_p
old JJ N
-DOCSTART- -X- O O 15172423

hypertensive JJ 4_p
patients NNS 4_p
with IN 4_p
left JJ 4_p
ventricular JJ 4_p
hypertrophy NN 4_p
. . 4_p

104 CD N
hypertensive JJ N
patients NNS N
with IN N
left JJ N
ventricular JJ N
hypertrophy NN N
( ( N
LVH NNP N
) ) N
. . N

hypertensive JJ N
patients NNS N
with IN N
LVH NNP N
. . N

-DOCSTART- -X- O O 4623522

nine CD 4_p
normal JJ 4_p
students NNS 4_p
with IN 4_p
and CC 4_p
without IN 4_p
the DT 4_p
anticonvulsant JJ 4_p
drug NN 4_p
phenytoin NN 4_p
. . 4_p

-DOCSTART- -X- O O 24517028

ten JJ 3_p
healthy JJ 4_p
male NN 2_p
volunteers NNS N
-DOCSTART- -X- O O 23688859

female JJ N
undergraduate JJ N
students NNS N
( ( N
n=342 NN N
) ) N
. . N

women NNS N
's POS N
-DOCSTART- -X- O O 1497864

autistic JJ 4_p
behavior NN 4_p
. . 4_p

Eight NNP 1_p
young JJ 1_p
adults NNS 1_p
who WP 1_p
were VBD 1_p
diagnosed VBN 1_p
with IN 1_p
autism NN 1_p
-DOCSTART- -X- O O 23246790

adults NNS 1_p
over IN 1_p
50 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
: : N
Participants NNS N
were VBD N
recruited VBN N
via IN N
direct JJ N
mailing NN N
within IN N
the DT N
participating VBG N
Municipal NNP N
Health NNP N
Council NNP N
regions NNS N
and CC N
randomized VBN N
to TO N
the DT N
printed VBN N
or CC N
Web-based VBN N
intervention NN N
by IN N
their PRP$ N
region NN N
. . N

-DOCSTART- -X- O O 7923916

patients NNS 4_p
with IN 4_p
Alzheimer NNP 4_p
's POS 4_p
disease NN 4_p
. . 4_p

patients NNS N
with IN N
Alzheimer NNP N
's POS N
disease NN N
( ( N
AD NNP N
) ) N
AD NNP N
patients NNS N
as IN N
compared VBN N
to TO N
age-matched JJ N
controls NNS N
. . N

AD NNP N
patients NNS N
AD NNP N
patients NNS N
. . N

AD NNP N
patients NNS N
-DOCSTART- -X- O O 10337657

prostate NN 4_p
cancer NN 4_p
. . N

Italian JJ N
PROSIT NNP N
study NN N
. . N

patients NNS N
with IN N
prostate JJ N
cancer NN N
and CC N
treated VBN N
with IN N
total JJ N
androgen NN N
ablation NN N
either DT N
for IN N
three CD N
or CC N
six CD N
months NNS N
before IN N
RP NNP N
. . N

Between NNP N
January NNP N
1996 CD N
and CC N
February NNP N
1998 CD N
, , N
259 CD N
men NNS N
with IN N
prostate NN N
cancer NN N
underwent JJ N
radical JJ N
retropubic NN N
prostatectomy NN N
and CC N
bilateral JJ N
pelvic JJ N
node NN N
dissection NN N
in IN N
the DT N
26 CD N
centres NNS N
participating VBG N
in IN N
the DT N
Italian JJ N
randomised VBD N
prospective JJ N
PROSIT NNP N
study NN N
. . N

114 CD N
patients NNS N
-DOCSTART- -X- O O 19368937

obese JJ 4_p
patients NNS 4_p
with IN N
chronic JJ 4_p
arthropathy JJ 4_p
] NN N
obese JJ 4_p
patients NNS 4_p
with IN N
an DT N
indication NN N
of IN N
replacement NN 4_p
surgery NN 4_p
for IN 4_p
degenerative JJ 4_p
osteoarthritis NN 4_p
Thirty NNP 3_p
six CD 3_p
patients NNS N
were VBD N
randomized VBN N
Obese JJ 4_p
patients NNS 4_p
with IN N
chronic JJ 4_p
osteoarthritis NN 4_p
-DOCSTART- -X- O O 16904970

inguinal JJ N
herniorrhaphy NN N
. . N

hernia NN N
recurrence NN N
and CC N
complications NNS N
on IN N
PRO NNP N
for IN N
participants NNS N
in IN N
the DT N
Veterans NNP N
Affairs NNPS N
trial NN N
of IN N
Open NNP N
or CC N
Laparoscopic NNP N
Repair NNP N
of IN N
Inguinal NNP N
Hernia NNP N
. . N

1603 CD N
patients NNS N
with IN N
PRO NNP N
data NNS N
, , N
105 CD N
had VBD N
a DT N
recurrence NN N
and CC N
342 CD N
had VBD N
a DT N
complication NN N
at IN N
2 CD N
years NNS N
. . N

-DOCSTART- -X- O O 17244100

Minority NNP 4_p
patients NNS 4_p
with IN 4_p
cancer NN 4_p
minority NN 4_p
patients NNS 4_p
Sixty-seven JJ 3_p
English-speaking NNP N
adult NN 1_p
cancer NN 4_p
outpatients NNS 4_p
, , N
including VBG N
15 CD 3_p
minorities NNS N
, , N
with IN N
moderate JJ N
pain NN N
over IN N
the DT N
prior JJ N
2 CD N
weeks NNS N
minority NN 4_p
patients NNS 4_p
-DOCSTART- -X- O O 12651674

neurosurgical JJ 4_p
patients NNS 4_p
. . N

neurosurgical JJ 4_p
patients NNS 4_p
Thirty NNP 3_p
neurosurgical JJ 4_p
patients NNS 4_p
neurosurgical JJ 4_p
patients NNS 4_p
. . N

-DOCSTART- -X- O O 15319704

restless JJ 4_p
legs JJ 4_p
syndrome NN 4_p
in IN 4_p
patients NNS 4_p
on IN 4_p
chronic JJ 4_p
hemodialysis NN 4_p
: : 4_p
patients NNS N
with IN N
renal JJ 4_p
failure NN 4_p
. . N

11 CD 3_p
patients NNS N
with IN N
RLS NNP N
on IN N
chronic JJ N
hemodialysis NN N
. . N

Eleven NNP N
patients NNS N
( ( N
7 CD 3_p
men NNS 2_p
, , N
4 CD 3_p
women NNS 2_p
) ) N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

The DT N
10 CD 3_p
patients NNS N
who WP 4_p
completed VBD 4_p
the DT 4_p
study NN 4_p
patients NNS N
on IN N
chronic JJ N
hemodialysis NN N
. . N

-DOCSTART- -X- O O 10850381

patients NNS 4_p
receiving VBG 4_p
chemotherapy NN 4_p
. . N

Patients NNS N
with IN N
newly RB 4_p
diagnosed VBN 4_p
small-cell NN 4_p
lung NN 4_p
cancer NN 4_p
( ( 4_p
SCLC NNP 4_p
) ) 4_p
-DOCSTART- -X- O O 25617202

community NN N
health NN N
workers NNS N
countries NNS 4_p
of IN 4_p
middle JJ 4_p
and CC 4_p
low JJ 4_p
income NN 4_p
. . N

province NN 4_p
of IN 4_p
Jujuy NNP 4_p
, , 4_p
Argentina NNP 4_p
, , N
between IN N
July NNP N
1 CD N
, , N
2012 CD N
, , N
and CC N
Dec NNP N
31 CD N
, , N
2012 CD N
. . N

Community NNP N
health NN N
workers NNS N
were VBD N
eligible JJ N
for IN N
the DT N
study NN N
if IN N
they PRP N
scored VBD N
highly RB N
on IN N
a DT N
performance NN N
score NN N
, , N
and CC N
women NNS 2_p
aged VBN 1_p
30 CD 1_p
years NNS 1_p
or CC 1_p
older JJR 1_p
were VBD N
eligible JJ N
for IN N
enrolment NN N
by IN N
the DT N
community NN N
health NN N
worker NN N
. . N

200 CD 3_p
community NN N
health NN N
workers NNS N
were VBD N
randomly RB N
allocated VBN N
in IN N
a DT N
1:1 CD N
ratio NN N
to TO N
either CC N
the DT N
intervention NN N
group NN N
191 CD 3_p
participating VBG N
community NN N
health NN N
workers NNS N
( ( N
94 CD 3_p
in IN N
the DT N
intervention NN N
group NN N
and CC N
97 CD 3_p
in IN N
the DT N
control NN N
group NN N
) ) N
initially RB N
contacted JJ N
7650 CD 3_p
women NNS 2_p
; : N
of IN N
3632 CD 3_p
women NNS 2_p
contacted VBN N
by IN N
community NN N
health NN N
workers NNS N
in IN N
the DT N
intervention NN N
group NN N
, , N
3049 CD 3_p
agreed VBD N
to TO N
participate VB N
; : N
of IN N
4018 CD 3_p
women NNS N
contacted VBN N
by IN N
community NN N
health NN N
workers NNS N
in IN N
the DT N
control NN N
group NN N
, , N
2964 CD 3_p
agreed VBD N
to TO N
participate VB N
. . N

-DOCSTART- -X- O O 3284632

treatment NN 4_p
of IN 4_p
dysthymic JJ 4_p
married JJ N
women NNS 4_p
dysthymic JJ 4_p
women NNS 2_p
-DOCSTART- -X- O O 11876893

patients NNS N
with IN N
ocular JJ 4_p
burns NNS 4_p
] FW N
patients NNS N
with IN N
ocular JJ 4_p
burns NNS 4_p
. . N

Fifty-five JJ 3_p
cases NNS N
of IN N
patients NNS N
with IN N
ocular JJ 4_p
burns NNS 4_p
( ( N
in IN N
88 CD 3_p
eyes NNS N
) ) N
49 CD 3_p
eyes NNS N
were VBD N
transplanted VBN N
patients NNS N
with IN N
ocular JJ 4_p
burns NNS 4_p
. . N

-DOCSTART- -X- O O 19523608

human JJ N
volunteer NN 4_p
trial NN 4_p
304 CD 3_p
men NNS N
aged VBN N
between IN N
16 CD N
and CC N
50 CD N
years NNS N
from IN N
Kolkata NNP N
, , N
India NNP N
. . N

adults NNS N
from IN N
a DT N
cholera NN N
endemic JJ N
region NN N
. . N

-DOCSTART- -X- O O 22834767

diabetes NNS 4_p
. . N

60 CD 3_p
individuals NNS N
with IN N
diabetes NNS 4_p
-DOCSTART- -X- O O 8590792

Hypertension NN 4_p
and CC N
non-insulin-dependent JJ 4_p
diabetes NNS 4_p
. . N

162 CD 3_p
non-insulin-dependent JJ 4_p
diabetic JJ 4_p
hypertensive NN 4_p
patients NNS N
non-insulin-dependent JJ 4_p
diabetic JJ 4_p
patients NNS N
-DOCSTART- -X- O O 1378689

cardiopulmonary JJ 4_p
bypass NN 4_p
post-operative JJ N
placebo-controlled JJ 4_p
study NN N
of IN N
145 CD 3_p
patients NNS N
. . N

patients NNS N
with IN N
severe JJ 4_p
thrombocytopenia NN 4_p
-DOCSTART- -X- O O 19122080

Fifty-six NNP 3_p
consecutive JJ N
patients NNS N
scheduled VBN 4_p
for IN 4_p
knee NN 4_p
arthroscopy NN 4_p
thirty-one JJ 3_p
female NN 2_p
patients NNS 3_p
and CC 3_p
twenty-five JJ 3_p
male NN 2_p
patients NNS 3_p
with IN N
a DT N
combined JJ N
average JJ 1_p
age NN 1_p
of IN 1_p
fifty JJ 1_p
years NNS 1_p
and CC N
an DT N
average JJ N
body NN N
mass NN N
index NN N
of IN N
30.9 CD N
. . N

-DOCSTART- -X- O O 11392343

children NNS N
with IN N
autistic JJ 4_p
disorder NN 4_p
. . N

children NNS N
with IN N
autism NN 4_p
. . N

Thirty-nine JJ 3_p
subjects NNS 3_p
( ( N
intent NN N
to TO N
treat VB N
; : N
5-19 CD N
years NNS N
old JJ N
; : N
IQ NNP N
> NNP N
35 CD N
) ) N
had VBD N
autism NN 4_p
diagnosed VBN 4_p
according VBG 4_p
to TO 4_p
DSM-IV NNP 4_p
and CC 4_p
ICD-10 NNP 4_p
criteria NNS 4_p
using VBG 4_p
the DT 4_p
Autism NNP 4_p
Diagnostic NNP 4_p
Interview-Revised JJ 4_p
and CC 4_p
the DT 4_p
Autism NNP 4_p
Diagnostic NNP 4_p
Observation NNP 4_p
Schedule-Generic NNP 4_p
. . N

children NNS N
with IN N
autistic JJ 4_p
disorder NN 4_p
-DOCSTART- -X- O O 500415

ovarian JJ 4_p
cancer NN 4_p
. . 4_p

-DOCSTART- -X- O O 22847319

pharmacodynamic NN 4_p
( ( 4_p
PD NNP 4_p
) ) 4_p
assay VBP 4_p
forearms NNS 4_p
of IN 4_p
human JJ 4_p
subjects NNS 4_p
-DOCSTART- -X- O O 3539897

bladder NN 4_p
cancer NN 4_p
. . 4_p

morbidity NN 4_p
in IN 4_p
the DT 4_p
bladder NN 4_p
patients NNS N
treated VBN N
with IN N
photons NNS N
-DOCSTART- -X- O O 2663834

autistic JJ 4_p
children NNS 1_p
. . 4_p

autistic JJ N
children NNS N
Forty-five JJ 3_p
children NNS 1_p
, , N
2.02 CD 3_p
to TO 3_p
7.58 CD 3_p
years NNS N
old JJ N
( ( N
M NNP 3_p
= NNP 3_p
4.49 CD 3_p
) ) N
-DOCSTART- -X- O O 24635110

completed VBN 4_p
RT NNP 4_p
in IN 4_p
patients NNS 4_p
with IN 4_p
head NN 4_p
and CC 4_p
neck NN 4_p
cancer NN 4_p
( ( 4_p
HNC NNP 4_p
) ) 4_p
Sixty-six JJ 3_p
consecutive JJ N
patients NNS N
from IN N
two CD N
RT NNP N
clinics NNS N
in IN N
Sweden NNP N
CONCLUSIONS JJ N
Patients NNS 4_p
with IN 4_p
HNC NNP 4_p
undergoing VBG 4_p
high JJ 4_p
dose NN 4_p
-DOCSTART- -X- O O 9006472

nurse JJ 4_p
run NN 4_p
clinics NNS 4_p
for IN 4_p
patients NNS 4_p
with IN 4_p
epilepsy NN 4_p
in IN 4_p
general JJ 4_p
practice NN 4_p
: : 4_p
nurse JJ 4_p
run NN 4_p
epilepsy NN 4_p
clinics NNS 4_p
in IN 4_p
primary JJ 4_p
care NN 4_p
. . 4_p

nurse JJ N
run NN N
clinics NNS N
versus VBP N
" RB N
usual JJ N
care NN N
. . N

" CC N
Six NNP N
general JJ N
practices NNS N
in IN N
the DT N
South NNP N
Thames NNPS N
region NN N
. . N

251 CD 3_p
patients NNS N
aged VBN N
over IN N
15 CD 1_p
years NNS 1_p
who WP N
were VBD N
taking VBG N
anti-epileptic JJ N
drugs NNS N
or CC N
had VBD N
a DT N
diagnosis NN N
of IN N
epilepsy NN 4_p
and CC N
an DT N
attack NN N
in IN N
the DT N
past JJ N
two CD N
years NNS N
who WP N
met VBD N
specified VBN N
inclusion NN N
criteria NNS N
and CC N
had VBD N
responded VBN N
to TO N
a DT N
questionnaire NN N
. . N

127 CD 3_p
patients NNS N
Nurse NNP 4_p
run VBP 4_p
clinics NNS 4_p
for IN 4_p
patients NNS 4_p
with IN 4_p
epilepsy NN 4_p
-DOCSTART- -X- O O 8904679

high-risk JJ 4_p
patients NNS 4_p
undergoing VBG 4_p
open JJ 4_p
heart NN 4_p
surgery NN 4_p
. . N

open-label JJ N
T3 NNP N
was VBD N
administered VBN N
to TO N
68 CD 3_p
high-risk JJ N
patients NNS N
undergoing VBG 4_p
open JJ 4_p
heart NN 4_p
surgery NN 4_p
. . N

patients NNS N
with IN N
high JJ N
estimated VBN N
mortality NN N
undergoing VBG N
open JJ 4_p
heart NN 4_p
surgery NN 4_p
. . N

-DOCSTART- -X- O O 8561059

postmenopausal JJ 4_p
women NNS 2_p
with IN N
and CC N
without IN N
hormone-replacement JJ 4_p
therapy NN 4_p
. . N

postmenopausal JJ 4_p
women NNS 2_p
consuming VBG N
a DT N
fish JJ N
oil NN N
supplement NN N
. . N

Forty-eight JJ 3_p
women NNS 4_p
, , N
equally RB N
divided VBD N
between IN N
women NNS 4_p
using VBG N
and CC N
not RB N
using VBG N
HRT NNP 4_p
-DOCSTART- -X- O O 9512218

Treatment NN N
of IN N
hyperinsulinaemia NN N
in IN N
polycystic JJ N
ovary JJ N
syndrome NN N
? . N
-DOCSTART- -X- O O 1575174

2 CD 4_p
separate JJ 4_p
multicenter NN 4_p
388 CD N
patients NNS N
with IN N
mild JJ N
to TO N
moderate VB N
uncomplicated JJ N
essential JJ N
hypertension NN N
. . N

-DOCSTART- -X- O O 20726258

infants NNS 1_p
after IN N
revaccinated VBN N
hepatitis NN 4_p
B NNP 4_p
vaccine NN N
] NN N
Non-and-low JJ N
response NN N
infants NNS 1_p
born VBN N
in IN N
2004 CD 1_p
2005 CD 1_p
administered VBD N
3 CD N
doses NNS N
of IN N
HepB NNP N
at IN N
0 CD N
, , N
1 CD N
, , N
6 CD N
months NNS N
in IN N
Guangzhou NNP N
, , N
Beijing NNP N
and CC N
Zhejiang NNP N
non-and-low JJ N
response NN N
children NNS N
103 CD 3_p
non-and-low JJ N
response NN N
children NNS 1_p
-DOCSTART- -X- O O 6841763

Type NN 4_p
A DT 4_p
coronary-prone JJ 4_p
behavior NN 4_p
-DOCSTART- -X- O O 3063541

locally RB 4_p
advanced JJ 4_p
prostatic JJ 4_p
cancer NN 4_p
. . 4_p

151 CD 3_p
patients NNS N
with IN N
locally RB N
advanced JJ N
prostatic JJ N
cancer NN N
( ( 4_p
T3-4 NNP 4_p
M0 NNP 4_p
) ) 4_p
, , N
representing VBG 4_p
38 CD 4_p
% NN 4_p
of IN 4_p
the DT 4_p
404 CD 4_p
cancer NN 4_p
patients NNS 4_p
in IN 4_p
a DT 4_p
Finnish JJ 4_p
multicenter NN 4_p
study NN 4_p
-DOCSTART- -X- O O 24293165

persistent JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
patients NNS N
51 CD 3_p
patients NNS N
who WP N
experienced VBD N
the DT N
first JJ N
episode NN N
of IN N
persistent JJ 4_p
AF NNP 4_p
receiving VBG N
amiodarone NN N
( ( N
600 CD N
mg NN N
) ) N
daily RB N
for IN N
4-6 JJ N
weeks NNS N
. . N

control NN N
group NN N
patients NNS N
-DOCSTART- -X- O O 26678641

pericardial JJ 4_p
effusion NN 4_p
after IN N
open-heart JJ 4_p
surgery NN 4_p
: : N
Pericardial NNP 4_p
effusion NN 4_p
( ( 4_p
PE NNP 4_p
) ) 4_p
PE NNP 4_p
after IN N
open-heart JJ 4_p
surgery NN 4_p
. . N

single-center JJ N
trial NN N
at IN N
Tehran NNP N
Heart NNP N
Center NNP N
. . N

A NNP N
total NN N
of IN N
149 CD 3_p
patients NNS N
with IN N
mild JJ 4_p
or CC 4_p
moderate JJ 4_p
PE NNP 4_p
in IN N
transthoracic NN N
echocardiography NN N
coronary JJ N
artery NN N
bypass NN N
graft NN N
surgery NN N
patients NNS N
PE NNP 4_p
. . N

PEs NNP 4_p
-DOCSTART- -X- O O 2073645

chronic JJ 4_p
stable JJ 4_p
angina NN 4_p
: : N
chronic JJ 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
. . N

Twelve VB 3_p
male NN 2_p
patients NNS N
with IN N
stable JJ 4_p
effort NN 4_p
angina NN 4_p
and CC N
without IN N
previous JJ N
myocardial JJ 4_p
infarction NN 4_p
were VBD N
studied VBN N
. . N

-DOCSTART- -X- O O 24939380

shoulder JJR 4_p
instability NN 4_p
Patients NNPS 1_p
( ( 1_p
> JJ 1_p
14 CD 1_p
years NNS 1_p
) ) 1_p
diagnosed VBD N
with IN N
multidirectional JJ 4_p
instability NN 4_p
or CC N
multidirectional JJ 4_p
laxity NN 4_p
with IN 4_p
anteroinferior JJ 4_p
instability NN 4_p
and CC 4_p
failed VBD 4_p
nonoperative JJ 4_p
treatment NN 4_p
were VBD N
enrolled VBN N
. . N

Patients NNS N
with IN N
bone JJ N
lesions NNS N
or CC N
labral JJ N
, , N
biceps JJ N
anchor NN N
, , N
or CC N
full-thickness JJ N
rotator NN N
cuff NN N
tears NNS N
were VBD N
excluded VBN N
intraoperatively RB N
. . N

RESULTS NNP N
Fifty-four JJ 3_p
subjects NNS N
( ( N
mean JJ 1_p
age NN 1_p
, , 1_p
23 CD 1_p
years NNS 1_p
; : N
37 CD N
women NNS 2_p
) ) N
were VBD N
randomized VBN N
( ( N
n JJ 3_p
= NNP 3_p
26 CD 3_p
) ) N
-DOCSTART- -X- O O 9801481

outpatient JJ 4_p
anesthesia NN 4_p
. . N

outpatients NNS N
undergoing VBG N
procedures NNS 4_p
greater JJR 4_p
than IN 4_p
2 CD 4_p
hours NNS 4_p
in IN 4_p
length NN 4_p
. . N

Thirty-three JJ 3_p
patients NNS 4_p
aged VBD N
18 CD 1_p
to TO 1_p
70 CD 1_p
years NNS N
Patients NNS N
patients NNS N
-DOCSTART- -X- O O 10889149

intestinal JJ 4_p
metaplasia NN 4_p
H. NNP 4_p
pylori FW 4_p
infection NN 4_p
: : N
Volunteers NNPS N
from IN N
the DT N
Yantai NNP N
County NNP N
in IN N
China NNP N
underwent JJ N
upper JJ N
endoscopy NN N
with IN N
biopsy NN N
specimens NNS N
obtained VBN N
from IN N
the DT N
antrum NN N
and CC N
corpus NN N
. . N

H. NNP N
pylori-infected JJ N
subjects NNS N
total NN N
of IN N
587 CD 3_p
H. NNP N
pylori-infected JJ N
subjects NNS N
were VBD N
randomized VBN N
to TO N
OAC NNP N
245 CD 3_p
patients NNS N
remained VBD N
H. NNP N
pylori NN N
infected VBD N
. . N

-DOCSTART- -X- O O 20070284

patients NNS N
with IN N
chronic JJ 4_p
hepatitis NN 4_p
C. NNP 4_p
Hepatitis NNP 4_p
C NNP 4_p
Antiviral NNP N
Long-Term NNP N
Treatment NNP N
against IN N
Cirrhosis NNP 4_p
( ( N
HALT-C NNP 4_p
) ) N
Trial NNP N
patients NNS N
with IN N
chronic JJ 4_p
hepatitis NN 4_p
C NNP 4_p
and CC N
advanced JJ 4_p
fibrosis NN 4_p
or CC N
cirrhosis NN 4_p
. . N

total NN N
of IN N
517 CD 3_p
HALT-C JJ 4_p
patients NNS N
received VBD N
peginterferon JJ N
alfa-2a JJ N
( ( N
90 CD N
microg/week NN N
) ) N
; : N
532 CD 3_p
received VBD N
no DT N
additional JJ N
treatment NN N
for IN N
3.5 CD N
years NNS N
. . N

Patients NNS N
with IN N
cirrhosis NN 4_p
( ( N
n JJ N
= NNP N
427 CD N
) ) N
patients NNS N
with IN N
fibrosis NN 4_p
( ( N
n JJ N
= NNP N
622 CD N
) ) N
. . N

in IN N
men NNS 3_p
, , N
sexual JJ N
health NN N
in IN N
a DT N
large JJ N
patient NN N
cohort NN N
-DOCSTART- -X- O O 17941914

infants NNS N
at IN N
risk NN N
of IN N
allergic JJ N
disease NN N
. . N

Sixty-one JJ N
mother-infant JJ N
pairs NNS N
were VBD N
included VBN N
, , N
special JJ N
emphasis NN N
being VBG N
placed VBN N
on IN N
the DT N
maternal JJ N
allergic NN N
status NN N
. . N

infants NNS N
of IN N
allergic NN N
, , N
atopic NN N
mothers NNS N
Allergic NNP N
mothers NNS N
-DOCSTART- -X- O O 380614

patients NNS 4_p
treated VBN 4_p
with IN 4_p
oral JJ 4_p
hypoglycaemic JJ 4_p
agents NNS 4_p
. . N

Twenty-two JJ 3_p
maturity-onset JJ N
type NN 4_p
diabetics NNS 4_p
treated VBD 4_p
with IN 4_p
oral JJ 4_p
hypoglycaemic JJ 4_p
agents NNS 4_p
thirteen JJ 3_p
patients NNS N
, , N
under IN N
reasonably RB N
good JJ N
control NN N
maturity-onset JJ N
diabetics NNS N
not RB N
adequately RB N
controlled VBN N
by IN N
diet NN N
combined VBN N
with IN N
oral JJ N
hypoglycaemic JJ N
agents NNS N
. . N

-DOCSTART- -X- O O 22696144

patients NNS N
undergoing VBG N
ACL NNP 4_p
reconstruction NN 4_p
. . N

107 CD 3_p
American JJ N
Society NNP N
of IN N
Anaesthesiologists NNP N
physical JJ N
status NN N
grade NN N
I PRP N
and CC N
II NNP N
patients NNS N
between IN 1_p
18 CD 1_p
and CC 1_p
65 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
who WP N
were VBD N
scheduled VBN N
to TO N
undergo VB N
elective JJ 4_p
anterior JJ 4_p
crucial JJ 4_p
ligament NN 4_p
( ( 4_p
ACL NNP 4_p
) ) 4_p
reconstruction NN 4_p
with IN N
hamstring VBG N
autografts NNS N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 16089221

post-tonsillectomy NN 4_p
. . 4_p

Thirty-seven JJ N
patients NNS N
from IN N
5 CD N
to TO N
14 CD N
years NNS N
old JJ N
undergoing JJ N
electrocautery NN N
tonsillectomy NN N
mouth NN N
rinse NN N
water NN N
rinse NN N
( ( N
control NN N
) ) N
treatment NN N
group NN N
control NN N
group NN N
. . N

-DOCSTART- -X- O O 23525780

in IN N
Baltimore NNP N
City NNP N
. . N

church-based JJ N
, , N
community-participatory JJ N
, , N
cluster-randomized JJ N
among IN N
urban JJ N
African JJ N
Americans NNPS N
-DOCSTART- -X- O O 2682347

children NNS 1_p
with IN N
autistic JJ 4_p
behavior NN N
. . N

13 CD 3_p
children NNS N
with IN N
autistic JJ 4_p
behavior NN 4_p
treated VBN N
with IN N
fenfluramine NN 4_p
. . 4_p

Six NNP N
children NNS N
( ( N
responders NNS N
) ) N
-DOCSTART- -X- O O 24839884

hyperactivity NN 4_p
in IN 4_p
autism NN 4_p
. . 4_p

hyperactivity NN N
in IN N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
. . 4_p

parents NNS N
of IN N
children NNS 1_p
aged VBN 1_p
5 CD 1_p
to TO 1_p
8 CD 1_p
years NNS 1_p
enrolled VBN N
in IN N
the DT N
Interactive NNP N
Autism NNP N
Network NNP N
. . N

57 CD 3_p
children NNS 1_p
from IN N
28 CD N
states NNS N
satisfied VBD N
all DT N
eligibility NN N
criteria NNS N
children NNS 1_p
with IN N
ASD NNP 4_p
-DOCSTART- -X- O O 2510260

duodenal JJ 4_p
ulcer JJ 4_p
Ninety-seven JJ 3_p
patients NNS N
received VBD N
rioprostil JJ N
, , N
600 CD N
micrograms NNS N
once-daily RB N
orally RB N
, , N
and CC N
110 CD 3_p
patients NNS N
received JJ N
ranitidine NN N
-DOCSTART- -X- O O 3318754

anorexia JJ N
nervosa NN N
and CC N
bulimia NN N
nervosa NN N
. . N

Eighty JJ 3_p
patients NNS N
( ( N
57 CD 3_p
with IN N
anorexia JJ 4_p
nervosa NN 4_p
; : N
23 CD 3_p
with IN N
bulimia NN 4_p
nervosa NN 4_p
) ) N
were VBD N
first RB N
admitted VBN N
to TO N
a DT N
specialized JJ N
unit NN N
to TO N
restore VB N
their PRP$ N
weight NN N
to TO N
normal JJ N
. . N

patients NNS N
whose WP$ N
illness NN N
was VBD N
not RB N
chronic JJ N
and CC N
had VBD N
begun VBN N
before IN N
the DT N
age NN N
of IN N
19 CD N
years NNS N
. . N

older JJR N
patients NNS N
. . N

-DOCSTART- -X- O O 1359258

patients NNS 4_p
with IN 4_p
low JJ 4_p
ejection NN 4_p
fractions NNS 4_p
. . N

6797 CD 3_p
patients NNS N
with IN 4_p
ejection NN 4_p
fractions NNS 4_p
< VBP 4_p
or CC 4_p
= VBP 4_p
0.35 CD 4_p
enrolled VBN 4_p
into IN 4_p
the DT 4_p
two CD 4_p
Studies NNS 4_p
of IN 4_p
Left NNP 4_p
Ventricular NNP 4_p
Dysfunction NNP 4_p
( ( 4_p
SOLVD NNP 4_p
) ) 4_p
trials NNS 4_p
. . N

Patients NNS N
with IN N
heart NN N
failure NN N
entered VBD N
the DT N
treatment NN N
trial NN N
( ( N
n JJ N
= NN N
2569 CD 3_p
) ) N
and CC N
those DT N
without IN N
heart NN N
failure NN N
entered VBD N
the DT N
prevention NN N
trial NN N
( ( N
n JJ N
= NN N
4228 CD 3_p
) ) N
. . N

362 CD 3_p
placebo NNS N
group NN N
595 CD 3_p
placebo NN N
group NN N
patients NNS N
with IN N
low JJ N
ejection NN N
fractions NNS N
. . N

-DOCSTART- -X- O O 17037712

dysmenorrhoea NN N
. . N

Kerman NNP 4_p
, , 4_p
Islamic NNP 4_p
Republic NNP 4_p
of IN 4_p
Iran NNP 4_p
in IN 4_p
2002 CD 4_p
primary JJ N
dysmenorrhoea NN N
. . N

Two CD N
groups NNS N
of IN N
high-school JJ N
girls NNS N
( ( N
mean JJ N
age NN N
13 CD N
years NNS N
) ) N
suffering VBG N
dysmenorrhoea NN N
were VBD N
randomized VBN N
-DOCSTART- -X- O O 7840362

Thirty-seven JJ N
outpatients NNS N
( ( N
11 CD N
men NNS N
and CC N
26 CD N
women NNS N
) ) N
meeting VBG N
DSM-III-R JJ N
criteria NNS N
for IN N
major JJ N
depressive JJ N
disorder NN N
-DOCSTART- -X- O O 20378181

chronic JJ 4_p
schizophrenia NN 4_p
. . N

chronic JJ 4_p
schizophrenia NN 4_p
in-patients NNS N
( ( N
n=35 NN 3_p
) ) N
Patients NNS N
stable JJ 4_p
antipsychotic JJ 4_p
treatment NN 4_p
chronic JJ 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 2141713

kidney NN 4_p
carcinoma NN 4_p
with IN 4_p
high JJ 4_p
risk NN 4_p
of IN 4_p
relapse NN 4_p
" NNP 4_p
] NNP 4_p
-DOCSTART- -X- O O 339662

laryngopharyngeal JJ N
epidermoid JJ N
carcinoma NN N
. . N

Twenty-four CD N
patients NNS N
, , N
with IN N
a DT N
biopsy-proven JJ N
laryngeal NN N
or CC N
hypopharyngeal NN N
carcinoma NN N
healthy JJ N
control-group NN N
. . N

patients NNS N
with IN N
laryngo-pharyngeal JJ N
cancer NN N
-DOCSTART- -X- O O 7272152

lower JJR N
oesophageal JJ N
sphincter NN N
pressure NN N
. . N

12 CD 3_p
healthy JJ 4_p
volunteers NNS 4_p
using VBG 4_p
oesophageal JJ 4_p
pressure NN 4_p
transducers NNS 4_p
. . 4_p

-DOCSTART- -X- O O 9400786

cytomegalovirus NN 4_p
retinitis NN 4_p
in IN N
patients NNS N
with IN N
acquired JJ N
immunodeficiency NN N
syndrome NN N
: : N
The DT N
Studies NNPS N
of IN N
Ocular JJ 4_p
Complications NNS 4_p
of IN N
AIDS NNP N
Research NNP N
Group NNP N
. . N

AIDS NNP N
Clinical JJ N
Trials NNP N
Group NNP N
. . N

Two CD 3_p
hundred VBD 3_p
nine CD 3_p
patients NNS N
with IN N
acquired JJ 4_p
immunodeficiency NN 4_p
syndrome NN 4_p
and CC N
active JJ N
CMV NNP 4_p
retinitis NN 4_p
were VBD N
enrolled VBN N
in IN N
a DT N
multicenter NN N
, , N
phase NN N
2/3 CD N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
. . N

Among IN N
patients NNS N
with IN N
newly RB N
diagnosed VBN N
retinitis NN N
-DOCSTART- -X- O O 24635039

at IN N
a DT N
community NN N
mental JJ N
health NN N
center NN N
. . N

at IN N
a DT N
community NN N
mental JJ N
health NN N
center NN N
Those DT N
who WP N
scheduled VBD N
intakes NNS N
-DOCSTART- -X- O O 3183852

childhood NN 1_p
hemolytic-uremic JJ N
syndrome NN N
: : N
1976 CD N
to TO N
1985 CD N
, , N
a DT N
total NN N
of IN N
58 CD 3_p
infants NNS 1_p
and CC 1_p
children NNS 1_p
with IN N
the DT N
hemolytic-uremic JJ 4_p
syndrome NN 4_p
childhood NN N
hemolytic-uremic JJ N
syndrome NN N
. . N

-DOCSTART- -X- O O 6377221

infants NNS 4_p
with IN 4_p
chronic JJ 4_p
bronchopulmonary JJ 4_p
dysplasia NN 4_p
: : 4_p
double-blind JJ 4_p
crossover NN 4_p
sequential JJ 4_p
trial NN 4_p
. . 4_p

ten JJ N
infants NNS N
with IN N
bronchopulmonary JJ N
dysplasia NN N
( ( N
BPD NNP N
) ) N
. . N

infants NNS N
' POS N
rate NN N
of IN N
weight NN N
infants NNS N
infants NNS N
infants NNS N
-DOCSTART- -X- O O 23715565

baseline NN N
BMI NNP N
and CC N
the DT N
risk NN N
of IN N
incident JJ N
distal JJ N
adenoma NN N
( ( N
1,213 CD N
cases NNS N
) ) N
, , N
recurrent JJ N
adenoma NN N
( ( N
752 CD N
cases NNS N
) ) N
, , N
and CC N
incident JJ N
colorectal NN N
cancer NN N
( ( N
966 CD N
cases NNS N
) ) N
among IN N
men NNS N
and CC N
women NNS N
, , N
ages VBZ N
55 CD N
to TO N
74 CD N
years NNS N
, , N
randomly RB N
assigned VBN N
to TO N
receive VB N
flexible JJ N
sigmoidoscopy NN N
screening NN N
as IN N
part NN N
of IN N
the DT N
Prostate NNP N
, , N
Lung NNP N
, , N
Colorectal NNP N
, , N
and CC N
Ovarian JJ N
Cancer NNP N
Screening NNP N
Trial NNP N
. . N

-DOCSTART- -X- O O 15553821

iron-deficiency NN 4_p
anemia NN 4_p
( ( N
IDA NNP N
) ) N
Patients NNPS N
with IN N
IDA NNP 4_p
the DT N
treated VBN N
group NN N
and CC N
the DT N
control NN N
group NN N
, , N
50 CD 3_p
in IN N
each DT N
group NN N
. . N

-DOCSTART- -X- O O 22133872

autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
: : 4_p
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
Thirty-two JJ 3_p
children NNS 1_p
, , 1_p
18-60 JJ 1_p
months NNS 1_p
-DOCSTART- -X- O O 15528910

enamel JJ 4_p
subsurface NN 4_p
lesions NNS 4_p
remineralized VBN N
by IN N
a DT N
sugar-free JJ N
chewing NN N
gum NN N
containing VBG N
casein JJ N
phosphopeptide-amorphous JJ N
calcium NN N
phosphate NN N
. . N

enamel JJ 4_p
lesions NNS 4_p
remineralized VBN N
in IN N
situ NN N
by IN N
a DT N
sugar-free JJ N
chewing NN N
gum NN N
containing VBG N
casein JJ N
phosphopeptide-amorphous JJ N
calcium NN N
phosphate NN N
nanocomplexes NNS N
( ( N
CPP-ACP JJ N
: : N
Recaldent NN N
) ) N
. . N

Subjects NNS N
wore RBR N
removable JJ N
palatal JJ N
appliances NNS N
with IN N
insets NNS N
of IN N
human JJ N
enamel NN N
containing VBG N
demineralized JJ N
subsurface NN 4_p
lesions NNS 4_p
and CC N
chewed VBD N
the DT N
gum NN N
for IN N
20 CD N
min NN N
4 CD N
times NNS N
per IN N
day NN N
for IN N
14 CD N
days NNS N
. . N

-DOCSTART- -X- O O 1527133

deep-vein JJ 4_p
thrombosis NN 4_p
and CC N
swelling NN N
after IN N
hemiarthroplasty NN 4_p
for IN 4_p
hip NN 4_p
fracture NN 4_p
. . N

82 CD 3_p
patients NNS N
treated VBN 4_p
by IN 4_p
hemiarthroplasty NN 4_p
for IN 4_p
subcapital JJ 4_p
fracture NN 4_p
of IN 4_p
the DT 4_p
femoral JJ 4_p
neck NN 4_p
. . N

-DOCSTART- -X- O O 22821273

contemporary JJ 4_p
coronary JJ 4_p
stent NN 4_p
trials NNS 4_p
: : 4_p
The DT 1_p
Resolute NNP 1_p
'All-Comers NNS 1_p
' POS 1_p
stent JJ 1_p
trial NN 1_p
. . 1_p

after IN 4_p
the DT 4_p
assigned JJ 4_p
percutaneous JJ 4_p
coronary JJ 4_p
intervention NN 4_p
or CC 4_p
at IN 4_p
discharge NN 4_p
. . 4_p

2121/2292 CD 4_p
patients NNS 4_p
( ( 4_p
92.5 CD 4_p
% NN 4_p
) ) 4_p
had VBD 4_p
an DT 4_p
analysable JJ 4_p
dataset NN 4_p
for IN 4_p
either DT 4_p
biomarker NN 4_p
. . 4_p

890/2121 CD 4_p
patients NNS 4_p
267/890 CD 1_p
patients NNS 1_p
-DOCSTART- -X- O O 7960300

A DT N
random JJ N
sample NN N
of IN N
800 CD N
employees NNS N
of IN N
a DT N
steel NN N
manufacturing VBG N
company NN N
All DT N
621 CD N
subjects NNS N
participating VBG N
in IN N
the DT N
research NN N
were VBD N
also RB N
tested VBN N
by IN N
urinalysis NN N
. . N

-DOCSTART- -X- O O 15929820

unstable JJ N
angina NN 4_p
] NNP N
patients NNS N
with IN N
unstable JJ 4_p
angina JJ 4_p
pectoris NN 4_p
. . N

total NN N
of IN N
213 CD 3_p
eligible JJ N
patients NNS N
were VBD N
enrolled VBN N
. . N

patients NNS N
with IN N
unstable JJ N
angina JJ N
pectoris NN N
. . N

-DOCSTART- -X- O O 21860188

patients NNS N
with IN N
rheumatic JJ N
valve NNS N
disease NN N
undergoing VBG N
valve JJ N
replacement NN N
surgery NN N
. . N

patients NNS N
undergoing VBG N
valve JJ N
replacement NN N
surgery NN N
. . N

Fifty-six JJ 1_p
patients NNS 1_p
with IN 1_p
valvular JJ 1_p
heart NN 1_p
disease NN 1_p
with IN 1_p
or CC 1_p
without IN 1_p
AF NNP 1_p
were VBD 1_p
randomly RB 1_p
divided VBN 1_p
-DOCSTART- -X- O O 16217314

needlescopic JJ 4_p
appendectomy JJ 4_p
laparoscopic NN 4_p
appendectomy NN 4_p
. . 4_p

randomized JJ N
controlled JJ N
trial NN N
. . N

-DOCSTART- -X- O O 19861631

hookworm NN N
infection NN N
. . N

participants NNS N
with IN N
allergic JJ N
rhinitis NN N
. . N

participants NNS N
were VBD N
sensitized VBN N
-DOCSTART- -X- O O 17276969

obese JJ 4_p
patients NNS 4_p
Sixty NNP 1_p
obese JJ 1_p
women NNS 1_p
were VBD 1_p
included VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

were VBD N
divided VBN N
into IN N
2 CD N
equal JJ N
groups-the JJ N
-DOCSTART- -X- O O 14745744

wives NNS N
of IN N
men NNS N
with IN N
prostate NN 4_p
cancer NN 4_p
. . N

wives NNS N
of IN N
men NNS 2_p
diagnosed VBN 4_p
with IN 4_p
prostate JJ 4_p
cancer NN 4_p
Sixty NNP 3_p
wives NNS 2_p
spouses NNS N
of IN N
men NNS N
with IN N
prostate NN 4_p
cancer NN 4_p
-DOCSTART- -X- O O 11408369

multiple JJ N
cytochrome NN N
P450s NNP N
. . N

12 CD 3_p
healthy JJ 4_p
male JJ 2_p
subjects NNS N
. . N

-DOCSTART- -X- O O 17715164

patients NNS N
with IN N
COPD NNP 4_p
: : N
patients NNS N
with IN N
stable JJ 4_p
COPD NNP 4_p
. . N

20 CD 3_p
ex-smoking JJ N
COPD NNP 4_p
patients NNS N
with IN N
post-bronchodilator NN N
forced JJ N
expiratory NN N
volume NN N
in IN N
one CD N
second NN N
( ( N
FEV NNP N
( ( N
1 CD N
) ) N
) ) N
> $ N
1.20 CD N
L NNP N
and CC N
FEV NNP N
( ( N
1 CD N
) ) N
/forced VBD N
vital JJ N
capacity NN N
< VBP N
70 CD N
% NN N
patients NNS N
with IN N
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
in IN 4_p
a DT 4_p
stable JJ 4_p
phase NN 4_p
inflammatory JJ 4_p
lung NN 4_p
diseases NNS 4_p
. . N

-DOCSTART- -X- O O 25568383

anti-phospholipase JJ 4_p
A2 NNP 4_p
antibody NN 4_p
growing VBG 1_p
beef NN N
calves NNS 1_p
. . N

70 CD 3_p
crossbred JJ N
weaned VBD N
calves NNS N
during IN N
a DT N
70-d JJ N
period NN N
using VBG N
a DT N
GrowSafe NNP N
system NN N
( ( N
GrowSafe NNP N
Systems NNPS N
Ltd. NNP N
Airdrie NNP N
, , N
AB NNP N
, , N
Canada NNP N
) ) N
at IN N
the DT N
University NNP N
of IN N
Florida NNP N
North NNP N
Florida NNP N
Research NNP N
and CC N
Education NNP N
Center NNP N
Feed NNP N
Efficiency NNP N
Facility NNP N
( ( N
FEF NNP N
) ) N
. . N

Calves NNS N
-DOCSTART- -X- O O 26068449

adults NNS 1_p
with IN N
poorly RB 4_p
controlled VBN 4_p
epilepsy NN 4_p
( ( 4_p
SMILE NNP 4_p
( ( 4_p
UK NNP 4_p
) ) 4_p
) ) N
: : N
SMILE NNP 4_p
( ( 4_p
self-management JJ 4_p
education NN 4_p
for IN N
adults NNS 1_p
with IN N
poorly RB 4_p
controlled VBN 4_p
epilepsy NN 4_p
) ) 4_p
trial NN N
SMILE NNP 4_p
is VBZ 4_p
a DT 4_p
pragmatic JJ 4_p
, , 4_p
parallel JJ 4_p
design NN 4_p
, , 4_p
two-arm JJ 4_p
, , 4_p
multi-centre JJ 4_p
randomised VBD 4_p
controlled JJ 4_p
superiority NN 4_p
trial NN 4_p
of IN 4_p
a DT 4_p
group-based JJ 4_p
interactive JJ 4_p
course NN 4_p
compared VBN 4_p
with IN 4_p
treatment NN 4_p
as IN 4_p
usual JJ 4_p
for IN 4_p
people NNS 4_p
who WP 4_p
have VBP 4_p
experienced VBN 4_p
two CD 4_p
or CC 4_p
more JJR 4_p
seizures NNS 4_p
in IN 4_p
the DT 4_p
past JJ 4_p
12 CD 4_p
months NNS 4_p
. . N

-DOCSTART- -X- O O 19047882

patients NNS N
with IN N
cancer NN N
. . N

342 CD 4_p
participants NNS 4_p
from IN 4_p
the DT 4_p
ongoing JJ 4_p
ESRA-C NNP 4_p
randomized VBD 4_p
clinical JJ 4_p
trial NN 4_p
. . 4_p

Research NN N
participants NNS N
for IN N
the DT N
ESRA-C NNP N
study NN N
were VBD N
recruited VBN N
from IN N
the DT N
Seattle NNP N
Cancer NNP N
Care NNP N
Alliance NNP N
, , N
a DT N
consortium NN N
among IN N
the DT N
University NNP N
of IN N
Washington NNP N
Medical NNP N
Center NNP N
, , N
Fred NNP N
Hutchinson NNP N
Cancer NNP N
Research NNP N
Center NNP N
, , N
and CC N
Children NNP N
's POS N
Hospital NNP N
and CC N
Regional NNP N
Medical NNP N
Center NNP N
in IN N
Seattle NNP N
, , N
WA NNP N
. . N

342 CD N
adult NN N
participants NNS N
who WP N
completed VBD N
both DT N
baseline NN N
and CC N
follow-up JJ N
survey NN N
sessions NNS N
. . N

recruitment NN 4_p
group NN 4_p
-DOCSTART- -X- O O 10715372

Three CD 3_p
groups NNS 3_p
of IN 3_p
six CD 3_p
women NNS N
were VBD N
admitted VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
use VB N
Acidform NNP N
with IN N
0 CD N
% NN N
, , N
2.5 CD N
% NN N
, , N
and CC N
5 CD N
% NN N
N-9 NNP N
. . N

10 CD N
volunteers NNS N
. . N

-DOCSTART- -X- O O 12233987

persons NNS N
with IN N
developmental JJ 4_p
disabilities NNS 4_p
. . N

2 CD 3_p
persons NNS N
with IN N
developmental JJ 4_p
disabilities NNS 4_p
-DOCSTART- -X- O O 9793091

membrane NN 4_p
leads NNS 4_p
. . N

multicenter NN N
ventricular JJ 4_p
leads NNS 4_p
: : N
Twenty-three CD 3_p
of IN N
the DT N
81 CD 3_p
patients NNS N
were VBD N
women NNS 2_p
; : N
the DT N
mean JJ N
age NN N
for IN N
all DT N
patients NNS N
was VBD N
74 CD 1_p
+/- JJ 1_p
10 CD 1_p
years NNS 1_p
. . N

-DOCSTART- -X- O O 18261537

renal JJ 4_p
transplant NN 4_p
recipients NNS N
with IN N
Renin-Angiotensin NNP 4_p
system NN 4_p
polymorphisms NN 4_p
. . N

renal JJ 4_p
transplant NN 4_p
recipients NNS N
with IN N
RAS NNP 4_p
polymorphisms NNS 4_p
. . 4_p

76 CD 3_p
recipients NNS N
were VBD N
recruited VBN N
randomly RB N
-DOCSTART- -X- O O 15641975

The DT N
root NN 4_p
canals NNS 4_p
of IN N
55 CD 3_p
human JJ N
maxillary JJ N
anterior NN N
teeth NNS N
-DOCSTART- -X- O O 21833823

autism NN 4_p
spectrum NN 4_p
conditions NNS 4_p
. . N

high-functioning JJ 1_p
adults NNS 1_p
with IN N
ASC NNP N
and CC N
age- JJ N
and CC N
IQ-matched JJ N
controls NNS N
with IN N
either DT N
a DT N
pro- JJ N
or CC N
non- JJ N
social JJ N
attitude NN N
. . N

control NN 4_p
participants NNS 4_p
individuals NNS 4_p
with IN 4_p
ASC NNP 4_p
. . N

high-functioning JJ N
adults NNS 1_p
with IN N
ASC NNP N
ASC NNP 4_p
. . 4_p

-DOCSTART- -X- O O 23562009

relapsing-remitting JJ 4_p
multiple JJ 4_p
sclerosis NN 4_p
( ( 4_p
SELECT NNP 4_p
) ) 4_p
: : 4_p
in IN N
patients NNS 4_p
with IN 4_p
relapsing-remitting JJ 4_p
multiple JJ 4_p
sclerosis NN 4_p
at IN N
76 CD N
centres NNS N
in IN N
the DT N
Czech NNP N
Republic NNP N
, , N
Germany NNP N
, , N
Hungary NNP N
, , N
India NNP N
, , N
Poland NNP N
, , N
Russia NNP N
, , N
Ukraine NNP N
, , N
Turkey NNP N
, , N
and CC N
the DT N
UK NNP N
between IN N
Feb NNP N
15 CD N
, , N
2008 CD N
, , N
and CC N
May NNP N
14 CD N
, , N
2010 CD N
. . N

Patients NNS N
aged VBN 1_p
18-55 JJ 1_p
years NNS 1_p
with IN N
relapsing-remitting JJ 4_p
multiple JJ 4_p
sclerosis NN 4_p
FINDINGS NNP N
204 CD 3_p
patients NNS 3_p
were VBD N
assigned VBN 4_p
to TO 4_p
receive VB 4_p
placebo NN 4_p
, , N
208 CD N
to TO N
daclizumab VB 4_p
HYP NNP 4_p
150 CD 4_p
mg NN 4_p
, , N
and CC N
209 CD N
to TO N
daclizumab VB 4_p
treatment NN 4_p
option NN 4_p
for IN 4_p
relapsing-remitting JJ 4_p
-DOCSTART- -X- O O 9809262

children NNS N
with IN N
autism NN N
: : N
community NN N
day-care NN N
centers NNS N
. . N

children NNS N
with IN N
autism NN N
in IN N
community NN N
day-care NN N
centers NNS N
. . N

Thirty-five JJ N
preschool NN N
children NNS N
with IN N
a DT N
DSM NNP N
III-R NNP N
diagnosis NN N
of IN N
autism NN N
or CC N
pervasive JJ N
developmental JJ N
disorder NN N
-DOCSTART- -X- O O 17014731

in IN 4_p
a DT 4_p
population NN 4_p
of IN 4_p
chronic JJ 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
patients NNS 4_p
persons NNS N
performing VBG N
supervised VBD N
Nordic NNP N
Walking NNP N
persons NNS N
who WP N
are VBP N
advised VBN N
to TO N
stay VB N
active JJ N
. . N

persons NNS N
receiving VBG N
supervised VBD N
Nordic NNP N
Walking NNP N
persons NNS N
doing VBG N
unsupervised JJ N
Nordic NNP N
Walking NNP N
. . N

One CD 4_p
hundred CD 4_p
and CC 4_p
fifty JJ 4_p
patients NNS 4_p
with IN 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
for IN 4_p
at IN 4_p
least JJS 4_p
eight CD 4_p
weeks NNS 4_p
and CC 4_p
referred VBD 4_p
to TO 4_p
a DT 4_p
specialized JJ 4_p
secondary JJ 4_p
sector NN 4_p
outpatient NN 4_p
back RB 4_p
pain NN 4_p
clinic NN 4_p
are VBP 4_p
included VBN 4_p
in IN 4_p
the DT 4_p
study NN 4_p
. . 4_p

three CD N
groups NNS N
: : N
A DT N
) ) N
Nordic NNP N
Walking NNP N
twice RB N
a DT N
week NN N
for IN N
eight CD N
weeks NNS N
under IN N
supervision NN N
of IN N
a DT N
specially RB N
trained JJ N
instructor NN N
; : N
B NNP N
) ) N
Unsupervised VBD N
Nordic NNP N
Walking NNP N
for IN N
eight CD N
weeks NNS N
after IN N
one CD N
training NN N
session NN N
with IN N
an DT N
instructor NN N
; : N
C NNP N
) ) N
A DT N
one CD N
hour NN N
motivational JJ N
talk NN N
including VBG N
advice NN N
to TO N
stay VB N
active JJ N
. . N

population NN N
of IN N
people NNS N
with IN N
chronic JJ N
LBP NNP N
. . N

-DOCSTART- -X- O O 11779598

clomiphene JJ 4_p
citrate-resistant JJ 4_p
women NNS 4_p
with IN 4_p
polycystic JJ 4_p
ovary JJ 4_p
syndrome NN 4_p
. . 4_p

clomiphene JJ N
citrate-resistant JJ N
women NNS N
with IN N
polycystic JJ N
ovary JJ N
syndrome NN N
( ( N
PCOS NNP N
) ) N
. . N

Infertility NNP N
clinic NN N
of IN N
a DT N
tertiary JJ N
referral NN N
center NN N
. . N

Fifty-six NNP N
women NNS N
with IN N
clomiphene JJ N
citrate-resistant JJ N
PCOS NNP N
. . N

clomiphene JJ N
citrate-resistant JJ N
women NNS N
with IN N
PCOS NNP N
. . N

-DOCSTART- -X- O O 17357577

patients NNS 4_p
with IN 4_p
fibrocystic JJ 4_p
breast NN 4_p
disease NN 4_p
] NNP N
. . N

patients NNS 4_p
with IN 4_p
fibrocystic JJ 4_p
mastopathy NN 4_p
. . N

Patients NNPS N
with IN N
diagnosis NN N
of IN N
fibrocystic JJ 4_p
breast NN 4_p
disease NN 4_p
were VBD N
included VBN N
39 CD 3_p
patients NNS N
with IN N
alpha JJ 4_p
dihidroergocriptine NN 4_p
and CC N
38 CD 3_p
with IN N
placebo NN 4_p
. . N

fribrocystic JJ 4_p
breast NN 4_p
disease NN 4_p
-DOCSTART- -X- O O 12096292

patients NNS N
undergoing VBG N
an DT N
initial JJ N
course NN N
of IN N
chemotherapy NN N
who WP N
report VBP N
pain NN N
and CC N
fatigue NN N
at IN N
baseline NN N
and CC N
who WP N
are VBP N
receiving VBG N
conventional JJ N
care NN N
alone RB N
with IN N
those DT N
receiving VBG N
conventional JJ N
care NN N
plus CC N
a DT N
nursing NN N
intervention NN N
Chemotherapy NNP N
clinics NNS N
of IN N
two CD N
comprehensive JJ N
and CC N
two CD N
community NN N
cancer NN 4_p
centers NNS N
. . N

53 CD 3_p
patients NNS N
in IN N
the DT N
experimental JJ N
arm NN N
and CC N
60 CD 3_p
in IN N
the DT N
control NN N
arm NN N
who WP N
reported VBD N
pain NN N
and CC N
fatigue NN N
at IN N
baseline NN N
. . N

-DOCSTART- -X- O O 1937073

25 CD 4_p
eyes NNS 4_p
of IN 4_p
25 CD 4_p
patients NNS 4_p
suffering VBG 4_p
from IN 4_p
bilateral JJ 4_p
primary JJ 4_p
open-angle JJ 4_p
glaucoma NN 4_p
( ( 4_p
POAG NNP 4_p
) ) 4_p
before IN 4_p
and CC 4_p
after IN 4_p
argon-laser JJ 4_p
trabeculoplasty NN 4_p
. . 4_p

-DOCSTART- -X- O O 10539493

schizophrenic JJ 4_p
patient NN N
-DOCSTART- -X- O O 17083268

100 CD 3_p
patients NNS N
with IN N
stage NN 4_p
I PRP 4_p
hypertension VBP 4_p
are VBP N
characterized VBN N
at IN N
baseline NN N
before IN N
being VBG N
treated VBN N
for IN N
1 CD N
year NN N
to TO N
obtain VB N
a DT N
goal NN N
BP NNP N
of IN N
less JJR N
than IN N
140/90 CD N
mm JJ N
Hg NNP N
-DOCSTART- -X- O O 6839001

12 CD 3_p
healthy JJ N
male JJ 2_p
subjects NNS N
. . N

-DOCSTART- -X- O O 12844393

fat JJ 4_p
intake NN 4_p
in IN N
rats NNS 4_p
. . N

subjects NNS 4_p
with IN 4_p
a DT 4_p
preference NN 4_p
for IN 4_p
a DT 4_p
high-fat JJ 4_p
diet NN 4_p
. . 4_p

nine CD 3_p
female NN 2_p
and CC N
three CD 3_p
male NN 2_p
healthy JJ N
subjects NNS N
( ( N
age NN 1_p
34 CD 1_p
( ( 1_p
sd VB 1_p
11 CD 1_p
) ) 1_p
years NNS N
, , N
BMI NNP N
24.5 CD N
( ( N
sd VB N
2.5 CD N
) ) N
kg/m NN N
( ( N
2 CD N
) ) N
) ) N
with IN N
a DT N
preference NN N
for IN N
a DT N
high-fat JJ N
diet NN N
ingested VBN N
ENT NNP N
( ( N
3 CD N
x RB N
15 CD N
mg/d NN N
) ) N
or CC N
placebo NN N
( ( N
PLA NNP N
) ) N
while IN N
consuming VBG N
a DT N
high-fat JJ N
diet JJ N
ad NN N
libitum NN N
for IN N
4 CD N
d. NNS N
Eight JJ N
subjects NNS N
subjects NNS N
with IN N
a DT N
preference NN N
for IN N
a DT N
high-fat JJ N
diet JJ N
-DOCSTART- -X- O O 6122555

Kenyan NNP 4_p
Africans NNPS 4_p
. . 4_p

-DOCSTART- -X- O O 8274583

patients NNS 4_p
with IN 4_p
depression NN 4_p
and CC 4_p
comorbidity NN 4_p
of IN 4_p
depression NN 4_p
and CC 4_p
panic NN 4_p
. . N

9 CD 3_p
control NN 4_p
subjects NNS 4_p
, , 4_p
8 CD 3_p
patients NNS N
suffering VBG N
from IN N
a DT N
major JJ 4_p
depressive JJ 4_p
episode NN 4_p
( ( 4_p
MDE NNP 4_p
) ) 4_p
, , N
and CC N
12 CD 3_p
patients NNS N
suffering VBG N
from IN N
concurrent JJ 4_p
MDE NNP 4_p
and CC 4_p
panic JJ 4_p
disorder NN 4_p
( ( 4_p
MDE NNP 4_p
+ NNP 4_p
P NNP 4_p
) ) 4_p
. . N

-DOCSTART- -X- O O 10224577

non-obstructive JJ N
mitral JJ N
mechanical JJ N
valve NN N
thrombosis NN N
. . N

Non-obstructive NNP N
prosthetic JJ 4_p
valve NN 4_p
thrombosis NN 4_p
( ( 4_p
PVT NNP 4_p
) ) 4_p
20 CD 3_p
consecutive JJ N
patients NNS N
were VBD N
found VBN N
by IN N
multiplane NN N
transesophageal NN N
echocardiography NN N
( ( N
TEE NNP N
) ) N
to TO N
have VB N
non-obstructive JJ 4_p
PVT NNP 4_p
. . 4_p

-DOCSTART- -X- O O 19574500

preinduced JJ 4_p
quadriceps NNS 4_p
fatigue VBP 4_p
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
and CC N
healthy JJ N
subjects NNS N
. . N

chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
( ( 4_p
COPD NNP 4_p
) ) 4_p
patients NNS N
with IN N
COPD NNP N
and CC N
healthy JJ N
subjects NNS N
. . N

Fifteen JJ 3_p
patients NNS 3_p
with IN N
COPD NNP 4_p
and CC N
nine CD N
age-matched JJ N
healthy JJ N
subjects NNS N
patients NNS 4_p
with IN 4_p
COPD NNP 4_p
. . N

peripheral JJ 4_p
muscle NN 4_p
fatigue NN 4_p
-DOCSTART- -X- O O 3884411

Seventy-six JJ N
patients NNS N
took VBD N
part NN N
in IN N
a DT N
randomized JJ N
, , N
comparative JJ N
study NN N
of IN N
the DT N
efficacy NN N
of IN N
buflomedil NN N
hydrochloride NN N
and CC N
dihydrogenated VBD 4_p
ergot JJ N
alkaloids NNS N
in IN N
the DT N
treatment NN N
of IN N
senile JJ N
dementia NN N
associated VBN N
with IN N
cerebrovascular JJ N
insufficiency NN N
. . N

senile JJ N
dementia NN N
associated VBN N
with IN N
cerebrovascular JJ N
insufficiency NN N
-DOCSTART- -X- O O 16845576

young JJ N
nonverbal JJ 4_p
children NNS 1_p
with IN N
autism NN 4_p
Ten CD 3_p
young JJ N
, , N
nonverbal JJ 4_p
children NNS 1_p
with IN N
autism NN 4_p
mild JJ 4_p
to TO 4_p
moderate VB 4_p
symptoms NNS 4_p
of IN 4_p
autism NN 4_p
, , N
better JJR N
motor NN 4_p
imitation NN 4_p
skills NNS 4_p
emerging VBG N
joint JJ 4_p
attention NN 4_p
skills NNS 4_p
. . N

-DOCSTART- -X- O O 10683506

healthy JJ 4_p
subjects NNS 4_p
. . 4_p

healthy JJ N
subjects NNS N
. . N

Twelve NNP 3_p
healthy JJ 3_p
volunteers NNS 3_p
, , N
six CD 3_p
men NNS 2_p
and CC N
six CD 3_p
women NNS 2_p
, , N
mean JJ 1_p
age NN 1_p
34.4 CD 1_p
( ( 1_p
range VB 1_p
23-48 CD 1_p
) ) 1_p
healthy JJ N
persons NNS N
-DOCSTART- -X- O O 15689804

combined VBN 4_p
rhegmatogenous JJ 4_p
retinal JJ 4_p
detachment NN 4_p
and CC 4_p
choroidal JJ 4_p
detachment NN 4_p
with IN N
or CC N
without IN N
oral JJ 4_p
corticosteroids NNS 4_p
: : N
choroidal JJ N
detachment NN N
( ( N
CD NN N
) ) N
in IN N
eyes NNS N
with IN N
primary JJ N
rhegmatogenous JJ N
retinal JJ N
detachment NN N
( ( N
RRD NNP N
) ) N
inflamed JJ N
eyes NNS N
with IN N
low JJ 4_p
intraocular JJ 4_p
pressure NN 4_p
Twenty NNP 3_p
eyes NNS N
with IN N
combined JJ 4_p
RRD NNP 4_p
and CC 4_p
CD NNP 4_p
that WDT N
underwent JJ N
primary JJ N
vitrectomy NN N
combined JJ 4_p
RRD NNP 4_p
and CC 4_p
CD NNP 4_p
improves VBZ N
-DOCSTART- -X- O O 16257339

previously RB N
treated VBN N
patients NNS N
with IN N
refractory JJ 4_p
advanced JJ 4_p
non-small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
: : 4_p
patients NNS N
with IN N
locally RB 4_p
advanced JJ 4_p
or CC 4_p
metastatic JJ 4_p
non-small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
. . N

1692 CD 3_p
patients NNS N
who WP N
were VBD N
refractory JJ 4_p
to TO 4_p
or CC 4_p
intolerant VB 4_p
of IN 4_p
their PRP$ 4_p
latest JJS 4_p
chemotherapy NN 4_p
regimen NNS 4_p
1129 CD 3_p
patients NNS N
were VBD N
assigned VBN N
gefitinib NNS N
and CC N
563 CD 3_p
placebo NN N
. . N

812 CD 3_p
patients NNS N
with IN N
adenocarcinoma NN N
never-smokers NNS N
Asian JJ N
origin NN N
never-smokers NNS N
and CC N
patients NNS N
of IN N
Asian JJ N
origin NN N
. . N

-DOCSTART- -X- O O 3089263

control NN 4_p
of IN 4_p
paroxysmal JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
and CC 4_p
atrial JJ 4_p
flutter NN 4_p
-DOCSTART- -X- O O 20723873

laparoscopic JJ 4_p
pelvic JJ 4_p
lymphadenectomy NN 4_p
for IN 4_p
gynecologic JJ 4_p
cancer NN 4_p
. . 4_p

Thirty NNP N
patients NNS N
with IN N
gynecologic JJ N
malignancy NN N
, , N
who WP N
had VBD N
laparoscopic VBN N
pelvic JJ N
lymphadenectomy NN N
lymphocele NNS N
in IN N
10 CD N
patients NNS N
patients NNS N
undergoing VBG N
laparoscopic JJ N
pelvic JJ N
lymphadenectomy NN N
. . N

-DOCSTART- -X- O O 9892252

patients NNS N
with IN N
schizophrenia NN 4_p
. . N

Forty-seven JJ 3_p
patients NNS N
with IN N
schizophrenia JJ 4_p
meeting NN N
criteria NNS N
for IN N
deficit NN 4_p
syndrome NN 4_p
Thirty-nine JJ 3_p
patients NNS N
-DOCSTART- -X- O O 11877686

patients NNS 4_p
with IN 4_p
peripheral JJ 4_p
arterial JJ 4_p
bypass NN 4_p
procedures NNS 4_p
: : 4_p
patients NNS N
with IN N
lower JJR N
extremity NN N
arterial JJ N
bypass NN N
surgery NN N
. . N

831 CD N
patients NNS N
who WP N
underwent JJ N
peripheral JJ N
arterial JJ N
bypass NN N
surgery NN N
long-term JJ N
treatment NN N
program NN N
of IN N
WASA NNP N
-DOCSTART- -X- O O 22475864

408 CD N
subjects NNS N
were VBD N
stratified VBN N
by IN N
age NN N
( ( N
18-59 JJ N
and CC N
> JJ N
60 CD N
years NNS N
) ) N
-DOCSTART- -X- O O 19928389

patients NNS N
with IN N
heart NN 4_p
failure NN 4_p
. . N

patients NNS N
with IN N
heart NN N
failure NN N
. . N

group NN N
of IN N
subjects NNS N
with IN N
stable JJ N
heart NN 4_p
failure NN 4_p
. . N

Twenty-five JJ 3_p
patients NNS N
All DT N
25 CD 3_p
patients NNS N
had VBD N
clinically RB 4_p
stable JJ 4_p
heart NN 4_p
failure NN 4_p
and CC N
left VBD N
ventricular JJ 4_p
ejection NN 4_p
fractions NNS 4_p
< VBP 4_p
40 CD 4_p
% NN 4_p
. . N

-DOCSTART- -X- O O 24874588

humans NNS N
. . N

Forty CD 3_p
patients NNS 3_p
were VBD N
randomized VBN N
after IN N
septoplasty NN 4_p
-DOCSTART- -X- O O 2406863

gastritis NN 4_p
due JJ 4_p
to TO 4_p
Campylobacter NNP 4_p
pylori NN 4_p
. . 4_p

Fifty JJ 4_p
patients NNS 4_p
gastritis NN N
associated VBN N
with IN N
Campylobacter NNP N
pylori NN N
. . N

18 CD N
patients NNS N
-DOCSTART- -X- O O 1631861

aortic JJ 4_p
valve NN 4_p
surgery NN 4_p
-- : 4_p
a DT 4_p
Thirty NNP N
patients NNS N
scheduled VBN N
for IN N
aortic JJ N
valve NNS N
replacement NN N
were VBD N
included VBN N
. . N

-DOCSTART- -X- O O 23715475

Chinese JJ N
women NNS 2_p
undergoing VBG N
heroin JJ 4_p
detoxification NN 4_p
: : N
Seventy-five JJ 3_p
women NNS N
aged VBN N
20-37 CD 1_p
years NNS 1_p
undergoing JJ N
detoxification NN N
for IN N
heroin NN N
dependence NN N
at IN N
AnKang NNP N
Hospital NNP N
Women NNS N
in IN N
the DT N
intervention NN N
group NN N
Most JJS N
female JJ 2_p
heroin NN 4_p
addicts NNS 4_p
were VBD N
young JJ N
and CC N
single JJ N
, , N
with IN N
a DT N
low JJ N
education NN N
level NN N
. . N

Most JJS N
had VBD N
used VBN N
heroin NN N
by IN N
injection NN N
. . N

Mood NNP N
state NN N
and CC N
quality NN N
of IN N
life NN N
of IN N
female JJ N
heroin NN N
addicts NNS N
-DOCSTART- -X- O O 19346279

in IN N
alcohol NN 4_p
dependence NN 4_p
: : N
on IN N
alcohol NN N
drinking NN N
indices NNS N
. . N

Seventy-one CD 3_p
alcohol-dependent JJ N
subjects NNS N
in IN N
patients NNS N
reporting VBG N
a DT N
comorbid NN 4_p
psychiatric JJ 4_p
disorder NN 4_p
. . N

-DOCSTART- -X- O O 25224595

in IN 4_p
stem NN 4_p
cell NN 4_p
transplantation NN 4_p
design NN 4_p
. . N

Patients NNS 1_p
≥16 JJ 1_p
years NNS 1_p
scheduled VBN N
for IN N
allogeneic JJ 4_p
stem NN 4_p
cell NN 4_p
transplantation NN 4_p
were VBD N
included VBN N
20 CD N
) ) N
or CC N
control VB 3_p
group NN 3_p
-DOCSTART- -X- O O 7692109

transurethral JJ 4_p
prostatectomy NN 4_p
. . 4_p

599 CD 3_p
evaluable JJ N
patients NNS N
with IN N
benign JJ 4_p
prostatic JJ 4_p
hypertrophy NN 4_p
at IN N
7 CD N
urological JJ N
units NNS N
. . N

transurethral JJ N
prostatectomy NN N
group NN N
1 CD N
-- : N
197 CD 3_p
patients NNS N
given VBN N
single-dose JJ N
ceftriaxone NN N
( ( N
2 CD N
gm NN N
. . N

) ) N
, , N
group NN N
2 CD N
-- : N
203 CD 3_p
patients NNS N
given VBN N
160/800 CD N
mg. JJ N
trimethoprimsulfamethoxazole NN N
and CC N
group NN N
3 CD N
-- : N
199 CD 3_p
controls NNS N
given VBN N
no DT N
antimicrobial JJ N
prophylaxis NN N
. . N

Patients NNS N
with IN N
a DT N
preoperative JJ N
indwelling NN N
catheter NN N
, , N
positive JJ N
urine JJ N
culture NN N
, , N
signs NNS N
of IN N
active JJ N
infection NN N
or CC N
preoperative JJ N
antibiotic JJ N
treatment NN N
were VBD N
excluded VBN N
. . N

transurethral JJ N
prostatectomy NN N
. . N

-DOCSTART- -X- O O 23688830

cognitive JJ N
behaviour NN N
therapy NN N
program NN N
for IN N
managing VBG N
chronic JJ N
pain NN N
and CC N
emotional JJ N
well-being NN N
. . N

Sixty-three JJ N
adults NNS N
with IN N
chronic JJ N
pain NN N
were VBD N
randomised VBN N
31 CD N
Treatment NNP N
Group NNP N
participants NNS N
people NNS N
with IN N
chronic JJ N
pain NN N
. . N

-DOCSTART- -X- O O 11021553

low-risk JJ N
trabeculectomy NN 4_p
. . N

population NN N
of IN N
low-risk JJ N
glaucoma NN 4_p
patients NNS N
in IN N
whom WP N
antimetabolites NNS N
might MD N
not RB N
be VB N
indicated VBN N
. . N

65 CD 3_p
eyes NNS N
was VBD N
designed VBN N
, , N
with IN N
31 CD 3_p
eyes NNS N
receiving VBG N
750 CD N
rads NNS N
of IN N
intraoperative JJ N
beta NN N
radiation NN N
( ( N
group NN N
1 CD N
) ) N
, , N
and CC N
34 CD 3_p
eyes NNS N
receiving VBG N
no DT N
supplementation NN N
( ( N
group NN N
2 CD N
) ) N
. . N

low-risk JJ 4_p
patients NNS 4_p
-DOCSTART- -X- O O 25668435

males NNS 2_p
with IN 4_p
and CC 4_p
without IN 4_p
autism NN 4_p
. . N

Autism NNP 4_p
spectrum JJ 4_p
conditions NNS 4_p
( ( 4_p
autism NN 4_p
) ) 4_p
individuals NNS 4_p
with IN 4_p
autism NN 4_p
for IN N
32 CD 3_p
adult NN N
males NNS 2_p
with IN N
autism NN 4_p
and CC N
34 CD N
controls NNS N
in IN N
a DT N
real-time JJ N
interaction NN N
-DOCSTART- -X- O O 1337070

Erythema JJ 4_p
migrans NNS 4_p
: : N
64 CD 3_p
patients NNS N
with IN N
typical JJ N
erythema NN 4_p
migrans NNS 4_p
. . N

-DOCSTART- -X- O O 6721970

caesarean JJ 4_p
section NN 4_p
in IN 4_p
severe JJ 4_p
pre-eclampsia NN 4_p
. . 4_p

patients NNS 4_p
undergoing VBG 4_p
Caesarean JJ 4_p
section NN 4_p
, , 4_p
either CC 4_p
enflurane NN 4_p
( ( 4_p
mean JJ 4_p
0.24 CD 4_p
MAC-h NN 4_p
) ) 4_p
or CC 4_p
halothane NN 4_p
( ( 4_p
mean JJ 4_p
0.23 CD 4_p
MAC-h NN 4_p
) ) 4_p
and CC 4_p
50 CD 4_p
% NN 4_p
nitrous JJ 4_p
oxide NN 4_p
in IN 4_p
oxygen NN 4_p
women NNS 4_p
( ( 4_p
n JJ 4_p
= NNP 4_p
12 CD 4_p
) ) 4_p
with IN 4_p
severe JJ 4_p
pre-eclampsia-eclampsia NN 4_p
and CC 4_p
to TO 4_p
16 CD 4_p
healthy JJ 4_p
pregnant JJ 4_p
patients NNS 4_p
with IN 4_p
normal JJ 4_p
renal JJ 4_p
and CC 4_p
hepatic JJ 4_p
function NN 4_p
. . 4_p

In IN N
patients NNS N
with IN N
severe JJ N
pre-eclampsia NN N
-DOCSTART- -X- O O 23118720

healthy JJ 4_p
volunteers NNS 4_p
Thirty NNP N
healthy JJ N
volunteers NNS N
-DOCSTART- -X- O O 2696035

trials NNS N
for IN N
adjuvant JJ N
therapy NN N
for IN N
breast NN 4_p
cancer NN 4_p
. . N

-DOCSTART- -X- O O 17377092

laser-assisted JJ 4_p
drug NN 4_p
delivery NN 4_p
enhancing VBG N
the DT N
delivery NN N
of IN N
topically RB N
applied VBN N
LMX-4 NNP N
cream NN N
prior RB 4_p
to TO 4_p
venipuncture NN 4_p
. . N

topical JJ N
anesthesia NN N
before IN 4_p
venipuncture NN 4_p
-DOCSTART- -X- O O 9055050

Outcome NNP 4_p
assessment NN 4_p
for IN 4_p
clinical JJ 4_p
trials NNS 4_p
: : N
adjudicators NNS 4_p
adjudication NN 4_p
committee NN 4_p
in IN 4_p
a DT 4_p
large JJ 4_p
randomized JJ 4_p
trial NN 4_p
potentially RB 4_p
operable JJ 4_p
lung NN 4_p
cancer NN 4_p
. . 4_p

Up IN 3_p
to TO 3_p
five CD 3_p
independent JJ 3_p
adjudicators NNS 3_p
Patients NNS N
patient NN N
-DOCSTART- -X- O O 4154124

Forty-six JJ 3_p
patients NNS N
with IN N
systemic JJ 4_p
poisoning NN 4_p
by IN 4_p
this DT 4_p
snake NN 4_p
23 CD 3_p
patients NNS 4_p
in IN 4_p
one CD 4_p
group NN 4_p
-DOCSTART- -X- O O 19272375

eleven RB 4_p
healthy JJ 4_p
volunteers NNS 4_p
-DOCSTART- -X- O O 7742155

Thirty-seven NNP N
healthy JJ N
volunteers NNS N
, , N
19 CD N
of IN N
whom WP N
had VBD N
consistently RB N
elevated VBN N
total JJ N
serum NN N
bilirubin NN N
( ( N
TSB NNP N
) ) N
concentrations NNS N
, , N
took VBD N
part NN N
volunteers NNS N
volunteers NNS N
volunteers NNS N
volunteers NNS N
-DOCSTART- -X- O O 21512834

pre-school JJ 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
. . 4_p

autism NN N
against IN N
ordinary JJ N
care NN N
, , N
with IN N
28 CD N
children NNS N
aged VBN N
2-5 CD N
years NNS N
-DOCSTART- -X- O O 25888263

asymptomatic JJ 4_p
and CC 4_p
minimally RB 4_p
symptomatic JJ 4_p
, , 4_p
chemotherapy-naive JJ 4_p
patients NNS 4_p
with IN 4_p
metastatic JJ 4_p
castration-resistant JJ 4_p
prostate NN 4_p
cancer NN 4_p
( ( 4_p
PREVAIL NNP 4_p
) ) N
: : N
asymptomatic JJ 4_p
and CC 4_p
minimally RB 4_p
symptomatic JJ 4_p
, , N
chemotherapy-naive JJ 4_p
patients NNS 4_p
with IN 4_p
metastatic JJ 4_p
castration-resistant JJ 4_p
prostate NN 4_p
cancer NN 4_p
. . N

patients NNS 4_p
were VBD 4_p
randomly RB 4_p
assigned VBN 4_p
( ( 4_p
1:1 CD 4_p
) ) 4_p
to TO 4_p
receive VB N
enzalutamide RB N
160 CD N
mg/day NN N
( ( N
n=872 JJ N
) ) N
or CC 4_p
placebo NN N
( ( N
n=845 JJ N
) ) N
orally RB N
. . N

occurrence NN 4_p
of IN 4_p
first JJ 4_p
skeletal-related JJ 4_p
event NN 4_p
in IN 4_p
chemotherapy-naive JJ 4_p
men NNS 2_p
with IN 4_p
metastatic JJ 4_p
-DOCSTART- -X- O O 1799151

neurosurgery NN N
. . N

trepanations NNS N
patients NNS N
undergoing VBG N
major JJ N
craniotomies NNS N
. . N

Only JJ N
clean JJ N
or CC N
clean JJ N
contaminated VBN N
cases NNS N
were VBD N
included VBN N
. . N

Excluded VBN N
were VBD N
contaminated VBN N
cases NNS N
, , N
operations NNS N
with IN N
a DT N
transnasal-transsphenoidal JJ N
approach NN N
, , N
shunt-operations NNS N
and CC N
patients NNS N
with IN N
any DT N
other JJ N
preoperative JJ N
infection NN N
or CC N
antibiotic JJ N
therapy NN N
. . N

Outpatients NNS N
were VBD N
excluded VBN N
due JJ N
to TO N
difficulties NNS N
in IN N
obtaining VBG N
sufficient JJ N
clinical JJ N
information NN N
. . N

From NNP N
originally RB N
918 CD 3_p
consecutive JJ N
patients NNS N
operated VBN N
on IN N
711 CD 3_p
fulfilled VBD N
the DT N
entry NN N
criteria NNS N
. . N

With IN N
regard NN N
to TO N
age NN N
, , N
sex NN N
, , N
diagnosis NN N
and CC N
the DT N
site NN N
of IN N
te JJ N
trepanation NN N
, , N
control NN N
patients NNS N
( ( N
n JJ N
= NNP N
355 CD 3_p
) ) N
and CC N
cefotiam $ N
treated VBN N
patients NNS N
( ( N
n JJ N
= NNP N
356 CD 3_p
) ) N
were VBD N
shown VBN N
to TO N
be VB N
comparable JJ N
. . N

different JJ N
primary JJ N
diagnoses NNS N
, , N
concomitant JJ N
steroidal NN N
therapy NN N
concomitant NN N
severe JJ N
internal JJ N
medical JJ N
diseases NNS N
-DOCSTART- -X- O O 20068494

Elite NNP N
sprint NN N
and CC N
middle-distance NN N
swimmers NNS N
( ( N
three CD 3_p
females NNS 2_p
and CC N
six CD 3_p
males NNS 2_p
; : N
aged VBN 1_p
21-26 JJ 1_p
yr NN N
) ) N
performed VBD N
6-13 JJ N
time NN N
trials NNS N
in IN N
training NN N
and CC N
competition NN N
in IN N
the DT N
9 CD N
wk NN N
before IN N
and CC N
including VBG N
Olympic-qualifying JJ N
trials NNS N
, , N
all DT N
in IN N
their PRP$ N
specialty NN N
event NN N
. . N

elite JJ N
athletes NNS N
. . N

-DOCSTART- -X- O O 6111083

moderate JJ 4_p
hypertension NN 4_p
. . N

10 CD 3_p
previously RB 3_p
untreated JJ 3_p
hypertensive JJ 3_p
patients NNS 3_p
. . N

-DOCSTART- -X- O O 17387189

open JJ 4_p
heart NN 4_p
surgery NN 4_p
Fifty-two JJ 4_p
patients NNS 4_p
undergoing VBG 4_p
coronary JJ 4_p
artery NN 4_p
bypass NN 4_p
on IN 4_p
cardiopulmonary JJ 4_p
bypass NN 4_p
-DOCSTART- -X- O O 3528402

premenopausal NN 4_p
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
breast NN 4_p
cancer NN 4_p
. . 4_p

122 CD 3_p
premenopausal JJ 4_p
women NNS 2_p
54 CD 3_p
evaluable JJ N
women NNS 2_p
treated VBN N
with IN N
tamoxifen NN N
, , N
24 CD N
% NN N
had VBD N
an DT N
objective JJ N
response NN N
, , N
as IN N
compared VBN N
with IN N
21 CD N
% NN N
of IN N
53 CD 3_p
women NNS 2_p
having VBG N
an DT N
oophorectomy NN N
58 CD 3_p
patients NNS N
premenopausal JJ 4_p
women NNS 2_p
-DOCSTART- -X- O O 10404444

general JJ 4_p
practitioners NNS 4_p
. . 4_p

General NNP N
Practitioners NNP N
( ( N
GPs NNP N
) ) N
paediatric JJ 1_p
asthma NN N
patients NNS N
60 CD N
patients NNS N
admitted VBN N
to TO N
the DT N
Royal NNP N
Children NNP N
's POS N
Hospital NNP N
, , N
Melbourne NNP N
, , N
with IN N
acute JJ 4_p
asthma NN 4_p
and CC N
an DT N
identifiable JJ N
GP NNP N
. . N

GPs NNP N
of IN N
the DT N
intervention NN N
patients NNS N
GPs NNP N
of IN N
intervention NN N
patients NNS N
GPs NNP N
in IN N
the DT N
postdischarge NN N
care NN N
of IN N
their PRP$ N
paediatric JJ 1_p
patients NNS N
with IN N
asthma JJ N
-DOCSTART- -X- O O 22617130

patients NNS N
with IN N
unresectable JJ N
and/or JJ N
recurrent NN N
advanced VBD N
gastric JJ 4_p
cancer NN 4_p
. . N

Patients NNPS N
with IN N
unresectable JJ 4_p
and/or JJ 4_p
recurrent NN 4_p
advanced VBD 4_p
gastric JJ 4_p
cancer NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
one CD N
of IN N
the DT N
two CD N
regimens NNS N
: : N
S-1 NNP N
( ( N
40 CD N
mg NN N
m NN N
( ( N
-2 NNP N
) ) N
twice RB N
daily RB N
) ) N
on IN N
days NNS N
1-14 JJ N
plus JJ N
paclitaxel NN N
( ( N
60 CD N
mg NN N
m NN N
( ( N
-2 NNP N
) ) N
) ) N
on IN N
days NNS N
1 CD N
, , N
8 CD N
, , N
and CC N
15 CD N
of IN N
a DT N
4-week JJ N
cycle NN N
( ( N
S-1+paclitaxel NNP N
) ) N
or CC N
S-1 NNP N
( ( N
40 CD N
mg NN N
m NN N
( ( N
-2 NNP N
) ) N
twice RB N
daily RB N
) ) N
on IN N
days NNS N
1-21 JJ N
plus JJ N
cisplatin NN N
( ( N
60 CD N
mg NN N
m NN N
( ( N
-2 NNP N
) ) N
) ) N
on IN N
day NN N
8 CD N
of IN N
a DT N
5-week JJ N
cycle NN N
( ( N
S-1+cisplatin NNP N
) ) N
. . N

83 CD N
patients NNS N
patients NNS N
with IN N
advanced JJ 4_p
gastric JJ 4_p
cancer NN 4_p
. . N

-DOCSTART- -X- O O 22583635

Long-term NNP N
followup NN N
was VBD N
assessed VBN N
in IN N
551 CD N
participants NNS N
enrolled VBN N
in IN N
a DT N
prospective JJ N
, , N
randomized JJ N
study NN N
of IN N
fluorescence NN N
cystoscopy NN N
for IN N
Ta NNP N
or CC N
T1 NNP N
urothelial JJ N
bladder NN N
cancer NN N
. . N

280 CD N
patients NNS N
in IN N
the DT N
white JJ N
light JJ N
cystoscopy NN N
group NN N
271 CD N
in IN N
the DT N
fluorescence NN N
cystoscopy NN N
group NN N
were VBD N
followed VBN N
with IN N
cystoscopy NN N
information NN N
was VBD N
obtained VBN N
for IN N
261 CD N
of IN N
the DT N
280 CD N
patients NNS N
( ( N
93 CD N
% NN N
) ) N
in IN N
the DT N
white JJ N
light NN N
group NN N
255 CD N
of IN N
the DT N
271 CD N
( ( N
94 CD N
% NN N
) ) N
in IN N
the DT N
fluorescence NN N
group NN N
. . N

-DOCSTART- -X- O O 484261

early JJ N
discharge NN N
after IN N
uncomplicated JJ N
myocardial JJ 4_p
infarction NN 4_p
. . N

383 CD 3_p
myocardial JJ 4_p
infarction NN 4_p
( ( 4_p
MI NNP 4_p
) ) 4_p
patients NNS N
aged VBN N
below IN N
70 CD 1_p
years NNS N
, , N
252 CD 3_p
( ( N
66 CD N
% NN N
) ) N
were VBD N
judged VBN N
after IN N
the DT N
third JJ N
day NN N
in IN N
hospital NN N
to TO N
have VB N
had VBN N
uncomplicated VBN 4_p
infarctions NNS 4_p
. . 4_p

-DOCSTART- -X- O O 3278798

standard-risk JJ N
acute JJ N
lymphoblastic JJ 4_p
leukemia NN 4_p
in IN N
childhood NN 1_p
( ( N
JCCLSG-S811 NNP N
) ) N
. . N

Japanese JJ N
Children NNP N
's POS N
Cancer NNP N
and CC N
Leukemia NNP N
Study NNP N
Group NNP N
. . N

1981 CD N
to TO N
1983 CD N
, , N
131 CD N
previously RB N
untreated JJ N
patients NNS N
with IN N
acute JJ N
lymphoblastic JJ N
leukemia NN N
( ( N
ALL DT N
) ) N
standard-risk JJ N
group NN N
119 CD 3_p
eligible JJ N
patients NNS N
-DOCSTART- -X- O O 11450818

Children NNP 4_p
's POS 4_p
attitudes NNS 4_p
and CC 4_p
behavioral JJ 4_p
intentions NNS 4_p
toward IN 4_p
a DT 4_p
peer NN 4_p
with IN 4_p
autistic JJ 4_p
behaviors NNS 4_p
: : 4_p
children NNS 4_p
's POS 4_p
ratings NNS 4_p
of IN 4_p
attitudes NNS 4_p
and CC 4_p
behavioral JJ 4_p
intentions NNS 4_p
toward IN 4_p
a DT 4_p
peer NN 4_p
presented VBN 4_p
with IN 4_p
or CC 4_p
without IN 4_p
autistic JJ 4_p
behaviors NNS 4_p
. . 4_p

Third- CD N
and CC N
sixth-grade JJ N
children NNS N
( ( N
N NNP N
= NNP N
233 CD N
) ) N
-DOCSTART- -X- O O 4127641

hypertensive JJ 4_p
patients NNS N
with IN N
thiazide-induced JJ 4_p
hypokalaemia NN 4_p
. . N

-DOCSTART- -X- O O 10690697

Aged-care JJ 1_p
health NN 1_p
services NNS 1_p
in IN N
Sydney NNP N
, , N
Australia NNP N
. . N

131 CD 3_p
women NNS 2_p
aged VBN 1_p
75 CD 1_p
years NNS 1_p
or CC 1_p
older JJR 1_p
, , N
who WP N
had VBD 4_p
two CD 4_p
or CC 4_p
more JJR 4_p
falls NNS 4_p
or CC 4_p
one CD 4_p
fall NN 4_p
requiring VBG 4_p
hospital JJ 4_p
admission NN 4_p
in IN 4_p
the DT 4_p
previous JJ 4_p
year NN 4_p
and CC N
who WP N
live VBP 4_p
at IN 4_p
home NN 4_p
. . N

Sixty-one JJ 3_p
subjects NNS N
were VBD N
in IN N
the DT N
intervention NN N
group NN N
70 CD 3_p
in IN N
the DT N
control NN N
group NN N
. . N

participants NNS N
recruited VBD N
at IN N
home NN N
-DOCSTART- -X- O O 24687182

adults NNS 1_p
with IN N
high-functioning JJ N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . N

adults NNS N
with IN N
high-functioning JJ N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( N
HF-ASD NNP N
) ) N
. . N

Twenty-five JJ 3_p
adults NNS 1_p
with IN N
HF-ASD NNP 4_p
adults NNS 1_p
with IN N
HF-ASD NNP 4_p
. . N

-DOCSTART- -X- O O 22940159

children NNS N
with IN N
visual-motor JJ N
integration NN N
difficulties NNS N
pre-existing JJ N
psychological JJ N
adjustment NN N
and CC N
self-esteem JJ N
levels NNS N
in IN N
kindergarten NN N
and CC N
first JJ N
grade NN N
children NNS N
with IN N
poor JJ N
visual-motor JJ N
integration NN N
skills NNS N
, , N
from IN N
low JJ N
socioeconomic JJ N
backgrounds NNS N
. . N

One CD N
hundred CD N
and CC N
sixteen JJ N
mainstream NN N
kindergarten NN N
and CC N
first-grade JJ N
children NNS N
, , N
from IN N
low JJ N
socioeconomic JJ N
backgrounds NNS N
, , N
scoring VBG N
below IN N
the DT N
25th CD N
percentile NN N
on IN N
a DT N
measure NN N
of IN N
visual-motor NN N
integration NN N
( ( N
VMI NNP N
) ) N
were VBD N
recruited VBN N
-DOCSTART- -X- O O 23065117

nonverbal JJ 4_p
children NNS 1_p
with IN N
autism NN 4_p
. . N

nonverbal JJ N
children NNS N
with IN N
autism NN N
. . N

Participants NNS N
were VBD N
12 CD 3_p
nonverbal JJ 4_p
children NNS 4_p
with IN N
autism NN 4_p
ages NNS 1_p
5 CD 1_p
through IN 1_p
7 CD 1_p
randomly RB N
assigned VBN N
to TO N
either DT N
treatment NN N
group NN N
. . N

children NNS N
with IN N
autism NN N
. . N

-DOCSTART- -X- O O 25001365

Neck NNP N
circumference NN N
and CC N
early JJ 4_p
stage NN 4_p
atherosclerosis NN 4_p
: : N
NC NNP N
and CC N
early JJ 4_p
stage NN 4_p
atherosclerosis NN 4_p
in IN N
Chinese JJ N
adults NNS 1_p
. . 1_p

central JJ N
China NNP N
. . N

In IN N
total JJ N
2,318 CD 3_p
men NNS 2_p
and CC N
women NNS 2_p
( ( N
18-64 JJ 1_p
y NN 1_p
) ) N
were VBD N
included VBN N
in IN N
the DT N
final JJ N
analyses NNS N
. . N

risk NN N
of IN N
early JJ 4_p
stage NN 4_p
atherosclerosis NN 4_p
in IN N
Chinese JJ 4_p
-DOCSTART- -X- O O 22066973

labor NN N
analgesia NN N
: : N
parturients NNS N
undergoing VBG N
labor NN N
during IN N
epidural JJ N
analgesia NN N
. . N

Sixty-one JJ N
parturients NNS N
undergoing VBG N
labor NN N
selected VBN N
for IN N
delivery NN N
with IN N
epidural JJ N
analgesia NNS N
-DOCSTART- -X- O O 23092665

cardiac NN N
surgery NN N
40 CD N
patients NNS N
scheduled VBN N
to TO N
undergo VB N
coronary JJ N
artery NN N
bypass NN N
grafting VBG N
with IN N
cardiopulmonary JJ N
bypass NN N
selected VBN 4_p
patients NNS 4_p
after IN 4_p
cardiac JJ 4_p
surgery NN 4_p
. . 4_p

-DOCSTART- -X- O O 16923411

Patients NNPS N
with IN N
chronic JJ 4_p
kidney NN 4_p
disease NN 4_p
, , N
including VBG N
kidney NN 4_p
transplant NN 4_p
recipients NNS 4_p
renal JJ 4_p
transplant NN 4_p
recipients NNS 4_p
. . N

Participants NNS N
are VBP N
clinically RB N
stable JJ N
renal JJ 4_p
transplant NN 4_p
recipients NNS 4_p
who WP N
are VBP N
6 CD N
months NNS N
or CC N
longer JJR N
posttransplant NN N
with IN N
elevated JJ 4_p
tHcy NN 4_p
. . N

Recruitment NN N
is VBZ N
expected VBN N
to TO N
continue VB N
until IN N
July NNP N
2006 CD N
From IN N
August NNP N
2002 CD N
through IN N
December NNP N
2004 CD N
, , N
2234 CD 3_p
of IN N
the DT N
target NN N
4000 CD 3_p
patients NNS N
were VBD N
enrolled VBN N
. . N

renal JJ 4_p
transplant NN 4_p
recipients NNS 4_p
-DOCSTART- -X- O O 15734707

serum NN 4_p
retinol JJ 4_p
concentration NN 4_p
of IN N
Filipino NNP 4_p
children NNS N
4-7 CD 1_p
years NNS 1_p
old JJ 1_p
. . N

542 CD 3_p
Filipino NNP N
children NNS N
aged VBD N
4 CD 1_p
to TO 1_p
7 CD 1_p
years NNS N
-DOCSTART- -X- O O 19106322

Belarus NNP N
. . N

The DT N
Promotion NN N
of IN N
Breastfeeding NNP N
Intervention NNP N
Trial NNP N
( ( N
PROBIT NNP N
) ) N
is VBZ N
a DT N
cluster-randomized JJ N
trial NN N
of IN N
a DT N
breast-feeding JJ N
promotion NN N
intervention NN N
17,046 CD 3_p
healthy JJ N
breast-fed JJ N
infants NNS N
were VBD N
enrolled VBN N
from IN N
31 CD N
Belarussian JJ N
maternity NN N
hospitals NNS N
and CC N
affiliated JJ N
clinics NNS N
13,889 CD 3_p
( ( N
81.5 CD N
% NN N
) ) N
were VBD N
followed VBN N
up RP N
at IN N
6.5 CD N
y NN N
-DOCSTART- -X- O O 9178124

heifers NNS 2_p
. . N

30 CD N
heifers NNS 2_p
30 CD N
heifers NNS 2_p
-DOCSTART- -X- O O 2064495

hypercholesterolemia NN 4_p
. . N

Two CD 3_p
hundred VBD 3_p
one CD 3_p
male NN N
and CC N
female JJ N
subjects NNS N
, , N
aged VBD N
20 CD 1_p
to TO 1_p
70 CD 1_p
years NNS N
, , N
with IN N
elevated VBN 4_p
low-density NN 4_p
lipoprotein NN 4_p
cholesterol NN 4_p
values NNS 4_p
( ( 4_p
in IN 4_p
the DT 4_p
75th CD 4_p
to TO 4_p
95th CD 4_p
percentiles NNS 4_p
) ) 4_p
, , N
participated VBN N
-DOCSTART- -X- O O 8628584

4 CD N
groups NNS N
of IN N
cancer NN N
patients NNS N
receiving VBG N
bone NN N
marrow NN N
transplants NNS N
( ( N
BMT NNP N
) ) N
: : N
( ( N
1 CD N
) ) N
treatment NN N
as IN N
usual JJ N
control NN N
, , N
( ( N
2 CD N
) ) N
therapist NN N
support NN N
, , N
( ( N
3 CD N
) ) N
relaxation NN N
and CC N
imagery NN N
training NN N
, , N
and CC N
( ( N
4 CD N
) ) N
training NN N
in IN N
a DT N
package NN N
of IN N
cognitive-behavioral JJ N
coping NN N
skills NNS N
which WDT N
included VBD N
relaxation NN N
and CC N
imagery NN N
. . N

94 CD N
patients NNS N
completed VBD N
the DT N
study NN N
which WDT N
involved VBD N
two CD N
training NN N
sessions NNS N
prior RB N
to TO N
treatment NN N
and CC N
twice RB N
a DT N
week NN N
'booster POS N
' POS N
sessions NNS N
during IN N
the DT N
first JJ N
5 CD N
weeks NNS N
of IN N
treatment NN N
. . N

-DOCSTART- -X- O O 24602973

81 CD 3_p
patients NNS N
undergoing JJ N
diagnostic JJ 4_p
or CC 4_p
therapeutic JJ 4_p
bronchoscopy NN 4_p
under IN 4_p
propofol NN 4_p
sedation NN 4_p
patients NNS 4_p
undergoing VBG 4_p
FFB NNP 4_p
of IN 4_p
relatively RB 4_p
short JJ 4_p
duration NN 4_p
-DOCSTART- -X- O O 14674492

class NN 4_p
II NNP 4_p
furcation NN 4_p
defects NNS 4_p
. . N

Class NNP N
II NNP N
furcation NN N
defects NNS N
Nine NNP 3_p
patients NNS N
, , N
with IN N
two CD N
comparable JJ N
Class NNP 4_p
II NNP 4_p
furcation NN 4_p
defects NNS 4_p
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

GTR-group NNP 4_p
or CC 4_p
OFD-group NNP 4_p
. . N

-DOCSTART- -X- O O 19786879

hearing VBG 4_p
rehabilitation NN 4_p
. . N

Hearing NNP 4_p
loss NN 4_p
adults NNS 1_p
with IN N
hearing VBG 4_p
impairment NN 4_p
. . 4_p

Thirteen JJ 3_p
individuals NNS N
with IN N
impaired JJ 4_p
hearing NN 4_p
were VBD N
tested VBN N
before IN N
and CC N
after IN N
6 CD 4_p
months NNS 4_p
of IN 4_p
hearing-aid JJ 4_p
use NN 4_p
19 CD 3_p
individuals NNS N
who WP N
had VBD N
worn VBN 4_p
hearing NN 4_p
aids NNS 4_p
for IN N
many JJ N
years NNS N
. . N

-DOCSTART- -X- O O 12056851

osteoarthritis NN 4_p
( ( N
OA NNP 4_p
) ) N
of IN N
the DT N
hip NN N
or CC N
knee NN N
Fifty NNP 3_p
patients NNS N
, , N
demographically RB N
balanced VBN N
, , N
with IN N
radiographically RB 4_p
proven JJ 4_p
primary JJ 4_p
hip NN 4_p
or CC 4_p
knee NN 4_p
OA NNP 4_p
completed VBD N
the DT N
classical JJ N
paper NN N
and CC N
the DT N
new JJ N
computerized JJ N
WOMAC NNP N
version NN N
. . N

-DOCSTART- -X- O O 11517983

horses NNS 4_p
to TO 4_p
be VB 4_p
anaesthetised VBN 4_p
with IN 4_p
isoflurane NN 4_p
. . N

Forty-eight JJ 3_p
horses NNS 4_p
subjected VBN 4_p
to TO 4_p
elective VB 4_p
surgery NN 4_p
three CD N
groups NNS N
of IN N
16 CD N
horses NNS N
. . N

-DOCSTART- -X- O O 19138400

peripheral JJ 4_p
stage NN 4_p
IA NNP 4_p
non-small NN 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
: : 4_p
patients NNS N
with IN N
operable JJ N
stage NN N
IA NNP N
lung NN N
cancer NN N
. . N

a DT N
planning NN N
study NN N
was VBD N
performed VBN N
in IN N
26 CD N
stage NN N
I PRP N
patients NNS N
, , N
of IN N
which WDT N
22 CD N
were VBD N
stage NN N
1A CD N
-DOCSTART- -X- O O 15188980

term NN N
neonates NNS 1_p
: : N
81 CD 3_p
full-term JJ N
neonates NNS N
, , N
up RB N
to TO N
4 CD 1_p
wk NN 1_p
of IN N
postnatal JJ N
age NN N
, , N
who WP N
needed VBD N
venepuncture NN N
for IN N
blood NN N
investigations NNS N
. . N

pain VB 4_p
in IN N
term NN N
neonates NNS N
. . N

-DOCSTART- -X- O O 8964729

healthy JJ 4_p
subjects NNS 4_p
. . 4_p

Subjects NNS N
normal JJ N
subjects NNS N
-DOCSTART- -X- O O 23566237

depressed JJ N
, , N
distensible JJ N
acne NN N
scars NNS N
moderate JJ N
to TO N
severe VB N
, , N
depressed JJ N
, , N
distensible JJ N
facial JJ N
acne NN N
scars NNS N
subjects NNS N
with IN N
bilateral JJ N
moderate NN N
to TO N
severe VB N
acne JJ N
scarring NN N
; : N
subjects NNS N
Subjects NNS N
( ( N
n JJ N
= NNP N
99 CD N
) ) N
-DOCSTART- -X- O O 7608035

autism NN 4_p
. . 4_p

-DOCSTART- -X- O O 8866262

glass NN N
ionomer-lined JJ N
amalgam NN N
and CC N
composite JJ N
restorations NNS N
. . N

extracted JJ N
upper JJ N
premolars NNS N
were VBD N
used VBN N
and CC N
ten JJ N
restorations NNS N
were VBD N
used VBN N
for IN N
each DT N
of IN N
the DT N
following JJ N
groups NNS N
: : N
( ( N
i NN N
) ) N
two CD N
layers NNS N
of IN N
copal JJ N
varnish JJ N
and CC N
amalgam NN N
; : N
( ( N
ii NN N
) ) N
conventional JJ N
glass-ionomer JJ N
and CC N
amalgam NN N
; : N
( ( N
iii NN N
) ) N
light-cured JJ N
glass-ionomer NN N
and CC N
amalgam NN N
; : N
( ( N
iv NN N
) ) N
bonding NN N
agent NN N
and CC N
light-cured JJ N
composite JJ N
resin NN N
; : N
( ( N
v NN N
) ) N
conventional JJ N
glass-ionomer JJ N
, , N
bonding JJ N
agent NN N
and CC N
light-cured JJ N
composite JJ N
resin NN N
; : N
( ( N
vi NN N
) ) N
light-cured JJ N
glass-ionomer NN N
, , N
extended VBD N
0.3 CD N
mm NN N
short NN N
of IN N
the DT N
enamel JJ N
margin NN N
bonding VBG N
agent NN N
and CC N
light-cured JJ N
composite JJ N
resin NN N
; : N
and CC N
( ( N
vii NN N
) ) N
light-cured JJ N
glass-ionomer NN N
, , N
extended VBD N
1 CD N
mm NN N
short NN N
of IN N
the DT N
enamel NN N
margin NN N
, , N
bonding VBG N
agent NN N
and CC N
light-cured JJ N
composite JJ N
resin NN N
. . N

teeth NNS N
-DOCSTART- -X- O O 22512510

school-age JJ 1_p
children NNS 1_p
who WP 1_p
have VBP 1_p
pragmatic JJ 1_p
and CC 1_p
social JJ 1_p
communication NN 1_p
problems NNS 1_p
with IN 1_p
or CC 1_p
without IN 1_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . N

Children NNPS N
who WP N
show VBP N
disproportionate JJ 4_p
difficulty NN 4_p
with IN 4_p
the DT 4_p
pragmatic JJ 4_p
as IN 4_p
compared VBN 4_p
with IN 4_p
the DT 4_p
structural JJ 4_p
aspects NNS 4_p
of IN 4_p
language NN 4_p
are VBP N
described VBN N
as IN N
having VBG N
pragmatic JJ 4_p
language NN 4_p
impairment NN 4_p
( ( 4_p
PLI NNP 4_p
) ) 4_p
or CC N
social JJ N
communication NN N
disorder NN N
( ( N
SCD NNP N
) ) N
. . N

children NNS N
who WP N
have VBP N
PLI VBN 4_p
with IN 4_p
or CC 4_p
without IN 4_p
features NNS 4_p
of IN 4_p
ASD NNP 4_p
. . N

88 CD 3_p
children NNS N
with IN N
pragmatic JJ N
and CC N
social JJ N
communication NN N
needs NNS N
aged VBD 1_p
5 CD 1_p
; : 1_p
11-10 JJ 1_p
; : 1_p
8 CD 1_p
, , N
recruited VBN N
from IN N
UK NNP N
speech NN N
and CC N
language NN N
therapy NN N
services NNS N
Children NNP 4_p
in IN 4_p
the DT 4_p
SCIP NNP 4_p
condition NN 4_p
6-11-year-old JJ 1_p
children NNS 1_p
who WP N
have VBP N
pragmatic JJ 4_p
and CC 4_p
social JJ 4_p
communication NN 4_p
needs NNS 4_p
. . N

-DOCSTART- -X- O O 19797985

children NNS 1_p
and CC N
adolescents NNS 1_p
with IN N
irritability NN 4_p
associated VBN N
with IN N
autistic JJ 4_p
disorder NN 4_p
. . N

children NNS 1_p
and CC N
adolescents NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
. . N

Two CD 3_p
hundred VBD 3_p
eighteen JJ 3_p
children NNS 1_p
and CC N
adolescents NNS 1_p
( ( N
aged VBN N
6-17 CD 1_p
years NNS 1_p
) ) N
with IN N
a DT N
diagnosis NN N
of IN N
autistic JJ 4_p
disorder NN 4_p
, , N
and CC N
with IN N
behaviors NNS N
such JJ N
as IN N
tantrums NNS 4_p
, , N
aggression NN 4_p
, , 4_p
self-injurious JJ 4_p
behavior NN 4_p
, , 4_p
or CC N
a DT N
combination NN N
of IN N
these DT N
symptoms NNS N
children NNS 1_p
and CC N
adolescents NNS 1_p
with IN N
irritability NN 4_p
associated VBN N
with IN N
autistic JJ 4_p
disorder NN 4_p
. . 4_p

-DOCSTART- -X- O O 15838684

20 CD 3_p
freshly RB 4_p
extracted VBN 4_p
, , N
non-periodontally RB 4_p
involved VBN 4_p
, , N
large JJ 4_p
human JJ 4_p
molars NNS 4_p
. . N

40 CD 3_p
specimens NNS N
-DOCSTART- -X- O O 23292082

Finland NNP 4_p
: : N
prostate NN 4_p
, , 4_p
breast NN 4_p
, , 4_p
and CC 4_p
colorectal JJ 4_p
cancer NN 4_p
risk NN 4_p
. . N

Finns NNP N
more JJR N
than IN N
4,000 CD 3_p
prostate JJ N
cancer NN N
cases NNS N
and CC N
5,000 CD 3_p
controls NNS N
. . N

In IN N
addition NN N
, , N
986 CD 3_p
breast NN N
cancer NN N
and CC N
442 CD 3_p
colorectal JJ N
cancer NN N
( ( N
CRC NNP N
) ) N
cases NNS N
were VBD N
studied VBN N
. . N

the DT N
Finnish JJ N
population NN N
and CC N
cases NNS N
mutation NN N
in IN N
prostate NN N
cancer NN N
-DOCSTART- -X- O O 18362489

patients NNS 4_p
with IN 4_p
hematuria NNS 4_p
related VBN 4_p
to TO 4_p
benign VB 4_p
prostate JJ 4_p
hyperplasia NN 4_p
. . N

patients NNS 4_p
with IN 4_p
hematuria NNS 4_p
secondary JJ 4_p
to TO 4_p
benign VB 4_p
prostatic JJ 4_p
hyperplasia NN 4_p
( ( 4_p
BPH NNP 4_p
) ) 4_p
. . N

30 CD 3_p
patients NNS 3_p
who WP N
were VBD N
candidates NNS 4_p
for IN 4_p
BPH NNP 4_p
surgery NN 4_p
All DT N
patients NNS N
had VBD N
history NN 4_p
of IN 4_p
gross JJ 4_p
hematuria NN 4_p
and CC 4_p
evaluated VBN 4_p
by IN 4_p
ultrasonography NN 4_p
and CC 4_p
cystoscopy NN 4_p
. . N

-DOCSTART- -X- O O 22374696

NPM1 NNP 4_p
mutated VBD 4_p
, , N
but CC 4_p
not RB 4_p
in IN 4_p
NPM1 NNP 4_p
unmutated VBD 4_p
, , N
AML NNP 4_p
with IN 4_p
a DT 4_p
normal JJ 4_p
karyotype NN 4_p
. . N

patients NNS 4_p
with IN 4_p
acute JJ 4_p
myeloid NN 4_p
leukemia NN 4_p
( ( 4_p
AML NNP 4_p
) ) 4_p
648 CD 3_p
normal JJ N
karyotype NN N
( ( N
NK NNP N
) ) N
AML NNP N
patients NNS N
329 CD 3_p
patients NNS N
with IN N
a DT N
mutated VBN N
NPM1 NNP N
gene NN N
( ( N
NPM1+ NNP N
) ) N
319 CD 3_p
patients NNS N
without IN N
a DT N
NPM1 NNP N
mutation NN N
( ( N
wtNPM1 NN N
) ) N
. . N

NPM1+ NNP N
subgroup NN N
NPM1-mutated JJ 4_p
AML NNP 4_p
. . N

-DOCSTART- -X- O O 12538218

endotracheal JJ 4_p
intubation NN 4_p
: : N
impending JJ N
hypoxic NN 4_p
patient NN N
. . N

Three CD 3_p
hundred VBD 3_p
adult NN 1_p
patients NNS N
were VBD N
enrolled VBN N
in IN N
this DT N
study NN N
. . N

difficult JJ 4_p
intubation NN 4_p
-DOCSTART- -X- O O 3124456

anemia NN 4_p
of IN N
chronic JJ 4_p
renal JJ 4_p
disease NN 4_p
: : N
iron-replete JJ N
hemodialysis NN N
patients NNS N
4 CD 3_p
androgen-treated JJ N
patients NNS N
chronic JJ N
hemodialysis NN N
patients NNS N
-DOCSTART- -X- O O 8849265

patients NNS 4_p
with IN 4_p
lung NN 4_p
cancer NN 4_p
who WP 4_p
had VBD 4_p
been VBN 4_p
treated VBN 4_p
with IN 4_p
myelosuppressive JJ 4_p
chemotherapy NN 4_p
and CC 4_p
then RB 4_p
with IN 4_p
subcutaneous JJ 4_p
rhG-CSF NN 4_p
( ( 4_p
lenograstim NN 4_p
, , 4_p
2 CD 4_p
micrograms NNS 4_p
per IN 4_p
kg NN 4_p
of IN 4_p
body NN 4_p
weight JJ 4_p
per IN 4_p
day NN 4_p
) ) 4_p
. . N

Twelve CD 3_p
patients NNS N
were VBD N
randomly RB N
assigned VBN N
-DOCSTART- -X- O O 20484620

newborns NNS 1_p
with IN N
neonatal JJ 4_p
abstinence NN 4_p
syndrome NN 4_p
. . N

newborns NNS 1_p
with IN N
neonatal JJ 4_p
abstinence NN 4_p
syndrome NN 4_p
36 CD 3_p
newborns NNS 1_p
, , N
aged VBD N
1 CD 1_p
to TO 1_p
25 CD 1_p
days NNS 1_p
( ( N
postnatal JJ N
age NN N
, , N
PNA NNP N
) ) N
and CC N
weighing VBG N
2.1 CD N
to TO N
3.9 CD N
kg NNS N
-DOCSTART- -X- O O 25142189

acute JJ 4_p
myeloid NN 4_p
leukaemia NN 4_p
. . N

in IN N
adult NN 1_p
patients NNS 1_p
with IN 4_p
previously RB 4_p
untreated VBN 4_p
AML NNP 4_p
receiving VBG 4_p
induction NN 4_p
therapy NN 4_p
with IN 4_p
idarubicin NN 4_p
, , N
high-dose JJ 4_p
cytarabine NN 4_p
and CC 4_p
etoposide NN 4_p
Among IN 3_p
155 CD 3_p
randomized JJ 3_p
patients NNS 3_p
-DOCSTART- -X- O O 10926339

newly RB N
detected VBN N
asthma NN 4_p
. . N

patients NNS N
with IN N
newly RB N
detected VBN N
asthma NN 4_p
. . N

101 CD 3_p
adult NN 3_p
patients NNS 3_p
with IN N
newly RB N
detected VBN N
bronchial JJ 4_p
asthma NN 4_p
who WP N
were VBD N
without IN N
inhaled VBN 4_p
steroid NN 4_p
or CC N
any DT N
regular JJ N
pharmacological JJ 4_p
treatment NN 4_p
for IN N
their PRP$ N
asthma NN 4_p
. . N

-DOCSTART- -X- O O 22565161

of IN N
ulcerative JJ 4_p
colitis NN 4_p
Overall NNP N
, , N
826 CD 3_p
patients NNS N
were VBD N
randomized VBN N
and CC N
dosed VBN N
-DOCSTART- -X- O O 19365716

children NNS 4_p
with IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorders NNP 4_p
. . N

children NNS 4_p
, , 4_p
ages VBZ 4_p
7-11 CD 4_p
, , N
diagnosed VBN 4_p
with IN 4_p
Autism NNP 4_p
Spectrum NNP 4_p
Disorders NNP 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
. . N

Eighteen JJ N
children NNS N
with IN N
ASD NNP 4_p
ten JJ N
non-ASD JJ N
children NNS N
individuals NNS N
with IN N
ASD NNP N
. . N

-DOCSTART- -X- O O 7707405

small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
in IN 4_p
complete JJ 4_p
remission NN 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
patients NNS 4_p
in IN 4_p
complete JJ 4_p
remission NN 4_p
. . N

patients NNS 4_p
with IN 4_p
small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
in IN 4_p
complete JJ 4_p
remission NN 4_p
. . N

300 CD 3_p
patients NNS 4_p
who WP 4_p
had VBD 4_p
small-cell NN 4_p
lung NN 4_p
cancer NN 4_p
that WDT 4_p
was VBD 4_p
in IN 4_p
complete JJ 4_p
remission NN 4_p
. . N

Two CD 3_p
hundred VBD 3_p
ninety-four JJ 3_p
patients NNS 3_p
who WP N
did VBD N
not RB N
have VB N
brain NN N
metastases NNS N
patients NNS 4_p
with IN 4_p
small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
in IN 4_p
complete JJ 4_p
remission NN 4_p
patients NNS 4_p
who WP 4_p
are VBP 4_p
in IN 4_p
complete JJ 4_p
remission NN 4_p
. . N

patients NNS 4_p
in IN 4_p
complete JJ 4_p
remission NN 4_p
-DOCSTART- -X- O O 8707361

kala-azar NN 4_p
. . N

288 CD 3_p
parasitologically RB 4_p
proved JJ 4_p
patients NNS 4_p
of IN 4_p
kala-azar NNS 4_p
Indian JJ 4_p
kala-azar JJ 4_p
patients NNS 4_p
-DOCSTART- -X- O O 7856515

exposure NN 4_p
to TO 4_p
acid VB 4_p
fog NN 4_p
: : 4_p
seven CD 3_p
healthy JJ 1_p
young JJ 1_p
men NNS 1_p
-DOCSTART- -X- O O 15798610

acute JJ 4_p
ischaemic JJ 4_p
stroke NN 4_p
. . N

within IN N
the DT N
first JJ N
6 CD N
hours NNS N
of IN N
acute JJ N
ischaemic JJ N
stroke NN N
. . N

Patients NNS N
fulfilling VBG N
the DT N
selection NN N
criteria NNS N
Fourteen CD 3_p
patients NNS N
were VBD N
given VBN N
IVF NNP N
and CC N
13 CD N
IAF NNP N
. . N

27 CD 3_p
patients NNS N
had VBD N
been VBN N
included VBN N
because IN N
of IN N
the DT N
mortality NN N
rate NN N
. . N

-DOCSTART- -X- O O 9076205

eyes NNS 4_p
with IN 4_p
severe JJ 4_p
proliferative JJ 4_p
vitreoretinopathy NN 4_p
: : 4_p
retinal JJ 4_p
detachment NN 4_p
with IN 4_p
proliferative JJ 4_p
vitreoretinopathy NN 4_p
( ( 4_p
PVR NNP 4_p
) ) 4_p
. . 4_p

Two-hundred JJ N
sixty-five JJ N
eyes NNS N
with IN N
PVR NNP N
Both DT N
cohorts NNS N
consisted VBD N
of IN N
eyes NNS N
that WDT N
had VBD N
and CC N
had VBD N
not RB N
undergone JJ N
vitrectomy NN N
for IN N
PVR NNP N
PVR NNP N
. . N

-DOCSTART- -X- O O 12116339

small JJ N
cell NN N
lung NN N
cancer NN N
patients NNS N
. . N

small JJ N
cell NN N
lung NN N
cancer NN N
( ( N
SCLC NNP N
) ) N
patients NNS N
11 CD N
patients NNS N
received VBD N
either RB N
standard JJ N
( ( N
four CD N
weekly RB N
) ) N
chemotherapy NN N
with IN N
ifosfamide NN N
, , N
carboplatin NN N
, , N
and CC N
etoposide RB N
( ( N
ICE NNP N
) ) N
or CC N
accelerated VBN N
( ( N
two CD N
weekly RB N
) ) N
ICE NNP N
with IN N
filgrastim NN N
( ( N
granulocyte JJ N
-DOCSTART- -X- O O 24375082

autistic JJ 4_p
children NNS 1_p
: : N
childhood NN 1_p
autism NN 4_p
subjects NNS N
with IN N
autism NN 4_p
Forty-five JJ 3_p
subjects NNS N
diagnosed VBN N
with IN N
autism NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
boiled VBN N
CM NNP N
for IN N
group NN N
I PRP N
( ( N
n JJ N
= NNP N
15 CD 3_p
) ) N
, , N
raw JJ N
CM NNP N
for IN N
group NN N
II NNP N
( ( N
n JJ N
= NNP N
15 CD 3_p
) ) N
, , N
and CC N
placebo NN N
for IN N
group NN N
III NNP N
( ( N
n JJ N
= NNP N
15 CD 3_p
) ) N
for IN N
2 CD N
wk NN N
. . N

in IN N
autistic JJ N
children NNS N
-DOCSTART- -X- O O 16822100

preschoolers NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . N

36 CD 3_p
preschoolers NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . 4_p

-DOCSTART- -X- O O 21946197

patients NNS N
with IN N
liver JJ 4_p
failure NN 4_p
] NNP 4_p
. . N

subjects NNS N
with IN N
liver JJ 4_p
failure NN 4_p
174 CD N
MARS NNP N
treatment NN N
sessions NNS N
for IN N
146 CD N
patients NNS N
with IN N
liver JJ N
failure NN N
and CC N
prothrombin JJ N
time NN N
activity NN N
percentage NN N
( ( N
PTA NNP N
) ) N
≤ VBD N
40 CD N
% NN N
were VBD N
randomly RB N
divided VBN N
into IN N
2 CD N
groups NNS N
: : N
92 CD N
MARS NNP N
treatment NN N
sessions NNS N
in IN N
the DT N
heparin-free JJ N
group NN N
and CC N
82 CD N
in IN N
the DT N
low-dose JJ N
heparin NN N
group NN N
-DOCSTART- -X- O O 25778317

patients NNS 4_p
with IN 4_p
advanced JJ 4_p
nasopharyngeal JJ 4_p
carcinoma NN 4_p
: : N
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
nasopharyngeal JJ 4_p
carcinoma NN 4_p
( ( 4_p
NPC NNP 4_p
) ) 4_p
. . N

Two CD 3_p
hundred VBD 3_p
patients NNS 3_p
with IN N
stage NN 4_p
III/IV NNP 4_p
NPC NNP 4_p
were VBD N
randomly RB N
allocated VBN N
treatment NN N
group NN N
( ( N
N=100 NNP N
) ) N
and CC N
the DT N
control NN N
group NN N
( ( N
N=100 NNP N
) ) N
. . N

patients NNS N
with IN N
advanced JJ 4_p
NPC NNP 4_p
-DOCSTART- -X- O O 23992605

post NN N
thrombotic JJ N
syndrome NN N
. . N

acute JJ N
deep JJ N
venous JJ N
thrombosis NN N
( ( N
DVT NNP N
) ) N
Sixty-nine JJ N
consecutive JJ N
patients NNS N
with IN N
acute JJ N
DVT NNP N
documented VBN N
by IN N
duplex JJ N
ultrasonography NN N
Patients NNS N
were VBD N
followed VBN N
clinically RB N
at IN N
months NNS N
1 CD N
, , N
3 CD N
, , N
6 CD N
, , N
12 CD N
, , N
18 CD N
, , N
and CC N
24 CD N
after IN N
the DT N
diagnosis NN N
of IN N
DVT NNP N
. . N

-DOCSTART- -X- O O 21188521

patients NNS N
with IN N
unresectable JJ 4_p
HCC NNP 4_p
and CC N
in IN N
HCC NNP 4_p
cell NN N
lines NNS N
. . N

HCC NNP 4_p
patients NNS N
HCC NNP 4_p
patients NNS N
who WP N
had VBD N
both DT N
elevated VBN N
AFP NNP N
and CC N
DCP NNP N
were VBD N
included VBN N
. . N

27-patient JJ 3_p
phase NN N
II NNP N
cohort NN N
-DOCSTART- -X- O O 16145415

transurethral JJ 4_p
prostate NN 4_p
surgery NN 4_p
: : N
101 CD 3_p
men NNS 2_p
with IN N
benign JJ 4_p
prostatic JJ 4_p
hyperplasia NN 4_p
96 CD 3_p
patients NNS N
with IN N
a DT N
mean JJ 1_p
age NN 1_p
+/- JJ 1_p
SD NNP 1_p
of IN 1_p
69.1 CD 1_p
+/- JJ 1_p
6.1 CD 1_p
years NNS 1_p
was VBD N
available JJ N
-DOCSTART- -X- O O 3313023

migraine NN 4_p
30 CD 3_p
children NNS 1_p
between IN 1_p
7 CD 1_p
and CC 1_p
17 CD 1_p
years NNS N
suffering VBG N
from IN N
at IN N
least JJS N
2 CD N
attacks/month NN N
of IN N
common JJ 4_p
or CC 4_p
classical JJ 4_p
migraine NN 4_p
since IN N
more JJR N
than IN N
1 CD N
year NN N
childhood NN 4_p
migraine NN 4_p
. . 4_p

-DOCSTART- -X- O O 5512598

autonomic JJ 4_p
processes NNS 4_p
. . 4_p

-DOCSTART- -X- O O 14984440

seasonal JJ 4_p
allergic JJ 4_p
rhinitis NN 4_p
. . N

allergic JJ 4_p
rhinitis NN 4_p
patients NNS N
with IN N
allergic JJ N
rhinitis NN N
Six NNP 3_p
female NN 2_p
and CC N
18 CD 3_p
male NN 2_p
volunteers NNS N
( ( N
median JJ N
age NN N
26 CD 1_p
years NNS 1_p
) ) N
with IN N
a DT N
history NN N
of IN N
allergic JJ 4_p
rhinitis NN 4_p
but CC N
currently RB N
free JJ N
of IN N
symptoms NNS N
were VBD N
included VBN N
humans NNS N
. . N

-DOCSTART- -X- O O 26225500

postoperative NN 4_p
pain NN 4_p
after IN 4_p
caesarean JJ 4_p
section NN 4_p
: : 4_p
patients NNS 4_p
with IN 4_p
chronic JJ 4_p
pain NN 4_p
. . 4_p

visceral JJ N
pain NN N
after IN N
caesarean JJ N
section NN N
. . N

caesarean JJ N
section NN N
A DT N
single JJ N
centre NN N
between IN N
June NNP N
2014 CD N
and CC N
December NNP N
2014 CD N
. . N

Fifty JJ 3_p
patients NNS N
who WP N
were VBD N
American JJ N
Society NNP N
of IN N
Anesthesiologists NNP 4_p
physical JJ N
status NN N
1 CD N
or CC N
2 CD N
, , N
with IN N
normal JJ N
singleton NN N
pregnancies NNS N
with IN N
a DT N
gestation NN N
of IN N
at IN N
least JJS N
37 CD N
weeks NNS N
, , N
and CC N
scheduled VBN N
for IN N
elective JJ 4_p
caesarean JJ 4_p
section NN 4_p
under IN 4_p
spinal JJ 4_p
anaesthesia NN 4_p
at IN N
all DT N
times NNS N
. . N

CONCLUSION VB N
-DOCSTART- -X- O O 8627197

onychomycosis NN 4_p
. . 4_p

-DOCSTART- -X- O O 24915929

autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
: : 4_p
Autism NNP 4_p
high-functioning JJ 4_p
individuals NNS N
with IN N
autism NN 4_p
and CC N
typically-developing NN N
controls NNS N
high-functioning JJ 4_p
individuals NNS N
with IN N
autism NN 4_p
individuals NNS N
with IN N
autism NN 4_p
. . N

-DOCSTART- -X- O O 1897766

40 CD 3_p
patients NNS N
undergoing JJ N
cholecystectomy NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
two CD N
groups NNS N
of IN N
20 CD 3_p
patients NNS N
each DT N
. . N

One CD N
group NN N
The DT N
other JJ N
group NN N
patients NNS N
-DOCSTART- -X- O O 17942872

In IN N
a DT N
population-based JJ N
screening NN N
program NN N
in IN N
Sweden NNP N
, , N
12,527 CD 3_p
women NNS 2_p
32 CD 1_p
to TO 1_p
38 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
were VBD N
randomly RB N
assigned VBN N
women NNS 2_p
in IN N
their PRP$ N
mid-30s NN 1_p
-DOCSTART- -X- O O 11743411

During IN N
a DT N
period NN N
of IN N
7.5 CD N
years NNS N
Twenty NNP 3_p
healthy JJ 4_p
women NNS 2_p
with IN N
a DT N
mean JJ 1_p
age NN 1_p
of IN 1_p
30 CD 1_p
years NNS 1_p
were VBD N
operated VBN N
on IN N
for IN N
breast NN 4_p
augmentation NN 4_p
. . N

Eighteen JJ 3_p
patients NNS 3_p
completed VBN N
1-year JJ N
and CC N
7.5-year JJ N
follow-up NN N
. . N

-DOCSTART- -X- O O 21355149

male JJ 2_p
osteoporosis NN 4_p
] NNP N
male JJ 2_p
osteoporosis NN 4_p
. . N

Fifty-five JJ 3_p
cases NNS 3_p
male JJ 2_p
osteoporosis NN 4_p
-DOCSTART- -X- O O 11214014

coronary JJ 4_p
artery NN 4_p
bypass NN 4_p
grafting VBG 4_p
patients NNS N
randomized VBN N
into IN N
allopurinol NN N
( ( N
n JJ N
= NNP N
14 CD 3_p
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
13 CD 3_p
) ) N
groups NNS N
. . N

All DT N
patients NNS N
in IN N
both DT N
groups NNS N
-DOCSTART- -X- O O 25481453

prescription NN 4_p
opioid NN 4_p
abusers NNS 4_p
. . 4_p

89 CD 3_p
PO-dependent JJ N
adults NNS 1_p
screened VBD N
for IN N
a DT N
trial NN N
evaluating VBG N
the DT N
relative JJ N
efficacy NN N
of IN N
buprenorphine NN N
taper NN N
durations NNS N
. . N

participants NNS N
reporting VBG N
lifetime NN N
heroin NN N
use NN N
≥5 NNP N
( ( N
H NNP N
( ( N
+ NNP N
) ) N
; : N
n=41 CC 3_p
) ) N
vs. FW N
< $ N
5 CD N
( ( N
H NNP N
( ( N
- : N
) ) N
; : N
n=48 CC N
) ) N
times NNS N
treatment-seeking JJ 4_p
PO NNP 4_p
abusers NNS 4_p
-DOCSTART- -X- O O 17367324

90 CD 4_p
Brazilian JJ 4_p
women NNS 4_p
, , 4_p
diagnosed VBD 4_p
to TO 4_p
CIN2 NNP 4_p
and CC 4_p
high-risk JJ 4_p
human JJ 4_p
papillomavirus NN 4_p
infection NN 4_p
, , 4_p
were VBD 4_p
randomized VBN 4_p
into IN 4_p
two CD 4_p
groups NNS 4_p
of IN 4_p
equal JJ 4_p
size NN 4_p
: : 4_p
45 CD 4_p
women NNS 4_p
whose WP$ 4_p
lesions NNS 4_p
were VBD 4_p
excised VBN 4_p
and CC 4_p
45 CD 4_p
women NNS 4_p
subjected VBN 4_p
to TO 4_p
prospective JJ 4_p
follow-up NN 4_p
at IN 4_p
3-month JJ 4_p
intervals NNS 4_p
at IN 4_p
least JJS 4_p
for IN 4_p
1 CD 4_p
year NN 4_p
( ( 4_p
mean JJ 4_p
6.8 CD 4_p
months NNS 4_p
) ) 4_p
. . 4_p

45 CD 4_p
women NNS 4_p
-DOCSTART- -X- O O 10489959

Assessment NN 4_p
of IN 4_p
the DT 4_p
pain NN 4_p
of IN 4_p
blood-sugar JJ 4_p
testing NN 4_p
: : 4_p
a DT 4_p
randomised JJ 4_p
controlled VBN 4_p
trial NN 4_p
. . 4_p

-DOCSTART- -X- O O 10379020

extremely-low-birth-weight JJ 4_p
infants NNS N
. . N

extremely-low-birth-weight JJ N
infants NNS 1_p
. . N

multicenter NN N
807 CD 3_p
infants NNS N
in IN N
need NN N
of IN N
respiratory JJ N
support NN N
24 CD N
hours NNS N
after IN N
birth NN N
. . N

The DT N
mean JJ N
birth NN N
weight NN N
was VBD N
770 CD N
g NN N
in IN N
the DT N
vitamin NN N
A NNP N
group NN N
and CC N
769 CD N
g NN N
in IN N
the DT N
control NN N
group NN N
, , N
and CC N
the DT N
respective JJ N
gestational JJ N
ages NNS N
were VBD N
26.8 CD N
and CC N
26.7 CD N
weeks NNS N
. . N

extremely-low-birth-weight JJ N
infants NNS N
. . N

-DOCSTART- -X- O O 25015354

X-linked JJ 4_p
retinitis NN 4_p
pigmentosa NN 4_p
: : 4_p
patients NNS 4_p
with IN 4_p
X-linked JJ 4_p
retinitis NN 4_p
pigmentosa NN 4_p
( ( 4_p
XLRP NNP 4_p
) ) 4_p
Males NNP N
( ( N
n JJ N
= VBZ N
78 CD N
; : N
7-31 CD N
years NNS N
) ) N
meeting NN N
entry NN N
criteria NNS N
were VBD N
enrolled VBN N
. . N

to TO N
patients NNS N
with IN N
XLRP NNP N
-DOCSTART- -X- O O 24610180

physicians NNS N
' POS N
OA NNP 4_p
is VBZ N
higher JJR N
among IN N
blacks NNS N
than IN N
whites NNS N
543 CD 3_p
family NN N
and CC N
internal JJ N
medicine NN N
physicians NNS N
Physicians NNPS N
Clinicians NNPS N
' POS N
-DOCSTART- -X- O O 9220179

congestive JJ 4_p
heart NN 4_p
failure NN 4_p
associated VBN N
with IN N
renal JJ 4_p
insufficiency NN 4_p
: : N
critically RB 4_p
ill JJ 4_p
patients NNS N
with IN N
oliguria NNS 4_p
or CC N
acute JJ 4_p
renal JJ 4_p
failure NN 4_p
. . N

20 CD 3_p
study NN N
patients NNS N
( ( N
mean JJ 1_p
age NN 1_p
74.3 CD 1_p
+/- JJ 1_p
15 CD 1_p
years NNS 1_p
) ) N
with IN N
severe JJ 4_p
CHF NNP 4_p
, , 4_p
10 CD 3_p
( ( N
Group NNP N
A NNP N
) ) N
-DOCSTART- -X- O O 23405154

chronic JJ 4_p
pancreatitis NN 4_p
patients NNS 4_p
with IN 4_p
pain NN 4_p
Sixty NNP N
chronic JJ N
pancreatitis NN N
patients NNS N
were VBD N
compared VBN N
to TO N
15 CD N
healthy JJ N
controls NNS N
. . N

patients NNS N
patients NNS N
-DOCSTART- -X- O O 16393600

nodular JJ 4_p
basal NN 4_p
cell NN 4_p
carcinoma NN 4_p
. . N

nodular JJ 4_p
basal NN 4_p
cell NN 4_p
carcinoma NN 4_p
( ( N
BCC NNP 4_p
) ) N
. . N

patients NNS N
with IN N
nodular JJ 4_p
BCC NNP 4_p
. . N

Twenty NNP N
patients NNS N
Twenty NNP 3_p
patients NNS N
imiquimod NN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
vehicle NN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
-DOCSTART- -X- O O 7075499

Fifteen JJ N
males NNS N
with IN N
angiographic JJ N
evidence NN N
of IN N
coronary JJ N
heart NN N
disease NN N
and CC N
stable JJ N
, , N
exercise-induced JJ N
angina NN N
pectoris NN N
-DOCSTART- -X- O O 1610994

transient JJ 4_p
renal JJ 4_p
dysfunction NN 4_p
Nineteen JJ N
patients NNS N
with IN N
normal JJ N
preoperative JJ N
creatinine NN N
clearances NNS N
who WP N
were VBD N
scheduled VBN N
for IN N
reconstructive JJ N
aortic JJ N
surgery NN N
-DOCSTART- -X- O O 16220761

after IN N
laparoscopic JJ N
myomectomy NN N
after IN N
laparoscopic JJ N
myomectomy NN N
( ( N
LM NNP N
) ) N
. . N

( ( N
Canadian JJ N
Task NNP N
Force NNP N
I PRP N
) ) N
University-affiliated JJ N
hospital NN N
. . N

A DT N
total NN N
of IN N
91 CD N
patients NNS N
showing VBG N
a DT N
minimal JJ N
myoma NN N
> VBD N
5 CD N
cm NN N
, , N
excluding VBG N
pedunculated VBN N
myomas NN N
, , N
underwent JJ N
LM NNP N
alone RB N
: : N
32 CD N
patients NNS N
in IN N
the DT N
control NN N
group NN N
, , N
29 CD N
in IN N
the DT N
fibrin NN N
gel NN N
group NN N
and CC N
30 CD N
patients NNS N
in IN N
the DT N
fibrin JJ N
sheet NN N
group NN N
. . N

-DOCSTART- -X- O O 24972577

cancer NN 4_p
pain NN 4_p
patients NNS 4_p
with IN 4_p
opioid-induced JJ 4_p
constipation NN 4_p
: : 4_p
opioid-induced JJ 4_p
constipation NN 4_p
Totally RB N
406 CD 3_p
cases NNS 3_p
enrolled VBD N
from IN N
53 CD N
collaborating VBG N
medical JJ N
centers NNS N
opioid-induced JJ 4_p
constipation NN 4_p
-DOCSTART- -X- O O 20431081

Arizona NNP 4_p
: : N
rural-metropolitan JJ N
remote JJ N
adult NN 1_p
patients NNS 1_p
with IN N
acute JJ 4_p
stroke NN 4_p
versus IN N
telephone NN N
consultation NN N
to TO N
assess VB N
eligibility NN N
for IN N
treatment NN N
with IN N
intravenous JJ N
thrombolysis NN N
. . N

From IN N
December NNP N
2007 CD N
to TO N
October NNP N
2008 CD N
, , N
54 CD 3_p
patients NNS 3_p
were VBD N
assessed VBN N
rural JJ N
remote JJ N
communities NNS N
lacking VBG N
sufficient JJ N
neurological JJ N
expertise NN N
. . N

-DOCSTART- -X- O O 2008691

infantile JJ 4_p
autism NN 4_p
. . 4_p

seven CD N
patients NNS N
with IN N
infantile JJ N
autism NN N
, , N
three CD N
before IN N
puberty NN N
and CC N
four CD N
after IN N
puberty NN N
highly RB N
socially RB N
handicapped JJ N
patients NNS N
-DOCSTART- -X- O O 17410213

pasture-fed JJ 4_p
dairy NN N
cows NNS N
. . N

dairy NN N
cows NNS N
under IN N
farming VBG N
conditions NNS N
in IN N
New NNP N
Zealand NNP N
. . N

Spring-calved JJ N
dairy NN N
cows NNS N
were VBD N
grazed VBN N
for IN N
101 CD N
days NNS N
in IN N
paddocks NNS N
that WDT N
were VBD N
either RB N
not RB N
fertilised VBN N
( ( N
Control NNP N
; : N
n=20 CC 3_p
) ) N
during IN N
the DT N
course NN N
of IN N
the DT N
study NN N
, , N
or CC N
were VBD N
fertilised VBN N
with IN N
40-50 JJ N
kg NNS N
nitrogen NN N
( ( N
N NNP N
) ) N
/ha VBP N
every DT N
4-6 JJ N
weeks NNS N
( ( N
High-N NNP N
; : N
n=20 NN 3_p
) ) N
. . N

pasture-fed JJ N
dairy NN N
cows NNS N
-DOCSTART- -X- O O 18716736

children NNS N
with IN N
Down NNP 4_p
syndrome NN 4_p
. . N

children NNS N
with IN N
diagnosis NN N
of IN N
Down NNP N
syndrome NN N
. . N

Eight NNP 3_p
children NNS 1_p
with IN N
Down NNP 4_p
syndrome NN 4_p
who WP N
displayed VBD N
autistic JJ 4_p
features NNS N
were VBD N
compared VBN N
with IN N
eight CD 3_p
Down NNP 4_p
syndrome NN 4_p
children NNS 4_p
without IN N
autistic JJ N
features NNS N
. . N

-DOCSTART- -X- O O 12042231

patients NNS 4_p
with IN 4_p
schizophrenia NN 4_p
. . N

representative JJ N
community NN N
sample NN N
of IN N
patients NNS N
with IN N
schizophrenia NN 4_p
in IN N
secondary JJ N
care NN N
settings NNS N
. . N

422 CD 3_p
patients NNS N
and CC N
carers NNS N
to TO N
compare VB N
a DT N
brief JJ N
CBT NNP N
intervention NN N
against IN N
treatment NN N
as IN N
usual JJ N
. . N

-DOCSTART- -X- O O 18322594

chronic JJ 4_p
hepatitis NN 4_p
B NNP 4_p
patients NNS 4_p
chronic JJ N
hepatitis NN N
B NNP N
patients NNS N
treated VBD N
with IN N
different JJ N
doses NNS N
of IN N
recombinant JJ N
hepatitis NN N
B NNP N
vaccine NN N
. . N

Seventy-two NNP N
chronic JJ N
hepatitis NN N
B NNP N
patients NNS N
who WP N
did VBD N
not RB N
use VB N
any DT N
anti-HBV JJ N
drugs NNS N
within IN N
6 CD N
months NNS N
The DT N
patients NNS N
in IN N
different JJ N
groups NNS N
were VBD N
treated VBN N
with IN N
different JJ N
doses NNS N
of IN N
recombinant JJ N
hepatitis NN N
B NNP N
vaccine NN N
patients NNS N
who WP N
were VBD N
ELISPOT NNP N
positive JJ N
patients NNS N
with IN N
chronic JJ N
hepatitis NN N
B NNP N
. . N

-DOCSTART- -X- O O 12855087

older JJR 1_p
women NNS 2_p
with IN N
breast NN 4_p
cancer NN 4_p
. . N

chemotherapy-related JJ N
symptom NN N
distress NN N
levels NNS N
in IN N
16 CD 3_p
women NNS 2_p
aged VBD N
50 CD 1_p
and CC 1_p
older JJR 1_p
. . N

older JJR 1_p
women NNS 2_p
with IN N
breast NN 4_p
cancer NN 4_p
women NNS N
-DOCSTART- -X- O O 14626750

Travis NNP N
Pharmacy NNP N
in IN N
Shenandoah NNP N
, , N
Iowa NNP N
. . N

Ninety-five JJ 3_p
patients NNS N
from IN N
southwestern JJ N
iowa NN N
and CC N
southeastern JJ N
Nebraska NNP N
88 CD 3_p
were VBD N
considered VBN N
eligible JJ N
for IN N
comparison NN N
( ( N
by IN N
continuing VBG N
through IN N
week NN N
2 CD N
of IN N
the DT N
study NN N
) ) N
. . N

MR NNP N
( ( N
n JJ N
= NNP N
45 CD N
) ) N
and CC N
RCD NNP N
( ( N
n JJ N
= NNP N
43 CD N
) ) N
-DOCSTART- -X- O O 11683484

sleep JJ 4_p
inertia NN 4_p
28 CD N
normal JJ N
adult NN N
volunteers NNS N
-DOCSTART- -X- O O 6984358

migraine NN 4_p
. . N

acute JJ N
migraine NN 4_p
attacks NNS N
acute JJ N
migraine NN N
attacks NNS N
in IN N
ten JJ N
patients NNS N
. . N

60 CD N
attacks NNS N
-DOCSTART- -X- O O 25840599

after IN N
allogeneic JJ 4_p
hematopoietic JJ 4_p
cell NN 4_p
transplantation NN 4_p
allogeneic JJ 4_p
hematopoietic JJ 4_p
cell NN 4_p
transplantation NN 4_p
matched JJ N
sibling NN N
or CC N
unrelated JJ N
donor NN N
transplant NN N
prolonged JJ N
sirolimus NN N
administration NN N
( ( N
≥ $ N
1 CD N
year NN N
post-transplant NN N
) ) N
. . N

Median JJ N
follow-up JJ N
time NN N
for IN N
surviving VBG N
patients NNS N
at IN N
time NN N
of IN N
this DT N
analysis NN N
was VBD N
41 CD N
months NNS N
( ( N
range VB N
27-60 CD N
) ) N
for IN N
sirolimus/tacrolimus NN N
and CC N
49 CD N
months NNS N
( ( N
range VB N
29-63 CD N
) ) N
for IN N
methotrexate/tacrolimus NN N
-DOCSTART- -X- O O 19073386

partial JJ 4_p
thickness NN 4_p
burns NNS 4_p
thermal JJ 4_p
2nd CD 4_p
degree NN 4_p
burns NNS 4_p
partial JJ N
thickness NN N
burns NNS N
. . N

40 CD 3_p
patients NNS N
received VBD N
either RB N
topical JJ N
treatment NN N
with IN N
Moist NNP N
Exposed VBD N
Burn NNP N
Ointment NNP N
( ( N
MEBO NNP N
) ) N
or CC N
standard JJ N
Flammazine NNP N
treatment NN N
. . N

All DT N
patients NNS N
suffered VBD N
from IN N
partial-thickness JJ 4_p
burn NN 4_p
injuries NNS 4_p
( ( N
< VB N
20 CD N
% NN N
TBSA NNP N
) ) N
. . N

limited JJ 4_p
partial JJ 4_p
thickness NN 4_p
thermal JJ 4_p
burns NNS 4_p
. . N

-DOCSTART- -X- O O 9207470

multiple JJ N
myeloma NN N
: : N
patients NNS N
entered VBN N
on IN N
the DT N
Eastern NNP 4_p
Cooperative NNP 4_p
Oncology NNP 4_p
Group NNP 4_p
phase VBD 4_p
III NNP 4_p
E9486 NNP 4_p
clinical JJ 4_p
trial NN 4_p
. . N

myeloma NN 4_p
patients NNS 4_p
CD19+ NNP N
B NNP N
cells NNS N
by IN N
flow JJ N
cytometry NN N
in IN N
previously RB N
untreated JJ N
newly RB N
diagnosed VBN N
myeloma NN N
patients NNS N
in IN N
Eastern NNP N
Cooperative NNP N
Oncology NNP N
Group NNP N
( ( N
ECOG NNP N
) ) N
phase NN N
III NNP N
trial NN N
E9486 NNP N
. . N

There EX N
were VBD N
628 CD 3_p
patients NNS 3_p
who WP N
were VBD N
eligible JJ N
for IN N
the DT N
clinical JJ N
protocol NN N
E9486 NNP N
, , N
but CC N
of IN N
these DT N
521 CD 3_p
were VBD N
also RB N
entered VBN N
on IN N
the DT N
companion NN N
laboratory NN N
study NN N
( ( N
E9487 NNP N
) ) N
and CC N
had VBD N
CD19 NNP N
data NNS N
. . N

patients NNS N
patients NNS N
. . N

-DOCSTART- -X- O O 19159477

stroke NN N
patients NNS N
-- : N
results NNS N
stroke NN N
patients NNS N
in IN N
Latium NNP N
( ( N
Italy NNP N
) ) N
emergency NN N
system NN N
. . N

stroke JJ N
patient JJ N
referrals NNS N
by IN N
Emergency NNP N
Medical NNP N
Service NNP N
( ( N
EMS NNP N
) ) N
and CC N
Emergency NNP N
Room NNP N
( ( N
ER NNP N
) ) N
health NN N
professionals NNS N
trained VBN N
in IN N
the DT N
ECP NNP N
, , N
with IN N
those DT N
of IN N
non-trained JJ N
EMS NNP N
and CC N
ER NNP N
controls NNS N
. . N

eligible JJ 4_p
( ( 4_p
aged VBN 4_p
< NNP 4_p
/= $ 4_p
80 CD 4_p
and CC 4_p
symptom JJ 4_p
onset NN 4_p
< NNP 4_p
/= VBZ 4_p
6 CD 4_p
hours NNS 4_p
) ) 4_p
stroke VBD 4_p
patients NNS 4_p
referred VBN 4_p
to TO 4_p
a DT 4_p
stroke NN 4_p
unit NN 4_p
( ( 4_p
SU NNP 4_p
) ) 4_p
. . 4_p

2656 CD N
patients NNS N
in IN N
the DT N
intervention NN N
arm NN N
and CC N
2239 CD N
in IN N
the DT N
control NN N
arm NN N
stroke NN N
patients NNS N
. . N

-DOCSTART- -X- O O 3548346

Eleven JJ N
patients NNS N
with IN N
well-documented JJ N
hepatorenal JJ N
syndrome NN N
-DOCSTART- -X- O O 8917026

severe JJ 4_p
head NN 4_p
injury NN 4_p
: : 4_p
patients NNS N
admitted VBN N
to TO N
the DT N
intensive JJ N
care NN N
unit NN N
after IN N
severe JJ N
head NN N
injury NN N
. . N

university NN N
Level NNP N
I PRP N
trauma VBP N
center NN N
. . N

Twenty NNP N
patients NNS N
admitted VBD N
with IN N
a DT N
Glasgow NNP N
Coma NNP N
Scale NNP N
score NN N
of IN N
< $ N
10 CD N
patients NNS 4_p
after IN 4_p
head JJ 4_p
injury NN 4_p
. . 4_p

-DOCSTART- -X- O O 21930490

Consecutive JJ 4_p
procedural JJ 4_p
angiograms NNS 4_p
of IN 4_p
patients NNS 4_p
randomly RB 4_p
assigned VBN 4_p
to TO 4_p
EES NNP 4_p
( ( 4_p
n=669 NN 4_p
) ) 4_p
or CC 4_p
PES NNP 4_p
( ( 4_p
n=333 RB 4_p
) ) 4_p
were VBD 4_p
analysed VBN 4_p
by IN 4_p
an DT 4_p
independent JJ 4_p
angiographic JJ 4_p
core NN 4_p
laboratory NN 4_p
. . 4_p

patients NNS N
receiving VBG N
EES NNP N
compared VBN N
to TO N
PES NNP N
Patients NNS N
treated VBD N
with IN N
EES NNP N
rather RB N
than IN N
PES NNP N
-DOCSTART- -X- O O 22818151

[ NNS 4_p
Localised VBN 4_p
prostate JJ 4_p
cancer NN 4_p
: : 4_p
carcinoma NN 4_p
of IN N
the DT N
elderly JJ N
man NN N
-DOCSTART- -X- O O 7928125

breastfeeding NN N
among IN N
Vietnamese JJ 4_p
women NNS 2_p
in IN N
Sydney NNP N
. . N

immigrant JJ 4_p
Vietnamese JJ 4_p
women NNS 2_p
in IN N
Western JJ N
countries NNS N
The DT N
sample NN N
consisted VBD N
of IN N
182 CD 3_p
prenatal JJ 4_p
Vietnamese JJ 4_p
women NNS 2_p
. . N

-DOCSTART- -X- O O 18242415

Guatemalan NNP 4_p
adults NNS 4_p
. . 4_p

1424 CD 4_p
Guatemalan NNP 4_p
individuals NNS 4_p
( ( 4_p
aged VBN 4_p
25-42 CD 4_p
years NNS 4_p
) ) 4_p
between IN 4_p
2002 CD 4_p
and CC 4_p
2004 CD 4_p
. . 4_p

accounted VBD 4_p
for IN 4_p
60 CD 4_p
% NN 4_p
of IN 4_p
the DT 4_p
2392 CD 4_p
children NNS 4_p
( ( 4_p
aged VBN 4_p
0-7 CD 4_p
years NNS 4_p
) ) 4_p
who WP 4_p
had VBD 4_p
been VBN 4_p
enrolled VBN 4_p
in IN 4_p
a DT 4_p
nutrition NN 4_p
intervention NN 4_p
study NN 4_p
during IN 4_p
1969-77 JJ 4_p
. . 4_p

-DOCSTART- -X- O O 12638099

acute JJ 4_p
nonspecific NN 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
( ( 4_p
LBP NNP 4_p
) ) 4_p
. . N

Five CD N
community-based JJ N
research NN N
facilities NNS N
. . N

Two-hundred JJ 3_p
nineteen JJ 3_p
subjects NNS N
, , N
aged VBD 1_p
18 CD 1_p
to TO 1_p
55 CD 1_p
years NNS 1_p
, , N
with IN N
acute JJ 4_p
nonspecific JJ 4_p
LBP NNP 4_p
. . N

-DOCSTART- -X- O O 7037697

Anderson NNP N
Hospital NNP N
randomized VBD N
trial NN N
of IN N
neutron NN N
and CC N
photon NN N
irradiation NN N
for IN N
locally RB N
advanced JJ 4_p
carcinoma NN 4_p
of IN N
the DT N
uterine JJ 4_p
cervix NN 4_p
. . 4_p

-DOCSTART- -X- O O 16394797

chronic JJ N
hepatitis NN N
C NNP N
resulting VBG N
from IN N
intravenous JJ N
drug NN N
use NN N
intravenous JJ N
drug NN N
users NNS N
( ( N
IVDUs NNP N
) ) N
with IN N
chronic JJ N
hepatitis NN N
C NNP N
( ( N
CHC NNP N
) ) N
treatment NN N
trial NN N
-- : N
was VBD N
performed VBN N
in IN N
Belgium NNP N
and CC N
The DT N
Netherlands NNP N
. . N

A NNP N
total NN N
of IN N
406 CD N
previously RB N
untreated JJ N
CHC NNP N
patients NNS N
, , N
including VBG N
98 CD N
( ( N
24 CD N
% NN N
) ) N
IVDUs NNP N
Benelux NNP N
patients NNS N
chronic VB N
hepatitis NN N
C NNP N
patients NNS N
who WP N
use VBP N
intravenous JJ N
drugs NNS N
. . N

-DOCSTART- -X- O O 18328868

Diabetes NNPS 4_p
: : 4_p
Families NNS N
of IN N
104 CD 3_p
adolescents NNS 1_p
with IN N
diabetes NNS 4_p
were VBD N
randomized VBN N
-DOCSTART- -X- O O 24195864

iron-depleted JJ N
female NN 2_p
rowers NNS N
. . N

female JJ 2_p
endurance NN N
athletes NNS N
nonanemic JJ 4_p
female NN 2_p
rowers NNS N
during IN N
training NN N
. . N

40 CD 3_p
rowers NNS 3_p
CONCLUSIONS NNP N
Female NNP 2_p
rowers NNS N
with IN N
depleted JJ N
for IN N
endurance NN 4_p
athletes NNS 4_p
-DOCSTART- -X- O O 3673207

clinical JJ N
responses NNS N
in IN N
man NN 2_p
. . N

177 CD 3_p
volunteers NNS N
. . N

-DOCSTART- -X- O O 1100179

childhood NN N
leukaemia NN N
. . N

after IN N
craniospinal JJ N
irradiation NN N
. . N

Leukaemia NNP N
in IN N
Childhood NNP N
. . N

acute JJ N
lymphoblastic JJ N
leukaemia NN N
patients NNS N
who WP N
had VBD N
received VBN N
craniospinal JJ N
irradiation NN N
. . N

children NNS N
-DOCSTART- -X- O O 10230191

young JJ N
children NNS N
with IN N
autism NN 4_p
. . N

young JJ 1_p
children NNS 1_p
with IN 4_p
autism NN 4_p
. . 4_p

Twenty-four JJ 3_p
children NNS N
with IN N
autism NN 4_p
, , N
3.0 CD N
to TO N
8.3 CD N
years NNS N
old JJ N
( ( N
mean JJ N
5.1 CD N
) ) N
who WP N
were VBD N
living VBG N
at IN N
home NN N
and CC N
attending VBG N
appropriate JJ N
school NN N
programs NNS N
-DOCSTART- -X- O O 19247233

Ten NNP 3_p
healthy JJ N
volunteers NNS N
superficial JJ 4_p
wounds NNS 4_p
. . 4_p

-DOCSTART- -X- O O 9572900

healthy JJ 4_p
volunteers NNS 4_p
. . 4_p

healthy JJ N
volunteers NNS N
. . N

-DOCSTART- -X- O O 10693733

Sun NNP N
protection NN N
counseling VBG N
for IN N
children NNS N
: : N
clinicians NNS 4_p
. . N

sun NN N
protection NN N
advice NN N
for IN N
children NNS N
Primary NNP N
care NN N
practices NNS N
caring VBG N
for IN N
children NNS N
in IN N
New NNP N
Hampshire NNP N
with IN N
special JJ N
attention NN N
to TO N
clinicians NNS N
serving VBG N
10 CD N
towns NNS N
that WDT N
were VBD N
involved VBN N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
of IN N
the DT N
multicomponent NN N
SunSafe NNP N
intervention NN N
involving VBG N
schools NNS N
, , N
recreation NN N
areas NNS N
, , N
and CC N
primary JJ N
care NN N
practices NNS N
. . N

all DT N
primary JJ 4_p
care NN 4_p
clinicians NNS 4_p
serving VBG 4_p
children NNS 4_p
Clinicians NNPS N
in IN N
10 CD N
systematically RB N
selected VBN N
rural JJ N
towns NNS N
261 CD 3_p
eligible JJ 3_p
clinicians NNS 3_p
responding VBG N
to TO N
the DT N
statewide NN N
survey NN N
participating VBG N
clinicians NNS N
. . N

-DOCSTART- -X- O O 8657237

patients NNS 4_p
with IN 4_p
multivessel JJ 4_p
disease NN 4_p
. . N

patients NNS 4_p
with IN 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
. . N

patients NNS N
with IN N
multivessel JJ N
disease NN N
suitable JJ N
for IN N
treatment NN N
with IN N
either DT N
procedure NN N
Patients NNPS N
with IN N
multivessel JJ N
disease NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
initial JJ N
treatment NN N
strategy NN N
of IN N
CABG NNP N
( ( N
n JJ N
= NNP N
914 CD N
) ) N
or CC N
PTCA NNP N
( ( N
n JJ N
= NNP N
915 CD N
) ) N
Among IN 4_p
diabetic JJ 4_p
patients NNS 4_p
who WP 4_p
were VBD 4_p
being VBG 4_p
treated VBN 4_p
with IN 4_p
insulin NN 4_p
or CC 4_p
oral JJ 4_p
hypoglycemic JJ 4_p
agents NNS 4_p
at IN 4_p
base NN 4_p
line NN 4_p
patients NNS N
with IN N
multivessel JJ N
disease NN N
treated JJ N
diabetics NNS N
-DOCSTART- -X- O O 11041498

proximal JJ 4_p
interphalangeal NN 4_p
joint NN 4_p
in IN 4_p
the DT 4_p
horse NN 4_p
Eight JJ 3_p
horses NNS 4_p
-DOCSTART- -X- O O 16197624

metastatic JJ 4_p
colorectal JJ 4_p
cancer NN 4_p
: : 4_p
southern JJ 4_p
Italy NNP 4_p
cooperative JJ 4_p
oncology NN 4_p
group NN 4_p
trials NNS 4_p
. . 4_p

metastatic JJ 4_p
colorectal NN 4_p
cancer NN 4_p
( ( 4_p
CRC NNP 4_p
) ) 4_p
. . 4_p

254 CD N
patients NNS N
elderly JJ 4_p
patients NNS 4_p
. . 4_p

-DOCSTART- -X- O O 2292547

CAPD NNP 4_p
peritonitis NN 4_p
. . N

Fifty-one CD 3_p
patients NNS 3_p
were VBD N
included VBN N
CAPD NNP N
peritonitis NN N
. . N

-DOCSTART- -X- O O 22401811

human JJ N
oocytes NNS N
274 CD N
oocytes NNS N
obtained VBN N
from IN N
46 CD 3_p
couples NNS N
undergoing JJ N
infertility NN 4_p
treatment NN N
. . N

-DOCSTART- -X- O O 20390261

children NNS 1_p
with IN N
systemic JJ 4_p
ventricular JJ 4_p
dysfunction NN 4_p
treated VBN N
with IN N
carvedilol NN N
. . N

adults NNS 1_p
and CC N
children NNS 1_p
. . N

in IN N
a DT N
population NN N
of IN N
children NNS 1_p
with IN N
systemic JJ 4_p
ventricular JJ 4_p
dysfunction NN 4_p
and CC N
symptomatic JJ 4_p
heart NN 4_p
failure NN 4_p
treated VBN N
with IN N
carvedilol NN N
or CC N
placebo NN N
. . N

Pediatric NNP N
Carvedilol NNP N
Trial NNP N
( ( N
PCT NNP N
) ) N
participants NNS N
( ( N
carvedilol JJ N
n RB N
= JJ N
161 CD N
; : N
placebo NN N
n IN N
= $ N
55 CD N
) ) N
children NNS N
treated VBD N
with IN N
carvedilol NN N
carvedilol NN N
group NN N
. . N

children NNS N
-DOCSTART- -X- O O 21042763

advanced JJ 4_p
upper JJ 4_p
gastrointestinal JJ 4_p
cancer NN 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
upper JJ 4_p
gastrointestinal JJ 4_p
adenocarcinoma NN 4_p
( ( 4_p
UGIA NNP 4_p
) ) 4_p
Seventy-three JJ 3_p
patients NNS 3_p
with IN N
advanced JJ 4_p
UGIA NNP 4_p
were VBD N
randomised VBN N
Patients NNS 4_p
with IN 4_p
normal JJ 4_p
levels NNS 4_p
, , 4_p
except IN 4_p
CA72-4 NNP 4_p
patients NNS 4_p
with IN 4_p
UGIA NNP 4_p
on IN 4_p
palliative JJ 4_p
chemotherapy NN 4_p
. . N

-DOCSTART- -X- O O 11835021

implantable JJ 4_p
cardioverter NN 4_p
defibrillators NNS 4_p
( ( N
ICDs NNP 4_p
) ) N
. . N

Patients NNPS 4_p
with IN 4_p
standard JJ 4_p
ICD NNP 4_p
indications NNS 4_p
undergo VBP N
defibrillation NN N
threshold NN N
testing NN N
( ( N
DFT NNP N
) ) N
at IN N
the DT N
time NN N
of IN N
ICD NNP 4_p
implant NN 4_p
, , N
with IN N
reconfirmation NN N
of IN N
lowest JJS N
successful JJ N
energy NN N
twice RB N
( ( N
DFT++ NNP N
) ) N
. . N

Enrollment NNP N
is VBZ N
complete JJ N
( ( N
702 CD 3_p
patients NNS N
) ) N
-DOCSTART- -X- O O 22048089

full-thickness JJ 4_p
rotator NN 4_p
cuff NN 4_p
tears NNS 4_p
: : N
arthroscopic NN N
rotator NN N
cuff NN N
repair NN N
with IN N
and CC N
without IN N
acromioplasty JJ N
. . N

Eighty-six JJ 3_p
patients NNS N
sixty-eight NN 3_p
of IN N
them PRP N
completed VBD N
the DT N
study NN N
. . N

Four CD N
participants NNS N
( ( N
9 CD N
% NN N
) ) N
in IN N
the DT N
group NN N
that WDT N
had VBD N
arthroscopic VBN N
cuff JJ N
repair NN N
alone RB N
, , N
one CD N
with IN N
a DT N
Type-2 JJ N
and CC N
three CD N
with IN N
a DT N
Type-3 JJ N
acromion NN N
, , N
required VBN N
additional JJ N
surgery NN N
patients NNS N
who WP N
had VBD N
rotator NN N
cuff NN N
repair NN N
with IN N
or CC N
without IN N
acromioplasty JJ N
. . N

group NN N
-DOCSTART- -X- O O 17516492

Parkinson NNP 4_p
's POS 4_p
disease NN 4_p
: : 4_p
Parkinson NNP 4_p
's POS 4_p
disease NN 4_p
( ( 4_p
PD NNP 4_p
) ) 4_p
. . N

36 CD 3_p
PD NNP 4_p
patients NNS N
, , N
using VBG N
Parkinson NNP 4_p
's POS 4_p
Disease NNP 4_p
Rating NNP N
Scale NNP N
( ( N
UPDRS NNP N
) ) N
I-IV NNP N
, , N
Beck NNP N
's POS N
Depression NNP N
Inventory NNP N
, , N
and CC N
Epworth NNP N
Sleepiness NNP N
Scale NNP N
. . N

-DOCSTART- -X- O O 10443725

men NNS 2_p
receiving VBG 4_p
finasteride NN 4_p
for IN 4_p
2 CD 4_p
years NNS 4_p
. . 4_p

men NNS N
with IN 4_p
urodynamically RB 4_p
documented VBN 4_p
bladder NN 4_p
outflow JJ 4_p
obstruction NN 4_p
( ( 4_p
BOO NNP 4_p
) ) 4_p
. . N

One CD 3_p
hundred VBD 3_p
twenty-one NN 3_p
men NNS N
with IN N
benign JJ 4_p
prostatic JJ 4_p
enlargement NN 4_p
( ( N
BPE NNP N
) ) N
and CC N
lower JJR 4_p
urinary JJ 4_p
tract NN 4_p
symptoms NNS 4_p
( ( N
LUTS NNP N
) ) N
Patients NNS N
who WP N
were VBD N
obstructed VBN N
according VBG N
to TO N
a DT N
modified VBN N
Abrams-Griffiths JJ N
nomogram NNS N
men NNS N
with IN N
BPE NNP N
and CC N
LUTS NNP N
-DOCSTART- -X- O O 15940774

patients NNS 4_p
with IN 4_p
osteoarthritis NN 4_p
of IN 4_p
the DT 4_p
knee NN 4_p
. . 4_p

1578 CD N
patients NNS N
with IN N
osteoarthritis JJ N
-DOCSTART- -X- O O 21990307

people NNS N
at IN N
normal JJ 4_p
risk NN 4_p
for IN 4_p
colorectal JJ 4_p
cancer NN 4_p
. . N

healthy JJ 4_p
volunteers NNS N
. . N

30 CD 3_p
subjects NNS N
for IN N
28 CD N
days NNS N
. . N

-DOCSTART- -X- O O 8624213

idiopathic JJ 4_p
dystonia NN 4_p
. . 4_p

-DOCSTART- -X- O O 16097539

Migration NN 4_p
of IN 4_p
the DT 4_p
acetabular JJ 4_p
component NN 4_p
: : N
significance NN 4_p
of IN 4_p
early JJ 4_p
radiolucency NN 4_p
: : N
prosthesis NN 4_p
fixation NN 4_p
. . N

50 CD 3_p
THAs NNP N
to TO N
either VB N
fingerpacking NN N
or CC N
sequential JJ N
pressurization NN N
( ( N
including VBG N
individual JJ N
pressurization NN N
of IN N
each DT N
anchorage NN N
hole NN N
) ) N
and CC N
followed VBD N
the DT N
patients NNS N
with IN N
RSA NNP N
for IN N
5 CD N
years NNS N
. . N

-DOCSTART- -X- O O 16505756

patients NNS N
with IN N
metastatic JJ N
gastric JJ N
cancer NN N
. . N

patients NNS N
with IN N
metastatic JJ N
gastric JJ N
adenocarcinoma NN N
. . N

134 CD N
eligible JJ N
patients NNS N
-DOCSTART- -X- O O 9885327

acute JJ 4_p
migraine NN 4_p
attacks NNS N
. . N

multicenter NN N
296 CD 3_p
patients NNS N
fulfilling VBG N
the DT N
International NNP N
Headache NNP N
Society NNP N
diagnostic JJ N
criteria NNS N
for IN N
migraine NN 4_p
were VBD N
enrolled VBN N
. . N

-DOCSTART- -X- O O 19779611

physical JJ 4_p
activity NN 4_p
and CC 4_p
diet NN 4_p
. . 4_p

adults NNS 1_p
with IN N
established VBN 4_p
chronic JJ 4_p
diseases NNS 4_p
in IN N
a DT N
low JJ 4_p
socio-economic JJ 4_p
area NN 4_p
of IN 4_p
a DT 4_p
major JJ 4_p
Australian JJ 4_p
city NN 4_p
February NNP N
2005 CD N
and CC N
November NNP N
2007 CD N
-DOCSTART- -X- O O 393286

hypertension NN 4_p
. . N

Twenty CD 3_p
patients NNS N
with IN N
essential JJ N
hypertension NN N
-DOCSTART- -X- O O 3010510

allogenic JJ 4_p
bone NN 4_p
marrow NN 4_p
transplantation NN 4_p
. . 4_p

after IN N
allogenic JJ N
bone NN N
marrow NN N
transplantation NN N
49 CD N
patients NNS N
were VBD N
randomized VBN N
in IN N
a DT N
multicenter NN N
controlled VBN N
study NN N
Six NNP N
of IN N
23 CD N
patients NNS N
-DOCSTART- -X- O O 15167457

hypertensive JJ 4_p
patients NNS 4_p
of IN 4_p
African JJ 4_p
descent NN 4_p
. . N

African JJ N
patients NNS N
patients NNS N
of IN N
East JJ N
African JJ N
descent NN N
Hypertensive JJ N
families NNS N
of IN N
East JJ N
African JJ N
descent NN N
from IN N
the DT N
general JJ N
population NN N
in IN N
the DT N
Seychelles NNP N
. . N

Fifty-two NNP 3_p
( ( N
29 CD 3_p
men NNS 2_p
and CC N
23 CD 3_p
women NNS 2_p
) ) N
out IN N
of IN N
62 CD N
eligible JJ N
hypertensive JJ N
patients NNS N
were VBD N
included.Main JJ N
-DOCSTART- -X- O O 15191587

METHODS NNP N
Three NNP N
groups NNS N
of IN N
30 CD 3_p
edentulous JJ N
patients NNS N
were VBD N
treated VBN N
with IN N
two CD N
endosseous JJ N
implants NNS N
of IN N
a DT N
mandibular JJ N
overdenture NN N
in IN N
the DT N
edentulous JJ N
patient NN N
-DOCSTART- -X- O O 24256459

children NNS N
on IN N
the DT N
autism NN 4_p
spectrum NN 4_p
. . 4_p

children NNS 1_p
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
) ) N
3rd-5th JJ 1_p
graders NNS 1_p
with IN N
ASD NNP N
( ( N
mean JJ N
IQ NNP N
= NNP N
108 CD N
; : N
UOT NNP N
n VBD N
= JJ N
47 CD N
; : N
SS NNP N
n VBD 3_p
= NNP 3_p
20 CD 3_p
) ) N
received VBD N
interventions NNS N
delivered VBN N
by IN N
school NN N
staff NN N
in IN N
small JJ N
group NN N
sessions NNS N
. . N

Students NNS 1_p
were VBD N
matched VBN N
for IN N
gender NN N
, , N
age NN N
, , N
race NN N
, , N
IQ NNP N
, , N
ASD NNP N
symptomotolgy NN N
, , N
medication NN N
status NN N
, , N
and CC N
parents NNS N
' POS N
education NN N
intervention NN N
for IN N
children NNS 1_p
with IN N
problem-solving NN N
in IN N
children NNS 1_p
with IN N
-DOCSTART- -X- O O 7708953

559 CD 3_p
patients NNS N
after IN 4_p
tumour JJ 4_p
excision NN 4_p
and CC 4_p
radiotherapy NN 4_p
for IN N
early JJ 4_p
breast NN 4_p
cancer NN 4_p
-DOCSTART- -X- O O 17179873

women NNS 2_p
with IN N
breast NN 4_p
cancer NN 4_p
and CC N
their PRP$ N
partners NNS 2_p
. . N

both DT N
women NNS 2_p
with IN N
breast NN 4_p
cancer NN 4_p
and CC N
their PRP$ N
partners NNS 2_p
women NNS 2_p
and CC N
their PRP$ N
partners NNS 2_p
. . N

women NNS 2_p
with IN N
breast NN 4_p
cancer NN 4_p
and CC N
their PRP$ N
partners NNS 2_p
. . N

Ninety-six JJ 3_p
women NNS 3_p
and CC N
their PRP$ N
96 CD 3_p
partners NNS 3_p
women NNS 2_p
with IN N
breast NN 4_p
cancer NN 4_p
women NNS 2_p
's POS N
partners NNS 2_p
' POS 2_p
partners NNS 2_p
women NNS 2_p
, , N
partners NNS 2_p
' POS N
-DOCSTART- -X- O O 25629971

The DT N
effect NN N
of IN N
power NN 4_p
asymmetries NNS 4_p
on IN N
cooperation NN N
and CC N
punishment NN N
in IN N
a DT N
prisoner NN N
's POS N
dilemma JJ N
game NN N
. . N

strong JJ N
players NNS N
to TO N
interact VB N
with IN N
weak JJ N
players NNS N
in IN N
an DT N
iterated JJ 4_p
prisoner NN 4_p
's POS 4_p
dilemma JJ 4_p
game NN 4_p
-DOCSTART- -X- O O 1908493

Eleven NNP 4_p
chronic JJ 4_p
renal JJ 4_p
failure NN 4_p
patients NNS N
and CC N
11 CD 4_p
matched JJ N
controls NNS N
the DT N
uremic JJ 4_p
patients NNS N
Uremic JJ N
patients NNS N
chronic JJ N
renal JJ N
failure NN N
patients NNS N
different JJ N
group NN N
of IN N
seven CD N
uremic JJ N
patients NNS N
uremic JJ N
patients NNS N
-DOCSTART- -X- O O 2112233

acute JJ 4_p
myocardial JJ 4_p
infarct NN 4_p
-DOCSTART- -X- O O 20884344

Fifty NNP 3_p
sedentary JJ 4_p
males NNS 2_p
-DOCSTART- -X- O O 9690103

stages NNS 4_p
of IN 4_p
dietary JJ 4_p
change NN 4_p
: : N
a DT 3_p
cohort NN 3_p
of IN 3_p
11,237 CD 3_p
employees NNS 3_p
. . N

persons NNS 4_p
in IN 4_p
later JJ 4_p
stages NNS 4_p
of IN 4_p
change NN 4_p
Employees NNS 4_p
from IN 4_p
intervention NN 4_p
work NN 4_p
sites NNS 4_p
who WP 4_p
were VBD 4_p
in IN 4_p
preaction NN 4_p
stages NNS 4_p
at IN 4_p
baseline NN 4_p
controls NNS 4_p
. . N

-DOCSTART- -X- O O 23164311

children NNS 1_p
after IN N
birth NN 4_p
asphyxia NN 4_p
resuscitated JJ 4_p
children NNS 1_p
. . N

parallel JJ N
group NN N
infants NNS 1_p
unresponsive JJ N
to TO N
stimulation NN N
who WP N
received VBD N
bag NN N
and CC N
mask NN N
ventilation NN N
as IN N
part NN N
of IN N
their PRP$ N
resuscitation NN N
at IN N
birth NN N
and CC N
infants NNS 1_p
who WP N
did VBD N
not RB N
require VB N
any DT N
resuscitation NN N
born VBN N
in IN N
rural JJ N
communities NNS N
in IN N
India NNP N
, , N
Pakistan NNP N
, , N
and CC N
Zambia NNP N
. . N

Intervention NN N
infants NNS 1_p
parent NN N
provided VBD N
EDI NNP N
in IN N
children NNS N
resuscitated VBN N
both DT N
nonresuscitated JJ N
and CC N
-DOCSTART- -X- O O 23438314

autism NN 4_p
. . N

children NNS 1_p
with IN N
autism NN 4_p
addition NN N
of IN N
a DT N
web-based JJ N
group NN N
. . N

Forty-nine JJ 3_p
teacher-child JJ N
dyads NNS N
child NN 1_p
. . N

young JJ N
children NNS 1_p
with IN N
autism NN 4_p
. . N

-DOCSTART- -X- O O 21410033

gastrointestinal JJ N
surgery NN N
. . N

patients NNS N
undergoing VBG N
elective JJ N
gastrointestial JJ N
surgery NN N
during IN N
the DT N
early JJ N
postoperative JJ N
period NN N
. . N

-DOCSTART- -X- O O 7809641

loco NN N
classico NN N
radius NN N
fracture NN N
. . N

50 CD N
patients NNS N
with IN N
type NN N
A DT N
2.2 CD N
, , N
A DT N
3.3 CD N
, , N
C NNP N
1.2 CD N
or CC N
C $ N
2.2 CD N
( ( N
AO NNP N
classification NN N
) ) N
fractures NNS N
of IN N
the DT N
radius NN N
5 CD N
patients NNS N
with IN N
significant JJ N
disability NN N
-DOCSTART- -X- O O 20043831

working VBG 4_p
population NN N
volunteers NNS 3_p
from IN N
1100 CD 3_p
eligible JJ 3_p
employees NNS 3_p
of IN N
a DT N
Finnish JJ N
insurance NN N
company NN N
. . N

-DOCSTART- -X- O O 14636372

bipolar JJ 4_p
disorder NN 4_p
: : N
bipolar NN 4_p
( ( N
BP NNP 4_p
) ) N
patients NNS N
. . N

Bipolar JJ 4_p
patients NNS N
were VBD N
studied VBN N
who WP N
had VBD 4_p
at IN 4_p
least JJS 4_p
one CD 4_p
episode NN 4_p
per IN 4_p
year NN 4_p
in IN N
the DT N
previous JJ N
2 CD N
years NNS N
despite IN N
ongoing VBG 4_p
prophylaxis NN 4_p
. . N

Patients NNS N
were VBD N
stable JJ 4_p
for IN 4_p
a DT 4_p
mean NN 4_p
of IN 4_p
4 CD 4_p
months NNS 4_p
( ( 4_p
range VB 4_p
1-13 NNS 4_p
) ) 4_p
before IN 4_p
entering VBG 4_p
the DT 4_p
study NN 4_p
. . N

studied VBN N
for IN N
23 CD 3_p
patients NNS N
. . N

-DOCSTART- -X- O O 15719741

gastric JJ 4_p
carcinoma NN 4_p
patients NNS N
gastric JJ 4_p
carcinoma NN 4_p
patients NNS N
all PDT N
the DT N
enrolled JJ N
patients NNS N
( ( N
30 CD 3_p
in IN N
the DT N
control NN N
and CC N
32 CD 3_p
in IN N
the DT N
trial NN N
group NN N
) ) N
before IN N
operation NN N
, , N
and CC N
3-4 JJ N
courses NNS N
of IN N
chemotherapy NN N
was VBD N
applied VBN N
to TO N
them PRP N
from IN N
3-4 JJ N
weeks NNS N
after IN N
operation NN N
. . N

patients NNS N
of IN N
blood NN 4_p
stasis NN 4_p
type NN 4_p
patients NNS N
of IN N
Pi-deficiency NNP 4_p
type NN 4_p
or CC 4_p
of IN 4_p
damp-heat JJ 4_p
type NN 4_p
-DOCSTART- -X- O O 23108780

postmenopausal JJ 4_p
osteoporotic JJ 4_p
women NNS 2_p
. . N

paired JJ N
biopsies NNS 4_p
of IN N
osteoporotic JJ 4_p
women NNS 2_p
treated VBN N
with IN N
either DT N
strontium NN N
ranelate NN N
or CC N
a DT N
placebo NN N
for IN N
36 CD N
months NNS N
paired JJ N
biopsies NNS N
of IN N
osteoporotic JJ 4_p
women NNS 2_p
treated VBN N
with IN N
either DT N
strontium NN N
ranelate NN N
( ( N
SrRan NNP N
) ) N
or CC N
a DT N
placebo NN N
for IN N
36 CD N
months NNS N
. . N

ten NN 3_p
paired JJ N
biopsies NNS N
-DOCSTART- -X- O O 7963648

16 CD N
Japanese JJ N
subjects NNS N
-DOCSTART- -X- O O 19002124

myocardial JJ 4_p
infarction NN 4_p
: : N
Patients NNPS N
with IN N
left JJ 4_p
ventricular JJ 4_p
ejection NN 4_p
fraction NN 4_p
less JJR 4_p
than IN 4_p
45 CD 4_p
% NN 4_p
after IN 4_p
AMI NNP 4_p
were VBD N
randomly RB N
assigned VBN N
stem NN N
cell NN N
delivery NN N
via IN N
intramyocardial JJ N
injection NN N
and CC N
intracoronary JJ N
infusion NN N
3-6 JJ N
weeks NNS N
or CC N
3-4 JJ N
months NNS N
after IN N
AMI NNP N
. . N

A DT N
total NN N
of IN N
60 CD 3_p
patients NNS N
were VBD N
treated VBN N
. . N

-DOCSTART- -X- O O 6927657

autistic JJ N
children NNS N
and CC N
adolescents NNS N
. . N

autistic JJ N
children NNS N
and CC N
adolescents VBZ N
10 CD N
autistic JJ N
subjects NNS N
10 CD N
autistic JJ N
subjects NNS N
20 CD N
subjects NNS N
autistic JJ N
children NNS N
. . N

-DOCSTART- -X- O O 8392359

infants NNS 4_p
. . 4_p

40 CD N
children NNS N
younger JJR N
than IN N
4 CD N
yr NNS N
having VBG N
elective JJ N
abdominal JJ N
surgery NN N
under IN N
general JJ N
anaesthesia NN N
supplemented VBN N
with IN N
either DT N
systemic JJ N
opioids NNS N
or CC N
extradural JJ N
bupivacaine NN N
. . N

-DOCSTART- -X- O O 19153828

patients NNS N
with IN N
early JJ N
breast NN 4_p
cancer NN 4_p
: : N
285 CD 3_p
premenopausal NN 4_p
breast NN 4_p
cancer NN 4_p
patients NNS N
, , N
in IN N
a DT N
randomized JJ N
adjuvant JJ N
trial NN N
( ( N
Zoladex NNP N
in IN N
premenopausal NN N
patients NNS N
( ( N
ZIPP NNP N
) ) N
) ) N
Node NNP N
positive JJ N
patients NNS N
-DOCSTART- -X- O O 7635420

primary JJ 4_p
biliary JJ 4_p
cirrhosis NN 4_p
: : N
Primary JJ 4_p
biliary JJ 4_p
cirrhosis NN 4_p
( ( 4_p
PBC NNP 4_p
) ) 4_p
is VBZ N
a DT N
chronic JJ N
, , N
progressive JJ N
, , N
cholestatic JJ N
liver NN 4_p
disease NN 4_p
. . N

from IN N
42 CD 3_p
patients NNS N
with IN N
PBC NNP 4_p
-DOCSTART- -X- O O 22151477

children NNS 1_p
and CC N
adults NNS 1_p
with IN N
autism NN 4_p
. . N

141 CD 3_p
children NNS 1_p
and CC 1_p
adults NNS 1_p
with IN N
autism NN 4_p
, , N
and CC N
pre NN N
and CC N
post NN N
symptoms NNS N
of IN N
autism NN N
None NN N
of IN N
the DT N
participants NNS N
had VBD N
taken VBN N
a DT N
vitamin/mineral JJ N
supplement NN N
in IN N
the DT N
two CD N
months NNS N
prior RB N
to TO N
the DT N
start NN N
of IN N
the DT N
study NN N
. . N

For IN N
a DT N
subset NN N
of IN N
the DT N
participants NNS N
( ( N
53 CD 3_p
children NNS 1_p
ages VBZ 1_p
5-16 JJ 1_p
) ) 1_p
children NNS 1_p
with IN N
autism NN 4_p
most JJS N
children NNS 1_p
and CC 1_p
adults NNS 1_p
with IN N
autism NN 4_p
. . N

-DOCSTART- -X- O O 9044492

Nurses NNS 4_p
without IN N
prior JJ 4_p
experience NN 4_p
in IN 4_p
the DT 4_p
use NN 4_p
of IN 4_p
the DT 4_p
laryngeal JJ 4_p
mask NN 4_p
airway NN 4_p
( ( 4_p
LMA NNP 4_p
) ) 4_p
Group NNP N
A NNP N
( ( N
32 CD 3_p
nurses NNS 4_p
) ) N
were VBD N
trained VBN N
only RB N
on IN N
a DT N
manikin NN N
and CC N
group NN N
B NNP N
( ( N
20 CD 3_p
nurses NNS 4_p
) ) N
were VBD N
trained VBN N
on IN N
a DT N
manikin NN N
and CC N
with IN N
live JJ N
anaesthetised VBN N
patient JJ N
practice NN N
in IN N
theatre NN N
( ( N
five CD N
successful JJ N
insertions NNS N
) ) N
. . N

live JJ N
patient NN N
in IN N
theatre JJ N
-DOCSTART- -X- O O 9403746

comatose NN 4_p
or CC 4_p
sedated VBN 4_p
patients NNS 4_p
undergoing JJ 4_p
femoral JJ 4_p
vein NN 4_p
catheterization NN 4_p
. . 4_p

comatose VBD N
or CC N
sedated VBN N
adults NNS N
. . N

patients NNS N
undergoing VBG N
superior JJ N
vena NNS N
cava JJ N
catheterization NN N
. . N

Sixty-one JJ 3_p
comatose NN N
or CC N
sedated VBN N
patients NNS N
admitted VBN N
to TO N
the DT N
ICU NNP N
who WP N
underwent JJ N
central JJ N
venous JJ N
catheterization NN N
. . N

31 CD 3_p
patients NNS N
underwent JJ N
femoral JJ N
vein NN N
catheterization NN N
and CC N
30 CD 3_p
patients NNS N
underwent JJ N
superior JJ N
vena NN N
cava NN N
catheterization NN N
, , N
either RB N
by IN N
axillary JJ N
( ( N
21 CD 3_p
patients NNS N
) ) N
or CC N
internal JJ N
jugular NN N
vein NN N
( ( N
10 CD N
patients NNS N
) ) N
cannulation NN N
. . N

comatose NN N
or CC N
sedated VBN N
patients NNS N
. . N

-DOCSTART- -X- O O 9076457

patients NNS 4_p
with IN 4_p
superficial JJ 4_p
bladder NN 4_p
carcinoma NN 4_p
. . 4_p

patients NNS 4_p
whose WP$ 4_p
superficial JJ 4_p
bladder NN 4_p
tumors NNS 4_p
had VBD 4_p
been VBN 4_p
removed VBN 4_p
by IN 4_p
transurethral JJ 4_p
resection NN 4_p
. . N

419 CD 3_p
patients NNS 3_p
were VBD N
evaluated VBN N
after IN N
a DT N
median JJ N
follow-up NN N
of IN N
57 CD N
months NNS N
. . N

-DOCSTART- -X- O O 23114568

adults NNS N
with IN N
and CC N
without IN N
Asperger NNP N
's POS N
syndrome NN N
. . N

Individuals NNS N
with IN N
Asperger NNP 4_p
's POS 4_p
syndrome NN 4_p
( ( 4_p
AS IN 4_p
) ) 4_p
individuals NNS N
with IN N
AS NNP 4_p
adults NNS N
with IN N
AS NNP 4_p
engaged VBN N
in IN N
structured JJ N
, , N
goal-directed JJ N
social JJ N
interactions NNS N
. . N

-DOCSTART- -X- O O 12443948

unexpected JJ N
perturbations NNS N
during IN N
human JJ N
walking NN N
. . N

healthy JJ 4_p
adults NNS 1_p
. . N

-DOCSTART- -X- O O 24214189

Japanese JJ 4_p
adult NN 1_p
healthy JJ 4_p
subjects NNS 4_p
: : 4_p
Japanese JJ 4_p
healthy JJ 4_p
subjects NNS 4_p
. . N

Forty-eight JJ N
Japanese JJ N
healthy JJ N
subjects NNS N
( ( N
males NNS N
24 CD N
; : N
females NNS N
24 CD N
) ) N
in IN N
a DT N
single-center JJ N
control NN N
for IN N
QT/QTc NNP N
-DOCSTART- -X- O O 10352397

obese JJ 4_p
adults NNS 1_p
. . N

obesity NN 4_p
. . N

24 CD 3_p
obese JJ 4_p
subjects NNS N
( ( N
22 CD 3_p
women NNS 2_p
and CC N
2 CD 3_p
men NNS 2_p
; : N
22-46 CD 1_p
years NNS 1_p
old JJ N
) ) N
obese JJ 4_p
subjects NNS N
-DOCSTART- -X- O O 3081148

Nine NNP 4_p
normal JJ 4_p
volunteers NNS 4_p
and CC 4_p
15 CD 4_p
patients NNS 4_p
with IN 4_p
pituitary JJ 4_p
disorders NNS 4_p
-DOCSTART- -X- O O 15160783

evaluating VBG N
antidepressant JJ 4_p
efficacy NN 4_p
. . N

-DOCSTART- -X- O O 9589305

Crohn NNP 4_p
's POS 4_p
disease NN 4_p
-DOCSTART- -X- O O 1640362

healthy JJ 4_p
volunteers NNS 4_p
. . 4_p

healthy JJ N
human JJ N
volunteers NNS N
. . N

-DOCSTART- -X- O O 23379240

patients NNS N
with IN N
BPH NNP 4_p
: : N
94 CD N
patients NNS N
patients NNS N
with IN N
symptoms NNS 4_p
of IN 4_p
I-II NNP 4_p
stages NNS 4_p
benign VBP 4_p
prostatic JJ 4_p
hyperplasia NN 4_p
( ( 4_p
BPH NNP 4_p
) ) 4_p
. . N

-DOCSTART- -X- O O 19912211

a DT N
single-centre JJ N
randomized JJ N
trial NN N
of IN N
202 CD 3_p
patients NNS N
. . N

transurethral JJ 4_p
resection NN 4_p
of IN 4_p
the DT 4_p
prostate NN 4_p
( ( 4_p
TURP NNP 4_p
) ) 4_p
202 CD 3_p
consecutive JJ N
patients NNS N
from IN N
the DT N
hospital NN N
waiting VBG N
list NN N
-DOCSTART- -X- O O 9706929

spinal JJ 4_p
anesthesia NN 4_p
after IN 4_p
prophylactic JJ 4_p
administration NN 4_p
of IN 4_p
intravenous JJ 4_p
fluids NNS 4_p
or CC 4_p
vasoconstrictors NNS 4_p
. . 4_p

spinal JJ 4_p
anesthesia NN 4_p
Patients NNS N
( ( N
n JJ N
= NN N
1066 CD 3_p
) ) N
All DT N
patients NNS N
breathed VBD N
O2-enriched NNP N
air NN N
during IN N
spinal JJ N
anesthesia NN N
( ( N
4 CD N
mL NN N
of IN N
plain JJ N
0.5 CD N
% NN N
bupivacaine NN N
) ) N
. . N

-DOCSTART- -X- O O 17450704

Women NNP 4_p
's POS 4_p
responses NNS 4_p
to TO 4_p
information NN 4_p
on IN 4_p
mammographic JJ 4_p
breast NN 4_p
density NN 4_p
. . 4_p

participants NNS N
of IN N
a DT N
screening JJ N
program NN N
. . N

sample NN N
of IN N
618 CD N
women NNS N
50 CD N
years NNS N
or CC N
older JJR N
with IN N
MBD NNP N
greater JJR N
than IN N
50 CD N
% NN N
of IN N
breast NN N
volume NN N
. . N

-DOCSTART- -X- O O 15037334

first JJ 4_p
episode NN 4_p
schizophrenia NN 4_p
. . N

schizophrenia NN 4_p
patients NNS N
with IN N
first JJ 4_p
episode NN 4_p
schizophrenia NN 4_p
; : N
that WDT N
is VBZ N
, , N
before IN N
the DT N
effects NNS N
of IN N
chronic JJ 4_p
illness NN 4_p
, , N
institutionalization NN N
, , N
or CC N
treatment NN N
307 CD 3_p
schizophrenia NN 4_p
subjects NNS N
in IN N
their PRP$ N
first JJ 4_p
episode NN 4_p
of IN 4_p
illness NN 4_p
Approximately RB N
two-thirds NNS 3_p
of IN N
the DT N
subjects NNS N
were VBD N
receiving VBG N
antipsychotic JJ N
treatment NN N
at IN N
the DT N
time NN N
of IN N
assessment NN N
; : N
however RB N
, , N
the DT N
duration NN N
of IN N
treatment NN N
was VBD N
limited VBN N
to TO N
12 CD N
weeks NNS N
or CC N
less JJR N
. . N

first JJ 4_p
episode NN 4_p
schizophrenia NN 4_p
patients NNS N
schizophrenia NN 4_p
-DOCSTART- -X- O O 3617996

85 CD 4_p
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
ovarian JJ 4_p
carcinomas NN 4_p
cases NNS N
of IN N
advanced JJ N
tumors NNS N
-DOCSTART- -X- O O 4165041

glucose NN 4_p
, , 4_p
glucagon NN 4_p
, , 4_p
and CC 4_p
tolbutamide NN 4_p
in IN 4_p
man NN 4_p
. . N

-DOCSTART- -X- O O 9048274

healthy JJ N
men NNS N
. . N

healthy JJ N
young JJ 1_p
male NN 2_p
volunteers NNS N
. . N

Eight CD 4_p
participants NNS N
( ( N
mean JJ N
age NN N
+/- JJ N
standard NN N
deviation NN N
, , N
22 CD N
+/- JJ N
0.9 CD N
years NNS N
) ) N
healthy JJ N
young JJ N
male JJ N
subjects NNS N
-DOCSTART- -X- O O 23624061

11 CD 3_p
healthy JJ N
participants NNS N
by IN N
a DT N
movable JJ N
platform NN N
that IN N
suddenly RB N
translated VBN N
forward RB N
or CC N
backward RB N
. . N

patients NNS N
with IN N
Parkinson NNP 4_p
's POS 4_p
disease NN 4_p
and CC N
progressive JJ N
supranuclear NN N
palsy NN N
. . N

-DOCSTART- -X- O O 14715180

patients NNS N
with IN N
implantable JJ 4_p
cardioverter NN 4_p
defibrillators NNS 4_p
. . N

patients NNS N
with IN N
implantable JJ 4_p
cardioverter NN 4_p
defibrillators NNS 4_p
( ( N
ICDs NNP N
) ) N
. . N

172 CD 3_p
patients NNS N
patients NNS N
with IN N
ICDs NNP 4_p
. . N

The DT N
majority NN N
of IN N
patients NNS N
had VBD N
a DT N
history NN N
of IN N
documented JJ N
remote JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
and CC 4_p
congestive JJ 4_p
heart NN 4_p
failure NN 4_p
New NNP N
York NNP N
Heart NNP N
Association NNP N
class NN N
II NNP N
or CC N
III NNP N
. . N

-DOCSTART- -X- O O 16904524

outpatients NNS N
with IN N
cancer NN 4_p
treated VBN N
by IN N
radiation NN N
therapy NN N
. . N

outpatients NNS N
with IN N
cancer NN 4_p
. . N

Sixty-four JJ 3_p
patients NNS 3_p
outpatients NNS N
with IN N
cancer NN 4_p
. . N

-DOCSTART- -X- O O 20828635

colorectal JJ 4_p
cancer NN 4_p
( ( 4_p
CRC NNP 4_p
) ) 4_p
asymptomatic JJ 4_p
patients NNS 4_p
who WP N
are VBP N
50-79years NNS 1_p
and CC N
are VBP 4_p
not RB 4_p
up-to-date JJ 4_p
with IN 4_p
CRC NNP 4_p
screening VBG 4_p
guidelines NNS 4_p
. . N

GERA NNP 4_p
or CC 4_p
Control NNP 4_p
group NN 4_p
. . N

Of IN N
2,223 CD 3_p
eligible JJ N
patients NNS N
, , N
562 CD 3_p
( ( N
25 CD N
% NN N
) ) N
have VBP N
enrolled VBN N
. . N

Patients NNS 4_p
who WP 4_p
enrolled VBD 4_p
in IN 4_p
the DT 4_p
study NN 4_p
were VBD 4_p
significantly RB 4_p
younger JJR 4_p
than IN 4_p
those DT 4_p
who WP 4_p
did VBD 4_p
not RB 4_p
( ( 4_p
p JJ 4_p
< NNP 4_p
0.001 CD 4_p
) ) 4_p
. . N

Participants NNS N
tended VBD N
to TO N
be VB N
50-59years JJ N
( ( N
64 CD N
% NN N
) ) N
, , N
female JJ 2_p
( ( 3_p
58 CD 3_p
% NN 3_p
) ) 3_p
, , N
white JJ N
( ( N
52 CD N
% NN N
) ) N
, , N
married VBD N
( ( N
51 CD N
% NN N
) ) N
, , N
and CC N
have VBP N
more JJR N
than IN N
a DT N
high JJ N
school NN N
education NN N
( ( N
67 CD N
% NN N
) ) N
. . N

One CD N
in IN N
four CD N
eligible JJ N
primary JJ N
care NN N
patients NNS N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 12459663

established VBN 4_p
postoperative JJ 4_p
nausea NN 4_p
and CC 4_p
vomiting NN 4_p
. . 4_p

treatment NN 4_p
of IN 4_p
established VBN 4_p
postoperative JJ 4_p
nausea NN 4_p
and CC 4_p
vomiting NN 4_p
( ( 4_p
PONV NNP 4_p
) ) 4_p
after IN 4_p
outpatient NN 4_p
laparoscopic NN 4_p
surgery NN 4_p
. . 4_p

268 CD 3_p
outpatients NNS N
90 CD 3_p
patients NNS N
developed VBD N
PONV NNP 4_p
established VBN 4_p
PONV NNP 4_p
. . 4_p

-DOCSTART- -X- O O 25380801

women NNS 4_p
during IN 4_p
puerperium NN 4_p
. . 4_p

fermented JJ N
milk NN N
containing VBG N
Lactobacillus NNP 4_p
casei NN 4_p
strain NN 4_p
Shirota NNP 4_p
( ( 4_p
LcS NNP 4_p
) ) 4_p
on IN N
stool NN N
consistency NN N
and CC N
frequency NN N
, , N
constipation-related JJ 4_p
symptoms NNS 4_p
and CC N
quality NN N
of IN N
life NN N
, , N
and CC N
incidence NN N
of IN N
haemorrhoids NNS N
in IN N
women NNS N
during IN N
puerperium NN N
. . N

Forty NNP N
women NNS N
who WP N
had VBD N
natural JJ 4_p
childbirth NN 4_p
were VBD N
randomised VBN N
to TO N
group NN N
consuming VBG N
either CC N
one CD N
bottle/day NN N
of IN N
fermented JJ N
milk NN N
containing VBG N
at IN N
least JJS N
6.5×109 CD N
cfu NN N
of IN N
LcS NNP N
, , N
or CC N
placebo NN 4_p
, , N
for IN N
6 CD N
weeks NNS N
after IN N
childbirth NN N
in IN N
women NNS N
during IN 4_p
puerperium NN 4_p
-DOCSTART- -X- O O 3911965

pollinosis NN 4_p
. . 4_p

164 CD 3_p
patients NNS N
pollinosis NN 4_p
. . 4_p

-DOCSTART- -X- O O 15224298

high-risk JJ 4_p
patients NNS N
for IN N
percutaneous JJ 4_p
intervention NN 4_p
and CC N
bypass NN 4_p
surgery NN 4_p
: : N
high-risk JJ 4_p
patients NNS 4_p
patients NNS N
with IN N
main-stem JJ 4_p
and CC 4_p
main-stem-equivalent JJ 4_p
stenosis NN 4_p
patients NNS 4_p
with IN 4_p
high JJ 4_p
risk NN 4_p
for IN N
both DT N
treatments NNS N
. . N

patients NNS N
with IN N
symptomatic JJ N
main-stem NN N
and CC N
main-stem-equivalent JJ N
lesions NNS N
with IN N
substantially RB N
increased VBN N
risk NN N
for IN N
bypass NN N
surgery NN N
. . N

( ( N
n JJ N
= NNP N
23 CD 3_p
) ) N
( ( N
n JJ N
= NNP N
21 CD 3_p
) ) N
. . N

Patients NNS N
of IN N
the DT N
stent NN 4_p
group NN 4_p
and CC N
the DT N
bypass NN 4_p
group NN 4_p
did VBD N
not RB N
differ VB N
in IN N
baseline NN N
characteristics NNS N
, , N
including VBG N
Parsonnet NNP N
score NN N
and CC N
quality-of-life JJ N
score NN N
. . N

high-risk JJ 4_p
patients NNS 4_p
for IN 4_p
stent JJ 4_p
implantation NN 4_p
and CC N
bypass NN 4_p
surgery NN 4_p
-DOCSTART- -X- O O 24393553

Japanese JJ N
patients NNS N
with IN 4_p
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
mellitus RB 4_p
. . N

Japanese JJ N
patients NNS N
with IN N
T2DM NNP 4_p
36 CD 3_p
T2DM NNP N
patients NNS N
( ( N
18 CD 3_p
patients NNS N
each DT N
in IN N
2.5 CD N
mg NN N
and CC N
10 CD N
mg NNS N
dose JJ N
group NN N
) ) N
-DOCSTART- -X- O O 8047747

Surrogate NNP N
and CC N
auxiliary JJ N
endpoints NNS N
in IN N
clinical JJ N
trials NNS N
, , N
with IN N
potential JJ N
applications NNS N
in IN N
cancer NN N
and CC N
AIDS NNP 4_p
research NN N
. . N

emphasis NN N
on IN N
cancer NN 4_p
and CC N
AIDS NNP 4_p
research NN N
settings NNS N
. . N

-DOCSTART- -X- O O 16379507

children NNS 1_p
with IN N
autism NN 4_p
. . N

101 CD 1_p
children NNS 1_p
and CC N
adolescents NNS 1_p
with IN N
a DT N
lifetime JJ N
diagnosis NN N
of IN N
autistic JJ 4_p
disorder NN 4_p
. . N

-DOCSTART- -X- O O 23605599

chemotherapy-induced JJ 4_p
mucositis NN 4_p
. . 4_p

24 CD 3_p
adult NN 1_p
patients NNS N
who WP N
underwent JJ N
chemotherapy NN N
during IN N
2009-2010 JJ N
. . N

-DOCSTART- -X- O O 15652441

cancer NN 4_p
pain NN 4_p
. . N

Chronic NNP 4_p
cancer NN 4_p
pain NN 4_p
patients NNS N
( ( N
n=25 JJ 3_p
) ) N
were VBD N
randomized VBN N
to TO N
OAD NNP N
morphine NN N
( ( N
mean JJ N
238 CD N
+/- JJ N
319 CD N
mg NN N
q24h NN N
) ) N
or CC N
twice-daily JJ N
-DOCSTART- -X- O O 17694216

provisional JJ 4_p
restorations NNS 4_p
: : 4_p
polymethyl NN 1_p
methacrylate NN 1_p
( ( 1_p
PMMA NNP 1_p
) ) 1_p
self-cured VBD 1_p
acrylic JJ 1_p
resin NN 1_p
provisional JJ 1_p
crowns NNS 1_p
. . 1_p

Three NNP N
types NNS N
of IN N
PMMA NNP N
surfaces NNS N
were VBD N
tested VBN N
: : N
( ( N
1 CD N
) ) N
polished VBN N
, , N
( ( N
2 CD N
) ) N
polished VBN N
and CC N
coated VBN N
with IN N
bonding NN N
agent NN N
, , N
and CC N
( ( N
3 CD N
) ) N
polished VBN N
and CC N
coated VBN N
with IN N
light-cured JJ N
liquid JJ N
polish NN N
. . N

-DOCSTART- -X- O O 20023215

in IN 4_p
HIV-associated JJ 4_p
B-cell NNP 4_p
non-Hodgkin JJ 4_p
lymphoma NN 4_p
. . 4_p

immunocompetent JJ N
patients NNS N
with IN N
B-cell NNP N
non-Hodgkin JJ N
lymphoma NN N
( ( N
NHL NNP 4_p
) ) N
. . N

HIV-associated NNP 4_p
NHL NNP 4_p
. . N

48 CD 3_p
evaluable JJ N
patients NNS N
53 CD 3_p
evaluable JJ N
patients NNS N
HIV-associated JJ 4_p
lymphoma NN 4_p
. . N

-DOCSTART- -X- O O 23101741

young JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
. . N

children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . N

Forty-eight JJ 1_p
18- JJ 1_p
to TO 1_p
30-month-old JJ 1_p
children NNS 1_p
with IN N
autism NN N
spectrum NN N
disorder NN N
Age-matched JJ N
typical JJ N
children NNS N
in IN N
young JJ N
children NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
-DOCSTART- -X- O O 11705818

patients NNS N
with IN N
advanced JJ 4_p
heart NN 4_p
failure NN 4_p
. . N

patients NNS N
with IN N
heart NN 4_p
failure NN 4_p
. . 4_p

142 CD 3_p
patients NNS 3_p
with IN N
symptomatic JJ 4_p
heart NN 4_p
failure NN 4_p
( ( N
New NNP N
York NNP N
Heart NNP N
Association NNP N
class NN N
III NNP N
and CC N
IV NNP N
) ) N
patients NNS N
with IN N
advanced JJ 4_p
heart NN 4_p
failure NN 4_p
-DOCSTART- -X- O O 23275644

Japan NNP N
open JJ 4_p
distal JJ 4_p
gastrectomy NN 4_p
in IN 4_p
patients NNS 4_p
with IN 4_p
clinical JJ 4_p
IA NNP 4_p
( ( 4_p
T1N0 NNP 4_p
) ) 4_p
or CC 4_p
IB NNP 4_p
[ NNP 4_p
T1N1 NNP 4_p
or CC N
T2 NNP 4_p
( ( 4_p
MP NNP 4_p
) ) 4_p
N0 NNP 4_p
] NNP 4_p
gastric JJ 4_p
cancer NN 4_p
. . 4_p

of IN N
920 CD 3_p
patients NNS 3_p
will MD N
be VB N
accrued VBN N
from IN N
33 CD N
institutions NNS N
within IN N
5 CD N
years NNS N
. . N

credentialed JJ N
surgeon NN N
-DOCSTART- -X- O O 11443835

patients NNS 4_p
undergoing JJ 4_p
gastroenterological JJ 4_p
and CC 4_p
hernia JJ 4_p
surgery NN 4_p
: : 4_p
an DT 4_p
analysis NN 4_p
of IN 4_p
374 CD 4_p
patients NNS 4_p
. . 4_p

374 CD 3_p
surgical JJ 4_p
patients NNS 4_p
with IN 4_p
gastrointestinal JJ 4_p
disease NN 4_p
and CC 4_p
hernias NN 4_p
of IN 4_p
the DT 4_p
abdominal JJ 4_p
wall NN 4_p
; : 4_p
surgical JJ N
patients NNS N
374 CD N
patients NNS N
evaluated VBN N
in IN N
this DT N
study NN N
-DOCSTART- -X- O O 3602327

elderly JJ 1_p
normal JJ N
volunteers NNS N
. . 1_p

-DOCSTART- -X- O O 24914426

disabled JJ N
children NNS 1_p
. . 1_p

disabled JJ N
children NNS 1_p
. . 1_p

Ninety NNP 3_p
patients NNS 3_p
aged VBN N
3-17 CD 1_p
years NNS 1_p
who WP N
were VBD N
treated VBN N
under IN N
general JJ N
anaesthesia NN 4_p
children NNS 1_p
with IN N
disability NN 4_p
-DOCSTART- -X- O O 10566623

Two CD 3_p
hundred CD 3_p
and CC 3_p
twenty-nine JJ 3_p
adult NN 1_p
patients NNS 4_p
with IN 4_p
differentiated JJ 4_p
thyroid NN 4_p
cancer NN 4_p
requiring VBG 4_p
radioiodine NN 4_p
WBS NNP 4_p
were VBD 4_p
studied VBN 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
disease NN 4_p
or CC 4_p
tissue NN 4_p
limited VBN 4_p
to TO 4_p
the DT 4_p
thyroid NN 4_p
bed NN 4_p
100 CD N
% NN N
of IN N
patients NNS N
, , N
respectively RB N
, , N
with IN N
metastatic JJ N
disease NN N
. . N

patients NNS N
with IN N
disease NN N
or CC N
tissue NN N
limited VBN N
to TO N
the DT N
thyroid NN N
bed NN N
patients NNS N
with IN N
metastatic JJ N
disease NN N
. . N

patients NNS N
undergoing JJ N
evaluation NN N
for IN N
thyroid JJ N
cancer NN N
persistence NN N
and CC N
recurrence NN N
. . N

-DOCSTART- -X- O O 8872685

splanchnic JJ 4_p
oxygenation NN 4_p
in IN N
humans NNS N
. . N

20 CD 3_p
ASA NNP N
physical JJ N
status NN N
I PRP N
, , N
II NNP N
, , N
and CC N
III NNP N
adults NNS 1_p
, , N
who WP N
underwent VBD N
major JJ N
abdominal JJ N
surgery NN N
requiring VBG N
mechanical JJ N
ventilation NN N
a DT N
few JJ N
hours NNS N
postoperatively RB N
. . N

-DOCSTART- -X- O O 12585724

children NNS 1_p
with IN N
autistic JJ 4_p
spectrum NN 4_p
disorders NNS 4_p
. . N

31 CD 3_p
children NNS N
with IN N
autistic JJ N
spectrum NN N
disorders NNS N
in IN N
an DT N
8-week JJ N
, , N
double-blinded JJ N
study NN N
-DOCSTART- -X- O O 23134960

cesarean JJ N
section NN N
] NNP N
one CD N
hundred CD N
and CC N
eighty VB N
singleton NN N
primiparas IN N
undergoing VBG N
elective JJ N
cesarean JJ N
section NN N
, , N
in IN N
Qingdao NNP N
Municipal NNP N
Hospital NNP N
, , N
and CC N
Qingdao NNP N
Hiser NNP N
Medical NNP N
Center NNP N
, , N
from IN N
November NNP N
2011 CD N
to TO N
March NNP N
2012 CD N
, , N
were VBD N
randomly RB N
assigned VBN N
-DOCSTART- -X- O O 1282182

coronary JJ 4_p
spasm NN 4_p
13 CD 3_p
patients NNS N
with IN N
vasospastic JJ 4_p
angina NNS 4_p
All DT N
patients NNS N
had VBD N
a DT N
coronary JJ 4_p
spasm NN 4_p
during IN N
coronary JJ 4_p
arteriography NN 4_p
, , N
either CC N
spontaneously RB N
or CC N
ergometrine-induced JJ N
. . N

patients NNS N
with IN N
vasospastic JJ 4_p
angina NN 4_p
. . N

-DOCSTART- -X- O O 17404138

children NNS 1_p
with IN N
autism NN 4_p
or CC N
asthma NN 4_p
and CC N
other JJ N
special JJ 4_p
health NN 4_p
care NN 4_p
needs NNS 4_p
: : N
parents NNS N
of IN N
children NNS 1_p
with IN N
autism NN 4_p
compared VBN N
with IN N
parents NNS N
of IN N
children NNS 1_p
with IN N
asthma NN 4_p
or CC N
other JJ N
special JJ 4_p
health NN 4_p
care NN 4_p
needs VBZ 4_p
Parents NNPS N
of IN N
495 CD 3_p
children NNS 1_p
with IN N
autism NN 4_p
, , N
parents NNS N
of IN N
6716 CD 3_p
children NNS 1_p
with IN N
asthma NN 4_p
, , N
and CC N
parents NNS N
of IN N
11,403 CD 3_p
children NNS N
with IN N
other JJ N
special JJ 4_p
health NN 4_p
care NN 4_p
needs VBZ 4_p
without IN N
asthma NN 4_p
. . N

-DOCSTART- -X- O O 507792

Anaerobic NNP 4_p
infection NN 4_p
in IN 4_p
cancer NN 4_p
patients NNS 4_p
: : N
cancer NN 4_p
patients NNS 4_p
having VBG 4_p
localized VBN 4_p
infections NNS 4_p
presumably RB 4_p
caused VBN 4_p
by IN 4_p
anaerobic JJ 4_p
pathogens NNS 4_p
. . N

rates NNS N
of IN N
favorable JJ N
response NN N
were VBD N
89 CD N
% NN N
in IN N
patients NNS N
receiving VBG N
clindamycine NN N
alone RB N
and CC N
78 CD N
% NN N
in IN N
patients NNS N
receiving VBG N
cefoxitin NN N
alone RB N
. . N

20 CD 3_p
of IN 3_p
24 CD 3_p
patients NNS N
( ( N
83 CD N
% NN N
) ) N
responded VBD N
to TO N
clindamycin VB N
and CC N
18 CD 3_p
of IN 3_p
22 CD 3_p
( ( N
82 CD N
% NN N
) ) N
responded VBD N
to TO N
cefoxitin VB N
. . N

-DOCSTART- -X- O O 15733631

complex JJ 4_p
regional JJ 4_p
pain NN 4_p
syndrome NN 4_p
Twenty VB 3_p
subjects NNS N
with IN N
chronic JJ 4_p
CRPS1 NNP 4_p
initiated VBN 4_p
by IN 4_p
wrist JJ 4_p
fracture NN 4_p
and CC N
who WP N
satisfied VBD N
stringent JJ N
inclusion NN N
criteria NNS N
-DOCSTART- -X- O O 22045148

patients NNS 4_p
requiring VBG 4_p
mechanical JJ 4_p
ventilation NN 4_p
postacute NN 4_p
care NN 4_p
a DT N
mean JJ N
length NN N
of IN N
stay NN N
of IN N
25 CD N
days NNS N
or CC N
more JJR N
. . N

patients NNS N
requiring VBG N
mechanical JJ N
ventilation NN N
patient NN N
receiving VBG N
mechanical JJ N
ventilation NN N
hospital JJ N
discharge NN N
and CC N
billing NN N
data NNS N
from IN N
the DT N
2005 CD N
Nationwide NNP N
Inpatient NNP N
Sample NNP N
for IN N
54 CD N
686 CD N
Medicare NNP N
beneficiaries NNS N
admitted VBD N
to TO N
US NNP N
community NN N
hospitals NNS N
who WP N
met VBD N
the DT N
study NN N
's POS N
eligibility NN N
criteria NNS N
. . N

-DOCSTART- -X- O O 12676060

individuals NNS N
with IN N
autism NN N
: : N
participants NNS N
with IN N
high-functioning JJ 4_p
autism NN 4_p
individuals NNS N
with IN N
autism NN N
, , N
known VBN N
as IN N
" JJ N
musical JJ N
savants NNS N
, , N
" NN N
Participants NNS N
were VBD N
all DT N
musically RB N
untrained JJ N
and CC N
were VBD N
divided VBN N
into IN N
a DT N
group NN 3_p
of IN 3_p
12 CD 3_p
high-functioning JJ 3_p
individuals NNS 3_p
with IN 3_p
autism NN 3_p
and CC N
a DT N
group NN 3_p
of IN 3_p
12 CD 3_p
normally RB 3_p
developing VBG 3_p
individuals NNS 3_p
. . N

autistic JJ N
individuals NNS N
-DOCSTART- -X- O O 25568377

laying VBG N
hens NNS N
. . N

laying VBG 4_p
hen JJ 4_p
Shaver NNP N
hens VBZ N
( ( N
total JJ 3_p
= NN 3_p
150 CD 3_p
and CC N
26 CD 1_p
wk NNS 1_p
old JJ 1_p
) ) N
laying VBG N
hens NNS N
-DOCSTART- -X- O O 21690083

for IN N
pre-school JJ 1_p
children NNS 1_p
with IN N
autistic JJ 4_p
spectrum NN 4_p
disorders NNS 4_p
care NN N
of IN N
preschool NN N
children NNS N
with IN N
autistic JJ 4_p
spectrum NN 4_p
disorder NN 4_p
-DOCSTART- -X- O O 9023640

patients NNS 4_p
with IN 4_p
Helicobacter NNP 4_p
pylori JJ 4_p
infection NN 4_p
. . 4_p

Fourteen JJ 3_p
patients NNS N
with IN N
Helicobacter NNP N
pylori FW N
infection NN N
-DOCSTART- -X- O O 21434781

components NNS 4_p
in IN 4_p
patients NNS 4_p
aged VBN 4_p
70 CD 4_p
years NNS 4_p
and CC 4_p
younger JJR 4_p
with IN 4_p
osteoarthritis NN 4_p
. . 4_p

22 CD N
patients NNS N
per IN N
group NN N
. . N

All DT 1_p
patients NNS 1_p
-DOCSTART- -X- O O 8127293

tamoxifen NN 4_p
prevent VB N
breast NN N
cancer NN N
in IN N
high-risk JJ N
women NNS N
. . N

-DOCSTART- -X- O O 2019772

granulocytopenic JJ 4_p
cancer NN 4_p
patients NNS 4_p
. . 4_p

747 CD 4_p
febrile JJ 4_p
granulocytopenic JJ 4_p
patients NNS 4_p
with IN 4_p
cancer NN 4_p
cancer NN N
patients NNS N
with IN N
fever NN N
and CC N
granulocytopenia NN N
. . N

-DOCSTART- -X- O O 17525360

patients NNS 4_p
experience JJ 4_p
trauma NN 4_p
to TO 4_p
the DT 4_p
trigeminal JJ 4_p
nerve NN 4_p
during IN 4_p
orthognathic JJ 4_p
surgery NN 4_p
, , 4_p
impairing VBG 4_p
sensation NN 4_p
and CC 4_p
sensory JJ 4_p
function NN 4_p
on IN 4_p
the DT 4_p
face NN 4_p
. . 4_p

people NNS N
who WP N
performed VBD N
sensory JJ N
re-training JJ N
exercises NNS N
reported VBD N
the DT N
retrained JJ N
persons NNS N
exhibited VBD N
less RBR N
impairment JJ N
-DOCSTART- -X- O O 8770304

mastectomy JJ N
patients NNS N
. . N

60 CD N
group NN N
I-II NNP N
( ( N
American JJ N
Society NNP N
of IN N
Anesthesiology NNP N
criteria NNS N
) ) N
mastectomy NN N
patients NNS N
, , N
20 CD N
in IN N
each DT N
group NN N
. . N

-DOCSTART- -X- O O 25279666

Dental NNP 4_p
prophylaxis NN 4_p
decreases VBZ 4_p
the DT N
risk NN N
of IN N
esophageal JJ 4_p
cancer NN 4_p
in IN N
males NNS 2_p
; : N
a DT N
nationwide JJ N
population-based JJ N
study NN N
in IN N
Taiwan NNP N
. . N

Esophageal NN 4_p
cancer NN 4_p
( ( 4_p
EC NNP 4_p
) ) 4_p
is VBZ N
also RB N
a DT N
common JJ N
cause NN N
of IN N
death NN N
due JJ N
to TO N
cancer NN 4_p
among IN N
males NNS 2_p
. . N

718,409 CD 3_p
subjects NNS N
were VBD N
recruited VBN N
from IN N
the DT N
Taiwan NNP N
National NNP 4_p
Health NNP 4_p
Insurance NNP 4_p
Research NNP 4_p
Database NNP 4_p
( ( 4_p
NHIRD NNP 4_p
) ) N
519,831 CD 3_p
subjects NNS N
were VBD N
diagnosed VBN N
with IN N
PD NNP N
682 CD 3_p
patients NNS N
developed VBD N
EC NNP N
( ( N
‰/y NN N
) ) N
. . N

The DT N
dental JJ N
prophylaxis NN N
group NN N
that IN N
male JJ 2_p
subjects NNS N
associated VBN N
with IN N
a DT N
higher JJR N
risk NN N
CI NNP N
= NNP N
0.44-0.65 NN N
) ) N
. . N

Further NNP N
subgroup NN N
analysis NN N
showed VBD N
that IN N
the DT N
dental JJ N
prophylaxis NN N
group NN N
-DOCSTART- -X- O O 15176685

patients NNS N
with IN N
asthma NN 4_p
. . N

patients NNS N
with IN N
a DT N
diagnosis NN N
of IN N
asthma NN 4_p
. . N

Adult NNP 1_p
asthma JJ 4_p
patients NNS N
undergoing VBG N
treatment NN N
with IN N
budesonide JJ N
400 CD N
microg NN N
b.i.d NN N
. . N

and CC N
salbutamol JJ N
200 CD N
microg NN N
p.r.n NN N
. . N

less JJR N
than IN N
twice RB N
weekly JJ N
were VBD N
studied VBN N
. . N

Arm VB N
A NNP N
( ( N
16 CD 3_p
males/six NN 2_p
females NNS 2_p
, , N
aged VBD N
48 CD 1_p
+/- JJ 1_p
16 CD 1_p
yrs NN N
) ) N
received VBD N
clarithromycin JJ N
250 CD N
mg NN N
b.i.d NN N
. . N

for IN N
8 CD N
weeks NNS N
, , N
arm NN N
B NNP N
( ( N
eight CD 3_p
males/12 NN 2_p
females NNS 2_p
, , N
aged VBD N
42 CD 1_p
+/- JJ 1_p
12 CD 1_p
yrs NN N
) ) N
clarithromycin-treated JJ 4_p
patients NNS N
. . N

patients NNS N
with IN N
asthma NN 4_p
. . N

-DOCSTART- -X- O O 1584260

patients NNS N
with IN N
cancer NN N
of IN N
the DT N
esophagus NN N
. . N

121 CD N
patients NNS N
demonstrated VBD N
a DT N
significant JJ N
advantage NN N
for IN N
survival NN N
in IN N
the DT N
patients NNS N
who WP N
received VBD N
chemotherapy NN N
and CC N
radiation NN N
therapy NN N
. . N

Seven JJ N
patients NNS N
in IN N
the DT N
radiotherapy NN N
group NN N
and CC N
25 CD N
in IN N
the DT N
combined-therapy JJ N
group NN N
-DOCSTART- -X- O O 12638834

spinal JJ 4_p
anaesthesia NN 4_p
for IN 4_p
caesarean JJ 4_p
section NN 4_p
. . 4_p

Parturients NNPS 4_p
( ( 4_p
ASA NNP 4_p
1 CD 4_p
and CC 4_p
2 CD 4_p
) ) 4_p
scheduled VBN 4_p
for IN 4_p
elective JJ 4_p
caesarean JJ 4_p
section NN 4_p
. . N

The DT N
patients NNS N
with IN N
abnormal JJ 4_p
spaces NNS 4_p
, , N
coagulopathy NN 4_p
, , N
infection NN 4_p
, , N
pre-eclampsia/eclampsia NN 4_p
or CC N
obesity NN 4_p
were VBD N
excluded VBN N
. . N

Sixty NNP 3_p
women NNS 2_p
were VBD N
studied VBN N
. . N

-DOCSTART- -X- O O 12743142

Eligibility NNP N
included VBD N
localized JJ N
prostate NN N
cancer NN N
with IN N
an DT N
elevated JJ N
prostate-specific JJ N
antigen NN N
( ( N
PSA NNP N
) ) N
< VBD N
or CC N
= $ N
100 CD N
ng/mL NN N
and CC N
an DT N
estimated VBN N
risk NN N
of IN N
lymph JJ N
node NN N
( ( N
LN NNP N
) ) N
involvement NN N
of IN N
15 CD N
% NN N
. . N

Between NNP 4_p
April NNP 4_p
1 CD 4_p
, , 4_p
1995 CD 4_p
, , 4_p
and CC 4_p
June NNP 4_p
1 CD 4_p
, , 4_p
1999 CD 4_p
, , 4_p
1,323 CD 4_p
patients NNS 4_p
were VBD 4_p
accrued VBN 4_p
. . 4_p

patients NNS N
with IN N
a DT N
risk NN N
of IN N
LN NNP N
involvement NN N
of IN N
15 CD N
% NN N
. . N

-DOCSTART- -X- O O 8932546

allergic JJ 4_p
rhinitis NN 4_p
and CC 4_p
urticaria NN 4_p
. . N

Eight CD 3_p
volunteers NNS 4_p
were VBD N
enrolled VBN N
-DOCSTART- -X- O O 2185565

marrow JJ 4_p
transplantation NN 4_p
] NN 4_p
-DOCSTART- -X- O O 23821414

irritability NN 4_p
in IN 4_p
children NNS 4_p
with IN 4_p
autistic JJ 4_p
disorder NN 4_p
: : N
autistic JJ 4_p
disorders NNS 4_p
. . N

irritability NN 4_p
in IN N
autistic JJ 4_p
children NNS N
who WP N
were VBD N
not RB N
optimally RB N
responding VBG N
male NN N
and CC N
female JJ N
outpatients NNS N
aged VBN N
5-12 CD N
years NNS N
with IN N
a DT N
diagnosis NN N
of IN N
autistic JJ N
disorder NN N
based VBN N
on IN N
the DT N
DSM-IV-TR NNP N
criteria NNS N
and CC N
a DT N
score NN N
of IN N
≥12 NN N
on IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist-Community NNP N
( ( N
ABC-C NNP N
) ) N
irritability NN N
subscale NN N
who WP N
had VBD N
discontinued VBN N
other JJ N
medications NNS N
because IN N
of IN N
a DT N
lack NN N
of IN N
efficacy NN N
RESULTS NNP N
Forty-nine JJ N
patients NNS N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
, , N
and CC N
forty JJ N
children NNS N
completed VBD N
the DT N
-DOCSTART- -X- O O 16700802

653 CD N
patients NNS N
with IN N
dermatophytoses NNS N
653 CD N
patients NNS N
included VBN N
in IN N
the DT N
trial NN N
-DOCSTART- -X- O O 25012645

spinal JJ 4_p
bone NN 4_p
metastases NNS 4_p
in IN 4_p
cancer NN 4_p
patients NNS 4_p
patients NNS 4_p
with IN 4_p
spinal JJ 4_p
bone NN 4_p
metastases NNS 4_p
. . N

60 CD 3_p
patients NNS 3_p
were VBD N
allocated VBN N
from IN N
September NNP N
2011 CD N
until IN N
March NNP N
2013 CD N
into IN N
one CD N
of IN N
the DT N
two CD N
groups NNS N
: : N
-DOCSTART- -X- O O 17977295

white JJ N
spot NN N
lesions NNS N
( ( N
WSL NNP N
) ) N
. . N

26 CD N
healthy JJ N
adolescents NNS N
( ( N
mean JJ N
age NN N
14.6 CD N
years NNS N
) ) N
exhibiting VBG N
60 CD N
teeth NNS N
with IN N
152 CD N
visible JJ N
WSL NNP N
sites NNS N
on IN N
incisors NNS N
and CC N
canines NNS N
immediately RB N
after IN N
debonding VBG N
of IN N
fixed VBN N
orthodontic JJ N
appliances NNS N
. . N

-DOCSTART- -X- O O 25197765

Subjects NNP 4_p
with IN 4_p
and CC 4_p
without IN 4_p
Pseudoexfoliation NNP 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
and CC 4_p
without IN 4_p
pseudoexfoliation NN 4_p
Totally NNP N
129 CD N
eyes NNS N
of IN N
129 CD 3_p
patients NNS 3_p
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Of IN N
the DT N
129 CD 3_p
eyes NNS N
; : N
31 CD N
had VBD N
pseudoexfoliation NN 4_p
syndrome NN 4_p
( ( N
PXS NNP N
) ) N
, , N
37 CD N
had VBD N
pseudoexfoliation NN 4_p
glaucoma NN 4_p
( ( N
PXG NNP N
) ) N
, , N
31 CD N
eyes NNS N
were VBD N
the DT N
fellow JJ N
eyes NNS N
of IN N
subjects NNS N
with IN N
unilateral JJ 4_p
pseudoexfoliation NN 4_p
syndrome NN 4_p
( ( N
subclinical JJ N
PXS NNP N
) ) N
and CC N
30 CD N
eyes NNS N
were VBD N
the DT N
eyes NNS N
of IN N
subjects NNS N
without IN 4_p
PXS NNP 4_p
( ( 4_p
controls NNS 4_p
) ) N
. . N

Patients NNPS N
-DOCSTART- -X- O O 345802

patients NNS 4_p
with IN 4_p
recurrent JJ 4_p
venous JJ 4_p
thrombosis NN 4_p
. . N

-DOCSTART- -X- O O 16304214

coronary JJ 4_p
artery NN 4_p
surgery NN 4_p
. . N

coronary JJ 4_p
artery JJ 4_p
bypass NN 4_p
grafting NN 4_p
45 CD 3_p
hypertensive JJ 4_p
coronary JJ 4_p
bypass NN 4_p
patients NNS N
-DOCSTART- -X- O O 2869714

muscle NN N
relaxants NNS N
Six CD 4_p
patients NNS N
in IN N
each DT N
group NN N
-DOCSTART- -X- O O 14649341

laparoscopic JJ N
cholecystectomy NN N
. . N

laparoscopic JJ 4_p
cholecystectomy NN 4_p
. . 4_p

patients NNS 4_p
undergoing VBG 4_p
laparoscopic JJ 4_p
cholecystectomy NN 4_p
. . 4_p

30 CD N
patients NNS N
in IN N
each DT N
group NN N
: : N
patients NNS N
undergoing VBG N
laparoscopic JJ N
cholecystectomy NN N
laparoscopic JJ N
cholecystectomy NN N
. . N

-DOCSTART- -X- O O 25029834

May NNP N
2008 CD N
to TO N
July NNP N
2010 CD N
, , N
78 CD 3_p
patients NNS N
with IN N
knee JJ 4_p
osteoarthritis NN 4_p
42 CD 3_p
patients NNS N
in IN N
the DT N
experimental JJ N
group NN N
, , N
including VBG N
16 CD 3_p
males NNS 2_p
and CC N
26 CD 3_p
females NNS 2_p
, , N
ranging VBG N
in IN N
age NN N
from IN N
41 CD 1_p
to TO 1_p
63 CD 1_p
years NNS N
, , N
with IN N
an DT N
average NN N
of IN N
( ( N
53.62 CD 1_p
+/- JJ 1_p
6.53 CD 1_p
) ) N
years NNS N
; : N
the DT N
disease NN N
course NN N
ranged VBD N
from IN N
8 CD N
to TO N
24 CD N
months NNS N
, , N
with IN N
an DT N
average NN N
of IN N
( ( N
10.35 CD N
+/- JJ N
6.42 CD N
) ) N
months NNS N
. . N

36 CD 3_p
patients NNS N
in IN N
the DT N
control NN N
group NN N
, , N
including VBG N
14 CD 3_p
males NNS 2_p
and CC N
22 CD 3_p
females NNS 2_p
, , N
ranging VBG N
in IN N
age NN N
from IN N
40 CD 1_p
to TO 1_p
62 CD 1_p
years NNS N
, , N
with IN N
an DT N
average NN N
of IN N
( ( N
54.34 CD 1_p
+/- JJ 1_p
7.67 CD 1_p
) ) N
years NNS N
; : N
the DT N
disease NN N
course NN N
ranged VBD N
from IN N
6 CD N
to TO N
25 CD N
months NNS N
, , N
with IN N
an DT N
average NN N
of IN N
( ( N
11.94 CD N
+/- JJ N
5.13 CD N
) ) N
months NNS N
. . N

with IN N
knee JJ 4_p
osteoarthritis NN 4_p
-DOCSTART- -X- O O 26139208

adolescent JJ 1_p
HIV NNP 4_p
prevention NN N
trial NN N
in IN N
Kenya NNP N
. . N

adolescent JJ 1_p
sub-Saharan JJ N
HIV NNP N
prevention NN N
adolescent JJ 1_p
orphans NNS N
in IN N
Kenya NNP N
. . N

837 CD 3_p
Kenyan NNP N
orphan MD N
youth VB 1_p
in IN N
grades NNS N
7 CD N
and CC N
8 CD N
enrolled VBN N
in IN N
an DT N
HIV NNP N
prevention NN N
clinical JJ N
trial NN N
with IN N
HSV-2 NNP N
biomarker NN N
outcomes NNS N
. . N

28 CD 3_p
adolescents NNS N
( ( N
3.3 CD N
% NN N
) ) N
22 CD N
positive JJ N
and CC N
all DT N
indeterminates NNS N
were VBD N
WB NNP N
tested VBD N
; : N
20 CD N
and CC N
5 CD N
, , N
respectively RB N
adolescent JJ 1_p
participants NNS 1_p
-DOCSTART- -X- O O 12642251

acute JJ 4_p
epicondylitis NN 4_p
. . N

pain NN 4_p
of IN 4_p
medial NN 4_p
or CC 4_p
lateral JJ 4_p
epicondylitis NN 4_p
( ( 4_p
tennis IN 4_p
elbow NN 4_p
) ) 4_p
. . N

patients NNS N
with IN N
medial JJ 4_p
or CC 4_p
lateral JJ 4_p
elbow NN 4_p
epicondylitis NN 4_p
. . N

199 CD N
patients NNS N
with IN N
elbow JJ N
epicondylitis NN 4_p
-DOCSTART- -X- O O 16264956

Chemotherapy NNP 4_p
for IN 4_p
metastatic JJ 4_p
NSCLC NNP 4_p
: : 4_p
-DOCSTART- -X- O O 10720081

patients NNS N
with IN N
adrenal JJ 4_p
incidentaloma NN 4_p
: : N
patients NNS N
with IN N
incidentally RB N
discovered VBN N
adrenal JJ 4_p
adenomas NN 4_p
. . 4_p

patients NNS N
who WP N
do VBP N
not RB N
present VB N
with IN N
any DT N
clear JJ N
Cushingoid NNP N
sign NN N
. . N

10 CD 3_p
patients NNS N
( ( N
3 CD 3_p
men NNS 2_p
and CC N
7 CD 3_p
women NNS 2_p
, , N
aged VBD N
48-63 JJ 1_p
yr NN 1_p
) ) N
with IN N
an DT N
adrenal JJ N
mass NN N
discovered VBD N
serendipitously RB N
Thirteen JJ 3_p
age-matched JJ N
healthy JJ 4_p
volunteers NNS 4_p
served VBD N
as IN N
controls NNS 4_p
. . N

Patients NNS N
with IN N
obesity NN 4_p
and/or NN 4_p
diabetes NNS 4_p
were VBD 4_p
excluded VBN 4_p
. . N

patients NNS N
bearing VBG N
adrenal JJ 4_p
incidentaloma NNS 4_p
patients NNS N
with IN N
incidental JJ 4_p
adrenal JJ 4_p
adenomas IN 4_p
-DOCSTART- -X- O O 20535539

children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
conditions NNS N
and CC N
severe JJ N
sleep NN 4_p
problems NNS 4_p
not RB N
amenable JJ N
to TO N
behaviour VB N
management NN N
strategies NNS N
: : N
Twenty-two JJ 3_p
children NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
who WP N
had VBD N
not RB N
responded VBN N
to TO N
supported VB N
behaviour JJ N
management NN N
strategies NNS N
for IN N
severe JJ N
dysomnias NN 4_p
17 CD 3_p
children NNS 1_p
completed VBD N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 15302308

Gonadotropin-releasing VBG 4_p
hormone NN 4_p
agonist NN 4_p
with IN 4_p
or CC 4_p
without IN 4_p
raloxifene NN 4_p
: : 4_p
-DOCSTART- -X- O O 23233021

autism NN 1_p
in IN 1_p
children NNS 1_p
. . 1_p

Sixty NNP 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
or CC 1_p
Asperger NNP 1_p
syndrome VBP 1_p
( ( 1_p
3-11 CD 1_p
years NNS 1_p
old JJ 1_p
) ) 1_p
-DOCSTART- -X- O O 23532629

previously RB N
untreated VBN N
advanced JJ 4_p
esophagogastric JJ 4_p
cancer NN 4_p
patients NNS 4_p
. . N

patients NNS N
within IN N
an DT N
open JJ N
label NN N
, , N
randomized VBD N
clinical JJ N
phase NN N
II NNP N
trial NN N
with IN N
advanced JJ 4_p
or CC 4_p
metastatic JJ 4_p
gastric/esophagogastric JJ 4_p
cancer NN 4_p
. . N

Previously RB 4_p
untreated VBD 4_p
patients NNS 4_p
were VBD 4_p
randomized VBN 4_p
Of IN N
118 CD 3_p
patients NNS 3_p
enrolled VBD 3_p
levels NNS N
in IN N
patients NNS N
with IN N
advanced JJ N
esophagogastric JJ N
cancer NN N
-DOCSTART- -X- O O 18843564

persons NNS 4_p
with IN 4_p
a DT 4_p
psychiatric JJ 4_p
disability NN 4_p
and CC 4_p
their PRP$ 4_p
staff NN 4_p
. . 4_p

persons NNS N
with IN N
psychiatric JJ N
disabilities NNS N
, , N
and CC N
their PRP$ N
caregivers NNS N
. . N

persons NNS N
with IN N
psychiatric JJ N
disabilities NNS N
persons NNS N
with IN N
a DT N
psychiatric JJ N
disability NN N
. . N

clients NNS 4_p
with IN 4_p
psychiatric JJ 4_p
disabilities NNS 4_p
living VBG 4_p
in IN 4_p
supported JJ 4_p
housing NN 4_p
and CC 4_p
their PRP$ 4_p
staff NN 4_p
. . 4_p

Forty-one CD 4_p
persons NNS 4_p
with IN 4_p
a DT 4_p
DSM- NNP 4_p
? . 4_p
V NNP 4_p
diagnosis NN 4_p
of IN 4_p
severe JJ 4_p
mental JJ 4_p
illness NN 4_p
from IN 4_p
psychiatric JJ 4_p
disability NN 4_p
from IN 4_p
10 CD 4_p
supported VBD 4_p
housing NN 4_p
facilities NNS 4_p
and CC 4_p
41 CD 4_p
of IN 4_p
their PRP$ 4_p
caregivers NNS 4_p
participated VBN 4_p
in IN 4_p
this DT 4_p
12-month JJ 4_p
study NN 4_p
during IN 4_p
2005-2006 JJ 4_p
in IN 4_p
Sweden NNP 4_p
. . 4_p

carers NNS 4_p
persons NNS N
with IN N
psychiatric JJ N
disabilities NNS N
. . N

-DOCSTART- -X- O O 9007148

dermoid JJ 4_p
cysts NNS 4_p
-- : N
a DT N
ovarian JJ 4_p
dermoid NN 4_p
cysts NNS 4_p
. . N

Thirty-eight JJ 3_p
women NNS 2_p
with IN N
benign JJ 4_p
ovarian JJ 4_p
dermoid NN 4_p
cyst NN 4_p
dermoid JJ 4_p
ovarian JJ 4_p
cysts NNS 4_p
-DOCSTART- -X- O O 23482575

pregnant JJ N
gilts NNS N
in IN N
their PRP$ N
offspring NN N
. . N

pregnant JJ N
gilts NNS N
in IN N
their PRP$ N
offspring NN N
. . N

33 CD 4_p
German JJ 4_p
Landrace NNP 4_p
gilts NNS 4_p
of IN N
the DT N
sows NNS N
The DT N
offspring VBG N
were VBD N
cross-fostered JJ N
offspring NN N
piglets NNS N
pigs NNS N
-DOCSTART- -X- O O 130920

A DT N
controlled JJ N
clinical JJ N
trial NN N
of IN N
a DT N
muscle NN N
relaxant NN N
analgesic JJ 4_p
combination NN N
in IN N
the DT N
treatment NN N
of IN N
acute JJ 4_p
lumbago NN 4_p
. . N

-DOCSTART- -X- O O 8644688

20 CD N
healthy JJ N
male NN N
volunteers NNS N
were VBD N
randomly RB N
assigned VBN N
-DOCSTART- -X- O O 20167900

adults NNS 1_p
: : 1_p
skin JJ 4_p
cancer NN 4_p
adults NNS 1_p
at IN N
moderate JJ 4_p
and CC 4_p
high JJ 4_p
risk NN 4_p
for IN 4_p
skin JJ 4_p
cancer NN 4_p
. . N

Adults NNP 1_p
at IN N
moderate NNP 4_p
and CC 4_p
high JJ 4_p
risk NN 4_p
for IN 4_p
skin JJ 4_p
cancer NN 4_p
were VBD N
recruited VBN N
in IN N
primary JJ N
health NN N
care NN N
settings NNS N
in IN N
Honolulu NNP N
, , N
HI NNP N
, , N
and CC N
Long NNP N
Island NNP N
, , N
NY NNP N
. . N

A DT N
total NN N
of IN N
596 CD 3_p
adults NNS 1_p
completed VBD N
the DT N
trial NN N
. . N

adults NNS 1_p
at IN N
increased VBN 4_p
risk NN 4_p
for IN 4_p
skin JJ 4_p
cancer NN 4_p
. . N

-DOCSTART- -X- O O 15180835

prethreshold JJ 4_p
retinopathy NN 4_p
of IN 4_p
prematurity NN 4_p
. . N

prethreshold JJ 4_p
retinopathy NN 4_p
of IN 4_p
prematurity NN 4_p
( ( 4_p
ROP NNP 4_p
) ) 4_p
Thirty-six JJ N
eyes NNS N
of IN N
18 CD 3_p
premature NN 3_p
infants NNS 3_p
less RBR N
than IN N
34 CD 1_p
weeks NNS 1_p
gestational JJ 1_p
age NN 1_p
and/or NN N
less JJR N
than IN N
1600 CD N
g JJ N
birth NN N
weight NN N
with IN N
prethreshold JJ 4_p
ROP NNP 4_p
Regression NNP 4_p
of IN 4_p
ROP NNP 4_p
36 CD N
eyes NNS N
-DOCSTART- -X- O O 22572567

pityriasis NN 4_p
versicolor NN 4_p
. . N

pityriasis NN 4_p
versicolor NN 4_p
; : N
pityriasis NN 4_p
versicolor NN 4_p
. . N

pityriasis NN 4_p
versicolor NN 4_p
. . N

Eighty NNP 3_p
patients NNS N
suffering VBG N
from IN N
pityriasis NN 4_p
versicolor NN 4_p
pityriasis NN 4_p
versicolor NN 4_p
. . N

-DOCSTART- -X- O O 11471578

osteoarthritis NN 4_p
of IN 4_p
the DT 4_p
hip NN 4_p
-- : N
a DT N
osteoarthritis NN N
( ( N
OA NNP N
) ) N
of IN N
the DT N
hip NN N
. . N

OA NNP N
of IN N
the DT N
hip NN N
Thirty-two JJ 3_p
patients NNS N
awaiting VBG 4_p
a DT 4_p
total JJ 4_p
hip NN 4_p
arthroplasty NN 4_p
Group NNP 3_p
A NNP 3_p
consisted VBD 3_p
of IN 3_p
three CD 3_p
men NNS 2_p
and CC 3_p
13 CD 3_p
women NNS 2_p
, , 3_p
and CC 3_p
group NN 3_p
B NNP 3_p
consisted VBD 3_p
of IN 3_p
four CD 3_p
men NNS 3_p
and CC 3_p
eight CD 3_p
women NNS 3_p
. . N

average JJ 1_p
age NN 1_p
in IN 1_p
group NN 1_p
A NNP 1_p
was VBD 1_p
66 CD 1_p
years NNS 1_p
and CC 1_p
in IN 1_p
group NN 1_p
B NNP 1_p
it PRP 1_p
was VBD 1_p
68 CD 1_p
years NNS 1_p
. . N

-DOCSTART- -X- O O 17149715

essential JJ 4_p
tremor NN 4_p
( ( 4_p
ET NNP 4_p
) ) 4_p
Twenty CD 3_p
patients NNS 3_p
( ( N
mean JJ N
age NN 1_p
, , 1_p
60 CD 1_p
+/- JJ 1_p
15 CD 1_p
years NNS 1_p
) ) 1_p
with IN N
ET NNP 4_p
-DOCSTART- -X- O O 18448859

children NNS 4_p
and CC 4_p
adolescents NNS 4_p
. . 4_p

75 CD N
children NNS N
and CC N
adolescents NNS N
( ( N
8-18 CD N
years NNS N
) ) N
Responders NNS 4_p
tended VBD 4_p
to TO 4_p
have VB 4_p
ADHD NNP 4_p
inattentive JJ 4_p
subtype NN 4_p
and CC 4_p
comorbid NN 4_p
neurodevelopmental JJ 4_p
disorders NNS 4_p
. . 4_p

A DT 4_p
subgroup NN 4_p
of IN 4_p
children NNS 4_p
and CC 4_p
adolescents NNS 4_p
with IN 4_p
ADHD NNP 4_p
-DOCSTART- -X- O O 17126434

We PRP N
used VBD N
data NNS N
from IN N
EORTC NNP N
22881-10882 JJ N
trial NN N
, , N
with IN N
median JJ N
follow-up NN N
of IN N
77.4 CD N
months NNS N
. . N

Patients NNS N
receiving VBG N
BCT NNP 4_p
and CC 4_p
50Gy CD 4_p
whole JJ 4_p
breast NN 4_p
irradiation NN 4_p
were VBD N
randomized VBN N
to TO N
no DT N
boost NN N
and CC N
16Gy CD N
boost NN N
younger JJR 1_p
patients NNS 1_p
8.4 CD N
% NN N
of IN N
the DT N
study NN N
population NN N
would MD N
receive VB N
67 CD N
% NN N
of IN N
the DT N
study NN N
population NN N
younger JJR N
patients NNS N
-DOCSTART- -X- O O 19958108

mydriasis NN 4_p
in IN 4_p
type NN 4_p
2 CD 4_p
diabetics NNS 4_p
and CC 4_p
non-diabetic JJ 4_p
patients NNS 4_p
. . N

type NN 4_p
2 CD 4_p
diabetics NNS 4_p
and CC 4_p
non-diabetic JJ 4_p
patients NNS 4_p
. . 4_p

A NNP N
total NN N
of IN N
50 CD 3_p
patients NNS N
( ( N
100 CD N
eyes NNS N
) ) N
scheduled VBD N
for IN N
fundoscopy NN N
were VBD N
dilated VBN N
with IN N
phenylephrine JJ 4_p
10 CD N
% NN N
and CC N
yropicamide RB N
1 CD N
% NN N
-DOCSTART- -X- O O 7646610

One CD 3_p
hundred VBD 3_p
seventy-seven JJ 3_p
women NNS 2_p
aged VBD N
41 CD 1_p
+/- JJ 1_p
8 CD 1_p
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
years NNS N
, , N
referred VBD N
for IN N
evaluation NN N
of IN N
excessive JJ 4_p
uterine JJ 4_p
bleeding NN 4_p
, , N
were VBD N
enrolled VBN N
hysteroscopy NN N
in IN N
an DT N
outpatient JJ N
population NN N
. . N

premenopausal JJ 1_p
women NNS N
-DOCSTART- -X- O O 6758263

upper JJ 4_p
abdominal JJ 4_p
laparotomies NNS 4_p
] VBP 4_p
-DOCSTART- -X- O O 12094254

bone NN 4_p
marrow NN 4_p
of IN 4_p
patients NNS 4_p
with IN 4_p
acute JJ 4_p
myeloid NN 4_p
leukemia NN 4_p
. . 4_p

In IN N
32 CD N
patients NNS N
with IN N
newly RB N
diagnosed VBN N
untreated JJ N
AML NNP N
10 CD N
control NN N
patients NNS N
-DOCSTART- -X- O O 15571828

STEMI NNP 4_p
Austrian JJ 4_p
multi-centre JJ 4_p
randomized VBN 4_p
ReoPro-BRIDGING NN 4_p
Study NNP 4_p
. . 4_p

ReoPro-BRIDGING JJ N
Austrian JJ N
multi-centre NN N
study NN N
Fifty-five JJ N
patients NNS N
with IN N
STEMI NNP N
were VBD N
randomized VBN N
either RB N
to TO N
start VB N
abciximab NN N
( ( N
0.25 CD N
mg/kg NN N
bolus NN N
followed VBN N
by IN N
10 CD N
microg/min NNS N
infusion NN N
) ) N
during IN N
the DT N
organization NN N
phase NN N
for IN N
pPCI NN N
( ( N
Group NNP N
1 CD N
, , N
n=28 NN N
) ) N
or CC N
immediately RB N
before IN N
pPCI NN N
( ( N
Group NNP N
2 CD N
, , N
n=27 NN N
) ) N
. . N

-DOCSTART- -X- O O 22525955

children NNS 1_p
with IN N
autism NN 4_p
receiving VBG N
targeted VBN N
interventions NNS N
on IN N
joint JJ N
attention NN N
and CC N
play NN N
. . N

children NNS 1_p
with IN N
an DT N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
over IN N
a DT N
5-year JJ N
period NN N
after IN N
receiving VBG N
targeted VBD N
early JJ N
interventions NNS N
that WDT N
focused VBD N
on IN N
joint JJ N
attention NN N
and CC N
play NN N
skills NNS N
. . N

Forty NNP 3_p
children NNS 1_p
from IN N
the DT N
original JJ N
study NN N
( ( N
n JJ N
= NNP N
58 CD N
) ) N
had VBD N
complete JJ N
data NNS N
at IN N
the DT N
5-year JJ N
follow-up NN N
. . N

children NNS 1_p
who WP N
participated VBD N
in IN N
preschool NN N
early JJ N
interventions NNS N
aimed VBN N
at IN N
targeting VBG N
core NN 4_p
developmental NN 4_p
difficulties NNS 4_p
. . N

-DOCSTART- -X- O O 25225698

patients NNS 4_p
with IN 4_p
cancer NN 4_p
using VBG 4_p
opioids NNS 4_p
. . N

-DOCSTART- -X- O O 20569725

atrial JJ 4_p
fibrillation NN 4_p
multicenter NN N
, , N
open-label JJ N
study NN N
of IN N
patients NNS N
with IN N
AF NNP N
lasting VBG N
> RB N
3 CD N
hours NNS N
and CC N
< NNP N
or CC N
=45 JJ N
days NNS N
Adult NNP 1_p
patients NNS 1_p
with IN N
AF NNP N
and CC N
an DT N
indication NN N
for IN N
conversion NN N
to TO N
SR NNP N
236 CD 3_p
hemodynamically RB N
stable JJ N
patients NNS N
with IN N
AF NNP N
167 CD 3_p
( ( N
71 CD N
% NN N
) ) N
had VBD N
recent-onset VBN N
AF NNP N
patients NNS N
with IN N
recent-onset JJ N
AF NNP N
. . N

-DOCSTART- -X- O O 16890144

myocardial JJ 4_p
relaxation NN 4_p
normal JJ 4_p
subjects NNS 4_p
. . N

Thirteen NNP 3_p
healthy JJ 4_p
volunteers NNS 4_p
( ( N
aged VBN 1_p
38.6 CD 1_p
+/- JJ 1_p
4 CD 1_p
years NNS 1_p
) ) N
-DOCSTART- -X- O O 6108319

101 CD 3_p
anxious JJ 4_p
outpatients NNS 4_p
symptoms NNS N
of IN N
anxiety NN N
patients NNS N
on IN N
ketazolam NN N
dropped VBD N
out IN N
of IN N
the DT N
study NN N
-DOCSTART- -X- O O 26665290

Sixty NNP 3_p
qualifying VBG 3_p
subjects NNS 3_p
were VBD N
randomly RB N
assigned VBN N
-DOCSTART- -X- O O 1359322

antimony-unresponsive JJ 4_p
kala-azar NN 4_p
. . N

120 CD 3_p
uncomplicated JJ N
and CC N
parasitologically RB N
confirmed VBN N
cases NNS N
of IN N
antimony-unresponsive JJ 4_p
kala-azar NN 4_p
. . N

-DOCSTART- -X- O O 23173253

knee NN 4_p
osteoarthritis NN 4_p
( ( 4_p
KOA NNP 4_p
, , 4_p
Bi NNP 4_p
syndrome NN 4_p
of IN 4_p
knee NN 4_p
) ) 4_p
Totally RB N
61 CD 3_p
patients NNS N
with IN N
grade NN 4_p
I PRP 4_p
to TO 4_p
III NNP 4_p
KOA NNP 4_p
-DOCSTART- -X- O O 11545629

eyes NNS N
with IN N
functioning VBG N
filtering VBG N
blebs NN N
: : N
eyes NNS N
with IN N
filtering VBG N
blebs NN N
. . N

36 CD 3_p
eyes NNS 3_p
of IN 3_p
34 CD 3_p
patients NNS 3_p
with IN N
functioning VBG N
filtering VBG N
blebs NNS N
who WP N
were VBD N
to TO N
undergo VB N
cataract NN N
surgery NN N
. . N

-DOCSTART- -X- O O 17082978

children NNS N
diagnosed VBN N
with IN N
Asperger NNP N
syndrome NN N
. . N

children NNS N
diagnosed VBN N
with IN N
Asperger NNP N
syndrome NN N
. . N

Forty-five JJ N
children NNS N
and CC N
their PRP$ N
parents NNS N
-DOCSTART- -X- O O 16909273

healthy JJ N
volunteers NNS N
. . N

healthy JJ N
volunteers NNS N
. . N

Twenty-four JJ N
volunteers NNS N
were VBD N
recruited VBN N
into IN N
an DT N
open-label JJ N
, , N
randomised JJ N
, , N
two-period JJ N
, , N
single-centre JJ N
study NN N
-DOCSTART- -X- O O 12237625

menorrhagia NN 4_p
. . N

Department NNP N
of IN N
Gynecology NNP N
of IN N
the DT N
University NNP N
of IN N
Naples NNP N
. . N

Eighty-two JJ N
patients NNS N
who WP N
were VBD N
affected VBN N
by IN N
menorrhagia NN N
that WDT N
was VBD N
unresponsive JJ 4_p
to TO 4_p
medical JJ 4_p
treatment NN 4_p
menorrhagia NN N
-DOCSTART- -X- O O 15979021

neuropathic JJ 4_p
pain NN 4_p
patients NNS N
: : N
60 CD 3_p
patients NNS N
with IN N
neuropathic JJ 4_p
pain NN 4_p
for IN N
8 CD N
weeks NNS N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
55 CD 3_p
patients NNS N
completed VBD N
the DT N
study NN N
. . N

groups NNS N
regarding VBG N
pain NN N
intensity NN N
and CC N
escape NN N
medication NN N
. . N

-DOCSTART- -X- O O 937075

Maximal NNP 4_p
bioavailability NN 4_p
of IN 4_p
digoxin NN 4_p
from IN 4_p
tablets NNS 4_p
and CC 4_p
oral JJ 4_p
solution NN 4_p
in IN 4_p
steady JJ 4_p
state NN 4_p
. . 4_p

-DOCSTART- -X- O O 701664

Nineteen JJ 3_p
ragweed-sensitive JJ 4_p
patients NNS N
were VBD 4_p
randomized VBN 4_p
into IN 4_p
2 CD 4_p
groups NNS 4_p
; : 4_p
10 CD 3_p
received VBD N
the DT N
polymerized JJ N
form NN N
and CC 4_p
9 CD 3_p
received VBD N
the DT N
monomeric JJ N
form NN N
. . 4_p

-DOCSTART- -X- O O 2607948

cardiovascular JJ 4_p
function NN 4_p
. . N

32 CD 3_p
healthy JJ N
middle-aged JJ N
males NNS 2_p
( ( N
X JJ N
age NN N
= VBD N
42.2 CD 1_p
+/- JJ 1_p
2.1 CD 1_p
yr NN 1_p
) ) N
. . N

-DOCSTART- -X- O O 4619431

arterial JJ 4_p
diseases NNS 4_p
] VBP N
-DOCSTART- -X- O O 10084579

gene NN N
in IN N
neonatal JJ 1_p
screening NN N
for IN N
congenital JJ 4_p
adrenal JJ 4_p
hyperplasia NN 4_p
. . N

neonatal JJ 1_p
screening NN N
samples NNS N
. . N

603 CD N
randomly RB N
chosen VBN N
New NNP N
Zealand NNP N
neonates NNS 1_p
Another DT 3_p
50 CD 3_p
samples NNS 3_p
from IN N
Swiss NNP N
and CC N
North NNP N
American JJ N
infants NNS N
with IN N
correlative JJ N
hormonal JJ N
New NNP N
Zealanders NNP N
. . N

newborn JJ 1_p
-DOCSTART- -X- O O 3825543

duodenal JJ 4_p
ulcer NN 4_p
patients NNS N
after IN N
short-term JJ N
treatment NN N
with IN N
cimetidine NN N
and CC N
antacids NNS N
. . N

20 CD N
patients NNS N
with IN N
endoscopically RB 4_p
proven JJ 4_p
duodenal JJ 4_p
ulcers NNS 4_p
-DOCSTART- -X- O O 22385102

keratosis NN 4_p
pilaris NN 4_p
: : 4_p
Keratosis NNP 4_p
pilaris NN 4_p
METHODS NNP N
Sixteen NNP N
Korean JJ N
patients NNS N
were VBD N
treated VBN N
with IN N
FCR™ NNP N
on IN N
both DT N
upper JJ N
arms NNS N
for IN N
five CD N
sessions NNS N
at IN N
2-week JJ N
intervals NNS N
patients NNS N
with IN N
-DOCSTART- -X- O O 15141043

colon NN 4_p
cancer NN 4_p
. . N

1990 CD N
for IN N
patients NNS 4_p
undergoing VBG 4_p
colectomy NN 4_p
for IN 4_p
cancer NN 4_p
. . N

48 CD N
institutions NNS N
and CC N
randomly RB N
assigned VBD N
872 CD 3_p
patients NNS N
with IN N
adenocarcinoma NN 4_p
of IN 4_p
the DT 4_p
colon NN 4_p
to TO N
undergo VB N
open JJ N
or CC N
laparoscopically RB N
assisted VBN N
colectomy NN N
performed VBN N
by IN N
credentialed JJ N
surgeons NNS N
. . N

-DOCSTART- -X- O O 20946200

obsessive JJ N
compulsive JJ N
disorder NN N
. . N

obsessive JJ N
compulsive JJ N
disorder NN N
( ( N
OCD NNP N
) ) N
. . N

One CD N
hundred CD N
and CC N
ten VB N
out-patients NNS N
with IN N
OCD NNP N
-DOCSTART- -X- O O 22007005

community-based JJ N
pediatric JJ 1_p
ADHD NNP 4_p
care NN N
: : N
pediatricians NNS N
' POS N
Forty-nine JJ 3_p
community-based JJ N
pediatricians NNS N
at IN N
8 CD N
practices NNS N
participated VBN N
in IN N
a DT N
cluster-randomized JJ N
trial NN N
. . N

numbers NNS N
of IN N
pediatricians NNS N
and CC N
the DT N
proportions NNS N
of IN N
patients NNS N
receiving VBG N
Medicaid NNP N
. . N

community-based JJ N
pediatric JJ N
settings NNS N
. . N

-DOCSTART- -X- O O 24433230

maternal JJ 4_p
and CC 4_p
newborn JJ 4_p
care NN 4_p
, , 4_p
with IN 4_p
prevention NN 4_p
of IN 4_p
mother-to-child JJ 4_p
transmission NN 4_p
of IN 4_p
HIV NNP 4_p
in IN 4_p
a DT 4_p
South JJ 4_p
African JJ 4_p
township NN 4_p
. . N

peri-urban JJ 3_p
poor JJ 3_p
. . N

30 CD 3_p
clusters NNS 3_p
( ( 3_p
15 CD 3_p
in IN 3_p
each DT 3_p
arm NN 3_p
) ) 3_p
to TO 3_p
evaluate VB 3_p
an DT 3_p
integrated VBN 3_p
, , 3_p
scalable JJ 3_p
package NN 3_p
providing VBG 3_p
two CD 3_p
pregnancy NN 3_p
visits NNS 3_p
and CC 3_p
five CD 3_p
post-natal JJ 3_p
home NN 3_p
visits NNS 3_p
delivered VBN 3_p
by IN 3_p
community NN 3_p
health NN 3_p
workers NNS 3_p
in IN 3_p
Umlazi NNP 3_p
, , 3_p
Durban NNP 3_p
, , 3_p
South NNP 3_p
Africa NNP 3_p
. . 3_p

12 CD 4_p
weeks NNS 4_p
post-natally RB 4_p
and CC 4_p
HIV-free JJ 4_p
infant NN 4_p
survival NN 4_p
. . N

12 CD 1_p
weeks NNS 1_p
of IN 1_p
infant JJ 1_p
age NN 1_p
-DOCSTART- -X- O O 1608405

unstable JJ 4_p
angina NN N
unstable JJ N
angina NNS N
. . N

patients NNS N
The DT N
study NN N
population NN N
included VBD N
403 CD 3_p
of IN N
the DT N
original JJ N
479 CD N
patients NNS N
in IN N
the DT N
trial NN N
who WP N
had VBD N
completed VBN N
six CD N
days NNS N
of IN N
blinded JJ N
therapy NN N
without IN N
refractory JJ N
angina NN N
or CC N
myocardial JJ N
infarction NN N
. . N

-DOCSTART- -X- O O 6403413

advanced JJ 4_p
ovarian JJ 4_p
cancer NN 4_p
. . N

May NNP N
1978 CD N
until IN N
November NNP N
1980 CD N
, , N
169 CD 3_p
previously RB 4_p
untreated JJ 4_p
patients NNS N
with IN N
advanced JJ 4_p
epithelial JJ 4_p
ovarian JJ 4_p
cancer NN 4_p
Eleven JJ 3_p
patients NNS N
153 CD 3_p
patients NNS N
evaluable JJ N
for IN N
response NN N
, , N
there EX N
were VBD N
47 CD N
, , N
or CC N
30.7 CD N
% NN N
, , N
complete JJ N
responders NNS N
158 CD 3_p
patients NNS N
-DOCSTART- -X- O O 25283504

indirect JJ 4_p
pharmacological JJ 4_p
response NN 4_p
model NN 4_p
in IN 4_p
healthy JJ 4_p
subjects NNS 4_p
. . 4_p

in IN N
healthy JJ 4_p
subjects NNS N
using VBG N
a DT N
pharmacokinetic/pharmacodynamic JJ 4_p
( ( N
PK/PD NNP N
) ) N
model NN N
. . N

in IN N
40 CD 3_p
healthy JJ N
Chinese JJ N
subjects NNS N
( ( N
4 CD N
groups NNS N
of IN N
10 CD N
subjects NNS N
each DT N
, , N
placebo VBZ N
4:1 CD N
ratio NN N
) ) N
who WP N
received VBD N
infusions NNS N
of IN N
uricase NN N
( ( N
single JJ N
doses NNS N
of IN N
0.1 CD N
, , N
0.2 CD N
, , N
and CC N
0.3 CD N
mg/kg NN N
; : N
multiple JJ N
doses NNS N
of IN N
0.2 CD N
mg·kg NN N
( ( N
-1 NNP N
) ) N
·d NN N
( ( N
-1 NNP N
) ) N
for IN N
7 CD N
d NN N
) ) N
. . N

Infusions NNS N
of IN N
uricase NN N
were VBD N
well RB N
tolerated VBN N
in IN N
all DT N
subjects NNS N
the DT N
effective JJ N
dose NN N
to TO N
be VB N
0.1 CD N
mg/kg NN N
in IN N
healthy JJ 4_p
subjects NNS N
-DOCSTART- -X- O O 998549

pregnancy NN 4_p
: : N
during IN N
pregnancy NN 4_p
on IN N
maternal JJ N
and CC N
fetal JJ N
plasma NN N
levels NNS N
-DOCSTART- -X- O O 19644973

patients NNS N
with IN N
rectal JJ 4_p
cancer NN 4_p
. . N

mid NN N
and CC N
low JJ N
rectal NN N
cancers NNS N
. . N

Some DT N
204 CD 3_p
patients NNS N
with IN N
mid NNS 4_p
and CC 4_p
low JJ 4_p
rectal NN 4_p
adenocarcinomas NN 4_p
were VBD N
allocated VBN N
randomly RB N
to TO N
open VB N
( ( N
103 CD N
) ) N
or CC N
laparoscopic NN N
( ( N
101 CD N
) ) N
surgery NN N
. . N

Most JJS N
patients NNS N
had VBD N
stage NN N
II NNP N
or CC N
III NNP N
disease NN N
-DOCSTART- -X- O O 10225743

critically RB N
ill JJ N
patients NNS N
critically RB 4_p
ill JJ 4_p
patients NNS 4_p
, , 4_p
especially RB 4_p
those DT 4_p
with IN 4_p
severe JJ 4_p
sepsis NN 4_p
. . 4_p

-DOCSTART- -X- O O 15223738

individuals NNS N
with IN N
a DT N
brain NN 4_p
injury NN 4_p
. . N

people NNS N
with IN N
a DT N
brain NN 4_p
injury NN 4_p
. . N

Sixteen JJ 3_p
outpatients NNS N
with IN N
a DT N
brain NN 4_p
injury NN 4_p
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 8872499

adults NNS N
with IN N
common JJ N
variable JJ N
immunodeficiency NN 4_p
. . N

The DT 4_p
setting NN 4_p
was VBD 4_p
at IN 4_p
University NNP 4_p
Hospital NNP 4_p
, , 4_p
Out-patient NNP 4_p
Clinic NNP 4_p
. . 4_p

patients NNS N
were VBD N
twenty-one JJ 3_p
adult NN N
patients NNS N
with IN N
common JJ N
variable JJ N
immunodeficiency NN N
. . N

-DOCSTART- -X- O O 22631032

healthy JJ 4_p
volunteers NNS 4_p
. . 4_p

healthy JJ N
volunteers NNS N
Healthy NNP 1_p
male NN 1_p
and CC 1_p
female JJ 1_p
volunteers NNS 1_p
aged VBN 1_p
18-75 CD 1_p
years NNS 1_p
were VBD 1_p
included VBN 1_p
. . 1_p

All DT N
volunteers NNS N
received VBD N
ASA NNP N
81 CD N
mg NN N
once RB N
daily JJ N
for IN N
5 CD N
days NNS N
prior RB N
to TO N
the DT N
study NN N
( ( N
pre-screen JJ N
) ) N
. . N

Subjects NNS N
were VBD N
eligible JJ N
for IN N
inclusion NN N
if IN N
they PRP N
had VBD N
aspirin VBN N
reactivity NN N
units NNS N
( ( N
ARU NNP N
, , N
as IN N
measured VBN N
by IN N
the DT N
VerifyNow NNP N
ASA NNP N
assay VBP N
) ) N
of IN N
< $ N
550 CD N
on IN N
Day NNP N
6 CD N
. . N

A DT N
total NN N
of IN N
29 CD N
volunteers NNS N
( ( N
19 CD N
aged VBN N
≥50 CD N
years NNS N
; : N
8 CD N
women NNS N
; : N
21 CD N
men NNS N
) ) N
were VBD N
evaluable JJ N
-DOCSTART- -X- O O 26181707

HIV NNP 4_p
treatment-naive JJ 4_p
patients NNS 4_p
-DOCSTART- -X- O O 1289508

elderly JJ 1_p
hypertensives NNS 4_p
. . N

Forty-two JJ 3_p
hypertensives NNS 4_p
60 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
or CC 1_p
above NN 1_p
, , N
without IN 4_p
evidence NN 4_p
of IN 4_p
ischemic JJ 4_p
disease NN 4_p
-DOCSTART- -X- O O 9850026

patients NNS 4_p
with IN 4_p
advanced-stage JJ 4_p
Hodgkin NNP 4_p
's POS 4_p
lymphoma NN 4_p
: : 4_p
German JJ N
advanced-stage JJ N
Hodgkin NNP N
's POS N
disease NN N
( ( N
HD NNP 4_p
) ) N
. . N

The DT N
randomized VBN N
, , N
three-arm JJ N
trial NN N
recruited VBD N
patients NNS N
in IN N
stages NNS N
IIB NNP N
and CC N
IIIA NNP N
with IN N
risk NN N
factors NNS N
and CC N
stages NNS N
IIIB NNP N
and CC N
IV NNP N
. . N

505 CD 3_p
assessable JJ N
patients NNS N
-DOCSTART- -X- O O 18726150

Asperger NNP 4_p
Syndrome NNP 4_p
. . 4_p

group NN 4_p
of IN 4_p
adults NNS 1_p
with IN 4_p
Asperger NNP 4_p
Syndrome NNP 4_p
( ( 4_p
AS IN 4_p
) ) 4_p
individuals NNS N
with IN N
AS NNP N
over-detected JJ N
faux NN N
pas NN N
stories NNS N
individuals NNS N
with IN N
AS NNP N
-DOCSTART- -X- O O 7705531

functional JJ N
ovarian JJ 4_p
cysts NNS 4_p
: : N
formed VBN N
functional JJ N
ovarian JJ 4_p
cysts NNS 4_p
. . N

Eighty NNP 3_p
patients NNS N
in IN N
whom WP N
ultrasonography NN N
revealed VBD N
unilateral JJ 4_p
, , 4_p
mobile JJ 4_p
, , 4_p
unilocular JJ 4_p
, , 4_p
thin-walled JJ 4_p
ovarian JJ 4_p
cysts NNS 4_p
without IN 4_p
internal JJ 4_p
echoes NNS 4_p
and CC 4_p
greater JJR 4_p
than IN 4_p
30 CD 4_p
mm NNS 4_p
but CC 4_p
not RB 4_p
exceeding VBG 4_p
60 CD 4_p
mm NN 4_p
in IN 4_p
diameter NN 4_p
were VBD N
enrolled VBN N
into IN N
the DT N
study NN N
. . N

functional JJ 4_p
ovarian JJ 4_p
cysts NNS 4_p
functional JJ N
ovarian JJ 4_p
cysts NNS 4_p
-DOCSTART- -X- O O 2245435

primary JJ 4_p
hypercholesterolemia NN 4_p
in IN 4_p
hypertensive JJ 4_p
patients NNS 4_p
treated VBN 4_p
with IN 4_p
hydrochlorothiazide JJ 4_p
] NN 4_p
hypercholesterolemic JJ N
patients NNS N
patients NNS N
with IN N
primary JJ N
hypercholesterolemia NN N
and CC N
mild-to-moderate JJ 4_p
essential JJ 4_p
hypertension NN 4_p
treated VBN N
with IN N
hydrochlorothiazide NN N
. . N

After IN N
10 CD N
weeks NNS N
standard JJ N
hypolipidemic JJ N
diet NN N
and CC N
hydrochlorothiazide NN N
( ( N
25 CD N
mg RB N
od NN N
) ) N
therapy NN N
, , N
30 CD 3_p
patients NNS N
whose WP$ N
cholesterol NN N
levels NNS N
were VBD N
still RB N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
250 CD N
mg/100 NNS N
ml NN N
and CC N
whose WP$ N
diastolic JJ N
blood NN N
pressure NN N
was VBD N
less JJR N
than IN N
95 CD N
mmHg NNS N
-DOCSTART- -X- O O 17575230

advanced JJ 4_p
breast NN 4_p
cancer NN 4_p
. . 4_p

advanced JJ 4_p
breast NN 4_p
cancer NN 4_p
. . 4_p

Patients NNPS N
with IN N
newly RB N
diagnosed VBN 4_p
metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
or CC N
locally RB N
recurrent JJ N
breast NN 4_p
cancer NN 4_p
The DT N
P600 NNP N
( ( N
47 CD 3_p
patients NNS 3_p
) ) 3_p
and CC N
P900 NNP 3_p
( ( 3_p
45 CD 3_p
patients NNS 3_p
) ) N
-DOCSTART- -X- O O 1573044

drug NN N
effects NNS N
and CC N
abuse NN N
liability NN N
in IN N
nondependent JJ 4_p
subjects NNS 4_p
. . N

15 CD 3_p
male NN N
, , N
experienced VBD 4_p
, , 4_p
intermittent JJ 4_p
nontherapeutic JJ 4_p
drug NN 4_p
users NNS 4_p
. . N

-DOCSTART- -X- O O 15673999

children NNS 4_p
with IN 4_p
autistic JJ 4_p
spectrum NN 4_p
disorder NN 4_p
. . 4_p

children NNS N
with IN N
autistic JJ N
spectrum NN N
disorder NN N
. . N

Twenty NNP N
( ( N
20 CD N
) ) N
children NNS N
with IN N
autistic JJ N
spectrum NN N
disorder NN N
, , N
ages VBZ N
3-8 CD N
years NNS N
. . N

autistic JJ 4_p
children NNS 4_p
-DOCSTART- -X- O O 10674229

humans NNS N
. . N

eight CD N
healthy JJ 4_p
volunteers NNS 4_p
( ( N
age NN 1_p
= VBZ 1_p
22 CD 1_p
+/- JJ 1_p
2 CD 1_p
y NN 1_p
, , N
body NN 4_p
mass NN 4_p
index NN 4_p
= VBD 4_p
24 CD 4_p
+/- JJ 4_p
1 CD 4_p
kg NN 4_p
) ) N
-DOCSTART- -X- O O 3333530

1981-1983 JJ 4_p
in IN 4_p
North NNP 4_p
Karelia NNP 4_p
, , 4_p
Finland NNP 4_p
middle-aged JJ 4_p
men NNS 4_p
and CC 4_p
women NNS 4_p
in IN 4_p
rural JJ 4_p
or CC 4_p
semirural JJ 4_p
areas NNS 4_p
and CC 4_p
comprised VBD 4_p
a DT 4_p
baseline NN 4_p
period NN 4_p
, , 4_p
a DT 4_p
six CD 4_p
week NN 4_p
( ( 4_p
or CC 4_p
12 CD 4_p
weeks NNS 4_p
in IN 4_p
the DT 4_p
third JJ 4_p
study NN 4_p
) ) 4_p
intervention NN 4_p
period NN 4_p
and CC 4_p
a DT 4_p
four CD 4_p
to TO 4_p
six CD 4_p
week NN 4_p
return NN 4_p
to TO 4_p
baseline VB 4_p
. . 4_p

-DOCSTART- -X- O O 10618526

200 CD 3_p
children NNS 1_p
with IN N
HBs-Ag NNP 4_p
negative JJ N
mothers NNS N
. . N

children NNS N
with IN N
serum JJ N
HBs-Ag JJ N
concentrations NNS N
over IN N
100 CD N
mIU/ml NNS N
than IN N
the DT N
accelerated JJ N
schedule NN N
. . N

children NNS N
who WP N
presented VBD N
anti-HBsAg JJ N
concentrations NNS N
below IN N
10 CD N
mUI/ml NN N
-DOCSTART- -X- O O 1829841

[ RB 4_p
4 CD 4_p
years NNS 4_p
' POS 4_p
experience NN 4_p
with IN 4_p
a DT 4_p
balloon-expandable JJ 4_p
endoprosthesis NN 4_p
. . 4_p

Experimental JJ 4_p
and CC 4_p
clinical JJ 4_p
application NN 4_p
] NNP 4_p
iliac JJ 4_p
arteries NNS 4_p
in IN 4_p
arterial JJ 4_p
occlusive JJ 4_p
disease NN 4_p
stenting VBG 4_p
2/62 CD 4_p
angioplasty JJ 4_p
5/69 CD 4_p
) ) 4_p
clinical JJ 4_p
trials NNS 4_p
canine NN N
-DOCSTART- -X- O O 6342928

1319 CD 3_p
children NNS N
aged VBN N
11-13 CD 1_p
years NNS 1_p
. . N

children NNS N
the DT N
MFP NNP N
test NN N
group NN N
( ( 3_p
444 CD 3_p
children NNS N
) ) N
and CC N
the DT N
MFP NNP N
control NN N
group NN N
( ( N
450 CD 3_p
children NNS N
) ) N
TMP NNP N
test NN N
group NN N
( ( N
425 CD 3_p
children NNS N
) ) N
three CD N
groups NNS N
of IN N
children NNS N
-DOCSTART- -X- O O 25179065

patients NNS N
with IN N
drug NN 4_p
and CC 4_p
alcohol NN 4_p
overuse NN 4_p
management NN N
of IN N
patients NNS N
with IN N
MOH NNP N
. . N

Norwegian JJ 4_p
general JJ 4_p
practice NN 4_p
. . N

four CD N
focus NN N
group NN N
interviews VBZ N
with IN N
22 CD 3_p
GPs NNP 3_p
who WP N
participated VBD N
in IN N
an DT N
intervention NN N
study NN N
on IN N
BI NNP N
for IN N
MOH NNP N
. . N

focus NN N
group NN N
interviews NNS N
. . N

-DOCSTART- -X- O O 7148967

hypertonus NN 4_p
. . 4_p

Ten CD 3_p
adults NNS 1_p
with IN N
hypertonic JJ 4_p
wrist NN N
flexors NNS N
volunteered VBD N
as IN N
subjects NNS N
hypertonus NN 4_p
. . 4_p

older JJR 1_p
subjects NNS N
younger JJR 1_p
adults NNS 1_p
-DOCSTART- -X- O O 12830748

patient JJ N
Patients NNS N
who WP N
were VBD N
taught VBN N
about IN N
their PRP$ N
health NN 4_p
problems NNS 4_p
while IN N
waiting VBG N
in IN N
the DT N
clinic NN N
( ( N
n JJ N
= NNP N
104 CD 3_p
) ) N
control NN N
group NN N
( ( N
n JJ N
= NNP N
101 CD 3_p
) ) N
. . N

-DOCSTART- -X- O O 14985215

age-related JJ N
macular JJ 4_p
degeneration NN 4_p
; : N
20 CD 3_p
healthy JJ 4_p
volunteers NNS N
-DOCSTART- -X- O O 15506067

15 CD 3_p
hypertensive JJ 4_p
patients NNS 4_p
-DOCSTART- -X- O O 7551999

rectal JJ 4_p
cancer NN 4_p
: : N
patients NNS N
with IN N
rectal JJ N
cancer NN N
treated VBN N
by IN N
abdominoperineal NN N
or CC N
anterior JJ N
resection NN N
, , N
with IN N
or CC N
without IN N
preoperative JJ N
radiotherapy NN N
1292 CD 3_p
patients NNS N
included VBN N
in IN N
two CD N
consecutive JJ N
controlled VBN N
randomized JJ N
trials NNS N
of IN N
preoperative JJ N
radiotherapy NN N
in IN N
operable JJ N
rectal JJ N
carcinoma NN N
. . N

rectal JJ N
cancer NN N
-DOCSTART- -X- O O 24682707

adults NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
: : N
young JJ 1_p
adults NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
. . N

Twenty-eight JJ 3_p
adults NNS 1_p
( ( 1_p
18-36 CD 1_p
years NNS 1_p
) ) 1_p
young JJ 1_p
adults NNS 1_p
with IN N
ASD NNP 4_p
. . N

-DOCSTART- -X- O O 17901383

subjects NNS N
with IN N
chronic JJ N
stroke NN N
. . N

chronic JJ N
stroke NN N
survivors NNS N
Eighty-eight JJ N
patients NNS N
with IN N
stroke NN N
patients NNS N
with IN N
chronic JJ N
stroke NN N
-DOCSTART- -X- O O 16850327

24-h JJ 4_p
intragastric JJ 4_p
pH NN 4_p
in IN 4_p
healthy JJ 4_p
subjects NNS 4_p
. . 4_p

24 CD 3_p
healthy JJ 3_p
subjects NNS 3_p
( ( 1_p
10 CD 3_p
men NNS 2_p
; : 1_p
mean JJ 1_p
age NN 1_p
26.2 CD 1_p
y NN 1_p
) ) 1_p
-DOCSTART- -X- O O 20863389

patients NNS N
with IN N
advanced JJ 4_p
cervical JJ 4_p
cancer NN 4_p
. . N

advanced JJ 4_p
cervical JJ 4_p
carcinoma NN 4_p
. . N

Between NNP N
May NNP N
2000 CD N
and CC N
May NNP N
2004 CD N
, , N
31 CD 3_p
women NNS N
with IN N
FIGO NNP 4_p
stage NN 4_p
IB2-IVA NNP 4_p
cervical JJ 4_p
cancer NN 4_p
or CC 4_p
with IN 4_p
postsurgical JJ 4_p
pelvic JJ 4_p
recurrence NN 4_p
were VBD N
enrolled VBN N
into IN N
this DT N
phase NN N
II NNP N
study NN N
RESULTS NNP N
Patient NNP N
and CC N
tumor NN N
characteristics NNS N
for IN N
advanced JJ N
carcinoma NN N
of IN N
the DT N
cervix NN N
-DOCSTART- -X- O O 21334061

chronic JJ 4_p
fatigue NN 4_p
syndrome NN 4_p
patients NNS N
meeting NN N
Oxford NNP N
criteria NN N
for IN N
chronic JJ 4_p
fatigue NN 4_p
syndrome NN 4_p
were VBD N
recruited VBN N
from IN N
six CD N
secondary-care JJ N
clinics NNS N
in IN N
the DT N
UK NNP N
641 CD 4_p
eligible JJ N
patients NNS N
meeting VBG N
international JJ N
criteria NNS N
for IN N
-DOCSTART- -X- O O 16238662

anxiety NN 4_p
in IN 4_p
children NNS 1_p
with IN 4_p
Asperger NNP 4_p
syndrome NN 4_p
. . 4_p

children NNS 1_p
diagnosed VBN 4_p
with IN 4_p
Asperger NNP 4_p
syndrome NN 4_p
( ( 4_p
AS IN 4_p
) ) 4_p
. . 4_p

Seventy-one JJ 3_p
children NNS 1_p
aged VBN N
ten NNS 1_p
to TO 1_p
twelve VB 1_p
years NNS 1_p
were VBD N
recruited VBN N
All DT N
children NNS 1_p
were VBD N
diagnosed VBN N
with IN N
AS NNP 4_p
and CC N
the DT N
presence NN N
of IN N
anxiety NN 4_p
symptoms NNS 4_p
children NNS 1_p
diagnosed VBN N
with IN N
Asperger NNP 4_p
syndrome NN 4_p
and CC N
exhibiting VBG N
anxiety NN 4_p
symptoms NNS N
-DOCSTART- -X- O O 16137240

high JJ 4_p
risk NN 4_p
patients NNS 4_p
. . N

patients NNS 4_p
undergoing VBG 4_p
open JJ 4_p
abdominal JJ 4_p
surgery NN 4_p
. . N

Fifty-six JJ N
patients NNS N
undergoing VBG N
open JJ N
abdominal JJ N
surgery NN N
, , N
at IN N
high JJ N
risk NN N
of IN N
developing VBG N
postoperative JJ N
pulmonary JJ N
complications NNS N
early JJ N
mobilisation-only JJ N
group NN N
early JJ N
mobilisation-plus-deep JJ N
breathing NN N
and CC N
coughing VBG N
group NN N
. . N

high JJ 4_p
risk NN 4_p
open JJ 4_p
abdominal JJ 4_p
surgery NN 4_p
subjects NNS 4_p
. . N

-DOCSTART- -X- O O 8787364

southern JJ N
Ghana NNP N
. . N

acellular JJ N
diphtheria/pertussis/tetanus NN 4_p
( ( N
ADPT NNP N
) ) N
in IN N
infants NNS 1_p
was VBD N
conducted VBN N
in IN N
a DT N
peri-urban JJ N
community NN N
( ( N
Ashaiman NNP N
) ) N
in IN N
southern JJ N
Ghana NNP N
. . N

pertussis NN 4_p
in IN N
children NNS 1_p
under IN N
5 CD 1_p
years NNS N
of IN N
age NN N
in IN N
the DT N
study NN N
area NN N
were VBD N
also RB N
determined VBN N
. . N

2 CD 3_p
% NN 3_p
( ( N
8/399 CD N
) ) N
to TO N
2.3 CD 3_p
% NN 3_p
( ( N
9/385 CD N
) ) N
of IN N
the DT N
acellular JJ N
vaccine NN N
recipients NNS N
as IN N
against IN N
31 CD 3_p
% NN 3_p
( ( N
122/394 CD N
) ) N
in IN N
the DT N
whole-cell JJ N
vaccine NN N
group NN N
. . N

-DOCSTART- -X- O O 8213019

outpatient JJ 4_p
paediatric JJ 1_p
anaesthesia NN 4_p
. . 4_p

31 CD 1_p
oral JJ 1_p
midazolam-atropine NN 1_p
premedicated VBD 1_p
children NNS 1_p
aged VBN 1_p
6.9 CD 1_p
( ( 1_p
s.e NN 1_p
. . 1_p

0.4 CD N
) ) N
years NNS N
who WP N
had VBD N
been VBN N
anaesthetised VBN 4_p
with IN 4_p
either DT 4_p
propofol/alfentanil/N2O NN 4_p
or CC 4_p
thiopentone/halothane/N2O NN 4_p
. . N

-DOCSTART- -X- O O 3299950

irritable JJ 4_p
colon NN 4_p
. . 4_p

-DOCSTART- -X- O O 15264973

pediatric JJ 1_p
obesity NN 4_p
. . N

Obese JJ 4_p
children NNS 1_p
-DOCSTART- -X- O O 10735838

venepuncture NN 4_p
. . N

venous JJ 4_p
cannulation NN 4_p
. . N

120 CD 3_p
children NNS 1_p
. . N

-DOCSTART- -X- O O 16915076

low JJ 4_p
back RB 4_p
pain NN 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
( ( 4_p
LBP NNP 4_p
) ) 4_p
and CC 4_p
disability NN 4_p
. . 4_p

Middle-aged JJ 1_p
working VBG N
men NNS 2_p
with IN N
recent JJ N
LBP NNP N
but CC N
without IN N
severe JJ N
disability NN N
training NN 4_p
LBP NNP N
and CC N
disability NN N
among IN N
middle JJ N
aged VBN N
working VBG N
men NNS N
. . N

-DOCSTART- -X- O O 16104966

Open JJ 4_p
flap NN 4_p
debridement NN 4_p
periodontal JJ 4_p
repair NN 4_p
. . N

Forty NNP 3_p
subjects NNS N
with IN N
chronic JJ 4_p
periodontitis NN 4_p
and CC N
presenting NN 4_p
, , 4_p
at IN 4_p
least JJS 4_p
, , 4_p
two CD 4_p
proximal JJ 4_p
sites NNS 4_p
in IN 4_p
anterior JJ 4_p
teeth NNS 4_p
( ( 4_p
upper JJ 4_p
or CC 4_p
lower JJR 4_p
) ) 4_p
with IN 4_p
probing VBG 4_p
depth JJ 4_p
> NN 4_p
or CC 4_p
=5 JJ 4_p
mm NNS 4_p
were VBD N
selected VBN N
. . N

-DOCSTART- -X- O O 19223284

OA NNP 4_p
patients NNS 4_p
RA NNP 4_p
patients NNS 4_p
A DT N
total NN N
of IN N
23 CD 3_p
504 CD 3_p
patients NNS N
-DOCSTART- -X- O O 17983307

cultural JJ 4_p
differences NNS 4_p
in IN 4_p
emotional JJ 4_p
self-reports NNS 4_p
. . 4_p

European JJ N
Americans NNPS N
were VBD N
more JJR N
accurate JJ N
than IN N
were VBD N
Asian JJ N
Americans NNPS N
European JJ N
Americans NNPS N
Asian JJ N
Americans NNPS N
. . N

-DOCSTART- -X- O O 23648162

cardiopulmonary JJ 4_p
resuscitation NN 4_p
] NNP N
Forty NNP N
cases NNS N
with IN N
respiration NN 4_p
and CC 4_p
cardiac JJ 4_p
arrest NN 4_p
in IN N
the DT N
department NN N
of IN N
critical JJ N
care NN N
medicine NN N
were VBD N
randomly RB N
divided VBN N
-DOCSTART- -X- O O 19805710

children NNS N
with IN N
cystic JJ 4_p
fibrosis NN 4_p
. . N

children NNS N
with IN N
cystic JJ 4_p
fibrosis NN 4_p
and CC N
pancreatic JJ 4_p
insufficiency NN 4_p
. . N

Cystic JJ N
fibrosis NN N
centers NNS N
in IN N
the DT N
eastern JJ N
, , N
midwestern JJ N
, , N
and CC N
southern JJ N
United NNP N
States NNPS N
. . N

Seventy-nine JJ 3_p
children NNS N
aged VBD 1_p
4 CD 1_p
to TO 1_p
12 CD 1_p
years NNS 1_p
below IN 4_p
the DT 4_p
40th CD 4_p
percentile NN 4_p
for IN 4_p
weight NN 4_p
for IN 4_p
age NN 4_p
were VBD N
recruited VBN N
. . N

-DOCSTART- -X- O O 19570717

migraine NN 4_p
with IN 4_p
aura NN 4_p
: : N
patients NNS N
who WP N
had VBD 4_p
at IN 4_p
least JJS 4_p
one CD 4_p
aura NN 4_p
attack NN 4_p
per IN 4_p
month NN 4_p
during IN 4_p
the DT 4_p
past JJ 4_p
3 CD 4_p
months NNS 4_p
. . N

39 CD 3_p
patients NNS N
were VBD N
included VBN N
in IN N
the DT N
study NN N
, , N
of IN N
whom WP N
31 CD 3_p
were VBD 3_p
included VBN 3_p
in IN 3_p
the DT 3_p
statistical JJ 3_p
analysis NN 3_p
of IN 3_p
efficacy NN 3_p
. . N

-DOCSTART- -X- O O 10385063

patients NNS 4_p
with IN 4_p
cirrhosis NN 4_p
of IN 4_p
the DT 4_p
liver NN 4_p
. . 4_p

76 CD 3_p
patients NNS 3_p
( ( N
26 CD 3_p
men NNS 2_p
and CC N
50 CD 3_p
women NNS 2_p
) ) N
with IN N
cirrhosis NN N
For IN N
men NNS 2_p
, , N
the DT N
mean JJ N
annual JJ N
change NN N
in IN N
BMD NNP N
was VBD N
1.1 CD N
% NN N
in IN N
the DT N
treated JJ N
group NN N
and CC N
-0.4 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
. . N

two CD 3_p
groups NNS 3_p
For IN N
women NNS 2_p
, , N
the DT N
mean JJ N
annual JJ N
change NN N
in IN N
BMD NNP N
was VBD N
-0.5 JJ N
% NN N
in IN N
the DT N
treated JJ N
group NN N
and CC N
-2.3 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
. . N

control NN N
group NN N
. . N

patients NNS 4_p
with IN 4_p
cirrhosis NN 4_p
of IN 4_p
the DT 4_p
liver NN 4_p
. . N

-DOCSTART- -X- O O 11029345

patients NNS N
with IN N
acute JJ 4_p
respiratory NN 4_p
distress NN 4_p
syndrome NN 4_p
. . N

patients NNS N
with IN N
acute JJ 4_p
respiratory NN 4_p
distress NN 4_p
syndrome NN 4_p
( ( 4_p
ARDS NNP 4_p
) ) N
patients NNS N
with IN N
ARDS NNP N
. . N

12 CD 3_p
patients NNS N
with IN N
ARDS NNP N
-DOCSTART- -X- O O 25078976

healthy JJ N
volunteers NNS N
: : N
studies NNS 3_p
( ( 3_p
24-28 JJ 3_p
participants/study NN 3_p
) ) 3_p
RESULTS VB N
One CD 3_p
hundred CD 3_p
and CC 3_p
twenty-eight JJ 3_p
healthy JJ 3_p
participants NNS 3_p
( ( 1_p
19-54 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
) ) 1_p
received VBD N
pregabalin NN N
-DOCSTART- -X- O O 24074927

locally RB 4_p
advanced JJ 4_p
cervix NN 4_p
carcinoma NN 4_p
: : 4_p
patients NNS 4_p
with IN 4_p
locally RB 4_p
advanced JJ 4_p
cervical JJ 4_p
cancer NN 4_p
( ( 4_p
LACC NNP 4_p
) ) 4_p
Between NNP N
January NNP N
2010 CD N
and CC N
January NNP N
2012 CD N
, , N
44 CD N
patients NNS N
with IN N
International NNP N
Federation NNP N
of IN N
Gynecology NNP N
and CC N
Obstetrics NNP N
( ( N
FIGO NNP N
2009 CD N
) ) N
stage NN N
IIB-IIIB NNP N
squamous JJ N
cell NN N
carcinoma NN N
of IN N
the DT N
cervix NN N
were VBD N
randomized VBN N
-DOCSTART- -X- O O 17164971

preterm JJ 1_p
infants NNS 1_p
. . N

VLBW NNP N
premature NN 4_p
infants NNS 4_p
. . N

Sixteen JJ 3_p
infants NNS 1_p
( ( N
mean JJ N
+/- JJ N
standard NN N
error NN N
of IN N
the DT N
mean JJ N
birth NN N
weight VBD N
1,009 CD N
+/- JJ N
55 CD N
g NN N
and CC N
gestational JJ N
age NN N
27.3 CD 1_p
+/- JJ 1_p
0.3 CD 1_p
weeks NNS 1_p
) ) N
-DOCSTART- -X- O O 12185505

primary JJ 4_p
mediastinal JJ 4_p
B-cell NNP 4_p
lymphoma NN 4_p
: : N
patients NNS 4_p
with IN 4_p
primary JJ 4_p
mediastinal JJ 4_p
B-cell NNP 4_p
lymphoma NN 4_p
( ( 4_p
PMBCL NNP 4_p
) ) 4_p
From IN N
1989 CD N
to TO N
1997 CD N
, , N
68 CD N
patients NNS N
diagnosed VBN N
with IN N
previously RB N
untreated VBN N
PMBCL NNP N
, , N
aged VBD N
18-65 CD N
years NNS N
and CC N
negative JJ N
for IN N
immunodeficiency NN N
virus NN N
test NN N
patients NNS N
with IN N
PMBCL NNP N
-DOCSTART- -X- O O 23902627

urban JJ N
population NN N
of IN N
primiparas NNS N
in IN N
Lebanon NNP N
: : N
mothers NNS N
who WP N
exclusively RB N
breastfeed VBP N
their PRP$ N
babies NNS N
Beirut NNP N
breastfeeding VBG N
behavior NN N
in IN N
this DT N
population NN N
. . N

Healthy JJ N
first-time JJ N
mothers NNS N
delivering VBG N
in IN N
the DT N
capital NN N
Beirut NNP N
between IN N
March NNP N
and CC N
July NNP N
2009 CD N
maternal JJ N
work NN N
planned VBN N
pregnancy NN N
intention NN N
to TO N
breastfeed VB N
source NN N
of IN N
maternal JJ N
emotional JJ N
support NN N
healthy JJ N
first-time JJ N
mothers NNS N
who WP N
exclusively RB N
breastfeed VBP N
in IN N
Beirut NNP N
-DOCSTART- -X- O O 21586215

gingival JJ N
health NN N
among IN N
adults NNS 1_p
with IN N
systemic JJ 4_p
sclerosis NN 4_p
. . N

among IN N
adults NNS 1_p
with IN N
systemic JJ 4_p
sclerosis NN 4_p
( ( N
SSc NNP 4_p
) ) N
. . N

Forty-eight JJ 3_p
patients NNS N
with IN N
SSc NNP 4_p
health NN N
in IN N
adults NNS N
with IN N
educating VBG N
patients NNS N
with IN N
-DOCSTART- -X- O O 17872451

type NN N
2 CD N
diabetic JJ N
patients NNS N
under IN N
good JJ N
glycemic JJ N
control NN N
. . N

type NN 4_p
2 CD 4_p
diabetes NNS 4_p
type NN N
2 CD N
diabetic JJ N
patients NNS N
who WP N
were VBD N
already RB N
under IN N
good JJ N
glycemic JJ N
control NN N
. . N

78 CD 4_p
drug-naive JJ 4_p
type NN 4_p
2 CD 4_p
diabetic JJ 4_p
patients NNS 4_p
whose WP$ 4_p
HbA1c NNP 4_p
was VBD 4_p
less JJR 4_p
than IN 4_p
6.5 CD 4_p
% NN 4_p
. . 4_p

Thirty-eight JJ N
patients NNS N
type NN N
2 CD N
diabetic JJ N
patients NNS N
with IN N
good JJ N
glycemic NNS N
control NN N
-DOCSTART- -X- O O 21595978

middle-aged JJ 1_p
adults NNS 1_p
with IN N
cardiovascular JJ 4_p
risk NN 4_p
factors NNS 4_p
. . N

The DT N
Stages NNPS N
to TO N
Healthy NNP N
Eating NNP N
Patterns NNP N
Study NNP N
( ( N
STEPs NNP N
) ) N
middle-aged JJ 1_p
adults NNS 1_p
with IN N
cardiovascular JJ 4_p
risk NN 4_p
factors NNS 4_p
middle-aged JJ 1_p
adults NNS 1_p
with IN N
cardiovascular JJ 4_p
risk NN 4_p
factors NNS 4_p
. . N

-DOCSTART- -X- O O 24291456

methamphetamine NN 4_p
dependence NN 4_p
: : 4_p
MA-dependent JJ 4_p
individuals NNS 4_p
. . 4_p

150 CD N
participants NNS N
with IN N
MA NNP N
dependence NN N
at IN N
a DT N
residential JJ N
treatment NN N
facility NN N
for IN N
addictive JJ N
disorders NNS N
to TO N
receive VB N
either RB N
a DT N
thrice-weekly JJ N
structured JJ N
aerobic NN N
and CC N
resistance NN N
exercise NN N
intervention NN N
or CC N
a DT N
health NN N
education NN N
condition NN N
. . N

-DOCSTART- -X- O O 10770979

2079 CD 3_p
men NNS 2_p
and CC N
women NNS 2_p
who WP N
were VBD N
35 CD 1_p
years NNS N
of IN N
age NN N
or CC N
older JJR N
and CC N
who WP N
had VBD N
had VBN N
one CD N
or CC N
more JJR N
histologically RB N
confirmed VBN N
colorectal JJ 4_p
adenomas NN 4_p
removed VBD N
within IN N
six CD N
months NNS N
before IN N
randomization NN N
A DT N
total NN N
of IN N
1905 CD 3_p
of IN N
the DT N
randomized JJ N
subjects NNS N
( ( N
91.6 CD N
percent NN N
) ) N
completed VBD N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 1996926

presyncopal JJ 4_p
symptom NN 4_p
limited VBD 4_p
lower JJR 4_p
body NN 4_p
negative JJ 4_p
pressure NN 4_p
exposures NNS 4_p
. . 4_p

11 CD 3_p
subjects NNS 4_p
were VBD 4_p
exposed VBN 4_p
to TO 4_p
4 CD 4_p
PSL-LBNP JJ 4_p
tests NNS 4_p
; : 4_p
nine CD 3_p
subjects NNS N
-DOCSTART- -X- O O 25086152

in IN N
a DT N
dental JJ N
school NN N
setting VBG N
. . N

patients NNS N
Fifty NNP 3_p
patients NNS N
were VBD N
recruited VBN N
in IN N
the DT N
school NN N
's POS N
Urgent NNP N
Care NNP N
Clinic NNP N
patients NNS N
. . N

-DOCSTART- -X- O O 16293958

stable JJ N
patients NNS N
with IN N
moderate-to-severe JJ 4_p
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
. . N

chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
( ( N
COPD NNP 4_p
) ) 4_p
114 CD 3_p
patients NNS N
with IN N
COPD NNP 4_p
of IN 4_p
moderate-to-severe JJ 4_p
degree NN 4_p
. . N

moderate-to-severe JJ 4_p
COPD NNP 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 10781855

adolescents NNS 4_p
healthy JJ N
adolescents NNS N
. . N

adolescents NNS N
. . N

-DOCSTART- -X- O O 15025886

Sixty-two NNP 4_p
( ( 4_p
62 CD 4_p
) ) 4_p
community-recruited JJ 4_p
patients NNS 4_p
with IN 4_p
fibromyalgia NN 4_p
( ( 4_p
FM NNP 4_p
) ) 4_p
Two CD 4_p
homeopaths NNS 4_p
jointly RB 4_p
performed VBD 4_p
case-taking JJ 4_p
interviews NNS 4_p
. . 4_p

A DT N
conventional JJ N
medical JJ N
provider NN N
independently RB N
evaluated VBD N
patients NNS N
with IN N
a DT N
standardized JJ N
history NN N
and CC N
physical JJ N
examination NN N
. . N

-DOCSTART- -X- O O 10660161

aortic JJ 4_p
valve NN 4_p
replacement NN 4_p
. . N

Stentless NNP N
( ( N
Freestyle NNP N
, , N
Toronto NNP N
, , N
n RB N
= VBZ N
106 CD 3_p
) ) N
or CC N
conventional JJ N
biological JJ N
aortic JJ N
valves NNS N
( ( N
Carpentier-Edwards NNP N
, , N
n JJ N
= NNP N
74 CD 3_p
) ) N
were VBD N
evaluated VBN N
patients NNS N
after IN N
aortic JJ 4_p
valve NN 4_p
replacement NN 4_p
. . N

-DOCSTART- -X- O O 2915887

metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
. . N

94 CD 4_p
evaluable JJ 4_p
patients NNS 4_p
with IN 4_p
metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
-DOCSTART- -X- O O 1497159

head NN 4_p
trauma NN 4_p
patients NNS N
: : N
head NN N
trauma IN N
patients NNS N
inner-city JJ N
county NN N
trauma NN N
center NN N
with IN N
70,000 CD N
patient JJ N
visits NNS N
per IN N
year NN N
. . N

Sequential NNP N
adult NN 1_p
head NN N
trauma NN N
patients NNS N
requiring VBG N
rapid-sequence JJ N
intubation NN N
who WP N
had VBD N
no DT N
contraindications NNS N
to TO N
succinylcholine VB N
or CC N
pancuronium VB N
. . N

head NN N
trauma NN N
patient JJ N
46 CD 3_p
patients NNS N
head NN N
trauma NN N
patients NNS N
in IN N
an DT N
ED NNP N
setting NN N
. . N

-DOCSTART- -X- O O 12512598

Cows NNS 4_p
were VBD N
enrolled VBN N
from IN N
24 CD N
dairy NN N
herds NNS N
from IN N
three CD N
geographical JJ N
regions NNS N
of IN N
Canada NNP N
. . N

Data NNP N
from IN N
248 CD 3_p
cows NNS N
and CC N
938 CD N
bacteriologically RB N
negative JJ N
quarters NNS N
at IN N
drying-off NN N
are VBP N
summarized VBN N
. . N

-DOCSTART- -X- O O 25292351

attention NN 4_p
deficit NN 4_p
hyperactivity NN 4_p
disorder NN 4_p
and CC N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . 4_p

Age-matched JJ 1_p
boys NNS 2_p
with IN N
ADHD NNP N
( ( N
n JJ N
= NNP N
17 CD 3_p
) ) N
, , N
ASD NNP N
( ( N
n JJ N
= NNP N
17 CD 3_p
) ) N
and CC N
controls NNS N
( ( N
n JJ N
= NNP N
22 CD 3_p
) ) N
dysfunction NN N
in IN N
ASD NNP 4_p
-DOCSTART- -X- O O 19103729

advanced JJ 4_p
nasopharyngeal JJ 4_p
carcinoma NN 4_p
. . N

patients NNS N
with IN N
nasopharyngeal JJ 4_p
carcinoma NN 4_p
( ( 4_p
NPC NNP 4_p
) ) 4_p
. . 4_p

42 CD 3_p
patients NNS 3_p
with IN N
NPC NNP 4_p
was VBD N
compared VBN N
with IN N
a DT N
control NN N
group NN N
of IN N
40 CD 3_p
patients NNS 3_p
with IN N
NPC NNP N
treated VBD N
with IN N
RT NNP N
alone RB N
. . N

patients NNS N
with IN N
NPC NNP N
patients NNS N
with IN N
NPC NNP N
patients NNS N
with IN N
NPC NNP 4_p
. . 4_p

-DOCSTART- -X- O O 16037751

postmenopausal JJ 4_p
women NNS 2_p
. . N

222 CD 3_p
postmenopausal JJ N
women NNS 2_p
45 CD 1_p
years NNS 1_p
and CC 1_p
older JJR 1_p
without IN N
cardiovascular JJ 4_p
disease NN 4_p
and CC N
with IN 4_p
low-density JJ 4_p
lipoprotein NN 4_p
( ( 4_p
LDL NNP 4_p
) ) 4_p
cholesterol NN 4_p
levels NNS 4_p
of IN 4_p
3.37 CD 4_p
mmol/L NN 4_p
or CC 4_p
greater JJR 4_p
( ( 4_p
> CD 4_p
or CC 4_p
= VB 4_p
130 CD 4_p
mg/dL NN 4_p
) ) N
. . N

postmenopausal JJ 4_p
women NNS 2_p
women NNS 2_p
-DOCSTART- -X- O O 14685645

post-stroke NN 4_p
depressed JJ 4_p
patients NNS 4_p
. . N

post-stroke JJ N
patients NNS N
affected VBN N
by IN N
anxious JJ 4_p
depression NN 4_p
or CC N
retarded VBN 4_p
depression NN 4_p
. . N

Seventy-four JJ 3_p
post-stroke NN 4_p
depressed JJ 4_p
patients NNS N
patients NNS N
PSD NNP 4_p
patients NNS N
-DOCSTART- -X- O O 25726411

myocardial JJ 4_p
ischemia NN 4_p
. . N

myocardial JJ 4_p
ischemia NN 4_p
. . N

Patients NNPS N
( ( N
men NNS 2_p
≥ VBP N
45 CD 1_p
years NNS 1_p
; : N
women NNS 2_p
≥ VBP N
50 CD 1_p
years NNS 1_p
) ) N
with IN N
known VBN N
or CC N
suspected VBN N
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
( ( N
n JJ N
= NNP N
124 CD 3_p
) ) N
obtained VBN N
for IN N
110 CD 3_p
patients NNS N
excluding VBG N
myocardial JJ 4_p
ischemia NN 4_p
-DOCSTART- -X- O O 26510728

children NNS 1_p
young JJ 1_p
children NNS 1_p
, , N
adolescents NNS 1_p
and CC N
adults NNS 1_p
with IN N
chronic JJ 4_p
fatigue NN 4_p
syndrome/myalgic NN 4_p
encephalomyelitis NN 4_p
( ( 4_p
CFS/ME NNP 4_p
) ) 4_p
. . N

cohorts NNS N
from IN N
8 CD N
paediatric NN N
and CC N
27 CD N
adult NN N
CFS/ME NNP N
services NNS N
in IN N
the DT N
UK NNP N
and CC N
a DT N
paediatric NN N
randomised VBD N
controlled VBN N
trial NN N
from IN N
the DT N
Netherlands NNP N
. . N

younger JJR 1_p
( ( 1_p
aged VBN 1_p
< RB 1_p
12 CD 1_p
years NNS 1_p
) ) 1_p
and CC N
older JJR 1_p
( ( 1_p
aged VBN 1_p
12-18 CD 1_p
years NNS 1_p
) ) 1_p
children NNS 1_p
with IN N
adults NNS 1_p
, , N
and CC N
logistic JJ N
regression NN N
to TO N
compare VB N
UK NNP N
and CC N
Dutch NNP N
adolescents NNS N
RESULTS NNP N
Younger NNP 1_p
children NNS 1_p
had VBD N
a DT N
more RBR N
equal JJ N
gender NN N
balance NN N
compared VBN N
to TO N
adolescents NNS 1_p
and CC 1_p
adults NNS 1_p
. . N

Adults NNS 1_p
longer JJR N
that DT N
children NNS 1_p
with IN N
CFS/ME NNP N
-DOCSTART- -X- O O 2885607

perioperative JJ 4_p
chemotherapy NN 4_p
for IN 4_p
early JJ 4_p
breast NN 4_p
cancer NN 4_p
. . N

-DOCSTART- -X- O O 17019624

children NNS 2_p
with IN N
autism NN 4_p
children NNS 1_p
( ( 1_p
5-12 CD 1_p
years NNS 1_p
) ) 1_p
with IN N
autism NN 4_p
55 CD 3_p
children NNS N
-DOCSTART- -X- O O 8169405

infants NNS 1_p
and CC N
young JJ 1_p
children NNS 1_p
. . N

Twenty-two NNP 3_p
healthy JJ 4_p
infants NNS 1_p
and CC 1_p
children NNS 1_p
-DOCSTART- -X- O O 20508979

in IN N
children NNS N
with IN N
high-functioning JJ N
autism NN N
and CC N
concurrent JJ N
anxiety NN N
disorders NNS N
. . N

children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
) ) N
Forty NNP N
children NNS N
with IN N
ASD NNP N
( ( N
7-11 CD N
years NNS N
) ) N
and CC N
their PRP$ N
primary JJ N
caregiver NN N
children NNS N
with IN N
ASD NNP N
. . N

-DOCSTART- -X- O O 10390407

asthmatic JJ 4_p
patients NNS N
. . N

asthmatic JJ 4_p
patients NNS N
. . N

Patients NNS N
severe JJ N
asthmatic JJ 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 6552999

140 CD 4_p
patients NNS 4_p
with IN 4_p
a DT 4_p
threatening JJ 4_p
premature NN 4_p
birth NN 4_p
at IN 4_p
the DT 4_p
greater JJR 4_p
than IN 4_p
or CC 4_p
equal JJ 4_p
to TO 4_p
24-less JJ 4_p
than IN 4_p
37 CD 4_p
week NN 4_p
of IN 4_p
gestation NN 4_p
77 CD N
% NN N
in IN N
the DT N
hexoprenalin NN N
and CC N
in IN N
74 CD N
% NN N
in IN N
the DT N
salbutamol NN N
group NN N
weight NN N
of IN N
the DT N
newborn NN N
was VBD N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
2500 CD N
g. NN N
66 CD N
% NN N
in IN N
both DT N
study NN N
groups NNS N
11 CD N
% NN N
of IN N
the DT N
mothers NNS N
in IN N
the DT N
hexoprenalin NN N
group NN N
had VBD N
side-effects NNS N
during IN N
infusion NN N
compared VBN N
to TO N
30 CD N
% NN N
in IN N
the DT N
salbutamol NN N
group NN N
. . N

-DOCSTART- -X- O O 7298122

children NNS 1_p
. . N

80 CD 3_p
school NN N
children NNS 1_p
with IN N
blood NN 4_p
pressures NNS 4_p
above IN 4_p
the DT 4_p
95th CD 4_p
percentile NN 4_p
for IN 4_p
age NN 4_p
and CC 4_p
sex NN 4_p
but CC 4_p
below IN 4_p
130/90 CD 4_p
mm NN 4_p
Hg NNP 4_p
at IN N
school NN N
screening VBG N
Twenty NNP 3_p
children NNS 1_p
aged VBD 1_p
6 CD 1_p
to TO 1_p
9 CD 1_p
years NNS 1_p
and CC N
their PRP$ N
families NNS N
-DOCSTART- -X- O O 11013281

patients NNS 4_p
with IN 4_p
small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
( ( 4_p
SCLC NNP 4_p
) ) 4_p
SCLC NNP N
patients NNS N
with IN N
brain NN N
metastases NNS N
One CD 4_p
hundred VBD 4_p
twenty NN 4_p
eligible JJ 4_p
patients NNS 4_p
-DOCSTART- -X- O O 15968406

venous JJ 4_p
thromboembolism NN 4_p
in IN N
cancer NN 4_p
patients NNS N
. . N

patients NNS N
with IN N
venous JJ 4_p
thromboembolism NN 4_p
patients NNS N
on IN N
long-term JJ N
therapy NN N
for IN N
acute JJ 4_p
venous JJ 4_p
thromboembolism NN 4_p
who WP N
have VBP N
active JJ 4_p
cancer NN 4_p
. . N

Consecutive JJ N
consenting VBG N
patients NNS N
from IN N
one CD N
center NN N
in IN N
a DT N
multicenter NN N
trial NN N
24 CD 3_p
patients NNS 3_p
who WP N
had VBD N
anti-Xa JJ 4_p
levels NNS 4_p
patients NNS N
with IN N
active JJ 4_p
cancer NN 4_p
-DOCSTART- -X- O O 9777717

Thailand NNP N
Philippines-two JJ N
27 CD 3_p
healthy JJ N
, , N
Thai NNP N
adults NNS 1_p
received VBD N
a DT N
40 CD N
IU NNP N
kg NN N
( ( N
-1 NNP N
) ) N
dose NN N
of IN N
either DT N
Erig NNP N
PMC NNP N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
or CC N
PHT-Erig NNP N
( ( N
n JJ N
= NNP N
15 CD N
) ) N
via IN N
the DT N
intramuscular NN N
( ( N
i.m JJ N
. . N

) ) N
route NN N
; : N
71 CD 3_p
healthy JJ N
volunteers NNS N
-DOCSTART- -X- O O 17722829

child NN 4_p
's POS 4_p
autism NN 4_p
] NN 4_p
children NNS 4_p
's POS 4_p
autism NN 4_p
. . 4_p

Forty NNP N
autistic JJ N
children NNS N
receiving VBG N
rehabilitation NN N
training NN N
child NN 4_p
's POS 4_p
autism NN 4_p
. . 4_p

-DOCSTART- -X- O O 12644413

type NN 4_p
2 CD 4_p
diabetic JJ 4_p
patients NNS N
during IN N
ophthalmic JJ 4_p
surgery NN N
. . N

type NN 4_p
2 CD 4_p
diabetic JJ 4_p
patients NNS N
. . N

type NN 4_p
2 CD 4_p
diabetic JJ 4_p
patients NNS N
-DOCSTART- -X- O O 16313112

children NNS 1_p
syncytial JJ 4_p
viral JJ 4_p
pneumonia NN 4_p
. . N

Seventy-two JJ 3_p
patients NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
, , N
the DT N
36 CD 3_p
patients NNS 3_p
in IN N
the DT N
treated JJ N
group NN N
were VBD N
treated VBN N
with IN N
FRCL NNP N
, , N
and CC N
the DT N
other JJ N
36 CD 3_p
patients NNS 3_p
in IN N
the DT N
control NN N
group NN N
simply RB N
treated VBD N
with IN N
Western JJ N
medicine NN N
. . N

-DOCSTART- -X- O O 17884602

patients NNS N
with IN N
palpitations NNS 4_p
. . N

Patients NNP N
( ( N
n=244 JJ 3_p
) ) N
One CD 3_p
hundred CD 3_p
and CC 3_p
seventeen JJ 3_p
patients NNS N
-DOCSTART- -X- O O 3543069

autistic JJ N
children NNS 1_p
. . N

infantile JJ 1_p
autism NN 4_p
. . 4_p

autistic JJ N
children NNS N
. . N

children NNS N
with IN N
autism NN N
, , N
12 CD 3_p
subjects NNS N
In IN N
addition NN N
, , N
four CD 3_p
cases NNS N
describing VBG N
unusual JJ N
effects NNS N
found VBN N
in IN N
a DT N
sample NN 3_p
of IN 3_p
170 CD 3_p
patients NNS 3_p
treated VBN N
with IN N
fenfluramine NN N
are VBP N
also RB N
reported VBN N
. . N

autism NN N
. . N

-DOCSTART- -X- O O 11156811

generalized VBN 4_p
social JJ 4_p
phobia NN 4_p
: : 4_p
Adult NNP 1_p
outpatients NNS N
with IN N
generalized JJ 4_p
social JJ 4_p
phobia NN 4_p
( ( N
N=204 NNP 3_p
) ) N
from IN N
10 CD N
Canadian JJ N
centers NNS N
134 CD 3_p
patients NNS N
given VBN N
sertraline JJ N
69 CD 3_p
patients NNS N
receiving VBG N
placebo NN N
-DOCSTART- -X- O O 10190267

Rett NNP 4_p
syndrome NN 4_p
: : 4_p
female JJ 4_p
patients NNS 4_p
. . 4_p

35 CD N
subjects NNS N
. . N

patients NNS N
with IN N
Rett NNP N
syndrome NN N
. . N

-DOCSTART- -X- O O 24337476

people NNS N
with IN N
mental JJ 4_p
illness NN 4_p
: : N
mentally RB 4_p
ill JJ 4_p
adults NNS N
. . N

Twelve NNP 3_p
, , 3_p
randomly RB N
assigned VBN N
, , N
participated VBN N
-DOCSTART- -X- O O 25428632

330 CD 3_p
patients NNS N
with IN N
a DT N
confirmed JJ N
MPE NNP N
requiring VBG N
intervention NN N
will MD N
be VB N
recruited VBN N
from IN N
UK NNP N
hospitals NNS N
. . N

-DOCSTART- -X- O O 23205617

acute JJ 4_p
tinnitus NN 4_p
: : N
minimal-contact JJ N
interventions NNS N
for IN N
acute JJ 4_p
tinnitus NN 4_p
. . N

337 CD 3_p
participants NNS N
, , N
87 CD 3_p
persons NNS N
took VBD N
part NN N
in IN N
the DT N
Internet NNP N
training NN N
. . N

The DT N
participants NNS N
were VBD N
as IN N
satisfied JJ N
with IN N
the DT N
Internet-based JJ N
training NN N
as IN N
with IN N
a DT N
face-to-face JJ N
group NN N
training NN N
. . N

-DOCSTART- -X- O O 19264972

16 CD 3_p
( ( N
8 CD 3_p
women NNS 2_p
) ) N
nonsmoking VBG N
adults NNS 1_p
-DOCSTART- -X- O O 23893098

youth NN 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
: : N
youth NN 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
youth NN 1_p
with IN N
ASD NNP 4_p
between IN N
the DT N
ages NNS N
of IN N
18-21 JJ 1_p
years NNS N
of IN N
age NN N
. . N

24 CD 3_p
( ( N
87.5 CD N
% NN N
) ) N
treatment NN N
group NN N
participants NNS N
16 CD 3_p
( ( N
6.25 CD N
% NN N
) ) N
of IN N
control NN N
group NN N
participants NNS N
-DOCSTART- -X- O O 19023654

parents NNS 4_p
of IN 4_p
a DT 4_p
child NN 4_p
diagnosed VBN 4_p
with IN 4_p
an DT 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . 4_p

Fifty-nine JJ 4_p
families NNS 4_p
with IN 4_p
a DT 4_p
child NN 4_p
with IN 4_p
ASD NNP 4_p
aged VBD 4_p
between IN 4_p
2 CD 4_p
and CC 4_p
9 CD 4_p
participated VBN 4_p
parental JJ 4_p
reports NNS 4_p
of IN 4_p
child JJ 4_p
behaviour NN 4_p
and CC 4_p
parenting NN 4_p
styles NNS 4_p
with IN 4_p
the DT 4_p
treatment NN 4_p
effects NNS 4_p
for IN 4_p
child NN 4_p
behaviour NN 4_p
, , 4_p
parental NN 4_p
over IN 4_p
reactivity NN 4_p
and CC 4_p
parental JJ 4_p
verbosity NN 4_p
parents NNS N
of IN N
children NNS N
with IN N
ASD NNP N
. . N

-DOCSTART- -X- O O 7976148

Oesophageal JJ 4_p
intubation NN 4_p
Forty NNP 4_p
patients NNS 4_p
had VBD N
both DT N
their PRP$ N
trachea NN N
and CC N
oesophagus NN N
intubated VBN N
anaesthetist NN 4_p
's POS 4_p
feeling NN N
when WRB N
he PRP N
squeezes VBZ N
the DT N
bag NN N
. . N

-DOCSTART- -X- O O 10036953

99 CD 3_p
patients NNS N
with IN N
H. NNP 4_p
pylori FW 4_p
infection NN 4_p
were VBD N
-DOCSTART- -X- O O 7559165

frequency NN 4_p
discrimination NN 4_p
. . 4_p

frequency NN N
discrimination NN N
listeners NNS N
three CD N
listeners NNS N
-DOCSTART- -X- O O 20674829

allergic JJ 4_p
rhinitis NN 4_p
610 CD 3_p
patients NNS 3_p
with IN N
moderate-to-severe JJ 4_p
nasal NN 4_p
symptoms NNS 4_p
patients NNS N
with IN N
moderate-to-severe JJ 4_p
seasonal JJ 4_p
allergic JJ 4_p
rhinitis NN 4_p
. . N

-DOCSTART- -X- O O 21586714

pregnancy-related JJ N
mortality NN N
and CC N
infant JJ N
mortality NN N
in IN N
rural JJ N
Bangladesh NNP N
: : N
pregnancy-related JJ N
and CC N
infant JJ N
mortality NN N
. . N

pregnant JJ 1_p
women NNS 1_p
13 CD 1_p
to TO 1_p
45 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
and CC 1_p
their PRP$ 1_p
live-born JJ 1_p
infants NNS 1_p
to TO 1_p
12 CD 1_p
weeks NNS 1_p
( ( 1_p
84 CD 1_p
days NNS 1_p
) ) 1_p
postpartum VBP 1_p
in IN 1_p
rural JJ 1_p
northern JJ 1_p
Bangladesh NNP 1_p
between IN 1_p
2001 CD 1_p
and CC 1_p
2007 CD 1_p
. . 1_p

Five CD N
hundred VBD N
ninety-six JJ N
community NN N
clusters NNS N
( ( N
study NN N
sectors NNS N
) ) N
were VBD N
randomized VBN N
for IN N
pregnant JJ N
women NNS N
. . N

Married JJ N
women NNS N
( ( N
n JJ N
= NNP N
125,257 CD N
) ) N
. . N

carotene NN N
in IN N
pregnant JJ N
women NNS N
in IN N
Bangladesh NNP N
-DOCSTART- -X- O O 3306431

multiple JJ 4_p
sclerosis NN 4_p
: : N
MS NNP 4_p
patients NNS N
-DOCSTART- -X- O O 10636373

hypertension NN 4_p
hypertensive JJ 4_p
patients NNS N
-DOCSTART- -X- O O 9825384

adults NNS 1_p
with IN N
asthma NN 4_p
. . N

inactive JJ 4_p
asthmatic JJ 4_p
patients NNS N
Thirty-two JJ 3_p
adults NNS N
with IN N
asthma NN 4_p
Ten CD 3_p
patients NNS N
, , N
5 CD 3_p
in IN N
each DT N
group NN N
-DOCSTART- -X- O O 14722336

caregiver NN N
patients NNS N
with IN N
Alzheimer NNP 4_p
's POS 4_p
disease NN 4_p
: : N
person NN N
with IN N
Alzheimer NNP 4_p
's POS 4_p
disease NN 4_p
. . N

406 CD 3_p
spouses-caregivers NNS N
of IN N
patients NNS N
with IN N
Alzheimer NNP 4_p
's POS 4_p
disease NN 4_p
-DOCSTART- -X- O O 23118244

insomnia NN 4_p
in IN N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . N

why WRB N
parents NNS N
seek VBP N
medical JJ N
intervention NN N
in IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASDs NNP 4_p
) ) N
. . N

Thirty-six JJ 3_p
children NNS 1_p
with IN N
ASD NNP 4_p
, , N
ages VBZ 1_p
2 CD 1_p
to TO 1_p
10 CD 1_p
years NNS 1_p
, , N
were VBD N
enrolled VBN N
. . N

All DT N
had VBD N
prolonged VBN N
sleep JJ N
latency NN N
confirmed VBN N
by IN N
actigraphy NN N
showing VBG N
a DT N
mean JJ N
sleep JJ N
latency NN N
of IN N
30 CD N
minutes NNS N
or CC N
more JJR N
. . N

Parents NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
the DT N
sleep JJ N
education NN N
pamphlet NN N
or CC N
no DT N
intervention NN N
. . N

sleep JJ N
latency NN N
in IN N
children NNS N
with IN N
ASDs NNP N
. . N

-DOCSTART- -X- O O 17156651

patients NNS N
with IN N
coronary JJ N
heart NN N
disease NN N
( ( N
CHD NNP N
) ) N
and CC N
its PRP$ N
equivalents NNS N
. . N

One CD N
hundred CD N
and CC N
ten JJ N
patients NNS N
with IN N
CHD NNP N
and CC N
its PRP$ N
equivalents NNS N
with IN N
serum JJ N
total JJ N
cholesterol NN N
( ( N
TC NNP N
) ) N
> VBD N
or CC N
= $ N
3.5 CD N
mmol/L NN N
-DOCSTART- -X- O O 8391792

proximal JJ 4_p
deep JJ 4_p
vein NN 4_p
thrombosis NN 4_p
. . N

deep JJ 4_p
vein NN 4_p
thrombosis NN 4_p
both DT N
in IN N
general JJ N
surgery NN N
and CC N
in IN N
high-risk JJ N
orthopedic JJ N
surgery NN N
. . N

patients NNS N
with IN N
proximal JJ 4_p
vein NN 4_p
thrombosis NN 4_p
. . N

There EX N
were VBD N
67 CD 3_p
patients NNS N
in IN N
each DT N
group NN N
. . N

deep JJ 4_p
vein NN 4_p
thrombosis NN 4_p
. . N

-DOCSTART- -X- O O 17341994

patients NNS 4_p
with IN 4_p
essential JJ 4_p
hypertension NN 4_p
. . N

-DOCSTART- -X- O O 341946

Placebo-controlled JJ 4_p
double-blind JJ 4_p
trial NN 4_p
of IN 4_p
mianserin NN 4_p
hydrochloride NN 4_p
. . 4_p

-DOCSTART- -X- O O 26068086

Patient-Reported NNP 4_p
Visual NNP 4_p
Function NNP 4_p
After IN 4_p
Ocriplasmin NNP 4_p
for IN 4_p
Vitreomacular NNP 4_p
Adhesion NNP 4_p
: : N
patient-reported JJ 4_p
visual JJ 4_p
function NN 4_p
in IN 4_p
symptomatic JJ 4_p
VMA/vitreomacular NNP 4_p
traction NN 4_p
( ( 4_p
VMT NNP 4_p
) ) 4_p
patients NNS 4_p
with IN 4_p
symptomatic JJ 4_p
VMA NNP 4_p
. . N

A NNP N
total NN N
of IN N
652 CD 3_p
patients NNS 3_p
with IN N
symptomatic JJ 4_p
VMA/VMT NNP 4_p
, , N
including VBG N
when WRB N
associated VBN N
with IN N
a DT N
macular JJ N
hole NN N
400 CD N
μm NN N
or CC N
smaller JJR N
INTERVENTIONS JJ N
Patients NNS N
with IN N
symptomatic JJ N
VMA/VMT NNP N
studies NNS N
, , N
464 CD 3_p
patients NNS 3_p
received VBN N
ocriplasmin JJ N
and CC N
188 CD 3_p
received VBD 3_p
placebo NN N
patient-reported JJ N
visual JJ N
-DOCSTART- -X- O O 22082673

One CD 3_p
hundred VBD 3_p
twenty-four JJ 3_p
patients NNS 3_p
with IN N
antiarrhythmic JJ 4_p
drug-refractory JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
with IN 4_p
left JJ 4_p
atrial JJ 4_p
dilatation NN 4_p
and CC 4_p
hypertension NN 4_p
( ( 3_p
42 CD 3_p
patients NNS 3_p
, , N
33 CD N
% NN N
) ) N
or CC N
failed VBN 4_p
prior JJ 4_p
CA NNP 4_p
( ( N
82 CD 3_p
patients NNS 3_p
, , N
67 CD N
% NN N
) ) N
atrial JJ 4_p
fibrillation NN 4_p
patients NNS N
with IN N
dilated JJ 4_p
left JJ 4_p
atrium NN 4_p
and CC 4_p
hypertension NN 4_p
or CC N
failed VBD 4_p
prior RB 4_p
atrial JJ 4_p
fibrillation NN 4_p
CA NNP 4_p
-DOCSTART- -X- O O 18330493

metabolic JJ 4_p
syndrome NN 4_p
. . N

patients NNS N
with IN N
metabolic JJ 4_p
syndrome VBP 4_p
subjects NNS N
with IN N
metabolic JJ 4_p
syndrome NN 4_p
were VBD N
treated VBN N
with IN N
allopurinol NN N
( ( N
n JJ N
= NNP N
28 CD 3_p
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
22 CD 3_p
) ) N
for IN N
one CD N
month NN N
. . N

patients NNS N
with IN N
metabolic JJ N
syndrome NN N
-DOCSTART- -X- O O 7975860

human JJ 4_p
immune NN 4_p
response NN 4_p
to TO 4_p
hepatitis VB 4_p
B NNP 4_p
surface NN 4_p
antigen NN 4_p
50 CD 3_p
subjects NNS N
receiving VBG 4_p
four CD 4_p
doses NNS 4_p
of IN 4_p
hepatitis NN 4_p
B NNP 4_p
vaccine NN 4_p
according VBG N
to TO N
a DT N
0 CD N
, , N
1 CD N
, , N
2 CD N
, , N
12 CD N
month NN N
vaccination NN N
scheme NN N
. . N

Twenty-three JJ N
subjects NNS N
were VBD N
given VBN N
a DT N
plasma-derived JJ N
vaccine NN N
( ( N
Hevac NNP N
B NNP N
) ) N
and CC N
27 CD N
received VBD N
a DT N
recombinant JJ N
HBsAg NNP N
vaccine NN N
( ( N
yeast-derived JJ N
; : N
Engerix-B NNP N
) ) N
. . N

-DOCSTART- -X- O O 15603203

Histamine NNP 4_p
intolerance-like NN 4_p
symptoms NNS 4_p
in IN N
healthy JJ 4_p
volunteers NNS N
10 CD 3_p
healthy JJ N
females NNS 2_p
( ( N
age NN 1_p
range NN 1_p
22-36 CD 1_p
years NNS 1_p
, , N
mean JJ N
29.1 CD N
+/- JJ N
5.4 CD N
) ) N
who WP N
were VBD N
hospitalized VBN N
and CC N
challenged VBN N
on IN N
two CD N
consecutive JJ N
days NNS N
with IN N
placebo NN N
( ( N
peppermint JJ N
tea NN N
) ) N
or CC N
75 CD N
mg NN N
of IN N
pure JJ N
histamine NN N
( ( N
equaling VBG N
124 CD N
mg JJ N
histamine NN N
dihydrochloride NN N
, , N
dissolved VBN N
in IN N
peppermint NN N
tea NN N
) ) N
. . N

healthy JJ N
females NNS 2_p
without IN N
a DT N
history NN N
of IN N
food NN N
intolerance NN N
. . N

-DOCSTART- -X- O O 26323772

Thirteen NNP N
volunteers NNS N
working VBG N
in IN N
a DT N
warehousing NN N
industry NN N
comprised VBD N
the DT N
bench JJ N
step NN N
exercise NN N
group NN N
( ( N
n=7 CC 3_p
) ) N
and CC N
the DT N
control NN N
group NN N
( ( N
n=6 RB 3_p
) ) N
. . N

-DOCSTART- -X- O O 16160627

children NNS N
with IN N
autistic JJ N
disorder NN N
: : N
Twelve NNP N
children NNS N
, , N
all DT N
boys NNS N
, , N
aged VBD N
4 CD N
to TO N
7 CD N
years NNS N
, , N
with IN N
a DT N
diagnosis NN N
of IN N
autistic JJ N
disorder NN N
and CC N
low JJ N
concentrations NNS N
of IN N
spinal JJ N
6R-l-erythro-5,6,7,8-tetrahydrobiopterin JJ N
( ( N
tetrahydrobiopterin NN N
) ) N
-DOCSTART- -X- O O 17972048

stroke NN 4_p
. . 4_p

-DOCSTART- -X- O O 2642730

Between IN N
November NNP N
1973 CD N
and CC N
July NNP N
1982 CD N
, , N
123 CD 3_p
women NNS 2_p
younger JJR 1_p
than IN 1_p
70 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
and CC N
at IN 4_p
clinical JJ 4_p
Stages NNP 4_p
I PRP 4_p
and CC 4_p
II NNP 4_p
were VBD N
enrolled VBN N
. . N

112 CD 3_p
were VBD N
treated VBN N
by IN N
the DT N
same JJ N
surgeon NN N
and CC N
confirmed VBD N
pathologically RB N
as IN N
having VBG N
invasive JJ 4_p
mammary JJ 4_p
carcinoma NN 4_p
. . N

patients NNS N
with IN N
lateral JJ 4_p
tumors NNS 4_p
patients NNS N
treated VBD N
between IN N
1960 CD N
and CC N
1978 CD N
-DOCSTART- -X- O O 12680863

non-asthmatic JJ 4_p
subjects NNS 4_p
with IN 4_p
seasonal JJ 4_p
allergic JJ 4_p
rhinitis NN 4_p
: : 4_p
risk NN 4_p
factor NN 4_p
for IN 4_p
asthma NN 4_p
in IN 4_p
affected JJ 4_p
individuals NNS 4_p
. . 4_p

16 CD 3_p
non-asthmatic JJ N
SAR NNP N
patients NNS N
( ( N
median JJ N
age NN N
25 CD N
years NNS N
, , N
56 CD 3_p
% NN 3_p
males NNS N
) ) N
SAR JJ N
patients NNS N
were VBD N
identified VBN N
by IN N
history NN N
, , N
skin-prick JJ N
test NN N
and CC N
specific JJ N
IgE NNP N
. . N

All DT N
patients NNS N
had VBD N
normal JJ N
lung JJ N
function/bronchial JJ N
hyper-responsiveness NN N
out IN N
of IN N
season NN N
and CC N
a DT N
negative JJ N
asthma/wheezing NN N
history NN N
. . N

SAR NNP N
patients NNS N
SAR NNP N
patients NNS N
-DOCSTART- -X- O O 2074057

non-Hodgkin NN 4_p
's POS 4_p
lymphoma NN 4_p
with IN 4_p
a DT 4_p
low JJ 4_p
grade NN 4_p
of IN 4_p
malignancy NN 4_p
-DOCSTART- -X- O O 17334477

uterine JJ 4_p
myoma NN 4_p
regression NN 4_p
. . N

This DT N
study NN N
took VBD N
place NN N
in IN N
the DT N
Department NNP N
of IN N
Obstetrics NNP N
and CC N
Gynecology NNP N
of IN N
Tabriz NNP N
University NNP N
of IN N
Medical NNP N
Sciences NNPS N
, , N
Tabriz NNP N
, , N
Iran NNP N
from IN N
July NNP N
2004 CD N
to TO N
December NNP N
2005 CD N
. . N

Fifty NNP 3_p
women NNS 3_p
with IN N
uterine JJ 4_p
myoma NN 4_p
, , N
who WP N
met VBD N
the DT N
criteria NNS N
of IN N
the DT N
study NN N
thoroughly RB N
-DOCSTART- -X- O O 15324531

patients NNS N
with IN N
periarthritis NN 4_p
pain NN N
of IN N
the DT N
shoulder NN N
previously RB N
unsuccessfully RB N
treated VBN N
with IN N
nonsteroidal JJ N
anti-inflammatory JJ N
drugs NNS N
other JJ N
than IN N
diclofenac NNS N
and CC N
oxaprozin NN N
. . N

eligible JJ 4_p
patients NNS 4_p
with IN 4_p
periarthritis NN 4_p
of IN 4_p
the DT 4_p
shoulder NN 4_p
patient-assessed JJ N
shoulder NN 4_p
pain NN 4_p
patient-assessed JJ N
quality NN N
of IN N
life NN N
on IN N
the DT N
Short-Form-36 NNP 3_p
( ( N
SF-36 NNP 3_p
) ) N
Acute NNP N
Health NNP N
Survey NNP N
Patients NNS N
also RB N
assessed VBD N
the DT N
overall JJ N
efficacy NN N
of IN N
oxaprozin NN N
as IN N
superior JJ N
to TO N
that DT N
of IN N
diclofenac NN N
patients NNS N
with IN N
periarthritis NN 4_p
of IN N
the DT N
shoulder NN N
refractory NN N
-DOCSTART- -X- O O 12551867

patients NNS N
with IN N
angina JJ 4_p
pectoris NN 4_p
and CC N
normal JJ N
coronary JJ N
arteriograms NNS 4_p
: : N
patients NNS N
with IN N
cardiac JJ 4_p
syndrome NN 4_p
X NNP 4_p
( ( N
CSX NNP N
) ) N
. . N

Nine NNP 3_p
patients NNS N
with IN N
CSX NNP N
and CC N
14 CD N
control NN N
subjects NNS N
underwent VBD N
a DT N
continuous JJ N
infusion NN N
of IN N
L-arginine NNP N
( ( N
0.125 CD N
g/min NN N
) ) N
or CC N
saline NN N
for IN N
120 CD N
minutes NNS N
. . N

patients NNS N
with IN N
CSX NNP N
controls NNS N
. . N

patients NNS N
with IN N
CSX NNP N
CSX NNP N
. . N

-DOCSTART- -X- O O 2936772

Two CD 3_p
hundred VBD 3_p
patients NNS 3_p
with IN N
moderate JJ 4_p
to TO 4_p
moderately RB 4_p
severe JJ 4_p
acne NNS 4_p
vulgaris NNS 4_p
-DOCSTART- -X- O O 19895777

Polish JJ N
emergency NN N
department NN N
: : N
drinking NN N
and CC N
related JJ N
problems NNS N
among IN N
at-risk JJ N
and CC N
dependent JJ N
drinkers NNS N
emergency NN 1_p
department NN 1_p
( ( 1_p
ED NNP 1_p
) ) 1_p
in IN 1_p
Sosnowiec NNP 1_p
, , 1_p
Poland NNP 1_p
, , 1_p
among IN 1_p
patients NNS 1_p
ages VBZ 1_p
18 CD 1_p
years NNS 1_p
and CC 1_p
older JJR 1_p
. . 1_p

Data NNP N
were VBD N
collected VBN N
over IN N
a DT N
23-week JJ N
period NN N
, , N
from IN N
4:00 CD N
PM NNP N
to TO N
midnight VB N
446 CD N
patients NNS N
being VBG N
recruited VBN N
into IN N
the DT N
study NN N
( ( N
90 CD N
% NN N
of IN N
those DT N
who WP N
screened VBD N
positive JJ N
) ) N
-DOCSTART- -X- O O 25186034

patients NNS 4_p
with IN 4_p
active JJ 4_p
rheumatoid NN 4_p
arthritis NN 4_p
: : N
Patients NNPS 1_p
ages VBZ 1_p
≥18 CD 1_p
years NNS 1_p
with IN N
active JJ N
RA NNP N
with IN N
an DT N
inadequate JJ N
response NN N
to TO N
≥1 VB N
tumor NN N
necrosis NN N
factor NN N
inhibitor NN N
( ( N
TNFi NNP N
) ) N
and CC N
receiving VBG N
stable JJ N
background NN N
methotrexate NN N
were VBD N
randomized VBN N
2:2:1:1 CD N
to TO N
tofacitinib VB N
5 CD N
mg NN N
or CC N
10 CD N
mg JJ N
twice RB N
daily RB N
, , N
or CC N
placebo NN N
advanced VBD N
to TO N
tofacitinib VB N
5 CD N
mg NN N
or CC N
10 CD N
mg JJ N
twice RB N
daily RB N
at IN N
month NN N
treatment NN N
in IN N
patients NNS N
with IN N
active JJ N
RA NNP N
and CC N
a DT N
previous JJ N
inadequate JJ N
response NN N
to TO N
TNFi NNP N
-DOCSTART- -X- O O 8918486

patients NNS N
with IN N
muscle-invasive JJ 4_p
bladder NN 4_p
cancer NN 4_p
improved VBD N
local JJ N
control NN N
or CC N
survival NN N
. . N

Ninety-nine NNP 3_p
eligible JJ N
patients NNS N
with IN N
T2 NNP 4_p
to TO 4_p
T4b NNP 4_p
transitional JJ 4_p
cell NN 4_p
bladder NN 4_p
cancer NN 4_p
participated VBD N
, , N
64 CD 3_p
% NN 3_p
with IN N
cT3b NN N
or CC N
cT4 NN N
. . N

-DOCSTART- -X- O O 12553591

autism NN 4_p
. . N

children NNS 1_p
with IN N
autism NN 4_p
. . N

Forty-two JJ 3_p
children NNS 1_p
with IN N
the DT N
diagnosis NN N
of IN N
autism NN 4_p
-DOCSTART- -X- O O 18633049

Twenty-two NNP 3_p
healthy JJ 4_p
female NN 2_p
volunteers NNS N
extra JJ N
1 CD N
group NN N
-DOCSTART- -X- O O 12564611

patients NNS N
with IN N
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
. . N

chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
( ( N
COPD NNP 4_p
) ) N
patients NNS N
with IN N
symptomatic JJ 4_p
, , 4_p
smoking-related JJ 4_p
COPD NNP 4_p
patients NNS N
with IN N
severe JJ 4_p
COPD NNP 4_p
( ( 4_p
stage NN 4_p
III NNP 4_p
) ) 4_p
than IN N
mild NN 4_p
( ( 4_p
stage NN 4_p
I PRP 4_p
) ) 4_p
elderly JJ 1_p
patients NNS N
-DOCSTART- -X- O O 3812946

prilocaine NN N
in IN N
volunteers NNS N
. . N

six CD 3_p
volunteers NNS N
. . N

-DOCSTART- -X- O O 25044079

in IN 4_p
vitro JJ 4_p
fertilization NN 4_p
: : 4_p
in IN N
human JJ N
clinical JJ N
IVF NNP N
PATIENT NNP N
( ( N
S NNP N
) ) N
Infertile NNP N
couples NNS N
( ( N
n=52 NN N
) ) N
with IN N
a DT N
female JJ N
partner NN N
less JJR N
than IN N
42 CD N
years NNS N
old JJ N
with IN N
eight CD N
or CC N
more JJR N
mature JJ N
oocytes VBZ N
retrieved VBN N
total NN N
of IN N
805 CD N
mature NN N
oocytes NNS N
-DOCSTART- -X- O O 3331506

Physicians NNS 4_p
' POS 4_p
management NN 4_p
of IN 4_p
hypertension NN 4_p
: : N
-DOCSTART- -X- O O 18343039

women NNS 2_p
suffering VBG N
from IN N
schizophrenia NN 4_p
: : N
women NNS 2_p
suffering VBG N
from IN N
schizophrenia NN 4_p
. . N

Nineteen JJ 3_p
women NNS 2_p
( ( N
mean JJ N
age=38.0 NN 1_p
years NNS 1_p
, , N
SD=9.9 NNP N
years NNS N
) ) N
with IN N
schizophrenia NN 4_p
hospitalized VBN N
for IN N
the DT N
first JJ N
time NN N
or CC N
repeatedly RB N
women NNS 2_p
with IN N
schizophrenia NN 4_p
. . N

-DOCSTART- -X- O O 7831456

autistic JJ 4_p
children NNS 4_p
. . 4_p

hospitalized VBN 4_p
autistic JJ 4_p
children NNS 4_p
( ( 4_p
n JJ 4_p
= NNP 4_p
41 CD 4_p
) ) 4_p
. . 4_p

17 CD 3_p
children NNS 1_p
14 CD 3_p
selected VBD 3_p
Children NNP N
's POS N
-DOCSTART- -X- O O 6423162

Endotracheal NNP 4_p
cuff NN 4_p
pressure NN 4_p
and CC 4_p
tracheal NN 4_p
mucosal NN 4_p
blood NN 4_p
flow NN 4_p
: : 4_p
four CD N
large JJ N
volume NN N
cuffs NNS N
. . N

Low JJ N
pressure NN N
cuffs NNS N
40 CD 3_p
patients NNS 4_p
undergoing JJ 4_p
surgery NN 4_p
-DOCSTART- -X- O O 21379582

Delayed VBN 4_p
perceptual JJ 4_p
awareness NN 4_p
rapid JJ 4_p
perceptual JJ 4_p
decisions NNS 4_p
. . 4_p

human JJ N
observers NNS N
-DOCSTART- -X- O O 15260182

student NN N
actors NNS N
' POS N
Twelve NNP N
student NN N
actors NNS N
( ( 4_p
6 CD 4_p
males NNS 4_p
, , 4_p
6 CD 4_p
females NNS 4_p
) ) 4_p
students NNS N
( ( N
3 CD N
males NNS N
, , N
3 CD N
females NNS N
) ) N
-DOCSTART- -X- O O 9676408

men NNS 4_p
with IN 4_p
BPH NNP 4_p
. . 4_p

benign JJ N
prostatic JJ N
hyperplasia NN N
( ( N
BPH NNP N
) ) N
60 CD N
patients NNS N
with IN N
symptomatic JJ N
BPH NNP N
was VBD N
performed VBN N
. . N

-DOCSTART- -X- O O 6307704

patients NNS 4_p
with IN 4_p
a DT 4_p
complete JJ 4_p
radiographic JJ 4_p
regression NN 4_p
of IN 4_p
small JJ 4_p
cell NN 4_p
bronchogenic JJ 4_p
carcinoma NN 4_p
. . 4_p

21 CD 3_p
patients NNS N
with IN N
small JJ N
cell NN N
bronchogenic JJ N
carcinoma NN N
who WP N
demonstrated VBD N
a DT N
complete JJ N
radiographic JJ N
regression NN N
of IN N
their PRP$ N
chest JJS N
lesions NNS N
after IN N
3-4 JJ N
months NNS N
of IN N
combination NN N
chemotherapy NN N
. . N

-DOCSTART- -X- O O 11411192

substance-abusing JJ 4_p
suicidal JJ 4_p
patient NN N
. . N

substance-abusing JJ 4_p
suicidal NN 4_p
patients NNS N
subjects NNS N
with IN N
alcohol NN 4_p
or CC 4_p
drug NN 4_p
abuse NN 4_p
. . N

substance-abusing JJ 4_p
suicidal JJ 4_p
patients NNS N
12 CD 3_p
patients NNS N
, , N
all DT N
of IN N
whom WP N
demonstrated VBD N
recent JJ 4_p
suicidal JJ 4_p
ideations NNS 4_p
and CC N
had VBD 4_p
made VBN 4_p
a DT 4_p
lifetime NN 4_p
suicide NN 4_p
attempt NN 4_p
. . N

subjects NNS N
with IN N
alcohol NN 4_p
or CC 4_p
substance NN 4_p
abuse NN 4_p
51 CD 3_p
subjects NNS N
, , N
of IN N
whom WP N
20 CD 3_p
( ( N
39 CD N
% NN N
) ) N
had VBD N
made VBN N
a DT N
suicide JJ 4_p
attempt NN 4_p
in IN 4_p
the DT 4_p
current JJ 4_p
depressive JJ 4_p
episode NN 4_p
, , N
31 CD 3_p
( ( N
61 CD N
% NN N
) ) N
had VBD N
made VBN N
a DT N
suicide JJ 4_p
attempt NN 4_p
in IN 4_p
their PRP$ 4_p
lifetime NN 4_p
, , N
and CC N
46 CD 3_p
( ( N
90 CD N
% NN N
) ) N
had VBD N
reported VBN N
suicidal JJ 4_p
ideations NNS 4_p
in IN N
the DT N
week NN N
before IN N
hospitalization NN N
. . N

substance-abusing JJ 4_p
suicidal NN 4_p
patients NNS N
substance-abusing JJ 4_p
suicidal JJ 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 18449445

head NN N
and CC N
neck NN N
cancer NN 4_p
surgery NN N
: : N
patients NNS N
with IN N
head NN N
and CC N
neck NN N
cancer NN 4_p
. . N

A DT N
population NN N
of IN N
44 CD 3_p
patients NNS 3_p
with IN N
oral JJ 4_p
and CC 4_p
laryngeal JJ 4_p
cancer NN 4_p
was VBD N
enrolled VBN N
in IN N
a DT N
randomized JJ N
trial NN N
. . N

head NN N
and CC N
neck NN N
cancer NN 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 2426069

A NNP 4_p
series NN 4_p
of IN 4_p
25 CD 4_p
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
esophageal NN 4_p
cancer NN 4_p
treated VBN 4_p
from IN 4_p
Mar NNP 4_p
. . 4_p

1981 CD N
to TO N
Sep. VB N
1982 CD N
by IN N
preoperative JJ N
chemotherapy NN N
plus CC N
surgery NN N
patients NNS N
came VBD N
from IN N
the DT N
hospitals NNS N
of IN N
the DT N
cooperative JJ N
research NN N
group NN N
By IN N
histology NN N
, , N
22 CD N
cases NNS N
were VBD N
squamous JJ N
cell NN N
carcinoma NN N
, , N
1 CD N
adenocarcinoma NN N
and CC N
2 CD N
squamous JJ N
adenocarcinoma NN N
. . N

-DOCSTART- -X- O O 24035299

pneumonectomy NN 4_p
: : N
10 CD 3_p
patients NNS N
undergoing JJ N
pneumonectomy NN 4_p
for IN N
lung NN 4_p
cancer NN 4_p
between IN N
July NNP N
2011 CD N
and CC N
July NNP N
2012 CD N
. . N

all DT N
consecutive JJ N
patients NNS N
who WP N
agreed VBD N
to TO N
take VB N
part NN N
in IN N
the DT N
study NN N
and CC N
in IN N
whom WP N
preservation NN N
of IN N
the DT N
phrenic JJ 4_p
nerve NN 4_p
during IN N
operation NN N
was VBD N
possible JJ N
, , N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 23773886

Early NNP 4_p
Psychosis NNP 4_p
. . 4_p

early JJ N
phase NN N
of IN N
a DT N
schizophrenia NN 4_p
spectrum NN 4_p
( ( 4_p
SS NNP 4_p
) ) 4_p
disorder NN 4_p
Eighty-five JJ 3_p
patients NNS 3_p
in IN N
early JJ N
phase NN N
of IN N
an DT N
SS NNP 4_p
disorder NN 4_p
eligible JJ N
participants NNS N
( ( N
n=77 NN 3_p
) ) N
patients NNS N
-DOCSTART- -X- O O 17934678

nurse JJ N
training NN N
in IN N
the DT N
use NN N
of IN N
asthma JJ 4_p
action NN N
plans NNS N
. . N

poorly-controlled JJ N
adult NN 1_p
asthma NN 4_p
patients NNS N
nurses NNS N
who WP N
deliver VBP N
asthma JJ 4_p
clinics NNS N
. . N

( ( N
n=13 JJ 3_p
practices NNS N
; : N
6=intervention CD 3_p
, , N
7=control CD 3_p
) ) N
asthma NN N
patients NNS N
identified VBN N
as IN N
being VBG N
poorly-controlled JJ N
from IN N
practice NN N
records NNS N
; : N
629 CD 3_p
patients NNS N
. . N

236 CD 3_p
( ( N
37 CD N
% NN N
) ) N
of IN N
these DT N
patients NNS N
consented VBD N
to TO N
provide VB N
questionnaire NN N
data NNS N
practice NN N
nurses NNS N
practice NN N
nurses NNS N
-DOCSTART- -X- O O 25066648

patients NNS 4_p
with IN 4_p
postmastectomy JJ 4_p
lymphedema NN 4_p
: : 4_p
in IN 4_p
patients NNS 4_p
with IN 4_p
lymphedema NN 4_p
METHODS NNP 3_p
45 CD 3_p
patients NNS 3_p
were VBD N
randomly RB 3_p
divided VBN 3_p
into IN 3_p
3 CD 3_p
groups NNS 3_p
decreasing VBG 4_p
lymphedema NN 4_p
-DOCSTART- -X- O O 12148711

African-American JJ N
renal JJ 4_p
transplant NN 4_p
patients NNS N
. . N

African-American JJ N
renal JJ N
transplant NN N
patients NNS N
African-American JJ N
renal JJ N
transplant NN N
patients NNS N
who WP N
did VBD N
not RB N
have VB N
clinical JJ N
pharmacy NN N
services NNS N
. . N

Renal NNP 3_p
transplant NN 3_p
patients NNS 3_p
( ( N
N NNP N
= NNP N
13 CD 3_p
) ) N
( ( N
N NNP N
= NNP N
10 CD 3_p
) ) N
African-American JJ N
renal JJ N
transplant NN N
patients NNS N
. . N

-DOCSTART- -X- O O 7516831

early JJ N
stage NN N
, , N
curable JJ N
prostate NN N
cancer NN N
: : N
In IN N
1,002 CD N
men NNS N
aged VBN N
45-80 JJ N
y NN N
prostate-specific JJ N
antigen NN N
( ( N
PSA NNP N
) ) N
, , N
digital JJ N
rectal JJ N
examination NN N
( ( N
DRE NNP N
) ) N
, , N
and CC N
transrectal JJ N
ultrasonography NN N
7,350 CD N
men NNS N
using VBG N
serum NN N
PSA NNP N
and CC N
DRE NNP N
as IN N
first JJ N
approach NN N
, , N
followed VBN N
by IN N
TRUS NNP N
only RB N
when WRB N
1 CD N
of IN N
these DT N
2 CD N
tests NNS N
was VBD N
abnormal JJ N
. . N

unselected JJ N
, , N
unscreened JJ N
population NN N
-DOCSTART- -X- O O 25719544

preterm JJ 1_p
infants NNS 1_p
: : 1_p
infant NN 1_p
fails VBZ 1_p
to TO 1_p
initiate VB 1_p
spontaneous JJ 1_p
breathing NN 1_p
after IN 1_p
birth NN 1_p
preterm NN 1_p
infants NNS 1_p
< VBP 1_p
33 CD 1_p
weeks NNS 1_p
gestational JJ 1_p
age NN 1_p
in IN 1_p
the DT 1_p
delivery NN 1_p
room NN 1_p
. . 1_p

Infants NNPS 1_p
born VBN 1_p
at IN 1_p
the DT 1_p
Royal NNP 1_p
Alexandra NNP 1_p
Hospital NNP 1_p
from IN N
April NNP 1_p
to TO 1_p
September NNP 1_p
2013 CD 1_p
at IN 1_p
< $ 1_p
33 CD 1_p
weeks NNS 1_p
gestational JJ 1_p
age NN 1_p
who WP 1_p
received VBD N
mask NN N
PPV NNP N
in IN N
the DT N
delivery NN N
room NN N
Fifty-six JJ 3_p
preterm JJ 1_p
infants NNS 1_p
( ( 1_p
n=28 NN 1_p
in IN 1_p
each DT 1_p
group NN 1_p
) ) 1_p
were VBD 1_p
enrolled VBN 1_p
; : N
mean±s.d NN N
. . N

gestational JJ 1_p
age NN 1_p
28±3 CD 1_p
weeks NNS 1_p
; : 1_p
birth NN 1_p
weight VBD 1_p
1210±448 CD 1_p
g NN 1_p
; : 1_p
and CC 1_p
30 CD 3_p
( ( 1_p
52 CD 1_p
% NN 1_p
) ) 1_p
were VBD 1_p
male JJ 1_p
mask NN 1_p
leak NN 1_p
in IN 1_p
preterm JJ 1_p
infants NNS 1_p
< VBP 1_p
33 CD 1_p
weeks NNS 1_p
gestational JJ 1_p
-DOCSTART- -X- O O 23066765

long-term JJ 4_p
hospitalized JJ 4_p
patients NNS 4_p
with IN N
schizophrenia NN 4_p
for IN N
discharge NN N
from IN N
hospital NN N
: : N
Community NNP N
Re-entry NNP N
Program-Japanese JJ N
Discharge NNP N
Preparation NNP N
Program NNP N
( ( N
DPP NNP N
) ) N
intervention NN N
condition NN N
( ( N
n JJ N
= NNP N
26 CD 3_p
) ) N
control NN N
condition NN N
( ( N
n JJ N
= NNP N
23 CD 3_p
) ) N
. . N

number NN N
of IN N
patients NNS N
who WP N
were VBD N
discharged VBN N
within IN N
6 CD N
months NNS N
after IN N
the DT N
end NN N
of IN N
a DT N
program NN N
. . N

long-term JJ 4_p
hospitalized JJ 4_p
psychiatric JJ 4_p
patients NNS 4_p
. . N

patients NNS N
with IN N
schizophrenia NN 4_p
in IN N
Japan NNP 4_p
. . N

-DOCSTART- -X- O O 9449870

Wuchereria NNP 4_p
bancrofti JJ 4_p
infection NN 4_p
in IN N
human JJ N
beings NNS N
and CC N
mosquitoes NNS N
. . N

14 CD N
communities NNS N
in IN N
matched JJ N
pairs NNS N
. . N

People NNS N
aged VBD N
5 CD 1_p
years NNS N
or CC N
older JJR N
in IN N
seven CD N
communities NNS N
received VBD N
randomly RB N
assigned VBN N
diethylcarbamazine NN N
6 CD N
mg/kg NN N
and CC N
people NNS N
in IN N
the DT N
other JJ N
seven CD N
communities NNS N
five CD N
communities NNS N
2219 CD 3_p
( ( N
87.6 CD N
% NN N
) ) N
of IN N
2534 CD 3_p
eligible JJ N
people NNS N
received VBD N
treatment NN N
. . N

-DOCSTART- -X- O O 20865676

patients NNS 4_p
in IN 4_p
heart NN 4_p
failure NN 4_p
with IN 4_p
preserved JJ 4_p
ejection NN 4_p
fraction NN 4_p
. . N

patients NNS 4_p
in IN 4_p
stable JJ 4_p
diastolic NN 4_p
and CC 4_p
right JJ 4_p
heart NN 4_p
failure NN 4_p
Thirty NNP 3_p
patients NNS 3_p
from IN N
the DT N
Heart NNP 4_p
Failure NNP 4_p
Clinic NNP 4_p
of IN 4_p
the DT 4_p
Instituto NNP 4_p
Nacional NNP 4_p
de FW 4_p
Ciencias NNP 4_p
Médicas NNP 4_p
y NNP 4_p
Nutrición NNP 4_p
" NNP 4_p
Salvador NNP 4_p
Zubirán NNP 4_p
" NNP 4_p
underwent JJ 4_p
photoplethysmography NN 4_p
using VBG 4_p
the DT 4_p
hyperemia NN 4_p
technique NN 4_p
treatment NN 4_p
of IN 4_p
diastolic JJ 4_p
heart NN 4_p
-DOCSTART- -X- O O 24730708

autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
: : 4_p
Autism NNP 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
METHOD NNP N
A NNP N
sample NN N
of IN N
14 CD 3_p
participants NNS 3_p
with IN N
ASD NNP N
and CC N
14 CD N
matched VBD N
controls NNS N
the DT 4_p
ASD NNP 4_p
and CC 4_p
control NN 4_p
groups NNS 4_p
the DT N
ASD NNP N
group NN N
-DOCSTART- -X- O O 19915222

PCI NNP N
. . N

percutaneous JJ N
coronary JJ N
intervention NN N
( ( N
PCI NNP N
) ) N
. . N

5362 CD 3_p
patients NNS N
who WP N
had VBD N
not RB N
been VBN N
treated VBN N
with IN N
clopidogrel NN N
to TO N
receive VB N
either DT N
cangrelor NN N
or CC N
placebo NN N
at IN N
the DT N
time NN N
of IN N
PCI NNP N
, , N
followed VBN N
by IN N
600 CD N
mg NNS N
of IN N
clopidogrel NN N
. . N

primary JJ N
end NN N
point NN N
occurred VBD N
in IN N
185 CD N
of IN N
2654 CD 3_p
patients NNS N
receiving VBG N
cangrelor NN N
( ( N
7.0 CD N
% NN N
) ) N
and CC N
in IN N
210 CD N
of IN N
2641 CD 3_p
patients NNS N
receiving VBG N
placebo NN N
( ( N
8.0 CD N
% NN N
) ) N
-DOCSTART- -X- O O 24387919

One CD 3_p
hundred VBD 3_p
forty-two JJ 3_p
patients NNS 3_p
-DOCSTART- -X- O O 21220480

patients NNS N
with IN N
hormone JJ N
receptor-positive JJ N
metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
: : N
Patients NNPS N
with IN N
newly RB N
metastatic JJ 4_p
disease NN 4_p
or CC N
recurred VBN N
after IN N
adjuvant JJ N
tamoxifen NN N
( ( N
stratum JJ N
1 CD N
) ) N
, , N
or CC N
recurred VBD N
during/after NN N
adjuvant JJ N
aromatase NN N
inhibitor NN N
( ( N
AI NNP N
) ) N
or CC N
after IN N
failed VBN N
first-line NN N
AI NNP N
( ( N
stratum JJ N
2 CD N
) ) N
, , N
were VBD N
eligible JJ N
. . N

subset VB N
appropriate JJ N
patients NNS N
-DOCSTART- -X- O O 88754

tongue NN N
and CC N
floor NN N
of IN N
the DT N
mouth NN 4_p
cancers NNS 4_p
. . N

Since IN N
January NNP N
1974 CD N
, , N
95 CD 3_p
patients NNS N
with IN N
anterior JJ 4_p
tongue NN 4_p
and CC 4_p
floor NN 4_p
of IN 4_p
the DT 4_p
mouth NN 4_p
cancers NNS 4_p
one-third NN 3_p
of IN N
the DT N
patients NNS N
received VBD N
chemotherapy NN N
one-third JJ 3_p
of IN N
the DT N
patients NNS N
received VBD N
immunotherapy JJ N
with IN N
weekly JJ N
C. NNP N
parvum NN N
injections NNS N
remaining VBG N
third NN 3_p
Patients NNS N
who WP N
previously RB N
received VBD N
radiotherapy NN N
-DOCSTART- -X- O O 19051459

rectal JJ N
cancer NN N
. . N

rectal JJ N
cancer NN N
patients NNS N
. . N

rectal JJ N
carcinoma NN N
patients NNS N
without IN N
distant JJ N
metastasis NN N
or CC N
peritoneal JJ N
carcinomatosis NN N
. . N

Between NNP N
January NNP N
1998 CD N
and CC N
December NNP N
2003 CD N
, , N
51 CD N
rectal JJ N
carcinoma NN N
patients NNS N
without IN N
distant JJ N
metastasis NN N
or CC N
peritoneal JJ N
carcinomatosis NN N
rectal JJ N
carcinoma NN N
patients NNS N
-DOCSTART- -X- O O 19965647

younger JJR 1_p
patients NNS N
with IN N
nonacute JJ 4_p
promyelocytic JJ 4_p
acute NN 4_p
myeloid NN 4_p
leukemia NN 4_p
: : N
genotypic JJ N
subgroups NNS N
defined VBN N
by IN N
mutations NNS 4_p
in IN 4_p
NPM1 NNP 4_p
, , 4_p
FLT3 NNP 4_p
, , 4_p
and CC 4_p
CEBPA NNP 4_p
. . N

chemotherapy VB N
for IN N
younger JJR 1_p
patients NNS N
with IN N
nonacute JJ 4_p
promyelocytic JJ 4_p
acute NN 4_p
myeloid NN 4_p
leukemia NN 4_p
and CC N
high-risk JJ 4_p
myelodysplastic JJ 4_p
syndrome NN 4_p
1075 CD 3_p
patients NNS N
less RBR 1_p
than IN 1_p
60 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
-DOCSTART- -X- O O 10429005

healthy JJ 4_p
neonates NNS 1_p
10 CD 3_p
term NN N
infants NNS 1_p
-DOCSTART- -X- O O 9720660

influenza VB 4_p
vaccine NN 4_p
in IN N
the DT N
elderly JJ 1_p
. . N

in IN N
elderly JJ 1_p
subjects NNS N
. . N

Seventy-one CD 3_p
elderly JJ 1_p
volunteers NNS N
, , N
aged VBN N
61-89 CD 1_p
years NNS 1_p
-DOCSTART- -X- O O 27348905

[ JJ 4_p
Diabetic NNP 4_p
constipation NN 4_p
diabetic JJ 4_p
constipation NN 4_p
. . 4_p

One CD 3_p
hundred CD 3_p
and CC 3_p
fifty JJ 3_p
patients NNS N
were VBD N
randomized VBN N
intoa RB N
comprehensive JJ N
group NN N
diabetic JJ 4_p
constipation NN 4_p
-DOCSTART- -X- O O 15474171

tapping VBG 4_p
oscillatory JJ 4_p
motion NN 4_p
. . N

finger NN 4_p
tapping NN 4_p
oscillatory JJ 4_p
motion NN 4_p
of IN 4_p
the DT 4_p
hand NN 4_p
. . N

tapping VBG 4_p
oscillatory JJ 4_p
condition NN 4_p
oscillatory JJ 4_p
character NN 4_p
-DOCSTART- -X- O O 25893544

Patients NNP 4_p
With IN 4_p
Metabolic NNP 4_p
Syndrome NNP 4_p
. . N

patients NNS 4_p
with IN 4_p
metabolic JJ 4_p
syndrome NN 4_p
, , 4_p
with IN 4_p
and CC 4_p
without IN 4_p
stable JJ 4_p
statin NN 4_p
therapy NN 4_p
. . N

patients NNS N
with IN N
metabolic JJ 4_p
syndrome NN 4_p
treated VBN 4_p
with IN 4_p
IPE NNP 4_p
4 CD 4_p
grams/day NN 4_p
, , N
IPE NNP N
2 CD N
grams/day NN N
, , N
or CC N
placebo NN N
in IN N
phase NN N
3 CD N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
studies NNS N
entitled VBN N
: : N
MARINE NNP N
[ NNP N
triglyceride NN N
( ( N
TG NNP N
) ) N
levels NNS N
≥500 CD N
and CC N
≤2000 CD N
mg/dL NN N
] NN N
and CC N
ANCHOR NNP N
[ NNP N
TG NNP N
levels NNS N
≥200 NNP N
and CC N
< $ N
500 CD N
mg/dL NN N
, , N
despite IN N
low-density JJ N
lipoprotein NN N
cholesterol NN N
( ( N
LDL-C NNP N
) ) N
control NN N
with IN N
stable JJ N
statin NN N
placebo NN N
in IN N
patients NNS N
with IN N
metabolic JJ 4_p
syndrome NN 4_p
in IN N
MARINE NNP N
( ( N
n=204 NN 3_p
) ) N
and CC N
ANCHOR NNP N
levels NNS N
in IN N
patients NNS N
with IN N
metabolic JJ 4_p
syndrome NN 4_p
and CC N
high JJ N
( ( N
≥200 JJ N
and CC N
< JJ N
500 CD N
mg/dL NN N
) ) N
or CC N
very RB N
high JJ N
( ( N
≥500 CD N
and CC N
≤2000 NNP N
mg/dL NN N
) ) N
TG NNP N
levels NNS N
, , N
with IN N
or CC N
without IN N
stable JJ N
-DOCSTART- -X- O O 14623199

feline JJ N
chlamydophilosis NN N
. . N

feline JJ N
chlamydophilosis NN N
cats NNS N
within IN N
an DT N
affected JJ N
group NN N
chlamydia NN N
( ( N
Chlamydophila NNP N
felis RB N
) ) N
infection NN N
in IN N
cats NNS N
. . N

five CD N
cats NNS N
treated VBN N
. . N

-DOCSTART- -X- O O 23039709

neonatal JJ 4_p
resuscitation NN 4_p
protocol-helping JJ 4_p
babies NNS 4_p
breathe VBP 4_p
at IN 4_p
birth NN 4_p
Nepal NNP N
low JJ N
and CC N
middle JJ N
income NN N
countries NNS N
tertiary JJ N
hospital NN N
in IN N
Nepal NNP N
. . N

skilled JJ N
birth NN N
attendants NNS N
tertiary JJ N
level NN N
maternity NN N
hospital NN N
in IN N
Nepal NNP N
. . N

-DOCSTART- -X- O O 23185761

cervical JJ N
high-risk JJ N
human JJ N
papilloma NN N
virus NN N
infection NN N
patients NNS N
] VBP N
cervical JJ N
high-risk JJ N
human JJ N
papilloma NN N
virus NN N
( ( N
HR-HPV NNP N
) ) N
infection NN N
. . N

Totally RB N
HR-HPV NNP N
infection NN N
70 CD N
patients NNS N
-DOCSTART- -X- O O 6496450

volunteers NNS N
at IN N
a DT N
low JJ 4_p
risk NN 4_p
of IN 4_p
infection NN 4_p
with IN 4_p
hepatitis NN 4_p
B NNP 4_p
virus NN 4_p
. . N

471 CD 3_p
healthy JJ 4_p
human JJ N
volunteers NNS N
, , N
who WP N
, , N
both DT N
in IN N
their PRP$ N
occupations NNS N
and CC N
in IN N
their PRP$ N
private JJ N
lives NNS N
, , N
had VBD N
been VBN N
at IN N
minimal JJ N
risk NN N
of IN N
being VBG N
infected VBN N
with IN N
hepatitis NN 4_p
B NNP 4_p
virus NN 4_p
. . N

-DOCSTART- -X- O O 18368792

patients NNS 4_p
with IN 4_p
Helicobacter NNP 4_p
pylori VBP 4_p
positive JJ 4_p
duodenal JJ 4_p
bulb NN 4_p
ulcer NN 4_p
] NNP N
patients NNS 4_p
Helicobacter NNP 4_p
pylori-positive JJ 4_p
patients NNS 4_p
with IN 4_p
duodenal JJ 4_p
bulb NN 4_p
ulcer NN 4_p
( ( 4_p
DBU NNP 4_p
) ) 4_p
One CD 3_p
hundred CD 3_p
and CC 3_p
twenty VB 3_p
four CD 3_p
randomly RB N
selected VBN N
patients NNS 4_p
with IN 4_p
DBU NNP 4_p
HP-positive JJ 4_p
patients NNS 4_p
-DOCSTART- -X- O O 24085050

atopic JJ 4_p
dermatitis NN 4_p
: : N
mild NN N
to TO N
moderate VB N
atopic NN 4_p
dermatitis NN 4_p
in IN N
children NNS 1_p
older JJR 1_p
than IN 1_p
two CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
and CC N
adults NNS 1_p
. . N

moderate JJ N
to TO N
severe VB N
atopic NN 4_p
dermatitis NN 4_p
in IN N
the DT N
patient JJ N
population NN N
between IN N
two CD 1_p
to TO 1_p
seventeen VB 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
moderate JJ N
to TO N
severe VB 4_p
atopic NN 4_p
dermatitis NN 4_p
in IN N
patients NNS N
18 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
and CC 1_p
older JJR 1_p
. . N

-DOCSTART- -X- O O 19552904

clomiphene JJ 4_p
citrate-resistant JJ 4_p
women NNS 2_p
with IN N
polycystic JJ 4_p
ovary JJ 4_p
syndrome NN 4_p
. . 4_p

women NNS 2_p
with IN N
clomiphene JJ 4_p
citrate NN 4_p
( ( 4_p
CC NNP 4_p
) ) 4_p
-resistant VBP 4_p
polycystic JJ 4_p
ovary JJ 4_p
syndrome NN 4_p
( ( 4_p
PCOS NNP 4_p
) ) 4_p
. . N

Thirty-seven JJ 3_p
women NNS N
with IN N
CC-resistant JJ 4_p
PCOS NNP 4_p
were VBD 4_p
randomly RB 4_p
assigned VBN 4_p
women NNS 2_p
with IN N
CC-resistant JJ 4_p
PCOS NNP 4_p
. . N

-DOCSTART- -X- O O 4220015

chronic JJ 4_p
aggressive JJ 4_p
hepatitides NNS 4_p
] VBP N
-DOCSTART- -X- O O 6131800

chronic JJ 4_p
alcoholic JJ 4_p
patients NNS N
. . N

32 CD 3_p
randomly RB N
selected VBN N
hospitalized VBN N
male JJ 2_p
alcoholic JJ 4_p
patients NNS N
with IN N
clinical JJ N
, , N
biochemical JJ N
and CC N
histological JJ N
evidence NN N
of IN N
hepatic JJ 4_p
damage NN 4_p
. . N

ethanol-induced JJ 4_p
liver NN 4_p
damage NN 4_p
patients NNS N
with IN N
alcoholic JJ 4_p
liver NN 4_p
disease NN 4_p
( ( 4_p
ALD NNP 4_p
) ) 4_p
. . N

-DOCSTART- -X- O O 3886510

patients NNS 4_p
with IN 4_p
gonarthrosis NN 4_p
and CC 4_p
coxarthrosis NN 4_p
] NN N
-DOCSTART- -X- O O 16480401

More JJR 4_p
than IN 4_p
50 CD 4_p
% NN 4_p
of IN 4_p
patients NNS 4_p
with IN 4_p
Crohn NNP 4_p
's POS 4_p
disease NN 4_p
Patients NNPS N
with IN N
steroid-dependent JJ N
Crohn NNP N
's POS N
disease NN N
( ( N
n JJ N
= NNP N
271 CD N
) ) N
were VBD N
enrolled VBN N
Steroid JJ 4_p
dependence NN 4_p
was VBD 4_p
defined VBN 4_p
as IN 4_p
use NN 4_p
of IN 4_p
prednisolone NN 4_p
or CC 4_p
prednisone NN 4_p
( ( 4_p
15-40 JJ 4_p
mg/day NN 4_p
) ) 4_p
or CC 4_p
budesonide NN 4_p
( ( 4_p
9 CD 4_p
mg/day NN 4_p
) ) 4_p
for IN 4_p
> NN 4_p
or CC 4_p
=8 JJ 4_p
weeks NNS 4_p
, , 4_p
a DT 4_p
previous JJ 4_p
failed JJ 4_p
attempt NN 4_p
to TO 4_p
decrease VB 4_p
or CC 4_p
discontinue VB 4_p
steroids NNS 4_p
within IN 4_p
8 CD 4_p
weeks NNS 4_p
of IN 4_p
screening NN 4_p
, , 4_p
and CC 4_p
a DT 4_p
Crohn NNP 4_p
's POS 4_p
Disease NNP 4_p
Activity NNP 4_p
Index NNP 4_p
score NN 4_p
of IN 4_p
< NN 4_p
or CC 4_p
=150 JJ 4_p
points NNS 4_p
. . 4_p

patients NNS N
with IN N
steroid JJ N
sparing NN N
patients NNS 4_p
with IN 4_p
steroid-dependent JJ 4_p
Crohn NNP 4_p
's POS 4_p
disease NN 4_p
. . 4_p

-DOCSTART- -X- O O 161652

78 CD 3_p
randomized VBD N
patients NNS N
with IN N
either DT N
Björk-Shiley NNP N
( ( N
B-S NNP N
) ) N
or CC N
Lillehei-Kaster JJ N
( ( N
L-K NNP N
) ) N
aortic JJ N
disc NN N
valve NN N
prostheses NNS N
were VBD N
re-admitted JJ N
for IN N
clinical JJ N
and CC N
haemodynamic JJ N
evaluation NN N
The DT N
patients NNS N
were VBD N
selected VBN N
that IN N
those DT N
with IN N
narrow JJ N
aortic JJ N
roots NNS N
were VBD N
over-represented JJ N
in IN N
75 CD 3_p
patients NNS N
and CC N
left VBD N
ventricular JJ N
catheterisation NN N
via IN N
the DT N
transseptal JJ N
approach NN N
was VBD N
performed VBN N
in IN N
42 CD 3_p
-DOCSTART- -X- O O 18486741

patients NNS N
with IN N
malignant JJ N
pleural JJ N
mesothelioma NN N
( ( N
MS01 NNP N
) ) N
: : N
409 CD N
patients NNS N
with IN N
malignant JJ N
pleural JJ N
mesothelioma NN N
, , N
from IN N
76 CD N
centres NNS N
in IN N
the DT N
UK NNP N
and CC N
two CD N
in IN N
Australia NNP N
-DOCSTART- -X- O O 20332358

pediatric JJ 1_p
type NN 4_p
1 CD 4_p
diabetes NNS 4_p
. . 4_p

adolescents NNS 1_p
with IN N
type JJ 4_p
1 CD 4_p
diabetes NNS 4_p
. . N

Eight NNP 3_p
subjects NNS N
adolescents NNS 1_p
with IN N
type JJ N
1 CD N
diabetes NNS N
. . N

-DOCSTART- -X- O O 14710214

patients NNS N
with IN N
progressive JJ 4_p
hormone-escaped JJ 4_p
metastatic JJ 4_p
prostate NN 4_p
cancer NN 4_p
. . N

92 CD 3_p
patients NNS N
were VBD N
randomised VBN N
into IN N
a DT N
Phase NNP N
II NNP N
study NN N
-DOCSTART- -X- O O 19515873

non-ST JJ 4_p
elevation NN 4_p
acute NN 4_p
coronary JJ 4_p
syndromes NNS 4_p
. . 4_p

non-ST-segment JJ N
elevation NN N
acute NN N
coronary JJ N
syndromes NNS N
. . N

240 CD N
patients NNS N
with IN N
either DT N
unstable JJ N
angina NN N
or CC N
non-ST-elevation JJ N
myocardial JJ N
infarction NN N
in IN N
the DT N
previous JJ N
2 CD N
weeks NNS N
-DOCSTART- -X- O O 18235123

Children NNP 1_p
's POS 1_p
Oncology NNP N
Group NNP N
. . N

Six NNP 3_p
hundred VBD 3_p
sixty-two JJ 3_p
patients NNS N
with IN N
osteosarcoma NN 4_p
without IN N
clinically RB N
detectable JJ N
metastatic JJ N
disease NN N
and CC N
whose WP$ N
disease NN N
was VBD N
considered VBN N
resectable JJ N
received VBD N
one CD N
of IN N
four CD N
prospectively RB N
randomized JJ N
treatments NNS N
. . N

-DOCSTART- -X- O O 3895875

Four CD 3_p
hundred VBD 3_p
two CD 3_p
patients NNS N
with IN N
suspected JJ N
myocardial JJ 4_p
infarction NN 4_p
seen VBN N
within IN N
6 CD N
hours NNS N
of IN N
the DT N
onset NN N
of IN N
symptoms NNS N
204 CD 3_p
patients NNS N
with IN N
acute JJ N
myocardial JJ N
infarction NN N
four CD N
patients NNS N
-DOCSTART- -X- O O 787788

Navajo NNP 4_p
school NN 4_p
children NNS 4_p
. . 4_p

868 CD N
children NNS N
. . N

Children NNP N
receiving VBG N
vitamin NN N
C NNP N
vitamin NN N
group NN N
Children NNP N
with IN N
high JJ N
plasma NN N
ascorbic JJ N
acid JJ N
-DOCSTART- -X- O O 17051443

toddlers NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
. . N

young JJ N
children NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
. . N

toddlers NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
. . N

-DOCSTART- -X- O O 14578078

humans NNS N
on IN N
a DT N
modified JJ N
temporal JJ N
generalization NN N
task NN N
with IN N
1 CD 4_p
, , N
3 CD 4_p
, , N
or CC N
5 CD 4_p
presentations NNS N
of IN N
the DT N
standard JJ N
duration NN N
. . N

-DOCSTART- -X- O O 17613280

mild JJ 4_p
acute JJ 4_p
pancreatitis NN 4_p
. . 4_p

Patients NNPS N
recovering VBG N
from IN N
mild JJ 4_p
acute JJ 4_p
pancreatitis NN 4_p
Patients NNS N
with IN N
mild JJ 4_p
pancreatitis NNS 4_p
121 CD 3_p
patients NNS N
: : N
66 CD N
to TO N
CLD NNP N
and CC N
55 CD N
to TO N
LFSD NNP N
. . N

-DOCSTART- -X- O O 23524942

locally RB 4_p
advanced JJ 4_p
squamous JJ 4_p
cell NN 4_p
head NN 4_p
and CC 4_p
neck NN 4_p
cancer NN 4_p
. . N

locally RB N
advanced JJ N
squamous JJ N
cell NN N
carcinoma NN 4_p
of IN N
the DT N
head NN N
and CC N
neck NN N
. . N

One CD 3_p
hundred CD 3_p
and CC 3_p
fifty-three JJ 3_p
patients NNS N
( ( N
all DT N
of IN N
whom WP N
had VBD N
stage NN N
III NNP N
or CC N
IV NNP N
unresectable JJ 4_p
disease NN 4_p
with IN N
no DT N
distant JJ N
metastases NNS N
and CC N
who WP N
had VBD N
received VBN N
two CD N
cycles NNS N
of IN N
taxol NN N
and CC N
cisplatin NN N
chemotherapy NN N
) ) N
patients NNS N
with IN N
locally RB 4_p
advanced VBN 4_p
head NN 4_p
and CC 4_p
neck NN 4_p
cancer NN 4_p
. . N

-DOCSTART- -X- O O 23578015

attention-deficit/hyperactivity NN 4_p
disorder NN 4_p
symptoms NNS 4_p
in IN N
children NNS 1_p
and CC N
adolescents NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
: : N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
88 CD 3_p
patients NNS 3_p
6-17 JJ 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
, , N
with IN N
ADHD NNP 4_p
and CC N
ASD NNP 4_p
children NNS 1_p
and CC N
adolescents NNS 1_p
with IN N
ASD NNP 4_p
children NNS 1_p
and CC N
adolescents NNS 1_p
with IN N
ASD NNP 4_p
-DOCSTART- -X- O O 1536276

seven CD 3_p
subjects NNS 4_p
with IN 4_p
autistic JJ 4_p
disorder NN 4_p
Seven NNP 3_p
subjects NNS N
, , N
ages VBZ 1_p
6-18 CD 1_p
years NNS 1_p
, , N
with IN N
autistic JJ 4_p
disorder NN 4_p
seven CD 3_p
subjects NNS N
-DOCSTART- -X- O O 14669937

Nine NNP 4_p
trained JJ 4_p
cyclists NNS 4_p
-DOCSTART- -X- O O 23955236

piglets NNS 4_p
porcine NN N
embryos NN N
the DT N
embryos NN N
Experiment JJ N
2 CD N
, , N
64 CD N
vitrified VBD N
embryos NN N
Similarly RB N
, , N
66 CD N
vitrified VBD N
embryos NN N
that IN N
porcine NN N
expanded VBN N
blastocysts NNS N
-DOCSTART- -X- O O 12791549

exposure NN N
prevention NN N
intervention NN 4_p
on IN 4_p
hazardous JJ 4_p
substance NN 4_p
exposures NNS 4_p
in IN 4_p
manufacturing VBG 4_p
work NN 4_p
sites NNS 4_p
an DT N
industrial JJ N
hygienist NN N
walk-through JJ N
inspection NN N
( ( N
N NNP N
= NNP N
131 CD N
manufacturing NN N
processes/areas NNS N
in IN N
17 CD N
large JJ N
work NN N
sites NNS N
) ) N
. . N

A DT N
second JJ N
hygienist NN N
-DOCSTART- -X- O O 7593098

osteonecrosis NN 4_p
of IN 4_p
the DT 4_p
femoral JJ 4_p
head NN 4_p
. . 4_p

37 CD 4_p
hips NNS 4_p
with IN 4_p
early-stage JJ 4_p
osteonecrosis NN 4_p
( ( 4_p
ON NNP 4_p
) ) 4_p
in IN 4_p
33 CD 4_p
patients NNS 4_p
were VBD 4_p
randomly RB 4_p
assigned VBN 4_p
early-stage NN N
ON NNP N
of IN N
the DT N
femoral JJ N
head NN N
. . N

-DOCSTART- -X- O O 22414202

children NNS N
with IN N
cerebral JJ N
palsy NN N
: : N
children NNS N
with IN N
cerebral JJ N
palsy NN N
( ( N
CP NNP N
) ) N
, , N
aged VBD N
7 CD N
to TO N
13 CD N
years NNS N
METHOD NNP N
Sixty-two JJ N
children NNS N
with IN N
spastic JJ N
CP NNP N
( ( N
39 CD N
males NNS N
, , N
23 CD N
females NNS N
; : N
mean JJ N
age NN N
10y CD N
1mo CD N
, , N
SD NNP N
1y CD N
8mo CD N
; : N
age NN N
range NN N
7-13y NNP N
) ) N
, , N
classified VBD N
as IN N
Gross NNP N
Motor NNP N
Function NNP N
Classification NNP N
System NNP N
( ( N
GMFCS NNP N
) ) N
levels NNS N
I PRP N
to TO N
III NNP N
for IN N
children NNS N
with IN N
bilateral JJ N
spastic JJ N
-DOCSTART- -X- O O 10992833

tracheal JJ 4_p
intubating NN 4_p
conditions NNS 4_p
60 CD 3_p
patients NNS 4_p
-DOCSTART- -X- O O 12176916

chronic JJ 4_p
myeloid NN 4_p
leukemia NN 4_p
blast NN 4_p
phase NN 4_p
. . N

Seventy-three JJ 3_p
eligible JJ N
patients NNS N
-DOCSTART- -X- O O 8980774

patients NNS N
with IN N
human JJ 4_p
immunodeficiency NN 4_p
virus NN 4_p
infection NN 4_p
. . N

human JJ 4_p
immunodeficiency NN 4_p
virus NN 4_p
type NN 4_p
1 CD 4_p
( ( 4_p
HIV-1 NNP 4_p
) ) 4_p
12 CD 4_p
HIV-infected JJ N
patients NNS N
( ( N
mean JJ N
[ NNP N
+/- JJ N
standard NN N
deviation NN N
] NNP N
CD4+ NNP N
cell NN N
count NN N
, , N
304 CD N
+/- JJ N
213/mm3 CD N
) ) N
were VBD N
enrolled VBN N
-DOCSTART- -X- O O 17010794

primary JJ 4_p
coronary JJ 4_p
intervention NN 4_p
: : 4_p
Fifty NNP 3_p
consecutive JJ N
patients NNS N
entered VBD N
the DT N
myocardial JJ N
contrast NN N
echocardiography NN N
( ( N
MCE NNP N
) ) N
substudy NN N
of IN N
the DT N
REMEDIA NNP N
( ( N
Randomized NNP N
Evaluation NNP N
of IN N
the DT N
Effect NNP N
of IN N
Mechanical NNP N
Reduction NNP N
of IN N
Distal NNP N
Embolization NNP N
by IN N
Thrombus NNP N
Aspiration NNP N
in IN N
Primary NNP N
and CC N
Rescue NNP N
Angioplasty NNP N
) ) N
trial NN N
total NN N
of IN N
25 CD 3_p
patients NNS N
were VBD N
randomized VBN N
to TO N
be VB N
pretreated VBN N
with IN N
thrombus JJ N
aspiration NN N
before IN N
PCI NNP N
of IN N
the DT N
culprit NN N
lesion NN N
and CC N
25 CD 3_p
received JJ N
standard JJ N
PCI NNP N
. . N

-DOCSTART- -X- O O 16784930

acutely RB N
decompensated VBN N
chronic JJ N
heart NN N
failure NN N
. . N

patients NNS N
with IN N
decompensated JJ N
heart NN N
failure NN N
( ( N
HF NNP N
) ) N
, , N
but CC N
without IN N
survival JJ N
benefits NNS N
. . N

Sixty-nine JJ N
patients NNS N
were VBD N
randomized VBN N
decompensated JJ N
HF NNP N
-DOCSTART- -X- O O 2468745

previously RB 4_p
treated VBN 4_p
patients NNS 4_p
with IN 4_p
metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
. . 4_p

Three CD N
hundred VBD N
twenty-five JJ N
women NNS N
with IN N
metastatic JJ N
adenocarcinoma NN N
of IN N
the DT N
breast NN N
who WP N
had VBD N
failed VBN N
one CD N
prior JJ N
chemotherapeutic JJ N
regimen NNS N
for IN N
advanced JJ N
disease NN N
-DOCSTART- -X- O O 21098003

cerebral JJ N
metabolic JJ N
ratio NN N
during IN N
maximal JJ N
whole JJ N
body NN N
exercise NN N
. . N

six CD N
male JJ N
oarsmen NNS N
( ( N
23±2 CD N
years NNS N
; : N
mean±S.D. NN N
) ) N
-DOCSTART- -X- O O 12918532

prevention NN 4_p
of IN 4_p
eclampsia NN 4_p
. . N

-DOCSTART- -X- O O 19708471

sensory JJ N
and CC N
self-regulation JJ N
problems NNS N
in IN N
young JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
: : N
46 CD 3_p
children NNS 1_p
with IN N
autism NN 4_p
< NNP N
age NN 1_p
6 CD 1_p
. . N

-DOCSTART- -X- O O 17074147

elderly JJ 1_p
hypertension NN 4_p
] NNP N
senile JJ 4_p
hypertension NN 4_p
. . N

138 CD 3_p
cases NNS N
of IN N
senile JJ 4_p
hypertension NN 4_p
complicating VBG N
with IN N
depression NN 4_p
were VBD N
studied VBN N
. . N

103 CD 3_p
senile JJ 4_p
hypertensive JJ 4_p
patients NNS 4_p
without IN 4_p
depression NN 4_p
in IN N
the DT N
same JJ N
period NN N
served VBD N
as IN N
controls NNS N
. . N

senile JJ 4_p
hypertensive JJ 4_p
patients NNS 4_p
-DOCSTART- -X- O O 11549539

ozone-induced JJ 4_p
lung NN 4_p
injury NN 4_p
in IN 4_p
human JJ 4_p
subjects NNS 4_p
. . 4_p

31 CD 3_p
healthy JJ N
nonsmoking VBG N
adults NNS N
( ( N
18 CD N
to TO N
35 CD N
yr NNS N
old JJ N
) ) N
-DOCSTART- -X- O O 9657576

COPD NNP 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
stable JJ 4_p
and CC 4_p
partially RB 4_p
reversible JJ 4_p
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
( ( 4_p
COPD NNP 4_p
) ) 4_p
. . 4_p

Sixteen JJ N
outpatients NNS N
with IN N
partially RB 4_p
reversible JJ 4_p
, , N
stable JJ 4_p
COPD NNP 4_p
patients NNS N
suffering VBG N
from IN N
partially RB N
reversible JJ N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
. . N

-DOCSTART- -X- O O 11199239

postgraduate NN N
cancer NN 4_p
pain NN N
education NN N
cancer NN 4_p
pain NN N
education NN N
program NN N
for IN N
nurses NNS N
of IN N
patients NNS N
from IN N
11 CD 4_p
different JJ 4_p
ethnic JJ 4_p
groups NNS 4_p
. . N

Four CD 3_p
hundred VBD 3_p
ninety NN 3_p
six CD 3_p
home NN N
, , N
hospital NN N
, , N
and CC N
hospice NN N
nurses NNS N
participated VBD N
in IN N
a DT N
one-day JJ N
workshop NN N
or CC N
two CD N
half-day JJ N
workshops NNS N
on IN N
cancer NN 4_p
pain NN 4_p
assessment NN 4_p
and CC 4_p
management NN 4_p
. . N

oncology NN N
nurse JJ N
Eighty-six JJ 3_p
nurses NNS N
served VBD N
as IN N
controls NNS N
. . N

postgraduate NN N
nurses NNS N
-DOCSTART- -X- O O 18590393

pediatric JJ N
moyamoya NN 4_p
disease NN 4_p
. . N

pediatric JJ 1_p
patients NNS N
undergoing JJ N
encephaloduroarteriomyosynangiosis NN N
( ( N
EDAMS NNP N
) ) N
operations NNS N
for IN N
the DT N
treatment NN N
of IN N
moyamoya JJ 4_p
disease NN 4_p
. . N

Pediatric NNP 1_p
patients NNS N
( ( N
age NN 1_p
3-13 CD 1_p
years NNS 1_p
) ) N
undergoing VBG N
EDAMS NNP 4_p
surgery NN 4_p
for IN N
moyamoya JJ 4_p
disease NN 4_p
were VBD N
randomly RB N
divided VBN N
into IN N
a DT N
nerve NN N
block NN N
( ( N
NB NNP N
) ) N
group NN N
( ( N
18 CD 3_p
cases NNS N
) ) N
or CC N
control VB N
group NN N
( ( N
21 CD 3_p
cases NNS N
) ) N
-DOCSTART- -X- O O 10757579

caudal NN 4_p
blockade NN 4_p
in IN N
children NNS 1_p
. . N

caudal JJ N
administration NN N
in IN N
children NNS N
. . N

40 CD 3_p
ASA NNP N
1 CD N
paediatric JJ 1_p
patients NNS 1_p
undergoing VBG N
subumbilical JJ 4_p
surgery NN 4_p
-DOCSTART- -X- O O 7211918

venous JJ N
thromboembolism NN N
. . N

Patients NNS N
with IN N
pulmonary JJ N
embolism NN N
or CC N
deep JJ N
venous JJ N
thrombosis NN N
patients NNS N
with IN N
an DT N
enhanced JJ N
risk NN N
of IN N
bleeding NN N
patients NNS N
without IN N
these DT N
risk NN N
factors NNS N
patients NNS N
receiving VBG N
continuous JJ N
heparin NN N
therapy NN N
. . N

patients NNS N
without IN N
risk NN N
factors NNS N
for IN N
bleeding NN N
patients NNS N
with IN N
a DT N
high JJ N
risk NN N
of IN N
bleeding NN N
-DOCSTART- -X- O O 20594308

patients NNS 4_p
with IN 4_p
generalized JJ 4_p
osteoarthritis NN 4_p
: : 4_p
patients NNS N
with IN N
generalized JJ N
osteoarthritis NN N
( ( N
GOA NNP N
) ) N
. . N

patients NNS N
with IN N
GOA NNP N
. . N

we PRP N
aim VBP N
to TO N
include VB N
170 CD N
patients NNS N
with IN N
GOA NNP N
. . N

patients NNS N
with IN N
GOA NNP N
. . N

-DOCSTART- -X- O O 8681312

patients NNS N
with IN N
amyotrophic JJ 4_p
lateral JJ 4_p
sclerosis NN 4_p
. . N

Fifty-seven CD 3_p
patients NNS N
with IN N
amyotrophic JJ 4_p
lateral JJ 4_p
sclerosis NN 4_p
( ( 4_p
ALS NNP 4_p
) ) 4_p
patients NNS N
with IN N
ALS NNP 4_p
-DOCSTART- -X- O O 1905592

symptomatic JJ N
and CC N
asymptomatic JJ N
episodes NNS N
of IN N
ST NNP 4_p
segment NN 4_p
depression NN 4_p
occurring VBG N
during IN N
daily JJ N
life NN N
and CC N
during IN N
exercise NN N
. . N

patients NNS N
with IN N
coronary JJ 4_p
disease NN 4_p
; : N
Sixty NNP 3_p
patients NNS N
with IN N
stable JJ 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
, , N
a DT N
positive JJ 4_p
treadmill NN 4_p
exercise NN 4_p
test NN 4_p
and CC N
asymptomatic JJ 4_p
ST NNP 4_p
segment NN 4_p
depression NN 4_p
on IN N
ambulatory JJ N
electrocardiographic JJ N
recording VBG N
were VBD N
assessed VBN N
in IN N
a DT N
multicenter NN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
cross-over JJ N
trial NN N
. . N

patients NNS N
with IN N
stable JJ N
coronary JJ N
artery NN N
disease NN N
. . N

-DOCSTART- -X- O O 18676757

patients NNS N
with IN N
metastatic JJ 4_p
colorectal JJ 4_p
cancer NN 4_p
. . N

patients NNS N
with IN N
metastatic JJ N
colorectal JJ N
cancer NN N
. . N

Patients NNPS N
with IN N
metastatic JJ N
colorectal JJ N
cancer NN N
patients NNS N
without IN N
disease JJ N
progression NN N
One CD 3_p
hundred VBD 3_p
eighteen JJ 3_p
patients NNS N
patients NNS N
with IN N
metastatic JJ N
colorectal JJ N
cancer NN N
. . N

-DOCSTART- -X- O O 16038713

healthy JJ 4_p
volunteers NNS N
. . N

23 CD 3_p
healthy JJ 4_p
male NN 2_p
volunteers NNS N
-DOCSTART- -X- O O 22659656

patients NNS N
with IN N
primary JJ N
hypertension NN N
] NN N
patients NNS 4_p
with IN 4_p
primary JJ 4_p
hypertension NN 4_p
. . 4_p

40 CD N
patients NNS N
with IN N
hypertension NN N
. . N

An DT N
additional JJ N
twenty NN N
healthy JJ N
people NNS N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
( ( N
normal JJ N
group NN N
) ) N
. . N

hypertension NN N
patient NN N
hypertension NN 4_p
patients NNS 4_p
-DOCSTART- -X- O O 23000125

children NNS N
vaccinated VBN N
with IN N
live JJ N
attenuated VBN N
influenza JJ N
vaccine NN N
. . N

children NNS N
vaccinated VBN N
with IN N
live JJ N
attenuated VBN N
influenza JJ N
vaccine NN N
( ( N
LAIV NNP N
) ) N
children NNS N
6-36 JJ N
months NNS N
of IN N
age NN N
. . N

-DOCSTART- -X- O O 20155309

children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Children NNP 1_p
with IN 1_p
autism NN 1_p
young JJ N
children NNS N
with IN N
autism NN N
21 CD N
young JJ N
children NNS N
with IN N
autism NN N
. . N

-DOCSTART- -X- O O 22134468

high JJ 4_p
risk NN 4_p
hypertensive JJ 4_p
subjects NNS N
with IN N
incidental JJ 4_p
and CC 4_p
unilateral JJ 4_p
renal JJ 4_p
artery NN 4_p
stenosis NN 4_p
percutaneous JJ 4_p
revascularization NN 4_p
high-risk JJ 4_p
hypertensive JJ 4_p
subjects NNS N
( ( N
HTs NNP N
) ) N
with IN N
incidental JJ 4_p
unilateral JJ 4_p
renal JJ 4_p
artery NN 4_p
stenosis NN 4_p
( ( 4_p
RAS NNP 4_p
) ) 4_p
Eighteen NNP N
HTs NNP N
aged VBD N
65.7 CD N
± JJ N
9.2 CD N
years NNS N
with IN N
angiographically RB N
diagnosed VBN N
unilateral JJ N
RAS NNP N
( ( N
≥ VB N
60 CD N
% NN N
) ) N
in IN N
all DT N
HTs NNP N
with IN N
unilateral JJ N
and CC N
incidental JJ N
-DOCSTART- -X- O O 18485420

autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
: : 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
. . 4_p

high-functioning JJ N
participants NNS N
with IN N
ASD NNP N
( ( N
N=15 NNP 3_p
) ) N
and CC N
an DT N
age- JJ N
and CC 1_p
IQ-matched JJ N
control NN N
group NN N
( ( N
N=18 NNP 3_p
) ) N
ASD NNP 4_p
. . 4_p

ASD NNP 4_p
-DOCSTART- -X- O O 15857741

women NNS N
with IN N
breast NN 4_p
cancer NN 4_p
. . N

96 CD 3_p
women NNS 2_p
with IN N
breast NN 4_p
cancer NN 4_p
who WP N
experienced VBD N
nausea NN 4_p
at IN 4_p
their PRP$ 4_p
first JJ 4_p
chemotherapy NN 4_p
treatment NN 4_p
. . N

female JJ 2_p
breast NN 4_p
cancer NN 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 10402369

poor JJ N
responder NN N
patients NNS N
. . N

poor JJ N
responder NN N
women NNS N
. . N

34 CD N
patients NNS N
undergoing JJ N
assisted JJ N
reproduction NN N
34 CD N
patients NNS N
poor JJ N
responder NN N
patients NNS N
-DOCSTART- -X- O O 20694273

stroke NN N
prevention NN N
in IN N
patients NNS N
with IN N
atrial JJ N
fibrillation NN N
. . N

patients NNS N
with IN N
non-valvular JJ N
atrial JJ N
fibrillation NN N
( ( N
AF NNP N
) ) N
. . N

multicentre NN N
, , N
multinational JJ N
study NN N
, , N
1,146 CD N
patients NNS N
with IN N
AF NNP N
and CC N
risk NN N
of IN N
stroke NN N
Mean NNP N
age NN N
was VBD N
65 CD N
+/- JJ N
8.7 CD N
years NNS N
and CC N
64.4 CD N
% NN N
were VBD N
warfarin-naïve JJ N
-DOCSTART- -X- O O 24261547

young JJ 1_p
children NNS 1_p
with IN N
severe JJ 4_p
autism NN 4_p
spectrum JJ 4_p
disorder NN 4_p
: : N
Twenty-three JJ 3_p
children NNS N
( ( 1_p
36-60 JJ 1_p
months NNS 1_p
) ) 1_p
with IN N
severe JJ 4_p
ASD NNP 4_p
received VBD N
either RB N
16 CD N
weeks NNS N
of IN N
FCMT NNP N
in IN N
addition NN N
to TO N
their PRP$ N
early JJ N
intervention NN N
programmes NNS N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
, , N
or CC N
their PRP$ N
early JJ N
intervention NN N
programme IN N
only RB N
( ( N
n JJ N
= NNP N
11 CD N
) ) N
. . N

children NNS 1_p
with IN N
severe JJ 4_p
ASD NNP 4_p
. . N

-DOCSTART- -X- O O 21935685

fentanyl-induced JJ N
cough NN N
during IN N
general JJ N
anesthesia JJ N
induction NN N
: : N
total NN N
of IN N
120 CD N
patients NNS N
, , N
American NNP N
Society NNP N
of IN N
Anesthesiologists NNP N
( ( N
ASA NNP N
) ) N
physical JJ N
status NN N
I-II NNP N
, , N
were VBD N
randomized VBN N
into IN N
two CD N
equally RB N
sized JJ N
groups NNS N
( ( N
n JJ N
= NNP N
60 CD N
) ) N
. . N

RESULTS NNP N
No NNP N
patient NN N
in IN N
the DT N
dezocine NN N
group NN N
and CC N
42 CD N
patients NNS N
in IN N
the DT N
control NN N
group NN N
suppressing VBG N
fentanyl-induced JJ N
cough NN N
in IN N
our PRP$ N
patients NNS N
-DOCSTART- -X- O O 8549538

feeding VBG 4_p
behaviour NN 4_p
. . 4_p

-DOCSTART- -X- O O 9499947

One CD 3_p
hundred VBD 3_p
consecutive JJ N
patients NNS N
with IN N
symptomatic JJ 4_p
gallstones NNS 4_p
without IN N
complications NNS N
were VBD N
randomized VBN N
into IN N
groups NNS N
; : N
group NN N
T NNP N
group NN N
R NNP N
The DT N
patients NNS N
-DOCSTART- -X- O O 18467912

gastric JJ 4_p
ulcer JJ 4_p
patients NNS N
. . N

401 CD 3_p
H. NNP 4_p
pylori-positive JJ 4_p
patients NNS 4_p
with IN 4_p
more JJR 4_p
than IN 4_p
or CC 4_p
equal JJ 4_p
to TO 4_p
two CD 4_p
GUs NNP 4_p
Patients NNS N
with IN N
unhealed JJ N
GUs NNP N
at IN N
4 CD N
weeks NNS N
Healed VBN N
patients NNS N
-DOCSTART- -X- O O 20185596

polycystic JJ 4_p
liver NN 4_p
volume NN 4_p
in IN 4_p
ADPKD NNP 4_p
: : 4_p
autosomal-dominant JJ N
polycystic JJ N
kidney NN N
disease NN N
( ( N
ADPKD NNP N
) ) N
. . N

12 CD N
patients NNS N
with IN N
ADPKD NNP N
. . N

-DOCSTART- -X- O O 447787

incorporating VBG N
patients NNS 4_p
from IN N
non-randomising JJ N
centres NNS N
into IN N
a DT N
randomised JJ N
clinical JJ N
trial NN N
. . N

-DOCSTART- -X- O O 17934527

patients NNS 4_p
after IN 4_p
hematopoietic JJ 4_p
stem NN 4_p
cell NN 4_p
transplantation NN 4_p
. . N

One CD 3_p
hundred VBD 3_p
fifty-seven JJ 3_p
patients NNS 3_p
were VBD N
screened VBN N
for IN N
cognitive JJ 4_p
deficits NNS 4_p
following VBG 4_p
HSCT NNP 4_p
for IN 4_p
malignant JJ 4_p
diseases NNS 4_p
at IN N
an DT N
in-patient JJ N
oncologic NN N
rehabilitation NN N
clinic NN N
. . N

Patients NNS N
showing VBG N
evidence NN N
of IN N
impairment NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
training VBG N
groups NNS N
: : N
individualized VBN N
PC-supported JJ N
training NN N
or CC N
neuropsychological JJ N
group NN N
therapy NN N
. . N

The DT N
control NN N
group NN N
consisted VBD N
of IN N
patients NNS N
who WP N
received VBD N
no DT N
specific JJ N
training NN N
. . N

-DOCSTART- -X- O O 20020319

for IN N
children NNS 1_p
with IN N
autism NN 4_p
and CC N
their PRP$ N
parents NNS N
Seventeen JJ 3_p
children NNS N
were VBD N
randomized VBN N
into IN N
the DT N
Intervention NNP N
( ( N
n JJ N
= NNP N
9 CD 3_p
) ) N
and CC N
Control NNP N
( ( N
n JJ N
= NNP N
8 CD 3_p
) ) N
groups NNS N
. . N

Children NNP N
with IN N
autism NN N
-DOCSTART- -X- O O 7893582

human JJ N
forearm NN N
. . N

human JJ N
forearm NN N
. . N

Subjects VBZ N
human JJ N
forearm NN N
of IN N
healthy JJ 4_p
salt NN 4_p
replete JJ 4_p
subjects NNS N
. . N

-DOCSTART- -X- O O 19365397

acute JJ 4_p
spinal JJ 4_p
cord NN 4_p
injury NN 4_p
. . 4_p

acute JJ N
spinal JJ N
cord NN N
injury NN N
( ( N
SCI NNP N
) ) N
patients NNS 4_p
with IN 4_p
and CC 4_p
without IN 4_p
therapeutic JJ 4_p
prophylaxis NN 4_p
. . N

Patients NNPS 4_p
admitted VBN 4_p
in IN 4_p
the DT 4_p
department NN 4_p
of IN 4_p
Physical NNP 4_p
Medicine NNP 4_p
& CC 4_p
Rehabilitation NNP 4_p
, , 4_p
SMS NNP 4_p
Medical NNP 4_p
College NNP 4_p
, , 4_p
Jaipur NNP 4_p
, , 4_p
India NNP 4_p
. . N

All DT N
297 CD 3_p
patients NNS N
received VBD 4_p
physical JJ 4_p
therapy NN 4_p
measures NNS 4_p
-DOCSTART- -X- O O 7557852

patients NNS N
with IN N
chronic JJ 4_p
active JJ 4_p
hepatitis NN 4_p
C. NNP 4_p
85 CD 3_p
patients NNS N
with IN N
chronic JJ 4_p
active JJ 4_p
hepatitis NN 4_p
C NNP 4_p
55 CD 3_p
patients NNS N
who WP N
responded VBD N
to TO N
interferon VB N
by IN N
normalization NN N
of IN N
alanine JJ N
transaminase NN N
( ( N
ALT NNP N
) ) N
, , N
median JJ N
APC NNP N
before IN N
treatment NN N
was VBD N
0.47 CD N
( ( N
range NN N
, , N
0.12 CD N
to TO N
0.98 CD N
; : N
normal JJ N
range NN N
, , N
0.34 CD N
to TO N
1.02 CD N
mL/min/kg NNS N
body NN N
wt NN N
) ) N
, , N
a DT N
value NN N
that WDT N
was VBD N
significantly RB N
greater JJR N
than IN N
in IN N
30 CD N
nonresponders NNS N
( ( N
0.23 CD N
; : N
0.08 CD N
to TO N
0.67 CD N
mL/min/kg NNS N
body NN N
wt NN N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
A DT N
second JJ N
, , N
independent JJ N
group NN N
of IN N
43 CD 3_p
patients NNS N
-DOCSTART- -X- O O 8881340

4 CD N
clients NNS N
. . N

2 CD N
clients NNS N
clients NNS N
with IN N
severe JJ N
to TO N
profound VB N
disabilities NNS N
. . N

-DOCSTART- -X- O O 25044819

family NN N
caregivers NNS N
of IN N
home NN N
based VBN N
palliative JJ 4_p
care NN 4_p
patients NNS 4_p
: : N
family NN N
caregivers NNS N
caregivers NNS N
of IN N
patients NNS N
with IN N
advanced JJ N
cancer NN 4_p
receiving VBG 4_p
home-based JJ 4_p
palliative JJ 4_p
care NN 4_p
. . N

caregivers NNS N
four CD N
sites NNS N
in IN N
Australia NNP N
. . N

Recruitment NNP N
to TO N
the DT N
one CD N
visit NN N
condition NN N
was VBD N
57 CD 3_p
, , N
the DT N
two CD N
visit NN N
condition NN N
93 CD 3_p
, , N
and CC N
the DT N
control NN 4_p
148 CD N
. . N

family NN N
caregivers NNS N
who WP N
are VBP N
supporting VBG N
a DT N
dying VBG N
relative NN N
. . N

-DOCSTART- -X- O O 15490072

growth NN 4_p
hormone-deficient JJ 4_p
adults NNS 1_p
] FW N
. . N

patients NNS N
with IN N
growth NN 4_p
hormone NN 4_p
deficiency NN 4_p
( ( 4_p
GHD NNP 4_p
) ) 4_p
. . N

patients NNS N
with IN N
GHD NNP 4_p
. . N

20 CD 3_p
adult NN 1_p
patients NNS N
with IN N
GHD NNP 4_p
( ( N
eleven JJ 3_p
male NN N
, , N
nine CD 3_p
female NN N
, , N
mean JJ N
age NN N
42.5 CD 1_p
years NNS 1_p
) ) 1_p
were VBD N
included VBN N
in IN N
the DT N
study NN N
-DOCSTART- -X- O O 23160656

healthy JJ N
men NNS 4_p
and CC N
women NNS 4_p
. . N

Sixteen NNP N
healthy JJ N
volunteers NNS N
( ( N
10 CD N
men NNS N
, , N
age NN N
43 CD N
± JJ N
19 CD N
years NNS N
; : N
mean VB N
± NNP N
SD NNP N
) ) N
-DOCSTART- -X- O O 8832772

autistic JJ 4_p
children NNS 4_p
. . 4_p

autistic JJ N
children NNS N
. . N

-DOCSTART- -X- O O 24612915

adult NN 1_p
patients NNS N
undergoing VBG N
laparoscopic JJ 4_p
cholecystectomy NN 4_p
. . N

Sixty-six JJ 3_p
patients NNS N
were VBD N
enrolled VBN N
. . N

Sixty JJ 3_p
patients NNS 3_p
completed VBD N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 25474530

1,800 CD 3_p
South NNP 3_p
Asians NNPS 3_p
. . N

1,799 CD 3_p
Bangladeshi NNP 3_p
individuals NNS 3_p
434 CD N
independent JJ N
trans-eQTL JJ N
associations NNS N
189 CD N
trans-eQTL NN N
associations NNS N
, , N
39 CD 3_p
were VBD N
significantly RB N
attenuated VBN N
-DOCSTART- -X- O O 19201326

Eighty NNP 3_p
freshly RB 3_p
extracted VBD 3_p
maxillary JJ 3_p
premolars NNS 3_p
were VBD N
randomly RB N
divided VBN N
into IN N
4 CD N
groups NNS N
( ( N
20 CD N
in IN N
each DT N
group NN N
) ) N
. . N

teeth NNS N
-DOCSTART- -X- O O 15769918

severe JJ N
neurological JJ N
manifestations NNS N
in IN N
systemic JJ N
lupus NN N
erythematosus NN N
. . N

Severe NNP N
neurological JJ N
involvement NN N
in IN N
systemic JJ N
lupus NN N
erythematosus NN N
( ( N
NPSLE NNP N
) ) N
two CD N
tertiary JJ N
care NN N
centres NNS N
of IN N
patients NNS N
with IN N
SLE NNP N
according VBG N
to TO N
the DT N
ACR NNP N
criteria NNS N
, , N
with IN N
incident NN N
( ( N
no DT N
more JJR N
than IN N
15 CD N
days NNS N
) ) N
onset NN N
of IN N
severe JJ N
NP NNP N
manifestations NNS N
such JJ N
as IN N
seizures NNS N
, , N
optic JJ N
neuritis NN N
, , N
peripheral JJ N
or CC N
cranial JJ N
neuropathy NN N
, , N
coma NN N
, , N
brainstem NN N
disease NN N
, , N
or CC N
transverse JJ N
myelitis NN N
. . N

32 CD N
patients NNS N
studied VBN N
-DOCSTART- -X- O O 16393740

HIV NNP N
risk NN N
reduction NN N
among IN N
women NNS N
. . N

333 CD N
seronegative JJ N
African JJ N
American JJ N
female JJ N
drug NN N
users NNS N
( ( N
aged VBN N
18-59 CD N
years NNS N
) ) N
participating VBG N
in IN N
an DT N
HIV NNP N
intervention NN N
and CC N
with IN N
higher JJR N
levels NNS N
of IN N
emotional JJ N
distress NN N
, , N
specifically RB N
symptoms NNS N
of IN N
depression NN N
and CC N
anxiety NN N
Participants NNS N
recruited VBN N
between IN N
June NNP N
1998 CD N
and CC N
January NNP N
2001 CD N
from IN N
inner-city NN N
Atlanta NNP N
( ( N
Georgia NNP N
, , N
U.S. NNP N
) ) N
neighborhoods NNS N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
enhanced JJ N
gender-specific JJ N
and CC N
culturally RB N
specific JJ N
HIV NNP N
intervention NN N
conditions NNS N
high-risk JJ N
women NNS N
who WP N
may MD N
be VB N
most RBS N
resistant JJ N
to TO N
behavioral JJ N
change NN N
. . N

-DOCSTART- -X- O O 1860302

Twelve NNP 1_p
healthy JJ 1_p
males NNS 1_p
with IN 1_p
a DT 1_p
mean JJ 1_p
age NN 1_p
of IN 1_p
35 CD 1_p
years NNS 1_p
-DOCSTART- -X- O O 24156287

blood NN 4_p
pressure NN 4_p
taking VBG 4_p
randomized VBD N
162 CD 3_p
first-year JJ 1_p
medical JJ 1_p
students NNS 1_p
into IN N
four CD N
groups NNS N
that WDT N
received VBD N
different JJ N
lead-in JJ N
statements NNS N
before IN N
measuring VBG 4_p
blood NN 4_p
pressure NN 4_p
on IN N
a DT N
manikin JJ N
simulator NN N
. . N

Student NNP 1_p
-DOCSTART- -X- O O 24231646

Humoral NNP 4_p
immunity NN 4_p
after IN 4_p
kidney NN 4_p
transplantation NN 4_p
: : 4_p
307 CD N
kidney NN N
transplant NN N
recipients NNS N
included VBD N
in IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
comparing VBG N
tacrolimus/mycophenolate NN N
mofetil NN N
( ( N
Tac/MMF NNP N
) ) N
vs. FW N
cyclosporine/azathioprine NN N
( ( N
CsA/AZA NNP N
) ) N
-DOCSTART- -X- O O 18717189

Seventeen NNP 3_p
healthy JJ 3_p
volunteers NNS 3_p
were VBD N
included VBN N
in IN N
this DT N
crossover NN N
trial NN N
. . N

-DOCSTART- -X- O O 26467901

progressive JJ 4_p
Multiple JJ 4_p
Sclerosis NNP 4_p
patients NNS 4_p
with IN 4_p
progressive JJ 4_p
multiple JJ 4_p
sclerosis NN 4_p
( ( 4_p
MS NNP 4_p
) ) 4_p
. . 4_p

a DT N
single JJ N
centre NN N
( ( N
Bristol NNP N
, , N
UK NNP N
) ) N
. . N

Eighty JJ 3_p
patients NNS 3_p
with IN N
progressive JJ N
MS NNP N
will MD N
be VB N
recruited VBN N
; : N
60 CD 3_p
will MD N
have VB N
secondary JJ 4_p
progressive JJ 4_p
disease NN 4_p
( ( 4_p
SPMS NNP 4_p
) ) 4_p
but CC N
a DT N
subset NN N
( ( N
n JJ 3_p
= NNP 3_p
20 CD 3_p
) ) N
will MD N
have VB N
primary JJ 4_p
progressive JJ 4_p
disease NN 4_p
( ( 4_p
PPMS NNP 4_p
) ) 4_p
. . N

progressive JJ 4_p
MS NNP 4_p
. . N

MS NNP N
patients NNS N
-DOCSTART- -X- O O 11331721

autism NN 4_p
: : N
children NNS 1_p
Sixty-four JJ 3_p
children NNS N
with IN N
autism NN N
( ( N
ages VBZ N
2-7 CD N
years NNS N
; : N
55 CD 3_p
boys NNS 2_p
and CC N
9 CD 3_p
girls NNS 2_p
) ) N
with IN N
a DT N
range NN N
of IN N
intelligence NN N
quotient NN N
and CC N
verbal JJ N
ability NN N
children NNS N
with IN N
autism NN N
. . N

-DOCSTART- -X- O O 15241630

25 CD N
randomly RB N
selected VBN N
patients NNS N
. . N

-DOCSTART- -X- O O 8790079

atrial JJ 4_p
fibrillation NN 4_p
. . N

nonvalvular JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
patients NNS N
using VBG N
2 CD N
different JJ N
elicitation NN N
methods NNS N
. . N

practices NNS N
of IN N
2 CD N
university-affiliated JJ N
family NN N
medicine NN N
centers NNS N
( ( N
8 CD N
physicians NNS N
each DT N
) ) N
, , N
14 CD N
community-based JJ N
family NN N
physicians NNS N
, , N
and CC N
2 CD N
cardiologists NNS N
. . N

Sixty-four JJ 3_p
patients NNS N
with IN N
nonvalvular JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
who WP N
were VBD N
initiated VBN N
with IN N
warfarin JJ N
therapy NN N
at IN N
least JJS N
3 CD N
months NNS N
before IN N
the DT N
study NN N
. . N

patients NNS N
with IN N
nonvalvular JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
. . N

-DOCSTART- -X- O O 3741313

High JJ 4_p
general JJ 4_p
anger NN 4_p
: : N
-DOCSTART- -X- O O 22146934

children NNS 1_p
with IN N
autism NN 4_p
. . N

children NNS 1_p
with IN N
autism NN 4_p
27 CD 3_p
young JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
. . N

children NNS 1_p
with IN N
ASD NNP 4_p
. . N

-DOCSTART- -X- O O 1457432

Leukocyte-depleted JJ 4_p
reperfusion NN 4_p
of IN 4_p
transplanted JJ 4_p
human JJ 4_p
hearts NNS 4_p
: : 4_p
20 CD N
patients NNS N
were VBD N
enrolled VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
clinical JJ N
trial NN N
to TO N
be VB N
treated VBN N
with IN N
either DT N
warm JJ N
whole NN N
blood NN N
reperfusion NN N
( ( N
group NN N
I PRP N
; : N
n CC N
= VB N
9 CD N
) ) N
( ( N
group NN N
II NNP N
; : N
n CC N
= VB N
11 CD N
) ) N
. . N

-DOCSTART- -X- O O 25223963

overweight JJ 4_p
and CC 4_p
obese JJ 4_p
adults NNS 1_p
: : N
overweight JJ 4_p
and CC 4_p
obese JJ 4_p
adults NNS 1_p
. . N

Fifty-nine NNP 3_p
healthy JJ 3_p
, , N
low-active JJ N
( ( N
exercise NN N
< VBZ N
60 CD N
min/week NN N
) ) N
, , N
overweight JJ N
( ( N
body JJ N
mass NN N
index NN N
25.0-39.9 JJ N
) ) N
adults NNS 1_p
( ( 1_p
18-65 JJ 1_p
) ) 1_p
intensity NN N
exercise NN N
. . N

All DT N
participants NNS N
used VBN N
electronic JJ 4_p
diaries NNS 4_p
and CC 4_p
heart NN 4_p
rate NN 4_p
adherence NN 4_p
to TO 4_p
exercise VB 4_p
programs NNS 4_p
among IN 4_p
-DOCSTART- -X- O O 17702798

transverse JJ 4_p
maxillary JJ 4_p
deficiencies NNS 4_p
. . 4_p

23 CD 3_p
patients NNS 3_p
( ( N
13 CD 3_p
females NNS 2_p
and CC N
10 CD 3_p
males NNS 2_p
) ) N
with IN N
a DT N
bilateral JJ N
maxillary JJ N
deficiency NN N
. . N

Twelve CD 3_p
patients NNS 3_p
( ( N
seven CD 3_p
females NNS 2_p
and CC N
five CD 3_p
males NNS 2_p
) ) N
with IN N
a DT N
mean JJ 1_p
age NN 1_p
of IN 1_p
14.8 CD 1_p
+/- JJ 1_p
0.3 CD 1_p
years NNS 1_p
11 CD 3_p
patients NNS 3_p
( ( N
six CD 3_p
females NNS 2_p
and CC N
five CD 3_p
males NNS 2_p
) ) N
with IN N
a DT N
mean JJ 1_p
age NN 1_p
of IN 1_p
15.1 CD 1_p
+/- JJ 1_p
0.7 CD 1_p
years NNS 1_p
-DOCSTART- -X- O O 21047593

Prostate NNP 4_p
Cancer NNP 4_p
. . 4_p

a DT N
total NN N
of IN N
56,294 CD 3_p
men NNS 2_p
aged VBN 1_p
55-74 CD 1_p
years NNS 1_p
were VBD N
screened VBN N
with IN N
serum NN N
prostate NN N
specific JJ N
antigen NN N
( ( N
PSA NNP N
) ) N
in IN N
five CD N
countries NNS N
of IN N
the DT N
European NNP N
Randomised VBD N
Study NNP N
of IN N
Screening NNP N
for IN N
Prostate NNP 4_p
Cancer NNP 4_p
( ( N
ERSPC NNP N
) ) N
with IN N
an DT N
overall JJ N
detection NN N
rate NN N
( ( N
prevalence NN N
) ) N
of IN N
2.8 CD N
% NN N
( ( N
1972 CD N
prostate NN N
cancers NNS N
) ) N
. . N

Prostate NNP 4_p
cancer NN 4_p
incidence NN N
among IN N
92,142 CD 3_p
men NNS 2_p
randomly RB N
allocated VBN N
to TO N
the DT N
control NN N
arm NN N
of IN N
the DT N
trial NN N
was VBD N
also RB N
assessed VBN N
. . N

Netherlands NNP N
Sweden NNP N
and CC N
Finland NNP N
Italy NNP N
Belgium NNP N
. . N

-DOCSTART- -X- O O 23727103

patients NNS N
suffering VBG N
a DT N
suspected JJ N
acute JJ 4_p
coronary JJ 4_p
syndrome NN 4_p
: : N
multi-centre NN N
pain NN N
and CC N
discomfort NN N
among IN N
patients NNS 4_p
who WP 4_p
suffer VBP 4_p
from IN 4_p
acute JJ 4_p
coronary JJ 4_p
syndrome NN 4_p
( ( 4_p
ACS NNP 4_p
) ) 4_p
multi-centre NN N
all DT N
, , N
890 CD 3_p
patients NNS 3_p
were VBD N
randomised VBN N
-DOCSTART- -X- O O 12270325

acute JJ 4_p
renal JJ 4_p
allograft NN 4_p
rejection NN 4_p
. . 4_p

-DOCSTART- -X- O O 11812696

outpatient JJ N
gynecological JJ N
laparoscopy NN N
. . N

Twenty NNP 3_p
ASA NNP 4_p
physical JJ 4_p
status NN 4_p
I PRP 4_p
patients NNS N
undergoing VBG N
gynecological JJ N
laparoscopy NN N
patients NNS N
SSA NNP N
group NN N
desflurane NN N
group NN N
. . N

-DOCSTART- -X- O O 18077065

able-bodied JJ N
participants NNS N
. . N

Participants NNS N
( ( N
n=14 CC N
) ) N
and CC N
a DT N
control NN N
group NN N
( ( N
n=7 RB N
) ) N
. . N

able-bodied JJ N
participants NNS N
. . N

-DOCSTART- -X- O O 24656872

preschoolers NNS 4_p
of IN 4_p
low JJ 4_p
socio-economic JJ 4_p
level NN 4_p
. . 4_p

preschoolers NNS N
from IN N
families NNS 4_p
treated VBN 4_p
at IN 4_p
basic JJ 4_p
health NN 4_p
centers NNS 4_p
in IN 4_p
Porto NNP 4_p
Alegre NNP 4_p
, , 4_p
RS NNP 4_p
, , 4_p
Brazil NNP 4_p
. . N

in IN 1_p
the DT 1_p
age NN 1_p
groups NNS 1_p
12-16 JJ 1_p
months NNS 1_p
and CC N
again RB N
at IN 1_p
2-3 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
. . 1_p

A DT N
total NN N
of IN N
388 CD 3_p
children NNS 3_p
aged VBN N
2-3 CD 1_p
years NNS 1_p
were VBD N
evaluated VBN N
; : N
-DOCSTART- -X- O O 17201540

attitude JJ N
certainty NN N
: : N
Attitude NNP N
certainty NN N
attitude NN N
certainty NN N
factor NN N
analysis NN N
and CC N
correlational JJ N
data NNS N
existing VBG N
attitude NN N
strength NN N
-DOCSTART- -X- O O 3885865

patients NNS N
treated VBN N
with IN N
CDDP NNP N
( ( N
80 CD N
mg/m2 NN N
) ) N
-DOCSTART- -X- O O 18852963

autistic JJ 4_p
children NNS 4_p
autistic JJ N
children NNS N
11 CD N
mothers NNS N
of IN N
children NNS N
diagnosed VBN N
, , N
according VBG N
to TO N
the DT N
criteria NNS N
established VBN N
by IN N
the DT N
DSM NNP N
IVtr NNP N
( ( N
APA NNP N
, , N
2002 CD N
) ) N
, , N
with IN N
autism NN N
( ( N
six CD N
) ) N
and CC N
with IN N
Asperger NNP N
Syndrome NNP N
( ( N
five CD N
) ) N
and CC N
who WP N
were VBD N
seen VBN N
at IN N
the DT N
Investigation NNP N
Laboratory NNP N
of IN N
Global NNP N
Developmental NNP N
Disorders NNP N
of IN N
the DT N
Federal NNP N
University NNP N
of IN N
São NNP N
Paulo NNP N
the DT N
Portuguese JJ N
language NN N
the DT N
mothers NNS N
of IN N
parents NNS N
-DOCSTART- -X- O O 19884541

children NNS N
previously RB N
randomly RB N
assigned VBN N
to TO N
intrathecal JJ N
methotrexate NN N
childhood NN N
acute NN N
lymphoblastic JJ 4_p
leukemia NN 4_p
. . N

children NNS 1_p
with IN N
acute JJ 4_p
lymphoblastic JJ 4_p
leukemia NN 4_p
( ( 4_p
ALL NNP 4_p
) ) 4_p
, , N
CNS NNP N
prophylaxis NN N
consists VBZ N
of IN N
either DT N
intrathecal JJ N
( ( N
IT NNP N
) ) N
methotrexate NN N
or CC N
triple VB N
IT NNP N
therapy NN N
( ( N
ie JJ N
, , N
methotrexate NN N
with IN N
both DT N
cytarabine NN N
and CC N
hydrocortisone NN N
) ) N
. . N

171 CD 3_p
children NNS 1_p
with IN N
standard-risk JJ N
ALL NNP N
, , N
age NN 1_p
1 CD 1_p
to TO 1_p
9.99 CD 1_p
years NNS 1_p
at IN N
diagnosis NN N
, , N
previously RB N
randomly RB N
assigned VBN N
to TO N
IT NNP N
methotrexate NNP N
( ( N
n JJ N
= NNP N
82 CD N
) ) N
or CC N
to TO N
triple VB N
IT NNP N
therapy NN N
( ( N
n JJ N
= NNP N
89 CD N
) ) N
on IN N
CCG NNP N
1952 CD N
, , N
underwent JJ N
neurocognitive JJ N
evaluation NN N
by IN N
a DT N
licensed JJ N
psychologist NN N
at IN N
a DT N
mean NN N
of IN N
5.9 CD N
years NNS N
after IN N
random JJ N
assignment NN N
. . N

Patients NNPS N
who WP N
received VBD N
IT NNP N
methotrexate NNP N
19.5 CD N
% NN N
of IN N
children NNS N
in IN N
the DT N
IT NNP N
methotrexate NNP N
group NN N
sex NN N
or CC N
age NN N
at IN N
diagnosis NN N
. . N

-DOCSTART- -X- O O 9261669

children NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
: : N
patients NNS N
with IN N
autism NN 4_p
. . N

Twelve CD 3_p
patients NNS N
were VBD N
enrolled VBN N
, , N
and CC N
10 CD 3_p
patients NNS N
( ( N
mean JJ N
age NN N
6 CD 1_p
years NNS 1_p
3 CD 1_p
months NNS 1_p
) ) N
were VBD N
able JJ N
to TO N
complete VB N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 24290135

models NNS 4_p
of IN 4_p
the DT 4_p
hip NN 4_p
seven CD N
a-p JJ N
hip NN N
radiographs NN N
21 CD N
femora NN N
was VBD N
built VBN N
and CC N
meshed VBN N
a DT N
patient-specific JJ N
3D CD N
finite JJ N
element NN N
model NN N
-DOCSTART- -X- O O 10100592

tumors NNS 4_p
of IN 4_p
hematopoietic JJ 4_p
organs NNS 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
tumors NNS 4_p
of IN 4_p
hematopoietic JJ 4_p
organs NNS 4_p
multiple JJ 4_p
institutions NNS 4_p
using VBG 4_p
a DT 4_p
central JJ 4_p
registration NN 4_p
system NN 4_p
. . N

( ( N
55/93 CD N
) ) N
( ( N
44/93 CD N
) ) N
-DOCSTART- -X- O O 15317925

Risk NN N
factors NNS N
for IN N
fracture NN N
in IN N
a DT N
UK JJ N
population NN N
: : N
fracture NN N
in IN N
older JJR N
women NNS N
UK NNP N
population NN N
. . N

fracture NN N
in IN N
older JJR N
women NNS N
. . N

CCS NNP N
included VBD N
4292 CD N
women NNS N
aged VBD N
> JJ N
70 CD N
years NNS N
. . N

-DOCSTART- -X- O O 8602105

cystic JJ 4_p
fibrosis NN 4_p
. . 4_p

-DOCSTART- -X- O O 6753858

hypertensive JJ 4_p
outpatients NNS 4_p
. . N

-DOCSTART- -X- O O 2195054

autism NN 4_p
. . N

20 CD 3_p
children NNS 1_p
with IN N
the DT N
syndrome NN N
of IN N
autism NN 4_p
. . N

children NNS 1_p
children NNS 1_p
patients NNS N
with IN N
autistic JJ 4_p
disorder NN N
. . N

-DOCSTART- -X- O O 16275518

33 CD 3_p
patients NNS N
with IN N
pulmonary JJ 4_p
hypertension NN 4_p
. . N

33 CD 3_p
age- JJ N
and CC N
sex-matched JJ N
control NN N
subjects NNS N
. . N

-DOCSTART- -X- O O 12033348

atrial JJ N
DFTs NNP N
in IN N
33 CD N
patients NNS N
. . N

-DOCSTART- -X- O O 375690

alcoholic JJ 4_p
cirrhosis NN 4_p
. . N

30 CD 3_p
patients NNS 3_p
with IN 4_p
biopsy-proven JJ 4_p
alcoholic JJ 4_p
liver NN 4_p
cirrhosis NN 4_p
. . 4_p

cirrhotics NNS N
-DOCSTART- -X- O O 10674681

Thailand NNP 4_p
. . 4_p

Patients NNS N
( ( N
15-65 CD N
years NNS N
old JJ N
) ) N
were VBD N
assigned VBN N
to TO N
1 CD N
of IN N
4 CD N
treatments NNS N
regimens VBZ N
in IN N
a DT N
serial JJ N
order NN N
. . N

Ninety NNP N
percent NN N
of IN N
the DT N
patients NNS N
were VBD N
infected VBN N
at IN N
Thailand-Myanmar NNP N
border NN N
. . N

-DOCSTART- -X- O O 10037531

acute NN 4_p
otitis NN 4_p
media NNS 4_p
. . 4_p

-DOCSTART- -X- O O 11284463

acute JJ 4_p
treatment NN 4_p
of IN 4_p
migraine NN 4_p
. . 4_p

1268 CD 4_p
outpatients NNS 4_p
treating VBG 4_p
a DT 4_p
single JJ 4_p
migraine NN 4_p
attack NN 4_p
. . 4_p

-DOCSTART- -X- O O 6227244

Down NNP 4_p
syndrome NN 4_p
. . 4_p

24 CD 3_p
Down NNP 4_p
syndrome NN 4_p
children NNS N
, , N
ages VBZ N
6 CD 1_p
to TO 1_p
17 CD 1_p
years NNS N
living VBG N
at IN N
home NN N
, , N
were VBD N
given VBN N
a DT N
megadose JJ N
multi-vitamin/mineral JJ N
supplement NN N
for IN N
4 CD N
months NNS N
. . N

23 CD 3_p
children NNS N
received VBD N
a DT N
placebo NN N
in IN N
identical JJ N
form NN N
. . N

-DOCSTART- -X- O O 1797999

patients NNS N
with IN N
hypertension NN 4_p
. . N

borderline JJ 4_p
hypertension NN 4_p
in IN N
Tecumseh NNP N
-DOCSTART- -X- O O 16714498

patients NNS N
. . N

Emergency NNP N
Department NNP N
, , N
University NNP N
Hospital NNP N
of IN N
Wales NNP N
. . N

A DT N
total NN N
of IN N
302 CD N
patients NNS N
aged VBN N
over IN N
15 CD N
years NNS N
. . N

-DOCSTART- -X- O O 24460069

patients NNS 4_p
with IN 4_p
breast NN 4_p
and CC 4_p
colorectal JJ 4_p
cancer NN 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
cancer NN 4_p
during IN 4_p
adjuvant JJ 4_p
chemotherapy NN 4_p
treatment NN 4_p
. . 4_p

patients NNS 4_p
with IN 4_p
breast NN 4_p
cancer NN 4_p
( ( 4_p
BRCA NNP 4_p
) ) 4_p
and CC 4_p
colorectal JJ 4_p
cancer NN 4_p
( ( 4_p
CRC NNP 4_p
) ) 4_p
during IN 4_p
adjuvant JJ 4_p
chemotherapy NN 4_p
. . 4_p

participants NNS N
participants NNS N
participants NNS N
intervention NN N
group NN N
. . N

intervention NN N
group NN N
control NN N
group NN N
. . N

intervention NN N
group NN N
-DOCSTART- -X- O O 25234471

children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . N

patients NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
compared VBN N
with IN N
patients NNS N
with IN N
other JJ N
neurological JJ 4_p
disorders NNS N
. . N

group NN N
of IN N
children NNS 1_p
with IN N
ASD NNP 4_p
( ( N
N NNP 3_p
= NNP 3_p
52 CD 3_p
, , N
average JJ 1_p
age NN 1_p
= JJ 1_p
6.2 CD 1_p
years NNS 1_p
) ) N
and CC N
a DT N
control NN N
group NN N
of IN N
children NNS 1_p
with IN N
other JJ N
neurological JJ N
disorders NNS N
( ( N
N NNP 3_p
= NNP 3_p
22 CD 3_p
, , N
average JJ N
age NN 1_p
= JJ 1_p
6.6 CD 1_p
years NNS 1_p
) ) N
, , N
matched VBN N
in IN N
terms NNS N
of IN N
intellectual JJ N
abilities NNS N
( ( N
Mann-Whitney NNP N
U NNP N
= NNP N
565.0 CD N
-DOCSTART- -X- O O 6762195

acute JJ 4_p
non-lymphocytic JJ 4_p
leukaemia NN 4_p
. . 4_p

Between NNP N
January NNP N
1975 CD N
and CC N
December NNP N
1977 CD N
, , N
264 CD N
adult NN N
patients NNS N
with IN N
acute JJ N
non-lymphocytic JJ N
leukaemia NN N
entered VBD N
the DT N
Australian JJ N
National NNP N
Leukaemia NNP N
Trial NNP N
. . N

251 CD N
evaluable JJ N
patients NNS N
-DOCSTART- -X- O O 19396947

patients NNS N
with IN N
cardiac JJ 4_p
syndrome-X NN 4_p
. . N

patients NNS N
with IN N
cardiac JJ 4_p
syndrome-X NN 4_p
( ( 4_p
CSX NNP 4_p
) ) 4_p
Thirty NNP 3_p
patients NNS N
, , N
17 CD 3_p
female NN 2_p
and CC N
13 CD 3_p
male NN 2_p
, , N
with IN N
CSX NNP 4_p
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

patients NNS N
with IN N
CSX NNP 4_p
-DOCSTART- -X- O O 24266796

temporal JJ N
brain NN N
injury NN N
: : N
patients NNS N
with IN N
TBI NNP N
in IN N
an DT N
over-selectivity JJ N
task NN N
. . N

Twenty-four JJ N
patients NNS N
who WP N
had VBD N
suffered VBN N
TBI NNP N
and CC N
reported VBD N
problems NNS N
with IN N
focused JJ N
or CC N
sustained JJ N
attention NN N
. . N

-DOCSTART- -X- O O 11860915

hepatitis NN 4_p
B NNP 4_p
vaccine NN 4_p
11 CD 4_p
years NNS 4_p
after IN 4_p
primary JJ 4_p
immunization NN 4_p
] NN 4_p
hepatitis NN 4_p
B NNP 4_p
vaccine NN 4_p
10 CD 4_p
years NNS 4_p
after IN 4_p
primary JJ 4_p
immunization NN 4_p
the DT N
efficacy NN N
and CC N
immune JJ N
memory NN N
11 CD N
years NNS N
following VBG N
hepatitis NN N
B NNP N
vaccination NN N
. . N

vaccine NN N
group NN N
and CC N
placebo-controlled JJ N
group NN N
-DOCSTART- -X- O O 25080906

after IN 4_p
cardiac JJ 4_p
surgery NN 4_p
in IN N
infants NNS 1_p
] NNP N
infants NNS 1_p
' POS 1_p
pulmonary JJ N
function NN N
after IN N
cardiac JJ 4_p
surgery NN 4_p
. . N

Sixty NNP 3_p
infants NNS 1_p
with IN N
congenital JJ 4_p
heart NN 4_p
diseases NNS 4_p
-DOCSTART- -X- O O 16413892

oral JJ 4_p
surgery NN 4_p
patients NNS 4_p
Forty-seven JJ 4_p
subjects NNS 4_p
were VBD 4_p
entered VBN 4_p
in IN 4_p
the DT 4_p
study NN 4_p
. . 4_p

-DOCSTART- -X- O O 9101850

63 CD 3_p
patients NNS N
undergoing JJ N
deep JJ 4_p
anterior JJ 4_p
resection NN 4_p
of IN 4_p
the DT 4_p
rectum NN 4_p
, , N
39 CD 3_p
patients NNS N
received VBD N
a DT N
straight JJ N
colo-anal JJ N
anastomosis NN N
-DOCSTART- -X- O O 21189767

tooth DT 4_p
enamel NN 4_p
. . 4_p

Two CD N
study NN N
groups NNS N
were VBD N
randomly RB N
formed VBN N
: : N
enamel NN 4_p
blocks NNS 4_p
brushed VBN N
with IN N
( ( N
a DT N
) ) N
the DT N
Gantrez-NNP JJ N
combination NN N
and CC N
( ( N
b NN N
) ) N
conventional JJ N
toothpaste NN N
, , N
for IN N
1 CD N
minute NN N
once RB N
daily JJ N
for IN N
4 CD N
weeks NNS N
, , N
then RB N
rinsed VBD N
with IN N
distilled JJ N
water NN N
and CC N
placed VBN N
in IN N
thymol JJ N
solution NN N
. . N

dental JJ 4_p
esthetics NNS 4_p
-DOCSTART- -X- O O 1595776

obese JJ N
type NN 4_p
2 CD 4_p
diabetes NNS 4_p
: : N
21 CD 3_p
obese JJ N
subjects NNS N
imperfectly RB N
controlled VBN N
by IN N
20 CD N
mg NNS N
of IN N
glyburide JJ N
daily JJ N
Eleven JJ 3_p
subjects NNS N
using VBG N
insulin NN N
plus CC N
10 CD N
mg NNS N
glyburide NN N
obese JJ N
persons NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes VBZ 4_p
-DOCSTART- -X- O O 10651597

osteoarthritis NN 4_p
of IN 4_p
the DT 4_p
knee NN 4_p
. . N

osteoarthritis NN 4_p
of IN 4_p
the DT 4_p
knee NN 4_p
. . N

Outpatient NNP N
physical JJ N
therapy NN N
department NN N
of IN N
a DT N
large JJ N
military JJ N
medical JJ N
center NN N
. . N

83 CD 3_p
patients NNS N
with IN N
osteoarthritis NN 4_p
of IN 4_p
the DT 4_p
knee NN 4_p
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
treatment NN N
( ( N
n JJ N
= VBZ N
42 CD 3_p
; : N
15 CD 3_p
men NNS 2_p
and CC N
27 CD 3_p
women NNS 2_p
[ JJ N
mean JJ N
age NN N
, , N
60 CD 1_p
+/- JJ 1_p
11 CD 1_p
years NNS N
] RB N
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= VBZ N
41 CD 3_p
; : N
19 CD 3_p
men NNS N
and CC N
22 CD 3_p
women NNS N
[ JJ N
mean JJ N
age NN N
, , N
62 CD 1_p
+/- JJ 1_p
10 CD 1_p
years NNS N
] RB N
) ) N
. . N

treatment NN N
group NN N
placebo NN N
group NN N
patients NNS N
with IN N
osteoarthritis NN 4_p
of IN 4_p
the DT 4_p
knee NN 4_p
-DOCSTART- -X- O O 25744288

experience NN 4_p
of IN 4_p
carers NNS 4_p
in IN 4_p
the DT 4_p
chemotherapy NN 4_p
outpatient JJ 4_p
setting NN 4_p
: : 4_p
carers NNS N
and CC N
staff NN N
. . N

carers NNS N
that WDT N
was VBD N
co-designed VBN N
by IN N
staff NN N
and CC N
carers NNS N
of IN N
patients NNS N
starting VBG N
chemotherapy NN N
. . N

Forty-seven JJ 3_p
carers NNS 3_p
were VBD 3_p
recruited VBN 3_p
, , N
randomised VBN N
between IN N
the DT N
intervention NN N
( ( 3_p
n JJ 3_p
= NNP 3_p
24 CD 3_p
) ) 3_p
and CC N
control NN 3_p
( ( 3_p
n JJ 3_p
= NNP 3_p
23 CD 3_p
) ) 3_p
groups NNS 3_p
. . N

questionnaire NN N
intervention NN N
process NN N
focus NN N
groups NNS N
. . N

carers NNS N
and CC N
HCPs NNP N
-DOCSTART- -X- O O 10734271

HIV NNP N
prevention NN N
human JJ N
immunodeficiency NN N
virus NN N
( ( N
HIV NNP N
) ) N
Students NNPS 1_p
enrolled VBD N
in IN N
a DT N
Human NNP N
Sexuality NNP N
course NN N
( ( N
N NNP N
= NNP N
152 CD N
) ) N
-DOCSTART- -X- O O 8478759

pediatric JJ 1_p
dental JJ 4_p
patients NNS 4_p
. . N

children NNS 1_p
undergoing VBG 4_p
dental JJ 4_p
extractions NNS 4_p
. . N

-DOCSTART- -X- O O 18035192

Korean JJ N
adults NNS 1_p
with IN N
mild NN N
to TO N
moderate VB N
hypertension NN 4_p
. . N

Korean JJ N
patients NNS N
with IN N
mild JJ 4_p
to TO 4_p
moderate VB 4_p
hypertension NN 4_p
. . N

13 CD 3_p
cardiology NN N
centers NNS N
across IN N
the DT N
Republic NNP N
of IN N
Korea NNP N
. . N

Male NNP 2_p
and CC N
female JJ 2_p
Korean JJ N
patients NNS N
aged VBD 1_p
18 CD 1_p
to TO 1_p
75 CD 1_p
years NNS N
having VBG N
uncomplicated JJ N
, , N
mild JJ N
to TO N
moderate VB N
, , N
essential JJ N
hypertension NN 4_p
( ( N
sitting VBG N
diastolic JJ N
blood NN N
pressure NN N
[ NNP N
SiDBP NNP N
] NNP N
90- CD N
< NNP N
110 CD N
mm NN N
Hg NNP N
) ) N
and CC N
receiving VBG N
no DT N
antihypertensives NNS N
in IN N
the DT N
2 CD N
weeks NNS N
before IN N
randomization NN N
were VBD N
eligible JJ N
. . N

A DT N
total NN N
of IN N
189 CD 3_p
patients NNS N
were VBD N
enrolled VBN N
( ( N
mean JJ 1_p
age NN 1_p
, , 1_p
53 CD 1_p
years NNS 1_p
; : N
105 CD 3_p
women NNS 2_p
, , N
84 CD 3_p
men NNS 2_p
; : N
mean VB N
body NN N
weight NN N
, , N
65.8 CD N
kg NN N
) ) N
. . N

188 CD 3_p
patients NNS N
were VBD N
treated VBN N
and CC N
included VBN N
in IN N
the DT N
ITT NNP N
analysis NN N
Korean JJ N
adults NNS 1_p
with IN N
mild NN 4_p
to TO 4_p
moderate VB 4_p
hypertension NN 4_p
. . N

-DOCSTART- -X- O O 6403021

ventricular JJ 4_p
arrhythmias NN 4_p
. . N

German JJ N
speaking NN N
countries NNS N
. . N

20 CD 3_p
patients NNS N
with IN N
ventricular JJ 4_p
arrhythmias NNS 4_p
( ( N
VA NNP 4_p
) ) N
of IN N
various JJ N
origin NN N
. . N

-DOCSTART- -X- O O 21261975

adult NN 4_p
critically RB 4_p
ill JJ 4_p
patients NNS 4_p
critically RB 4_p
ill JJ 4_p
patients NNS 4_p
treated VBN 4_p
in IN 4_p
intensive JJ 4_p
care NN 4_p
units NNS 4_p
( ( 4_p
ICU NNP 4_p
) ) N
patients NNS 4_p
for IN 4_p
whom WP 4_p
enteral JJ 4_p
nutrition NN 4_p
( ( 4_p
EN NNP 4_p
) ) 4_p
does VBZ 4_p
not RB 4_p
reach VB 4_p
caloric JJ 4_p
targets NNS 4_p
. . N

early JJ N
PN NNP N
group NN N
late JJ N
PN NNP N
group NN N
-DOCSTART- -X- O O 1376306

head NN 4_p
and CC 4_p
neck NN 4_p
cancer NN 4_p
: : N
Between IN N
December NNP N
1982 CD N
and CC N
October NNP N
1986 CD N
, , N
131 CD N
patients NNS N
with IN N
stage JJ 4_p
II-III-IV NNP 4_p
squamous JJ 4_p
cell NN 4_p
carcinoma NN 4_p
of IN 4_p
the DT 4_p
oropharynx NN 4_p
or CC 4_p
oral JJ 4_p
cavity NN 4_p
A DT N
total NN N
of IN N
116 CD 3_p
patients NNS 3_p
were VBD 3_p
evaluable JJ 3_p
. . N

-DOCSTART- -X- O O 17926617

children NNS 1_p
of IN N
autism NN 4_p
] NNP N
Sixty NNP 3_p
children NNS 1_p
of IN N
autism NN 4_p
-DOCSTART- -X- O O 12113323

autism NN 4_p
: : N
children NNS 1_p
Six NNP 3_p
children NNS N
enrolled VBD N
children NNS 1_p
-DOCSTART- -X- O O 7774537

pregnant JJ 4_p
Pakistani NNP 4_p
women NNS 2_p
in IN N
Oslo NNP N
. . N

pregnant JJ 4_p
Pakistani NNP N
immigrant NN N
women NNS 2_p
group NN N
of IN N
Norwegian JJ 4_p
women NNS 2_p
. . N

women NNS 2_p
in IN N
the DT N
18th CD 4_p
week NN 4_p
of IN 4_p
pregnancy NN 4_p
. . N

Women NNP 2_p
referred VBD N
to TO N
routine VB N
ultrasound JJ N
examination NN N
at IN N
Aker NNP N
and CC N
Ullevål NNP N
Hospitals NNP N
in IN N
Norway NNP N
. . N

SUBJECTS NNP N
All NNP N
( ( N
58 CD N
) ) N
healthy JJ N
women NNS N
of IN N
Pakistani NNP N
origin NN N
referred VBD N
from IN N
October NNP N
of IN N
1991 CD N
to TO N
January NNP N
of IN N
1992 CD N
were VBD N
included VBN N
, , N
of IN N
whom WP N
38 CD N
( ( N
66 CD N
% NN N
) ) N
participated VBD N
. . N

Forty-five JJ N
Norwegian JJ N
women NNS N
were VBD N
randomly RB N
included VBN N
in IN N
the DT N
same JJ N
period NN N
and CC N
38 CD N
( ( N
84 CD N
% NN N
) ) N
of IN N
these DT N
women NNS N
participated VBD N
-DOCSTART- -X- O O 8376638

adolescents NNS 1_p
. . N

Two CD 3_p
hundred CD 3_p
and CC 3_p
thirty-seven JJ 3_p
students NNS N
, , N
drawn NN N
from IN N
six CD N
homeroom NN N
grade NN N
eight CD N
classes NNS N
-DOCSTART- -X- O O 26244758

Presumed NNP 4_p
Early-Stage NNP 4_p
Endometrial NNP 4_p
Cancer NNP 4_p
: : N
women NNS 2_p
are VBP N
more RBR N
likely JJ N
to TO N
be VB N
older JJR 1_p
or CC N
obese JJ N
. . N

Women NNP 2_p
with IN N
presumed JJ N
early JJ N
endometrial JJ N
cancer NN N
were VBD N
included VBN N
. . N

1408 CD 3_p
women NNS 2_p
, , N
1309 CD 3_p
( ( N
93 CD N
% NN N
) ) N
received VBD N
OH NNP 4_p
99 CD 3_p
( ( N
7 CD N
% NN N
) ) N
had VBD N
LH NNP 4_p
. . N

-DOCSTART- -X- O O 22531825

Three CD N
groups NNS N
of IN N
unimpaired JJ 4_p
participants NNS N
trained VBN N
with IN N
the DT N
target NN N
arm JJ N
movement NN N
broken VBD N
down RB N
in IN N
three CD N
ways NNS N
: : N
1 CD N
) ) N
elbow NN N
flexion/extension NN N
and CC N
the DT N
unified JJ N
shoulder NN N
motion NN N
independently RB N
( ( N
" JJ N
anatomical JJ N
" NNP N
decomposition NN N
) ) N
, , N
2 CD N
) ) N
three CD N
component JJ N
shoulder NN N
motions NNS N
in IN N
Euler NNP N
coordinates NNS N
and CC N
elbow JJ N
flexion/extension NN N
( ( N
" JJ N
Euler NNP N
" NNP N
decomposition NN N
) ) N
, , N
or CC N
3 CD N
) ) N
the DT N
motion NN N
of IN N
the DT N
tip NN N
of IN N
the DT N
elbow NN N
and CC N
motion NN N
of IN N
the DT N
hand NN N
with IN N
respect NN N
to TO N
the DT N
elbow NN N
, , N
independently RB N
( ( N
" JJ N
visual JJ N
" NNP N
decomposition NN N
) ) N
. . N

less JJR N
experience NN N
with IN N
the DT N
target NN N
motion NN N
-DOCSTART- -X- O O 1411449

many JJ N
athletes NNS N
26 CD 3_p
athletes NNS 3_p
. . N

stressed JJ 4_p
athletes NNS N
-DOCSTART- -X- O O 23802768

advanced VBD 4_p
melanoma NN 4_p
. . N

patients NNS N
with IN N
BRAF NNP 4_p
( ( 4_p
V600E/K NNP 4_p
) ) 4_p
advanced VBD 4_p
melanoma NN 4_p
treated VBN N
with IN N
vemurafenib NN N
. . N

patients NNS N
enrolled VBN N
in IN N
the DT N
BRIM2 NNP 4_p
( ( N
n JJ N
= NNP N
59 CD 3_p
) ) N
and CC N
BRIM3 NNP 4_p
( ( N
n JJ N
= NNP N
150 CD 3_p
) ) N
-DOCSTART- -X- O O 6482920

patients NNS N
with IN N
intestinal JJ 4_p
perforation NN 4_p
after IN N
abdominal JJ 4_p
trauma NN 4_p
145 CD 3_p
patients NNS N
who WP N
presented VBD N
with IN N
abdominal JJ 4_p
trauma NN 4_p
and CC N
intestinal JJ 4_p
perforation NN 4_p
at IN N
two CD N
hospitals NNS N
between IN N
July NNP N
1979 CD N
and CC N
June NNP N
1982 CD N
. . N

Patients NNS N
with IN N
postoperative JJ 4_p
sepsis NN 4_p
-DOCSTART- -X- O O 19926166

preterm JJ 1_p
neonates NNS 1_p
: : N
preterm NN 4_p
neonates NNS 1_p
preterm JJ N
neonates NNS N
. . N

Preterm NNP 4_p
neonates NNS 1_p
without IN N
other JJ N
risk NN 4_p
factors NNS 4_p
for IN 4_p
infection NN 4_p
admitted VBN N
in IN N
the DT N
first JJ 1_p
12h CD 1_p
of IN 1_p
life NN 1_p
low JJ N
risk NN N
preterm NN N
neonates VBZ N
-DOCSTART- -X- O O 16335132

broiler NN 4_p
chickens NNS 4_p
during IN N
the DT N
starting NN N
and CC N
growing/finishing NN N
phases NNS N
. . N

at IN 4_p
least JJS 4_p
4 CD N
replicates NNS N
per IN N
treatment NN N
( ( N
50 CD N
chicks NNS N
per IN N
replicate NN N
) ) 4_p
were VBD 4_p
used VBN 4_p
. . 4_p

Corn-soybean-meal-and JJ 4_p
soybean-oil-based JJ 4_p
diets NNS 4_p
were VBD N
fed VBN N
and CC N
birds NNS N
were VBD N
raised VBN N
in IN N
a DT N
house NN 4_p
impervious JJ 4_p
to TO 4_p
ultraviolet VB 4_p
light NN 4_p
. . N

birds NNS 4_p
in IN N
experiment JJ N
1 CD N
. . N

birds NNS 4_p
in IN N
experiment JJ N
1 CD N
-DOCSTART- -X- O O 8709689

honey-bee JJ 4_p
stings NNS 4_p
patients NNS N
on IN N
the DT N
immediate JJ N
treatment NN N
of IN N
bee JJ N
stings NNS N
-DOCSTART- -X- O O 15091267

tibial JJ 4_p
fractures NNS N
patients NNS N
with IN N
tibial JJ N
shaft NN N
fractures NNS N
. . N

Level NNP N
1 CD N
trauma NN N
center NN N
. . N

Forty-five JJ N
patients NNS N
with IN N
displaced NNS N
closed VBD N
and CC N
open JJ N
Gustilo NNP N
type NN N
I-IIIA NNP N
fractures NNS N
of IN N
the DT N
central JJ N
two CD N
thirds NNS N
of IN N
the DT N
tibia NN N
. . N

patients NNS N
with IN N
tibial JJ N
shaft NN N
fractures NNS N
-DOCSTART- -X- O O 1331023

autistic JJ N
children NNS N
: : N
20 CD N
autistic JJ N
children NNS N
received VBD N
40 CD N
mg/day NN N
of IN N
the DT N
neuropeptide NN N
ORG NNP N
2766 CD N
, , N
a DT N
synthetic JJ N
analog NN N
of IN N
ACTH NNP N
( ( N
4-9 JJ N
) ) N
, , N
for IN N
8 CD N
weeks NNS N
. . N

-DOCSTART- -X- O O 7616334

The DT N
Central NNP N
Medical NNP N
Unit NNP N
( ( N
CMU NNP N
) ) N
-- : N
a DT N
freestanding JJ N
primary NN N
care NN N
medical JJ N
clinic NN N
staffed VBN N
by IN N
physicians NNS N
and CC N
nurse JJ N
practitioners NNS N
. . N

Injection NNP N
drug NN N
users NNS N
( ( N
IDUs NNP N
) ) N
seeking VBG N
substance NN 4_p
abuse NN 4_p
treatment NN N
between IN N
the DT N
ages NNS N
of IN N
18 CD 1_p
and CC 1_p
50 CD 1_p
years NNS 1_p
who WP N
were VBD N
addicted VBN N
to TO N
opioids NNS N
( ( N
e.g. NN N
heroin NN N
) ) N
and CC N
not RB N
currently RB N
in IN N
drug NN N
treatment NN N
. . N

One CD 3_p
hundred VBD 3_p
forty JJ 3_p
opioid-addicted JJ N
IDUs NNP N
were VBD N
referred VBN N
to TO N
the DT N
medical JJ N
clinic NN N
for IN N
AOD NNP N
. . N

Among IN N
the DT N
125 CD 3_p
patients NNS N
who WP N
enrolled VBD N
in IN N
the DT N
study NN N
, , N
57 CD 3_p
selected VBN N
clonidine NN N
and CC N
68 CD 3_p
selected VBN N
clonidine/naltrexone NN N
. . N

IDUs NNP N
who WP N
are VBP N
addicted VBN 4_p
to TO 4_p
opioids NNS 4_p
. . N

-DOCSTART- -X- O O 23381958

healthy JJ 4_p
subjects NNS N
. . N

healthy JJ 4_p
subjects NNS N
. . N

healthy JJ 4_p
young JJ 1_p
male JJ 2_p
subjects NNS N
RESULTS NNP N
Fourteen JJ N
subjects NNS N
were VBD N
enrolled VBN N
and CC N
completed VBN N
the DT N
-DOCSTART- -X- O O 12375315

rheumatoid JJ 4_p
arthritis NN 4_p
10 CD 3_p
healthy JJ 4_p
subjects NNS N
received VBN N
-DOCSTART- -X- O O 24317552

Eleven NNP 4_p
healthy JJ 4_p
subjects NNS 4_p
-DOCSTART- -X- O O 17259154

inflammatory JJ 4_p
responses NNS 4_p
induced VBN N
by IN N
oesophagectomy JJ 4_p
] NNP N
inflammatory JJ 4_p
responses NNS 4_p
induced VBN N
by IN N
oesophagectomy NN N
. . N

Forty NNP 3_p
patients NNS N
with IN N
esophageal JJ 4_p
cancer NN 4_p
( ( N
without IN N
serious JJ 4_p
hypertension NN 4_p
, , N
heart NN 4_p
disease NN 4_p
, , N
or CC N
respiratory JJ 4_p
function NN 4_p
impairment NN 4_p
, , N
including VBG N
34 CD 2_p
men NNS 2_p
and CC N
6 CD 2_p
women NNS 2_p
aged VBD N
46 CD 1_p
to TO 1_p
70 CD 1_p
years NNS 1_p
) ) N
scheduled VBD N
for IN N
oesophagectomy JJ N
via IN N
left JJ N
thoracotomy NN N
were VBD N
randomly RB N
divided VBN N
into IN N
control NN N
group NN N
( ( N
n=20 CC N
) ) N
and CC N
UTI NNP N
group NN N
( ( N
n=20 RB N
) ) N
. . N

-DOCSTART- -X- O O 16230665

beef NN N
heifers NNS N
fed VBP N
high- JJ N
or CC N
low-starch JJ N
diets NNS N
for IN N
different JJ N
periods NNS N
before IN N
breeding VBG N
. . N

Spring-born JJ N
Hereford NNP N
x NNP N
Angus NNP N
heifers NNS N
( ( N
n JJ N
= NNP N
206 CD N
) ) N
heifers NNS N
( ( N
205 CD N
+/- JJ N
5 CD N
kg NN N
; : N
n CC N
= VB N
68 CD N
) ) N
grazing NN N
dormant JJ N
native JJ N
pasture NN N
Heifers NNS N
HS NNP N
and CC N
LS NNP N
heifers NNS N
HS NNP N
and CC N
LS NNP N
heifers NNS N
HS NNP N
and CC N
LS NNP N
heifers NNS N
heifers NNS N
-DOCSTART- -X- O O 23942708

finishing VBG 4_p
steers NNS 4_p
. . 4_p

A DT N
total NN N
of IN N
4,178 CD N
steers NNS N
( ( N
mean JJ N
initial JJ N
BW NNP N
= NNP N
403.9 CD N
± VBD N
16.04 CD N
kg NN N
) ) N
were VBD N
used VBN N
to TO N
test VB N
-DOCSTART- -X- O O 24637998

positron NN N
emission NN N
tomography-negative JJ N
stage NN N
I/II NNP N
Hodgkin NNP N
lymphoma NN N
patients NNS N
with IN N
clinical JJ N
stage NN N
I/II NNP N
Hodgkin NNP N
lymphoma NN N
( ( N
HL NNP N
) ) N
. . N

patients NNS N
attaining VBG N
a DT N
negative JJ N
early JJ N
PET NNP N
scan NN N
after IN N
two CD N
cycles NNS N
of IN N
ABVD NNP N
Patients NNP N
age NN 1_p
15 CD 1_p
to TO 1_p
70 CD 1_p
years NNS 1_p
with IN N
untreated JJ N
clinical JJ N
stage NN N
I/II NNP N
HL NNP N
were VBD N
eligible JJ N
. . N

The DT N
analysis NN N
included VBD N
1,137 CD 3_p
patients NNS N
. . N

favorable JJ 3_p
subgroup NN 3_p
unfavorable JJ 3_p
subgroup NN 3_p
-DOCSTART- -X- O O 10661479

hemodialysis NN 4_p
patients NNS N
during IN N
growth NN 4_p
hormone CD 4_p
treatment NN 4_p
. . N

Adult NNP 1_p
patients NNS N
with IN N
chronic JJ 4_p
renal JJ 4_p
failure NN 4_p
( ( 4_p
CRF NNP 4_p
) ) 4_p
20 CD 3_p
adult NN 1_p
enfeebled VBD 4_p
hemodialysis NN 4_p
patients NNS N
-DOCSTART- -X- O O 24189342

humans NNS 4_p
: : 4_p
living NN 4_p
humans NNS 4_p
A DT N
total NN N
of IN N
35 CD N
healthy JJ N
men NNS N
were VBD N
studied VBN N
humans NNS N
-DOCSTART- -X- O O 6345111

symptomatic JJ 4_p
reflux NN 4_p
esophagitis NN 4_p
. . N

32 CD 3_p
patients NNS N
with IN N
chronic JJ 4_p
heartburn NN 4_p
. . N

Entry NN N
criteria NNS N
included VBD N
the DT N
presence NN N
of IN N
symptomatic JJ N
gastroesophageal NN N
reflux NN N
confirmed VBN N
by IN N
both DT N
an DT N
acid JJ N
perfusion NN N
( ( N
Bernstein NNP N
) ) N
test NN N
and CC N
by IN N
intraesophageal JJ N
pH NN N
probe NN N
. . N

-DOCSTART- -X- O O 12059064

Upper NNP 4_p
gastrointestinal JJ 4_p
endoscopy NN 4_p
( ( N
UGIE NNP N
) ) N
Eight NNP 3_p
normal JJ N
male NN 2_p
volunteers NNS N
undergoing VBG N
UGIE NNP N
with IN N
sedation NN N
( ( N
0.1 CD N
mg/kg NN N
of IN N
midazolam NN N
) ) N
and CC N
without IN N
it PRP N
( ( N
two CD N
endoscopies NNS N
per IN N
volunteer NN N
in IN N
random JJ N
order NN N
) ) N
-DOCSTART- -X- O O 7429786

antacids NNS 4_p
: : 4_p
-DOCSTART- -X- O O 23965288

adolescents NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
: : N
children NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . N

sample NN N
of IN N
higher JJR N
functioning NN N
adolescents NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
and CC 4_p
comorbid NN 4_p
anxiety NN 4_p
disorders NNS 4_p
enrolled VBD N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
( ( N
n JJ N
= NNP N
30 CD N
) ) N
. . N

-DOCSTART- -X- O O 12616671

concurrent JJ N
administration NN N
of IN N
risperidone NN N
and CC N
donepezil NN N
. . N

24 CD 3_p
healthy JJ 4_p
men NNS N
young JJ 1_p
healthy JJ 4_p
subjects NNS N
-DOCSTART- -X- O O 2240543

100 CD N
patients NNS N
. . N

patients NNS 4_p
with IN 4_p
a DT 4_p
laryngoscope NN 4_p
. . 4_p

-DOCSTART- -X- O O 20620365

zirconia NN 4_p
copings NNS 4_p
Zirconia NNP N
cores NNS N
zirconia NN N
copings NNS N
single JJ N
crowns NNS N
9 CD 3_p
stone NN N
cast NN N
replicas NN N
were VBD N
fabricated VBN N
, , N
numbered VBN N
, , N
and CC N
distributed VBD N
into IN N
8 CD N
ceramic JJ N
ZrO NNP N
( ( N
2 CD N
) ) N
CAD/CAM NNP N
system NN N
groups NNS N
( ( N
Lava NNP N
Frame NNP N
0.3 CD N
and CC N
0.5 CD N
, , N
IPS NNP N
e.max VBZ N
ZirCAD NNP N
, , N
VITA NNP N
YZ NNP N
, , N
Procera NNP N
AllZircon NNP N
, , N
Digizon NNP N
, , N
DC NNP N
Zircon NNP N
, , N
and CC N
Cercon NNP N
Base NNP N
) ) N
and CC N
to TO N
a DT N
lithium NN N
disilicate JJ N
glass-ceramic JJ N
control NN N
group NN N
( ( N
IPS NNP N
e.max RB N
Press NNP N
) ) N
using VBG N
a DT N
simple JJ N
computer-generated JJ N
randomization NN N
method NN N
. . N

ZrO NNP N
( ( N
2 CD N
) ) N
copings NNS N
zirconia NN N
copings NNS N
-DOCSTART- -X- O O 9919095

The DT 4_p
preparation NN 4_p
of IN 4_p
patients NNS 4_p
for IN 4_p
cardiac JJ 4_p
surgery NN 4_p
. . N

patients NNS 4_p
attending VBG 4_p
a DT 4_p
preadmission NN 4_p
teaching VBG 4_p
program NN 4_p
prior RB 4_p
to TO 4_p
cardiac VB 4_p
surgery NN 4_p
. . 4_p

-DOCSTART- -X- O O 18492829

piglet NN N
small JJ N
intestine NN N
from IN N
28-d-old JJ 1_p
pigs NNS N
weaned VBD N
at IN N
21 CD 1_p
d NN 1_p
of IN N
age NN N
and CC N
from IN N
age-matched JJ N
suckling VBG N
piglets NNS N
. . N

young JJ N
mammals NNS N
. . N

-DOCSTART- -X- O O 18157013

hepatocellular JJ 4_p
carcinomas NN 4_p
. . N

85 CD 3_p
HCC NNP N
patients NNS N
after IN N
transcatheter JJ N
arterial JJ N
chemoembolization NN N
and CC N
radiofrequency NN N
ablation NN N
therapy NN N
were VBD N
randomized VBN N
to TO N
immunotherapy VB N
group NN N
and CC N
no DT N
adjuvant JJ N
therapy NN N
group NN N
. . N

All DT N
patients NNS N
were VBD N
screened VBN N
by IN N
computed JJ N
tomography NN N
every DT N
2 CD N
months NNS N
to TO N
observe VB N
the DT N
tumor NN 4_p
recurrent NN 4_p
conditions NNS 4_p
. . N

HCC NNP 4_p
patients NNS N
-DOCSTART- -X- O O 21317341

lambs NNS 4_p
and CC N
steers NNS 4_p
fed VBP 4_p
to TO 4_p
meet VB 4_p
requirements NNS 4_p
of IN 4_p
natural JJ 4_p
markets NNS 4_p
. . N

lambs NNS 4_p
and CC N
cattle NNS 4_p
destined VBD 4_p
for IN 4_p
all DT 4_p
natural JJ 4_p
markets NNS 4_p
. . N

1 CD N
, , N
48 CD N
Dorset NNP N
× NNP N
Hampshire NNP N
lambs NN N
( ( N
initial JJ N
BW NNP N
29.4 CD N
± VBD N
0.1 CD N
kg NN N
) ) N
characteristics NNS N
. . N

Lambs NNP N
were VBD N
allotted VBN N
to TO N
12 CD N
pens NNS N
( ( N
4 CD N
lambs NNS N
per IN N
pen NN N
) ) N
, , N
and CC N
blocked VBN N
by IN N
sex NN N
and CC N
BW NNP N
Exp NNP N
. . N

2 CD N
, , N
168 CD N
crossbred VBD N
steers NNS N
( ( N
initial JJ N
BW NNP N
300 CD N
± VBD N
0.7 CD N
kg NN N
) ) N
for IN N
lambs NN N
and CC N
steers NNS N
-DOCSTART- -X- O O 25022743

autistic JJ 4_p
children NNS 4_p
-- : 4_p
a DT 4_p
severe JJ 4_p
sleep NN 4_p
problems NNS 4_p
in IN 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
. . 4_p

Participants NNS 4_p
were VBD 4_p
aged VBN 4_p
between IN 4_p
5 CD 4_p
years NNS 4_p
and CC 4_p
16 CD 4_p
years NNS 4_p
10 CD 4_p
months NNS 4_p
, , 4_p
with IN 4_p
a DT 4_p
confirmed JJ 4_p
ASD NNP 4_p
diagnosis NN 4_p
and CC 4_p
severe JJ 4_p
sleep NN 4_p
problems NNS 4_p
, , 4_p
refractory NN 4_p
to TO 4_p
community-based JJ 4_p
interventions NNS 4_p
. . 4_p

Seventy-three JJ N
children NNS N
were VBD N
randomized VBN N
and CC N
analysis NN N
conducted VBN N
on IN N
67 CD N
children NNS N
who WP N
completed VBD N
the DT N
study NN N
. . N

children NNS N
with IN N
ASD NNP N
-DOCSTART- -X- O O 22182296

behavioral JJ N
parent NN N
training NN N
in IN N
children NNS 1_p
with IN N
ADHD NNP 4_p
: : N
children NNS 1_p
with IN N
attention NN 4_p
deficit/hyperactivity NN 4_p
disorder NN 4_p
( ( 4_p
ADHD NNP 4_p
) ) 4_p
Study NNP N
subjects NNS N
were VBD N
a DT N
subsample NN N
( ( N
n JJ N
= NN N
50 CD 3_p
, , N
for IN N
whom WP N
DAT1 NNP N
genotypes NNS N
were VBD N
available JJ N
) ) N
of IN N
a DT N
randomized VBN N
controlled VBN N
BPT NNP N
effectiveness NN N
study NN N
( ( N
N NNP N
= NNP N
94 CD 3_p
) ) N
comparing VBG N
BPT NNP N
plus CC N
ongoing JJ N
routine JJ N
clinical JJ N
care NN N
( ( N
RCC NNP N
) ) N
versus NN N
RCC NNP N
alone RB N
in IN N
referred JJ N
children NNS N
( ( N
4-12 CD N
years NNS N
old JJ N
) ) N
with IN N
ADHD NNP 4_p
. . N

-DOCSTART- -X- O O 16846734

patients NNS N
with IN N
metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
( ( N
MBC NNP N
) ) N
who WP N
had VBD N
previously RB N
received VBN N
anthracyclines NNS N
. . N

total NN N
of IN N
210 CD 3_p
patients NNS N
204 CD 3_p
patients NNS N
evaluable JJ N
for IN N
response NN N
assessment NN N
, , N
the DT N
response NN N
rates NNS N
were VBD N
48.6 CD N
% NN N
for IN N
GP1 NNP N
, , N
52.2 CD N
% NN N
for IN N
GP2 NNP N
, , N
and CC N
52.3 CD N
% NN N
for IN N
GD NNP N
. . N

208 CD 3_p
patients NNS N
evaluable JJ N
for IN N
safety NN N
-DOCSTART- -X- O O 7196452

infertile JJ 4_p
and CC N
control JJ 4_p
subjects NNS N
: : N
-DOCSTART- -X- O O 8978338

adenomas NN 4_p
183 CD 3_p
patients NNS 3_p
. . 3_p

Patients NNS N
with IN N
two CD N
or CC N
more JJR N
adenomas NNS N
patients NNS 4_p
with IN 4_p
no DT 4_p
or CC 4_p
one CD 4_p
adenoma NN 4_p
-DOCSTART- -X- O O 21042930

HIV-infected JJ 4_p
prisoners NNS 4_p
HIV-infected JJ 4_p
releasees NNS 4_p
. . 4_p

for IN N
HIV-infected JJ N
state NN N
prison NN N
inmates NNS N
the DT N
104 CD N
inmates NNS N
enrolled VBD N
, , N
89 CD N
had VBD N
at IN N
least JJS N
1 CD N
post-release JJ N
study NN N
visit NN N
utilization NN N
for IN N
HIV-infected JJ N
individuals NNS N
released VBN N
-DOCSTART- -X- O O 22608375

individuals NNS N
in IN N
an DT N
RCT NNP N
of IN N
pharmacotherapy NN N
and CC N
counseling VBG N
for IN N
smoking VBG N
cessation NN N
individuals NNS 4_p
enrolled VBN 4_p
in IN 4_p
a DT 4_p
comparative JJ 4_p
effectiveness NN 4_p
trial NN 4_p
of IN 4_p
cessation NN 4_p
therapies NNS 4_p
between IN 4_p
October NNP 4_p
2005 CD 4_p
and CC 4_p
May NNP 4_p
2007 CD 4_p
( ( 4_p
1346 CD 4_p
total NN 4_p
participants NNS 4_p
; : 4_p
1338 CD 4_p
with IN 4_p
requisite JJ 4_p
data NNS 4_p
for IN 4_p
further JJ 4_p
analysis NN 4_p
) ) 4_p
. . 4_p

-DOCSTART- -X- O O 20689977

cancer NN N
patients NNS N
. . N

cancer NN N
patients NNS N
with IN N
dysfunctional JJ N
fear NN N
of IN N
progression NN N
. . N

cancer NN N
patients NNS N
receiving VBG N
inpatient JJ N
rehabilitation NN N
. . N

A DT N
total NN N
of IN N
174 CD N
patients NNS N
were VBD N
included VBN N
in IN N
the DT N
economic JJ N
evaluation NN N
. . N

cancer NN N
patients NNS N
with IN N
high JJ N
levels NNS N
of IN N
anxiety NN N
. . N

-DOCSTART- -X- O O 12406050

breast NN 4_p
cancer NN 4_p
women NNS 4_p
receiving VBG 4_p
adjuvant JJ 4_p
chemotherapy NN 4_p
or CC 4_p
radiation NN 4_p
therapy NN 4_p
for IN 4_p
newly RB 4_p
diagnosed VBN 4_p
breast NN 4_p
cancer NN 4_p
Fifty-two NNP 3_p
patients NNS N
with IN N
newly RB N
diagnosed VBN N
breast NN N
cancer NN N
women NNS N
Women NNS N
-DOCSTART- -X- O O 12105288

obese JJ 4_p
breast NN 4_p
cancer NN 4_p
survivors NNS 4_p
. . 4_p

women NNS N
who WP N
have VBP N
had VBN N
breast VBN N
cancer NN N
obese JJ 4_p
women NNS 4_p
who WP 4_p
have VBP 4_p
had VBD 4_p
a DT 4_p
diagnosis NN 4_p
of IN 4_p
breast NN 4_p
cancer NN 4_p
. . 4_p

Forty-eight JJ N
women NNS N
( ( N
body NN N
mass NN N
index NN N
of IN N
30 CD N
to TO N
44 CD N
kg/m NNS N
( ( N
2 CD N
) ) N
) ) N
were VBD N
enrolled VBN N
. . N

-DOCSTART- -X- O O 23639612

invasive JJ N
aspergillosis NN N
in IN N
high-risk JJ N
haematology NN N
patients NNS N
: : N
haematology NN N
patients NNS N
at IN N
high JJ N
risk NN N
of IN N
invasive JJ N
aspergillosis NN N
. . N

eligible JJ N
patients NNS N
were VBD N
adults NNS N
undergoing VBG N
allogeneic JJ N
stem-cell JJ N
transplantation NN N
or CC N
chemotherapy NN N
for IN N
acute JJ N
leukaemia NN N
, , N
with IN N
no DT N
history NN N
of IN N
invasive JJ N
fungal JJ N
disease NN N
. . N

240 CD N
eligible JJ N
patients NNS N
were VBD N
recruited VBN N
from IN N
six CD N
Australian JJ N
centres NNS N
between IN N
Sept NNP N
30 CD N
, , N
2005 CD N
, , N
and CC N
Nov NNP N
19 CD N
, , N
2009 CD N
. . N

in IN N
high-risk JJ N
haematology NN N
patients NNS N
-DOCSTART- -X- O O 23504941

primary JJ 1_p
school NN 1_p
children NNS 1_p
. . 1_p

primary JJ 1_p
school NN 1_p
children NNS 1_p
. . 1_p

Data NNP N
for IN N
90 CD 3_p
children NNS 1_p
( ( N
49 CD 3_p
boys NNS 2_p
, , N
41 CD 3_p
girls NNS 2_p
, , N
9.3 CD N
± JJ N
1.4 CD N
years NNS N
) ) N
from IN N
three CD N
Irish JJ N
primary NN N
schools NNS N
. . N

In IN N
each DT N
school NN N
one CD N
class NN N
was VBD N
randomly RB N
assigned VBN N
as IN N
the DT N
intervention NN N
group NN N
and CC N
another DT N
as IN N
controls NNS N
-DOCSTART- -X- O O 20054544

robot-assisted JJ N
endoscopic NN N
thyroidectomy NN N
Postoperative NNP 4_p
pain NN 4_p
following VBG 4_p
endoscopic NN 4_p
thyroidectomy NN 4_p
124 CD 3_p
women NNS 3_p
21-60 CD N
years NNS N
of IN N
age NN N
who WP N
were VBD N
scheduled VBN N
for IN N
elective JJ N
gasless NN N
robot-assisted JJ N
endoscopic NN N
thyroidectomy NN N
via IN N
the DT N
transaxillary JJ N
approach NN N
. . N

pain NN N
management NN N
in IN N
patients NNS N
with IN N
moderate JJ 4_p
to TO 4_p
severe VB 4_p
postoperative JJ 4_p
pain NN 4_p
after IN N
gasless JJ N
robot-assisted JJ N
endoscopic NN N
thyroidectomy NN N
performed VBD N
via IN N
the DT N
transaxillary JJ N
approach NN N
. . N

-DOCSTART- -X- O O 23782126

autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
: : 4_p
46 CD N
children NNS N
, , N
3-7 CD N
years NNS N
of IN N
age NN N
diagnosed VBN N
with IN N
an DT N
ASD NNP N
-DOCSTART- -X- O O 371644

unstable JJ 4_p
angina NN 4_p
at IN N
rest NN N
12 CD 3_p
patients NNS 3_p
admitted VBN N
to TO N
our PRP$ N
coronary JJ N
care NN N
unit NN N
because IN N
of IN N
frequent JJ N
daily JJ N
attacks NNS N
of IN N
angina NN 4_p
at IN N
rest NN N
attributed VBN N
to TO N
coronary JJ 4_p
vasospasm NN 4_p
. . N

patients NNS N
with IN N
frequent JJ N
attacks NNS N
of IN N
angina NN 4_p
at IN N
rest NN N
. . N

-DOCSTART- -X- O O 12356338

healthy JJ N
young JJ N
adults NNS N
. . N

nonsmoking VBG N
adults NNS N
( ( N
6 CD N
male NN N
, , N
5 CD N
female NN N
; : N
ages VBZ N
23-36 CD N
years NNS N
) ) N
-DOCSTART- -X- O O 22215436

children NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . N

children NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
. . N

60 CD 3_p
elementary-aged JJ 1_p
children NNS 1_p
with IN N
ASD NNP 4_p
. . N

-DOCSTART- -X- O O 16772581

dairy NN N
cows NNS N
36 CD 3_p
primiparous JJ 3_p
and CC N
40 CD 3_p
multiparous JJ 3_p
Holstein NNP N
cows NNS N
cows VBZ N
consuming VBG N
WCGF NNP N
consuming VBG N
WCGF NNP N
-DOCSTART- -X- O O 2285871

hypertensive JJ N
response NN N
to TO N
tracheal VB 4_p
intubation NN 4_p
at IN N
the DT N
time NN N
of IN N
general JJ N
anesthesia NN 4_p
-DOCSTART- -X- O O 14699228

patients NNS 4_p
with IN 4_p
myasthenia JJ 4_p
gravis NN 4_p
. . 4_p

Patients NNPS N
with IN N
myasthenia NNP N
gravis FW N
receive JJ N
pyridostigmine NN N
, , N
an DT N
anticholinesterase NN N
agent NN N
patients NNS N
with IN N
myasthenia JJ N
gravis NN N
on IN N
pyridostigmine NN N
therapy NN N
. . N

Medically NNP N
( ( N
oral JJ N
pyridostigmine NN N
) ) N
well-controlled JJ N
adult NN N
patients NNS N
with IN N
myasthenia JJ N
gravis NNS N
who WP N
were VBD N
posted VBN N
for IN N
thymectomy NN N
Fourteen JJ N
patients NNS N
myasthenia JJ N
gravis NN N
-DOCSTART- -X- O O 26650831

chemotherapy NN 4_p
in IN 4_p
breast NN 4_p
cancer NN 4_p
. . 4_p

breast NN 4_p
cancer NN 4_p
subtype NN 4_p
. . 4_p

Patients NNPS N
with IN N
invasive JJ 4_p
breast NN 4_p
cancer NN 4_p
were VBD N
enrolled VBN N
in IN N
the DT N
INTENS NNP N
study NN N
between IN N
2006 CD N
and CC N
2009 CD N
. . N

We PRP N
included VBD N
182 CD 3_p
patients NNS 3_p
, , N
of IN N
whom WP N
data NNS N
were VBD N
available JJ N
for IN N
post-NAC JJ N
MRI NNP N
( ( N
n=155 NN N
) ) N
, , N
US NNP N
( ( N
n=123 NN N
) ) N
, , N
and CC N
histopathological JJ 4_p
tumour NN 4_p
size NN 4_p
. . N

-DOCSTART- -X- O O 21206549

nocturnal JJ 4_p
sleep JJ 4_p
disruption NN 4_p
: : 4_p
patients NNS 4_p
with IN 4_p
narcolepsy JJ 4_p
. . 4_p

narcolepsy JJ 1_p
patients NNS 1_p
228 CD 1_p
adult NN 1_p
patients NNS 1_p
with IN 1_p
narcolepsy/cataplexy NNS 1_p
in IN 1_p
the DT 1_p
United NNP 1_p
States NNPS 1_p
, , 1_p
Canada NNP 1_p
, , 1_p
and CC 1_p
Europe NNP 1_p
. . 1_p

receiving VBG N
6 CD N
and CC N
9 CD N
g/night NN N
doses NNS N
-DOCSTART- -X- O O 23407221

tuberculosis NN N
in IN N
an DT N
immigrant JJ N
population NN N
. . N

Immigrants NNS 4_p
with IN 4_p
LTBI NNP 4_p
. . N

in IN N
Barcelona NNP N
, , N
Spain NNP N
, , N
from IN N
April NNP N
2001 CD N
to TO N
April NNP N
2005 CD N
. . N

590 CD 3_p
subjects NNS N
enrolled VBN N
-DOCSTART- -X- O O 9989713

long-standing JJ N
adductor-related JJ 4_p
groin NN 4_p
pain NN 4_p
in IN N
athletes NNS 4_p
: : N
adductor-related JJ 4_p
groin NN 4_p
pain NN 4_p
. . N

adductor-related JJ 4_p
groin NN 4_p
pain NN 4_p
in IN N
athletes NNS 4_p
. . N

68 CD 3_p
athletes NNS N
with IN N
long-standing JJ N
( ( N
median JJ N
40 CD N
weeks NNS N
) ) N
adductor-related JJ 4_p
groin NN 4_p
pain NN 4_p
-- : N
after IN N
examination NN N
according VBG N
to TO N
a DT N
standardised VBN N
protocol NN N
-- : N
were VBD N
randomly RB N
assigned VBN N
to TO N
AT NNP N
or CC N
PT NNP N
. . N

23 CD N
patients NNS N
in IN N
the DT N
AT NNP N
group NN N
and CC N
four CD N
in IN N
the DT N
PT NNP N
group NN N
returned VBD N
to TO N
sports NNS N
without IN N
groin NN N
pain NN N
( ( N
odds NNS N
-DOCSTART- -X- O O 11331049

health NN N
economics NNS N
of IN N
realtime NN N
teledermatology NN N
compared VBN N
with IN N
conventional JJ N
care NN N
: : N
urban JJ N
versus NN N
rural JJ N
perspective NN N
. . N

patients NNS N
from IN N
urban JJ N
and CC N
rural JJ N
areas NNS N
. . N

Over IN N
two CD N
years NNS N
, , N
274 CD 3_p
patients NNS N
required VBD N
a DT N
hospital JJ N
outpatient NN N
dermatology NN N
referral JJ N
-- : N
126 CD 3_p
patients NNS N
( ( N
46 CD N
% NN N
) ) N
urban JJ N
patients NNS N
rural JJ N
patients NNS N
. . N

in IN N
urban JJ N
areas NNS N
in IN N
rural JJ N
areas NNS N
-DOCSTART- -X- O O 24925605

Families NNS 1_p
enrolled VBD N
between IN N
15 CD N
March NNP N
and CC N
25 CD N
May NNP N
2012 CD N
Both DT N
groups NNS N
2012 CD N
) ) N
. . N

A DT 3_p
total NN 3_p
of IN 3_p
137 CD 3_p
families NNS 3_p
period NN N
. . N

Parents NNS N
who WP N
received VBD N
an DT N
incentive NN N
were VBD N
more RBR N
likely JJ N
to TO N
return VB N
a DT N
completed VBN N
survey NN N
in IN N
the DT N
6 CD N
weeks NNS N
than IN N
those DT N
who WP N
did VBD N
not RB N
( ( N
21 CD N
% NN N
vs. FW N
6 CD N
% NN N
, , N
P NNP N
= NNP N
0.009 CD N
) ) N
-DOCSTART- -X- O O 8238214

eyes NNS N
with IN N
severe JJ N
proliferative JJ 4_p
vitreoretinopathy NN 4_p
. . N

117 CD 3_p
of IN N
404 CD 3_p
eyes NNS N
( ( N
29 CD N
% NN N
) ) N
with IN N
severe JJ N
proliferative JJ 4_p
vitreoretinopathy NN 4_p
( ( N
> CD N
or CC N
= VB N
C-3 NNP N
, , N
full-thickness JJ N
retinal JJ N
folds NNS N
in IN N
three CD N
or CC N
more JJR N
quadrants NNS N
) ) N
Forty-six JJ 3_p
eyes NNS N
-DOCSTART- -X- O O 24309381

young JJ 1_p
adults NNS 1_p
with IN N
sickle NN 4_p
cell NN 4_p
disease NN 4_p
. . N

Young NNP 1_p
adults NNS 1_p
with IN N
sickle NN 4_p
cell NN 4_p
disease NN 4_p
( ( 4_p
SCD NNP 4_p
) ) 4_p
Young NNP 1_p
adults NNS 1_p
with IN N
SCD NNP 4_p
ages VBZ 1_p
18 CD 1_p
to TO 1_p
35 CD 1_p
years NNS 1_p
( ( N
n JJ 3_p
= NNP 3_p
90 CD 3_p
) ) N
young JJ 1_p
adults NNS 1_p
with IN N
SCD NNP 4_p
. . N

-DOCSTART- -X- O O 8708726

small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
. . N

small-cell JJ N
lung NN N
cancer NN N
( ( N
SCLC NNP N
) ) N
patients NNS N
who WP N
responded VBD N
to TO N
six CD N
courses NNS N
of IN N
induction NN N
chemotherapy NN N
with IN N
ifosfamide NN N
, , N
etoposide RB N
, , N
and CC N
an DT N
anthracycline NN N
( ( N
doxorubicin NN N
or CC N
epirubicin NN N
) ) N
. . N

Among IN N
235 CD 3_p
eligible JJ N
patients NNS N
initially RB N
registered VBD N
, , N
91 CD 3_p
were VBD N
randomized VBN N
to TO N
receive VB N
maintenance NN N
therapy NN N
, , N
including VBG N
seven CD 3_p
patients NNS N
who WP N
were VBD N
no RB N
longer RBR N
responding VBG N
. . N

-DOCSTART- -X- O O 25622776

during IN 4_p
prescription NN 4_p
opioid JJ 4_p
dependence NN 4_p
treatment NN 4_p
. . 4_p

outpatient JJ N
participants NNS 4_p
with IN 4_p
prescription NN 4_p
opioid JJ 4_p
dependence NN 4_p
who WP 4_p
received VBD 4_p
12 CD 4_p
weeks NNS 4_p
of IN 4_p
buprenorphine-naloxone NN 4_p
and CC 4_p
counseling NN 4_p
in IN 4_p
a DT 4_p
multi-site JJ 4_p
clinical JJ 4_p
trial NN 4_p
( ( N
N=353 NNP 3_p
) ) N
. . N

individuals NNS 4_p
with IN 4_p
prescription NN 4_p
opioid JJ 4_p
addiction NN 4_p
. . N

-DOCSTART- -X- O O 23212807

Risperidone CD N
dosing NN N
in IN N
children NNS N
and CC N
adolescents NNS N
with IN N
autistic JJ N
disorder NN N
: : N
children NNS N
and CC N
adolescents NNS N
with IN N
autism NN N
. . N

Patients NNS N
( ( N
N NNP N
= NNP N
96 CD N
; : N
5-17 CD N
years NNS N
) ) N
significantly RB N
only RB N
in IN N
the DT N
high-dose JJ N
more RBR N
frequently RB N
in IN N
high-versus JJ N
low-dose JJ N
-DOCSTART- -X- O O 8210973

cyclosporin-treated JJ 4_p
renal JJ 4_p
transplant NN 4_p
recipients NNS 4_p
: : 4_p
Twenty NNP 3_p
nine CD 3_p
stable JJ 4_p
renal JJ 4_p
transplant NN 4_p
recipients NNS 4_p
, , N
10 CD 3_p
receiving VBG N
cyclosporin NN N
, , N
10 CD 3_p
cyclosporin-prednisolone NN N
and CC N
nine CD 3_p
azathioprine-prednisolone NN N
-DOCSTART- -X- O O 7218018

We PRP N
randomized VBD 4_p
50 CD 3_p
patients NNS N
-DOCSTART- -X- O O 22476876

adults NNS 1_p
with IN 4_p
an DT 4_p
increased VBN 4_p
risk NN 4_p
of IN 4_p
cardiovascular JJ 4_p
disease NN 4_p
: : N
people NNS 4_p
at IN 4_p
risk NN 4_p
of IN 4_p
cardiovascular JJ 4_p
disease NN 4_p
( ( 4_p
CVD NNP 4_p
) ) 4_p
Participants NNS 4_p
with IN 4_p
a DT 4_p
CVD NNP 4_p
relative JJ 4_p
risk NN 4_p
of IN 4_p
1.5 CD 4_p
assessed VBN 4_p
by IN 4_p
risk NN 4_p
scores NNS 4_p
-DOCSTART- -X- O O 10575594

Thirty NNP 3_p
postmenopausal JJ 4_p
women NNS 2_p
with IN N
reduced JJ 4_p
bone NN 4_p
mineral JJ 4_p
density NN 4_p
were VBD N
divided VBN N
randomly RB N
into IN N
two CD N
groups NNS N
based VBN N
on IN N
the DT N
chronological JJ N
sequence NN N
of IN N
their PRP$ N
first JJ N
visit NN N
to TO N
the DT N
Osteoporosis NNP 4_p
Clinic NNP N
of IN N
Katsuragi NNP N
Hospital NNP N
. . N

-DOCSTART- -X- O O 16230666

primiparous JJ N
and CC N
mature JJ N
beef NN N
cows NNS N
. . N

primiparous JJ N
and CC N
multiparous JJ N
, , N
spring-calving JJ N
, , N
crossbred JJ N
beef NN N
cows NNS N
cows NNS N
Primiparous JJ N
cows NNS N
cows NNS N
beef NN N
cows NNS N
-DOCSTART- -X- O O 12956656

15 CD 3_p
healthy JJ N
volunteers NNS N
. . N

subjects NNS N
wore VBP N
from IN N
0900 CD N
to TO N
1700 CD N
h NN N
an DT N
upper JJ N
removable JJ N
acrylic JJ N
appliance NN N
holding VBG N
one CD N
polished JJ N
enamel NN N
and CC N
one CD N
polished VBN N
dentine NN N
specimen NNS N
. . N

-DOCSTART- -X- O O 10637238

metastatic JJ 4_p
, , 4_p
hormone-sensitive JJ 4_p
breast NN 4_p
cancer NN 4_p
: : N
An DT N
Eastern JJ N
Cooperative NNP N
Oncology NNP N
Group NNP N
study NN N
. . N

Between NNP N
January NNP N
1988 CD N
and CC N
December NNP N
1992 CD N
, , N
231 CD 3_p
patients NNS N
with IN N
estrogen JJ N
receptor NN N
( ( N
ER NNP N
) ) N
-positive CD N
or CC N
ER-unknown JJ N
metastatic JJ N
breast NN N
cancer NN N
-DOCSTART- -X- O O 2590611

thromboxane NN 4_p
and CC 4_p
prostaglandin JJ 4_p
biosynthesis NN 4_p
in IN N
man NN 2_p
. . N

nine CD 3_p
healthy JJ 4_p
male NN 2_p
volunteers NNS N
. . N

-DOCSTART- -X- O O 24564308

anesthesia NN N
in IN N
dogs NNS N
sedated VBN N
with IN N
acepromazine NN N
and CC N
oxymorphone NN N
. . N

dogs NNS N
sedated VBN N
with IN N
acepromazine JJ N
maleate NN N
and CC N
oxymorphone NN N
hydrochloride NN N
. . N

ANIMALS $ N
10 CD 4_p
healthy JJ N
adult NN N
Beagles NNP N
. . N

-DOCSTART- -X- O O 20647058

evidence-based JJ N
prescription NN N
drug NN N
label NN N
on IN N
actual JJ N
medication NN N
use NN N
. . N

randomly VB N
sampled VBN N
patients NNS 4_p
who WP 4_p
receive VBP 4_p
their PRP$ 4_p
care NN 4_p
from IN 4_p
free JJ 4_p
clinics NNS 4_p
, , 4_p
mobile JJ 4_p
vans NNS 4_p
and CC 4_p
federally RB 4_p
qualified JJ 4_p
health NN 4_p
centers NNS 4_p
( ( N
FQHCs NNP N
) ) N
in IN N
Northern NNP N
Virginia NNP N
. . N

patients NNS 4_p
with IN 4_p
diabetes NNS 4_p
or CC 4_p
hypertension NN 4_p
; : N
-DOCSTART- -X- O O 839327

low-birth-weight JJ 4_p
infants NNS 1_p
. . N

appropriate-for-gestational JJ 1_p
age NN 1_p
, , N
low-birth-weight JJ 4_p
infants NNS 1_p
-DOCSTART- -X- O O 7733424

Forty NNP N
work-sites NNS N
-DOCSTART- -X- O O 12169964

primary JJ 4_p
open-angle JJ 4_p
glaucoma NN 4_p
. . N

eyes NNS 4_p
with IN 4_p
open-angle JJ 4_p
glaucoma NN 4_p
. . N

A NNP N
total NN N
of IN N
90 CD 3_p
eyes NNS 3_p
of IN 3_p
90 CD 3_p
patients NNS 3_p
with IN N
primary JJ 4_p
open-angle JJ 4_p
glaucoma NN 4_p
or CC 4_p
pseudoexfoliative JJ 4_p
glaucoma NN 4_p
underwent JJ N
deep JJ N
sclerectomy NN N
. . N

-DOCSTART- -X- O O 8198938

stable JJ 4_p
angina NN 4_p
. . 4_p

149 CD 3_p
men NNS 4_p
with IN 4_p
stable JJ 4_p
angina NN 4_p
. . 4_p

-DOCSTART- -X- O O 17426001

postoperative JJ 4_p
pain NN 4_p
radical JJ N
surgery NN N
for IN N
gastric JJ 4_p
carcinoma NN 4_p
] NNP N
radical JJ N
surgery NN N
for IN N
gastric JJ N
carcinoma NN N
. . N

Sixty-six JJ 3_p
patients NNS N
with IN N
gastric JJ N
carcinoma NN N
scheduled VBN N
for IN N
gastrectomy NN N
after IN N
gastrectomy NN N
for IN N
gastric JJ N
carcinoma NN N
. . N

-DOCSTART- -X- O O 20587582

long-term JJ 4_p
exogenous JJ N
subclinical JJ N
hyperthyroid NN N
patients NNS N
Totally NNP N
25 CD N
patients NNS N
with IN N
a DT N
history NN N
of IN N
differentiated JJ N
thyroid JJ N
carcinoma NN N
on IN N
long-term JJ N
TSH-suppressive JJ N
levothyroxine NN N
( ( N
l-T JJ N
( ( N
4 CD N
) ) N
) ) N
substitution NN N
Additionally RB N
40 CD N
euthyroid JJ N
controls NNS N
were VBD N
studied VBN N
. . N

-DOCSTART- -X- O O 12932301

chronic JJ N
whiplash NN N
disorders NNS N
Whiplash-associated JJ N
disorder NN N
patients NNS N
with IN N
chronic JJ N
whiplash NN N
associated VBN N
disorders NNS N
people NNS N
with IN N
chronic JJ N
( ( N
symptoms NNS N
of IN N
> JJ N
3 CD N
months NNS N
duration NN N
) ) N
whiplash NN N
. . N

whiplash NN N
associated VBN N
disorders NNS N
. . N

whiplash NN N
and CC N
chronic JJ N
pain NN N
. . N

-DOCSTART- -X- O O 15294387

Participants NNS N
Participants NNS N
EEG NNP 4_p
participant NN 4_p
had VBD 4_p
a DT 4_p
yoked VBN 4_p
control NN 4_p
partner NN 4_p
experimental JJ 4_p
group NN 4_p
. . N

-DOCSTART- -X- O O 23416308

healthy JJ 4_p
volunteers NNS 4_p
. . 4_p

75 CD N
healthy JJ N
volunteers NNS N
( ( N
8 CD N
subjects NNS N
in IN N
each DT N
of IN N
the DT N
10 CD N
cohorts NNS N
; : N
5 CD N
subjects NNS N
participated VBN N
in IN N
two CD N
cohorts NNS N
) ) N
were VBD N
randomized VBN N
( ( N
6:2 CD N
) ) N
-DOCSTART- -X- O O 7069027

depressed JJ 4_p
psychiatric JJ 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 8131429

aspiration NN N
following VBG N
stroke NN 4_p
, , N
the DT N
clinical JJ N
records NNS N
of IN N
26 CD 3_p
patients NNS 3_p
with IN N
aspiration NN N
and CC N
33 CD 3_p
randomly RB N
selected VBN N
, , N
case-matched JJ N
, , N
dysphagic JJ 4_p
controls NNS 4_p
without IN 4_p
videofluoroscopic JJ 4_p
evidence NN 4_p
of IN 4_p
aspiration NN 4_p
were VBD N
reviewed VBN N
. . N

Patients NNS N
were VBD N
assessed VBN N
a DT N
mean NN N
of IN N
2 CD N
+/- JJ N
1 CD N
SD NNP N
months NNS N
poststroke NN 4_p
and CC N
were VBD N
followed VBN N
for IN N
a DT N
mean NN N
of IN N
16 CD N
+/- JJ N
8 CD N
SD NNP N
months NNS N
poststroke RB 4_p
. . 4_p

-DOCSTART- -X- O O 3533340

soft-tissue JJ 4_p
rheumatism NN 4_p
: : N
between-patient NN N
controlled VBD N
trial NN N
in IN N
73 CD 3_p
outpatients NNS 4_p
affected VBN 4_p
by IN 4_p
scapulo-humeral JJ 4_p
periarthritis NN 4_p
or CC 4_p
elbow NN 4_p
epicondylitis NN 4_p
. . N

-DOCSTART- -X- O O 2491829

acute JJ 4_p
myeloid NN 4_p
leukemia NN 4_p
. . N

Fifty-four CD 3_p
patients NNS 4_p
treated VBN 4_p
with IN 4_p
daunorubicin NN 4_p
, , 4_p
cytosine JJ 4_p
arabinoside NN 4_p
and CC 4_p
thioquanine NN 4_p
for IN 4_p
acute JJ 4_p
myeloid NN 4_p
leukemia NN 4_p
patients NNS N
undergoing JJ N
remission NN N
induction NN N
therapy NN N
for IN N
acute JJ N
myeloid NN N
leukemia NN N
. . N

-DOCSTART- -X- O O 26902035

during IN N
the DT N
hepatectomy NN 4_p
Between NNP N
June NNP N
2011 CD N
and CC N
August NNP N
2012 CD N
, , N
a DT N
total NN N
of IN N
40 CD 3_p
patients NNS 3_p
undergoing JJ N
major JJ N
hepatectomy NN 4_p
The DT N
two CD N
groups NNS N
were VBD N
comparable JJ N
in IN N
terms NNS N
of IN N
demographics NNS N
, , N
indications NNS N
for IN N
surgery NN N
, , N
extent NN N
of IN N
hepatectomy NN 4_p
, , N
and CC N
intraoperative JJ N
blood NN N
loss NN N
. . N

